Naloxone	227508	0	B
reverses	-	9	O
the	-	18	O
antihypertensive	-	22	O
effect	-	39	O
of	-	46	O
clonidine	-	49	B
.	-	58	O

In	227508	60	O
unanesthetized	-	63	O
,	-	77	O
spontaneously	-	79	O
hypertensive	-	93	O
rats	-	106	O
the	-	111	O
decrease	-	115	O
in	-	124	O
blood	-	127	O
pressure	-	133	O
and	-	142	O
heart	-	146	O
rate	-	152	O
produced	-	157	O
by	-	166	O
intravenous	-	169	O
clonidine	-	181	B
,	-	190	O
5	-	192	O
to	-	194	O
20	-	197	O
micrograms	-	200	O
/	-	210	O
kg	-	211	O
,	-	213	O
was	-	215	O
inhibited	-	219	O
or	-	229	O
reversed	-	232	O
by	-	241	O
nalozone	-	244	B
,	-	252	O
0	-	254	O
.	-	255	O
2	-	256	O
to	-	258	O
2	-	261	O
mg	-	263	O
/	-	265	O
kg	-	266	O
.	-	268	O

The	227508	270	O
hypotensive	-	274	O
effect	-	286	O
of	-	293	O
100	-	296	O
mg	-	300	O
/	-	302	O
kg	-	303	O
alpha	-	306	B
-	-	311	I
methyldopa	-	312	I
was	-	323	O
also	-	327	O
partially	-	332	O
reversed	-	342	O
by	-	351	O
naloxone	-	354	B
.	-	362	O

Naloxone	227508	364	B
alone	-	373	O
did	-	379	O
not	-	383	O
affect	-	387	O
either	-	394	O
blood	-	401	O
pressure	-	407	O
or	-	416	O
heart	-	419	O
rate	-	425	O
.	-	429	O

In	227508	431	O
brain	-	434	O
membranes	-	440	O
from	-	450	O
spontaneously	-	455	O
hypertensive	-	469	O
rats	-	482	O
clonidine	-	487	B
,	-	496	O
10	-	498	O
(	-	500	O
-	-	501	O
8	-	502	O
)	-	503	O
to	-	505	O
10	-	508	O
(	-	510	O
-	-	511	O
5	-	512	O
)	-	513	O

M	227508	515	O
,	-	516	O
did	-	518	O
not	-	522	O
influence	-	526	O
stereoselective	-	536	O
binding	-	552	O
of	-	560	O
[	-	563	B
3H	-	564	I
]	-	566	I
-	-	567	I
naloxone	-	568	I
(	-	577	O
8	-	578	O
nM	-	580	O
)	-	582	O
,	-	583	O
and	-	585	O
naloxone	-	589	B
,	-	597	O
10	-	599	O
(	-	601	O
-	-	602	O
8	-	603	O
)	-	604	O
to	-	606	O
10	-	609	O
(	-	611	O
-	-	612	O
4	-	613	O
)	-	614	O

M	227508	616	O
,	-	617	O
did	-	619	O
not	-	623	O
influence	-	627	O
clonidine	-	637	B
-	-	646	O
suppressible	-	647	O
binding	-	660	O
of	-	668	O
[	-	671	B
3H	-	672	I
]	-	674	I
-	-	675	I
dihydroergocryptine	-	676	I
(	-	696	O
1	-	697	O
nM	-	699	O
)	-	701	O
.	-	702	O

These	227508	704	O
findings	-	710	O
indicate	-	719	O
that	-	728	O
in	-	733	O
spontaneously	-	736	O
hypertensive	-	750	O
rats	-	763	O
the	-	768	O
effects	-	772	O
of	-	780	O
central	-	783	O
alpha	-	791	O
-	-	796	O
adrenoceptor	-	797	O
stimulation	-	810	O
involve	-	822	O
activation	-	830	O
of	-	841	O
opiate	-	844	O
receptors	-	851	O
.	-	860	O

As	227508	862	O
naloxone	-	865	B
and	-	874	O
clonidine	-	878	B
do	-	888	O
not	-	891	O
appear	-	895	O
to	-	902	O
interact	-	905	O
with	-	914	O
the	-	919	O
same	-	923	O
receptor	-	928	O
site	-	937	O
,	-	941	O
the	-	943	O
observed	-	947	O
functional	-	956	O
antagonism	-	967	O
suggests	-	978	O
the	-	987	O
release	-	991	O
of	-	999	O
an	-	1002	O
endogenous	-	1005	O
opiate	-	1016	O
by	-	1023	O
clonidine	-	1026	B
or	-	1036	O
alpha	-	1039	B
-	-	1044	I
methyldopa	-	1045	I
and	-	1056	O
the	-	1060	O
possible	-	1064	O
role	-	1073	O
of	-	1078	O
the	-	1081	O
opiate	-	1085	O
in	-	1092	O
the	-	1095	O
central	-	1099	O
control	-	1107	O
of	-	1115	O
sympathetic	-	1118	O
tone	-	1130	O
.	-	1134	O

Lidocaine	354896	0	B
-	-	9	O
induced	-	10	O
cardiac	-	18	O
asystole	-	26	O
.	-	34	O

Intravenous	354896	36	O
administration	-	48	O
of	-	63	O
a	-	66	O
single	-	68	O
50	-	75	O
-	-	77	O
mg	-	78	O
bolus	-	81	O
of	-	87	O
lidocaine	-	90	B
in	-	100	O
a	-	103	O
67	-	105	O
-	-	107	O
year	-	108	O
-	-	112	O
old	-	113	O
man	-	117	O
resulted	-	121	O
in	-	130	O
profound	-	133	O
depression	-	142	O
of	-	153	O
the	-	156	O
activity	-	160	O
of	-	169	O
the	-	172	O
sinoatrial	-	176	O
and	-	187	O
atrioventricular	-	191	O
nodal	-	208	O
pacemakers	-	214	O
.	-	224	O

The	354896	226	O
patient	-	230	O
had	-	238	O
no	-	242	O
apparent	-	245	O
associated	-	254	O
conditions	-	265	O
which	-	276	O
might	-	282	O
have	-	288	O
predisposed	-	293	O
him	-	305	O
to	-	309	O
the	-	312	O
development	-	316	O
of	-	328	O
bradyarrhythmias	-	331	O
;	-	347	O
and	-	349	O
,	-	352	O
thus	-	354	O
,	-	358	O
this	-	360	O
probably	-	365	O
represented	-	374	O
a	-	386	O
true	-	388	O
idiosyncrasy	-	393	O
to	-	406	O
lidocaine	-	409	B
.	-	418	O

Suxamethonium	435349	0	B
infusion	-	14	O
rate	-	23	O
and	-	28	O
observed	-	32	O
fasciculations	-	41	O
.	-	55	O

A	435349	57	O
dose	-	59	O
-	-	63	O
response	-	64	O
study	-	73	O
.	-	78	O

Suxamethonium	435349	80	B
chloride	-	94	I

(	435349	103	O
Sch	-	104	B
)	-	107	O
was	-	109	O
administered	-	113	O
i	-	126	O
.	-	127	O
v	-	128	O
.	-	129	O

to	435349	131	O
36	-	134	O
adult	-	137	O
males	-	143	O
at	-	149	O
six	-	152	O
rates	-	156	O
:	-	161	O
0	-	163	O
.	-	164	O
25	-	165	O
mg	-	168	O
s	-	171	O
-	-	172	O
1	-	173	O
to	-	175	O
20	-	178	O
mg	-	181	O
s	-	184	O
-	-	185	O
1	-	186	O
.	-	187	O

The	435349	189	O
infusion	-	193	O
was	-	202	O
discontinued	-	206	O
either	-	219	O
when	-	226	O
there	-	231	O
was	-	237	O
no	-	241	O
muscular	-	244	O
response	-	253	O
to	-	262	O
tetanic	-	265	O
stimulation	-	273	O
of	-	285	O
the	-	288	O
ulnar	-	292	O
nerve	-	298	O
or	-	304	O
when	-	307	O
Sch	-	312	B
120	-	316	O
mg	-	320	O
was	-	323	O
exceeded	-	327	O
.	-	335	O

Six	435349	337	O
additional	-	341	O
patients	-	352	O
received	-	361	O
a	-	370	O
30	-	372	O
-	-	374	O
mg	-	375	O
i	-	378	O
.	-	379	O
v	-	380	O
.	-	381	O

bolus	435349	383	O
dose	-	389	O
.	-	393	O

Fasciculations	435349	395	O
in	-	410	O
six	-	413	O
areas	-	417	O
of	-	423	O
the	-	426	O
body	-	430	O
were	-	435	O
scored	-	440	O
from	-	447	O
0	-	452	O
to	-	454	O
3	-	457	O
and	-	459	O
summated	-	463	O
as	-	472	O
a	-	475	O
total	-	477	O
fasciculation	-	483	O
score	-	497	O
.	-	502	O

The	435349	504	O
times	-	508	O
to	-	514	O
first	-	517	O
fasciculation	-	523	O
,	-	536	O
twitch	-	538	O
suppression	-	545	O
and	-	557	O
tetanus	-	561	O
suppression	-	569	O
were	-	581	O
inversely	-	586	O
related	-	596	O
to	-	604	O
the	-	607	O
infusion	-	611	O
rates	-	620	O
.	-	625	O

Fasciculations	435349	627	O
in	-	642	O
the	-	645	O
six	-	649	O
areas	-	653	O
and	-	659	O
the	-	663	O
total	-	667	O
fasciculation	-	673	O
score	-	687	O
were	-	693	O
related	-	698	O
directly	-	706	O
to	-	715	O
the	-	718	O
rate	-	722	O
of	-	727	O
infusion	-	730	O
.	-	738	O

Total	435349	740	O
fasciculation	-	746	O
scores	-	760	O
in	-	767	O
the	-	770	O
30	-	774	O
-	-	776	O
mg	-	777	O
bolus	-	780	O
group	-	786	O
and	-	792	O
the	-	796	O
5	-	800	O
-	-	801	O
mg	-	802	O
s	-	805	O
-	-	806	O
1	-	807	O
and	-	809	O
20	-	813	O
-	-	815	O
mg	-	816	O
s	-	819	O
-	-	820	O
1	-	821	O
infusion	-	823	O
groups	-	832	O
were	-	839	O
not	-	844	O
significantly	-	848	O
different	-	862	O
.	-	871	O

Galanthamine	603022	0	B
hydrobromide	-	13	I
,	-	25	O
a	-	27	O
longer	-	29	O
acting	-	36	O
anticholinesterase	-	43	O
drug	-	62	O
,	-	66	O
in	-	68	O
the	-	71	O
treatment	-	75	O
of	-	85	O
the	-	88	O
central	-	92	O
effects	-	100	O
of	-	108	O
scopolamine	-	111	B
(	-	123	O
Hyoscine	-	124	B
)	-	132	O
.	-	133	O

Galanthamine	603022	135	B
hydrobromide	-	148	I
,	-	160	O
an	-	162	O
anticholinesterase	-	165	O
drug	-	184	O
capable	-	189	O
of	-	197	O
penetrating	-	200	O
the	-	212	O
blood	-	216	O
-	-	221	O
brain	-	222	O
barrier	-	228	O
,	-	235	O
was	-	237	O
used	-	241	O
in	-	246	O
a	-	249	O
patient	-	251	O
demonstrating	-	259	O
central	-	273	O
effects	-	281	O
of	-	289	O
scopolamine	-	292	B
(	-	304	O
hyoscine	-	305	B
)	-	313	O
overdosage	-	315	O
.	-	325	O

It	603022	327	O
is	-	330	O
longer	-	333	O
acting	-	340	O
than	-	347	O
physostigmine	-	352	B
and	-	366	O
is	-	370	O
used	-	373	O
in	-	378	O
anaesthesia	-	381	O
to	-	393	O
reverse	-	396	O
the	-	404	O
non	-	408	O
-	-	411	O
depolarizing	-	412	O
neuromuscular	-	425	O
block	-	439	O
.	-	444	O

However	603022	446	O
,	-	453	O
studies	-	455	O
into	-	463	O
the	-	468	O
dose	-	472	O
necessary	-	477	O
to	-	487	O
combating	-	490	O
scopolamine	-	500	B
intoxication	-	512	O
are	-	525	O
indicated	-	529	O
.	-	538	O

Effects	1378968	0	O
of	-	8	O
uninephrectomy	-	11	O
and	-	26	O
high	-	30	O
protein	-	35	O
feeding	-	43	O
on	-	51	O
lithium	-	54	B
-	-	61	O
induced	-	62	O
chronic	-	70	O
renal	-	78	O
failure	-	84	O
in	-	92	O
rats	-	95	O
.	-	99	O

Rats	1378968	101	O
with	-	106	O
lithium	-	111	B
-	-	118	O
induced	-	119	O
nephropathy	-	127	O
were	-	139	O
subjected	-	144	O
to	-	154	O
high	-	157	O
protein	-	162	O
(	-	170	O
HP	-	171	O
)	-	173	O
feeding	-	175	O
,	-	182	O
uninephrectomy	-	184	O
(	-	199	O
NX	-	200	O
)	-	202	O
or	-	204	O
a	-	207	O
combination	-	209	O
of	-	221	O
these	-	224	O
,	-	229	O
in	-	231	O
an	-	234	O
attempt	-	237	O
to	-	245	O
induce	-	248	O
glomerular	-	255	O
hyperfiltration	-	266	O
and	-	282	O
further	-	286	O
progression	-	294	O
of	-	306	O
renal	-	309	O
failure	-	315	O
.	-	322	O

Newborn	1378968	324	O
female	-	332	O
Wistar	-	339	O
rats	-	346	O
were	-	351	O
fed	-	356	O
a	-	360	O
lithium	-	362	B
-	-	369	O
containing	-	370	O
diet	-	381	O
(	-	386	O
50	-	387	O
mmol	-	390	O
/	-	394	O
kg	-	395	O
)	-	397	O
for	-	399	O
8	-	403	O
weeks	-	405	O
and	-	411	O
then	-	415	O
randomized	-	420	O
to	-	431	O
normal	-	434	O
diet	-	441	O
,	-	445	O
HP	-	447	O
diet	-	450	O
(	-	455	O
40	-	456	O
vs	-	459	O
.	-	461	O
19	-	463	O
%	-	465	O
)	-	466	O
,	-	467	O
NX	-	469	O
or	-	472	O
HP	-	475	O
+	-	477	O
NX	-	478	O
for	-	481	O
another	-	485	O
8	-	493	O
weeks	-	495	O
.	-	500	O

Corresponding	1378968	502	O
non	-	516	O
-	-	519	O
lithium	-	520	B
pretreated	-	528	O
groups	-	539	O
were	-	546	O
generated	-	551	O
.	-	560	O

When	1378968	562	O
comparing	-	567	O
all	-	577	O
lithium	-	581	B
treated	-	589	O
versus	-	597	O
non	-	604	O
-	-	607	O
lithium	-	608	B
-	-	615	O
treated	-	616	O
groups	-	624	O
,	-	630	O
lithium	-	632	B
caused	-	640	O
a	-	647	O
reduction	-	649	O
in	-	659	O
glomerular	-	662	O
filtration	-	673	O
rate	-	684	O
(	-	689	O
GFR	-	690	O
)	-	693	O
without	-	695	O
significant	-	703	O
changes	-	715	O
in	-	723	O
effective	-	726	O
renal	-	736	O
plasma	-	742	O
flow	-	749	O
(	-	754	O
as	-	755	O
determined	-	758	O
by	-	769	O
a	-	772	O
marker	-	774	O
secreted	-	781	O
into	-	790	O
the	-	795	O
proximal	-	799	O
tubules	-	808	O
)	-	815	O
or	-	817	O
lithium	-	820	B
clearance	-	828	O
.	-	837	O

Consequently	1378968	839	O
,	-	851	O
lithium	-	853	B
pretreatment	-	861	O
caused	-	874	O
a	-	881	O
fall	-	883	O
in	-	888	O
filtration	-	891	O
fraction	-	902	O
and	-	911	O
an	-	915	O
increase	-	918	O
in	-	927	O
fractional	-	930	O
Li	-	941	B
excretion	-	944	O
.	-	953	O

Lithium	1378968	955	B
also	-	963	O
caused	-	968	O
proteinuria	-	975	O
and	-	987	O
systolic	-	991	O
hypertension	-	1000	O
in	-	1013	O
absence	-	1016	O
of	-	1024	O
glomerulosclerosis	-	1027	O
.	-	1045	O

HP	1378968	1047	O
failed	-	1050	O
to	-	1057	O
accentuante	-	1060	O
progression	-	1072	O
of	-	1084	O
renal	-	1087	O
failure	-	1093	O
and	-	1101	O
in	-	1105	O
fact	-	1108	O
tended	-	1113	O
to	-	1120	O
increase	-	1123	O
GFR	-	1132	O
and	-	1136	O
decrease	-	1140	O
plasma	-	1149	O
creatinine	-	1156	B
levels	-	1167	O
in	-	1174	O
lithium	-	1177	B
pretreated	-	1185	O
rats	-	1196	O
.	-	1200	O

NX	1378968	1202	O
caused	-	1205	O
an	-	1212	O
additive	-	1215	O
deterioration	-	1224	O
in	-	1238	O
GFR	-	1241	O
which	-	1245	O
,	-	1250	O
however	-	1252	O
,	-	1259	O
was	-	1261	O
ameliorated	-	1265	O
by	-	1277	O
HP	-	1280	O
.	-	1282	O

NX	1378968	1284	O
+	-	1286	O
HP	-	1287	O
caused	-	1290	O
a	-	1297	O
further	-	1299	O
rise	-	1307	O
in	-	1312	O
blood	-	1315	O
pressure	-	1321	O
in	-	1330	O
Li	-	1333	B
-	-	1335	O
pretreated	-	1336	O
rats	-	1347	O
.	-	1351	O

The	1378968	1353	O
results	-	1357	O
indicate	-	1365	O
that	-	1374	O
Li	-	1379	B
-	-	1381	O
induced	-	1382	O
nephropathy	-	1390	O
,	-	1401	O
even	-	1403	O
when	-	1408	O
the	-	1413	O
GFR	-	1417	O
is	-	1421	O
only	-	1424	O
modestly	-	1429	O
reduced	-	1438	O
,	-	1445	O
is	-	1447	O
associated	-	1450	O
with	-	1461	O
proteinuria	-	1466	O
and	-	1478	O
arterial	-	1482	O
systolic	-	1491	O
hypertension	-	1500	O
.	-	1512	O

In	1378968	1514	O
this	-	1517	O
model	-	1522	O
of	-	1528	O
chronic	-	1531	O
renal	-	1539	O
failure	-	1545	O
the	-	1553	O
decline	-	1557	O
in	-	1565	O
GFR	-	1568	O
is	-	1572	O
not	-	1575	O
accompanied	-	1579	O
by	-	1591	O
a	-	1594	O
corresponding	-	1596	O
fall	-	1610	O
in	-	1615	O
effective	-	1618	O
renal	-	1628	O
plasma	-	1634	O
flow	-	1641	O
,	-	1645	O
which	-	1647	O
may	-	1653	O
be	-	1657	O
the	-	1660	O
functional	-	1664	O
expression	-	1675	O
of	-	1686	O
the	-	1689	O
formation	-	1693	O
of	-	1703	O
nonfiltrating	-	1706	O
atubular	-	1720	O
glomeruli	-	1729	O
.	-	1738	O

The	1378968	1740	O
fractional	-	1744	O
reabsorption	-	1755	O
of	-	1768	O
tubular	-	1771	O
fluid	-	1779	O
by	-	1785	O
the	-	1788	O
proximal	-	1792	O
tubules	-	1801	O
is	-	1809	O
reduced	-	1812	O
,	-	1819	O
leaving	-	1821	O
the	-	1829	O
distal	-	1833	O
delivery	-	1840	O
unchanged	-	1849	O
.	-	1858	O
(	-	1859	O
ABSTRACT	-	1860	O
TRUNCATED	-	1869	O
AT	-	1879	O
250	-	1882	O
WORDS	-	1886	O
)	-	1891	O

Treatment	1420741	0	O
of	-	10	O
Crohn	-	13	O
's	-	18	O
disease	-	21	O
with	-	29	O
fusidic	-	34	B
acid	-	42	I
:	-	46	O
an	-	48	O
antibiotic	-	51	O
with	-	62	O
immunosuppressive	-	67	O
properties	-	85	O
similar	-	96	O
to	-	104	O
cyclosporin	-	107	B
.	-	118	O

Fusidic	1420741	120	O
acid	-	128	O
is	-	133	O
an	-	136	O
antibiotic	-	139	O
with	-	150	O
T	-	155	O
-	-	156	O
cell	-	157	O
specific	-	162	O
immunosuppressive	-	171	O
effects	-	189	O
similar	-	197	O
to	-	205	O
those	-	208	O
of	-	214	O
cyclosporin	-	217	B
.	-	228	O

Because	1420741	230	O
of	-	238	O
the	-	241	O
need	-	245	O
for	-	250	O
the	-	254	O
development	-	258	O
of	-	270	O
new	-	273	O
treatments	-	277	O
for	-	288	O
Crohn	-	292	O
's	-	297	O
disease	-	300	O
,	-	307	O
a	-	309	O
pilot	-	311	O
study	-	317	O
was	-	323	O
undertaken	-	327	O
to	-	338	O
estimate	-	341	O
the	-	350	O
pharmacodynamics	-	354	O
and	-	371	O
tolerability	-	375	O
of	-	388	O
fusidic	-	391	B
acid	-	399	I
treatment	-	404	O
in	-	414	O
chronic	-	417	O
active	-	425	O
,	-	431	O
therapy	-	433	O
-	-	440	O
resistant	-	441	O
patients	-	451	O
.	-	459	O

Eight	1420741	461	O
Crohn	-	467	O
's	-	472	O
disease	-	475	O
patients	-	483	O
were	-	492	O
included	-	497	O
.	-	505	O

Fusidic	1420741	507	B
acid	-	515	I
was	-	520	O
administered	-	524	O
orally	-	537	O
in	-	544	O
a	-	547	O
dose	-	549	O
of	-	554	O
500	-	557	O
mg	-	561	O
t	-	564	O
.	-	565	O
d	-	566	O
.	-	567	O
s	-	568	O
.	-	569	O

and	1420741	571	O
the	-	575	O
treatment	-	579	O
was	-	589	O
planned	-	593	O
to	-	601	O
last	-	604	O
8	-	609	O
weeks	-	611	O
.	-	616	O

The	1420741	618	O
disease	-	622	O
activity	-	630	O
was	-	639	O
primarily	-	643	O
measured	-	653	O
by	-	662	O
a	-	665	O
modified	-	667	O
individual	-	676	O
grading	-	687	O
score	-	695	O
.	-	700	O

Five	1420741	702	O
of	-	707	O
8	-	710	O
patients	-	712	O
(	-	721	O
63	-	722	O
%	-	724	O
)	-	725	O
improved	-	727	O
during	-	736	O
fusidic	-	743	B
acid	-	751	I
treatment	-	756	O
:	-	765	O
3	-	767	O
at	-	769	O
two	-	772	O
weeks	-	776	O
and	-	782	O
2	-	786	O
after	-	788	O
four	-	794	O
weeks	-	799	O
.	-	804	O

There	1420741	806	O
were	-	812	O
no	-	817	O
serious	-	820	O
clinical	-	828	O
side	-	837	O
effects	-	842	O
,	-	849	O
but	-	851	O
dose	-	855	O
reduction	-	860	O
was	-	870	O
required	-	874	O
in	-	883	O
two	-	886	O
patients	-	890	O
because	-	899	O
of	-	907	O
nausea	-	910	O
.	-	916	O

Biochemically	1420741	918	O
,	-	931	O
an	-	933	O
increase	-	936	O
in	-	945	O
alkaline	-	948	O
phosphatases	-	957	O
was	-	970	O
noted	-	974	O
in	-	980	O
5	-	983	O
of	-	985	O
8	-	988	O
cases	-	990	O
(	-	996	O
63	-	997	O
%	-	999	O
)	-	1000	O
,	-	1001	O
and	-	1003	O
the	-	1007	O
greatest	-	1011	O
increases	-	1020	O
were	-	1030	O
seen	-	1035	O
in	-	1040	O
those	-	1043	O
who	-	1049	O
had	-	1053	O
elevated	-	1057	O
levels	-	1066	O
prior	-	1073	O
to	-	1079	O
treatment	-	1082	O
.	-	1091	O

All	1420741	1093	O
reversed	-	1097	O
to	-	1106	O
pre	-	1109	O
-	-	1112	O
treatment	-	1113	O
levels	-	1123	O
after	-	1130	O
cessation	-	1136	O
of	-	1146	O
treatment	-	1149	O
.	-	1158	O

The	1420741	1160	O
results	-	1164	O
of	-	1172	O
this	-	1175	O
pilot	-	1180	O
study	-	1186	O
suggest	-	1192	O
that	-	1200	O
fusidic	-	1205	B
acid	-	1213	I
may	-	1218	O
be	-	1222	O
of	-	1225	O
benefit	-	1228	O
in	-	1236	O
selected	-	1239	O
chronic	-	1248	O
active	-	1256	O
Crohn	-	1263	O
's	-	1268	O
disease	-	1271	O
patients	-	1279	O
in	-	1288	O
whom	-	1291	O
conventional	-	1296	O
treatment	-	1309	O
is	-	1319	O
ineffective	-	1322	O
.	-	1333	O

Because	1420741	1335	O
there	-	1343	O
seems	-	1349	O
to	-	1355	O
exist	-	1358	O
a	-	1364	O
scientific	-	1366	O
rationale	-	1377	O
for	-	1387	O
the	-	1391	O
use	-	1395	O
of	-	1399	O
fusidic	-	1402	B
acid	-	1410	I
at	-	1415	O
the	-	1418	O
cytokine	-	1422	O
level	-	1431	O
in	-	1437	O
inflammatory	-	1440	O
bowel	-	1453	O
disease	-	1459	O
,	-	1466	O
we	-	1468	O
suggest	-	1471	O
that	-	1479	O
the	-	1484	O
role	-	1488	O
of	-	1493	O
this	-	1496	O
treatment	-	1501	O
should	-	1511	O
be	-	1518	O
further	-	1521	O
investigated	-	1529	O
.	-	1541	O

Electrocardiographic	1601297	0	O
evidence	-	21	O
of	-	30	O
myocardial	-	33	O
injury	-	44	O
in	-	51	O
psychiatrically	-	54	O
hospitalized	-	70	O
cocaine	-	83	B
abusers	-	91	O
.	-	98	O

The	1601297	100	O
electrocardiograms	-	104	O
(	-	123	O
ECG	-	124	O
)	-	127	O
of	-	129	O
99	-	132	O
cocaine	-	135	B
-	-	142	O
abusing	-	143	O
patients	-	151	O
were	-	160	O
compared	-	165	O
with	-	174	O
the	-	179	O
ECGs	-	183	O
of	-	188	O
50	-	191	O
schizophrenic	-	194	O
controls	-	208	O
.	-	216	O

Eleven	1601297	218	O
of	-	225	O
the	-	228	O
cocaine	-	232	B
abusers	-	240	O
and	-	248	O
none	-	252	O
of	-	257	O
the	-	260	O
controls	-	264	O
had	-	273	O
ECG	-	277	O
evidence	-	281	O
of	-	290	O
significant	-	293	O
myocardial	-	305	O
injury	-	316	O
defined	-	323	O
as	-	331	O
myocardial	-	334	O
infarction	-	345	O
,	-	355	O
ischemia	-	357	O
,	-	365	O
and	-	367	O
bundle	-	371	O
branch	-	378	O
block	-	385	O
.	-	390	O

Sulpiride	1967484	0	B
-	-	9	O
induced	-	10	O
tardive	-	18	O
dystonia	-	26	O
.	-	34	O

Sulpiride	1967484	36	B
is	-	46	O
a	-	49	O
selective	-	51	O
D2	-	61	O
-	-	63	O
receptor	-	64	O
antagonist	-	73	O
with	-	84	O
antipsychotic	-	89	O
and	-	103	O
antidepressant	-	107	B
properties	-	122	O
.	-	132	O

Although	1967484	134	O
initially	-	143	O
thought	-	153	O
to	-	161	O
be	-	164	O
free	-	167	O
of	-	172	O
extrapyramidal	-	175	O
side	-	190	O
effects	-	195	O
,	-	202	O
sulpiride	-	204	B
-	-	213	O
induced	-	214	O
tardive	-	222	O
dyskinesia	-	230	O
and	-	241	O
parkinsonism	-	245	O
have	-	258	O
been	-	263	O
reported	-	268	O
occasionally	-	277	O
.	-	289	O

We	1967484	291	O
studied	-	294	O
a	-	302	O
37	-	304	O
-	-	306	O
year	-	307	O
-	-	311	O
old	-	312	O
man	-	316	O
who	-	320	O
developed	-	324	O
persistent	-	334	O
segmental	-	345	O
dystonia	-	355	O
within	-	364	O
2	-	371	O
months	-	373	O
after	-	380	O
starting	-	386	O
sulpiride	-	395	B
therapy	-	405	O
.	-	412	O

We	1967484	414	O
could	-	417	O
not	-	423	O
find	-	427	O
any	-	432	O
previous	-	436	O
reports	-	445	O
of	-	453	O
sulpiride	-	456	B
-	-	465	O
induced	-	466	O
tardive	-	474	O
dystonia	-	482	O
.	-	490	O

Ocular	2234245	0	O
and	-	7	O
auditory	-	11	O
toxicity	-	20	O
in	-	29	O
hemodialyzed	-	32	O
patients	-	45	O
receiving	-	54	O
desferrioxamine	-	64	B
.	-	79	O

During	2234245	81	O
an	-	88	O
18	-	91	O
-	-	93	O
month	-	94	O
period	-	100	O
of	-	107	O
study	-	110	O
41	-	116	O
hemodialyzed	-	119	O
patients	-	132	O
receiving	-	141	O
desferrioxamine	-	151	B
(	-	167	O
10	-	168	O
-	-	170	O
40	-	171	O
mg	-	174	O
/	-	176	O
kg	-	177	O
BW	-	180	O
/	-	182	O
3	-	183	O
times	-	185	O
weekly	-	191	O
)	-	197	O
for	-	199	O
the	-	203	O
first	-	207	O
time	-	213	O
were	-	218	O
monitored	-	223	O
for	-	233	O
detection	-	237	O
of	-	247	O
audiovisual	-	250	O
toxicity	-	262	O
.	-	270	O

6	2234245	272	O
patients	-	274	O
presented	-	283	O
clinical	-	293	O
symptoms	-	302	O
of	-	311	O
visual	-	314	O
or	-	321	O
auditory	-	324	O
toxicity	-	333	O
.	-	341	O

Moreover	2234245	343	O
,	-	351	O
detailed	-	353	O
ophthalmologic	-	362	O
and	-	377	O
audiologic	-	381	O
studies	-	392	O
disclosed	-	400	O
abnormalities	-	410	O
in	-	424	O
7	-	427	O
more	-	429	O
asymptomatic	-	434	O
patients	-	447	O
.	-	455	O

Visual	2234245	457	O
toxicity	-	464	O
was	-	473	O
of	-	477	O
retinal	-	480	O
origin	-	488	O
and	-	495	O
was	-	499	O
characterized	-	503	O
by	-	517	O
a	-	520	O
tritan	-	522	O
-	-	528	O
type	-	529	O
dyschromatopsy	-	534	O
,	-	548	O
sometimes	-	550	O
associated	-	560	O
with	-	571	O
a	-	576	O
loss	-	578	O
of	-	583	O
visual	-	586	O
acuity	-	593	O
and	-	600	O
pigmentary	-	604	O
retinal	-	615	O
deposits	-	623	O
.	-	631	O

Auditory	2234245	633	O
toxicity	-	642	O
was	-	651	O
characterized	-	655	O
by	-	669	O
a	-	672	O
mid	-	674	O
-	-	677	O
to	-	679	O
high	-	682	O
-	-	686	O
frequency	-	687	O
neurosensorial	-	697	O
hearing	-	712	O
loss	-	720	O
and	-	725	O
the	-	729	O
lesion	-	733	O
was	-	740	O
of	-	744	O
the	-	747	O
cochlear	-	751	O
type	-	760	O
.	-	764	O

Desferrioxamine	2234245	766	B
withdrawal	-	782	O
resulted	-	793	O
in	-	802	O
a	-	805	O
complete	-	807	O
recovery	-	816	O
of	-	825	O
visual	-	828	O
function	-	835	O
in	-	844	O
1	-	847	O
patient	-	849	O
and	-	857	O
partial	-	861	O
recovery	-	869	O
in	-	878	O
3	-	881	O
,	-	882	O
and	-	884	O
a	-	888	O
complete	-	890	O
reversal	-	899	O
of	-	908	O
hearing	-	911	O
loss	-	919	O
in	-	924	O
3	-	927	O
patients	-	929	O
and	-	938	O
partial	-	942	O
recovery	-	950	O
in	-	959	O
3	-	962	O
.	-	963	O

This	2234245	965	O
toxicity	-	970	O
appeared	-	979	O
in	-	988	O
patients	-	991	O
receiving	-	1000	O
the	-	1010	O
higher	-	1014	O
doses	-	1021	O
of	-	1027	O
desferrioxamine	-	1030	B
or	-	1046	O
coincided	-	1049	O
with	-	1059	O
the	-	1064	O
normalization	-	1068	O
of	-	1082	O
ferritin	-	1085	O
or	-	1094	O
aluminium	-	1097	B
serum	-	1107	O
levels	-	1113	O
.	-	1119	O

The	2234245	1121	O
data	-	1125	O
indicate	-	1130	O
that	-	1139	O
audiovisual	-	1144	O
toxicity	-	1156	O
is	-	1165	O
not	-	1168	O
an	-	1172	O
infrequent	-	1175	O
complication	-	1186	O
in	-	1199	O
hemodialyzed	-	1202	O
patients	-	1215	O
receiving	-	1224	O
desferrioxamine	-	1234	B
.	-	1249	O

Periodical	2234245	1251	O
audiovisual	-	1262	O
monitoring	-	1274	O
should	-	1285	O
be	-	1292	O
performed	-	1295	O
on	-	1305	O
hemodialyzed	-	1308	O
patients	-	1321	O
receiving	-	1330	O
the	-	1340	O
drug	-	1344	O
in	-	1349	O
order	-	1352	O
to	-	1358	O
detect	-	1361	O
adverse	-	1368	O
effects	-	1376	O
as	-	1384	O
early	-	1387	O
as	-	1393	O
possible	-	1396	O
.	-	1404	O

Myasthenia	2385256	0	O
gravis	-	11	O
presenting	-	18	O
as	-	29	O
weakness	-	32	O
after	-	41	O
magnesium	-	47	B
administration	-	57	O
.	-	71	O

We	2385256	73	O
studied	-	76	O
a	-	84	O
patient	-	86	O
with	-	94	O
no	-	99	O
prior	-	102	O
history	-	108	O
of	-	116	O
neuromuscular	-	119	O
disease	-	133	O
who	-	141	O
became	-	145	O
virtually	-	152	O
quadriplegic	-	162	O
after	-	175	O
parenteral	-	181	O
magnesium	-	192	B
administration	-	202	O
for	-	217	O
preeclampsia	-	221	O
.	-	233	O

The	2385256	235	O
serum	-	239	O
magnesium	-	245	B
concentration	-	255	O
was	-	269	O
3	-	273	O
.	-	274	O
0	-	275	O
mEq	-	277	O
/	-	280	O
L	-	281	O
,	-	282	O
which	-	284	O
is	-	290	O
usually	-	293	O
well	-	301	O
tolerated	-	306	O
.	-	315	O

The	2385256	317	O
magnesium	-	321	B
was	-	331	O
stopped	-	335	O
and	-	343	O
she	-	347	O
recovered	-	351	O
over	-	361	O
a	-	366	O
few	-	368	O
days	-	372	O
.	-	376	O

While	2385256	378	O
she	-	384	O
was	-	388	O
weak	-	392	O
,	-	396	O
2	-	398	O
-	-	399	O
Hz	-	400	O
repetitive	-	403	O
stimulation	-	414	O
revealed	-	426	O
a	-	435	O
decrement	-	437	O
without	-	447	O
significant	-	455	O
facilitation	-	467	O
at	-	480	O
rapid	-	483	O
rates	-	489	O
or	-	495	O
after	-	498	O
exercise	-	504	O
,	-	512	O
suggesting	-	514	O
postsynaptic	-	525	O
neuromuscular	-	538	O
blockade	-	552	O
.	-	560	O

After	2385256	562	O
her	-	568	O
strength	-	572	O
returned	-	581	O
,	-	589	O
repetitive	-	591	O
stimulation	-	602	O
was	-	614	O
normal	-	618	O
,	-	624	O
but	-	626	O
single	-	630	O
fiber	-	637	O
EMG	-	643	O
revealed	-	647	O
increased	-	656	O
jitter	-	666	O
and	-	673	O
blocking	-	677	O
.	-	685	O

Her	2385256	687	O
acetylcholine	-	691	B
receptor	-	705	O
antibody	-	714	O
level	-	723	O
was	-	729	O
markedly	-	733	O
elevated	-	742	O
.	-	750	O

Although	2385256	752	O
paralysis	-	761	O
after	-	771	O
magnesium	-	777	B
administration	-	787	O
has	-	802	O
been	-	806	O
described	-	811	O
in	-	821	O
patients	-	824	O
with	-	833	O
known	-	838	O
myasthenia	-	844	O
gravis	-	855	O
,	-	861	O
it	-	863	O
has	-	866	O
not	-	870	O
previously	-	874	O
been	-	885	O
reported	-	890	O
to	-	899	O
be	-	902	O
the	-	905	O
initial	-	909	O
or	-	917	O
only	-	920	O
manifestation	-	925	O
of	-	939	O
the	-	942	O
disease	-	946	O
.	-	953	O

Patients	2385256	955	O
who	-	964	O
are	-	968	O
unusually	-	972	O
sensitive	-	982	O
to	-	992	O
the	-	995	O
neuromuscular	-	999	O
effects	-	1013	O
of	-	1021	O
magnesium	-	1024	B
should	-	1034	O
be	-	1041	O
suspected	-	1044	O
of	-	1054	O
having	-	1057	O
an	-	1064	O
underlying	-	1067	O
disorder	-	1078	O
of	-	1087	O
neuromuscular	-	1090	O
transmission	-	1104	O
.	-	1116	O

Chloroacetaldehyde	2505783	0	B
and	-	19	O
its	-	23	O
contribution	-	27	O
to	-	40	O
urotoxicity	-	43	O
during	-	55	O
treatment	-	62	O
with	-	72	O
cyclophosphamide	-	77	B
or	-	94	O
ifosfamide	-	97	B
.	-	107	O

An	2505783	109	O
experimental	-	112	O
study	-	125	O
/	-	130	O
short	-	131	O
communication	-	137	O
.	-	150	O

Based	2505783	152	O
on	-	158	O
clinical	-	161	O
data	-	170	O
,	-	174	O
indicating	-	176	O
that	-	187	O
chloroacetaldehyde	-	192	B
(	-	211	O
CAA	-	212	B
)	-	215	O
is	-	217	O
an	-	220	O
important	-	223	O
metabolite	-	233	O
of	-	244	O
oxazaphosphorine	-	247	O
cytostatics	-	264	O
,	-	275	O
an	-	277	O
experimental	-	280	O
study	-	293	O
was	-	299	O
carried	-	303	O
out	-	311	O
in	-	315	O
order	-	318	O
to	-	324	O
elucidate	-	327	O
the	-	337	O
role	-	341	O
of	-	346	O
CAA	-	349	B
in	-	353	O
the	-	356	O
development	-	360	O
of	-	372	O
hemorrhagic	-	375	O
cystitis	-	387	O
.	-	395	O

The	2505783	397	O
data	-	401	O
demonstrate	-	406	O
that	-	418	O
CAA	-	423	B
after	-	427	O
i	-	433	O
.	-	434	O
v	-	435	O
.	-	436	O

administration	2505783	438	O
does	-	453	O
not	-	458	O
contribute	-	462	O
to	-	473	O
bladder	-	476	O
damage	-	484	O
.	-	490	O

When	2505783	492	O
instilled	-	497	O
directly	-	507	O
into	-	516	O
the	-	521	O
bladder	-	525	O
,	-	532	O
CAA	-	534	B
exerts	-	538	O
urotoxic	-	545	O
effects	-	554	O
,	-	561	O
it	-	563	O
is	-	566	O
,	-	568	O
however	-	570	O
,	-	577	O
susceptible	-	579	O
to	-	591	O
detoxification	-	594	O
with	-	609	O
mesna	-	614	B
.	-	619	O

Source	2515254	0	O
of	-	7	O
pain	-	10	O
and	-	15	O
primitive	-	19	O
dysfunction	-	29	O
in	-	41	O
migraine	-	44	O
:	-	52	O
an	-	54	O
identical	-	57	O
site	-	67	O
?	-	71	O

Twenty	2515254	73	O
common	-	80	O
migraine	-	87	O
patients	-	96	O
received	-	105	O
a	-	114	O
one	-	116	O
sided	-	120	O
frontotemporal	-	126	O
application	-	141	O
of	-	153	O
nitroglycerin	-	156	B
(	-	170	O
10	-	171	O
patients	-	174	O
)	-	182	O
or	-	184	O
placebo	-	187	O
ointment	-	195	O
(	-	204	O
10	-	205	O
patients	-	208	O
)	-	216	O
in	-	218	O
a	-	221	O
double	-	223	O
blind	-	230	O
study	-	236	O
.	-	241	O

Early	2515254	243	O
onset	-	249	O
migraine	-	255	O
attacks	-	264	O
were	-	272	O
induced	-	277	O
by	-	285	O
nitroglycerin	-	288	B
in	-	302	O
seven	-	305	O
out	-	311	O
of	-	315	O
10	-	318	O
patients	-	321	O
versus	-	330	O
no	-	337	O
patient	-	340	O
in	-	348	O
the	-	351	O
placebo	-	355	O
group	-	363	O
.	-	368	O

Subsequently	2515254	370	O
20	-	383	O
migraine	-	386	O
patients	-	395	O
,	-	403	O
who	-	405	O
developed	-	409	O
an	-	419	O
early	-	422	O
onset	-	428	O
attack	-	434	O
with	-	441	O
frontotemporal	-	446	O
nitroglycerin	-	461	B
,	-	474	O
received	-	476	O
the	-	485	O
drug	-	489	O
in	-	494	O
a	-	497	O
second	-	499	O
induction	-	506	O
test	-	516	O
at	-	521	O
other	-	524	O
body	-	530	O
areas	-	535	O
.	-	540	O

No	2515254	542	O
early	-	545	O
onset	-	551	O
migraine	-	557	O
was	-	566	O
observed	-	570	O
.	-	578	O

Thus	2515254	580	O
the	-	585	O
migraine	-	589	O
-	-	597	O
inducing	-	598	O
effect	-	607	O
of	-	614	O
nitroglycerin	-	617	B
seems	-	631	O
to	-	637	O
depend	-	640	O
on	-	647	O
direct	-	650	O
stimulation	-	657	O
of	-	669	O
the	-	672	O
habitual	-	676	O
site	-	685	O
of	-	690	O
pain	-	693	O
,	-	697	O
suggesting	-	699	O
that	-	710	O
the	-	715	O
frontotemporal	-	719	O
region	-	734	O
is	-	741	O
of	-	744	O
crucial	-	747	O
importance	-	755	O
in	-	766	O
the	-	769	O
development	-	773	O
of	-	785	O
a	-	788	O
migraine	-	790	O
crisis	-	799	O
.	-	805	O

This	2515254	807	O
is	-	812	O
not	-	815	O
consistent	-	819	O
with	-	830	O
a	-	835	O
CNS	-	837	O
origin	-	841	O
of	-	848	O
migraine	-	851	O
attack	-	860	O
.	-	866	O

Clotiazepam	2572625	0	B
-	-	11	O
induced	-	12	O
acute	-	20	O
hepatitis	-	26	O
.	-	35	O

We	2572625	37	O
report	-	40	O
the	-	47	O
case	-	51	O
of	-	56	O
a	-	59	O
patient	-	61	O
who	-	69	O
developed	-	73	O
acute	-	83	O
hepatitis	-	89	O
with	-	99	O
extensive	-	104	O
hepatocellular	-	114	O
necrosis	-	129	O
,	-	137	O
7	-	139	O
months	-	141	O
after	-	148	O
the	-	154	O
onset	-	158	O
of	-	164	O
administration	-	167	O
of	-	182	O
clotiazepam	-	185	B
,	-	196	O
a	-	198	O
thienodiazepine	-	200	B
derivative	-	216	O
.	-	226	O

Clotiazepam	2572625	228	B
withdrawal	-	240	O
was	-	251	O
followed	-	255	O
by	-	264	O
prompt	-	267	O
recovery	-	274	O
.	-	282	O

The	2572625	284	O
administration	-	288	O
of	-	303	O
several	-	306	O
benzodiazepines	-	314	B
,	-	329	O
chemically	-	331	O
related	-	342	O
to	-	350	O
clotiazepam	-	353	B
,	-	364	O
did	-	366	O
not	-	370	O
interfere	-	374	O
with	-	384	O
recovery	-	389	O
and	-	398	O
did	-	402	O
not	-	406	O
induce	-	410	O
any	-	417	O
relapse	-	421	O
of	-	429	O
hepatitis	-	432	O
.	-	441	O

This	2572625	443	O
observation	-	448	O
shows	-	460	O
that	-	466	O
clotiazepam	-	471	B
can	-	483	O
induce	-	487	O
acute	-	494	O
hepatitis	-	500	O
and	-	510	O
suggests	-	514	O
that	-	523	O
there	-	528	O
is	-	534	O
no	-	537	O
cross	-	540	O
hepatotoxicity	-	546	O
between	-	561	O
clotiazepam	-	569	B
and	-	581	O
several	-	585	O
benzodiazepines	-	593	B
.	-	608	O

Arterial	2632720	0	O
hypertension	-	9	O
as	-	22	O
a	-	25	O
complication	-	27	O
of	-	40	O
prolonged	-	43	O
ketoconazole	-	53	B
treatment	-	66	O
.	-	75	O

Two	2632720	77	O
of	-	81	O
14	-	84	O
patients	-	87	O
with	-	96	O
Cushing	-	101	O
's	-	108	O
syndrome	-	111	O
treated	-	120	O
on	-	128	O
a	-	131	O
long	-	133	O
-	-	137	O
term	-	138	O
basis	-	143	O
with	-	149	O
ketoconazole	-	154	B
developed	-	167	O
sustained	-	177	O
hypertension	-	187	O
.	-	199	O

In	2632720	201	O
both	-	204	O
cases	-	209	O
normal	-	215	O
plasma	-	222	O
and	-	229	O
urinary	-	233	O
free	-	241	O
cortisol	-	246	B
levels	-	255	O
had	-	262	O
been	-	266	O
achieved	-	271	O
following	-	280	O
ketoconazole	-	290	B
therapy	-	303	O
,	-	310	O
yet	-	312	O
continuous	-	316	O
blood	-	327	O
pressure	-	333	O
monitoring	-	342	O
demonstrated	-	353	O
hypertension	-	366	O
31	-	379	O
(	-	382	O
patient	-	383	O
1	-	391	O
)	-	392	O
and	-	394	O
52	-	398	O
weeks	-	401	O
(	-	407	O
patient	-	408	O
2	-	416	O
)	-	417	O
after	-	419	O
treatment	-	425	O
.	-	434	O

In	2632720	436	O
patient	-	439	O
1	-	447	O
,	-	448	O
plasma	-	450	O
levels	-	457	O
of	-	464	O
deoxycorticosterone	-	467	B
and	-	487	O
11	-	491	B
-	-	493	I
deoxycortisol	-	494	I
were	-	508	O
elevated	-	513	O
.	-	521	O

In	2632720	523	O
patient	-	526	O
2	-	534	O
,	-	535	O
in	-	537	O
addition	-	540	O
to	-	549	O
an	-	552	O
increase	-	555	O
in	-	564	O
both	-	567	O
deoxycorticosterone	-	572	B
and	-	592	O
11	-	596	B
-	-	598	I
deoxycortisol	-	599	I
levels	-	613	O
,	-	619	O
plasma	-	621	O
aldosterone	-	628	B
values	-	640	O
were	-	647	O
raised	-	652	O
,	-	658	O
with	-	660	O
a	-	665	O
concomitant	-	667	O
suppression	-	679	O
of	-	691	O
renin	-	694	O
levels	-	700	O
.	-	706	O

Our	2632720	708	O
findings	-	712	O
show	-	721	O
that	-	726	O
long	-	731	O
-	-	735	O
term	-	736	O
treatment	-	741	O
with	-	751	O
high	-	756	O
doses	-	761	O
of	-	767	O
ketoconazole	-	770	B
may	-	783	O
induce	-	787	O
enzyme	-	794	O
blockade	-	801	O
leading	-	810	O
to	-	818	O
mineralocorticoid	-	821	O
-	-	838	O
related	-	839	O
hypertension	-	847	O
.	-	859	O

Effects	2670794	0	O
of	-	8	O
an	-	11	O
inhibitor	-	14	O
of	-	24	O
angiotensin	-	27	B
converting	-	39	O
enzyme	-	50	O
(	-	57	O
Captopril	-	58	B
)	-	67	O
on	-	69	O
pulmonary	-	72	O
and	-	82	O
renal	-	86	O
insufficiency	-	92	O
due	-	106	O
to	-	110	O
intravascular	-	113	O
coagulation	-	127	O
in	-	139	O
the	-	142	O
rat	-	146	O
.	-	149	O

Induction	2670794	151	O
of	-	161	O
intravascular	-	164	O
coagulation	-	178	O
and	-	190	O
inhibition	-	194	O
of	-	205	O
fibrinolysis	-	208	O
by	-	221	O
injection	-	224	O
of	-	234	O
thrombin	-	237	O
and	-	246	O
tranexamic	-	250	B
acid	-	261	I
(	-	266	O
AMCA	-	267	B
)	-	271	O
in	-	273	O
the	-	276	O
rat	-	280	O
gives	-	284	O
rise	-	290	O
to	-	295	O
pulmonary	-	298	O
and	-	308	O
renal	-	312	O
insufficiency	-	318	O
resembling	-	332	O
that	-	343	O
occurring	-	348	O
after	-	358	O
trauma	-	364	O
or	-	371	O
sepsis	-	374	O
in	-	381	O
man	-	384	O
.	-	387	O

Injection	2670794	389	O
of	-	399	O
Captopril	-	402	B
(	-	412	O
1	-	413	O
mg	-	415	O
/	-	417	O
kg	-	418	O
)	-	420	O
,	-	421	O
an	-	423	O
inhibitor	-	426	O
of	-	436	O
angiotensin	-	439	B
converting	-	451	O
enzyme	-	462	O
(	-	469	O
ACE	-	470	O
)	-	473	O
,	-	474	O
reduced	-	476	O
both	-	484	O
pulmonary	-	489	O
and	-	499	O
renal	-	503	O
insufficiency	-	509	O
in	-	523	O
this	-	526	O
rat	-	531	O
model	-	535	O
.	-	540	O

The	2670794	542	O
lung	-	546	O
weights	-	551	O
were	-	559	O
lower	-	564	O
and	-	570	O
PaO2	-	574	O
was	-	579	O
improved	-	583	O
in	-	592	O
rats	-	595	O
given	-	600	O
this	-	606	O
enzyme	-	611	O
-	-	617	O
blocking	-	618	O
agent	-	627	O
.	-	632	O

The	2670794	634	O
contents	-	638	O
of	-	647	O
albumin	-	650	O
in	-	658	O
the	-	661	O
lungs	-	665	O
were	-	671	O
not	-	676	O
changed	-	680	O
,	-	687	O
indicating	-	689	O
that	-	700	O
Captopril	-	705	B
did	-	715	O
not	-	719	O
influence	-	723	O
the	-	733	O
extravasation	-	737	O
of	-	751	O
protein	-	754	O
.	-	761	O

Renal	2670794	763	O
damage	-	769	O
as	-	776	O
reflected	-	779	O
by	-	789	O
an	-	792	O
increase	-	795	O
in	-	804	O
serum	-	807	O
urea	-	813	B
and	-	818	O
in	-	822	O
kidney	-	825	O
weight	-	832	O
was	-	839	O
prevented	-	843	O
by	-	853	O
Captopril	-	856	B
.	-	865	O

The	2670794	867	O
amount	-	871	O
of	-	878	O
fibrin	-	881	O
in	-	888	O
the	-	891	O
kidneys	-	895	O
was	-	903	O
also	-	907	O
considerably	-	912	O
lower	-	925	O
than	-	931	O
in	-	936	O
animals	-	939	O
which	-	947	O
received	-	953	O
thrombin	-	962	O
and	-	971	O
AMCA	-	975	B
alone	-	980	O
.	-	985	O

It	2670794	987	O
is	-	990	O
suggested	-	993	O
that	-	1003	O
the	-	1008	O
effects	-	1012	O
of	-	1020	O
Captopril	-	1023	B
on	-	1033	O
the	-	1036	O
lungs	-	1040	O
may	-	1046	O
be	-	1050	O
attributable	-	1053	O
to	-	1066	O
a	-	1069	O
vasodilatory	-	1071	O
effect	-	1084	O
due	-	1091	O
to	-	1095	O
a	-	1098	O
reduction	-	1100	O
in	-	1110	O
the	-	1113	O
circulating	-	1117	O
level	-	1129	O
of	-	1135	O
Angiotension	-	1138	B
II	-	1151	I
and	-	1154	O
an	-	1158	O
increase	-	1161	O
in	-	1170	O
prostacyclin	-	1173	B
(	-	1186	O
secondary	-	1187	O
to	-	1197	O
an	-	1200	O
increase	-	1203	O
in	-	1212	O
bradykinin	-	1215	B
)	-	1225	O
.	-	1226	O

Captopril	2670794	1228	B
may	-	1238	O
,	-	1241	O
by	-	1243	O
the	-	1246	O
same	-	1250	O
mechanism	-	1255	O
,	-	1264	O
reduce	-	1266	O
the	-	1273	O
increase	-	1277	O
in	-	1286	O
glomerular	-	1289	O
filtration	-	1300	O
that	-	1311	O
is	-	1316	O
known	-	1319	O
to	-	1325	O
occur	-	1328	O
after	-	1334	O
an	-	1340	O
injection	-	1343	O
of	-	1353	O
thrombin	-	1356	O
,	-	1364	O
thereby	-	1366	O
diminishing	-	1374	O
the	-	1386	O
aggregation	-	1390	O
of	-	1402	O
fibrin	-	1405	O
monomers	-	1412	O
in	-	1421	O
the	-	1424	O
glomeruli	-	1428	O
,	-	1437	O
with	-	1439	O
the	-	1444	O
result	-	1448	O
that	-	1455	O
less	-	1460	O
fibrin	-	1465	O
will	-	1472	O
be	-	1477	O
deposited	-	1480	O
and	-	1490	O
thus	-	1494	O
less	-	1499	O
kidney	-	1504	O
damage	-	1511	O
will	-	1518	O
be	-	1523	O
produced	-	1526	O
.	-	1534	O

A	2696505	0	O
randomized	-	2	O
comparison	-	13	O
of	-	24	O
labetalol	-	27	B
and	-	37	O
nitroprusside	-	41	B
for	-	55	O
induced	-	59	O
hypotension	-	67	O
.	-	78	O

In	2696505	80	O
a	-	83	O
randomized	-	85	O
study	-	96	O
,	-	101	O
labetalol	-	103	B
-	-	112	O
induced	-	113	O
hypotension	-	121	O
and	-	133	O
nitroprusside	-	137	B
-	-	150	O
induced	-	151	O
hypotension	-	159	O
were	-	171	O
compared	-	176	O
in	-	185	O
20	-	188	O
patients	-	191	O
(	-	200	O
10	-	201	O
in	-	204	O
each	-	207	O
group	-	212	O
)	-	217	O
scheduled	-	219	O
for	-	229	O
major	-	233	O
orthopedic	-	239	O
procedures	-	250	O
.	-	260	O

Each	2696505	262	O
patient	-	267	O
was	-	275	O
subjected	-	279	O
to	-	289	O
an	-	292	O
identical	-	295	O
anesthetic	-	305	O
protocol	-	316	O
and	-	325	O
similar	-	329	O
drug	-	337	O
-	-	341	O
induced	-	342	O
reductions	-	350	O
in	-	361	O
mean	-	364	O
arterial	-	369	O
blood	-	378	O
pressure	-	384	O
(	-	393	O
BP	-	394	O
)	-	396	O
(	-	398	O
50	-	399	O
to	-	402	O
55	-	405	O
mmHg	-	408	O
)	-	412	O
.	-	413	O

Nitroprusside	2696505	415	O
infusion	-	429	O
was	-	438	O
associated	-	442	O
with	-	453	O
a	-	458	O
significant	-	460	O
(	-	472	O
p	-	473	O
less	-	475	O
than	-	480	O
0	-	485	O
.	-	486	O
05	-	487	O
)	-	489	O
increase	-	491	O
in	-	500	O
heart	-	503	O
rate	-	509	O
and	-	514	O
cardiac	-	518	O
output	-	526	O
;	-	532	O
rebound	-	534	O
hypertension	-	542	O
was	-	555	O
observed	-	559	O
in	-	568	O
three	-	571	O
patients	-	577	O
after	-	586	O
discontinuation	-	592	O
of	-	608	O
nitroprusside	-	611	B
.	-	624	O

Labetalol	2696505	626	B
administration	-	636	O
was	-	651	O
not	-	655	O
associated	-	659	O
with	-	670	O
any	-	675	O
of	-	679	O
these	-	682	O
findings	-	688	O
.	-	696	O

Arterial	2696505	698	O
PO2	-	707	B
decreased	-	711	O
in	-	721	O
both	-	724	O
groups	-	729	O
.	-	735	O

It	2696505	737	O
was	-	740	O
concluded	-	744	O
that	-	754	O
labetalol	-	759	B
offers	-	769	O
advantages	-	776	O
over	-	787	O
nitroprusside	-	792	B
.	-	805	O

Chronic	2924746	0	O
carbamazepine	-	8	B
treatment	-	22	O
in	-	32	O
the	-	35	O
rat	-	39	O
:	-	42	O
efficacy	-	44	O
,	-	52	O
toxicity	-	54	O
,	-	62	O
and	-	64	O
effect	-	68	O
on	-	75	O
plasma	-	78	O
and	-	85	O
tissue	-	89	O
folate	-	96	B
concentrations	-	103	O
.	-	117	O

Folate	2924746	119	B
depletion	-	126	O
has	-	136	O
often	-	140	O
been	-	146	O
a	-	151	O
problem	-	153	O
in	-	161	O
chronic	-	164	O
antiepileptic	-	172	O
drug	-	186	O
(	-	191	O
AED	-	192	O
)	-	195	O
therapy	-	197	O
.	-	204	O

Carbamazepine	2924746	206	B
(	-	220	O
CBZ	-	221	B
)	-	224	O
,	-	225	O
a	-	227	O
commonly	-	229	O
used	-	238	O
AED	-	243	O
,	-	246	O
has	-	248	O
been	-	252	O
implicated	-	257	O
in	-	268	O
some	-	271	O
clinical	-	276	O
studies	-	285	O
.	-	292	O

A	2924746	294	O
rat	-	296	O
model	-	300	O
was	-	306	O
developed	-	310	O
to	-	320	O
examine	-	323	O
the	-	331	O
effects	-	335	O
of	-	343	O
chronic	-	346	O
CBZ	-	354	B
treatment	-	358	O
on	-	368	O
folate	-	371	B
concentrations	-	378	O
in	-	393	O
the	-	396	O
rat	-	400	O
.	-	403	O

In	2924746	405	O
the	-	408	O
course	-	412	O
of	-	419	O
developing	-	422	O
this	-	433	O
model	-	438	O
,	-	443	O
a	-	445	O
common	-	447	O
vehicle	-	454	O
,	-	461	O
propylene	-	463	B
glycol	-	473	I
,	-	479	O
by	-	481	O
itself	-	484	O
in	-	491	O
high	-	494	O
doses	-	499	O
,	-	504	O
was	-	506	O
found	-	510	O
to	-	516	O
exhibit	-	519	O
protective	-	527	O
properties	-	538	O
against	-	549	O
induced	-	557	O
seizures	-	565	O
and	-	574	O
inhibited	-	578	O
weight	-	588	O
gain	-	595	O
.	-	599	O

Seizures	2924746	601	O
induced	-	610	O
by	-	618	O
hexafluorodiethyl	-	621	B
ether	-	639	I
(	-	645	O
HFDE	-	646	B
)	-	650	O
were	-	652	O
also	-	657	O
found	-	662	O
to	-	668	O
be	-	671	O
a	-	674	O
more	-	676	O
sensitive	-	681	O
measure	-	691	O
of	-	699	O
protection	-	702	O
by	-	713	O
CBZ	-	716	B
than	-	720	O
seizures	-	725	O
induced	-	734	O
by	-	742	O
maximal	-	745	O
electroshock	-	753	O
(	-	766	O
MES	-	767	O
)	-	770	O
.	-	771	O

Oral	2924746	773	O
administration	-	778	O
of	-	793	O
CBZ	-	796	B
as	-	800	O
an	-	803	O
aqueous	-	806	O
suspension	-	814	O
every	-	825	O
8	-	831	O
h	-	833	O
at	-	835	O
a	-	838	O
dose	-	840	O
of	-	845	O
250	-	848	O
mg	-	852	O
/	-	854	O
kg	-	855	O
was	-	858	O
continuously	-	862	O
protective	-	875	O
against	-	886	O
HFDE	-	894	B
-	-	898	O
induced	-	899	O
seizures	-	907	O
and	-	916	O
was	-	920	O
minimally	-	924	O
toxic	-	934	O
as	-	940	O
measured	-	943	O
by	-	952	O
weight	-	955	O
gain	-	962	O
over	-	967	O
8	-	972	O
weeks	-	974	O
of	-	980	O
treatment	-	983	O
.	-	992	O

The	2924746	994	O
CBZ	-	998	B
levels	-	1002	O
measured	-	1009	O
in	-	1018	O
plasma	-	1021	O
and	-	1028	O
brain	-	1032	O
of	-	1038	O
these	-	1041	O
animals	-	1047	O
,	-	1054	O
however	-	1056	O
,	-	1063	O
were	-	1065	O
below	-	1070	O
those	-	1076	O
normally	-	1082	O
considered	-	1091	O
protective	-	1102	O
.	-	1112	O

This	2924746	1114	O
treatment	-	1119	O
with	-	1129	O
CBZ	-	1134	B
had	-	1138	O
no	-	1142	O
apparent	-	1145	O
adverse	-	1154	O
effect	-	1162	O
on	-	1169	O
folate	-	1172	B
concentrations	-	1179	O
in	-	1194	O
the	-	1197	O
rat	-	1201	O
,	-	1204	O
and	-	1206	O
,	-	1209	O
indeed	-	1211	O
,	-	1217	O
the	-	1219	O
folate	-	1223	B
concentration	-	1230	O
increased	-	1244	O
in	-	1254	O
liver	-	1257	O
after	-	1263	O
6	-	1269	O
weeks	-	1271	O
of	-	1277	O
treatment	-	1280	O
and	-	1290	O
in	-	1294	O
plasma	-	1297	O
at	-	1304	O
8	-	1307	O
weeks	-	1309	O
of	-	1315	O
treatment	-	1318	O
.	-	1327	O

Inhibition	2951327	0	O
of	-	11	O
sympathoadrenal	-	14	O
activity	-	30	O
by	-	39	O
atrial	-	42	O
natriuretic	-	49	O
factor	-	61	O
in	-	68	O
dogs	-	71	O
.	-	75	O

In	2951327	77	O
six	-	80	O
conscious	-	84	O
,	-	93	O
trained	-	95	O
dogs	-	103	O
,	-	107	O
maintained	-	109	O
on	-	120	O
a	-	123	O
normal	-	125	O
sodium	-	132	B
intake	-	139	O
of	-	146	O
2	-	149	O
to	-	151	O
4	-	154	O
mEq	-	156	O
/	-	159	O
kg	-	160	O
/	-	162	O
day	-	163	O
,	-	166	O
sympathetic	-	168	O
activity	-	180	O
was	-	189	O
assessed	-	193	O
as	-	202	O
the	-	205	O
release	-	209	O
rate	-	217	O
of	-	222	O
norepinephrine	-	225	B
and	-	240	O
epinephrine	-	244	B
during	-	256	O
15	-	263	O
-	-	265	O
minute	-	266	O
i	-	273	O
.	-	274	O
v	-	275	O
.	-	276	O

infusions	2951327	278	O
of	-	288	O
human	-	291	O
alpha	-	297	O
-	-	302	O
atrial	-	303	O
natriuretic	-	310	O
factor	-	322	O
.	-	328	O

Mean	2951327	330	O
arterial	-	335	O
pressure	-	344	O
(	-	353	O
as	-	354	O
a	-	357	O
percentage	-	359	O
of	-	370	O
control	-	373	O
+	-	381	O
/	-	382	O
-	-	383	O

SEM	2951327	385	O
)	-	388	O
during	-	390	O
randomized	-	397	O
infusions	-	408	O
of	-	418	O
0	-	421	O
.	-	422	O
03	-	423	O
,	-	425	O
0	-	427	O
.	-	428	O
1	-	429	O
,	-	430	O
0	-	432	O
.	-	433	O
3	-	434	O
,	-	435	O
or	-	437	O
1	-	440	O
.	-	441	O
0	-	442	O
microgram	-	444	O
/	-	453	O
kg	-	454	O
/	-	456	O
min	-	457	O
was	-	461	O
99	-	465	O
+	-	468	O
/	-	469	O
-	-	470	O

1	2951327	472	O
,	-	473	O
95	-	475	O
+	-	478	O
/	-	479	O
-	-	480	O

1	2951327	482	O
(	-	484	O
p	-	485	O
less	-	487	O
than	-	492	O
0	-	497	O
.	-	498	O
05	-	499	O
)	-	501	O
,	-	502	O
93	-	504	O
+	-	507	O
/	-	508	O
-	-	509	O

1	2951327	511	O
(	-	513	O
p	-	514	O
less	-	516	O
than	-	521	O
0	-	526	O
.	-	527	O
01	-	528	O
)	-	530	O
,	-	531	O
or	-	533	O
79	-	536	O
+	-	539	O
/	-	540	O
-	-	541	O

6	2951327	543	O
%	-	544	O
(	-	546	O
p	-	547	O
less	-	549	O
than	-	554	O
0	-	559	O
.	-	560	O
001	-	561	O
)	-	564	O
,	-	565	O
respectively	-	567	O
,	-	579	O
but	-	581	O
no	-	585	O
tachycardia	-	588	O
and	-	600	O
no	-	604	O
augmentation	-	607	O
of	-	620	O
the	-	623	O
norepinephrine	-	627	B
release	-	642	O
rate	-	650	O
(	-	655	O
up	-	656	O
to	-	659	O
0	-	662	O
.	-	663	O
3	-	664	O
microgram	-	666	O
/	-	675	O
kg	-	676	O
/	-	678	O
min	-	679	O
)	-	682	O
were	-	684	O
observed	-	689	O
,	-	697	O
which	-	699	O
is	-	705	O
in	-	708	O
contrast	-	711	O
to	-	720	O
comparable	-	723	O
hypotension	-	734	O
induced	-	746	O
by	-	754	O
hydralazine	-	757	B
or	-	769	O
nitroglycerin	-	772	B
.	-	785	O

The	2951327	787	O
release	-	791	O
rate	-	799	O
of	-	804	O
epinephrine	-	807	B
(	-	819	O
control	-	820	O
,	-	827	O
6	-	829	O
.	-	830	O
7	-	831	O
+	-	833	O
/	-	834	O
-	-	835	O

0	2951327	837	O
.	-	838	O
6	-	839	O
ng	-	841	O
/	-	843	O
kg	-	844	O
/	-	846	O
min	-	847	O
)	-	850	O
declined	-	852	O
immediately	-	861	O
during	-	873	O
infusions	-	880	O
of	-	890	O
atrial	-	893	O
natriuretic	-	900	O
factor	-	912	O
to	-	919	O
a	-	922	O
minimum	-	924	O
of	-	932	O
49	-	935	O
+	-	938	O
/	-	939	O
-	-	940	O

5	2951327	942	O
%	-	943	O
of	-	945	O
control	-	948	O
(	-	956	O
p	-	957	O
less	-	959	O
than	-	964	O
0	-	969	O
.	-	970	O
001	-	971	O
)	-	974	O
during	-	976	O
0	-	983	O
.	-	984	O
1	-	985	O
microgram	-	987	O
/	-	996	O
kg	-	997	O
/	-	999	O
min	-	1000	O
and	-	1004	O
to	-	1008	O
63	-	1011	O
+	-	1014	O
/	-	1015	O
-	-	1016	O

5	2951327	1018	O
%	-	1019	O
(	-	1021	O
0	-	1022	O
.	-	1023	O
1	-	1024	O
greater	-	1026	O
than	-	1034	O
p	-	1039	O
greater	-	1041	O
than	-	1049	O
0	-	1054	O
.	-	1055	O
05	-	1056	O
)	-	1058	O
or	-	1060	O
95	-	1063	O
+	-	1066	O
/	-	1067	O
-	-	1068	O

13	2951327	1070	O
%	-	1072	O
(	-	1074	O
not	-	1075	O
significant	-	1079	O
)	-	1090	O
during	-	1092	O
0	-	1099	O
.	-	1100	O
3	-	1101	O
or	-	1103	O
1	-	1106	O
.	-	1107	O
0	-	1108	O
microgram	-	1110	O
/	-	1119	O
kg	-	1120	O
/	-	1122	O
min	-	1123	O
.	-	1126	O

Steady	2951327	1128	O
state	-	1135	O
arterial	-	1141	O
plasma	-	1150	O
concentrations	-	1157	O
of	-	1172	O
atrial	-	1175	O
natriuretic	-	1182	O
factor	-	1194	O
were	-	1201	O
39	-	1206	O
+	-	1209	O
/	-	1210	O
-	-	1211	O

10	2951327	1213	O
pg	-	1216	O
/	-	1218	O
ml	-	1219	O
(	-	1222	O
n	-	1223	O
=	-	1225	O
6	-	1227	O
)	-	1228	O
during	-	1230	O
infusions	-	1237	O
of	-	1247	O
saline	-	1250	O
and	-	1257	O
284	-	1261	O
+	-	1265	O
/	-	1266	O
-	-	1267	O

24	2951327	1269	O
pg	-	1272	O
/	-	1274	O
ml	-	1275	O
(	-	1278	O
n	-	1279	O
=	-	1281	O
6	-	1283	O
)	-	1284	O
and	-	1286	O
1520	-	1290	O
+	-	1295	O
/	-	1296	O
-	-	1297	O

300	2951327	1299	O
pg	-	1303	O
/	-	1305	O
ml	-	1306	O
(	-	1309	O
n	-	1310	O
=	-	1312	O
9	-	1314	O
)	-	1315	O
during	-	1317	O
0	-	1324	O
.	-	1325	O
03	-	1326	O
and	-	1329	O
0	-	1333	O
.	-	1334	O
1	-	1335	O
microgram	-	1337	O
/	-	1346	O
kg	-	1347	O
/	-	1349	O
min	-	1350	O
infusions	-	1354	O
of	-	1364	O
the	-	1367	O
factor	-	1371	O
.	-	1377	O
(	-	1378	O
ABSTRACT	-	1379	O
TRUNCATED	-	1388	O
AT	-	1398	O
250	-	1401	O
WORDS	-	1405	O
)	-	1410	O

Death	3192036	0	O
from	-	6	O
chemotherapy	-	11	O
in	-	24	O
gestational	-	27	O
trophoblastic	-	39	O
disease	-	53	O
.	-	60	O

Multiple	3192036	62	O
cytotoxic	-	71	O
drug	-	81	O
administration	-	86	O
is	-	101	O
the	-	104	O
generally	-	108	O
accepted	-	118	O
treatment	-	127	O
of	-	137	O
patients	-	140	O
with	-	149	O
a	-	154	O
high	-	156	O
-	-	160	O
risk	-	161	O
stage	-	166	O
of	-	172	O
choriocarcinoma	-	175	O
.	-	190	O

Based	3192036	192	O
on	-	198	O
this	-	201	O
principle	-	206	O
a	-	216	O
27	-	218	O
-	-	220	O
year	-	221	O
old	-	226	O
woman	-	230	O
,	-	235	O
classified	-	237	O
as	-	248	O
being	-	251	O
in	-	257	O
the	-	260	O
high	-	264	O
-	-	268	O
risk	-	269	O
group	-	274	O
(	-	280	O
Goldstein	-	281	O
and	-	291	O
Berkowitz	-	295	O
score	-	305	O
:	-	310	O
11	-	312	O
)	-	314	O
,	-	315	O
was	-	317	O
treated	-	321	O
with	-	329	O
multiple	-	334	O
cytotoxic	-	343	O
drugs	-	353	O
.	-	358	O

The	3192036	360	O
multiple	-	364	O
drug	-	373	O
schema	-	378	O
consisted	-	385	O
of	-	395	O
:	-	397	O
Etoposide	-	399	B
16	-	409	O
.	-	411	O
213	-	412	O
,	-	415	O
Methotrexate	-	417	B
,	-	429	O
Cyclophosphamide	-	431	B
,	-	447	O
Actomycin	-	449	B
-	-	458	I
D	-	459	I
,	-	460	O
and	-	462	O
Cisplatin	-	466	B
.	-	475	O

On	3192036	477	O
the	-	480	O
first	-	484	O
day	-	490	O
of	-	494	O
the	-	497	O
schedule	-	501	O
,	-	509	O
moderate	-	511	O
high	-	520	O
doses	-	525	O
of	-	531	O
Methotrexate	-	534	B
,	-	546	O
Etoposide	-	548	B
and	-	558	O
Cyclophosphamide	-	562	B
were	-	579	O
administered	-	584	O
.	-	596	O

Within	3192036	598	O
8	-	605	O
hours	-	607	O
after	-	613	O
initiation	-	619	O
of	-	630	O
therapy	-	633	O
the	-	641	O
patient	-	645	O
died	-	653	O
with	-	658	O
a	-	663	O
clinical	-	665	O
picture	-	674	O
resembling	-	682	O
massive	-	693	O
pulmonary	-	701	O
obstruction	-	711	O
due	-	723	O
to	-	727	O
choriocarcinomic	-	730	O
tissue	-	747	O
plugs	-	754	O
,	-	759	O
probably	-	761	O
originating	-	770	O
from	-	782	O
the	-	787	O
uterus	-	791	O
.	-	797	O

Formation	3192036	799	O
of	-	809	O
these	-	812	O
plugs	-	818	O
was	-	824	O
probably	-	828	O
due	-	837	O
to	-	841	O
extensive	-	844	O
tumor	-	854	O
necrosis	-	860	O
at	-	869	O
the	-	872	O
level	-	876	O
of	-	882	O
the	-	885	O
walls	-	889	O
of	-	895	O
the	-	898	O
major	-	902	O
uterine	-	908	O
veins	-	916	O
,	-	921	O
which	-	923	O
resulted	-	929	O
in	-	938	O
an	-	941	O
open	-	944	O
exchange	-	949	O
of	-	958	O
tumor	-	961	O
plugs	-	967	O
to	-	973	O
the	-	976	O
vascular	-	980	O
spaces	-	989	O
;	-	995	O
decrease	-	997	O
in	-	1006	O
tumor	-	1009	O
tissue	-	1015	O
coherence	-	1022	O
secondary	-	1032	O
to	-	1042	O
chemotherapy	-	1045	O
may	-	1058	O
have	-	1062	O
further	-	1067	O
contributed	-	1075	O
to	-	1087	O
the	-	1090	O
formation	-	1094	O
of	-	1104	O
tumor	-	1107	O
emboli	-	1113	O
.	-	1119	O

In	3192036	1121	O
view	-	1124	O
of	-	1129	O
the	-	1132	O
close	-	1136	O
time	-	1142	O
association	-	1147	O
between	-	1159	O
the	-	1167	O
start	-	1171	O
of	-	1177	O
chemotherapy	-	1180	O
and	-	1193	O
the	-	1197	O
acute	-	1201	O
onset	-	1207	O
of	-	1213	O
massive	-	1216	O
embolism	-	1224	O
other	-	1233	O
explanations	-	1239	O
,	-	1251	O
such	-	1253	O
as	-	1258	O
spontaneous	-	1261	O
necrosis	-	1273	O
,	-	1281	O
must	-	1283	O
be	-	1288	O
considered	-	1291	O
less	-	1302	O
likely	-	1307	O
.	-	1313	O

Patients	3192036	1315	O
with	-	1324	O
large	-	1329	O
pelvic	-	1335	O
tumor	-	1342	O
loads	-	1348	O
are	-	1354	O
,	-	1357	O
according	-	1359	O
to	-	1369	O
existing	-	1372	O
classifications	-	1381	O
,	-	1396	O
at	-	1398	O
high	-	1401	O
risk	-	1406	O
to	-	1411	O
die	-	1414	O
and	-	1418	O
to	-	1422	O
develop	-	1425	O
drug	-	1433	O
resistance	-	1438	O
.	-	1448	O

Notwithstanding	3192036	1450	O
these	-	1466	O
facts	-	1472	O
our	-	1478	O
findings	-	1482	O
suggest	-	1491	O
that	-	1499	O
these	-	1504	O
patients	-	1510	O
might	-	1519	O
benefit	-	1525	O
from	-	1533	O
relatively	-	1538	O
mild	-	1549	O
initial	-	1554	O
treatment	-	1562	O
,	-	1571	O
especially	-	1573	O
true	-	1584	O
for	-	1589	O
patients	-	1593	O
not	-	1602	O
previously	-	1606	O
exposed	-	1617	O
to	-	1625	O
this	-	1628	O
drug	-	1633	O
.	-	1637	O

Close	3192036	1639	O
observation	-	1645	O
of	-	1657	O
the	-	1660	O
response	-	1664	O
status	-	1673	O
both	-	1680	O
clinically	-	1685	O
and	-	1696	O
with	-	1700	O
beta	-	1705	O
-	-	1709	O
hCG	-	1710	O
values	-	1714	O
may	-	1721	O
indicate	-	1725	O
whether	-	1734	O
and	-	1742	O
when	-	1746	O
more	-	1751	O
agressive	-	1756	O
combination	-	1766	O
chemotherapy	-	1778	O
should	-	1791	O
be	-	1798	O
started	-	1801	O
.	-	1808	O
(	-	1809	O
ABSTRACT	-	1810	O
TRUNCATED	-	1819	O
AT	-	1829	O
250	-	1832	O
WORDS	-	1836	O
)	-	1841	O

Sexual	3409645	0	O
dysfunction	-	7	O
among	-	19	O
patients	-	25	O
with	-	34	O
arthritis	-	39	O
.	-	48	O

The	3409645	50	O
relationship	-	54	O
of	-	67	O
arthritis	-	70	O
and	-	80	O
sexual	-	84	O
dysfunction	-	91	O
was	-	103	O
investigated	-	107	O
among	-	120	O
169	-	126	O
patients	-	130	O
with	-	139	O
rheumatoid	-	144	O
arthritis	-	155	O
,	-	164	O
osteoarthritis	-	166	O
and	-	181	O
spondyloarthropathy	-	185	O
,	-	204	O
130	-	206	O
of	-	210	O
whom	-	213	O
were	-	218	O
pair	-	223	O
-	-	227	O
matched	-	228	O
to	-	236	O
controls	-	239	O
.	-	247	O

Assessments	3409645	249	O
of	-	261	O
marital	-	264	O
happiness	-	272	O
and	-	282	O
depressed	-	286	O
mood	-	296	O
were	-	301	O
also	-	306	O
made	-	311	O
using	-	316	O
the	-	322	O
CES	-	326	O
-	-	329	O
D	-	330	O
and	-	332	O
the	-	336	O
Azrin	-	340	O
Marital	-	346	O
Happiness	-	354	O
Scale	-	364	O
(	-	370	O
AMHS	-	371	O
)	-	375	O
.	-	376	O

Sexual	3409645	378	O
dysfunctions	-	385	O
were	-	398	O
found	-	403	O
to	-	409	O
be	-	412	O
common	-	415	O
among	-	422	O
patients	-	428	O
and	-	437	O
controls	-	441	O
,	-	449	O
the	-	451	O
majority	-	455	O
in	-	464	O
both	-	467	O
groups	-	472	O
reporting	-	479	O
one	-	489	O
or	-	493	O
more	-	496	O
dysfunctions	-	501	O
.	-	513	O

Impotence	3409645	515	O
was	-	525	O
more	-	529	O
common	-	534	O
among	-	541	O
male	-	547	O
patients	-	552	O
than	-	561	O
controls	-	566	O
and	-	575	O
was	-	579	O
found	-	583	O
to	-	589	O
be	-	592	O
associated	-	595	O
with	-	606	O
co	-	611	O
-	-	613	O
morbidity	-	614	O
and	-	624	O
the	-	628	O
taking	-	632	O
of	-	639	O
methotrexate	-	642	B
.	-	654	O

Depressed	3409645	656	O
mood	-	666	O
was	-	671	O
more	-	675	O
common	-	680	O
among	-	687	O
patients	-	693	O
and	-	702	O
was	-	706	O
associated	-	710	O
with	-	721	O
certain	-	726	O
sexual	-	734	O
difficulties	-	741	O
,	-	753	O
but	-	755	O
not	-	759	O
with	-	763	O
impotence	-	768	O
.	-	777	O

Marital	3409645	779	O
unhappiness	-	787	O
,	-	798	O
as	-	800	O
indicated	-	803	O
by	-	813	O
AMHS	-	816	O
scores	-	821	O
,	-	827	O
was	-	829	O
not	-	833	O
associated	-	837	O
with	-	848	O
arthritis	-	853	O
but	-	863	O
was	-	867	O
associated	-	871	O
with	-	882	O
sexual	-	887	O
dysfunction	-	894	O
,	-	905	O
sexual	-	907	O
dissatisfaction	-	914	O
and	-	930	O
being	-	934	O
female	-	940	O
.	-	946	O

Does	3412544	0	O
paracetamol	-	5	B
cause	-	17	O
urothelial	-	23	O
cancer	-	34	O
or	-	41	O
renal	-	44	O
papillary	-	50	O
necrosis	-	60	O
?	-	68	O

The	3412544	70	O
risk	-	74	O
of	-	79	O
developing	-	82	O
renal	-	93	O
papillary	-	99	O
necrosis	-	109	O
or	-	118	O
cancer	-	121	O
of	-	128	O
the	-	131	O
renal	-	135	O
pelvis	-	141	O
,	-	147	O
ureter	-	149	O
or	-	156	O
bladder	-	159	O
associated	-	167	O
with	-	178	O
consumption	-	183	O
of	-	195	O
either	-	198	O
phenacetin	-	205	B
or	-	216	O
paracetamol	-	219	B
was	-	231	O
calculated	-	235	O
from	-	246	O
data	-	251	O
acquired	-	256	O
by	-	265	O
questionnaire	-	268	O
from	-	282	O
381	-	287	O
cases	-	291	O
and	-	297	O
808	-	301	O
controls	-	305	O
.	-	313	O

The	3412544	315	O
risk	-	319	O
of	-	324	O
renal	-	327	O
papillary	-	333	O
necrosis	-	343	O
was	-	352	O
increased	-	356	O
nearly	-	366	O
20	-	373	O
-	-	375	O
fold	-	376	O
by	-	381	O
consumption	-	384	O
of	-	396	O
phenacetin	-	399	B
,	-	409	O
which	-	411	O
also	-	417	O
increased	-	422	O
the	-	432	O
risk	-	436	O
for	-	441	O
cancer	-	445	O
of	-	452	O
the	-	455	O
renal	-	459	O
pelvis	-	465	O
and	-	472	O
bladder	-	476	O
but	-	484	O
not	-	488	O
for	-	492	O
ureteric	-	496	O
cancer	-	505	O
.	-	511	O

By	3412544	513	O
contrast	-	516	O
,	-	524	O
we	-	526	O
were	-	529	O
unable	-	534	O
to	-	541	O
substantiate	-	544	O
an	-	557	O
increased	-	560	O
risk	-	570	O
from	-	575	O
paracetamol	-	580	B
consumption	-	592	O
for	-	604	O
renal	-	608	O
papillary	-	614	O
necrosis	-	624	O
or	-	633	O
any	-	636	O
of	-	640	O
these	-	643	O
cancers	-	649	O
although	-	657	O
there	-	666	O
was	-	672	O
a	-	676	O
suggestion	-	678	O
of	-	689	O
an	-	692	O
association	-	695	O
with	-	707	O
cancer	-	712	O
of	-	719	O
the	-	722	O
ureter	-	726	O
.	-	732	O

Dapsone	3425586	0	B
-	-	7	O
associated	-	8	O
Heinz	-	19	O
body	-	25	O
hemolytic	-	30	O
anemia	-	40	O
in	-	47	O
a	-	50	O
Cambodian	-	52	O
woman	-	62	O
with	-	68	O
hemoglobin	-	73	O
E	-	84	O
trait	-	86	O
.	-	91	O

A	3425586	93	O
Cambodian	-	95	O
woman	-	105	O
with	-	111	O
hemoglobin	-	116	O
E	-	127	O
trait	-	129	O
(	-	135	O
AE	-	136	O
)	-	138	O
and	-	140	O
leprosy	-	144	O
developed	-	152	O
a	-	162	O
Heinz	-	164	O
body	-	170	O
hemolytic	-	175	O
anemia	-	185	O
while	-	192	O
taking	-	198	O
a	-	205	O
dose	-	207	O
of	-	212	O
dapsone	-	215	B
(	-	223	O
50	-	224	O
mg	-	227	O
/	-	229	O
day	-	230	O
)	-	233	O
not	-	235	O
usually	-	239	O
associated	-	247	O
with	-	258	O
clinical	-	263	O
hemolysis	-	272	O
.	-	281	O

Her	3425586	283	O
red	-	287	O
blood	-	291	O
cells	-	297	O
(	-	303	O
RBCs	-	304	O
)	-	308	O
had	-	310	O
increased	-	314	O
incubated	-	324	O
Heinz	-	334	O
body	-	340	O
formation	-	345	O
,	-	354	O
decreased	-	356	O
reduced	-	366	O
glutathione	-	374	B
(	-	386	O
GSH	-	387	B
)	-	390	O
,	-	391	O
and	-	393	O
decreased	-	397	O
GSH	-	407	B
stability	-	411	O
.	-	420	O

The	3425586	422	O
pentose	-	426	B
phosphate	-	434	I
shunt	-	444	O
activity	-	450	O
of	-	459	O
the	-	462	O
dapsone	-	466	B
-	-	473	O
exposed	-	474	O
AE	-	482	O
RBCs	-	485	O
was	-	490	O
increased	-	494	O
compared	-	504	O
to	-	513	O
normal	-	516	O
RBCs	-	523	O
.	-	527	O

Although	3425586	529	O
the	-	538	O
AE	-	542	O
RBCs	-	545	O
from	-	550	O
an	-	555	O
individual	-	558	O
not	-	569	O
taking	-	573	O
dapsone	-	580	B
had	-	588	O
increased	-	592	O
incubated	-	602	O
Heinz	-	612	O
body	-	618	O
formation	-	623	O
,	-	632	O
the	-	634	O
GSH	-	638	B
content	-	642	O
and	-	650	O
GSH	-	654	B
stability	-	658	O
were	-	668	O
normal	-	673	O
.	-	679	O

The	3425586	681	O
pentose	-	685	B
phosphate	-	693	I
shunt	-	703	O
activity	-	709	O
of	-	718	O
the	-	721	O
non	-	725	O
-	-	728	O
dapsone	-	729	B
-	-	736	O
exposed	-	737	O
AE	-	745	O
RBCs	-	748	O
was	-	753	O
decreased	-	757	O
compared	-	767	O
to	-	776	O
normal	-	779	O
RBCs	-	786	O
.	-	790	O

Thus	3425586	792	O
,	-	796	O
AE	-	798	O
RBCs	-	801	O
appear	-	806	O
to	-	813	O
have	-	816	O
an	-	821	O
increased	-	824	O
sensitivity	-	834	O
to	-	846	O
oxidant	-	849	O
stress	-	857	O
both	-	864	O
in	-	869	O
vitro	-	872	O
and	-	878	O
in	-	882	O
vivo	-	885	O
,	-	889	O
since	-	891	O
dapsone	-	897	B
does	-	905	O
not	-	910	O
cause	-	914	O
hemolytic	-	920	O
anemia	-	930	O
at	-	937	O
this	-	940	O
dose	-	945	O
in	-	950	O
hematologically	-	953	O
normal	-	969	O
individuals	-	976	O
.	-	987	O

Given	3425586	989	O
the	-	995	O
influx	-	999	O
of	-	1006	O
Southeast	-	1009	O
Asians	-	1019	O
into	-	1026	O
the	-	1031	O
United	-	1035	O
States	-	1042	O
,	-	1048	O
oxidant	-	1050	O
medications	-	1058	O
should	-	1070	O
be	-	1077	O
used	-	1080	O
with	-	1085	O
caution	-	1090	O
,	-	1097	O
especially	-	1099	O
if	-	1110	O
an	-	1113	O
infection	-	1116	O
is	-	1126	O
present	-	1129	O
,	-	1136	O
in	-	1138	O
individuals	-	1141	O
of	-	1153	O
ethnic	-	1156	O
backgrounds	-	1163	O
that	-	1175	O
have	-	1180	O
an	-	1185	O
increased	-	1188	O
prevalence	-	1198	O
of	-	1209	O
hemoglobin	-	1212	O
E	-	1223	O
.	-	1224	O

Severe	3437726	0	O
complications	-	7	O
of	-	21	O
antianginal	-	24	O
drug	-	36	O
therapy	-	41	O
in	-	49	O
a	-	52	O
patient	-	54	O
identified	-	62	O
as	-	73	O
a	-	76	O
poor	-	78	O
metabolizer	-	83	O
of	-	95	O
metoprolol	-	98	B
,	-	108	O
propafenone	-	110	B
,	-	121	O
diltiazem	-	123	B
,	-	132	O
and	-	134	O
sparteine	-	138	B
.	-	147	O

A	3437726	149	O
47	-	151	O
-	-	153	O
year	-	154	O
-	-	158	O
old	-	159	O
patient	-	163	O
suffering	-	171	O
from	-	181	O
coronary	-	186	O
artery	-	195	O
disease	-	202	O
was	-	210	O
admitted	-	214	O
to	-	223	O
the	-	226	O
CCU	-	230	O
in	-	234	O
shock	-	237	O
with	-	243	O
III	-	248	O
.	-	251	O

AV	3437726	253	O
block	-	256	O
,	-	261	O
severe	-	263	O
hypotension	-	270	O
,	-	281	O
and	-	283	O
impairment	-	287	O
of	-	298	O
ventricular	-	301	O
function	-	313	O
.	-	321	O

One	3437726	323	O
week	-	327	O
prior	-	332	O
to	-	338	O
admission	-	341	O
a	-	351	O
therapy	-	353	O
with	-	361	O
standard	-	366	O
doses	-	375	O
of	-	381	O
metoprolol	-	384	B
(	-	395	O
100	-	396	O
mg	-	400	O
t	-	403	O
.	-	404	O
i	-	405	O
.	-	406	O
d	-	407	O
.	-	408	O

and	3437726	410	O
then	-	414	O
100	-	419	O
mg	-	423	O
b	-	426	O
.	-	427	O
i	-	428	O
.	-	429	O
d	-	430	O
.	-	431	O
)	-	432	O
had	-	434	O
been	-	438	O
initiated	-	443	O
.	-	452	O

Two	3437726	454	O
days	-	458	O
before	-	463	O
admission	-	470	O
diltiazem	-	480	B
(	-	490	O
60	-	491	O
mg	-	494	O
b	-	497	O
.	-	498	O
i	-	499	O
.	-	500	O
d	-	501	O
.	-	502	O
)	-	503	O
was	-	505	O
prescribed	-	509	O
in	-	520	O
addition	-	523	O
.	-	531	O

Analyses	3437726	533	O
of	-	542	O
a	-	545	O
blood	-	547	O
sample	-	553	O
revealed	-	560	O
unusually	-	569	O
high	-	579	O
plasma	-	584	O
concentrations	-	591	O
of	-	606	O
metoprolol	-	609	B
(	-	620	O
greater	-	621	O
than	-	629	O
3000	-	634	O
ng	-	639	O
/	-	641	O
ml	-	642	O
)	-	644	O
and	-	646	O
diltiazem	-	650	B
(	-	660	O
526	-	661	O
ng	-	665	O
/	-	667	O
ml	-	668	O
)	-	670	O
.	-	671	O

The	3437726	673	O
patient	-	677	O
recovered	-	685	O
within	-	695	O
1	-	702	O
week	-	704	O
following	-	709	O
discontinuation	-	719	O
of	-	735	O
antianginal	-	738	O
therapy	-	750	O
.	-	757	O

Three	3437726	759	O
months	-	765	O
later	-	772	O
the	-	778	O
patient	-	782	O
was	-	790	O
exposed	-	794	O
to	-	802	O
a	-	805	O
single	-	807	O
dose	-	814	O
of	-	819	O
metoprolol	-	822	B
,	-	832	O
diltiazem	-	834	B
,	-	843	O
propafenone	-	845	B
(	-	857	O
since	-	858	O
he	-	864	O
had	-	867	O
received	-	871	O
this	-	880	O
drug	-	885	O
in	-	890	O
the	-	893	O
past	-	897	O
)	-	901	O
,	-	902	O
and	-	904	O
sparteine	-	908	B
(	-	918	O
as	-	919	O
a	-	922	O
probe	-	924	O
for	-	930	O
the	-	934	O
debrisoquine	-	938	B
/	-	950	O
sparteine	-	951	B
type	-	961	O
polymorphism	-	966	O
of	-	979	O
oxidative	-	982	O
drug	-	992	O
metabolism	-	997	O
)	-	1007	O
.	-	1008	O

It	3437726	1010	O
was	-	1013	O
found	-	1017	O
that	-	1023	O
he	-	1028	O
was	-	1031	O
a	-	1035	O
poor	-	1037	O
metabolizer	-	1042	O
of	-	1054	O
all	-	1057	O
four	-	1061	O
drugs	-	1066	O
,	-	1071	O
indicating	-	1073	O
that	-	1084	O
their	-	1089	O
metabolism	-	1095	O
is	-	1106	O
under	-	1109	O
the	-	1115	O
same	-	1119	O
genetic	-	1124	O
control	-	1132	O
.	-	1139	O

Therefore	3437726	1141	O
,	-	1150	O
patients	-	1152	O
belonging	-	1161	O
to	-	1171	O
the	-	1174	O
poor	-	1178	O
-	-	1182	O
metabolizer	-	1183	O
phenotype	-	1195	O
of	-	1205	O
sparteine	-	1208	B
/	-	1217	O
debrisoquine	-	1218	B
polymorphism	-	1231	O
in	-	1244	O
drug	-	1247	O
metabolism	-	1252	O
,	-	1262	O
which	-	1264	O
constitutes	-	1270	O
6	-	1282	O
.	-	1283	O
4	-	1284	O
%	-	1285	O
of	-	1287	O
the	-	1290	O
German	-	1294	O
population	-	1301	O
,	-	1311	O
may	-	1313	O
experience	-	1317	O
adverse	-	1328	O
drug	-	1336	O
reactions	-	1341	O
when	-	1351	O
treated	-	1356	O
with	-	1364	O
standard	-	1369	O
doses	-	1378	O
of	-	1384	O
one	-	1387	O
of	-	1391	O
these	-	1394	O
drugs	-	1400	O
alone	-	1406	O
.	-	1411	O

Moreover	3437726	1413	O
,	-	1421	O
the	-	1423	O
coadministration	-	1427	O
of	-	1444	O
these	-	1447	O
frequently	-	1453	O
used	-	1464	O
drugs	-	1469	O
is	-	1475	O
expected	-	1478	O
to	-	1487	O
be	-	1490	O
especially	-	1493	O
harmful	-	1504	O
in	-	1512	O
this	-	1515	O
subgroup	-	1520	O
of	-	1529	O
patients	-	1532	O
.	-	1540	O

Triazolam	3693336	0	B
-	-	9	O
induced	-	10	O
brief	-	18	O
episodes	-	24	O
of	-	33	O
secondary	-	36	O
mania	-	46	O
in	-	52	O
a	-	55	O
depressed	-	57	O
patient	-	67	O
.	-	74	O

Large	3693336	76	O
doses	-	82	O
of	-	88	O
triazolam	-	91	B
repeatedly	-	101	O
induced	-	112	O
brief	-	120	O
episodes	-	126	O
of	-	135	O
mania	-	138	O
in	-	144	O
a	-	147	O
depressed	-	149	O
elderly	-	159	O
woman	-	167	O
.	-	172	O

Features	3693336	174	O
of	-	183	O
organic	-	186	O
mental	-	194	O
disorder	-	201	O
(	-	210	O
delirium	-	211	O
)	-	219	O
were	-	221	O
not	-	226	O
present	-	230	O
.	-	237	O

Manic	3693336	239	O
excitement	-	245	O
was	-	256	O
coincident	-	260	O
with	-	271	O
the	-	276	O
duration	-	280	O
of	-	289	O
action	-	292	O
of	-	299	O
triazolam	-	302	B
.	-	311	O

The	3693336	313	O
possible	-	317	O
contribution	-	326	O
of	-	339	O
the	-	342	O
triazolo	-	346	B
group	-	355	O
to	-	361	O
changes	-	364	O
in	-	372	O
affective	-	375	O
status	-	385	O
is	-	392	O
discussed	-	395	O
.	-	404	O

On	3780846	0	O
the	-	3	O
mechanisms	-	7	O
of	-	18	O
the	-	21	O
development	-	25	O
of	-	37	O
tolerance	-	40	O
to	-	50	O
the	-	53	O
muscular	-	57	O
rigidity	-	66	O
produced	-	75	O
by	-	84	O
morphine	-	87	B
in	-	96	O
rats	-	99	O
.	-	103	O

The	3780846	105	O
development	-	109	O
of	-	121	O
tolerance	-	124	O
to	-	134	O
the	-	137	O
muscular	-	141	O
rigidity	-	150	O
produced	-	159	O
by	-	168	O
morphine	-	171	B
was	-	180	O
studied	-	184	O
in	-	192	O
rats	-	195	O
.	-	199	O

Saline	3780846	201	O
-	-	207	O
pretreated	-	208	O
controls	-	219	O
given	-	228	O
a	-	234	O
test	-	236	O
dose	-	241	O
of	-	246	O
morphine	-	249	B
(	-	258	O
20	-	259	O
mg	-	262	O
/	-	264	O
kg	-	265	O
i	-	268	O
.	-	269	O
p	-	270	O
.	-	271	O
)	-	272	O
showed	-	274	O
a	-	281	O
pronounced	-	283	O
rigidity	-	294	O
recorded	-	303	O
as	-	312	O
tonic	-	315	O
activity	-	321	O
in	-	330	O
the	-	333	O
electromyogram	-	337	O
.	-	351	O

Rats	3780846	353	O
treated	-	358	O
for	-	366	O
11	-	370	O
days	-	373	O
with	-	378	O
morphine	-	383	B
and	-	392	O
withdrawn	-	396	O
for	-	406	O
36	-	410	O
-	-	412	O
40	-	413	O
h	-	416	O
showed	-	418	O
differences	-	425	O
in	-	437	O
the	-	440	O
development	-	444	O
of	-	456	O
tolerance	-	459	O
:	-	468	O
about	-	470	O
half	-	476	O
of	-	481	O
the	-	484	O
animals	-	488	O
showed	-	496	O
a	-	503	O
rigidity	-	505	O
after	-	514	O
the	-	520	O
test	-	524	O
dose	-	529	O
of	-	534	O
morphine	-	537	B
that	-	546	O
was	-	551	O
not	-	555	O
significantly	-	559	O
less	-	573	O
than	-	578	O
in	-	583	O
the	-	586	O
controls	-	590	O
and	-	599	O
were	-	603	O
akinetic	-	608	O
(	-	617	O
A	-	618	O
group	-	620	O
)	-	625	O
.	-	626	O

The	3780846	628	O
other	-	632	O
rats	-	638	O
showed	-	643	O
a	-	650	O
strong	-	652	O
decrease	-	659	O
in	-	668	O
the	-	671	O
rigidity	-	675	O
and	-	684	O
the	-	688	O
occurrence	-	692	O
of	-	703	O
stereotyped	-	706	O
(	-	718	O
S	-	719	O
)	-	720	O
licking	-	722	O
and	-	730	O
/	-	733	O
or	-	734	O
gnawing	-	737	O
in	-	745	O
presence	-	748	O
of	-	757	O
akinetic	-	760	O
or	-	769	O
hyperkinetic	-	772	O
(	-	785	O
K	-	786	O
)	-	787	O
behaviour	-	789	O
(	-	799	O
AS	-	800	O
/	-	802	O
KS	-	803	O
group	-	806	O
)	-	811	O
,	-	812	O
suggesting	-	814	O
signs	-	825	O
of	-	831	O
dopaminergic	-	834	O
activation	-	847	O
.	-	857	O

The	3780846	859	O
rigidity	-	863	O
was	-	872	O
considerably	-	876	O
decreased	-	889	O
in	-	899	O
both	-	902	O
groups	-	907	O
after	-	914	O
20	-	920	O
days	-	923	O
'	-	927	O
treatment	-	929	O
.	-	938	O

In	3780846	940	O
a	-	943	O
further	-	945	O
series	-	953	O
of	-	960	O
experiments	-	963	O
,	-	974	O
haloperidol	-	976	B
(	-	988	O
0	-	989	O
.	-	990	O
2	-	991	O
mg	-	993	O
/	-	995	O
kg	-	996	O
i	-	999	O
.	-	1000	O
p	-	1001	O
.	-	1002	O
)	-	1003	O
was	-	1005	O
used	-	1009	O
in	-	1014	O
order	-	1017	O
to	-	1023	O
block	-	1026	O
the	-	1032	O
dopaminergic	-	1036	O
activation	-	1049	O
and	-	1060	O
to	-	1064	O
estimate	-	1067	O
the	-	1076	O
real	-	1080	O
degree	-	1085	O
of	-	1092	O
the	-	1095	O
tolerance	-	1099	O
to	-	1109	O
the	-	1112	O
rigidity	-	1116	O
without	-	1125	O
any	-	1133	O
dopaminergic	-	1137	O
interference	-	1150	O
.	-	1162	O

Haloperidol	3780846	1164	B
enhanced	-	1176	O
the	-	1185	O
rigidity	-	1189	O
in	-	1198	O
the	-	1201	O
A	-	1205	O
group	-	1207	O
.	-	1212	O

However	3780846	1214	O
,	-	1221	O
the	-	1223	O
level	-	1227	O
in	-	1233	O
the	-	1236	O
AS	-	1240	O
/	-	1242	O
KS	-	1243	O
group	-	1246	O
remained	-	1252	O
considerably	-	1261	O
lower	-	1274	O
than	-	1280	O
in	-	1285	O
the	-	1288	O
A	-	1292	O
group	-	1294	O
.	-	1299	O

The	3780846	1301	O
results	-	1305	O
suggest	-	1313	O
that	-	1321	O
rigidity	-	1326	O
,	-	1334	O
which	-	1336	O
is	-	1342	O
assumed	-	1345	O
to	-	1353	O
be	-	1356	O
due	-	1359	O
to	-	1363	O
an	-	1366	O
action	-	1369	O
of	-	1376	O
morphine	-	1379	B
in	-	1388	O
the	-	1391	O
striatum	-	1395	O
,	-	1403	O
can	-	1405	O
be	-	1409	O
antagonized	-	1412	O
by	-	1424	O
another	-	1427	O
process	-	1435	O
leading	-	1443	O
to	-	1451	O
dopaminergic	-	1454	O
activation	-	1467	O
in	-	1478	O
the	-	1481	O
striatum	-	1485	O
.	-	1493	O

Nevertheless	3780846	1495	O
,	-	1507	O
there	-	1509	O
occurs	-	1515	O
some	-	1522	O
real	-	1527	O
tolerance	-	1532	O
to	-	1542	O
this	-	1545	O
effect	-	1550	O
.	-	1556	O

The	3780846	1558	O
rapid	-	1562	O
alternations	-	1568	O
of	-	1581	O
rigidity	-	1584	O
and	-	1593	O
the	-	1597	O
signs	-	1601	O
of	-	1607	O
dopaminergic	-	1610	O
activation	-	1623	O
observed	-	1634	O
in	-	1643	O
the	-	1646	O
animals	-	1650	O
of	-	1658	O
the	-	1661	O
AS	-	1665	O
/	-	1667	O
KS	-	1668	O
group	-	1671	O
might	-	1677	O
be	-	1683	O
due	-	1686	O
to	-	1690	O
rapid	-	1693	O
shifts	-	1699	O
in	-	1706	O
the	-	1709	O
predominance	-	1713	O
of	-	1726	O
various	-	1729	O
DA	-	1737	O
-	-	1739	O
innervated	-	1740	O
structures	-	1751	O
.	-	1761	O

Compression	3800626	0	O
neuropathy	-	12	O
of	-	23	O
the	-	26	O
radial	-	30	O
nerve	-	37	O
due	-	43	O
to	-	47	O
pentazocine	-	50	B
-	-	61	O
induced	-	62	O
fibrous	-	70	O
myopathy	-	78	O
.	-	86	O

Fibrous	3800626	88	O
myopathy	-	96	O
is	-	105	O
a	-	108	O
common	-	110	O
,	-	116	O
well	-	118	O
-	-	122	O
known	-	123	O
side	-	129	O
effect	-	134	O
of	-	141	O
repeated	-	144	O
pentazocine	-	153	B
injection	-	165	O
.	-	174	O

However	3800626	176	O
,	-	183	O
compression	-	185	O
neuropathy	-	197	O
due	-	208	O
to	-	212	O
fibrotic	-	215	O
muscle	-	224	O
affected	-	231	O
by	-	240	O
pentazocine	-	243	B
-	-	254	O
induced	-	255	O
myopathy	-	263	O
has	-	272	O
not	-	276	O
previously	-	280	O
been	-	291	O
reported	-	296	O
.	-	304	O

In	3800626	306	O
a	-	309	O
37	-	311	O
-	-	313	O
year	-	314	O
-	-	318	O
old	-	319	O
woman	-	323	O
with	-	329	O
documented	-	334	O
pentazocine	-	345	B
-	-	356	O
induced	-	357	O
fibrous	-	365	O
myopathy	-	373	O
of	-	382	O
triceps	-	385	O
and	-	393	O
deltoid	-	397	O
muscles	-	405	O
bilaterally	-	413	O
and	-	425	O
a	-	429	O
three	-	431	O
-	-	436	O
week	-	437	O
history	-	442	O
of	-	450	O
right	-	453	O
wrist	-	459	O
drop	-	465	O
,	-	469	O
electrodiagnostic	-	471	O
examination	-	489	O
showed	-	501	O
a	-	508	O
severe	-	510	O
but	-	517	O
partial	-	521	O
lesion	-	529	O
of	-	536	O
the	-	539	O
right	-	543	O
radial	-	549	O
nerve	-	556	O
distal	-	562	O
to	-	569	O
the	-	572	O
branches	-	576	O
to	-	585	O
the	-	588	O
triceps	-	592	O
,	-	599	O
in	-	601	O
addition	-	604	O
to	-	613	O
the	-	616	O
fibrous	-	620	O
myopathy	-	628	O
.	-	636	O

Surgery	3800626	638	O
revealed	-	646	O
the	-	655	O
right	-	659	O
radial	-	665	O
nerve	-	672	O
to	-	678	O
be	-	681	O
severely	-	684	O
compressed	-	693	O
by	-	704	O
the	-	707	O
densely	-	711	O
fibrotic	-	719	O
lateral	-	728	O
head	-	736	O
of	-	741	O
the	-	744	O
triceps	-	748	O
.	-	755	O

Decompression	3800626	757	O
and	-	771	O
neurolysis	-	775	O
were	-	786	O
performed	-	791	O
with	-	801	O
good	-	806	O
subsequent	-	811	O
recovery	-	822	O
of	-	831	O
function	-	834	O
.	-	842	O

Recurrent	3827439	0	O
reversible	-	10	O
acute	-	21	O
renal	-	27	O
failure	-	33	O
from	-	41	O
amphotericin	-	46	B
.	-	58	O

A	3827439	60	O
patient	-	62	O
with	-	70	O
cryptogenic	-	75	O
cirrhosis	-	87	O
and	-	97	O
disseminated	-	101	O
sporotrichosis	-	114	O
developed	-	129	O
acute	-	139	O
renal	-	145	O
failure	-	151	O
immediately	-	159	O
following	-	171	O
the	-	181	O
administration	-	185	O
of	-	200	O
amphotericin	-	203	B
B	-	216	I
on	-	218	O
four	-	221	O
separate	-	226	O
occasions	-	235	O
.	-	244	O

The	3827439	246	O
abruptness	-	250	O
of	-	261	O
the	-	264	O
renal	-	268	O
failure	-	274	O
and	-	282	O
its	-	286	O
reversibility	-	290	O
within	-	304	O
days	-	311	O
suggests	-	316	O
that	-	325	O
there	-	330	O
was	-	336	O
a	-	340	O
functional	-	342	O
component	-	353	O
to	-	363	O
the	-	366	O
renal	-	370	O
dysfunction	-	376	O
.	-	387	O

We	3827439	389	O
propose	-	392	O
that	-	400	O
amphotericin	-	405	B
,	-	417	O
in	-	419	O
the	-	422	O
setting	-	426	O
of	-	434	O
reduced	-	437	O
effective	-	445	O
arterial	-	455	O
volume	-	464	O
,	-	470	O
may	-	472	O
activate	-	476	O
tubuloglomerular	-	485	O
feedback	-	502	O
,	-	510	O
thereby	-	512	O
contributing	-	520	O
to	-	533	O
acute	-	536	O
renal	-	542	O
failure	-	548	O
.	-	555	O

Pneumonitis	3997294	0	O
with	-	12	O
pleural	-	17	O
and	-	25	O
pericardial	-	29	O
effusion	-	41	O
and	-	50	O
neuropathy	-	54	O
during	-	65	O
amiodarone	-	72	B
therapy	-	83	O
.	-	90	O

A	3997294	92	O
patient	-	94	O
with	-	102	O
sinuatrial	-	107	O
disease	-	118	O
and	-	126	O
implanted	-	130	O
pacemaker	-	140	O
was	-	150	O
treated	-	154	O
with	-	162	O
amiodarone	-	167	B
(	-	178	O
maximum	-	179	O
dose	-	187	O
1000	-	192	O
mg	-	197	O
,	-	199	O
maintenance	-	201	O
dose	-	213	O
800	-	218	O
mg	-	222	O
daily	-	225	O
)	-	230	O
for	-	232	O
10	-	236	O
months	-	239	O
,	-	245	O
for	-	247	O
control	-	251	O
of	-	259	O
supraventricular	-	262	O
tachyarrhythmias	-	279	O
.	-	295	O

He	3997294	297	O
developed	-	300	O
pneumonitis	-	310	O
,	-	321	O
pleural	-	323	O
and	-	331	O
pericardial	-	335	O
effusions	-	347	O
,	-	356	O
and	-	358	O
a	-	362	O
predominantly	-	364	O
proximal	-	378	O
motor	-	387	O
neuropathy	-	393	O
.	-	403	O

Immediate	3997294	405	O
but	-	415	O
gradual	-	419	O
improvement	-	427	O
followed	-	439	O
withdrawal	-	448	O
of	-	459	O
amiodarone	-	462	B
and	-	473	O
treatment	-	477	O
with	-	487	O
prednisolone	-	492	B
.	-	504	O

Review	3997294	506	O
of	-	513	O
this	-	516	O
and	-	521	O
previously	-	525	O
reported	-	536	O
cases	-	545	O
indicates	-	551	O
the	-	561	O
need	-	565	O
for	-	570	O
early	-	574	O
diagnosis	-	580	O
of	-	590	O
amiodarone	-	593	B
pneumonitis	-	604	O
,	-	615	O
immediate	-	617	O
withdrawal	-	627	O
of	-	638	O
amiodarone	-	641	B
,	-	651	O
and	-	653	O
prompt	-	657	O
but	-	664	O
continued	-	668	O
steroid	-	678	B
therapy	-	686	O
to	-	694	O
ensure	-	697	O
full	-	704	O
recovery	-	709	O
.	-	717	O

Indomethacin	4071154	0	B
-	-	12	O
induced	-	13	O
renal	-	21	O
insufficiency	-	27	O
:	-	40	O
recurrence	-	42	O
on	-	53	O
rechallenge	-	56	O
.	-	67	O

We	4071154	69	O
have	-	72	O
reported	-	77	O
a	-	86	O
case	-	88	O
of	-	93	O
acute	-	96	O
oliguric	-	102	O
renal	-	111	O
failure	-	117	O
with	-	125	O
hyperkalemia	-	130	O
in	-	143	O
a	-	146	O
patient	-	148	O
with	-	156	O
cirrhosis	-	161	O
,	-	170	O
ascites	-	172	O
,	-	179	O
and	-	181	O
cor	-	185	O
pulmonale	-	189	O
after	-	199	O
indomethacin	-	205	B
therapy	-	218	O
.	-	225	O

Prompt	4071154	227	O
restoration	-	234	O
of	-	246	O
renal	-	249	O
function	-	255	O
followed	-	264	O
drug	-	273	O
withdrawal	-	278	O
,	-	288	O
while	-	290	O
re	-	296	O
-	-	298	O
exposure	-	299	O
to	-	308	O
a	-	311	O
single	-	313	O
dose	-	320	O
of	-	325	O
indomethacin	-	328	B
caused	-	341	O
recurrence	-	348	O
of	-	359	O
acute	-	362	O
reversible	-	368	O
oliguria	-	379	O
.	-	387	O

Our	4071154	389	O
case	-	393	O
supports	-	398	O
the	-	407	O
hypothesis	-	411	O
that	-	422	O
endogenous	-	427	O
renal	-	438	O
prostaglandins	-	444	B
play	-	459	O
a	-	464	O
role	-	466	O
in	-	471	O
the	-	474	O
maintenance	-	478	O
of	-	490	O
renal	-	493	O
blood	-	499	O
flow	-	505	O
when	-	510	O
circulating	-	515	O
plasma	-	527	O
volume	-	534	O
is	-	541	O
diminished	-	544	O
.	-	554	O

Since	4071154	556	O
nonsteroidal	-	562	O
anti	-	575	O
-	-	579	O
inflammatory	-	580	O
agents	-	593	O
interfere	-	600	O
with	-	610	O
this	-	615	O
compensatory	-	620	O
mechanism	-	633	O
and	-	643	O
may	-	647	O
cause	-	651	O
acute	-	657	O
renal	-	663	O
failure	-	669	O
,	-	676	O
they	-	678	O
should	-	683	O
be	-	690	O
used	-	693	O
with	-	698	O
caution	-	703	O
in	-	711	O
such	-	714	O
patients	-	719	O
.	-	727	O

Comparison	6103707	0	O
of	-	11	O
the	-	14	O
subjective	-	18	O
effects	-	29	O
and	-	37	O
plasma	-	41	O
concentrations	-	48	O
following	-	63	O
oral	-	73	O
and	-	78	O
i	-	82	O
.	-	83	O
m	-	84	O
.	-	85	O

administration	6103707	87	O
of	-	102	O
flunitrazepam	-	105	B
in	-	119	O
volunteers	-	122	O
.	-	132	O

Flunitrazepam	6103707	134	B
0	-	148	O
.	-	149	O
5	-	150	O
,	-	151	O
1	-	153	O
.	-	154	O
0	-	155	O
or	-	157	O
2	-	160	O
.	-	161	O
0	-	162	O
mg	-	164	O
was	-	167	O
given	-	171	O
by	-	177	O
the	-	180	O
oral	-	184	O
or	-	189	O
i	-	192	O
.	-	193	O
m	-	194	O
.	-	195	O

routes	6103707	197	O
to	-	204	O
groups	-	207	O
of	-	214	O
volunteers	-	217	O
and	-	228	O
its	-	232	O
effects	-	236	O
compared	-	244	O
.	-	252	O

Plasma	6103707	254	O
concentrations	-	261	O
of	-	276	O
the	-	279	O
drug	-	283	O
were	-	288	O
estimated	-	293	O
by	-	303	O
gas	-	306	O
-	-	309	O
liquid	-	310	O
chromatography	-	317	O
,	-	331	O
in	-	333	O
a	-	336	O
smaller	-	338	O
number	-	346	O
of	-	353	O
the	-	356	O
subjects	-	360	O
.	-	368	O

The	6103707	370	O
most	-	374	O
striking	-	379	O
effect	-	388	O
was	-	395	O
sedation	-	399	O
which	-	408	O
increased	-	414	O
with	-	424	O
the	-	429	O
dose	-	433	O
,	-	437	O
2	-	439	O
mg	-	441	O
producing	-	444	O
deep	-	454	O
sleep	-	459	O
although	-	465	O
the	-	474	O
subjects	-	478	O
could	-	487	O
still	-	493	O
be	-	499	O
aroused	-	502	O
.	-	509	O

The	6103707	511	O
effects	-	515	O
of	-	523	O
i	-	526	O
.	-	527	O
m	-	528	O
.	-	529	O

administration	6103707	531	O
were	-	546	O
apparent	-	551	O
earlier	-	560	O
and	-	568	O
sometimes	-	572	O
lasted	-	582	O
longer	-	589	O
than	-	596	O
those	-	601	O
following	-	607	O
oral	-	617	O
administration	-	622	O
.	-	636	O

Dizziness	6103707	638	O
was	-	648	O
less	-	652	O
marked	-	657	O
than	-	664	O
sedation	-	669	O
,	-	677	O
but	-	679	O
increased	-	683	O
with	-	693	O
the	-	698	O
dose	-	702	O
.	-	706	O

There	6103707	708	O
was	-	714	O
pain	-	718	O
on	-	723	O
i	-	726	O
.	-	727	O
m	-	728	O
.	-	729	O

injection	6103707	731	O
of	-	741	O
flunitrazepam	-	744	B
significantly	-	758	O
more	-	772	O
often	-	777	O
than	-	783	O
with	-	788	O
isotonic	-	793	O
saline	-	802	O
.	-	808	O

Plasma	6103707	810	O
concentrations	-	817	O
varied	-	832	O
with	-	839	O
dose	-	844	O
and	-	849	O
route	-	853	O
and	-	859	O
corresponded	-	863	O
qualitatively	-	876	O
with	-	890	O
the	-	895	O
subjective	-	899	O
effects	-	910	O
.	-	917	O

The	6103707	919	O
drug	-	923	O
was	-	928	O
still	-	932	O
present	-	938	O
in	-	946	O
measurable	-	949	O
quantities	-	960	O
after	-	971	O
24	-	977	O
h	-	980	O
even	-	982	O
with	-	987	O
the	-	992	O
smallest	-	996	O
dose	-	1005	O
.	-	1009	O

Changes	6229975	0	O
in	-	8	O
heart	-	11	O
size	-	17	O
during	-	22	O
long	-	29	O
-	-	33	O
term	-	34	O
timolol	-	39	B
treatment	-	47	O
after	-	57	O
myocardial	-	63	O
infarction	-	74	O
.	-	84	O

The	6229975	86	O
effect	-	90	O
of	-	97	O
long	-	100	O
-	-	104	O
term	-	105	O
timolol	-	110	B
treatment	-	118	O
on	-	128	O
heart	-	131	O
size	-	137	O
after	-	142	O
myocardial	-	148	O
infarction	-	159	O
was	-	170	O
evaluated	-	174	O
by	-	184	O
X	-	187	O
-	-	188	O
ray	-	189	O
in	-	193	O
a	-	196	O
double	-	198	O
-	-	204	O
blind	-	205	O
study	-	211	O
including	-	217	O
241	-	227	O
patients	-	231	O
(	-	240	O
placebo	-	241	O
126	-	249	O
,	-	252	O
timolol	-	254	B
115	-	262	O
)	-	265	O
.	-	266	O

The	6229975	268	O
follow	-	272	O
-	-	278	O
up	-	279	O
period	-	282	O
was	-	289	O
12	-	293	O
months	-	296	O
.	-	302	O

The	6229975	304	O
timolol	-	308	B
-	-	315	O
treated	-	316	O
patients	-	324	O
showed	-	333	O
a	-	340	O
small	-	342	O
but	-	348	O
significant	-	352	O
increase	-	364	O
in	-	373	O
heart	-	376	O
size	-	382	O
from	-	387	O
baseline	-	392	O
in	-	401	O
contrast	-	404	O
to	-	413	O
a	-	416	O
decrease	-	418	O
in	-	427	O
the	-	430	O
placebo	-	434	O
group	-	442	O
.	-	447	O

These	6229975	449	O
differences	-	455	O
may	-	467	O
be	-	471	O
caused	-	474	O
by	-	481	O
timolol	-	484	B
-	-	491	O
induced	-	492	O
bradycardia	-	500	O
and	-	512	O
a	-	516	O
compensatory	-	518	O
increase	-	531	O
in	-	540	O
end	-	543	O
-	-	546	O
diastolic	-	547	O
volume	-	557	O
.	-	563	O

The	6229975	565	O
timolol	-	569	B
-	-	576	O
related	-	577	O
increase	-	585	O
in	-	594	O
heart	-	597	O
size	-	603	O
was	-	608	O
observed	-	612	O
only	-	621	O
in	-	626	O
patients	-	629	O
with	-	638	O
normal	-	643	O
and	-	650	O
borderline	-	654	O
heart	-	665	O
size	-	671	O
.	-	675	O

In	6229975	677	O
patients	-	680	O
with	-	689	O
cardiomegaly	-	694	O
,	-	706	O
the	-	708	O
increase	-	712	O
in	-	721	O
heart	-	724	O
size	-	730	O
was	-	735	O
similar	-	739	O
in	-	747	O
both	-	750	O
groups	-	755	O
.	-	761	O

After	6229975	763	O
re	-	769	O
-	-	771	O
infarction	-	772	O
,	-	782	O
heart	-	784	O
size	-	790	O
increased	-	795	O
in	-	805	O
the	-	808	O
placebo	-	812	O
group	-	820	O
and	-	826	O
remained	-	830	O
unchanged	-	839	O
in	-	849	O
the	-	852	O
timolol	-	856	B
group	-	864	O
.	-	869	O

Vitamin	6286738	0	B
D3	-	8	I
toxicity	-	11	O
in	-	20	O
dairy	-	23	O
cows	-	29	O
.	-	33	O

Large	6286738	35	O
parenteral	-	41	O
doses	-	52	O
of	-	58	O
vitamin	-	61	B
D3	-	69	I
(	-	72	O
15	-	73	O
to	-	76	O
17	-	79	O
.	-	81	O
5	-	82	O
x	-	84	O
10	-	86	O
(	-	88	O
6	-	89	O
)	-	90	O
IU	-	92	O
vitamin	-	95	B
D3	-	103	I
)	-	105	O
were	-	107	O
associated	-	112	O
with	-	123	O
prolonged	-	128	O
hypercalcemia	-	138	O
,	-	151	O
hyperphosphatemia	-	153	O
,	-	170	O
and	-	172	O
large	-	176	O
increases	-	182	O
of	-	192	O
vitamin	-	195	B
D3	-	203	I
and	-	206	O
its	-	210	O
metabolites	-	214	O
in	-	226	O
the	-	229	O
blood	-	233	O
plasma	-	239	O
of	-	246	O
nonlactating	-	249	O
nonpregnant	-	262	O
and	-	274	O
pregnant	-	278	O
Jersey	-	287	O
cows	-	294	O
.	-	298	O

Calcium	6286738	300	B
concentrations	-	308	O
1	-	323	O
day	-	325	O
postpartum	-	329	O
were	-	340	O
higher	-	345	O
in	-	352	O
cows	-	355	O
treated	-	360	O
with	-	368	O
vitamin	-	373	B
D3	-	381	I
about	-	384	O
32	-	390	O
days	-	393	O
prepartum	-	398	O
(	-	408	O
8	-	409	O
.	-	410	O
8	-	411	O
mg	-	413	O
/	-	415	O
100	-	416	O
ml	-	420	O
)	-	422	O
than	-	424	O
in	-	429	O
control	-	432	O
cows	-	440	O
(	-	445	O
5	-	446	O
.	-	447	O
5	-	448	O
mg	-	450	O
/	-	452	O
100	-	453	O
ml	-	457	O
)	-	459	O
.	-	460	O

None	6286738	462	O
of	-	467	O
the	-	470	O
cows	-	474	O
treated	-	479	O
with	-	487	O
vitamin	-	492	B
D3	-	500	I
showed	-	503	O
signs	-	510	O
of	-	516	O
milk	-	519	O
fever	-	524	O
during	-	530	O
the	-	537	O
peripartal	-	541	O
period	-	552	O
;	-	558	O
however	-	560	O
,	-	567	O
22	-	569	O
%	-	571	O
of	-	573	O
the	-	576	O
control	-	580	O
cows	-	588	O
developed	-	593	O
clinical	-	603	O
signs	-	612	O
of	-	618	O
milk	-	621	O
fever	-	626	O
during	-	632	O
this	-	639	O
period	-	644	O
.	-	650	O

Signs	6286738	652	O
of	-	658	O
vitamin	-	661	B
D3	-	669	I
toxicity	-	672	O
were	-	681	O
not	-	686	O
observed	-	690	O
in	-	699	O
nonlactating	-	702	O
nonpregnant	-	715	O
cows	-	727	O
;	-	731	O
however	-	733	O
,	-	740	O
pregnant	-	742	O
cows	-	751	O
commonly	-	756	O
developed	-	765	O
severe	-	775	O
signs	-	782	O
of	-	788	O
vitamin	-	791	B
D3	-	799	I
toxicity	-	802	O
and	-	811	O
10	-	815	O
of	-	818	O
17	-	821	O
cows	-	824	O
died	-	829	O
.	-	833	O

There	6286738	835	O
was	-	841	O
widespread	-	845	O
metastatic	-	856	O
calcification	-	867	O
in	-	881	O
the	-	884	O
cows	-	888	O
that	-	893	O
died	-	898	O
.	-	902	O

Because	6286738	904	O
of	-	912	O
the	-	915	O
extreme	-	919	O
toxicity	-	927	O
of	-	936	O
vitamin	-	939	B
D3	-	947	I
in	-	950	O
pregnant	-	953	O
Jersey	-	962	O
cows	-	969	O
and	-	974	O
the	-	978	O
low	-	982	O
margin	-	986	O
of	-	993	O
safety	-	996	O
between	-	1003	O
doses	-	1011	O
of	-	1017	O
vitamin	-	1020	B
D3	-	1028	I
that	-	1031	O
prevent	-	1036	O
milk	-	1044	O
fever	-	1049	O
and	-	1055	O
doses	-	1059	O
that	-	1065	O
induce	-	1070	O
milk	-	1077	O
fever	-	1082	O
,	-	1087	O
we	-	1089	O
concluded	-	1092	O
that	-	1102	O
vitamin	-	1107	B
D3	-	1115	I
can	-	1118	O
not	-	1121	O
be	-	1125	O
used	-	1128	O
practically	-	1133	O
to	-	1145	O
prevent	-	1148	O
milk	-	1156	O
fever	-	1161	O
when	-	1167	O
injected	-	1172	O
several	-	1181	O
weeks	-	1189	O
prepartum	-	1195	O
.	-	1204	O

Diseases	6287825	0	O
of	-	9	O
peripheral	-	12	O
nerves	-	23	O
as	-	30	O
seen	-	33	O
in	-	38	O
the	-	41	O
Nigerian	-	45	O
African	-	54	O
.	-	61	O

The	6287825	63	O
anatomical	-	67	O
and	-	78	O
aetiological	-	82	O
diagnoses	-	95	O
of	-	105	O
peripheral	-	108	O
nerve	-	119	O
disease	-	125	O
excluding	-	133	O
its	-	143	O
primary	-	147	O
benign	-	155	O
and	-	162	O
malignant	-	166	O
disorders	-	176	O
,	-	185	O
as	-	187	O
seen	-	190	O
in	-	195	O
358	-	198	O
Nigerians	-	202	O
are	-	212	O
presented	-	216	O
.	-	225	O

There	6287825	227	O
is	-	233	O
a	-	236	O
male	-	238	O
preponderance	-	243	O
and	-	257	O
the	-	261	O
peak	-	265	O
incidence	-	270	O
is	-	280	O
in	-	283	O
the	-	286	O
fourth	-	290	O
decade	-	297	O
.	-	303	O

Sensori	6287825	305	O
-	-	312	O
motor	-	313	O
neuropathy	-	319	O
was	-	330	O
the	-	334	O
commonest	-	338	O
presentation	-	348	O
(	-	361	O
50	-	362	O
%	-	364	O
)	-	365	O
.	-	366	O

Guillain	6287825	368	O
-	-	376	O
Barr	-	377	O
syndrome	-	384	O
was	-	393	O
the	-	397	O
commonest	-	401	O
identifiable	-	411	O
cause	-	424	O
(	-	430	O
15	-	431	O
.	-	433	O
6	-	434	O
%	-	435	O
)	-	436	O
,	-	437	O
accounting	-	439	O
for	-	450	O
half	-	454	O
of	-	459	O
the	-	462	O
cases	-	466	O
with	-	472	O
motor	-	477	O
neuropathy	-	483	O
.	-	493	O

Peripheral	6287825	495	O
neuropathy	-	506	O
due	-	517	O
to	-	521	O
nutritional	-	524	O
deficiency	-	536	O
of	-	547	O
thiamine	-	550	B
and	-	559	O
riboflavin	-	563	B
was	-	574	O
common	-	578	O
(	-	585	O
10	-	586	O
.	-	588	O
1	-	589	O
%	-	590	O
)	-	591	O
and	-	593	O
presented	-	597	O
mainly	-	607	O
as	-	614	O
sensory	-	617	O
and	-	625	O
sensori	-	629	O
-	-	636	O
motor	-	637	O
neuropathy	-	643	O
.	-	653	O

Diabetes	6287825	655	O
mellitus	-	664	O
was	-	673	O
the	-	677	O
major	-	681	O
cause	-	687	O
of	-	693	O
autonomic	-	696	O
neuropathy	-	706	O
.	-	716	O

Isoniazid	6287825	718	B
was	-	728	O
the	-	732	O
most	-	736	O
frequent	-	741	O
agent	-	750	O
in	-	756	O
drug	-	759	O
-	-	763	O
induced	-	764	O
neuropathy	-	772	O
.	-	782	O

Migraine	6287825	784	O
(	-	793	O
20	-	794	O
%	-	796	O
)	-	797	O
was	-	799	O
not	-	803	O
an	-	807	O
uncommon	-	810	O
cause	-	819	O
of	-	825	O
cranial	-	828	O
neuropathy	-	836	O
although	-	847	O
malignancies	-	856	O
arising	-	869	O
from	-	877	O
the	-	882	O
reticuloendothelial	-	886	O
system	-	906	O
or	-	913	O
related	-	916	O
structures	-	924	O
of	-	935	O
the	-	938	O
head	-	942	O
and	-	947	O
neck	-	951	O
were	-	956	O
more	-	961	O
frequent	-	966	O
(	-	975	O
26	-	976	O
%	-	978	O
)	-	979	O
.	-	980	O

In	6287825	982	O
26	-	985	O
.	-	987	O
5	-	988	O
%	-	989	O
of	-	991	O
all	-	994	O
the	-	998	O
cases	-	1002	O
,	-	1007	O
the	-	1009	O
aetiology	-	1013	O
of	-	1023	O
the	-	1026	O
neuropathy	-	1030	O
was	-	1041	O
undetermined	-	1045	O
.	-	1057	O

Heredofamilial	6287825	1059	O
and	-	1074	O
connective	-	1078	O
tissue	-	1089	O
disorders	-	1096	O
were	-	1106	O
rare	-	1111	O
.	-	1115	O

Some	6287825	1117	O
of	-	1122	O
the	-	1125	O
factors	-	1129	O
related	-	1137	O
to	-	1145	O
the	-	1148	O
clinical	-	1152	O
presentation	-	1161	O
and	-	1174	O
pathogenesis	-	1178	O
of	-	1191	O
the	-	1194	O
neuropathies	-	1198	O
are	-	1211	O
briefly	-	1215	O
discussed	-	1223	O
.	-	1232	O

A	6386793	0	O
double	-	2	O
-	-	8	O
blind	-	9	O
study	-	15	O
of	-	21	O
the	-	24	O
efficacy	-	28	O
and	-	37	O
safety	-	41	O
of	-	48	O
dothiepin	-	51	B
hydrochloride	-	61	I
in	-	75	O
the	-	78	O
treatment	-	82	O
of	-	92	O
major	-	95	O
depressive	-	101	O
disorder	-	112	O
.	-	120	O

In	6386793	122	O
a	-	125	O
6	-	127	O
-	-	128	O
week	-	129	O
double	-	134	O
-	-	140	O
blind	-	141	O
parallel	-	147	O
treatment	-	156	O
study	-	166	O
,	-	171	O
dothiepin	-	173	B
and	-	183	O
amitriptyline	-	187	B
were	-	201	O
compared	-	206	O
to	-	215	O
placebo	-	218	O
in	-	226	O
the	-	229	O
treatment	-	233	O
of	-	243	O
33	-	246	O
depressed	-	249	O
outpatients	-	259	O
.	-	270	O

Dothiepin	6386793	272	B
and	-	282	O
amitriptyline	-	286	B
were	-	300	O
equally	-	305	O
effective	-	313	O
in	-	323	O
alleviating	-	326	O
the	-	338	O
symptoms	-	342	O
of	-	351	O
depressive	-	354	O
illness	-	365	O
,	-	372	O
and	-	374	O
both	-	378	O
were	-	383	O
significantly	-	388	O
superior	-	402	O
to	-	411	O
placebo	-	414	O
.	-	421	O

The	6386793	423	O
overall	-	427	O
incidence	-	435	O
of	-	445	O
side	-	448	O
effects	-	453	O
and	-	461	O
the	-	465	O
frequency	-	469	O
and	-	479	O
severity	-	483	O
of	-	492	O
blurred	-	495	O
vision	-	503	O
,	-	509	O
dry	-	511	O
mouth	-	515	O
,	-	520	O
and	-	522	O
drowsiness	-	526	O
were	-	537	O
significantly	-	542	O
less	-	556	O
with	-	561	O
dothiepin	-	566	B
than	-	576	O
with	-	581	O
amitriptyline	-	586	B
.	-	599	O

Dothiepin	6386793	601	B
also	-	611	O
produced	-	616	O
fewer	-	625	O
CNS	-	631	O
and	-	635	O
cardiovascular	-	639	O
effects	-	654	O
.	-	661	O

There	6386793	663	O
were	-	669	O
no	-	674	O
clinically	-	677	O
important	-	688	O
changes	-	698	O
in	-	706	O
laboratory	-	709	O
parameters	-	720	O
.	-	730	O

Dothiepin	6386793	732	B
thus	-	742	O
was	-	747	O
found	-	751	O
to	-	757	O
be	-	760	O
an	-	763	O
effective	-	766	O
antidepressant	-	776	B
drug	-	791	O
associated	-	796	O
with	-	807	O
fewer	-	812	O
side	-	818	O
effects	-	823	O
than	-	831	O
amitriptyline	-	836	B
in	-	850	O
the	-	853	O
treatment	-	857	O
of	-	867	O
depressed	-	870	O
outpatients	-	880	O
.	-	891	O

Behavioral	6387529	0	O
effects	-	11	O
of	-	19	O
diazepam	-	22	B
and	-	31	O
propranolol	-	35	B
in	-	47	O
patients	-	50	O
with	-	59	O
panic	-	64	O
disorder	-	70	O
and	-	79	O
agoraphobia	-	83	O
.	-	94	O

The	6387529	96	O
effects	-	100	O
of	-	108	O
oral	-	111	O
doses	-	116	O
of	-	122	O
diazepam	-	125	B
(	-	134	O
single	-	135	O
dose	-	142	O
of	-	147	O
10	-	150	O
mg	-	153	O
and	-	156	O
a	-	160	O
median	-	162	O
dose	-	169	O
of	-	174	O
30	-	177	O
mg	-	180	O
/	-	182	O
day	-	183	O
for	-	187	O
2	-	191	O
weeks	-	193	O
)	-	198	O
and	-	200	O
propranolol	-	204	B
(	-	216	O
single	-	217	O
dose	-	224	O
of	-	229	O
80	-	232	O
mg	-	235	O
and	-	238	O
a	-	242	O
median	-	244	O
dose	-	251	O
of	-	256	O
240	-	259	O
mg	-	263	O
/	-	265	O
day	-	266	O
for	-	270	O
2	-	274	O
weeks	-	276	O
)	-	281	O
on	-	283	O
psychological	-	286	O
performance	-	300	O
of	-	312	O
patients	-	315	O
with	-	324	O
panic	-	329	O
disorders	-	335	O
and	-	345	O
agoraphobia	-	349	O
were	-	361	O
investigated	-	366	O
in	-	379	O
a	-	382	O
double	-	384	O
-	-	390	O
blind	-	391	O
,	-	396	O
randomized	-	398	O
and	-	409	O
crossover	-	413	O
design	-	423	O
.	-	429	O

Both	6387529	431	O
drugs	-	436	O
impaired	-	442	O
immediate	-	451	O
free	-	461	O
recall	-	466	O
but	-	473	O
the	-	477	O
decrease	-	481	O
was	-	490	O
greater	-	494	O
for	-	502	O
diazepam	-	506	B
than	-	515	O
propranolol	-	520	B
.	-	531	O

Delayed	6387529	533	O
free	-	541	O
recall	-	546	O
was	-	553	O
also	-	557	O
impaired	-	562	O
but	-	571	O
the	-	575	O
two	-	579	O
drugs	-	583	O
did	-	589	O
not	-	593	O
differ	-	597	O
.	-	603	O

Patients	6387529	605	O
tapped	-	614	O
faster	-	621	O
after	-	628	O
propranolol	-	634	B
than	-	646	O
diazepam	-	651	B
and	-	660	O
they	-	664	O
were	-	669	O
more	-	674	O
sedated	-	679	O
after	-	687	O
diazepam	-	693	B
than	-	702	O
propranolol	-	707	B
.	-	718	O

After	6387529	720	O
2	-	726	O
weeks	-	728	O
of	-	734	O
treatment	-	737	O
,	-	746	O
patients	-	748	O
tested	-	757	O
5	-	764	O
-	-	765	O
8	-	766	O
h	-	768	O
after	-	770	O
the	-	776	O
last	-	780	O
dose	-	785	O
of	-	790	O
medication	-	793	O
did	-	804	O
not	-	808	O
show	-	812	O
any	-	817	O
decrement	-	821	O
of	-	831	O
performance	-	834	O
.	-	845	O

These	6387529	847	O
results	-	853	O
are	-	861	O
similar	-	865	O
to	-	873	O
those	-	876	O
previously	-	882	O
found	-	893	O
in	-	899	O
healthy	-	902	O
subjects	-	910	O
.	-	918	O

Accumulation	6387529	920	O
of	-	933	O
drugs	-	936	O
was	-	942	O
not	-	946	O
reflected	-	950	O
in	-	960	O
prolonged	-	963	O
behavioral	-	973	O
impairment	-	984	O
.	-	994	O

Effect	6692345	0	O
of	-	7	O
aspirin	-	10	B
on	-	18	O
N	-	21	B
-	-	22	I
[	-	23	I
4	-	24	I
-	-	25	I
(	-	26	I
5	-	27	I
-	-	28	I
nitro	-	29	I
-	-	34	I
2	-	35	I
-	-	36	I
furyl	-	37	I
)	-	42	I
-	-	43	I
2	-	44	I
-	-	45	I
thiazolyl	-	46	I
]	-	55	I
-	-	56	I
formamide	-	57	I
-	-	66	O
induced	-	67	O
epithelial	-	75	O
proliferation	-	86	O
in	-	100	O
the	-	103	O
urinary	-	107	O
bladder	-	115	O
and	-	123	O
forestomach	-	127	O
of	-	139	O
the	-	142	O
rat	-	146	O
.	-	149	O

The	6692345	151	O
co	-	155	O
-	-	157	O
administration	-	158	O
of	-	173	O
aspirin	-	176	B
with	-	184	O
N	-	189	B
-	-	190	I
[	-	191	I
4	-	192	I
-	-	193	I
(	-	194	I
5	-	195	I
-	-	196	I
nitro	-	197	I
-	-	202	I
2	-	203	I
-	-	204	I
furyl	-	205	I
)	-	210	I
-	-	211	I
2	-	212	I
-	-	213	I
thiazolyl	-	214	I
]	-	223	I
-	-	224	I
formamide	-	225	I
(	-	235	O
FANFT	-	236	B
)	-	241	O
to	-	243	O
rats	-	246	O
resulted	-	251	O
in	-	260	O
a	-	263	O
reduced	-	265	O
incidence	-	273	O
of	-	283	O
FANFT	-	286	B
-	-	291	O
induced	-	292	O
bladder	-	300	O
carcinomas	-	308	O
but	-	319	O
a	-	323	O
concomitant	-	325	O
induction	-	337	O
of	-	347	O
forestomach	-	350	O
tumors	-	362	O
.	-	368	O

An	6692345	370	O
autoradiographic	-	373	O
study	-	390	O
was	-	396	O
performed	-	400	O
on	-	410	O
male	-	413	O
F	-	418	O
-	-	419	O
344	-	420	O
rats	-	424	O
fed	-	429	O
diet	-	433	O
containing	-	438	O
FANFT	-	449	B
at	-	455	O
a	-	458	O
level	-	460	O
of	-	466	O
0	-	469	O
.	-	470	O
2	-	471	O
%	-	472	O
and	-	474	O
/	-	477	O
or	-	478	O
aspirin	-	481	B
at	-	489	O
a	-	492	O
level	-	494	O
of	-	500	O
0	-	503	O
.	-	504	O
5	-	505	O
%	-	506	O
to	-	508	O
evaluate	-	511	O
the	-	520	O
effect	-	524	O
of	-	531	O
aspirin	-	534	B
on	-	542	O
the	-	545	O
increased	-	549	O
cell	-	559	O
proliferation	-	564	O
induced	-	578	O
by	-	586	O
FANFT	-	589	B
in	-	595	O
the	-	598	O
forestomach	-	602	O
and	-	614	O
bladder	-	618	O
.	-	625	O

FANFT	6692345	627	B
-	-	632	O
induced	-	633	O
cell	-	641	O
proliferation	-	646	O
in	-	660	O
the	-	663	O
bladder	-	667	O
was	-	675	O
significantly	-	679	O
suppressed	-	693	O
by	-	704	O
aspirin	-	707	B
co	-	715	O
-	-	717	O
administration	-	718	O
after	-	733	O
4	-	739	O
weeks	-	741	O
but	-	747	O
not	-	751	O
after	-	755	O
12	-	761	O
weeks	-	764	O
.	-	769	O

In	6692345	771	O
the	-	774	O
forestomach	-	778	O
,	-	789	O
and	-	791	O
also	-	795	O
in	-	800	O
the	-	803	O
liver	-	807	O
,	-	812	O
aspirin	-	814	B
did	-	822	O
not	-	826	O
affect	-	830	O
the	-	837	O
FANFT	-	841	B
-	-	846	O
induced	-	847	O
increase	-	855	O
in	-	864	O
labeling	-	867	O
index	-	876	O
.	-	881	O

The	6692345	883	O
present	-	887	O
results	-	895	O
are	-	903	O
consistent	-	907	O
with	-	918	O
the	-	923	O
carcinogenicity	-	927	O
experiment	-	943	O
suggesting	-	954	O
that	-	965	O
different	-	970	O
mechanisms	-	980	O
are	-	991	O
involved	-	995	O
in	-	1004	O
FANFT	-	1007	B
carcinogenesis	-	1013	O
in	-	1028	O
the	-	1031	O
bladder	-	1035	O
and	-	1043	O
forestomach	-	1047	O
,	-	1058	O
and	-	1060	O
that	-	1064	O
aspirin	-	1069	B
's	-	1076	O
effect	-	1079	O
on	-	1086	O
FANFT	-	1089	B
in	-	1095	O
the	-	1098	O
forestomach	-	1102	O
is	-	1114	O
not	-	1117	O
due	-	1121	O
to	-	1125	O
an	-	1128	O
irritant	-	1131	O
effect	-	1140	O
associated	-	1147	O
with	-	1158	O
increased	-	1163	O
cell	-	1173	O
proliferation	-	1178	O
.	-	1191	O

Also	6692345	1193	O
,	-	1197	O
there	-	1199	O
appears	-	1205	O
to	-	1213	O
be	-	1216	O
an	-	1219	O
adaptation	-	1222	O
by	-	1233	O
the	-	1236	O
rats	-	1240	O
to	-	1245	O
the	-	1248	O
chronic	-	1252	O
ingestion	-	1260	O
of	-	1270	O
aspirin	-	1273	B
.	-	1280	O

Provocation	6773726	0	O
of	-	12	O
postural	-	15	O
hypotension	-	24	O
by	-	36	O
nitroglycerin	-	39	B
in	-	53	O
diabetic	-	56	O
autonomic	-	65	O
neuropathy	-	75	O
?	-	85	O

The	6773726	87	O
effect	-	91	O
of	-	98	O
nitroglycerin	-	101	B
on	-	115	O
heart	-	118	O
rate	-	124	O
and	-	129	O
systolic	-	133	O
blood	-	142	O
pressure	-	148	O
was	-	157	O
compared	-	161	O
in	-	170	O
5	-	173	O
normal	-	175	O
subjects	-	182	O
,	-	190	O
12	-	192	O
diabetic	-	195	O
subjects	-	204	O
without	-	213	O
autonomic	-	221	O
neuropathy	-	231	O
,	-	241	O
and	-	243	O
5	-	247	O
diabetic	-	249	O
subjects	-	258	O
with	-	267	O
autonomic	-	272	O
neuropathy	-	282	O
.	-	292	O

The	6773726	294	O
magnitude	-	298	O
and	-	308	O
time	-	312	O
course	-	317	O
of	-	324	O
the	-	327	O
increase	-	331	O
in	-	340	O
heart	-	343	O
rate	-	349	O
and	-	354	O
the	-	358	O
decrease	-	362	O
in	-	371	O
systolic	-	374	O
blood	-	383	O
pressure	-	389	O
after	-	398	O
nitroglycerin	-	404	B
were	-	418	O
similar	-	423	O
in	-	431	O
the	-	434	O
normal	-	438	O
and	-	445	O
diabetic	-	449	O
subjects	-	458	O
without	-	467	O
autonomic	-	475	O
neuropathy	-	485	O
,	-	495	O
whereas	-	497	O
a	-	505	O
lesser	-	507	O
increase	-	514	O
in	-	523	O
heart	-	526	O
rate	-	532	O
and	-	537	O
a	-	541	O
greater	-	543	O
decrease	-	551	O
in	-	560	O
systolic	-	563	O
blood	-	572	O
pressure	-	578	O
occurred	-	587	O
in	-	596	O
the	-	599	O
diabetic	-	603	O
subjects	-	612	O
with	-	621	O
autonomic	-	626	O
neuropathy	-	636	O
.	-	646	O

It	6773726	648	O
is	-	651	O
therefore	-	654	O
suggested	-	664	O
that	-	674	O
caution	-	679	O
should	-	687	O
be	-	694	O
exercised	-	697	O
when	-	707	O
prescribing	-	712	O
vasodilator	-	724	O
drugs	-	736	O
in	-	742	O
diabetic	-	745	O
patients	-	754	O
,	-	762	O
particularly	-	764	O
those	-	777	O
with	-	783	O
autonomic	-	788	O
neuropathy	-	798	O
.	-	808	O

Characterization	6888657	0	O
of	-	17	O
estrogen	-	20	B
-	-	28	O
induced	-	29	O
adenohypophyseal	-	37	O
tumors	-	54	O
in	-	61	O
the	-	64	O
Fischer	-	68	O
344	-	76	O
rat	-	80	O
.	-	83	O

Pituitary	6888657	85	O
tumors	-	95	O
were	-	102	O
induced	-	107	O
in	-	115	O
F344	-	118	O
female	-	123	O
rats	-	130	O
by	-	135	O
chronic	-	138	O
treatment	-	146	O
with	-	156	O
diethylstilbestrol	-	161	B
(	-	180	O
DES	-	181	B
,	-	184	O
8	-	186	O
-	-	187	O
10	-	188	O
mg	-	191	O
)	-	193	O
implanted	-	195	O
subcutaneously	-	205	O
in	-	220	O
silastic	-	223	O
capsules	-	232	O
.	-	240	O

Over	6888657	242	O
a	-	247	O
range	-	249	O
of	-	255	O
1	-	258	O
-	-	259	O
150	-	260	O
days	-	264	O
of	-	269	O
DES	-	272	B
treatment	-	276	O
,	-	285	O
pairs	-	287	O
of	-	293	O
control	-	296	O
and	-	304	O
DES	-	308	B
-	-	311	O
treated	-	312	O
rats	-	320	O
were	-	325	O
sacrificed	-	330	O
,	-	340	O
and	-	342	O
their	-	346	O
pituitaries	-	352	O
dissociated	-	364	O
enzymatically	-	376	O
into	-	390	O
single	-	395	O
-	-	401	O
cell	-	402	O
preparations	-	407	O
.	-	419	O

The	6888657	421	O
cell	-	425	O
populations	-	430	O
were	-	442	O
examined	-	447	O
regarding	-	456	O
total	-	466	O
cell	-	472	O
recovery	-	477	O
correlated	-	486	O
with	-	497	O
gland	-	502	O
weight	-	508	O
,	-	514	O
intracellular	-	516	O
prolactin	-	530	O
(	-	540	O
PRL	-	541	O
)	-	544	O
content	-	546	O
and	-	554	O
subsequent	-	558	O
release	-	569	O
in	-	577	O
primary	-	580	O
culture	-	588	O
,	-	595	O
immunocytochemical	-	597	O
PRL	-	616	O
staining	-	620	O
,	-	628	O
density	-	630	O
and	-	638	O
/	-	641	O
or	-	642	O
size	-	645	O
alterations	-	650	O
via	-	662	O
separation	-	666	O
on	-	677	O
Ficoll	-	680	O
-	-	686	O
Hypaque	-	687	O
and	-	695	O
by	-	699	O
unit	-	702	O
gravity	-	707	O
sedimentation	-	715	O
,	-	728	O
and	-	730	O
cell	-	734	O
cycle	-	739	O
analysis	-	745	O
,	-	753	O
after	-	755	O
acriflavine	-	761	B
DNA	-	773	O
staining	-	777	O
,	-	785	O
by	-	787	O
laser	-	790	O
flow	-	796	O
cytometry	-	801	O
.	-	810	O

Total	6888657	812	O
cell	-	818	O
yields	-	823	O
from	-	830	O
DES	-	835	B
-	-	838	O
treated	-	839	O
pituitaries	-	847	O
increased	-	859	O
from	-	869	O
1	-	874	O
.	-	875	O
3	-	876	O
times	-	878	O
control	-	884	O
yields	-	892	O
at	-	899	O
8	-	902	O
days	-	904	O
of	-	909	O
treatment	-	912	O
to	-	922	O
58	-	925	O
.	-	927	O
9	-	928	O
times	-	930	O
control	-	936	O
values	-	944	O
by	-	951	O
day	-	954	O
150	-	958	O
.	-	961	O

Intracellular	6888657	963	O
PRL	-	977	O
content	-	981	O
ranged	-	989	O
from	-	996	O
1	-	1001	O
.	-	1002	O
9	-	1003	O
to	-	1005	O
9	-	1008	O
.	-	1009	O
4	-	1010	O
times	-	1012	O
control	-	1018	O
levels	-	1026	O
,	-	1032	O
and	-	1034	O
PRL	-	1038	O
release	-	1042	O
in	-	1050	O
vitro	-	1053	O
was	-	1059	O
significantly	-	1063	O
and	-	1077	O
consistently	-	1081	O
higher	-	1094	O
than	-	1101	O
controls	-	1106	O
,	-	1114	O
after	-	1116	O
at	-	1122	O
least	-	1125	O
8	-	1131	O
days	-	1133	O
of	-	1138	O
DES	-	1141	B
exposure	-	1145	O
.	-	1153	O

Beyond	6888657	1155	O
8	-	1162	O
days	-	1164	O
of	-	1169	O
DES	-	1172	B
exposure	-	1176	O
,	-	1184	O
the	-	1186	O
immunochemically	-	1190	O
PRL	-	1207	O
-	-	1210	O
positive	-	1211	O
proportion	-	1220	O
of	-	1231	O
cells	-	1234	O
increased	-	1240	O
to	-	1250	O
over	-	1253	O
50	-	1258	O
%	-	1260	O
of	-	1262	O
the	-	1265	O
total	-	1269	O
population	-	1275	O
.	-	1285	O

Increased	6888657	1287	O
density	-	1297	O
and	-	1305	O
/	-	1308	O
or	-	1309	O
size	-	1312	O
and	-	1317	O
PRL	-	1321	O
content	-	1325	O
were	-	1333	O
indicated	-	1338	O
for	-	1348	O
the	-	1352	O
majority	-	1356	O
of	-	1365	O
the	-	1368	O
PRL	-	1372	O
cell	-	1376	O
population	-	1381	O
in	-	1392	O
both	-	1395	O
types	-	1400	O
of	-	1406	O
separation	-	1409	O
protocols	-	1420	O
.	-	1429	O

All	6888657	1431	O
these	-	1435	O
effects	-	1441	O
of	-	1449	O
DES	-	1452	B
were	-	1456	O
more	-	1461	O
pronounced	-	1466	O
among	-	1477	O
previously	-	1483	O
ovariectomized	-	1494	O
animals	-	1509	O
.	-	1516	O

The	6888657	1518	O
data	-	1522	O
extend	-	1527	O
the	-	1534	O
findings	-	1538	O
of	-	1547	O
other	-	1550	O
investigators	-	1556	O
,	-	1569	O
further	-	1571	O
establishing	-	1579	O
the	-	1592	O
DES	-	1596	B
-	-	1599	O
induced	-	1600	O
tumor	-	1608	O
as	-	1614	O
a	-	1617	O
model	-	1619	O
for	-	1625	O
study	-	1629	O
of	-	1635	O
PRL	-	1638	O
cellular	-	1642	O
control	-	1651	O
mechanisms	-	1659	O
.	-	1669	O

Triamterene	7265370	0	B
nephrolithiasis	-	12	O
complicating	-	28	O
dyazide	-	41	B
therapy	-	49	O
.	-	56	O

A	7265370	58	O
case	-	60	O
of	-	65	O
triamterene	-	68	B
nephrolithiasis	-	80	O
is	-	96	O
reported	-	99	O
in	-	108	O
a	-	111	O
man	-	113	O
after	-	117	O
4	-	123	O
years	-	125	O
of	-	131	O
hydrochlorothiazide	-	134	B
-	-	153	I
triamterene	-	154	I
therapy	-	166	O
for	-	174	O
hypertension	-	178	O
.	-	190	O

The	7265370	192	O
stone	-	196	O
passed	-	202	O
spontaneously	-	209	O
and	-	223	O
was	-	227	O
found	-	231	O
to	-	237	O
contain	-	240	O
a	-	248	O
triamterene	-	250	B
metabolite	-	262	O
admixed	-	273	O
with	-	281	O
uric	-	286	B
acid	-	291	I
salts	-	296	I
.	-	301	O

Factors	7265370	303	O
affecting	-	311	O
triamterene	-	321	B
nephrolithiasis	-	333	O
are	-	349	O
discussed	-	353	O
and	-	363	O
2	-	367	O
previously	-	369	O
reported	-	380	O
cases	-	389	O
are	-	395	O
reviewed	-	399	O
.	-	407	O

Metabolic	7423039	0	O
involvement	-	10	O
in	-	22	O
adriamycin	-	25	B
cardiotoxicity	-	36	O
.	-	50	O

The	7423039	52	O
cardiotoxic	-	56	O
effects	-	68	O
of	-	76	O
adriamycin	-	79	B
were	-	90	O
studied	-	95	O
in	-	103	O
mammalian	-	106	O
myocardial	-	116	O
cells	-	127	O
in	-	133	O
culture	-	136	O
as	-	144	O
a	-	147	O
model	-	149	O
system	-	155	O
.	-	161	O

Adriamycin	7423039	163	B
inhibited	-	174	O
cell	-	184	O
growth	-	189	O
and	-	196	O
the	-	200	O
rhythmic	-	204	O
contractions	-	213	O
characteristic	-	226	O
of	-	241	O
myocardial	-	244	O
cells	-	255	O
in	-	261	O
culture	-	264	O
.	-	271	O

A	7423039	273	O
possible	-	275	O
involvement	-	284	O
of	-	296	O
energy	-	299	O
metabolism	-	306	O
was	-	317	O
suggested	-	321	O
previously	-	331	O
,	-	341	O
and	-	343	O
in	-	347	O
this	-	350	O
study	-	355	O
the	-	361	O
adenylate	-	365	O
energy	-	375	O
charge	-	382	O
and	-	389	O
phosphorylcreatine	-	393	B
mole	-	412	O
fraction	-	417	O
were	-	426	O
determined	-	431	O
in	-	442	O
the	-	445	O
adriamycin	-	449	B
-	-	459	O
treated	-	460	O
cells	-	468	O
.	-	473	O

The	7423039	475	O
adenylate	-	479	O
energy	-	489	O
charge	-	496	O
was	-	503	O
found	-	507	O
to	-	513	O
be	-	516	O
significantly	-	519	O
decreased	-	533	O
,	-	542	O
while	-	544	O
the	-	550	O
phophorylcreatine	-	554	B
mole	-	572	O
fraction	-	577	O
was	-	586	O
unchanged	-	590	O
.	-	599	O

Such	7423039	601	O
disparity	-	606	O
suggests	-	616	O
an	-	625	O
inhibition	-	628	O
of	-	639	O
creatine	-	642	B
phosphokinase	-	651	O
.	-	664	O

The	7423039	666	O
addition	-	670	O
of	-	679	O
1	-	682	O
mM	-	684	O
adenosine	-	687	B
to	-	697	O
the	-	700	O
myocardial	-	704	O
cell	-	715	O
cultures	-	720	O
markedly	-	729	O
increases	-	738	O
the	-	748	O
ATP	-	752	B
concentration	-	756	O
through	-	770	O
a	-	778	O
pathway	-	780	O
reportedly	-	788	O
leading	-	799	O
to	-	807	O
a	-	810	O
compartmentalized	-	812	O
ATP	-	830	B
pool	-	834	O
.	-	838	O

In	7423039	840	O
the	-	843	O
adriamycin	-	847	B
-	-	857	O
treated	-	858	O
cells	-	866	O
,	-	871	O
the	-	873	O
addition	-	877	O
of	-	886	O
adenosine	-	889	B
increased	-	899	O
the	-	909	O
adenylate	-	913	O
charge	-	923	O
and	-	930	O
,	-	933	O
concomitant	-	935	O
with	-	947	O
this	-	952	O
inrcease	-	957	O
,	-	965	O
the	-	967	O
cells	-	971	O
'	-	976	O
functional	-	978	O
integrity	-	989	O
,	-	998	O
in	-	1000	O
terms	-	1003	O
of	-	1009	O
percentage	-	1012	O
of	-	1023	O
beating	-	1026	O
cells	-	1034	O
and	-	1040	O
rate	-	1044	O
of	-	1049	O
contractions	-	1052	O
,	-	1064	O
was	-	1066	O
maintained	-	1070	O
.	-	1080	O

Age	7444978	0	O
-	-	3	O
dependent	-	4	O
sensitivity	-	14	O
of	-	26	O
the	-	29	O
rat	-	33	O
to	-	37	O
neurotoxic	-	40	O
effects	-	51	O
of	-	59	O
streptomycin	-	62	B
.	-	74	O

Streptomycin	7444978	76	B
sulfate	-	89	O
(	-	97	O
300	-	98	O
mg	-	102	O
/	-	104	O
kg	-	105	O
s	-	108	O
.	-	109	O
c	-	110	O
.	-	111	O
)	-	112	O
was	-	114	O
injected	-	118	O
for	-	127	O
various	-	131	O
periods	-	139	O
into	-	147	O
preweanling	-	152	O
rats	-	164	O
and	-	169	O
for	-	173	O
3	-	177	O
weeks	-	179	O
into	-	185	O
weanling	-	190	O
rats	-	199	O
.	-	203	O

Beginning	7444978	205	O
at	-	215	O
8	-	218	O
days	-	220	O
of	-	225	O
age	-	228	O
,	-	231	O
body	-	233	O
movement	-	238	O
and	-	247	O
hearing	-	251	O
were	-	259	O
examined	-	264	O
for	-	273	O
6	-	277	O
and	-	279	O
up	-	283	O
to	-	286	O
17	-	289	O
weeks	-	292	O
,	-	297	O
respectively	-	299	O
.	-	311	O

Abnormal	7444978	313	O
movements	-	322	O
and	-	332	O
deafness	-	336	O
occurred	-	345	O
only	-	354	O
in	-	359	O
rats	-	362	O
treated	-	367	O
during	-	375	O
the	-	382	O
preweaning	-	386	O
period	-	397	O
;	-	403	O
within	-	405	O
this	-	412	O
period	-	417	O
the	-	424	O
greatest	-	428	O
sensitivities	-	437	O
for	-	451	O
these	-	455	O
abnormalities	-	461	O
occurred	-	475	O
from	-	484	O
2	-	489	O
to	-	491	O
11	-	494	O
-	-	496	O
17	-	497	O
and	-	500	O
5	-	504	O
to	-	506	O
11	-	509	O
days	-	512	O
of	-	517	O
age	-	520	O
,	-	523	O
respectively	-	525	O
,	-	537	O
indicating	-	539	O
that	-	550	O
the	-	555	O
cochlea	-	559	O
is	-	567	O
more	-	570	O
sensitive	-	575	O
to	-	585	O
streptomycin	-	588	B
than	-	601	O
the	-	606	O
site	-	610	O
(	-	615	O
vestibular	-	616	O
or	-	627	O
central	-	630	O
)	-	637	O
responsible	-	639	O
for	-	651	O
the	-	655	O
dyskinesias	-	659	O
.	-	670	O

Crescentic	7834920	0	O
fibrillary	-	11	O
glomerulonephritis	-	22	O
associated	-	41	O
with	-	52	O
intermittent	-	57	O
rifampin	-	70	B
therapy	-	79	O
for	-	87	O
pulmonary	-	91	O
tuberculosis	-	101	O
.	-	113	O

This	7834920	115	O
case	-	120	O
study	-	125	O
reveals	-	131	O
an	-	139	O
unusual	-	142	O
finding	-	150	O
of	-	158	O
rapidly	-	161	O
proliferative	-	169	O
crescentic	-	183	O
glomerulonephritis	-	194	O
in	-	213	O
a	-	216	O
patient	-	218	O
treated	-	226	O
with	-	234	O
rifampin	-	239	B
who	-	248	O
had	-	252	O
no	-	256	O
other	-	259	O
identifiable	-	265	O
causes	-	278	O
for	-	285	O
developing	-	289	O
this	-	300	O
disease	-	305	O
.	-	312	O

This	7834920	314	O
patient	-	319	O
underwent	-	327	O
a	-	337	O
10	-	339	O
-	-	341	O
month	-	342	O
regimen	-	348	O
of	-	356	O
rifampin	-	359	B
and	-	368	O
isoniazid	-	372	B
for	-	382	O
pulmonary	-	386	O
tuberculosis	-	396	O
and	-	409	O
was	-	413	O
discovered	-	417	O
to	-	428	O
have	-	431	O
developed	-	436	O
signs	-	446	O
of	-	452	O
severe	-	455	O
renal	-	462	O
failure	-	468	O
five	-	476	O
weeks	-	481	O
after	-	487	O
completion	-	493	O
of	-	504	O
therapy	-	507	O
.	-	514	O

Renal	7834920	516	O
biopsy	-	522	O
revealed	-	529	O
severe	-	538	O
glomerulonephritis	-	545	O
with	-	564	O
crescents	-	569	O
,	-	578	O
electron	-	580	O
dense	-	589	O
fibrillar	-	595	O
deposits	-	605	O
and	-	614	O
moderate	-	618	O
lymphocytic	-	627	O
interstitial	-	639	O
infiltrate	-	652	O
.	-	662	O

Other	7834920	664	O
possible	-	670	O
causes	-	679	O
of	-	686	O
rapidly	-	689	O
progressive	-	697	O
glomerulonephritis	-	709	O
were	-	728	O
investigated	-	733	O
and	-	746	O
ruled	-	750	O
out	-	756	O
.	-	759	O

This	7834920	761	O
report	-	766	O
documents	-	773	O
the	-	783	O
unusual	-	787	O
occurrence	-	795	O
of	-	806	O
rapidly	-	809	O
progressive	-	817	O
glomerulonephritis	-	829	O
with	-	848	O
crescents	-	853	O
and	-	863	O
fibrillar	-	867	O
glomerulonephritis	-	877	O
in	-	896	O
a	-	899	O
patient	-	901	O
treated	-	909	O
with	-	917	O
rifampin	-	922	B
.	-	930	O

Time	7881871	0	O
course	-	5	O
of	-	12	O
lipid	-	15	O
peroxidation	-	21	O
in	-	34	O
puromycin	-	37	B
aminonucleoside	-	47	I
-	-	62	O
induced	-	63	O
nephropathy	-	71	O
.	-	82	O

Reactive	7881871	84	O
oxygen	-	93	B
species	-	100	O
have	-	108	O
been	-	113	O
implicated	-	118	O
in	-	129	O
the	-	132	O
pathogenesis	-	136	O
of	-	149	O
acute	-	152	O
puromycin	-	158	B
aminonucleoside	-	168	I
(	-	184	O
PAN	-	185	B
)	-	188	O
-	-	189	O
induced	-	190	O
nephropathy	-	198	O
,	-	209	O
with	-	211	O
antioxidants	-	216	O
significantly	-	229	O
reducing	-	243	O
the	-	252	O
proteinuria	-	256	O
.	-	267	O

The	7881871	269	O
temporal	-	273	O
relationship	-	282	O
between	-	295	O
lipid	-	303	O
peroxidation	-	309	O
in	-	322	O
the	-	325	O
kidney	-	329	O
and	-	336	O
proteinuria	-	340	O
was	-	352	O
examined	-	356	O
in	-	365	O
this	-	368	O
study	-	373	O
.	-	378	O

Rats	7881871	380	O
were	-	385	O
treated	-	390	O
with	-	398	O
a	-	403	O
single	-	405	O
IV	-	412	O
injection	-	415	O
of	-	425	O
puromycin	-	428	B
aminonucleoside	-	438	I
,	-	453	O
(	-	455	O
PAN	-	456	B
,	-	459	O
7	-	461	O
.	-	462	O
5	-	463	O
mg	-	465	O
/	-	467	O
kg	-	468	O
)	-	470	O
and	-	472	O
24	-	476	O
hour	-	479	O
urine	-	484	O
samples	-	490	O
were	-	498	O
obtained	-	503	O
prior	-	512	O
to	-	518	O
sacrifice	-	521	O
on	-	531	O
days	-	534	O
3	-	539	O
,	-	540	O
5	-	541	O
,	-	542	O
7	-	543	O
,	-	544	O
10	-	545	O
,	-	547	O
17	-	548	O
,	-	550	O
27	-	551	O
,	-	553	O
41	-	554	O

(	7881871	557	O
N	-	558	O
=	-	560	O
5	-	562	O
-	-	563	O
10	-	564	O
per	-	567	O
group	-	571	O
)	-	576	O
.	-	577	O

The	7881871	579	O
kidneys	-	583	O
were	-	591	O
removed	-	596	O
,	-	603	O
flushed	-	605	O
with	-	613	O
ice	-	618	O
cold	-	622	O
TRIS	-	627	O
buffer	-	632	O
.	-	638	O

Kidney	7881871	640	O
cortices	-	647	O
from	-	656	O
each	-	661	O
animal	-	666	O
were	-	673	O
used	-	678	O
to	-	683	O
prepare	-	686	O
homogenates	-	694	O
.	-	705	O

Tissue	7881871	707	O
lipid	-	714	O
peroxidation	-	720	O
was	-	733	O
measured	-	737	O
in	-	746	O
whole	-	749	O
homogenates	-	755	O
as	-	767	O
well	-	770	O
as	-	775	O
in	-	778	O
lipid	-	781	O
extracts	-	787	O
from	-	796	O
homogenates	-	801	O
as	-	813	O
thiobarbituric	-	816	B
acid	-	831	I
reactive	-	836	O
substances	-	845	O
.	-	855	O

Proteinuria	7881871	857	O
was	-	869	O
evident	-	873	O
at	-	881	O
day	-	884	O
5	-	888	O
,	-	889	O
peaked	-	891	O
at	-	898	O
day	-	901	O
7	-	905	O
and	-	907	O
persisted	-	911	O
to	-	921	O
day	-	924	O
27	-	928	O
.	-	930	O

Lipid	7881871	932	O
peroxidation	-	938	O
in	-	951	O
homogenates	-	954	O
was	-	966	O
maximal	-	970	O
at	-	978	O
day	-	981	O
3	-	985	O
and	-	987	O
declined	-	991	O
rapidly	-	1000	O
to	-	1008	O
control	-	1011	O
levels	-	1019	O
by	-	1026	O
day	-	1029	O
17	-	1033	O
.	-	1035	O

This	7881871	1037	O
study	-	1042	O
supports	-	1048	O
the	-	1057	O
role	-	1061	O
of	-	1066	O
lipid	-	1069	O
peroxidation	-	1075	O
in	-	1088	O
mediating	-	1091	O
the	-	1101	O
proteinuric	-	1105	O
injury	-	1117	O
in	-	1124	O
PAN	-	1127	B
nephropathy	-	1131	O
.	-	1142	O

Clomipramine	7930386	0	B
-	-	12	O
induced	-	13	O
sleep	-	21	O
disturbance	-	27	O
does	-	39	O
not	-	44	O
impair	-	48	O
its	-	55	O
prolactin	-	59	O
-	-	68	O
releasing	-	69	O
action	-	79	O
.	-	85	O

The	7930386	87	O
present	-	91	O
study	-	99	O
was	-	105	O
undertaken	-	109	O
to	-	120	O
examine	-	123	O
the	-	131	O
role	-	135	O
of	-	140	O
sleep	-	143	O
disturbance	-	149	O
,	-	160	O
induced	-	162	O
by	-	170	O
clomipramine	-	173	B
administration	-	186	O
,	-	200	O
on	-	202	O
the	-	205	O
secretory	-	209	O
rate	-	219	O
of	-	224	O
prolactin	-	227	O
(	-	237	O
PRL	-	238	O
)	-	241	O
in	-	243	O
addition	-	246	O
to	-	255	O
the	-	258	O
direct	-	262	O
drug	-	269	O
effect	-	274	O
.	-	280	O

Two	7930386	282	O
groups	-	286	O
of	-	293	O
supine	-	296	O
subjects	-	303	O
were	-	312	O
studied	-	317	O
under	-	325	O
placebo	-	331	O
-	-	338	O
controlled	-	339	O
conditions	-	350	O
,	-	360	O
one	-	362	O
during	-	366	O
the	-	373	O
night	-	377	O
,	-	382	O
when	-	384	O
sleeping	-	389	O
(	-	398	O
n	-	399	O
=	-	401	O
7	-	403	O
)	-	404	O
and	-	406	O
the	-	410	O
other	-	414	O
at	-	420	O
daytime	-	423	O
,	-	430	O
when	-	432	O
awake	-	437	O
(	-	443	O
n	-	444	O
=	-	446	O
6	-	448	O
)	-	449	O
.	-	450	O

Each	7930386	452	O
subject	-	457	O
received	-	465	O
a	-	474	O
single	-	476	O
50	-	483	O
mg	-	486	O
dose	-	489	O
of	-	494	O
clomipramine	-	497	B
given	-	510	O
orally	-	516	O
2	-	523	O
hours	-	525	O
before	-	531	O
blood	-	538	O
collection	-	544	O
.	-	554	O

Plasma	7930386	556	O
PRL	-	563	O
concentrations	-	567	O
were	-	582	O
analysed	-	587	O
at	-	596	O
10	-	599	O
min	-	602	O
intervals	-	606	O
and	-	616	O
underlying	-	620	O
secretory	-	631	O
rates	-	641	O
calculated	-	647	O
by	-	658	O
a	-	661	O
deconvolution	-	663	O
procedure	-	677	O
.	-	686	O

For	7930386	688	O
both	-	692	O
experiments	-	697	O
the	-	709	O
drug	-	713	O
intake	-	718	O
led	-	725	O
to	-	729	O
significant	-	732	O
increases	-	744	O
in	-	754	O
PRL	-	757	O
secretion	-	761	O
,	-	770	O
acting	-	772	O
preferentially	-	779	O
on	-	794	O
tonic	-	797	O
secretion	-	803	O
as	-	813	O
pulse	-	816	O
amplitude	-	822	O
and	-	832	O
frequency	-	836	O
did	-	846	O
not	-	850	O
differ	-	854	O
significantly	-	861	O
from	-	875	O
corresponding	-	880	O
control	-	894	O
values	-	902	O
.	-	908	O

During	7930386	910	O
the	-	917	O
night	-	921	O
clomipramine	-	927	B
ingestion	-	940	O
altered	-	950	O
the	-	958	O
complete	-	962	O
sleep	-	971	O
architecture	-	977	O
in	-	990	O
that	-	993	O
it	-	998	O
suppressed	-	1001	O
REM	-	1012	O
sleep	-	1016	O
and	-	1022	O
the	-	1026	O
sleep	-	1030	O
cycles	-	1036	O
and	-	1043	O
induced	-	1047	O
increased	-	1055	O
wakefulness	-	1065	O
.	-	1076	O

As	7930386	1078	O
the	-	1081	O
relative	-	1085	O
increase	-	1094	O
in	-	1103	O
PRL	-	1106	O
secretion	-	1110	O
expressed	-	1120	O
as	-	1130	O
a	-	1133	O
percentage	-	1135	O
of	-	1146	O
the	-	1149	O
mean	-	1153	O
did	-	1158	O
not	-	1162	O
significantly	-	1166	O
differ	-	1180	O
between	-	1187	O
the	-	1195	O
night	-	1199	O
and	-	1205	O
day	-	1209	O
time	-	1213	O
studies	-	1218	O
(	-	1226	O
46	-	1227	O
+	-	1230	O
/	-	1231	O
-	-	1232	O

19	7930386	1234	O
%	-	1236	O
vs	-	1238	O
34	-	1241	O
+	-	1244	O
/	-	1245	O
-	-	1246	O

10	7930386	1248	O
%	-	1250	O
)	-	1251	O
,	-	1252	O
it	-	1254	O
can	-	1257	O
be	-	1261	O
concluded	-	1264	O
that	-	1274	O
the	-	1279	O
observed	-	1283	O
sleep	-	1292	O
disturbance	-	1298	O
did	-	1310	O
not	-	1314	O
interfere	-	1318	O
with	-	1328	O
the	-	1333	O
drug	-	1337	O
action	-	1342	O
per	-	1349	O
se	-	1353	O
.	-	1355	O

The	7930386	1357	O
presence	-	1361	O
of	-	1370	O
REM	-	1373	O
sleep	-	1377	O
was	-	1383	O
shown	-	1387	O
not	-	1393	O
to	-	1397	O
be	-	1400	O
a	-	1403	O
determining	-	1405	O
factor	-	1417	O
either	-	1424	O
for	-	1431	O
secretory	-	1435	O
pulse	-	1445	O
amplitude	-	1451	O
and	-	1461	O
frequency	-	1465	O
,	-	1474	O
as	-	1476	O
,	-	1478	O
for	-	1480	O
both	-	1484	O
,	-	1488	O
mean	-	1490	O
nocturnal	-	1495	O
values	-	1505	O
were	-	1512	O
similar	-	1517	O
with	-	1525	O
and	-	1530	O
without	-	1534	O
prior	-	1542	O
clomipramine	-	1548	B
ingestion	-	1561	O
.	-	1570	O

Angioedema	7988234	0	O
following	-	11	O
the	-	21	O
intravenous	-	25	O
administration	-	37	O
of	-	52	O
metoprolol	-	55	B
.	-	65	O

A	7988234	67	O
72	-	69	O
-	-	71	O
year	-	72	O
-	-	76	O
old	-	77	O
woman	-	81	O
was	-	87	O
admitted	-	91	O
to	-	100	O
the	-	103	O
hospital	-	107	O
with	-	116	O
""""	-	121	O
flash	-	122	O
""""	-	127	O
pulmonary	-	129	O
edema	-	139	O
,	-	144	O
preceded	-	146	O
by	-	155	O
chest	-	158	O
pain	-	164	O
,	-	168	O
requiring	-	170	O
intubation	-	180	O
.	-	190	O

Her	7988234	192	O
medical	-	196	O
history	-	204	O
included	-	212	O
coronary	-	221	O
artery	-	230	O
disease	-	237	O
with	-	245	O
previous	-	250	O
myocardial	-	259	O
infarctions	-	270	O
,	-	281	O
hypertension	-	283	O
,	-	295	O
and	-	297	O
diabetes	-	301	O
mellitus	-	310	O
.	-	318	O

A	7988234	320	O
history	-	322	O
of	-	330	O
angioedema	-	333	O
secondary	-	344	O
to	-	354	O
lisinopril	-	357	B
therapy	-	368	O
was	-	376	O
elicited	-	380	O
.	-	388	O

Current	7988234	390	O
medications	-	398	O
did	-	410	O
not	-	414	O
include	-	418	O
angiotensin	-	426	B
-	-	437	O
converting	-	438	O
enzyme	-	449	O
inhibitors	-	456	O
or	-	467	O
beta	-	470	O
-	-	474	O
blockers	-	475	O
.	-	483	O

She	7988234	485	O
had	-	489	O
no	-	493	O
previous	-	496	O
beta	-	505	O
-	-	509	O
blocking	-	510	O
drug	-	519	O
exposure	-	524	O
.	-	532	O

During	7988234	534	O
the	-	541	O
first	-	545	O
day	-	551	O
of	-	555	O
hospitalization	-	558	O
(	-	574	O
while	-	575	O
intubated	-	581	O
)	-	590	O
,	-	591	O
intravenous	-	593	O
metoprolol	-	605	B
was	-	616	O
given	-	620	O
,	-	625	O
resulting	-	627	O
in	-	637	O
severe	-	640	O
angioedema	-	647	O
.	-	657	O

The	7988234	659	O
angioedema	-	663	O
resolved	-	674	O
after	-	683	O
therapy	-	689	O
with	-	697	O
intravenous	-	702	O
steroids	-	714	B
and	-	723	O
diphenhydramine	-	727	B
hydrochloride	-	743	O
.	-	756	O

Effect	8073369	0	O
of	-	7	O
coniine	-	10	B
on	-	18	O
the	-	21	O
developing	-	25	O
chick	-	36	O
embryo	-	42	O
.	-	48	O

Coniine	8073369	50	B
,	-	57	O
an	-	59	O
alkaloid	-	62	O
from	-	71	O
Conium	-	76	O
maculatum	-	83	O
(	-	93	O
poison	-	94	O
hemlock	-	101	O
)	-	108	O
,	-	109	O
has	-	111	O
been	-	115	O
shown	-	120	O
to	-	126	O
be	-	129	O
teratogenic	-	132	O
in	-	144	O
livestock	-	147	O
.	-	156	O

The	8073369	158	O
major	-	162	O
teratogenic	-	168	O
outcome	-	180	O
is	-	188	O
arthrogryposis	-	191	O
,	-	205	O
presumably	-	207	O
due	-	218	O
to	-	222	O
nicotinic	-	225	O
receptor	-	235	O
blockade	-	244	O
.	-	252	O

However	8073369	254	O
,	-	261	O
coniine	-	263	B
has	-	271	O
failed	-	275	O
to	-	282	O
produce	-	285	O
arthrogryposis	-	293	O
in	-	308	O
rats	-	311	O
or	-	316	O
mice	-	319	O
and	-	324	O
is	-	328	O
only	-	331	O
weakly	-	336	O
teratogenic	-	343	O
in	-	355	O
rabbits	-	358	O
.	-	365	O

The	8073369	367	O
purpose	-	371	O
of	-	379	O
this	-	382	O
study	-	387	O
was	-	393	O
to	-	397	O
evaluate	-	400	O
and	-	409	O
compare	-	413	O
the	-	421	O
effects	-	425	O
of	-	433	O
coniine	-	436	B
and	-	444	O
nicotine	-	448	B
in	-	457	O
the	-	460	O
developing	-	464	O
chick	-	475	O
.	-	480	O

Concentrations	8073369	482	O
of	-	497	O
coniine	-	500	B
and	-	508	O
nicotine	-	512	B
sulfate	-	521	O
were	-	529	O
0	-	534	O
.	-	535	O
015	-	536	O
%	-	539	O
,	-	540	O
0	-	542	O
.	-	543	O
03	-	544	O
%	-	546	O
,	-	547	O
0	-	549	O
.	-	550	O
075	-	551	O
%	-	554	O
,	-	555	O
0	-	557	O
.	-	558	O
15	-	559	O
%	-	561	O
,	-	562	O
0	-	564	O
.	-	565	O
75	-	566	O
%	-	568	O
,	-	569	O
1	-	571	O
.	-	572	O
5	-	573	O
%	-	574	O
,	-	575	O
3	-	577	O
%	-	578	O
,	-	579	O
and	-	581	O
6	-	585	O
%	-	586	O
and	-	588	O
1	-	592	O
%	-	593	O
,	-	594	O
5	-	596	O
%	-	597	O
,	-	598	O
and	-	600	O
10	-	604	O
%	-	606	O
,	-	607	O
respectively	-	609	O
.	-	621	O

Both	8073369	623	O
compounds	-	628	O
caused	-	638	O
deformations	-	645	O
and	-	658	O
lethality	-	662	O
in	-	672	O
a	-	675	O
dose	-	677	O
-	-	681	O
dependent	-	682	O
manner	-	692	O
.	-	698	O

All	8073369	700	O
concentrations	-	704	O
of	-	719	O
nicotine	-	722	B
sulfate	-	731	O
caused	-	739	O
some	-	746	O
lethality	-	751	O
but	-	761	O
a	-	765	O
no	-	767	O
effect	-	770	O
level	-	777	O
for	-	783	O
coniine	-	787	B
lethality	-	795	O
was	-	805	O
0	-	809	O
.	-	810	O
75	-	811	O
%	-	813	O
.	-	814	O

The	8073369	816	O
deformations	-	820	O
caused	-	833	O
by	-	840	O
both	-	843	O
coniine	-	848	B
and	-	856	O
nicotine	-	860	B
sulfate	-	869	O
were	-	877	O
excessive	-	882	O
flexion	-	892	O
or	-	900	O
extension	-	903	O
of	-	913	O
one	-	916	O
or	-	920	O
more	-	923	O
toes	-	928	O
.	-	932	O

No	8073369	934	O
histopathological	-	937	O
alterations	-	955	O
or	-	967	O
differences	-	970	O
in	-	982	O
bone	-	985	O
formation	-	990	O
were	-	1000	O
seen	-	1005	O
in	-	1010	O
the	-	1013	O
limbs	-	1017	O
or	-	1023	O
toes	-	1026	O
of	-	1031	O
any	-	1034	O
chicks	-	1038	O
from	-	1045	O
any	-	1050	O
group	-	1054	O
;	-	1059	O
however	-	1061	O
,	-	1068	O
extensive	-	1070	O
cranial	-	1080	O
hemorrhage	-	1088	O
occurred	-	1099	O
in	-	1108	O
all	-	1111	O
nicotine	-	1115	B
sulfate	-	1124	O
-	-	1131	O
treated	-	1132	O
chicks	-	1140	O
.	-	1146	O

There	8073369	1148	O
was	-	1154	O
a	-	1158	O
statistically	-	1160	O
significant	-	1174	O
(	-	1186	O
P	-	1187	O
<	-	1189	O
or	-	1191	O
=	-	1194	O
0	-	1196	O
.	-	1197	O
01	-	1198	O
)	-	1200	O
decrease	-	1202	O
in	-	1211	O
movement	-	1214	O
in	-	1223	O
coniine	-	1226	B
and	-	1234	O
nicotine	-	1238	B
sulfate	-	1247	O
treated	-	1255	O
chicks	-	1263	O
as	-	1270	O
determined	-	1273	O
by	-	1284	O
ultrasound	-	1287	O
.	-	1297	O

Control	8073369	1299	O
chicks	-	1307	O
were	-	1314	O
in	-	1319	O
motion	-	1322	O
an	-	1329	O
average	-	1332	O
of	-	1340	O
33	-	1343	O
.	-	1345	O
67	-	1346	O
%	-	1348	O
of	-	1350	O
the	-	1353	O
time	-	1357	O
,	-	1361	O
while	-	1363	O
coniine	-	1369	B
-	-	1376	O
treated	-	1377	O
chicks	-	1385	O
were	-	1392	O
only	-	1397	O
moving	-	1402	O
8	-	1409	O
.	-	1410	O
95	-	1411	O
%	-	1413	O
of	-	1415	O
a	-	1418	O
5	-	1420	O
-	-	1421	O
min	-	1422	O
interval	-	1426	O
,	-	1434	O
and	-	1436	O
no	-	1440	O
movement	-	1443	O
was	-	1452	O
observed	-	1456	O
for	-	1465	O
nicotine	-	1469	B
sulfate	-	1478	O
treated	-	1486	O
chicks	-	1494	O
.	-	1500	O

In	8073369	1502	O
summary	-	1505	O
,	-	1512	O
the	-	1514	O
chick	-	1518	O
embryo	-	1524	O
provides	-	1531	O
a	-	1540	O
reliable	-	1542	O
and	-	1551	O
simple	-	1555	O
experimental	-	1562	O
animal	-	1575	O
model	-	1582	O
of	-	1588	O
coniine	-	1591	B
-	-	1598	O
induced	-	1599	O
arthrogryposis	-	1607	O
.	-	1621	O

Data	8073369	1623	O
from	-	1628	O
this	-	1633	O
model	-	1638	O
support	-	1644	O
a	-	1652	O
mechanism	-	1654	O
involving	-	1664	O
nicotinic	-	1674	O
receptor	-	1684	O
blockade	-	1693	O
with	-	1702	O
subsequent	-	1707	O
decreased	-	1718	O
fetal	-	1728	O
movement	-	1734	O
.	-	1742	O

Epidural	8302922	0	O
blood	-	9	O
flow	-	15	O
during	-	20	O
prostaglandin	-	27	B
E1	-	41	I
or	-	44	O
trimethaphan	-	47	B
induced	-	60	O
hypotension	-	68	O
.	-	79	O

To	8302922	81	O
evaluate	-	84	O
the	-	93	O
effect	-	97	O
of	-	104	O
prostaglandin	-	107	B
E1	-	121	I
(	-	124	O
PGE1	-	125	B
)	-	129	O
or	-	131	O
trimethaphan	-	134	B
(	-	147	O
TMP	-	148	B
)	-	151	O
induced	-	153	O
hypotension	-	161	O
on	-	173	O
epidural	-	176	O
blood	-	185	O
flow	-	191	O
(	-	196	O
EBF	-	197	O
)	-	200	O
during	-	202	O
spinal	-	209	O
surgery	-	216	O
,	-	223	O
EBF	-	225	O
was	-	229	O
measured	-	233	O
using	-	242	O
the	-	248	O
heat	-	252	O
clearance	-	257	O
method	-	267	O
in	-	274	O
30	-	277	O
patients	-	280	O
who	-	289	O
underwent	-	293	O
postero	-	303	O
-	-	310	O
lateral	-	311	O
interbody	-	319	O
fusion	-	329	O
under	-	336	O
isoflurane	-	342	B
anaesthesia	-	353	O
.	-	364	O

An	8302922	366	O
initial	-	369	O
dose	-	377	O
of	-	382	O
0	-	385	O
.	-	386	O
1	-	387	O
microgram	-	389	O
.	-	398	O
kg	-	399	O
-	-	401	O
1	-	402	O
.	-	403	O
min	-	404	O
-	-	407	O
1	-	408	O
of	-	410	O
PGE1	-	413	B
(	-	418	O
15	-	419	O
patients	-	422	O
)	-	430	O
,	-	431	O
or	-	433	O
10	-	436	O
micrograms	-	439	O
.	-	449	O
kg	-	450	O
-	-	452	O
1	-	453	O
.	-	454	O
min	-	455	O
-	-	458	O
1	-	459	O
of	-	461	O
TMP	-	464	B
(	-	468	O
15	-	469	O
patients	-	472	O
)	-	480	O
was	-	482	O
administered	-	486	O
intravenously	-	499	O
after	-	513	O
the	-	519	O
dural	-	523	O
opening	-	529	O
and	-	537	O
the	-	541	O
dose	-	545	O
was	-	550	O
adjusted	-	554	O
to	-	563	O
maintain	-	566	O
the	-	575	O
mean	-	579	O
arterial	-	584	O
blood	-	593	O
pressure	-	599	O
(	-	608	O
MAP	-	609	O
)	-	612	O
at	-	614	O
about	-	617	O
60	-	623	O
mmHg	-	626	O
.	-	630	O

The	8302922	632	O
hypotensive	-	636	O
drug	-	648	O
was	-	653	O
discontinued	-	657	O
at	-	670	O
the	-	673	O
completion	-	677	O
of	-	688	O
the	-	691	O
operative	-	695	O
procedure	-	705	O
.	-	714	O

After	8302922	716	O
starting	-	722	O
PGE1	-	731	B
or	-	736	O
TMP	-	739	B
,	-	742	O
MAP	-	744	O
and	-	748	O
rate	-	752	O
pressure	-	757	O
product	-	766	O
(	-	774	O
RPP	-	775	O
)	-	778	O
decreased	-	780	O
significantly	-	790	O
compared	-	804	O
with	-	813	O
preinfusion	-	818	O
values	-	830	O
(	-	837	O
P	-	838	O
<	-	840	O
0	-	842	O
.	-	843	O
01	-	844	O
)	-	846	O
,	-	847	O
and	-	849	O
the	-	853	O
degree	-	857	O
of	-	864	O
hypotension	-	867	O
due	-	879	O
to	-	883	O
PGE1	-	886	B
remained	-	891	O
constant	-	900	O
until	-	909	O
60	-	915	O
min	-	918	O
after	-	922	O
its	-	928	O
discontinuation	-	932	O
.	-	947	O

Heart	8302922	949	O
rate	-	955	O
(	-	960	O
HR	-	961	O
)	-	963	O
did	-	965	O
not	-	969	O
change	-	973	O
in	-	980	O
either	-	983	O
group	-	990	O
.	-	995	O

EBFF	8302922	997	O
did	-	1002	O
not	-	1006	O
change	-	1010	O
during	-	1017	O
PGE1	-	1024	B
infusion	-	1029	O
whereas	-	1038	O
in	-	1046	O
the	-	1049	O
TMP	-	1053	B
group	-	1057	O
,	-	1062	O
EBF	-	1064	O
decreased	-	1068	O
significantly	-	1078	O
at	-	1092	O
30	-	1095	O
and	-	1098	O
60	-	1102	O
min	-	1105	O
after	-	1109	O
the	-	1115	O
start	-	1119	O
of	-	1125	O
TMP	-	1128	B
(	-	1132	O
preinfusion	-	1133	O
:	-	1144	O
45	-	1146	O
.	-	1148	O
9	-	1149	O
+	-	1151	O
/	-	1152	O
-	-	1153	O

13	8302922	1155	O
.	-	1157	O
9	-	1158	O
ml	-	1160	O
/	-	1162	O
100g	-	1163	O
/	-	1167	O
min	-	1168	O
.	-	1171	O

30	8302922	1173	O
min	-	1176	O
:	-	1179	O
32	-	1181	O
.	-	1183	O
3	-	1184	O
+	-	1186	O
/	-	1187	O
-	-	1188	O

9	8302922	1190	O
.	-	1191	O
9	-	1192	O
ml	-	1194	O
/	-	1196	O
100	-	1197	O

g	8302922	1201	O
/	-	1202	O
min	-	1203	O
(	-	1207	O
P	-	1208	O
<	-	1210	O
0	-	1212	O
.	-	1213	O
05	-	1214	O
)	-	1216	O
.	-	1217	O

60	8302922	1219	O
min	-	1222	O
:	-	1225	O
30	-	1227	O
+	-	1230	O
/	-	1231	O
-	-	1232	O

7	8302922	1234	O
.	-	1235	O
5	-	1236	O
ml	-	1238	O
/	-	1240	O
100	-	1241	O
g	-	1245	O
/	-	1246	O
min	-	1247	O
(	-	1251	O
P	-	1252	O
<	-	1254	O
0	-	1256	O
.	-	1257	O
05	-	1258	O
)	-	1260	O
)	-	1261	O
.	-	1262	O

These	8302922	1264	O
results	-	1270	O
suggest	-	1278	O
that	-	1286	O
PGE1	-	1291	B
may	-	1296	O
be	-	1300	O
preferable	-	1303	O
to	-	1314	O
TMP	-	1317	B
for	-	1321	O
hypotensive	-	1325	O
anaesthesia	-	1337	O
in	-	1349	O
spinal	-	1352	O
surgery	-	1359	O
because	-	1367	O
TMP	-	1375	B
decreased	-	1379	O
EBF	-	1389	O
.	-	1392	O

Immunohistochemical	8410052	0	O
studies	-	20	O
with	-	28	O
antibodies	-	33	O
to	-	44	O
neurofilament	-	47	O
proteins	-	61	O
on	-	70	O
axonal	-	73	O
damage	-	80	O
in	-	87	O
experimental	-	90	O
focal	-	103	O
lesions	-	109	O
in	-	117	O
rat	-	120	O
.	-	123	O

Immunohistochemistry	8410052	125	O
with	-	146	O
monoclonal	-	151	O
antibodies	-	162	O
against	-	173	O
neurofilament	-	181	O
(	-	195	O
NF	-	196	O
)	-	198	O
proteins	-	200	O
of	-	209	O
middle	-	212	O
and	-	219	O
high	-	223	O
molecular	-	228	O
weight	-	238	O
class	-	245	O
,	-	250	O
NF	-	252	O
-	-	254	O
M	-	255	O
and	-	257	O
NF	-	261	O
-	-	263	O
H	-	264	O
,	-	265	O
was	-	267	O
used	-	271	O
to	-	276	O
study	-	279	O
axonal	-	285	O
injury	-	292	O
in	-	299	O
the	-	302	O
borderzone	-	306	O
of	-	317	O
focal	-	320	O
lesions	-	326	O
in	-	334	O
rats	-	337	O
.	-	341	O

Focal	8410052	343	O
injury	-	349	O
in	-	356	O
the	-	359	O
cortex	-	363	O
was	-	370	O
produced	-	374	O
by	-	383	O
infusion	-	386	O
of	-	395	O
lactate	-	398	B
at	-	406	O
acid	-	409	O
pH	-	414	O
or	-	417	O
by	-	420	O
stab	-	423	O
caused	-	428	O
by	-	435	O
needle	-	438	O
insertion	-	445	O
.	-	454	O

Infarcts	8410052	456	O
in	-	465	O
substantia	-	468	O
nigra	-	479	O
pars	-	485	O
reticulata	-	490	O
were	-	501	O
evoked	-	506	O
by	-	513	O
prolonged	-	516	O
pilocarpine	-	526	B
-	-	537	O
induced	-	538	O
status	-	546	O
epilepticus	-	553	O
.	-	564	O

Immunohistochemical	8410052	566	O
staining	-	586	O
for	-	595	O
NFs	-	599	O
showed	-	603	O
characteristic	-	610	O
terminal	-	625	O
clubs	-	634	O
of	-	640	O
axons	-	643	O
in	-	649	O
the	-	652	O
borderzone	-	656	O
of	-	667	O
lesions	-	670	O
.	-	677	O

Differences	8410052	679	O
in	-	691	O
the	-	694	O
labelling	-	698	O
pattern	-	708	O
occurred	-	716	O
with	-	725	O
different	-	730	O
antibodies	-	740	O
which	-	751	O
apparently	-	757	O
depended	-	768	O
on	-	777	O
molecular	-	780	O
weight	-	790	O
class	-	797	O
of	-	803	O
NFs	-	806	O
and	-	810	O
phosphorylation	-	814	O
state	-	830	O
.	-	835	O

These	8410052	837	O
immunohistochemical	-	843	O
changes	-	863	O
of	-	871	O
NFs	-	874	O
can	-	878	O
serve	-	882	O
as	-	888	O
a	-	891	O
marker	-	893	O
for	-	900	O
axonal	-	904	O
damage	-	911	O
in	-	918	O
various	-	921	O
experimental	-	929	O
traumatic	-	942	O
or	-	952	O
ischemic	-	955	O
lesions	-	964	O
.	-	971	O

Increase	8423889	0	O
of	-	9	O
Parkinson	-	12	O
disability	-	22	O
after	-	33	O
fluoxetine	-	39	B
medication	-	50	O
.	-	60	O

Depression	8423889	62	O
is	-	73	O
a	-	76	O
major	-	78	O
clinical	-	84	O
feature	-	93	O
of	-	101	O
Parkinson	-	104	O
's	-	113	O
disease	-	116	O
.	-	123	O

We	8423889	125	O
report	-	128	O
the	-	135	O
increased	-	139	O
amount	-	149	O
of	-	156	O
motor	-	159	O
disability	-	165	O
in	-	176	O
four	-	179	O
patients	-	184	O
with	-	193	O
idiopathic	-	198	O
Parkinson	-	209	O
's	-	218	O
disease	-	221	O
after	-	229	O
exposure	-	235	O
to	-	244	O
the	-	247	O
antidepressant	-	251	B
fluoxetine	-	266	B
.	-	276	O

The	8423889	278	O
possibility	-	282	O
of	-	294	O
a	-	297	O
clinically	-	299	O
relevant	-	310	O
dopamine	-	319	B
-	-	327	O
antagonistic	-	328	O
capacity	-	341	O
of	-	350	O
fluoxetine	-	353	B
in	-	364	O
Parkinson	-	367	O
's	-	376	O
disease	-	379	O
patients	-	387	O
must	-	396	O
be	-	401	O
considered	-	404	O
.	-	414	O

Acetaminophen	8682684	0	B
-	-	13	O
induced	-	14	O
hypotension	-	22	O
.	-	33	O

Through	8682684	35	O
30	-	43	O
years	-	46	O
of	-	52	O
widespread	-	55	O
use	-	66	O
,	-	69	O
acetaminophen	-	71	B
has	-	85	O
been	-	89	O
shown	-	94	O
to	-	100	O
be	-	103	O
a	-	106	O
remarkably	-	108	O
safe	-	119	O
medication	-	124	O
in	-	135	O
therapeutic	-	138	O
dosages	-	150	O
.	-	157	O

The	8682684	159	O
potential	-	163	O
for	-	173	O
acetaminophen	-	177	B
to	-	191	O
produce	-	194	O
cardiovascular	-	202	O
toxicities	-	217	O
is	-	228	O
very	-	231	O
low	-	236	O
.	-	239	O

However	8682684	241	O
,	-	248	O
acetaminophen	-	250	B
has	-	264	O
been	-	268	O
demonstrated	-	273	O
to	-	286	O
produce	-	289	O
symptoms	-	297	O
of	-	306	O
anaphylaxis	-	309	O
,	-	320	O
including	-	322	O
hypotension	-	332	O
,	-	343	O
in	-	345	O
sensitive	-	348	O
individuals	-	358	O
.	-	369	O

This	8682684	371	O
article	-	376	O
describes	-	384	O
two	-	394	O
critically	-	398	O
ill	-	409	O
patients	-	413	O
in	-	422	O
whom	-	425	O
transient	-	430	O
episodes	-	440	O
of	-	449	O
hypotension	-	452	O
reproducibly	-	464	O
developed	-	477	O
after	-	487	O
administration	-	493	O
of	-	508	O
acetaminophen	-	511	B
.	-	524	O

Other	8682684	526	O
symptoms	-	532	O
of	-	541	O
allergic	-	544	O
reactions	-	553	O
were	-	563	O
not	-	568	O
clinically	-	572	O
detectable	-	583	O
.	-	593	O

The	8682684	595	O
hypotensive	-	599	O
episodes	-	611	O
were	-	620	O
severe	-	625	O
enough	-	632	O
to	-	639	O
require	-	642	O
vasopressor	-	650	O
administration	-	662	O
.	-	676	O

The	8682684	678	O
reports	-	682	O
illustrate	-	690	O
the	-	701	O
need	-	705	O
for	-	710	O
clinicians	-	714	O
to	-	725	O
consider	-	728	O
acetaminophen	-	737	B
in	-	751	O
patients	-	754	O
with	-	763	O
hypotension	-	768	O
of	-	780	O
unknown	-	783	O
origin	-	791	O
.	-	797	O

Acute	9625142	0	O
hepatitis	-	6	O
,	-	15	O
autoimmune	-	17	O
hemolytic	-	28	O
anemia	-	38	O
,	-	44	O
and	-	46	O
erythroblastocytopenia	-	50	O
induced	-	73	O
by	-	81	O
ceftriaxone	-	84	B
.	-	95	O

An	9625142	97	O
80	-	100	O
-	-	102	O
yr	-	103	O
-	-	105	O
old	-	106	O
man	-	110	O
developed	-	114	O
acute	-	124	O
hepatitis	-	130	O
shortly	-	140	O
after	-	148	O
ingesting	-	154	O
oral	-	164	O
ceftriaxone	-	169	B
.	-	180	O

Although	9625142	182	O
the	-	191	O
transaminases	-	195	O
gradually	-	209	O
returned	-	219	O
to	-	228	O
baseline	-	231	O
after	-	240	O
withholding	-	246	O
the	-	258	O
beta	-	262	B
lactam	-	267	I
antibiotic	-	274	O
,	-	284	O
there	-	286	O
was	-	292	O
a	-	296	O
gradual	-	298	O
increase	-	306	O
in	-	315	O
serum	-	318	O
bilirubin	-	324	B
and	-	334	O
a	-	338	O
decrease	-	340	O
in	-	349	O
hemoglobin	-	352	O
concentration	-	363	O
caused	-	377	O
by	-	384	O
an	-	387	O
autoimmune	-	390	O
hemolytic	-	401	O
anemia	-	411	O
and	-	418	O
erythroblastocytopenia	-	422	O
.	-	444	O

These	9625142	446	O
responded	-	452	O
to	-	462	O
systemic	-	465	O
steroids	-	474	B
and	-	483	O
immunoglobulins	-	487	O
.	-	502	O

Despite	9625142	504	O
the	-	512	O
widespread	-	516	O
use	-	527	O
of	-	531	O
these	-	534	O
agents	-	540	O
this	-	547	O
triad	-	552	O
of	-	558	O
side	-	561	O
effects	-	566	O
has	-	574	O
not	-	578	O
previously	-	582	O
been	-	593	O
reported	-	598	O
in	-	607	O
connection	-	610	O
with	-	621	O
beta	-	626	B
lactam	-	631	I
antibiotics	-	638	O
.	-	649	O

Adverse	9766615	0	O
effects	-	8	O
of	-	16	O
the	-	19	O
atypical	-	23	O
antipsychotics	-	32	O
.	-	46	O

Collaborative	9766615	48	O
Working	-	62	O
Group	-	70	O
on	-	76	O
Clinical	-	79	O
Trial	-	88	O
Evaluations	-	94	O
.	-	105	O

Adverse	9766615	107	O
effects	-	115	O
of	-	123	O
antipsychotics	-	126	O
often	-	141	O
lead	-	147	O
to	-	152	O
noncompliance	-	155	O
.	-	168	O

Thus	9766615	170	O
,	-	174	O
clinicians	-	176	O
should	-	187	O
address	-	194	O
patients	-	202	O
'	-	210	O
concerns	-	212	O
about	-	221	O
adverse	-	227	O
effects	-	235	O
and	-	243	O
attempt	-	247	O
to	-	255	O
choose	-	258	O
medications	-	265	O
that	-	277	O
will	-	282	O
improve	-	287	O
their	-	295	O
patients	-	301	O
'	-	309	O
quality	-	311	O
of	-	319	O
life	-	322	O
as	-	327	O
well	-	330	O
as	-	335	O
overall	-	338	O
health	-	346	O
.	-	352	O

The	9766615	354	O
side	-	358	O
effect	-	363	O
profiles	-	370	O
of	-	379	O
the	-	382	O
atypical	-	386	O
antipsychotics	-	395	O
are	-	410	O
more	-	414	O
advantageous	-	419	O
than	-	432	O
those	-	437	O
of	-	443	O
the	-	446	O
conventional	-	450	O
neuroleptics	-	463	O
.	-	475	O

Conventional	9766615	477	O
agents	-	490	O
are	-	497	O
associated	-	501	O
with	-	512	O
unwanted	-	517	O
central	-	526	O
nervous	-	534	O
system	-	542	O
effects	-	549	O
,	-	556	O
including	-	558	O
extrapyramidal	-	568	O
symptoms	-	583	O
(	-	592	O
EPS	-	593	O
)	-	596	O
,	-	597	O
tardive	-	599	O
dyskinesia	-	607	O
,	-	617	O
sedation	-	619	O
,	-	627	O
and	-	629	O
possible	-	633	O
impairment	-	642	O
of	-	653	O
some	-	656	O
cognitive	-	661	O
measures	-	671	O
,	-	679	O
as	-	681	O
well	-	684	O
as	-	689	O
cardiac	-	692	O
effects	-	700	O
,	-	707	O
orthostatic	-	709	O
hypotension	-	721	O
,	-	732	O
hepatic	-	734	O
changes	-	742	O
,	-	749	O
anticholinergic	-	751	O
side	-	767	O
effects	-	772	O
,	-	779	O
sexual	-	781	O
dysfunction	-	788	O
,	-	799	O
and	-	801	O
weight	-	805	O
gain	-	812	O
.	-	816	O

The	9766615	818	O
newer	-	822	O
atypical	-	828	O
agents	-	837	O
have	-	844	O
a	-	849	O
lower	-	851	O
risk	-	857	O
of	-	862	O
EPS	-	865	O
,	-	868	O
but	-	870	O
are	-	874	O
associated	-	878	O
in	-	889	O
varying	-	892	O
degrees	-	900	O
with	-	908	O
sedation	-	913	O
,	-	921	O
cardiovascular	-	923	O
effects	-	938	O
,	-	945	O
anticholinergic	-	947	O
effects	-	963	O
,	-	970	O
weight	-	972	O
gain	-	979	O
,	-	983	O
sexual	-	985	O
dysfunction	-	992	O
,	-	1003	O
hepatic	-	1005	O
effects	-	1013	O
,	-	1020	O
lowered	-	1022	O
seizure	-	1030	O
threshold	-	1038	O
(	-	1048	O
primarily	-	1049	O
clozapine	-	1059	B
)	-	1068	O
,	-	1069	O
and	-	1071	O
agranulocytosis	-	1075	O
(	-	1091	O
clozapine	-	1092	B
only	-	1102	O
)	-	1106	O
.	-	1107	O

Since	9766615	1109	O
the	-	1115	O
incidence	-	1119	O
and	-	1129	O
severity	-	1133	O
of	-	1142	O
specific	-	1145	O
adverse	-	1154	O
effects	-	1162	O
differ	-	1170	O
among	-	1177	O
the	-	1183	O
various	-	1187	O
atypicals	-	1195	O
,	-	1204	O
the	-	1206	O
clinician	-	1210	O
should	-	1220	O
carefully	-	1227	O
consider	-	1237	O
which	-	1246	O
side	-	1252	O
effects	-	1257	O
are	-	1265	O
most	-	1269	O
likely	-	1274	O
to	-	1281	O
lead	-	1284	O
to	-	1289	O
the	-	1292	O
individual	-	1296	O
's	-	1306	O
dissatisfaction	-	1309	O
and	-	1325	O
noncompliance	-	1329	O
before	-	1343	O
choosing	-	1350	O
an	-	1359	O
antipsychotic	-	1362	O
for	-	1376	O
a	-	1380	O
particular	-	1382	O
patient	-	1393	O
.	-	1400	O

Effects	10193204	0	O
of	-	8	O
tetrandrine	-	11	B
and	-	23	O
fangchinoline	-	27	B
on	-	41	O
experimental	-	44	O
thrombosis	-	57	O
in	-	68	O
mice	-	71	O
and	-	76	O
human	-	80	O
platelet	-	86	O
aggregation	-	95	O
.	-	106	O

Tetrandrine	10193204	108	B
(	-	120	O
TET	-	121	B
)	-	124	O
and	-	126	O
fangchinoline	-	130	B
(	-	144	O
FAN	-	145	B
)	-	148	O
are	-	150	O
two	-	154	O
naturally	-	158	O
occurring	-	168	O
analogues	-	178	O
with	-	188	O
a	-	193	O
bisbenzylisoquinoline	-	195	B
structure	-	217	O
.	-	226	O

The	10193204	228	O
present	-	232	O
study	-	240	O
was	-	246	O
undertaken	-	250	O
to	-	261	O
investigate	-	264	O
the	-	276	O
effects	-	280	O
of	-	288	O
TET	-	291	B
and	-	295	O
FAN	-	299	B
on	-	303	O
the	-	306	O
experimental	-	310	O
thrombosis	-	323	O
induced	-	334	O
by	-	342	O
collagen	-	345	O
plus	-	354	O
epinephrine	-	359	B
(	-	371	O
EP	-	372	B
)	-	374	O
in	-	376	O
mice	-	379	O
,	-	383	O
and	-	385	O
platelet	-	389	O
aggregation	-	398	O
and	-	410	O
blood	-	414	O
coagulation	-	420	O
in	-	432	O
vitro	-	435	O
.	-	440	O

In	10193204	442	O
the	-	445	O
in	-	449	O
vivo	-	452	O
study	-	457	O
,	-	462	O
the	-	464	O
administration	-	468	O
(	-	483	O
50	-	484	O
mg	-	487	O
/	-	489	O
kg	-	490	O
,	-	492	O
i	-	494	O
.	-	495	O
p	-	496	O
.	-	497	O
)	-	498	O

of	10193204	500	O
TET	-	503	B
and	-	507	O
FAN	-	511	B
in	-	515	O
mice	-	518	O
showed	-	523	O
the	-	530	O
inhibition	-	534	O
of	-	545	O
thrombosis	-	548	O
by	-	559	O
55	-	562	O
%	-	564	O
and	-	566	O
35	-	570	O
%	-	572	O
,	-	573	O
respectively	-	575	O
,	-	587	O
while	-	589	O
acetylsalicylic	-	595	B
acid	-	611	I
(	-	616	O
ASA	-	617	B
,	-	620	O
50	-	622	O
mg	-	625	O
/	-	627	O
kg	-	628	O
,	-	630	O
i	-	632	O
.	-	633	O
p	-	634	O
.	-	635	O
)	-	636	O
,	-	637	O
a	-	639	O
positive	-	641	O
control	-	650	O
,	-	657	O
showed	-	659	O
only	-	666	O
30	-	671	O
%	-	673	O
inhibition	-	675	O
.	-	685	O

In	10193204	687	O
the	-	690	O
vitro	-	694	O
human	-	700	O
platelet	-	706	O
aggregations	-	715	O
induced	-	728	O
by	-	736	O
the	-	739	O
agonists	-	743	O
used	-	752	O
in	-	757	O
tests	-	760	O
,	-	765	O
TET	-	767	B
and	-	771	O
FAN	-	775	B
showed	-	779	O
the	-	786	O
inhibitions	-	790	O
dose	-	802	O
dependently	-	807	O
.	-	818	O

In	10193204	820	O
addition	-	823	O
,	-	831	O
neither	-	833	O
TET	-	841	B
nor	-	845	O
FAN	-	849	B
showed	-	853	O
any	-	860	O
anticoagulation	-	864	O
activities	-	880	O
in	-	891	O
the	-	894	O
measurement	-	898	O
of	-	910	O
the	-	913	O
activated	-	917	O
partial	-	927	O
thromboplastin	-	935	O
time	-	950	O
(	-	955	O
APTT	-	956	O
)	-	960	O
,	-	961	O
prothrombin	-	963	O
time	-	975	O
(	-	980	O
PT	-	981	O
)	-	983	O
and	-	985	O
thrombin	-	989	O
time	-	998	O
(	-	1003	O
TT	-	1004	O
)	-	1006	O
using	-	1008	O
human	-	1014	O
-	-	1019	O
citrated	-	1020	O
plasma	-	1029	O
.	-	1035	O

These	10193204	1037	O
results	-	1043	O
suggest	-	1051	O
that	-	1059	O
antithrombosis	-	1064	O
of	-	1079	O
TET	-	1082	B
and	-	1086	O
FAN	-	1090	B
in	-	1094	O
mice	-	1097	O
may	-	1102	O
be	-	1106	O
mainly	-	1109	O
related	-	1116	O
to	-	1124	O
the	-	1127	O
antiplatelet	-	1131	O
aggregation	-	1144	O
activities	-	1156	O
.	-	1166	O

Gemcitabine	10526274	0	B
plus	-	12	O
vinorelbine	-	17	B
in	-	29	O
nonsmall	-	32	O
cell	-	41	O
lung	-	46	O
carcinoma	-	51	O
patients	-	61	O
age	-	70	O
70	-	74	O
years	-	77	O
or	-	83	O
older	-	86	O
or	-	92	O
patients	-	95	O
who	-	104	O
can	-	108	O
not	-	111	O
receive	-	115	O
cisplatin	-	123	B
.	-	132	O

Oncopaz	10526274	134	O
Cooperative	-	142	O
Group	-	154	O
.	-	159	O

BACKGROUND	10526274	161	O
:	-	171	O

Although	10526274	173	O
the	-	182	O
prevalence	-	186	O
of	-	197	O
nonsmall	-	200	O
cell	-	209	O
lung	-	214	O
carcinoma	-	219	O
(	-	229	O
NSCLC	-	230	O
)	-	235	O
is	-	237	O
high	-	240	O
among	-	245	O
elderly	-	251	O
patients	-	259	O
,	-	267	O
few	-	269	O
data	-	273	O
are	-	278	O
available	-	282	O
regarding	-	292	O
the	-	302	O
efficacy	-	306	O
and	-	315	O
toxicity	-	319	O
of	-	328	O
chemotherapy	-	331	O
in	-	344	O
this	-	347	O
group	-	352	O
of	-	358	O
patients	-	361	O
.	-	369	O

Recent	10526274	371	O
reports	-	378	O
indicate	-	386	O
that	-	395	O
single	-	400	O
agent	-	407	O
therapy	-	413	O
with	-	421	O
vinorelbine	-	426	B
(	-	438	O
VNB	-	439	B
)	-	442	O
or	-	444	O
gemcitabine	-	447	B
(	-	459	O
GEM	-	460	B
)	-	463	O
may	-	465	O
obtain	-	469	O
a	-	476	O
response	-	478	O
rate	-	487	O
of	-	492	O
20	-	495	O
-	-	497	O
30	-	498	O
%	-	500	O
in	-	502	O
elderly	-	505	O
patients	-	513	O
,	-	521	O
with	-	523	O
acceptable	-	528	O
toxicity	-	539	O
and	-	548	O
improvement	-	552	O
in	-	564	O
symptoms	-	567	O
and	-	576	O
quality	-	580	O
of	-	588	O
life	-	591	O
.	-	595	O

In	10526274	597	O
the	-	600	O
current	-	604	O
study	-	612	O
the	-	618	O
efficacy	-	622	O
and	-	631	O
toxicity	-	635	O
of	-	644	O
the	-	647	O
combination	-	651	O
of	-	663	O
GEM	-	666	B
and	-	670	O
VNB	-	674	B
in	-	678	O
elderly	-	681	O
patients	-	689	O
with	-	698	O
advanced	-	703	O
NSCLC	-	712	O
or	-	718	O
those	-	721	O
with	-	727	O
some	-	732	O
contraindication	-	737	O
to	-	754	O
receiving	-	757	O
cisplatin	-	767	B
were	-	777	O
assessed	-	782	O
.	-	790	O

METHODS	10526274	792	O
:	-	799	O

Forty	10526274	801	O
-	-	806	O
nine	-	807	O
patients	-	812	O
with	-	821	O
advanced	-	826	O
NSCLC	-	835	O
were	-	841	O
included	-	846	O
,	-	854	O
38	-	856	O
of	-	859	O
whom	-	862	O
were	-	867	O
age	-	872	O
>	-	876	O

/	10526274	877	O
=	-	878	O

70	10526274	880	O
years	-	883	O
and	-	889	O
11	-	893	O
were	-	896	O
age	-	901	O
<	-	905	O
70	-	907	O
years	-	910	O
but	-	916	O
who	-	920	O
had	-	924	O
some	-	928	O
contraindication	-	933	O
to	-	950	O
receiving	-	953	O
cisplatin	-	963	B
.	-	972	O

All	10526274	974	O
patients	-	978	O
were	-	987	O
evaluable	-	992	O
for	-	1002	O
response	-	1006	O
and	-	1015	O
toxicity	-	1019	O
.	-	1027	O

Treatment	10526274	1029	O
was	-	1039	O
comprised	-	1043	O
of	-	1053	O
VNB	-	1056	B
,	-	1059	O
25	-	1061	O
mg	-	1064	O
/	-	1066	O
m	-	1067	O
(	-	1068	O
2	-	1069	O
)	-	1070	O
,	-	1071	O
plus	-	1073	O
GEM	-	1078	B
,	-	1081	O
1000	-	1083	O
mg	-	1088	O
/	-	1090	O
m	-	1091	O
(	-	1092	O
2	-	1093	O
)	-	1094	O
,	-	1095	O
both	-	1097	O
on	-	1102	O
Days	-	1105	O
1	-	1110	O
,	-	1111	O
8	-	1113	O
,	-	1114	O
and	-	1116	O
15	-	1120	O
every	-	1123	O
28	-	1129	O
days	-	1132	O
.	-	1136	O

Patients	10526274	1138	O
received	-	1147	O
a	-	1156	O
minimum	-	1158	O
of	-	1166	O
three	-	1169	O
courses	-	1175	O
unless	-	1183	O
progressive	-	1190	O
disease	-	1202	O
was	-	1210	O
detected	-	1214	O
.	-	1222	O

RESULTS	10526274	1224	O
:	-	1231	O

One	10526274	1233	O
hundred	-	1237	O
sixty	-	1245	O
-	-	1250	O
five	-	1251	O
courses	-	1256	O
were	-	1264	O
administered	-	1269	O
,	-	1281	O
with	-	1283	O
a	-	1288	O
median	-	1290	O
of	-	1297	O
3	-	1300	O
.	-	1301	O

6	10526274	1303	O
courses	-	1305	O
per	-	1313	O
patient	-	1317	O
.	-	1324	O

The	10526274	1326	O
overall	-	1330	O
response	-	1338	O
rate	-	1347	O
was	-	1352	O
26	-	1356	O
%	-	1358	O
(	-	1360	O
95	-	1361	O
%	-	1363	O
confidence	-	1365	O
interval	-	1376	O
,	-	1384	O
15	-	1386	O
-	-	1388	O
41	-	1389	O
%	-	1391	O
)	-	1392	O
.	-	1393	O

Two	10526274	1395	O
patients	-	1399	O
attained	-	1408	O
a	-	1417	O
complete	-	1419	O
response	-	1428	O
(	-	1437	O
4	-	1438	O
%	-	1439	O
)	-	1440	O
and	-	1442	O
11	-	1446	O
patients	-	1449	O
(	-	1458	O
22	-	1459	O
%	-	1461	O
)	-	1462	O
achieved	-	1464	O
a	-	1473	O
partial	-	1475	O
response	-	1483	O
.	-	1491	O

Eastern	10526274	1493	O
Cooperative	-	1501	O
Oncology	-	1513	O
Group	-	1522	O
performance	-	1528	O
status	-	1540	O
improved	-	1547	O
in	-	1556	O
35	-	1559	O
%	-	1561	O
of	-	1563	O
those	-	1566	O
patients	-	1572	O
with	-	1581	O
an	-	1586	O
initial	-	1589	O
value	-	1597	O
>	-	1603	O
0	-	1605	O
,	-	1606	O
whereas	-	1608	O
relief	-	1616	O
of	-	1623	O
at	-	1626	O
least	-	1629	O
1	-	1635	O
symptom	-	1637	O
without	-	1645	O
worsening	-	1653	O
of	-	1663	O
other	-	1666	O
symptoms	-	1672	O
was	-	1681	O
noted	-	1685	O
in	-	1691	O
27	-	1694	O
patients	-	1697	O
(	-	1706	O
55	-	1707	O
%	-	1709	O
)	-	1710	O
.	-	1711	O

The	10526274	1713	O
median	-	1717	O
time	-	1724	O
to	-	1729	O
progression	-	1732	O
was	-	1744	O
16	-	1748	O
weeks	-	1751	O
and	-	1757	O
the	-	1761	O
1	-	1765	O
-	-	1766	O
year	-	1767	O
survival	-	1772	O
rate	-	1781	O
was	-	1786	O
33	-	1790	O
%	-	1792	O
.	-	1793	O

Toxicity	10526274	1795	O
was	-	1804	O
mild	-	1808	O
.	-	1812	O

Six	10526274	1814	O
patients	-	1818	O
(	-	1827	O
12	-	1828	O
%	-	1830	O
)	-	1831	O
had	-	1833	O
World	-	1837	O
Health	-	1843	O
Organization	-	1850	O
Grade	-	1863	O
3	-	1869	O
-	-	1870	O
4	-	1871	O
neutropenia	-	1873	O
,	-	1884	O
2	-	1886	O
patients	-	1888	O
(	-	1897	O
4	-	1898	O
%	-	1899	O
)	-	1900	O
had	-	1902	O
Grade	-	1906	O
3	-	1912	O
-	-	1913	O
4	-	1914	O
thrombocytopenia	-	1916	O
,	-	1932	O
and	-	1934	O
2	-	1938	O
patients	-	1940	O
(	-	1949	O
4	-	1950	O
%	-	1951	O
)	-	1952	O
had	-	1954	O
Grade	-	1958	O
3	-	1964	O
neurotoxicity	-	1966	O
.	-	1979	O

Three	10526274	1981	O
patients	-	1987	O
with	-	1996	O
severe	-	2001	O
neutropenia	-	2008	O
(	-	2020	O
6	-	2021	O
%	-	2022	O
)	-	2023	O
died	-	2025	O
of	-	2030	O
sepsis	-	2033	O
.	-	2039	O

The	10526274	2041	O
median	-	2045	O
age	-	2052	O
of	-	2056	O
those	-	2059	O
patients	-	2065	O
developing	-	2074	O
Grade	-	2085	O
3	-	2091	O
-	-	2092	O
4	-	2093	O
neutropenia	-	2095	O
was	-	2107	O
significantly	-	2111	O
higher	-	2125	O
than	-	2132	O
that	-	2137	O
of	-	2142	O
the	-	2145	O
remaining	-	2149	O
patients	-	2159	O
(	-	2168	O
75	-	2169	O
years	-	2172	O
vs	-	2178	O
.	-	2180	O
72	-	2182	O
years	-	2185	O
;	-	2190	O
P	-	2192	O
=	-	2194	O
0	-	2196	O
.	-	2197	O
047	-	2198	O
)	-	2201	O
.	-	2202	O

CONCLUSIONS	10526274	2204	O
:	-	2215	O

The	10526274	2217	O
combination	-	2221	O
of	-	2233	O
GEM	-	2236	B
and	-	2240	O
VNB	-	2244	B
is	-	2248	O
moderately	-	2251	O
active	-	2262	O
and	-	2269	O
well	-	2273	O
tolerated	-	2278	O
except	-	2288	O
in	-	2295	O
patients	-	2298	O
age	-	2307	O
>	-	2311	O
/	-	2312	O
=	-	2313	O
75	-	2315	O
years	-	2318	O
.	-	2323	O

This	10526274	2325	O
age	-	2330	O
group	-	2334	O
had	-	2340	O
an	-	2344	O
increased	-	2347	O
risk	-	2357	O
of	-	2362	O
myelosuppression	-	2365	O
.	-	2381	O

Therefore	10526274	2383	O
the	-	2393	O
prophylactic	-	2397	O
use	-	2410	O
of	-	2414	O
granulocyte	-	2417	O
-	-	2428	O
colony	-	2429	O
stimulating	-	2436	O
factor	-	2448	O
should	-	2455	O
be	-	2462	O
considered	-	2465	O
with	-	2476	O
this	-	2481	O
treatment	-	2486	O
.	-	2495	O

New	10526274	2497	O
chemotherapy	-	2501	O
combinations	-	2514	O
with	-	2527	O
higher	-	2532	O
activity	-	2539	O
and	-	2548	O
lower	-	2552	O
toxicity	-	2558	O
are	-	2567	O
needed	-	2571	O
for	-	2578	O
elderly	-	2582	O
patients	-	2590	O
with	-	2599	O
advanced	-	2604	O
NSCLC	-	2613	O
.	-	2618	O

Warfarin	10669626	0	B
-	-	8	O
induced	-	9	O
artery	-	17	O
calcification	-	24	O
is	-	38	O
accelerated	-	41	O
by	-	53	O
growth	-	56	O
and	-	63	O
vitamin	-	67	B
D	-	75	I
.	-	76	O

The	10669626	78	O
present	-	82	O
studies	-	90	O
demonstrate	-	98	O
that	-	110	O
growth	-	115	O
and	-	122	O
vitamin	-	126	B
D	-	134	I
treatment	-	136	O
enhance	-	146	O
the	-	154	O
extent	-	158	O
of	-	165	O
artery	-	168	O
calcification	-	175	O
in	-	189	O
rats	-	192	O
given	-	197	O
sufficient	-	203	O
doses	-	214	O
of	-	220	O
Warfarin	-	223	B
to	-	232	O
inhibit	-	235	O
gamma	-	243	O
-	-	248	O
carboxylation	-	249	O
of	-	263	O
matrix	-	266	O
Gla	-	273	O
protein	-	277	O
,	-	284	O
a	-	286	O
calcification	-	288	O
inhibitor	-	302	O
known	-	312	O
to	-	318	O
be	-	321	O
expressed	-	324	O
by	-	334	O
smooth	-	337	O
muscle	-	344	O
cells	-	351	O
and	-	357	O
macrophages	-	361	O
in	-	373	O
the	-	376	O
artery	-	380	O
wall	-	387	O
.	-	391	O

The	10669626	393	O
first	-	397	O
series	-	403	O
of	-	410	O
experiments	-	413	O
examined	-	425	O
the	-	434	O
influence	-	438	O
of	-	448	O
age	-	451	O
and	-	455	O
growth	-	459	O
status	-	466	O
on	-	473	O
artery	-	476	O
calcification	-	483	O
in	-	497	O
Warfarin	-	500	B
-	-	508	O
treated	-	509	O
rats	-	517	O
.	-	521	O

Treatment	10669626	523	O
for	-	533	O
2	-	537	O
weeks	-	539	O
with	-	545	O
Warfarin	-	550	B
caused	-	559	O
massive	-	566	O
focal	-	574	O
calcification	-	580	O
of	-	594	O
the	-	597	O
artery	-	601	O
media	-	608	O
in	-	614	O
20	-	617	O
-	-	619	O
day	-	620	O
-	-	623	O
old	-	624	O
rats	-	628	O
and	-	633	O
less	-	637	O
extensive	-	642	O
focal	-	652	O
calcification	-	658	O
in	-	672	O
42	-	675	O
-	-	677	O
day	-	678	O
-	-	681	O
old	-	682	O
rats	-	686	O
.	-	690	O

In	10669626	692	O
contrast	-	695	O
,	-	703	O
no	-	705	O
artery	-	708	O
calcification	-	715	O
could	-	729	O
be	-	735	O
detected	-	738	O
in	-	747	O
10	-	750	O
-	-	752	O
month	-	753	O
-	-	758	O
old	-	759	O
adult	-	763	O
rats	-	769	O
even	-	774	O
after	-	779	O
4	-	785	O
weeks	-	787	O
of	-	793	O
Warfarin	-	796	B
treatment	-	805	O
.	-	814	O

To	10669626	816	O
directly	-	819	O
examine	-	828	O
the	-	836	O
importance	-	840	O
of	-	851	O
growth	-	854	O
to	-	861	O
Warfarin	-	864	B
-	-	872	O
induced	-	873	O
artery	-	881	O
calcification	-	888	O
in	-	902	O
animals	-	905	O
of	-	913	O
the	-	916	O
same	-	920	O
age	-	925	O
,	-	928	O
20	-	930	O
-	-	932	O
day	-	933	O
-	-	936	O
old	-	937	O
rats	-	941	O
were	-	946	O
fed	-	951	O
for	-	955	O
2	-	959	O
weeks	-	961	O
either	-	967	O
an	-	974	O
ad	-	977	O
libitum	-	980	O
diet	-	988	O
or	-	993	O
a	-	996	O
6	-	998	O
-	-	999	O
g	-	1000	O
/	-	1001	O
d	-	1002	O
restricted	-	1004	O
diet	-	1015	O
that	-	1020	O
maintains	-	1025	O
weight	-	1035	O
but	-	1042	O
prevents	-	1046	O
growth	-	1055	O
.	-	1061	O

Concurrent	10669626	1063	O
treatment	-	1074	O
of	-	1084	O
both	-	1087	O
dietary	-	1092	O
groups	-	1100	O
with	-	1107	O
Warfarin	-	1112	B
produced	-	1121	O
massive	-	1130	O
focal	-	1138	O
calcification	-	1144	O
of	-	1158	O
the	-	1161	O
artery	-	1165	O
media	-	1172	O
in	-	1178	O
the	-	1181	O
ad	-	1185	O
libitum	-	1188	O
-	-	1195	O
fed	-	1196	O
rats	-	1200	O
but	-	1205	O
no	-	1209	O
detectable	-	1212	O
artery	-	1223	O
calcification	-	1230	O
in	-	1244	O
the	-	1247	O
restricted	-	1251	O
-	-	1261	O
diet	-	1262	O
,	-	1266	O
growth	-	1268	O
-	-	1274	O
inhibited	-	1275	O
group	-	1285	O
.	-	1290	O

Although	10669626	1292	O
the	-	1301	O
explanation	-	1305	O
for	-	1317	O
the	-	1321	O
association	-	1325	O
between	-	1337	O
artery	-	1345	O
calcification	-	1352	O
and	-	1366	O
growth	-	1370	O
status	-	1377	O
can	-	1384	O
not	-	1387	O
be	-	1391	O
determined	-	1394	O
from	-	1405	O
the	-	1410	O
present	-	1414	O
study	-	1422	O
,	-	1427	O
there	-	1429	O
was	-	1435	O
a	-	1439	O
relationship	-	1441	O
between	-	1454	O
higher	-	1462	O
serum	-	1469	O
phosphate	-	1475	B
and	-	1485	O
susceptibility	-	1489	O
to	-	1504	O
artery	-	1507	O
calcification	-	1514	O
,	-	1527	O
with	-	1529	O
30	-	1534	O
%	-	1536	O
higher	-	1538	O
levels	-	1545	O
of	-	1552	O
serum	-	1555	O
phosphate	-	1561	B
in	-	1571	O
young	-	1574	O
,	-	1579	O
ad	-	1581	O
libitum	-	1584	O
-	-	1591	O
fed	-	1592	O
rats	-	1596	O
compared	-	1601	O
with	-	1610	O
either	-	1615	O
of	-	1622	O
the	-	1625	O
groups	-	1629	O
that	-	1636	O
was	-	1641	O
resistant	-	1645	O
to	-	1655	O
Warfarin	-	1658	B
-	-	1666	O
induced	-	1667	O
artery	-	1675	O
calcification	-	1682	O
,	-	1695	O
ie	-	1697	O
,	-	1699	O
the	-	1701	O
10	-	1705	O
-	-	1707	O
month	-	1708	O
-	-	1713	O
old	-	1714	O
rats	-	1718	O
and	-	1723	O
the	-	1727	O
restricted	-	1731	O
-	-	1741	O
diet	-	1742	O
,	-	1746	O
growth	-	1748	O
-	-	1754	O
inhibited	-	1755	O
young	-	1765	O
rats	-	1771	O
.	-	1775	O

This	10669626	1777	O
observation	-	1782	O
suggests	-	1794	O
that	-	1803	O
increased	-	1808	O
susceptibility	-	1818	O
to	-	1833	O
Warfarin	-	1836	B
-	-	1844	O
induced	-	1845	O
artery	-	1853	O
calcification	-	1860	O
could	-	1874	O
be	-	1880	O
related	-	1883	O
to	-	1891	O
higher	-	1894	O
serum	-	1901	O
phosphate	-	1907	B
levels	-	1917	O
.	-	1923	O

The	10669626	1925	O
second	-	1929	O
set	-	1936	O
of	-	1940	O
experiments	-	1943	O
examined	-	1955	O
the	-	1964	O
possible	-	1968	O
synergy	-	1977	O
between	-	1985	O
vitamin	-	1993	B
D	-	2001	I
and	-	2003	O
Warfarin	-	2007	B
in	-	2016	O
artery	-	2019	O
calcification	-	2026	O
.	-	2039	O

High	10669626	2041	O
doses	-	2046	O
of	-	2052	O
vitamin	-	2055	B
D	-	2063	I
are	-	2065	O
known	-	2069	O
to	-	2075	O
cause	-	2078	O
calcification	-	2084	O
of	-	2098	O
the	-	2101	O
artery	-	2105	O
media	-	2112	O
in	-	2118	O
as	-	2121	O
little	-	2124	O
as	-	2131	O
3	-	2134	O
to	-	2136	O
4	-	2139	O
days	-	2141	O
.	-	2145	O

High	10669626	2147	O
doses	-	2152	O
of	-	2158	O
the	-	2161	O
vitamin	-	2165	B
K	-	2173	I
antagonist	-	2175	O
Warfarin	-	2186	B
are	-	2195	O
also	-	2199	O
known	-	2204	O
to	-	2210	O
cause	-	2213	O
calcification	-	2219	O
of	-	2233	O
the	-	2236	O
artery	-	2240	O
media	-	2247	O
,	-	2252	O
but	-	2254	O
at	-	2258	O
treatment	-	2261	O
times	-	2271	O
of	-	2277	O
2	-	2280	O
weeks	-	2282	O
or	-	2288	O
longer	-	2291	O
yet	-	2298	O
not	-	2302	O
at	-	2306	O
1	-	2309	O
week	-	2311	O
.	-	2315	O

In	10669626	2317	O
the	-	2320	O
current	-	2324	O
study	-	2332	O
,	-	2337	O
we	-	2339	O
investigated	-	2342	O
the	-	2355	O
synergy	-	2359	O
between	-	2367	O
these	-	2375	O
2	-	2381	O
treatments	-	2383	O
and	-	2394	O
found	-	2398	O
that	-	2404	O
concurrent	-	2409	O
Warfarin	-	2420	B
administration	-	2429	O
dramatically	-	2444	O
increased	-	2457	O
the	-	2467	O
extent	-	2471	O
of	-	2478	O
calcification	-	2481	O
in	-	2495	O
the	-	2498	O
media	-	2502	O
of	-	2508	O
vitamin	-	2511	B
D	-	2519	I
-	-	2520	O
treated	-	2521	O
rats	-	2529	O
at	-	2534	O
3	-	2537	O
and	-	2539	O
4	-	2543	O
days	-	2545	O
.	-	2549	O

There	10669626	2551	O
was	-	2557	O
a	-	2561	O
close	-	2563	O
parallel	-	2569	O
between	-	2578	O
the	-	2586	O
effect	-	2590	O
of	-	2597	O
vitamin	-	2600	B
D	-	2608	I
dose	-	2610	O
on	-	2615	O
artery	-	2618	O
calcification	-	2625	O
and	-	2639	O
the	-	2643	O
effect	-	2647	O
of	-	2654	O
vitamin	-	2657	B
D	-	2665	I
dose	-	2667	O
on	-	2672	O
the	-	2675	O
elevation	-	2679	O
of	-	2689	O
serum	-	2692	O
calcium	-	2698	B
,	-	2705	O
which	-	2707	O
suggests	-	2713	O
that	-	2722	O
vitamin	-	2727	B
D	-	2735	I
may	-	2737	O
induce	-	2741	O
artery	-	2748	O
calcification	-	2755	O
through	-	2769	O
its	-	2777	O
effect	-	2781	O
on	-	2788	O
serum	-	2791	O
calcium	-	2797	B
.	-	2804	O

Because	10669626	2806	O
Warfarin	-	2814	B
treatment	-	2823	O
had	-	2833	O
no	-	2837	O
effect	-	2840	O
on	-	2847	O
the	-	2850	O
elevation	-	2854	O
in	-	2864	O
serum	-	2867	O
calcium	-	2873	B
produced	-	2881	O
by	-	2890	O
vitamin	-	2893	B
D	-	2901	I
,	-	2902	O
the	-	2904	O
synergy	-	2908	O
between	-	2916	O
Warfarin	-	2924	B
and	-	2933	O
vitamin	-	2937	B
D	-	2945	I
is	-	2947	O
probably	-	2950	O
best	-	2959	O
explained	-	2964	O
by	-	2974	O
the	-	2977	O
hypothesis	-	2981	O
that	-	2992	O
Warfarin	-	2997	B
inhibits	-	3006	O
the	-	3015	O
activity	-	3019	O
of	-	3028	O
matrix	-	3031	O
Gla	-	3038	O
protein	-	3042	O
as	-	3050	O
a	-	3053	O
calcification	-	3055	O
inhibitor	-	3069	O
.	-	3078	O

High	10669626	3080	O
levels	-	3085	O
of	-	3092	O
matrix	-	3095	O
Gla	-	3102	O
protein	-	3106	O
are	-	3114	O
found	-	3118	O
at	-	3124	O
sites	-	3127	O
of	-	3133	O
artery	-	3136	O
calcification	-	3143	O
in	-	3157	O
rats	-	3160	O
treated	-	3165	O
with	-	3173	O
vitamin	-	3178	B
D	-	3186	I
plus	-	3188	O
Warfarin	-	3193	B
,	-	3201	O
and	-	3203	O
chemical	-	3207	O
analysis	-	3216	O
showed	-	3225	O
that	-	3232	O
the	-	3237	O
protein	-	3241	O
that	-	3249	O
accumulated	-	3254	O
was	-	3266	O
indeed	-	3270	O
not	-	3277	O
gamma	-	3281	B
-	-	3286	I
carboxylated	-	3287	I
.	-	3299	O

These	10669626	3301	O
observations	-	3307	O
indicate	-	3320	O
that	-	3329	O
although	-	3334	O
the	-	3343	O
gamma	-	3347	B
-	-	3352	I
carboxyglutamate	-	3353	I
residues	-	3370	O
of	-	3379	O
matrix	-	3382	O
Gla	-	3389	O
protein	-	3393	O
are	-	3401	O
apparently	-	3405	O
required	-	3416	O
for	-	3425	O
its	-	3429	O
function	-	3433	O
as	-	3442	O
a	-	3445	O
calcification	-	3447	O
inhibitor	-	3461	O
,	-	3470	O
they	-	3472	O
are	-	3477	O
not	-	3481	O
required	-	3485	O
for	-	3494	O
its	-	3498	O
accumulation	-	3502	O
at	-	3515	O
calcification	-	3518	O
sites	-	3532	O
.	-	3537	O

Antidepressant	11379838	0	B
-	-	14	O
induced	-	15	O
mania	-	23	O
in	-	29	O
bipolar	-	32	O
patients	-	40	O
:	-	48	O
identification	-	50	O
of	-	65	O
risk	-	68	O
factors	-	73	O
.	-	80	O

BACKGROUND	11379838	82	O
:	-	92	O
Concerns	-	94	O
about	-	103	O
possible	-	109	O
risks	-	118	O
of	-	124	O
switching	-	127	O
to	-	137	O
mania	-	140	O
associated	-	146	O
with	-	157	O
antidepressants	-	162	B
continue	-	178	O
to	-	187	O
interfere	-	190	O
with	-	200	O
the	-	205	O
establishment	-	209	O
of	-	223	O
an	-	226	O
optimal	-	229	O
treatment	-	237	O
paradigm	-	247	O
for	-	256	O
bipolar	-	260	O
depression	-	268	O
.	-	278	O

METHOD	11379838	280	O
:	-	286	O

The	11379838	288	O
response	-	292	O
of	-	301	O
44	-	304	O
patients	-	307	O
meeting	-	316	O
DSM	-	324	O
-	-	327	O
IV	-	328	O
criteria	-	331	O
for	-	340	O
bipolar	-	344	O
disorder	-	352	O
to	-	361	O
naturalistic	-	364	O
treatment	-	377	O
was	-	387	O
assessed	-	391	O
for	-	400	O
at	-	404	O
least	-	407	O
6	-	413	O
weeks	-	415	O
using	-	421	O
the	-	427	O
Montgomery	-	431	O
-	-	441	O
Asberg	-	442	O
Depression	-	449	O
Rating	-	460	O
Scale	-	467	O
and	-	473	O
the	-	477	O
Bech	-	481	O
-	-	485	O
Rafaelson	-	486	O
Mania	-	496	O
Rating	-	502	O
Scale	-	509	O
.	-	514	O

Patients	11379838	516	O
who	-	525	O
experienced	-	529	O
a	-	541	O
manic	-	543	O
or	-	549	O
hypomanic	-	552	O
switch	-	562	O
were	-	569	O
compared	-	574	O
with	-	583	O
those	-	588	O
who	-	594	O
did	-	598	O
not	-	602	O
on	-	606	O
several	-	609	O
variables	-	617	O
including	-	627	O
age	-	637	O
,	-	640	O
sex	-	642	O
,	-	645	O
diagnosis	-	647	O
(	-	657	O
DSM	-	658	O
-	-	661	O
IV	-	662	O
bipolar	-	665	O
I	-	673	O
vs	-	675	O
.	-	677	O
bipolar	-	679	O
II	-	687	O
)	-	689	O
,	-	690	O
number	-	692	O
of	-	699	O
previous	-	702	O
manic	-	711	O
episodes	-	717	O
,	-	725	O
type	-	727	O
of	-	732	O
antidepressant	-	735	B
therapy	-	750	O
used	-	758	O
(	-	763	O
electroconvulsive	-	764	O
therapy	-	782	O
vs	-	790	O
.	-	792	O
antidepressant	-	794	B
drugs	-	809	O
and	-	815	O
,	-	818	O
more	-	820	O
particularly	-	825	O
,	-	837	O
selective	-	839	O
serotonin	-	849	B
reuptake	-	859	I
inhibitors	-	868	I
[	-	879	O
SSRIs	-	880	B
]	-	885	O
)	-	886	O
,	-	887	O
use	-	889	O
and	-	893	O
type	-	897	O
of	-	902	O
mood	-	905	O
stabilizers	-	910	O
(	-	922	O
lithium	-	923	B
vs	-	931	O
.	-	933	O
anticonvulsants	-	935	O
)	-	950	O
,	-	951	O
and	-	953	O
temperament	-	957	O
of	-	969	O
the	-	972	O
patient	-	976	O
,	-	983	O
assessed	-	985	O
during	-	994	O
a	-	1001	O
normothymic	-	1003	O
period	-	1015	O
using	-	1022	O
the	-	1028	O
hyperthymia	-	1032	O
component	-	1044	O
of	-	1054	O
the	-	1057	O
Semi	-	1061	O
-	-	1065	O
structured	-	1066	O
Affective	-	1077	O
Temperament	-	1087	O
Interview	-	1099	O
.	-	1108	O

RESULTS	11379838	1110	O
:	-	1117	O

Switches	11379838	1119	O
to	-	1128	O
hypomania	-	1131	O
or	-	1141	O
mania	-	1144	O
occurred	-	1150	O
in	-	1159	O
27	-	1162	O
%	-	1164	O
of	-	1166	O
all	-	1169	O
patients	-	1173	O
(	-	1182	O
N	-	1183	O
=	-	1185	O
12	-	1187	O
)	-	1189	O
(	-	1191	O
and	-	1192	O
in	-	1196	O
24	-	1199	O
%	-	1201	O
of	-	1203	O
the	-	1206	O
subgroup	-	1210	O
of	-	1219	O
patients	-	1222	O
treated	-	1231	O
with	-	1239	O
SSRIs	-	1244	B
[	-	1250	O
8	-	1251	O
/	-	1252	O
33	-	1253	O
]	-	1255	O
)	-	1256	O
;	-	1257	O
16	-	1259	O
%	-	1261	O
(	-	1263	O
N	-	1264	O
=	-	1266	O
7	-	1268	O
)	-	1269	O
experienced	-	1271	O
manic	-	1283	O
episodes	-	1289	O
,	-	1297	O
and	-	1299	O
11	-	1303	O
%	-	1305	O
(	-	1307	O
N	-	1308	O
=	-	1310	O
5	-	1312	O
)	-	1313	O
experienced	-	1315	O
hypomanic	-	1327	O
episodes	-	1337	O
.	-	1345	O

Sex	11379838	1347	O
,	-	1350	O
age	-	1352	O
,	-	1355	O
diagnosis	-	1357	O
(	-	1367	O
bipolar	-	1368	O
I	-	1376	O
vs	-	1378	O
.	-	1380	O
bipolar	-	1382	O
II	-	1390	O
)	-	1392	O
,	-	1393	O
and	-	1395	O
additional	-	1399	O
treatment	-	1410	O
did	-	1420	O
not	-	1424	O
affect	-	1428	O
the	-	1435	O
risk	-	1439	O
of	-	1444	O
switching	-	1447	O
.	-	1456	O

The	11379838	1458	O
incidence	-	1462	O
of	-	1472	O
mood	-	1475	O
switches	-	1480	O
seemed	-	1489	O
not	-	1496	O
to	-	1500	O
differ	-	1503	O
between	-	1510	O
patients	-	1518	O
receiving	-	1527	O
an	-	1537	O
anticonvulsant	-	1540	O
and	-	1555	O
those	-	1559	O
receiving	-	1565	O
no	-	1575	O
mood	-	1578	O
stabilizer	-	1583	O
.	-	1593	O

In	11379838	1595	O
contrast	-	1598	O
,	-	1606	O
mood	-	1608	O
switches	-	1613	O
were	-	1622	O
less	-	1627	O
frequent	-	1632	O
in	-	1641	O
patients	-	1644	O
receiving	-	1653	O
lithium	-	1663	B
(	-	1671	O
15	-	1672	O
%	-	1674	O
,	-	1675	O
4	-	1677	O
/	-	1678	O
26	-	1679	O
)	-	1681	O
than	-	1683	O
in	-	1688	O
patients	-	1691	O
not	-	1700	O
treated	-	1704	O
with	-	1712	O
lithium	-	1717	B
(	-	1725	O
44	-	1726	O
%	-	1728	O
,	-	1729	O
8	-	1731	O
/	-	1732	O
18	-	1733	O
;	-	1735	O
p	-	1737	O
=	-	1739	O
.	-	1741	O
04	-	1742	O
)	-	1744	O
.	-	1745	O

The	11379838	1747	O
number	-	1751	O
of	-	1758	O
previous	-	1761	O
manic	-	1770	O
episodes	-	1776	O
did	-	1785	O
not	-	1789	O
affect	-	1793	O
the	-	1800	O
probability	-	1804	O
of	-	1816	O
switching	-	1819	O
,	-	1828	O
whereas	-	1830	O
a	-	1838	O
high	-	1840	O
score	-	1845	O
on	-	1851	O
the	-	1854	O
hyperthymia	-	1858	O
component	-	1870	O
of	-	1880	O
the	-	1883	O
Semistructured	-	1887	O
Affective	-	1902	O
Temperament	-	1912	O
Interview	-	1924	O
was	-	1934	O
associated	-	1938	O
with	-	1949	O
a	-	1954	O
greater	-	1956	O
risk	-	1964	O
of	-	1969	O
switching	-	1972	O
(	-	1982	O
p	-	1983	O
=	-	1985	O
.	-	1987	O
008	-	1988	O
)	-	1991	O
.	-	1992	O

CONCLUSION	11379838	1994	O
:	-	2004	O

The	11379838	2006	O
frequency	-	2010	O
of	-	2020	O
mood	-	2023	O
switching	-	2028	O
associated	-	2038	O
with	-	2049	O
acute	-	2054	O
antidepressant	-	2060	B
therapy	-	2075	O
may	-	2083	O
be	-	2087	O
reduced	-	2090	O
by	-	2098	O
lithium	-	2101	B
treatment	-	2109	O
.	-	2118	O

Particular	11379838	2120	O
attention	-	2131	O
should	-	2141	O
be	-	2148	O
paid	-	2151	O
to	-	2156	O
patients	-	2159	O
with	-	2168	O
a	-	2173	O
hyperthymic	-	2175	O
temperament	-	2187	O
,	-	2198	O
who	-	2200	O
have	-	2204	O
a	-	2209	O
greater	-	2211	O
risk	-	2219	O
of	-	2224	O
mood	-	2227	O
switches	-	2232	O
.	-	2240	O

Caffeine	11419773	0	B
-	-	8	O
induced	-	9	O
cardiac	-	17	O
arrhythmia	-	25	O
:	-	35	O
an	-	37	O
unrecognised	-	40	O
danger	-	53	O
of	-	60	O
healthfood	-	63	O
products	-	74	O
.	-	82	O

We	11419773	84	O
describe	-	87	O
a	-	96	O
25	-	98	O
-	-	100	O
year	-	101	O
-	-	105	O
old	-	106	O
woman	-	110	O
with	-	116	O
pre	-	121	O
-	-	124	O
existing	-	125	O
mitral	-	134	O
valve	-	141	O
prolapse	-	147	O
who	-	156	O
developed	-	160	O
intractable	-	170	O
ventricular	-	182	O
fibrillation	-	194	O
after	-	207	O
consuming	-	213	O
a	-	223	O
""""	-	225	O
natural	-	226	O
energy	-	234	O
""""	-	240	O
guarana	-	242	O
health	-	250	O
drink	-	257	O
containing	-	263	O
a	-	274	O
high	-	276	O
concentration	-	281	O
of	-	295	O
caffeine	-	298	B
.	-	306	O

This	11419773	308	O
case	-	313	O
highlights	-	318	O
the	-	329	O
need	-	333	O
for	-	338	O
adequate	-	342	O
labelling	-	351	O
and	-	361	O
regulation	-	365	O
of	-	376	O
such	-	379	O
products	-	384	O
.	-	392	O

Bladder	11581460	0	O
retention	-	8	O
of	-	18	O
urine	-	21	O
as	-	27	O
a	-	30	O
result	-	32	O
of	-	39	O
continuous	-	42	O
intravenous	-	53	O
infusion	-	65	O
of	-	74	O
fentanyl	-	77	B
:	-	85	O
2	-	87	O
case	-	89	O
reports	-	94	O
.	-	101	O

Sedation	11581460	103	O
has	-	112	O
been	-	116	O
commonly	-	121	O
used	-	130	O
in	-	135	O
the	-	138	O
neonate	-	142	O
to	-	150	O
decrease	-	153	O
the	-	162	O
stress	-	166	O
and	-	173	O
pain	-	177	O
from	-	182	O
the	-	187	O
noxious	-	191	O
stimuli	-	199	O
and	-	207	O
invasive	-	211	O
procedures	-	220	O
in	-	231	O
the	-	234	O
neonatal	-	238	O
intensive	-	247	O
care	-	257	O
unit	-	262	O
,	-	266	O
as	-	268	O
well	-	271	O
as	-	276	O
to	-	279	O
facilitate	-	282	O
synchrony	-	293	O
between	-	303	O
ventilator	-	311	O
and	-	322	O
spontaneous	-	326	O
breaths	-	338	O
.	-	345	O

Fentanyl	11581460	347	B
,	-	355	O
an	-	357	O
opioid	-	360	O
analgesic	-	367	O
,	-	376	O
is	-	378	O
frequently	-	381	O
used	-	392	O
in	-	397	O
the	-	400	O
neonatal	-	404	O
intensive	-	413	O
care	-	423	O
unit	-	428	O
setting	-	433	O
for	-	441	O
these	-	445	O
very	-	451	O
purposes	-	456	O
.	-	464	O

Various	11581460	466	O
reported	-	474	O
side	-	483	O
effects	-	488	O
of	-	496	O
fentanyl	-	499	B
administration	-	508	O
include	-	523	O
chest	-	531	O
wall	-	537	O
rigidity	-	542	O
,	-	550	O
hypotension	-	552	O
,	-	563	O
respiratory	-	565	O
depression	-	577	O
,	-	587	O
and	-	589	O
bradycardia	-	593	O
.	-	604	O

Here	11581460	606	O
,	-	610	O
2	-	612	O
cases	-	614	O
of	-	620	O
urinary	-	623	O
bladder	-	631	O
retention	-	639	O
leading	-	649	O
to	-	657	O
renal	-	660	O
pelvocalyceal	-	666	O
dilatation	-	680	O
mimicking	-	691	O
hydronephrosis	-	701	O
as	-	716	O
a	-	719	O
result	-	721	O
of	-	728	O
continuous	-	731	O
infusion	-	742	O
of	-	751	O
fentanyl	-	754	B
are	-	763	O
reported	-	767	O
.	-	775	O

Combined	11706060	0	O
antiretroviral	-	9	O
therapy	-	24	O
causes	-	32	O
cardiomyopathy	-	39	O
and	-	54	O
elevates	-	58	O
plasma	-	67	O
lactate	-	74	B
in	-	82	O
transgenic	-	85	O
AIDS	-	96	O
mice	-	101	O
.	-	105	O

Highly	11706060	107	O
active	-	114	O
antiretroviral	-	121	O
therapy	-	136	O
(	-	144	O
HAART	-	145	O
)	-	150	O
is	-	152	O
implicated	-	155	O
in	-	166	O
cardiomyopathy	-	169	O
(	-	184	O
CM	-	185	O
)	-	187	O
and	-	189	O
in	-	193	O
elevated	-	196	O
plasma	-	205	O
lactate	-	212	B
(	-	220	O
LA	-	221	B
)	-	223	O
in	-	225	O
AIDS	-	228	O
through	-	233	O
mechanisms	-	241	O
of	-	252	O
mitochondrial	-	255	O
dysfunction	-	269	O
.	-	280	O

To	11706060	282	O
determine	-	285	O
mitochondrial	-	295	O
events	-	309	O
from	-	316	O
HAART	-	321	O
in	-	327	O
vivo	-	330	O
,	-	334	O
8	-	336	O
-	-	337	O
week	-	338	O
-	-	342	O
old	-	343	O
hemizygous	-	347	O
transgenic	-	358	O
AIDS	-	369	O
mice	-	374	O
(	-	379	O
NL4	-	380	O
-	-	383	O
3Delta	-	384	O
gag	-	391	O
/	-	394	O
pol	-	395	O
;	-	398	O
TG	-	400	O
)	-	402	O
and	-	404	O
wild	-	408	O
-	-	412	O
type	-	413	O
FVB	-	418	O
/	-	421	O
n	-	422	O
littermates	-	424	O
were	-	436	O
treated	-	441	O
with	-	449	O
the	-	454	O
HAART	-	458	O
combination	-	464	O
of	-	476	O
zidovudine	-	479	B
,	-	489	O
lamivudine	-	491	B
,	-	501	O
and	-	503	O
indinavir	-	507	B
or	-	517	O
vehicle	-	520	O
control	-	528	O
for	-	536	O
10	-	540	O
days	-	543	O
or	-	548	O
35	-	551	O
days	-	554	O
.	-	558	O

At	11706060	560	O
termination	-	563	O
of	-	575	O
the	-	578	O
experiments	-	582	O
,	-	593	O
mice	-	595	O
underwent	-	600	O
echocardiography	-	610	O
,	-	626	O
quantitation	-	628	O
of	-	641	O
abundance	-	644	O
of	-	654	O
molecular	-	657	O
markers	-	667	O
of	-	675	O
CM	-	678	O
(	-	681	O
ventricular	-	682	O
mRNA	-	694	O
encoding	-	699	O
atrial	-	708	O
natriuretic	-	715	O
factor	-	727	O
[	-	734	O
ANF	-	735	O
]	-	738	O
and	-	740	O
sarcoplasmic	-	744	O
calcium	-	757	B
ATPase	-	765	O
[	-	772	O
SERCA2	-	773	O
]	-	779	O
)	-	780	O
,	-	781	O
and	-	783	O
determination	-	787	O
of	-	801	O
plasma	-	804	O
LA	-	811	B
.	-	813	O

Myocardial	11706060	815	O
histologic	-	826	O
features	-	837	O
were	-	846	O
analyzed	-	851	O
semiquantitatively	-	860	O
and	-	879	O
results	-	883	O
were	-	891	O
confirmed	-	896	O
by	-	906	O
transmission	-	909	O
electron	-	922	O
microscopy	-	931	O
.	-	941	O

After	11706060	943	O
35	-	949	O
days	-	952	O
in	-	957	O
the	-	960	O
TG	-	964	O
+	-	967	O
HAART	-	969	O
cohort	-	975	O
,	-	981	O
left	-	983	O
ventricular	-	988	O
mass	-	1000	O
increased	-	1005	O
160	-	1015	O
%	-	1018	O
by	-	1020	O
echocardiography	-	1023	O
.	-	1039	O

Molecularly	11706060	1041	O
,	-	1052	O
ANF	-	1054	O
mRNA	-	1058	O
increased	-	1063	O
250	-	1073	O
%	-	1076	O
and	-	1078	O
SERCA2	-	1082	O
mRNA	-	1089	O
decreased	-	1094	O
57	-	1104	O
%	-	1106	O
.	-	1107	O

Biochemically	11706060	1109	O
,	-	1122	O
LA	-	1124	B
was	-	1127	O
elevated	-	1131	O
(	-	1140	O
8	-	1141	O
.	-	1142	O
5	-	1143	O
+	-	1145	O
/	-	1146	O
-	-	1147	O

2	11706060	1149	O
.	-	1150	O
0	-	1151	O
mM	-	1153	O
)	-	1155	O
.	-	1156	O

Pathologically	11706060	1158	O
,	-	1172	O
granular	-	1174	O
cytoplasmic	-	1183	O
changes	-	1195	O
were	-	1203	O
found	-	1208	O
in	-	1214	O
cardiac	-	1217	O
myocytes	-	1225	O
,	-	1233	O
indicating	-	1235	O
enlarged	-	1246	O
,	-	1254	O
damaged	-	1256	O
mitochondria	-	1264	O
.	-	1276	O

Findings	11706060	1278	O
were	-	1287	O
confirmed	-	1292	O
ultrastructurally	-	1302	O
.	-	1319	O

No	11706060	1321	O
changes	-	1324	O
were	-	1332	O
found	-	1337	O
in	-	1343	O
other	-	1346	O
cohorts	-	1352	O
.	-	1359	O

After	11706060	1361	O
10	-	1367	O
days	-	1370	O
,	-	1374	O
only	-	1376	O
ANF	-	1381	O
was	-	1385	O
elevated	-	1389	O
,	-	1397	O
and	-	1399	O
only	-	1403	O
in	-	1408	O
the	-	1411	O
TG	-	1415	O
+	-	1418	O
HAART	-	1420	O
cohort	-	1426	O
.	-	1432	O

Results	11706060	1434	O
show	-	1442	O
that	-	1447	O
cumulative	-	1452	O
HAART	-	1463	O
caused	-	1469	O
mitochondrial	-	1476	O
CM	-	1490	O
with	-	1493	O
elevated	-	1498	O
LA	-	1507	B
in	-	1510	O
AIDS	-	1513	O
transgenic	-	1518	O
mice	-	1529	O
.	-	1533	O

Oral	11752354	0	B
contraceptives	-	5	I
and	-	20	O
the	-	24	O
risk	-	28	O
of	-	33	O
myocardial	-	36	O
infarction	-	47	O
.	-	57	O

BACKGROUND	11752354	59	O
:	-	69	O

An	11752354	71	O
association	-	74	O
between	-	86	O
the	-	94	O
use	-	98	O
of	-	102	O
oral	-	105	B
contraceptives	-	110	I
and	-	125	O
the	-	129	O
risk	-	133	O
of	-	138	O
myocardial	-	141	O
infarction	-	152	O
has	-	163	O
been	-	167	O
found	-	172	O
in	-	178	O
some	-	181	O
,	-	185	O
but	-	187	O
not	-	191	O
all	-	195	O
,	-	198	O
studies	-	200	O
.	-	207	O

We	11752354	209	O
investigated	-	212	O
this	-	225	O
association	-	230	O
,	-	241	O
according	-	243	O
to	-	253	O
the	-	256	O
type	-	260	O
of	-	265	O
progestagen	-	268	B
included	-	280	O
in	-	289	O
third	-	292	O
-	-	297	O
generation	-	298	O
(	-	309	O
i	-	310	O
.	-	311	O
e	-	312	O
.	-	313	O
,	-	314	O
desogestrel	-	316	B
or	-	328	O
gestodene	-	331	B
)	-	340	O
and	-	342	O
second	-	346	O
-	-	352	O
generation	-	353	O
(	-	364	O
i	-	365	O
.	-	366	O
e	-	367	O
.	-	368	O
,	-	369	O
levonorgestrel	-	371	B
)	-	385	O
oral	-	387	B
contraceptives	-	392	I
,	-	406	O
the	-	408	O
dose	-	412	O
of	-	417	O
estrogen	-	420	B
,	-	428	O
and	-	430	O
the	-	434	O
presence	-	438	O
or	-	447	O
absence	-	450	O
of	-	458	O
prothrombotic	-	461	O
mutations	-	475	O
METHODS	-	485	O
:	-	492	O

In	11752354	494	O
a	-	497	O
nationwide	-	499	O
,	-	509	O
population	-	511	O
-	-	521	O
based	-	522	O
,	-	527	O
case	-	529	O
-	-	533	O
control	-	534	O
study	-	542	O
,	-	547	O
we	-	549	O
identified	-	552	O
and	-	563	O
enrolled	-	567	O
248	-	576	O
women	-	580	O
18	-	586	O
through	-	589	O
49	-	597	O
years	-	600	O
of	-	606	O
age	-	609	O
who	-	613	O
had	-	617	O
had	-	621	O
a	-	625	O
first	-	627	O
myocardial	-	633	O
infarction	-	644	O
between	-	655	O
1990	-	663	O
and	-	668	O
1995	-	672	O
and	-	677	O
925	-	681	O
control	-	685	O
women	-	693	O
who	-	699	O
had	-	703	O
not	-	707	O
had	-	711	O
a	-	715	O
myocardial	-	717	O
infarction	-	728	O
and	-	739	O
who	-	743	O
were	-	747	O
matched	-	752	O
for	-	760	O
age	-	764	O
,	-	767	O
calendar	-	769	O
year	-	778	O
of	-	783	O
the	-	786	O
index	-	790	O
event	-	796	O
,	-	801	O
and	-	803	O
area	-	807	O
of	-	812	O
residence	-	815	O
.	-	824	O

Subjects	11752354	826	O
supplied	-	835	O
information	-	844	O
on	-	856	O
oral	-	859	B
-	-	863	I
contraceptive	-	864	I
use	-	878	O
and	-	882	O
major	-	886	O
cardiovascular	-	892	O
risk	-	907	O
factors	-	912	O
.	-	919	O

An	11752354	921	O
analysis	-	924	O
for	-	933	O
factor	-	937	O
V	-	944	O
Leiden	-	946	O
and	-	953	O
the	-	957	O
G20210A	-	961	O
mutation	-	969	O
in	-	978	O
the	-	981	O
prothrombin	-	985	O
gene	-	997	O
was	-	1002	O
conducted	-	1006	O
in	-	1016	O
217	-	1019	O
patients	-	1023	O
and	-	1032	O

763	11752354	1036	O
controls	-	1040	O
RESULTS	-	1049	O
:	-	1056	O

The	11752354	1058	O
odds	-	1062	O
ratio	-	1067	O
for	-	1073	O
myocardial	-	1077	O
infarction	-	1088	O
among	-	1099	O
women	-	1105	O
who	-	1111	O
used	-	1115	O
any	-	1120	O
type	-	1124	O
of	-	1129	O
combined	-	1132	O
oral	-	1141	B
contraceptive	-	1146	I
,	-	1159	O
as	-	1161	O
compared	-	1164	O
with	-	1173	O
nonusers	-	1178	O
,	-	1186	O
was	-	1188	O
2	-	1192	O
.	-	1193	O
0	-	1194	O
(	-	1196	O
95	-	1197	O
percent	-	1200	O
confidence	-	1208	O
interval	-	1219	O
,	-	1227	O
1	-	1229	O
.	-	1230	O
5	-	1231	O
to	-	1233	O
2	-	1236	O
.	-	1237	O
8	-	1238	O
)	-	1239	O
.	-	1240	O

The	11752354	1242	O
adjusted	-	1246	O
odds	-	1255	O
ratio	-	1260	O
was	-	1266	O
2	-	1270	O
.	-	1271	O
5	-	1272	O
(	-	1274	O
95	-	1275	O
percent	-	1278	O
confidence	-	1286	O
interval	-	1297	O
,	-	1305	O
1	-	1307	O
.	-	1308	O
5	-	1309	O
to	-	1311	O
4	-	1314	O
.	-	1315	O
1	-	1316	O
)	-	1317	O
among	-	1319	O
women	-	1325	O
who	-	1331	O
used	-	1335	O
second	-	1340	O
-	-	1346	O
generation	-	1347	O
oral	-	1358	B
contraceptives	-	1363	I
and	-	1378	O
1	-	1382	O
.	-	1383	O
3	-	1384	O
(	-	1386	O
95	-	1387	O
percent	-	1390	O
confidence	-	1398	O
interval	-	1409	O
,	-	1417	O
0	-	1419	O
.	-	1420	O
7	-	1421	O
to	-	1423	O
2	-	1426	O
.	-	1427	O
5	-	1428	O
)	-	1429	O
among	-	1431	O
those	-	1437	O
who	-	1443	O
used	-	1447	O
third	-	1452	O
-	-	1457	O
generation	-	1458	O
oral	-	1469	B
contraceptives	-	1474	I
.	-	1488	O

Among	11752354	1490	O
women	-	1496	O
who	-	1502	O
used	-	1506	O
oral	-	1511	B
contraceptives	-	1516	I
,	-	1530	O
the	-	1532	O
odds	-	1536	O
ratio	-	1541	O
was	-	1547	O
2	-	1551	O
.	-	1552	O
1	-	1553	O
(	-	1555	O
95	-	1556	O
percent	-	1559	O
confidence	-	1567	O
interval	-	1578	O
,	-	1586	O
1	-	1588	O
.	-	1589	O
5	-	1590	O
to	-	1592	O
3	-	1595	O
.	-	1596	O
0	-	1597	O
)	-	1598	O
for	-	1600	O
those	-	1604	O
without	-	1610	O
a	-	1618	O
prothrombotic	-	1620	O
mutation	-	1634	O
and	-	1643	O
1	-	1647	O
.	-	1648	O
9	-	1649	O
(	-	1651	O
95	-	1652	O
percent	-	1655	O
confidence	-	1663	O
interval	-	1674	O
,	-	1682	O
0	-	1684	O
.	-	1685	O
6	-	1686	O
to	-	1688	O
5	-	1691	O
.	-	1692	O
5	-	1693	O
)	-	1694	O
for	-	1696	O
those	-	1700	O
with	-	1706	O
a	-	1711	O
mutation	-	1713	O
CONCLUSIONS	-	1722	O
:	-	1733	O
The	-	1735	O
risk	-	1739	O
of	-	1744	O
myocardial	-	1747	O
infarction	-	1758	O
was	-	1769	O
increased	-	1773	O
among	-	1783	O
women	-	1789	O
who	-	1795	O
used	-	1799	O
second	-	1804	O
-	-	1810	O
generation	-	1811	O
oral	-	1822	B
contraceptives	-	1827	I
.	-	1841	O

The	11752354	1843	O
results	-	1847	O
with	-	1855	O
respect	-	1860	O
to	-	1868	O
the	-	1871	O
use	-	1875	O
of	-	1879	O
third	-	1882	O
-	-	1887	O
generation	-	1888	O
oral	-	1899	B
contraceptives	-	1904	I
were	-	1919	O
inconclusive	-	1924	O
but	-	1937	O
suggested	-	1941	O
that	-	1951	O
the	-	1956	O
risk	-	1960	O
was	-	1965	O
lower	-	1969	O
than	-	1975	O
the	-	1980	O
risk	-	1984	O
associated	-	1989	O
with	-	2000	O
second	-	2005	O
-	-	2011	O
generation	-	2012	O
oral	-	2023	B
contraceptives	-	2028	I
.	-	2042	O

The	11752354	2044	O
risk	-	2048	O
of	-	2053	O
myocardial	-	2056	O
infarction	-	2067	O
was	-	2078	O
similar	-	2082	O
among	-	2090	O
women	-	2096	O
who	-	2102	O
used	-	2106	O
oral	-	2111	B
contraceptives	-	2116	I
whether	-	2131	O
or	-	2139	O
not	-	2142	O
they	-	2146	O
had	-	2151	O
a	-	2155	O
prothrombotic	-	2157	O
mutation	-	2171	O
.	-	2179	O

Effects	12369736	0	O
of	-	8	O
5	-	11	O
-	-	12	O
HT1B	-	13	O
receptor	-	18	O
ligands	-	27	O
microinjected	-	35	O
into	-	49	O
the	-	54	O
accumbal	-	58	O
shell	-	67	O
or	-	73	O
core	-	76	O
on	-	81	O
the	-	84	O
cocaine	-	88	B
-	-	95	O
induced	-	96	O
locomotor	-	104	O
hyperactivity	-	114	O
in	-	128	O
rats	-	131	O
.	-	135	O

The	12369736	137	O
present	-	141	O
study	-	149	O
was	-	155	O
designed	-	159	O
to	-	168	O
examine	-	171	O
the	-	179	O
effect	-	183	O
of	-	190	O
5	-	193	O
-	-	194	O
HT1B	-	195	O
receptor	-	200	O
ligands	-	209	O
microinjected	-	217	O
into	-	231	O
the	-	236	O
subregions	-	240	O
of	-	251	O
the	-	254	O
nucleus	-	258	O
accumbens	-	266	O
(	-	276	O
the	-	277	O
shell	-	281	O
and	-	287	O
the	-	291	O
core	-	295	O
)	-	299	O
on	-	301	O
the	-	304	O
locomotor	-	308	O
hyperactivity	-	318	O
induced	-	332	O
by	-	340	O
cocaine	-	343	B
in	-	351	O
rats	-	354	O
.	-	358	O

Male	12369736	360	O
Wistar	-	365	O
rats	-	372	O
were	-	377	O
implanted	-	382	O
bilaterally	-	392	O
with	-	404	O
cannulae	-	409	O
into	-	418	O
the	-	423	O
accumbens	-	427	O
shell	-	437	O
or	-	443	O
core	-	446	O
,	-	450	O
and	-	452	O
then	-	456	O
were	-	461	O
locally	-	466	O
injected	-	474	O
with	-	483	O
GR	-	488	B
55562	-	491	I
(	-	497	O
an	-	498	O
antagonist	-	501	O
of	-	512	O
5	-	515	O
-	-	516	O
HT1B	-	517	O
receptors	-	522	O
)	-	531	O
or	-	533	O
CP	-	536	B
93129	-	539	I
(	-	545	O
an	-	546	O
agonist	-	549	O
of	-	557	O
5	-	560	O
-	-	561	O
HT1B	-	562	O
receptors	-	567	O
)	-	576	O
.	-	577	O

Given	12369736	579	O
alone	-	585	O
to	-	591	O
any	-	594	O
accumbal	-	598	O
subregion	-	607	O
,	-	616	O
GR	-	618	B
55562	-	621	I
(	-	627	O
0	-	628	O
.	-	629	O
1	-	630	O
-	-	631	O
10	-	632	O
microg	-	635	O
/	-	641	O
side	-	642	O
)	-	646	O
or	-	648	O
CP	-	651	B
93129	-	654	I
(	-	660	O
0	-	661	O
.	-	662	O
1	-	663	O
-	-	664	O
10	-	665	O
microg	-	668	O
/	-	674	O
side	-	675	O
)	-	679	O
did	-	681	O
not	-	685	O
change	-	689	O
basal	-	696	O
locomotor	-	702	O
activity	-	712	O
.	-	720	O

Systemic	12369736	722	O
cocaine	-	731	B
(	-	739	O
10	-	740	O
mg	-	743	O
/	-	745	O
kg	-	746	O
)	-	748	O
significantly	-	750	O
increased	-	764	O
the	-	774	O
locomotor	-	778	O
activity	-	788	O
of	-	797	O
rats	-	800	O
.	-	804	O

GR	12369736	806	B
55562	-	809	I
(	-	815	O
0	-	816	O
.	-	817	O
1	-	818	O
-	-	819	O
10	-	820	O
microg	-	823	O
/	-	829	O
side	-	830	O
)	-	834	O

,	12369736	835	O
administered	-	837	O
intra	-	850	O
-	-	855	O
accumbens	-	856	O
shell	-	866	O
prior	-	872	O
to	-	878	O
cocaine	-	881	B
,	-	888	O
dose	-	890	O
-	-	894	O
dependently	-	895	O
attenuated	-	907	O
the	-	918	O
psychostimulant	-	922	O
-	-	937	O
induced	-	938	O
locomotor	-	946	O
hyperactivity	-	956	O
.	-	969	O

Such	12369736	971	O
attenuation	-	976	O
was	-	988	O
not	-	992	O
found	-	996	O
in	-	1002	O
animals	-	1005	O
which	-	1013	O
had	-	1019	O
been	-	1023	O
injected	-	1028	O
with	-	1037	O
GR	-	1042	B
55562	-	1045	I
into	-	1051	O
the	-	1056	O
accumbens	-	1060	O
core	-	1070	O
.	-	1074	O

When	12369736	1076	O
injected	-	1081	O
into	-	1090	O
the	-	1095	O
accumbens	-	1099	O
shell	-	1109	O
(	-	1115	O
but	-	1116	O
not	-	1120	O
the	-	1124	O
core	-	1128	O
)	-	1132	O
before	-	1134	O
cocaine	-	1141	B
,	-	1148	O
CP	-	1150	B
93129	-	1153	I
(	-	1159	O
0	-	1160	O
.	-	1161	O
1	-	1162	O
-	-	1163	O
10	-	1164	O
microg	-	1167	O
/	-	1173	O
side	-	1174	O
)	-	1178	O
enhanced	-	1180	O
the	-	1189	O
locomotor	-	1193	O
response	-	1203	O
to	-	1212	O
cocaine	-	1215	B
;	-	1222	O
the	-	1224	O
maximum	-	1228	O
effect	-	1236	O
being	-	1243	O
observed	-	1249	O
after	-	1258	O
10	-	1264	O
microg	-	1267	O
/	-	1273	O
side	-	1274	O
of	-	1279	O
the	-	1282	O
agonist	-	1286	O
.	-	1293	O

The	12369736	1295	O
later	-	1299	O
enhancement	-	1305	O
was	-	1317	O
attenuated	-	1321	O
after	-	1332	O
intra	-	1338	O
-	-	1343	O
accumbens	-	1344	O
shell	-	1354	O
treatment	-	1360	O
with	-	1370	O
GR	-	1375	B
55562	-	1378	I
(	-	1384	O
1	-	1385	O
microg	-	1387	O
/	-	1393	O
side	-	1394	O
)	-	1398	O
.	-	1399	O

Our	12369736	1401	O
findings	-	1405	O
indicate	-	1414	O
that	-	1423	O
cocaine	-	1428	B
induced	-	1436	O
hyperlocomotion	-	1444	O
is	-	1460	O
modified	-	1463	O
by	-	1472	O
5	-	1475	O
-	-	1476	O
HT1B	-	1477	O
receptor	-	1482	O
ligands	-	1491	O
microinjected	-	1499	O
into	-	1513	O
the	-	1518	O
accumbens	-	1522	O
shell	-	1532	O
,	-	1537	O
but	-	1539	O
not	-	1543	O
core	-	1547	O
,	-	1551	O
this	-	1553	O
modification	-	1558	O
consisting	-	1571	O
in	-	1582	O
inhibitory	-	1585	O
and	-	1596	O
facilitatory	-	1600	O
effects	-	1613	O
of	-	1621	O
the	-	1624	O
5	-	1628	O
-	-	1629	O
HT1B	-	1630	O
receptor	-	1635	O
antagonist	-	1644	O
(	-	1655	O
GR	-	1656	B
55562	-	1659	I
)	-	1664	O
and	-	1666	O
agonist	-	1670	O
(	-	1678	O
CP	-	1679	B
93129	-	1682	I
)	-	1687	O
,	-	1688	O
respectively	-	1690	O
.	-	1702	O

In	12369736	1704	O
other	-	1707	O
words	-	1713	O
,	-	1718	O
the	-	1720	O
present	-	1724	O
results	-	1732	O
suggest	-	1740	O
that	-	1748	O
the	-	1753	O
accumbal	-	1757	O
shell	-	1766	O
5	-	1772	O
-	-	1773	O
HT1B	-	1774	O
receptors	-	1779	O
play	-	1789	O
a	-	1794	O
permissive	-	1796	O
role	-	1807	O
in	-	1812	O
the	-	1815	O
behavioural	-	1819	O
response	-	1831	O
to	-	1840	O
the	-	1843	O
psychostimulant	-	1847	O
.	-	1862	O

Ticlopidine	12639165	0	B
-	-	11	O
induced	-	12	O
cholestatic	-	20	O
hepatitis	-	32	O
.	-	41	O

OBJECTIVE	12639165	43	O
:	-	52	O

To	12639165	54	O
report	-	57	O
2	-	64	O
cases	-	66	O
of	-	72	O
ticlopidine	-	75	B
-	-	86	O
induced	-	87	O
cholestatic	-	95	O
hepatitis	-	107	O
,	-	116	O
investigate	-	118	O
its	-	130	O
mechanism	-	134	O
,	-	143	O
and	-	145	O
compare	-	149	O
the	-	157	O
observed	-	161	O
main	-	170	O
characteristics	-	175	O
with	-	191	O
those	-	196	O
of	-	202	O
the	-	205	O
published	-	209	O
cases	-	219	O
.	-	224	O

CASE	12639165	226	O
SUMMARIES	-	231	O
:	-	240	O

Two	12639165	242	O
patients	-	246	O
developed	-	255	O
prolonged	-	265	O
cholestatic	-	275	O
hepatitis	-	287	O
after	-	297	O
receiving	-	303	O
ticlopidine	-	313	B
following	-	325	O
percutaneous	-	335	O
coronary	-	348	O
angioplasty	-	357	O
,	-	368	O
with	-	370	O
complete	-	375	O
remission	-	384	O
during	-	394	O
the	-	401	O
follow	-	405	O
-	-	411	O
up	-	412	O
period	-	415	O
.	-	421	O

T	12639165	423	O
-	-	424	O
cell	-	425	O
stimulation	-	430	O
by	-	442	O
therapeutic	-	445	O
concentration	-	457	O
of	-	471	O
ticlopidine	-	474	B
was	-	486	O
demonstrated	-	490	O
in	-	503	O
vitro	-	506	O
in	-	512	O
the	-	515	O
patients	-	519	O
,	-	527	O
but	-	529	O
not	-	533	O
in	-	537	O
healthy	-	540	O
controls	-	548	O
.	-	556	O

DISCUSSION	12639165	558	O
:	-	568	O

Cholestatic	12639165	570	O
hepatitis	-	582	O
is	-	592	O
a	-	595	O
rare	-	597	O
complication	-	602	O
of	-	615	O
the	-	618	O
antiplatelet	-	622	O
agent	-	635	O
ticlopidine	-	641	B
;	-	652	O
several	-	654	O
cases	-	662	O
have	-	668	O
been	-	673	O
reported	-	678	O
but	-	687	O
few	-	691	O
in	-	695	O
the	-	698	O
English	-	702	O
literature	-	710	O
.	-	720	O

Our	12639165	722	O
patients	-	726	O
developed	-	735	O
jaundice	-	745	O
following	-	754	O
treatment	-	764	O
with	-	774	O
ticlopidine	-	779	B
and	-	791	O
showed	-	795	O
the	-	802	O
clinical	-	806	O
and	-	815	O
laboratory	-	819	O
characteristics	-	830	O
of	-	846	O
cholestatic	-	849	O
hepatitis	-	861	O
,	-	870	O
which	-	872	O
resolved	-	878	O
after	-	887	O
discontinuation	-	893	O
of	-	909	O
the	-	912	O
drug	-	916	O
.	-	920	O

Hepatitis	12639165	922	O
may	-	932	O
develop	-	936	O
weeks	-	944	O
after	-	950	O
discontinuation	-	956	O
of	-	972	O
the	-	975	O
drug	-	979	O
and	-	984	O
may	-	988	O
run	-	992	O
a	-	996	O
prolonged	-	998	O
course	-	1008	O
,	-	1014	O
but	-	1016	O
complete	-	1020	O
remission	-	1029	O
was	-	1039	O
observed	-	1043	O
in	-	1052	O
all	-	1055	O
reported	-	1059	O
cases	-	1068	O
.	-	1073	O

An	12639165	1075	O
objective	-	1078	O
causality	-	1088	O
assessment	-	1098	O
revealed	-	1109	O
that	-	1118	O
the	-	1123	O
adverse	-	1127	O
drug	-	1135	O
event	-	1140	O
was	-	1146	O
probably	-	1150	O
related	-	1159	O
to	-	1167	O
the	-	1170	O
use	-	1174	O
of	-	1178	O
ticlopidine	-	1181	B
.	-	1192	O

The	12639165	1194	O
mechanisms	-	1198	O
of	-	1209	O
this	-	1212	O
ticlopidine	-	1217	B
-	-	1228	O
induced	-	1229	O
cholestasis	-	1237	O
are	-	1249	O
unclear	-	1253	O
.	-	1260	O

Immune	12639165	1262	O
mechanisms	-	1269	O
may	-	1280	O
be	-	1284	O
involved	-	1287	O
in	-	1296	O
the	-	1299	O
drug	-	1303	O
's	-	1307	O
hepatotoxicity	-	1310	O
,	-	1324	O
as	-	1326	O
suggested	-	1329	O
by	-	1339	O
the	-	1342	O
T	-	1346	O
-	-	1347	O
cell	-	1348	O
stimulation	-	1353	O
study	-	1365	O
reported	-	1371	O
here	-	1380	O
.	-	1384	O

CONCLUSIONS	12639165	1386	O
:	-	1397	O

Cholestatic	12639165	1399	O
hepatitis	-	1411	O
is	-	1421	O
a	-	1424	O
rare	-	1426	O
adverse	-	1431	O
effect	-	1439	O
of	-	1446	O
ticlopidine	-	1449	B
that	-	1461	O
may	-	1466	O
be	-	1470	O
immune	-	1473	O
mediated	-	1480	O
.	-	1488	O

Patients	12639165	1490	O
receiving	-	1499	O
the	-	1509	O
drug	-	1513	O
should	-	1518	O
be	-	1525	O
monitored	-	1528	O
with	-	1538	O
liver	-	1543	O
function	-	1549	O
tests	-	1558	O
along	-	1564	O
with	-	1570	O
complete	-	1575	O
blood	-	1584	O
cell	-	1590	O
counts	-	1595	O
.	-	1601	O

This	12639165	1603	O
complication	-	1608	O
will	-	1621	O
be	-	1626	O
observed	-	1629	O
even	-	1638	O
less	-	1643	O
often	-	1648	O
in	-	1654	O
the	-	1657	O
future	-	1661	O
as	-	1668	O
ticlopidine	-	1671	B
is	-	1683	O
being	-	1686	O
replaced	-	1692	O
by	-	1701	O
the	-	1704	O
newer	-	1708	O
antiplatelet	-	1714	O
agent	-	1727	O
clopidogrel	-	1733	B
.	-	1744	O

Epithelial	12653683	0	O
sodium	-	11	B
channel	-	18	O
(	-	26	O
ENaC	-	27	O
)	-	31	O
subunit	-	33	O
mRNA	-	41	O
and	-	46	O
protein	-	50	O
expression	-	58	O
in	-	69	O
rats	-	72	O
with	-	77	O
puromycin	-	82	B
aminonucleoside	-	92	I
-	-	107	O
induced	-	108	O
nephrotic	-	116	O
syndrome	-	126	O
.	-	134	O

In	12653683	136	O
experimental	-	139	O
nephrotic	-	152	O
syndrome	-	162	O
,	-	170	O
urinary	-	172	O
sodium	-	180	B
excretion	-	187	O
is	-	197	O
decreased	-	200	O
during	-	210	O
the	-	217	O
early	-	221	O
phase	-	227	O
of	-	233	O
the	-	236	O
disease	-	240	O
.	-	247	O

The	12653683	249	O
molecular	-	253	O
mechanism	-	263	O
(	-	272	O
s	-	273	O
)	-	274	O
leading	-	276	O
to	-	284	O
salt	-	287	O
retention	-	292	O
has	-	302	O
not	-	306	O
been	-	310	O
completely	-	315	O
elucidated	-	326	O
.	-	336	O

The	12653683	338	O
rate	-	342	O
-	-	346	O
limiting	-	347	O
constituent	-	356	O
of	-	368	O
collecting	-	371	O
duct	-	382	O
sodium	-	387	B
transport	-	394	O
is	-	404	O
the	-	407	O
epithelial	-	411	O
sodium	-	422	B
channel	-	429	O
(	-	437	O
ENaC	-	438	O
)	-	442	O
.	-	443	O

We	12653683	445	O
examined	-	448	O
the	-	457	O
abundance	-	461	O
of	-	471	O
ENaC	-	474	O
subunit	-	479	O
mRNAs	-	487	O
and	-	493	O
proteins	-	497	O
in	-	506	O
puromycin	-	509	B
aminonucleoside	-	519	I
(	-	535	O
PAN	-	536	B
)	-	539	O
-	-	540	O
induced	-	541	O
nephrotic	-	549	O
syndrome	-	559	O
.	-	567	O

The	12653683	569	O
time	-	573	O
courses	-	578	O
of	-	586	O
urinary	-	589	O
sodium	-	597	B
excretion	-	604	O
,	-	613	O
plasma	-	615	O
aldosterone	-	622	B
concentration	-	634	O
and	-	648	O
proteinuria	-	652	O
were	-	664	O
studied	-	669	O
in	-	677	O
male	-	680	O
Sprague	-	685	O
-	-	692	O
Dawley	-	693	O
rats	-	700	O
treated	-	705	O
with	-	713	O
a	-	718	O
single	-	720	O
dose	-	727	O
of	-	732	O
either	-	735	O
PAN	-	742	B
or	-	746	O
vehicle	-	749	O
.	-	756	O

The	12653683	758	O
relative	-	762	O
amounts	-	771	O
of	-	779	O
alphaENaC	-	782	O
,	-	791	O
betaENaC	-	793	O
and	-	802	O
gammaENaC	-	806	O
mRNAs	-	816	O
were	-	822	O
determined	-	827	O
in	-	838	O
kidneys	-	841	O
from	-	849	O
these	-	854	O
rats	-	860	O
by	-	865	O
real	-	868	O
-	-	872	O
time	-	873	O
quantitative	-	878	O
TaqMan	-	891	O
PCR	-	898	O
,	-	901	O
and	-	903	O
the	-	907	O
amounts	-	911	O
of	-	919	O
proteins	-	922	O
by	-	931	O
Western	-	934	O
blot	-	942	O
.	-	946	O

The	12653683	948	O
kinetics	-	952	O
of	-	961	O
urinary	-	964	O
sodium	-	972	B
excretion	-	979	O
and	-	989	O
the	-	993	O
appearance	-	997	O
of	-	1008	O
proteinuria	-	1011	O
were	-	1023	O
comparable	-	1028	O
with	-	1039	O
those	-	1044	O
reported	-	1050	O
previously	-	1059	O
.	-	1069	O

Sodium	12653683	1071	B
retention	-	1078	O
occurred	-	1088	O
on	-	1097	O
days	-	1100	O
2	-	1105	O
,	-	1106	O
3	-	1108	O
and	-	1110	O
6	-	1114	O
after	-	1116	O
PAN	-	1122	B
injection	-	1126	O
.	-	1135	O

A	12653683	1137	O
significant	-	1139	O
up	-	1151	O
-	-	1153	O
regulation	-	1154	O
of	-	1165	O
alphaENaC	-	1168	O
and	-	1178	O
betaENaC	-	1182	O
mRNA	-	1191	O
abundance	-	1196	O
on	-	1206	O
days	-	1209	O
1	-	1214	O
and	-	1216	O
2	-	1220	O
preceded	-	1222	O
sodium	-	1231	B
retention	-	1238	O
on	-	1248	O
days	-	1251	O
2	-	1256	O
and	-	1258	O
3	-	1262	O
.	-	1263	O

Conversely	12653683	1265	O
,	-	1275	O
down	-	1277	O
-	-	1281	O
regulation	-	1282	O
of	-	1293	O
alphaENaC	-	1296	O
,	-	1305	O
betaENaC	-	1307	O
and	-	1316	O
gammaENaC	-	1320	O
mRNA	-	1330	O
expression	-	1335	O
on	-	1346	O
day	-	1349	O
3	-	1353	O
occurred	-	1355	O
in	-	1364	O
the	-	1367	O
presence	-	1371	O
of	-	1380	O
high	-	1383	O
aldosterone	-	1388	B
concentrations	-	1400	O
,	-	1414	O
and	-	1416	O
was	-	1420	O
followed	-	1424	O
by	-	1433	O
a	-	1436	O
return	-	1438	O
of	-	1445	O
sodium	-	1448	B
excretion	-	1455	O
to	-	1465	O
control	-	1468	O
values	-	1476	O
.	-	1482	O

The	12653683	1484	O
amounts	-	1488	O
of	-	1496	O
alphaENaC	-	1499	O
,	-	1508	O
betaENaC	-	1510	O
and	-	1519	O
gammaENaC	-	1523	O
proteins	-	1533	O
were	-	1542	O
not	-	1547	O
increased	-	1551	O
during	-	1561	O
PAN	-	1568	B
-	-	1571	O
induced	-	1572	O
sodium	-	1580	B
retention	-	1587	O
.	-	1596	O

In	12653683	1598	O
conclusion	-	1601	O
,	-	1611	O
ENaC	-	1613	O
mRNA	-	1618	O
expression	-	1623	O
,	-	1633	O
especially	-	1635	O
alphaENaC	-	1646	O
,	-	1655	O
is	-	1657	O
increased	-	1660	O
in	-	1670	O
the	-	1673	O
very	-	1677	O
early	-	1682	O
phase	-	1688	O
of	-	1694	O
the	-	1697	O
experimental	-	1701	O
model	-	1714	O
of	-	1720	O
PAN	-	1723	B
-	-	1726	O
induced	-	1727	O
nephrotic	-	1735	O
syndrome	-	1745	O
in	-	1754	O
rats	-	1757	O
,	-	1761	O
but	-	1763	O
appears	-	1767	O
to	-	1775	O
escape	-	1778	O
from	-	1785	O
the	-	1790	O
regulation	-	1794	O
by	-	1805	O
aldosterone	-	1808	B
after	-	1820	O
day	-	1826	O
3	-	1830	O
.	-	1831	O

NO	14659530	0	B
-	-	2	O
induced	-	3	O
migraine	-	11	O
attack	-	20	O
:	-	26	O
strong	-	28	O
increase	-	35	O
in	-	44	O
plasma	-	47	O
calcitonin	-	54	B
gene	-	65	I
-	-	69	I
related	-	70	I
peptide	-	78	I
(	-	86	O
CGRP	-	87	B
)	-	91	O
concentration	-	93	O
and	-	107	O
negative	-	111	O
correlation	-	120	O
with	-	132	O
platelet	-	137	O
serotonin	-	146	B
release	-	156	O
.	-	163	O

The	14659530	165	O
aim	-	169	O
of	-	173	O
the	-	176	O
present	-	180	O
study	-	188	O
was	-	194	O
to	-	198	O
investigate	-	201	O
changes	-	213	O
in	-	221	O
the	-	224	O
plasma	-	228	O
calcitonin	-	235	B
gene	-	246	I
-	-	250	I
related	-	251	I
peptide	-	259	I
(	-	267	O
CGRP	-	268	B
)	-	272	O
concentration	-	274	O
and	-	288	O
platelet	-	292	O
serotonin	-	301	B
(	-	311	O
5	-	312	B
-	-	313	I
hydroxytriptamine	-	314	I
,	-	331	O
5	-	333	B
-	-	334	I
HT	-	335	I
)	-	337	O
content	-	339	O
during	-	347	O
the	-	354	O
immediate	-	358	O
headache	-	368	O
and	-	377	O
the	-	381	O
delayed	-	385	O
genuine	-	393	O
migraine	-	401	O
attack	-	410	O
provoked	-	417	O
by	-	426	O
nitroglycerin	-	429	B
.	-	442	O

Fifteen	14659530	444	O
female	-	452	O
migraineurs	-	459	O
(	-	471	O
without	-	472	O
aura	-	480	O
)	-	484	O
and	-	486	O
eight	-	490	O
controls	-	496	O
participated	-	505	O
in	-	518	O
the	-	521	O
study	-	525	O
.	-	530	O

Sublingual	14659530	532	O
nitroglycerin	-	543	B
(	-	557	O
0	-	558	O
.	-	559	O
5	-	560	O
mg	-	562	O
)	-	564	O
was	-	566	O
administered	-	570	O
.	-	582	O

Blood	14659530	584	O
was	-	590	O
collected	-	594	O
from	-	604	O
the	-	609	O
antecubital	-	613	O
vein	-	625	O
four	-	630	O
times	-	635	O
:	-	640	O
60	-	642	O
min	-	645	O
before	-	649	O
and	-	656	O
after	-	660	O
the	-	666	O
nitroglycerin	-	670	B
application	-	684	O
,	-	695	O
and	-	697	O
60	-	701	O
and	-	704	O
120	-	708	O
min	-	712	O
after	-	716	O
the	-	722	O
beginning	-	726	O
of	-	736	O
the	-	739	O
migraine	-	743	O
attack	-	752	O
(	-	759	O
mean	-	760	O
344	-	765	O
and	-	769	O
404	-	773	O
min	-	777	O
;	-	780	O
12	-	782	O
subjects	-	785	O
)	-	793	O
.	-	794	O

In	14659530	796	O
those	-	799	O
subjects	-	805	O
who	-	814	O
had	-	818	O
no	-	822	O
migraine	-	825	O
attack	-	834	O
(	-	841	O
11	-	842	O
subjects	-	845	O
)	-	853	O
a	-	855	O
similar	-	857	O
time	-	865	O
schedule	-	870	O
was	-	879	O
used	-	883	O
.	-	887	O

Plasma	14659530	889	O
CGRP	-	896	B
concentration	-	901	O
increased	-	915	O
significantly	-	925	O
(	-	939	O
P	-	940	O
<	-	941	O
0	-	942	O
.	-	943	O
01	-	944	O
)	-	946	O
during	-	948	O
the	-	955	O
migraine	-	959	O
attack	-	968	O
and	-	975	O
returned	-	979	O
to	-	988	O
baseline	-	991	O
after	-	1000	O
the	-	1006	O
cessation	-	1010	O
of	-	1020	O
the	-	1023	O
migraine	-	1027	O
.	-	1035	O

In	14659530	1037	O
addition	-	1040	O
,	-	1048	O
both	-	1050	O
change	-	1055	O
and	-	1062	O
peak	-	1066	O
,	-	1070	O
showed	-	1072	O
significant	-	1079	O
positive	-	1091	O
correlations	-	1100	O
with	-	1113	O
migraine	-	1118	O
headache	-	1127	O
intensity	-	1136	O
(	-	1146	O
P	-	1147	O
<	-	1148	O
0	-	1149	O
.	-	1150	O
001	-	1151	O
)	-	1154	O
.	-	1155	O

However	14659530	1157	O
,	-	1164	O
plasma	-	1166	O
CGRP	-	1173	B
concentrations	-	1178	O
failed	-	1193	O
to	-	1200	O
change	-	1203	O
during	-	1210	O
immediate	-	1217	O
headache	-	1227	O
and	-	1236	O
in	-	1240	O
the	-	1243	O
subjects	-	1247	O
with	-	1256	O
no	-	1261	O
migraine	-	1264	O
attack	-	1273	O
.	-	1279	O

Basal	14659530	1281	O
CGRP	-	1287	B
concentration	-	1292	O
was	-	1306	O
significantly	-	1310	O
higher	-	1324	O
and	-	1331	O
platelet	-	1335	O
5	-	1344	B
-	-	1345	I
HT	-	1346	I
content	-	1349	O
tended	-	1357	O
to	-	1364	O
be	-	1367	O
lower	-	1370	O
in	-	1376	O
subjects	-	1379	O
who	-	1388	O
experienced	-	1392	O
a	-	1404	O
migraine	-	1406	O
attack	-	1415	O
.	-	1421	O

Platelet	14659530	1423	O
serotonin	-	1432	B
content	-	1442	O
decreased	-	1450	O
significantly	-	1460	O
(	-	1474	O
P	-	1475	O
<	-	1476	O
0	-	1477	O
.	-	1478	O
01	-	1479	O
)	-	1481	O
after	-	1483	O
nitroglycerin	-	1489	B
in	-	1503	O
subjects	-	1506	O
with	-	1515	O
no	-	1520	O
migraine	-	1523	O
attack	-	1532	O
but	-	1539	O
no	-	1543	O
consistent	-	1546	O
change	-	1557	O
was	-	1564	O
observed	-	1568	O
in	-	1577	O
patients	-	1580	O
with	-	1589	O
migraine	-	1594	O
attack	-	1603	O
.	-	1609	O

In	14659530	1611	O
conclusion	-	1614	O
,	-	1624	O
the	-	1626	O
fact	-	1630	O
that	-	1635	O
plasma	-	1640	O
CGRP	-	1647	B
concentration	-	1652	O
correlates	-	1666	O
with	-	1677	O
the	-	1682	O
timing	-	1686	O
and	-	1693	O
severity	-	1697	O
of	-	1706	O
a	-	1709	O
migraine	-	1711	O
headache	-	1720	O
suggests	-	1729	O
a	-	1738	O
direct	-	1740	O
relationship	-	1747	O
between	-	1760	O
CGRP	-	1768	B
and	-	1773	O
migraine	-	1777	O
.	-	1785	O

In	14659530	1787	O
contrast	-	1790	O
,	-	1798	O
serotonin	-	1800	B
release	-	1810	O
from	-	1818	O
platelets	-	1823	O
does	-	1833	O
not	-	1838	O
provoke	-	1842	O
migraine	-	1850	O
,	-	1858	O
it	-	1860	O
may	-	1863	O
even	-	1867	O
counteract	-	1872	O
the	-	1883	O
headache	-	1887	O
and	-	1896	O
the	-	1900	O
concomitant	-	1904	O
CGRP	-	1916	B
release	-	1921	O
in	-	1929	O
this	-	1932	O
model	-	1937	O
.	-	1942	O

Coronary	15804801	0	O
aneurysm	-	9	O
after	-	18	O
implantation	-	24	O
of	-	37	O
a	-	40	O
paclitaxel	-	42	B
-	-	52	O
eluting	-	53	O
stent	-	61	O
.	-	66	O

Formation	15804801	68	O
of	-	78	O
coronary	-	81	O
aneurysm	-	90	O
is	-	99	O
a	-	102	O
rare	-	104	O
complication	-	109	O
of	-	122	O
stenting	-	125	O
with	-	134	O
bare	-	139	O
metal	-	144	O
stents	-	150	O
,	-	156	O
but	-	158	O
based	-	162	O
on	-	168	O
experimental	-	171	O
studies	-	184	O
drug	-	192	O
-	-	196	O
eluting	-	197	O
stents	-	205	O
may	-	212	O
induce	-	216	O
toxic	-	223	O
effects	-	229	O
on	-	237	O
the	-	240	O
vessel	-	244	O
wall	-	251	O
with	-	256	O
incomplete	-	261	O
stent	-	272	O
apposition	-	278	O
,	-	288	O
aneurysm	-	290	O
formation	-	299	O
and	-	309	O
with	-	313	O
the	-	318	O
potential	-	322	O
of	-	332	O
stent	-	335	O
thrombosis	-	341	O
or	-	352	O
vessel	-	355	O
rupture	-	362	O
.	-	369	O

We	15804801	371	O
present	-	374	O
a	-	382	O
43	-	384	O
-	-	386	O
year	-	387	O
-	-	391	O
old	-	392	O
man	-	396	O
who	-	400	O
developed	-	404	O
a	-	414	O
coronary	-	416	O
aneurysm	-	425	O
in	-	434	O
the	-	437	O
right	-	441	O
coronary	-	447	O
artery	-	456	O
6	-	463	O
months	-	465	O
after	-	472	O
receiving	-	478	O
a	-	488	O
paclitaxel	-	490	B
-	-	500	O
eluting	-	501	O
stent	-	509	O
.	-	514	O

The	15804801	516	O
patient	-	520	O
was	-	528	O
asymptomatic	-	532	O
and	-	545	O
the	-	549	O
aneurysm	-	553	O
was	-	562	O
detected	-	566	O
in	-	575	O
a	-	578	O
routine	-	580	O
control	-	588	O
.	-	595	O

Angiography	15804801	597	O
and	-	609	O
intracoronary	-	613	O
ultrasound	-	627	O
demonstrated	-	638	O
lack	-	651	O
of	-	656	O
contact	-	659	O
between	-	667	O
stent	-	675	O
and	-	681	O
vessel	-	685	O
wall	-	692	O
in	-	697	O
a	-	700	O
15	-	702	O
-	-	704	O
mm	-	705	O
long	-	708	O
segment	-	713	O
with	-	721	O
maximal	-	726	O
aneurysm	-	734	O
diameter	-	743	O
of	-	752	O
6	-	755	O
.	-	756	O
0	-	757	O
mm	-	759	O
.	-	761	O

The	15804801	763	O
patient	-	767	O
was	-	775	O
successfully	-	779	O
treated	-	792	O
with	-	800	O
a	-	805	O
graft	-	807	O
stent	-	813	O
.	-	818	O

Behavioral	16160878	0	O
effects	-	11	O
of	-	19	O
urotensin	-	22	B
-	-	31	I
II	-	32	I
centrally	-	35	O
administered	-	45	O
in	-	58	O
mice	-	61	O
.	-	65	O

Urotensin	16160878	67	B
-	-	76	I
II	-	77	I
(	-	80	O
U	-	81	B
-	-	82	I
II	-	83	I
)	-	85	O
receptors	-	87	O
are	-	97	O
widely	-	101	O
distributed	-	108	O
in	-	120	O
the	-	123	O
central	-	127	O
nervous	-	135	O
system	-	143	O
.	-	149	O

Intracerebroventricular	16160878	151	O
(	-	175	O
i	-	176	O
.	-	177	O
c	-	178	O
.	-	179	O
v	-	180	O
.	-	181	O
)	-	182	O
injection	-	184	O
of	-	194	O
U	-	197	B
-	-	198	I
II	-	199	I
causes	-	202	O
hypertension	-	209	O
and	-	222	O
bradycardia	-	226	O
and	-	238	O
stimulates	-	242	O
prolactin	-	253	O
and	-	263	O
thyrotropin	-	267	O
secretion	-	279	O
.	-	288	O

However	16160878	290	O
,	-	297	O
the	-	299	O
behavioral	-	303	O
effects	-	314	O
of	-	322	O
centrally	-	325	O
administered	-	335	O
U	-	348	B
-	-	349	I
II	-	350	I
have	-	353	O
received	-	358	O
little	-	367	O
attention	-	374	O
.	-	383	O

In	16160878	385	O
the	-	388	O
present	-	392	O
study	-	400	O
,	-	405	O
we	-	407	O
tested	-	410	O
the	-	417	O
effects	-	421	O
of	-	429	O
i	-	432	O
.	-	433	O
c	-	434	O
.	-	435	O
v	-	436	O
.	-	437	O

injections	16160878	439	O
of	-	450	O
U	-	453	B
-	-	454	I
II	-	455	I
on	-	458	O
behavioral	-	461	O
,	-	471	O
metabolic	-	473	O
,	-	482	O
and	-	484	O
endocrine	-	488	O
responses	-	498	O
in	-	508	O
mice	-	511	O
.	-	515	O

Administration	16160878	517	O
of	-	532	O
graded	-	535	O
doses	-	542	O
of	-	548	O
U	-	551	B
-	-	552	I
II	-	553	I
(	-	556	O
1	-	557	O
-	-	558	O
10	-	559	O
,	-	561	O
000	-	562	O
ng	-	566	O
/	-	568	O
mouse	-	569	O
)	-	574	O
provoked	-	576	O
:	-	584	O
(	-	586	O
1	-	587	O
)	-	588	O
a	-	590	O
dose	-	592	O
-	-	596	O
dependent	-	597	O
reduction	-	607	O
in	-	617	O
the	-	620	O
number	-	624	O
of	-	631	O
head	-	634	O
dips	-	639	O
in	-	644	O
the	-	647	O
hole	-	651	O
-	-	655	O
board	-	656	O
test	-	662	O
;	-	666	O
(	-	668	O
2	-	669	O
)	-	670	O
a	-	672	O
dose	-	674	O
-	-	678	O
dependent	-	679	O
reduction	-	689	O
in	-	699	O
the	-	702	O
number	-	706	O
of	-	713	O
entries	-	716	O
in	-	724	O
the	-	727	O
white	-	731	O
chamber	-	737	O
in	-	745	O
the	-	748	O
black	-	752	O
-	-	757	O
and	-	758	O
-	-	761	O
white	-	762	O
compartment	-	768	O
test	-	780	O
,	-	784	O
and	-	786	O
in	-	790	O
the	-	793	O
number	-	797	O
of	-	804	O
entries	-	807	O
in	-	815	O
the	-	818	O
central	-	822	O
platform	-	830	O
and	-	839	O
open	-	843	O
arms	-	848	O
in	-	853	O
the	-	856	O
plus	-	860	O
-	-	864	O
maze	-	865	O
test	-	870	O
;	-	874	O
and	-	876	O
(	-	880	O
3	-	881	O
)	-	882	O
a	-	884	O
dose	-	886	O
-	-	890	O
dependent	-	891	O
increase	-	901	O
in	-	910	O
the	-	913	O
duration	-	917	O
of	-	926	O
immobility	-	929	O
in	-	940	O
the	-	943	O
forced	-	947	O
-	-	953	O
swimming	-	954	O
test	-	963	O
and	-	968	O
tail	-	972	O
suspension	-	977	O
test	-	988	O
.	-	992	O

Intracerebroventricular	16160878	994	O
injection	-	1018	O
of	-	1028	O
U	-	1031	B
-	-	1032	I
II	-	1033	I
also	-	1036	O
caused	-	1041	O
an	-	1048	O
increase	-	1051	O
in	-	1060	O
:	-	1062	O
food	-	1064	O
intake	-	1069	O
at	-	1076	O
doses	-	1079	O
of	-	1085	O
100	-	1088	O
and	-	1092	O
1	-	1096	O
,	-	1097	O
000	-	1098	O
ng	-	1102	O
/	-	1104	O
mouse	-	1105	O
,	-	1110	O
water	-	1112	O
intake	-	1118	O
at	-	1125	O
doses	-	1128	O
of	-	1134	O
100	-	1137	O
-	-	1140	O
10	-	1141	O
,	-	1143	O
000	-	1144	O
ng	-	1148	O
/	-	1150	O
mouse	-	1151	O
,	-	1156	O
and	-	1158	O
horizontal	-	1162	O
locomotion	-	1173	O
activity	-	1184	O
at	-	1193	O
a	-	1196	O
dose	-	1198	O
of	-	1203	O
10	-	1206	O
,	-	1208	O
000	-	1209	O
ng	-	1213	O
/	-	1215	O
mouse	-	1216	O
.	-	1221	O

Whatever	16160878	1223	O
was	-	1232	O
the	-	1236	O
dose	-	1240	O
,	-	1244	O
the	-	1246	O
central	-	1250	O
administration	-	1258	O
of	-	1273	O
U	-	1276	B
-	-	1277	I
II	-	1278	I
had	-	1281	O
no	-	1285	O
effect	-	1288	O
on	-	1295	O
body	-	1298	O
temperature	-	1303	O
,	-	1314	O
nociception	-	1316	O
,	-	1327	O
apomorphine	-	1329	B
-	-	1340	O
induced	-	1341	O
penile	-	1349	O
erection	-	1356	O
and	-	1365	O
climbing	-	1369	O
behavior	-	1378	O
,	-	1386	O
and	-	1388	O
stress	-	1392	O
-	-	1398	O
induced	-	1399	O
plasma	-	1407	O
corticosterone	-	1414	B
level	-	1429	O
.	-	1434	O

Taken	16160878	1436	O
together	-	1442	O
,	-	1450	O
the	-	1452	O
present	-	1456	O
study	-	1464	O
demonstrates	-	1470	O
that	-	1483	O
the	-	1488	O
central	-	1492	O
injection	-	1500	O
of	-	1510	O
U	-	1513	B
-	-	1514	I
II	-	1515	I
at	-	1518	O
doses	-	1521	O
of	-	1527	O
1	-	1530	O
-	-	1531	O
10	-	1532	O
,	-	1534	O
000	-	1535	O
ng	-	1539	O
/	-	1541	O
mouse	-	1542	O
induces	-	1548	O
anxiogenic	-	1556	O
-	-	1566	O
and	-	1568	O
depressant	-	1572	O
-	-	1582	O
like	-	1583	O
effects	-	1588	O
in	-	1596	O
mouse	-	1599	O
.	-	1604	O

These	16160878	1606	O
data	-	1612	O
suggest	-	1617	O
that	-	1625	O
U	-	1630	B
-	-	1631	I
II	-	1632	I
may	-	1635	O
be	-	1639	O
involved	-	1642	O
in	-	1651	O
some	-	1654	O
aspects	-	1659	O
of	-	1667	O
psychiatric	-	1670	O
disorders	-	1682	O
.	-	1691	O

Recurrent	16274958	0	O
dysphonia	-	10	O
and	-	20	O
acitretin	-	24	B
.	-	33	O

We	16274958	35	O
report	-	38	O
the	-	45	O
case	-	49	O
of	-	54	O
a	-	57	O
woman	-	59	O
complaining	-	65	O
of	-	77	O
dysphonia	-	80	O
while	-	90	O
she	-	96	O
was	-	100	O
treated	-	104	O
by	-	112	O
acitretin	-	115	B
.	-	124	O

Her	16274958	126	O
symptoms	-	130	O
totally	-	139	O
regressed	-	147	O
after	-	157	O
drug	-	163	O
withdrawal	-	168	O
and	-	179	O
reappeared	-	183	O
when	-	194	O
acitretin	-	199	B
was	-	209	O
reintroduced	-	213	O
.	-	225	O

To	16274958	227	O
our	-	230	O
knowledge	-	234	O
,	-	243	O
this	-	245	O
is	-	250	O
the	-	253	O
first	-	257	O
case	-	263	O
of	-	268	O
acitretin	-	271	B
-	-	280	O
induced	-	281	O
dysphonia	-	289	O
.	-	298	O

This	16274958	300	O
effect	-	305	O
may	-	312	O
be	-	316	O
related	-	319	O
to	-	327	O
the	-	330	O
pharmacological	-	334	O
effect	-	350	O
of	-	357	O
this	-	360	O
drug	-	365	O
on	-	370	O
mucous	-	373	O
membranes	-	380	O
.	-	389	O

Pharmacological	16330766	0	O
modulation	-	16	O
of	-	27	O
pain	-	30	O
-	-	34	O
related	-	35	O
brain	-	43	O
activity	-	49	O
during	-	58	O
normal	-	65	O
and	-	72	O
central	-	76	O
sensitization	-	84	O
states	-	98	O
in	-	105	O
humans	-	108	O
.	-	114	O

Abnormal	16330766	116	O
processing	-	125	O
of	-	136	O
somatosensory	-	139	O
inputs	-	153	O
in	-	160	O
the	-	163	O
central	-	167	O
nervous	-	175	O
system	-	183	O
(	-	190	O
central	-	191	O
sensitization	-	199	O
)	-	212	O
is	-	214	O
the	-	217	O
mechanism	-	221	O
accounting	-	231	O
for	-	242	O
the	-	246	O
enhanced	-	250	O
pain	-	259	O
sensitivity	-	264	O
in	-	276	O
the	-	279	O
skin	-	283	O
surrounding	-	288	O
tissue	-	300	O
injury	-	307	O
(	-	314	O
secondary	-	315	O
hyperalgesia	-	325	O
)	-	337	O
.	-	338	O

Secondary	16330766	340	O
hyperalgesia	-	350	O
shares	-	363	O
clinical	-	370	O
characteristics	-	379	O
with	-	395	O
neurogenic	-	400	O
hyperalgesia	-	411	O
in	-	424	O
patients	-	427	O
with	-	436	O
neuropathic	-	441	O
pain	-	453	O
.	-	457	O

Abnormal	16330766	459	O
brain	-	468	O
responses	-	474	O
to	-	484	O
somatosensory	-	487	O
stimuli	-	501	O
have	-	509	O
been	-	514	O
found	-	519	O
in	-	525	O
patients	-	528	O
with	-	537	O
hyperalgesia	-	542	O
as	-	555	O
well	-	558	O
as	-	563	O
in	-	566	O
normal	-	569	O
subjects	-	576	O
during	-	585	O
experimental	-	592	O
central	-	605	O
sensitization	-	613	O
.	-	626	O

The	16330766	628	O
aim	-	632	O
of	-	636	O
this	-	639	O
study	-	644	O
was	-	650	O
to	-	654	O
assess	-	657	O
the	-	664	O
effects	-	668	O
of	-	676	O
gabapentin	-	679	B
,	-	689	O
a	-	691	O
drug	-	693	O
effective	-	698	O
in	-	708	O
neuropathic	-	711	O
pain	-	723	O
patients	-	728	O
,	-	736	O
on	-	738	O
brain	-	741	O
processing	-	747	O
of	-	758	O
nociceptive	-	761	O
information	-	773	O
in	-	785	O
normal	-	788	O
and	-	795	O
central	-	799	O
sensitization	-	807	O
states	-	821	O
.	-	827	O

Using	16330766	829	O
functional	-	835	O
magnetic	-	846	O
resonance	-	855	O
imaging	-	865	O
(	-	873	O
fMRI	-	874	O
)	-	878	O
in	-	880	O
normal	-	883	O
volunteers	-	890	O
,	-	900	O
we	-	902	O
studied	-	905	O
the	-	913	O
gabapentin	-	917	B
-	-	927	O
induced	-	928	O
modulation	-	936	O
of	-	947	O
brain	-	950	O
activity	-	956	O
in	-	965	O
response	-	968	O
to	-	977	O
nociceptive	-	980	O
mechanical	-	992	O
stimulation	-	1003	O
of	-	1015	O
normal	-	1018	O
skin	-	1025	O
and	-	1030	O
capsaicin	-	1034	B
-	-	1043	O
induced	-	1044	O
secondary	-	1052	O
hyperalgesia	-	1062	O
.	-	1074	O

The	16330766	1076	O
dose	-	1080	O
of	-	1085	O
gabapentin	-	1088	B
was	-	1099	O
1	-	1103	O
,	-	1104	O
800	-	1105	O
mg	-	1109	O
per	-	1112	O
os	-	1116	O
,	-	1118	O
in	-	1120	O
a	-	1123	O
single	-	1125	O
administration	-	1132	O
.	-	1146	O

We	16330766	1148	O
found	-	1151	O
that	-	1157	O
(	-	1162	O
i	-	1163	O
)	-	1164	O
gabapentin	-	1166	B
reduced	-	1177	O
the	-	1185	O
activations	-	1189	O
in	-	1201	O
the	-	1204	O
bilateral	-	1208	O
operculoinsular	-	1218	O
cortex	-	1234	O
,	-	1240	O
independently	-	1242	O
of	-	1256	O
the	-	1259	O
presence	-	1263	O
of	-	1272	O
central	-	1275	O
sensitization	-	1283	O
;	-	1296	O
(	-	1298	O
ii	-	1299	O
)	-	1301	O
gabapentin	-	1303	B
reduced	-	1314	O
the	-	1322	O
activation	-	1326	O
in	-	1337	O
the	-	1340	O
brainstem	-	1344	O
,	-	1353	O
only	-	1355	O
during	-	1360	O
central	-	1367	O
sensitization	-	1375	O
;	-	1388	O
(	-	1390	O
iii	-	1391	O
)	-	1394	O
gabapentin	-	1396	B
suppressed	-	1407	O
stimulus	-	1418	O
-	-	1426	O
induced	-	1427	O
deactivations	-	1435	O
,	-	1448	O
only	-	1450	O
during	-	1455	O
central	-	1462	O
sensitization	-	1470	O
;	-	1483	O
this	-	1485	O
effect	-	1490	O
was	-	1497	O
more	-	1501	O
robust	-	1506	O
than	-	1513	O
the	-	1518	O
effect	-	1522	O
on	-	1529	O
brain	-	1532	O
activation	-	1538	O
.	-	1548	O

The	16330766	1550	O
observed	-	1554	O
drug	-	1563	O
-	-	1567	O
induced	-	1568	O
effects	-	1576	O
were	-	1584	O
not	-	1589	O
due	-	1593	O
to	-	1597	O
changes	-	1600	O
in	-	1608	O
the	-	1611	O
baseline	-	1615	O
fMRI	-	1624	O
signal	-	1629	O
.	-	1635	O

These	16330766	1637	O
findings	-	1643	O
indicate	-	1652	O
that	-	1661	O
gabapentin	-	1666	B
has	-	1677	O
a	-	1681	O
measurable	-	1683	O
antinociceptive	-	1694	O
effect	-	1710	O
and	-	1717	O
a	-	1721	O
stronger	-	1723	O
antihyperalgesic	-	1732	O
effect	-	1749	O
most	-	1756	O
evident	-	1761	O
in	-	1769	O
the	-	1772	O
brain	-	1776	O
areas	-	1782	O
undergoing	-	1788	O
deactivation	-	1799	O
,	-	1811	O
thus	-	1813	O
supporting	-	1818	O
the	-	1829	O
concept	-	1833	O
that	-	1841	O
gabapentin	-	1846	B
is	-	1857	O
more	-	1860	O
effective	-	1865	O
in	-	1875	O
modulating	-	1878	O
nociceptive	-	1889	O
transmission	-	1901	O
when	-	1914	O
central	-	1919	O
sensitization	-	1927	O
is	-	1941	O
present	-	1944	O
.	-	1951	O

MDMA	16574712	0	B
polydrug	-	5	O
users	-	14	O
show	-	20	O
process	-	25	O
-	-	32	O
specific	-	33	O
central	-	42	O
executive	-	50	O
impairments	-	60	O
coupled	-	72	O
with	-	80	O
impaired	-	85	O
social	-	94	O
and	-	101	O
emotional	-	105	O
judgement	-	115	O
processes	-	125	O
.	-	134	O

In	16574712	136	O
recent	-	139	O
years	-	146	O
working	-	152	O
memory	-	160	O
deficits	-	167	O
have	-	176	O
been	-	181	O
reported	-	186	O
in	-	195	O
users	-	198	O
of	-	204	O
MDMA	-	207	B
(	-	212	O
3	-	213	B
,	-	214	I
4	-	215	I
-	-	216	I
methylenedioxymethamphetamine	-	217	I
,	-	246	O
ecstasy	-	248	B
)	-	255	O
.	-	256	O

The	16574712	258	O
current	-	262	O
study	-	270	O
aimed	-	276	O
to	-	282	O
assess	-	285	O
the	-	292	O
impact	-	296	O
of	-	303	O
MDMA	-	306	B
use	-	311	O
on	-	315	O
three	-	318	O
separate	-	324	O
central	-	333	O
executive	-	341	O
processes	-	351	O
(	-	361	O
set	-	362	O
shifting	-	366	O
,	-	374	O
inhibition	-	376	O
and	-	387	O
memory	-	391	O
updating	-	398	O
)	-	406	O
and	-	408	O
also	-	412	O
on	-	417	O
""""	-	420	O
prefrontal	-	421	O
""""	-	431	O
mediated	-	433	O
social	-	442	O
and	-	449	O
emotional	-	453	O
judgement	-	463	O
processes	-	473	O
.	-	482	O

Fifteen	16574712	484	O
polydrug	-	492	O
ecstasy	-	501	B
users	-	509	O
and	-	515	O
15	-	519	O
polydrug	-	522	O
non	-	531	O
-	-	534	O
ecstasy	-	535	B
user	-	543	O
controls	-	548	O
completed	-	557	O
a	-	567	O
general	-	569	O
drug	-	577	O
use	-	582	O
questionnaire	-	586	O
,	-	599	O
the	-	601	O
Brixton	-	605	O
Spatial	-	613	O
Anticipation	-	621	O
task	-	634	O
(	-	639	O
set	-	640	O
shifting	-	644	O
)	-	652	O
,	-	653	O
Backward	-	655	O
Digit	-	664	O
Span	-	670	O
procedure	-	675	O
(	-	685	O
memory	-	686	O
updating	-	693	O
)	-	701	O
,	-	702	O
Inhibition	-	704	O
of	-	715	O
Return	-	718	O
(	-	725	O
inhibition	-	726	O
)	-	736	O
,	-	737	O
an	-	739	O
emotional	-	742	O
intelligence	-	752	O
scale	-	765	O
,	-	770	O
the	-	772	O
Tromso	-	776	O
Social	-	783	O
Intelligence	-	790	O
Scale	-	803	O
and	-	809	O
the	-	813	O
Dysexecutive	-	817	O
Questionnaire	-	830	O
(	-	844	O
DEX	-	845	O
)	-	848	O
.	-	849	O

Compared	16574712	851	O
with	-	860	O
MDMA	-	865	B
-	-	869	O
free	-	870	O
polydrug	-	875	O
controls	-	884	O
,	-	892	O
MDMA	-	894	B
polydrug	-	899	O
users	-	908	O
showed	-	914	O
impairments	-	921	O
in	-	933	O
set	-	936	O
shifting	-	940	O
and	-	949	O
memory	-	953	O
updating	-	960	O
,	-	968	O
and	-	970	O
also	-	974	O
in	-	979	O
social	-	982	O
and	-	989	O
emotional	-	993	O
judgement	-	1003	O
processes	-	1013	O
.	-	1022	O

The	16574712	1024	O
latter	-	1028	O
two	-	1035	O
deficits	-	1039	O
remained	-	1048	O
significant	-	1057	O
after	-	1069	O
controlling	-	1075	O
for	-	1087	O
other	-	1091	O
drug	-	1097	O
use	-	1102	O
.	-	1105	O

These	16574712	1107	O
data	-	1113	O
lend	-	1118	O
further	-	1123	O
support	-	1131	O
to	-	1139	O
the	-	1142	O
proposal	-	1146	O
that	-	1155	O
cognitive	-	1160	O
processes	-	1170	O
mediated	-	1180	O
by	-	1189	O
the	-	1192	O
prefrontal	-	1196	O
cortex	-	1207	O
may	-	1214	O
be	-	1218	O
impaired	-	1221	O
by	-	1230	O
recreational	-	1233	O
ecstasy	-	1246	B
use	-	1254	O
.	-	1257	O

Severe	17111419	0	O
citrate	-	7	B
toxicity	-	15	O
complicating	-	24	O
volunteer	-	37	O
apheresis	-	47	O
platelet	-	57	O
donation	-	66	O
.	-	74	O

We	17111419	76	O
report	-	79	O
a	-	86	O
case	-	88	O
of	-	93	O
severe	-	96	O
citrate	-	103	B
toxicity	-	111	O
during	-	120	O
volunteer	-	127	O
donor	-	137	O
apheresis	-	143	O
platelet	-	153	O
collection	-	162	O
.	-	172	O

The	17111419	174	O
donor	-	178	O
was	-	184	O
a	-	188	O
40	-	190	O
-	-	192	O
year	-	193	O
-	-	197	O
old	-	198	O
female	-	202	O
,	-	208	O
first	-	210	O
-	-	215	O
time	-	216	O
apheresis	-	221	O
platelet	-	231	O
donor	-	240	O
.	-	245	O

Past	17111419	247	O
medical	-	252	O
history	-	260	O
was	-	268	O
remarkable	-	272	O
for	-	283	O
hypertension	-	287	O
,	-	299	O
hyperlipidemia	-	301	O
,	-	315	O
and	-	317	O
depression	-	321	O
.	-	331	O

Reported	17111419	333	O
medications	-	342	O
included	-	354	O
bumetanide	-	363	B
,	-	373	O
pravastatin	-	375	B
,	-	386	O
and	-	388	O
paroxetine	-	392	B
.	-	402	O

Thirty	17111419	404	O
minutes	-	411	O
from	-	419	O
the	-	424	O
start	-	428	O
of	-	434	O
the	-	437	O
procedure	-	441	O
,	-	450	O
the	-	452	O
donor	-	456	O
noted	-	462	O
tingling	-	468	O
around	-	477	O
the	-	484	O
mouth	-	488	O
,	-	493	O
hands	-	495	O
,	-	500	O
and	-	502	O
feet	-	506	O
.	-	510	O

She	17111419	512	O
then	-	516	O
very	-	521	O
rapidly	-	526	O
developed	-	534	O
acute	-	544	O
onset	-	550	O
of	-	556	O
severe	-	559	O
facial	-	566	O
and	-	573	O
extremity	-	577	O
tetany	-	587	O
.	-	593	O

Empirical	17111419	595	O
treatment	-	605	O
with	-	615	O
intravenous	-	620	O
calcium	-	632	B
gluconate	-	640	I
was	-	650	O
initiated	-	654	O
,	-	663	O
and	-	665	O
muscle	-	669	O
contractions	-	676	O
slowly	-	689	O
subsided	-	696	O
over	-	705	O
approximately	-	710	O
10	-	724	O
to	-	727	O
15	-	730	O
minutes	-	733	O
.	-	740	O

The	17111419	742	O
events	-	746	O
are	-	753	O
consistent	-	757	O
with	-	768	O
a	-	773	O
severe	-	775	O
reaction	-	782	O
to	-	791	O
calcium	-	794	B
chelation	-	802	O
by	-	812	O
sodium	-	815	B
citrate	-	822	I
anticoagulant	-	830	O
resulting	-	844	O
in	-	854	O
symptomatic	-	857	O
systemic	-	869	O
hypocalcemia	-	878	O
.	-	890	O

Upon	17111419	892	O
additional	-	897	O
retrospective	-	908	O
analysis	-	922	O
,	-	930	O
it	-	932	O
was	-	935	O
noted	-	939	O
that	-	945	O
bumetanide	-	950	B
is	-	961	O
a	-	964	O
loop	-	966	B
diuretic	-	971	I
that	-	980	O
may	-	985	O
cause	-	989	O
significant	-	995	O
hypocalcemia	-	1007	O
.	-	1019	O

We	17111419	1021	O
conclude	-	1024	O
that	-	1033	O
careful	-	1038	O
screening	-	1046	O
for	-	1056	O
medications	-	1060	O
and	-	1072	O
underlying	-	1076	O
conditions	-	1087	O
predisposing	-	1098	O
to	-	1111	O
hypocalcemia	-	1114	O
is	-	1127	O
recommended	-	1130	O
to	-	1142	O
help	-	1145	O
prevent	-	1150	O
severe	-	1158	O
reactions	-	1165	O
due	-	1175	O
to	-	1179	O
citrate	-	1182	B
toxicity	-	1190	O
.	-	1198	O

Laboratory	17111419	1200	O
measurement	-	1211	O
of	-	1223	O
pre	-	1226	O
-	-	1229	O
procedure	-	1230	O
serum	-	1240	O
calcium	-	1246	B
levels	-	1254	O
in	-	1261	O
selected	-	1264	O
donors	-	1273	O
may	-	1280	O
identify	-	1284	O
cases	-	1293	O
requiring	-	1299	O
heightened	-	1309	O
vigilance	-	1320	O
.	-	1329	O

The	17111419	1331	O
case	-	1335	O
also	-	1340	O
illustrates	-	1345	O
the	-	1357	O
importance	-	1361	O
of	-	1372	O
maintaining	-	1375	O
preparedness	-	1387	O
for	-	1400	O
managing	-	1404	O
rare	-	1413	O
but	-	1418	O
serious	-	1422	O
reactions	-	1430	O
in	-	1440	O
volunteer	-	1443	O
apheresis	-	1453	O
blood	-	1463	O
donors	-	1469	O
.	-	1475	O

Proteinuria	17175308	0	O
after	-	12	O
conversion	-	18	O
to	-	29	O
sirolimus	-	32	B
in	-	42	O
renal	-	45	O
transplant	-	51	O
recipients	-	62	O
.	-	72	O

Sirolimus	17175308	74	B
(	-	84	O
SRL	-	85	B
)	-	88	O
is	-	90	O
a	-	93	O
new	-	95	O
,	-	98	O
potent	-	100	O
immunosuppressive	-	107	O
agent	-	125	O
.	-	130	O

More	17175308	132	O
recently	-	137	O
,	-	145	O
proteinuria	-	147	O
has	-	159	O
been	-	163	O
reported	-	168	O
as	-	177	O
a	-	180	O
consequence	-	182	O
of	-	194	O
sirolimus	-	197	B
therapy	-	207	O
,	-	214	O
although	-	216	O
the	-	225	O
mechanism	-	229	O
has	-	239	O
remained	-	243	O
unclear	-	252	O
.	-	259	O

We	17175308	261	O
retrospectively	-	264	O
examined	-	280	O
the	-	289	O
records	-	293	O
of	-	301	O
25	-	304	O
renal	-	307	O
transplant	-	313	O
patients	-	324	O
,	-	332	O
who	-	334	O
developed	-	338	O
or	-	348	O
displayed	-	351	O
increased	-	361	O
proteinuria	-	371	O
after	-	383	O
SRL	-	389	B
conversion	-	393	O
.	-	403	O

The	17175308	405	O
patient	-	409	O
cohort	-	417	O
(	-	424	O
14	-	425	O
men	-	428	O
,	-	431	O
11	-	433	O
women	-	436	O
)	-	441	O
was	-	443	O
treated	-	447	O
with	-	455	O
SRL	-	460	B
as	-	464	O
conversion	-	467	O
therapy	-	478	O
,	-	485	O
due	-	487	O
to	-	491	O
chronic	-	494	O
allograft	-	502	O
nephropathy	-	512	O
(	-	524	O
CAN	-	525	O
)	-	528	O
(	-	530	O
n	-	531	O
=	-	533	O
15	-	535	O
)	-	537	O
neoplasia	-	539	O
(	-	549	O
n	-	550	O
=	-	552	O
8	-	554	O
)	-	555	O
;	-	556	O
Kaposi	-	558	O
's	-	564	O
sarcoma	-	567	O
,	-	574	O
Four	-	576	O
skin	-	581	O
cancers	-	586	O
,	-	593	O
One	-	595	O
intestinal	-	599	O
tumors	-	610	O
,	-	616	O
One	-	618	O
renal	-	622	O
cell	-	628	O
carsinom	-	633	O
)	-	641	O
or	-	643	O
BK	-	646	O
virus	-	649	O
nephropathy	-	655	O
(	-	667	O
n	-	668	O
=	-	670	O
2	-	672	O
)	-	673	O
.	-	674	O

SRL	17175308	676	B
was	-	680	O
started	-	684	O
at	-	692	O
a	-	695	O
mean	-	697	O
of	-	702	O
78	-	705	O
+	-	708	O
/	-	709	O
-	-	710	O

42	17175308	712	O
(	-	715	O
15	-	716	O
to	-	719	O
163	-	722	O
)	-	725	O
months	-	727	O
after	-	734	O
transplantation	-	740	O
.	-	755	O

Mean	17175308	757	O
follow	-	762	O
-	-	768	O
up	-	769	O
on	-	772	O
SRL	-	775	B
therapy	-	779	O
was	-	787	O
20	-	791	O
+	-	794	O
/	-	795	O
-	-	796	O

12	17175308	798	O
(	-	801	O
6	-	802	O
to	-	804	O
43	-	807	O
)	-	809	O
months	-	811	O
.	-	817	O

Proteinuria	17175308	819	O
increased	-	831	O
from	-	841	O
0	-	846	O
.	-	847	O
445	-	848	O
(	-	852	O
0	-	853	O
to	-	855	O
1	-	858	O
.	-	859	O
5	-	860	O
)	-	861	O
g	-	863	O
/	-	864	O
d	-	865	O
before	-	867	O
conversion	-	874	O
to	-	885	O
3	-	888	O
.	-	889	O
2	-	890	O
g	-	892	O
/	-	893	O
dL	-	894	O
(	-	897	O
0	-	898	O
.	-	899	O
2	-	900	O
to	-	902	O
12	-	905	O
)	-	907	O
after	-	909	O
conversion	-	915	O
(	-	926	O
P	-	927	O
=	-	929	O
0	-	931	O
.	-	932	O
001	-	933	O
)	-	936	O
.	-	937	O

Before	17175308	939	O
conversion	-	946	O
8	-	957	O
(	-	959	O
32	-	960	O
%	-	962	O
)	-	963	O
patients	-	965	O
had	-	974	O
no	-	978	O
proteinuria	-	981	O
,	-	992	O
whereas	-	994	O
afterwards	-	1002	O
all	-	1013	O
patients	-	1017	O
had	-	1026	O
proteinuria	-	1030	O
.	-	1041	O

In	17175308	1043	O
28	-	1046	O
%	-	1048	O
of	-	1050	O
patients	-	1053	O
proteinuria	-	1062	O
remained	-	1074	O
unchanged	-	1083	O
,	-	1092	O
whereas	-	1094	O
it	-	1102	O
increased	-	1105	O
in	-	1115	O
68	-	1118	O
%	-	1120	O
of	-	1122	O
patients	-	1125	O
.	-	1133	O

In	17175308	1135	O
40	-	1138	O
%	-	1140	O
it	-	1142	O
increased	-	1145	O
by	-	1155	O
more	-	1158	O
than	-	1163	O
100	-	1168	O
%	-	1171	O
.	-	1172	O

Twenty	17175308	1174	O
-	-	1180	O
eight	-	1181	O
percent	-	1187	O
of	-	1195	O
patients	-	1198	O
showed	-	1207	O
increased	-	1214	O
proteinuria	-	1224	O
to	-	1236	O
the	-	1239	O
nephrotic	-	1243	O
range	-	1253	O
.	-	1258	O

Biopsies	17175308	1260	O
performed	-	1269	O
in	-	1279	O
five	-	1282	O
patients	-	1287	O
revealed	-	1296	O
new	-	1305	O
pathological	-	1309	O
changes	-	1322	O
:	-	1329	O
One	-	1331	O
membranoproliferative	-	1335	O
glomerulopathy	-	1357	O
and	-	1372	O
interstitial	-	1376	O
nephritis	-	1389	O
.	-	1398	O

These	17175308	1400	O
patients	-	1406	O
showed	-	1415	O
persistently	-	1422	O
good	-	1435	O
graft	-	1440	O
function	-	1446	O
.	-	1454	O

Serum	17175308	1456	O
creatinine	-	1462	B
values	-	1473	O
did	-	1480	O
not	-	1484	O
change	-	1488	O
significantly	-	1495	O
:	-	1508	O
1	-	1510	O
.	-	1511	O
98	-	1512	O
+	-	1515	O
/	-	1516	O
-	-	1517	O

0	17175308	1519	O
.	-	1520	O
8	-	1521	O
mg	-	1523	O
/	-	1525	O
dL	-	1526	O
before	-	1529	O
SRL	-	1536	B
therapy	-	1540	O
and	-	1548	O
2	-	1552	O
.	-	1553	O
53	-	1554	O
+	-	1557	O
/	-	1558	O
-	-	1559	O

1	17175308	1561	O
.	-	1562	O
9	-	1563	O
mg	-	1565	O
/	-	1567	O
dL	-	1568	O
at	-	1571	O
last	-	1574	O
follow	-	1579	O
-	-	1585	O
up	-	1586	O

(	17175308	1589	O
P	-	1590	O
=	-	1592	O
.	-	1594	O
14	-	1595	O
)	-	1597	O
.	-	1598	O

Five	17175308	1600	O
grafts	-	1605	O
were	-	1612	O
lost	-	1617	O
and	-	1622	O
the	-	1626	O
patients	-	1630	O
returned	-	1639	O
to	-	1648	O
dialysis	-	1651	O
.	-	1659	O

Five	17175308	1661	O
patients	-	1666	O
displayed	-	1675	O
CAN	-	1685	O
and	-	1689	O
Kaposi	-	1693	O
's	-	1699	O
sarcoma	-	1702	O
.	-	1709	O

Mean	17175308	1711	O
urinary	-	1716	O
protein	-	1724	O
of	-	1732	O
patients	-	1735	O
who	-	1744	O
returned	-	1748	O
to	-	1757	O
dialysis	-	1760	O
was	-	1769	O
1	-	1773	O
.	-	1774	O
26	-	1775	O
(	-	1778	O
0	-	1779	O
.	-	1780	O
5	-	1781	O
to	-	1783	O
3	-	1786	O
.	-	1787	O
5	-	1788	O
)	-	1789	O

g	17175308	1791	O

/	17175308	1792	O
d	-	1793	O
before	-	1795	O
and	-	1802	O
4	-	1806	O
.	-	1807	O
7	-	1808	O
(	-	1810	O
3	-	1811	O
to	-	1813	O
12	-	1816	O
)	-	1818	O
g	-	1820	O
/	-	1821	O
d	-	1822	O
after	-	1824	O
conversion	-	1830	O
(	-	1841	O
P	-	1842	O
=	-	1844	O
.	-	1846	O
01	-	1847	O
)	-	1849	O
.	-	1850	O

Mean	17175308	1852	O
serum	-	1857	O
creatinine	-	1863	B
level	-	1874	O
before	-	1880	O
conversion	-	1887	O
was	-	1898	O
2	-	1902	O
.	-	1903	O
21	-	1904	O
mg	-	1907	O
/	-	1909	O
dL	-	1910	O
and	-	1913	O
thereafter	-	1917	O
,	-	1927	O
4	-	1929	O
.	-	1930	O
93	-	1931	O
mg	-	1934	O
/	-	1936	O
dL	-	1937	O
(	-	1940	O
P	-	1941	O
=	-	1943	O
.	-	1945	O
02	-	1946	O
)	-	1948	O
.	-	1949	O

Heavy	17175308	1951	O
proteinuria	-	1957	O
was	-	1969	O
common	-	1973	O
after	-	1980	O
the	-	1986	O
use	-	1990	O
of	-	1994	O
SRL	-	1997	B
as	-	2001	O
rescue	-	2004	O
therapy	-	2011	O
for	-	2019	O
renal	-	2023	O
transplantation	-	2029	O
.	-	2044	O

Therefore	17175308	2046	O
,	-	2055	O
conversion	-	2057	O
should	-	2068	O
be	-	2075	O
considered	-	2078	O
for	-	2089	O
patients	-	2093	O
who	-	2102	O
have	-	2106	O
not	-	2111	O
developed	-	2115	O
advanced	-	2125	O
CAN	-	2134	O
and	-	2138	O
proteinuria	-	2142	O
.	-	2153	O

The	17175308	2155	O
possibility	-	2159	O
of	-	2171	O
de	-	2174	O
novo	-	2177	O
glomerular	-	2182	O
pathology	-	2193	O
under	-	2203	O
SRL	-	2209	B
treatment	-	2213	O
requires	-	2223	O
further	-	2232	O
investigation	-	2240	O
by	-	2254	O
renal	-	2257	O
biopsy	-	2263	O
.	-	2269	O

In	17244258	0	O
vitro	-	3	O
characterization	-	9	O
of	-	26	O
parasympathetic	-	29	O
and	-	45	O
sympathetic	-	49	O
responses	-	61	O
in	-	71	O
cyclophosphamide	-	74	B
-	-	90	O
induced	-	91	O
cystitis	-	99	O
in	-	108	O
the	-	111	O
rat	-	115	O
.	-	118	O

In	17244258	120	O
cyclophosphamide	-	123	B
-	-	139	O
induced	-	140	O
cystitis	-	148	O
in	-	157	O
the	-	160	O
rat	-	164	O
,	-	167	O
detrusor	-	169	O
function	-	178	O
is	-	187	O
impaired	-	190	O
and	-	199	O
the	-	203	O
expression	-	207	O
and	-	218	O
effects	-	222	O
of	-	230	O
muscarinic	-	233	O
receptors	-	244	O
altered	-	254	O
.	-	261	O

Whether	17244258	263	O
or	-	271	O
not	-	274	O
the	-	278	O
neuronal	-	282	O
transmission	-	291	O
may	-	304	O
be	-	308	O
affected	-	311	O
by	-	320	O
cystitis	-	323	O
was	-	332	O
presently	-	336	O
investigated	-	346	O
.	-	358	O

Responses	17244258	360	O
of	-	370	O
urinary	-	373	O
strip	-	381	O
preparations	-	387	O
from	-	400	O
control	-	405	O
and	-	413	O
cyclophosphamide	-	417	B
-	-	433	O
pretreated	-	434	O
rats	-	445	O
to	-	450	O
electrical	-	453	O
field	-	464	O
stimulation	-	470	O
and	-	482	O
to	-	486	O
agonists	-	489	O
were	-	498	O
assessed	-	503	O
in	-	512	O
the	-	515	O
absence	-	519	O
and	-	527	O
presence	-	531	O
of	-	540	O
muscarinic	-	543	O
,	-	553	O
adrenergic	-	555	O
and	-	566	O
purinergic	-	570	O
receptor	-	581	O
antagonists	-	590	O
.	-	601	O

Generally	17244258	603	O
,	-	612	O
atropine	-	614	B
reduced	-	623	O
contractions	-	631	O
,	-	643	O
but	-	645	O
in	-	649	O
contrast	-	652	O
to	-	661	O
controls	-	664	O
,	-	672	O
it	-	674	O
also	-	677	O
reduced	-	682	O
responses	-	690	O
to	-	700	O
low	-	703	O
electrical	-	707	O
field	-	718	O
stimulation	-	724	O
intensity	-	736	O
(	-	746	O
1	-	747	O
-	-	748	O
5	-	749	O
Hz	-	751	O
)	-	753	O
in	-	755	O
inflamed	-	758	O
preparations	-	767	O
.	-	779	O

In	17244258	781	O
both	-	784	O
types	-	789	O
,	-	794	O
purinoceptor	-	796	O
desensitization	-	809	O
with	-	825	O
alpha	-	830	B
,	-	835	I
beta	-	836	I
-	-	840	I
methylene	-	841	I
adenosine	-	851	I
-	-	860	I
5'	-	861	I
-	-	863	I
triphosphate	-	864	I
(	-	877	O
alpha	-	878	B
,	-	883	I
beta	-	884	I
-	-	888	I
meATP	-	889	I
)	-	894	O
caused	-	896	O
further	-	903	O
reductions	-	911	O
at	-	922	O
low	-	925	O
frequencies	-	929	O
(	-	941	O
<	-	942	O
10	-	943	O
Hz	-	946	O
)	-	948	O
.	-	949	O

The	17244258	951	O
muscarinic	-	955	O
receptor	-	966	O
antagonists	-	975	O
atropine	-	987	B
,	-	995	O
4	-	997	B
-	-	998	I
diphenylacetoxy	-	999	I
-	-	1014	I
N	-	1015	I
-	-	1016	I
methylpiperidine	-	1017	I
(	-	1034	O
4	-	1035	B
-	-	1036	I
DAMP	-	1037	I
)	-	1041	O
(	-	1043	O
'	-	1044	O
M	-	1045	O
(	-	1046	O
1	-	1047	O
)	-	1048	O
/	-	1049	O
M	-	1050	O
(	-	1051	O
3	-	1052	O
)	-	1053	O
/	-	1054	O
M	-	1055	O
(	-	1056	O
5	-	1057	O
)	-	1058	O
-	-	1059	O
selective	-	1060	O
'	-	1069	O
)	-	1070	O
,	-	1071	O
methoctramine	-	1073	B
(	-	1087	O
'	-	1088	O
M	-	1089	O
(	-	1090	O
2	-	1091	O
)	-	1092	O
-	-	1093	O
selective	-	1094	O
'	-	1103	O
)	-	1104	O
and	-	1106	O
pirenzepine	-	1110	B
(	-	1122	O
'	-	1123	O
M	-	1124	O
(	-	1125	O
1	-	1126	O
)	-	1127	O
-	-	1128	O
selective	-	1129	O
'	-	1138	O
)	-	1139	O
antagonized	-	1141	O
the	-	1153	O
tonic	-	1157	O
component	-	1163	O
of	-	1173	O
the	-	1176	O
electrical	-	1180	O
field	-	1191	O
stimulation	-	1197	O
-	-	1208	O
evoked	-	1209	O
contractile	-	1216	O
response	-	1228	O
more	-	1237	O
potently	-	1242	O
than	-	1251	O
the	-	1256	O
phasic	-	1260	O
component	-	1267	O
.	-	1276	O

4	17244258	1278	B
-	-	1279	I
DAMP	-	1280	I
inhibited	-	1285	O
the	-	1295	O
tonic	-	1299	O
contractions	-	1305	O
in	-	1318	O
controls	-	1321	O
more	-	1330	O
potently	-	1335	O
than	-	1344	O
methoctramine	-	1349	B
and	-	1363	O
pirenzepine	-	1367	B
.	-	1378	O

In	17244258	1380	O
inflamed	-	1383	O
preparations	-	1392	O
,	-	1404	O
the	-	1406	O
muscarinic	-	1410	O
receptor	-	1421	O
antagonism	-	1430	O
on	-	1441	O
the	-	1444	O
phasic	-	1448	O
component	-	1455	O
of	-	1465	O
the	-	1468	O
electrical	-	1472	O
field	-	1483	O
stimulation	-	1489	O
-	-	1500	O
evoked	-	1501	O
contraction	-	1508	O
was	-	1520	O
decreased	-	1524	O
and	-	1534	O
the	-	1538	O
pirenzepine	-	1542	B
and	-	1554	O
4	-	1558	B
-	-	1559	I
DAMP	-	1560	I
antagonism	-	1565	O
on	-	1576	O
the	-	1579	O
tonic	-	1583	O
component	-	1589	O
was	-	1599	O
much	-	1603	O
less	-	1608	O
efficient	-	1613	O
than	-	1623	O
in	-	1628	O
controls	-	1631	O
.	-	1639	O

In	17244258	1641	O
contrast	-	1644	O
to	-	1653	O
controls	-	1656	O
,	-	1664	O
methoctramine	-	1666	B
increased	-	1680	O
-	-	1690	O
-	-	1691	O
instead	-	1693	O
of	-	1701	O
decreased	-	1704	O
-	-	1714	O
-	-	1715	O
the	-	1717	O
tonic	-	1721	O
responses	-	1727	O
at	-	1737	O
high	-	1740	O
frequencies	-	1745	O
.	-	1756	O

While	17244258	1758	O
contractions	-	1764	O
to	-	1777	O
carbachol	-	1780	B
and	-	1790	O
ATP	-	1794	B
were	-	1798	O
the	-	1803	O
same	-	1807	O
in	-	1812	O
inflamed	-	1815	O
and	-	1824	O
in	-	1828	O
control	-	1831	O
strips	-	1839	O
when	-	1846	O
related	-	1851	O
to	-	1859	O
a	-	1862	O
reference	-	1864	O
potassium	-	1874	B
response	-	1884	O
,	-	1892	O
isoprenaline	-	1894	B
-	-	1906	O
induced	-	1907	O
relaxations	-	1915	O
were	-	1927	O
smaller	-	1932	O
in	-	1940	O
inflamed	-	1943	O
strips	-	1952	O
.	-	1958	O

Thus	17244258	1960	O
,	-	1964	O
in	-	1966	O
cystitis	-	1969	O
substantial	-	1978	O
changes	-	1990	O
of	-	1998	O
the	-	2001	O
efferent	-	2005	O
functional	-	2014	O
responses	-	2025	O
occur	-	2035	O
.	-	2040	O

While	17244258	2042	O
postjunctional	-	2048	O
beta	-	2063	O
-	-	2067	O
adrenoceptor	-	2068	O
-	-	2080	O
mediated	-	2081	O
relaxations	-	2090	O
are	-	2102	O
reduced	-	2106	O
,	-	2113	O
effects	-	2115	O
by	-	2123	O
prejunctional	-	2126	O
inhibitory	-	2140	O
muscarinic	-	2151	O
receptors	-	2162	O
may	-	2172	O
be	-	2176	O
increased	-	2179	O
.	-	2188	O

Associations	18020536	0	O
between	-	13	O
use	-	21	O
of	-	25	O
benzodiazepines	-	28	B
or	-	44	O
related	-	47	O
drugs	-	55	O
and	-	61	O
health	-	65	O
,	-	71	O
physical	-	73	O
abilities	-	82	O
and	-	92	O
cognitive	-	96	O
function	-	106	O
:	-	114	O
a	-	116	O
non	-	118	O
-	-	121	O
randomised	-	122	O
clinical	-	133	O
study	-	142	O
in	-	148	O
the	-	151	O
elderly	-	155	O
.	-	162	O

OBJECTIVE	18020536	164	O
:	-	173	O

To	18020536	175	O
describe	-	178	O
associations	-	187	O
between	-	200	O
the	-	208	O
use	-	212	O
of	-	216	O
benzodiazepines	-	219	B
or	-	235	O
related	-	238	O
drugs	-	246	O
(	-	252	O
BZDs	-	253	B
/	-	257	O
RDs	-	258	O
)	-	261	O
and	-	263	O
health	-	267	O
,	-	273	O
functional	-	275	O
abilities	-	286	O
and	-	296	O
cognitive	-	300	O
function	-	310	O
in	-	319	O
the	-	322	O
elderly	-	326	O
.	-	333	O

METHODS	18020536	335	O
:	-	342	O

A	18020536	344	O
non	-	346	O
-	-	349	O
randomised	-	350	O
clinical	-	361	O
study	-	370	O
of	-	376	O
patients	-	379	O
aged	-	388	O
>	-	393	O
or	-	395	O
=	-	398	O
65	-	399	O
years	-	402	O
admitted	-	408	O
to	-	417	O
acute	-	420	O
hospital	-	426	O
wards	-	435	O
during	-	441	O
1	-	448	O
month	-	450	O
.	-	455	O

164	18020536	457	O
patients	-	461	O
(	-	470	O
mean	-	471	O
age	-	476	O
+	-	480	O
/	-	481	O
-	-	482	O

standard	18020536	484	O
deviation	-	493	O
[	-	503	O
SD	-	504	O
]	-	506	O
81	-	508	O
.	-	510	O
6	-	511	O
+	-	513	O
/	-	514	O
-	-	515	O

6	18020536	517	O
.	-	518	O
8	-	519	O
years	-	521	O
)	-	526	O
were	-	528	O
admitted	-	533	O
.	-	541	O

Of	18020536	543	O
these	-	546	O
,	-	551	O
nearly	-	553	O
half	-	560	O
(	-	565	O
n	-	566	O
=	-	568	O
78	-	570	O
)	-	572	O
had	-	574	O
used	-	578	O
BZDs	-	583	B
/	-	587	O
RDs	-	588	O
before	-	592	O
admission	-	599	O
,	-	608	O
and	-	610	O
the	-	614	O
remainder	-	618	O
(	-	628	O
n	-	629	O
=	-	631	O
86	-	633	O
)	-	635	O
were	-	637	O
non	-	642	O
-	-	645	O
users	-	646	O
.	-	651	O

Cognitive	18020536	653	O
ability	-	663	O
was	-	671	O
assessed	-	675	O
by	-	684	O
the	-	687	O
Mini	-	691	O
-	-	695	O
Mental	-	696	O
State	-	703	O
Examination	-	709	O
(	-	721	O
MMSE	-	722	O
)	-	726	O
.	-	727	O

Patients	18020536	729	O
scoring	-	738	O
>	-	746	O
or	-	748	O
=	-	751	O
20	-	752	O
MMSE	-	755	O
sum	-	760	O
points	-	764	O
were	-	771	O
interviewed	-	776	O
(	-	788	O
n	-	789	O
=	-	791	O
79	-	793	O
)	-	795	O
and	-	797	O
questioned	-	801	O
regarding	-	812	O
symptoms	-	822	O
and	-	831	O
functional	-	835	O
abilities	-	846	O
during	-	856	O
the	-	863	O
week	-	867	O
prior	-	872	O
to	-	878	O
admission	-	881	O
.	-	890	O

Data	18020536	892	O
on	-	897	O
use	-	900	O
of	-	904	O
BZDs	-	907	B
/	-	911	O
RDs	-	912	O
before	-	916	O
admission	-	923	O
,	-	932	O
current	-	934	O
medications	-	942	O
and	-	954	O
discharge	-	958	O
diagnoses	-	968	O
were	-	978	O
collected	-	983	O
from	-	993	O
medical	-	998	O
records	-	1006	O
.	-	1013	O

Health	18020536	1015	O
,	-	1021	O
physical	-	1023	O
abilities	-	1032	O
and	-	1042	O
cognitive	-	1046	O
function	-	1056	O
were	-	1065	O
compared	-	1070	O
between	-	1079	O
BZD	-	1087	O
/	-	1090	O
RD	-	1091	O
users	-	1094	O
and	-	1100	O
non	-	1104	O
-	-	1107	O
users	-	1108	O
,	-	1113	O
and	-	1115	O
adjustments	-	1119	O
were	-	1131	O
made	-	1136	O
for	-	1141	O
confounding	-	1145	O
variables	-	1157	O
.	-	1166	O

The	18020536	1168	O
residual	-	1172	O
serum	-	1181	O
concentrations	-	1187	O
of	-	1202	O
oxazepam	-	1205	B
,	-	1213	O
temazepam	-	1215	B
and	-	1225	O
zopiclone	-	1229	B
were	-	1239	O
analysed	-	1244	O
.	-	1252	O

RESULTS	18020536	1254	O
:	-	1261	O

The	18020536	1263	O
mean	-	1267	O
+	-	1272	O
/	-	1273	O
-	-	1274	O

SD	18020536	1276	O
duration	-	1279	O
of	-	1288	O
BZD	-	1291	O
/	-	1294	O
RD	-	1295	O
use	-	1298	O
was	-	1302	O
7	-	1306	O
+	-	1308	O
/	-	1309	O
-	-	1310	O

7	18020536	1312	O
years	-	1314	O
(	-	1320	O
range	-	1321	O
1	-	1327	O
-	-	1328	O
31	-	1329	O
)	-	1331	O
.	-	1332	O

Two	18020536	1334	O
or	-	1338	O
three	-	1341	O
BZDs	-	1347	B
/	-	1351	O
RDs	-	1352	O
were	-	1356	O
concomitantly	-	1361	O
taken	-	1375	O
by	-	1381	O
26	-	1384	O
%	-	1386	O
of	-	1388	O
users	-	1391	O
(	-	1397	O
n	-	1398	O
=	-	1400	O
20	-	1402	O
)	-	1404	O
.	-	1405	O

Long	18020536	1407	O
-	-	1411	O
term	-	1412	O
use	-	1417	O
of	-	1421	O
these	-	1424	O
drugs	-	1430	O
was	-	1436	O
associated	-	1440	O
with	-	1451	O
female	-	1456	O
sex	-	1463	O
and	-	1467	O
use	-	1471	O
of	-	1475	O
a	-	1478	O
higher	-	1480	O
number	-	1487	O
of	-	1494	O
drugs	-	1497	O
with	-	1503	O
effects	-	1508	O
on	-	1516	O
the	-	1519	O
CNS	-	1523	O
,	-	1526	O
which	-	1528	O
tended	-	1534	O
to	-	1541	O
be	-	1544	O
related	-	1547	O
to	-	1555	O
diagnosed	-	1558	O
dementia	-	1568	O
.	-	1576	O

After	18020536	1578	O
adjustment	-	1584	O
for	-	1595	O
these	-	1599	O
variables	-	1605	O
as	-	1615	O
confounders	-	1618	O
,	-	1629	O
use	-	1631	O
of	-	1635	O
BZDs	-	1638	B
/	-	1642	O
RDs	-	1643	O
was	-	1647	O
not	-	1651	O
associated	-	1655	O
with	-	1666	O
cognitive	-	1671	O
function	-	1681	O
as	-	1690	O
measured	-	1693	O
by	-	1702	O
the	-	1705	O
MMSE	-	1709	O
.	-	1713	O

However	18020536	1715	O
,	-	1722	O
use	-	1724	O
of	-	1728	O
BZDs	-	1731	B
/	-	1735	O
RDs	-	1736	O
was	-	1740	O
associated	-	1744	O
with	-	1755	O
dizziness	-	1760	O
,	-	1769	O
inability	-	1771	O
to	-	1781	O
sleep	-	1784	O
after	-	1790	O
awaking	-	1796	O
at	-	1804	O
night	-	1807	O
and	-	1813	O
tiredness	-	1817	O
in	-	1827	O
the	-	1830	O
mornings	-	1834	O
during	-	1843	O
the	-	1850	O
week	-	1854	O
prior	-	1859	O
to	-	1865	O
admission	-	1868	O
and	-	1878	O
with	-	1882	O
stronger	-	1887	O
depressive	-	1896	O
symptoms	-	1907	O
measured	-	1916	O
at	-	1925	O
the	-	1928	O
beginning	-	1932	O
of	-	1942	O
the	-	1945	O
hospital	-	1949	O
stay	-	1958	O
.	-	1962	O

Use	18020536	1964	O
of	-	1968	O
BZDs	-	1971	B
/	-	1975	O
RDs	-	1976	O
tended	-	1980	O
to	-	1987	O
be	-	1990	O
associated	-	1993	O
with	-	2004	O
a	-	2009	O
reduced	-	2011	O
ability	-	2019	O
to	-	2027	O
walk	-	2030	O
and	-	2035	O
shorter	-	2039	O
night	-	2047	O
-	-	2052	O
time	-	2053	O
sleep	-	2058	O
during	-	2064	O
the	-	2071	O
week	-	2075	O
prior	-	2080	O
to	-	2086	O
admission	-	2089	O
.	-	2098	O

A	18020536	2100	O
higher	-	2102	O
residual	-	2109	O
serum	-	2118	O
concentration	-	2124	O
of	-	2138	O
temazepam	-	2141	B
correlated	-	2151	O
with	-	2162	O
a	-	2167	O
lower	-	2169	O
MMSE	-	2175	O
sum	-	2180	O
score	-	2184	O
after	-	2190	O
adjustment	-	2196	O
for	-	2207	O
confounding	-	2211	O
variables	-	2223	O
.	-	2232	O

CONCLUSIONS	18020536	2234	O
:	-	2245	O

Long	18020536	2247	O
-	-	2251	O
term	-	2252	O
use	-	2257	O
and	-	2261	O
concomitant	-	2265	O
use	-	2277	O
of	-	2281	O
more	-	2284	O
than	-	2289	O
one	-	2294	O
BZD	-	2298	O
/	-	2301	O
RD	-	2302	O
were	-	2305	O
common	-	2310	O
in	-	2317	O
elderly	-	2320	O
patients	-	2328	O
hospitalised	-	2337	O
because	-	2350	O
of	-	2358	O
acute	-	2361	O
illnesses	-	2367	O
.	-	2376	O

Long	18020536	2378	O
-	-	2382	O
term	-	2383	O
use	-	2388	O
was	-	2392	O
associated	-	2396	O
with	-	2407	O
daytime	-	2412	O
and	-	2420	O
night	-	2424	O
-	-	2429	O
time	-	2430	O
symptoms	-	2435	O
indicative	-	2444	O
of	-	2455	O
poorer	-	2458	O
health	-	2465	O
and	-	2472	O
potentially	-	2476	O
caused	-	2488	O
by	-	2495	O
the	-	2498	O
adverse	-	2502	O
effects	-	2510	O
of	-	2518	O
these	-	2521	O
drugs	-	2527	O
.	-	2532	O

Acute	18023325	0	O
vocal	-	6	O
fold	-	12	O
palsy	-	17	O
after	-	23	O
acute	-	29	O
disulfiram	-	35	B
intoxication	-	46	O
.	-	58	O

Acute	18023325	60	O
peripheral	-	66	O
neuropathy	-	77	O
caused	-	88	O
by	-	95	O
a	-	98	O
disulfiram	-	100	B
overdose	-	111	O
is	-	120	O
very	-	123	O
rare	-	128	O
and	-	133	O
there	-	137	O
is	-	143	O
no	-	146	O
report	-	149	O
of	-	156	O
it	-	159	O
leading	-	162	O
to	-	170	O
vocal	-	173	O
fold	-	179	O
palsy	-	184	O
.	-	189	O

A	18023325	191	O
49	-	193	O
-	-	195	O
year	-	196	O
-	-	200	O
old	-	201	O
woman	-	205	O
was	-	211	O
transferred	-	215	O
to	-	227	O
our	-	230	O
department	-	234	O
because	-	245	O
of	-	253	O
quadriparesis	-	256	O
,	-	269	O
lancinating	-	271	O
pain	-	283	O
,	-	287	O
sensory	-	289	O
loss	-	297	O
,	-	301	O
and	-	303	O
paresthesia	-	307	O
of	-	319	O
the	-	322	O
distal	-	326	O
limbs	-	333	O
.	-	338	O

One	18023325	340	O
month	-	344	O
previously	-	350	O
,	-	360	O
she	-	362	O
had	-	366	O
taken	-	370	O
a	-	376	O
single	-	378	O
high	-	385	O
dose	-	390	O
of	-	395	O
disulfiram	-	398	B
(	-	409	O
130	-	410	O
tablets	-	414	O
of	-	422	O
ALCOHOL	-	425	B
STOP	-	433	O
TAB	-	438	O
,	-	441	O
Shin	-	443	O
-	-	447	O
Poong	-	448	O
Pharm	-	454	O
.	-	459	O

Co	18023325	461	O
.	-	463	O
,	-	464	O
Ansan	-	466	O
,	-	471	O
Korea	-	473	O
)	-	478	O
in	-	480	O
a	-	483	O
suicide	-	485	O
attempt	-	493	O
.	-	500	O

She	18023325	502	O
was	-	506	O
not	-	510	O
an	-	514	O
alcoholic	-	517	O
.	-	526	O

For	18023325	528	O
the	-	532	O
first	-	536	O
few	-	542	O
days	-	546	O
after	-	551	O
ingestion	-	557	O
,	-	566	O
she	-	568	O
was	-	572	O
in	-	576	O
a	-	579	O
confused	-	581	O
state	-	590	O
and	-	596	O
had	-	600	O
mild	-	604	O
to	-	609	O
moderate	-	612	O
ataxia	-	621	O
and	-	628	O
giddiness	-	632	O
.	-	641	O

She	18023325	643	O
noticed	-	647	O
hoarseness	-	655	O
and	-	666	O
distally	-	670	O
accentuated	-	679	O
motor	-	691	O
and	-	697	O
sensory	-	701	O
dysfunction	-	709	O
after	-	721	O
she	-	727	O
had	-	731	O
recovered	-	735	O
from	-	745	O
this	-	750	O
state	-	755	O
.	-	760	O

A	18023325	762	O
nerve	-	764	O
conduction	-	770	O
study	-	781	O
was	-	787	O
consistent	-	791	O
with	-	802	O
severe	-	807	O
sensorimotor	-	814	O
axonal	-	827	O
polyneuropathy	-	834	O
.	-	848	O

Laryngeal	18023325	850	O
electromyography	-	860	O
(	-	877	O
thyroarytenoid	-	878	O
muscle	-	893	O
)	-	899	O
showed	-	901	O
ample	-	908	O
denervation	-	914	O
potentials	-	926	O
.	-	936	O

Laryngoscopy	18023325	938	O
revealed	-	951	O
asymmetric	-	960	O
vocal	-	971	O
fold	-	977	O
movements	-	982	O
during	-	992	O
phonation	-	999	O
.	-	1008	O

Her	18023325	1010	O
vocal	-	1014	O
change	-	1020	O
and	-	1027	O
weakness	-	1031	O
began	-	1040	O
to	-	1046	O
improve	-	1049	O
spontaneously	-	1057	O
about	-	1071	O
3	-	1077	O
weeks	-	1079	O
after	-	1085	O
transfer	-	1091	O
.	-	1099	O

This	18023325	1101	O
was	-	1106	O
a	-	1110	O
case	-	1112	O
of	-	1117	O
acute	-	1120	O
palsy	-	1126	O
of	-	1132	O
the	-	1135	O
recurrent	-	1139	O
laryngeal	-	1149	O
nerve	-	1159	O
and	-	1165	O
superimposed	-	1169	O
severe	-	1182	O
acute	-	1189	O
sensorimotor	-	1195	O
axonal	-	1208	O
polyneuropathy	-	1215	O
caused	-	1230	O
by	-	1237	O
high	-	1240	O
-	-	1244	O
dose	-	1245	O
disulfiram	-	1250	B
intoxication	-	1261	O
.	-	1273	O

Higher	18208574	0	O
optical	-	7	O
density	-	15	O
of	-	23	O
an	-	26	O
antigen	-	29	O
assay	-	37	O
predicts	-	43	O
thrombosis	-	52	O
in	-	63	O
patients	-	66	O
with	-	75	O
heparin	-	80	B
-	-	87	O
induced	-	88	O
thrombocytopenia	-	96	O
.	-	112	O

OBJECTIVES	18208574	114	O
:	-	124	O

To	18208574	126	O
correlate	-	129	O
optical	-	139	O
density	-	147	O
and	-	155	O
percent	-	159	O
inhibition	-	167	O
of	-	178	O
a	-	181	O
two	-	183	O
-	-	186	O
step	-	187	O
heparin	-	192	B
-	-	199	O
induced	-	200	O
thrombocytopenia	-	208	O
(	-	225	O
HIT	-	226	O
)	-	229	O
antigen	-	231	O
assay	-	239	O
with	-	245	O
thrombosis	-	250	O
;	-	260	O
the	-	262	O
assay	-	266	O
utilizes	-	272	O
reaction	-	281	O
inhibition	-	290	O
characteristics	-	301	O
of	-	317	O
a	-	320	O
high	-	322	O
heparin	-	327	B
concentration	-	335	O
.	-	348	O

PATIENTS	18208574	350	O
AND	-	359	O
METHODS	-	363	O
:	-	370	O

Patients	18208574	372	O
with	-	381	O
more	-	386	O
than	-	391	O
50	-	396	O
%	-	398	O
decrease	-	400	O
in	-	409	O
platelet	-	412	O
count	-	421	O
or	-	427	O
thrombocytopenia	-	430	O
(	-	447	O
<	-	448	O
150	-	449	O
x	-	453	O
10	-	455	O
(	-	457	O
9	-	458	O
)	-	459	O
/	-	460	O
L	-	461	O
)	-	462	O
after	-	464	O
exposure	-	470	O
to	-	479	O
heparin	-	482	B
,	-	489	O
who	-	491	O
had	-	495	O
a	-	499	O
positive	-	501	O
two	-	510	O
-	-	513	O
step	-	514	O
antigen	-	519	O
assay	-	527	O
[	-	533	O
optical	-	534	O
density	-	542	O
(	-	550	O
OD	-	551	O
)	-	553	O
>	-	555	O
0	-	556	O
.	-	557	O
4	-	558	O
and	-	560	O
>	-	564	O
50	-	565	O
inhibition	-	568	O
with	-	579	O
high	-	584	O
concentration	-	589	O
of	-	603	O
heparin	-	606	B
]	-	613	O
were	-	615	O
included	-	620	O
in	-	629	O
the	-	632	O
study	-	636	O
.	-	641	O

RESULTS	18208574	643	O
:	-	650	O

Forty	18208574	652	O
of	-	658	O
94	-	661	O
HIT	-	664	O
patients	-	668	O
had	-	677	O
thrombosis	-	681	O
at	-	692	O
diagnosis	-	695	O
;	-	704	O
54	-	706	O
/	-	708	O
94	-	709	O
had	-	712	O
isolated	-	716	O
-	-	724	O
HIT	-	725	O
without	-	729	O
thrombosis	-	737	O
.	-	747	O

Eight	18208574	749	O
of	-	755	O
the	-	758	O
isolated	-	762	O
-	-	770	O
HIT	-	771	O
patients	-	775	O
developed	-	784	O
thrombosis	-	794	O
within	-	805	O
the	-	812	O
next	-	816	O
30	-	821	O
d	-	824	O
;	-	825	O
thus	-	827	O
,	-	831	O
a	-	833	O
total	-	835	O
of	-	841	O
48	-	844	O
patients	-	847	O
had	-	856	O
thrombosis	-	860	O
at	-	871	O
day	-	874	O
30	-	878	O
.	-	880	O

At	18208574	882	O
diagnosis	-	885	O
there	-	895	O
was	-	901	O
no	-	905	O
significant	-	908	O
difference	-	920	O
in	-	931	O
OD	-	934	O
between	-	937	O
HIT	-	945	O
patients	-	949	O
with	-	958	O
thrombosis	-	963	O
and	-	974	O
those	-	978	O
with	-	984	O
isolated	-	989	O
-	-	997	O
HIT	-	998	O
.	-	1001	O

However	18208574	1003	O
,	-	1010	O
OD	-	1012	O
was	-	1015	O
significantly	-	1019	O
higher	-	1033	O
in	-	1040	O
all	-	1043	O
patients	-	1047	O
with	-	1056	O
thrombosis	-	1061	O
(	-	1072	O
n	-	1073	O
=	-	1075	O
48	-	1077	O
,	-	1079	O
1	-	1081	O
.	-	1082	O
34	-	1083	O
+	-	1086	O
/	-	1087	O
-	-	1088	O

0	18208574	1090	O
.	-	1091	O
89	-	1092	O
)	-	1094	O
,	-	1095	O
including	-	1097	O
isolated	-	1107	O
-	-	1115	O
HIT	-	1116	O
patients	-	1120	O
who	-	1129	O
later	-	1133	O
developed	-	1139	O
thrombosis	-	1149	O
within	-	1160	O
30	-	1167	O
d	-	1170	O
(	-	1172	O
n	-	1173	O
=	-	1175	O
8	-	1177	O
,	-	1178	O
1	-	1180	O
.	-	1181	O
84	-	1182	O
+	-	1185	O
/	-	1186	O
-	-	1187	O
0	-	1189	O
.	-	1190	O
64	-	1191	O
)	-	1193	O

as	18208574	1195	O
compared	-	1198	O
to	-	1207	O
isolated	-	1210	O
-	-	1218	O
HIT	-	1219	O
patients	-	1223	O
who	-	1232	O
did	-	1236	O
not	-	1240	O
develop	-	1244	O
thrombosis	-	1252	O
(	-	1263	O
0	-	1264	O
.	-	1265	O
96	-	1266	O
+	-	1269	O
/	-	1270	O
-	-	1271	O

0	18208574	1273	O
.	-	1274	O
75	-	1275	O
;	-	1277	O
P	-	1279	O
=	-	1281	O
0	-	1283	O
.	-	1284	O
011	-	1285	O
and	-	1289	O
P	-	1293	O
=	-	1295	O
0	-	1297	O
.	-	1298	O
008	-	1299	O
)	-	1302	O
.	-	1303	O

The	18208574	1305	O
Receiver	-	1309	O
Operative	-	1318	O
Characteristic	-	1328	O
Curve	-	1343	O
showed	-	1349	O
that	-	1356	O
OD	-	1361	O
>	-	1364	O
1	-	1365	O
.	-	1366	O
27	-	1367	O
in	-	1370	O
the	-	1373	O
isolated	-	1377	O
-	-	1385	O
HIT	-	1386	O
group	-	1390	O
had	-	1396	O
a	-	1400	O
significantly	-	1402	O
higher	-	1416	O
chance	-	1423	O
of	-	1430	O
developing	-	1433	O
thrombosis	-	1444	O
by	-	1455	O
day	-	1458	O
30	-	1462	O
.	-	1464	O

None	18208574	1466	O
of	-	1471	O
these	-	1474	O
groups	-	1480	O
showed	-	1487	O
significant	-	1494	O
difference	-	1506	O
in	-	1517	O
percent	-	1520	O
inhibition	-	1528	O
.	-	1538	O

Multivariate	18208574	1540	O
analysis	-	1553	O
showed	-	1562	O
a	-	1569	O
2	-	1571	O
.	-	1572	O
8	-	1573	O
-	-	1574	O
fold	-	1575	O
increased	-	1580	O
risk	-	1590	O
of	-	1595	O
thrombosis	-	1598	O
in	-	1609	O
females	-	1612	O
.	-	1619	O

Similarly	18208574	1621	O
,	-	1630	O
thrombotic	-	1632	O
risk	-	1643	O
increased	-	1648	O
with	-	1658	O
age	-	1663	O
and	-	1667	O
OD	-	1671	O
values	-	1674	O
.	-	1680	O

CONCLUSION	18208574	1682	O
:	-	1692	O

Higher	18208574	1694	O
OD	-	1701	O
is	-	1704	O
associated	-	1707	O
with	-	1718	O
significant	-	1723	O
risk	-	1735	O
of	-	1740	O
subsequent	-	1743	O
thrombosis	-	1754	O
in	-	1765	O
patients	-	1768	O
with	-	1777	O
isolated	-	1782	O
-	-	1790	O
HIT	-	1791	O
;	-	1794	O
percent	-	1796	O
inhibition	-	1804	O
,	-	1814	O
however	-	1816	O
,	-	1823	O
was	-	1825	O
not	-	1829	O
predictive	-	1833	O
.	-	1843	O

Central	18343374	0	O
retinal	-	8	O
vein	-	16	O
occlusion	-	21	O
associated	-	31	O
with	-	42	O
clomiphene	-	47	B
-	-	57	O
induced	-	58	O
ovulation	-	66	O
.	-	75	O

OBJECTIVE	18343374	77	O
:	-	86	O

To	18343374	88	O
report	-	91	O
a	-	98	O
case	-	100	O
of	-	105	O
central	-	108	O
retinal	-	116	O
vein	-	124	O
occlusion	-	129	O
associated	-	139	O
with	-	150	O
clomiphene	-	155	B
citrate	-	166	I
(	-	174	O
CC	-	175	B
)	-	177	O
.	-	178	O

DESIGN	18343374	180	O
:	-	186	O

Case	18343374	188	O
study	-	193	O
.	-	198	O

SETTING	18343374	200	O
:	-	207	O

Ophthalmology	18343374	209	O
clinic	-	223	O
of	-	230	O
an	-	233	O
academic	-	236	O
hospital	-	245	O
.	-	253	O

PATIENT	18343374	255	O
(	-	262	O
S	-	263	O
)	-	264	O

:	18343374	265	O
A	-	267	O
36	-	269	O
-	-	271	O
year	-	272	O
-	-	276	O
old	-	277	O
woman	-	281	O
referred	-	287	O
from	-	296	O
the	-	301	O
infertility	-	305	O
clinic	-	317	O
for	-	324	O
blurred	-	328	O
vision	-	336	O
.	-	342	O

INTERVENTION	18343374	344	O
(	-	356	O
S	-	357	O
)	-	358	O
:	-	359	O

Ophthalmic	18343374	361	O
examination	-	372	O
after	-	384	O
CC	-	390	B
therapy	-	393	O
.	-	400	O

MAIN	18343374	402	O
OUTCOME	-	407	O
MEASURE	-	415	O
(	-	422	O
S	-	423	O
)	-	424	O
:	-	425	O

Central	18343374	427	O
retinal	-	435	O
vein	-	443	O
occlusion	-	448	O
after	-	458	O
ovulation	-	464	O
induction	-	474	O
with	-	484	O
CC	-	489	B
.	-	491	O

RESULT	18343374	493	O
(	-	499	O
S	-	500	O
)	-	501	O
:	-	502	O

A	18343374	504	O
36	-	506	O
-	-	508	O
year	-	509	O
-	-	513	O
old	-	514	O
Chinese	-	518	O
woman	-	526	O
developed	-	532	O
central	-	542	O
retinal	-	550	O
vein	-	558	O
occlusion	-	563	O
after	-	573	O
eight	-	579	O
courses	-	585	O
of	-	593	O
CC	-	596	B
.	-	598	O

A	18343374	600	O
search	-	602	O
of	-	609	O
the	-	612	O
literature	-	616	O
on	-	627	O
the	-	630	O
thromboembolic	-	634	O
complications	-	649	O
of	-	663	O
CC	-	666	B
does	-	669	O
not	-	674	O
include	-	678	O
this	-	686	O
severe	-	691	O
ophthalmic	-	698	O
complication	-	709	O
,	-	721	O
although	-	723	O
mild	-	732	O
visual	-	737	O
disturbance	-	744	O
after	-	756	O
CC	-	762	B
intake	-	765	O
is	-	772	O
not	-	775	O
uncommon	-	779	O
.	-	787	O

CONCLUSION	18343374	789	O
(	-	799	O
S	-	800	O
)	-	801	O

:	18343374	802	O
This	-	804	O
is	-	809	O
the	-	812	O
first	-	816	O
reported	-	822	O
case	-	831	O
of	-	836	O
central	-	839	O
retinal	-	847	O
vein	-	855	O
occlusion	-	860	O
after	-	870	O
treatment	-	876	O
with	-	886	O
CC	-	891	B
.	-	893	O

Extra	18343374	895	O
caution	-	901	O
is	-	909	O
warranted	-	912	O
in	-	922	O
treating	-	925	O
infertility	-	934	O
patients	-	946	O
with	-	955	O
CC	-	960	B
,	-	962	O
and	-	964	O
patients	-	968	O
should	-	977	O
be	-	984	O
well	-	987	O
informed	-	992	O
of	-	1001	O
this	-	1004	O
side	-	1009	O
effect	-	1014	O
before	-	1021	O
commencement	-	1028	O
of	-	1041	O
therapy	-	1044	O
.	-	1051	O

Nicotine	18417364	0	B
-	-	8	O
induced	-	9	O
nystagmus	-	17	O
correlates	-	27	O
with	-	38	O
midpontine	-	43	O
activation	-	54	O
.	-	64	O

The	18417364	66	O
pathomechanism	-	70	O
of	-	85	O
nicotine	-	88	B
-	-	96	O
induced	-	97	O
nystagmus	-	105	O
(	-	115	O
NIN	-	116	O
)	-	119	O
is	-	121	O
unknown	-	124	O
.	-	131	O

The	18417364	133	O
aim	-	137	O
of	-	141	O
this	-	144	O
study	-	149	O
was	-	155	O
to	-	159	O
delineate	-	162	O
brain	-	172	O
structures	-	178	O
that	-	189	O
are	-	194	O
involved	-	198	O
in	-	207	O
NIN	-	210	O
generation	-	214	O
.	-	224	O

Eight	18417364	226	O
healthy	-	232	O
volunteers	-	240	O
inhaled	-	251	O
nicotine	-	259	B
in	-	268	O
darkness	-	271	O
during	-	280	O
a	-	287	O
functional	-	289	O
magnetic	-	300	O
resonance	-	309	O
imaging	-	319	O
(	-	327	O
fMRI	-	328	O
)	-	332	O
experiment	-	334	O
;	-	344	O
eye	-	346	O
movements	-	350	O
were	-	360	O
registered	-	365	O
using	-	376	O
video	-	382	O
-	-	387	O
oculography	-	388	O
.	-	399	O

NIN	18417364	401	O
correlated	-	405	O
with	-	416	O
blood	-	421	O
oxygen	-	427	B
level	-	434	O
-	-	439	O
dependent	-	440	O
(	-	450	O
BOLD	-	451	O
)	-	455	O
activity	-	457	O
levels	-	466	O
in	-	473	O
a	-	476	O
midpontine	-	478	O
site	-	489	O
in	-	494	O
the	-	497	O
posterior	-	501	O
basis	-	511	O
pontis	-	517	O
.	-	523	O

NIN	18417364	525	O
-	-	528	O
induced	-	529	O
midpontine	-	537	O
activation	-	548	O
may	-	559	O
correspond	-	563	O
to	-	574	O
activation	-	577	O
of	-	588	O
the	-	591	O
dorsomedial	-	595	O
pontine	-	607	O
nuclei	-	615	O
and	-	622	O
the	-	626	O
nucleus	-	630	O
reticularis	-	638	O
tegmenti	-	650	O
pontis	-	659	O
,	-	665	O
structures	-	667	O
known	-	678	O
to	-	684	O
participate	-	687	O
in	-	699	O
the	-	702	O
generation	-	706	O
of	-	717	O
multidirectional	-	720	O
saccades	-	737	O
and	-	746	O
smooth	-	750	O
pursuit	-	757	O
eye	-	765	O
movements	-	769	O
.	-	778	O

Protective	18442015	0	O
effect	-	11	O
of	-	18	O
verapamil	-	21	B
on	-	31	O
gastric	-	34	O
hemorrhagic	-	42	O
ulcers	-	54	O
in	-	61	O
severe	-	64	O
atherosclerotic	-	71	O
rats	-	87	O
.	-	91	O

Studies	18442015	93	O
concerning	-	101	O
with	-	112	O
pathogenesis	-	117	O
of	-	130	O
gastric	-	133	O
hemorrhage	-	141	O
and	-	152	O
mucosal	-	156	O
ulceration	-	164	O
produced	-	175	O
in	-	184	O
atherosclerotic	-	187	O
rats	-	203	O
are	-	208	O
lacking	-	212	O
.	-	219	O

The	18442015	221	O
aim	-	225	O
of	-	229	O
this	-	232	O
study	-	237	O
is	-	243	O
to	-	246	O
examine	-	249	O
the	-	257	O
role	-	261	O
of	-	266	O
gastric	-	269	O
acid	-	277	O
back	-	282	O
-	-	286	O
diffusion	-	287	O
,	-	296	O
mast	-	298	O
cell	-	303	O
histamine	-	308	B
release	-	318	O
,	-	325	O
lipid	-	327	O
peroxide	-	333	O
(	-	342	O
LPO	-	343	O
)	-	346	O
generation	-	348	O
and	-	359	O
mucosal	-	363	O
microvascular	-	371	O
permeability	-	385	O
in	-	398	O
modulating	-	401	O
gastric	-	412	O
hemorrhage	-	420	O
and	-	431	O
ulcer	-	435	O
in	-	441	O
rats	-	444	O
with	-	449	O
atherosclerosis	-	454	O
induced	-	470	O
by	-	478	O
coadministration	-	481	O
of	-	498	O
vitamin	-	501	B
D2	-	509	I
and	-	512	O
cholesterol	-	516	B
.	-	527	O

Additionally	18442015	529	O
,	-	541	O
the	-	543	O
protective	-	547	O
effect	-	558	O
of	-	565	O
verapamil	-	568	B
on	-	578	O
this	-	581	O
ulcer	-	586	O
model	-	592	O
was	-	598	O
evaluated	-	602	O
.	-	611	O

Male	18442015	613	O
Wistar	-	618	O
rats	-	625	O
were	-	630	O
challenged	-	635	O
intragastrically	-	646	O
once	-	663	O
daily	-	668	O
for	-	674	O
9	-	678	O
days	-	680	O
with	-	685	O
1	-	690	O
.	-	691	O
0	-	692	O
ml	-	694	O
/	-	696	O
kg	-	697	O
of	-	700	O
corn	-	703	O
oil	-	708	O
containing	-	712	O
vitamin	-	723	B
D2	-	731	I
and	-	734	O
cholesterol	-	738	B
to	-	750	O
induce	-	753	O
atherosclerosis	-	760	O
.	-	775	O

Control	18442015	777	O
rats	-	785	O
received	-	790	O
corn	-	799	O
oil	-	804	O
only	-	808	O
.	-	812	O

After	18442015	814	O
gastric	-	820	O
surgery	-	828	O
,	-	835	O
rat	-	837	O
stomachs	-	841	O
were	-	850	O
irrigated	-	855	O
for	-	865	O
3	-	869	O
h	-	871	O
with	-	873	O
either	-	878	O
simulated	-	885	O
gastric	-	895	O
juice	-	903	O
or	-	909	O
normal	-	912	O
saline	-	919	O
.	-	925	O

Gastric	18442015	927	O
acid	-	935	O
back	-	940	O
-	-	944	O
diffusion	-	945	O
,	-	954	O
mucosal	-	956	O
LPO	-	964	O
generation	-	968	O
,	-	978	O
histamine	-	980	B
concentration	-	990	O
,	-	1003	O
microvascular	-	1005	O
permeability	-	1019	O
,	-	1031	O
luminal	-	1033	B
hemoglobin	-	1041	O
content	-	1052	O
and	-	1060	O
ulcer	-	1064	O
areas	-	1070	O
were	-	1076	O
determined	-	1081	O
.	-	1091	O

Elevated	18442015	1093	O
atherosclerotic	-	1102	O
parameters	-	1118	O
,	-	1128	O
such	-	1130	O
as	-	1135	O
serum	-	1138	O
calcium	-	1144	B
,	-	1151	O
total	-	1153	O
cholesterol	-	1159	B
and	-	1171	O
low	-	1175	O
-	-	1178	O
density	-	1179	O
lipoprotein	-	1187	O
concentration	-	1199	O
were	-	1213	O
obtained	-	1218	O
in	-	1227	O
atherosclerotic	-	1230	O
rats	-	1246	O
.	-	1250	O

Severe	18442015	1252	O
gastric	-	1259	O
ulcers	-	1267	O
accompanied	-	1274	O
with	-	1286	O
increased	-	1291	O
ulcerogenic	-	1301	O
factors	-	1313	O
,	-	1320	O
including	-	1322	O
gastric	-	1332	O
acid	-	1340	O
back	-	1345	O
-	-	1349	O
diffusion	-	1350	O
,	-	1359	O
histamine	-	1361	B
release	-	1371	O
,	-	1378	O
LPO	-	1380	O
generation	-	1384	O
and	-	1395	O
luminal	-	1399	B
hemoglobin	-	1407	O
content	-	1418	O
were	-	1426	O
also	-	1431	O
observed	-	1436	O
in	-	1445	O
these	-	1448	O
rats	-	1454	O
.	-	1458	O

Moreover	18442015	1460	O
,	-	1468	O
a	-	1470	O
positive	-	1472	O
correlation	-	1481	O
of	-	1493	O
histamine	-	1496	B
to	-	1506	O
gastric	-	1509	O
hemorrhage	-	1517	O
and	-	1528	O
to	-	1532	O
ulcer	-	1535	O
was	-	1541	O
found	-	1545	O
in	-	1551	O
those	-	1554	O
atherosclerotic	-	1560	O
rats	-	1576	O
.	-	1580	O

This	18442015	1582	O
hemorrhagic	-	1587	O
ulcer	-	1599	O
and	-	1605	O
various	-	1609	O
ulcerogenic	-	1617	O
parameters	-	1629	O
were	-	1640	O
dose	-	1645	O
-	-	1649	O
dependently	-	1650	O
ameliorated	-	1662	O
by	-	1674	O
daily	-	1677	O
intragastric	-	1683	O
verapamil	-	1696	B
.	-	1705	O

Atherosclerosis	18442015	1707	O
could	-	1723	O
produce	-	1729	O
gastric	-	1737	O
hemorrhagic	-	1745	O
ulcer	-	1757	O
via	-	1763	O
aggravation	-	1767	O
of	-	1779	O
gastric	-	1782	O
acid	-	1790	O
back	-	1795	O
-	-	1799	O
diffusion	-	1800	O
,	-	1809	O
LPO	-	1811	O
generation	-	1815	O
,	-	1825	O
histamine	-	1827	B
release	-	1837	O
and	-	1845	O
microvascular	-	1849	O
permeability	-	1863	O
that	-	1876	O
could	-	1881	O
be	-	1887	O
ameliorated	-	1890	O
by	-	1902	O
verapamil	-	1905	B
in	-	1915	O
rats	-	1918	O
.	-	1922	O

Adriamycin	18619688	0	B
-	-	10	O
induced	-	11	O
autophagic	-	19	O
cardiomyocyte	-	30	O
death	-	44	O
plays	-	50	O
a	-	56	O
pathogenic	-	58	O
role	-	69	O
in	-	74	O
a	-	77	O
rat	-	79	O
model	-	83	O
of	-	89	O
heart	-	92	O
failure	-	98	O
.	-	105	O

BACKGROUND	18619688	107	O
:	-	117	O

The	18619688	119	O
mechanisms	-	123	O
underlying	-	134	O
heart	-	145	O
failure	-	151	O
induced	-	159	O
by	-	167	O
adriamycin	-	170	B
are	-	181	O
very	-	185	O
complicated	-	190	O
and	-	202	O
still	-	206	O
unclear	-	212	O
.	-	219	O

The	18619688	221	O
aim	-	225	O
of	-	229	O
this	-	232	O
study	-	237	O
was	-	243	O
to	-	247	O
investigate	-	250	O
whether	-	262	O
autophagy	-	270	O
was	-	280	O
involved	-	284	O
in	-	293	O
the	-	296	O
progression	-	300	O
of	-	312	O
heart	-	315	O
failure	-	321	O
induced	-	329	O
by	-	337	O
adriamycin	-	340	B
,	-	350	O
so	-	352	O
that	-	355	O
we	-	360	O
can	-	363	O
develop	-	367	O
a	-	375	O
novel	-	377	O
treatment	-	383	O
strategy	-	393	O
for	-	402	O
heart	-	406	O
failure	-	412	O
.	-	419	O

METHODS	18619688	421	O
:	-	428	O
3	-	430	B
-	-	431	I
methyladenine	-	432	I

(	18619688	446	O
3MA	-	447	B
)	-	450	O
,	-	451	O
a	-	453	O
specific	-	455	O
inhibitor	-	464	O
on	-	474	O
autophagy	-	477	O
was	-	487	O
used	-	491	O
in	-	496	O
a	-	499	O
heart	-	501	O
failure	-	507	O
model	-	515	O
of	-	521	O
rats	-	524	O
induced	-	529	O
by	-	537	O
adriamycin	-	540	B
.	-	550	O

Neonatal	18619688	552	O
cardiomyocytes	-	561	O
were	-	576	O
isolated	-	581	O
from	-	590	O
Sprague	-	595	O
-	-	602	O
Dawley	-	603	O
rat	-	610	O
hearts	-	614	O
and	-	621	O
randomly	-	625	O
divided	-	634	O
into	-	642	O
controls	-	647	O
,	-	655	O
an	-	657	O
adriamycin	-	660	B
-	-	670	O
treated	-	671	O
group	-	679	O
,	-	684	O
and	-	686	O
a	-	690	O
3MA	-	692	B
plus	-	696	O
adriamycin	-	701	B
-	-	711	O
treated	-	712	O
group	-	720	O
.	-	725	O

We	18619688	727	O
then	-	730	O
examined	-	735	O
the	-	744	O
morphology	-	748	O
,	-	758	O
expression	-	760	O
of	-	771	O
beclin	-	774	O
1	-	781	O
gene	-	783	O
,	-	787	O
mitochondrial	-	789	O
permeability	-	803	O
transition	-	816	O
(	-	827	O
MPT	-	828	O
)	-	831	O
,	-	832	O
and	-	834	O
Na	-	838	O
+	-	840	O
-	-	841	O
K	-	842	B
+	-	843	O
ATPase	-	845	O
activity	-	852	O
in	-	861	O
vivo	-	864	O
.	-	868	O

We	18619688	870	O
also	-	873	O
assessed	-	878	O
cell	-	887	O
viability	-	892	O
,	-	901	O
mitochondrial	-	903	O
membrane	-	917	O
potential	-	926	O
changes	-	936	O
and	-	944	O
counted	-	948	O
autophagic	-	956	O
vacuoles	-	967	O
in	-	976	O
cultured	-	979	O
cardiomyocytes	-	988	O
.	-	1002	O

In	18619688	1004	O
addition	-	1007	O
,	-	1015	O
we	-	1017	O
analyzed	-	1020	O
the	-	1029	O
expression	-	1033	O
of	-	1044	O
autophagy	-	1047	O
associated	-	1057	O
gene	-	1068	O
,	-	1072	O
beclin	-	1074	O
1	-	1081	O
using	-	1083	O
RT	-	1089	O
-	-	1091	O
PCR	-	1092	O
and	-	1096	O
Western	-	1100	O
blotting	-	1108	O
in	-	1117	O
an	-	1120	O
animal	-	1123	O
model	-	1130	O
.	-	1135	O

RESULTS	18619688	1137	O
:	-	1144	O

3MA	18619688	1146	B
significantly	-	1150	O
improved	-	1164	O
cardiac	-	1173	O
function	-	1181	O
and	-	1190	O
reduced	-	1194	O
mitochondrial	-	1202	O
injury	-	1216	O
.	-	1222	O

Furthermore	18619688	1224	O
,	-	1235	O
adriamycin	-	1237	B
induced	-	1248	O
the	-	1256	O
formation	-	1260	O
of	-	1270	O
autophagic	-	1273	O
vacuoles	-	1284	O
,	-	1292	O
and	-	1294	O
3MA	-	1298	B
strongly	-	1302	O
downregulated	-	1311	O
the	-	1325	O
expression	-	1329	O
of	-	1340	O
beclin	-	1343	O
1	-	1350	O
in	-	1352	O
adriamycin	-	1355	B
-	-	1365	O
induced	-	1366	O
failing	-	1374	O
heart	-	1382	O
and	-	1388	O
inhibited	-	1392	O
the	-	1402	O
formation	-	1406	O
of	-	1416	O
autophagic	-	1419	O
vacuoles	-	1430	O
.	-	1438	O

CONCLUSION	18619688	1440	O
:	-	1450	O

Autophagic	18619688	1452	O
cardiomyocyte	-	1463	O
death	-	1477	O
plays	-	1483	O
an	-	1489	O
important	-	1492	O
role	-	1502	O
in	-	1507	O
the	-	1510	O
pathogenesis	-	1514	O
of	-	1527	O
heart	-	1530	O
failure	-	1536	O
in	-	1544	O
rats	-	1547	O
induced	-	1552	O
by	-	1560	O
adriamycin	-	1563	B
.	-	1573	O

Mitochondrial	18619688	1575	O
injury	-	1589	O
may	-	1596	O
be	-	1600	O
involved	-	1603	O
in	-	1612	O
the	-	1615	O
progression	-	1619	O
of	-	1631	O
heart	-	1634	O
failure	-	1640	O
caused	-	1648	O
by	-	1655	O
adriamycin	-	1658	B
via	-	1669	O
the	-	1673	O
autophagy	-	1677	O
pathway	-	1687	O
.	-	1694	O

Confusion	19308880	0	O
,	-	9	O
a	-	11	O
rather	-	13	O
serious	-	20	O
adverse	-	28	O
drug	-	36	O
reaction	-	41	O
with	-	50	O
valproic	-	55	B
acid	-	64	I
:	-	68	O
a	-	70	O
review	-	72	O
of	-	79	O
the	-	82	O
French	-	86	O
Pharmacovigilance	-	93	O
database	-	111	O
.	-	119	O

INTRODUCTION	19308880	121	O
:	-	133	O

Confusion	19308880	135	O
is	-	145	O
an	-	148	O
adverse	-	151	O
drug	-	159	O
reaction	-	164	O
frequently	-	173	O
observed	-	184	O
with	-	193	O
valproic	-	198	B
acid	-	207	I
.	-	211	O

Some	19308880	213	O
case	-	218	O
reports	-	223	O
are	-	231	O
published	-	235	O
in	-	245	O
the	-	248	O
literature	-	252	O
but	-	263	O
no	-	267	O
systematic	-	270	O
study	-	281	O
from	-	287	O
a	-	292	O
sample	-	294	O
of	-	301	O
patients	-	304	O
has	-	313	O
been	-	317	O
published	-	322	O
.	-	331	O

We	19308880	333	O
performed	-	336	O
this	-	346	O
study	-	351	O
in	-	357	O
order	-	360	O
to	-	366	O
describe	-	369	O
the	-	378	O
main	-	382	O
characteristics	-	387	O
of	-	403	O
this	-	406	O
adverse	-	411	O
drug	-	419	O
reaction	-	424	O
.	-	432	O

METHODS	19308880	434	O
:	-	441	O

Using	19308880	443	O
the	-	449	O
French	-	453	O
Pharmacovigilance	-	460	O
database	-	478	O
,	-	486	O
we	-	488	O
selected	-	491	O
the	-	500	O
cases	-	504	O
of	-	510	O
confusion	-	513	O
reported	-	523	O
since	-	532	O
1985	-	538	O
with	-	543	O
valproic	-	548	B
acid	-	557	I
.	-	561	O

RESULTS	19308880	563	O
:	-	570	O

272	19308880	572	O
cases	-	576	O
of	-	582	O
confusion	-	585	O
were	-	595	O
reported	-	600	O
with	-	609	O
valproic	-	614	B
acid	-	623	I
:	-	627	O
153	-	629	O
women	-	633	O
and	-	639	O
119	-	643	O
men	-	647	O
.	-	650	O

Confusion	19308880	652	O
mostly	-	662	O
occurred	-	669	O
during	-	678	O
the	-	685	O
two	-	689	O
first	-	693	O
weeks	-	699	O
following	-	705	O
valproic	-	715	B
acid	-	724	I
exposure	-	729	O
(	-	738	O
39	-	739	O
.	-	741	O
7	-	742	O
%	-	743	O
)	-	744	O
.	-	745	O

It	19308880	747	O
was	-	750	O
""""	-	754	O
serious	-	755	O
""""	-	762	O
for	-	764	O
almost	-	768	O
2	-	775	O
/	-	776	O
3	-	777	O
of	-	779	O
the	-	782	O
patients	-	786	O
(	-	795	O
62	-	796	O
.	-	798	O
5	-	799	O
%	-	800	O
)	-	801	O
and	-	803	O
its	-	807	O
outcome	-	811	O
favourable	-	819	O
in	-	830	O
most	-	833	O
of	-	838	O
the	-	841	O
cases	-	845	O
(	-	851	O
82	-	852	O
%	-	854	O
)	-	855	O
.	-	856	O

The	19308880	858	O
occurrence	-	862	O
of	-	873	O
this	-	876	O
ADR	-	881	O
was	-	885	O
more	-	889	O
frequent	-	894	O
in	-	903	O
patients	-	906	O
aged	-	915	O
between	-	920	O
61	-	928	O
and	-	931	O
80	-	935	O
years	-	938	O
.	-	943	O

CONCLUSION	19308880	945	O
:	-	955	O

This	19308880	957	O
work	-	962	O
shows	-	967	O
that	-	973	O
confusion	-	978	O
with	-	988	O
valproic	-	993	B
acid	-	1002	I
is	-	1007	O
a	-	1010	O
serious	-	1012	O
,	-	1019	O
rather	-	1021	O
frequent	-	1028	O
but	-	1037	O
reversible	-	1041	O
adverse	-	1052	O
drug	-	1060	O
reaction	-	1065	O
.	-	1073	O

It	19308880	1075	O
occurs	-	1078	O
especially	-	1085	O
in	-	1096	O
older	-	1099	O
patients	-	1105	O
and	-	1114	O
during	-	1118	O
the	-	1125	O
first	-	1129	O
two	-	1135	O
weeks	-	1139	O
of	-	1145	O
treatment	-	1148	O
.	-	1157	O

Learning	19631624	0	O
and	-	9	O
memory	-	13	O
deficits	-	20	O
in	-	29	O
ecstasy	-	32	B
users	-	40	O
and	-	46	O
their	-	50	O
neural	-	56	O
correlates	-	63	O
during	-	74	O
a	-	81	O
face	-	83	O
-	-	87	O
learning	-	88	O
task	-	97	O
.	-	101	O

It	19631624	103	O
has	-	106	O
been	-	110	O
consistently	-	115	O
shown	-	128	O
that	-	134	O
ecstasy	-	139	B
users	-	147	O
display	-	153	O
impairments	-	161	O
in	-	173	O
learning	-	176	O
and	-	185	O
memory	-	189	O
performance	-	196	O
.	-	207	O

In	19631624	209	O
addition	-	212	O
,	-	220	O
working	-	222	O
memory	-	230	O
processing	-	237	O
in	-	248	O
ecstasy	-	251	B
users	-	259	O
has	-	265	O
been	-	269	O
shown	-	274	O
to	-	280	O
be	-	283	O
associated	-	286	O
with	-	297	O
neural	-	302	O
alterations	-	309	O
in	-	321	O
hippocampal	-	324	O
and	-	336	O
/	-	339	O
or	-	340	O
cortical	-	343	O
regions	-	352	O
as	-	360	O
measured	-	363	O
by	-	372	O
functional	-	375	O
magnetic	-	386	O
resonance	-	395	O
imaging	-	405	O
(	-	413	O
fMRI	-	414	O
)	-	418	O
.	-	419	O

Using	19631624	421	O
functional	-	427	O
imaging	-	438	O
and	-	446	O
a	-	450	O
face	-	452	O
-	-	456	O
learning	-	457	O
task	-	466	O
,	-	470	O
we	-	472	O
investigated	-	475	O
neural	-	488	O
correlates	-	495	O
of	-	506	O
encoding	-	509	O
and	-	518	O
recalling	-	522	O
face	-	532	O
-	-	536	O
name	-	537	O
associations	-	542	O
in	-	555	O
20	-	558	O
recreational	-	561	O
drug	-	574	O
users	-	579	O
whose	-	585	O
predominant	-	591	O
drug	-	603	O
use	-	608	O
was	-	612	O
ecstasy	-	616	B
and	-	624	O
20	-	628	O
controls	-	631	O
.	-	639	O

To	19631624	641	O
address	-	644	O
the	-	652	O
potential	-	656	O
confounding	-	666	O
effects	-	678	O
of	-	686	O
the	-	689	O
cannabis	-	693	B
use	-	702	O
of	-	706	O
the	-	709	O
ecstasy	-	713	B
using	-	721	O
group	-	727	O
,	-	732	O
a	-	734	O
second	-	736	O
analysis	-	743	O
included	-	752	O
14	-	761	O
previously	-	764	O
tested	-	775	O
cannabis	-	782	B
users	-	791	O
(	-	797	O
Nestor	-	798	O
,	-	804	O
L	-	806	O
.	-	807	O
,	-	808	O
Roberts	-	810	O
,	-	817	O
G	-	819	O
.	-	820	O
,	-	821	O
Garavan	-	823	O
,	-	830	O
H	-	832	O
.	-	833	O
,	-	834	O
Hester	-	836	O
,	-	842	O
R	-	844	O
.	-	845	O
,	-	846	O
2008	-	848	O
.	-	852	O

Deficits	19631624	854	O
in	-	863	O
learning	-	866	O
and	-	875	O
memory	-	879	O
:	-	885	O
parahippocampal	-	887	O
hyperactivity	-	903	O
and	-	917	O
frontocortical	-	921	O
hypoactivity	-	936	O
in	-	949	O
cannabis	-	952	B
users	-	961	O
.	-	966	O

Neuroimage	19631624	968	O
40	-	979	O
,	-	981	O
1328	-	983	O
-	-	987	O
1339	-	988	O
)	-	992	O
.	-	993	O

Ecstasy	19631624	995	B
users	-	1003	O
performed	-	1009	O
significantly	-	1019	O
worse	-	1033	O
in	-	1039	O
learning	-	1042	O
and	-	1051	O
memory	-	1055	O
compared	-	1062	O
to	-	1071	O
controls	-	1074	O
and	-	1083	O
cannabis	-	1087	B
users	-	1096	O
.	-	1101	O

A	19631624	1103	O
conjunction	-	1105	O
analysis	-	1117	O
of	-	1126	O
the	-	1129	O
encode	-	1133	O
and	-	1140	O
recall	-	1144	O
phases	-	1151	O
of	-	1158	O
the	-	1161	O
task	-	1165	O
revealed	-	1170	O
ecstasy	-	1179	B
-	-	1186	O
specific	-	1187	O
hyperactivity	-	1196	O
in	-	1210	O
bilateral	-	1213	O
frontal	-	1223	O
regions	-	1231	O
,	-	1238	O
left	-	1240	O
temporal	-	1245	O
,	-	1253	O
right	-	1255	O
parietal	-	1261	O
,	-	1269	O
bilateral	-	1271	O
temporal	-	1281	O
,	-	1289	O
and	-	1291	O
bilateral	-	1295	O
occipital	-	1305	O
brain	-	1315	O
regions	-	1321	O
.	-	1328	O

Ecstasy	19631624	1330	B
-	-	1337	O
specific	-	1338	O
hypoactivity	-	1347	O
was	-	1360	O
evident	-	1364	O
in	-	1372	O
the	-	1375	O
right	-	1379	O
dorsal	-	1385	O
anterior	-	1392	O
cingulated	-	1401	O
cortex	-	1412	O
(	-	1419	O
ACC	-	1420	O
)	-	1423	O
and	-	1425	O
left	-	1429	O
posterior	-	1434	O
cingulated	-	1444	O
cortex	-	1455	O
.	-	1461	O

In	19631624	1463	O
both	-	1466	O
ecstasy	-	1471	B
and	-	1479	O
cannabis	-	1483	B
groups	-	1492	O
brain	-	1499	O
activation	-	1505	O
was	-	1516	O
decreased	-	1520	O
in	-	1530	O
the	-	1533	O
right	-	1537	O
medial	-	1543	O
frontal	-	1550	O
gyrus	-	1558	O
,	-	1563	O
left	-	1565	O
parahippocampal	-	1570	O
gyrus	-	1586	O
,	-	1591	O
left	-	1593	O
dorsal	-	1598	O
cingulate	-	1605	O
gyrus	-	1615	O
,	-	1620	O
and	-	1622	O
left	-	1626	O
caudate	-	1631	O
.	-	1638	O

These	19631624	1640	O
results	-	1646	O
elucidated	-	1654	O
ecstasy	-	1665	B
-	-	1672	O
related	-	1673	O
deficits	-	1681	O
,	-	1689	O
only	-	1691	O
some	-	1696	O
of	-	1701	O
which	-	1704	O
might	-	1710	O
be	-	1716	O
attributed	-	1719	O
to	-	1730	O
cannabis	-	1733	B
use	-	1742	O
.	-	1745	O

These	19631624	1747	O
ecstasy	-	1753	B
-	-	1760	O
specific	-	1761	O
effects	-	1770	O
may	-	1778	O
be	-	1782	O
related	-	1785	O
to	-	1793	O
the	-	1796	O
vulnerability	-	1800	O
of	-	1814	O
isocortical	-	1817	O
and	-	1829	O
allocortical	-	1833	O
regions	-	1846	O
to	-	1854	O
the	-	1857	O
neurotoxic	-	1861	O
effects	-	1872	O
of	-	1880	O
ecstasy	-	1883	B
.	-	1890	O

Prolonged	20003049	0	O
elevation	-	10	O
of	-	20	O
plasma	-	23	O
argatroban	-	30	B
in	-	41	O
a	-	44	O
cardiac	-	46	O
transplant	-	54	O
patient	-	65	O
with	-	73	O
a	-	78	O
suspected	-	80	O
history	-	90	O
of	-	98	O
heparin	-	101	B
-	-	108	O
induced	-	109	O
thrombocytopenia	-	117	O
with	-	134	O
thrombosis	-	139	O
.	-	149	O

BACKGROUND	20003049	151	O
:	-	161	O

Direct	20003049	163	O
thrombin	-	170	O
inhibitors	-	179	O
(	-	190	O
DTIs	-	191	O
)	-	195	O
provide	-	197	O
an	-	205	O
alternative	-	208	O
method	-	220	O
of	-	227	O
anticoagulation	-	230	O
for	-	246	O
patients	-	250	O
with	-	259	O
a	-	264	O
history	-	266	O
of	-	274	O
heparin	-	277	B
-	-	284	O
induced	-	285	O
thrombocytopenia	-	293	O
(	-	310	O
HIT	-	311	O
)	-	314	O
or	-	316	O
HIT	-	319	O
with	-	323	O
thrombosis	-	328	O
(	-	339	O
HITT	-	340	O
)	-	344	O
undergoing	-	346	O
cardiopulmonary	-	357	O
bypass	-	373	O
(	-	380	O
CPB	-	381	O
)	-	384	O
.	-	385	O

In	20003049	387	O
the	-	390	O
following	-	394	O
report	-	404	O
,	-	410	O
a	-	412	O
65	-	414	O
-	-	416	O
year	-	417	O
-	-	421	O
old	-	422	O
critically	-	426	O
ill	-	437	O
patient	-	441	O
with	-	449	O
a	-	454	O
suspected	-	456	O
history	-	466	O
of	-	474	O
HITT	-	477	O
was	-	482	O
administered	-	486	O
argatroban	-	499	B
for	-	510	O
anticoagulation	-	514	O
on	-	530	O
bypass	-	533	O
during	-	540	O
heart	-	547	O
transplantation	-	553	O
.	-	568	O

The	20003049	570	O
patient	-	574	O
required	-	582	O
massive	-	591	O
transfusion	-	599	O
support	-	611	O
(	-	619	O
55	-	620	O
units	-	623	O
of	-	629	O
red	-	632	O
blood	-	636	O
cells	-	642	O
,	-	647	O
42	-	649	O
units	-	652	O
of	-	658	O
fresh	-	661	O
-	-	666	O
frozen	-	667	O
plasma	-	674	O
,	-	680	O
40	-	682	O
units	-	685	O
of	-	691	O
cryoprecipitate	-	694	O
,	-	709	O
40	-	711	O
units	-	714	O
of	-	720	O
platelets	-	723	O
,	-	732	O
and	-	734	O
three	-	738	O
doses	-	744	O
of	-	750	O
recombinant	-	753	O
Factor	-	765	O
VIIa	-	772	O
)	-	776	O
for	-	778	O
severe	-	782	O
intraoperative	-	789	O
and	-	804	O
postoperative	-	808	O
bleeding	-	822	O
.	-	830	O

STUDY	20003049	832	O
DESIGN	-	838	O
AND	-	845	O
METHODS	-	849	O
:	-	856	O
Plasma	-	858	O
samples	-	865	O
from	-	873	O
before	-	878	O
and	-	885	O

after	20003049	889	O
CPB	-	895	O
were	-	899	O
analyzed	-	904	O
postoperatively	-	913	O
for	-	929	O
argatroban	-	933	B
concentration	-	944	O
using	-	958	O
a	-	964	O
modified	-	966	O
ecarin	-	975	O
clotting	-	982	O
time	-	991	O
(	-	996	O
ECT	-	997	O
)	-	1000	O
assay	-	1002	O
.	-	1007	O

RESULTS	20003049	1009	O
:	-	1016	O

Unexpectedly	20003049	1018	O
high	-	1031	O
concentrations	-	1036	O
of	-	1051	O
argatroban	-	1054	B
were	-	1065	O
measured	-	1070	O
in	-	1079	O
these	-	1082	O
samples	-	1088	O
(	-	1096	O
range	-	1097	O
,	-	1102	O
0	-	1104	O
-	-	1105	O
32	-	1106	O
microg	-	1109	O
/	-	1115	O
mL	-	1116	O
)	-	1118	O
,	-	1119	O
and	-	1121	O
a	-	1125	O
prolonged	-	1127	O
plasma	-	1137	O
argatroban	-	1144	B
half	-	1155	O
life	-	1160	O
(	-	1165	O
t	-	1166	O
(	-	1167	O
1	-	1168	O
/	-	1169	O
2	-	1170	O
)	-	1171	O
)	-	1172	O
of	-	1174	O
514	-	1177	O
minutes	-	1181	O
was	-	1189	O
observed	-	1193	O
(	-	1202	O
published	-	1203	O
elimination	-	1213	O
t	-	1225	O
(	-	1226	O
1	-	1227	O
/	-	1228	O
2	-	1229	O
)	-	1230	O
is	-	1232	O
39	-	1235	O
-	-	1237	O
51	-	1238	O
minutes	-	1241	O
[	-	1249	O
<	-	1250	O
or	-	1252	O
=	-	1255	O
181	-	1257	O
minutes	-	1261	O
with	-	1269	O
hepatic	-	1274	O
impairment	-	1282	O
]	-	1292	O
)	-	1293	O
.	-	1294	O

CONCLUSIONS	20003049	1296	O
:	-	1307	O

Correlation	20003049	1309	O
of	-	1321	O
plasma	-	1324	O
argatroban	-	1331	B
concentration	-	1342	O
versus	-	1356	O
the	-	1363	O
patient	-	1367	O
's	-	1374	O
coagulation	-	1377	O
variables	-	1389	O
and	-	1399	O
clinical	-	1403	O
course	-	1412	O
suggest	-	1419	O
that	-	1427	O
prolonged	-	1432	O
elevated	-	1442	O
levels	-	1451	O
of	-	1458	O
plasma	-	1461	O
argatroban	-	1468	B
may	-	1479	O
have	-	1483	O
contributed	-	1488	O
to	-	1500	O
the	-	1503	O
patient	-	1507	O
's	-	1514	O
extended	-	1517	O
coagulopathy	-	1526	O
.	-	1538	O

Because	20003049	1540	O
DTIs	-	1548	O
do	-	1553	O
not	-	1556	O
have	-	1560	O
reversal	-	1565	O
agents	-	1574	O
,	-	1580	O
surgical	-	1582	O
teams	-	1591	O
and	-	1597	O
transfusion	-	1601	O
services	-	1613	O
should	-	1622	O
remain	-	1629	O
aware	-	1636	O
of	-	1642	O
the	-	1645	O
possibility	-	1649	O
of	-	1661	O
massive	-	1664	O
transfusion	-	1672	O
events	-	1684	O
during	-	1691	O
anticoagulation	-	1698	O
with	-	1714	O
these	-	1719	O
agents	-	1725	O
.	-	1731	O

This	20003049	1733	O
is	-	1738	O
the	-	1741	O
first	-	1745	O
report	-	1751	O
to	-	1758	O
measure	-	1761	O
plasma	-	1769	O
argatroban	-	1776	B
concentration	-	1787	O
in	-	1801	O
the	-	1804	O
context	-	1808	O
of	-	1816	O
CPB	-	1819	O
and	-	1823	O
extended	-	1827	O
coagulopathy	-	1836	O
.	-	1848	O

Antituberculosis	20196116	0	B
therapy	-	17	O
-	-	24	O
induced	-	25	O
acute	-	33	O
liver	-	39	O
failure	-	45	O
:	-	52	O
magnitude	-	54	O
,	-	63	O
profile	-	65	O
,	-	72	O
prognosis	-	74	O
,	-	83	O
and	-	85	O
predictors	-	89	O
of	-	100	O
outcome	-	103	O
.	-	110	O

Antituberculosis	20196116	112	B
therapy	-	129	O
(	-	137	O
ATT	-	138	O
)	-	141	O
-	-	142	O
associated	-	143	O
acute	-	154	O
liver	-	160	O
failure	-	166	O
(	-	174	O
ATT	-	175	O
-	-	178	O
ALF	-	179	O
)	-	182	O
is	-	184	O
the	-	187	O
commonest	-	191	O
drug	-	201	O
-	-	205	O
induced	-	206	O
ALF	-	214	O
in	-	218	O
South	-	221	O
Asia	-	227	O
.	-	231	O

Prospective	20196116	233	O
studies	-	245	O
on	-	253	O
ATT	-	256	O
-	-	259	O
ALF	-	260	O
are	-	264	O
lacking	-	268	O
.	-	275	O

The	20196116	277	O
current	-	281	O
study	-	289	O
prospectively	-	295	O
evaluated	-	309	O
the	-	319	O
magnitude	-	323	O
,	-	332	O
clinical	-	334	O
course	-	343	O
,	-	349	O
outcome	-	351	O
,	-	358	O
and	-	360	O
prognostic	-	364	O
factors	-	375	O
in	-	383	O
ATT	-	386	O
-	-	389	O
ALF	-	390	O
.	-	393	O

From	20196116	395	O
January	-	400	O
1986	-	408	O
to	-	413	O
January	-	416	O
2009	-	424	O
,	-	428	O
1223	-	430	O
consecutive	-	435	O
ALF	-	447	O
patients	-	451	O
were	-	460	O
evaluated	-	465	O
:	-	474	O
ATT	-	476	O
alone	-	480	O
was	-	486	O
the	-	490	O
cause	-	494	O
in	-	500	O
70	-	503	O
(	-	506	O
5	-	507	O
.	-	508	O
7	-	509	O
%	-	510	O
)	-	511	O
patients	-	513	O
.	-	521	O

Another	20196116	523	O
15	-	531	O
(	-	534	O
1	-	535	O
.	-	536	O
2	-	537	O
%	-	538	O
)	-	539	O
had	-	541	O
ATT	-	545	O
and	-	549	O
simultaneous	-	553	O
hepatitis	-	566	O
virus	-	576	O
infection	-	582	O
.	-	591	O

In	20196116	593	O
44	-	596	O
(	-	599	O
62	-	600	O
.	-	602	O
8	-	603	O
%	-	604	O
)	-	605	O
patients	-	607	O
,	-	615	O
ATT	-	617	O
was	-	621	O
prescribed	-	625	O
empirically	-	636	O
without	-	648	O
definitive	-	656	O
evidence	-	667	O
of	-	676	O
tuberculosis	-	679	O
.	-	691	O

ATT	20196116	693	O
-	-	696	O
ALF	-	697	O
patients	-	701	O
were	-	710	O
younger	-	715	O
(	-	723	O
32	-	724	O
.	-	726	O
87	-	727	O
[	-	730	O
+	-	731	O
/	-	732	O
-	-	733	O
15	-	734	O
.	-	736	O
8	-	737	O
]	-	738	O
years	-	740	O
)	-	745	O
,	-	746	O
and	-	748	O
49	-	752	O
(	-	755	O
70	-	756	O
%	-	758	O
)	-	759	O
of	-	761	O
them	-	764	O
were	-	769	O
women	-	774	O
.	-	779	O

Most	20196116	781	O
had	-	786	O
hyperacute	-	790	O
presentation	-	801	O
;	-	813	O
the	-	815	O
median	-	819	O
icterus	-	826	O
encephalopathy	-	834	O
interval	-	849	O
was	-	858	O
4	-	862	O
.	-	863	O
5	-	864	O
(	-	866	O
0	-	867	O
-	-	868	O
30	-	869	O
)	-	871	O
days	-	873	O
.	-	877	O

The	20196116	879	O
median	-	883	O
duration	-	890	O
of	-	899	O
ATT	-	902	O
before	-	906	O
ALF	-	913	O
was	-	917	O
30	-	921	O
(	-	924	O
7	-	925	O
-	-	926	O
350	-	927	O
)	-	930	O
days	-	932	O
.	-	936	O

At	20196116	938	O
presentation	-	941	O
,	-	953	O
advanced	-	955	O
encephalopathy	-	964	O
and	-	979	O
cerebral	-	983	O
edema	-	992	O
were	-	998	O
present	-	1003	O
in	-	1011	O
51	-	1014	O
(	-	1017	O
76	-	1018	O
%	-	1020	O
)	-	1021	O
and	-	1023	O
29	-	1027	O
(	-	1030	O
41	-	1031	O
.	-	1033	O
4	-	1034	O
%	-	1035	O
)	-	1036	O
patients	-	1038	O
,	-	1046	O
respectively	-	1048	O
.	-	1060	O

Gastrointestinal	20196116	1062	O
bleed	-	1079	O
,	-	1084	O
seizures	-	1086	O
,	-	1094	O
infection	-	1096	O
,	-	1105	O
and	-	1107	O
acute	-	1111	O
renal	-	1117	O
failure	-	1123	O
were	-	1131	O
documented	-	1136	O
in	-	1147	O
seven	-	1150	O
(	-	1156	O
10	-	1157	O
%	-	1159	O
)	-	1160	O
,	-	1161	O
five	-	1163	O
(	-	1168	O
7	-	1169	O
.	-	1170	O
1	-	1171	O
%	-	1172	O
)	-	1173	O
,	-	1174	O
26	-	1176	O
(	-	1179	O
37	-	1180	O
.	-	1182	O
1	-	1183	O
%	-	1184	O
)	-	1185	O
,	-	1186	O
and	-	1188	O
seven	-	1192	O
(	-	1198	O
10	-	1199	O
%	-	1201	O
)	-	1202	O
patients	-	1204	O
,	-	1212	O
respectively	-	1214	O
.	-	1226	O

Compared	20196116	1228	O
with	-	1237	O
hepatitis	-	1242	O
E	-	1252	O
virus	-	1254	O
(	-	1260	O
HEV	-	1261	O
)	-	1264	O
and	-	1266	O
non	-	1270	O
-	-	1273	O
A	-	1274	O
non	-	1276	O
-	-	1279	O
E	-	1280	O
-	-	1281	O
induced	-	1282	O
ALF	-	1290	O
,	-	1293	O
ATT	-	1295	O
-	-	1298	O
ALF	-	1299	O
patients	-	1303	O
had	-	1312	O
nearly	-	1316	O
similar	-	1323	O
presentations	-	1331	O
except	-	1345	O
for	-	1352	O
older	-	1356	O
age	-	1362	O
and	-	1366	O
less	-	1370	O
elevation	-	1375	O
of	-	1385	O
liver	-	1388	O
enzymes	-	1394	O
.	-	1401	O

The	20196116	1403	O
mortality	-	1407	O
rate	-	1417	O
among	-	1422	O
patients	-	1428	O
with	-	1437	O
ATT	-	1442	O
-	-	1445	O
ALF	-	1446	O
was	-	1450	O
high	-	1454	O
(	-	1459	O
67	-	1460	O
.	-	1462	O
1	-	1463	O
%	-	1464	O
,	-	1465	O
n	-	1467	O
=	-	1469	O
47	-	1471	O
)	-	1473	O
,	-	1474	O
and	-	1476	O
only	-	1480	O
23	-	1485	O
(	-	1488	O
32	-	1489	O
.	-	1491	O
9	-	1492	O
%	-	1493	O
)	-	1494	O
patients	-	1496	O
recovered	-	1505	O
with	-	1515	O
medical	-	1520	O
treatment	-	1528	O
.	-	1537	O

In	20196116	1539	O
multivariate	-	1542	O
analysis	-	1555	O
,	-	1563	O
three	-	1565	O
factors	-	1571	O
independently	-	1579	O
predicted	-	1593	O
mortality	-	1603	O
:	-	1612	O
serum	-	1614	O
bilirubin	-	1620	B
(	-	1630	O
>	-	1631	O
or	-	1632	O
=	-	1634	O
10	-	1635	O
.	-	1637	O
8	-	1638	O
mg	-	1640	O
/	-	1642	O
dL	-	1643	O
)	-	1645	O
,	-	1646	O
prothrombin	-	1648	O
time	-	1660	O
(	-	1665	O
PT	-	1666	O
)	-	1668	O
prolongation	-	1670	O
(	-	1683	O
>	-	1684	O
or	-	1685	O
=	-	1687	O
26	-	1688	O
seconds	-	1691	O
)	-	1698	O
,	-	1699	O
and	-	1701	O
grade	-	1705	O
III	-	1711	O
/	-	1714	O
IV	-	1715	O
encephalopathy	-	1718	O
at	-	1733	O
presentation	-	1736	O
.	-	1748	O

CONCLUSION	20196116	1750	O
:	-	1760	O

ATT	20196116	1762	O
-	-	1765	O
ALF	-	1766	O
constituted	-	1770	O
5	-	1782	O
.	-	1783	O
7	-	1784	O
%	-	1785	O
of	-	1787	O
ALF	-	1790	O
at	-	1794	O
our	-	1797	O
center	-	1801	O
and	-	1808	O
had	-	1812	O
a	-	1816	O
high	-	1818	O
mortality	-	1823	O
rate	-	1833	O
.	-	1837	O

Because	20196116	1839	O
the	-	1847	O
mortality	-	1851	O
rate	-	1861	O
is	-	1866	O
so	-	1869	O
high	-	1872	O
,	-	1876	O
determining	-	1878	O
which	-	1890	O
factors	-	1896	O
are	-	1904	O
predictors	-	1908	O
is	-	1919	O
less	-	1922	O
important	-	1927	O
.	-	1936	O

A	20196116	1938	O
high	-	1940	O
proportion	-	1945	O
of	-	1956	O
patients	-	1959	O
had	-	1968	O
consumed	-	1972	O
ATT	-	1981	O
empirically	-	1985	O
,	-	1996	O
which	-	1998	O
could	-	2004	O
have	-	2010	O
been	-	2015	O
prevented	-	2020	O
.	-	2029	O

Central	20470218	0	O
nervous	-	8	O
system	-	16	O
complications	-	23	O
during	-	37	O
treatment	-	44	O
of	-	54	O
acute	-	57	O
lymphoblastic	-	63	O
leukemia	-	77	O
in	-	86	O
a	-	89	O
single	-	91	O
pediatric	-	98	O
institution	-	108	O
.	-	119	O

Central	20470218	121	O
nervous	-	129	O
system	-	137	O
(	-	144	O
CNS	-	145	O
)	-	148	O
complications	-	150	O
during	-	164	O
treatment	-	171	O
of	-	181	O
childhood	-	184	O
acute	-	194	O
lymphoblastic	-	200	O
leukemia	-	214	O
(	-	223	O
ALL	-	224	O
)	-	227	O
remain	-	229	O
a	-	236	O
challenging	-	238	O
clinical	-	250	O
problem	-	259	O
.	-	266	O

Outcome	20470218	268	O
improvement	-	276	O
with	-	288	O
more	-	293	O
intensive	-	298	O
chemotherapy	-	308	O
has	-	321	O
significantly	-	325	O
increased	-	339	O
the	-	349	O
incidence	-	353	O
and	-	363	O
severity	-	367	O
of	-	376	O
adverse	-	379	O
events	-	387	O
.	-	393	O

This	20470218	395	O
study	-	400	O
analyzed	-	406	O
the	-	415	O
incidence	-	419	O
of	-	429	O
neurological	-	432	O
complications	-	445	O
during	-	459	O
ALL	-	466	O
treatment	-	470	O
in	-	480	O
a	-	483	O
single	-	485	O
pediatric	-	492	O
institution	-	502	O
,	-	513	O
focusing	-	515	O
on	-	524	O
clinical	-	527	O
,	-	535	O
radiological	-	537	O
,	-	549	O
and	-	551	O
electrophysiological	-	555	O
findings	-	576	O
.	-	584	O

Exclusion	20470218	586	O
criteria	-	596	O
included	-	605	O
CNS	-	614	O
leukemic	-	618	O
infiltration	-	627	O
at	-	640	O
diagnosis	-	643	O
,	-	652	O
therapy	-	654	O
-	-	661	O
related	-	662	O
peripheral	-	670	O
neuropathy	-	681	O
,	-	691	O
late	-	693	O
-	-	697	O
onset	-	698	O
encephalopathy	-	704	O
,	-	718	O
or	-	720	O
long	-	723	O
-	-	727	O
term	-	728	O
neurocognitive	-	733	O
defects	-	748	O
.	-	755	O

During	20470218	757	O
a	-	764	O
9	-	766	O
-	-	767	O
year	-	768	O
period	-	773	O
,	-	779	O
we	-	781	O
retrospectively	-	784	O
collected	-	800	O
27	-	810	O
neurological	-	813	O
events	-	826	O
(	-	833	O
11	-	834	O
%	-	836	O
)	-	837	O
in	-	839	O
as	-	842	O
many	-	845	O
patients	-	850	O
,	-	858	O
from	-	860	O
253	-	865	O
children	-	869	O
enrolled	-	878	O
in	-	887	O
the	-	890	O
ALL	-	894	O
front	-	898	O
-	-	903	O
line	-	904	O
protocol	-	909	O
.	-	917	O

CNS	20470218	919	O
complications	-	923	O
included	-	937	O
posterior	-	946	O
reversible	-	956	O
leukoencephalopathy	-	967	O
syndrome	-	987	O
(	-	996	O
n	-	997	O
=	-	999	O
10	-	1001	O
)	-	1003	O
,	-	1004	O
stroke	-	1006	O
(	-	1013	O
n	-	1014	O
=	-	1016	O
5	-	1018	O
)	-	1019	O
,	-	1020	O
temporal	-	1022	O
lobe	-	1031	O
epilepsy	-	1036	O
(	-	1045	O
n	-	1046	O
=	-	1048	O
2	-	1050	O
)	-	1051	O
,	-	1052	O
high	-	1054	O
-	-	1058	O
dose	-	1059	O
methotrexate	-	1064	B
toxicity	-	1077	O
(	-	1086	O
n	-	1087	O
=	-	1089	O
2	-	1091	O
)	-	1092	O
,	-	1093	O
syndrome	-	1095	O
of	-	1104	O
inappropriate	-	1107	O
antidiuretic	-	1121	O
hormone	-	1134	O
secretion	-	1142	O
(	-	1152	O
n	-	1153	O
=	-	1155	O
1	-	1157	O
)	-	1158	O
,	-	1159	O
and	-	1161	O
other	-	1165	O
unclassified	-	1171	O
events	-	1184	O
(	-	1191	O
n	-	1192	O
=	-	1194	O
7	-	1196	O
)	-	1197	O
.	-	1198	O

In	20470218	1200	O
conclusion	-	1203	O
,	-	1213	O
CNS	-	1215	O
complications	-	1219	O
are	-	1233	O
frequent	-	1237	O
events	-	1246	O
during	-	1253	O
ALL	-	1260	O
therapy	-	1264	O
,	-	1271	O
and	-	1273	O
require	-	1277	O
rapid	-	1285	O
detection	-	1291	O
and	-	1301	O
prompt	-	1305	O
treatment	-	1312	O
to	-	1322	O
limit	-	1325	O
permanent	-	1331	O
damage	-	1341	O
.	-	1347	O

Safety	20722491	0	O
of	-	7	O
capecitabine	-	10	B
:	-	22	O
a	-	24	O
review	-	26	O
.	-	32	O

IMPORTANCE	20722491	34	O
OF	-	45	O
THE	-	48	O
FIELD	-	52	O
:	-	57	O

Fluoropyrimidines	20722491	59	B
,	-	76	O
in	-	78	O
particular	-	81	O
5	-	92	B
-	-	93	I
fluorouracil	-	94	I
(	-	107	O
5	-	108	B
-	-	109	I
FU	-	110	I
)	-	112	O
,	-	113	O
have	-	115	O
been	-	120	O
the	-	125	O
mainstay	-	129	O
of	-	138	O
treatment	-	141	O
for	-	151	O
several	-	155	O
solid	-	163	O
tumors	-	169	O
,	-	175	O
including	-	177	O
colorectal	-	187	O
,	-	197	O
breast	-	199	O
and	-	206	O
head	-	210	O
and	-	215	O
neck	-	219	O
cancers	-	224	O
,	-	231	O
for	-	233	O
>	-	237	O
40	-	239	O
years	-	242	O
.	-	247	O

AREAS	20722491	249	O

COVERED	20722491	255	O
IN	-	263	O
THIS	-	266	O
REVIEW	-	271	O

:	20722491	277	O
This	-	279	O
article	-	284	O
reviews	-	292	O
the	-	300	O
pharmacology	-	304	O
and	-	317	O
efficacy	-	321	O
of	-	330	O
capecitabine	-	333	B
with	-	346	O
a	-	351	O
special	-	353	O
emphasis	-	361	O
on	-	370	O
its	-	373	O
safety	-	377	O
.	-	383	O

WHAT	20722491	385	O
THE	-	390	O
READER	-	394	O
WILL	-	401	O
GAIN	-	406	O
:	-	410	O

The	20722491	412	O
reader	-	416	O
will	-	423	O
gain	-	428	O
better	-	433	O
insight	-	440	O
into	-	448	O
the	-	453	O
safety	-	457	O
of	-	464	O
capecitabine	-	467	B
in	-	480	O
special	-	483	O
populations	-	491	O
such	-	503	O
as	-	508	O
patients	-	511	O
with	-	520	O
advanced	-	525	O
age	-	534	O
,	-	537	O
renal	-	539	O
and	-	545	O
kidney	-	549	O
disease	-	556	O
.	-	563	O

We	20722491	565	O
also	-	568	O
explore	-	573	O
different	-	581	O
dosing	-	591	O
and	-	598	O
schedules	-	602	O
of	-	612	O
capecitabine	-	615	B
administration	-	628	O
.	-	642	O

TAKE	20722491	644	O
HOME	-	649	O
MESSAGE	-	654	O
:	-	661	O

Capecitabine	20722491	663	B
is	-	676	O
an	-	679	O
oral	-	682	O
prodrug	-	687	O
of	-	695	O
5	-	698	B
-	-	699	I
FU	-	700	I
and	-	703	O
was	-	707	O
developed	-	711	O
to	-	721	O
fulfill	-	724	O
the	-	732	O
need	-	736	O
for	-	741	O
a	-	745	O
more	-	747	O
convenient	-	752	O
therapy	-	763	O
and	-	771	O
provide	-	775	O
an	-	783	O
improved	-	786	O
safety	-	795	O
/	-	801	O
efficacy	-	802	O
profile	-	811	O
.	-	818	O

It	20722491	820	O
has	-	823	O
shown	-	827	O
promising	-	833	O
results	-	843	O
alone	-	851	O
or	-	857	O
in	-	860	O
combination	-	863	O
with	-	875	O
other	-	880	O
chemotherapeutic	-	886	O
agents	-	903	O
in	-	910	O
colorectal	-	913	O
,	-	923	O
breast	-	925	O
,	-	931	O
pancreaticobiliary	-	933	O
,	-	951	O
gastric	-	953	O
,	-	960	O
renal	-	962	O
cell	-	968	O
and	-	973	O
head	-	977	O
and	-	982	O
neck	-	986	O
cancers	-	991	O
.	-	998	O

The	20722491	1000	O
most	-	1004	O
commonly	-	1009	O
reported	-	1018	O
toxic	-	1027	O
effects	-	1033	O
of	-	1041	O
capecitabine	-	1044	B
are	-	1057	O
diarrhea	-	1061	O
,	-	1069	O
nausea	-	1071	O
,	-	1077	O
vomiting	-	1079	O
,	-	1087	O
stomatitis	-	1089	O
and	-	1100	O
hand	-	1104	O
-	-	1108	O
foot	-	1109	O
syndrome	-	1114	O
.	-	1122	O

Capecitabine	20722491	1124	B
has	-	1137	O
a	-	1141	O
well	-	1143	O
-	-	1147	O
established	-	1148	O
safety	-	1160	O
profile	-	1167	O
and	-	1175	O
can	-	1179	O
be	-	1183	O
given	-	1186	O
safely	-	1192	O
to	-	1199	O
patients	-	1202	O
with	-	1211	O
advanced	-	1216	O
age	-	1225	O
,	-	1228	O
hepatic	-	1230	O
and	-	1238	O
renal	-	1242	O
dysfunctions	-	1248	O
.	-	1260	O

Effects	20882060	0	O
of	-	8	O
pallidal	-	11	O
neurotensin	-	20	B
on	-	32	O
haloperidol	-	35	B
-	-	46	O
induced	-	47	O
parkinsonian	-	55	O
catalepsy	-	68	O
:	-	77	O
behavioral	-	79	O
and	-	90	O
electrophysiological	-	94	O
studies	-	115	O
.	-	122	O

OBJECTIVE	20882060	124	O
:	-	133	O
The	-	135	O
globus	-	139	O
pallidus	-	146	O
plays	-	155	O
a	-	161	O
critical	-	163	O
role	-	172	O
in	-	177	O
movement	-	180	O
regulation	-	189	O
.	-	199	O

Previous	20882060	201	O
studies	-	210	O
have	-	218	O
indicated	-	223	O
that	-	233	O
the	-	238	O
globus	-	242	O
pallidus	-	249	O
receives	-	258	O
neurotensinergic	-	267	O
innervation	-	284	O
from	-	296	O
the	-	301	O
striatum	-	305	O
,	-	313	O
and	-	315	O
systemic	-	319	O
administration	-	328	O
of	-	343	O
a	-	346	O
neurotensin	-	348	B
analog	-	360	O
could	-	367	O
produce	-	373	O
antiparkinsonian	-	381	O
effects	-	398	O
.	-	405	O

The	20882060	407	O
present	-	411	O
study	-	419	O
aimed	-	425	O
to	-	431	O
investigate	-	434	O
the	-	446	O
effects	-	450	O
of	-	458	O
pallidal	-	461	O
neurotensin	-	470	B
on	-	482	O
haloperidol	-	485	B
-	-	496	O
induced	-	497	O
parkinsonian	-	505	O
symptoms	-	518	O
.	-	526	O

METHODS	20882060	528	O
:	-	535	O

Behavioral	20882060	537	O
experiments	-	548	O
and	-	560	O
electrophysiological	-	564	O
recordings	-	585	O
were	-	596	O
performed	-	601	O
in	-	611	O
the	-	614	O
present	-	618	O
study	-	626	O
.	-	631	O

RESULTS	20882060	633	O
:	-	640	O

Bilateral	20882060	642	O
infusions	-	652	O
of	-	662	O
neurotensin	-	665	B
into	-	677	O
the	-	682	O
globus	-	686	O
pallidus	-	693	O
reversed	-	702	O
haloperidol	-	711	B
-	-	722	O
induced	-	723	O
parkinsonian	-	731	O
catalepsy	-	744	O
in	-	754	O
rats	-	757	O
.	-	761	O

Electrophysiological	20882060	763	O
recordings	-	784	O
showed	-	795	O
that	-	802	O
microinjection	-	807	O
of	-	822	O
neurotensin	-	825	B
induced	-	837	O
excitation	-	845	O
of	-	856	O
pallidal	-	859	O
neurons	-	868	O
in	-	876	O
the	-	879	O
presence	-	883	O
of	-	892	O
systemic	-	895	O
haloperidol	-	904	B
administration	-	916	O
.	-	930	O

The	20882060	932	O
neurotensin	-	936	B
type	-	948	I
-	-	952	I
1	-	953	I
receptor	-	955	I
antagonist	-	964	I
SR48692	-	975	B
blocked	-	983	O
both	-	991	O
the	-	996	O
behavioral	-	1000	O
and	-	1011	O
the	-	1015	O
electrophysiological	-	1019	O
effects	-	1040	O
induced	-	1048	O
by	-	1056	O
neurotensin	-	1059	B
.	-	1070	O

CONCLUSION	20882060	1072	O
:	-	1082	O

Activation	20882060	1084	O
of	-	1095	O
pallidal	-	1098	O
neurotensin	-	1107	B
receptors	-	1119	O
may	-	1129	O
be	-	1133	O
involved	-	1136	O
in	-	1145	O
neurotensin	-	1148	B
-	-	1159	O
induced	-	1160	O
antiparkinsonian	-	1168	O
effects	-	1185	O
.	-	1192	O

Antihypertensive	26094	0	O
drugs	-	17	O
and	-	23	O
depression	-	27	O
:	-	37	O
a	-	39	O
reappraisal	-	41	O
.	-	52	O

Eighty	26094	54	O
-	-	60	O
nine	-	61	O
new	-	66	O
referral	-	70	O
hypertensive	-	79	O
out	-	92	O
-	-	95	O
patients	-	96	O
and	-	105	O
46	-	109	O
new	-	112	O
referral	-	116	O
non	-	125	O
-	-	128	O
hypertensive	-	129	O
chronically	-	142	O
physically	-	154	O
ill	-	165	O
out	-	169	O
-	-	172	O
patients	-	173	O
completed	-	182	O
a	-	192	O
mood	-	194	O
rating	-	199	O
scale	-	206	O
at	-	212	O
regular	-	215	O
intervals	-	223	O
for	-	233	O
one	-	237	O
year	-	241	O
.	-	245	O

The	26094	247	O
results	-	251	O
showed	-	259	O
a	-	266	O
high	-	268	O
prevalence	-	273	O
of	-	284	O
depression	-	287	O
in	-	298	O
both	-	301	O
groups	-	306	O
of	-	313	O
patients	-	316	O
,	-	324	O
with	-	326	O
no	-	331	O
preponderance	-	334	O
in	-	348	O
the	-	351	O
hypertensive	-	355	O
group	-	368	O
.	-	373	O

Hypertensive	26094	375	O
patients	-	388	O
with	-	397	O
psychiatric	-	402	O
histories	-	414	O
had	-	424	O
a	-	428	O
higher	-	430	O
prevalence	-	437	O
of	-	448	O
depression	-	451	O
than	-	462	O
the	-	467	O
comparison	-	471	O
patients	-	482	O
.	-	490	O

This	26094	492	O
was	-	497	O
accounted	-	501	O
for	-	511	O
by	-	515	O
a	-	518	O
significant	-	520	O
number	-	532	O
of	-	539	O
depressions	-	542	O
occurring	-	554	O
in	-	564	O
methyl	-	567	B
dopa	-	574	I
treated	-	579	O
patients	-	587	O
with	-	596	O
psychiatric	-	601	O
histories	-	613	O
.	-	622	O

Pulmonary	322550	0	O
shunt	-	10	O
and	-	16	O
cardiovascular	-	20	O
responses	-	35	O
to	-	45	O
CPAP	-	48	O
during	-	53	O
nitroprusside	-	60	B
-	-	73	O
induced	-	74	O
hypotension	-	82	O
.	-	93	O

The	322550	95	O
effects	-	99	O
of	-	107	O
continuous	-	110	O
positive	-	121	O
airway	-	130	O
pressure	-	137	O
(	-	146	O
CPAP	-	147	O
)	-	151	O
on	-	153	O
cardiovascular	-	156	O
dynamics	-	171	O
and	-	180	O
pulmonary	-	184	O
shunt	-	194	O
(	-	200	O
QS	-	201	O
/	-	203	O
QT	-	204	O
)	-	206	O
were	-	208	O
investigated	-	213	O
in	-	226	O
12	-	229	O
dogs	-	232	O
before	-	237	O
and	-	244	O
during	-	248	O
sodium	-	255	B
nitroprusside	-	262	I
infusion	-	276	O
that	-	285	O
decreased	-	290	O
mean	-	300	O
arterial	-	305	O
blood	-	314	O
pressure	-	320	O
40	-	329	O
-	-	331	O
50	-	332	O
per	-	335	O
cent	-	339	O
.	-	343	O

Before	322550	345	O
nitroprusside	-	352	B
infusion	-	366	O
,	-	374	O
5	-	376	O
cm	-	378	O
H2O	-	381	B
CPAP	-	385	O
significantly	-	390	O
,	-	403	O
P	-	405	O
less	-	407	O
than	-	412	O
.	-	417	O
05	-	418	O
,	-	420	O
decreased	-	422	O
arterial	-	432	O
blood	-	441	O
pressure	-	447	O
,	-	455	O
but	-	457	O
did	-	461	O
not	-	465	O
significantly	-	469	O
alter	-	483	O
heart	-	489	O
rate	-	495	O
,	-	499	O
cardiac	-	501	O
output	-	509	O
,	-	515	O
systemic	-	517	O
vascular	-	526	O
resistance	-	535	O
,	-	545	O
or	-	547	O
QS	-	550	O
/	-	552	O
QT	-	553	O
.	-	555	O

Ten	322550	557	O
cm	-	561	O
H2O	-	564	B
CPAP	-	568	O
before	-	573	O
nitroprusside	-	580	B
infusion	-	594	O
produced	-	603	O
a	-	612	O
further	-	614	O
decrease	-	622	O
in	-	631	O
arterial	-	634	O
blood	-	643	O
pressure	-	649	O
and	-	658	O
significantly	-	662	O
increased	-	676	O
heart	-	686	O
rate	-	692	O
and	-	697	O
decreased	-	701	O
cardiac	-	711	O
output	-	719	O
and	-	726	O
QS	-	730	O
/	-	732	O
QT	-	733	O
.	-	735	O

Nitroprusside	322550	737	B
caused	-	751	O
significant	-	758	O
decreases	-	770	O
in	-	780	O
arterial	-	783	O
blood	-	792	O
pressure	-	798	O
and	-	807	O
systemic	-	811	O
vascular	-	820	O
resistance	-	829	O
and	-	840	O
increases	-	844	O
in	-	854	O
heart	-	857	O
rate	-	863	O
,	-	867	O
but	-	869	O
did	-	873	O
not	-	877	O
change	-	881	O
cardiac	-	888	O
output	-	896	O
or	-	903	O
QS	-	906	O
/	-	908	O
QT	-	909	O
.	-	911	O

Five	322550	913	O
cm	-	918	O
H2O	-	921	B
CPAP	-	925	O
during	-	930	O
nitroprusside	-	937	B
did	-	951	O
not	-	955	O
further	-	959	O
alter	-	967	O
any	-	973	O
of	-	977	O
the	-	980	O
above	-	984	O
-	-	989	O
mentioned	-	990	O
variables	-	1000	O
.	-	1009	O

However	322550	1011	O
,	-	1018	O
10	-	1020	O
cm	-	1023	O
H2O	-	1026	B
CPAP	-	1030	O
decreased	-	1035	O
arterial	-	1045	O
blood	-	1054	O
pressure	-	1060	O
,	-	1068	O
cardiac	-	1070	O
output	-	1078	O
,	-	1084	O
and	-	1086	O
QS	-	1090	O
/	-	1092	O
QT	-	1093	O
.	-	1095	O

These	322550	1097	O
data	-	1103	O
indicate	-	1108	O
that	-	1117	O
nitroprusside	-	1122	B
infusion	-	1136	O
rates	-	1145	O
that	-	1151	O
decrease	-	1156	O
mean	-	1165	O
arterial	-	1170	O
blood	-	1179	O
pressure	-	1185	O
by	-	1194	O
40	-	1197	O
-	-	1199	O
50	-	1200	O
per	-	1203	O
cent	-	1207	O
do	-	1212	O
not	-	1215	O
change	-	1219	O
cardiac	-	1226	O
output	-	1234	O
or	-	1241	O
QS	-	1244	O
/	-	1246	O
QT	-	1247	O
.	-	1249	O

During	322550	1251	O
nitroprusside	-	1258	B
infusion	-	1272	O
low	-	1281	O
levels	-	1285	O
of	-	1292	O
CPAP	-	1295	O
do	-	1300	O
not	-	1303	O
markedly	-	1307	O
alter	-	1316	O
cardiovascular	-	1322	O
dynamics	-	1337	O
,	-	1345	O
but	-	1347	O
high	-	1351	O
levels	-	1356	O
of	-	1363	O
CPAP	-	1366	O
(	-	1371	O
10	-	1372	O
cm	-	1375	O
H2O	-	1378	B
)	-	1381	O
,	-	1382	O
while	-	1384	O
decreasing	-	1390	O
QS	-	1401	O
/	-	1403	O
QT	-	1404	O
,	-	1406	O
produce	-	1408	O
marked	-	1416	O
decreases	-	1423	O
in	-	1433	O
arterial	-	1436	O
blood	-	1445	O
pressure	-	1451	O
and	-	1460	O
cardiac	-	1464	O
output	-	1472	O
.	-	1478	O

Mediation	869641	0	O
of	-	10	O
enhanced	-	13	O
reflex	-	22	O
vagal	-	29	O
bradycardia	-	35	O
by	-	47	O
L	-	50	B
-	-	51	I
dopa	-	52	I
via	-	57	O
central	-	61	O
dopamine	-	69	B
formation	-	78	O
in	-	88	O
dogs	-	91	O
.	-	95	O

L	869641	97	B
-	-	98	I
Dopa	-	99	I
(	-	104	O
5	-	105	O
mg	-	107	O
/	-	109	O
kg	-	110	O
i	-	113	O
.	-	114	O
v	-	115	O
.	-	116	O
)	-	117	O

decreased	869641	119	O
blood	-	129	O
pressure	-	135	O
and	-	144	O
heart	-	148	O
rate	-	154	O
after	-	159	O
extracerebral	-	165	O
decarboxylase	-	179	O
inhibition	-	193	O
with	-	204	O
MK	-	209	B
-	-	211	I
486	-	212	I
(	-	216	O
25	-	217	O
mg	-	220	O
/	-	222	O
kg	-	223	O
i	-	226	O
.	-	227	O
v	-	228	O
.	-	229	O
)	-	230	O

in	869641	232	O
anesthetize	-	235	O
MAO	-	247	B
-	-	250	O
inhibited	-	251	O
dogs	-	261	O
.	-	265	O

In	869641	267	O
addition	-	270	O
,	-	278	O
reflex	-	280	O
bradycardia	-	287	O
caused	-	299	O
by	-	306	O
injected	-	309	O
norepinephrine	-	318	B
was	-	333	O
significantly	-	337	O
enhanced	-	351	O
by	-	360	O
L	-	363	B
-	-	364	I
dopa	-	365	I
,	-	369	O
DL	-	371	B
-	-	373	I
Threo	-	374	I
-	-	379	I
dihydroxyphenylserine	-	380	I
had	-	402	O
no	-	406	O
effect	-	409	O
on	-	416	O
blood	-	419	O
pressure	-	425	O
,	-	433	O
heart	-	435	O
rate	-	441	O
or	-	446	O
reflex	-	449	O
responses	-	456	O
to	-	466	O
norepinephrine	-	469	B
.	-	483	O

FLA	869641	485	B
-	-	488	I
63	-	489	I
,	-	491	O
a	-	493	O
dopamine	-	495	B
-	-	503	O
beta	-	504	O
-	-	508	O
oxidase	-	509	O
inhibitor	-	517	O
,	-	526	O
did	-	528	O
not	-	532	O
have	-	536	O
any	-	541	O
effect	-	545	O
on	-	552	O
the	-	555	O
hypotension	-	559	O
,	-	570	O
bradycardia	-	572	O
or	-	584	O
reflex	-	587	O
-	-	593	O
enhancing	-	594	O
effect	-	604	O
of	-	611	O
L	-	614	B
-	-	615	I
dopa	-	616	I
.	-	620	O

Pimozide	869641	622	B
did	-	631	O
not	-	635	O
affect	-	639	O
the	-	646	O
actions	-	650	O
of	-	658	O
L	-	661	B
-	-	662	I
dopa	-	663	I
on	-	668	O
blood	-	671	O
pressure	-	677	O
and	-	686	O
heart	-	690	O
rate	-	696	O
but	-	701	O
completely	-	705	O
blocked	-	716	O
the	-	724	O
enhancement	-	728	O
of	-	740	O
reflexes	-	743	O
.	-	751	O

Removal	869641	753	O
of	-	761	O
the	-	764	O
carotid	-	768	O
sinuses	-	776	O
caused	-	784	O
an	-	791	O
elevation	-	794	O
blood	-	804	O
pressure	-	810	O
and	-	819	O
heart	-	823	O
rate	-	829	O
and	-	834	O
abolished	-	838	O
the	-	848	O
negative	-	852	O
chronotropic	-	861	O
effect	-	874	O
of	-	881	O
norepinephrine	-	884	B
.	-	898	O

However	869641	900	O
,	-	907	O
L	-	909	B
-	-	910	I
dopa	-	911	I
restored	-	916	O
the	-	925	O
bradycardia	-	929	O
caused	-	941	O
by	-	948	O
norepinephrine	-	951	B
in	-	966	O
addition	-	969	O
to	-	978	O
decreasing	-	981	O
blood	-	992	O
pressure	-	998	O
and	-	1007	O
heart	-	1011	O
rate	-	1017	O
.	-	1021	O

5	869641	1023	B
-	-	1024	I
HTP	-	1025	I
(	-	1029	O
5	-	1030	O
mg	-	1032	O
/	-	1034	O
kg	-	1035	O
i	-	1038	O
.	-	1039	O
v	-	1040	O
.	-	1041	O
)	-	1042	O

decreased	869641	1044	O
blood	-	1054	O
pressure	-	1060	O
and	-	1069	O
heart	-	1073	O
rate	-	1079	O
and	-	1084	O
decreased	-	1088	O
the	-	1098	O
reflex	-	1102	O
bradycardia	-	1109	O
to	-	1121	O
norepinephrine	-	1124	B
.	-	1138	O

It	869641	1140	O
is	-	1143	O
concluded	-	1146	O
that	-	1156	O
L	-	1161	B
-	-	1162	I
dopa	-	1163	I
enhances	-	1168	O
reflex	-	1177	O
bradycardia	-	1184	O
through	-	1196	O
central	-	1204	O
alpha	-	1212	O
-	-	1217	O
receptor	-	1218	O
stimulation	-	1227	O
.	-	1238	O

Furthermore	869641	1240	O
,	-	1251	O
the	-	1253	O
effects	-	1257	O
are	-	1265	O
mediated	-	1269	O
through	-	1278	O
dopamine	-	1286	B
rather	-	1295	O
than	-	1302	O
norepinephrine	-	1307	B
and	-	1322	O
do	-	1326	O
not	-	1329	O
require	-	1333	O
the	-	1341	O
carotid	-	1345	O
sinus	-	1353	O
baroreceptors	-	1359	O
.	-	1372	O

Cocaine	1749407	0	B
-	-	7	O
induced	-	8	O
myocardial	-	16	O
infarction	-	27	O
:	-	37	O
clinical	-	39	O
observations	-	48	O
and	-	61	O
pathogenetic	-	65	O
considerations	-	78	O
.	-	92	O

Clinical	1749407	94	O
and	-	103	O
experimental	-	107	O
data	-	120	O
published	-	125	O
to	-	135	O
date	-	138	O
suggest	-	143	O
several	-	151	O
possible	-	159	O
mechanisms	-	168	O
by	-	179	O
which	-	182	O
cocaine	-	188	B
may	-	196	O
result	-	200	O
in	-	207	O
acute	-	210	O
myocardial	-	216	O
infarction	-	227	O
.	-	237	O

In	1749407	239	O
individuals	-	242	O
with	-	254	O
preexisting	-	259	O
,	-	270	O
high	-	272	O
-	-	276	O
grade	-	277	O
coronary	-	283	O
arterial	-	292	O
narrowing	-	301	O
,	-	310	O
acute	-	312	O
myocardial	-	318	O
infarction	-	329	O
may	-	340	O
result	-	344	O
from	-	351	O
an	-	356	O
increase	-	359	O
in	-	368	O
myocardial	-	371	O
oxygen	-	382	B
demand	-	389	O
associated	-	396	O
with	-	407	O
cocaine	-	412	B
-	-	419	O
induced	-	420	O
increase	-	428	O
in	-	437	O
rate	-	440	O
-	-	444	O
pressure	-	445	O
product	-	454	O
.	-	461	O

In	1749407	463	O
other	-	466	O
individuals	-	472	O
with	-	484	O
no	-	489	O
underlying	-	492	O
atherosclerotic	-	503	O
obstruction	-	519	O
,	-	530	O
coronary	-	532	O
occlusion	-	541	O
may	-	551	O
be	-	555	O
due	-	558	O
to	-	562	O
spasm	-	565	O
,	-	570	O
thrombus	-	572	O
,	-	580	O
or	-	582	O
both	-	585	O
.	-	589	O

With	1749407	591	O
regard	-	596	O
to	-	603	O
spasm	-	606	O
,	-	611	O
the	-	613	O
clinical	-	617	O
findings	-	626	O
are	-	635	O
largely	-	639	O
circumstantial	-	647	O
,	-	661	O
and	-	663	O
the	-	667	O
locus	-	671	O
of	-	677	O
cocaine	-	680	B
-	-	687	O
induced	-	688	O
vasoconstriction	-	696	O
remains	-	713	O
speculative	-	721	O
.	-	732	O

Although	1749407	734	O
certain	-	743	O
clinical	-	751	O
and	-	760	O
experimental	-	764	O
findings	-	777	O
support	-	786	O
the	-	794	O
hypothesis	-	798	O
that	-	809	O
spasm	-	814	O
involves	-	820	O
the	-	829	O
epicardial	-	833	O
,	-	843	O
medium	-	845	O
-	-	851	O
size	-	852	O
vessels	-	857	O
,	-	864	O
other	-	866	O
data	-	872	O
suggest	-	877	O
intramural	-	885	O
vasoconstriction	-	896	O
.	-	912	O

Diffuse	1749407	914	O
intramural	-	922	O
vasoconstriction	-	933	O
is	-	950	O
not	-	953	O
consistent	-	957	O
with	-	968	O
reports	-	973	O
of	-	981	O
segmental	-	984	O
,	-	993	O
discrete	-	995	O
infarction	-	1004	O
.	-	1014	O

Whereas	1749407	1016	O
certain	-	1024	O
in	-	1032	O
vivo	-	1035	O
data	-	1040	O
suggest	-	1045	O
that	-	1053	O
these	-	1058	O
effects	-	1064	O
are	-	1072	O
alpha	-	1076	O
-	-	1081	O
mediated	-	1082	O
,	-	1090	O
other	-	1092	O
in	-	1098	O
vitro	-	1101	O
data	-	1107	O
suggest	-	1112	O
the	-	1120	O
opposite	-	1124	O
.	-	1132	O

The	1749407	1134	O
finding	-	1138	O
of	-	1146	O
cocaine	-	1149	B
-	-	1156	O
induced	-	1157	O
vasoconstriction	-	1165	O
in	-	1182	O
segments	-	1185	O
of	-	1194	O
(	-	1197	O
noninnervated	-	1198	O
)	-	1211	O
human	-	1213	O
umbilical	-	1219	O
artery	-	1229	O
suggests	-	1236	O
that	-	1245	O
the	-	1250	O
presence	-	1254	O
or	-	1263	O
absence	-	1266	O
of	-	1274	O
intact	-	1277	O
innervation	-	1284	O
is	-	1296	O
not	-	1299	O
sufficient	-	1303	O
to	-	1314	O
explain	-	1317	O
the	-	1325	O
discrepant	-	1329	O
data	-	1340	O
involving	-	1345	O
the	-	1355	O
possibility	-	1359	O
of	-	1371	O
alpha	-	1374	O
-	-	1379	O
mediated	-	1380	O
effects	-	1389	O
.	-	1396	O

Finally	1749407	1398	O
,	-	1405	O
the	-	1407	O
contribution	-	1411	O
of	-	1424	O
a	-	1427	O
primary	-	1429	O
,	-	1436	O
thrombotic	-	1438	O
effect	-	1449	O
of	-	1456	O
cocaine	-	1459	B
has	-	1467	O
not	-	1471	O
been	-	1475	O
excluded	-	1480	O
.	-	1488	O

Rabbit	1786266	0	O
syndrome	-	7	O
,	-	15	O
antidepressant	-	17	B
use	-	32	O
,	-	35	O
and	-	37	O
cerebral	-	41	O
perfusion	-	50	O
SPECT	-	60	O
scan	-	66	O
findings	-	71	O
.	-	79	O

The	1786266	81	O
rabbit	-	85	O
syndrome	-	92	O
is	-	101	O
an	-	104	O
extrapyramidal	-	107	O
side	-	122	O
effect	-	127	O
associated	-	134	O
with	-	145	O
chronic	-	150	O
neuroleptic	-	158	O
therapy	-	170	O
.	-	177	O

Its	1786266	179	O
occurrence	-	183	O
in	-	194	O
a	-	197	O
patient	-	199	O
being	-	207	O
treated	-	213	O
with	-	221	O
imipramine	-	226	B
is	-	237	O
described	-	240	O
,	-	249	O
representing	-	251	O
the	-	264	O
first	-	268	O
reported	-	274	O
case	-	283	O
of	-	288	O
this	-	291	O
syndrome	-	296	O
in	-	305	O
conjunction	-	308	O
with	-	320	O
antidepressants	-	325	B
.	-	340	O

Repeated	1786266	342	O
cerebral	-	351	O
perfusion	-	360	O
SPECT	-	370	O
scans	-	376	O
revealed	-	382	O
decreased	-	391	O
basal	-	401	O
ganglia	-	407	O
perfusion	-	415	O
while	-	425	O
the	-	431	O
movement	-	435	O
disorder	-	444	O
was	-	453	O
present	-	457	O
,	-	464	O
and	-	466	O
a	-	470	O
return	-	472	O
to	-	479	O
normal	-	482	O
perfusion	-	489	O
when	-	499	O
the	-	504	O
rabbit	-	508	O
syndrome	-	515	O
resolved	-	524	O
.	-	532	O

Acute	1835291	0	O
bronchodilating	-	6	O
effects	-	22	O
of	-	30	O
ipratropium	-	33	B
bromide	-	45	I
and	-	53	O
theophylline	-	57	B
in	-	70	O
chronic	-	73	O
obstructive	-	81	O
pulmonary	-	93	O
disease	-	103	O
.	-	110	O

The	1835291	112	O
bronchodilator	-	116	O
effects	-	131	O
of	-	139	O
a	-	142	O
single	-	144	O
dose	-	151	O
of	-	156	O
ipratropium	-	159	B
bromide	-	171	I
aerosol	-	179	O
(	-	187	O
36	-	188	O
micrograms	-	191	O
)	-	201	O
and	-	203	O
short	-	207	O
-	-	212	O
acting	-	213	O
theophylline	-	220	B
tablets	-	233	O
(	-	241	O

dose	1835291	242	O
titrated	-	247	O
to	-	256	O
produce	-	259	O
serum	-	267	O
levels	-	273	O
of	-	280	O
10	-	283	O
-	-	285	O
20	-	286	O
micrograms	-	289	O
/	-	299	O
mL	-	300	O
)	-	302	O
were	-	304	O
compared	-	309	O
in	-	318	O
a	-	321	O
double	-	323	O
-	-	329	O
blind	-	330	O
,	-	335	O
placebo	-	337	O
-	-	344	O
controlled	-	345	O
crossover	-	356	O
study	-	366	O
in	-	372	O
21	-	375	O
patients	-	378	O
with	-	387	O
stable	-	392	O
,	-	398	O
chronic	-	400	O
obstructive	-	408	O
pulmonary	-	420	O
disease	-	430	O
.	-	437	O

Mean	1835291	439	O
peak	-	444	O
forced	-	449	O
expiratory	-	456	O
volume	-	467	O
in	-	474	O
1	-	477	O
second	-	479	O
(	-	486	O
FEV1	-	487	O
)	-	491	O
increases	-	493	O
over	-	503	O
baseline	-	508	O
and	-	517	O
the	-	521	O
proportion	-	525	O
of	-	536	O
patients	-	539	O
attaining	-	548	O
at	-	558	O
least	-	561	O
a	-	567	O
15	-	569	O
%	-	571	O
increase	-	573	O
in	-	582	O
the	-	585	O
FEV1	-	589	O
(	-	594	O
responders	-	595	O
)	-	605	O
were	-	607	O
31	-	612	O
%	-	614	O
and	-	616	O
90	-	620	O
%	-	622	O
,	-	623	O
respectively	-	625	O
,	-	637	O
for	-	639	O
ipratropium	-	643	B
and	-	655	O
17	-	659	O
%	-	661	O
and	-	663	O
50	-	667	O
%	-	669	O
,	-	670	O
respectively	-	672	O
,	-	684	O
for	-	686	O
theophylline	-	690	B
.	-	702	O

The	1835291	704	O
average	-	708	O
FEV1	-	716	O
increases	-	721	O
during	-	731	O
the	-	738	O
6	-	742	O
-	-	743	O
hour	-	744	O
observation	-	749	O
period	-	761	O
were	-	768	O
18	-	773	O
%	-	775	O
for	-	777	O
ipratropium	-	781	B
and	-	793	O
8	-	797	O
%	-	798	O
for	-	800	O
theophylline	-	804	B
.	-	816	O

The	1835291	818	O
mean	-	822	O
duration	-	827	O
of	-	836	O
action	-	839	O
was	-	846	O
3	-	850	O
.	-	851	O
8	-	852	O
hours	-	854	O
with	-	860	O
ipratropium	-	865	B
and	-	877	O
2	-	881	O
.	-	882	O
4	-	883	O
hours	-	885	O
with	-	891	O
theophylline	-	896	B
.	-	908	O

While	1835291	910	O
side	-	916	O
effects	-	921	O
were	-	929	O
rare	-	934	O
,	-	938	O
those	-	940	O
experienced	-	946	O
after	-	958	O
theophylline	-	964	B
use	-	977	O
did	-	981	O
involve	-	985	O
the	-	993	O
cardiovascular	-	997	O
and	-	1012	O
gastrointestinal	-	1016	O
systems	-	1033	O
.	-	1040	O

These	1835291	1042	O
results	-	1048	O
show	-	1056	O
that	-	1061	O
ipratropium	-	1066	B
is	-	1078	O
a	-	1081	O
more	-	1083	O
potent	-	1088	O
bronchodilator	-	1095	O
than	-	1110	O
oral	-	1115	O
theophylline	-	1120	B
in	-	1133	O
patients	-	1136	O
with	-	1145	O
chronic	-	1150	O
airflow	-	1158	O
obstruction	-	1166	O
.	-	1177	O

Irreversible	1919871	0	O
damage	-	13	O
to	-	20	O
the	-	23	O
medullary	-	27	O
interstitium	-	37	O
in	-	50	O
experimental	-	53	O
analgesic	-	66	O
nephropathy	-	76	O
in	-	88	O
F344	-	91	O
rats	-	96	O
.	-	100	O

Renal	1919871	102	O
papillary	-	108	O
necrosis	-	118	O
(	-	127	O
RPN	-	128	O
)	-	131	O
and	-	133	O
a	-	137	O
decreased	-	139	O
urinary	-	149	O
concentrating	-	157	O
ability	-	171	O
developed	-	179	O
during	-	189	O
continuous	-	196	O
long	-	207	O
-	-	211	O
term	-	212	O
treatment	-	217	O
with	-	227	O
aspirin	-	232	B
and	-	240	O
paracetamol	-	244	B
in	-	256	O
female	-	259	O
Fischer	-	266	O
344	-	274	O
rats	-	278	O
.	-	282	O

Renal	1919871	284	O
structure	-	290	O
and	-	300	O
concentrating	-	304	O
ability	-	318	O
were	-	326	O
examined	-	331	O
after	-	340	O
a	-	346	O
recovery	-	348	O
period	-	357	O
of	-	364	O
up	-	367	O
to	-	370	O
18	-	373	O
weeks	-	376	O
,	-	381	O
when	-	383	O
no	-	388	O
analgesics	-	391	O
were	-	402	O
given	-	407	O
,	-	412	O
to	-	414	O
investigate	-	417	O
whether	-	429	O
the	-	437	O
analgesic	-	441	O
-	-	450	O
induced	-	451	O
changes	-	459	O
were	-	467	O
reversible	-	472	O
.	-	482	O

There	1919871	484	O
was	-	490	O
no	-	494	O
evidence	-	497	O
of	-	506	O
repair	-	509	O
to	-	516	O
the	-	519	O
damaged	-	523	O
medullary	-	531	O
interstitial	-	541	O
matrix	-	554	O
,	-	560	O
or	-	562	O
proliferation	-	565	O
of	-	579	O
remaining	-	582	O
undamaged	-	592	O
type	-	602	O
1	-	607	O
medullary	-	609	O
interstitial	-	619	O
cells	-	632	O
after	-	638	O
the	-	644	O
recovery	-	648	O
period	-	657	O
following	-	664	O
analgesic	-	674	O
treatment	-	684	O
.	-	693	O

The	1919871	695	O
recovery	-	699	O
of	-	708	O
urinary	-	711	O
concentrating	-	719	O
ability	-	733	O
was	-	741	O
related	-	745	O
to	-	753	O
the	-	756	O
length	-	760	O
of	-	767	O
analgesic	-	770	O
treatment	-	780	O
and	-	790	O
the	-	794	O
extent	-	798	O
of	-	805	O
the	-	808	O
resulting	-	812	O
inner	-	822	O
medullary	-	828	O
structural	-	838	O
damage	-	849	O
.	-	855	O

During	1919871	857	O
the	-	864	O
early	-	868	O
stages	-	874	O
of	-	881	O
analgesic	-	884	O
treatment	-	894	O
,	-	903	O
the	-	905	O
changes	-	909	O
in	-	917	O
urinary	-	920	O
concentrating	-	928	O
ability	-	942	O
were	-	950	O
reversible	-	955	O
,	-	965	O
but	-	967	O
after	-	971	O
prolonged	-	977	O
analgesic	-	987	O
treatment	-	997	O
,	-	1006	O
maximum	-	1008	O
urinary	-	1016	O
concentrating	-	1024	O
ability	-	1038	O
failed	-	1046	O
to	-	1053	O
recover	-	1056	O
.	-	1063	O

This	1919871	1065	O
study	-	1070	O
shows	-	1076	O
that	-	1082	O
prolonged	-	1087	O
analgesic	-	1097	O
treatment	-	1107	O
in	-	1117	O
Fischer	-	1120	O
344	-	1128	O
rats	-	1132	O
causes	-	1137	O
progressive	-	1144	O
and	-	1156	O
irreversible	-	1160	O
damage	-	1173	O
to	-	1180	O
the	-	1183	O
interstitial	-	1187	O
matrix	-	1200	O
and	-	1207	O
type	-	1211	O
1	-	1216	O
interstitial	-	1218	O
cells	-	1231	O
leading	-	1237	O
to	-	1245	O
RPN	-	1248	O
.	-	1251	O

The	1919871	1253	O
associated	-	1257	O
urinary	-	1268	O
concentrating	-	1276	O
defect	-	1290	O
is	-	1297	O
reversible	-	1300	O
only	-	1311	O
during	-	1316	O
the	-	1323	O
early	-	1327	O
stages	-	1333	O
of	-	1340	O
structural	-	1343	O
damage	-	1354	O
to	-	1361	O
the	-	1364	O
inner	-	1368	O
medulla	-	1374	O
.	-	1381	O

Less	1987816	0	O
frequent	-	5	O
lithium	-	14	B
administration	-	22	O
and	-	37	O
lower	-	41	O
urine	-	47	O
volume	-	53	O
.	-	59	O

OBJECTIVE	1987816	61	O
:	-	70	O
This	-	72	O
study	-	77	O
was	-	83	O
designed	-	87	O
to	-	96	O
determine	-	99	O
whether	-	109	O
patients	-	117	O
maintained	-	126	O
on	-	137	O
a	-	140	O
regimen	-	142	O
of	-	150	O
lithium	-	153	B
on	-	161	O
a	-	164	O
once	-	166	O
-	-	170	O
per	-	171	O
-	-	174	O
day	-	175	O
schedule	-	179	O
have	-	188	O
lower	-	193	O
urine	-	199	O
volumes	-	205	O
than	-	213	O
do	-	218	O
patients	-	221	O
receiving	-	230	O
multiple	-	240	O
doses	-	249	O
per	-	255	O
day	-	259	O
.	-	262	O

METHOD	1987816	264	O
:	-	270	O

This	1987816	272	O
was	-	277	O
a	-	281	O
cross	-	283	O
-	-	288	O
sectional	-	289	O
study	-	299	O
of	-	305	O
85	-	308	O
patients	-	311	O
from	-	320	O
a	-	325	O
lithium	-	327	B
clinic	-	335	O
who	-	342	O
received	-	346	O
different	-	355	O
dose	-	365	O
schedules	-	370	O
.	-	379	O

Patients	1987816	381	O
were	-	390	O
admitted	-	395	O
to	-	404	O
the	-	407	O
hospital	-	411	O
for	-	420	O
measurement	-	424	O
of	-	436	O
lithium	-	439	B
level	-	447	O
,	-	452	O
creatinine	-	454	B
clearance	-	465	O
,	-	474	O
urine	-	476	O
volume	-	482	O
,	-	488	O
and	-	490	O
maximum	-	494	O
osmolality	-	502	O
.	-	512	O

RESULTS	1987816	514	O
:	-	521	O

Multiple	1987816	523	O
daily	-	532	O
doses	-	538	O
of	-	544	O
lithium	-	547	B
were	-	555	O
associated	-	560	O
with	-	571	O
higher	-	576	O
urine	-	583	O
volumes	-	589	O
.	-	596	O

The	1987816	598	O
dosing	-	602	O
schedule	-	609	O
,	-	617	O
duration	-	619	O
of	-	628	O
lithium	-	631	B
treatment	-	639	O
,	-	648	O
and	-	650	O
daily	-	654	O
dose	-	660	O
of	-	665	O
lithium	-	668	B
did	-	676	O
not	-	680	O
affect	-	684	O
maximum	-	691	O
osmolality	-	699	O
or	-	710	O
creatinine	-	713	B
clearance	-	724	O
.	-	733	O

CONCLUSIONS	1987816	735	O
:	-	746	O

Urine	1987816	748	O
volume	-	754	O
can	-	761	O
be	-	765	O
reduced	-	768	O
by	-	776	O
giving	-	779	O
lithium	-	786	B
once	-	794	O
daily	-	799	O
and	-	805	O
/	-	808	O
or	-	809	O
by	-	812	O
lowering	-	815	O
the	-	824	O
total	-	828	O
daily	-	834	O
dose	-	840	O
.	-	844	O

Lithium	1987816	846	B
-	-	853	O
induced	-	854	O
polyuria	-	862	O
seems	-	871	O
to	-	877	O
be	-	880	O
related	-	883	O
to	-	891	O
extrarenal	-	894	O
as	-	905	O
well	-	908	O
as	-	913	O
to	-	916	O
renal	-	919	O
effects	-	925	O
.	-	932	O

Effect	2054792	0	O
of	-	7	O
adriamycin	-	10	B
combined	-	21	O
with	-	30	O
whole	-	35	O
body	-	41	O
hyperthermia	-	46	O
on	-	59	O
tumor	-	62	O
and	-	68	O
normal	-	72	O
tissues	-	79	O
.	-	86	O

Thermal	2054792	88	O
enhancement	-	96	O
of	-	108	O
Adriamycin	-	111	B
-	-	121	O
mediated	-	122	O
antitumor	-	131	O
activity	-	141	O
and	-	150	O
normal	-	154	O
tissue	-	161	O
toxicities	-	168	O
by	-	179	O
whole	-	182	O
body	-	188	O
hyperthermia	-	193	O
were	-	206	O
compared	-	211	O
using	-	220	O
a	-	226	O
F344	-	228	O
rat	-	233	O
model	-	237	O
.	-	242	O

Antitumor	2054792	244	O
activity	-	254	O
was	-	263	O
studied	-	267	O
using	-	275	O
a	-	281	O
tumor	-	283	O
growth	-	289	O
delay	-	296	O
assay	-	302	O
.	-	307	O

Acute	2054792	309	O
normal	-	315	O
tissue	-	322	O
toxicities	-	329	O
(	-	340	O
i	-	341	O
.	-	342	O
e	-	343	O
.	-	344	O
,	-	345	O
leukopenia	-	347	O
and	-	358	O
thrombocytopenia	-	362	O
)	-	378	O
and	-	380	O
late	-	384	O
normal	-	389	O
tissue	-	396	O
toxicities	-	403	O
(	-	414	O
i	-	415	O
.	-	416	O
e	-	417	O
.	-	418	O
,	-	419	O
myocardial	-	421	O
and	-	432	O
kidney	-	436	O
injury	-	443	O
)	-	449	O
were	-	451	O
evaluated	-	456	O
by	-	466	O
functional	-	469	O
/	-	479	O
physiological	-	480	O
assays	-	494	O
and	-	501	O
by	-	505	O
morphological	-	508	O
techniques	-	522	O
.	-	532	O

Whole	2054792	534	O
body	-	540	O
hyperthermia	-	545	O
(	-	558	O
120	-	559	O
min	-	563	O
at	-	567	O
41	-	570	O
.	-	572	O
5	-	573	O
degrees	-	575	O
C	-	583	O
)	-	584	O
enhanced	-	586	O
both	-	595	O
Adriamycin	-	600	B
-	-	610	O
mediated	-	611	O
antitumor	-	620	O
activity	-	630	O
and	-	639	O
toxic	-	643	O
side	-	649	O
effects	-	654	O
.	-	661	O

The	2054792	663	O
thermal	-	667	O
enhancement	-	675	O
ratio	-	687	O
calculated	-	693	O
for	-	704	O
antitumor	-	708	O
activity	-	718	O
was	-	727	O
1	-	731	O
.	-	732	O
6	-	733	O
.	-	734	O

Thermal	2054792	736	O
enhancement	-	744	O
ratios	-	756	O
estimated	-	763	O
for	-	773	O
""""	-	777	O
acute	-	778	O
""""	-	783	O
hematological	-	785	O
changes	-	799	O
were	-	807	O
1	-	812	O
.	-	813	O
3	-	814	O
,	-	815	O
whereas	-	817	O
those	-	825	O
estimated	-	831	O
for	-	841	O
""""	-	845	O
late	-	846	O
""""	-	850	O
damage	-	852	O
(	-	859	O
based	-	860	O
on	-	866	O
morphological	-	869	O
cardiac	-	883	O
and	-	891	O
renal	-	895	O
lesions	-	901	O
)	-	908	O
varied	-	910	O
between	-	917	O
2	-	925	O
.	-	926	O
4	-	927	O
and	-	929	O
4	-	933	O
.	-	934	O
3	-	935	O
.	-	936	O

Thus	2054792	938	O
,	-	942	O
while	-	944	O
whole	-	950	O
body	-	956	O
hyperthermia	-	961	O
enhances	-	974	O
Adriamycin	-	983	B
-	-	993	O
mediated	-	994	O
antitumor	-	1003	O
effect	-	1013	O
,	-	1019	O
normal	-	1021	O
tissue	-	1028	O
toxicity	-	1035	O
is	-	1044	O
also	-	1047	O
increased	-	1052	O
,	-	1061	O
and	-	1063	O
the	-	1067	O
potential	-	1071	O
therapeutic	-	1081	O
gain	-	1093	O
of	-	1098	O
the	-	1101	O
combined	-	1105	O
modality	-	1114	O
treatment	-	1123	O
is	-	1133	O
eroded	-	1136	O
.	-	1142	O

Prazosin	2304736	0	B
-	-	8	O
induced	-	9	O
stress	-	17	O
incontinence	-	24	O
.	-	36	O

A	2304736	38	O
case	-	40	O
of	-	45	O
genuine	-	48	O
stress	-	56	O
incontinence	-	63	O
due	-	76	O
to	-	80	O
prazosin	-	83	B
,	-	91	O
a	-	93	O
common	-	95	O
antihypertensive	-	102	O
drug	-	119	O
,	-	123	O
is	-	125	O
presented	-	128	O
.	-	137	O

Prazosin	2304736	139	B
exerts	-	148	O
its	-	155	O
antihypertensive	-	159	O
effects	-	176	O
through	-	184	O
vasodilatation	-	192	O
caused	-	207	O
by	-	214	O
selective	-	217	O
blockade	-	227	O
of	-	236	O
postsynaptic	-	239	O
alpha	-	252	O
-	-	257	O
1	-	258	O
adrenergic	-	260	O
receptors	-	271	O
.	-	280	O

As	2304736	282	O
an	-	285	O
alpha	-	288	O
-	-	293	O
blocker	-	294	O
,	-	301	O
it	-	303	O
also	-	306	O
exerts	-	311	O
a	-	318	O
significant	-	320	O
relaxant	-	332	O
effect	-	341	O
on	-	348	O
the	-	351	O
bladder	-	355	O
neck	-	363	O
and	-	368	O
urethra	-	372	O
.	-	379	O

The	2304736	381	O
patient	-	385	O
's	-	392	O
clinical	-	395	O
course	-	404	O
is	-	411	O
described	-	414	O
and	-	424	O
correlated	-	428	O
with	-	439	O
initial	-	444	O
urodynamic	-	452	O
studies	-	463	O
while	-	471	O
on	-	477	O
prazosin	-	480	B
and	-	489	O
subsequent	-	493	O
studies	-	504	O
while	-	512	O
taking	-	518	O
verapamil	-	525	B
.	-	534	O

Her	2304736	536	O
incontinence	-	540	O
resolved	-	553	O
with	-	562	O
the	-	567	O
change	-	571	O
of	-	578	O
medication	-	581	O
.	-	591	O

The	2304736	593	O
restoration	-	597	O
of	-	609	O
continence	-	612	O
was	-	623	O
accompanied	-	627	O
by	-	639	O
a	-	642	O
substantial	-	644	O
rise	-	656	O
in	-	661	O
maximum	-	664	O
urethral	-	672	O
pressure	-	681	O
,	-	689	O
maximum	-	691	O
urethral	-	699	O
closure	-	708	O
pressure	-	716	O
,	-	724	O
and	-	726	O
functional	-	730	O
urethral	-	741	O
length	-	750	O
.	-	756	O

Patients	2304736	758	O
who	-	767	O
present	-	771	O
with	-	779	O
stress	-	784	O
incontinence	-	791	O
while	-	804	O
taking	-	810	O
prazosin	-	817	B
should	-	826	O
change	-	833	O
their	-	840	O
antihypertensive	-	846	O
medication	-	863	O
before	-	874	O
considering	-	881	O
surgery	-	893	O
,	-	900	O
because	-	902	O
their	-	910	O
incontinence	-	916	O
may	-	929	O
resolve	-	933	O
spontaneously	-	941	O
with	-	955	O
a	-	960	O
change	-	962	O
in	-	969	O
drug	-	972	O
therapy	-	977	O
.	-	984	O

Myocardial	2312209	0	O
infarction	-	11	O
following	-	22	O
sublingual	-	32	O
administration	-	43	O
of	-	58	O
isosorbide	-	61	B
dinitrate	-	72	I
.	-	81	O

A	2312209	83	O
78	-	85	O
-	-	87	O
year	-	88	O
-	-	92	O
old	-	93	O
with	-	97	O
healed	-	102	O
septal	-	109	O
necrosis	-	116	O
suffered	-	125	O
a	-	134	O
recurrent	-	136	O
myocardial	-	146	O
infarction	-	157	O
of	-	168	O
the	-	171	O
anterior	-	175	O
wall	-	184	O
following	-	189	O
the	-	199	O
administration	-	203	O
of	-	218	O
isosorbide	-	221	B
dinitrate	-	232	I
5	-	242	O
mg	-	244	O
sublingually	-	247	O
.	-	259	O

After	2312209	261	O
detailing	-	267	O
the	-	277	O
course	-	281	O
of	-	288	O
events	-	291	O
,	-	297	O
we	-	299	O
discuss	-	302	O
the	-	310	O
role	-	314	O
of	-	319	O
paradoxical	-	322	O
coronary	-	334	O
spasm	-	343	O
and	-	349	O
hypotension	-	353	O
-	-	364	O
mediated	-	365	O
myocardial	-	374	O
ischemia	-	385	O
occurring	-	394	O
downstream	-	404	O
to	-	415	O
significant	-	418	O
coronary	-	430	O
arterial	-	439	O
stenosis	-	448	O
in	-	457	O
the	-	460	O
pathophysiology	-	464	O
of	-	480	O
acute	-	483	O
coronary	-	489	O
insufficiency	-	498	O
.	-	511	O

Fluoxetine	2549018	0	B
-	-	10	O
induced	-	11	O
akathisia	-	19	O
:	-	28	O
clinical	-	30	O
and	-	39	O
theoretical	-	43	O
implications	-	55	O
.	-	67	O

Five	2549018	69	O
patients	-	74	O
receiving	-	83	O
fluoxetine	-	93	B
for	-	104	O
the	-	108	O
treatment	-	112	O
of	-	122	O
obsessive	-	125	O
compulsive	-	135	O
disorder	-	146	O
or	-	155	O
major	-	158	O
depression	-	164	O
developed	-	175	O
akathisia	-	185	O
.	-	194	O

The	2549018	196	O
typical	-	200	O
fluoxetine	-	208	B
-	-	218	O
induced	-	219	O
symptoms	-	227	O
of	-	236	O
restlessness	-	239	O
,	-	251	O
constant	-	253	O
pacing	-	262	O
,	-	268	O
purposeless	-	270	O
movements	-	282	O
of	-	292	O
the	-	295	O
feet	-	299	O
and	-	304	O
legs	-	308	O
,	-	312	O
and	-	314	O
marked	-	318	O
anxiety	-	325	O
were	-	333	O
indistinguishable	-	338	O
from	-	356	O
those	-	361	O
of	-	367	O
neuroleptic	-	370	O
-	-	381	O
induced	-	382	O
akathisia	-	390	O
.	-	399	O

Three	2549018	401	O
patients	-	407	O
who	-	416	O
had	-	420	O
experienced	-	424	O
neuroleptic	-	436	O
-	-	447	O
induced	-	448	O
akathisia	-	456	O
in	-	466	O
the	-	469	O
past	-	473	O
reported	-	478	O
that	-	487	O
the	-	492	O
symptoms	-	496	O
of	-	505	O
fluoxetine	-	508	B
-	-	518	O
induced	-	519	O
akathisia	-	527	O
were	-	537	O
identical	-	542	O
,	-	551	O
although	-	553	O
somewhat	-	562	O
milder	-	571	O
.	-	577	O

Akathisia	2549018	579	O
appeared	-	589	O
to	-	598	O
be	-	601	O
a	-	604	O
common	-	606	O
side	-	613	O
effect	-	618	O
of	-	625	O
fluoxetine	-	628	B
and	-	639	O
generally	-	643	O
responded	-	653	O
well	-	663	O
to	-	668	O
treatment	-	671	O
with	-	681	O
the	-	686	O
beta	-	690	O
-	-	694	O
adrenergic	-	695	O
antagonist	-	706	O
propranolol	-	717	B
,	-	728	O
dose	-	730	O
reduction	-	735	O
,	-	744	O
or	-	746	O
both	-	749	O
.	-	753	O

The	2549018	755	O
authors	-	759	O
suggest	-	767	O
that	-	775	O
fluoxetine	-	780	B
-	-	790	O
induced	-	791	O
akathisia	-	799	O
may	-	809	O
be	-	813	O
caused	-	816	O
by	-	823	O
serotonergically	-	826	O
mediated	-	843	O
inhibition	-	852	O
of	-	863	O
dopaminergic	-	866	O
neurotransmission	-	879	O
and	-	897	O
that	-	901	O
the	-	906	O
pathophysiology	-	910	O
of	-	926	O
fluoxetine	-	929	B
-	-	939	O
induced	-	940	O
akathisia	-	948	O
and	-	958	O
tricyclic	-	962	O
antidepressant	-	972	B
-	-	986	O
induced	-	987	O
""""	-	995	O
jitteriness	-	996	O
""""	-	1007	O
may	-	1009	O
be	-	1013	O
identical	-	1016	O
.	-	1025	O

Chronic	2611118	0	O
active	-	8	O
hepatitis	-	15	O
associated	-	25	O
with	-	36	O
diclofenac	-	41	B
sodium	-	52	I
therapy	-	59	O
.	-	66	O

Diclofenac	2611118	68	B
sodium	-	79	I
(	-	86	O
Voltarol	-	87	B
,	-	95	O
Geigy	-	97	O
Pharmaceuticals	-	103	O
)	-	118	O
is	-	120	O
a	-	123	O
non	-	125	O
-	-	128	O
steroidal	-	129	O
anti	-	139	O
-	-	143	O
inflammatory	-	144	O
derivative	-	157	O
of	-	168	O
phenylacetic	-	171	B
acid	-	184	I
.	-	188	O

Although	2611118	190	O
generally	-	199	O
well	-	209	O
-	-	213	O
tolerated	-	214	O
,	-	223	O
asymptomatic	-	225	O
abnormalities	-	238	O
of	-	252	O
liver	-	255	O
function	-	261	O
have	-	270	O
been	-	275	O
recorded	-	280	O
and	-	289	O
,	-	292	O
less	-	294	O
commonly	-	299	O
,	-	307	O
severe	-	309	O
hepatitis	-	316	O
induced	-	326	O
by	-	334	O
diclofenac	-	337	B
.	-	347	O

The	2611118	349	O
patient	-	353	O
described	-	361	O
developed	-	371	O
chronic	-	381	O
active	-	389	O
hepatitis	-	396	O
after	-	406	O
six	-	412	O
months	-	416	O
therapy	-	423	O
with	-	431	O
diclofenac	-	436	B
sodium	-	447	I
which	-	454	O
progressed	-	460	O
despite	-	471	O
the	-	479	O
withdrawal	-	483	O
of	-	494	O
the	-	497	O
drug	-	501	O
,	-	505	O
a	-	507	O
finding	-	509	O
not	-	517	O
previously	-	521	O
reported	-	532	O
.	-	540	O

Stroke	2673163	0	O
associated	-	7	O
with	-	18	O
cocaine	-	23	B
use	-	31	O
.	-	34	O

We	2673163	36	O
describe	-	39	O
eight	-	48	O
patients	-	54	O
in	-	63	O
whom	-	66	O
cocaine	-	71	B
use	-	79	O
was	-	83	O
related	-	87	O
to	-	95	O
stroke	-	98	O
and	-	105	O
review	-	109	O
39	-	116	O
cases	-	119	O
from	-	125	O
the	-	130	O
literature	-	134	O
.	-	144	O

Among	2673163	146	O
these	-	152	O
47	-	158	O
patients	-	161	O
the	-	170	O
mean	-	174	O
(	-	179	O
+	-	180	O
/	-	181	O
-	-	182	O
SD	-	184	O
)	-	186	O
age	-	188	O
was	-	192	O
32	-	196	O
.	-	198	O
5	-	199	O
+	-	201	O
/	-	202	O
-	-	203	O

12	2673163	205	O
.	-	207	O
1	-	208	O
years	-	210	O
;	-	215	O
76	-	217	O
%	-	219	O
(	-	221	O
34	-	222	O
/	-	224	O
45	-	225	O
)	-	227	O
were	-	229	O
men	-	234	O
.	-	237	O

Stroke	2673163	239	O
followed	-	246	O
cocaine	-	255	B
use	-	263	O
by	-	267	O
inhalation	-	270	O
,	-	280	O
intranasal	-	282	O
,	-	292	O
intravenous	-	294	O
,	-	305	O
and	-	307	O
intramuscular	-	311	O
routes	-	325	O
.	-	331	O

Intracranial	2673163	333	O
aneurysms	-	346	O
or	-	356	O
arteriovenous	-	359	O
malformations	-	373	O
were	-	387	O
present	-	392	O
in	-	400	O
17	-	403	O
of	-	406	O
32	-	409	O
patients	-	412	O
studied	-	421	O
angiographically	-	429	O
or	-	446	O
at	-	449	O
autopsy	-	452	O
;	-	459	O
cerebral	-	461	O
vasculitis	-	470	O
was	-	481	O
present	-	485	O
in	-	493	O
two	-	496	O
patients	-	500	O
.	-	508	O

Cerebral	2673163	510	O
infarction	-	519	O
occurred	-	530	O
in	-	539	O
10	-	542	O
patients	-	545	O
(	-	554	O
22	-	555	O
%	-	557	O
)	-	558	O
,	-	559	O
intracerebral	-	561	O
hemorrhage	-	575	O
in	-	586	O
22	-	589	O
(	-	592	O
49	-	593	O
%	-	595	O
)	-	596	O
,	-	597	O
and	-	599	O
subarachnoid	-	603	O
hemorrhage	-	616	O
in	-	627	O
13	-	630	O
(	-	633	O
29	-	634	O
%	-	636	O
)	-	637	O
.	-	638	O

These	2673163	640	O
data	-	646	O
indicate	-	651	O
that	-	660	O
(	-	665	O
1	-	666	O
)	-	667	O
the	-	669	O
apparent	-	673	O
incidence	-	682	O
of	-	692	O
stroke	-	695	O
related	-	702	O
to	-	710	O
cocaine	-	713	B
use	-	721	O
is	-	725	O
increasing	-	728	O
;	-	738	O
(	-	740	O
2	-	741	O
)	-	742	O
cocaine	-	744	B
-	-	751	O
associated	-	752	O
stroke	-	763	O
occurs	-	770	O
primarily	-	777	O
in	-	787	O
young	-	790	O
adults	-	796	O
;	-	802	O
(	-	804	O
3	-	805	O
)	-	806	O
stroke	-	808	O
may	-	815	O
follow	-	819	O
any	-	826	O
route	-	830	O
of	-	836	O
cocaine	-	839	B
administration	-	847	O
;	-	861	O
(	-	863	O
4	-	864	O
)	-	865	O
stroke	-	867	O
after	-	874	O
cocaine	-	880	B
use	-	888	O
is	-	892	O
frequently	-	895	O
associated	-	906	O
with	-	917	O
intracranial	-	922	O
aneurysms	-	935	O
and	-	945	O
arteriovenous	-	949	O
malformations	-	963	O
;	-	976	O
and	-	978	O
(	-	982	O
5	-	983	O
)	-	984	O
in	-	986	O
cocaine	-	989	B
-	-	996	O
associated	-	997	O
stroke	-	1008	O
,	-	1014	O
the	-	1016	O
frequency	-	1020	O
of	-	1030	O
intracranial	-	1033	O
hemorrhage	-	1046	O
exceeds	-	1057	O
that	-	1065	O
of	-	1070	O
cerebral	-	1073	O
infarction	-	1082	O
.	-	1092	O

Glyburide	3107448	0	B
-	-	9	O
induced	-	10	O
hepatitis	-	18	O
.	-	27	O

Drug	3107448	29	O
-	-	33	O
induced	-	34	O
hepatotoxicity	-	42	O
,	-	56	O
although	-	58	O
common	-	67	O
,	-	73	O
has	-	75	O
been	-	79	O
reported	-	84	O
only	-	93	O
infrequently	-	98	O
with	-	111	O
sulfonylureas	-	116	B
.	-	129	O

For	3107448	131	O
glyburide	-	135	B
,	-	144	O
a	-	146	O
second	-	148	O
-	-	154	O
generation	-	155	O
sulfonylurea	-	166	B
,	-	178	O
only	-	180	O
two	-	185	O
brief	-	189	O
reports	-	195	O
of	-	203	O
hepatotoxicity	-	206	O
exist	-	221	O
.	-	226	O

Two	3107448	228	O
patients	-	232	O
with	-	241	O
type	-	246	O
II	-	251	O
diabetes	-	254	O
mellitus	-	263	O
developed	-	272	O
an	-	282	O
acute	-	285	O
hepatitis	-	291	O
-	-	300	O
like	-	301	O
syndrome	-	306	O
soon	-	315	O
after	-	320	O
initiation	-	326	O
of	-	337	O
glyburide	-	340	B
therapy	-	350	O
.	-	357	O

There	3107448	359	O
was	-	365	O
no	-	369	O
serologic	-	372	O
evidence	-	382	O
of	-	391	O
viral	-	394	O
infection	-	400	O
,	-	409	O
and	-	411	O
a	-	415	O
liver	-	417	O
biopsy	-	423	O
sample	-	430	O
showed	-	437	O
a	-	444	O
histologic	-	446	O
pattern	-	457	O
consistent	-	465	O
with	-	476	O
drug	-	481	O
-	-	485	O
induced	-	486	O
hepatitis	-	494	O
.	-	503	O

Both	3107448	505	O
patients	-	510	O
recovered	-	519	O
quickly	-	529	O
after	-	537	O
stopping	-	543	O
glyburide	-	552	B
therapy	-	562	O
and	-	570	O
have	-	574	O
remained	-	579	O
well	-	588	O
for	-	593	O
a	-	597	O
follow	-	599	O
-	-	605	O
up	-	606	O
period	-	609	O
of	-	616	O
1	-	619	O
year	-	621	O
.	-	625	O

Glyburide	3107448	627	B
can	-	637	O
produce	-	641	O
an	-	649	O
acute	-	652	O
hepatitis	-	658	O
-	-	667	O
like	-	668	O
illness	-	673	O
in	-	681	O
some	-	684	O
persons	-	689	O
.	-	696	O

Systolic	3341566	0	O
pressure	-	9	O
variation	-	18	O
is	-	28	O
greater	-	31	O
during	-	39	O
hemorrhage	-	46	O
than	-	57	O
during	-	62	O
sodium	-	69	B
nitroprusside	-	76	I
-	-	89	O
induced	-	90	O
hypotension	-	98	O
in	-	110	O
ventilated	-	113	O
dogs	-	124	O
.	-	128	O

The	3341566	130	O
systolic	-	134	O
pressure	-	143	O
variation	-	152	O
(	-	162	O
SPV	-	163	O
)	-	166	O
,	-	167	O
which	-	169	O
is	-	175	O
the	-	178	O
difference	-	182	O
between	-	193	O
the	-	201	O
maximal	-	205	O
and	-	213	O
minimal	-	217	O
values	-	225	O
of	-	232	O
the	-	235	O
systolic	-	239	O
blood	-	248	O
pressure	-	254	O
(	-	263	O
SBP	-	264	O
)	-	267	O
after	-	269	O
one	-	275	O
positive	-	279	O
-	-	287	O
pressure	-	288	O
breath	-	297	O
,	-	303	O
was	-	305	O
studied	-	309	O
in	-	317	O
ventilated	-	320	O
dogs	-	331	O
subjected	-	336	O
to	-	346	O
hypotension	-	349	O
.	-	360	O

Mean	3341566	362	O
arterial	-	367	O
pressure	-	376	O
was	-	385	O
decreased	-	389	O
to	-	399	O
50	-	402	O
mm	-	405	O
Hg	-	408	O
for	-	411	O
30	-	415	O
minutes	-	418	O
either	-	426	O
by	-	433	O
hemorrhage	-	436	O
(	-	447	O
HEM	-	448	O
,	-	451	O
n	-	453	O
=	-	455	O
7	-	457	O
)	-	458	O
or	-	460	O
by	-	463	O
continuous	-	466	O
infusion	-	477	O
of	-	486	O
sodium	-	489	B
nitroprusside	-	496	I
(	-	510	O
SNP	-	511	B
,	-	514	O
n	-	516	O
=	-	518	O
7	-	520	O
)	-	521	O
.	-	522	O

During	3341566	524	O
HEM	-	531	O
-	-	534	O
induced	-	535	O
hypotension	-	543	O
the	-	555	O
cardiac	-	559	O
output	-	567	O
was	-	574	O
significantly	-	578	O
lower	-	592	O
and	-	598	O
systemic	-	602	O
vascular	-	611	O
resistance	-	620	O
higher	-	631	O
compared	-	638	O
with	-	647	O
that	-	652	O
in	-	657	O
the	-	660	O
SNP	-	664	B
group	-	668	O
.	-	673	O

The	3341566	675	O
systemic	-	679	O
,	-	687	O
central	-	689	O
venous	-	697	O
,	-	703	O
pulmonary	-	705	O
capillary	-	715	O
wedge	-	725	O
pressures	-	731	O
,	-	740	O
and	-	742	O
heart	-	746	O
rates	-	752	O
,	-	757	O
were	-	759	O
similar	-	764	O
in	-	772	O
the	-	775	O
two	-	779	O
groups	-	783	O
.	-	789	O

Analysis	3341566	791	O
of	-	800	O
the	-	803	O
respiratory	-	807	O
changes	-	819	O
in	-	827	O
the	-	830	O
arterial	-	834	O
pressure	-	843	O
waveform	-	852	O
enabled	-	861	O
differentiation	-	869	O
between	-	885	O
the	-	893	O
two	-	897	O
groups	-	901	O
.	-	907	O

The	3341566	909	O
SPV	-	913	O
during	-	917	O
hypotension	-	924	O
was	-	936	O
15	-	940	O
.	-	942	O
7	-	943	O
+	-	945	O
/	-	946	O
-	-	947	O

6	3341566	949	O
.	-	950	O
7	-	951	O
mm	-	953	O
Hg	-	956	O
in	-	959	O
the	-	962	O
HEM	-	966	O
group	-	970	O
,	-	975	O
compared	-	977	O
with	-	986	O
9	-	991	O
.	-	992	O
1	-	993	O
+	-	995	O
/	-	996	O
-	-	997	O

2	3341566	999	O
.	-	1000	O
0	-	1001	O
mm	-	1003	O
Hg	-	1006	O
in	-	1009	O
the	-	1012	O
SNP	-	1016	B
group	-	1020	O
(	-	1026	O
P	-	1027	O
less	-	1029	O
than	-	1034	O
0	-	1039	O
.	-	1040	O
02	-	1041	O
)	-	1043	O
.	-	1044	O

The	3341566	1046	O
delta	-	1050	O
down	-	1056	O
,	-	1060	O
which	-	1062	O
is	-	1068	O
the	-	1071	O
measure	-	1075	O
of	-	1083	O
decrease	-	1086	O
of	-	1095	O
SBP	-	1098	O
after	-	1102	O
a	-	1108	O
mechanical	-	1110	O
breath	-	1121	O
,	-	1127	O
was	-	1129	O
20	-	1133	O
.	-	1135	O
3	-	1136	O
+	-	1138	O
/	-	1139	O
-	-	1140	O

8	3341566	1142	O
.	-	1143	O
4	-	1144	O
and	-	1146	O
10	-	1150	O
.	-	1152	O
1	-	1153	O
+	-	1155	O
/	-	1156	O
-	-	1157	O

3	3341566	1159	O
.	-	1160	O
8	-	1161	O
mm	-	1163	O
Hg	-	1166	O
in	-	1169	O
the	-	1172	O
HEM	-	1176	O
and	-	1180	O
SNP	-	1184	B
groups	-	1188	O
,	-	1194	O
respectively	-	1196	O
,	-	1208	O
during	-	1210	O
hypotension	-	1217	O
(	-	1229	O
P	-	1230	O
less	-	1232	O
than	-	1237	O
0	-	1242	O
.	-	1243	O
02	-	1244	O
)	-	1246	O
.	-	1247	O

It	3341566	1249	O
is	-	1252	O
concluded	-	1255	O
that	-	1265	O
increases	-	1270	O
in	-	1280	O
the	-	1283	O
SPV	-	1287	O
and	-	1291	O
the	-	1295	O
delta	-	1299	O
down	-	1305	O
are	-	1310	O
characteristic	-	1314	O
of	-	1329	O
a	-	1332	O
hypotensive	-	1334	O
state	-	1346	O
due	-	1352	O
to	-	1356	O
a	-	1359	O
predominant	-	1361	O
decrease	-	1373	O
in	-	1382	O
preload	-	1385	O
.	-	1392	O

They	3341566	1394	O
are	-	1399	O
thus	-	1403	O
more	-	1408	O
important	-	1413	O
during	-	1423	O
absolute	-	1430	O
hypovolemia	-	1439	O
than	-	1451	O
during	-	1456	O
deliberate	-	1463	O
hypotension	-	1474	O
.	-	1485	O

Drug	3564823	0	O
-	-	4	O
induced	-	5	O
arterial	-	13	O
spasm	-	22	O
relieved	-	28	O
by	-	37	O
lidocaine	-	40	B
.	-	49	O

Case	3564823	51	O
report	-	56	O
.	-	62	O

Following	3564823	64	O
major	-	74	O
intracranial	-	80	O
surgery	-	93	O
in	-	101	O
a	-	104	O
35	-	106	O
-	-	108	O
year	-	109	O
-	-	113	O
old	-	114	O
man	-	118	O
,	-	121	O
sodium	-	123	B
pentothal	-	130	I
was	-	140	O
intravenously	-	144	O
infused	-	158	O
to	-	166	O
minimize	-	169	O
cerebral	-	178	O
ischaemia	-	187	O
.	-	196	O

Intense	3564823	198	O
vasospasm	-	206	O
with	-	216	O
threatened	-	221	O
gangrene	-	232	O
arose	-	241	O
in	-	247	O
the	-	250	O
arm	-	254	O
used	-	258	O
for	-	263	O
the	-	267	O
infusion	-	271	O
.	-	279	O

Since	3564823	281	O
the	-	287	O
cranial	-	291	O
condition	-	299	O
precluded	-	309	O
use	-	319	O
of	-	323	O
more	-	326	O
usual	-	331	O
methods	-	337	O
,	-	344	O
lidocaine	-	346	B
was	-	356	O
given	-	360	O
intra	-	366	O
-	-	371	O
arterially	-	372	O
,	-	382	O
with	-	384	O
careful	-	389	O
cardiovascular	-	397	O
monitoring	-	412	O
,	-	422	O
to	-	424	O
counteract	-	427	O
the	-	438	O
vasospasm	-	442	O
.	-	451	O

The	3564823	453	O
treatment	-	457	O
was	-	467	O
rapidly	-	471	O
successful	-	479	O
.	-	489	O

Cerebral	3676049	0	O
blood	-	9	O
flow	-	15	O
and	-	20	O
metabolism	-	24	O
during	-	35	O
isoflurane	-	42	B
-	-	52	O
induced	-	53	O
hypotension	-	61	O
in	-	73	O
patients	-	76	O
subjected	-	85	O
to	-	95	O
surgery	-	98	O
for	-	106	O
cerebral	-	110	O
aneurysms	-	119	O
.	-	128	O

Cerebral	3676049	130	O
blood	-	139	O
flow	-	145	O
and	-	150	O
cerebral	-	154	O
metabolic	-	163	O
rate	-	173	O
for	-	178	O
oxygen	-	182	B
were	-	189	O
measured	-	194	O
during	-	203	O
isoflurane	-	210	B
-	-	220	O
induced	-	221	O
hypotension	-	229	O
in	-	241	O
10	-	244	O
patients	-	247	O
subjected	-	256	O
to	-	266	O
craniotomy	-	269	O
for	-	280	O
clipping	-	284	O
of	-	293	O
a	-	296	O
cerebral	-	298	O
aneurysm	-	307	O
.	-	315	O

Flow	3676049	317	O
and	-	322	O
metabolism	-	326	O
were	-	337	O
measured	-	342	O
5	-	351	O
-	-	352	O
13	-	353	O
days	-	356	O
after	-	361	O
the	-	367	O
subarachnoid	-	371	O
haemorrhage	-	384	O
by	-	396	O
a	-	399	O
modification	-	401	O
of	-	414	O
the	-	417	O
classical	-	421	O
Kety	-	431	O
-	-	435	O
Schmidt	-	436	O
technique	-	444	O
using	-	454	O
xenon	-	460	B
-	-	465	O
133	-	466	O
i	-	470	O
.	-	471	O
v	-	472	O
.	-	473	O

Anaesthesia	3676049	475	O
was	-	487	O
maintained	-	491	O
with	-	502	O
an	-	507	O
inspired	-	510	O
isoflurane	-	519	B
concentration	-	530	O
of	-	544	O
0	-	547	O
.	-	548	O
75	-	549	O
%	-	551	O
(	-	553	O
plus	-	554	O
67	-	559	O
%	-	561	O
nitrous	-	563	B
oxide	-	571	I
in	-	577	O
oxygen	-	580	B
)	-	586	O
,	-	587	O
during	-	589	O
which	-	596	O
CBF	-	602	O
and	-	606	O
CMRO2	-	610	O
were	-	616	O
34	-	621	O
.	-	623	O
3	-	624	O
+	-	626	O
/	-	627	O
-	-	628	O

2	3676049	630	O
.	-	631	O
1	-	632	O
ml	-	634	O
/	-	636	O
100	-	637	O
g	-	641	O
min	-	643	O
-	-	646	O
1	-	647	O
and	-	649	O
2	-	653	O
.	-	654	O
32	-	655	O
+	-	658	O
/	-	659	O
-	-	660	O

0	3676049	662	O
.	-	663	O
16	-	664	O
ml	-	667	O
/	-	669	O
100	-	670	O
g	-	674	O
min	-	676	O
-	-	679	O
1	-	680	O
at	-	682	O
PaCO2	-	685	O
4	-	691	O
.	-	692	O
1	-	693	O
+	-	695	O
/	-	696	O
-	-	697	O

0	3676049	699	O
.	-	700	O
1	-	701	O
kPa	-	703	O
(	-	707	O
mean	-	708	O
+	-	713	O
/	-	714	O
-	-	715	O

SEM	3676049	717	O
)	-	720	O
.	-	721	O

Controlled	3676049	723	O
hypotension	-	734	O
to	-	746	O
an	-	749	O
average	-	752	O
MAP	-	760	O
of	-	764	O
50	-	767	O
-	-	769	O
55	-	770	O
mm	-	773	O

Hg	3676049	776	B
was	-	779	O
induced	-	783	O
by	-	791	O
increasing	-	794	O
the	-	805	O
dose	-	809	O
of	-	814	O
isoflurane	-	817	B
,	-	827	O
and	-	829	O
maintained	-	833	O
at	-	844	O
an	-	847	O
inspired	-	850	O
concentration	-	859	O
of	-	873	O
2	-	876	O
.	-	877	O
2	-	878	O
+	-	880	O
/	-	881	O
-	-	882	O

0	3676049	884	O
.	-	885	O
2	-	886	O
%	-	887	O
.	-	888	O

This	3676049	890	O
resulted	-	895	O
in	-	904	O
a	-	907	O
significant	-	909	O
decrease	-	921	O
in	-	930	O
CMRO2	-	933	O
(	-	939	O
to	-	940	O
1	-	943	O
.	-	944	O
73	-	945	O
+	-	948	O
/	-	949	O
-	-	950	O

0	3676049	952	O
.	-	953	O
16	-	954	O
ml	-	957	O
/	-	959	O
100	-	960	O
g	-	964	O
min	-	966	O
-	-	969	O
1	-	970	O
)	-	971	O
,	-	972	O
while	-	974	O
CBF	-	980	O
was	-	984	O
unchanged	-	988	O
.	-	997	O

After	3676049	999	O
the	-	1005	O
clipping	-	1009	O
of	-	1018	O
the	-	1021	O
aneurysm	-	1025	O
the	-	1034	O
isoflurane	-	1038	B
concentration	-	1049	O
was	-	1063	O
reduced	-	1067	O
to	-	1075	O
0	-	1078	O
.	-	1079	O
75	-	1080	O
%	-	1082	O
.	-	1083	O

There	3676049	1085	O
was	-	1091	O
a	-	1095	O
significant	-	1097	O
increase	-	1109	O
in	-	1118	O
CBF	-	1121	O
,	-	1124	O
although	-	1126	O
CMRO2	-	1135	O
was	-	1141	O
unchanged	-	1145	O
,	-	1154	O
compared	-	1156	O
with	-	1165	O
pre	-	1170	O
-	-	1173	O
hypotensive	-	1174	O
values	-	1186	O
.	-	1192	O

These	3676049	1194	O
changes	-	1200	O
might	-	1208	O
offer	-	1214	O
protection	-	1220	O
to	-	1231	O
brain	-	1234	O
tissue	-	1240	O
during	-	1247	O
periods	-	1254	O
of	-	1262	O
induced	-	1265	O
hypotension	-	1273	O
.	-	1284	O

Allergic	3719553	0	O
reaction	-	9	O
to	-	18	O
5	-	21	B
-	-	22	I
fluorouracil	-	23	I
infusion	-	36	O
.	-	44	O

An	3719553	46	O
allergic	-	49	O
reaction	-	58	O
consisting	-	67	O
of	-	78	O
angioneurotic	-	81	O
edema	-	95	O
secondary	-	101	O
to	-	111	O
continuous	-	114	O
infusion	-	125	O
5	-	134	B
-	-	135	I
fluorouracil	-	136	I
occurred	-	149	O
in	-	158	O
a	-	161	O
patient	-	163	O
with	-	171	O
recurrent	-	176	O
carcinoma	-	186	O
of	-	196	O
the	-	199	O
oral	-	203	O
cavity	-	208	O
,	-	214	O
cirrhosis	-	216	O
,	-	225	O
and	-	227	O
cisplatin	-	231	B
-	-	240	O
induced	-	241	O
impaired	-	249	O
renal	-	258	O
function	-	264	O
.	-	272	O

This	3719553	274	O
reaction	-	279	O
occurred	-	288	O
during	-	297	O
the	-	304	O
sixth	-	308	O
and	-	314	O
seventh	-	318	O
courses	-	326	O
of	-	334	O
infusional	-	337	O
chemotherapy	-	348	O
.	-	360	O

Oral	3719553	362	O
diphenhydramine	-	367	B
and	-	383	O
prednisone	-	387	B
were	-	398	O
ineffective	-	403	O
in	-	415	O
preventing	-	418	O
the	-	429	O
recurrence	-	433	O
of	-	444	O
the	-	447	O
allergic	-	451	O
reaction	-	460	O
.	-	468	O

Discontinuance	3719553	470	O
of	-	485	O
effective	-	488	O
chemotherapy	-	498	O
in	-	511	O
this	-	514	O
patient	-	519	O
during	-	527	O
partial	-	534	O
remission	-	542	O
resulted	-	552	O
in	-	561	O
fatal	-	564	O
disease	-	570	O
progression	-	578	O
.	-	589	O

Amiodarone	4008111	0	B
-	-	10	O
induced	-	11	O
sinoatrial	-	19	O
block	-	30	O
.	-	35	O

We	4008111	37	O
observed	-	40	O
sinoatrial	-	49	O
block	-	60	O
due	-	66	O
to	-	70	O
chronic	-	73	O
amiodarone	-	81	B
administration	-	92	O
in	-	107	O
a	-	110	O
5	-	112	O
-	-	113	O
year	-	114	O
-	-	118	O
old	-	119	O
boy	-	123	O
with	-	127	O
primary	-	132	O
cardiomyopathy	-	140	O
,	-	154	O
Wolff	-	156	O
-	-	161	O
Parkinson	-	162	O
-	-	171	O
White	-	172	O
syndrome	-	178	O
and	-	187	O
supraventricular	-	191	O
tachycardia	-	208	O
.	-	219	O

Reduction	4008111	221	O
in	-	231	O
the	-	234	O
dosage	-	238	O
of	-	245	O
amiodarone	-	248	B
resulted	-	259	O
in	-	268	O
the	-	271	O
disappearance	-	275	O
of	-	289	O
the	-	292	O
sinoatrial	-	296	O
block	-	307	O
and	-	313	O
the	-	317	O
persistence	-	321	O
of	-	333	O
asymptomatic	-	336	O
sinus	-	349	O
bradycardia	-	355	O
.	-	366	O

Possible	6133211	0	O
teratogenicity	-	9	O
of	-	24	O
sulphasalazine	-	27	B
.	-	41	O

Three	6133211	43	O
infants	-	49	O
,	-	56	O
born	-	58	O
of	-	63	O
two	-	66	O
mothers	-	70	O
with	-	78	O
inflammatory	-	83	O
bowel	-	96	O
disease	-	102	O
who	-	110	O
received	-	114	O
treatment	-	123	O
with	-	133	O
sulphasalazine	-	138	B
throughout	-	153	O
pregnancy	-	164	O
,	-	173	O
were	-	175	O
found	-	180	O
to	-	186	O
have	-	189	O
major	-	194	O
congenital	-	200	O
anomalies	-	211	O
.	-	220	O

In	6133211	222	O
the	-	225	O
singleton	-	229	O
pregnancy	-	239	O
,	-	248	O
the	-	250	O
mother	-	254	O
had	-	261	O
ulcerative	-	265	O
colitis	-	276	O
,	-	283	O
and	-	285	O
the	-	289	O
infant	-	293	O
,	-	299	O
a	-	301	O
male	-	303	O
,	-	307	O
had	-	309	O
coarctation	-	313	O
of	-	325	O
the	-	328	O
aorta	-	332	O
and	-	338	O
a	-	342	O
ventricular	-	344	O
septal	-	356	O
defect	-	363	O
.	-	369	O

In	6133211	371	O
the	-	374	O
twin	-	378	O
pregnancy	-	383	O
,	-	392	O
the	-	394	O
mother	-	398	O
had	-	405	O
Crohn	-	409	O
's	-	414	O
disease	-	417	O
.	-	424	O

The	6133211	426	O
first	-	430	O
twin	-	436	O
,	-	440	O
a	-	442	O
female	-	444	O
,	-	450	O
had	-	452	O
a	-	456	O
left	-	458	O
Potter	-	463	O
-	-	469	O
type	-	470	O
IIa	-	475	O
polycystic	-	479	O
kidney	-	490	O
and	-	497	O
a	-	501	O
rudimentary	-	503	O
left	-	515	O
uterine	-	520	O
cornu	-	528	O
.	-	533	O

The	6133211	535	O
second	-	539	O
twin	-	546	O
,	-	550	O
a	-	552	O
male	-	554	O
,	-	558	O
had	-	560	O
some	-	564	O
features	-	569	O
of	-	578	O
Potter	-	581	O
's	-	587	O
facies	-	590	O
,	-	596	O
hypoplastic	-	598	O
lungs	-	610	O
,	-	615	O
absent	-	617	O
kidneys	-	624	O
and	-	632	O
ureters	-	636	O
,	-	643	O
and	-	645	O
talipes	-	649	O
equinovarus	-	657	O
.	-	668	O

Despite	6133211	670	O
reports	-	678	O
to	-	686	O
the	-	689	O
contrary	-	693	O
,	-	701	O
it	-	703	O
is	-	706	O
suggested	-	709	O
that	-	719	O
sulphasalazine	-	724	B
may	-	739	O
be	-	743	O
teratogenic	-	746	O
.	-	757	O

Veno	6503301	0	O
-	-	4	O
occlusive	-	5	O
liver	-	15	O
disease	-	21	O
after	-	29	O
dacarbazine	-	35	B
therapy	-	47	O
(	-	55	O
DTIC	-	56	B
)	-	60	O
for	-	62	O
melanoma	-	66	O
.	-	74	O

A	6503301	76	O
case	-	78	O
of	-	83	O
veno	-	86	O
-	-	90	O
occlusive	-	91	O
disease	-	101	O
of	-	109	O
the	-	112	O
liver	-	116	O
with	-	122	O
fatal	-	127	O
outcome	-	133	O
after	-	141	O
dacarbazine	-	147	B
(	-	159	O
DTIC	-	160	B
)	-	164	O
therapy	-	166	O
for	-	174	O
melanoma	-	178	O
is	-	187	O
reported	-	190	O
.	-	198	O

There	6503301	200	O
was	-	206	O
a	-	210	O
fulminant	-	212	O
clinical	-	222	O
course	-	231	O
from	-	238	O
start	-	243	O
of	-	249	O
symptoms	-	252	O
until	-	261	O
death	-	267	O
.	-	272	O

At	6503301	274	O
autopsy	-	277	O
the	-	285	O
liver	-	289	O
was	-	295	O
enlarged	-	299	O
and	-	308	O
firm	-	312	O
with	-	317	O
signs	-	322	O
of	-	328	O
venous	-	331	O
congestion	-	338	O
.	-	348	O

Small	6503301	350	O
-	-	355	O
and	-	357	O
medium	-	361	O
-	-	367	O
sized	-	368	O
hepatic	-	374	O
veins	-	382	O
were	-	388	O
blocked	-	393	O
by	-	401	O
thrombosis	-	404	O
.	-	414	O

Eosinophilic	6503301	416	O
infiltrations	-	429	O
were	-	443	O
found	-	448	O
around	-	454	O
the	-	461	O
vessels	-	465	O
.	-	472	O

Published	6503301	474	O
cases	-	484	O
from	-	490	O
the	-	495	O
literature	-	499	O
are	-	510	O
reviewed	-	514	O
and	-	523	O
pertinent	-	527	O
features	-	537	O
discussed	-	546	O
.	-	555	O

A	6727060	0	O
case	-	2	O
of	-	7	O
tardive	-	10	O
dyskinesia	-	18	O
caused	-	29	O
by	-	36	O
metoclopramide	-	39	B
.	-	53	O

Abnormal	6727060	55	O
involuntary	-	64	O
movements	-	76	O
appeared	-	86	O
in	-	95	O
the	-	98	O
mouth	-	102	O
,	-	107	O
tongue	-	109	O
,	-	115	O
neck	-	117	O
and	-	122	O
abdomen	-	126	O
of	-	134	O
a	-	137	O
64	-	139	O
-	-	141	O
year	-	142	O
-	-	146	O
old	-	147	O
male	-	151	O
patient	-	156	O
after	-	164	O
he	-	170	O
took	-	173	O
metoclopramide	-	178	B
for	-	193	O
gastrointestinal	-	197	O
disorder	-	214	O
in	-	223	O
a	-	226	O
regimen	-	228	O
of	-	236	O
30	-	239	O
mg	-	242	O
per	-	245	O
day	-	249	O
for	-	253	O
a	-	257	O
total	-	259	O
of	-	265	O
about	-	268	O
260	-	274	O
days	-	278	O
.	-	282	O

The	6727060	284	O
symptoms	-	288	O
exacerbated	-	297	O
to	-	309	O
a	-	312	O
maximum	-	314	O
in	-	322	O
a	-	325	O
month	-	327	O
.	-	332	O

When	6727060	334	O
the	-	339	O
metoclopramide	-	343	B
administration	-	358	O
was	-	373	O
discontinued	-	377	O
,	-	389	O
the	-	391	O
abnormal	-	395	O
movements	-	404	O
gradually	-	414	O
improved	-	424	O
to	-	433	O
a	-	436	O
considerable	-	438	O
extent	-	451	O
.	-	457	O

Attention	6727060	459	O
to	-	469	O
the	-	472	O
possible	-	476	O
induction	-	485	O
of	-	495	O
specific	-	498	O
tardive	-	507	O
dyskinesia	-	515	O
is	-	526	O
called	-	529	O
for	-	536	O
in	-	540	O
the	-	543	O
use	-	547	O
of	-	551	O
this	-	554	O
drug	-	559	O
.	-	563	O

Further	7083920	0	O
observations	-	8	O
on	-	21	O
the	-	24	O
electrophysiologic	-	28	O
effects	-	47	O
of	-	55	O
oral	-	58	O
amiodarone	-	63	B
therapy	-	74	O
.	-	81	O

A	7083920	83	O
case	-	85	O
is	-	90	O
presented	-	93	O
of	-	103	O
a	-	106	O
reversible	-	108	O
intra	-	119	O
-	-	124	O
Hisian	-	125	O
block	-	132	O
occurring	-	138	O
under	-	148	O
amiodarone	-	154	B
treatment	-	165	O
for	-	175	O
atrial	-	179	O
tachycardia	-	186	O
in	-	198	O
a	-	201	O
patient	-	203	O
without	-	211	O
clear	-	219	O
intraventricular	-	225	O
conduction	-	242	O
abnormalities	-	253	O
.	-	266	O

His	7083920	268	O
bundle	-	272	O
recordings	-	279	O
showed	-	290	O
an	-	297	O
atrial	-	300	O
tachycardia	-	307	O
with	-	319	O
intermittent	-	324	O
exit	-	337	O
block	-	342	O
and	-	348	O
greatly	-	352	O
prolonged	-	360	O
BH	-	370	O
and	-	373	O
HV	-	377	O
intervals	-	380	O
(	-	390	O
40	-	391	O
and	-	394	O
100	-	398	O
msec	-	402	O
,	-	406	O
respectively	-	408	O
)	-	420	O
.	-	421	O

Thirty	7083920	423	O
days	-	430	O
after	-	435	O
amiodarone	-	441	B
discontinuation	-	452	O
,	-	467	O
His	-	469	O
bundle	-	473	O
electrograms	-	480	O
showed	-	493	O
atrial	-	500	O
flutter	-	507	O
without	-	515	O
intra	-	523	O
-	-	528	O
Hisian	-	529	O
or	-	536	O
infra	-	539	O
-	-	544	O
Hisian	-	545	O
delay	-	552	O
.	-	557	O

Amiodarone	7083920	559	B
should	-	570	O
be	-	577	O
used	-	580	O
with	-	585	O
caution	-	590	O
during	-	598	O
long	-	605	O
-	-	609	O
term	-	610	O
oral	-	615	O
therapy	-	620	O
in	-	628	O
patients	-	631	O
with	-	640	O
or	-	645	O
without	-	648	O
clear	-	656	O
intraventricular	-	662	O
conduction	-	679	O
defects	-	690	O
.	-	697	O

Busulfan	7269015	0	B
-	-	8	O
induced	-	9	O
hemorrhagic	-	17	O
cystitis	-	29	O
.	-	37	O

A	7269015	39	O
case	-	41	O
of	-	46	O
a	-	49	O
busulfan	-	51	B
-	-	59	O
induced	-	60	O
hemorrhage	-	68	O
cystitis	-	79	O
is	-	88	O
reported	-	91	O
.	-	99	O

Spontaneous	7269015	101	O
resolution	-	113	O
occurred	-	124	O
following	-	133	O
cessation	-	143	O
of	-	153	O
the	-	156	O
drug	-	160	O
.	-	164	O

The	7269015	166	O
similarity	-	170	O
between	-	181	O
the	-	189	O
histologic	-	193	O
appearances	-	204	O
of	-	216	O
busulfan	-	219	B
cystitis	-	228	O
and	-	237	O
both	-	241	O
radiation	-	246	O
and	-	256	O
cyclophosphamide	-	260	B
-	-	276	O
induced	-	277	O
cystitis	-	285	O
is	-	294	O
discussed	-	297	O
and	-	307	O
the	-	311	O
world	-	315	O
literature	-	321	O
reviewed	-	332	O
.	-	340	O

In	7269015	342	O
view	-	345	O
of	-	350	O
the	-	353	O
known	-	357	O
tendency	-	363	O
of	-	372	O
busulfan	-	375	B
to	-	384	O
induce	-	387	O
cellular	-	394	O
atypia	-	403	O
and	-	410	O
carcinoma	-	414	O
in	-	424	O
other	-	427	O
sites	-	433	O
,	-	438	O
periodic	-	440	O
urinary	-	449	O
cytology	-	457	O
is	-	466	O
suggested	-	469	O
in	-	479	O
patients	-	482	O
on	-	491	O
long	-	494	O
-	-	498	O
term	-	499	O
therapy	-	504	O
.	-	511	O

Rebound	7352670	0	O
hypertensive	-	8	O
after	-	21	O
sodium	-	27	B
nitroprusside	-	34	I
prevented	-	48	O
by	-	58	O
saralasin	-	61	B
in	-	71	O
rats	-	74	O
.	-	78	O

The	7352670	80	O
role	-	84	O
of	-	89	O
the	-	92	O
renin	-	96	O
-	-	101	O
-	-	102	O
angiotensin	-	103	B
system	-	115	O
in	-	122	O
the	-	125	O
maintenance	-	129	O
of	-	141	O
blood	-	144	O
pressure	-	150	O
during	-	159	O
halothane	-	166	B
anesthesia	-	176	O
and	-	187	O
sodium	-	191	B
nitroprusside	-	198	I
(	-	212	O
SNP	-	213	B
)	-	216	O
-	-	217	O
induced	-	218	O
hypotension	-	226	O
was	-	238	O
evaluated	-	242	O
.	-	251	O

Control	7352670	253	O
rats	-	261	O
received	-	266	O
halothane	-	275	B
anesthesia	-	285	O
(	-	296	O
1	-	297	O
MAC	-	299	O
)	-	302	O
for	-	304	O
one	-	308	O
hour	-	312	O
,	-	316	O
followed	-	318	O
by	-	327	O
SNP	-	330	B
infusion	-	334	O
,	-	342	O
40	-	344	O
microgram	-	347	O
/	-	356	O
kg	-	357	O
/	-	359	O
min	-	360	O
,	-	363	O
for	-	365	O
30	-	369	O
min	-	372	O
,	-	375	O
followed	-	377	O
by	-	386	O
a	-	389	O
30	-	391	O
-	-	393	O
min	-	394	O
recovery	-	398	O
period	-	407	O
.	-	413	O

A	7352670	415	O
second	-	417	O
group	-	424	O
of	-	430	O
rats	-	433	O
was	-	438	O
treated	-	442	O
identically	-	450	O
and	-	462	O
,	-	465	O
in	-	467	O
addition	-	470	O
,	-	478	O
received	-	480	O
an	-	489	O
infusion	-	492	O
of	-	501	O
saralasin	-	504	B
(	-	514	O
a	-	515	O
competitive	-	517	O
inhibitor	-	529	O
of	-	539	O
angiotensin	-	542	B
II	-	554	I
)	-	556	O
throughout	-	558	O
the	-	569	O
experimental	-	573	O
period	-	586	O
.	-	592	O

In	7352670	594	O
each	-	597	O
group	-	602	O
,	-	607	O
SNP	-	609	B
infusion	-	613	O
resulted	-	622	O
in	-	631	O
an	-	634	O
initial	-	637	O
decrease	-	645	O
in	-	654	O
blood	-	657	O
pressure	-	663	O
from	-	672	O
86	-	677	O
torr	-	680	O
and	-	685	O
83	-	689	O
torr	-	692	O
,	-	696	O
respectively	-	698	O
,	-	710	O
to	-	712	O
48	-	715	O
torr	-	718	O
.	-	722	O

During	7352670	724	O
the	-	731	O
SNP	-	735	B
infusion	-	739	O
the	-	748	O
control	-	752	O
animals	-	760	O
demonstrated	-	768	O
a	-	781	O
progressive	-	783	O
increase	-	795	O
in	-	804	O
blood	-	807	O
pressure	-	813	O
to	-	822	O
61	-	825	O
torr	-	828	O
,	-	832	O
whereas	-	834	O
the	-	842	O
saralasin	-	846	B
-	-	855	O
treated	-	856	O
animals	-	864	O
showed	-	872	O
no	-	879	O
change	-	882	O
.	-	888	O

Following	7352670	890	O
discontinuation	-	900	O
of	-	916	O
SNP	-	919	B
,	-	922	O
blood	-	924	O
pressure	-	930	O
in	-	939	O
the	-	942	O
control	-	946	O
animals	-	954	O
rebounded	-	962	O
to	-	972	O
94	-	975	O
torr	-	978	O
,	-	982	O
as	-	984	O
compared	-	987	O
with	-	996	O
78	-	1001	O
torr	-	1004	O
in	-	1009	O
the	-	1012	O
saralasin	-	1016	B
-	-	1025	O
treated	-	1026	O
rats	-	1034	O
.	-	1038	O

This	7352670	1040	O
study	-	1045	O
indicates	-	1051	O
that	-	1061	O
with	-	1066	O
stable	-	1071	O
halothane	-	1078	B
anesthesia	-	1088	O
,	-	1098	O
the	-	1100	O
partial	-	1104	O
recovery	-	1112	O
of	-	1121	O
blood	-	1124	O
pressure	-	1130	O
during	-	1139	O
SNP	-	1146	B
infusion	-	1150	O
and	-	1159	O
the	-	1163	O
post	-	1167	O
-	-	1171	O
SNP	-	1172	B
rebound	-	1176	O
of	-	1184	O
blood	-	1187	O
pressure	-	1193	O
can	-	1202	O
be	-	1206	O
completely	-	1209	O
blocked	-	1220	O
by	-	1228	O
saralasin	-	1231	B
.	-	1240	O

This	7352670	1242	O
demonstrates	-	1247	O
the	-	1260	O
participation	-	1264	O
of	-	1278	O
the	-	1281	O
renin	-	1285	O
-	-	1290	O
-	-	1291	O
angiotensin	-	1292	B
system	-	1304	O
in	-	1311	O
antagonizing	-	1314	O
the	-	1327	O
combined	-	1331	O
hypotensive	-	1340	O
effects	-	1352	O
of	-	1360	O
halothane	-	1363	B
and	-	1373	O
SNP	-	1377	B
.	-	1380	O

Toxic	7504976	0	O
hepatitis	-	6	O
induced	-	16	O
by	-	24	O
antithyroid	-	27	O
drugs	-	39	O
:	-	44	O
four	-	46	O
cases	-	51	O
including	-	57	O
one	-	67	O
with	-	71	O
cross	-	76	O
-	-	81	O
reactivity	-	82	O
between	-	93	O
carbimazole	-	101	B
and	-	113	O
benzylthiouracil	-	117	B
.	-	133	O

OBJECTIVE	7504976	135	O
:	-	144	O
This	-	146	O
study	-	151	O
was	-	157	O
conducted	-	161	O
to	-	171	O
assess	-	174	O
the	-	181	O
occurrence	-	185	O
of	-	196	O
hepatic	-	199	O
adverse	-	207	O
effects	-	215	O
encountered	-	223	O
with	-	235	O
antithyroid	-	240	O
drugs	-	252	O
.	-	257	O

METHODS	7504976	259	O
:	-	266	O

Retrospective	7504976	268	O
review	-	282	O
of	-	289	O
medical	-	292	O
records	-	300	O
of	-	308	O
236	-	311	O
patients	-	315	O
with	-	324	O
hyperthyroidism	-	329	O
admitted	-	345	O
in	-	354	O
our	-	357	O
department	-	361	O
(	-	372	O
in	-	373	O
-	-	375	O
or	-	377	O
out	-	380	O
-	-	383	O
patients	-	384	O
)	-	392	O
from	-	394	O
1986	-	399	O
to	-	404	O
1992	-	407	O
.	-	411	O

RESULTS	7504976	413	O
:	-	420	O

Four	7504976	422	O
patients	-	427	O
(	-	436	O
1	-	437	O
.	-	438	O
7	-	439	O
%	-	440	O
)	-	441	O
were	-	443	O
identified	-	448	O
with	-	459	O
toxic	-	464	O
hepatitis	-	470	O
which	-	480	O
could	-	486	O
reasonably	-	492	O
be	-	503	O
attributed	-	506	O
to	-	517	O
the	-	520	O
use	-	524	O
of	-	528	O
antithyroid	-	531	O
agent	-	543	O
.	-	548	O

Two	7504976	550	O
patients	-	554	O
had	-	563	O
a	-	567	O
cholestatic	-	569	O
hepatitis	-	581	O
induced	-	591	O
by	-	599	O
carbimazole	-	602	B
(	-	614	O
N	-	615	B
omercazole	-	618	I
)	-	628	O
.	-	629	O

Two	7504976	631	O
others	-	635	O
had	-	642	O
a	-	646	O
mixed	-	648	O
(	-	654	O
cholestatic	-	655	O
and	-	667	O
cytolytic	-	671	O
)	-	680	O
hepatitis	-	682	O
following	-	692	O
carbimazole	-	702	B
.	-	713	O

One	7504976	715	O
of	-	719	O
the	-	722	O
latter	-	726	O
two	-	733	O
patients	-	737	O
further	-	746	O
experienced	-	754	O
a	-	766	O
cytolytic	-	768	O
hepatitis	-	778	O
which	-	788	O
appeared	-	794	O
after	-	803	O
Benzylthiouracil	-	809	B
(	-	826	O
Basd	-	827	B
ne	-	833	I
)	-	835	O
had	-	837	O
replaced	-	841	O
carbimazole	-	850	B
.	-	861	O

Biological	7504976	863	O
features	-	874	O
of	-	883	O
hepatitis	-	886	O
disappeared	-	896	O
in	-	908	O
all	-	911	O
cases	-	915	O
after	-	921	O
cessation	-	927	O
of	-	937	O
the	-	940	O
incriminated	-	944	O
drug	-	957	O
,	-	961	O
while	-	963	O
biliary	-	969	O
,	-	976	O
viral	-	978	O
and	-	984	O
immunological	-	988	O
searches	-	1002	O
were	-	1011	O
negative	-	1016	O
.	-	1024	O

Only	7504976	1026	O
2	-	1031	O
patients	-	1033	O
of	-	1042	O
our	-	1045	O
retrospective	-	1049	O
study	-	1063	O
experienced	-	1069	O
a	-	1081	O
mild	-	1083	O
or	-	1088	O
severe	-	1091	O
neutropenia	-	1098	O
.	-	1109	O

CONCLUSION	7504976	1111	O
:	-	1121	O

Toxic	7504976	1123	O
hepatitis	-	1129	O
is	-	1139	O
a	-	1142	O
potential	-	1144	O
adverse	-	1154	O
effect	-	1162	O
of	-	1169	O
antithyroid	-	1172	O
drugs	-	1184	O
which	-	1190	O
warrants	-	1196	O
,	-	1204	O
as	-	1206	O
for	-	1209	O
haematological	-	1213	O
disturbances	-	1228	O
,	-	1240	O
a	-	1242	O
pre	-	1244	O
-	-	1247	O
therapeutic	-	1248	O
determination	-	1260	O
and	-	1274	O
a	-	1278	O
careful	-	1280	O
follow	-	1288	O
-	-	1294	O
up	-	1295	O
of	-	1298	O
relevant	-	1301	O
biological	-	1310	O
markers	-	1321	O
.	-	1328	O

Moreover	7504976	1330	O
,	-	1338	O
hepatotoxicity	-	1340	O
may	-	1355	O
not	-	1359	O
be	-	1363	O
restricted	-	1366	O
to	-	1377	O
one	-	1380	O
class	-	1384	O
of	-	1390	O
antithyroid	-	1393	O
agents	-	1405	O
.	-	1411	O

Study	7628595	0	O
of	-	6	O
the	-	9	O
role	-	13	O
of	-	18	O
vitamin	-	21	B
B12	-	29	I
and	-	33	O
folinic	-	37	B
acid	-	45	I
supplementation	-	50	O
in	-	66	O
preventing	-	69	O
hematologic	-	80	O
toxicity	-	92	O
of	-	101	O
zidovudine	-	104	B
.	-	114	O

A	7628595	116	O
prospective	-	118	O
,	-	129	O
randomized	-	131	O
study	-	142	O
was	-	148	O
conducted	-	152	O
to	-	162	O
evaluate	-	165	O
the	-	174	O
role	-	178	O
of	-	183	O
vitamin	-	186	B
B12	-	194	I
and	-	198	O
folinic	-	202	B
acid	-	210	I
supplementation	-	215	O
in	-	231	O
preventing	-	234	O
zidovudine	-	245	B
(	-	256	O
ZDV	-	257	B
)	-	260	O
-	-	261	O
induced	-	262	O
bone	-	270	O
marrow	-	275	O
suppression	-	282	O
.	-	293	O

Seventy	7628595	295	O
-	-	302	O
five	-	303	O
human	-	308	O
immunodeficiency	-	314	O
virus	-	331	O
(	-	337	O
HIV	-	338	O
)	-	341	O
-	-	342	O
infected	-	343	O
patients	-	352	O
with	-	361	O
CD4	-	366	O
+	-	369	O
cell	-	371	O
counts	-	376	O
<	-	383	O
500	-	385	O
/	-	388	O
mm3	-	389	O
were	-	393	O
randomized	-	398	O
to	-	409	O
receive	-	412	O
either	-	420	O
ZDV	-	427	B
(	-	431	O
500	-	432	O
mg	-	436	O
daily	-	439	O
)	-	444	O
alone	-	446	O
(	-	452	O
group	-	453	O
I	-	459	O
,	-	460	O
n	-	462	O
=	-	464	O
38	-	466	O
)	-	468	O
or	-	470	O
in	-	473	O
combination	-	476	O
with	-	488	O
folinic	-	493	B
acid	-	501	I
(	-	506	O
15	-	507	O
mg	-	510	O
daily	-	513	O
)	-	518	O
and	-	520	O
intramascular	-	524	O
vitamin	-	538	B
B12	-	546	I
(	-	550	O
1000	-	551	O
micrograms	-	556	O
monthly	-	567	O
)	-	574	O
(	-	576	O
group	-	577	O
II	-	583	O
,	-	585	O
n	-	587	O
=	-	589	O
37	-	591	O
)	-	593	O
.	-	594	O

Finally	7628595	596	O
,	-	603	O
15	-	605	O
patients	-	608	O
were	-	617	O
excluded	-	622	O
from	-	631	O
the	-	636	O
study	-	640	O
(	-	646	O
noncompliance	-	647	O
14	-	661	O
,	-	663	O
death	-	665	O
1	-	671	O
)	-	672	O
;	-	673	O
thus	-	675	O
,	-	679	O
60	-	681	O
patients	-	684	O
(	-	693	O
31	-	694	O
in	-	697	O
group	-	700	O
I	-	706	O
and	-	708	O
29	-	712	O
in	-	715	O
group	-	718	O
II	-	724	O
)	-	726	O
were	-	728	O
eligible	-	733	O
for	-	742	O
analysis	-	746	O
.	-	754	O

No	7628595	756	O
significant	-	759	O
differences	-	771	O
between	-	783	O
groups	-	791	O
were	-	798	O
found	-	803	O
at	-	809	O
enrollment	-	812	O
.	-	822	O

During	7628595	824	O
the	-	831	O
study	-	835	O
,	-	840	O
vitamin	-	842	B
B12	-	850	I
and	-	854	O
folate	-	858	B
levels	-	865	O
were	-	872	O
significantly	-	877	O
higher	-	891	O
in	-	898	O
group	-	901	O
II	-	907	O
patients	-	910	O
;	-	918	O
however	-	920	O
,	-	927	O
no	-	929	O
differences	-	932	O
in	-	944	O
hemoglobin	-	947	O
,	-	957	O
hematocrit	-	959	O
,	-	969	O
mean	-	971	O
corpuscular	-	976	O
volume	-	988	O
,	-	994	O
and	-	996	O
white	-	1000	O
-	-	1005	O
cell	-	1006	O
,	-	1010	O
neutrophil	-	1012	O
and	-	1023	O
platelet	-	1027	O
counts	-	1036	O
were	-	1043	O
observed	-	1048	O
between	-	1057	O
groups	-	1065	O
at	-	1072	O
3	-	1075	O
,	-	1076	O
6	-	1078	O
,	-	1079	O
9	-	1081	O
and	-	1083	O
12	-	1087	O
months	-	1090	O
.	-	1096	O

Severe	7628595	1098	O
hematologic	-	1105	O
toxicity	-	1117	O
(	-	1126	O
neutrophil	-	1127	O
count	-	1138	O
<	-	1144	O
1000	-	1146	O
/	-	1150	O
mm3	-	1151	O

and	7628595	1155	O
/	-	1158	O
or	-	1159	O
hemoglobin	-	1162	O
<	-	1173	O
8	-	1175	O
g	-	1177	O
/	-	1178	O
dl	-	1179	O
)	-	1181	O
occurred	-	1183	O
in	-	1192	O
4	-	1195	O
patients	-	1197	O
assigned	-	1206	O
to	-	1215	O
group	-	1218	O

I	7628595	1224	O
and	-	1226	O
7	-	1230	O
assigned	-	1232	O
to	-	1241	O
group	-	1244	O
II	-	1250	O
.	-	1252	O

There	7628595	1254	O
was	-	1260	O
no	-	1264	O
correlation	-	1267	O
between	-	1279	O
vitamin	-	1287	B
B12	-	1295	I
or	-	1299	O
folate	-	1302	B
levels	-	1309	O
and	-	1316	O
development	-	1320	O
of	-	1332	O
myelosuppression	-	1335	O
.	-	1351	O

Vitamin	7628595	1353	B
B12	-	1361	I
and	-	1365	O
folinic	-	1369	B
acid	-	1377	I
supplementation	-	1382	O
of	-	1398	O
ZDV	-	1401	B
therapy	-	1405	O
does	-	1413	O
not	-	1418	O
seem	-	1422	O
useful	-	1427	O
in	-	1434	O
preventing	-	1437	O
or	-	1448	O
reducing	-	1451	O
ZDV	-	1460	B
-	-	1463	O
induced	-	1464	O
myelotoxicity	-	1472	O
in	-	1486	O
the	-	1489	O
overall	-	1493	O
treated	-	1501	O
population	-	1509	O
,	-	1519	O
although	-	1521	O
a	-	1530	O
beneficial	-	1532	O
effect	-	1543	O
in	-	1550	O
certain	-	1553	O
subgroups	-	1561	O
of	-	1571	O
patients	-	1574	O
can	-	1583	O
not	-	1586	O
be	-	1590	O
excluded	-	1593	O
.	-	1601	O

Acute	7858459	0	O
confusion	-	6	O
induced	-	16	O
by	-	24	O
a	-	27	O
high	-	29	O
-	-	33	O
dose	-	34	O
infusion	-	39	O
of	-	48	O
5	-	51	B
-	-	52	I
fluorouracil	-	53	I
and	-	66	O
folinic	-	70	B
acid	-	78	I
.	-	82	O

A	7858459	84	O
61	-	86	O
-	-	88	O
year	-	89	O
-	-	93	O
old	-	94	O
man	-	98	O
was	-	102	O
treated	-	106	O
with	-	114	O
combination	-	119	O
chemotherapy	-	131	O
incorporating	-	144	O
cisplatinum	-	158	B
,	-	169	O
etoposide	-	171	B
,	-	180	O
high	-	182	O
-	-	186	O
dose	-	187	O
5	-	192	B
-	-	193	I
fluorouracil	-	194	I
(	-	207	O
2	-	208	O
,	-	209	O
250	-	210	O
mg	-	214	O
/	-	216	O
m2	-	217	O
/	-	219	O
24	-	220	O
hours	-	223	O
)	-	228	O
and	-	230	O
folinic	-	234	B
acid	-	242	I
for	-	247	O
an	-	251	O
inoperable	-	254	O
gastric	-	265	O
adenocarcinoma	-	273	O
.	-	287	O

He	7858459	289	O
developed	-	292	O
acute	-	302	O
neurologic	-	308	O
symptoms	-	319	O
of	-	328	O
mental	-	331	O
confusion	-	338	O
,	-	347	O
disorientation	-	349	O
and	-	364	O
irritability	-	368	O
,	-	380	O
and	-	382	O
then	-	386	O
lapsed	-	391	O
into	-	398	O
a	-	403	O
deep	-	405	O
coma	-	410	O
,	-	414	O
lasting	-	416	O
for	-	424	O
approximately	-	428	O
40	-	442	O
hours	-	445	O
during	-	451	O
the	-	458	O
first	-	462	O
dose	-	468	O
(	-	473	O
day	-	474	O
2	-	478	O
)	-	479	O
of	-	481	O
5	-	484	B
-	-	485	I
fluorouracil	-	486	I
and	-	499	O
folinic	-	503	B
acid	-	511	I
infusion	-	516	O
.	-	524	O

This	7858459	526	O
complication	-	531	O
reappeared	-	544	O
on	-	555	O
day	-	558	O
25	-	562	O
during	-	565	O
the	-	572	O
second	-	576	O
dose	-	583	O
of	-	588	O
5	-	591	B
-	-	592	I
fluorouracil	-	593	I
and	-	606	O
folinic	-	610	B
acid	-	618	I
,	-	622	O
which	-	624	O
were	-	630	O
then	-	635	O
the	-	640	O
only	-	644	O
drugs	-	649	O
given	-	655	O
.	-	660	O

Because	7858459	662	O
folinic	-	670	B
acid	-	678	I
was	-	683	O
unlikely	-	687	O
to	-	696	O
be	-	699	O
associated	-	702	O
with	-	713	O
this	-	718	O
condition	-	723	O
,	-	732	O
neurotoxicity	-	734	O
due	-	748	O
to	-	752	O
high	-	755	O
-	-	759	O
dose	-	760	O
5	-	765	B
-	-	766	I
fluorouracil	-	767	I
was	-	780	O
highly	-	784	O
suspected	-	791	O
.	-	800	O

The	7858459	802	O
pathogenesis	-	806	O
of	-	819	O
5	-	822	B
-	-	823	I
fluorouracil	-	824	I
neurotoxicity	-	837	O
may	-	851	O
be	-	855	O
due	-	858	O
to	-	862	O
a	-	865	O
Krebs	-	867	O
cycle	-	873	O
blockade	-	879	O
by	-	888	O
fluoroacetate	-	891	B
and	-	905	O
fluorocitrate	-	909	B
,	-	922	O
thiamine	-	924	B
deficiency	-	933	O
,	-	943	O
or	-	945	O
dihydrouracil	-	948	B
dehydrogenase	-	962	O
deficiency	-	976	O
.	-	986	O

High	7858459	988	O
-	-	992	O
dose	-	993	O
5	-	998	B
-	-	999	I
fluorouracil	-	1000	I
/	-	1012	O
folinic	-	1013	B
acid	-	1021	I
infusion	-	1026	O
therapy	-	1035	O
has	-	1043	O
recently	-	1047	O
become	-	1056	O
a	-	1063	O
popular	-	1065	O
regimen	-	1073	O
for	-	1081	O
various	-	1085	O
cancers	-	1093	O
.	-	1100	O

It	7858459	1102	O
is	-	1105	O
necessary	-	1108	O
that	-	1118	O
both	-	1123	O
oncologists	-	1128	O
and	-	1140	O
neurologists	-	1144	O
be	-	1157	O
fully	-	1160	O
aware	-	1166	O
of	-	1172	O
this	-	1175	O
unusual	-	1180	O
complication	-	1188	O
.	-	1200	O

Effect	7862923	0	O
of	-	7	O
switching	-	10	O
carbamazepine	-	20	B
to	-	34	O
oxcarbazepine	-	37	B
on	-	51	O
the	-	54	O
plasma	-	58	O
levels	-	65	O
of	-	72	O
neuroleptics	-	75	O
.	-	87	O

A	7862923	89	O
case	-	91	O
report	-	96	O
.	-	102	O

Carbamazepine	7862923	104	B
was	-	118	O
switched	-	122	O
to	-	131	O
its	-	134	O
10	-	138	O
-	-	140	O
keto	-	141	O
analogue	-	146	O
oxcarbazepine	-	155	B
among	-	169	O
six	-	175	O
difficult	-	179	O
-	-	188	O
to	-	189	O
-	-	191	O
treat	-	192	O
schizophrenic	-	198	O
or	-	212	O
organic	-	215	O
psychotic	-	223	O
patients	-	233	O
using	-	242	O
concomitantly	-	248	O
haloperidol	-	262	B
,	-	273	O
chlorpromazine	-	275	B
or	-	290	O
clozapine	-	293	B
.	-	302	O

This	7862923	304	O
change	-	309	O
resulted	-	316	O
within	-	325	O
2	-	332	O
-	-	333	O
4	-	334	O
weeks	-	336	O
in	-	342	O
the	-	345	O
50	-	349	O
-	-	351	O
200	-	352	O
%	-	355	O
increase	-	357	O
in	-	366	O
the	-	369	O
plasma	-	373	O
levels	-	380	O
of	-	387	O
these	-	390	O
neuroleptics	-	396	O
and	-	409	O
the	-	413	O
appearance	-	417	O
of	-	428	O
extrapyramidal	-	431	O
symptoms	-	446	O
.	-	454	O

None	7862923	456	O
of	-	461	O
the	-	464	O
patients	-	468	O
showed	-	477	O
any	-	484	O
clinical	-	488	O
deteriotation	-	497	O
during	-	511	O
the	-	518	O
following	-	522	O
3	-	532	O
-	-	533	O
6	-	534	O
months	-	536	O
.	-	542	O

The	7862923	544	O
results	-	548	O
of	-	556	O
this	-	559	O
case	-	564	O
report	-	569	O
support	-	576	O
the	-	584	O
idea	-	588	O
that	-	593	O
in	-	598	O
contrast	-	601	O
with	-	610	O
carbamazepine	-	615	B
oxcarbazepine	-	629	B
does	-	643	O
not	-	648	O
induce	-	652	O
the	-	659	O
hepatic	-	663	O
microsomal	-	671	O
enzyme	-	682	O
systems	-	689	O
regulating	-	697	O
the	-	708	O
inactivation	-	712	O
of	-	725	O
antipsychotic	-	728	O
drugs	-	742	O
.	-	747	O

Erythema	7919560	0	O
multiforme	-	9	O
and	-	20	O
hypersensitivity	-	24	O
myocarditis	-	41	O
caused	-	53	O
by	-	60	O
ampicillin	-	63	B
.	-	73	O

OBJECTIVE	7919560	75	O
:	-	84	O

To	7919560	86	O
report	-	89	O
a	-	96	O
case	-	98	O
of	-	103	O
erythema	-	106	O
multiforme	-	115	O
and	-	126	O
hypersensitivity	-	130	O
myocarditis	-	147	O
caused	-	159	O
by	-	166	O
ampicillin	-	169	B
.	-	179	O

CASE	7919560	181	O
SUMMARY	-	186	O
:	-	193	O

A	7919560	195	O
13	-	197	O
-	-	199	O
year	-	200	O
-	-	204	O
old	-	205	O
boy	-	209	O
was	-	213	O
treated	-	217	O
with	-	225	O
ampicillin	-	230	B
and	-	241	O
gentamicin	-	245	B
because	-	256	O
of	-	264	O
suspected	-	267	O
septicemia	-	277	O
.	-	287	O

Medications	7919560	289	O
were	-	301	O
discontinued	-	306	O
when	-	319	O
erythema	-	324	O
multiforme	-	333	O
and	-	344	O
congestive	-	348	O
heart	-	359	O
failure	-	365	O
caused	-	373	O
by	-	380	O
myocarditis	-	383	O
occurred	-	395	O
.	-	403	O

The	7919560	405	O
patient	-	409	O
was	-	417	O
treated	-	421	O
with	-	429	O
methylprednisolone	-	434	B
and	-	453	O
gradually	-	457	O
improved	-	467	O
.	-	475	O

Macrophage	7919560	477	O
-	-	487	O
migration	-	488	O
inhibition	-	498	O
(	-	509	O
MIF	-	510	O
)	-	513	O
test	-	515	O
with	-	520	O
ampicillin	-	525	B
was	-	536	O
positive	-	540	O
.	-	548	O

DISCUSSION	7919560	550	O
:	-	560	O

After	7919560	562	O
most	-	568	O
infections	-	573	O
causing	-	584	O
erythema	-	592	O
multiforme	-	601	O
and	-	612	O
myocarditis	-	616	O
were	-	628	O
ruled	-	633	O
out	-	639	O
,	-	642	O
a	-	644	O
drug	-	646	O
-	-	650	O
induced	-	651	O
allergic	-	659	O
reaction	-	668	O
was	-	677	O
suspected	-	681	O
.	-	690	O

Positive	7919560	692	O
MIF	-	701	O
test	-	705	O
for	-	710	O
ampicillin	-	714	B
showed	-	725	O
sensitization	-	732	O
of	-	746	O
the	-	749	O
patient	-	753	O
's	-	760	O
lymphocytes	-	763	O
to	-	775	O
ampicillin	-	778	B
.	-	788	O

CONCLUSIONS	7919560	790	O
:	-	801	O

Hypersensitivity	7919560	803	O
myocarditis	-	820	O
is	-	832	O
a	-	835	O
rare	-	837	O
and	-	842	O
dangerous	-	846	O
manifestation	-	856	O
of	-	870	O
allergy	-	873	O
to	-	881	O
penicillins	-	884	B
.	-	895	O

Immediate	8092427	0	O
allergic	-	10	O
reactions	-	19	O
to	-	29	O
amoxicillin	-	32	B
.	-	43	O

A	8092427	45	O
large	-	47	O
group	-	53	O
of	-	59	O
patients	-	62	O
with	-	71	O
suspected	-	76	O
allergic	-	86	O
reactions	-	95	O
to	-	105	O
beta	-	108	B
-	-	112	I
lactam	-	113	I
antibiotics	-	120	O
was	-	132	O
evaluated	-	136	O
.	-	145	O

A	8092427	147	O
detailed	-	149	O
clinical	-	158	O
history	-	167	O
,	-	174	O
together	-	176	O
with	-	185	O
skin	-	190	O
tests	-	195	O
,	-	200	O
RAST	-	202	O
(	-	207	O
radioallergosorbent	-	208	O
test	-	228	O
)	-	232	O
,	-	233	O
and	-	235	O
controlled	-	239	O
challenge	-	250	O
tests	-	260	O
,	-	265	O
was	-	267	O
used	-	271	O
to	-	276	O
establish	-	279	O
whether	-	289	O
patients	-	297	O
allergic	-	306	O
to	-	315	O
beta	-	318	B
-	-	322	I
lactam	-	323	I
antibiotics	-	330	O
had	-	342	O
selective	-	346	O
immediate	-	356	O
allergic	-	366	O
responses	-	375	O
to	-	385	O
amoxicillin	-	388	B
(	-	400	O
AX	-	401	B
)	-	403	O
or	-	405	O
were	-	408	O
cross	-	413	O
-	-	418	O
reacting	-	419	O
with	-	428	O
other	-	433	O
penicillin	-	439	B
derivatives	-	450	O
.	-	461	O

Skin	8092427	463	O
tests	-	468	O
were	-	474	O
performed	-	479	O
with	-	489	O
benzylpenicilloyl	-	494	B
-	-	511	I
poly	-	512	I
-	-	516	I
L	-	517	I
-	-	518	I
lysine	-	519	I
(	-	526	O
BPO	-	527	B
-	-	530	I
PLL	-	531	I
)	-	534	O
,	-	535	O
benzylpenicilloate	-	537	B
,	-	555	O
benzylpenicillin	-	557	B
(	-	574	O
PG	-	575	B
)	-	577	O
,	-	578	O
ampicillin	-	580	B
(	-	591	O
AMP	-	592	B
)	-	595	O
,	-	596	O
and	-	598	O
AX	-	602	B
.	-	604	O

RAST	8092427	606	O
for	-	611	O
BPO	-	615	B
-	-	618	I
PLL	-	619	I
and	-	623	O
AX	-	627	B
-	-	629	O
PLL	-	630	O
was	-	634	O
done	-	638	O
.	-	642	O

When	8092427	644	O
both	-	649	O
skin	-	654	O
test	-	659	O
and	-	664	O
RAST	-	668	O
for	-	673	O
BPO	-	677	B
were	-	681	O
negative	-	686	O
,	-	694	O
single	-	696	O
-	-	702	O
blind	-	703	O
,	-	708	O
placebo	-	710	O
-	-	717	O
controlled	-	718	O
challenge	-	729	O
tests	-	739	O
were	-	745	O
done	-	750	O
to	-	755	O
ensure	-	758	O
tolerance	-	765	O
of	-	775	O
PG	-	778	B
or	-	781	O
sensitivity	-	784	O
to	-	796	O
AX	-	799	B
.	-	801	O

A	8092427	803	O
total	-	805	O
of	-	811	O
177	-	814	O
patients	-	818	O
were	-	827	O
diagnosed	-	832	O
as	-	842	O
allergic	-	845	O
to	-	854	O
beta	-	857	B
-	-	861	I
lactam	-	862	I
antibiotics	-	869	O
.	-	880	O

We	8092427	882	O
selected	-	885	O
the	-	894	O
54	-	898	O
(	-	901	O
30	-	902	O
.	-	904	O
5	-	905	O
%	-	906	O
)	-	907	O
cases	-	909	O
of	-	915	O
immediate	-	918	O
AX	-	928	B
allergy	-	931	O
with	-	939	O
good	-	944	O
tolerance	-	949	O
of	-	959	O
PG	-	962	B
.	-	964	O

Anaphylaxis	8092427	966	O
was	-	978	O
seen	-	982	O
in	-	987	O
37	-	990	O
patients	-	993	O
(	-	1002	O
69	-	1003	O
%	-	1005	O
)	-	1006	O
,	-	1007	O
the	-	1009	O
other	-	1013	O
17	-	1019	O
(	-	1022	O
31	-	1023	O
%	-	1025	O
)	-	1026	O
having	-	1028	O
urticaria	-	1035	O
and	-	1045	O
/	-	1048	O
or	-	1049	O
angioedema	-	1052	O
.	-	1062	O

All	8092427	1064	O
the	-	1068	O
patients	-	1072	O
were	-	1081	O
skin	-	1086	O
test	-	1091	O
negative	-	1096	O
to	-	1105	O
BPO	-	1108	B
;	-	1111	O
49	-	1113	O
of	-	1116	O
51	-	1119	O
(	-	1122	O
96	-	1123	O
%	-	1125	O
)	-	1126	O
were	-	1128	O
also	-	1133	O
negative	-	1138	O
to	-	1147	O
MDM	-	1150	O
,	-	1153	O
and	-	1155	O
44	-	1159	O
of	-	1162	O
46	-	1165	O
(	-	1168	O
96	-	1169	O
%	-	1171	O
)	-	1172	O
to	-	1174	O
PG	-	1177	B
.	-	1179	O

Skin	8092427	1181	O
tests	-	1186	O
with	-	1192	O
AX	-	1197	B
were	-	1200	O
positive	-	1205	O
in	-	1214	O
34	-	1217	O
(	-	1220	O
63	-	1221	O
%	-	1223	O
)	-	1224	O
patients	-	1226	O
.	-	1234	O

RAST	8092427	1236	O
was	-	1241	O
positive	-	1245	O
for	-	1254	O
AX	-	1258	B
in	-	1261	O
22	-	1264	O
patients	-	1267	O
(	-	1276	O
41	-	1277	O
%	-	1279	O
)	-	1280	O
and	-	1282	O
to	-	1286	O
BPO	-	1289	B
in	-	1293	O
just	-	1296	O
5	-	1301	O
(	-	1303	O
9	-	1304	O
%	-	1305	O
)	-	1306	O
.	-	1307	O

None	8092427	1309	O
of	-	1314	O
the	-	1317	O
sera	-	1321	O
with	-	1326	O
negative	-	1331	O
RAST	-	1340	O
for	-	1345	O
AX	-	1349	B
were	-	1352	O
positive	-	1357	O
to	-	1366	O
BPO	-	1369	B
.	-	1372	O

Challenge	8092427	1374	O
tests	-	1384	O
with	-	1390	O
AX	-	1395	B
were	-	1398	O
performed	-	1403	O
in	-	1413	O
23	-	1416	O
subjects	-	1419	O
(	-	1428	O
43	-	1429	O
%	-	1431	O
)	-	1432	O
to	-	1434	O
establish	-	1437	O
the	-	1447	O
diagnosis	-	1451	O
of	-	1461	O
immediate	-	1464	O
allergic	-	1474	O
reaction	-	1483	O
to	-	1492	O
AX	-	1495	B
,	-	1497	O
and	-	1499	O
in	-	1503	O
15	-	1506	O
cases	-	1509	O
(	-	1515	O
28	-	1516	O
%	-	1518	O
)	-	1519	O
both	-	1521	O
skin	-	1526	O
test	-	1531	O
and	-	1536	O
RAST	-	1540	O
for	-	1545	O
AX	-	1549	B
were	-	1552	O
negative	-	1557	O
.	-	1565	O

PG	8092427	1567	B
was	-	1570	O
well	-	1574	O
tolerated	-	1579	O
by	-	1589	O
all	-	1592	O
54	-	1596	O
patients	-	1599	O
.	-	1607	O

We	8092427	1609	O
describe	-	1612	O
the	-	1621	O
largest	-	1625	O
group	-	1633	O
of	-	1639	O
AX	-	1642	B
-	-	1644	O
allergic	-	1645	O
patients	-	1654	O
who	-	1663	O
have	-	1667	O
tolerated	-	1672	O
PG	-	1682	B
reported	-	1685	O
so	-	1694	O
far	-	1697	O
.	-	1700	O

Diagnosis	8092427	1702	O
of	-	1712	O
these	-	1715	O
patients	-	1721	O
can	-	1730	O
be	-	1734	O
achieved	-	1737	O
only	-	1746	O
if	-	1751	O
specific	-	1754	O
AX	-	1763	B
-	-	1765	O
related	-	1766	O
reagents	-	1774	O
are	-	1783	O
employed	-	1787	O
.	-	1795	O

Further	8092427	1797	O
studies	-	1805	O
are	-	1813	O
necessary	-	1817	O
to	-	1827	O
determine	-	1830	O
the	-	1840	O
exact	-	1844	O
extent	-	1850	O
of	-	1857	O
this	-	1860	O
problem	-	1865	O
and	-	1873	O
to	-	1877	O
improve	-	1880	O
the	-	1888	O
efficacy	-	1892	O
of	-	1901	O
diagnostic	-	1904	O
methods	-	1915	O
.	-	1922	O

Persistent	8638206	0	O
paralysis	-	11	O
after	-	21	O
prolonged	-	27	O
use	-	37	O
of	-	41	O
atracurium	-	44	B
in	-	55	O
the	-	58	O
absence	-	62	O
of	-	70	O
corticosteroids	-	73	O
.	-	88	O

Neuromuscular	8638206	90	O
blocking	-	104	O
agents	-	113	O
(	-	120	O
NMBAs	-	121	O
)	-	126	O
are	-	128	O
often	-	132	O
used	-	138	O
for	-	143	O
patients	-	147	O
requiring	-	156	O
prolonged	-	166	O
mechanical	-	176	O
ventilation	-	187	O
.	-	198	O

Reports	8638206	200	O
of	-	208	O
persistent	-	211	O
paralysis	-	222	O
after	-	232	O
the	-	238	O
discontinuance	-	242	O
of	-	257	O
these	-	260	O
drugs	-	266	O
have	-	272	O
most	-	277	O
often	-	282	O
involved	-	288	O
aminosteroid	-	297	O
-	-	309	O
based	-	310	O
NMBAs	-	316	O
such	-	322	O
as	-	327	O
vecuronium	-	330	B
bromide	-	341	I
,	-	348	O
especially	-	350	O
when	-	361	O
used	-	366	O
in	-	371	O
conjunction	-	374	O
with	-	386	O
corticosteroids	-	391	O
.	-	406	O

Atracurium	8638206	408	B
besylate	-	419	I
,	-	427	O
a	-	429	O
short	-	431	O
-	-	436	O
acting	-	437	O
benzylisoquinolinium	-	444	B
NMBA	-	465	O
that	-	470	O
is	-	475	O
eliminated	-	478	O
independently	-	489	O
of	-	503	O
renal	-	506	O
or	-	512	O
hepatic	-	515	O
function	-	523	O
,	-	531	O
has	-	533	O
also	-	537	O
been	-	542	O
associated	-	547	O
with	-	558	O
persistent	-	563	O
paralysis	-	574	O
,	-	583	O
but	-	585	O
only	-	589	O
when	-	594	O
used	-	599	O
with	-	604	O
corticosteroids	-	609	O
.	-	624	O

We	8638206	626	O
report	-	629	O
a	-	636	O
case	-	638	O
of	-	643	O
atracurium	-	646	B
-	-	656	O
related	-	657	O
paralysis	-	665	O
persisting	-	675	O
for	-	686	O
approximately	-	690	O
50	-	704	O
hours	-	707	O
in	-	713	O
a	-	716	O
patient	-	718	O
who	-	726	O
was	-	730	O
not	-	734	O
treated	-	738	O
with	-	746	O
corticosteroids	-	751	O
.	-	766	O

Habitual	8669433	0	O
use	-	9	O
of	-	13	O
acetaminophen	-	16	B
as	-	30	O
a	-	33	O
risk	-	35	O
factor	-	40	O
for	-	47	O
chronic	-	51	O
renal	-	59	O
failure	-	65	O
:	-	72	O
a	-	74	O
comparison	-	76	O
with	-	87	O
phenacetin	-	92	B
.	-	102	O

Six	8669433	104	O
epidemiologic	-	108	O
studies	-	122	O
in	-	130	O
the	-	133	O
United	-	137	O
States	-	144	O
and	-	151	O
Europe	-	155	O
indicate	-	162	O
that	-	171	O
habitual	-	176	O
use	-	185	O
of	-	189	O
phenacetin	-	192	B
is	-	203	O
associated	-	206	O
with	-	217	O
the	-	222	O
development	-	226	O
of	-	238	O
chronic	-	241	O
renal	-	249	O
failure	-	255	O
and	-	263	O
end	-	267	O
-	-	270	O
stage	-	271	O
renal	-	277	O
disease	-	283	O
(	-	291	O
ESRD	-	292	O
)	-	296	O
,	-	297	O
with	-	299	O
a	-	304	O
relative	-	306	O
risk	-	315	O
in	-	320	O
the	-	323	O
range	-	327	O
of	-	333	O
4	-	336	O
to	-	338	O
19	-	341	O
.	-	343	O

As	8669433	345	O
a	-	348	O
result	-	350	O
of	-	357	O
these	-	360	O
and	-	366	O
other	-	370	O
studies	-	376	O
,	-	383	O
phenacetin	-	385	B
has	-	396	O
now	-	400	O
been	-	404	O
withdrawn	-	409	O
from	-	419	O
the	-	424	O
market	-	428	O
in	-	435	O
most	-	438	O
countries	-	443	O
.	-	452	O

However	8669433	454	O
,	-	461	O
three	-	463	O
case	-	469	O
control	-	474	O
studies	-	482	O
,	-	489	O
one	-	491	O
each	-	495	O
in	-	500	O
North	-	503	O
Carolina	-	509	O
,	-	517	O
northern	-	519	O
Maryland	-	528	O
,	-	536	O
and	-	538	O
West	-	542	O
Berlin	-	547	O
,	-	553	O
Germany	-	555	O
,	-	562	O
showed	-	564	O
that	-	571	O
habitual	-	576	O
use	-	585	O
of	-	589	O
acetaminophen	-	592	B
is	-	606	O
also	-	609	O
associated	-	614	O
with	-	625	O
chronic	-	630	O
renal	-	638	O
failure	-	644	O
and	-	652	O
ESRD	-	656	O
,	-	660	O
with	-	662	O
a	-	667	O
relative	-	669	O
risk	-	678	O
in	-	683	O
the	-	686	O
range	-	690	O
of	-	696	O
2	-	699	O
to	-	701	O
4	-	704	O
.	-	705	O

These	8669433	707	O
studies	-	713	O
suggest	-	721	O
that	-	729	O
both	-	734	O
phenacetin	-	739	B
and	-	750	O
acetaminophen	-	754	B
may	-	768	O
contribute	-	772	O
to	-	783	O
the	-	786	O
burden	-	790	O
of	-	797	O
ESRD	-	800	O
,	-	804	O
with	-	806	O
the	-	811	O
risk	-	815	O
of	-	820	O
the	-	823	O
latter	-	827	O
being	-	834	O
somewhat	-	840	O
less	-	849	O
than	-	854	O
that	-	859	O
of	-	864	O
the	-	867	O
former	-	871	O
.	-	877	O

This	8669433	879	O
apparent	-	884	O
difference	-	893	O
in	-	904	O
risk	-	907	O
may	-	912	O
not	-	916	O
be	-	920	O
due	-	923	O
to	-	927	O
differences	-	930	O
in	-	942	O
nephrotoxic	-	945	O
potential	-	957	O
of	-	967	O
the	-	970	O
drugs	-	974	O
themselves	-	980	O
.	-	990	O

A	8669433	992	O
lower	-	994	O
relative	-	1000	O
risk	-	1009	O
would	-	1014	O
be	-	1020	O
expected	-	1023	O
for	-	1032	O
acetaminophen	-	1036	B
if	-	1050	O
the	-	1053	O
risk	-	1057	O
of	-	1062	O
both	-	1065	O
drugs	-	1070	O
in	-	1076	O
combination	-	1079	O
with	-	1091	O
other	-	1096	O
analgesics	-	1102	O
was	-	1113	O
higher	-	1117	O
than	-	1124	O
the	-	1129	O
risk	-	1133	O
of	-	1138	O
either	-	1141	O
agent	-	1148	O
alone	-	1154	O
.	-	1159	O

Thus	8669433	1161	O
,	-	1165	O
acetaminophen	-	1167	B
has	-	1181	O
been	-	1185	O
used	-	1190	O
both	-	1195	O
as	-	1200	O
a	-	1203	O
single	-	1205	O
agent	-	1212	O
and	-	1218	O
in	-	1222	O
combination	-	1225	O
with	-	1237	O
other	-	1242	O
analgesics	-	1248	O
,	-	1258	O
whereas	-	1260	O
phenacetin	-	1268	B
was	-	1279	O
available	-	1283	O
only	-	1293	O
in	-	1298	O
combinations	-	1301	O
.	-	1313	O

The	8669433	1315	O
possibility	-	1319	O
that	-	1331	O
habitual	-	1336	O
use	-	1345	O
of	-	1349	O
acetaminophen	-	1352	B
alone	-	1366	O
increases	-	1372	O
the	-	1382	O
risk	-	1386	O
of	-	1391	O
ESRD	-	1394	O
has	-	1399	O
not	-	1403	O
been	-	1407	O
clearly	-	1412	O
demonstrated	-	1420	O
,	-	1432	O
but	-	1434	O
can	-	1438	O
not	-	1441	O
be	-	1445	O
dismissed	-	1448	O
.	-	1457	O

Reduction	8690168	0	O
of	-	10	O
heparan	-	13	B
sulphate	-	21	I
-	-	29	O
associated	-	30	O
anionic	-	41	O
sites	-	49	O
in	-	55	O
the	-	58	O
glomerular	-	62	O
basement	-	73	O
membrane	-	82	O
of	-	91	O
rats	-	94	O
with	-	99	O
streptozotocin	-	104	B
-	-	118	O
induced	-	119	O
diabetic	-	127	O
nephropathy	-	136	O
.	-	147	O

Heparan	8690168	149	B
sulphate	-	157	I
-	-	165	O
associated	-	166	O
anionic	-	177	O
sites	-	185	O
in	-	191	O
the	-	194	O
glomerular	-	198	O
basement	-	209	O
membrane	-	218	O
were	-	227	O
studied	-	232	O
in	-	240	O
rats	-	243	O
8	-	248	O
months	-	250	O
after	-	257	O
induction	-	263	O
of	-	273	O
diabetes	-	276	O
by	-	285	O
streptozotocin	-	288	B
and	-	303	O
in	-	307	O
age	-	310	O
-	-	313	O
adn	-	315	O
sex	-	319	O
-	-	322	O
matched	-	323	O
control	-	331	O
rats	-	339	O
,	-	343	O
employing	-	345	O
the	-	355	O
cationic	-	359	O
dye	-	368	O
cuprolinic	-	372	B
blue	-	383	I
.	-	387	O

Morphometric	8690168	389	O
analysis	-	402	O
at	-	411	O
the	-	414	O
ultrastructural	-	418	O
level	-	434	O
was	-	440	O
performed	-	444	O
using	-	454	O
a	-	460	O
computerized	-	462	O
image	-	475	O
processor	-	481	O
.	-	490	O

The	8690168	492	O
heparan	-	496	B
sulphate	-	504	I
specificity	-	513	O
of	-	525	O
the	-	528	O
cuprolinic	-	532	B
blue	-	543	I
staining	-	548	O
was	-	557	O
demonstrated	-	561	O
by	-	574	O
glycosaminoglycan	-	577	B
-	-	594	O
degrading	-	595	O
enzymes	-	605	O
,	-	612	O
showing	-	614	O
that	-	622	O
pretreatment	-	627	O
of	-	640	O
the	-	643	O
sections	-	647	O
with	-	656	O
heparitinase	-	661	O
abolished	-	674	O
all	-	684	O
staining	-	688	O
,	-	696	O
whereas	-	698	O
chondroitinase	-	706	O
ABC	-	721	O
had	-	725	O
no	-	729	O
effect	-	732	O
.	-	738	O

The	8690168	740	O
majority	-	744	O
of	-	753	O
anionic	-	756	O
sites	-	764	O
(	-	770	O
74	-	771	O
%	-	773	O
in	-	775	O
diabetic	-	778	O
and	-	787	O
81	-	791	O
%	-	793	O
in	-	795	O
control	-	798	O
rats	-	806	O
)	-	810	O
were	-	812	O
found	-	817	O
within	-	823	O
the	-	830	O
lamina	-	834	O
rara	-	841	O
externa	-	846	O
of	-	854	O
the	-	857	O
glomerular	-	861	O
basement	-	872	O
membrane	-	881	O
.	-	889	O

A	8690168	891	O
minority	-	893	O
of	-	902	O
anionic	-	905	O
sites	-	913	O
were	-	919	O
scattered	-	924	O
throughout	-	934	O
the	-	945	O
lamina	-	949	O
densa	-	956	O
and	-	962	O
lamina	-	966	O
rara	-	973	O
interna	-	978	O
,	-	985	O
and	-	987	O
were	-	991	O
significantly	-	996	O
smaller	-	1010	O
than	-	1018	O
those	-	1023	O
in	-	1029	O
the	-	1032	O
lamina	-	1036	O
rara	-	1043	O
externa	-	1048	O
of	-	1056	O
the	-	1059	O
glomerular	-	1063	O
basement	-	1074	O
membrane	-	1083	O
(	-	1092	O
p	-	1093	O
<	-	1094	O
0	-	1095	O
.	-	1096	O
001	-	1097	O
and	-	1101	O
p	-	1105	O
<	-	1106	O
0	-	1107	O
.	-	1108	O
01	-	1109	O
for	-	1112	O
diabetic	-	1116	O
and	-	1125	O
control	-	1129	O
rats	-	1137	O
,	-	1141	O
respectively	-	1143	O
)	-	1155	O
.	-	1156	O

Diabetic	8690168	1158	O
rats	-	1167	O
progressively	-	1172	O
developed	-	1186	O
albuminuria	-	1196	O
reaching	-	1208	O
40	-	1217	O
.	-	1219	O
3	-	1220	O
(	-	1222	O
32	-	1223	O
.	-	1225	O
2	-	1226	O
-	-	1227	O
62	-	1228	O
.	-	1230	O
0	-	1231	O
)	-	1232	O
mg	-	1234	O
/	-	1236	O
24	-	1237	O

h	8690168	1240	O
after	-	1242	O
8	-	1248	O
months	-	1250	O
in	-	1257	O
contrast	-	1260	O
to	-	1269	O
the	-	1272	O
control	-	1276	O
animals	-	1284	O
(	-	1292	O
0	-	1293	O
.	-	1294	O
8	-	1295	O
(	-	1297	O
0	-	1298	O
.	-	1299	O
2	-	1300	O
-	-	1301	O
0	-	1302	O
.	-	1303	O
9	-	1304	O
)	-	1305	O
mg	-	1307	O
/	-	1309	O
24	-	1310	O
h	-	1313	O
,	-	1314	O
p	-	1316	O
<	-	1317	O
0	-	1318	O
.	-	1319	O
002	-	1320	O
)	-	1323	O
.	-	1324	O

At	8690168	1326	O
the	-	1329	O
same	-	1333	O
time	-	1338	O
,	-	1342	O
the	-	1344	O
number	-	1348	O
of	-	1355	O
heparan	-	1358	B
sulphate	-	1366	I
anionic	-	1375	O
sites	-	1383	O
and	-	1389	O
the	-	1393	O
total	-	1397	O
anionic	-	1403	O
site	-	1411	O
surface	-	1416	O
(	-	1424	O
number	-	1425	O
of	-	1432	O
anionic	-	1435	O
sites	-	1443	O
x	-	1449	O
mean	-	1451	O
anionic	-	1456	O
site	-	1464	O
surface	-	1469	O
)	-	1476	O
in	-	1478	O
the	-	1481	O
lamina	-	1485	O
rara	-	1492	O
externa	-	1497	O
of	-	1505	O
the	-	1508	O
glomerular	-	1512	O
basement	-	1523	O
membrane	-	1532	O
was	-	1541	O
reduced	-	1545	O
by	-	1553	O
19	-	1556	O
%	-	1558	O
(	-	1560	O
p	-	1561	O
<	-	1562	O
0	-	1563	O
.	-	1564	O
021	-	1565	O
)	-	1568	O
and	-	1570	O
by	-	1574	O
26	-	1577	O
%	-	1579	O
(	-	1581	O
p	-	1582	O
<	-	1583	O
0	-	1584	O
.	-	1585	O
02	-	1586	O
)	-	1588	O
,	-	1589	O
respectively	-	1591	O
.	-	1603	O

Number	8690168	1605	O
and	-	1612	O
total	-	1616	O
anionic	-	1622	O
site	-	1630	O
surface	-	1635	O
in	-	1643	O
the	-	1646	O
remaining	-	1650	O
part	-	1660	O
of	-	1665	O
the	-	1668	O
glomerular	-	1672	O
basement	-	1683	O
membrane	-	1692	O
(	-	1701	O
lamina	-	1702	O
densa	-	1709	O
and	-	1715	O
lamina	-	1719	O
rara	-	1726	O
interna	-	1731	O
)	-	1738	O
were	-	1740	O
not	-	1745	O
significantly	-	1749	O
changed	-	1763	O
.	-	1770	O

We	8690168	1772	O
conclude	-	1775	O
that	-	1784	O
in	-	1789	O
streptozotocin	-	1792	B
-	-	1806	O
diabetic	-	1807	O
rats	-	1816	O
with	-	1821	O
an	-	1826	O
increased	-	1829	O
urinary	-	1839	O
albumin	-	1847	O
excretion	-	1855	O
,	-	1864	O
a	-	1866	O
reduced	-	1868	O
heparan	-	1876	B
sulphate	-	1884	I
charge	-	1893	O
barrier	-	1900	O
/	-	1907	O
density	-	1908	O
is	-	1916	O
found	-	1919	O
at	-	1925	O
the	-	1928	O
lamina	-	1932	O
rara	-	1939	O
externa	-	1944	O
of	-	1952	O
the	-	1955	O
glomerular	-	1959	O
basement	-	1970	O
membrane	-	1979	O
.	-	1987	O

Effect	8739323	0	O
of	-	7	O
some	-	10	O
anticancer	-	15	O
drugs	-	26	O
and	-	32	O
combined	-	36	O
chemotherapy	-	45	O
on	-	58	O
renal	-	61	O
toxicity	-	67	O
.	-	75	O

The	8739323	77	O
nephrotoxic	-	81	O
action	-	93	O
of	-	100	O
anticancer	-	103	O
drugs	-	114	O
such	-	120	O
as	-	125	O
nitrogranulogen	-	128	B
(	-	144	O
NG	-	145	B
)	-	147	O
,	-	148	O
methotrexate	-	150	B
(	-	163	O
MTX	-	164	B
)	-	167	O
,	-	168	O
5	-	170	B
-	-	171	I
fluorouracil	-	172	I
(	-	185	O
5	-	186	B
-	-	187	I
FU	-	188	I
)	-	190	O
and	-	192	O
cyclophosphamide	-	196	B
(	-	213	O
CY	-	214	B
)	-	216	O
administered	-	218	O
alone	-	231	O
or	-	237	O
in	-	240	O
combination	-	243	O
[	-	255	O
MTX	-	256	B
+	-	260	O
5	-	262	B
-	-	263	I
FU	-	264	I
+	-	267	O
CY	-	269	B
(	-	272	O
CMF	-	273	O
)	-	276	O
]	-	277	O
was	-	279	O
evaluated	-	283	O
in	-	293	O
experiments	-	296	O
on	-	308	O
Wistar	-	311	O
rats	-	318	O
.	-	322	O

After	8739323	324	O
drug	-	330	O
administration	-	335	O
,	-	349	O
creatinine	-	351	B
concentrations	-	362	O
in	-	377	O
the	-	380	O
plasma	-	384	O
and	-	391	O
in	-	395	O
the	-	398	O
urine	-	402	O
of	-	408	O
the	-	411	O
rats	-	415	O
were	-	420	O
determined	-	425	O
,	-	435	O
as	-	437	O
well	-	440	O
as	-	445	O
creatinine	-	448	B
clearance	-	459	O
.	-	468	O

Histopathologic	8739323	470	O
evaluation	-	486	O
of	-	497	O
the	-	500	O
kidneys	-	504	O
was	-	512	O
also	-	516	O
performed	-	521	O
.	-	530	O

After	8739323	532	O
MTX	-	538	B
administration	-	542	O
a	-	557	O
significant	-	559	O
increase	-	571	O
(	-	580	O
p	-	581	O
=	-	583	O
0	-	585	O
.	-	586	O
0228	-	587	O
)	-	591	O
in	-	593	O
the	-	596	O
plasma	-	600	O
creatinine	-	607	B
concentration	-	618	O
and	-	632	O
a	-	636	O
significant	-	638	O
(	-	650	O
p	-	651	O
=	-	653	O
0	-	655	O
.	-	656	O
0001	-	657	O
)	-	661	O
decrease	-	663	O
in	-	672	O
creatinine	-	675	B
clearance	-	686	O
was	-	696	O
noted	-	700	O
compared	-	706	O
to	-	715	O
controls	-	718	O
.	-	726	O

After	8739323	728	O
the	-	734	O
administration	-	738	O
of	-	753	O
NG	-	756	B
,	-	758	O
5	-	760	B
-	-	761	I
FU	-	762	I
and	-	765	O
CY	-	769	B
neither	-	772	O
a	-	780	O
statistically	-	782	O
significant	-	796	O
increase	-	808	O
in	-	817	O
creatinine	-	820	B
concentration	-	831	O
nor	-	845	O
an	-	849	O
increase	-	852	O
in	-	861	O
creatinine	-	864	B
clearance	-	875	O
was	-	885	O
observed	-	889	O
compared	-	898	O
to	-	907	O
the	-	910	O
group	-	914	O
receiving	-	920	O
no	-	930	O
cytostatics	-	933	O
.	-	944	O

Following	8739323	946	O
polytherapy	-	956	O
according	-	968	O
to	-	978	O
the	-	981	O
CMF	-	985	O
regimen	-	989	O
,	-	996	O
a	-	998	O
statistically	-	1000	O
significant	-	1014	O
decrease	-	1026	O
(	-	1035	O
p	-	1036	O
=	-	1038	O
0	-	1040	O
.	-	1041	O
0343	-	1042	O
)	-	1046	O
in	-	1048	O
creatinine	-	1051	B
clearance	-	1062	O
was	-	1072	O
found	-	1076	O
,	-	1081	O
but	-	1083	O
creatinine	-	1087	B
concentration	-	1098	O
did	-	1112	O
not	-	1116	O
increase	-	1120	O
significantly	-	1129	O
compared	-	1143	O
to	-	1152	O
controls	-	1155	O
.	-	1163	O

CY	8739323	1165	B
caused	-	1168	O
hemorrhagic	-	1175	O
cystitis	-	1187	O
in	-	1196	O
40	-	1199	O
%	-	1201	O
of	-	1203	O
rats	-	1206	O
,	-	1210	O
but	-	1212	O
it	-	1216	O
did	-	1219	O
not	-	1223	O
cause	-	1227	O
this	-	1233	O
complication	-	1238	O
when	-	1251	O
combined	-	1256	O
with	-	1265	O
5	-	1270	B
-	-	1271	I
FU	-	1272	I
and	-	1275	O
MTX	-	1279	B
.	-	1282	O

Histologic	8739323	1284	O
changes	-	1295	O
were	-	1303	O
found	-	1308	O
in	-	1314	O
rat	-	1317	O
kidneys	-	1321	O
after	-	1329	O
administration	-	1335	O
of	-	1350	O
MTX	-	1353	B
,	-	1356	O
CY	-	1358	B
and	-	1361	O
NG	-	1365	B
,	-	1367	O
while	-	1369	O
no	-	1375	O
such	-	1378	O
change	-	1383	O
was	-	1390	O
observed	-	1394	O
after	-	1403	O
5	-	1409	B
-	-	1410	I
FU	-	1411	I
and	-	1414	O
joint	-	1418	O
administration	-	1424	O
of	-	1439	O
MTX	-	1442	B
+	-	1446	O
5	-	1448	B
-	-	1449	I
FU	-	1450	I
+	-	1453	O
CY	-	1455	B
compared	-	1458	O
to	-	1467	O
controls	-	1470	O
.	-	1478	O

Our	8739323	1480	O
studies	-	1484	O
indicate	-	1492	O
that	-	1501	O
nephrotoxicity	-	1506	O
of	-	1521	O
MTX	-	1524	B
+	-	1528	O
5	-	1530	B
-	-	1531	I
FU	-	1532	I
+	-	1535	O
CY	-	1537	B
administered	-	1540	O
jointly	-	1553	O
is	-	1561	O
lower	-	1564	O
than	-	1570	O
in	-	1575	O
monotherapy	-	1578	O
.	-	1589	O

Lithium	8752018	0	B
-	-	7	O
associated	-	8	O
cognitive	-	19	O
and	-	29	O
functional	-	33	O
deficits	-	44	O
reduced	-	53	O
by	-	61	O
a	-	64	O
switch	-	66	O
to	-	73	O
divalproex	-	76	B
sodium	-	87	I
:	-	93	O
a	-	95	O
case	-	97	O
series	-	102	O
.	-	108	O

BACKGROUND	8752018	110	O
:	-	120	O

Lithium	8752018	122	B
remains	-	130	O
a	-	138	O
first	-	140	O
-	-	145	O
line	-	146	O
treatment	-	151	O
for	-	161	O
the	-	165	O
acute	-	169	O
and	-	175	O
maintenance	-	179	O
treatment	-	191	O
of	-	201	O
bipolar	-	204	O
disorder	-	212	O
.	-	220	O

Although	8752018	222	O
much	-	231	O
has	-	236	O
been	-	240	O
written	-	245	O
about	-	253	O
the	-	259	O
management	-	263	O
of	-	274	O
the	-	277	O
more	-	281	O
common	-	286	O
adverse	-	293	O
effects	-	301	O
of	-	309	O
lithium	-	312	B
,	-	319	O
such	-	321	O
as	-	326	O
polyuria	-	329	O
and	-	338	O
tremor	-	342	O
,	-	348	O
more	-	350	O
subtle	-	355	O
lithium	-	362	B
side	-	370	O
effects	-	375	O
such	-	383	O
as	-	388	O
cognitive	-	391	O
deficits	-	401	O
,	-	409	O
loss	-	411	O
of	-	416	O
creativity	-	419	O
,	-	429	O
and	-	431	O
functional	-	435	O
impairments	-	446	O
remain	-	458	O
understudied	-	465	O
.	-	477	O

This	8752018	479	O
report	-	484	O
summarizes	-	491	O
our	-	502	O
experience	-	506	O
in	-	517	O
switching	-	520	O
bipolar	-	530	O
patients	-	538	O
from	-	547	O
lithium	-	552	B
to	-	560	O
divalproex	-	563	B
sodium	-	574	I
to	-	581	O
alleviate	-	584	O
such	-	594	O
cognitive	-	599	O
and	-	609	O
functional	-	613	O
impairments	-	624	O
.	-	635	O

METHOD	8752018	637	O
:	-	643	O

Open	8752018	645	O
,	-	649	O
case	-	651	O
series	-	656	O
design	-	663	O
.	-	669	O

RESULTS	8752018	671	O
:	-	678	O

We	8752018	680	O
report	-	683	O
seven	-	690	O
cases	-	696	O
where	-	702	O
substitution	-	708	O
of	-	721	O
lithium	-	724	B
,	-	731	O
either	-	733	O
fully	-	740	O
or	-	746	O
partially	-	749	O
,	-	758	O
with	-	760	O
divalproex	-	765	B
sodium	-	776	I
was	-	783	O
extremely	-	787	O
helpful	-	797	O
in	-	805	O
reducing	-	808	O
the	-	817	O
cognitive	-	821	O
,	-	830	O
motivational	-	832	O
,	-	844	O
or	-	846	O
creative	-	849	O
deficits	-	858	O
attributed	-	867	O
to	-	878	O
lithium	-	881	B
in	-	889	O
our	-	892	O
bipolar	-	896	O
patients	-	904	O
.	-	912	O

CONCLUSION	8752018	914	O
:	-	924	O

In	8752018	926	O
this	-	929	O
preliminary	-	934	O
report	-	946	O
,	-	952	O
divalproex	-	954	B
sodium	-	965	I
was	-	972	O
a	-	976	O
superior	-	978	O
alternative	-	987	O
to	-	999	O
lithium	-	1002	B
in	-	1010	O
bipolar	-	1013	O
patients	-	1021	O
experiencing	-	1030	O
cognitive	-	1043	O
deficits	-	1053	O
,	-	1061	O
loss	-	1063	O
of	-	1068	O
creativity	-	1071	O
,	-	1081	O
and	-	1083	O
functional	-	1087	O
impairments	-	1098	O
.	-	1109	O

Treatment	9390208	0	O
of	-	10	O
previously	-	13	O
treated	-	24	O
metastatic	-	32	O
breast	-	43	O
cancer	-	50	O
by	-	57	O
mitoxantrone	-	60	B
and	-	73	O
48	-	77	O
-	-	79	O
hour	-	80	O
continuous	-	85	O
infusion	-	96	O
of	-	105	O
high	-	108	O
-	-	112	O
dose	-	113	O
5	-	118	B
-	-	119	I
FU	-	120	I
and	-	123	O
leucovorin	-	127	B
(	-	138	O
MFL	-	139	B
)	-	142	O
:	-	143	O
low	-	145	O
palliative	-	149	O
benefit	-	160	O
and	-	168	O
high	-	172	O
treatment	-	177	O
-	-	186	O
related	-	187	O
toxicity	-	195	O
.	-	203	O

For	9390208	205	O
previously	-	209	O
treated	-	220	O
advanced	-	228	O
breast	-	237	O
cancer	-	244	O
,	-	250	O
there	-	252	O
is	-	258	O
no	-	261	O
standard	-	264	O
second	-	273	O
-	-	279	O
line	-	280	O
therapy	-	285	O
.	-	292	O

Combination	9390208	294	O
chemotherapy	-	306	O
with	-	319	O
mitoxantrone	-	324	B
,	-	336	O
high	-	338	O
-	-	342	O
dose	-	343	O
5	-	348	B
-	-	349	I
fluorouracil	-	350	I
(	-	363	O
5	-	364	B
-	-	365	I
FU	-	366	I
)	-	368	O
and	-	370	O
leucovorin	-	374	B
(	-	385	O
MFL	-	386	B
regimen	-	390	I
)	-	397	O
had	-	399	O
been	-	403	O
reported	-	408	O
as	-	417	O
an	-	420	O
effective	-	423	O
and	-	433	O
well	-	437	O
tolerated	-	442	O
regimen	-	452	O
.	-	459	O

From	9390208	461	O
October	-	466	O
1993	-	474	O
to	-	479	O
November	-	482	O
1995	-	491	O
,	-	495	O
we	-	497	O
treated	-	500	O
13	-	508	O
patients	-	511	O
with	-	520	O
previously	-	525	O
chemotherapy	-	536	O
-	-	548	O
treated	-	549	O
metastatic	-	557	O
breast	-	568	O
cancer	-	575	O
by	-	582	O
mitoxantrone	-	585	B
,	-	597	O
12	-	599	O
mg	-	602	O
/	-	604	O
m2	-	605	O
,	-	607	O
on	-	609	O
day	-	612	O
1	-	616	O
and	-	618	O
continuous	-	622	O
infusion	-	633	O
of	-	642	O
5	-	645	B
-	-	646	I
FU	-	647	I
,	-	649	O
3000	-	651	O
mg	-	656	O
/	-	658	O
m2	-	659	O
,	-	661	O
together	-	663	O
with	-	672	O
leucovorin	-	677	B
,	-	687	O
300	-	689	O
mg	-	693	O
/	-	695	O
m2	-	696	O
,	-	698	O
for	-	700	O
48	-	704	O
h	-	707	O
from	-	709	O
day	-	714	O
1	-	718	O
to	-	720	O
2	-	723	O
.	-	724	O

Each	9390208	726	O
course	-	731	O
of	-	738	O
chemotherapy	-	741	O
was	-	754	O
given	-	758	O
every	-	764	O
4	-	770	O
weeks	-	772	O
.	-	777	O

Most	9390208	779	O
of	-	784	O
these	-	787	O
patients	-	793	O
had	-	802	O
more	-	806	O
than	-	811	O
two	-	816	O
metastatic	-	820	O
sites	-	831	O
,	-	836	O
with	-	838	O
lung	-	843	O
metastasis	-	848	O
predominant	-	859	O
.	-	870	O

Seven	9390208	872	O
patients	-	878	O
had	-	887	O
been	-	891	O
treated	-	896	O
with	-	904	O
anthracycline	-	909	B
.	-	922	O

Seven	9390208	924	O
patients	-	930	O
had	-	939	O
previously	-	943	O
received	-	954	O
radiotherapy	-	963	O
and	-	976	O
seven	-	980	O
had	-	986	O
received	-	990	O
hormone	-	999	O
therapy	-	1007	O
.	-	1014	O

Median	9390208	1016	O
number	-	1023	O
of	-	1030	O
courses	-	1033	O
of	-	1041	O
MFL	-	1044	B
regimen	-	1048	I
given	-	1056	O
was	-	1062	O
six	-	1066	O
and	-	1070	O
the	-	1074	O
median	-	1078	O
cumulative	-	1085	O
dose	-	1096	O
of	-	1101	O
mitoxantrone	-	1104	B
was	-	1117	O

68	9390208	1121	O
.	-	1123	O
35	-	1124	O
mg	-	1127	O
/	-	1129	O
m2	-	1130	O
.	-	1132	O

One	9390208	1134	O
patient	-	1138	O
had	-	1146	O
complete	-	1150	O
response	-	1159	O
,	-	1167	O
seven	-	1169	O
had	-	1175	O
stable	-	1179	O
disease	-	1186	O
,	-	1193	O
none	-	1195	O
had	-	1200	O
partial	-	1204	O
response	-	1212	O
and	-	1221	O
five	-	1225	O
had	-	1230	O
progressive	-	1234	O
disease	-	1246	O
.	-	1253	O

The	9390208	1255	O
overall	-	1259	O
objective	-	1267	O
response	-	1277	O
rate	-	1286	O
was	-	1291	O
7	-	1295	O
.	-	1296	O
6	-	1297	O
%	-	1298	O
.	-	1299	O

The	9390208	1301	O
median	-	1305	O
follow	-	1312	O
-	-	1318	O
up	-	1319	O
period	-	1322	O
was	-	1329	O
14	-	1333	O
months	-	1336	O
.	-	1342	O

Median	9390208	1344	O
survival	-	1351	O
was	-	1360	O
16	-	1364	O
months	-	1367	O
.	-	1373	O

Median	9390208	1375	O
progression	-	1382	O
-	-	1393	O
free	-	1394	O
survival	-	1399	O
was	-	1408	O
5	-	1412	O
months	-	1414	O
.	-	1420	O

A	9390208	1422	O
complete	-	1424	O
responder	-	1433	O
had	-	1443	O
relapse	-	1447	O
-	-	1454	O
free	-	1455	O
survival	-	1460	O
up	-	1469	O
to	-	1472	O
17	-	1475	O
months	-	1478	O
.	-	1484	O

Major	9390208	1486	O
toxicities	-	1492	O
were	-	1503	O
cardiotoxicity	-	1508	O
and	-	1523	O
leukopenia	-	1527	O
.	-	1537	O

Eight	9390208	1539	O
patients	-	1545	O
were	-	1554	O
dead	-	1559	O
in	-	1564	O
the	-	1567	O
last	-	1571	O
follow	-	1576	O
-	-	1582	O
up	-	1583	O
;	-	1585	O
two	-	1587	O
of	-	1591	O
them	-	1594	O
died	-	1599	O
of	-	1604	O
treatment	-	1607	O
-	-	1616	O
related	-	1617	O
toxicity	-	1625	O
.	-	1633	O

The	9390208	1635	O
MFL	-	1639	B
regimen	-	1643	I
achieves	-	1651	O
little	-	1660	O
palliative	-	1667	O
benefit	-	1678	O
and	-	1686	O
induces	-	1690	O
severe	-	1698	O
toxicity	-	1705	O
at	-	1714	O
a	-	1717	O
fairly	-	1719	O
high	-	1726	O
rate	-	1731	O
.	-	1735	O

Administration	9390208	1737	O
of	-	1752	O
this	-	1755	O
regimen	-	1760	O
to	-	1768	O
breast	-	1771	O
cancer	-	1778	O
patients	-	1785	O
who	-	1794	O
have	-	1798	O
been	-	1803	O
treated	-	1808	O
by	-	1816	O
chemotherapy	-	1819	O
and	-	1832	O
those	-	1836	O
with	-	1842	O
impaired	-	1847	O
heart	-	1856	O
function	-	1862	O
requires	-	1871	O
careful	-	1880	O
attention	-	1888	O
.	-	1897	O

Upregulation	9406968	0	O
of	-	13	O
the	-	16	O
expression	-	20	O
of	-	31	O
vasopressin	-	34	B
gene	-	46	O
in	-	51	O
the	-	54	O
paraventricular	-	58	O
and	-	74	O
supraoptic	-	78	O
nuclei	-	89	O
of	-	96	O
the	-	99	O
lithium	-	103	B
-	-	110	O
induced	-	111	O
diabetes	-	119	O
insipidus	-	128	O
rat	-	138	O
.	-	141	O

The	9406968	143	O
expression	-	147	O
of	-	158	O
arginine	-	161	B
vasopressin	-	170	I
(	-	182	O
AVP	-	183	B
)	-	186	O
gene	-	188	O
in	-	193	O
the	-	196	O
paraventricular	-	200	O
(	-	216	O
PVN	-	217	O
)	-	220	O
and	-	222	O
supraoptic	-	226	O
nuclei	-	237	O
(	-	244	O
SON	-	245	O
)	-	248	O
was	-	250	O
investigated	-	254	O
in	-	267	O
rats	-	270	O
with	-	275	O
lithium	-	280	B
(	-	288	O
Li	-	289	B
)	-	291	O
-	-	292	O
induced	-	293	O
polyuria	-	301	O
,	-	309	O
using	-	311	O
in	-	317	O
situ	-	320	O
hybridization	-	325	O
histochemistry	-	339	O
and	-	354	O
radioimmunoassay	-	358	O
.	-	374	O

The	9406968	376	O
male	-	380	O
Wistar	-	385	O
rats	-	392	O
consuming	-	397	O
a	-	407	O
diet	-	409	O
that	-	414	O
contained	-	419	O
LiCl	-	429	B
(	-	434	O
60	-	435	O
mmol	-	438	O
/	-	442	O
kg	-	443	O
)	-	445	O
for	-	447	O
4	-	451	O
weeks	-	453	O
developed	-	459	O
marked	-	469	O
polyuria	-	476	O
.	-	484	O

The	9406968	486	O
Li	-	490	B
-	-	492	O
treated	-	493	O
rats	-	501	O
produced	-	506	O
a	-	515	O
large	-	517	O
volume	-	523	O
of	-	530	O
hypotonic	-	533	O
urine	-	543	O
with	-	549	O
low	-	554	O
ionic	-	558	O
concentrations	-	564	O
.	-	578	O

Plasma	9406968	580	O
sodium	-	587	B
concentrations	-	594	O
were	-	609	O
found	-	614	O
to	-	620	O
be	-	623	O
slightly	-	626	O
increased	-	635	O
in	-	645	O
the	-	648	O
Li	-	652	B
-	-	654	O
treated	-	655	O
rats	-	663	O
compared	-	668	O
with	-	677	O
those	-	682	O
in	-	688	O
controls	-	691	O
.	-	699	O

Plasma	9406968	701	O
concentration	-	708	O
of	-	722	O
AVP	-	725	B
and	-	729	O
transcripts	-	733	O
of	-	745	O
AVP	-	748	B
gene	-	752	O
in	-	757	O
the	-	760	O
PVN	-	764	O
and	-	768	O
SON	-	772	O
were	-	776	O
significantly	-	781	O
increased	-	795	O
in	-	805	O
the	-	808	O
Li	-	812	B
-	-	814	O
treated	-	815	O
rats	-	823	O
compared	-	828	O
with	-	837	O
controls	-	842	O
.	-	850	O

These	9406968	852	O
results	-	858	O
suggest	-	866	O
that	-	874	O
dehydration	-	879	O
and	-	891	O
/	-	894	O
or	-	895	O
the	-	898	O
activation	-	902	O
of	-	913	O
visceral	-	916	O
afferent	-	925	O
inputs	-	934	O
may	-	941	O
contribute	-	945	O
to	-	956	O
the	-	959	O
elevation	-	963	O
of	-	973	O
plasma	-	976	O
AVP	-	983	B
and	-	987	O
the	-	991	O
upregulation	-	995	O
of	-	1008	O
AVP	-	1011	B
gene	-	1015	O
expression	-	1020	O
in	-	1031	O
the	-	1034	O
PVN	-	1038	O
and	-	1042	O
the	-	1046	O
SON	-	1050	O
of	-	1054	O
the	-	1057	O
Li	-	1061	B
-	-	1063	O
induced	-	1064	O
diabetes	-	1072	O
insipidus	-	1081	O
rat	-	1091	O
.	-	1094	O

Suxamethonium	9587734	0	B
-	-	13	O
induced	-	14	O
cardiac	-	22	O
arrest	-	30	O
and	-	37	O
death	-	41	O
following	-	47	O
5	-	57	O
days	-	59	O
of	-	64	O
immobilization	-	67	O
.	-	81	O

The	9587734	83	O
present	-	87	O
report	-	95	O
describes	-	102	O
a	-	112	O
case	-	114	O
of	-	119	O
cardiac	-	122	O
arrest	-	130	O
and	-	137	O
subsequent	-	141	O
death	-	152	O
as	-	158	O
a	-	161	O
result	-	163	O
of	-	170	O
hyperkalaemia	-	173	O
following	-	187	O
the	-	197	O
use	-	201	O
of	-	205	O
suxamethonium	-	208	B
in	-	222	O
a	-	225	O
23	-	227	O
-	-	229	O
year	-	230	O
-	-	234	O
old	-	235	O
Malawian	-	239	O
woman	-	248	O
.	-	253	O

Five	9587734	255	O
days	-	260	O
after	-	265	O
the	-	271	O
onset	-	275	O
of	-	281	O
the	-	284	O
symptoms	-	288	O
of	-	297	O
meningitis	-	300	O
,	-	310	O
the	-	312	O
patient	-	316	O
aspirated	-	324	O
stomach	-	334	O
contents	-	342	O
and	-	351	O
needed	-	355	O
endotracheal	-	362	O
intubation	-	375	O
.	-	385	O

Forty	9587734	387	O
seconds	-	393	O
after	-	401	O
injection	-	407	O
of	-	417	O
suxamethonium	-	420	B
,	-	433	O
bradycardia	-	435	O
and	-	447	O
cardiac	-	451	O
arrest	-	459	O
occurred	-	466	O
.	-	474	O

Attempts	9587734	476	O
to	-	485	O
resuscitate	-	488	O
the	-	500	O
patient	-	504	O
were	-	512	O
not	-	517	O
successful	-	521	O
.	-	531	O

The	9587734	533	O
serum	-	537	O
level	-	543	O
of	-	549	O
potassium	-	552	B
was	-	562	O
observed	-	566	O
to	-	575	O
be	-	578	O
8	-	581	O
.	-	582	O
4	-	583	O
mequiv	-	585	O
L	-	592	O
-	-	593	O
1	-	594	O
.	-	595	O

Apart	9587734	597	O
from	-	603	O
the	-	608	O
reduction	-	612	O
in	-	622	O
the	-	625	O
patient	-	629	O
's	-	636	O
level	-	639	O
of	-	645	O
consciousness	-	648	O
,	-	661	O
there	-	663	O
were	-	669	O
no	-	674	O
signs	-	677	O
of	-	683	O
motor	-	686	O
neurone	-	692	O
damage	-	700	O
or	-	707	O
of	-	710	O
any	-	713	O
of	-	717	O
the	-	720	O
other	-	724	O
known	-	730	O
predisposing	-	736	O
conditions	-	749	O
for	-	760	O
hyperkalaemia	-	764	O
following	-	778	O
the	-	788	O
administration	-	792	O
of	-	807	O
suxamethonium	-	810	B
.	-	823	O

It	9587734	825	O
is	-	828	O
postulated	-	831	O
that	-	842	O
her	-	847	O
death	-	851	O
was	-	857	O
caused	-	861	O
by	-	868	O
hypersensitivity	-	871	O
to	-	888	O
suxamethonium	-	891	B
,	-	904	O
associated	-	906	O
with	-	917	O
her	-	922	O
5	-	926	O
-	-	927	O
day	-	928	O
immobilization	-	932	O
.	-	946	O

An	9698967	0	O
unusual	-	3	O
toxic	-	11	O
reaction	-	17	O
to	-	26	O
axillary	-	29	O
block	-	38	O
by	-	44	O
mepivacaine	-	47	B
with	-	59	O
adrenaline	-	64	B
.	-	74	O

An	9698967	76	O
increase	-	79	O
in	-	88	O
blood	-	91	O
pressure	-	97	O
,	-	105	O
accompanied	-	107	O
by	-	119	O
atrial	-	122	O
fibrillation	-	129	O
,	-	141	O
agitation	-	143	O
,	-	152	O
incomprehensible	-	154	O
shouts	-	171	O
and	-	178	O
loss	-	182	O
of	-	187	O
consciousness	-	190	O
,	-	203	O
was	-	205	O
observed	-	209	O
in	-	218	O
an	-	221	O
elderly	-	224	O
,	-	231	O
ASA	-	233	O
classification	-	237	O
group	-	252	O
II	-	258	O
,	-	260	O
cardiovascularly	-	262	O
medicated	-	279	O
male	-	289	O
,	-	293	O
12	-	295	O
min	-	298	O
after	-	302	O
performance	-	308	O
of	-	320	O
axillary	-	323	O
block	-	332	O
with	-	338	O
mepivacaine	-	343	B
850	-	355	O
mg	-	359	O
containing	-	362	O
adrenaline	-	373	B
0	-	384	O
.	-	385	O
225	-	386	O
mg	-	390	O
,	-	392	O
for	-	394	O
correction	-	398	O
of	-	409	O
Dupuytren	-	412	O
's	-	421	O
contracture	-	424	O
.	-	435	O

After	9698967	437	O
intravenous	-	443	O
administration	-	455	O
of	-	470	O
labetalol	-	473	B
,	-	482	O
metoprolol	-	484	B
and	-	495	O
midazolam	-	499	B
the	-	509	O
patient	-	513	O
's	-	520	O
condition	-	523	O
improved	-	533	O
,	-	541	O
and	-	543	O
15	-	547	O
min	-	550	O
later	-	554	O
he	-	560	O
woke	-	563	O
up	-	568	O
.	-	570	O

The	9698967	572	O
block	-	576	O
was	-	582	O
successful	-	586	O
and	-	597	O
surgery	-	601	O
was	-	609	O
conducted	-	613	O
as	-	623	O
scheduled	-	626	O
despite	-	636	O
persisting	-	644	O
atrial	-	655	O
fibrillation	-	662	O
.	-	674	O

Postoperatively	9698967	676	O
,	-	691	O
the	-	693	O
patient	-	697	O
refused	-	705	O
DC	-	713	O
cardioversion	-	716	O
and	-	730	O
was	-	734	O
treated	-	738	O
medically	-	746	O
.	-	755	O

Both	9698967	757	O
the	-	762	O
temporal	-	766	O
relationship	-	775	O
of	-	788	O
events	-	791	O
and	-	798	O
the	-	802	O
response	-	806	O
to	-	815	O
treatment	-	818	O
suggest	-	828	O
that	-	836	O
a	-	841	O
rapid	-	843	O
systemic	-	849	O
absorption	-	858	O
of	-	869	O
mepivacaine	-	872	B
with	-	884	O
adrenaline	-	889	B

and	9698967	900	O
/	-	903	O
or	-	904	O
interaction	-	907	O
of	-	919	O
these	-	922	O
drugs	-	928	O
with	-	934	O
the	-	939	O
patient	-	943	O
's	-	950	O
cardiovascular	-	953	O
medications	-	968	O
were	-	980	O
responsible	-	985	O
for	-	997	O
the	-	1001	O
perioperative	-	1005	O
complications	-	1019	O
.	-	1032	O

Clinical	9855119	0	O
and	-	9	O
histopathologic	-	13	O
examination	-	29	O
of	-	41	O
renal	-	44	O
allografts	-	50	O
treated	-	61	O
with	-	69	O
tacrolimus	-	74	B
(	-	85	O
FK506	-	86	B
)	-	91	O
for	-	93	O
at	-	97	O
least	-	100	O
one	-	106	O
year	-	110	O
.	-	114	O

BACKGROUND	9855119	116	O
:	-	126	O

We	9855119	128	O
clinically	-	131	O
and	-	142	O
pathologically	-	146	O
analyzed	-	161	O
renal	-	170	O
allografts	-	176	O
from	-	187	O
1	-	192	O
9	-	194	O
renal	-	196	O
transplant	-	202	O
patients	-	213	O
treated	-	222	O
with	-	230	O
tacrolimus	-	235	B
(	-	246	O
FK506	-	247	B
)	-	252	O
for	-	254	O
more	-	258	O
than	-	263	O
1	-	268	O
year	-	270	O
.	-	274	O

METHODS	9855119	276	O
:	-	283	O

Twenty	9855119	285	O
-	-	291	O
six	-	292	O
renal	-	296	O
allograft	-	302	O
biopsy	-	312	O
specimens	-	319	O
from	-	329	O
1	-	334	O
9	-	336	O
renal	-	338	O
transplant	-	344	O
patients	-	355	O
who	-	364	O
underwent	-	368	O
transplantations	-	378	O
between	-	395	O
1991	-	403	O
and	-	408	O
1993	-	412	O
were	-	417	O
evaluated	-	422	O
.	-	431	O

Thirteen	9855119	433	O
biopsies	-	442	O
were	-	451	O
performed	-	456	O
from	-	466	O
stable	-	471	O
functioning	-	478	O
renal	-	490	O
allografts	-	496	O
with	-	507	O
informed	-	512	O
consent	-	521	O
(	-	529	O
nonepisode	-	530	O
biopsy	-	541	O
)	-	547	O
and	-	549	O
the	-	553	O
other	-	557	O
13	-	563	O
were	-	566	O
from	-	571	O
dysfunctional	-	576	O
renal	-	590	O
allografts	-	596	O
with	-	607	O
a	-	612	O
clinical	-	614	O
indication	-	623	O
for	-	634	O
biopsy	-	638	O
(	-	645	O
episode	-	646	O
biopsy	-	654	O
)	-	660	O
.	-	661	O

RESULTS	9855119	663	O
:	-	670	O

The	9855119	672	O
main	-	676	O
pathologic	-	681	O
diagnoses	-	692	O
(	-	702	O
some	-	703	O
overlap	-	708	O
)	-	715	O
were	-	717	O
acute	-	722	O
rejection	-	728	O
(	-	738	O
AR	-	739	O
;	-	741	O
n	-	743	O
=	-	745	O
4	-	747	O
)	-	748	O
,	-	749	O
chronic	-	751	O
rejection	-	759	O
(	-	769	O
CR	-	770	O
;	-	772	O
n	-	774	O
=	-	775	O
5	-	776	O
)	-	777	O
,	-	778	O
AR	-	780	O
+	-	782	O
CR	-	783	O
(	-	786	O
n	-	787	O
=	-	789	O
4	-	790	O
)	-	791	O
,	-	792	O
recurrent	-	794	O
IgA	-	804	O
nephropathy	-	808	O
(	-	820	O
n	-	821	O
=	-	823	O
5	-	824	O
)	-	825	O
,	-	826	O
normal	-	828	O
findings	-	835	O
(	-	844	O
n	-	845	O
=	-	847	O
2	-	848	O
)	-	849	O
,	-	850	O
minimal	-	852	O
-	-	859	O
type	-	860	O
chronic	-	865	O
FK506	-	873	B
nephropathy	-	879	O
(	-	891	O
n	-	892	O
=	-	894	O
9	-	896	O
)	-	897	O
,	-	898	O
and	-	900	O
mild	-	904	O
-	-	908	O
type	-	909	O
FK506	-	914	B
nephropathy	-	920	O
(	-	932	O
n	-	933	O
=	-	935	O
11	-	937	O
)	-	939	O
.	-	940	O

Of	9855119	942	O
the	-	945	O
nonepisode	-	949	O
biopsies	-	960	O
,	-	968	O
7	-	970	O
and	-	972	O
4	-	976	O
biopsies	-	978	O
showed	-	987	O
minimal	-	994	O
-	-	1001	O
type	-	1002	O
and	-	1007	O
mild	-	1011	O
-	-	1015	O
type	-	1016	O
chronic	-	1021	O
FK506	-	1029	B
nephropathy	-	1035	O
,	-	1046	O
respectively	-	1048	O
.	-	1060	O

Chronic	9855119	1062	O
FK506	-	1070	B
nephropathy	-	1076	O
consisted	-	1088	O
of	-	1098	O
rough	-	1101	O
and	-	1107	O
foamy	-	1111	O
tubular	-	1117	O
vacuolization	-	1125	O
(	-	1139	O
5	-	1140	O
biopsies	-	1142	O
)	-	1150	O
,	-	1151	O
arteriolopathy	-	1153	O
(	-	1168	O
angiodegeneration	-	1169	O
of	-	1187	O
the	-	1190	O
arteriolar	-	1194	O
wall	-	1205	O
;	-	1209	O
20	-	1211	O
biopsies	-	1214	O
)	-	1222	O
,	-	1223	O
focal	-	1225	O
segmental	-	1231	O
glomerulosclerosis	-	1241	O
(	-	1260	O
4	-	1261	O
biopsies	-	1263	O
)	-	1271	O
and	-	1273	O
the	-	1277	O
striped	-	1281	O
form	-	1289	O
of	-	1294	O
interstitial	-	1297	O
fibrosis	-	1310	O
(	-	1319	O
11	-	1320	O
biopsies	-	1323	O
)	-	1331	O
.	-	1332	O

The	9855119	1334	O
serum	-	1338	O
creatinine	-	1344	B
levels	-	1355	O
of	-	1362	O
patients	-	1365	O
in	-	1374	O
the	-	1377	O
mild	-	1381	O
-	-	1385	O
type	-	1386	O
chronic	-	1391	O
FK506	-	1399	B
nephropathy	-	1405	O
group	-	1417	O
,	-	1422	O
which	-	1424	O
included	-	1430	O
7	-	1439	O
episode	-	1441	O
biopsies	-	1449	O
,	-	1457	O
were	-	1459	O
statistically	-	1464	O
higher	-	1478	O
than	-	1485	O
those	-	1490	O
in	-	1496	O
the	-	1499	O
minimum	-	1503	O
-	-	1510	O
type	-	1511	O
chronic	-	1516	O
FK506	-	1524	B
-	-	1529	O
nephropathy	-	1530	O
group	-	1542	O
(	-	1548	O
P	-	1549	O
<	-	1550	O
0	-	1552	O
.	-	1553	O
001	-	1554	O
)	-	1557	O
.	-	1558	O

CONCLUSIONS	9855119	1560	O
:	-	1571	O

This	9855119	1573	O
study	-	1578	O
demonstrates	-	1584	O
that	-	1597	O
chronic	-	1602	O
FK506	-	1610	B
nephropathy	-	1616	O
consists	-	1628	O
primarily	-	1637	O
of	-	1647	O
arteriolopathy	-	1650	O
manifesting	-	1665	O
as	-	1677	O
insudative	-	1680	O
hyalinosis	-	1691	O
of	-	1702	O
the	-	1705	O
arteriolar	-	1709	O
wall	-	1720	O
,	-	1724	O
and	-	1726	O
suggests	-	1730	O
that	-	1739	O
mild	-	1744	O
-	-	1748	O
type	-	1749	O
chronic	-	1754	O
FK506	-	1762	B
nephropathy	-	1768	O
is	-	1780	O
a	-	1783	O
condition	-	1785	O
which	-	1795	O
may	-	1801	O
lead	-	1805	O
to	-	1810	O
deterioration	-	1813	O
of	-	1827	O
renal	-	1830	O
allograft	-	1836	O
function	-	1846	O
.	-	1854	O

Memory	9869257	0	O
facilitation	-	7	O
and	-	20	O
stimulation	-	24	O
of	-	36	O
endogenous	-	39	O
nerve	-	50	O
growth	-	56	O
factor	-	63	O
synthesis	-	70	O
by	-	80	O
the	-	83	O
acetylcholine	-	87	B
releaser	-	101	O
PG	-	110	B
-	-	112	I
9	-	113	I
.	-	114	O

The	9869257	116	O
effects	-	120	O
of	-	128	O
PG	-	131	B
-	-	133	I
9	-	134	I
(	-	136	O
3alpha	-	137	B
-	-	143	I
tropyl	-	144	I
2	-	151	I
-	-	152	I
(	-	153	I
p	-	154	I
-	-	155	I
bromophenyl	-	156	I
)	-	167	I
propionate	-	168	I
)	-	178	O
,	-	179	O
the	-	181	O
acetylcholine	-	185	B
releaser	-	199	O
,	-	207	O
on	-	209	O
memory	-	212	O
processes	-	219	O
and	-	229	O
nerve	-	233	O
growth	-	239	O
factor	-	246	O
(	-	253	O
NGF	-	254	O
)	-	257	O
synthesis	-	259	O
were	-	269	O
evaluated	-	274	O
.	-	283	O

In	9869257	285	O
the	-	288	O
mouse	-	292	O
passive	-	298	O
-	-	305	O
avoidance	-	306	O
test	-	316	O
,	-	320	O
PG	-	322	B
-	-	324	I
9	-	325	I
(	-	327	O
10	-	328	O
-	-	330	O
30	-	331	O
mg	-	334	O
/	-	336	O
kg	-	337	O
,	-	339	O
i	-	341	O
.	-	342	O
p	-	343	O
.	-	344	O
)	-	345	O
,	-	346	O
administered	-	348	O
20	-	361	O
min	-	364	O
before	-	368	O
the	-	375	O
training	-	379	O
session	-	388	O
,	-	395	O
prevented	-	397	O
amnesia	-	407	O
induced	-	415	O
by	-	423	O
both	-	426	O
the	-	431	O
non	-	435	O
selective	-	439	O
antimuscarinic	-	449	O
drug	-	464	O
scopolamine	-	469	B
and	-	481	O
the	-	485	O
M1	-	489	O
-	-	491	O
selective	-	492	O
antagonist	-	502	O
S	-	513	B
-	-	514	I
(	-	515	I
-	-	516	I
)	-	517	I
-	-	518	I
ET	-	519	I
-	-	521	I
126	-	522	I
.	-	525	O

In	9869257	527	O
the	-	530	O
same	-	534	O
experimental	-	539	O
conditions	-	552	O
,	-	562	O
PG	-	564	B
-	-	566	I
9	-	567	I
(	-	569	O
5	-	570	O
-	-	571	O
20	-	572	O
microg	-	575	O
per	-	582	O
mouse	-	586	O
,	-	591	O
i	-	593	O
.	-	594	O
c	-	595	O
.	-	596	O
v	-	597	O
.	-	598	O
)	-	599	O
was	-	601	O
also	-	605	O
able	-	610	O
to	-	615	O
prevent	-	618	O
antimuscarine	-	626	O
-	-	639	O
induced	-	640	O
amnesia	-	648	O
,	-	655	O
demonstrating	-	657	O
a	-	671	O
central	-	673	O
localization	-	681	O
of	-	694	O
the	-	697	O
activity	-	701	O
.	-	709	O

At	9869257	711	O
the	-	714	O
highest	-	718	O
effective	-	726	O
doses	-	736	O
,	-	741	O
PG	-	743	B
-	-	745	I
9	-	746	I
did	-	748	O
not	-	752	O
produce	-	756	O
any	-	764	O
collateral	-	768	O
symptoms	-	779	O
as	-	788	O
revealed	-	791	O
by	-	800	O
the	-	803	O
Irwin	-	807	O
test	-	813	O
,	-	817	O
and	-	819	O
it	-	823	O
did	-	826	O
not	-	830	O
modify	-	834	O
spontaneous	-	841	O
motility	-	853	O
and	-	862	O
inspection	-	866	O
activity	-	877	O
,	-	885	O
as	-	887	O
revealed	-	890	O
by	-	899	O
the	-	902	O
hole	-	906	O
-	-	910	O
board	-	911	O
test	-	917	O
.	-	921	O

PG	9869257	923	B
-	-	925	I
9	-	926	I
was	-	928	O
also	-	932	O
able	-	937	O
to	-	942	O
increase	-	945	O
the	-	954	O
amount	-	958	O
of	-	965	O
NGF	-	968	O
secreted	-	972	O
in	-	981	O
vitro	-	984	O
by	-	990	O
astrocytes	-	993	O
in	-	1004	O
a	-	1007	O
dose	-	1009	O
-	-	1013	O
dependent	-	1014	O
manner	-	1024	O
.	-	1030	O

The	9869257	1032	O
maximal	-	1036	O
NGF	-	1044	O
contents	-	1048	O
obtained	-	1057	O
by	-	1066	O
PG	-	1069	B
-	-	1071	I
9	-	1072	I
were	-	1074	O
17	-	1079	O
.	-	1081	O
6	-	1082	O
-	-	1083	O
fold	-	1084	O
of	-	1089	O
the	-	1092	O
control	-	1096	O
value	-	1104	O
.	-	1109	O

During	9869257	1111	O
culture	-	1118	O
,	-	1125	O
no	-	1127	O
morphological	-	1130	O
changes	-	1144	O
were	-	1152	O
found	-	1157	O
at	-	1163	O
effective	-	1166	O
concentrations	-	1176	O
of	-	1191	O
PG	-	1194	B
-	-	1196	I
9	-	1197	I
.	-	1198	O

The	9869257	1200	O
current	-	1204	O
work	-	1212	O
indicates	-	1217	O
the	-	1227	O
ability	-	1231	O
of	-	1239	O
PG	-	1242	B
-	-	1244	I
9	-	1245	I
to	-	1247	O
induce	-	1250	O
beneficial	-	1257	O
effects	-	1268	O
on	-	1276	O
cognitive	-	1279	O
processes	-	1289	O
and	-	1299	O
stimulate	-	1303	O
activity	-	1313	O
of	-	1322	O
NGF	-	1325	O
synthesis	-	1329	O
in	-	1339	O
astroglial	-	1342	O
cells	-	1353	O
.	-	1358	O

Therefore	9869257	1360	O
,	-	1369	O
PG	-	1371	B
-	-	1373	I
9	-	1374	I
could	-	1376	O
represent	-	1382	O
a	-	1392	O
potential	-	1394	O
useful	-	1404	O
drug	-	1411	O
able	-	1416	O
to	-	1421	O
improve	-	1424	O
the	-	1432	O
function	-	1436	O
of	-	1445	O
impaired	-	1448	O
cognitive	-	1457	O
processes	-	1467	O
.	-	1476	O

Angioedema	10342929	0	O
due	-	11	O
to	-	15	O
ACE	-	18	B
inhibitors	-	22	I
:	-	32	O
common	-	34	O
and	-	41	O
inadequately	-	45	O
diagnosed	-	58	O
.	-	67	O

The	10342929	69	O
estimated	-	73	O
incidence	-	83	O
of	-	93	O
angioedema	-	96	O
during	-	107	O
angiotensin	-	114	B
-	-	125	I
converting	-	126	I
enzyme	-	137	I
(	-	144	I
ACE	-	145	I
)	-	148	I
inhibitor	-	150	I
treatment	-	160	O
is	-	170	O
between	-	173	O
1	-	181	O
and	-	183	O
7	-	187	O
per	-	189	O
thousand	-	193	O
patients	-	202	O
.	-	210	O

This	10342929	212	O
potentially	-	217	O
serious	-	229	O
adverse	-	237	O
effect	-	245	O
is	-	252	O
often	-	255	O
preceded	-	261	O
by	-	270	O
minor	-	273	O
manifestations	-	279	O
that	-	294	O
may	-	299	O
serve	-	303	O
as	-	309	O
a	-	312	O
warning	-	314	O
.	-	321	O

Recurarization	10457883	0	O
in	-	15	O
the	-	18	O
recovery	-	22	O
room	-	31	O
.	-	35	O

A	10457883	37	O
case	-	39	O
of	-	44	O
recurarization	-	47	O
in	-	62	O
the	-	65	O
recovery	-	69	O
room	-	78	O
is	-	83	O
reported	-	86	O
.	-	94	O

Accumulation	10457883	96	O
of	-	109	O
atracurium	-	112	B
in	-	123	O
the	-	126	O
intravenous	-	130	O
line	-	142	O
led	-	147	O
to	-	151	O
recurarization	-	154	O
after	-	169	O
flushing	-	175	O
the	-	184	O
line	-	188	O
in	-	193	O
the	-	196	O
recovery	-	200	O
room	-	209	O
.	-	213	O

A	10457883	215	O
respiratory	-	217	O
arrest	-	229	O
with	-	236	O
severe	-	241	O
desaturation	-	248	O
and	-	261	O
bradycardia	-	265	O
occurred	-	277	O
.	-	285	O

Circumstances	10457883	287	O
leading	-	301	O
to	-	309	O
this	-	312	O
event	-	317	O
and	-	323	O
the	-	327	O
mechanisms	-	331	O
enabling	-	342	O
a	-	351	O
neuromuscular	-	353	O
blockade	-	367	O
to	-	376	O
occur	-	379	O
,	-	384	O
following	-	386	O
the	-	396	O
administration	-	400	O
of	-	415	O
a	-	418	O
small	-	420	O
dose	-	426	O
of	-	431	O
relaxant	-	434	O
,	-	442	O
are	-	444	O
discussed	-	448	O
.	-	457	O

Recurrent	10739826	0	O
use	-	10	O
of	-	14	O
newer	-	17	O
oral	-	23	B
contraceptives	-	28	I
and	-	43	O
the	-	47	O
risk	-	51	O
of	-	56	O
venous	-	59	O
thromboembolism	-	66	O
.	-	81	O

The	10739826	83	O
epidemiological	-	87	O
studies	-	103	O
that	-	111	O
assessed	-	116	O
the	-	125	O
risk	-	129	O
of	-	134	O
venous	-	137	O
thromboembolism	-	144	O
(	-	160	O
VTE	-	161	O
)	-	164	O
associated	-	166	O
with	-	177	O
newer	-	182	O
oral	-	188	B
contraceptives	-	193	I
(	-	208	O
OC	-	209	B
)	-	211	O
did	-	213	O
not	-	217	O
distinguish	-	221	O
between	-	233	O
patterns	-	241	O
of	-	250	O
OC	-	253	B
use	-	256	O
,	-	259	O
namely	-	261	O
first	-	268	O
-	-	273	O
time	-	274	O
users	-	279	O
,	-	284	O
repeaters	-	286	O
and	-	296	O
switchers	-	300	O
.	-	309	O

Data	10739826	311	O
from	-	316	O
a	-	321	O
Transnational	-	323	O
case	-	337	O
-	-	341	O
control	-	342	O
study	-	350	O
were	-	356	O
used	-	361	O
to	-	366	O
assess	-	369	O
the	-	376	O
risk	-	380	O
of	-	385	O
VTE	-	388	O
for	-	392	O
the	-	396	O
latter	-	400	O
patterns	-	407	O
of	-	416	O
use	-	419	O
,	-	422	O
while	-	424	O
accounting	-	430	O
for	-	441	O
duration	-	445	O
of	-	454	O
use	-	457	O
.	-	460	O

Over	10739826	462	O
the	-	467	O
period	-	471	O
1993	-	478	O
-	-	482	O
1996	-	483	O
,	-	487	O
551	-	489	O
cases	-	493	O
of	-	499	O
VTE	-	502	O
were	-	506	O
identified	-	511	O
in	-	522	O
Germany	-	525	O
and	-	533	O
the	-	537	O
UK	-	541	O
along	-	544	O
with	-	550	O
2066	-	555	O
controls	-	560	O
.	-	568	O

Totals	10739826	570	O
of	-	577	O
128	-	580	O
cases	-	584	O
and	-	590	O
650	-	594	O
controls	-	598	O
were	-	607	O
analysed	-	612	O
for	-	621	O
repeat	-	625	O
use	-	632	O
and	-	636	O
135	-	640	O
cases	-	644	O
and	-	650	O
622	-	654	O
controls	-	658	O
for	-	667	O
switching	-	671	O
patterns	-	681	O
.	-	689	O

The	10739826	691	O
adjusted	-	695	O
rate	-	704	O
ratio	-	709	O
of	-	715	O
VTE	-	718	O
for	-	722	O
repeat	-	726	O
users	-	733	O
of	-	739	O
third	-	742	O
generation	-	748	O
OC	-	759	B
was	-	762	O
0	-	766	O
.	-	767	O
6	-	768	O
(	-	770	O
95	-	771	O
%	-	773	O
CI	-	775	O
:	-	777	O
0	-	778	O
.	-	779	O
3	-	780	O
-	-	781	O
1	-	782	O
.	-	783	O
2	-	784	O
)	-	785	O
relative	-	787	O
to	-	796	O
repeat	-	799	O
users	-	806	O
of	-	812	O
second	-	815	O
generation	-	822	O
pills	-	833	O
,	-	838	O
whereas	-	840	O
it	-	848	O
was	-	851	O
1	-	855	O
.	-	856	O
3	-	857	O
(	-	859	O
95	-	860	O
%	-	862	O
CI	-	864	O
:	-	866	O
0	-	867	O
.	-	868	O
7	-	869	O
-	-	870	O
2	-	871	O
.	-	872	O
4	-	873	O
)	-	874	O
for	-	876	O
switchers	-	880	O
from	-	890	O
second	-	895	O
to	-	902	O
third	-	905	O
generation	-	911	O
pills	-	922	O
relative	-	928	O
to	-	937	O
switchers	-	940	O
from	-	950	O
third	-	955	O
to	-	961	O
second	-	964	O
generation	-	971	O
pills	-	982	O
.	-	987	O

We	10739826	989	O
conclude	-	992	O
that	-	1001	O
second	-	1006	O
and	-	1013	O
third	-	1017	O
generation	-	1023	O
agents	-	1034	O
are	-	1041	O
associated	-	1045	O
with	-	1056	O
equivalent	-	1061	O
risks	-	1072	O
of	-	1078	O
VTE	-	1081	O
when	-	1085	O
the	-	1090	O
same	-	1094	O
agent	-	1099	O
is	-	1105	O
used	-	1108	O
repeatedly	-	1113	O
after	-	1124	O
interruption	-	1130	O
periods	-	1143	O
or	-	1151	O
when	-	1154	O
users	-	1159	O
are	-	1165	O
switched	-	1169	O
between	-	1178	O
the	-	1186	O
two	-	1190	O
generations	-	1194	O
of	-	1206	O
pills	-	1209	O
.	-	1214	O

These	10739826	1216	O
analyses	-	1222	O
suggest	-	1231	O
that	-	1239	O
the	-	1244	O
higher	-	1248	O
risk	-	1255	O
observed	-	1260	O
for	-	1269	O
the	-	1273	O
newer	-	1277	O
OC	-	1283	B
in	-	1286	O
other	-	1289	O
studies	-	1295	O
may	-	1303	O
be	-	1307	O
the	-	1310	O
result	-	1314	O
of	-	1321	O
inadequate	-	1324	O
comparisons	-	1335	O
of	-	1347	O
pill	-	1350	O
users	-	1355	O
with	-	1361	O
different	-	1366	O
patterns	-	1376	O
of	-	1385	O
pill	-	1388	O
use	-	1393	O
.	-	1396	O

Development	10791295	0	O
of	-	12	O
apomorphine	-	15	B
-	-	26	O
induced	-	27	O
aggressive	-	35	O
behavior	-	46	O
:	-	54	O
comparison	-	56	O
of	-	67	O
adult	-	70	O
male	-	76	O
and	-	81	O
female	-	85	O
Wistar	-	92	O
rats	-	99	O
.	-	103	O

The	10791295	105	O
development	-	109	O
of	-	121	O
apomorphine	-	124	B
-	-	135	O
induced	-	136	O
(	-	144	O
1	-	145	O
.	-	146	O
0	-	147	O
mg	-	149	O
/	-	151	O
kg	-	152	O
s	-	155	O
.	-	156	O
c	-	157	O
.	-	158	O

once	10791295	160	O
daily	-	165	O
)	-	170	O
aggressive	-	172	O
behavior	-	183	O
of	-	192	O
adult	-	195	O
male	-	201	O
and	-	206	O
female	-	210	O
Wistar	-	217	O
rats	-	224	O
obtained	-	229	O
from	-	238	O
the	-	243	O
same	-	247	O
breeder	-	252	O
was	-	260	O
studied	-	264	O
in	-	272	O
two	-	275	O
consecutive	-	279	O
sets	-	291	O
.	-	295	O

In	10791295	297	O
male	-	300	O
animals	-	305	O
,	-	312	O
repeated	-	314	O
apomorphine	-	323	B
treatment	-	335	O
induced	-	345	O
a	-	353	O
gradual	-	355	O
development	-	363	O
of	-	375	O
aggressive	-	378	O
behavior	-	389	O
as	-	398	O
evidenced	-	401	O
by	-	411	O
the	-	414	O
increased	-	418	O
intensity	-	428	O
of	-	438	O
aggressiveness	-	441	O
and	-	456	O
shortened	-	460	O
latency	-	470	O
before	-	478	O
the	-	485	O
first	-	489	O
attack	-	495	O
toward	-	502	O
the	-	509	O
opponent	-	513	O
.	-	521	O

In	10791295	523	O
female	-	526	O
rats	-	533	O
,	-	537	O
only	-	539	O
a	-	544	O
weak	-	546	O
tendency	-	551	O
toward	-	560	O
aggressiveness	-	567	O
was	-	582	O
found	-	586	O
.	-	591	O

In	10791295	593	O
conclusion	-	596	O
,	-	606	O
the	-	608	O
present	-	612	O
study	-	620	O
demonstrates	-	626	O
gender	-	639	O
differences	-	646	O
in	-	658	O
the	-	661	O
development	-	665	O
of	-	677	O
the	-	680	O
apomorphine	-	684	B
-	-	695	O
induced	-	696	O
aggressive	-	704	O
behavior	-	715	O
and	-	724	O
indicates	-	728	O
that	-	738	O
the	-	743	O
female	-	747	O
rats	-	754	O
do	-	759	O
not	-	762	O
fill	-	766	O
the	-	771	O
validation	-	775	O
criteria	-	786	O
for	-	795	O
use	-	799	O
in	-	803	O
this	-	806	O
method	-	811	O
.	-	817	O

Serotonergic	11147747	0	B
antidepressants	-	13	I
and	-	29	O
urinary	-	33	O
incontinence	-	41	O
.	-	53	O

Many	11147747	55	O
new	-	60	O
serotonergic	-	64	B
antidepressants	-	77	I
have	-	93	O
been	-	98	O
introduced	-	103	O
over	-	114	O
the	-	119	O
past	-	123	O
decade	-	128	O
.	-	134	O

Although	11147747	136	O
urinary	-	145	O
incontinence	-	153	O
is	-	166	O
listed	-	169	O
as	-	176	O
one	-	179	O
side	-	183	O
effect	-	188	O
of	-	195	O
these	-	198	O
drugs	-	204	O
in	-	210	O
their	-	213	O
package	-	219	O
inserts	-	227	O
there	-	235	O
is	-	241	O
only	-	244	O
one	-	249	O
report	-	253	O
in	-	260	O
the	-	263	O
literature	-	267	O
.	-	277	O

This	11147747	279	O
concerns	-	284	O
2	-	293	O
male	-	295	O
patients	-	300	O
who	-	309	O
experienced	-	313	O
incontinence	-	325	O
while	-	338	O
taking	-	344	O
venlafaxine	-	351	B
.	-	362	O

In	11147747	364	O
the	-	367	O
present	-	371	O
paper	-	379	O
the	-	385	O
authors	-	389	O
describe	-	397	O
2	-	406	O
female	-	408	O
patients	-	415	O
who	-	424	O
developed	-	428	O
incontinence	-	438	O
secondary	-	451	O
to	-	461	O
the	-	464	O
selective	-	468	O
serotonin	-	478	B
reuptake	-	488	O
inhibitors	-	497	O
paroxetine	-	508	B
and	-	519	O
sertraline	-	523	B
,	-	533	O
as	-	535	O
well	-	538	O
as	-	543	O
a	-	546	O
third	-	548	O
who	-	554	O
developed	-	558	O
this	-	568	O
side	-	573	O
effect	-	578	O
on	-	585	O
venlafaxine	-	588	B
.	-	599	O

In	11147747	601	O
2	-	604	O
of	-	606	O
the	-	609	O
3	-	613	O
cases	-	615	O
the	-	621	O
patients	-	625	O
were	-	634	O
also	-	639	O
taking	-	644	O
lithium	-	651	B
carbonate	-	659	I
and	-	669	O
beta	-	673	O
-	-	677	O
blockers	-	678	O
,	-	686	O
both	-	688	O
of	-	693	O
which	-	696	O
could	-	702	O
have	-	708	O
contributed	-	713	O
to	-	725	O
the	-	728	O
incontinence	-	732	O
.	-	744	O

Animal	11147747	746	O
studies	-	753	O
suggest	-	761	O
that	-	769	O
incontinence	-	774	O
secondary	-	787	O
to	-	797	O
serotonergic	-	800	B
antidepressants	-	813	I
could	-	829	O
be	-	835	O
mediated	-	838	O
by	-	847	O
the	-	850	O
5HT4	-	854	O
receptors	-	859	O
found	-	869	O
on	-	875	O
the	-	878	O
bladder	-	882	O
.	-	889	O

Further	11147747	891	O
research	-	899	O
is	-	908	O
needed	-	911	O
to	-	918	O
delineate	-	921	O
the	-	931	O
frequency	-	935	O
of	-	945	O
this	-	948	O
troubling	-	953	O
side	-	963	O
effect	-	968	O
and	-	975	O
how	-	979	O
best	-	983	O
to	-	988	O
treat	-	991	O
it	-	997	O
.	-	999	O

Hypotension	11198499	0	O
following	-	12	O
the	-	22	O
initiation	-	26	O
of	-	37	O
tizanidine	-	40	B
in	-	51	O
a	-	54	O
patient	-	56	O
treated	-	64	O
with	-	72	O
an	-	77	O
angiotensin	-	80	B
converting	-	92	O
enzyme	-	103	O
inhibitor	-	110	O
for	-	120	O
chronic	-	124	O
hypertension	-	132	O
.	-	144	O

Centrally	11198499	146	O
acting	-	156	O
alpha	-	163	O
-	-	168	O
2	-	169	O
adrenergic	-	171	O
agonists	-	182	O
are	-	191	O
one	-	195	O
of	-	199	O
several	-	202	O
pharmacologic	-	210	O
agents	-	224	O
used	-	231	O
in	-	236	O
the	-	239	O
treatment	-	243	O
of	-	253	O
spasticity	-	256	O
related	-	267	O
to	-	275	O
disorders	-	278	O
of	-	288	O
the	-	291	O
central	-	295	O
nervous	-	303	O
system	-	311	O
.	-	317	O

In	11198499	319	O
addition	-	322	O
to	-	331	O
their	-	334	O
effects	-	340	O
on	-	348	O
spasticity	-	351	O
,	-	361	O
certain	-	363	O
adverse	-	371	O
cardiorespiratory	-	379	O
effects	-	397	O
have	-	405	O
been	-	410	O
reported	-	415	O
.	-	423	O

Adults	11198499	425	O
chronically	-	432	O
treated	-	444	O
with	-	452	O
angiotensin	-	457	B
converting	-	469	O
enzyme	-	480	O
inhibitors	-	487	O
may	-	498	O
have	-	502	O
a	-	507	O
limited	-	509	O
ability	-	517	O
to	-	525	O
respond	-	528	O
to	-	536	O
hypotension	-	539	O
when	-	551	O
the	-	556	O
sympathetic	-	560	O
response	-	572	O
is	-	581	O
simultaneously	-	584	O
blocked	-	599	O
.	-	606	O

The	11198499	608	O
authors	-	612	O
present	-	620	O
a	-	628	O
10	-	630	O
-	-	632	O
year	-	633	O
-	-	637	O
old	-	638	O
boy	-	642	O
chronically	-	646	O
treated	-	658	O
with	-	666	O
lisinopril	-	671	B
,	-	681	O
an	-	683	O
angiotensin	-	686	B
converting	-	698	O
enzyme	-	709	O
inhibitor	-	716	O
,	-	725	O
to	-	727	O
control	-	730	O
hypertension	-	738	O
who	-	751	O
developed	-	755	O
hypotension	-	765	O
following	-	777	O
the	-	787	O
addition	-	791	O
of	-	800	O
tizanidine	-	803	B
,	-	813	O
an	-	815	O
alpha	-	818	O
-	-	823	O
2	-	824	O
agonist	-	826	O
,	-	833	O
for	-	835	O
the	-	839	O
treatment	-	843	O
of	-	853	O
spasticity	-	856	O
.	-	866	O

The	11198499	868	O
possible	-	872	O
interaction	-	881	O
of	-	893	O
tizanidine	-	896	B
and	-	907	O
other	-	911	O
antihypertensive	-	917	O
agents	-	934	O
should	-	941	O
be	-	948	O
kept	-	951	O
in	-	956	O
mind	-	959	O
when	-	964	O
prescribing	-	969	O
therapy	-	981	O
to	-	989	O
treat	-	992	O
either	-	998	O
hypertension	-	1005	O
or	-	1018	O
spasticity	-	1021	O
in	-	1032	O
such	-	1035	O
patients	-	1040	O
.	-	1048	O

Peritubular	11391224	0	O
capillary	-	12	O
basement	-	22	O
membrane	-	31	O
reduplication	-	40	O
in	-	54	O
allografts	-	57	O
and	-	68	O
native	-	72	O
kidney	-	79	O
disease	-	86	O
:	-	93	O
a	-	95	O
clinicopathologic	-	97	O
study	-	115	O
of	-	121	O
278	-	124	O
consecutive	-	128	O
renal	-	140	O
specimens	-	146	O
.	-	155	O

BACKGROUND	11391224	157	O
:	-	167	O

An	11391224	169	O
association	-	172	O
has	-	184	O
been	-	188	O
found	-	193	O
between	-	199	O
transplant	-	207	O
glomerulopathy	-	218	O
(	-	233	O
TG	-	234	O
)	-	236	O
and	-	238	O
reduplication	-	242	O
of	-	256	O
peritubular	-	259	O
capillary	-	271	O
basement	-	281	O
membranes	-	290	O
(	-	300	O
PTCR	-	301	O
)	-	305	O
.	-	306	O

Although	11391224	308	O
such	-	317	O
an	-	322	O
association	-	325	O
is	-	337	O
of	-	340	O
practical	-	343	O
and	-	353	O
theoretical	-	357	O
importance	-	369	O
,	-	379	O
only	-	381	O
one	-	386	O
prospective	-	390	O
study	-	402	O
has	-	408	O
tried	-	412	O
to	-	418	O
confirm	-	421	O
it	-	429	O
.	-	431	O

METHODS	11391224	433	O
:	-	440	O

We	11391224	442	O
examined	-	445	O
278	-	454	O
consecutive	-	458	O
renal	-	470	O
specimens	-	476	O
(	-	486	O
from	-	487	O
135	-	492	O
transplants	-	496	O
and	-	508	O
143	-	512	O
native	-	516	O
kidneys	-	523	O
)	-	530	O
for	-	532	O
ultrastructural	-	536	O
evidence	-	552	O
of	-	561	O
PTCR	-	564	O
.	-	568	O

In	11391224	570	O
addition	-	573	O
to	-	582	O
renal	-	585	O
allografts	-	591	O
with	-	602	O
TG	-	607	O
,	-	609	O
we	-	611	O
also	-	614	O
examined	-	619	O
grafts	-	628	O
with	-	635	O
acute	-	640	O
rejection	-	646	O
,	-	655	O
recurrent	-	657	O
glomerulonephritis	-	667	O
,	-	685	O
chronic	-	687	O
allograft	-	695	O
nephropathy	-	705	O
and	-	717	O
stable	-	721	O
grafts	-	728	O
(	-	735	O
""""	-	736	O
protocol	-	737	O
biopsies	-	746	O
""""	-	754	O
)	-	755	O
.	-	756	O

Native	11391224	758	O
kidney	-	765	O
specimens	-	772	O
included	-	782	O
a	-	791	O
wide	-	793	O
range	-	798	O
of	-	804	O
glomerulopathies	-	807	O
as	-	824	O
well	-	827	O
as	-	832	O
cases	-	835	O
of	-	841	O
thrombotic	-	844	O
microangiopathy	-	855	O
,	-	870	O
malignant	-	872	O
hypertension	-	882	O
,	-	894	O
acute	-	896	O
interstitial	-	902	O
nephritis	-	915	O
,	-	924	O
and	-	926	O
acute	-	930	O
tubular	-	936	O
necrosis	-	944	O
.	-	952	O

RESULTS	11391224	954	O
:	-	961	O

We	11391224	963	O
found	-	966	O
PTCR	-	972	O
in	-	977	O
14	-	980	O
of	-	983	O
15	-	986	O
cases	-	989	O
of	-	995	O
TG	-	998	O
,	-	1000	O
in	-	1002	O
7	-	1005	O
transplant	-	1007	O
biopsy	-	1018	O
specimens	-	1025	O
without	-	1035	O
TG	-	1043	O
,	-	1045	O
and	-	1047	O
in	-	1051	O
13	-	1054	O
of	-	1057	O
143	-	1060	O
native	-	1064	O
kidney	-	1071	O
biopsy	-	1078	O
specimens	-	1085	O
.	-	1094	O

These	11391224	1096	O
13	-	1102	O
included	-	1105	O
cases	-	1114	O
of	-	1120	O
malignant	-	1123	O
hypertension	-	1133	O
,	-	1145	O
thrombotic	-	1147	O
microangiopathy	-	1158	O
,	-	1173	O
lupus	-	1175	O
nephritis	-	1181	O
,	-	1190	O
Henoch	-	1192	O
-	-	1198	O
Schonlein	-	1199	O
nephritis	-	1209	O
,	-	1218	O
crescentic	-	1220	O
glomerulonephritis	-	1231	O
,	-	1249	O
and	-	1251	O
cocaine	-	1255	B
-	-	1262	O
related	-	1263	O
acute	-	1271	O
renal	-	1277	O
failure	-	1283	O
.	-	1290	O

Mild	11391224	1292	O
PTCR	-	1297	O
in	-	1302	O
allografts	-	1305	O
without	-	1316	O
TG	-	1324	O
did	-	1327	O
not	-	1331	O
predict	-	1335	O
renal	-	1343	O
failure	-	1349	O
or	-	1357	O
significant	-	1360	O
proteinuria	-	1372	O
after	-	1384	O
follow	-	1390	O
-	-	1396	O
up	-	1397	O
periods	-	1400	O
of	-	1408	O
between	-	1411	O
3	-	1419	O
months	-	1421	O
and	-	1428	O
1	-	1432	O
year	-	1434	O
.	-	1438	O

CONCLUSIONS	11391224	1440	O
:	-	1451	O

We	11391224	1453	O
conclude	-	1456	O
that	-	1465	O
in	-	1470	O
transplants	-	1473	O
,	-	1484	O
there	-	1486	O
is	-	1492	O
a	-	1495	O
strong	-	1497	O
association	-	1504	O
between	-	1516	O
well	-	1524	O
-	-	1528	O
developed	-	1529	O
PTCR	-	1539	O
and	-	1544	O
TG	-	1548	O
,	-	1550	O
while	-	1552	O
the	-	1558	O
significance	-	1562	O
of	-	1575	O
mild	-	1578	O
PTCR	-	1583	O
and	-	1588	O
its	-	1592	O
predictive	-	1596	O
value	-	1607	O
in	-	1613	O
the	-	1616	O
absence	-	1620	O
of	-	1628	O
TG	-	1631	O
is	-	1634	O
unclear	-	1637	O
.	-	1644	O

PTCR	11391224	1646	O
also	-	1651	O
occurs	-	1656	O
in	-	1663	O
certain	-	1666	O
native	-	1674	O
kidney	-	1681	O
diseases	-	1688	O
,	-	1696	O
though	-	1698	O
the	-	1705	O
association	-	1709	O
is	-	1721	O
not	-	1724	O
as	-	1728	O
strong	-	1731	O
as	-	1738	O
that	-	1741	O
for	-	1746	O
TG	-	1750	O
.	-	1752	O

We	11391224	1754	O
suggest	-	1757	O
that	-	1765	O
repeated	-	1770	O
endothelial	-	1779	O
injury	-	1791	O
,	-	1797	O
including	-	1799	O
immunologic	-	1809	O
injury	-	1821	O
,	-	1827	O
may	-	1829	O
be	-	1833	O
the	-	1836	O
cause	-	1840	O
of	-	1846	O
this	-	1849	O
lesion	-	1854	O
both	-	1861	O
in	-	1866	O
allografts	-	1869	O
and	-	1880	O
native	-	1884	O
kidneys	-	1891	O
.	-	1898	O

Conformationally	11426838	0	O
restricted	-	17	O
analogs	-	28	O
of	-	36	O
BD1008	-	39	B
and	-	46	O
an	-	50	O
antisense	-	53	O
oligodeoxynucleotide	-	63	B
targeting	-	84	O
sigma1	-	94	O
receptors	-	101	O
produce	-	111	O
anti	-	119	O
-	-	123	O
cocaine	-	124	B
effects	-	132	O
in	-	140	O
mice	-	143	O
.	-	147	O

Cocaine	11426838	149	B
's	-	156	O
ability	-	159	O
to	-	167	O
interact	-	170	O
with	-	179	O
sigma	-	184	O
receptors	-	190	O
suggests	-	200	O
that	-	209	O
these	-	214	O
proteins	-	220	O
mediate	-	229	O
some	-	237	O
of	-	242	O
its	-	245	O
behavioral	-	249	O
effects	-	260	O
.	-	267	O

Therefore	11426838	269	O
,	-	278	O
three	-	280	O
novel	-	286	O
sigma	-	292	O
receptor	-	298	O
ligands	-	307	O
with	-	315	O
antagonist	-	320	O
activity	-	331	O
were	-	340	O
evaluated	-	345	O
in	-	355	O
Swiss	-	358	O
Webster	-	364	O
mice	-	372	O
:	-	376	O
BD1018	-	378	B
(	-	385	O
3S	-	386	B
-	-	388	I
1	-	389	I
-	-	390	I
[	-	391	I
2	-	392	I
-	-	393	I
(	-	394	I
3	-	395	I
,	-	396	I
4	-	397	I
-	-	398	I
dichlorophenyl	-	399	I
)	-	413	I
ethyl	-	414	I
]	-	419	I
-	-	420	I
1	-	421	I
,	-	422	I
4	-	423	I
-	-	424	I
diazabicyclo	-	425	I
[	-	437	I
4	-	438	I
.	-	439	I
3	-	440	I
.	-	441	I
0	-	442	I
]	-	443	I
nonane	-	444	I
)	-	450	O
,	-	451	O
BD1063	-	453	B
(	-	460	O
1	-	461	B
-	-	462	I
[	-	463	I
2	-	464	I
-	-	465	I
(	-	466	I
3	-	467	I
,	-	468	I
4	-	469	I
-	-	470	I
dichlorophenyl	-	471	I
)	-	485	I
ethyl	-	486	I
]	-	491	I
-	-	492	I
4	-	493	I
-	-	494	I
methylpiperazine	-	495	I
)	-	511	O
,	-	512	O
and	-	514	O
LR132	-	518	B

(	11426838	524	O
1R	-	525	O
,	-	527	O
2S	-	528	O
-	-	530	O
(	-	531	O
+	-	532	O
)	-	533	O
-	-	534	O
cis	-	535	O
-	-	538	O
N	-	539	O
-	-	540	O
[	-	541	O
2	-	542	O
-	-	543	O
(	-	544	O
3	-	545	O
,	-	546	O
4	-	547	O
-	-	548	O
dichlorophenyl	-	549	O
)	-	563	O
ethyl	-	564	O
]	-	569	O
-	-	570	O
2	-	571	O
-	-	572	O
(	-	573	O
1	-	574	O
-	-	575	O
pyrrolidinyl	-	576	O
)	-	588	O
cyclohexylamine	-	589	O
)	-	604	O
.	-	605	O

Competition	11426838	607	O
binding	-	619	O
assays	-	627	O
demonstrated	-	634	O
that	-	647	O
all	-	652	O
three	-	656	O
compounds	-	662	O
have	-	672	O
high	-	677	O
affinities	-	682	O
for	-	693	O
sigma1	-	697	O
receptors	-	704	O
.	-	713	O

The	11426838	715	O
three	-	719	O
compounds	-	725	O
vary	-	735	O
in	-	740	O
their	-	743	O
affinities	-	749	O
for	-	760	O
sigma2	-	764	O
receptors	-	771	O
and	-	781	O
exhibit	-	785	O
negligible	-	793	O
affinities	-	804	O
for	-	815	O
dopamine	-	819	B
,	-	827	O
opioid	-	829	O
,	-	835	O
GABA	-	837	B
(	-	841	O
A	-	842	O
)	-	843	O
and	-	845	O
NMDA	-	849	B
receptors	-	854	O
.	-	863	O

In	11426838	865	O
behavioral	-	868	O
studies	-	879	O
,	-	886	O
pre	-	888	O
-	-	891	O
treatment	-	892	O
of	-	902	O
mice	-	905	O
with	-	910	O
BD1018	-	915	B
,	-	921	O
BD1063	-	923	B
,	-	929	O
or	-	931	O
LR132	-	934	B
significantly	-	940	O
attenuated	-	954	O
cocaine	-	965	B
-	-	972	O
induced	-	973	O
convulsions	-	981	O
and	-	993	O
lethality	-	997	O
.	-	1006	O

Moreover	11426838	1008	O
,	-	1016	O
post	-	1018	O
-	-	1022	O
treatment	-	1023	O
with	-	1033	O
LR132	-	1038	B
prevented	-	1044	O
cocaine	-	1054	B
-	-	1061	O
induced	-	1062	O
lethality	-	1070	O
in	-	1080	O
a	-	1083	O
significant	-	1085	O
proportion	-	1097	O
of	-	1108	O
animals	-	1111	O
.	-	1118	O

In	11426838	1120	O
contrast	-	1123	O
to	-	1132	O
the	-	1135	O
protection	-	1139	O
provided	-	1150	O
by	-	1159	O
the	-	1162	O
putative	-	1166	O
antagonists	-	1175	O
,	-	1186	O
the	-	1188	O
well	-	1192	O
-	-	1196	O
characterized	-	1197	O
sigma	-	1211	O
receptor	-	1217	O
agonist	-	1226	O
di	-	1234	B
-	-	1236	I
o	-	1237	I
-	-	1238	I
tolylguanidine	-	1239	I
(	-	1254	O
DTG	-	1255	B
)	-	1258	O
and	-	1260	O
the	-	1264	O
novel	-	1268	O
sigma	-	1274	O
receptor	-	1280	O
agonist	-	1289	O
BD1031	-	1297	B
(	-	1304	O
3R	-	1305	B
-	-	1307	I
1	-	1308	I
-	-	1309	I
[	-	1310	I
2	-	1311	I
-	-	1312	I
(	-	1313	I
3	-	1314	I
,	-	1315	I
4	-	1316	I
-	-	1317	I
dichlorophenyl	-	1318	I
)	-	1332	I
ethyl	-	1333	I
]	-	1338	I
-	-	1339	I
1	-	1340	I
,	-	1341	I
4	-	1342	I
-	-	1343	I
diazabicyclo	-	1344	I
[	-	1356	I
4	-	1357	I
.	-	1358	I
3	-	1359	I
.	-	1360	I
0	-	1361	I
]	-	1362	I
nonane	-	1363	I
)	-	1369	O
each	-	1371	O
worsened	-	1376	O
the	-	1385	O
behavioral	-	1389	O
toxicity	-	1400	O
of	-	1409	O
cocaine	-	1412	B
.	-	1419	O

At	11426838	1421	O
doses	-	1424	O
where	-	1430	O
alone	-	1436	O
,	-	1441	O
they	-	1443	O
produced	-	1448	O
no	-	1457	O
significant	-	1460	O
effects	-	1472	O
on	-	1480	O
locomotion	-	1483	O
,	-	1493	O
BD1018	-	1495	B
,	-	1501	O
BD1063	-	1503	B
and	-	1510	O
LR132	-	1514	B
significantly	-	1520	O
attenuated	-	1534	O
the	-	1545	O
locomotor	-	1549	O
stimulatory	-	1559	O
effects	-	1571	O
of	-	1579	O
cocaine	-	1582	B
.	-	1589	O

To	11426838	1591	O
further	-	1594	O
validate	-	1602	O
the	-	1611	O
hypothesis	-	1615	O
that	-	1626	O
the	-	1631	O
anti	-	1635	O
-	-	1639	O
cocaine	-	1640	B
effects	-	1648	O
of	-	1656	O
the	-	1659	O
novel	-	1663	O
ligands	-	1669	O
involved	-	1677	O
antagonism	-	1686	O
of	-	1697	O
sigma	-	1700	O
receptors	-	1706	O
,	-	1715	O
an	-	1717	O
antisense	-	1720	O
oligodeoxynucleotide	-	1730	B
against	-	1751	O
sigma1	-	1759	O
receptors	-	1766	O
was	-	1776	O
also	-	1780	O
shown	-	1785	O
to	-	1791	O
significantly	-	1794	O
attenuate	-	1808	O
the	-	1818	O
convulsive	-	1822	O
and	-	1833	O
locomotor	-	1837	O
stimulatory	-	1847	O
effects	-	1859	O
of	-	1867	O
cocaine	-	1870	B
.	-	1877	O

Together	11426838	1879	O
,	-	1887	O
the	-	1889	O
data	-	1893	O
suggests	-	1898	O
that	-	1907	O
functional	-	1912	O
antagonism	-	1923	O
of	-	1934	O
sigma	-	1937	O
receptors	-	1943	O
is	-	1953	O
capable	-	1956	O
of	-	1964	O
attenuating	-	1967	O
a	-	1979	O
number	-	1981	O
of	-	1988	O
cocaine	-	1991	B
-	-	1998	O
induced	-	1999	O
behaviors	-	2007	O
.	-	2016	O

Pharmacokinetic	11569530	0	O
/	-	15	O
pharmacodynamic	-	16	O
assessment	-	32	O
of	-	43	O
the	-	46	O
effects	-	50	O
of	-	58	O
E4031	-	61	B
,	-	66	O
cisapride	-	68	B
,	-	77	O
terfenadine	-	79	B
and	-	91	O
terodiline	-	95	B
on	-	106	O
monophasic	-	109	O
action	-	120	O
potential	-	127	O
duration	-	137	O
in	-	146	O
dog	-	149	O
.	-	152	O

1	11569530	154	O
.	-	155	O

Torsades	11569530	157	O
de	-	166	O
pointes	-	169	O
(	-	177	O
TDP	-	178	O
)	-	181	O
is	-	183	O
a	-	186	O
potentially	-	188	O
fatal	-	200	O
ventricular	-	206	O
tachycardia	-	218	O
associated	-	230	O
with	-	241	O
increases	-	246	O
in	-	256	O
QT	-	259	O
interval	-	262	O
and	-	271	O
monophasic	-	275	O
action	-	286	O
potential	-	293	O
duration	-	303	O
(	-	312	O
MAPD	-	313	O
)	-	317	O
.	-	318	O

TDP	11569530	320	O
is	-	324	O
a	-	327	O
side	-	329	O
-	-	333	O
effect	-	334	O
that	-	341	O
has	-	346	O
led	-	350	O
to	-	354	O
withdrawal	-	357	O
of	-	368	O
several	-	371	O
drugs	-	379	O
from	-	385	O
the	-	390	O
market	-	394	O
(	-	401	O
e	-	402	O
.	-	403	O
g	-	404	O
.	-	405	O
terfenadine	-	407	B
and	-	419	O
terodiline	-	423	B
)	-	433	O
.	-	434	O

2	11569530	436	O
.	-	437	O

The	11569530	439	O
potential	-	443	O
of	-	453	O
compounds	-	456	O
to	-	466	O
cause	-	469	O
TDP	-	475	O
was	-	479	O
evaluated	-	483	O
by	-	493	O
monitoring	-	496	O
their	-	507	O
effects	-	513	O
on	-	521	O
MAPD	-	524	O
in	-	529	O
dog	-	532	O
.	-	535	O

Four	11569530	537	O
compounds	-	542	O
known	-	552	O
to	-	558	O
increase	-	561	O
QT	-	570	O
interval	-	573	O
and	-	582	O
cause	-	586	O
TDP	-	592	O
were	-	596	O
investigated	-	601	O
:	-	613	O
terfenadine	-	615	B
,	-	626	O
terodiline	-	628	B
,	-	638	O
cisapride	-	640	B
and	-	650	O
E4031	-	654	B
.	-	659	O

On	11569530	661	O
the	-	664	O
basis	-	668	O
that	-	674	O
only	-	679	O
free	-	684	O
drug	-	689	O
in	-	694	O
the	-	697	O
systemic	-	701	O
circulation	-	710	O
will	-	722	O
elicit	-	727	O
a	-	734	O
pharmacological	-	736	O
response	-	752	O
target	-	761	O
,	-	767	O
free	-	769	O
concentrations	-	774	O
in	-	789	O
plasma	-	792	O
were	-	799	O
selected	-	804	O
to	-	813	O
mimic	-	816	O
the	-	822	O
free	-	826	O
drug	-	831	O
exposures	-	836	O
in	-	846	O
man	-	849	O
.	-	852	O

Infusion	11569530	854	O
regimens	-	863	O
were	-	872	O
designed	-	877	O
that	-	886	O
rapidly	-	891	O
achieved	-	899	O
and	-	908	O
maintained	-	912	O
target	-	923	O
-	-	929	O
free	-	930	O
concentrations	-	935	O
of	-	950	O
these	-	953	O
drugs	-	959	O
in	-	965	O
plasma	-	968	O
and	-	975	O
data	-	979	O
on	-	984	O
the	-	987	O
relationship	-	991	O
between	-	1004	O
free	-	1012	O
concentration	-	1017	O
and	-	1031	O
changes	-	1035	O
in	-	1043	O
MAPD	-	1046	O
were	-	1051	O
obtained	-	1056	O
for	-	1065	O
these	-	1069	O
compounds	-	1075	O
.	-	1084	O

3	11569530	1086	O
.	-	1087	O

These	11569530	1089	O
data	-	1095	O
indicate	-	1100	O
that	-	1109	O
the	-	1114	O
free	-	1118	O
ED50	-	1123	O
in	-	1128	O
plasma	-	1131	O
for	-	1138	O
terfenadine	-	1142	B
(	-	1154	O
1	-	1155	O
.	-	1156	O
9	-	1157	O
nM	-	1159	O
)	-	1161	O
,	-	1162	O
terodiline	-	1164	B
(	-	1175	O
76	-	1176	O
nM	-	1179	O
)	-	1181	O
,	-	1182	O
cisapride	-	1184	B
(	-	1194	O
11	-	1195	O
nM	-	1198	O
)	-	1200	O
and	-	1202	O
E4031	-	1206	B
(	-	1212	O
1	-	1213	O
.	-	1214	O
9	-	1215	O
nM	-	1217	O
)	-	1219	O
closely	-	1221	O
correlate	-	1229	O
with	-	1239	O
the	-	1244	O
free	-	1248	O
concentration	-	1253	O
in	-	1267	O
man	-	1270	O
causing	-	1274	O
QT	-	1282	O
effects	-	1285	O
.	-	1292	O

For	11569530	1294	O
compounds	-	1298	O
that	-	1308	O
have	-	1313	O
shown	-	1318	O
TDP	-	1324	O
in	-	1328	O
the	-	1331	O
clinic	-	1335	O
(	-	1342	O
terfenadine	-	1343	B
,	-	1354	O
terodiline	-	1356	B
,	-	1366	O
cisapride	-	1368	B
)	-	1377	O
there	-	1379	O
is	-	1385	O
little	-	1388	O
differentiation	-	1395	O
between	-	1411	O
the	-	1419	O
dog	-	1423	O
ED50	-	1427	O
and	-	1432	O
the	-	1436	O
efficacious	-	1440	O
free	-	1452	O
plasma	-	1457	O
concentrations	-	1464	O
in	-	1479	O
man	-	1482	O
(	-	1486	O
<	-	1487	O
10	-	1489	O
-	-	1491	O
fold	-	1492	O
)	-	1496	O
reflecting	-	1498	O
their	-	1509	O
limited	-	1515	O
safety	-	1523	O
margins	-	1530	O
.	-	1537	O

These	11569530	1539	O
data	-	1545	O
underline	-	1550	O
the	-	1560	O
need	-	1564	O
to	-	1569	O
maximize	-	1572	O
the	-	1581	O
therapeutic	-	1585	O
ratio	-	1597	O
with	-	1603	O
respect	-	1608	O
to	-	1616	O
TDP	-	1619	O
in	-	1623	O
potential	-	1626	O
development	-	1636	O
candidates	-	1648	O
and	-	1659	O
the	-	1663	O
importance	-	1667	O
of	-	1678	O
using	-	1681	O
free	-	1687	O
drug	-	1692	O
concentrations	-	1697	O
in	-	1712	O
pharmacokinetic	-	1715	O
/	-	1730	O
pharmacodynamic	-	1731	O
studies	-	1747	O
.	-	1754	O

Fatal	11587867	0	O
myeloencephalopathy	-	6	O
due	-	26	O
to	-	30	O
accidental	-	33	O
intrathecal	-	44	O
vincristin	-	56	B
administration	-	67	O
:	-	81	O
a	-	83	O
report	-	85	O
of	-	92	O
two	-	95	O
cases	-	99	O
.	-	104	O

We	11587867	106	O
report	-	109	O
on	-	116	O
two	-	119	O
fatal	-	123	O
cases	-	129	O
of	-	135	O
accidental	-	138	O
intrathecal	-	149	O
vincristine	-	161	B
instillation	-	173	O
in	-	186	O
a	-	189	O
5	-	191	O
-	-	192	O
year	-	193	O
old	-	198	O
girl	-	202	O
with	-	207	O
recurrent	-	212	O
acute	-	222	O
lymphoblastic	-	228	O
leucemia	-	242	O
and	-	251	O
a	-	255	O
57	-	257	O
-	-	259	O
year	-	260	O
old	-	265	O
man	-	269	O
with	-	273	O
lymphoblastic	-	278	O
lymphoma	-	292	O
.	-	300	O

The	11587867	302	O
girl	-	306	O
died	-	311	O
seven	-	316	O
days	-	322	O
,	-	326	O
the	-	328	O
man	-	332	O
four	-	336	O
weeks	-	341	O
after	-	347	O
intrathecal	-	353	O
injection	-	365	O
of	-	375	O
vincristine	-	378	B
.	-	389	O

Clinically	11587867	391	O
,	-	401	O
the	-	403	O
onset	-	407	O
was	-	413	O
characterized	-	417	O
by	-	431	O
the	-	434	O
signs	-	438	O
of	-	444	O
opistothonus	-	447	O
,	-	459	O
sensory	-	461	O
and	-	469	O
motor	-	473	O
dysfunction	-	479	O
and	-	491	O
ascending	-	495	O
paralysis	-	505	O
.	-	514	O

Histological	11587867	516	O
and	-	529	O
immunohistochemical	-	533	O
investigations	-	553	O
(	-	568	O
HE	-	569	O
-	-	571	O
LFB	-	572	O
,	-	575	O
CD	-	577	O
-	-	579	O
68	-	580	O
,	-	582	O
Neurofilament	-	584	O
)	-	597	O
revealed	-	599	O
degeneration	-	608	O
of	-	621	O
myelin	-	624	O
and	-	631	O
axons	-	635	O
as	-	641	O
well	-	644	O
as	-	649	O
pseudocystic	-	652	O
transformation	-	665	O
in	-	680	O
areas	-	683	O
exposed	-	689	O
to	-	697	O
vincristine	-	700	B
,	-	711	O
accompanied	-	713	O
by	-	725	O
secondary	-	728	O
changes	-	738	O
with	-	746	O
numerous	-	751	O
prominent	-	760	O
macrophages	-	770	O
.	-	781	O

The	11587867	783	O
clinical	-	787	O
course	-	796	O
and	-	803	O
histopathological	-	807	O
results	-	825	O
of	-	833	O
the	-	836	O
two	-	840	O
cases	-	844	O
are	-	850	O
presented	-	854	O
.	-	863	O

A	11587867	865	O
review	-	867	O
of	-	874	O
all	-	877	O
reported	-	881	O
cases	-	890	O
in	-	896	O
the	-	899	O
literature	-	903	O
is	-	914	O
given	-	917	O
.	-	922	O

A	11587867	924	O
better	-	926	O
controlled	-	933	O
regimen	-	944	O
for	-	952	O
administering	-	956	O
vincristine	-	970	B
and	-	982	O
intrathecal	-	986	O
chemotherapy	-	998	O
is	-	1011	O
recommended	-	1014	O
.	-	1025	O

Intravenous	11679859	0	O
administration	-	12	O
of	-	27	O
prochlorperazine	-	30	B
by	-	47	O
15	-	50	O
-	-	52	O
minute	-	53	O
infusion	-	60	O
versus	-	69	O
2	-	76	O
-	-	77	O
minute	-	78	O
bolus	-	85	O
does	-	91	O
not	-	96	O
affect	-	100	O
the	-	107	O
incidence	-	111	O
of	-	121	O
akathisia	-	124	O
:	-	133	O
a	-	135	O
prospective	-	137	O
,	-	148	O
randomized	-	150	O
,	-	160	O
controlled	-	162	O
trial	-	173	O
.	-	178	O

STUDY	11679859	180	O
OBJECTIVE	-	186	O
:	-	195	O
We	-	197	O
sought	-	200	O
to	-	207	O
compare	-	210	O
the	-	218	O
rate	-	222	O
of	-	227	O
akathisia	-	230	O
after	-	240	O
administration	-	246	O
of	-	261	O
intravenous	-	264	O
prochlorperazine	-	276	B
as	-	293	O
a	-	296	O
2	-	298	O
-	-	299	O
minute	-	300	O
bolus	-	307	O
or	-	313	O
15	-	316	O
-	-	318	O
minute	-	319	O
infusion	-	326	O
.	-	334	O

METHODS	11679859	336	O
:	-	343	O

We	11679859	345	O
conducted	-	348	O
a	-	358	O
prospective	-	360	O
,	-	371	O
randomized	-	373	O
,	-	383	O
double	-	385	O
-	-	391	O
blind	-	392	O
study	-	398	O
in	-	404	O
the	-	407	O
emergency	-	411	O
department	-	421	O
of	-	432	O
a	-	435	O
central	-	437	O
-	-	444	O
city	-	445	O
teaching	-	450	O
hospital	-	459	O
.	-	467	O

Patients	11679859	469	O
aged	-	478	O
18	-	483	O
years	-	486	O
or	-	492	O
older	-	495	O
treated	-	501	O
with	-	509	O
prochlorperazine	-	514	B
for	-	531	O
headache	-	535	O
,	-	543	O
nausea	-	545	O
,	-	551	O
or	-	553	O
vomiting	-	556	O
were	-	565	O
eligible	-	570	O
for	-	579	O
inclusion	-	583	O
.	-	592	O

Study	11679859	594	O
participants	-	600	O
were	-	613	O
randomized	-	618	O
to	-	629	O
receive	-	632	O
10	-	640	O
mg	-	643	O
of	-	646	O
prochlorperazine	-	649	B
administered	-	666	O
intravenously	-	679	O
by	-	693	O
means	-	696	O
of	-	702	O
2	-	705	O
-	-	706	O
minute	-	707	O
push	-	714	O
(	-	719	O
bolus	-	720	O
group	-	726	O
)	-	731	O
or	-	733	O
10	-	736	O
mg	-	739	O
diluted	-	742	O
in	-	750	O
50	-	753	O
mL	-	756	O
of	-	759	O
normal	-	762	O
saline	-	769	O
solution	-	776	O
administered	-	785	O
by	-	798	O
means	-	801	O
of	-	807	O
intravenous	-	810	O
infusion	-	822	O
during	-	831	O
a	-	838	O
15	-	840	O
-	-	842	O
minute	-	843	O
period	-	850	O
(	-	857	O
infusion	-	858	O
group	-	867	O
)	-	872	O
.	-	873	O

The	11679859	875	O
main	-	879	O
outcome	-	884	O
was	-	892	O
the	-	896	O
number	-	900	O
of	-	907	O
study	-	910	O
participants	-	916	O
experiencing	-	929	O
akathisia	-	942	O
within	-	952	O
60	-	959	O
minutes	-	962	O
of	-	970	O
administration	-	973	O
.	-	987	O

Akathisia	11679859	989	O
was	-	999	O
defined	-	1003	O
as	-	1011	O
either	-	1014	O
a	-	1021	O
spontaneous	-	1023	O
report	-	1035	O
of	-	1042	O
restlessness	-	1045	O
or	-	1058	O
agitation	-	1061	O
or	-	1071	O
a	-	1074	O
change	-	1076	O
of	-	1083	O
2	-	1086	O
or	-	1088	O
more	-	1091	O
in	-	1096	O
the	-	1099	O
patient	-	1103	O
-	-	1110	O
reported	-	1111	O
akathisia	-	1120	O
rating	-	1130	O
scale	-	1137	O
and	-	1143	O
a	-	1147	O
change	-	1149	O
of	-	1156	O
at	-	1159	O
least	-	1162	O
1	-	1168	O
in	-	1170	O
the	-	1173	O
investigator	-	1177	O
-	-	1189	O
observed	-	1190	O
akathisia	-	1199	O
rating	-	1209	O
scale	-	1216	O
.	-	1221	O

The	11679859	1223	O
intensity	-	1227	O
of	-	1237	O
headache	-	1240	O
and	-	1249	O
nausea	-	1253	O
was	-	1260	O
measured	-	1264	O
with	-	1273	O
a	-	1278	O
100	-	1280	O
-	-	1283	O
mm	-	1284	O
visual	-	1287	O
analog	-	1294	O
scale	-	1301	O
.	-	1306	O

RESULTS	11679859	1308	O
:	-	1315	O

One	11679859	1317	O
hundred	-	1321	O
patients	-	1329	O
were	-	1338	O
enrolled	-	1343	O
.	-	1351	O

One	11679859	1353	O
study	-	1357	O
participant	-	1363	O
was	-	1375	O
excluded	-	1379	O
after	-	1388	O
protocol	-	1394	O
violation	-	1403	O
.	-	1412	O

Seventy	11679859	1414	O
-	-	1421	O
three	-	1422	O
percent	-	1428	O
(	-	1436	O
73	-	1437	O
/	-	1439	O
99	-	1440	O
)	-	1442	O
of	-	1444	O
the	-	1447	O
study	-	1451	O
participants	-	1457	O
were	-	1470	O
treated	-	1475	O
for	-	1483	O
headache	-	1487	O
and	-	1496	O
70	-	1500	O
%	-	1502	O
(	-	1504	O
70	-	1505	O
/	-	1507	O
99	-	1508	O
)	-	1510	O
for	-	1512	O
nausea	-	1516	O
.	-	1522	O

In	11679859	1524	O
the	-	1527	O
bolus	-	1531	O
group	-	1537	O
,	-	1542	O
26	-	1544	O
.	-	1546	O
0	-	1547	O
%	-	1548	O
(	-	1550	O
13	-	1551	O
/	-	1553	O
50	-	1554	O
)	-	1556	O
had	-	1558	O
akathisia	-	1562	O
compared	-	1572	O
with	-	1581	O
32	-	1586	O
.	-	1588	O
7	-	1589	O
%	-	1590	O
(	-	1592	O
16	-	1593	O
/	-	1595	O
49	-	1596	O
)	-	1598	O
in	-	1600	O
the	-	1603	O
infusion	-	1607	O
group	-	1616	O
(	-	1622	O
Delta	-	1623	O
=	-	1628	O
-	-	1629	O
6	-	1630	O
.	-	1631	O
7	-	1632	O
%	-	1633	O
;	-	1634	O
95	-	1636	O
%	-	1638	O
confidence	-	1640	O
interval	-	1651	O
[	-	1660	O
CI	-	1661	O
]	-	1663	O
-	-	1665	O
24	-	1666	O
.	-	1668	O
6	-	1669	O
%	-	1670	O
to	-	1672	O
11	-	1675	O
.	-	1677	O
2	-	1678	O
%	-	1679	O
)	-	1680	O
.	-	1681	O

The	11679859	1683	O
difference	-	1687	O
between	-	1698	O
the	-	1706	O
bolus	-	1710	O
and	-	1716	O
infusion	-	1720	O
groups	-	1729	O
in	-	1736	O
the	-	1739	O
percentage	-	1743	O
of	-	1754	O
participants	-	1757	O
who	-	1770	O
saw	-	1774	O
a	-	1778	O
50	-	1780	O
%	-	1782	O
reduction	-	1784	O
in	-	1794	O
their	-	1797	O
headache	-	1803	O
intensity	-	1812	O
within	-	1822	O
30	-	1829	O
minutes	-	1832	O
was	-	1840	O
11	-	1844	O
.	-	1846	O
8	-	1847	O
%	-	1848	O
(	-	1850	O
95	-	1851	O
%	-	1853	O
CI	-	1855	O
-	-	1858	O
9	-	1859	O
.	-	1860	O
6	-	1861	O
%	-	1862	O
to	-	1864	O
33	-	1867	O
.	-	1869	O
3	-	1870	O
%	-	1871	O
)	-	1872	O
.	-	1873	O

The	11679859	1875	O
difference	-	1879	O
in	-	1890	O
the	-	1893	O
percentage	-	1897	O
of	-	1908	O
patients	-	1911	O
with	-	1920	O
a	-	1925	O
50	-	1927	O
%	-	1929	O
reduction	-	1931	O
in	-	1941	O
their	-	1944	O
nausea	-	1950	O
was	-	1957	O
12	-	1961	O
.	-	1963	O
6	-	1964	O
%	-	1965	O
(	-	1967	O
95	-	1968	O
%	-	1970	O
CI	-	1972	O
-	-	1975	O
4	-	1976	O
.	-	1977	O
6	-	1978	O
%	-	1979	O
to	-	1981	O
29	-	1984	O
.	-	1986	O
8	-	1987	O
%	-	1988	O
)	-	1989	O
.	-	1990	O

CONCLUSION	11679859	1992	O
:	-	2002	O

A	11679859	2004	O
50	-	2006	O
%	-	2008	O
reduction	-	2010	O
in	-	2020	O
the	-	2023	O
incidence	-	2027	O
of	-	2037	O
akathisia	-	2040	O
when	-	2050	O
prochlorperazine	-	2055	B
was	-	2072	O
administered	-	2076	O
by	-	2089	O
means	-	2092	O
of	-	2098	O
15	-	2101	O
-	-	2103	O
minute	-	2104	O
intravenous	-	2111	O
infusion	-	2123	O
versus	-	2132	O
a	-	2139	O
2	-	2141	O
-	-	2142	O
minute	-	2143	O
intravenous	-	2150	O
push	-	2162	O
was	-	2167	O
not	-	2171	O
detected	-	2175	O
.	-	2183	O

The	11679859	2185	O
efficacy	-	2189	O
of	-	2198	O
prochlorperazine	-	2201	B
in	-	2218	O
the	-	2221	O
treatment	-	2225	O
of	-	2235	O
headache	-	2238	O
and	-	2247	O
nausea	-	2251	O
likewise	-	2258	O
did	-	2267	O
not	-	2271	O
appear	-	2275	O
to	-	2282	O
be	-	2285	O
affected	-	2288	O
by	-	2297	O
the	-	2300	O
rate	-	2304	O
of	-	2309	O
administration	-	2312	O
,	-	2326	O
although	-	2328	O
no	-	2337	O
formal	-	2340	O
statistical	-	2347	O
comparisons	-	2359	O
were	-	2371	O
made	-	2376	O
.	-	2380	O

Antithymocyte	12041669	0	B
globulin	-	14	I
in	-	23	O
the	-	26	O
treatment	-	30	O
of	-	40	O
D	-	43	B
-	-	44	I
penicillamine	-	45	I
-	-	58	O
induced	-	59	O
aplastic	-	67	O
anemia	-	76	O
.	-	82	O

A	12041669	84	O
patient	-	86	O
who	-	94	O
received	-	98	O
antithymocyte	-	107	B
globulin	-	121	I
therapy	-	130	O
for	-	138	O
aplastic	-	142	O
anemia	-	151	O
due	-	158	O
to	-	162	O
D	-	165	B
-	-	166	I
penicillamine	-	167	I
therapy	-	181	O
is	-	189	O
described	-	192	O
.	-	201	O

Bone	12041669	203	O
marrow	-	208	O
recovery	-	215	O
and	-	224	O
peripheral	-	228	O
blood	-	239	O
recovery	-	245	O
were	-	254	O
complete	-	259	O
1	-	268	O
month	-	270	O
and	-	276	O
3	-	280	O
months	-	282	O
,	-	288	O
respectively	-	290	O
,	-	302	O
after	-	304	O
treatment	-	310	O
,	-	319	O
and	-	321	O
blood	-	325	O
transfusion	-	331	O
or	-	343	O
other	-	346	O
therapies	-	352	O
were	-	362	O
not	-	367	O
necessary	-	371	O
in	-	381	O
a	-	384	O
follow	-	386	O
-	-	392	O
up	-	393	O
period	-	396	O
of	-	403	O
more	-	406	O
than	-	411	O
2	-	416	O
years	-	418	O
.	-	423	O

Use	12041669	425	O
of	-	429	O
antithymocyte	-	432	B
globulin	-	446	I
may	-	455	O
be	-	459	O
the	-	462	O
optimal	-	466	O
treatment	-	474	O
of	-	484	O
D	-	487	B
-	-	488	I
penicillamine	-	489	I
-	-	502	O
induced	-	503	O
aplastic	-	511	O
anemia	-	520	O
.	-	526	O

The	12198388	0	O
relationship	-	4	O
between	-	17	O
hippocampal	-	25	O
acetylcholine	-	37	B
release	-	51	O
and	-	59	O
cholinergic	-	63	O
convulsant	-	75	O
sensitivity	-	86	O
in	-	98	O
withdrawal	-	101	O
seizure	-	112	O
-	-	119	O
prone	-	120	O
and	-	126	O
withdrawal	-	130	O
seizure	-	141	O
-	-	148	O
resistant	-	149	O
selected	-	159	O
mouse	-	168	O
lines	-	174	O
.	-	179	O

BACKGROUND	12198388	181	O
:	-	191	O

The	12198388	193	O
septo	-	197	O
-	-	202	O
hippocampal	-	203	O
cholinergic	-	215	O
pathway	-	227	O
has	-	235	O
been	-	239	O
implicated	-	244	O
in	-	255	O
epileptogenesis	-	258	O
,	-	273	O
and	-	275	O
genetic	-	279	O
factors	-	287	O
influence	-	295	O
the	-	305	O
response	-	309	O
to	-	318	O
cholinergic	-	321	O
agents	-	333	O
,	-	339	O
but	-	341	O
limited	-	345	O
data	-	353	O
are	-	358	O
available	-	362	O
on	-	372	O
cholinergic	-	375	O
involvement	-	387	O
in	-	399	O
alcohol	-	402	B
withdrawal	-	410	O
severity	-	421	O
.	-	429	O

Thus	12198388	431	O
,	-	435	O
the	-	437	O
relationship	-	441	O
between	-	454	O
cholinergic	-	462	O
activity	-	474	O
and	-	483	O
responsiveness	-	487	O
and	-	502	O
alcohol	-	506	B
withdrawal	-	514	O
was	-	525	O
investigated	-	529	O
in	-	542	O
a	-	545	O
genetic	-	547	O
animal	-	555	O
model	-	562	O
of	-	568	O
ethanol	-	571	B
withdrawal	-	579	O
severity	-	590	O
.	-	598	O

METHODS	12198388	600	O
:	-	607	O

Cholinergic	12198388	609	O
convulsant	-	621	O
sensitivity	-	632	O
was	-	644	O
examined	-	648	O
in	-	657	O
alcohol	-	660	B
-	-	667	O
na	-	668	O
ve	-	672	O
Withdrawal	-	675	O
Seizure	-	686	O
-	-	693	O
Prone	-	694	O
(	-	700	O
WSP	-	701	O
)	-	704	O
and	-	706	O
-	-	709	O
Resistant	-	710	O
(	-	720	O
WSR	-	721	O
)	-	724	O
mice	-	726	O
.	-	730	O

Animals	12198388	732	O
were	-	740	O
administered	-	745	O
nicotine	-	758	B
,	-	766	O
carbachol	-	768	B
,	-	777	O
or	-	779	O
neostigmine	-	782	B
via	-	794	O
timed	-	798	O
tail	-	804	O
vein	-	809	O
infusion	-	814	O
,	-	822	O
and	-	824	O
the	-	828	O
latencies	-	832	O
to	-	842	O
onset	-	845	O
of	-	851	O
tremor	-	854	O
and	-	861	O
clonus	-	865	O
were	-	872	O
recorded	-	877	O
and	-	886	O
converted	-	890	O
to	-	900	O
threshold	-	903	O
dose	-	913	O
.	-	917	O

We	12198388	919	O
also	-	922	O
used	-	927	O
microdialysis	-	932	O
to	-	946	O
measure	-	949	O
basal	-	957	O
and	-	963	O
potassium	-	967	B
-	-	976	O
stimulated	-	977	O
acetylcholine	-	988	B
(	-	1002	O
ACh	-	1003	B
)	-	1006	O
release	-	1008	O
in	-	1016	O
the	-	1019	O
CA1	-	1023	O
region	-	1027	O
of	-	1034	O
the	-	1037	O
hippocampus	-	1041	O
.	-	1052	O

Potassium	12198388	1054	B
was	-	1064	O
applied	-	1068	O
by	-	1076	O
reverse	-	1079	O
dialysis	-	1087	O
twice	-	1096	O
,	-	1101	O
separated	-	1103	O
by	-	1113	O
75	-	1116	O
min	-	1119	O
.	-	1122	O

Hippocampal	12198388	1124	O
ACh	-	1136	B
also	-	1140	O
was	-	1145	O
measured	-	1149	O
during	-	1158	O
testing	-	1165	O
for	-	1173	O
handling	-	1177	O
-	-	1185	O
induced	-	1186	O
convulsions	-	1194	O
.	-	1205	O

RESULTS	12198388	1207	O
:	-	1214	O

Sensitivity	12198388	1216	O
to	-	1228	O
several	-	1231	O
convulsion	-	1239	O
endpoints	-	1250	O
induced	-	1260	O
by	-	1268	O
nicotine	-	1271	B
,	-	1279	O
carbachol	-	1281	B
,	-	1290	O
and	-	1292	O
neostigmine	-	1296	B
were	-	1308	O
significantly	-	1313	O
greater	-	1327	O
in	-	1335	O
WSR	-	1338	O
versus	-	1342	O
WSP	-	1349	O
mice	-	1353	O
.	-	1357	O

In	12198388	1359	O
microdialysis	-	1362	O
experiments	-	1376	O
,	-	1387	O
the	-	1389	O
lines	-	1393	O
did	-	1399	O
not	-	1403	O
differ	-	1407	O
in	-	1414	O
basal	-	1417	O
release	-	1423	O
of	-	1431	O
ACh	-	1434	B
,	-	1437	O
and	-	1439	O
50	-	1443	O
mM	-	1446	O
KCl	-	1449	B
increased	-	1453	O
ACh	-	1463	B
output	-	1467	O
in	-	1474	O
both	-	1477	O
lines	-	1482	O
of	-	1488	O
mice	-	1491	O
.	-	1495	O

However	12198388	1497	O
,	-	1504	O
the	-	1506	O
increase	-	1510	O
in	-	1519	O
release	-	1522	O
of	-	1530	O
ACh	-	1533	B
produced	-	1537	O
by	-	1546	O
the	-	1549	O
first	-	1553	O
application	-	1559	O
of	-	1571	O
KCl	-	1574	B
was	-	1578	O
2	-	1582	O
-	-	1583	O
fold	-	1584	O
higher	-	1589	O
in	-	1596	O
WSP	-	1599	O
versus	-	1603	O
WSR	-	1610	O
mice	-	1614	O
.	-	1618	O

When	12198388	1620	O
hippocampal	-	1625	O
ACh	-	1637	B
was	-	1641	O
measured	-	1645	O
during	-	1654	O
testing	-	1661	O
for	-	1669	O
handling	-	1673	O
-	-	1681	O
induced	-	1682	O
convulsions	-	1690	O
,	-	1701	O
extracellular	-	1703	O
ACh	-	1717	B
was	-	1721	O
significantly	-	1725	O
elevated	-	1739	O
(	-	1748	O
192	-	1749	O
%	-	1752	O
)	-	1753	O
in	-	1755	O
WSP	-	1758	O
mice	-	1762	O
,	-	1766	O
but	-	1768	O
was	-	1772	O
nonsignificantly	-	1776	O
elevated	-	1793	O
(	-	1802	O
59	-	1803	O
%	-	1805	O
)	-	1806	O
in	-	1808	O
WSR	-	1811	O
mice	-	1815	O
.	-	1819	O

CONCLUSIONS	12198388	1821	O
:	-	1832	O

These	12198388	1834	O
results	-	1840	O
suggest	-	1848	O
that	-	1856	O
differences	-	1861	O
in	-	1873	O
cholinergic	-	1876	O
activity	-	1888	O
and	-	1897	O
postsynaptic	-	1901	O
sensitivity	-	1914	O
to	-	1926	O
cholinergic	-	1929	O
convulsants	-	1941	O
may	-	1953	O
be	-	1957	O
associated	-	1960	O
with	-	1971	O
ethanol	-	1976	B
withdrawal	-	1984	O
severity	-	1995	O
and	-	2004	O
implicate	-	2008	O
cholinergic	-	2018	O
mechanisms	-	2030	O
in	-	2041	O
alcohol	-	2044	B
withdrawal	-	2052	O
.	-	2062	O

Specifically	12198388	2064	O
,	-	2076	O
WSP	-	2078	O
mice	-	2082	O
may	-	2087	O
have	-	2091	O
lower	-	2096	O
sensitivity	-	2102	O
to	-	2114	O
cholinergic	-	2117	O
convulsants	-	2129	O
compared	-	2141	O
with	-	2150	O
WSR	-	2155	O
because	-	2159	O
of	-	2167	O
postsynaptic	-	2170	O
receptor	-	2183	O
desensitization	-	2192	O
brought	-	2208	O
on	-	2216	O
by	-	2219	O
higher	-	2222	O
activity	-	2229	O
of	-	2238	O
cholinergic	-	2241	O
neurons	-	2253	O
.	-	2260	O

Prenatal	12574103	0	O
dexamethasone	-	9	B
programs	-	23	O
hypertension	-	32	O
and	-	45	O
renal	-	49	O
injury	-	55	O
in	-	62	O
the	-	65	O
rat	-	69	O
.	-	72	O

Dexamethasone	12574103	74	O
is	-	88	O
frequently	-	91	O
administered	-	102	O
to	-	115	O
the	-	118	O
developing	-	122	O
fetus	-	133	O
to	-	139	O
accelerate	-	142	O
pulmonary	-	153	O
development	-	163	O
.	-	174	O

The	12574103	176	O
purpose	-	180	O
of	-	188	O
the	-	191	O
present	-	195	O
study	-	203	O
was	-	209	O
to	-	213	O
determine	-	216	O
if	-	226	O
prenatal	-	229	O
dexamethasone	-	238	B
programmed	-	252	O
a	-	263	O
progressive	-	265	O
increase	-	277	O
in	-	286	O
blood	-	289	O
pressure	-	295	O
and	-	304	O
renal	-	308	O
injury	-	314	O
in	-	321	O
rats	-	324	O
.	-	328	O

Pregnant	12574103	330	O
rats	-	339	O
were	-	344	O
given	-	349	O
either	-	355	O
vehicle	-	362	O
or	-	370	O
2	-	373	O
daily	-	375	O
intraperitoneal	-	381	O
injections	-	397	O
of	-	408	O
dexamethasone	-	411	B
(	-	425	O
0	-	426	O
.	-	427	O
2	-	428	O
mg	-	430	O
/	-	432	O
kg	-	433	O
body	-	436	O
weight	-	441	O
)	-	447	O
on	-	449	O
gestational	-	452	O
days	-	464	O
11	-	469	O
and	-	472	O
12	-	476	O
,	-	478	O
13	-	480	O
and	-	483	O
14	-	487	O
,	-	489	O
15	-	491	O
and	-	494	O
16	-	498	O
,	-	500	O
17	-	502	O
and	-	505	O
18	-	509	O
,	-	511	O
or	-	513	O
19	-	516	O
and	-	519	O
20	-	523	O
.	-	525	O

Offspring	12574103	527	O
of	-	537	O
rats	-	540	O
administered	-	545	O
dexamethasone	-	558	B
on	-	572	O
days	-	575	O
15	-	580	O
and	-	583	O
16	-	587	O
gestation	-	590	O
had	-	600	O
a	-	604	O
20	-	606	O
%	-	608	O
reduction	-	610	O
in	-	620	O
glomerular	-	623	O
number	-	634	O
compared	-	641	O
with	-	650	O
control	-	655	O
at	-	663	O
6	-	666	O
to	-	668	O
9	-	671	O
months	-	673	O
of	-	680	O
age	-	683	O
(	-	687	O
22	-	688	O
527	-	691	O
+	-	694	O
/	-	695	O
-	-	696	O
509	-	697	O
versus	-	701	O
28	-	708	O
050	-	711	O
+	-	714	O
/	-	715	O
-	-	716	O
561	-	717	O
,	-	720	O
P	-	722	O
<	-	723	O
0	-	724	O
.	-	725	O
05	-	726	O
)	-	728	O
,	-	729	O
which	-	731	O
was	-	737	O
comparable	-	741	O
to	-	752	O
the	-	755	O
percent	-	759	O
reduction	-	767	O
in	-	777	O
glomeruli	-	780	O
measured	-	790	O
at	-	799	O
3	-	802	O
weeks	-	804	O
of	-	810	O
age	-	813	O
.	-	816	O

Six	12574103	818	O
-	-	821	O
to	-	823	O
9	-	826	O
-	-	827	O
month	-	828	O
old	-	834	O
rats	-	838	O
receiving	-	843	O
prenatal	-	853	O
dexamethasone	-	862	B
on	-	876	O
days	-	879	O
17	-	884	O
and	-	887	O
18	-	891	O
of	-	894	O
gestation	-	897	O

had	12574103	907	O
a	-	911	O
17	-	913	O
%	-	915	O
reduction	-	917	O
in	-	927	O
glomeruli	-	930	O
(	-	940	O
23	-	941	O
380	-	944	O
+	-	947	O
/	-	948	O
-	-	949	O
587	-	950	O
)	-	953	O
compared	-	955	O
with	-	964	O
control	-	969	O
rats	-	977	O
(	-	982	O
P	-	983	O
<	-	984	O
0	-	985	O
.	-	986	O
05	-	987	O
)	-	989	O
.	-	990	O

Male	12574103	992	O
rats	-	997	O
that	-	1002	O
received	-	1007	O
prenatal	-	1016	O
dexamethasone	-	1025	B
on	-	1039	O
days	-	1042	O
15	-	1047	O
and	-	1050	O
16	-	1054	O
,	-	1056	O
17	-	1058	O
and	-	1061	O
18	-	1065	O
,	-	1067	O
and	-	1069	O
13	-	1073	O
and	-	1076	O
14	-	1080	O
of	-	1083	O
gestation	-	1086	O
had	-	1096	O
elevated	-	1100	O
blood	-	1109	O
pressures	-	1115	O
at	-	1125	O
6	-	1128	O
months	-	1130	O
of	-	1137	O
age	-	1140	O
;	-	1143	O
the	-	1145	O
latter	-	1149	O
group	-	1156	O
did	-	1162	O
not	-	1166	O
have	-	1170	O
a	-	1175	O
reduction	-	1177	O
in	-	1187	O
glomerular	-	1190	O
number	-	1201	O
.	-	1207	O

Adult	12574103	1209	O
rats	-	1215	O
given	-	1220	O
dexamethasone	-	1226	B
on	-	1240	O
days	-	1243	O
15	-	1248	O
and	-	1251	O
16	-	1255	O
of	-	1258	O
gestation	-	1261	O
had	-	1271	O
more	-	1275	O
glomeruli	-	1280	O
with	-	1290	O
glomerulosclerosis	-	1295	O
than	-	1314	O
control	-	1319	O
rats	-	1327	O
.	-	1331	O

This	12574103	1333	O
study	-	1338	O
shows	-	1344	O
that	-	1350	O
prenatal	-	1355	O
dexamethasone	-	1364	B
in	-	1378	O
rats	-	1381	O
results	-	1386	O
in	-	1394	O
a	-	1397	O
reduction	-	1399	O
in	-	1409	O
glomerular	-	1412	O
number	-	1423	O
,	-	1429	O
glomerulosclerosis	-	1431	O
,	-	1449	O
and	-	1451	O
hypertension	-	1455	O
when	-	1468	O
administered	-	1473	O
at	-	1486	O
specific	-	1489	O
points	-	1498	O
during	-	1505	O
gestation	-	1512	O
.	-	1521	O

Hypertension	12574103	1523	O
was	-	1536	O
observed	-	1540	O
in	-	1549	O
animals	-	1552	O
that	-	1560	O
had	-	1565	O
a	-	1569	O
reduction	-	1571	O
in	-	1581	O
glomeruli	-	1584	O
as	-	1594	O
well	-	1597	O
as	-	1602	O
in	-	1605	O
a	-	1608	O
group	-	1610	O
that	-	1616	O
did	-	1621	O
not	-	1625	O
have	-	1629	O
a	-	1634	O
reduction	-	1636	O
in	-	1646	O
glomerular	-	1649	O
number	-	1660	O
,	-	1666	O
suggesting	-	1668	O
that	-	1679	O
a	-	1684	O
reduction	-	1686	O
in	-	1696	O
glomerular	-	1699	O
number	-	1710	O
is	-	1717	O
not	-	1720	O
the	-	1724	O
sole	-	1728	O
cause	-	1733	O
for	-	1739	O
the	-	1743	O
development	-	1747	O
of	-	1759	O
hypertension	-	1762	O
.	-	1774	O

The	12615818	0	O
risk	-	4	O
of	-	9	O
venous	-	12	O
thromboembolism	-	19	O
in	-	35	O
women	-	38	O
prescribed	-	44	O
cyproterone	-	55	B
acetate	-	67	I
in	-	75	O
combination	-	78	O
with	-	90	O
ethinyl	-	95	B
estradiol	-	103	I
:	-	112	O
a	-	114	O
nested	-	116	O
cohort	-	123	O
analysis	-	130	O
and	-	139	O
case	-	143	O
-	-	147	O
control	-	148	O
study	-	156	O
.	-	161	O

BACKGROUND	12615818	163	O
:	-	173	O

Cyproterone	12615818	175	B
acetate	-	187	I
combined	-	195	O
with	-	204	O
ethinyl	-	209	B
estradiol	-	217	I
(	-	227	O
CPA	-	228	B
/	-	231	O
EE	-	232	B
)	-	234	O
is	-	236	O
licensed	-	239	O
in	-	248	O
the	-	251	O
UK	-	255	O
for	-	258	O
the	-	262	O
treatment	-	266	O
of	-	276	O
women	-	279	O
with	-	285	O
acne	-	290	O
and	-	295	O
hirsutism	-	299	O
and	-	309	O
is	-	313	O
also	-	316	O
a	-	321	O
treatment	-	323	O
option	-	333	O
for	-	340	O
polycystic	-	344	O
ovary	-	355	O
syndrome	-	361	O
(	-	370	O
PCOS	-	371	O
)	-	375	O
.	-	376	O

Previous	12615818	378	O
studies	-	387	O
have	-	395	O
demonstrated	-	400	O
an	-	413	O
increased	-	416	O
risk	-	426	O
of	-	431	O
venous	-	434	O
thromboembolism	-	441	O
(	-	457	O
VTE	-	458	O
)	-	461	O
associated	-	463	O
with	-	474	O
CPA	-	479	B
/	-	482	O
EE	-	483	B
compared	-	486	O
with	-	495	O
conventional	-	500	O
combined	-	513	O
oral	-	522	B
contraceptives	-	527	I
(	-	542	O
COCs	-	543	O
)	-	547	O
.	-	548	O

We	12615818	550	O
believe	-	553	O
the	-	561	O
results	-	565	O
of	-	573	O
those	-	576	O
studies	-	582	O
may	-	590	O
have	-	594	O
been	-	599	O
affected	-	604	O
by	-	613	O
residual	-	616	O
confounding	-	625	O
.	-	636	O

METHODS	12615818	638	O
:	-	645	O

Using	12615818	647	O
the	-	653	O
General	-	657	O
Practice	-	665	O
Research	-	674	O
Database	-	683	O
we	-	692	O
conducted	-	695	O
a	-	705	O
cohort	-	707	O
analysis	-	714	O
and	-	723	O
case	-	727	O
-	-	731	O
control	-	732	O
study	-	740	O
nested	-	746	O
within	-	753	O
a	-	760	O
population	-	762	O
of	-	773	O
women	-	776	O
aged	-	782	O
between	-	787	O
15	-	795	O
and	-	798	O
39	-	802	O
years	-	805	O
with	-	811	O
acne	-	816	O
,	-	820	O
hirsutism	-	822	O
or	-	832	O
PCOS	-	835	O
to	-	840	O
estimate	-	843	O
the	-	852	O
risk	-	856	O
of	-	861	O
VTE	-	864	O
associated	-	868	O
with	-	879	O
CPA	-	884	B
/	-	887	O
EE	-	888	B
.	-	890	O

RESULTS	12615818	892	O
:	-	899	O

The	12615818	901	O
age	-	905	O
-	-	908	O
adjusted	-	909	O
incidence	-	918	O
rate	-	928	O
ratio	-	933	O
for	-	939	O
CPA	-	943	B
/	-	946	O
EE	-	947	B
versus	-	950	O
conventional	-	957	O
COCs	-	970	O
was	-	975	O
2	-	979	O
.	-	980	O
20	-	981	O
[	-	984	O
95	-	985	O
%	-	987	O
confidence	-	989	O
interval	-	1000	O
(	-	1009	O
CI	-	1010	O
)	-	1012	O
1	-	1014	O
.	-	1015	O
35	-	1016	O
-	-	1018	O
3	-	1019	O
.	-	1020	O
58	-	1021	O
]	-	1023	O
.	-	1024	O

Using	12615818	1026	O
as	-	1032	O
the	-	1035	O
reference	-	1039	O
group	-	1049	O
women	-	1055	O
who	-	1061	O
were	-	1065	O
not	-	1070	O
using	-	1074	O
oral	-	1080	O
contraception	-	1085	O
,	-	1098	O
had	-	1100	O
no	-	1104	O
recent	-	1107	O
pregnancy	-	1114	O
or	-	1124	O
menopausal	-	1127	O
symptoms	-	1138	O
,	-	1146	O
the	-	1148	O
case	-	1152	O
-	-	1156	O
control	-	1157	O
analysis	-	1165	O
gave	-	1174	O
an	-	1179	O
adjusted	-	1182	O
odds	-	1191	O
ratio	-	1196	O
(	-	1202	O
OR	-	1203	O
(	-	1205	O
adj	-	1206	O
)	-	1209	O
)	-	1210	O
of	-	1212	O
7	-	1215	O
.	-	1216	O
44	-	1217	O
(	-	1220	O
95	-	1221	O
%	-	1223	O
CI	-	1225	O
3	-	1228	O
.	-	1229	O
67	-	1230	O
-	-	1232	O
15	-	1233	O
.	-	1235	O
08	-	1236	O
)	-	1238	O
for	-	1240	O
CPA	-	1244	B
/	-	1247	O
EE	-	1248	B
use	-	1251	O
compared	-	1255	O
with	-	1264	O
an	-	1269	O
OR	-	1272	O
(	-	1274	O
adj	-	1275	O
)	-	1278	O
of	-	1280	O
2	-	1283	O
.	-	1284	O
58	-	1285	O
(	-	1288	O
95	-	1289	O
%	-	1291	O
CI	-	1293	O
1	-	1296	O
.	-	1297	O
60	-	1298	O
-	-	1300	O
4	-	1301	O
.	-	1302	O
18	-	1303	O
)	-	1305	O
for	-	1307	O
use	-	1311	O
of	-	1315	O
conventional	-	1318	O
COCs	-	1331	O
.	-	1335	O

CONCLUSIONS	12615818	1337	O
:	-	1348	O

We	12615818	1350	O
have	-	1353	O
demonstrated	-	1358	O
an	-	1371	O
increased	-	1374	O
risk	-	1384	O
of	-	1389	O
VTE	-	1392	O
associated	-	1396	O
with	-	1407	O
the	-	1412	O
use	-	1416	O
of	-	1420	O
CPA	-	1423	B
/	-	1426	O
EE	-	1427	B
in	-	1430	O
women	-	1433	O
with	-	1439	O
acne	-	1444	O
,	-	1448	O
hirsutism	-	1450	O
or	-	1460	O
PCOS	-	1463	O
although	-	1468	O
residual	-	1477	O
confounding	-	1486	O
by	-	1498	O
indication	-	1501	O
can	-	1512	O
not	-	1515	O
be	-	1519	O
excluded	-	1522	O
.	-	1530	O

Pseudoacromegaly	12789195	0	O
induced	-	17	O
by	-	25	O
the	-	28	O
long	-	32	O
-	-	36	O
term	-	37	O
use	-	42	O
of	-	46	O
minoxidil	-	49	B
.	-	58	O

Acromegaly	12789195	60	O
is	-	71	O
an	-	74	O
endocrine	-	77	O
disorder	-	87	O
caused	-	96	O
by	-	103	O
chronic	-	106	O
excessive	-	114	O
growth	-	124	O
hormone	-	131	O
secretion	-	139	O
from	-	149	O
the	-	154	O
anterior	-	158	O
pituitary	-	167	O
gland	-	177	O
.	-	182	O

Significant	12789195	184	O
disfiguring	-	196	O
changes	-	208	O
occur	-	216	O
as	-	222	O
a	-	225	O
result	-	227	O
of	-	234	O
bone	-	237	O
,	-	241	O
cartilage	-	243	O
,	-	252	O
and	-	254	O
soft	-	258	O
tissue	-	263	O
hypertrophy	-	270	O
,	-	281	O
including	-	283	O
the	-	293	O
thickening	-	297	O
of	-	308	O
the	-	311	O
skin	-	315	O
,	-	319	O
coarsening	-	321	O
of	-	332	O
facial	-	335	O
features	-	342	O
,	-	350	O
and	-	352	O
cutis	-	356	O
verticis	-	362	O
gyrata	-	371	O
.	-	377	O

Pseudoacromegaly	12789195	379	O
,	-	395	O
on	-	397	O
the	-	400	O
other	-	404	O
hand	-	410	O
,	-	414	O
is	-	416	O
the	-	419	O
presence	-	423	O
of	-	432	O
similar	-	435	O
acromegaloid	-	443	O
features	-	456	O
in	-	465	O
the	-	468	O
absence	-	472	O
of	-	480	O
elevated	-	483	O
growth	-	492	O
hormone	-	499	O
or	-	507	O
insulin	-	510	O
-	-	517	O
like	-	518	O
growth	-	523	O
factor	-	530	O
levels	-	537	O
.	-	543	O

We	12789195	545	O
present	-	548	O
a	-	556	O
patient	-	558	O
with	-	566	O
pseudoacromegaly	-	571	O
that	-	588	O
resulted	-	593	O
from	-	602	O
the	-	607	O
long	-	611	O
-	-	615	O
term	-	616	O
use	-	621	O
of	-	625	O
minoxidil	-	628	B
at	-	638	O
an	-	641	O
unusually	-	644	O
high	-	654	O
dose	-	659	O
.	-	663	O

This	12789195	665	O
is	-	670	O
the	-	673	O
first	-	677	O
case	-	683	O
report	-	688	O
of	-	695	O
pseudoacromegaly	-	698	O
as	-	715	O
a	-	718	O
side	-	720	O
effect	-	725	O
of	-	732	O
minoxidil	-	735	B
use	-	745	O
.	-	748	O

Combined	12820454	0	O
androgen	-	9	O
blockade	-	18	O
-	-	26	O
induced	-	27	O
anemia	-	35	O
in	-	42	O
prostate	-	45	O
cancer	-	54	O
patients	-	61	O
without	-	70	O
bone	-	78	O
involvement	-	83	O
.	-	94	O

BACKGROUND	12820454	96	O
:	-	106	O

To	12820454	108	O
determine	-	111	O
the	-	121	O
onset	-	125	O
and	-	131	O
extent	-	135	O
of	-	142	O
combined	-	145	O
androgen	-	154	O
blockade	-	163	O
(	-	172	O
CAB	-	173	O
)	-	176	O
-	-	177	O
induced	-	178	O
anemia	-	186	O
in	-	193	O
prostate	-	196	O
cancer	-	205	O
patients	-	212	O
without	-	221	O
bone	-	229	O
involvement	-	234	O
.	-	245	O

PATIENTS	12820454	247	O
AND	-	256	O
METHODS	-	260	O
:	-	267	O

Forty	12820454	269	O
-	-	274	O
two	-	275	O
patients	-	279	O
with	-	288	O
biopsy	-	293	O
-	-	299	O
proven	-	300	O
prostatic	-	307	O
adenocarcinoma	-	317	O
[	-	332	O
26	-	333	O
with	-	336	O
stage	-	341	O
C	-	347	O
(	-	349	O
T3N0M0	-	350	O
)	-	356	O
and	-	358	O
16	-	362	O
with	-	365	O
stage	-	370	O
D1	-	376	O
(	-	379	O
T3N1M0	-	380	O
)	-	386	O
]	-	387	O
were	-	389	O
included	-	394	O
in	-	403	O
this	-	406	O
study	-	411	O
.	-	416	O

All	12820454	418	O
patients	-	422	O
received	-	431	O
CAB	-	440	O
[	-	444	O
leuprolide	-	445	B
acetate	-	456	I
(	-	464	O
LHRH	-	465	B
-	-	469	I
A	-	470	I
)	-	471	O
3	-	473	O
.	-	474	O
75	-	475	O
mg	-	478	O
,	-	480	O
intramuscularly	-	482	O
,	-	497	O
every	-	499	O
28	-	505	O
days	-	508	O
plus	-	513	O
250	-	518	O
mg	-	522	O
flutamide	-	525	B
,	-	534	O
tid	-	536	O
,	-	539	O
per	-	541	O
Os	-	545	O
]	-	547	O
and	-	549	O
were	-	553	O
evaluated	-	558	O
for	-	568	O
anemia	-	572	O
by	-	579	O
physical	-	582	O
examination	-	591	O
and	-	603	O
laboratory	-	607	O
tests	-	618	O
at	-	624	O
baseline	-	627	O
and	-	636	O
4	-	640	O
subsequent	-	642	O
intervals	-	653	O
(	-	663	O
1	-	664	O
,	-	665	O
2	-	667	O
,	-	668	O
3	-	670	O
and	-	672	O
6	-	676	O
months	-	678	O
post	-	685	O
-	-	689	O
CAB	-	690	O
)	-	693	O
.	-	694	O

Hb	12820454	696	O
,	-	698	O
PSA	-	700	O
and	-	704	O
Testosterone	-	708	B
measurements	-	721	O
were	-	734	O
recorded	-	739	O
.	-	747	O

Patients	12820454	749	O
with	-	758	O
stage	-	763	O
D2	-	769	O
-	-	771	O
3	-	772	O
disease	-	774	O
,	-	781	O
abnormal	-	783	O
hemoglobin	-	792	O
level	-	803	O
or	-	809	O
renal	-	812	O
and	-	818	O
liver	-	822	O
function	-	828	O
tests	-	837	O
that	-	843	O
were	-	848	O
higher	-	853	O
than	-	860	O
the	-	865	O
upper	-	869	O
limits	-	875	O
were	-	882	O
excluded	-	887	O
from	-	896	O
the	-	901	O
study	-	905	O
.	-	910	O

The	12820454	912	O
duration	-	916	O
of	-	925	O
the	-	928	O
study	-	932	O
was	-	938	O
six	-	942	O
months	-	946	O
.	-	952	O

RESULTS	12820454	954	O
:	-	961	O

The	12820454	963	O
mean	-	967	O
hemoglobin	-	972	O
(	-	983	O
Hb	-	984	O
)	-	986	O
levels	-	988	O
were	-	995	O
significantly	-	1000	O
declined	-	1014	O
in	-	1023	O
all	-	1026	O
patients	-	1030	O
from	-	1039	O
baseline	-	1044	O
of	-	1053	O
14	-	1056	O
.	-	1058	O
2	-	1059	O
g	-	1061	O
/	-	1062	O
dl	-	1063	O
to	-	1066	O
14	-	1069	O
.	-	1071	O
0	-	1072	O
g	-	1074	O
/	-	1075	O
dl	-	1076	O
,	-	1078	O
13	-	1080	O
.	-	1082	O
5	-	1083	O
g	-	1085	O
/	-	1086	O
dl	-	1087	O
,	-	1089	O
13	-	1091	O
.	-	1093	O
2	-	1094	O
g	-	1096	O
/	-	1097	O
dl	-	1098	O
and	-	1101	O
12	-	1105	O
.	-	1107	O
7	-	1108	O
g	-	1110	O
/	-	1111	O
dl	-	1112	O
at	-	1115	O
1	-	1118	O
,	-	1119	O
2	-	1121	O
,	-	1122	O
3	-	1124	O
and	-	1126	O
6	-	1130	O
months	-	1132	O
post	-	1139	O
-	-	1143	O
CAB	-	1144	O
,	-	1147	O
respectively	-	1149	O
.	-	1161	O

Severe	12820454	1163	O
and	-	1170	O
clinically	-	1174	O
evident	-	1185	O
anemia	-	1193	O
of	-	1200	O
Hb	-	1203	O

<	12820454	1206	O
11	-	1208	O
g	-	1211	O
/	-	1212	O
dl	-	1213	O
with	-	1216	O
clinical	-	1221	O
symptoms	-	1230	O
was	-	1239	O
detected	-	1243	O
in	-	1252	O
6	-	1255	O
patients	-	1257	O
(	-	1266	O
14	-	1267	O
.	-	1269	O
3	-	1270	O
%	-	1271	O
)	-	1272	O
.	-	1273	O

This	12820454	1275	O
CAB	-	1280	O
-	-	1283	O
induced	-	1284	O
anemia	-	1292	O
was	-	1299	O
normochromic	-	1303	O
and	-	1316	O
normocytic	-	1320	O
.	-	1330	O

At	12820454	1332	O
six	-	1335	O
months	-	1339	O
post	-	1346	O
-	-	1350	O
CAB	-	1351	O
,	-	1354	O
patients	-	1356	O
with	-	1365	O
severe	-	1370	O
anemia	-	1377	O
had	-	1384	O
a	-	1388	O
Hb	-	1390	O
mean	-	1393	O
value	-	1398	O
of	-	1404	O
10	-	1407	O
.	-	1409	O
2	-	1410	O
+	-	1412	O
/	-	1413	O
-	-	1414	O

0	12820454	1416	O
.	-	1417	O
1	-	1418	O
g	-	1420	O
/	-	1421	O
dl	-	1422	O
(	-	1425	O
X	-	1426	O
+	-	1428	O
/	-	1429	O
-	-	1430	O

SE	12820454	1432	O
)	-	1434	O
,	-	1435	O
whereas	-	1437	O
the	-	1445	O
other	-	1449	O
patients	-	1455	O
had	-	1464	O
mild	-	1468	O
anemia	-	1473	O
with	-	1480	O
Hb	-	1485	O
mean	-	1488	O
value	-	1493	O
of	-	1499	O
13	-	1502	O
.	-	1504	O
2	-	1505	O
+	-	1507	O
/	-	1508	O
-	-	1509	O

0	12820454	1511	O
.	-	1512	O
17	-	1513	O
(	-	1516	O
X	-	1517	O
+	-	1519	O
/	-	1520	O
-	-	1521	O
SE	-	1523	O
)	-	1525	O
.	-	1526	O

The	12820454	1528	O
development	-	1532	O
of	-	1544	O
severe	-	1547	O
anemia	-	1554	O
at	-	1561	O
6	-	1564	O
months	-	1566	O
post	-	1573	O
-	-	1577	O
CAB	-	1578	O
was	-	1582	O
predictable	-	1586	O
by	-	1598	O
the	-	1601	O
reduction	-	1605	O
of	-	1615	O
Hb	-	1618	O
baseline	-	1621	O
value	-	1630	O
of	-	1636	O
more	-	1639	O
than	-	1644	O
2	-	1649	O
.	-	1650	O
5	-	1651	O
g	-	1653	O
/	-	1654	O
dl	-	1655	O
after	-	1658	O
3	-	1664	O
months	-	1666	O
of	-	1673	O
CAB	-	1676	O
(	-	1680	O
p	-	1681	O
=	-	1683	O
0	-	1685	O
.	-	1686	O
01	-	1687	O
)	-	1689	O
.	-	1690	O

The	12820454	1692	O
development	-	1696	O
of	-	1708	O
severe	-	1711	O
CAB	-	1718	O
-	-	1721	O
induced	-	1722	O
anemia	-	1730	O
in	-	1737	O
prostate	-	1740	O
cancer	-	1749	O
patients	-	1756	O
did	-	1765	O
not	-	1769	O
correlate	-	1773	O
with	-	1783	O
T	-	1788	O
baseline	-	1790	O
values	-	1799	O
(	-	1806	O
T	-	1807	O
<	-	1809	O
3	-	1811	O
ng	-	1813	O
/	-	1815	O
ml	-	1816	O
versus	-	1819	O
T	-	1826	O
>	-	1828	O
or	-	1830	O
=	-	1833	O
3	-	1835	O
ng	-	1837	O
/	-	1839	O
ml	-	1840	O
)	-	1842	O
,	-	1843	O
with	-	1845	O
age	-	1850	O
(	-	1854	O
<	-	1855	O
76	-	1857	O
yrs	-	1860	O
versus	-	1864	O
>	-	1871	O
or	-	1873	O
=	-	1876	O
76	-	1878	O
yrs	-	1881	O
)	-	1884	O
,	-	1885	O
and	-	1887	O
clinical	-	1891	O
stage	-	1900	O
(	-	1906	O
stage	-	1907	O
C	-	1913	O
versus	-	1915	O
stage	-	1922	O
D1	-	1928	O
)	-	1930	O
.	-	1931	O

Severe	12820454	1933	O
and	-	1940	O
clinically	-	1944	O
evident	-	1955	O
anemia	-	1963	O
was	-	1970	O
easily	-	1974	O
corrected	-	1981	O
by	-	1991	O
subcutaneous	-	1994	O
injections	-	2007	O
(	-	2018	O
3	-	2019	O
times	-	2021	O
/	-	2026	O
week	-	2027	O
for	-	2032	O
1	-	2036	O
month	-	2038	O
)	-	2043	O
of	-	2045	O
recombinant	-	2048	O
erythropoietin	-	2060	O
(	-	2075	O
rHuEPO	-	2076	O
-	-	2082	O
beta	-	2083	O
)	-	2087	O
.	-	2088	O

CONCLUSION	12820454	2090	O
:	-	2100	O

Our	12820454	2102	O
data	-	2106	O
suggest	-	2111	O
that	-	2119	O
rHuEPO	-	2124	O
-	-	2130	O
beta	-	2131	O
correctable	-	2136	O
CAB	-	2148	O
-	-	2151	O
induced	-	2152	O
anemia	-	2160	O
occurs	-	2167	O
in	-	2174	O
14	-	2177	O
.	-	2179	O
3	-	2180	O
%	-	2181	O
of	-	2183	O
prostate	-	2186	O
cancer	-	2195	O
patients	-	2202	O
after	-	2211	O
6	-	2217	O
months	-	2219	O
of	-	2226	O
therapy	-	2229	O
.	-	2236	O

Reversible	14657095	0	O
dilated	-	11	O
cardiomyopathy	-	19	O
related	-	34	O
to	-	42	O
amphotericin	-	45	B
B	-	58	I
therapy	-	60	O
.	-	67	O

We	14657095	69	O
describe	-	72	O
a	-	81	O
patient	-	83	O
who	-	91	O
developed	-	95	O
dilated	-	105	O
cardiomyopathy	-	113	O
and	-	128	O
clinical	-	132	O
congestive	-	141	O
heart	-	152	O
failure	-	158	O
after	-	166	O
2	-	172	O
months	-	174	O
of	-	181	O
therapy	-	184	O
with	-	192	O
amphotericin	-	197	B
B	-	210	I
(	-	212	O
AmB	-	213	B
)	-	216	O
for	-	218	O
disseminated	-	222	O
coccidioidomycosis	-	235	O
.	-	253	O

His	14657095	255	O
echocardiographic	-	259	O
abnormalities	-	277	O
and	-	291	O
heart	-	295	O
failure	-	301	O
resolved	-	309	O
after	-	318	O
posaconazole	-	324	B
was	-	337	O
substituted	-	341	O
for	-	353	O
AmB	-	357	B
.	-	360	O

It	14657095	362	O
is	-	365	O
important	-	368	O
to	-	378	O
recognize	-	381	O
the	-	391	O
rare	-	395	O
and	-	400	O
potentially	-	404	O
reversible	-	416	O
toxicity	-	427	O
of	-	436	O
AmB	-	439	B
.	-	442	O

Risks	14765563	0	O
of	-	6	O
the	-	9	O
consumption	-	13	O
of	-	25	O
beverages	-	28	O
containing	-	38	O
quinine	-	49	B
.	-	56	O

Although	14765563	58	O
the	-	67	O
United	-	71	O
States	-	78	O
Food	-	85	O
and	-	90	O
Drug	-	94	O
Administration	-	99	O
banned	-	114	O
its	-	121	O
use	-	125	O
for	-	129	O
nocturnal	-	133	O
leg	-	143	O
cramps	-	147	O
due	-	154	O
to	-	158	O
lack	-	161	O
of	-	166	O
safety	-	169	O
and	-	176	O
efficacy	-	180	O
,	-	188	O
quinine	-	190	B
is	-	198	O
widely	-	201	O
available	-	208	O
in	-	218	O
beverages	-	221	O
including	-	231	O
tonic	-	241	O
water	-	247	O
and	-	253	O
bitter	-	257	O
lemon	-	264	O
.	-	269	O

Numerous	14765563	271	O
anecdotal	-	280	O
reports	-	290	O
suggest	-	298	O
that	-	306	O
products	-	311	O
containing	-	320	O
quinine	-	331	B
may	-	339	O
produce	-	343	O
neurological	-	351	O
complications	-	364	O
,	-	377	O
including	-	379	O
confusion	-	389	O
,	-	398	O
altered	-	400	O
mental	-	408	O
status	-	415	O
,	-	421	O
seizures	-	423	O
,	-	431	O
and	-	433	O
coma	-	437	O
,	-	441	O
particularly	-	443	O
in	-	456	O
older	-	459	O
women	-	465	O
.	-	470	O

Psychologists	14765563	472	O
need	-	486	O
to	-	491	O
inquire	-	494	O
about	-	502	O
consumption	-	508	O
of	-	520	O
quinine	-	523	B
-	-	530	O
containing	-	531	O
beverages	-	542	O
as	-	552	O
part	-	555	O
of	-	560	O
an	-	563	O
evaluation	-	566	O
process	-	577	O
.	-	584	O

Organophosphate	15036754	0	B
-	-	15	O
induced	-	16	O
convulsions	-	24	O
and	-	36	O
prevention	-	40	O
of	-	51	O
neuropathological	-	54	O
damages	-	72	O
.	-	79	O

Such	15036754	81	O
organophosphorus	-	86	B
(	-	103	O
OP	-	104	B
)	-	106	O
compounds	-	108	O
as	-	118	O
diisopropylfluorophosphate	-	121	B
(	-	148	O
DFP	-	149	B
)	-	152	O
,	-	153	O
sarin	-	155	B
and	-	161	O
soman	-	165	B
are	-	171	O
potent	-	175	O
inhibitors	-	182	O
of	-	193	O
acetylcholinesterases	-	196	O
(	-	218	O
AChEs	-	219	O
)	-	224	O
and	-	226	O
butyrylcholinesterases	-	230	O
(	-	253	O
BChEs	-	254	O
)	-	259	O
.	-	260	O

The	15036754	262	O
acute	-	266	O
toxicity	-	272	O
of	-	281	O
OPs	-	284	B
is	-	288	O
the	-	291	O
result	-	295	O
of	-	302	O
their	-	305	O
irreversible	-	311	O
binding	-	324	O
with	-	332	O
AChEs	-	337	O
in	-	343	O
the	-	346	O
central	-	350	O
nervous	-	358	O
system	-	366	O
(	-	373	O
CNS	-	374	O
)	-	377	O
,	-	378	O
which	-	380	O
elevates	-	386	O
acetylcholine	-	395	B
(	-	409	O
ACh	-	410	B
)	-	413	O
levels	-	415	O
.	-	421	O

The	15036754	423	O
protective	-	427	O
action	-	438	O
of	-	445	O
subcutaneously	-	448	O
(	-	463	O
SC	-	464	O
)	-	466	O
administered	-	468	O
antidotes	-	481	O
or	-	491	O
their	-	494	O
combinations	-	500	O
in	-	513	O
DFP	-	516	B
(	-	520	O
2	-	521	O
.	-	522	O
0	-	523	O
mg	-	525	O
/	-	527	O
kg	-	528	O
BW	-	531	O
)	-	533	O
intoxication	-	535	O
was	-	548	O
studied	-	552	O
in	-	560	O
9	-	563	O
-	-	564	O
10	-	565	O
-	-	567	O
weeks	-	568	O
-	-	573	O
old	-	574	O
Han	-	578	O
-	-	581	O
Wistar	-	582	O
male	-	589	O
rats	-	594	O
.	-	598	O

The	15036754	600	O
rats	-	604	O
received	-	609	O
AChE	-	618	O
reactivator	-	623	O
pralidoxime	-	635	B
-	-	646	I
2	-	647	I
-	-	648	I
chloride	-	649	I
(	-	658	O
2PAM	-	659	B
)	-	663	O
(	-	665	O
30	-	666	O
.	-	668	O
0	-	669	O
mg	-	671	O
/	-	673	O
kg	-	674	O
BW	-	677	O
)	-	679	O
,	-	680	O
anticonvulsant	-	682	O
diazepam	-	697	B
(	-	706	O
2	-	707	O
.	-	708	O
0	-	709	O
mg	-	711	O
/	-	713	O
kg	-	714	O
BW	-	717	O
)	-	719	O
,	-	720	O
A	-	722	O
(	-	723	O
1	-	724	O
)	-	725	O
-	-	726	O
adenosine	-	727	B
receptor	-	737	O
agonist	-	746	O
N	-	754	B
(	-	755	I
6	-	756	I
)	-	757	I
-	-	758	I
cyclopentyl	-	759	I
adenosine	-	771	I
(	-	781	O
CPA	-	782	B
)	-	785	O
(	-	787	O
2	-	788	O
.	-	789	O
0	-	790	O
mg	-	792	O
/	-	794	O
kg	-	795	O
BW	-	798	O
)	-	800	O
,	-	801	O
NMDA	-	803	B
-	-	807	O
receptor	-	808	O
antagonist	-	817	O
dizocilpine	-	828	B
maleate	-	840	I
(	-	848	O
+	-	849	O
-	-	850	O
MK801	-	851	O
hydrogen	-	857	O
maleate	-	866	O
)	-	873	O
(	-	875	O
2	-	876	O
.	-	877	O
0	-	878	O
mg	-	880	O
/	-	882	O
kg	-	883	O
BW	-	886	O
)	-	888	O
or	-	890	O
their	-	893	O
combinations	-	899	O
with	-	912	O
cholinolytic	-	917	O
drug	-	930	O
atropine	-	935	B
sulfate	-	944	I
(	-	952	O
50	-	953	O
.	-	955	O
0	-	956	O
mg	-	958	O
/	-	960	O
kg	-	961	O
BW	-	964	O
)	-	966	O
immediately	-	968	O
or	-	980	O
30	-	983	O
min	-	986	O
after	-	990	O
the	-	996	O
single	-	1000	O
SC	-	1007	O
injection	-	1010	O
of	-	1020	O
DFP	-	1023	B
.	-	1026	O

The	15036754	1028	O
control	-	1032	O
rats	-	1040	O
received	-	1045	O
atropine	-	1054	B
sulfate	-	1063	I
,	-	1070	O
but	-	1072	O
also	-	1076	O
saline	-	1081	O
and	-	1088	O
olive	-	1092	O
oil	-	1098	O
instead	-	1102	O
of	-	1110	O
other	-	1113	O
antidotes	-	1119	O
and	-	1129	O
DFP	-	1133	B
,	-	1136	O
respectively	-	1138	O
.	-	1150	O

All	15036754	1152	O
rats	-	1156	O
were	-	1161	O
terminated	-	1166	O
either	-	1177	O
24	-	1184	O
h	-	1187	O
or	-	1189	O
3	-	1192	O
weeks	-	1194	O
after	-	1200	O
the	-	1206	O
DFP	-	1210	B
injection	-	1214	O
.	-	1223	O

The	15036754	1225	O
rats	-	1229	O
treated	-	1234	O
with	-	1242	O
DFP	-	1247	B
-	-	1250	O
atropine	-	1251	B
showed	-	1260	O
severe	-	1267	O
typical	-	1274	O
OP	-	1282	B
-	-	1284	O
induced	-	1285	O
toxicity	-	1293	O
signs	-	1302	O
.	-	1307	O

When	15036754	1309	O
CPA	-	1314	B
,	-	1317	O
diazepam	-	1319	B
or	-	1328	O
2PAM	-	1331	B
was	-	1336	O
given	-	1340	O
immediately	-	1346	O
after	-	1358	O
DFP	-	1364	B
-	-	1367	O
atropine	-	1368	B
,	-	1376	O
these	-	1378	O
treatments	-	1384	O
prevented	-	1395	O
,	-	1404	O
delayed	-	1406	O
or	-	1414	O
shortened	-	1417	O
the	-	1427	O
occurrence	-	1431	O
of	-	1442	O
serious	-	1445	O
signs	-	1453	O
of	-	1459	O
poisoning	-	1462	O
.	-	1471	O

Atropine	15036754	1473	B
-	-	1481	O
MK801	-	1482	B
did	-	1488	O
not	-	1492	O
offer	-	1496	O
any	-	1502	O
additional	-	1506	O
protection	-	1517	O
against	-	1528	O
DFP	-	1536	B
toxicity	-	1540	O
.	-	1548	O

In	15036754	1550	O
conclusion	-	1553	O
,	-	1563	O
CPA	-	1565	B
,	-	1568	O
diazepam	-	1570	B
and	-	1579	O
2PAM	-	1583	B
in	-	1588	O
combination	-	1591	O
with	-	1603	O
atropine	-	1608	B
prevented	-	1617	O
the	-	1627	O
occurrence	-	1631	O
of	-	1642	O
serious	-	1645	O
signs	-	1653	O
of	-	1659	O
poisoning	-	1662	O
and	-	1672	O
thus	-	1676	O
reduced	-	1681	O
the	-	1689	O
toxicity	-	1693	O
of	-	1702	O
DFP	-	1705	B
in	-	1709	O
rat	-	1712	O
.	-	1715	O

Differential	15145918	0	O
modulation	-	13	O
by	-	24	O
estrogen	-	27	B
of	-	36	O
alpha2	-	39	O
-	-	45	O
adrenergic	-	46	O
and	-	57	O
I1	-	61	O
-	-	63	O
imidazoline	-	64	B
receptor	-	76	O
-	-	84	O
mediated	-	85	O
hypotension	-	94	O
in	-	106	O
female	-	109	O
rats	-	116	O
.	-	120	O

We	15145918	122	O
have	-	125	O
recently	-	130	O
shown	-	139	O
that	-	145	O
estrogen	-	150	B
negatively	-	159	O
modulates	-	170	O
the	-	180	O
hypotensive	-	184	O
effect	-	196	O
of	-	203	O
clonidine	-	206	B
(	-	216	O
mixed	-	217	O
alpha2	-	223	O
-	-	229	O
/	-	230	O
I1	-	231	O
-	-	233	O
receptor	-	234	O
agonist	-	243	O
)	-	250	O
in	-	252	O
female	-	255	O
rats	-	262	O
and	-	267	O
implicates	-	271	O
the	-	282	O
cardiovascular	-	286	O
autonomic	-	301	O
control	-	311	O
in	-	319	O
this	-	322	O
interaction	-	327	O
.	-	338	O

The	15145918	340	O
present	-	344	O
study	-	352	O
investigated	-	358	O
whether	-	371	O
this	-	379	O
effect	-	384	O
of	-	391	O
estrogen	-	394	B
involves	-	403	O
interaction	-	412	O
with	-	424	O
alpha2	-	429	O
-	-	435	O

and	15145918	437	O
/	-	440	O
or	-	441	O
I1	-	444	O
-	-	446	O
receptors	-	447	O
.	-	456	O

Changes	15145918	458	O
evoked	-	466	O
by	-	473	O
a	-	476	O
single	-	478	O
intraperitoneal	-	485	O
injection	-	501	O
of	-	511	O
rilmenidine	-	514	B
(	-	526	O
600	-	527	O
microg	-	531	O
/	-	537	O
kg	-	538	O
)	-	540	O
or	-	542	O
alpha	-	545	B
-	-	550	I
methyldopa	-	551	I
(	-	562	O
100	-	563	O
mg	-	567	O
/	-	569	O
kg	-	570	O
)	-	572	O
,	-	573	O
selective	-	575	O
I1	-	585	O
-	-	587	O
and	-	589	O
alpha2	-	593	O
-	-	599	O
receptor	-	600	O
agonists	-	609	O
,	-	617	O
respectively	-	619	O
,	-	631	O
in	-	633	O
blood	-	636	O
pressure	-	642	O
,	-	650	O
hemodynamic	-	652	O
variability	-	664	O
,	-	675	O
and	-	677	O
locomotor	-	681	O
activity	-	691	O
were	-	700	O
assessed	-	705	O
in	-	714	O
radiotelemetered	-	717	O
sham	-	734	O
-	-	738	O
operated	-	739	O
and	-	748	O
ovariectomized	-	752	O
(	-	767	O
Ovx	-	768	O
)	-	771	O
Sprague	-	773	O
-	-	780	O
Dawley	-	781	O
female	-	788	O
rats	-	795	O
with	-	800	O
or	-	805	O
without	-	808	O
12	-	816	O
-	-	818	O
wk	-	819	O
estrogen	-	822	B
replacement	-	831	O
.	-	842	O

Three	15145918	844	O
time	-	850	O
domain	-	855	O
indexes	-	862	O
of	-	870	O
hemodynamic	-	873	O
variability	-	885	O
were	-	897	O
employed	-	902	O
:	-	910	O
the	-	912	O
standard	-	916	O
deviation	-	925	O
of	-	935	O
mean	-	938	O
arterial	-	943	O
pressure	-	952	O
as	-	961	O
a	-	964	O
measure	-	966	O
of	-	974	O
blood	-	977	O
pressure	-	983	O
variability	-	992	O
and	-	1004	O
the	-	1008	O
standard	-	1012	O
deviation	-	1021	O
of	-	1031	O
beat	-	1034	O
-	-	1038	O
to	-	1039	O
-	-	1041	O
beat	-	1042	O
intervals	-	1047	O
(	-	1057	O
SDRR	-	1058	O
)	-	1062	O
and	-	1064	O

the	15145918	1068	O
root	-	1072	O
mean	-	1077	O
square	-	1082	O
of	-	1089	O
successive	-	1092	O
differences	-	1103	O
in	-	1115	O
R	-	1118	O
-	-	1119	O
wave	-	1120	O
-	-	1124	O
to	-	1125	O
-	-	1127	O
R	-	1128	O
-	-	1129	O
wave	-	1130	O
intervals	-	1135	O
as	-	1145	O
measures	-	1148	O
of	-	1157	O
heart	-	1160	O
rate	-	1166	O
variability	-	1171	O
.	-	1182	O

In	15145918	1184	O
sham	-	1187	O
-	-	1191	O
operated	-	1192	O
rats	-	1201	O
,	-	1205	O
rilmenidine	-	1207	B
or	-	1219	O
alpha	-	1222	B
-	-	1227	I
methyldopa	-	1228	I
elicited	-	1239	O
similar	-	1248	O
hypotension	-	1256	O
that	-	1268	O
lasted	-	1273	O
at	-	1280	O
least	-	1283	O
5	-	1289	O
h	-	1291	O
and	-	1293	O
was	-	1297	O
associated	-	1301	O
with	-	1312	O
reductions	-	1317	O
in	-	1328	O
standard	-	1331	O
deviation	-	1340	O
of	-	1350	O
mean	-	1353	O
arterial	-	1358	O
pressure	-	1367	O
.	-	1375	O

SDRR	15145918	1377	O
was	-	1382	O
reduced	-	1386	O
only	-	1394	O
by	-	1399	O
alpha	-	1402	B
-	-	1407	I
methyldopa	-	1408	I
.	-	1418	O

Ovx	15145918	1420	O
significantly	-	1424	O
enhanced	-	1438	O
the	-	1447	O
hypotensive	-	1451	O
response	-	1463	O
to	-	1472	O
alpha	-	1475	B
-	-	1480	I
methyldopa	-	1481	I
,	-	1491	O
in	-	1493	O
contrast	-	1496	O
to	-	1505	O
no	-	1508	O
effect	-	1511	O
on	-	1518	O
rilmenidine	-	1521	B
hypotension	-	1533	O
.	-	1544	O

The	15145918	1546	O
enhanced	-	1550	O
alpha	-	1559	B
-	-	1564	I
methyldopa	-	1565	I
hypotension	-	1576	O
in	-	1588	O
Ovx	-	1591	O
rats	-	1595	O
was	-	1600	O
paralleled	-	1604	O
with	-	1615	O
further	-	1620	O
reduction	-	1628	O
in	-	1638	O
SDRR	-	1641	O
and	-	1646	O
a	-	1650	O
reduced	-	1652	O
locomotor	-	1660	O
activity	-	1670	O
.	-	1678	O

Estrogen	15145918	1680	O
replacement	-	1689	O
(	-	1701	O
17beta	-	1702	B
-	-	1708	I
estradiol	-	1709	I
subcutaneous	-	1719	O
pellet	-	1732	O
,	-	1738	O
14	-	1740	O
.	-	1742	O
2	-	1743	O
microg	-	1745	O
/	-	1751	O
day	-	1752	O
,	-	1755	O
12	-	1757	O
wk	-	1760	O
)	-	1762	O
of	-	1764	O
Ovx	-	1767	O
rats	-	1771	O
restored	-	1776	O
the	-	1785	O
hemodynamic	-	1789	O
and	-	1801	O
locomotor	-	1805	O
effects	-	1815	O
of	-	1823	O
alpha	-	1826	B
-	-	1831	I
methyldopa	-	1832	I
to	-	1843	O
sham	-	1846	O
-	-	1850	O
operated	-	1851	O
levels	-	1860	O
.	-	1866	O

These	15145918	1868	O
findings	-	1874	O
suggest	-	1883	O
that	-	1891	O
estrogen	-	1896	B
downregulates	-	1905	O
alpha2	-	1919	O
-	-	1925	O
but	-	1927	O
not	-	1931	O
I1	-	1935	O
-	-	1937	O
receptor	-	1938	O
-	-	1946	O
mediated	-	1947	O
hypotension	-	1956	O
and	-	1968	O
highlight	-	1972	O
a	-	1982	O
role	-	1984	O
for	-	1989	O
the	-	1993	O
cardiac	-	1997	O
autonomic	-	2005	O
control	-	2015	O
in	-	2023	O
alpha	-	2026	B
-	-	2031	I
methyldopa	-	2032	I
-	-	2042	O
estrogen	-	2043	B
interaction	-	2052	O
.	-	2063	O

Cardioprotective	15233872	0	O
effect	-	17	O
of	-	24	O
tincture	-	27	B
of	-	36	I
Crataegus	-	39	I
on	-	49	O
isoproterenol	-	52	B
-	-	65	O
induced	-	66	O
myocardial	-	74	O
infarction	-	85	O
in	-	96	O
rats	-	99	O
.	-	103	O

Tincture	15233872	105	B
of	-	114	I
Crataegus	-	117	I
(	-	127	O
TCR	-	128	B
)	-	131	O
,	-	132	O
an	-	134	O
alcoholic	-	137	B
extract	-	147	I
of	-	155	I
the	-	158	I
berries	-	162	I
of	-	170	I
hawthorn	-	173	I
(	-	182	O
Crataegus	-	183	B
oxycantha	-	193	I
)	-	202	O
,	-	203	O
is	-	205	O
used	-	208	O
in	-	213	O
herbal	-	216	O
and	-	223	O
homeopathic	-	227	O
medicine	-	239	O
.	-	247	O

The	15233872	249	O
present	-	253	O
study	-	261	O
was	-	267	O
done	-	271	O
to	-	276	O
investigate	-	279	O
the	-	291	O
protective	-	295	O
effect	-	306	O
of	-	313	O
TCR	-	316	B
on	-	320	O
experimentally	-	323	O
induced	-	338	O
myocardial	-	346	O
infarction	-	357	O
in	-	368	O
rats	-	371	O
.	-	375	O

Pretreatment	15233872	377	O
of	-	390	O
TCR	-	393	B
,	-	396	O
at	-	398	O
a	-	401	O
dose	-	403	O
of	-	408	O
0	-	411	O
.	-	412	O
5	-	413	O
mL	-	415	O
/	-	417	O
100	-	418	O
g	-	422	O
bodyweight	-	424	O
per	-	435	O
day	-	439	O
,	-	442	O
orally	-	444	O
for	-	451	O
30	-	455	O
days	-	458	O
,	-	462	O
prevented	-	464	O
the	-	474	O
increase	-	478	O
in	-	487	O
lipid	-	490	O
peroxidation	-	496	O
and	-	509	O
activity	-	513	O
of	-	522	O
marker	-	525	O
enzymes	-	532	O
observed	-	540	O
in	-	549	O
isoproterenol	-	552	B
-	-	565	O
induced	-	566	O
rats	-	574	O
(	-	579	O
85	-	580	O
mg	-	583	O
kg	-	586	O
(	-	588	O
-	-	589	O
1	-	590	O
)	-	591	O

s	15233872	593	O
.	-	594	O

c	15233872	596	O
.	-	597	O
for	-	599	O
2	-	603	O
days	-	605	O
at	-	610	O
an	-	613	O
interval	-	616	O
of	-	625	O
24	-	628	O
h	-	631	O
)	-	632	O
.	-	633	O

TCR	15233872	635	B
prevented	-	639	O
the	-	649	O
isoproterenol	-	653	B
-	-	666	O
induced	-	667	O
decrease	-	675	O
in	-	684	O
antioxidant	-	687	O
enzymes	-	699	O
in	-	707	O
the	-	710	O
heart	-	714	O
and	-	720	O
increased	-	724	O
the	-	734	O
rate	-	738	O
of	-	743	O
ADP	-	746	B
-	-	749	O
stimulated	-	750	O
oxygen	-	761	B
uptake	-	768	O
and	-	775	O
respiratory	-	779	O
coupling	-	791	O
ratio	-	800	O
.	-	805	O

TCR	15233872	807	B
protected	-	811	O
against	-	821	O
pathological	-	829	O
changes	-	842	O
induced	-	850	O
by	-	858	O
isoproterenol	-	861	B
in	-	875	O
rat	-	878	O
heart	-	882	O
.	-	887	O

The	15233872	889	O
results	-	893	O
show	-	901	O
that	-	906	O
pretreatment	-	911	O
with	-	924	O
TCR	-	929	B
may	-	933	O
be	-	937	O
useful	-	940	O
in	-	947	O
preventing	-	950	O
the	-	961	O
damage	-	965	O
induced	-	972	O
by	-	980	O
isoproterenol	-	983	B
in	-	997	O
rat	-	1000	O
heart	-	1004	O
.	-	1009	O

Safety	15458908	0	O
and	-	7	O
adverse	-	11	O
effects	-	19	O
associated	-	27	O
with	-	38	O
raloxifene	-	43	B
:	-	53	O
multiple	-	55	O
outcomes	-	64	O
of	-	73	O
raloxifene	-	76	B
evaluation	-	87	O
.	-	97	O

OBJECTIVE	15458908	99	O
:	-	108	O

To	15458908	110	O
examine	-	113	O
the	-	121	O
effect	-	125	O
of	-	132	O
raloxifene	-	135	B
on	-	146	O
major	-	149	O
adverse	-	155	O
events	-	163	O
that	-	170	O
occur	-	175	O
with	-	181	O
postmenopausal	-	186	O
estrogen	-	201	B
therapy	-	210	O
or	-	218	O
tamoxifen	-	221	B
.	-	230	O

METHODS	15458908	232	O
:	-	239	O

The	15458908	241	O
Multiple	-	245	O
Outcomes	-	254	O
of	-	263	O
Raloxifene	-	266	B
Evaluation	-	277	O
,	-	287	O
a	-	289	O
multicenter	-	291	O
,	-	302	O
randomized	-	304	O
,	-	314	O
double	-	316	O
-	-	322	O
blind	-	323	O
trial	-	329	O
,	-	334	O
enrolled	-	336	O
7	-	345	O
,	-	346	O
705	-	347	O
postmenopausal	-	351	O
women	-	366	O
with	-	372	O
osteoporosis	-	377	O
.	-	389	O

Women	15458908	391	O
were	-	397	O
randomly	-	402	O
assigned	-	411	O
to	-	420	O
raloxifene	-	423	B
60	-	434	O
mg	-	437	O
/	-	439	O
d	-	440	O
or	-	442	O
120	-	445	O
mg	-	449	O
/	-	451	O
d	-	452	O
or	-	454	O
placebo	-	457	O
.	-	464	O

Outcomes	15458908	466	O
included	-	475	O
venous	-	484	O
thromboembolism	-	491	O
,	-	506	O
cataracts	-	508	O
,	-	517	O
gallbladder	-	519	O
disease	-	531	O
,	-	538	O
and	-	540	O
endometrial	-	544	O
hyperplasia	-	556	O
or	-	568	O
cancer	-	571	O
.	-	577	O

RESULTS	15458908	579	O
:	-	586	O

During	15458908	588	O
a	-	595	O
mean	-	597	O
follow	-	602	O
-	-	608	O
up	-	609	O
of	-	612	O
3	-	615	O
.	-	616	O
3	-	617	O
years	-	619	O
,	-	624	O
raloxifene	-	626	B
was	-	637	O
associated	-	641	O
with	-	652	O
an	-	657	O
increased	-	660	O
risk	-	670	O
for	-	675	O
venous	-	679	O
thromboembolism	-	686	O
(	-	702	O
relative	-	703	O
risk	-	712	O
[	-	717	O
RR	-	718	O
]	-	720	O
2	-	722	O
.	-	723	O
1	-	724	O
;	-	725	O
95	-	727	O
%	-	729	O
confidence	-	731	O
interval	-	742	O
[	-	751	O
CI	-	752	O
]	-	754	O
1	-	756	O
.	-	757	O
2	-	758	O
-	-	759	O
3	-	760	O
.	-	761	O
8	-	762	O
)	-	763	O
.	-	764	O

The	15458908	766	O
excess	-	770	O
event	-	777	O
rate	-	783	O
was	-	788	O
1	-	792	O
.	-	793	O
8	-	794	O
per	-	796	O
1	-	800	O
,	-	801	O
000	-	802	O
woman	-	806	O
-	-	811	O
years	-	812	O
(	-	818	O
95	-	819	O
%	-	821	O
CI	-	823	O
-	-	826	O
0	-	827	O
.	-	828	O
5	-	829	O
-	-	830	O
4	-	831	O
.	-	832	O
1	-	833	O
)	-	834	O
,	-	835	O
and	-	837	O
the	-	841	O
number	-	845	O
needed	-	852	O
to	-	859	O
treat	-	862	O
to	-	868	O
cause	-	871	O
1	-	877	O
event	-	879	O
was	-	885	O
170	-	889	O
(	-	893	O
95	-	894	O
%	-	896	O
CI	-	898	O
100	-	901	O
-	-	904	O
582	-	905	O
)	-	908	O
over	-	910	O
3	-	915	O
.	-	916	O
3	-	917	O
years	-	919	O
.	-	924	O

Risk	15458908	926	O
in	-	931	O
the	-	934	O
raloxifene	-	938	B
group	-	949	O
was	-	955	O
higher	-	959	O
than	-	966	O
in	-	971	O
the	-	974	O
placebo	-	978	O
group	-	986	O
for	-	992	O
the	-	996	O
first	-	1000	O
2	-	1006	O
years	-	1008	O
,	-	1013	O
but	-	1015	O
decreased	-	1019	O
to	-	1029	O
about	-	1032	O
the	-	1038	O
same	-	1042	O
rate	-	1047	O
as	-	1052	O
in	-	1055	O
the	-	1058	O
placebo	-	1062	O
group	-	1070	O
thereafter	-	1076	O
.	-	1086	O

Raloxifene	15458908	1088	B
did	-	1099	O
not	-	1103	O
increase	-	1107	O
risk	-	1116	O
for	-	1121	O
cataracts	-	1125	O
(	-	1135	O
RR	-	1136	O
0	-	1139	O
.	-	1140	O
9	-	1141	O
;	-	1142	O
95	-	1144	O
%	-	1146	O
CI	-	1148	O
0	-	1151	O
.	-	1152	O
8	-	1153	O
-	-	1154	O
1	-	1155	O
.	-	1156	O
1	-	1157	O
)	-	1158	O
,	-	1159	O
gallbladder	-	1161	O
disease	-	1173	O
(	-	1181	O
RR	-	1182	O
1	-	1185	O
.	-	1186	O
0	-	1187	O
;	-	1188	O
95	-	1190	O
%	-	1192	O
CI	-	1194	O
0	-	1197	O
.	-	1198	O
7	-	1199	O
-	-	1200	O
1	-	1201	O
.	-	1202	O
3	-	1203	O
)	-	1204	O
,	-	1205	O
endometrial	-	1207	O
hyperplasia	-	1219	O
(	-	1231	O
RR	-	1232	O
1	-	1235	O
.	-	1236	O
3	-	1237	O
;	-	1238	O
95	-	1240	O
%	-	1242	O
CI	-	1244	O
0	-	1247	O
.	-	1248	O
4	-	1249	O
-	-	1250	O
5	-	1251	O
.	-	1252	O
1	-	1253	O
)	-	1254	O
,	-	1255	O
or	-	1257	O
endometrial	-	1260	O
cancer	-	1272	O
(	-	1279	O
RR	-	1280	O
0	-	1283	O
.	-	1284	O
9	-	1285	O
;	-	1286	O
95	-	1288	O
%	-	1290	O
CI	-	1292	O
0	-	1295	O
.	-	1296	O
3	-	1297	O
-	-	1298	O
2	-	1299	O
.	-	1300	O
7	-	1301	O
)	-	1302	O
.	-	1303	O

CONCLUSION	15458908	1305	O
:	-	1315	O

Raloxifene	15458908	1317	B
was	-	1328	O
associated	-	1332	O
with	-	1343	O
an	-	1348	O
increased	-	1351	O
risk	-	1361	O
for	-	1366	O
venous	-	1370	O
thromboembolism	-	1377	O
,	-	1392	O
but	-	1394	O
there	-	1398	O
was	-	1404	O
no	-	1408	O
increased	-	1411	O
risk	-	1421	O
for	-	1426	O
cataracts	-	1430	O
,	-	1439	O
gallbladder	-	1441	O
disease	-	1453	O
,	-	1460	O
endometrial	-	1462	O
hyperplasia	-	1474	O
,	-	1485	O
or	-	1487	O
endometrial	-	1490	O
cancer	-	1502	O
.	-	1508	O

LEVEL	15458908	1510	O
OF	-	1516	O
EVIDENCE	-	1519	O
:	-	1527	O

I	15458908	1529	O

Ceftriaxone	15737522	0	B
-	-	11	O
associated	-	12	O
biliary	-	23	O
pseudolithiasis	-	31	O
in	-	47	O
paediatric	-	50	O
surgical	-	61	O
patients	-	70	O
.	-	78	O

It	15737522	80	O
is	-	83	O
well	-	86	O
known	-	91	O
that	-	97	O
ceftriaxone	-	102	B
leads	-	114	O
to	-	120	O
pseudolithiasis	-	123	O
in	-	139	O
some	-	142	O
patients	-	147	O
.	-	155	O

Clinical	15737522	157	O
and	-	166	O
experimental	-	170	O
studies	-	183	O
also	-	191	O
suggest	-	196	O
that	-	204	O
situations	-	209	O
causing	-	220	O
gallbladder	-	228	O
dysfunction	-	240	O
,	-	251	O
such	-	253	O
as	-	258	O
fasting	-	261	O
,	-	268	O
may	-	270	O
have	-	274	O
a	-	279	O
role	-	281	O
for	-	286	O
the	-	290	O
development	-	294	O
of	-	306	O
pseudolithiasis	-	309	O
.	-	324	O

In	15737522	326	O
this	-	329	O
study	-	334	O
,	-	339	O
we	-	341	O
prospectively	-	344	O
evaluated	-	358	O
the	-	368	O
incidence	-	372	O
and	-	382	O
clinical	-	386	O
importance	-	395	O
of	-	406	O
pseudolithiasis	-	409	O
in	-	425	O
paediatric	-	428	O
surgical	-	439	O
patients	-	448	O
receiving	-	457	O
ceftriaxone	-	467	B
treatment	-	479	O
,	-	488	O
who	-	490	O
often	-	494	O
had	-	500	O
to	-	504	O
fast	-	507	O
in	-	512	O
the	-	515	O
post	-	519	O
-	-	523	O
operative	-	524	O
period	-	534	O
.	-	540	O

Fifty	15737522	542	O
children	-	548	O
who	-	557	O
were	-	561	O
given	-	566	O
ceftriaxone	-	572	B
were	-	584	O
evaluated	-	589	O
by	-	599	O
serial	-	602	O
abdominal	-	609	O
sonograms	-	619	O
.	-	628	O

Of	15737522	630	O
those	-	633	O
,	-	638	O
13	-	640	O
(	-	643	O
26	-	644	O
%	-	646	O
)	-	647	O
developed	-	649	O
biliary	-	659	O
pathology	-	667	O
.	-	676	O

Comparison	15737522	678	O
of	-	689	O
the	-	692	O
patients	-	696	O
with	-	705	O
or	-	710	O
without	-	713	O
pseudolithiasis	-	721	O
revealed	-	737	O
no	-	746	O
significant	-	749	O
difference	-	761	O
with	-	772	O
respect	-	777	O
to	-	785	O
age	-	788	O
,	-	791	O
sex	-	793	O
,	-	796	O
duration	-	798	O
of	-	807	O
the	-	810	O
treatment	-	814	O
and	-	824	O
starvation	-	828	O
variables	-	839	O
.	-	848	O

After	15737522	850	O
cessation	-	856	O
of	-	866	O
the	-	869	O
treatment	-	873	O
,	-	882	O
pseudolithiasis	-	884	O
resolved	-	900	O
spontaneously	-	909	O
within	-	923	O
a	-	930	O
short	-	932	O
period	-	938	O
.	-	944	O

The	15737522	946	O
incidence	-	950	O
of	-	960	O
pseudolithiasis	-	963	O
is	-	979	O
not	-	982	O
affected	-	986	O
by	-	995	O
fasting	-	998	O
.	-	1005	O

Evaluation	16005948	0	O
of	-	11	O
the	-	14	O
anticocaine	-	18	O
monoclonal	-	30	O
antibody	-	41	O
GNC92H2	-	50	B
as	-	58	O
an	-	61	O
immunotherapy	-	64	O
for	-	78	O
cocaine	-	82	O
overdose	-	90	O
.	-	98	O

The	16005948	100	O
illicit	-	104	O
use	-	112	O
of	-	116	O
cocaine	-	119	B
continues	-	127	O
in	-	137	O
epidemic	-	140	O
proportions	-	149	O
and	-	161	O
treatment	-	165	O
for	-	175	O
cocaine	-	179	O
overdose	-	187	O
remains	-	196	O
elusive	-	204	O
.	-	211	O

Current	16005948	213	O
protein	-	221	O
-	-	228	O
based	-	229	O
technology	-	235	O
offers	-	246	O
a	-	253	O
new	-	255	O
therapeutic	-	259	O
venue	-	271	O
by	-	277	O
which	-	280	O
antibodies	-	286	O
bind	-	297	O
the	-	302	O
drug	-	306	O
in	-	311	O
the	-	314	O
blood	-	318	O
stream	-	324	O
,	-	330	O
inactivating	-	332	O
its	-	345	O
toxic	-	349	O
effects	-	355	O
.	-	362	O

The	16005948	364	O
therapeutic	-	368	O
potential	-	380	O
of	-	390	O
the	-	393	O
anticocaine	-	397	O
antibody	-	409	O
GNC92H2	-	418	B
was	-	426	O
examined	-	430	O
using	-	439	O
a	-	445	O
model	-	447	O
of	-	453	O
cocaine	-	456	O
overdose	-	464	O
.	-	472	O

Swiss	16005948	474	O
albino	-	480	O
mice	-	487	O
prepared	-	492	O
with	-	501	O
intrajugular	-	506	O
catheters	-	519	O
were	-	529	O
tested	-	534	O
in	-	541	O
photocell	-	544	O
cages	-	554	O
after	-	560	O
administration	-	566	O
of	-	581	O
93	-	584	O
mg	-	587	O
/	-	589	O
kg	-	590	O
(	-	593	O
LD50	-	594	O
)	-	598	O
of	-	600	O
cocaine	-	603	B
and	-	611	O
GNC92H2	-	615	B
infusions	-	623	O
ranging	-	633	O
from	-	641	O
30	-	646	O
to	-	649	O
190	-	652	O
mg	-	656	O
/	-	658	O
kg	-	659	O
.	-	661	O

GNC92H2	16005948	663	B
was	-	671	O
delivered	-	675	O
30	-	685	O
min	-	688	O
before	-	692	O
,	-	698	O
concomitantly	-	700	O
or	-	714	O
3	-	717	O
min	-	719	O
after	-	723	O
cocaine	-	729	B
treatment	-	737	O
.	-	746	O

Significant	16005948	748	O
blockade	-	760	O
of	-	769	O
cocaine	-	772	B
toxicity	-	780	O
was	-	789	O
observed	-	793	O
with	-	802	O
the	-	807	O
higher	-	811	O
dose	-	818	O
of	-	823	O
GNC92H2	-	826	B
(	-	834	O
190	-	835	O
mg	-	839	O
/	-	841	O
kg	-	842	O
)	-	844	O
,	-	845	O
where	-	847	O
premorbid	-	853	O
behaviors	-	863	O
were	-	873	O
reduced	-	878	O
up	-	886	O
to	-	889	O
40	-	892	O
%	-	894	O
,	-	895	O
seizures	-	897	O
up	-	906	O
to	-	909	O
77	-	912	O
%	-	914	O
and	-	916	O
death	-	920	O
by	-	926	O
72	-	929	O
%	-	931	O
.	-	932	O

Importantly	16005948	934	O
,	-	945	O
GNC92H2	-	947	B
prevented	-	955	O
death	-	965	O
even	-	971	O
post	-	976	O
-	-	980	O
cocaine	-	981	B
injection	-	989	O
.	-	998	O

The	16005948	1000	O
results	-	1004	O
support	-	1012	O
the	-	1020	O
important	-	1024	O
potential	-	1034	O
of	-	1044	O
GNC92H2	-	1047	B
as	-	1055	O
a	-	1058	O
therapeutic	-	1060	O
tool	-	1072	O
against	-	1077	O
cocaine	-	1085	O
overdose	-	1093	O
.	-	1101	O

The	16167916	0	O
effects	-	4	O
of	-	12	O
short	-	15	O
-	-	20	O
term	-	21	O
raloxifene	-	26	B
therapy	-	37	O
on	-	45	O
fibrinolysis	-	48	O
markers	-	61	O
:	-	68	O
TAFI	-	70	O
,	-	74	O
tPA	-	76	O
,	-	79	O
and	-	81	O
PAI	-	85	O
-	-	88	O
1	-	89	O
.	-	90	O

BACKGROUND	16167916	92	O
:	-	102	O
Markers	-	104	O
of	-	112	O
fibrinolysis	-	115	O
,	-	127	O
thrombin	-	129	O
-	-	137	O
activatable	-	138	O
fibrinolysis	-	150	O
inhibitor	-	163	O
(	-	173	O
TAFI	-	174	O
)	-	178	O
,	-	179	O
tissue	-	181	O
-	-	187	O
type	-	188	O
plasminogen	-	193	O
activator	-	205	O
(	-	215	O
tPA	-	216	O
)	-	219	O
,	-	220	O
and	-	222	O
plasminogen	-	226	O
activator	-	238	O
inhibitor	-	248	O
-	-	257	O
1	-	258	O

(	16167916	260	O
PAI	-	261	O
-	-	264	O
1	-	265	O
)	-	266	O
levels	-	268	O
were	-	275	O
studied	-	280	O
for	-	288	O
the	-	292	O
evaluation	-	296	O
of	-	307	O
short	-	310	O
-	-	315	O
term	-	316	O
effects	-	321	O
of	-	329	O
raloxifene	-	332	B
administration	-	343	O
in	-	358	O
postmenopausal	-	361	O
women	-	376	O
.	-	381	O

METHODS	16167916	383	O
:	-	390	O

Thirty	16167916	392	O
-	-	398	O
nine	-	399	O
postmenopausal	-	404	O
women	-	419	O
with	-	425	O
osteopenia	-	430	O
or	-	441	O
osteoporosis	-	444	O
were	-	457	O
included	-	462	O
in	-	471	O
this	-	474	O
prospective	-	479	O
,	-	490	O
controlled	-	492	O
clinical	-	503	O
study	-	512	O
.	-	517	O

Twenty	16167916	519	O
-	-	525	O
five	-	526	O
women	-	531	O
were	-	537	O
given	-	542	O
raloxifene	-	548	B
hydrochloride	-	559	I
(	-	573	O
60	-	574	O
mg	-	577	O
/	-	579	O
day	-	580	O
)	-	583	O
plus	-	585	O
calcium	-	590	B
(	-	598	O
500	-	599	O
mg	-	603	O
/	-	605	O
day	-	606	O
)	-	609	O
.	-	610	O

Age	16167916	612	O
-	-	615	O
matched	-	616	O
controls	-	624	O
(	-	633	O
n	-	634	O
=	-	636	O
14	-	638	O
)	-	640	O
were	-	642	O
given	-	647	O
only	-	653	O
calcium	-	658	B
.	-	665	O

Plasma	16167916	667	O
TAFI	-	674	O
,	-	678	O
tPA	-	680	O
,	-	683	O
and	-	685	O
PAI	-	689	O
-	-	692	O
1	-	693	O

antigen	16167916	695	O
levels	-	703	O
were	-	710	O
measured	-	715	O
at	-	724	O
baseline	-	727	O
and	-	736	O
after	-	740	O
3	-	746	O
months	-	748	O
of	-	755	O
treatment	-	758	O
by	-	768	O
commercially	-	771	O
available	-	784	O
ELISA	-	794	O
kits	-	800	O
.	-	804	O

Variations	16167916	806	O
of	-	817	O
individuals	-	820	O
were	-	832	O
assessed	-	837	O
by	-	846	O
Wilcoxon	-	849	O
's	-	857	O
test	-	860	O
.	-	864	O

Relationship	16167916	866	O
between	-	879	O
those	-	887	O
markers	-	893	O
and	-	901	O
demographic	-	905	O
characteristics	-	917	O
were	-	933	O
investigated	-	938	O
.	-	950	O

RESULTS	16167916	952	O
:	-	959	O

Three	16167916	961	O
months	-	967	O
of	-	974	O
raloxifene	-	977	B
treatment	-	988	O
was	-	998	O
associated	-	1002	O
with	-	1013	O
a	-	1018	O
significant	-	1020	O
decrease	-	1032	O
in	-	1041	O
the	-	1044	O
plasma	-	1048	O
TAFI	-	1055	O
antigen	-	1060	O
concentrations	-	1068	O
(	-	1083	O
16	-	1084	O
%	-	1086	O
change	-	1088	O
,	-	1094	O
P	-	1096	O
<	-	1098	O
0	-	1100	O
.	-	1101	O
01	-	1102	O
)	-	1104	O
,	-	1105	O
and	-	1107	O
a	-	1111	O
significant	-	1113	O
increase	-	1125	O
in	-	1134	O
tPA	-	1137	O
antigen	-	1141	O
concentrations	-	1149	O
(	-	1164	O
25	-	1165	O
%	-	1167	O
change	-	1169	O
,	-	1175	O
P	-	1177	O
<	-	1179	O
0	-	1181	O
.	-	1182	O
05	-	1183	O
)	-	1185	O
.	-	1186	O

A	16167916	1188	O
significant	-	1190	O
correlation	-	1202	O
was	-	1214	O
found	-	1218	O
between	-	1224	O
baseline	-	1232	O
TAFI	-	1241	O
antigen	-	1246	O
concentrations	-	1254	O
and	-	1269	O
the	-	1273	O
duration	-	1277	O
of	-	1286	O
amenorrhea	-	1289	O
(	-	1300	O
P	-	1301	O
<	-	1303	O
0	-	1305	O
.	-	1306	O
05	-	1307	O
;	-	1309	O
r	-	1311	O
=	-	1313	O
0	-	1315	O
.	-	1316	O
33	-	1317	O
)	-	1319	O
.	-	1320	O

CONCLUSION	16167916	1322	O
:	-	1332	O

We	16167916	1334	O
suggest	-	1337	O
that	-	1345	O
the	-	1350	O
increased	-	1354	O
risk	-	1364	O
of	-	1369	O
venous	-	1372	O
thromboembolism	-	1379	O
due	-	1395	O
to	-	1399	O
raloxifene	-	1402	B
treatment	-	1413	O
may	-	1423	O
be	-	1427	O
related	-	1430	O
to	-	1438	O
increased	-	1441	O
tPA	-	1451	O
levels	-	1455	O
,	-	1461	O
but	-	1463	O
not	-	1467	O
TAFI	-	1471	O
levels	-	1476	O
.	-	1482	O

Ketoconazole	16403073	0	B
induced	-	13	O
torsades	-	21	O
de	-	30	O
pointes	-	33	O
without	-	41	O
concomitant	-	49	O
use	-	61	O
of	-	65	O
QT	-	68	O
interval	-	71	O
-	-	79	O
prolonging	-	80	O
drug	-	91	O
.	-	95	O

Ketoconazole	16403073	97	B
is	-	110	O
not	-	113	O
known	-	117	O
to	-	123	O
be	-	126	O
proarrhythmic	-	129	O
without	-	143	O
concomitant	-	151	O
use	-	163	O
of	-	167	O
QT	-	170	O
interval	-	173	O
-	-	181	O
prolonging	-	182	O
drugs	-	193	O
.	-	198	O

We	16403073	200	O
report	-	203	O
a	-	210	O
woman	-	212	O
with	-	218	O
coronary	-	223	O
artery	-	232	O
disease	-	239	O
who	-	247	O
developed	-	251	O
a	-	261	O
markedly	-	263	O
prolonged	-	272	O
QT	-	282	O
interval	-	285	O
and	-	294	O
torsades	-	298	O
de	-	307	O
pointes	-	310	O
(	-	318	O
TdP	-	319	O
)	-	322	O
after	-	324	O
taking	-	330	O
ketoconazole	-	337	B
for	-	350	O
treatment	-	354	O
of	-	364	O
fungal	-	367	O
infection	-	374	O
.	-	383	O

Her	16403073	385	O
QT	-	389	O
interval	-	392	O
returned	-	401	O
to	-	410	O
normal	-	413	O
upon	-	420	O
withdrawal	-	425	O
of	-	436	O
ketoconazole	-	439	B
.	-	451	O

Genetic	16403073	453	O
study	-	461	O
did	-	467	O
not	-	471	O
find	-	475	O
any	-	480	O
mutation	-	484	O
in	-	493	O
her	-	496	O
genes	-	500	O
that	-	506	O
encode	-	511	O
cardiac	-	518	O
IKr	-	526	O
channel	-	530	O
proteins	-	538	O
.	-	546	O

We	16403073	548	O
postulate	-	551	O
that	-	561	O
by	-	566	O
virtue	-	569	O
of	-	576	O
its	-	579	O
direct	-	583	O
blocking	-	590	O
action	-	599	O
on	-	606	O
IKr	-	609	O
,	-	612	O
ketoconazole	-	614	B
alone	-	627	O
may	-	633	O
prolong	-	637	O
QT	-	645	O
interval	-	648	O
and	-	657	O
induce	-	661	O
TdP	-	668	O
.	-	671	O

This	16403073	673	O
calls	-	678	O
for	-	684	O
attention	-	688	O
when	-	698	O
ketoconazole	-	703	B
is	-	716	O
administered	-	719	O
to	-	732	O
patients	-	735	O
with	-	744	O
risk	-	749	O
factors	-	754	O
for	-	762	O
acquired	-	766	O
long	-	775	O
QT	-	780	O
syndrome	-	783	O
.	-	791	O

Pharmacological	16755009	0	O
evidence	-	16	O
for	-	25	O
the	-	29	O
potential	-	33	O
of	-	43	O
Daucus	-	46	O
carota	-	53	O
in	-	60	O
the	-	63	O
management	-	67	O
of	-	78	O
cognitive	-	81	O
dysfunctions	-	91	O
.	-	103	O

The	16755009	105	O
present	-	109	O
study	-	117	O
was	-	123	O
aimed	-	127	O
at	-	133	O
investigating	-	136	O
the	-	150	O
effects	-	154	O
of	-	162	O
Daucus	-	165	O
carota	-	172	O
seeds	-	179	O
on	-	185	O
cognitive	-	188	O
functions	-	198	O
,	-	207	O
total	-	209	O
serum	-	215	O
cholesterol	-	221	B
levels	-	233	O
and	-	240	O
brain	-	244	O
cholinesterase	-	250	O
activity	-	265	O
in	-	274	O
mice	-	277	O
.	-	281	O

The	16755009	283	O
ethanolic	-	287	O
extract	-	297	B
of	-	305	I
Daucus	-	308	I
carota	-	315	I
seeds	-	322	I
(	-	328	O
DCE	-	329	B
)	-	332	O
was	-	334	O
administered	-	338	O
orally	-	351	O
in	-	358	O
three	-	361	O
doses	-	367	O
(	-	373	O
100	-	374	O
,	-	377	O
200	-	379	O
,	-	382	O
400	-	384	O
mg	-	388	O
/	-	390	O
kg	-	391	O
)	-	393	O
for	-	395	O
seven	-	399	O
successive	-	405	O
days	-	416	O
to	-	421	O
different	-	424	O
groups	-	434	O
of	-	441	O
young	-	444	O
and	-	450	O
aged	-	454	O
mice	-	459	O
.	-	463	O

Elevated	16755009	465	O
plus	-	474	O
maze	-	479	O
and	-	484	O
passive	-	488	O
avoidance	-	496	O
apparatus	-	506	O
served	-	516	O
as	-	523	O
the	-	526	O
exteroceptive	-	530	O
behavioral	-	544	O
models	-	555	O
for	-	562	O
testing	-	566	O
memory	-	574	O
.	-	580	O

Diazepam	16755009	582	B
-	-	590	O
,	-	591	O
scopolamine	-	593	B
-	-	604	O
and	-	606	O
ageing	-	610	O
-	-	616	O
induced	-	617	O
amnesia	-	625	O
served	-	633	O
as	-	640	O
the	-	643	O
interoceptive	-	647	O
behavioral	-	661	O
models	-	672	O
.	-	678	O

DCE	16755009	680	B
(	-	684	O
200	-	685	O
,	-	688	O
400	-	690	O
mg	-	694	O
/	-	696	O
kg	-	697	O
,	-	699	O
p	-	701	O
.	-	702	O
o	-	703	O
.	-	704	O
)	-	705	O
showed	-	707	O
significant	-	714	O
improvement	-	726	O
in	-	738	O
memory	-	741	O
scores	-	748	O
of	-	755	O
young	-	758	O
and	-	764	O
aged	-	768	O
mice	-	773	O
.	-	777	O

The	16755009	779	O
extent	-	783	O
of	-	790	O
memory	-	793	O
improvement	-	800	O
evoked	-	812	O
by	-	819	O
DCE	-	822	B
was	-	826	O
23	-	830	O
%	-	832	O
at	-	834	O
the	-	837	O
dose	-	841	O
of	-	846	O
200	-	849	O
mg	-	853	O
/	-	855	O
kg	-	856	O
and	-	859	O
35	-	863	O
%	-	865	O
at	-	867	O
the	-	870	O
dose	-	874	O
of	-	879	O
400	-	882	O
mg	-	886	O
/	-	888	O
kg	-	889	O
in	-	892	O
young	-	895	O
mice	-	901	O
using	-	906	O
elevated	-	912	O
plus	-	921	O
maze	-	926	O
.	-	930	O

Similarly	16755009	932	O
,	-	941	O
significant	-	943	O
improvements	-	955	O
in	-	968	O
memory	-	971	O
scores	-	978	O
were	-	985	O
observed	-	990	O
using	-	999	O
passive	-	1005	O
avoidance	-	1013	O
apparatus	-	1023	O
and	-	1033	O
aged	-	1037	O
mice	-	1042	O
.	-	1046	O

Furthermore	16755009	1048	O
,	-	1059	O
DCE	-	1061	B
reversed	-	1065	O
the	-	1074	O
amnesia	-	1078	O
induced	-	1086	O
by	-	1094	O
scopolamine	-	1097	B
(	-	1109	O
0	-	1110	O
.	-	1111	O
4	-	1112	O
mg	-	1114	O
/	-	1116	O
kg	-	1117	O
,	-	1119	O
i	-	1121	O
.	-	1122	O
p	-	1123	O
.	-	1124	O
)	-	1125	O
and	-	1127	O
diazepam	-	1131	B
(	-	1140	O
1	-	1141	O
mg	-	1143	O
/	-	1145	O
kg	-	1146	O
,	-	1148	O
i	-	1150	O
.	-	1151	O
p	-	1152	O
.	-	1153	O
)	-	1154	O
.	-	1155	O

Daucus	16755009	1157	B
carota	-	1164	I
extract	-	1171	I
(	-	1179	O
200	-	1180	O
,	-	1183	O
400	-	1185	O
mg	-	1189	O
/	-	1191	O
kg	-	1192	O
,	-	1194	O
p	-	1196	O
.	-	1197	O
o	-	1198	O
.	-	1199	O
)	-	1200	O

reduced	16755009	1202	O
significantly	-	1210	O
the	-	1224	O
brain	-	1228	O
acetylcholinesterase	-	1234	O
activity	-	1255	O
and	-	1264	O
cholesterol	-	1268	B
levels	-	1280	O
in	-	1287	O
young	-	1290	O
and	-	1296	O
aged	-	1300	O
mice	-	1305	O
.	-	1309	O

The	16755009	1311	O
extent	-	1315	O
of	-	1322	O
inhibition	-	1325	O
of	-	1336	O
brain	-	1339	O
cholinesterase	-	1345	O
activity	-	1360	O
evoked	-	1369	O
by	-	1376	O
DCE	-	1379	B
at	-	1383	O
the	-	1386	O
dose	-	1390	O
of	-	1395	O
400	-	1398	O
mg	-	1402	O
/	-	1404	O
kg	-	1405	O
was	-	1408	O
22	-	1412	O
%	-	1414	O
in	-	1416	O
young	-	1419	O
and	-	1425	O
19	-	1429	O
%	-	1431	O
in	-	1433	O
aged	-	1436	O
mice	-	1441	O
.	-	1445	O

There	16755009	1447	O
was	-	1453	O
a	-	1457	O
remarkable	-	1459	O
reduction	-	1470	O
in	-	1480	O
total	-	1483	O
cholesterol	-	1489	B
level	-	1501	O
as	-	1507	O
well	-	1510	O
,	-	1514	O
to	-	1516	O
the	-	1519	O
extent	-	1523	O
of	-	1530	O
23	-	1533	O
%	-	1535	O
in	-	1537	O
young	-	1540	O
and	-	1546	O
21	-	1550	O
%	-	1552	O
in	-	1554	O
aged	-	1557	O
animals	-	1562	O
with	-	1570	O
this	-	1575	O
dose	-	1580	O
of	-	1585	O
DCE	-	1588	B
.	-	1591	O

Therefore	16755009	1593	O
,	-	1602	O
DCE	-	1604	B
may	-	1608	O
prove	-	1612	O
to	-	1618	O
be	-	1621	O
a	-	1624	O
useful	-	1626	O
remedy	-	1633	O
for	-	1640	O
the	-	1644	O
management	-	1648	O
of	-	1659	O
cognitive	-	1662	O
dysfunctions	-	1672	O
on	-	1685	O
account	-	1688	O
of	-	1696	O
its	-	1699	O
multifarious	-	1703	O
beneficial	-	1716	O
effects	-	1727	O
such	-	1735	O
as	-	1740	O
,	-	1742	O
memory	-	1744	O
improving	-	1751	O
property	-	1761	O
,	-	1769	O
cholesterol	-	1771	B
lowering	-	1783	O
property	-	1792	O
and	-	1801	O
anticholinesterase	-	1805	O
activity	-	1824	O
.	-	1832	O

Cauda	16904497	0	O
equina	-	6	O
syndrome	-	13	O
after	-	22	O
epidural	-	28	O
steroid	-	37	B
injection	-	45	O
:	-	54	O
a	-	56	O
case	-	58	O
report	-	63	O
.	-	69	O

OBJECTIVE	16904497	71	O
:	-	80	O
Conventional	-	82	O
treatment	-	95	O
methods	-	105	O
of	-	113	O
lumbusacral	-	116	O
radiculopathy	-	128	O
are	-	142	O
physical	-	146	O
therapy	-	155	O
,	-	162	O
epidural	-	164	O
steroid	-	173	B
injections	-	181	O
,	-	191	O
oral	-	193	O
medications	-	198	O
,	-	209	O
and	-	211	O
spinal	-	215	O
manipulative	-	222	O
therapy	-	235	O
.	-	242	O

Cauda	16904497	244	O
equina	-	250	O
syndrome	-	257	O
is	-	266	O
a	-	269	O
rare	-	271	O
complication	-	276	O
of	-	289	O
epidural	-	292	O
anesthesia	-	301	O
.	-	311	O

The	16904497	313	O
following	-	317	O
case	-	327	O
is	-	332	O
a	-	335	O
report	-	337	O
of	-	344	O
cauda	-	347	O
equina	-	353	O
syndrome	-	360	O
possibly	-	369	O
caused	-	378	O
by	-	385	O
epidural	-	388	O
injection	-	397	O
of	-	407	O
triamcinolone	-	410	B
and	-	424	O
bupivacaine	-	428	B
.	-	439	O

CLINICAL	16904497	441	O
FEATURES	-	450	O
:	-	458	O

A	16904497	460	O
50	-	462	O
-	-	464	O
year	-	465	O
-	-	469	O
old	-	470	O
woman	-	474	O
with	-	480	O
low	-	485	O
back	-	489	O
and	-	494	O
right	-	498	O
leg	-	504	O
pain	-	508	O
was	-	513	O
scheduled	-	517	O
for	-	527	O
epidural	-	531	O
steroid	-	540	B
injection	-	548	O
.	-	557	O

INTERVENTION	16904497	559	O
AND	-	572	O
OUTCOME	-	576	O
:	-	583	O

An	16904497	585	O
18	-	588	O
-	-	590	O
gauge	-	591	O
Touhy	-	597	O
needle	-	603	O
was	-	610	O
inserted	-	614	O
until	-	623	O
loss	-	629	O
of	-	634	O
resistance	-	637	O
occurred	-	648	O
at	-	657	O
the	-	660	O
L4	-	664	O
-	-	666	O
5	-	667	O
level	-	669	O
.	-	674	O

Spread	16904497	676	O
of	-	683	O
the	-	686	O
contrast	-	690	O
medium	-	699	O
within	-	706	O
the	-	713	O
epidural	-	717	O
space	-	726	O
was	-	732	O
determined	-	736	O
by	-	747	O
radiographic	-	750	O
imaging	-	763	O
.	-	770	O

After	16904497	772	O
verifying	-	778	O
the	-	788	O
epidural	-	792	O
space	-	801	O
,	-	806	O
bupivacaine	-	808	B
and	-	820	O
triamcinolone	-	824	B
diacetate	-	838	I
were	-	848	O
injected	-	853	O
.	-	861	O

After	16904497	863	O
the	-	869	O
injection	-	873	O
,	-	882	O
there	-	884	O
was	-	890	O
a	-	894	O
reduction	-	896	O
in	-	906	O
radicular	-	909	O
symptoms	-	919	O
.	-	927	O

Three	16904497	929	O
hours	-	935	O
later	-	941	O
,	-	946	O
she	-	948	O
complained	-	952	O
of	-	963	O
perineal	-	966	O
numbness	-	975	O
and	-	984	O
lower	-	988	O
extremity	-	994	O
weakness	-	1004	O
.	-	1012	O

The	16904497	1014	O
neurologic	-	1018	O
evaluation	-	1029	O
revealed	-	1040	O
loss	-	1049	O
of	-	1054	O
sensation	-	1057	O
in	-	1067	O
the	-	1070	O
saddle	-	1074	O
area	-	1081	O
and	-	1086	O
medial	-	1090	O
aspect	-	1097	O
of	-	1104	O
her	-	1107	O
right	-	1111	O
leg	-	1117	O
.	-	1120	O

There	16904497	1122	O
was	-	1128	O
a	-	1132	O
decrease	-	1134	O
in	-	1143	O
the	-	1146	O
perception	-	1150	O
of	-	1161	O
pinprick	-	1164	O
test	-	1173	O
.	-	1177	O

Deep	16904497	1179	O
-	-	1183	O
tendon	-	1184	O
reflexes	-	1191	O
were	-	1200	O
decreased	-	1205	O
especially	-	1215	O
in	-	1226	O
the	-	1229	O
right	-	1233	O
leg	-	1239	O
.	-	1242	O

She	16904497	1244	O
was	-	1248	O
unable	-	1252	O
to	-	1259	O
urinate	-	1262	O
.	-	1269	O

The	16904497	1271	O
patient	-	1275	O
's	-	1282	O
symptoms	-	1285	O
improved	-	1294	O
slightly	-	1303	O
over	-	1312	O
the	-	1317	O
next	-	1321	O
few	-	1326	O
hours	-	1330	O
.	-	1335	O

She	16904497	1337	O
had	-	1341	O
a	-	1345	O
gradual	-	1347	O
return	-	1355	O
of	-	1362	O
motor	-	1365	O
function	-	1371	O
and	-	1380	O
ability	-	1384	O
of	-	1392	O
feeling	-	1395	O
Foley	-	1403	O
catheter	-	1409	O
.	-	1417	O

All	16904497	1419	O
of	-	1423	O
the	-	1426	O
symptoms	-	1430	O
were	-	1439	O
completely	-	1444	O
resolved	-	1455	O
over	-	1464	O
the	-	1469	O
next	-	1473	O
8	-	1478	O
hours	-	1480	O
.	-	1485	O

CONCLUSION	16904497	1487	O
:	-	1497	O

Complications	16904497	1499	O
associated	-	1513	O
with	-	1524	O
epidural	-	1529	O
steroid	-	1538	B
injections	-	1546	O
are	-	1557	O
rare	-	1561	O
.	-	1565	O

Clinical	16904497	1567	O
examination	-	1576	O
and	-	1588	O
continued	-	1592	O
vigilance	-	1602	O
for	-	1612	O
neurologic	-	1616	O
deterioration	-	1627	O
after	-	1641	O
epidural	-	1647	O
steroid	-	1656	B
injections	-	1664	O
is	-	1675	O
important	-	1678	O
.	-	1687	O

High	16938416	0	O
-	-	4	O
dose	-	5	O
testosterone	-	10	B
is	-	23	O
associated	-	26	O
with	-	37	O
atherosclerosis	-	42	O
in	-	58	O
postmenopausal	-	61	O
women	-	76	O
.	-	81	O

OBJECTIVES	16938416	83	O
:	-	93	O

To	16938416	95	O
study	-	98	O
the	-	104	O
long	-	108	O
-	-	112	O
term	-	113	O
effects	-	118	O
of	-	126	O
androgen	-	129	O
treatment	-	138	O
on	-	148	O
atherosclerosis	-	151	O
in	-	167	O
postmenopausal	-	170	O
women	-	185	O
.	-	190	O

METHODS	16938416	192	O
:	-	199	O

In	16938416	201	O
a	-	204	O
population	-	206	O
-	-	216	O
based	-	217	O
study	-	223	O
in	-	229	O
513	-	232	O
naturally	-	236	O
postmenopausal	-	246	O
women	-	261	O
aged	-	267	O
54	-	272	O
-	-	274	O
67	-	275	O
years	-	278	O
,	-	283	O
we	-	285	O
studied	-	288	O
the	-	296	O
association	-	300	O
between	-	312	O
self	-	320	O
-	-	324	O
reported	-	325	O
intramuscularly	-	334	O
administered	-	350	O
high	-	363	O
-	-	367	O
dose	-	368	O
estrogen	-	373	B
-	-	381	O
testosterone	-	382	B
therapy	-	395	O
(	-	403	O
estradiol	-	404	B
-	-	413	I
and	-	415	I
testosterone	-	419	I
esters	-	432	I
)	-	438	O
and	-	440	O
aortic	-	444	O
atherosclerosis	-	451	O
.	-	466	O

Aortic	16938416	468	O
atherosclerosis	-	475	O
was	-	491	O
diagnosed	-	495	O
by	-	505	O
radiographic	-	508	O
detection	-	521	O
of	-	531	O
calcified	-	534	O
deposits	-	544	O
in	-	553	O
the	-	556	O
abdominal	-	560	O
aorta	-	570	O
,	-	575	O
which	-	577	O
have	-	583	O
been	-	588	O
shown	-	593	O
to	-	599	O
reflect	-	602	O
intima	-	610	O
atherosclerosis	-	617	O
.	-	632	O

Hormone	16938416	634	O
therapy	-	642	O
users	-	650	O
were	-	656	O
compared	-	661	O
with	-	670	O
never	-	675	O
users	-	681	O
.	-	686	O

RESULTS	16938416	688	O
:	-	695	O

Intramuscular	16938416	697	O
hormone	-	711	O
therapy	-	719	O
use	-	727	O
for	-	731	O
1	-	735	O
year	-	737	O
or	-	742	O
longer	-	745	O
was	-	752	O
reported	-	756	O
by	-	765	O
25	-	768	O
women	-	771	O
.	-	776	O

In	16938416	778	O
almost	-	781	O
half	-	788	O
of	-	793	O
these	-	796	O
women	-	802	O
severe	-	808	O
atherosclerosis	-	815	O
of	-	831	O
the	-	834	O
aorta	-	838	O
was	-	844	O
present	-	848	O
(	-	856	O
n	-	857	O
=	-	858	O
11	-	859	O
)	-	861	O
,	-	862	O
while	-	864	O
in	-	870	O
women	-	873	O
without	-	879	O
hormone	-	887	O
use	-	895	O
severe	-	899	O
atherosclerosis	-	906	O
of	-	922	O
the	-	925	O
aorta	-	929	O
was	-	935	O
present	-	939	O
in	-	947	O
less	-	950	O
than	-	955	O
20	-	960	O
%	-	962	O
(	-	964	O
OR	-	965	O
3	-	968	O
.	-	969	O
1	-	970	O
;	-	971	O
95	-	973	O
%	-	975	O
CI	-	977	O
,	-	979	O
1	-	981	O
.	-	982	O
1	-	983	O
-	-	984	O
8	-	985	O
.	-	986	O
5	-	987	O
,	-	988	O
adjusted	-	990	O
for	-	999	O
age	-	1003	O
,	-	1006	O
years	-	1008	O
since	-	1014	O
menopause	-	1020	O
,	-	1029	O
smoking	-	1031	O
,	-	1038	O
and	-	1040	O
body	-	1044	O
mass	-	1049	O
index	-	1054	O
)	-	1059	O
.	-	1060	O

The	16938416	1062	O
association	-	1066	O
remained	-	1078	O
after	-	1087	O
additional	-	1093	O
adjustment	-	1104	O
for	-	1115	O
diabetes	-	1119	O
,	-	1127	O
cholesterol	-	1129	B
level	-	1141	O
,	-	1146	O
systolic	-	1148	O
blood	-	1157	O
pressure	-	1163	O
,	-	1171	O
or	-	1173	O
alcohol	-	1176	B
use	-	1184	O
.	-	1187	O

No	16938416	1189	O
association	-	1192	O
was	-	1204	O
found	-	1208	O
for	-	1214	O
hormone	-	1218	O
use	-	1226	O
less	-	1230	O
than	-	1235	O
1	-	1240	O
year	-	1242	O
.	-	1246	O

CONCLUSION	16938416	1248	O
:	-	1258	O

Our	16938416	1260	O
results	-	1264	O
suggest	-	1272	O
that	-	1280	O
high	-	1285	O
-	-	1289	O
dose	-	1290	O
testosterone	-	1295	B
therapy	-	1308	O
may	-	1316	O
adversely	-	1320	O
affect	-	1330	O
atherosclerosis	-	1337	O
in	-	1353	O
postmenopausal	-	1356	O
women	-	1371	O
and	-	1377	O
indicate	-	1381	O
that	-	1390	O
androgen	-	1395	O
replacement	-	1404	O
in	-	1416	O
these	-	1419	O
women	-	1425	O
may	-	1431	O
not	-	1435	O
be	-	1439	O
harmless	-	1442	O
.	-	1450	O

Sirolimus	17147461	0	B
-	-	9	O
associated	-	10	O
proteinuria	-	21	O
and	-	33	O
renal	-	37	O
dysfunction	-	43	O
.	-	54	O

Sirolimus	17147461	56	B
is	-	66	O
a	-	69	O
novel	-	71	O
immunosuppressant	-	77	O
with	-	95	O
potent	-	100	O
antiproliferative	-	107	O
actions	-	125	O
through	-	133	O
its	-	141	O
ability	-	145	O
to	-	153	O
inhibit	-	156	O
the	-	164	O
raptor	-	168	O
-	-	174	O
containing	-	175	O
mammalian	-	186	O
target	-	196	O
of	-	203	O
rapamycin	-	206	B
protein	-	216	O
kinase	-	224	O
.	-	230	O

Sirolimus	17147461	232	B
represents	-	242	O
a	-	253	O
major	-	255	O
therapeutic	-	261	O
advance	-	273	O
in	-	281	O
the	-	284	O
prevention	-	288	O
of	-	299	O
acute	-	302	O
renal	-	308	O
allograft	-	314	O
rejection	-	324	O
and	-	334	O
chronic	-	338	O
allograft	-	346	O
nephropathy	-	356	O
.	-	367	O

Its	17147461	369	O
role	-	373	O
in	-	378	O
the	-	381	O
therapy	-	385	O
of	-	393	O
glomerulonephritis	-	396	O
,	-	414	O
autoimmunity	-	416	O
,	-	428	O
cystic	-	430	O
renal	-	437	O
diseases	-	443	O
and	-	452	O
renal	-	456	O
cancer	-	462	O
is	-	469	O
under	-	472	O
investigation	-	478	O
.	-	491	O

Because	17147461	493	O
sirolimus	-	501	B
does	-	511	O
not	-	516	O
share	-	520	O
the	-	526	O
vasomotor	-	530	O
renal	-	540	O
adverse	-	546	O
effects	-	554	O
exhibited	-	562	O
by	-	572	O
calcineurin	-	575	O
inhibitors	-	587	O
,	-	597	O
it	-	599	O
has	-	602	O
been	-	606	O
designated	-	611	O
a	-	622	O
'	-	624	O
non	-	625	O
-	-	628	O
nephrotoxic	-	629	O
drug	-	641	O
'	-	645	O
.	-	646	O

However	17147461	648	O
,	-	655	O
clinical	-	657	O
reports	-	666	O
suggest	-	674	O
that	-	682	O
,	-	686	O
under	-	688	O
some	-	694	O
circumstances	-	699	O
,	-	712	O
sirolimus	-	714	B
is	-	724	O
associated	-	727	O
with	-	738	O
proteinuria	-	743	O
and	-	755	O
acute	-	759	O
renal	-	765	O
dysfunction	-	771	O
.	-	782	O

A	17147461	784	O
common	-	786	O
risk	-	793	O
factor	-	798	O
appears	-	805	O
to	-	813	O
be	-	816	O
presence	-	819	O
of	-	828	O
pre	-	831	O
-	-	834	O
existing	-	835	O
chronic	-	844	O
renal	-	852	O
damage	-	858	O
.	-	864	O

The	17147461	866	O
mechanisms	-	870	O
of	-	881	O
sirolimus	-	884	B
-	-	893	O
associated	-	894	O
proteinuria	-	905	O
are	-	917	O
multifactorial	-	921	O
and	-	936	O
may	-	940	O
be	-	944	O
due	-	947	O
to	-	951	O
an	-	954	O
increase	-	957	O
in	-	966	O
glomerular	-	969	O
capillary	-	980	O
pressure	-	990	O
following	-	999	O
calcineurin	-	1009	O
inhibitor	-	1021	O
withdrawal	-	1031	O
.	-	1041	O

It	17147461	1043	O
has	-	1046	O
also	-	1050	O
been	-	1055	O
suggested	-	1060	O
that	-	1070	O
sirolimus	-	1075	B
directly	-	1085	O
causes	-	1094	O
increased	-	1101	O
glomerular	-	1111	O
permeability	-	1122	O
/	-	1134	O
injury	-	1135	O
,	-	1141	O
but	-	1143	O
evidence	-	1147	O
for	-	1156	O
this	-	1160	O
mechanism	-	1165	O
is	-	1175	O
currently	-	1178	O
inconclusive	-	1188	O
.	-	1200	O

The	17147461	1202	O
acute	-	1206	O
renal	-	1212	O
dysfunction	-	1218	O
associated	-	1230	O
with	-	1241	O
sirolimus	-	1246	B
(	-	1256	O
such	-	1257	O
as	-	1262	O
in	-	1265	O
delayed	-	1268	O
graft	-	1276	O
function	-	1282	O
)	-	1290	O
may	-	1292	O
be	-	1296	O
due	-	1299	O
to	-	1303	O
suppression	-	1306	O
of	-	1318	O
compensatory	-	1321	O
renal	-	1334	O
cell	-	1340	O
proliferation	-	1345	O
and	-	1359	O
survival	-	1363	O
/	-	1371	O
repair	-	1372	O
processes	-	1379	O
.	-	1388	O

Although	17147461	1390	O
these	-	1399	O
adverse	-	1405	O
effects	-	1413	O
occur	-	1421	O
in	-	1427	O
some	-	1430	O
patients	-	1435	O
,	-	1443	O
their	-	1445	O
occurrence	-	1451	O
could	-	1462	O
be	-	1468	O
minimised	-	1471	O
by	-	1481	O
knowledge	-	1484	O
of	-	1494	O
the	-	1497	O
molecular	-	1501	O
effects	-	1511	O
of	-	1519	O
sirolimus	-	1522	B
on	-	1532	O
the	-	1535	O
kidney	-	1539	O
,	-	1545	O
the	-	1547	O
use	-	1551	O
of	-	1555	O
sirolimus	-	1558	B
in	-	1568	O
appropriate	-	1571	O
patient	-	1583	O
populations	-	1591	O
,	-	1602	O
close	-	1604	O
monitoring	-	1610	O
of	-	1621	O
proteinuria	-	1624	O
and	-	1636	O
renal	-	1640	O
function	-	1646	O
,	-	1654	O
use	-	1656	O
of	-	1660	O
angiotensin	-	1663	B
-	-	1674	O
converting	-	1675	O
enzyme	-	1686	O
inhibitors	-	1693	O
or	-	1704	O
angiotensin	-	1707	B
II	-	1719	I
receptor	-	1722	O
blockers	-	1731	O
if	-	1740	O
proteinuria	-	1743	O
occurs	-	1755	O
and	-	1762	O
withdrawal	-	1766	O
if	-	1777	O
needed	-	1780	O
.	-	1786	O

Further	17147461	1788	O
long	-	1796	O
-	-	1800	O
term	-	1801	O
analysis	-	1806	O
of	-	1815	O
renal	-	1818	O
allograft	-	1824	O
studies	-	1834	O
using	-	1842	O
sirolimus	-	1848	B
as	-	1858	O
de	-	1861	O
novo	-	1864	O
immunosuppression	-	1869	O
along	-	1887	O
with	-	1893	O
clinical	-	1898	O
and	-	1907	O
laboratory	-	1911	O
studies	-	1922	O
will	-	1930	O
refine	-	1935	O
these	-	1942	O
issues	-	1948	O
in	-	1955	O
the	-	1958	O
future	-	1962	O
.	-	1968	O

Progressive	17241784	0	O
myopathy	-	12	O
with	-	21	O
up	-	26	O
-	-	28	O
regulation	-	29	O
of	-	40	O
MHC	-	43	O
-	-	46	O

I	17241784	47	O
associated	-	49	O
with	-	60	O
statin	-	65	B
therapy	-	72	O
.	-	79	O

Statins	17241784	81	B
can	-	89	O
cause	-	93	O
a	-	99	O
necrotizing	-	101	O
myopathy	-	113	O
and	-	122	O
hyperCKaemia	-	126	O
which	-	139	O
is	-	145	O
reversible	-	148	O
on	-	159	O
cessation	-	162	O
of	-	172	O
the	-	175	O
drug	-	179	O
.	-	183	O

What	17241784	185	O
is	-	190	O
less	-	193	O
well	-	198	O
known	-	203	O
is	-	209	O
a	-	212	O
phenomenon	-	214	O
whereby	-	225	O
statins	-	233	B
may	-	241	O
induce	-	245	O
a	-	252	O
myopathy	-	254	O
,	-	262	O
which	-	264	O
persists	-	270	O
or	-	279	O
may	-	282	O
progress	-	286	O
after	-	295	O
stopping	-	301	O
the	-	310	O
drug	-	314	O
.	-	318	O

We	17241784	320	O
investigated	-	323	O
the	-	336	O
muscle	-	340	O
pathology	-	347	O
in	-	357	O
8	-	360	O
such	-	362	O
cases	-	367	O
.	-	372	O

All	17241784	374	O
had	-	378	O
myofibre	-	382	O
necrosis	-	391	O
but	-	400	O
only	-	404	O
3	-	409	O
had	-	411	O
an	-	415	O
inflammatory	-	418	O
infiltrate	-	431	O
.	-	441	O

In	17241784	443	O
all	-	446	O
cases	-	450	O
there	-	456	O
was	-	462	O
diffuse	-	466	O
or	-	474	O
multifocal	-	477	O
up	-	488	O
-	-	490	O
regulation	-	491	O
of	-	502	O
MHC	-	505	O
-	-	508	O
I	-	509	O
expression	-	511	O
even	-	522	O
in	-	527	O
non	-	530	O
-	-	533	O
necrotic	-	534	O
fibres	-	543	O
.	-	549	O

Progressive	17241784	551	O
improvement	-	563	O
occurred	-	575	O
in	-	584	O
7	-	587	O
cases	-	589	O
after	-	595	O
commencement	-	601	O
of	-	614	O
prednisolone	-	617	B
and	-	630	O
methotrexate	-	634	B
,	-	646	O
and	-	648	O
in	-	652	O
one	-	655	O
case	-	659	O
spontaneously	-	664	O
.	-	677	O

These	17241784	679	O
observations	-	685	O
suggest	-	698	O
that	-	706	O
statins	-	711	B
may	-	719	O
initiate	-	723	O
an	-	732	O
immune	-	735	O
-	-	741	O
mediated	-	742	O
myopathy	-	751	O
that	-	760	O
persists	-	765	O
after	-	774	O
withdrawal	-	780	O
of	-	791	O
the	-	794	O
drug	-	798	O
and	-	803	O
responds	-	807	O
to	-	816	O
immunosuppressive	-	819	O
therapy	-	837	O
.	-	844	O

The	17241784	846	O
mechanism	-	850	O
of	-	860	O
this	-	863	O
myopathy	-	868	O
is	-	877	O
uncertain	-	880	O
but	-	890	O
may	-	894	O
involve	-	898	O
the	-	906	O
induction	-	910	O
by	-	920	O
statins	-	923	B
of	-	931	O
an	-	934	O
endoplasmic	-	937	O
reticulum	-	949	O
stress	-	959	O
response	-	966	O
with	-	975	O
associated	-	980	O
up	-	991	O
-	-	993	O
regulation	-	994	O
of	-	1005	O
MHC	-	1008	O
-	-	1011	O
I	-	1012	O
expression	-	1014	O
and	-	1025	O
antigen	-	1029	O
presentation	-	1037	O
by	-	1050	O
muscle	-	1053	O
fibres	-	1060	O
.	-	1066	O

Direct	17261653	0	O
inhibition	-	7	O
of	-	18	O
cardiac	-	21	O
hyperpolarization	-	29	O
-	-	46	O
activated	-	47	O
cyclic	-	57	B
nucleotide	-	64	I
-	-	74	O
gated	-	75	O
pacemaker	-	81	O
channels	-	91	O
by	-	100	O
clonidine	-	103	B
.	-	112	O

BACKGROUND	17261653	114	O
:	-	124	O
Inhibition	-	126	O
of	-	137	O
cardiac	-	140	O
sympathetic	-	148	O
tone	-	160	O
represents	-	165	O
an	-	176	O
important	-	179	O
strategy	-	189	O
for	-	198	O
treatment	-	202	O
of	-	212	O
cardiovascular	-	215	O
disease	-	230	O
,	-	237	O
including	-	239	O
arrhythmia	-	249	O
,	-	259	O
coronary	-	261	O
heart	-	270	O
disease	-	276	O
,	-	283	O
and	-	285	O
chronic	-	289	O
heart	-	297	O
failure	-	303	O
.	-	310	O

Activation	17261653	312	O
of	-	323	O
presynaptic	-	326	O
alpha2	-	338	O
-	-	344	O
adrenoceptors	-	345	O
is	-	359	O
the	-	362	O
most	-	366	O
widely	-	371	O
accepted	-	378	O
mechanism	-	387	O
of	-	397	O
action	-	400	O
of	-	407	O
the	-	410	O
antisympathetic	-	414	O
drug	-	430	O
clonidine	-	435	B
;	-	444	O
however	-	446	O
,	-	453	O
other	-	455	O
target	-	461	O
proteins	-	468	O
have	-	477	O
been	-	482	O
postulated	-	487	O
to	-	498	O
contribute	-	501	O
to	-	512	O
the	-	515	O
in	-	519	O
vivo	-	522	O
actions	-	527	O
of	-	535	O
clonidine	-	538	B
.	-	547	O

METHODS	17261653	549	O
AND	-	557	O
RESULTS	-	561	O
:	-	568	O

To	17261653	570	O
test	-	573	O
whether	-	578	O
clonidine	-	586	B
elicits	-	596	O
pharmacological	-	604	O
effects	-	620	O
independent	-	628	O
of	-	640	O
alpha2	-	643	O
-	-	649	O
adrenoceptors	-	650	O
,	-	663	O
we	-	665	O
have	-	668	O
generated	-	673	O
mice	-	683	O
with	-	688	O
a	-	693	O
targeted	-	695	O
deletion	-	704	O
of	-	713	O
all	-	716	O
3	-	720	O
alpha2	-	722	O
-	-	728	O
adrenoceptor	-	729	O
subtypes	-	742	O
(	-	751	O
alpha2ABC	-	752	O
-	-	761	O
/	-	762	O
-	-	763	O
)	-	764	O
.	-	765	O

Alpha2ABC	17261653	767	O
-	-	776	O
/	-	777	O
-	-	778	O
mice	-	780	O
were	-	785	O
completely	-	790	O
unresponsive	-	801	O
to	-	814	O
the	-	817	O
analgesic	-	821	O
and	-	831	O
hypnotic	-	835	O
effects	-	844	O
of	-	852	O
clonidine	-	855	B
;	-	864	O
however	-	866	O
,	-	873	O
clonidine	-	875	B
significantly	-	885	O
lowered	-	899	O
heart	-	907	O
rate	-	913	O
in	-	918	O
alpha2ABC	-	921	O
-	-	930	O
/	-	931	O
-	-	932	O
mice	-	934	O
by	-	939	O
up	-	942	O
to	-	945	O
150	-	948	O
bpm	-	952	O
.	-	955	O

Clonidine	17261653	957	B
-	-	966	O
induced	-	967	O
bradycardia	-	975	O
in	-	987	O
conscious	-	990	O
alpha2ABC	-	1000	O
-	-	1009	O
/	-	1010	O
-	-	1011	O
mice	-	1013	O
was	-	1018	O
32	-	1022	O
.	-	1024	O
3	-	1025	O
%	-	1026	O
(	-	1028	O
10	-	1029	O
microg	-	1032	O
/	-	1038	O
kg	-	1039	O
)	-	1041	O
and	-	1043	O
26	-	1047	O
.	-	1049	O
6	-	1050	O
%	-	1051	O
(	-	1053	O
100	-	1054	O
microg	-	1058	O
/	-	1064	O
kg	-	1065	O
)	-	1067	O
of	-	1069	O
the	-	1072	O
effect	-	1076	O
in	-	1083	O
wild	-	1086	O
-	-	1090	O
type	-	1091	O
mice	-	1096	O
.	-	1100	O

A	17261653	1102	O
similar	-	1104	O
bradycardic	-	1112	O
effect	-	1124	O
of	-	1131	O
clonidine	-	1134	B
was	-	1144	O
observed	-	1148	O
in	-	1157	O
isolated	-	1160	O
spontaneously	-	1169	O
beating	-	1183	O
right	-	1191	O
atria	-	1197	O
from	-	1203	O
alpha2ABC	-	1208	O
-	-	1217	O
knockout	-	1218	O
and	-	1227	O
wild	-	1231	O
-	-	1235	O
type	-	1236	O
mice	-	1241	O
.	-	1245	O

Clonidine	17261653	1247	B
inhibited	-	1257	O
the	-	1267	O
native	-	1271	O
pacemaker	-	1278	O
current	-	1288	O
(	-	1296	O
I	-	1297	O
(	-	1298	O
f	-	1299	O
)	-	1300	O
)	-	1301	O
in	-	1303	O
isolated	-	1306	O
sinoatrial	-	1315	O
node	-	1326	O
pacemaker	-	1331	O
cells	-	1341	O
and	-	1347	O
the	-	1351	O
I	-	1355	O
(	-	1356	O
f	-	1357	O
)	-	1358	O
-	-	1359	O
generating	-	1360	O
hyperpolarization	-	1371	O
-	-	1388	O
activated	-	1389	O
cyclic	-	1399	B
nucleotide	-	1406	I
-	-	1416	O
gated	-	1417	O
(	-	1423	O
HCN	-	1424	O
)	-	1427	O
2	-	1429	O
and	-	1431	O
HCN4	-	1435	O
channels	-	1440	O
in	-	1449	O
transfected	-	1452	O
HEK293	-	1464	O
cells	-	1471	O
.	-	1476	O

As	17261653	1478	O
a	-	1481	O
consequence	-	1483	O
of	-	1495	O
blocking	-	1498	O
I	-	1507	O
(	-	1508	O
f	-	1509	O
)	-	1510	O
,	-	1511	O
clonidine	-	1513	B
reduced	-	1523	O
the	-	1531	O
slope	-	1535	O
of	-	1541	O
the	-	1544	O
diastolic	-	1548	O
depolarization	-	1558	O
and	-	1573	O
the	-	1577	O
frequency	-	1581	O
of	-	1591	O
pacemaker	-	1594	O
potentials	-	1604	O
in	-	1615	O
sinoatrial	-	1618	O
node	-	1629	O
cells	-	1634	O
from	-	1640	O
wild	-	1645	O
-	-	1649	O
type	-	1650	O
and	-	1655	O
alpha2ABC	-	1659	O
-	-	1668	O
knockout	-	1669	O
mice	-	1678	O
.	-	1682	O

CONCLUSIONS	17261653	1684	O
:	-	1695	O

Direct	17261653	1697	O
inhibition	-	1704	O
of	-	1715	O
cardiac	-	1718	O
HCN	-	1726	O
pacemaker	-	1730	O
channels	-	1740	O
contributes	-	1749	O
to	-	1761	O
the	-	1764	O
bradycardic	-	1768	O
effects	-	1780	O
of	-	1788	O
clonidine	-	1791	B
gene	-	1801	O
-	-	1805	O
targeted	-	1806	O
mice	-	1815	O
in	-	1820	O
vivo	-	1823	O
,	-	1827	O
and	-	1829	O
thus	-	1833	O
,	-	1837	O
clonidine	-	1839	B
-	-	1848	O
like	-	1849	O
drugs	-	1854	O
represent	-	1860	O
novel	-	1870	O
structures	-	1876	O
for	-	1887	O
future	-	1891	O
HCN	-	1898	O
channel	-	1902	O
inhibitors	-	1910	O
.	-	1920	O

Influence	17343925	0	O
of	-	10	O
smoking	-	13	B
on	-	21	O
developing	-	24	O
cochlea	-	35	O
.	-	42	O

Does	17343925	44	O
smoking	-	49	B
during	-	57	O
pregnancy	-	64	O
affect	-	74	O
the	-	81	O
amplitudes	-	85	O
of	-	96	O
transient	-	99	O
evoked	-	109	O
otoacoustic	-	116	O
emissions	-	128	O
in	-	138	O
newborns	-	141	O
?	-	149	O

OBJECTIVE	17343925	151	O
:	-	160	O
Maternal	-	162	O
tobacco	-	171	O
smoking	-	179	B
has	-	187	O
negative	-	191	O
effects	-	200	O
on	-	208	O
fetal	-	211	O
growth	-	217	O
.	-	223	O

The	17343925	225	O
influence	-	229	O
of	-	239	O
smoking	-	242	B
during	-	250	O
pregnancy	-	257	O
on	-	267	O
the	-	270	O
developing	-	274	O
cochlea	-	285	O
has	-	293	O
not	-	297	O
been	-	301	O
estimated	-	306	O
,	-	315	O
although	-	317	O
smoking	-	326	B
has	-	334	O
been	-	338	O
positively	-	343	O
associated	-	354	O
with	-	365	O
hearing	-	370	O
loss	-	378	O
in	-	383	O
adults	-	386	O
.	-	392	O

The	17343925	394	O
objective	-	398	O
of	-	408	O
this	-	411	O
study	-	416	O
was	-	422	O
to	-	426	O
determine	-	429	O
the	-	439	O
effects	-	443	O
of	-	451	O
maternal	-	454	O
smoking	-	463	B
on	-	471	O
transient	-	474	O
evoked	-	484	O
otoacoustic	-	491	O
emissions	-	503	O
(	-	513	O
TEOAEs	-	514	O
)	-	520	O
of	-	522	O
healthy	-	525	O
neonates	-	533	O
.	-	541	O

METHODS	17343925	543	O
:	-	550	O

This	17343925	552	O
study	-	557	O
was	-	563	O
undertaken	-	567	O
as	-	578	O
part	-	581	O
of	-	586	O
neonatal	-	589	O
screening	-	598	O
for	-	608	O
hearing	-	612	O
impairment	-	620	O
and	-	631	O
involved	-	635	O
both	-	644	O
ears	-	649	O
of	-	654	O
200	-	657	O
newborns	-	661	O
.	-	669	O

Newborns	17343925	671	O
whose	-	680	O
mothers	-	686	O
reported	-	694	O
smoking	-	703	B
during	-	711	O
pregnancy	-	718	O
(	-	728	O
n	-	729	O
=	-	730	O
200	-	731	O
ears	-	735	O
)	-	739	O
were	-	741	O
compared	-	746	O
to	-	755	O
a	-	758	O
control	-	760	O
group	-	768	O
of	-	774	O
newborns	-	777	O
(	-	786	O
n	-	787	O
=	-	788	O
200	-	789	O
ears	-	793	O
)	-	797	O
,	-	798	O
whose	-	800	O
mothers	-	806	O
were	-	814	O
non	-	819	O
-	-	822	O
smokers	-	823	O
.	-	830	O

Exposure	17343925	832	O
to	-	841	O
tobacco	-	844	O
was	-	852	O
characterized	-	856	O
as	-	870	O
low	-	873	O
(	-	877	O
<	-	878	O
5	-	879	O
cigarettes	-	881	O
per	-	892	O
day	-	896	O
,	-	899	O
n	-	901	O
=	-	902	O
88	-	903	O
ears	-	906	O
)	-	910	O
,	-	911	O
moderate	-	913	O
(	-	922	O
5	-	923	O
<	-	924	O
or	-	926	O
=	-	929	O
cigarettes	-	930	O
per	-	941	O
day	-	945	O
<	-	948	O
10	-	949	O
,	-	951	O
n	-	953	O
=	-	954	O
76	-	955	O
)	-	957	O
or	-	959	O
high	-	962	O
(	-	967	O
>	-	968	O
or	-	970	O
=	-	973	O
10	-	974	O
cigarettes	-	977	O
per	-	988	O
day	-	992	O
,	-	995	O
n	-	997	O
=	-	998	O
36	-	999	O
)	-	1001	O
.	-	1002	O

RESULTS	17343925	1004	O
:	-	1011	O

In	17343925	1013	O
exposed	-	1016	O
neonates	-	1024	O
,	-	1032	O
TEOAEs	-	1034	O
mean	-	1041	O
response	-	1046	O
(	-	1055	O
across	-	1056	O
frequency	-	1063	O
)	-	1072	O
and	-	1074	O
mean	-	1078	O
amplitude	-	1083	O
at	-	1093	O
4000Hz	-	1096	O
was	-	1103	O
significantly	-	1107	O
lower	-	1121	O
than	-	1127	O
in	-	1132	O
non	-	1135	O
-	-	1138	O
exposed	-	1139	O
neonates	-	1147	O
.	-	1155	O

Comparisons	17343925	1157	O
between	-	1169	O
exposed	-	1177	O
newborns	-	1185	O
'	-	1193	O
subgroups	-	1195	O
revealed	-	1205	O
no	-	1214	O
significant	-	1217	O
differences	-	1229	O
.	-	1240	O

However	17343925	1242	O
,	-	1249	O
by	-	1251	O
comparing	-	1254	O
each	-	1264	O
subgroup	-	1269	O
to	-	1278	O
control	-	1281	O
group	-	1289	O
,	-	1294	O
we	-	1296	O
found	-	1299	O
statistically	-	1305	O
significant	-	1319	O
decreases	-	1331	O
of	-	1341	O
TEOAEs	-	1344	O
amplitudes	-	1351	O
at	-	1362	O
4000Hz	-	1365	O
for	-	1372	O
all	-	1376	O
three	-	1380	O
groups	-	1386	O
.	-	1392	O

Mean	17343925	1394	O
TEOAEs	-	1399	O
responses	-	1406	O
of	-	1416	O
highly	-	1419	O
exposed	-	1426	O
newborns	-	1434	O
were	-	1443	O
also	-	1448	O
significantly	-	1453	O
lower	-	1467	O
in	-	1473	O
comparison	-	1476	O
to	-	1487	O
our	-	1490	O
control	-	1494	O
group	-	1502	O
.	-	1507	O

CONCLUSION	17343925	1509	O
:	-	1519	O

In	17343925	1521	O
utero	-	1524	O
,	-	1529	O
exposure	-	1531	O
to	-	1540	O
tobacco	-	1543	O
smoking	-	1551	B
seems	-	1559	O
to	-	1565	O
have	-	1568	O
a	-	1573	O
small	-	1575	O
impact	-	1581	O
on	-	1588	O
outer	-	1591	O
hair	-	1597	O
cells	-	1602	O
.	-	1607	O

These	17343925	1609	O
effects	-	1615	O
seem	-	1623	O
to	-	1628	O
be	-	1631	O
equally	-	1634	O
true	-	1642	O
for	-	1647	O
all	-	1651	O
exposed	-	1655	O
newborns	-	1663	O
,	-	1671	O
regardless	-	1673	O
of	-	1684	O
the	-	1687	O
degree	-	1691	O
of	-	1698	O
exposure	-	1701	O
.	-	1709	O

Further	17343925	1711	O
studies	-	1719	O
are	-	1727	O
needed	-	1731	O
in	-	1738	O
order	-	1741	O
to	-	1747	O
establish	-	1750	O
a	-	1760	O
potential	-	1762	O
negative	-	1772	O
effect	-	1781	O
of	-	1788	O
maternal	-	1791	O
smoking	-	1800	B
on	-	1808	O
the	-	1811	O
neonate	-	1815	O
's	-	1822	O
hearing	-	1825	O
acuity	-	1833	O
.	-	1839	O

Neuroinflammation	17400887	0	O
and	-	18	O
behavioral	-	22	O
abnormalities	-	33	O
after	-	47	O
neonatal	-	53	O
terbutaline	-	62	B
treatment	-	74	O
in	-	84	O
rats	-	87	O
:	-	91	O
implications	-	93	O
for	-	106	O
autism	-	110	O
.	-	116	O

Autism	17400887	118	O
is	-	125	O
a	-	128	O
neurodevelopmental	-	130	O
disorder	-	149	O
presenting	-	158	O
before	-	169	O
3	-	176	O
years	-	178	O
of	-	184	O
age	-	187	O
with	-	191	O
deficits	-	196	O
in	-	205	O
communication	-	208	O
and	-	222	O
social	-	226	O
skills	-	233	O
and	-	240	O
repetitive	-	244	O
behaviors	-	255	O
.	-	264	O

In	17400887	266	O
addition	-	269	O
to	-	278	O
genetic	-	281	O
influences	-	289	O
,	-	299	O
recent	-	301	O
studies	-	308	O
suggest	-	316	O
that	-	324	O
prenatal	-	329	O
drug	-	338	O
or	-	343	O
chemical	-	346	O
exposures	-	355	O
are	-	365	O
risk	-	369	O
factors	-	374	O
for	-	382	O
autism	-	386	O
.	-	392	O

Terbutaline	17400887	394	B
,	-	405	O
a	-	407	O
beta2	-	409	O
-	-	414	O
adrenoceptor	-	415	O
agonist	-	428	O
used	-	436	O
to	-	441	O
arrest	-	444	O
preterm	-	451	O
labor	-	459	O
,	-	464	O
has	-	466	O
been	-	470	O
associated	-	475	O
with	-	486	O
increased	-	491	O
concordance	-	501	O
for	-	513	O
autism	-	517	O
in	-	524	O
dizygotic	-	527	O
twins	-	537	O
.	-	542	O

We	17400887	544	O
studied	-	547	O
the	-	555	O
effects	-	559	O
of	-	567	O
terbutaline	-	570	B
on	-	582	O
microglial	-	585	O
activation	-	596	O
in	-	607	O
different	-	610	O
brain	-	620	O
regions	-	626	O
and	-	634	O
behavioral	-	638	O
outcomes	-	649	O
in	-	658	O
developing	-	661	O
rats	-	672	O
.	-	676	O

Newborn	17400887	678	O
rats	-	686	O
were	-	691	O
given	-	696	O
terbutaline	-	702	B
(	-	714	O
10	-	715	O
mg	-	718	O
/	-	720	O
kg	-	721	O
)	-	723	O
daily	-	725	O
on	-	731	O
postnatal	-	734	O
days	-	744	O
(	-	749	O
PN	-	750	O
)	-	752	O
2	-	754	O
to	-	756	O
5	-	759	O
or	-	761	O
PN	-	764	O
11	-	767	O
to	-	770	O
14	-	773	O
and	-	776	O
examined	-	780	O
24	-	789	O
h	-	792	O
after	-	794	O
the	-	800	O
last	-	804	O
dose	-	809	O
and	-	814	O
at	-	818	O
PN	-	821	O
30	-	824	O
.	-	826	O

Immunohistochemical	17400887	828	O
studies	-	848	O
showed	-	856	O
that	-	863	O
administration	-	868	O
of	-	883	O
terbutaline	-	886	B
on	-	898	O
PN	-	901	O
2	-	904	O
to	-	906	O
5	-	909	O
produced	-	911	O
a	-	920	O
robust	-	922	O
increase	-	929	O
in	-	938	O
microglial	-	941	O
activation	-	952	O
on	-	963	O
PN	-	966	O
30	-	969	O
in	-	972	O
the	-	975	O
cerebral	-	979	O
cortex	-	988	O
,	-	994	O
as	-	996	O
well	-	999	O
as	-	1004	O
in	-	1007	O
cerebellar	-	1010	O
and	-	1021	O
cerebrocortical	-	1025	O
white	-	1041	O
matter	-	1047	O
.	-	1053	O

None	17400887	1055	O
of	-	1060	O
these	-	1063	O
effects	-	1069	O
occurred	-	1077	O
in	-	1086	O
animals	-	1089	O
given	-	1097	O
terbutaline	-	1103	B
on	-	1115	O
PN	-	1118	O
11	-	1121	O
to	-	1124	O
14	-	1127	O
.	-	1129	O

In	17400887	1131	O
behavioral	-	1134	O
tests	-	1145	O
,	-	1150	O
animals	-	1152	O
treated	-	1160	O
with	-	1168	O
terbutaline	-	1173	B
on	-	1185	O
PN	-	1188	O
2	-	1191	O
to	-	1193	O
5	-	1196	O
showed	-	1198	O
consistent	-	1205	O
patterns	-	1216	O
of	-	1225	O
hyper	-	1228	O
-	-	1233	O
reactivity	-	1234	O
to	-	1245	O
novelty	-	1248	O
and	-	1256	O
aversive	-	1260	O
stimuli	-	1269	O
when	-	1277	O
assessed	-	1282	O
in	-	1291	O
a	-	1294	O
novel	-	1296	O
open	-	1302	O
field	-	1307	O
,	-	1312	O
as	-	1314	O
well	-	1317	O
as	-	1322	O
in	-	1325	O
the	-	1328	O
acoustic	-	1332	O
startle	-	1341	O
response	-	1349	O
test	-	1358	O
.	-	1362	O

Our	17400887	1364	O
findings	-	1368	O
indicate	-	1377	O
that	-	1386	O
beta2	-	1391	O
-	-	1396	O
adrenoceptor	-	1397	O
overstimulation	-	1410	O
during	-	1426	O
an	-	1433	O
early	-	1436	O
critical	-	1442	O
period	-	1451	O
results	-	1458	O
in	-	1466	O
microglial	-	1469	O
activation	-	1480	O
associated	-	1491	O
with	-	1502	O
innate	-	1507	O
neuroinflammatory	-	1514	O
pathways	-	1532	O
and	-	1541	O
behavioral	-	1545	O
abnormalities	-	1556	O
,	-	1569	O
similar	-	1571	O
to	-	1579	O
those	-	1582	O
described	-	1588	O
in	-	1598	O
autism	-	1601	O
.	-	1607	O

This	17400887	1609	O
study	-	1614	O
provides	-	1620	O
a	-	1629	O
useful	-	1631	O
animal	-	1638	O
model	-	1645	O
for	-	1651	O
understanding	-	1655	O
the	-	1669	O
neuropathological	-	1673	O
processes	-	1691	O
underlying	-	1701	O
autism	-	1712	O
spectrum	-	1719	O
disorders	-	1728	O
.	-	1737	O

Acute	17612891	0	O
myocarditis	-	6	O
associated	-	18	O
with	-	29	O
clozapine	-	34	B
.	-	43	O

OBJECTIVE	17612891	45	O
:	-	54	O
A	-	56	O
case	-	58	O
of	-	63	O
acute	-	66	O
myocarditis	-	72	O
associated	-	84	O
with	-	95	O
the	-	100	O
commencement	-	104	O
of	-	117	O
clozapine	-	120	B
is	-	130	O
described	-	133	O
,	-	142	O
highlighting	-	144	O
the	-	157	O
onset	-	161	O
,	-	166	O
course	-	168	O
and	-	175	O
possible	-	179	O
contributing	-	188	O
factors	-	201	O
.	-	208	O

There	17612891	210	O
is	-	216	O
an	-	219	O
urgent	-	222	O
need	-	229	O
to	-	234	O
raise	-	237	O
awareness	-	243	O
about	-	253	O
this	-	259	O
potentially	-	264	O
fatal	-	276	O
complication	-	282	O
of	-	295	O
clozapine	-	298	B
use	-	308	O
.	-	311	O

RESULTS	17612891	313	O
:	-	320	O

A	17612891	322	O
20	-	324	O
-	-	326	O
year	-	327	O
-	-	331	O
old	-	332	O
male	-	336	O
with	-	341	O
schizophrenia	-	346	O
developed	-	360	O
a	-	370	O
sudden	-	372	O
onset	-	379	O
of	-	385	O
myocarditis	-	388	O
after	-	400	O
commencement	-	406	O
of	-	419	O
clozapine	-	422	B
.	-	431	O

The	17612891	433	O
patient	-	437	O
recovered	-	445	O
with	-	455	O
intensive	-	460	O
medical	-	470	O
support	-	478	O
.	-	485	O

The	17612891	487	O
symptoms	-	491	O
occurred	-	500	O
around	-	509	O
2	-	516	O
weeks	-	518	O
after	-	524	O
starting	-	530	O
clozapine	-	539	B
in	-	549	O
an	-	552	O
inpatient	-	555	O
setting	-	565	O
.	-	572	O

Possible	17612891	574	O
contributing	-	583	O
factors	-	596	O
may	-	604	O
have	-	608	O
been	-	613	O
concomitant	-	618	O
antidepressant	-	630	B
use	-	645	O
and	-	649	O
unaccustomed	-	653	O
physical	-	666	O
activity	-	675	O
.	-	683	O

CONCLUSIONS	17612891	685	O
:	-	696	O

Myocarditis	17612891	698	O
is	-	710	O
an	-	713	O
increasingly	-	716	O
recognized	-	729	O
complication	-	740	O
associated	-	753	O
with	-	764	O
the	-	769	O
use	-	773	O
of	-	777	O
clozapine	-	780	B
.	-	789	O

It	17612891	791	O
can	-	794	O
be	-	798	O
fatal	-	801	O
if	-	807	O
not	-	810	O
recognized	-	814	O
and	-	825	O
treated	-	829	O
early	-	837	O
.	-	842	O

Considering	17612891	844	O
that	-	856	O
clozapine	-	861	B
remains	-	871	O
the	-	879	O
gold	-	883	O
standard	-	888	O
in	-	897	O
treatment	-	900	O
of	-	910	O
resistant	-	913	O
psychosis	-	923	O
,	-	932	O
there	-	934	O
is	-	940	O
an	-	943	O
urgent	-	946	O
need	-	953	O
to	-	958	O
raise	-	961	O
awareness	-	967	O
among	-	977	O
medical	-	983	O
and	-	991	O
paramedical	-	995	O
staff	-	1007	O
involved	-	1013	O
in	-	1022	O
the	-	1025	O
care	-	1029	O
of	-	1034	O
these	-	1037	O
patients	-	1043	O
.	-	1051	O

There	17612891	1053	O
are	-	1059	O
also	-	1063	O
implications	-	1068	O
for	-	1081	O
recommendations	-	1085	O
and	-	1101	O
regulations	-	1105	O
regarding	-	1117	O
the	-	1127	O
use	-	1131	O
of	-	1135	O
clozapine	-	1138	B
.	-	1147	O

Encephalopathy	18081909	0	O
induced	-	15	O
by	-	23	O
levetiracetam	-	26	B
added	-	40	O
to	-	46	O
valproate	-	49	B
.	-	58	O

BACKGROUND	18081909	60	O
:	-	70	O

We	18081909	72	O
report	-	75	O
on	-	82	O
the	-	85	O
manifestation	-	89	O
of	-	103	O
a	-	106	O
levetiracetam	-	108	B
(	-	122	O
LEV	-	123	B
)	-	126	O
-	-	127	O
induced	-	128	O
encephalopathy	-	136	O
.	-	150	O

FINDINGS	18081909	152	O
:	-	160	O

A	18081909	162	O
28	-	164	O
-	-	166	O
year	-	167	O
-	-	171	O
old	-	172	O
man	-	176	O
suffering	-	180	O
from	-	190	O
idiopathic	-	195	O
epilepsy	-	206	O
with	-	215	O
generalized	-	220	O
seizures	-	232	O
was	-	241	O
treated	-	245	O
with	-	253	O
LEV	-	258	B
(	-	262	O
3000	-	263	O
mg	-	268	O
)	-	270	O
added	-	272	O
to	-	278	O
valproate	-	281	B
(	-	291	O
VPA	-	292	B
)	-	295	O
(	-	297	O
2000	-	298	O
mg	-	303	O
)	-	305	O
.	-	306	O

Frequency	18081909	308	O
of	-	318	O
generalized	-	321	O
tonic	-	333	O
-	-	338	O
clonic	-	339	O
seizures	-	346	O
increased	-	355	O
from	-	365	O
one	-	370	O
per	-	374	O
6	-	378	O
months	-	380	O
to	-	387	O
two	-	390	O
per	-	394	O
month	-	398	O
.	-	403	O

Neuropsychological	18081909	405	O
testing	-	424	O
showed	-	432	O
impaired	-	439	O
word	-	448	O
fluency	-	453	O
,	-	460	O
psychomotor	-	462	O
speed	-	474	O
and	-	480	O
working	-	484	O
memory	-	492	O
.	-	498	O

The	18081909	500	O
interictal	-	504	O
electroencephalogram	-	515	O
(	-	536	O
EEG	-	537	O
)	-	540	O
showed	-	542	O
a	-	549	O
generalized	-	551	O
slowing	-	563	O
to	-	571	O
5	-	574	O
per	-	576	O
second	-	580	O
theta	-	587	O
rhythms	-	593	O
with	-	601	O
bilateral	-	606	O
generalized	-	616	O
high	-	628	O
-	-	632	O
amplitude	-	633	O
discharges	-	643	O
.	-	653	O

OUTCOME	18081909	655	O
:	-	662	O

Following	18081909	664	O
discontinuation	-	674	O
of	-	690	O
LEV	-	693	B
,	-	696	O
EEG	-	698	O
and	-	702	O
neuropsychological	-	706	O
findings	-	725	O
improved	-	734	O
and	-	743	O
seizure	-	747	O
frequency	-	755	O
decreased	-	765	O
.	-	774	O

Norepinephrine	18083142	0	B
signaling	-	15	O
through	-	25	O
beta	-	33	O
-	-	37	O
adrenergic	-	38	O
receptors	-	49	O
is	-	59	O
critical	-	62	O
for	-	71	O
expression	-	75	O
of	-	86	O
cocaine	-	89	B
-	-	96	O
induced	-	97	O
anxiety	-	105	O
.	-	112	O

BACKGROUND	18083142	114	O
:	-	124	O

Cocaine	18083142	126	B
is	-	134	O
a	-	137	O
widely	-	139	O
abused	-	146	O
psychostimulant	-	153	O
that	-	169	O
has	-	174	O
both	-	178	O
rewarding	-	183	O
and	-	193	O
aversive	-	197	O
properties	-	206	O
.	-	216	O

While	18083142	218	O
the	-	224	O
mechanisms	-	228	O
underlying	-	239	O
cocaine	-	250	B
's	-	257	O
rewarding	-	260	O
effects	-	270	O
have	-	278	O
been	-	283	O
studied	-	288	O
extensively	-	296	O
,	-	307	O
less	-	309	O
attention	-	314	O
has	-	324	O
been	-	328	O
paid	-	333	O
to	-	338	O
the	-	341	O
unpleasant	-	345	O
behavioral	-	356	O
states	-	367	O
induced	-	374	O
by	-	382	O
cocaine	-	385	B
,	-	392	O
such	-	394	O
as	-	399	O
anxiety	-	402	O
.	-	409	O

METHODS	18083142	411	O
:	-	418	O

In	18083142	420	O
this	-	423	O
study	-	428	O
,	-	433	O
we	-	435	O
evaluated	-	438	O
the	-	448	O
performance	-	452	O
of	-	464	O
dopamine	-	467	B
beta	-	476	O
-	-	480	O
hydroxylase	-	481	O
knockout	-	493	O
(	-	502	O
Dbh	-	503	O
-	-	507	O
/	-	508	O
-	-	509	O
)	-	510	O
mice	-	512	O
,	-	516	O
which	-	518	O
lack	-	524	O
norepinephrine	-	529	B
(	-	544	O
NE	-	545	B
)	-	547	O
,	-	548	O
in	-	550	O
the	-	553	O
elevated	-	557	O
plus	-	566	O
maze	-	571	O
(	-	576	O
EPM	-	577	O
)	-	580	O
to	-	582	O
examine	-	585	O
the	-	593	O
contribution	-	597	O
of	-	610	O
noradrenergic	-	613	O
signaling	-	627	O
to	-	637	O
cocaine	-	640	B
-	-	647	O
induced	-	648	O
anxiety	-	656	O
.	-	663	O

RESULTS	18083142	665	O
:	-	672	O

We	18083142	674	O
found	-	677	O
that	-	683	O
cocaine	-	688	B
dose	-	696	O
-	-	700	O
dependently	-	701	O
increased	-	713	O
anxiety	-	723	O
-	-	730	O
like	-	731	O
behavior	-	736	O
in	-	745	O
control	-	748	O
(	-	756	O
Dbh	-	757	O
+	-	761	O
/	-	762	O
-	-	763	O

)	18083142	764	O
mice	-	766	O
,	-	770	O
as	-	772	O
measured	-	775	O
by	-	784	O
a	-	787	O
decrease	-	789	O
in	-	798	O
open	-	801	O
arm	-	806	O
exploration	-	810	O
.	-	821	O

The	18083142	823	O
Dbh	-	827	O
-	-	831	O
/	-	832	O
-	-	833	O
mice	-	835	O
had	-	840	O
normal	-	844	O
baseline	-	851	O
performance	-	860	O
in	-	872	O
the	-	875	O
EPM	-	879	O
but	-	883	O
were	-	887	O
completely	-	892	O
resistant	-	903	O
to	-	913	O
the	-	916	O
anxiogenic	-	920	O
effects	-	931	O
of	-	939	O
cocaine	-	942	B
.	-	949	O

Cocaine	18083142	951	B
-	-	958	O
induced	-	959	O
anxiety	-	967	O
was	-	975	O
also	-	979	O
attenuated	-	984	O
in	-	995	O
Dbh	-	998	O
+	-	1002	O
/	-	1003	O
-	-	1004	O

mice	18083142	1006	O
following	-	1011	O
administration	-	1021	O
of	-	1036	O
disulfiram	-	1039	B
,	-	1049	O
a	-	1051	O
dopamine	-	1053	B
beta	-	1062	O
-	-	1066	O
hydroxylase	-	1067	O
(	-	1079	O
DBH	-	1080	O
)	-	1083	O
inhibitor	-	1085	O
.	-	1094	O

In	18083142	1096	O
experiments	-	1099	O
using	-	1111	O
specific	-	1117	O
adrenergic	-	1126	O
antagonists	-	1137	O
,	-	1148	O
we	-	1150	O
found	-	1153	O
that	-	1159	O
pretreatment	-	1164	O
with	-	1177	O
the	-	1182	O
beta	-	1186	O
-	-	1190	O
adrenergic	-	1191	O
receptor	-	1202	O
antagonist	-	1211	O
propranolol	-	1222	B
blocked	-	1234	O
cocaine	-	1242	B
-	-	1249	O
induced	-	1250	O
anxiety	-	1258	O
-	-	1265	O
like	-	1266	O
behavior	-	1271	O
in	-	1280	O
Dbh	-	1283	O
+	-	1287	O
/	-	1288	O
-	-	1289	O

and	18083142	1291	O
wild	-	1295	O
-	-	1299	O
type	-	1300	O
C57BL6	-	1305	O
/	-	1311	O
J	-	1312	O
mice	-	1314	O
,	-	1318	O
while	-	1320	O
the	-	1326	O
alpha	-	1330	O
(	-	1335	O
1	-	1336	O
)	-	1337	O
antagonist	-	1339	O
prazosin	-	1350	B
and	-	1359	O
the	-	1363	O
alpha	-	1367	O
(	-	1372	O
2	-	1373	O
)	-	1374	O
antagonist	-	1376	O
yohimbine	-	1387	B
had	-	1397	O
no	-	1401	O
effect	-	1404	O
.	-	1410	O

CONCLUSIONS	18083142	1412	O
:	-	1423	O

These	18083142	1425	O
results	-	1431	O
indicate	-	1439	O
that	-	1448	O
noradrenergic	-	1453	O
signaling	-	1467	O
via	-	1477	O
beta	-	1481	O
-	-	1485	O
adrenergic	-	1486	O
receptors	-	1497	O
is	-	1507	O
required	-	1510	O
for	-	1519	O
cocaine	-	1523	B
-	-	1530	O
induced	-	1531	O
anxiety	-	1539	O
in	-	1547	O
mice	-	1550	O
.	-	1554	O

Clonidine	18182964	0	B
for	-	10	O
attention	-	14	O
-	-	23	O
deficit	-	24	O
/	-	31	O
hyperactivity	-	32	O
disorder	-	46	O
:	-	54	O
II	-	56	O
.	-	58	O

ECG	18182964	60	O
changes	-	64	O
and	-	72	O
adverse	-	76	O
events	-	84	O
analysis	-	91	O
.	-	99	O

OBJECTIVE	18182964	101	O
:	-	110	O

To	18182964	112	O
examine	-	115	O
the	-	123	O
safety	-	127	O
and	-	134	O
tolerability	-	138	O
of	-	151	O
clonidine	-	154	B
used	-	164	O
alone	-	169	O
or	-	175	O
with	-	178	O
methylphenidate	-	183	B
in	-	199	O
children	-	202	O
with	-	211	O
attention	-	216	O
-	-	225	O
deficit	-	226	O
/	-	233	O
hyperactivity	-	234	O
disorder	-	248	O
(	-	257	O
ADHD	-	258	O
)	-	262	O
.	-	263	O

METHOD	18182964	265	O
:	-	271	O

In	18182964	273	O
a	-	276	O
16	-	278	O
-	-	280	O
week	-	281	O
multicenter	-	286	O
,	-	297	O
double	-	299	O
-	-	305	O
blind	-	306	O
trial	-	312	O
,	-	317	O
122	-	319	O
children	-	323	O
with	-	332	O
ADHD	-	337	O
were	-	342	O
randomly	-	347	O
assigned	-	356	O
to	-	365	O
clonidine	-	368	B
(	-	378	O
n	-	379	O
=	-	381	O
31	-	383	O
)	-	385	O
,	-	386	O
methylphenidate	-	388	B
(	-	404	O
n	-	405	O
=	-	407	O
29	-	409	O
)	-	411	O
,	-	412	O
clonidine	-	414	B
and	-	424	O
methylphenidate	-	428	B
(	-	444	O
n	-	445	O
=	-	447	O
32	-	449	O
)	-	451	O
,	-	452	O
or	-	454	O
placebo	-	457	O
(	-	465	O
n	-	466	O
=	-	468	O
30	-	470	O
)	-	472	O
.	-	473	O

Doses	18182964	475	O
were	-	481	O
flexibly	-	486	O
titrated	-	495	O
up	-	504	O
to	-	507	O
0	-	510	O
.	-	511	O
6	-	512	O
mg	-	514	O
/	-	516	O
day	-	517	O
for	-	521	O
clonidine	-	525	B
and	-	535	O
60	-	539	O
mg	-	542	O
/	-	544	O
day	-	545	O
for	-	549	O
methylphenidate	-	553	B
(	-	569	O
both	-	570	O
with	-	575	O
divided	-	580	O
dosing	-	588	O
)	-	594	O
.	-	595	O

Groups	18182964	597	O
were	-	604	O
compared	-	609	O
regarding	-	618	O
adverse	-	628	O
events	-	636	O
and	-	643	O
changes	-	647	O
from	-	655	O
baseline	-	660	O
to	-	669	O
week	-	672	O
16	-	677	O
in	-	680	O
electrocardiograms	-	683	O
and	-	702	O
vital	-	706	O
signs	-	712	O
.	-	717	O

RESULTS	18182964	719	O
:	-	726	O

There	18182964	728	O
were	-	734	O
more	-	739	O
incidents	-	744	O
of	-	754	O
bradycardia	-	757	O
in	-	769	O
subjects	-	772	O
treated	-	781	O
with	-	789	O
clonidine	-	794	B
compared	-	804	O
with	-	813	O
those	-	818	O
not	-	824	O
treated	-	828	O
with	-	836	O
clonidine	-	841	B
(	-	851	O
17	-	852	O
.	-	854	O
5	-	855	O
%	-	856	O
versus	-	858	O
3	-	865	O
.	-	866	O
4	-	867	O
%	-	868	O
;	-	869	O
p	-	871	O
=	-	873	O
.	-	874	O
02	-	875	O
)	-	877	O
,	-	878	O
but	-	880	O
no	-	884	O
other	-	887	O
significant	-	893	O
group	-	905	O
differences	-	911	O
regarding	-	923	O
electrocardiogram	-	933	O
and	-	951	O
other	-	955	O
cardiovascular	-	961	O
outcomes	-	976	O
.	-	984	O

There	18182964	986	O
were	-	992	O
no	-	997	O
suggestions	-	1000	O
of	-	1012	O
interactions	-	1015	O
between	-	1028	O
clonidine	-	1036	B
and	-	1046	O
methylphenidate	-	1050	B
regarding	-	1066	O
cardiovascular	-	1076	O
outcomes	-	1091	O
.	-	1099	O

Moderate	18182964	1101	O
or	-	1110	O
severe	-	1113	O
adverse	-	1120	O
events	-	1128	O
were	-	1135	O
more	-	1140	O
common	-	1145	O
in	-	1152	O
subjects	-	1155	O
on	-	1164	O
clonidine	-	1167	B
(	-	1177	O
79	-	1178	O
.	-	1180	O
4	-	1181	O
%	-	1182	O
versus	-	1184	O
49	-	1191	O
.	-	1193	O
2	-	1194	O
%	-	1195	O
;	-	1196	O
p	-	1198	O
=	-	1200	O
.	-	1201	O
0006	-	1202	O
)	-	1206	O
but	-	1208	O
not	-	1212	O
associated	-	1216	O
with	-	1227	O
higher	-	1232	O
rates	-	1239	O
of	-	1245	O
early	-	1248	O
study	-	1254	O
withdrawal	-	1260	O
.	-	1270	O

Drowsiness	18182964	1272	O
was	-	1283	O
common	-	1287	O
on	-	1294	O
clonidine	-	1297	B
,	-	1306	O
but	-	1308	O
generally	-	1312	O
resolved	-	1322	O
by	-	1331	O
6	-	1334	O
to	-	1336	O
8	-	1339	O
weeks	-	1341	O
.	-	1346	O

CONCLUSIONS	18182964	1348	O
:	-	1359	O

Clonidine	18182964	1361	B
,	-	1370	O
used	-	1372	O
alone	-	1377	O
or	-	1383	O
with	-	1386	O
methylphenidate	-	1391	B
,	-	1406	O
appears	-	1408	O
safe	-	1416	O
and	-	1421	O
well	-	1425	O
tolerated	-	1430	O
in	-	1440	O
childhood	-	1443	O
ADHD	-	1453	O
.	-	1457	O

Physicians	18182964	1459	O
prescribing	-	1470	O
clonidine	-	1482	B
should	-	1492	O
monitor	-	1499	O
for	-	1507	O
bradycardia	-	1511	O
and	-	1523	O
advise	-	1527	O
patients	-	1534	O
about	-	1543	O
the	-	1549	O
high	-	1553	O
likelihood	-	1558	O
of	-	1569	O
initial	-	1572	O
drowsiness	-	1580	O
.	-	1590	O

Thalidomide	18217897	0	B
has	-	12	O
limited	-	16	O
single	-	24	O
-	-	30	O
agent	-	31	O
activity	-	37	O
in	-	46	O
relapsed	-	49	O
or	-	58	O
refractory	-	61	O
indolent	-	72	O
non	-	81	O
-	-	84	O
Hodgkin	-	85	O
lymphomas	-	93	O
:	-	102	O
a	-	104	O
phase	-	106	O
II	-	112	O
trial	-	115	O
of	-	121	O
the	-	124	O
Cancer	-	128	O
and	-	135	O
Leukemia	-	139	O
Group	-	148	O
B	-	154	O
.	-	155	O
Thalidomide	-	157	B
is	-	169	O
an	-	172	O
immunomodulatory	-	175	O
agent	-	192	O
with	-	198	O
demonstrated	-	203	O
activity	-	216	O
in	-	225	O
multiple	-	228	O
myeloma	-	237	O
,	-	244	O
mantle	-	246	O
cell	-	253	O
lymphoma	-	258	O
and	-	267	O
lymphoplasmacytic	-	271	O
lymphoma	-	289	O
.	-	297	O

Its	18217897	299	O
activity	-	303	O
is	-	312	O
believed	-	315	O
to	-	324	O
be	-	327	O
due	-	330	O
modulation	-	334	O
of	-	345	O
the	-	348	O
tumour	-	352	O
milieu	-	359	O
,	-	365	O
including	-	367	O
downregulation	-	377	O
of	-	392	O
angiogenesis	-	395	O
and	-	408	O
inflammatory	-	412	O
cytokines	-	425	O
.	-	434	O

Between	18217897	436	O
July	-	444	O
2001	-	449	O
and	-	454	O
April	-	458	O
2004	-	464	O
,	-	468	O
24	-	470	O
patients	-	473	O
with	-	482	O
relapsed	-	487	O
/	-	495	O
refractory	-	496	O
indolent	-	507	O
lymphomas	-	516	O
received	-	526	O
thalidomide	-	535	B
200	-	547	O
mg	-	551	O
daily	-	554	O
with	-	560	O
escalation	-	565	O
by	-	576	O
100	-	579	O
mg	-	583	O
daily	-	586	O
every	-	592	O
1	-	598	O
-	-	599	O
2	-	600	O
weeks	-	602	O
as	-	608	O
tolerated	-	611	O
,	-	620	O
up	-	622	O
to	-	625	O
a	-	628	O
maximum	-	630	O
of	-	638	O
800	-	641	O
mg	-	645	O
daily	-	648	O
.	-	653	O

Patients	18217897	655	O
had	-	664	O
received	-	668	O
a	-	677	O
median	-	679	O
of	-	686	O
2	-	689	O
(	-	691	O
range	-	692	O
,	-	697	O
1	-	699	O
-	-	700	O
4	-	701	O
)	-	702	O
prior	-	704	O
regimens	-	710	O
.	-	718	O

Of	18217897	720	O
24	-	723	O
evaluable	-	726	O
patients	-	736	O
,	-	744	O
two	-	746	O
achieved	-	750	O
a	-	759	O
complete	-	761	O
remission	-	770	O
and	-	780	O
one	-	784	O
achieved	-	788	O
a	-	797	O
partial	-	799	O
remission	-	807	O
for	-	817	O
an	-	821	O
overall	-	824	O
response	-	832	O
rate	-	841	O
of	-	846	O
12	-	849	O
.	-	851	O
5	-	852	O
%	-	853	O
(	-	855	O
95	-	856	O
%	-	858	O
confidence	-	860	O
interval	-	871	O
:	-	879	O
2	-	881	O
.	-	882	O
6	-	883	O
-	-	884	O
32	-	885	O
.	-	887	O
4	-	888	O
%	-	889	O
)	-	890	O
.	-	891	O

Eleven	18217897	893	O
patients	-	900	O
progressed	-	909	O
during	-	920	O
therapy	-	927	O
.	-	934	O

Grade	18217897	936	O
3	-	942	O
-	-	943	O
4	-	944	O
adverse	-	946	O
effects	-	954	O
included	-	962	O
myelosuppression	-	971	O
,	-	987	O
fatigue	-	989	O
,	-	996	O
somnolence	-	998	O
/	-	1008	O
depressed	-	1009	O
mood	-	1019	O
,	-	1023	O
neuropathy	-	1025	O
and	-	1036	O
dyspnea	-	1040	O
.	-	1047	O

Of	18217897	1049	O
concern	-	1052	O
was	-	1060	O
the	-	1064	O
occurrence	-	1068	O
of	-	1079	O
four	-	1082	O
thromboembolic	-	1087	O
events	-	1102	O
.	-	1108	O

Our	18217897	1110	O
results	-	1114	O
failed	-	1122	O
to	-	1129	O
demonstrate	-	1132	O
an	-	1144	O
important	-	1147	O
response	-	1157	O
rate	-	1166	O
to	-	1171	O
single	-	1174	O
agent	-	1181	O
thalidomide	-	1187	B
in	-	1199	O
indolent	-	1202	O
lymphomas	-	1211	O
and	-	1221	O
contrast	-	1225	O
with	-	1234	O
the	-	1239	O
higher	-	1243	O
activity	-	1250	O
level	-	1259	O
reported	-	1265	O
with	-	1274	O
the	-	1279	O
second	-	1283	O
generation	-	1290	O
immunomodulatory	-	1301	O
agent	-	1318	O
,	-	1323	O
lenalidomide	-	1325	B
.	-	1337	O

Intracavernous	18996674	0	O
epinephrine	-	15	B
:	-	26	O
a	-	28	O
minimally	-	30	O
invasive	-	40	O
treatment	-	49	O
for	-	59	O
priapism	-	63	O
in	-	72	O
the	-	75	O
emergency	-	79	O
department	-	89	O
.	-	99	O

Priapism	18996674	101	O
is	-	110	O
the	-	113	O
prolonged	-	117	O
erection	-	127	O
of	-	136	O
the	-	139	O
penis	-	143	O
in	-	149	O
the	-	152	O
absence	-	156	O
of	-	164	O
sexual	-	167	O
arousal	-	174	O
.	-	181	O

A	18996674	183	O
45	-	185	O
-	-	187	O
year	-	188	O
-	-	192	O
old	-	193	O
man	-	197	O
,	-	200	O
an	-	202	O
admitted	-	205	O
frequent	-	214	O
cocaine	-	223	B
user	-	231	O
,	-	235	O
presented	-	237	O
to	-	247	O
the	-	250	O
Emergency	-	254	O
Department	-	264	O
(	-	275	O
ED	-	276	O
)	-	278	O
on	-	280	O
two	-	283	O
separate	-	287	O
occasions	-	296	O
with	-	306	O
a	-	311	O
history	-	313	O
of	-	321	O
priapism	-	324	O
after	-	333	O
cocaine	-	339	B
use	-	347	O
.	-	350	O

The	18996674	352	O
management	-	356	O
options	-	367	O
in	-	375	O
the	-	378	O
ED	-	382	O
,	-	384	O
as	-	386	O
exemplified	-	389	O
by	-	401	O
four	-	404	O
individual	-	409	O
case	-	420	O
reports	-	425	O
,	-	432	O
in	-	434	O
particular	-	437	O
the	-	448	O
use	-	452	O
of	-	456	O
a	-	459	O
minimally	-	461	O
invasive	-	471	O
method	-	480	O
of	-	487	O
intracorporal	-	490	O
epinephrine	-	504	B
instillation	-	516	O
,	-	528	O
are	-	530	O
discussed	-	534	O
.	-	543	O

Effect	19058010	0	O
of	-	7	O
green	-	10	B
tea	-	16	I
and	-	20	O
vitamin	-	24	B
E	-	32	I
combination	-	34	O
in	-	46	O
isoproterenol	-	49	B
induced	-	63	O
myocardial	-	71	O
infarction	-	82	O
in	-	93	O
rats	-	96	O
.	-	100	O

The	19058010	102	O
present	-	106	O
study	-	114	O
was	-	120	O
aimed	-	124	O
to	-	130	O
investigate	-	133	O
the	-	145	O
combined	-	149	O
effects	-	158	O
of	-	166	O
green	-	169	B
tea	-	175	I
and	-	179	O
vitamin	-	183	B
E	-	191	I
on	-	193	O
heart	-	196	O
weight	-	202	O
,	-	208	O
body	-	210	O
weight	-	215	O
,	-	221	O
serum	-	223	O
marker	-	229	O
enzymes	-	236	O
,	-	243	O
lipid	-	245	O
peroxidation	-	251	O
,	-	263	O
endogenous	-	265	O
antioxidants	-	276	O
and	-	289	O
membrane	-	293	O
bound	-	302	O
ATPases	-	308	O
in	-	316	O
isoproterenol	-	319	B
(	-	333	O
ISO	-	334	B
)	-	337	O
-	-	338	O
induced	-	339	O
myocardial	-	347	O
infarction	-	358	O
in	-	369	O
rats	-	372	O
.	-	376	O

Adult	19058010	378	O
male	-	384	O
albino	-	389	O
rats	-	396	O
,	-	400	O
treated	-	402	O
with	-	410	O
ISO	-	415	B
(	-	419	O
200	-	420	O
mg	-	424	O
/	-	426	O
kg	-	427	O
,	-	429	O
s	-	431	O
.	-	432	O
c	-	433	O
.	-	434	O
)	-	435	O
for	-	437	O
2	-	441	O
days	-	443	O
at	-	448	O
an	-	451	O
interval	-	454	O
of	-	463	O
24	-	466	O
h	-	469	O
caused	-	471	O
a	-	478	O
significant	-	480	O
(	-	492	O
P	-	493	O
<	-	494	O
0	-	495	O
.	-	496	O
05	-	497	O
)	-	499	O
elevation	-	501	O
of	-	511	O
heart	-	514	O
weight	-	520	O
,	-	526	O
serum	-	528	O
marker	-	534	O
enzymes	-	541	O
,	-	548	O
lipid	-	550	O
peroxidation	-	556	O
and	-	569	O
Ca	-	573	B
+	-	575	O
2	-	576	O
ATPase	-	578	O
level	-	585	O
whereas	-	591	O
there	-	599	O
was	-	605	O
a	-	609	O
significant	-	611	O
(	-	623	O
P	-	624	O
<	-	625	O
0	-	626	O
.	-	627	O
05	-	628	O
)	-	630	O
decrease	-	632	O
in	-	641	O
body	-	644	O
weight	-	649	O
,	-	655	O
endogenous	-	657	O
antioxidants	-	668	O
,	-	680	O
Na	-	682	B
+	-	684	O
/	-	685	O
K	-	687	B
+	-	688	O
ATPase	-	690	O
and	-	697	O
Mg	-	701	B
+	-	703	O
2	-	704	O
ATPase	-	706	O
levels	-	713	O
.	-	719	O

Administration	19058010	721	O
of	-	736	O
green	-	739	B
tea	-	745	I
(	-	749	O
100	-	750	O
mg	-	754	O
/	-	756	O
kg	-	757	O
/	-	759	O
day	-	760	O
,	-	763	O
p	-	765	O
.	-	766	O
o	-	767	O
.	-	768	O
)	-	769	O
and	-	771	O
vitamin	-	775	B
E	-	783	I
(	-	785	O
100	-	786	O
mg	-	790	O
/	-	792	O
kg	-	793	O
/	-	795	O
day	-	796	O
,	-	799	O
p	-	801	O
.	-	802	O
o	-	803	O
.	-	804	O
)	-	805	O
together	-	807	O
for	-	816	O
30	-	820	O
consecutive	-	823	O
days	-	835	O
and	-	840	O
challenged	-	844	O
with	-	855	O
ISO	-	860	B
on	-	864	O
the	-	867	O
day	-	871	O
29th	-	875	O
and	-	880	O
30th	-	884	O
,	-	888	O
showed	-	890	O
a	-	897	O
significant	-	899	O
(	-	911	O
P	-	912	O
<	-	913	O
0	-	914	O
.	-	915	O
05	-	916	O
)	-	918	O
decrease	-	920	O
in	-	929	O
heart	-	932	O
weight	-	938	O
,	-	944	O
serum	-	946	O
marker	-	952	O
enzymes	-	959	O
,	-	966	O
lipid	-	968	O
peroxidation	-	974	O
,	-	986	O
Ca	-	988	B
+	-	990	O
2	-	991	O
ATPase	-	993	O
and	-	1000	O
a	-	1004	O
significant	-	1006	O
increase	-	1018	O
in	-	1027	O
the	-	1030	O
body	-	1034	O
weight	-	1039	O
,	-	1045	O
endogenous	-	1047	O
antioxidants	-	1058	O
,	-	1070	O
Na	-	1072	B
+	-	1074	O
/	-	1075	O
K	-	1076	B
+	-	1077	O
ATPase	-	1079	O
and	-	1086	O
Mg	-	1090	B
+	-	1092	O
2	-	1093	O
ATPase	-	1095	O
when	-	1102	O
compared	-	1107	O
with	-	1116	O
ISO	-	1121	B
treated	-	1125	O
group	-	1133	O
and	-	1139	O
green	-	1143	B
tea	-	1149	I
or	-	1153	O
vitamin	-	1156	B
E	-	1164	I
alone	-	1166	O
treated	-	1172	O
groups	-	1180	O
.	-	1186	O

These	19058010	1188	O
findings	-	1194	O
indicate	-	1203	O
the	-	1212	O
synergistic	-	1216	O
protective	-	1228	O
effect	-	1239	O
of	-	1246	O
green	-	1249	B
tea	-	1255	I
and	-	1259	O
vitamin	-	1263	B
E	-	1271	I
during	-	1273	O
ISO	-	1280	B
induced	-	1284	O
myocardial	-	1292	O
infarction	-	1303	O
in	-	1314	O
rats	-	1317	O
.	-	1321	O

Development	19581773	0	O
of	-	12	O
ocular	-	15	O
myasthenia	-	22	O
during	-	33	O
pegylated	-	40	B
interferon	-	50	I
and	-	61	O
ribavirin	-	65	B
treatment	-	75	O
for	-	85	O
chronic	-	89	O
hepatitis	-	97	O
C	-	107	O
.	-	108	O
A	-	110	O
63	-	112	O
-	-	114	O
year	-	115	O
-	-	119	O
old	-	120	O
male	-	124	O
experienced	-	129	O
sudden	-	141	O
diplopia	-	148	O
after	-	157	O
9	-	163	O
weeks	-	165	O
of	-	171	O
administration	-	174	O
of	-	189	O
pegylated	-	192	B
interferon	-	202	I
(	-	213	I
IFN	-	214	I
)	-	217	I
alpha	-	219	I
-	-	224	I
2b	-	225	I
and	-	228	O
ribavirin	-	232	B
for	-	242	O
chronic	-	246	O
hepatitis	-	254	O
C	-	264	O
(	-	266	O
CHC	-	267	O
)	-	270	O
.	-	271	O

Ophthalmologic	19581773	273	O
examinations	-	288	O
showed	-	301	O
ptosis	-	308	O
on	-	315	O
the	-	318	O
right	-	322	O
upper	-	328	O
lid	-	334	O
and	-	338	O
restricted	-	342	O
right	-	353	O
eye	-	359	O
movement	-	363	O
without	-	372	O
any	-	380	O
other	-	384	O
neurological	-	390	O
signs	-	403	O
.	-	408	O

A	19581773	410	O
brain	-	412	O
imaging	-	418	O
study	-	426	O
and	-	432	O
repetitive	-	436	O
nerve	-	447	O
stimulation	-	453	O
test	-	465	O
indicated	-	470	O
no	-	480	O
abnormality	-	483	O
.	-	494	O

The	19581773	496	O
acetylcholine	-	500	B
receptor	-	514	O
antibody	-	523	O
titer	-	532	O
and	-	538	O
response	-	542	O
to	-	551	O
acetylcholinesterase	-	554	O
inhibitors	-	575	O
were	-	586	O
negative	-	591	O
,	-	599	O
and	-	601	O
the	-	605	O
results	-	609	O
of	-	617	O
thyroid	-	620	O
function	-	628	O
tests	-	637	O
were	-	643	O
normal	-	648	O
.	-	654	O

The	19581773	656	O
patient	-	660	O
's	-	667	O
ophthalmological	-	670	O
symptoms	-	687	O
improved	-	696	O
rapidly	-	705	O
3	-	713	O
weeks	-	715	O
after	-	721	O
discontinuation	-	727	O
of	-	743	O
pegylated	-	746	B
IFN	-	756	I
alpha	-	760	I
-	-	765	I
2b	-	766	I
and	-	769	O
ribavirin	-	773	B
.	-	782	O

The	19581773	784	O
ocular	-	788	O
myasthenia	-	795	O
associated	-	806	O
with	-	817	O
combination	-	822	O
therapy	-	834	O
of	-	842	O
pegylated	-	845	B
IFN	-	855	I
alpha	-	859	I
-	-	864	I
2b	-	865	I
and	-	868	O
ribavirin	-	872	B
for	-	882	O
CHC	-	886	O
is	-	890	O
very	-	893	O
rarely	-	898	O
reported	-	905	O
;	-	913	O
therefore	-	915	O
,	-	924	O
we	-	926	O
present	-	929	O
this	-	937	O
case	-	942	O
with	-	947	O
a	-	952	O
review	-	954	O
of	-	961	O
the	-	964	O
various	-	968	O
eye	-	976	O
complications	-	980	O
of	-	994	O
IFN	-	997	B
therapy	-	1001	O
.	-	1008	O

The	19759529	0	O
glycine	-	4	B
transporter	-	12	O
-	-	23	O
1	-	24	O
inhibitor	-	26	O
SSR103800	-	36	B
displays	-	46	O
a	-	55	O
selective	-	57	O
and	-	67	O
specific	-	71	O
antipsychotic	-	80	O
-	-	93	O
like	-	94	O
profile	-	99	O
in	-	107	O
normal	-	110	O
and	-	117	O
transgenic	-	121	O
mice	-	132	O
.	-	136	O

Schizophrenia	19759529	138	O
has	-	152	O
been	-	156	O
initially	-	161	O
associated	-	171	O
with	-	182	O
dysfunction	-	187	O
in	-	199	O
dopamine	-	202	B
neurotransmission	-	211	O
.	-	228	O

However	19759529	230	O
,	-	237	O
the	-	239	O
observation	-	243	O
that	-	255	O
antagonists	-	260	O
of	-	272	O
the	-	275	O
glutamate	-	279	B
N	-	289	B
-	-	290	I
methyl	-	291	I
-	-	297	I
D	-	298	I
-	-	299	I
aspartate	-	300	I
(	-	310	O
NMDA	-	311	B
)	-	315	O
receptor	-	317	O
produce	-	326	O
schizophrenic	-	334	O
-	-	347	O
like	-	348	O
symptoms	-	353	O
in	-	362	O
humans	-	365	O
has	-	372	O
led	-	376	O
to	-	380	O
the	-	383	O
idea	-	387	O
of	-	392	O
a	-	395	O
dysfunctioning	-	397	O
of	-	412	O
the	-	415	O
glutamatergic	-	419	O
system	-	433	O
via	-	440	O
its	-	444	O
NMDA	-	448	B
receptor	-	453	O
.	-	461	O

As	19759529	463	O
a	-	466	O
result	-	468	O
,	-	474	O
there	-	476	O
is	-	482	O
a	-	485	O
growing	-	487	O
interest	-	495	O
in	-	504	O
the	-	507	O
development	-	511	O
of	-	523	O
pharmacological	-	526	O
agents	-	542	O
with	-	549	O
potential	-	554	O
antipsychotic	-	564	O
properties	-	578	O
that	-	589	O
enhance	-	594	O
the	-	602	O
activity	-	606	O
of	-	615	O
the	-	618	O
glutamatergic	-	622	O
system	-	636	O
via	-	643	O
a	-	647	O
modulation	-	649	O
of	-	660	O
the	-	663	O
NMDA	-	667	B
receptor	-	672	O
.	-	680	O

Among	19759529	682	O
them	-	688	O
are	-	693	O
glycine	-	697	B
transporter	-	705	O
-	-	716	O
1	-	717	O

(	19759529	719	O
GlyT1	-	720	O
)	-	725	O
inhibitors	-	727	O
such	-	738	O
as	-	743	O
SSR103800	-	746	B
,	-	755	O
which	-	757	O
indirectly	-	763	O
enhance	-	774	O
NMDA	-	782	B
receptor	-	787	O
function	-	796	O
by	-	805	O
increasing	-	808	O
the	-	819	O
glycine	-	823	B
(	-	831	O
a	-	832	O
co	-	834	O
-	-	836	O
agonist	-	837	O
for	-	845	O
the	-	849	O
NMDA	-	853	B
receptor	-	858	O
)	-	866	O
levels	-	868	O
in	-	875	O
the	-	878	O
synapse	-	882	O
.	-	889	O

This	19759529	891	O
study	-	896	O
aimed	-	902	O
at	-	908	O
investigating	-	911	O
the	-	925	O
potential	-	929	O
antipsychotic	-	939	O
-	-	952	O
like	-	953	O
properties	-	958	O
of	-	969	O
SSR103800	-	972	B
,	-	981	O
with	-	983	O
a	-	988	O
particular	-	990	O
focus	-	1001	O
on	-	1007	O
models	-	1010	O
of	-	1017	O
hyperactivity	-	1020	O
,	-	1033	O
involving	-	1035	O
either	-	1045	O
drug	-	1052	O
challenge	-	1057	O
(	-	1067	O
ie	-	1068	O
,	-	1070	O
amphetamine	-	1072	B
and	-	1084	O
MK	-	1088	B
-	-	1090	I
801	-	1091	I
)	-	1094	O
or	-	1096	O
transgenic	-	1099	O
mice	-	1110	O
(	-	1115	O
ie	-	1116	O
,	-	1118	O
NMDA	-	1120	B
Nr1	-	1125	O
(	-	1128	O
neo	-	1129	O
-	-	1132	O
/	-	1133	O
-	-	1134	O
)	-	1135	O
and	-	1137	O
DAT	-	1141	O
(	-	1144	O
-	-	1145	O
/	-	1146	O
-	-	1147	O
)	-	1148	O
)	-	1149	O
.	-	1150	O

Results	19759529	1152	O
showed	-	1160	O
that	-	1167	O
SSR103800	-	1172	B
(	-	1182	O
10	-	1183	O
-	-	1185	O
30	-	1186	O
mg	-	1189	O
/	-	1191	O
kg	-	1192	O
p	-	1195	O
.	-	1196	O
o	-	1197	O
.	-	1198	O
)	-	1199	O

blocked	19759529	1201	O
hyperactivity	-	1209	O
induced	-	1223	O
by	-	1231	O
the	-	1234	O
non	-	1238	O
-	-	1241	O
competitive	-	1242	O
NMDA	-	1254	B
receptor	-	1259	O
antagonist	-	1268	O
,	-	1278	O
MK	-	1280	B
-	-	1282	I
801	-	1283	I
and	-	1287	O
partially	-	1291	O
reversed	-	1301	O
spontaneous	-	1310	O
hyperactivity	-	1322	O
of	-	1336	O
NMDA	-	1339	B
Nr1	-	1344	O
(	-	1347	O
neo	-	1348	O
-	-	1351	O
/	-	1352	O
-	-	1353	O
)	-	1354	O
mice	-	1356	O
.	-	1360	O

In	19759529	1362	O
contrast	-	1365	O
,	-	1373	O
SSR103800	-	1375	B
failed	-	1385	O
to	-	1392	O
affect	-	1395	O
hyperactivity	-	1402	O
induced	-	1416	O
by	-	1424	O
amphetamine	-	1427	B
or	-	1439	O
naturally	-	1442	O
observed	-	1452	O
in	-	1461	O
dopamine	-	1464	B
transporter	-	1473	O
(	-	1485	O
DAT	-	1486	O
(	-	1489	O
-	-	1490	O
/	-	1491	O
-	-	1492	O
)	-	1493	O
)	-	1494	O
knockout	-	1496	O
mice	-	1505	O

(	19759529	1510	O
10	-	1511	O
-	-	1513	O
30	-	1514	O
mg	-	1517	O
/	-	1519	O
kg	-	1520	O
p	-	1523	O
.	-	1524	O
o	-	1525	O
.	-	1526	O
)	-	1527	O
.	-	1528	O

Importantly	19759529	1530	O
,	-	1541	O
both	-	1543	O
classical	-	1548	O
(	-	1558	O
haloperidol	-	1559	B
)	-	1570	O
and	-	1572	O
atypical	-	1576	O
(	-	1585	O
olanzapine	-	1586	B
,	-	1596	O
clozapine	-	1598	B
and	-	1608	O
aripiprazole	-	1612	B
)	-	1624	O
antipsychotics	-	1626	O
were	-	1641	O
effective	-	1646	O
in	-	1656	O
all	-	1659	O
these	-	1663	O
models	-	1669	O
of	-	1676	O
hyperactivity	-	1679	O
.	-	1692	O

However	19759529	1694	O
,	-	1701	O
unlike	-	1703	O
these	-	1710	O
latter	-	1716	O
,	-	1722	O
SSR103800	-	1724	B
did	-	1734	O
not	-	1738	O
produce	-	1742	O
catalepsy	-	1750	O
(	-	1760	O
retention	-	1761	O
on	-	1771	O
the	-	1774	O
bar	-	1778	O
test	-	1782	O
)	-	1786	O
up	-	1788	O
to	-	1791	O
30	-	1794	O
mg	-	1797	O
/	-	1799	O
kg	-	1800	O
p	-	1803	O
.	-	1804	O
o	-	1805	O
.	-	1806	O

Together	19759529	1808	O
these	-	1817	O
findings	-	1823	O
show	-	1832	O
that	-	1837	O
the	-	1842	O
GlyT1	-	1846	O
inhibitor	-	1852	O
,	-	1861	O
SSR103800	-	1863	B
,	-	1872	O
produces	-	1874	O
antipsychotic	-	1883	O
-	-	1896	O
like	-	1897	O
effects	-	1902	O
,	-	1909	O
which	-	1911	O
differ	-	1917	O
from	-	1924	O
those	-	1929	O
observed	-	1935	O
with	-	1944	O
compounds	-	1949	O
primarily	-	1959	O
targeting	-	1969	O
the	-	1979	O
dopaminergic	-	1983	O
system	-	1996	O
,	-	2002	O
and	-	2004	O
has	-	2008	O
a	-	2012	O
reduced	-	2014	O
side	-	2022	O
-	-	2026	O
effect	-	2027	O
potential	-	2034	O
as	-	2044	O
compared	-	2047	O
with	-	2056	O
these	-	2061	O
latter	-	2067	O
drugs	-	2074	O
.	-	2079	O

Phenylephrine	19957053	0	B
but	-	14	O
not	-	18	O
ephedrine	-	22	B
reduces	-	32	O
frontal	-	40	O
lobe	-	48	O
oxygenation	-	53	O
following	-	65	O
anesthesia	-	75	O
-	-	85	O
induced	-	86	O
hypotension	-	94	O
.	-	105	O

BACKGROUND	19957053	107	O
:	-	117	O
Vasopressor	-	119	O
agents	-	131	O
are	-	138	O
used	-	142	O
to	-	147	O
correct	-	150	O
anesthesia	-	158	O
-	-	168	O
induced	-	169	O
hypotension	-	177	O
.	-	188	O

We	19957053	190	O
describe	-	193	O
the	-	202	O
effect	-	206	O
of	-	213	O
phenylephrine	-	216	B
and	-	230	O
ephedrine	-	234	B
on	-	244	O
frontal	-	247	O
lobe	-	255	O
oxygenation	-	260	O
(	-	272	O
S	-	273	O
(	-	274	O
c	-	275	O
)	-	276	O
O	-	277	O
(	-	278	O
2	-	279	O
)	-	280	O
)	-	281	O
following	-	283	O
anesthesia	-	293	O
-	-	303	O
induced	-	304	O
hypotension	-	312	O
.	-	323	O

METHODS	19957053	325	O
:	-	332	O

Following	19957053	334	O
induction	-	344	O
of	-	354	O
anesthesia	-	357	O
by	-	368	O
fentanyl	-	371	B
(	-	380	O
0	-	381	O
.	-	382	O
15	-	383	O
mg	-	386	O
kg	-	389	O
(	-	391	O
-	-	392	O
1	-	393	O
)	-	394	O
)	-	395	O
and	-	397	O
propofol	-	401	B
(	-	410	O
2	-	411	O
.	-	412	O
0	-	413	O
mg	-	415	O
kg	-	418	O
(	-	420	O
-	-	421	O
1	-	422	O
)	-	423	O
)	-	424	O
,	-	425	O
13	-	427	O
patients	-	430	O
received	-	439	O
phenylephrine	-	448	B
(	-	462	O
0	-	463	O
.	-	464	O
1	-	465	O
mg	-	467	O
iv	-	470	O
)	-	472	O
and	-	474	O
12	-	478	O
patients	-	481	O
received	-	490	O
ephedrine	-	499	B
(	-	509	O
10	-	510	O
mg	-	513	O
iv	-	516	O
)	-	518	O
to	-	520	O
restore	-	523	O
mean	-	531	O
arterial	-	536	O
pressure	-	545	O
(	-	554	O
MAP	-	555	O
)	-	558	O
.	-	559	O

Heart	19957053	561	O
rate	-	567	O
(	-	572	O
HR	-	573	O
)	-	575	O
,	-	576	O
MAP	-	578	O
,	-	581	O
stroke	-	583	O
volume	-	590	O
(	-	597	O
SV	-	598	O
)	-	600	O
,	-	601	O
cardiac	-	603	O
output	-	611	O
(	-	618	O
CO	-	619	O
)	-	621	O
,	-	622	O
and	-	624	O
frontal	-	628	O
lobe	-	636	O
oxygenation	-	641	O
(	-	653	O
S	-	654	O
(	-	655	O
c	-	656	O
)	-	657	O
O	-	658	O
(	-	659	O
2	-	660	O
)	-	661	O
)	-	662	O
were	-	664	O
registered	-	669	O
.	-	679	O

RESULTS	19957053	681	O
:	-	688	O

Induction	19957053	690	O
of	-	700	O
anesthesia	-	703	O
was	-	714	O
followed	-	718	O
by	-	727	O
a	-	730	O
decrease	-	732	O
in	-	741	O
MAP	-	744	O
,	-	747	O
HR	-	749	O
,	-	751	O
SV	-	753	O
,	-	755	O
and	-	757	O
CO	-	761	O
concomitant	-	764	O
with	-	776	O
an	-	781	O
elevation	-	784	O
in	-	794	O
S	-	797	O
(	-	798	O
c	-	799	O
)	-	800	O
O	-	801	O
(	-	802	O
2	-	803	O
)	-	804	O
.	-	805	O

After	19957053	807	O
administration	-	813	O
of	-	828	O
phenylephrine	-	831	B
,	-	844	O
MAP	-	846	O
increased	-	850	O
(	-	860	O
51	-	861	O
+	-	864	O
/	-	865	O
-	-	866	O

12	19957053	868	O
to	-	871	O
81	-	874	O
+	-	877	O
/	-	878	O
-	-	879	O

13	19957053	881	O
mmHg	-	884	O
;	-	888	O
P	-	890	O
<	-	892	O
0	-	894	O
.	-	895	O
001	-	896	O
;	-	899	O
mean	-	901	O
+	-	906	O
/	-	907	O
-	-	908	O

SD	19957053	910	O
)	-	912	O
.	-	913	O

However	19957053	915	O
,	-	922	O
a	-	924	O
14	-	926	O
%	-	928	O
(	-	930	O
from	-	931	O
70	-	936	O
+	-	939	O
/	-	940	O
-	-	941	O

8	19957053	943	O
%	-	944	O
to	-	946	O
60	-	949	O
+	-	952	O
/	-	953	O
-	-	954	O

7	19957053	956	O
%	-	957	O
)	-	958	O
reduction	-	960	O
in	-	970	O
S	-	973	O
(	-	974	O
c	-	975	O
)	-	976	O
O	-	977	O
(	-	978	O
2	-	979	O
)	-	980	O

(	19957053	982	O
P	-	983	O
<	-	985	O
0	-	987	O
.	-	988	O
05	-	989	O
)	-	991	O
followed	-	993	O
with	-	1002	O
no	-	1007	O
change	-	1010	O
in	-	1017	O
CO	-	1020	O
(	-	1023	O
3	-	1024	O
.	-	1025	O
7	-	1026	O
+	-	1028	O
/	-	1029	O
-	-	1030	O

1	19957053	1032	O
.	-	1033	O
1	-	1034	O
to	-	1036	O
3	-	1039	O
.	-	1040	O
4	-	1041	O
+	-	1043	O
/	-	1044	O
-	-	1045	O

0	19957053	1047	O
.	-	1048	O
9	-	1049	O
l	-	1051	O
min	-	1053	O
(	-	1056	O
-	-	1057	O
1	-	1058	O
)	-	1059	O
)	-	1060	O
.	-	1061	O

The	19957053	1063	O
administration	-	1067	O
of	-	1082	O
ephedrine	-	1085	B
led	-	1095	O
to	-	1099	O
a	-	1102	O
similar	-	1104	O
increase	-	1112	O
in	-	1121	O
MAP	-	1124	O
(	-	1128	O
53	-	1129	O
+	-	1132	O
/	-	1133	O
-	-	1134	O

9	19957053	1136	O
to	-	1138	O
79	-	1141	O
+	-	1144	O
/	-	1145	O
-	-	1146	O

8	19957053	1148	O
mmHg	-	1150	O
;	-	1154	O
P	-	1156	O
<	-	1158	O
0	-	1160	O
.	-	1161	O
001	-	1162	O
)	-	1165	O
,	-	1166	O
restored	-	1168	O
CO	-	1177	O
(	-	1180	O
3	-	1181	O
.	-	1182	O
2	-	1183	O
+	-	1185	O
/	-	1186	O
-	-	1187	O

1	19957053	1189	O
.	-	1190	O
2	-	1191	O
to	-	1193	O
5	-	1196	O
.	-	1197	O
0	-	1198	O
+	-	1200	O
/	-	1201	O
-	-	1202	O

1	19957053	1204	O
.	-	1205	O
3	-	1206	O
l	-	1208	O
min	-	1210	O
(	-	1213	O
-	-	1214	O
1	-	1215	O
)	-	1216	O
)	-	1217	O
,	-	1218	O
and	-	1220	O
preserved	-	1224	O
S	-	1234	O
(	-	1235	O
c	-	1236	O
)	-	1237	O
O	-	1238	O
(	-	1239	O
2	-	1240	O
)	-	1241	O
.	-	1242	O

CONCLUSIONS	19957053	1244	O
:	-	1255	O

The	19957053	1257	O
utilization	-	1261	O
of	-	1273	O
phenylephrine	-	1276	B
to	-	1290	O
correct	-	1293	O
hypotension	-	1301	O
induced	-	1313	O
by	-	1321	O
anesthesia	-	1324	O
has	-	1335	O
a	-	1339	O
negative	-	1341	O
impact	-	1350	O
on	-	1357	O
S	-	1360	O
(	-	1361	O
c	-	1362	O
)	-	1363	O
O	-	1364	O
(	-	1365	O
2	-	1366	O
)	-	1367	O
while	-	1369	O
ephedrine	-	1375	B
maintains	-	1385	O
frontal	-	1395	O
lobe	-	1403	O
oxygenation	-	1408	O
potentially	-	1420	O
related	-	1432	O
to	-	1440	O
an	-	1443	O
increase	-	1446	O
in	-	1455	O
CO	-	1458	O
.	-	1460	O

A	20619828	0	O
novel	-	2	O
,	-	7	O
multiple	-	9	O
symptom	-	18	O
model	-	26	O
of	-	32	O
obsessive	-	35	O
-	-	44	O
compulsive	-	45	O
-	-	55	O
like	-	56	O
behaviors	-	61	O
in	-	71	O
animals	-	74	O
.	-	81	O

BACKGROUND	20619828	83	O
:	-	93	O

Current	20619828	95	O
animal	-	103	O
models	-	110	O
of	-	117	O
obsessive	-	120	O
-	-	129	O
compulsive	-	130	O
disorder	-	141	O
(	-	150	O
OCD	-	151	O
)	-	154	O
typically	-	156	O
involve	-	166	O
acute	-	174	O
,	-	179	O
drug	-	181	O
-	-	185	O
induced	-	186	O
symptom	-	194	O
provocation	-	202	O
or	-	214	O
a	-	217	O
genetic	-	219	O
association	-	227	O
with	-	239	O
stereotypies	-	244	O
or	-	257	O
anxiety	-	260	O
.	-	267	O

None	20619828	269	O
of	-	274	O
these	-	277	O
current	-	283	O
models	-	291	O
demonstrate	-	298	O
multiple	-	310	O
OCD	-	319	O
-	-	322	O
like	-	323	O
behaviors	-	328	O
.	-	337	O

METHODS	20619828	339	O
:	-	346	O

Neonatal	20619828	348	O
rats	-	357	O
were	-	362	O
treated	-	367	O
with	-	375	O
the	-	380	O
tricyclic	-	384	O
antidepressant	-	394	B
clomipramine	-	409	B
or	-	422	O
vehicle	-	425	O
between	-	433	O
days	-	441	O
9	-	446	O
and	-	448	O
16	-	452	O
twice	-	455	O
daily	-	461	O
and	-	467	O
behaviorally	-	471	O
tested	-	484	O
in	-	491	O
adulthood	-	494	O
.	-	503	O

RESULTS	20619828	505	O
:	-	512	O

Clomipramine	20619828	514	B
exposure	-	527	O
in	-	536	O
immature	-	539	O
rats	-	548	O
produced	-	553	O
significant	-	562	O
behavioral	-	574	O
and	-	585	O
biochemical	-	589	O
changes	-	601	O
that	-	609	O
include	-	614	O
enhanced	-	622	O
anxiety	-	631	O
(	-	639	O
elevated	-	640	O
plus	-	649	O
maze	-	654	O
and	-	659	O
marble	-	663	O
burying	-	670	O
)	-	677	O
,	-	678	O
behavioral	-	680	O
inflexibility	-	691	O
(	-	705	O
perseveration	-	706	O
in	-	720	O
the	-	723	O
spontaneous	-	727	O
alternation	-	739	O
task	-	751	O
and	-	756	O
impaired	-	760	O
reversal	-	769	O
learning	-	778	O
)	-	786	O
,	-	787	O
working	-	789	O
memory	-	797	O
impairment	-	804	O
(	-	815	O
e	-	816	O
.	-	817	O
g	-	818	O
.	-	819	O
,	-	820	O
win	-	822	O
-	-	825	O
shift	-	826	O
paradigm	-	832	O
)	-	840	O
,	-	841	O
hoarding	-	843	O
,	-	851	O
and	-	853	O
corticostriatal	-	857	O
dysfunction	-	873	O
.	-	884	O

Dopamine	20619828	886	B
D2	-	895	O
receptors	-	898	O
were	-	908	O
elevated	-	913	O
in	-	922	O
the	-	925	O
striatum	-	929	O
,	-	937	O
whereas	-	939	O
serotonin	-	947	B
2C	-	957	O
,	-	959	O
but	-	961	O
not	-	965	O
serotonin	-	969	B
1A	-	979	O
,	-	981	O
receptors	-	983	O
were	-	993	O
elevated	-	998	O
in	-	1007	O
the	-	1010	O
orbital	-	1014	O
frontal	-	1022	O
cortex	-	1030	O
.	-	1036	O

CONCLUSIONS	20619828	1038	O
:	-	1049	O

This	20619828	1051	O
is	-	1056	O
the	-	1059	O
first	-	1063	O
demonstration	-	1069	O
of	-	1083	O
multiple	-	1086	O
symptoms	-	1095	O
consistent	-	1104	O
with	-	1115	O
an	-	1120	O
OCD	-	1123	O
-	-	1126	O
like	-	1127	O
profile	-	1132	O
in	-	1140	O
animals	-	1143	O
.	-	1150	O

Moreover	20619828	1152	O
,	-	1160	O
these	-	1162	O
behaviors	-	1168	O
are	-	1178	O
accompanied	-	1182	O
by	-	1194	O
biochemical	-	1197	O
changes	-	1209	O
in	-	1217	O
brain	-	1220	O
regions	-	1226	O
previously	-	1234	O
identified	-	1245	O
as	-	1256	O
relevant	-	1259	O
to	-	1268	O
OCD	-	1271	O
.	-	1274	O

This	20619828	1276	O
novel	-	1281	O
model	-	1287	O
of	-	1293	O
OCD	-	1296	O
demonstrates	-	1300	O
that	-	1313	O
drug	-	1318	O
exposure	-	1323	O
during	-	1332	O
a	-	1339	O
sensitive	-	1341	O
period	-	1351	O
can	-	1358	O
program	-	1362	O
disease	-	1370	O
-	-	1377	O
like	-	1378	O
systems	-	1383	O
permanently	-	1391	O
,	-	1402	O
which	-	1404	O
could	-	1410	O
have	-	1416	O
implications	-	1421	O
for	-	1434	O
current	-	1438	O
and	-	1446	O
future	-	1450	O
therapeutic	-	1457	O
strategies	-	1469	O
for	-	1480	O
this	-	1484	O
and	-	1489	O
other	-	1493	O
psychiatric	-	1499	O
disorders	-	1511	O
.	-	1520	O

Late	891050	0	O
recovery	-	5	O
of	-	14	O
renal	-	17	O
function	-	23	O
in	-	32	O
a	-	35	O
woman	-	37	O
with	-	43	O
the	-	48	O
hemolytic	-	52	O
uremic	-	62	O
syndrome	-	69	O
.	-	77	O

A	891050	79	O
case	-	81	O
is	-	86	O
reported	-	89	O
of	-	98	O
the	-	101	O
hemolytic	-	105	O
uremic	-	115	O
syndrome	-	122	O
(	-	131	O
HUS	-	132	O
)	-	135	O
in	-	137	O
a	-	140	O
woman	-	142	O
taking	-	148	O
oral	-	155	B
contraceptives	-	160	I
.	-	174	O

She	891050	176	O
was	-	180	O
treated	-	184	O
with	-	192	O
heparin	-	197	B
,	-	204	O
dipyridamole	-	206	B
and	-	219	O
hemodialysis	-	223	O
;	-	235	O
and	-	237	O
after	-	241	O
more	-	247	O
than	-	252	O
three	-	257	O
months	-	263	O
,	-	269	O
her	-	271	O
urinary	-	275	O
output	-	283	O
rose	-	290	O
above	-	295	O
500	-	301	O
ml	-	305	O
;	-	307	O
and	-	309	O
six	-	313	O
months	-	317	O
after	-	324	O
the	-	330	O
onset	-	334	O
of	-	340	O
anuria	-	343	O
,	-	349	O
dialysis	-	351	O
treatment	-	360	O
was	-	370	O
stopped	-	374	O
.	-	381	O

This	891050	383	O
case	-	388	O
emphasizes	-	393	O
the	-	404	O
possibility	-	408	O
that	-	420	O
HUS	-	425	O
in	-	429	O
adults	-	432	O
is	-	439	O
not	-	442	O
invariably	-	446	O
irreversible	-	457	O
and	-	470	O
that	-	474	O
,	-	478	O
despite	-	480	O
prolonged	-	488	O
oliguria	-	498	O
,	-	506	O
recovery	-	508	O
of	-	517	O
renal	-	520	O
function	-	526	O
can	-	535	O
be	-	539	O
obtained	-	542	O
.	-	550	O

Therefore	891050	552	O
,	-	561	O
in	-	563	O
adult	-	566	O
patients	-	572	O
affected	-	581	O
by	-	590	O
HUS	-	593	O
,	-	596	O
dialysis	-	598	O
should	-	607	O
not	-	614	O
be	-	618	O
discontinued	-	621	O
prematurely	-	634	O
;	-	645	O
moreover	-	647	O
,	-	655	O
bilateral	-	657	O
nephrectomy	-	667	O
,	-	678	O
for	-	680	O
treatment	-	684	O
of	-	694	O
severe	-	697	O
hypertension	-	704	O
and	-	717	O
microangiopathic	-	721	O
hemolytic	-	738	O
anemia	-	748	O
,	-	754	O
should	-	756	O
be	-	763	O
performed	-	766	O
with	-	776	O
caution	-	781	O
.	-	788	O

Effects	983936	0	O
of	-	8	O
acetylsalicylic	-	11	B
acid	-	27	I
,	-	31	O
dipyridamole	-	33	B
,	-	45	O
and	-	47	O
hydrocortisone	-	51	B
on	-	66	O
epinephrine	-	69	B
-	-	80	O
induced	-	81	O
myocardial	-	89	O
injury	-	100	O
in	-	107	O
dogs	-	110	O
.	-	114	O

A	983936	116	O
reproducible	-	118	O
model	-	131	O
for	-	137	O
producing	-	141	O
diffuse	-	151	O
myocardial	-	159	O
injury	-	170	O
(	-	177	O
epinephrine	-	178	B
infusion	-	190	O
)	-	198	O
has	-	200	O
been	-	204	O
developed	-	209	O
to	-	219	O
study	-	222	O
the	-	228	O
cardioprotective	-	232	O
effects	-	249	O
of	-	257	O
agents	-	260	O
or	-	267	O
maneuvers	-	270	O
which	-	280	O
might	-	286	O
alter	-	292	O
the	-	298	O
evolution	-	302	O
of	-	312	O
acute	-	315	O
myocardial	-	321	O
infarction	-	332	O
.	-	342	O

Infusions	983936	344	O
of	-	354	O
epinephrine	-	357	B
(	-	369	O
4	-	370	O
mug	-	372	O
per	-	376	O
kilogram	-	380	O
per	-	389	O
minute	-	393	O
for	-	400	O
6	-	404	O
hours	-	406	O
)	-	411	O
increased	-	413	O
radiocalcium	-	423	B
uptakes	-	436	O
into	-	444	O
intact	-	449	O
myocardium	-	456	O
and	-	467	O
each	-	471	O
of	-	476	O
its	-	479	O
subcellular	-	483	O
components	-	495	O
with	-	506	O
the	-	511	O
mitochondrial	-	515	O
fraction	-	529	O
showing	-	538	O
the	-	546	O
most	-	550	O
consistent	-	555	O
changes	-	566	O
when	-	574	O
compared	-	579	O
to	-	588	O
saline	-	591	O
-	-	597	O
infused	-	598	O
control	-	606	O
animals	-	614	O
(	-	622	O
4	-	623	O
,	-	624	O
957	-	625	O
vs	-	629	O
.	-	631	O
827	-	633	O
counts	-	637	O
per	-	644	O
minute	-	648	O
per	-	655	O
gram	-	659	O
of	-	664	O
dried	-	667	O
tissue	-	673	O
or	-	680	O
fraction	-	683	O
)	-	691	O
.	-	692	O

Myocardial	983936	694	O
concentrations	-	705	O
of	-	720	O
calcium	-	723	B
also	-	731	O
increased	-	736	O
significantly	-	746	O
(	-	760	O
12	-	761	O
.	-	763	O
0	-	764	O
vs	-	766	O
.	-	768	O
5	-	770	O
.	-	771	O
0	-	772	O
mg	-	774	O
.	-	776	O
per	-	777	O
100	-	781	O
Gm	-	785	O
.	-	787	O

of	983936	789	O
fat	-	792	O
-	-	795	O
free	-	796	O
dry	-	801	O
weight	-	805	O
)	-	811	O
.	-	812	O

Infusions	983936	814	O
of	-	824	O
calcium	-	827	B
chloride	-	835	I
sufficient	-	844	O
to	-	855	O
raise	-	858	O
serum	-	864	O
calcium	-	870	B
concentrations	-	878	O
2	-	893	O
mEq	-	895	O
.	-	898	O

per	983936	900	O
liter	-	904	O
failed	-	910	O
to	-	917	O
increase	-	920	O
calcium	-	929	B
influx	-	937	O
into	-	944	O
the	-	949	O
myocardial	-	953	O
cell	-	964	O
.	-	968	O

Mitochondrial	983936	970	O
radiocalcium	-	984	B
uptakes	-	997	O
were	-	1005	O
significantly	-	1010	O
decreased	-	1024	O
in	-	1034	O
animals	-	1037	O
pretreated	-	1045	O
with	-	1056	O
acetylsalicylic	-	1061	B
acid	-	1077	I
or	-	1082	O
dipyridamole	-	1085	B
or	-	1098	O
when	-	1101	O
hydrocortisone	-	1106	B
was	-	1121	O
added	-	1125	O
to	-	1131	O
the	-	1134	O
epinephrine	-	1138	B
infusion	-	1150	O
(	-	1159	O
2	-	1160	O
,	-	1161	O
682	-	1162	O
,	-	1165	O
2	-	1166	O
,	-	1167	O
803	-	1168	O
,	-	1171	O
and	-	1173	O
3	-	1177	O
,	-	1178	O
424	-	1179	O
counts	-	1183	O
per	-	1190	O
minute	-	1194	O
per	-	1201	O
gram	-	1205	O
of	-	1210	O
dried	-	1213	O
fraction	-	1219	O
,	-	1227	O
respectively	-	1229	O
)	-	1241	O
.	-	1242	O

Myocardial	983936	1244	O
calcium	-	1255	B
concentrations	-	1263	O
also	-	1278	O
were	-	1283	O
decreased	-	1288	O
(	-	1298	O
11	-	1299	O
.	-	1301	O
2	-	1302	O
,	-	1303	O
8	-	1305	O
.	-	1306	O
3	-	1307	O
,	-	1308	O
and	-	1310	O
8	-	1314	O
.	-	1315	O
9	-	1316	O
mg	-	1318	O
.	-	1320	O

per	983936	1322	O
100	-	1326	O
Gm	-	1330	O
.	-	1332	O

of	983936	1334	O
fat	-	1337	O
-	-	1340	O
free	-	1341	O
dry	-	1346	O
weight	-	1350	O
,	-	1356	O
respectively	-	1358	O
)	-	1370	O
in	-	1372	O
the	-	1375	O
three	-	1379	O
treatment	-	1385	O
groups	-	1395	O
,	-	1401	O
being	-	1403	O
significantly	-	1409	O
decreased	-	1423	O
only	-	1433	O
in	-	1438	O
the	-	1441	O
last	-	1445	O
two	-	1450	O
.	-	1453	O

Evidence	983936	1455	O
of	-	1464	O
microscopic	-	1467	O
damage	-	1479	O
was	-	1486	O
graded	-	1490	O
as	-	1497	O
less	-	1500	O
severe	-	1505	O
in	-	1512	O
the	-	1515	O
three	-	1519	O
treatment	-	1525	O
groups	-	1535	O
.	-	1541	O

Acetylsalicylic	983936	1543	B
acid	-	1559	I
,	-	1563	O
dipyridamole	-	1565	B
,	-	1577	O
and	-	1579	O
hydrocortisone	-	1583	B
all	-	1598	O
appear	-	1602	O
to	-	1609	O
have	-	1612	O
cardioprotective	-	1617	O
effects	-	1634	O
when	-	1642	O
tested	-	1647	O
in	-	1654	O
this	-	1657	O
model	-	1662	O
.	-	1667	O

Changes	1428568	0	O
in	-	8	O
depressive	-	11	O
status	-	22	O
associated	-	29	O
with	-	40	O
topical	-	45	O
beta	-	53	O
-	-	57	O
blockers	-	58	O
.	-	66	O

Depression	1428568	68	O
and	-	79	O
sexual	-	83	O
dysfunction	-	90	O
have	-	102	O
been	-	107	O
related	-	112	O
to	-	120	O
side	-	123	O
effects	-	128	O
of	-	136	O
topical	-	139	O
beta	-	147	O
-	-	151	O
blockers	-	152	O
.	-	160	O

We	1428568	162	O
performed	-	165	O
a	-	175	O
preliminary	-	177	O
study	-	189	O
in	-	195	O
order	-	198	O
to	-	204	O
determine	-	207	O
any	-	217	O
difference	-	221	O
between	-	232	O
a	-	240	O
non	-	242	O
selective	-	246	O
beta	-	256	O
-	-	260	O
blocker	-	261	O
(	-	269	O
timolol	-	270	B
)	-	277	O
and	-	279	O
a	-	283	O
selective	-	285	O
beta	-	295	O
-	-	299	O
blocker	-	300	O
(	-	308	O
betaxolol	-	309	B
)	-	318	O
regarding	-	320	O
CNS	-	330	O
side	-	334	O
effects	-	339	O
.	-	346	O

Eight	1428568	348	O
glaucomatous	-	354	O
patients	-	367	O
chronically	-	376	O
treated	-	388	O
with	-	396	O
timolol	-	401	B
0	-	409	O
.	-	410	O
5	-	411	O
%	-	412	O
/	-	413	O
12h	-	414	O
,	-	417	O
suffering	-	419	O
from	-	429	O
depression	-	434	O
diagnosed	-	445	O
through	-	455	O
DMS	-	463	O
-	-	466	O
III	-	467	O
-	-	470	O
R	-	471	O
criteria	-	473	O
,	-	481	O
were	-	483	O
included	-	488	O
in	-	497	O
the	-	500	O
study	-	504	O
.	-	509	O

During	1428568	511	O
the	-	518	O
six	-	522	O
-	-	525	O
month	-	526	O
follow	-	532	O
up	-	539	O
,	-	541	O
depression	-	543	O
was	-	554	O
quantified	-	558	O
through	-	569	O
the	-	577	O
Beck	-	581	O
and	-	586	O
Zung	-	590	O
-	-	594	O
Conde	-	595	O
scales	-	601	O
every	-	608	O
two	-	614	O
months	-	618	O
.	-	624	O

In	1428568	626	O
a	-	629	O
double	-	631	O
blind	-	638	O
cross	-	644	O
-	-	649	O
over	-	650	O
study	-	655	O
with	-	661	O
control	-	666	O
group	-	674	O
,	-	679	O
the	-	681	O
patients	-	685	O
under	-	694	O
timolol	-	700	B
treatment	-	708	O
presented	-	718	O
higher	-	728	O
depression	-	735	O
values	-	746	O
measured	-	753	O
through	-	762	O
the	-	770	O
Beck	-	774	O
and	-	779	O
the	-	783	O
Zung	-	787	O
-	-	791	O
Conde	-	792	O
scales	-	798	O
(	-	805	O
p	-	806	O
<	-	808	O
0	-	810	O
.	-	811	O
001	-	812	O
vs	-	816	O
control	-	819	O
)	-	826	O
.	-	827	O

These	1428568	829	O
results	-	835	O
suggest	-	843	O
that	-	851	O
betaxolol	-	856	B
could	-	866	O
be	-	872	O
less	-	875	O
of	-	880	O
a	-	883	O
depression	-	885	O
-	-	895	O
inducer	-	896	O
than	-	904	O
timolol	-	909	B
in	-	917	O
predisposed	-	920	O
patients	-	932	O
.	-	940	O

Long	1720453	0	O
-	-	4	O
term	-	5	O
follow	-	10	O
-	-	16	O
up	-	17	O
of	-	20	O
ifosfamide	-	23	B
renal	-	34	O
toxicity	-	40	O
in	-	49	O
children	-	52	O
treated	-	61	O
for	-	69	O
malignant	-	73	O
mesenchymal	-	83	O
tumors	-	95	O
:	-	101	O
an	-	103	O
International	-	106	O
Society	-	120	O
of	-	128	O
Pediatric	-	131	O
Oncology	-	141	O
report	-	150	O
.	-	156	O

The	1720453	158	O
renal	-	162	O
function	-	168	O
of	-	177	O
74	-	180	O
children	-	183	O
with	-	192	O
malignant	-	197	O
mesenchymal	-	207	O
tumors	-	219	O
in	-	226	O
complete	-	229	O
remission	-	238	O
and	-	248	O
who	-	252	O
have	-	256	O
received	-	261	O
the	-	270	O
same	-	274	O
ifosfamide	-	279	B
chemotherapy	-	290	O
protocol	-	303	O
(	-	312	O
International	-	313	O
Society	-	327	O
of	-	335	O
Pediatric	-	338	O
Oncology	-	348	O
Malignant	-	357	O
Mesenchymal	-	367	O
Tumor	-	379	O
Study	-	385	O
84	-	391	O
[	-	394	O
SIOP	-	395	O
MMT	-	400	O
84	-	404	O
]	-	406	O
)	-	407	O
were	-	409	O
studied	-	414	O
1	-	422	O
year	-	424	O
after	-	429	O
the	-	435	O
completion	-	439	O
of	-	450	O
treatment	-	453	O
.	-	462	O

Total	1720453	464	O
cumulative	-	470	O
doses	-	481	O
were	-	487	O
36	-	492	O
or	-	495	O
60	-	498	O
g	-	501	O
/	-	502	O
m2	-	503	O
of	-	506	O
ifosfamide	-	509	B
(	-	520	O
six	-	521	O
or	-	525	O
10	-	528	O
cycles	-	531	O
of	-	538	O
ifosfamide	-	541	B
,	-	551	I
vincristine	-	553	I
,	-	564	I
and	-	566	I
dactinomycin	-	570	I
[	-	583	O
IVA	-	584	B
]	-	587	O
)	-	588	O
.	-	589	O

None	1720453	591	O
of	-	596	O
them	-	599	O
had	-	604	O
received	-	608	O
cisplatin	-	617	B
chemotherapy	-	627	O
.	-	639	O

Ages	1720453	641	O
ranged	-	646	O
from	-	653	O
4	-	658	O
months	-	660	O
to	-	667	O
17	-	670	O
years	-	673	O
;	-	678	O
58	-	680	O
patients	-	683	O
were	-	692	O
males	-	697	O
and	-	703	O
42	-	707	O
females	-	710	O
.	-	717	O

The	1720453	719	O
most	-	723	O
common	-	728	O
primary	-	735	O
tumor	-	743	O
site	-	749	O
was	-	754	O
the	-	758	O
head	-	762	O
and	-	767	O
neck	-	771	O
.	-	775	O

Renal	1720453	777	O
function	-	783	O
was	-	792	O
investigated	-	796	O
by	-	809	O
measuring	-	812	O
plasma	-	822	O
and	-	829	O
urinary	-	833	O
electrolytes	-	841	O
,	-	853	O
glucosuria	-	855	O
,	-	865	O
proteinuria	-	867	O
,	-	878	O
aminoaciduria	-	880	O
,	-	893	O
urinary	-	895	O
pH	-	903	O
,	-	905	O
osmolarity	-	907	O
,	-	917	O
creatinine	-	919	B
clearance	-	930	O
,	-	939	O
phosphate	-	941	B
tubular	-	951	O
reabsorption	-	959	O
,	-	971	O
beta	-	973	O
2	-	978	O
microglobulinuria	-	980	O
,	-	997	O
and	-	999	O
lysozymuria	-	1003	O
.	-	1014	O

Fifty	1720453	1016	O
-	-	1021	O
eight	-	1022	O
patients	-	1028	O
(	-	1037	O
78	-	1038	O
%	-	1040	O
)	-	1041	O
had	-	1043	O
normal	-	1047	O
renal	-	1054	O
tests	-	1060	O
,	-	1065	O
whereas	-	1067	O
16	-	1075	O
patients	-	1078	O
(	-	1087	O
22	-	1088	O
%	-	1090	O
)	-	1091	O
had	-	1093	O
renal	-	1097	O
abnormalities	-	1103	O
.	-	1116	O

Two	1720453	1118	O
subsets	-	1122	O
of	-	1130	O
patients	-	1133	O
were	-	1142	O
identified	-	1147	O
from	-	1158	O
this	-	1163	O
latter	-	1168	O
group	-	1175	O
:	-	1180	O
the	-	1182	O
first	-	1186	O
included	-	1192	O
four	-	1201	O
patients	-	1206	O
(	-	1215	O
5	-	1216	O
%	-	1217	O
of	-	1219	O
the	-	1222	O
total	-	1226	O
population	-	1232	O
)	-	1242	O
who	-	1244	O
developed	-	1248	O
major	-	1258	O
toxicity	-	1264	O
resulting	-	1273	O
in	-	1283	O
Fanconi	-	1286	O
's	-	1293	O
syndrome	-	1296	O
(	-	1305	O
TDFS	-	1306	O
)	-	1310	O
;	-	1311	O
and	-	1313	O
the	-	1317	O
second	-	1321	O
group	-	1328	O
included	-	1334	O
five	-	1343	O
patients	-	1348	O
with	-	1357	O
elevated	-	1362	O
beta	-	1371	O
2	-	1376	O
microglobulinuria	-	1378	O
and	-	1396	O
low	-	1400	O
phosphate	-	1404	B
reabsorption	-	1414	O
.	-	1426	O

The	1720453	1428	O
remaining	-	1432	O
seven	-	1442	O
patients	-	1448	O
had	-	1457	O
isolated	-	1461	O
beta	-	1470	O
2	-	1475	O
microglobulinuria	-	1477	O
.	-	1494	O

Severe	1720453	1496	O
toxicity	-	1503	O
was	-	1512	O
correlated	-	1516	O
with	-	1527	O
the	-	1532	O
higher	-	1536	O
cumulative	-	1543	O
dose	-	1554	O
of	-	1559	O
60	-	1562	O
g	-	1565	O
/	-	1566	O
m2	-	1567	O
of	-	1570	O
ifosfamide	-	1573	B
,	-	1583	O
a	-	1585	O
younger	-	1587	O
age	-	1595	O
(	-	1599	O
less	-	1600	O
than	-	1605	O
2	-	1610	O
1	-	1612	O
/	-	1613	O
2	-	1614	O
years	-	1616	O
old	-	1622	O
)	-	1625	O
,	-	1626	O
and	-	1628	O
a	-	1632	O
predominance	-	1634	O
of	-	1647	O
vesicoprostatic	-	1650	O
tumor	-	1666	O
involvement	-	1672	O
.	-	1683	O

This	1720453	1685	O
low	-	1690	O
percentage	-	1694	O
(	-	1705	O
5	-	1706	O
%	-	1707	O
)	-	1708	O
of	-	1710	O
TDFS	-	1713	O
must	-	1718	O
be	-	1723	O
evaluated	-	1726	O
with	-	1736	O
respect	-	1741	O
to	-	1749	O
the	-	1752	O
efficacy	-	1756	O
of	-	1765	O
ifosfamide	-	1768	B
in	-	1779	O
the	-	1782	O
treatment	-	1786	O
of	-	1796	O
mesenchymal	-	1799	O
tumors	-	1811	O
in	-	1818	O
children	-	1821	O
.	-	1829	O

Evidence	1833784	0	O
for	-	9	O
an	-	13	O
involvement	-	16	O
of	-	28	O
D1	-	31	O
and	-	34	O
D2	-	38	O
dopamine	-	41	B
receptors	-	50	O
in	-	60	O
mediating	-	63	O
nicotine	-	73	B
-	-	81	O
induced	-	82	O
hyperactivity	-	90	O
in	-	104	O
rats	-	107	O
.	-	111	O

Previous	1833784	113	O
studies	-	122	O
have	-	130	O
suggested	-	135	O
that	-	145	O
repeated	-	150	O
exposure	-	159	O
of	-	168	O
rats	-	171	O
to	-	176	O
the	-	179	O
drug	-	183	O
or	-	188	O
to	-	191	O
the	-	194	O
experimental	-	198	O
environment	-	211	O
is	-	223	O
necessary	-	226	O
to	-	236	O
observe	-	239	O
nicotine	-	247	B
-	-	255	O
induced	-	256	O
locomotor	-	264	O
stimulation	-	274	O
.	-	285	O

In	1833784	287	O
the	-	290	O
present	-	294	O
study	-	302	O
the	-	308	O
role	-	312	O
of	-	317	O
habituation	-	320	O
to	-	332	O
the	-	335	O
experimental	-	339	O
environment	-	352	O
on	-	364	O
the	-	367	O
stimulant	-	371	O
effect	-	381	O
of	-	388	O
nicotine	-	391	B
in	-	400	O
rats	-	403	O
was	-	408	O
examined	-	412	O
.	-	420	O

In	1833784	422	O
addition	-	425	O
,	-	433	O
the	-	435	O
role	-	439	O
of	-	444	O
dopamine	-	447	B
receptors	-	456	O
in	-	466	O
mediating	-	469	O
nicotine	-	479	B
-	-	487	O
induced	-	488	O
locomotor	-	496	O
stimulation	-	506	O
was	-	518	O
investigated	-	522	O
by	-	535	O
examining	-	538	O
the	-	548	O
effects	-	552	O
of	-	560	O
selective	-	563	O
D1	-	573	O
and	-	576	O
D2	-	580	O
dopamine	-	583	B
receptor	-	592	O
antagonists	-	601	O
on	-	613	O
activity	-	616	O
induced	-	625	O
by	-	633	O
nicotine	-	636	B
.	-	644	O

Locomotor	1833784	646	O
activity	-	656	O
was	-	665	O
assessed	-	669	O
in	-	678	O
male	-	681	O
Sprague	-	686	O
-	-	693	O
Dawley	-	694	O
rats	-	701	O
tested	-	706	O
in	-	713	O
photocell	-	716	O
cages	-	726	O
.	-	731	O

Nicotine	1833784	733	B
(	-	742	O
1	-	743	O
.	-	744	O
0	-	745	O
mg	-	747	O
/	-	749	O
kg	-	750	O
)	-	752	O
caused	-	754	O
a	-	761	O
significant	-	763	O
increase	-	775	O
in	-	784	O
locomotor	-	787	O
activity	-	797	O
in	-	806	O
rats	-	809	O
that	-	814	O
were	-	819	O
habituated	-	824	O
to	-	835	O
the	-	838	O
test	-	842	O
environment	-	847	O
,	-	858	O
but	-	860	O
had	-	864	O
only	-	868	O
a	-	873	O
weak	-	875	O
and	-	880	O
delayed	-	884	O
stimulant	-	892	O
action	-	902	O
in	-	909	O
rats	-	912	O
that	-	917	O
were	-	922	O
unfamiliar	-	927	O
with	-	938	O
the	-	943	O
test	-	947	O
environment	-	952	O
.	-	963	O

The	1833784	965	O
stimulant	-	969	O
action	-	979	O
of	-	986	O
nicotine	-	989	B
was	-	998	O
blocked	-	1002	O
by	-	1010	O
the	-	1013	O
central	-	1017	O
nicotinic	-	1025	O
antagonist	-	1035	O
mecamylamine	-	1046	B
but	-	1059	O
not	-	1063	O
by	-	1067	O
the	-	1070	O
peripheral	-	1074	O
nicotinic	-	1085	O
blocker	-	1095	O
hexamethonium	-	1103	B
,	-	1116	O
indicating	-	1118	O
that	-	1129	O
the	-	1134	O
response	-	1138	O
is	-	1147	O
probably	-	1150	O
mediated	-	1159	O
by	-	1168	O
central	-	1171	O
nicotinic	-	1179	O
receptors	-	1189	O
.	-	1198	O

Nicotine	1833784	1200	B
-	-	1208	O
induced	-	1209	O
hyperactivity	-	1217	O
was	-	1231	O
blocked	-	1235	O
by	-	1243	O
the	-	1246	O
selective	-	1250	O
D1	-	1260	O
antagonist	-	1263	O
SCH	-	1274	B
23390	-	1278	I
,	-	1283	O
the	-	1285	O
selective	-	1289	O
D2	-	1299	O
antagonist	-	1302	O
raclopride	-	1313	B
and	-	1324	O
the	-	1328	O
D1	-	1332	O
/	-	1334	O
D2	-	1335	O
antagonist	-	1338	O
fluphenazine	-	1349	B
.	-	1361	O

Pretreatment	1833784	1363	O
with	-	1376	O
the	-	1381	O
D2	-	1385	O
agonist	-	1388	O
PHNO	-	1396	B
enhanced	-	1401	O
nicotine	-	1410	B
-	-	1418	O
induced	-	1419	O
hyperactivity	-	1427	O
,	-	1440	O
whereas	-	1442	O
the	-	1450	O
D1	-	1454	O
agonist	-	1457	O
SKF	-	1465	B
38393	-	1469	I
had	-	1475	O
no	-	1479	O
effect	-	1482	O
.	-	1488	O

The	1833784	1490	O
results	-	1494	O
indicate	-	1502	O
that	-	1511	O
acute	-	1516	O
nicotine	-	1522	B
injection	-	1531	O
induces	-	1541	O
a	-	1549	O
pronounced	-	1551	O
hyperactivity	-	1562	O
in	-	1576	O
rats	-	1579	O
habituated	-	1584	O
to	-	1595	O
the	-	1598	O
test	-	1602	O
environment	-	1607	O
.	-	1618	O

The	1833784	1620	O
effect	-	1624	O
appears	-	1631	O
to	-	1639	O
be	-	1642	O
mediated	-	1645	O
by	-	1654	O
central	-	1657	O
nicotine	-	1665	B
receptors	-	1674	O
,	-	1683	O
possibly	-	1685	O
located	-	1694	O
on	-	1702	O
dopaminergic	-	1705	O
neurons	-	1718	O
,	-	1725	O
and	-	1727	O
also	-	1731	O
requires	-	1736	O
the	-	1745	O
activation	-	1749	O
of	-	1760	O
both	-	1763	O
D1	-	1768	O
and	-	1771	O
D2	-	1775	O
dopamine	-	1778	B
receptors	-	1787	O
.	-	1796	O

Neuropsychiatric	1867351	0	O
side	-	17	O
effects	-	22	O
after	-	30	O
the	-	36	O
use	-	40	O
of	-	44	O
mefloquine	-	47	B
.	-	57	O

This	1867351	59	O
study	-	64	O
describes	-	70	O
neuropsychiatric	-	80	O
side	-	97	O
effects	-	102	O
in	-	110	O
patients	-	113	O
after	-	122	O
treatment	-	128	O
with	-	138	O
mefloquine	-	143	B
.	-	153	O

Reactions	1867351	155	O
consisted	-	165	O
mainly	-	175	O
of	-	182	O
seizures	-	185	O
,	-	193	O
acute	-	195	O
psychoses	-	201	O
,	-	210	O
anxiety	-	212	O
neurosis	-	220	O
,	-	228	O
and	-	230	O
major	-	234	O
disturbances	-	240	O
of	-	253	O
sleep	-	256	O
-	-	261	O
wake	-	262	O
rhythm	-	267	O
.	-	273	O

Side	1867351	275	O
effects	-	280	O
occurred	-	288	O
after	-	297	O
both	-	303	O
therapeutic	-	308	O
and	-	320	O
prophylactic	-	324	O
intake	-	337	O
and	-	344	O
were	-	348	O
graded	-	353	O
from	-	360	O
moderate	-	365	O
to	-	374	O
severe	-	377	O
.	-	383	O

In	1867351	385	O
a	-	388	O
risk	-	390	O
analysis	-	395	O
of	-	404	O
neuropsychiatric	-	407	O
side	-	424	O
effects	-	429	O
in	-	437	O
Germany	-	440	O
,	-	447	O
it	-	449	O
is	-	452	O
estimated	-	455	O
that	-	465	O
one	-	470	O
of	-	474	O
8	-	477	O
,	-	478	O
000	-	479	O
mefloquine	-	483	B
users	-	494	O
suffers	-	500	O
from	-	508	O
such	-	513	O
reactions	-	518	O
.	-	527	O

The	1867351	529	O
incidence	-	533	O
calculation	-	543	O
revealed	-	555	O
that	-	564	O
one	-	569	O
of	-	573	O
215	-	576	O
therapeutic	-	580	O
users	-	592	O
had	-	598	O
reactions	-	602	O
,	-	611	O
compared	-	613	O
with	-	622	O
one	-	627	O
of	-	631	O
13	-	634	O
,	-	636	O
000	-	637	O
in	-	641	O
the	-	644	O
prophylaxis	-	648	O
group	-	660	O
,	-	665	O
making	-	667	O
the	-	674	O
risk	-	678	O
of	-	683	O
neuropsychiatric	-	686	O
reactions	-	703	O
after	-	713	O
mefloquine	-	719	B
treatment	-	730	O
60	-	740	O
times	-	743	O
higher	-	749	O
than	-	756	O
after	-	761	O
prophylaxis	-	767	O
.	-	778	O

Therefore	1867351	780	O
,	-	789	O
certain	-	791	O
limitations	-	799	O
for	-	811	O
malaria	-	815	O
prophylaxis	-	823	O
and	-	835	O
treatment	-	839	O
with	-	849	O
mefloquine	-	854	B
are	-	865	O
recommended	-	869	O
.	-	880	O

Reduction	2070391	0	O
in	-	10	O
injection	-	13	O
pain	-	23	O
using	-	28	O
buffered	-	34	O
lidocaine	-	43	B
as	-	53	O
a	-	56	O
local	-	58	O
anesthetic	-	64	O
before	-	75	O
cardiac	-	82	O
catheterization	-	90	O
.	-	105	O

Previous	2070391	107	O
reports	-	116	O
have	-	124	O
suggested	-	129	O
that	-	139	O
pain	-	144	O
associated	-	149	O
with	-	160	O
the	-	165	O
injection	-	169	O
of	-	179	O
lidocaine	-	182	B
is	-	192	O
related	-	195	O
to	-	203	O
the	-	206	O
acidic	-	210	O
pH	-	217	O
of	-	220	O
the	-	223	O
solution	-	227	O
.	-	235	O

To	2070391	237	O
determine	-	240	O
if	-	250	O
the	-	253	O
addition	-	257	O
of	-	266	O
a	-	269	O
buffering	-	271	O
solution	-	281	O
to	-	290	O
adjust	-	293	O
the	-	300	O
pH	-	304	O
of	-	307	O
lidocaine	-	310	B
into	-	320	O
the	-	325	O
physiologic	-	329	O
range	-	341	O
would	-	347	O
reduce	-	353	O
pain	-	360	O
during	-	365	O
injection	-	372	O
,	-	381	O
we	-	383	O
performed	-	386	O
a	-	396	O
blinded	-	398	O
randomized	-	406	O
study	-	417	O
in	-	423	O
patients	-	426	O
undergoing	-	435	O
cardiac	-	446	O
catheterization	-	454	O
.	-	469	O

Twenty	2070391	471	O
patients	-	478	O
were	-	487	O
asked	-	492	O
to	-	498	O
quantify	-	501	O
the	-	510	O
severity	-	514	O
of	-	523	O
pain	-	526	O
after	-	531	O
receiving	-	537	O
standard	-	547	O
lidocaine	-	556	B
in	-	566	O
one	-	569	O
femoral	-	573	O
area	-	581	O
and	-	586	O
buffered	-	590	O
lidocaine	-	599	B
in	-	609	O
the	-	612	O
opposite	-	616	O
femoral	-	625	O
area	-	633	O
.	-	637	O

The	2070391	639	O
mean	-	643	O
pain	-	648	O
score	-	653	O
for	-	659	O
buffered	-	663	O
lidocaine	-	672	B
was	-	682	O
significantly	-	686	O
lower	-	700	O
than	-	706	O
the	-	711	O
mean	-	715	O
score	-	720	O
for	-	726	O
standard	-	730	O
lidocaine	-	739	B
(	-	749	O
2	-	750	O
.	-	751	O
7	-	752	O
+	-	754	O
/	-	755	O
-	-	756	O

1	2070391	758	O
.	-	759	O
9	-	760	O
vs	-	762	O
.	-	764	O
3	-	766	O
.	-	767	O
8	-	768	O
+	-	770	O
/	-	771	O
-	-	772	O

2	2070391	774	O
.	-	775	O
2	-	776	O
,	-	777	O
P	-	779	O
=	-	781	O
0	-	783	O
.	-	784	O
03	-	785	O
)	-	787	O
.	-	788	O

The	2070391	790	O
pH	-	794	O
adjustment	-	797	O
of	-	808	O
standard	-	811	O
lidocaine	-	820	B
can	-	830	O
be	-	834	O
accomplished	-	837	O
easily	-	850	O
in	-	857	O
the	-	860	O
catheterization	-	864	O
laboratory	-	880	O
before	-	891	O
injection	-	898	O
and	-	908	O
results	-	912	O
in	-	920	O
a	-	923	O
reduction	-	925	O
of	-	935	O
the	-	938	O
pain	-	942	O
occurring	-	947	O
during	-	957	O
the	-	964	O
infiltration	-	968	O
of	-	981	O
tissues	-	984	O
.	-	991	O

Randomized	2266990	0	O
,	-	10	O
double	-	12	O
-	-	18	O
blind	-	19	O
trial	-	25	O
of	-	31	O
mazindol	-	34	B
in	-	43	O
Duchenne	-	46	O
dystrophy	-	55	O
.	-	64	O

There	2266990	66	O
is	-	72	O
evidence	-	75	O
that	-	84	O
growth	-	89	O
hormone	-	96	O
may	-	104	O
be	-	108	O
related	-	111	O
to	-	119	O
the	-	122	O
progression	-	126	O
of	-	138	O
weakness	-	141	O
in	-	150	O
Duchenne	-	153	O
dystrophy	-	162	O
.	-	171	O

We	2266990	173	O
conducted	-	176	O
a	-	186	O
12	-	188	O
-	-	190	O
month	-	191	O
controlled	-	197	O
trial	-	208	O
of	-	214	O
mazindol	-	217	B
,	-	225	O
a	-	227	O
putative	-	229	O
growth	-	238	O
hormone	-	245	O
secretion	-	253	O
inhibitor	-	263	O
,	-	272	O
in	-	274	O
83	-	277	O
boys	-	280	O
with	-	285	O
Duchenne	-	290	O
dystrophy	-	299	O
.	-	308	O

Muscle	2266990	310	O
strength	-	317	O
,	-	325	O
contractures	-	327	O
,	-	339	O
functional	-	341	O
ability	-	352	O
and	-	360	O
pulmonary	-	364	O
function	-	374	O
were	-	383	O
tested	-	388	O
at	-	395	O
baseline	-	398	O
,	-	406	O
and	-	408	O
6	-	412	O
and	-	414	O
12	-	418	O
months	-	421	O
after	-	428	O
treatment	-	434	O
with	-	444	O
mazindol	-	449	B
(	-	458	O
3	-	459	O
mg	-	461	O
/	-	463	O
d	-	464	O
)	-	465	O
or	-	467	O
placebo	-	470	O
.	-	477	O

The	2266990	479	O
study	-	483	O
was	-	489	O
designed	-	493	O
to	-	502	O
have	-	505	O
a	-	510	O
power	-	512	O
of	-	518	O
greater	-	521	O
than	-	529	O
0	-	534	O
.	-	535	O
90	-	536	O
to	-	539	O
detect	-	542	O
a	-	549	O
slowing	-	551	O
to	-	559	O
25	-	562	O
%	-	564	O
of	-	566	O
the	-	569	O
expected	-	573	O
rate	-	582	O
of	-	587	O
progression	-	590	O
of	-	602	O
weakness	-	605	O
at	-	614	O
P	-	617	O
less	-	619	O
than	-	624	O
0	-	629	O
.	-	630	O
05	-	631	O
.	-	633	O

Mazindol	2266990	635	B
did	-	644	O
not	-	648	O
benefit	-	652	O
strength	-	660	O
at	-	669	O
any	-	672	O
point	-	676	O
in	-	682	O
the	-	685	O
study	-	689	O
.	-	694	O

Side	2266990	696	O
effects	-	701	O
attributable	-	709	O
to	-	722	O
mazindol	-	725	B
included	-	734	O
decreased	-	743	O
appetite	-	753	O
(	-	762	O
36	-	763	O
%	-	765	O
)	-	766	O
,	-	767	O
dry	-	769	O
mouth	-	773	O
(	-	779	O
10	-	780	O
%	-	782	O
)	-	783	O
,	-	784	O
behavioral	-	786	O
change	-	797	O
(	-	804	O
22	-	805	O
%	-	807	O
)	-	808	O
,	-	809	O
and	-	811	O
gastrointestinal	-	815	O
symptoms	-	832	O
(	-	841	O
18	-	842	O
%	-	844	O
)	-	845	O
;	-	846	O
mazindol	-	848	B
dosage	-	857	O
was	-	864	O
reduced	-	868	O
in	-	876	O
43	-	879	O
%	-	881	O
of	-	883	O
patients	-	886	O
.	-	894	O

The	2266990	896	O
effect	-	900	O
of	-	907	O
mazindol	-	910	B
on	-	919	O
GH	-	922	O
secretion	-	925	O
was	-	935	O
estimated	-	939	O
indirectly	-	949	O
by	-	960	O
comparing	-	963	O
the	-	973	O
postabsorptive	-	977	O
IGF	-	992	O
-	-	995	O
I	-	996	O
levels	-	998	O
obtained	-	1005	O
following	-	1014	O
3	-	1024	O
,	-	1025	O
6	-	1027	O
,	-	1028	O
9	-	1030	O
,	-	1031	O
and	-	1033	O
12	-	1037	O
months	-	1040	O
in	-	1047	O
the	-	1050	O
mazindol	-	1054	B
treated	-	1063	O
to	-	1071	O
those	-	1074	O
in	-	1080	O
the	-	1083	O
placebo	-	1087	O
groups	-	1095	O
.	-	1101	O

Although	2266990	1103	O
mazindol	-	1112	B
-	-	1120	O
treated	-	1121	O
patients	-	1129	O
gained	-	1138	O
less	-	1145	O
weight	-	1150	O
and	-	1157	O
height	-	1161	O
than	-	1168	O
placebo	-	1173	O
-	-	1180	O
treated	-	1181	O
patients	-	1189	O
,	-	1197	O
no	-	1199	O
significant	-	1202	O
effect	-	1214	O
on	-	1221	O
IGF	-	1224	O
-	-	1227	O
I	-	1228	O
levels	-	1230	O
was	-	1237	O
observed	-	1241	O
.	-	1249	O

Mazindol	2266990	1251	B
doses	-	1260	O
not	-	1266	O
slow	-	1270	O
the	-	1275	O
progression	-	1279	O
of	-	1291	O
weakness	-	1294	O
in	-	1303	O
Duchenne	-	1306	O
dystrophy	-	1315	O
.	-	1324	O

Pentoxifylline	2348231	0	B
(	-	15	O
Trental	-	16	B
)	-	23	O
does	-	25	O
not	-	30	O
inhibit	-	34	O
dipyridamole	-	42	B
-	-	54	O
induced	-	55	O
coronary	-	63	O
hyperemia	-	72	O
:	-	81	O
implications	-	83	O
for	-	96	O
dipyridamole	-	100	B
-	-	112	O
thallium	-	113	B
-	-	121	O
201	-	122	O
myocardial	-	126	O
imaging	-	137	O
.	-	144	O

Dipyridamole	2348231	146	B
-	-	158	O
thallium	-	159	B
-	-	167	O
201	-	168	O
imaging	-	172	O
is	-	180	O
often	-	183	O
performed	-	189	O
in	-	199	O
patients	-	202	O
unable	-	211	O
to	-	218	O
exercise	-	221	O
because	-	230	O
of	-	238	O
peripheral	-	241	O
vascular	-	252	O
disease	-	261	O
.	-	268	O

Many	2348231	270	O
of	-	275	O
these	-	278	O
patients	-	284	O
are	-	293	O
taking	-	297	O
pentoxifylline	-	304	B
(	-	319	O
Trental	-	320	B
)	-	327	O
,	-	328	O
a	-	330	O
methylxanthine	-	332	B
derivative	-	347	O
which	-	358	O
may	-	364	O
improve	-	368	O
intermittent	-	376	O
claudication	-	389	O
.	-	401	O

Whether	2348231	403	O
pentoxifylline	-	411	B
inhibits	-	426	O
dipyridamole	-	435	B
-	-	447	O
induced	-	448	O
coronary	-	456	O
hyperemia	-	465	O
like	-	475	O
other	-	480	O
methylxanthines	-	486	B
such	-	502	O
as	-	507	O
theophylline	-	510	B
and	-	523	O
should	-	527	O
be	-	534	O
stopped	-	537	O
prior	-	545	O
to	-	551	O
dipyridamole	-	554	B
-	-	566	O
thallium	-	567	B
-	-	575	O
201	-	576	O
imaging	-	580	O
is	-	588	O
unknown	-	591	O
.	-	598	O

Therefore	2348231	600	O
,	-	609	O
we	-	611	O
studied	-	614	O
the	-	622	O
hyperemic	-	626	O
response	-	636	O
to	-	645	O
dipyridamole	-	648	B
in	-	661	O
seven	-	664	O
open	-	670	O
-	-	674	O
chest	-	675	O
anesthetized	-	681	O
dogs	-	694	O
after	-	699	O
pretreatment	-	705	O
with	-	718	O
either	-	723	O
pentoxifylline	-	730	B
(	-	745	O
0	-	746	O
,	-	747	O
7	-	749	O
.	-	750	O
5	-	751	O
,	-	752	O
or	-	754	O
15	-	757	O
mg	-	760	O
/	-	762	O
kg	-	763	O
i	-	766	O
.	-	767	O
v	-	768	O
.	-	769	O
)	-	770	O
or	-	772	O
theophylline	-	775	B
(	-	788	O
3	-	789	O
mg	-	791	O
/	-	793	O
kg	-	794	O
i	-	797	O
.	-	798	O
v	-	799	O
.	-	800	O
)	-	801	O
.	-	802	O

Baseline	2348231	804	O
circumflex	-	813	O
coronary	-	824	O
blood	-	833	O
flows	-	839	O
did	-	845	O
not	-	849	O
differ	-	853	O
significantly	-	860	O
among	-	874	O
treatment	-	880	O
groups	-	890	O
.	-	896	O

Dipyridamole	2348231	898	B
significantly	-	911	O
increased	-	925	O
coronary	-	935	O
blood	-	944	O
flow	-	950	O
before	-	955	O
and	-	962	O
after	-	966	O
7	-	972	O
.	-	973	O
5	-	974	O
or	-	976	O
15	-	979	O
mm	-	982	O
/	-	984	O
kg	-	985	O
i	-	988	O
.	-	989	O
v	-	990	O
.	-	991	O

pentoxifylline	2348231	993	B
(	-	1008	O
p	-	1009	O
less	-	1011	O
than	-	1016	O
0	-	1021	O
.	-	1022	O
002	-	1023	O
)	-	1026	O
.	-	1027	O

Neither	2348231	1029	O
dose	-	1037	O
of	-	1042	O
pentoxifylline	-	1045	B
significantly	-	1060	O
decreased	-	1074	O
the	-	1084	O
dipyridamole	-	1088	B
-	-	1100	O
induced	-	1101	O
hyperemia	-	1109	O
,	-	1118	O
while	-	1120	O
peak	-	1126	O
coronary	-	1131	O
blood	-	1140	O
flow	-	1146	O
was	-	1151	O
significantly	-	1155	O
lower	-	1169	O
after	-	1175	O
theophylline	-	1181	B
(	-	1194	O
p	-	1195	O
less	-	1197	O
than	-	1202	O
0	-	1207	O
.	-	1208	O
01	-	1209	O
)	-	1211	O
.	-	1212	O

We	2348231	1214	O
conclude	-	1217	O
that	-	1226	O
pentoxyifylline	-	1231	B
does	-	1247	O
not	-	1252	O
inhibit	-	1256	O
dipyridamole	-	1264	B
-	-	1276	O
induced	-	1277	O
coronary	-	1285	O
hyperemia	-	1294	O
even	-	1304	O
at	-	1309	O
high	-	1312	O
doses	-	1317	O
.	-	1322	O

Cause	2355241	0	O
of	-	6	O
death	-	9	O
among	-	15	O
patients	-	21	O
with	-	30	O
Parkinson	-	35	O
's	-	44	O
disease	-	47	O
:	-	54	O
a	-	56	O
rare	-	58	O
mortality	-	63	O
due	-	73	O
to	-	77	O
cerebral	-	80	O
haemorrhage	-	89	O
.	-	100	O

Causes	2355241	102	O
of	-	109	O
death	-	112	O
,	-	117	O
with	-	119	O
special	-	124	O
reference	-	132	O
to	-	142	O
cerebral	-	145	O
haemorrhage	-	154	O
,	-	165	O
among	-	167	O
240	-	173	O
patients	-	177	O
with	-	186	O
pathologically	-	191	O
verified	-	206	O
Parkinson	-	215	O
's	-	224	O
disease	-	227	O
were	-	235	O
investigated	-	240	O
using	-	253	O
the	-	259	O
Annuals	-	263	O
of	-	271	O
the	-	274	O
Pathological	-	278	O
Autopsy	-	291	O
Cases	-	299	O
in	-	305	O
Japan	-	308	O
from	-	314	O
1981	-	319	O
to	-	324	O
1985	-	327	O
.	-	331	O

The	2355241	333	O
leading	-	337	O
causes	-	345	O
of	-	352	O
death	-	355	O
were	-	361	O
pneumonia	-	366	O
and	-	376	O
bronchitis	-	380	O
(	-	391	O
44	-	392	O
.	-	394	O
1	-	395	O
%	-	396	O
)	-	397	O
,	-	398	O
malignant	-	400	O
neoplasms	-	410	O
(	-	420	O
11	-	421	O
.	-	423	O
6	-	424	O
%	-	425	O
)	-	426	O
,	-	427	O
heart	-	429	O
diseases	-	435	O
(	-	444	O
4	-	445	O
.	-	446	O
1	-	447	O
%	-	448	O
)	-	449	O
,	-	450	O
cerebral	-	452	O
infarction	-	461	O
(	-	472	O
3	-	473	O
.	-	474	O
7	-	475	O
%	-	476	O
)	-	477	O
and	-	479	O
septicaemia	-	483	O
(	-	495	O
3	-	496	O
.	-	497	O
3	-	498	O
%	-	499	O
)	-	500	O
.	-	501	O

Cerebral	2355241	503	O
haemorrhage	-	512	O
was	-	524	O
the	-	528	O
11th	-	532	O
most	-	537	O
frequent	-	542	O
cause	-	551	O
of	-	557	O
death	-	560	O
,	-	565	O
accounting	-	567	O
for	-	578	O
only	-	582	O
0	-	587	O
.	-	588	O
8	-	589	O
%	-	590	O
of	-	592	O
deaths	-	595	O
among	-	602	O
the	-	608	O
patients	-	612	O
,	-	620	O
whereas	-	622	O
it	-	630	O
was	-	633	O
the	-	637	O
5th	-	641	O
most	-	645	O
common	-	650	O
cause	-	657	O
of	-	663	O
death	-	666	O
among	-	672	O
the	-	678	O
Japanese	-	682	O
general	-	691	O
population	-	699	O
in	-	710	O
1985	-	713	O
.	-	717	O

The	2355241	719	O
low	-	723	O
incidence	-	727	O
of	-	737	O
cerebral	-	740	O
haemorrhage	-	749	O
as	-	761	O
a	-	764	O
cause	-	766	O
of	-	772	O
death	-	775	O
in	-	781	O
patients	-	784	O
with	-	793	O
Parkinson	-	798	O
's	-	807	O
disease	-	810	O
may	-	818	O
reflect	-	822	O
the	-	830	O
hypotensive	-	834	O
effect	-	846	O
of	-	853	O
levodopa	-	856	B
and	-	865	O
a	-	869	O
hypotensive	-	871	O
mechanism	-	883	O
due	-	893	O
to	-	897	O
reduced	-	900	O
noradrenaline	-	908	B
levels	-	922	O
in	-	929	O
the	-	932	O
parkinsonian	-	936	O
brain	-	949	O
.	-	954	O

Tolerance	2445283	0	O
and	-	10	O
antiviral	-	14	O
effect	-	24	O
of	-	31	O
ribavirin	-	34	B
in	-	44	O
patients	-	47	O
with	-	56	O
Argentine	-	61	O
hemorrhagic	-	71	O
fever	-	83	O
.	-	88	O

Tolerance	2445283	90	O
and	-	100	O
antiviral	-	104	O
effect	-	114	O
of	-	121	O
ribavirin	-	124	B
was	-	134	O
studied	-	138	O
in	-	146	O
6	-	149	O
patients	-	151	O
with	-	160	O
Argentine	-	165	O
hemorrhagic	-	175	O
fever	-	187	O
(	-	193	O
AHF	-	194	O
)	-	197	O
of	-	199	O
more	-	202	O
than	-	207	O
8	-	212	O
days	-	214	O
of	-	219	O
evolution	-	222	O
.	-	231	O

Administration	2445283	233	O
of	-	248	O
ribavirin	-	251	B
resulted	-	261	O
in	-	270	O
a	-	273	O
neutralization	-	275	O
of	-	290	O
viremia	-	293	O
and	-	301	O
a	-	305	O
drop	-	307	O
of	-	312	O
endogenous	-	315	O
interferon	-	326	O
titers	-	337	O
.	-	343	O

The	2445283	345	O
average	-	349	O
time	-	357	O
of	-	362	O
death	-	365	O
was	-	371	O
delayed	-	375	O
.	-	382	O

A	2445283	384	O
reversible	-	386	O
anemia	-	397	O
was	-	404	O
the	-	408	O
only	-	412	O
adverse	-	417	O
effect	-	425	O
observed	-	432	O
.	-	440	O

From	2445283	442	O
these	-	447	O
results	-	453	O
,	-	460	O
we	-	462	O
conclude	-	465	O
that	-	474	O
ribavirin	-	479	B
has	-	489	O
an	-	493	O
antiviral	-	496	O
effect	-	506	O
in	-	513	O
advanced	-	516	O
cases	-	525	O
of	-	531	O
AHF	-	534	O
,	-	537	O
and	-	539	O
that	-	543	O
anemia	-	548	O
,	-	554	O
the	-	556	O
only	-	560	O
secondary	-	565	O
reaction	-	575	O
observed	-	584	O
,	-	592	O
can	-	594	O
be	-	598	O
easily	-	601	O
managed	-	608	O
.	-	615	O

The	2445283	617	O
possible	-	621	O
beneficial	-	630	O
effect	-	641	O
of	-	648	O
ribavirin	-	651	B
during	-	661	O
the	-	668	O
initial	-	672	O
days	-	680	O
of	-	685	O
AHF	-	688	O
is	-	692	O
discussed	-	695	O
.	-	704	O

Dipyridamole	2950248	0	B
-	-	12	O
induced	-	13	O
myocardial	-	21	O
ischemia	-	32	O
.	-	40	O

Angina	2950248	42	O
and	-	49	O
ischemic	-	53	O
electrocardiographic	-	62	O
changes	-	83	O
occurred	-	91	O
after	-	100	O
administration	-	106	O
of	-	121	O
oral	-	124	O
dipyridamole	-	129	B
in	-	142	O
four	-	145	O
patients	-	150	O
awaiting	-	159	O
urgent	-	168	O
myocardial	-	175	O
revascularization	-	186	O
procedures	-	204	O
.	-	214	O

To	2950248	216	O
our	-	219	O
knowledge	-	223	O
,	-	232	O
this	-	234	O
has	-	239	O
not	-	243	O
previously	-	247	O
been	-	258	O
reported	-	263	O
as	-	272	O
a	-	275	O
side	-	277	O
effect	-	282	O
of	-	289	O
preoperative	-	292	O
dipyridamole	-	305	B
therapy	-	318	O
,	-	325	O
although	-	327	O
dipyridamole	-	336	B
-	-	348	O
induced	-	349	O
myocardial	-	357	O
ischemia	-	368	O
has	-	377	O
been	-	381	O
demonstrated	-	386	O
to	-	399	O
occur	-	402	O
in	-	408	O
animals	-	411	O
and	-	419	O
humans	-	423	O
with	-	430	O
coronary	-	435	O
artery	-	444	O
disease	-	451	O
.	-	458	O

Epicardial	2950248	460	O
coronary	-	471	O
collateral	-	480	O
vessels	-	491	O
were	-	499	O
demonstrated	-	504	O
in	-	517	O
all	-	520	O
four	-	524	O
patients	-	529	O
;	-	537	O
a	-	539	O
coronary	-	541	O
""""	-	550	O
steal	-	551	O
""""	-	556	O
phenomenon	-	558	O
may	-	569	O
be	-	573	O
the	-	576	O
mechanism	-	580	O
of	-	590	O
the	-	593	O
dipyridamole	-	597	B
-	-	609	O
induced	-	610	O
ischemia	-	618	O
observed	-	627	O
.	-	635	O

Inhibition	3015567	0	O
of	-	11	O
immunoreactive	-	14	O
corticotropin	-	29	O
-	-	42	O
releasing	-	43	O
factor	-	53	O
secretion	-	60	O
into	-	70	O
the	-	75	O
hypophysial	-	79	O
-	-	90	O
portal	-	91	O
circulation	-	98	O
by	-	110	O
delayed	-	113	O
glucocorticoid	-	121	O
feedback	-	136	O
.	-	144	O

Nitroprusside	3015567	146	B
-	-	159	O
induced	-	160	O
hypotension	-	168	O
evokes	-	180	O

ACTH	3015567	187	O
secretion	-	192	O
which	-	202	O
is	-	208	O
primarily	-	211	O
mediated	-	221	O
by	-	230	O
enhanced	-	233	O
secretion	-	242	O
of	-	252	O
immunoreactive	-	255	O
corticotropin	-	270	O
-	-	283	O
releasing	-	284	O
factor	-	294	O
(	-	301	O
irCRF	-	302	O
)	-	307	O
into	-	309	O
the	-	314	O
hypophysial	-	318	O
-	-	329	O
portal	-	330	O
circulation	-	337	O
.	-	348	O

Portal	3015567	350	O
plasma	-	357	O
concentrations	-	364	O
of	-	379	O
neither	-	382	O
arginine	-	390	B
vasopressin	-	399	I
nor	-	411	O
oxytocin	-	415	B
are	-	424	O
significantly	-	428	O
altered	-	442	O
in	-	450	O
this	-	453	O
paradigm	-	458	O
.	-	466	O

Application	3015567	468	O
of	-	480	O
a	-	483	O
delayed	-	485	O
feedback	-	493	O
signal	-	502	O
,	-	508	O
in	-	510	O
the	-	513	O
form	-	517	O
of	-	522	O
a	-	525	O
2	-	527	O
-	-	528	O
h	-	529	O
systemic	-	531	O
corticosterone	-	540	B
infusion	-	555	O
in	-	564	O
urethane	-	567	B
-	-	575	O
anesthetized	-	576	O
rats	-	589	O
with	-	594	O
pharmacological	-	599	O
blockade	-	615	O
of	-	624	O
glucocorticoid	-	627	O
synthesis	-	642	O
,	-	651	O
is	-	653	O
without	-	656	O
effect	-	664	O
on	-	671	O
the	-	674	O
resting	-	678	O
secretion	-	686	O
of	-	696	O
arginine	-	699	B
vasopressin	-	708	I
and	-	720	O
oxytocin	-	724	B
at	-	733	O
any	-	736	O
corticosterone	-	740	B
feedback	-	755	O
dose	-	764	O
tested	-	769	O
.	-	775	O

Resting	3015567	777	O
irCRF	-	785	O
levels	-	791	O
are	-	798	O
suppressed	-	802	O
only	-	813	O
at	-	818	O
the	-	821	O
highest	-	825	O
corticosterone	-	833	B
infusion	-	848	O
rate	-	857	O
,	-	861	O
which	-	863	O
resulted	-	869	O
in	-	878	O
systemic	-	881	O
corticosterone	-	890	B
levels	-	905	O
of	-	912	O
40	-	915	O
micrograms	-	918	O
/	-	928	O
dl	-	929	O
.	-	931	O

Suppression	3015567	933	O
of	-	945	O
irCRF	-	948	O
secretion	-	954	O
in	-	964	O
response	-	967	O
to	-	976	O
nitroprusside	-	979	B
-	-	992	O
induced	-	993	O
hypotension	-	1001	O
is	-	1013	O
observed	-	1016	O
and	-	1025	O
occurs	-	1029	O
at	-	1036	O
a	-	1039	O
plasma	-	1041	O
corticosterone	-	1048	B
level	-	1063	O
between	-	1069	O
8	-	1077	O
-	-	1078	O
12	-	1079	O
micrograms	-	1082	O
/	-	1092	O
dl	-	1093	O
.	-	1095	O

These	3015567	1097	O
studies	-	1103	O
provide	-	1111	O
further	-	1119	O
evidence	-	1127	O
for	-	1136	O
a	-	1140	O
strong	-	1142	O
central	-	1149	O
component	-	1157	O
of	-	1167	O
the	-	1170	O
delayed	-	1174	O
feedback	-	1182	O
process	-	1191	O
which	-	1199	O
is	-	1205	O
mediated	-	1208	O
by	-	1217	O
modulation	-	1220	O
of	-	1231	O
irCRF	-	1234	O
release	-	1240	O
.	-	1247	O

Noradrenergic	3031535	0	O
involvement	-	14	O
in	-	26	O
catalepsy	-	29	O
induced	-	39	O
by	-	47	O
delta	-	50	B
9	-	56	I
-	-	57	I
tetrahydrocannabinol	-	58	I
.	-	78	O

In	3031535	80	O
order	-	83	O
to	-	89	O
elucidate	-	92	O
the	-	102	O
role	-	106	O
of	-	111	O
the	-	114	O
catecholaminergic	-	118	O
system	-	136	O
in	-	143	O
the	-	146	O
cataleptogenic	-	150	O
effect	-	165	O
of	-	172	O
delta	-	175	B
9	-	181	I
-	-	182	I
tetrahydrocannabinol	-	183	I
(	-	204	O
THC	-	205	B
)	-	208	O
,	-	209	O
the	-	211	O
effect	-	215	O
of	-	222	O
pretreatment	-	225	O
with	-	238	O
6	-	243	B
-	-	244	I
hydroxydopamine	-	245	I
(	-	261	O
6	-	262	B
-	-	263	I
OHDA	-	264	I
)	-	268	O
or	-	270	O
with	-	273	O
desipramine	-	278	B
and	-	290	O
6	-	294	B
-	-	295	I
OHDA	-	296	I
and	-	301	O
lesions	-	305	O
of	-	313	O
the	-	316	O
locus	-	320	O
coeruleus	-	326	O
were	-	336	O
investigated	-	341	O
in	-	354	O
rats	-	357	O
.	-	361	O

The	3031535	363	O
cataleptogenic	-	367	O
effect	-	382	O
of	-	389	O
THC	-	392	B
was	-	396	O
significantly	-	400	O
reduced	-	414	O
in	-	422	O
rats	-	425	O
treated	-	430	O
with	-	438	O
6	-	443	B
-	-	444	I
OHDA	-	445	I
and	-	450	O
in	-	454	O
rats	-	457	O
with	-	462	O
lesions	-	467	O
of	-	475	O
the	-	478	O
locus	-	482	O
coeruleus	-	488	O
but	-	498	O
not	-	502	O
in	-	506	O
rats	-	509	O
treated	-	514	O
with	-	522	O
desipramine	-	527	B
and	-	539	O
6	-	543	B
-	-	544	I
OHDA	-	545	I
,	-	549	O
as	-	551	O
compared	-	554	O
with	-	563	O
control	-	568	O
rats	-	576	O
.	-	580	O

On	3031535	582	O
the	-	585	O
contrary	-	589	O
,	-	597	O
the	-	599	O
cataleptogenic	-	603	O
effect	-	618	O
of	-	625	O
haloperidol	-	628	B
was	-	640	O
significantly	-	644	O
reduced	-	658	O
in	-	666	O
rats	-	669	O
treated	-	674	O
with	-	682	O
desipramine	-	687	B
and	-	699	O
6	-	703	B
-	-	704	I
OHDA	-	705	I
but	-	710	O
not	-	714	O
in	-	718	O
rats	-	721	O
treated	-	726	O
with	-	734	O
6	-	739	B
-	-	740	I
OHDA	-	741	I
or	-	746	O
in	-	749	O
rats	-	752	O
with	-	757	O
lesions	-	762	O
of	-	770	O
the	-	773	O
locus	-	777	O
coeruleus	-	783	O
.	-	792	O

These	3031535	794	O
results	-	800	O
indicate	-	808	O
that	-	817	O
noradrenergic	-	822	O
neurons	-	836	O
have	-	844	O
an	-	849	O
important	-	852	O
role	-	862	O
in	-	867	O
the	-	870	O
manifestation	-	874	O
of	-	888	O
catalepsy	-	891	O
induced	-	901	O
by	-	909	O
THC	-	912	B
,	-	915	O
whereas	-	917	O
dopaminergic	-	925	O
neurons	-	938	O
are	-	946	O
important	-	950	O
in	-	960	O
catalepsy	-	963	O
induced	-	973	O
by	-	981	O
haloperidol	-	984	B
.	-	995	O

Intracranial	3125768	0	O
pressure	-	13	O
increases	-	22	O
during	-	32	O
alfentanil	-	39	B
-	-	49	O
induced	-	50	O
rigidity	-	58	O
.	-	66	O

Intracranial	3125768	68	O
pressure	-	81	O
(	-	90	O
ICP	-	91	O
)	-	94	O
was	-	96	O
measured	-	100	O
during	-	109	O
alfentanil	-	116	B
-	-	126	O
induced	-	127	O
rigidity	-	135	O
in	-	144	O
rats	-	147	O
.	-	151	O

Ten	3125768	153	O
rats	-	157	O
had	-	162	O
arterial	-	166	O
,	-	174	O
central	-	176	O
venous	-	184	O
(	-	191	O
CVP	-	192	O
)	-	195	O
,	-	196	O
and	-	198	O
subdural	-	202	O
cannulae	-	211	O
inserted	-	220	O
under	-	229	O
halothane	-	235	B
anesthesia	-	245	O
.	-	255	O

The	3125768	257	O
animals	-	261	O
were	-	269	O
mechanically	-	274	O
ventilated	-	287	O
to	-	298	O
achieve	-	301	O
normocarbia	-	309	O
(	-	321	O
PCO2	-	322	O
=	-	327	O
42	-	329	O
+	-	332	O
/	-	333	O
-	-	334	O

1	3125768	336	O
mmHg	-	338	O
,	-	342	O
mean	-	344	O
+	-	349	O
/	-	350	O
-	-	351	O

SE	3125768	353	O
)	-	355	O
.	-	356	O

Following	3125768	358	O
instrumentation	-	368	O
,	-	383	O
halothane	-	385	B
was	-	395	O
discontinued	-	399	O
and	-	412	O
alfentanil	-	416	B
(	-	427	O
125	-	428	O
mu	-	432	O
/	-	434	O
kg	-	435	O
)	-	437	O
administered	-	439	O
iv	-	452	O
during	-	455	O
emergence	-	462	O
from	-	472	O
halothane	-	477	B
anesthesia	-	487	O
.	-	497	O

In	3125768	499	O
the	-	502	O
five	-	506	O
rats	-	511	O
that	-	516	O
developed	-	521	O
somatic	-	531	O
rigidity	-	539	O
,	-	547	O
ICP	-	549	O
and	-	553	O
CVP	-	557	O
increased	-	561	O
significantly	-	571	O
above	-	585	O
baseline	-	591	O
(	-	600	O
delta	-	601	O
ICP	-	607	O
7	-	611	O
.	-	612	O
5	-	613	O
+	-	615	O
/	-	616	O
-	-	617	O

1	3125768	619	O
.	-	620	O
0	-	621	O
mmHg	-	623	O
,	-	627	O
delta	-	629	O
CVP	-	635	O
5	-	639	O
.	-	640	O
9	-	641	O
+	-	643	O
/	-	644	O
-	-	645	O

1	3125768	647	O
.	-	648	O
3	-	649	O
mmHg	-	651	O
)	-	655	O
.	-	656	O

These	3125768	658	O
variables	-	664	O
returned	-	674	O
to	-	683	O
baseline	-	686	O
when	-	695	O
rigidity	-	700	O
was	-	709	O
abolished	-	713	O
with	-	723	O
metocurine	-	728	B
.	-	738	O

In	3125768	740	O
five	-	743	O
rats	-	748	O
that	-	753	O
did	-	758	O
not	-	762	O
become	-	766	O
rigid	-	773	O
,	-	778	O
ICP	-	780	O
and	-	784	O
CVP	-	788	O
did	-	792	O
not	-	796	O
change	-	800	O
following	-	807	O
alfentanil	-	817	B
.	-	827	O

These	3125768	829	O
observations	-	835	O
suggest	-	848	O
that	-	856	O
rigidity	-	861	O
should	-	870	O
be	-	877	O
prevented	-	880	O
when	-	890	O
alfentanil	-	895	B
,	-	905	O
and	-	907	O
,	-	910	O
presumably	-	912	O
,	-	922	O
other	-	924	O
opiates	-	930	O
,	-	937	O
are	-	939	O
used	-	943	O
in	-	948	O
the	-	951	O
anesthetic	-	955	O
management	-	966	O
of	-	977	O
patients	-	980	O
with	-	989	O
ICP	-	994	O
problems	-	998	O
.	-	1006	O

Adverse	3187073	0	O
cardiac	-	8	O
effects	-	16	O
during	-	24	O
induction	-	31	O
chemotherapy	-	41	O
treatment	-	54	O
with	-	64	O
cis	-	69	B
-	-	72	I
platin	-	73	I
and	-	80	O
5	-	84	B
-	-	85	I
fluorouracil	-	86	I
.	-	98	O

Survival	3187073	100	O
for	-	109	O
patients	-	113	O
with	-	122	O
advanced	-	127	O
head	-	136	O
and	-	141	O
neck	-	145	O
carcinoma	-	150	O
and	-	160	O
esophageal	-	164	O
carcinoma	-	175	O
is	-	185	O
poor	-	188	O
with	-	193	O
radiotherapy	-	198	O
and	-	211	O
/	-	214	O
or	-	215	O
surgery	-	218	O
.	-	225	O

Obviously	3187073	227	O
,	-	236	O
there	-	238	O
is	-	244	O
a	-	247	O
need	-	249	O
for	-	254	O
effective	-	258	O
chemotherapy	-	268	O
.	-	280	O

In	3187073	282	O
the	-	285	O
present	-	289	O
study	-	297	O
,	-	302	O
cis	-	304	B
-	-	307	I
platin	-	308	I
(	-	315	O
80	-	316	O
-	-	318	O
120	-	319	O
mg	-	323	O
/	-	325	O
m2BSA	-	326	O
)	-	331	O
and	-	333	O
5	-	337	B
-	-	338	I
FU	-	339	I
(	-	342	O
1000	-	343	O
mg	-	348	O
/	-	350	O
m2BSA	-	351	O
daily	-	357	O
as	-	363	O
a	-	366	O
continuous	-	368	O
infusion	-	379	O
during	-	388	O
5	-	395	O
days	-	397	O
)	-	401	O
were	-	403	O
given	-	408	O
to	-	414	O
76	-	417	O
patients	-	420	O
before	-	429	O
radiotherapy	-	436	O
and	-	449	O
surgery	-	453	O
.	-	460	O

The	3187073	462	O
aim	-	466	O
of	-	470	O
the	-	473	O
study	-	477	O
was	-	483	O
to	-	487	O
clarify	-	490	O
the	-	498	O
incidence	-	502	O
and	-	512	O
severity	-	516	O
of	-	525	O
adverse	-	528	O
cardiac	-	536	O
effects	-	544	O
to	-	552	O
this	-	555	O
treatment	-	560	O
.	-	569	O

Before	3187073	571	O
treatment	-	578	O
all	-	588	O
patients	-	592	O
had	-	601	O
a	-	605	O
cardiac	-	607	O
evaluation	-	615	O
and	-	626	O
during	-	630	O
treatment	-	637	O
serial	-	647	O
ECG	-	654	O
recordings	-	658	O
were	-	669	O
performed	-	674	O
.	-	683	O

In	3187073	685	O
the	-	688	O
pre	-	692	O
-	-	695	O
treatment	-	696	O
evaluation	-	706	O
,	-	716	O
signs	-	718	O
of	-	724	O
cardiovascular	-	727	O
disease	-	742	O
were	-	750	O
found	-	755	O
in	-	761	O
33	-	764	O
patients	-	767	O
(	-	776	O
43	-	777	O
%	-	779	O
)	-	780	O
.	-	781	O

During	3187073	783	O
treatment	-	790	O
,	-	799	O
adverse	-	801	O
cardiac	-	809	O
effects	-	817	O
were	-	825	O
observed	-	830	O
in	-	839	O
14	-	842	O
patients	-	845	O
(	-	854	O
18	-	855	O
%	-	857	O
)	-	858	O
.	-	859	O

The	3187073	861	O
mean	-	865	O
age	-	870	O
of	-	874	O
these	-	877	O
patients	-	883	O
was	-	892	O
the	-	896	O
same	-	900	O
as	-	905	O
for	-	908	O
the	-	912	O
entire	-	916	O
group	-	923	O
,	-	928	O
64	-	930	O
years	-	933	O
.	-	938	O

The	3187073	940	O
incidence	-	944	O
of	-	954	O
cardiotoxicity	-	957	O
was	-	972	O
not	-	976	O
higher	-	980	O
in	-	987	O
patients	-	990	O
with	-	999	O
signs	-	1004	O
of	-	1010	O
cardiovascular	-	1013	O
disease	-	1028	O
than	-	1036	O
in	-	1041	O
those	-	1044	O
without	-	1050	O
in	-	1058	O
the	-	1061	O
pre	-	1065	O
-	-	1068	O
treatment	-	1069	O
evaluation	-	1079	O
.	-	1089	O

The	3187073	1091	O
most	-	1095	O
common	-	1100	O
signs	-	1107	O
of	-	1113	O
cardiotoxicity	-	1116	O
were	-	1131	O
chest	-	1136	O
pain	-	1142	O
,	-	1146	O
ST	-	1148	O
-	-	1150	O
T	-	1151	O
wave	-	1153	O
changes	-	1158	O
and	-	1166	O
atrial	-	1170	O
fibrillation	-	1177	O
.	-	1189	O

This	3187073	1191	O
was	-	1196	O
followed	-	1200	O
by	-	1209	O
ventricular	-	1212	O
fibrillation	-	1224	O
in	-	1237	O
one	-	1240	O
patient	-	1244	O
and	-	1252	O
sudden	-	1256	O
death	-	1263	O
in	-	1269	O
another	-	1272	O
.	-	1279	O

It	3187073	1281	O
is	-	1284	O
concluded	-	1287	O
that	-	1297	O
patients	-	1302	O
on	-	1311	O
5	-	1314	B
-	-	1315	I
FU	-	1316	I
treatment	-	1319	O
should	-	1329	O
be	-	1336	O
under	-	1339	O
close	-	1345	O
supervision	-	1351	O
and	-	1363	O
that	-	1367	O
the	-	1372	O
treatment	-	1376	O
should	-	1386	O
be	-	1393	O
discontinued	-	1396	O
if	-	1409	O
chest	-	1412	O
pain	-	1418	O
or	-	1423	O
tachyarrhythmia	-	1426	O
is	-	1442	O
observed	-	1445	O
.	-	1453	O

Verapamil	3371379	0	B
-	-	9	O
induced	-	10	O
carbamazepine	-	18	B
neurotoxicity	-	32	O
.	-	45	O

A	3371379	47	O
report	-	49	O
of	-	56	O
two	-	59	O
cases	-	63	O
.	-	68	O

Two	3371379	70	O
patients	-	74	O
with	-	83	O
signs	-	88	O
of	-	94	O
carbamazepine	-	97	B
neurotoxicity	-	111	O
after	-	125	O
combined	-	131	O
treatment	-	140	O
with	-	150	O
verapamil	-	155	B
showed	-	165	O
complete	-	172	O
recovery	-	181	O
after	-	190	O
discontinuation	-	196	O
of	-	212	O
the	-	215	O
calcium	-	219	B
entry	-	227	O
blocker	-	233	O
.	-	240	O

Use	3371379	242	O
of	-	246	O
verapamil	-	249	B
in	-	259	O
combination	-	262	O
with	-	274	O
carbamazepine	-	279	B
should	-	293	O
either	-	300	O
be	-	307	O
avoided	-	310	O
or	-	318	O
prescribed	-	321	O
only	-	332	O
with	-	337	O
appropriate	-	342	O
adjustment	-	354	O
of	-	365	O
the	-	368	O
carbamazepine	-	372	B
dose	-	386	O
(	-	391	O
usually	-	392	O
reduction	-	400	O
of	-	410	O
the	-	413	O
carbamazepine	-	417	B
dose	-	431	O
by	-	436	O
one	-	439	O
half	-	443	O
)	-	447	O
.	-	448	O

Serial	3503576	0	O
studies	-	7	O
of	-	15	O
auditory	-	18	O
neurotoxicity	-	27	O
in	-	41	O
patients	-	44	O
receiving	-	53	O
deferoxamine	-	63	B
therapy	-	76	O
.	-	83	O

Visual	3503576	85	O
and	-	92	O
auditory	-	96	O
neurotoxicity	-	105	O
was	-	119	O
previously	-	123	O
documented	-	134	O
in	-	145	O
42	-	148	O
of	-	151	O
89	-	154	O
patients	-	157	O
with	-	166	O
transfusion	-	171	O
-	-	182	O
dependent	-	183	O
anemia	-	193	O
who	-	200	O
were	-	204	O
receiving	-	209	O
iron	-	219	B
chelation	-	224	O
therapy	-	234	O
with	-	242	O
daily	-	247	O
subcutaneous	-	253	O
deferoxamine	-	266	B
.	-	278	O

Twenty	3503576	280	O
-	-	286	O
two	-	287	O
patients	-	291	O
in	-	300	O
the	-	303	O
affected	-	307	O
group	-	316	O
had	-	322	O
abnormal	-	326	O
audiograms	-	335	O
with	-	346	O
deficits	-	351	O
mostly	-	360	O
in	-	367	O
the	-	370	O
high	-	374	O
frequency	-	379	O
range	-	389	O
of	-	395	O
4	-	398	O
,	-	399	O
000	-	400	O
to	-	404	O
8	-	407	O
,	-	408	O
000	-	409	O
Hz	-	413	O
and	-	416	O
in	-	420	O
the	-	423	O
hearing	-	427	O
threshold	-	435	O
levels	-	445	O
of	-	452	O
30	-	455	O
to	-	458	O
100	-	461	O
decibels	-	465	O
.	-	473	O

When	3503576	475	O
deferoxamine	-	480	B
therapy	-	493	O
was	-	501	O
discontinued	-	505	O
and	-	518	O
serial	-	522	O
studies	-	529	O
were	-	537	O
performed	-	542	O
,	-	551	O
audiograms	-	553	O
in	-	564	O
seven	-	567	O
cases	-	573	O
reverted	-	579	O
to	-	588	O
normal	-	591	O
or	-	598	O
near	-	601	O
normal	-	606	O
within	-	613	O
two	-	620	O
to	-	624	O
three	-	627	O
weeks	-	633	O
,	-	638	O
and	-	640	O
nine	-	644	O
of	-	649	O
13	-	652	O
patients	-	655	O
with	-	664	O
symptoms	-	669	O
became	-	678	O
asymptomatic	-	685	O
.	-	697	O

Audiograms	3503576	699	O
from	-	710	O
15	-	715	O
patients	-	718	O
remained	-	727	O
abnormal	-	736	O
and	-	745	O
four	-	749	O
patients	-	754	O
required	-	763	O
hearing	-	772	O
aids	-	780	O
because	-	785	O
of	-	793	O
permanent	-	796	O
disability	-	806	O
.	-	816	O

Since	3503576	818	O
18	-	824	O
of	-	827	O
the	-	830	O
22	-	834	O
patients	-	837	O
were	-	846	O
initially	-	851	O
receiving	-	861	O
deferoxamine	-	871	B
doses	-	884	O
in	-	890	O
excess	-	893	O
of	-	900	O
the	-	903	O
commonly	-	907	O
recommended	-	916	O
50	-	928	O
mg	-	931	O
/	-	933	O
kg	-	934	O
per	-	937	O
dose	-	941	O
,	-	945	O
therapy	-	947	O
was	-	955	O
restarted	-	959	O
with	-	969	O
lower	-	974	O
doses	-	980	O
,	-	985	O
usually	-	987	O
50	-	995	O
mg	-	998	O
/	-	1000	O
kg	-	1001	O
per	-	1004	O
dose	-	1008	O
or	-	1013	O
less	-	1016	O
depending	-	1021	O
on	-	1031	O
the	-	1034	O
degree	-	1038	O
of	-	1045	O
auditory	-	1048	O
abnormality	-	1057	O
,	-	1068	O
and	-	1070	O
with	-	1074	O
the	-	1079	O
exception	-	1083	O
of	-	1093	O
two	-	1096	O
cases	-	1100	O
no	-	1106	O
further	-	1109	O
toxicity	-	1117	O
was	-	1126	O
demonstrated	-	1130	O
.	-	1142	O

Auditory	3503576	1144	O
deterioration	-	1153	O
and	-	1167	O
improvement	-	1171	O
,	-	1182	O
demonstrated	-	1184	O
serially	-	1197	O
in	-	1206	O
individual	-	1209	O
patients	-	1220	O
receiving	-	1229	O
and	-	1239	O
not	-	1243	O
receiving	-	1247	O
deferoxamine	-	1257	B
,	-	1269	O
respectively	-	1271	O
,	-	1283	O
provided	-	1285	O
convincing	-	1294	O
evidence	-	1305	O
for	-	1314	O
a	-	1318	O
cause	-	1320	O
-	-	1325	O
and	-	1326	O
-	-	1329	O
effect	-	1330	O
relation	-	1337	O
between	-	1346	O
deferoxamine	-	1354	B
administration	-	1367	O
and	-	1382	O
ototoxicity	-	1386	O
.	-	1397	O

Based	3503576	1399	O
on	-	1405	O
these	-	1408	O
data	-	1414	O
,	-	1418	O
a	-	1420	O
plan	-	1422	O
of	-	1427	O
management	-	1430	O
was	-	1441	O
developed	-	1445	O
that	-	1455	O
allows	-	1460	O
effective	-	1467	O
yet	-	1477	O
safe	-	1481	O
administration	-	1486	O
of	-	1501	O
deferoxamine	-	1504	B
.	-	1516	O

A	3503576	1518	O
dose	-	1520	O
of	-	1525	O
50	-	1528	O
mg	-	1531	O
/	-	1533	O
kg	-	1534	O
is	-	1537	O
recommended	-	1540	O
in	-	1552	O
those	-	1555	O
without	-	1561	O
audiogram	-	1569	O
abnormalities	-	1579	O
.	-	1592	O

With	3503576	1594	O
mild	-	1599	O
toxicity	-	1604	O
,	-	1612	O
a	-	1614	O
reduction	-	1616	O
to	-	1626	O
30	-	1629	O
or	-	1632	O
40	-	1635	O
mg	-	1638	O
/	-	1640	O
kg	-	1641	O
per	-	1644	O
dose	-	1648	O
should	-	1653	O
result	-	1660	O
in	-	1667	O
a	-	1670	O
reversal	-	1672	O
of	-	1681	O
the	-	1684	O
abnormal	-	1688	O
results	-	1697	O
to	-	1705	O
normal	-	1708	O
within	-	1715	O
four	-	1722	O
weeks	-	1727	O
.	-	1732	O

Moderate	3503576	1734	O
abnormalities	-	1743	O
require	-	1757	O
a	-	1765	O
reduction	-	1767	O
of	-	1777	O
deferoxamine	-	1780	B
to	-	1793	O
25	-	1796	O
mg	-	1799	O
/	-	1801	O
kg	-	1802	O
per	-	1805	O
dose	-	1809	O
with	-	1814	O
careful	-	1819	O
monitoring	-	1827	O
.	-	1837	O

In	3503576	1839	O
those	-	1842	O
with	-	1848	O
symptoms	-	1853	O
of	-	1862	O
hearing	-	1865	O
loss	-	1873	O
,	-	1877	O
the	-	1879	O
drug	-	1883	O
should	-	1888	O
be	-	1895	O
stopped	-	1898	O
for	-	1906	O
four	-	1910	O
weeks	-	1915	O
,	-	1920	O
and	-	1922	O
when	-	1926	O
the	-	1931	O
audiogram	-	1935	O
is	-	1945	O
stable	-	1948	O
or	-	1955	O
improved	-	1958	O
,	-	1966	O
therapy	-	1968	O
should	-	1976	O
be	-	1983	O
restarted	-	1986	O
at	-	1996	O
10	-	1999	O
to	-	2002	O
25	-	2005	O
mg	-	2008	O
/	-	2010	O
kg	-	2011	O
per	-	2014	O
dose	-	2018	O
.	-	2022	O

Serial	3503576	2024	O
audiograms	-	2031	O
should	-	2042	O
be	-	2049	O
performed	-	2052	O
every	-	2062	O
six	-	2068	O
months	-	2072	O
in	-	2079	O
those	-	2082	O
without	-	2088	O
problems	-	2096	O
and	-	2105	O
more	-	2109	O
frequently	-	2114	O
in	-	2125	O
young	-	2128	O
patients	-	2134	O
with	-	2143	O
normal	-	2148	O
serum	-	2155	O
ferritin	-	2161	O
values	-	2170	O
and	-	2177	O
in	-	2181	O
those	-	2184	O
with	-	2190	O
auditory	-	2195	O
dysfunction	-	2204	O
.	-	2215	O

Flurbiprofen	3560095	0	B
in	-	13	O
the	-	16	O
treatment	-	20	O
of	-	30	O
juvenile	-	33	O
rheumatoid	-	42	O
arthritis	-	53	O
.	-	62	O

Thirty	3560095	64	O
-	-	70	O
four	-	71	O
patients	-	76	O
with	-	85	O
juvenile	-	90	O
rheumatoid	-	99	O
arthritis	-	110	O
,	-	119	O
who	-	121	O
were	-	125	O
treated	-	130	O
with	-	138	O
flurbiprofen	-	143	B
at	-	156	O
a	-	159	O
maximum	-	161	O
dose	-	169	O
of	-	174	O
4	-	177	O
mg	-	179	O
/	-	181	O
kg	-	182	O
/	-	184	O
day	-	185	O
,	-	188	O
had	-	190	O
statistically	-	194	O
significant	-	208	O
decreases	-	220	O
from	-	230	O
baseline	-	235	O
in	-	244	O
6	-	247	O
arthritis	-	249	O
indices	-	259	O
after	-	267	O
12	-	273	O
weeks	-	276	O
of	-	282	O
treatment	-	285	O
.	-	294	O

Improvements	3560095	296	O
were	-	309	O
seen	-	314	O
in	-	319	O
the	-	322	O
number	-	326	O
of	-	333	O
tender	-	336	O
joints	-	343	O
,	-	349	O
the	-	351	O
severity	-	355	O
of	-	364	O
swelling	-	367	O
and	-	376	O
tenderness	-	380	O
,	-	390	O
the	-	392	O
time	-	396	O
of	-	401	O
walk	-	404	O
50	-	409	O
feet	-	412	O
,	-	416	O
the	-	418	O
duration	-	422	O
of	-	431	O
morning	-	434	O
stiffness	-	442	O
and	-	452	O
the	-	456	O
circumference	-	460	O
of	-	474	O
the	-	477	O
left	-	481	O
knee	-	486	O
.	-	490	O

The	3560095	492	O
most	-	496	O
frequently	-	501	O
observed	-	512	O
side	-	521	O
effect	-	526	O
was	-	533	O
fecal	-	537	O
occult	-	543	O
blood	-	550	O
(	-	556	O
25	-	557	O
%	-	559	O
of	-	561	O
patients	-	564	O
)	-	572	O
;	-	573	O
however	-	575	O
,	-	582	O
there	-	584	O
was	-	590	O
no	-	594	O
other	-	597	O
evidence	-	603	O
of	-	612	O
gastrointestinal	-	615	O
(	-	632	O
GI	-	633	O
)	-	635	O
bleeding	-	637	O
in	-	646	O
these	-	649	O
patients	-	655	O
.	-	663	O

One	3560095	665	O
patient	-	669	O
was	-	677	O
prematurely	-	681	O
discontinued	-	693	O
from	-	706	O
the	-	711	O
study	-	715	O
for	-	721	O
severe	-	725	O
headache	-	732	O
and	-	741	O
abdominal	-	745	O
pain	-	755	O
.	-	759	O

Most	3560095	761	O
side	-	766	O
effects	-	771	O
were	-	779	O
mild	-	784	O
and	-	789	O
related	-	793	O
to	-	801	O
the	-	804	O
GI	-	808	O
tract	-	811	O
.	-	816	O

The	3714122	0	O
correlation	-	4	O
between	-	16	O
neurotoxic	-	24	O
esterase	-	35	O
inhibition	-	44	O
and	-	55	O
mipafox	-	59	B
-	-	66	O
induced	-	67	O
neuropathic	-	75	O
damage	-	87	O
in	-	94	O
rats	-	97	O
.	-	101	O

The	3714122	103	O
correlation	-	107	O
between	-	119	O
neuropathic	-	127	O
damage	-	139	O
and	-	146	O
inhibition	-	150	O
of	-	161	O
neurotoxic	-	164	O
esterase	-	175	O
or	-	184	O
neuropathy	-	187	O
target	-	198	O
enzyme	-	205	O
(	-	212	O
NTE	-	213	O
)	-	216	O
was	-	218	O
examined	-	222	O
in	-	231	O
rats	-	234	O
acutely	-	239	O
exposed	-	247	O
to	-	255	O
Mipafox	-	258	B
(	-	266	O
N	-	267	B
,	-	268	I
N'	-	270	I
-	-	272	I
diisopropylphosphorodiamidofluoridate	-	273	I
)	-	310	O
,	-	311	O
a	-	313	O
neurotoxic	-	315	O
organophosphate	-	326	B
.	-	341	O

Brain	3714122	343	O
and	-	349	O
spinal	-	353	O
cord	-	360	O
NTE	-	365	O
activities	-	369	O
were	-	380	O
measured	-	385	O
in	-	394	O
Long	-	397	O
-	-	401	O
Evans	-	402	O
male	-	408	O
rats	-	413	O
1	-	418	O
hr	-	420	O
post	-	423	O
-	-	427	O
exposure	-	428	O
to	-	437	O
various	-	440	O
dosages	-	448	O
of	-	456	O
Mipafox	-	459	B
(	-	467	O
ip	-	468	O
,	-	470	O
1	-	472	O
-	-	473	O
15	-	474	O
mg	-	477	O
/	-	479	O
kg	-	480	O
)	-	482	O
.	-	483	O

These	3714122	485	O
data	-	491	O
were	-	496	O
correlated	-	501	O
with	-	512	O
histologically	-	517	O
scored	-	532	O
cervical	-	539	O
cord	-	548	O
damage	-	553	O
in	-	560	O
a	-	563	O
separate	-	565	O
group	-	574	O
of	-	580	O
similarly	-	583	O
dosed	-	593	O
rats	-	599	O
sampled	-	604	O
14	-	612	O
-	-	614	O
21	-	615	O
days	-	618	O
post	-	623	O
-	-	627	O
exposure	-	628	O
.	-	636	O

Those	3714122	638	O
dosages	-	644	O
(	-	652	O
greater	-	653	O
than	-	661	O
or	-	666	O
equal	-	669	O
to	-	675	O
10	-	678	O
mg	-	681	O
/	-	683	O
kg	-	684	O
)	-	686	O
that	-	688	O
inhibited	-	693	O
mean	-	703	O
NTE	-	708	O
activity	-	712	O
in	-	721	O
the	-	724	O
spinal	-	728	O
cord	-	735	O
greater	-	740	O
than	-	748	O
or	-	753	O
equal	-	756	O
to	-	762	O
73	-	765	O
%	-	767	O
and	-	769	O
brain	-	773	O
greater	-	779	O
than	-	787	O
or	-	792	O
equal	-	795	O
to	-	801	O
67	-	804	O
%	-	806	O
of	-	808	O
control	-	811	O
values	-	819	O
produced	-	826	O
severe	-	835	O
(	-	842	O
greater	-	843	O
than	-	851	O
or	-	856	O
equal	-	859	O
to	-	865	O
3	-	868	O
)	-	869	O
cervical	-	871	O
cord	-	880	O
pathology	-	885	O
in	-	895	O
85	-	898	O
%	-	900	O
of	-	902	O
the	-	905	O
rats	-	909	O
.	-	913	O

In	3714122	915	O
contrast	-	918	O
,	-	926	O
dosages	-	928	O
of	-	936	O
Mipafox	-	939	B
(	-	947	O
less	-	948	O
than	-	953	O
or	-	958	O
equal	-	961	O
to	-	967	O
5	-	970	O
mg	-	972	O
/	-	974	O
kg	-	975	O
)	-	977	O
which	-	979	O
inhibited	-	985	O
mean	-	995	O
NTE	-	1000	O
activity	-	1004	O
in	-	1013	O
spinal	-	1016	O
cord	-	1023	O
less	-	1028	O
than	-	1033	O
or	-	1038	O
equal	-	1041	O
to	-	1047	O
61	-	1050	O
%	-	1052	O
and	-	1054	O
brain	-	1058	O
less	-	1064	O
than	-	1069	O
or	-	1074	O
equal	-	1077	O
to	-	1083	O
60	-	1086	O
%	-	1088	O
produced	-	1090	O
this	-	1099	O
degree	-	1104	O
of	-	1111	O
cord	-	1114	O
damage	-	1119	O
in	-	1126	O
only	-	1129	O
9	-	1134	O
%	-	1135	O
of	-	1137	O
the	-	1140	O
animals	-	1144	O
.	-	1151	O

These	3714122	1153	O
data	-	1159	O
indicate	-	1164	O
that	-	1173	O
a	-	1178	O
critical	-	1180	O
percentage	-	1189	O
of	-	1200	O
NTE	-	1203	O
inhibition	-	1207	O
in	-	1218	O
brain	-	1221	O
and	-	1227	O
spinal	-	1231	O
cord	-	1238	O
sampled	-	1243	O
shortly	-	1251	O
after	-	1259	O
Mipafox	-	1265	B
exposure	-	1273	O
can	-	1282	O
predict	-	1286	O
neuropathic	-	1294	O
damage	-	1306	O
in	-	1313	O
rats	-	1316	O
several	-	1321	O
weeks	-	1329	O
later	-	1335	O
.	-	1340	O

Cerebral	3828020	0	O
infarction	-	9	O
with	-	20	O
a	-	25	O
single	-	27	O
oral	-	34	O
dose	-	39	O
of	-	44	O
phenylpropanolamine	-	47	B
.	-	66	O

Phenylpropanolamine	3828020	68	B
(	-	88	O
PPA	-	89	B
)	-	92	O
,	-	93	O
a	-	95	O
synthetic	-	97	O
sympathomimetic	-	107	O
that	-	123	O
is	-	128	O
structurally	-	131	O
similar	-	144	O
to	-	152	O
amphetamine	-	155	B
,	-	166	O
is	-	168	O
available	-	171	O
over	-	181	O
the	-	186	O
counter	-	190	O
in	-	198	O
anorectics	-	201	O
,	-	211	O
nasal	-	213	O
congestants	-	219	O
,	-	230	O
and	-	232	O
cold	-	236	O
preparations	-	241	O
.	-	253	O

Its	3828020	255	O
prolonged	-	259	O
use	-	269	O
or	-	273	O
overuse	-	276	O
has	-	284	O
been	-	288	O
associated	-	293	O
with	-	304	O
seizures	-	309	O
,	-	317	O
intracerebral	-	319	O
hemorrhage	-	333	O
,	-	343	O
neuropsychiatric	-	345	O
symptoms	-	362	O
,	-	370	O
and	-	372	O
nonhemorrhagic	-	376	O
cerebral	-	391	O
infarction	-	400	O
.	-	410	O

We	3828020	412	O
report	-	415	O
the	-	422	O
case	-	426	O
of	-	431	O
a	-	434	O
young	-	436	O
woman	-	442	O
who	-	448	O
suffered	-	452	O
a	-	461	O
cerebral	-	463	O
infarction	-	472	O
after	-	483	O
taking	-	489	O
a	-	496	O
single	-	498	O
oral	-	505	O
dose	-	510	O
of	-	515	O
PPA	-	518	B
.	-	521	O

Treatment	4812392	0	O
of	-	10	O
psoriasis	-	13	O
with	-	23	O
azathioprine	-	28	B
.	-	40	O

Azathioprine	4812392	42	B
treatment	-	55	O
benefited	-	65	O
19	-	75	O
(	-	78	O
66	-	79	O
%	-	81	O
)	-	82	O
out	-	84	O
of	-	88	O
29	-	91	O
patients	-	94	O
suffering	-	103	O
from	-	113	O
severe	-	118	O
psoriasis	-	125	O
.	-	134	O

Haematological	4812392	136	O
complications	-	151	O
were	-	165	O
not	-	170	O
troublesome	-	174	O
and	-	186	O
results	-	190	O
of	-	198	O
biochemical	-	201	O
liver	-	213	O
function	-	219	O
tests	-	228	O
remained	-	234	O
normal	-	243	O
.	-	249	O

Minimal	4812392	251	O
cholestasis	-	259	O
was	-	271	O
seen	-	275	O
in	-	280	O
two	-	283	O
cases	-	287	O
and	-	293	O
portal	-	297	O
fibrosis	-	304	O
of	-	313	O
a	-	316	O
reversible	-	318	O
degree	-	329	O
in	-	336	O
eight	-	339	O
.	-	344	O

Liver	4812392	346	O
biopsies	-	352	O
should	-	361	O
be	-	368	O
undertaken	-	371	O
at	-	382	O
regular	-	385	O
intervals	-	393	O
if	-	403	O
azathioprine	-	406	B
therapy	-	419	O
is	-	427	O
continued	-	430	O
so	-	440	O
that	-	443	O
structural	-	448	O
liver	-	459	O
damage	-	465	O
may	-	472	O
be	-	476	O
detected	-	479	O
at	-	488	O
an	-	491	O
early	-	494	O
and	-	500	O
reversible	-	504	O
stage	-	515	O
.	-	520	O

Maternal	6518066	0	O
lithium	-	9	B
and	-	17	O
neonatal	-	21	O

Ebstein	6518066	30	O
's	-	37	O
anomaly	-	40	O
:	-	47	O
evaluation	-	49	O
with	-	60	O
cross	-	65	O
-	-	70	O
sectional	-	71	O
echocardiography	-	81	O
.	-	97	O

Cross	6518066	99	O
-	-	104	O
sectional	-	105	O
echocardiography	-	115	O
was	-	132	O
used	-	136	O
to	-	141	O
evaluate	-	144	O
two	-	153	O
neonates	-	157	O
whose	-	166	O
mothers	-	172	O
ingested	-	180	O
lithium	-	189	B
during	-	197	O
pregnancy	-	204	O
.	-	213	O

In	6518066	215	O
one	-	218	O
infant	-	222	O
,	-	228	O
Ebstein	-	230	O
's	-	237	O
anomaly	-	240	O
of	-	248	O
the	-	251	O
tricuspid	-	255	O
valve	-	265	O
was	-	271	O
identified	-	275	O
.	-	285	O

In	6518066	287	O
the	-	290	O
other	-	294	O
infant	-	300	O
cross	-	307	O
-	-	312	O
sectional	-	313	O
echocardiography	-	323	O
provided	-	340	O
reassurance	-	349	O
that	-	361	O
the	-	366	O
infant	-	370	O
did	-	377	O
not	-	381	O
have	-	385	O
Ebstein	-	390	O
's	-	397	O
anomaly	-	400	O
.	-	407	O

Cross	6518066	409	O
-	-	414	O
sectional	-	415	O
echocardiographic	-	425	O
screening	-	443	O
of	-	453	O
newborns	-	456	O
exposed	-	465	O
to	-	473	O
lithium	-	476	B
during	-	484	O
gestation	-	491	O
can	-	501	O
provide	-	505	O
highly	-	513	O
accurate	-	520	O
,	-	528	O
noninvasive	-	530	O
assessment	-	542	O
of	-	553	O
the	-	556	O
presence	-	560	O
or	-	569	O
absence	-	572	O
of	-	580	O
lithium	-	583	B
-	-	590	O
induced	-	591	O
cardiac	-	599	O
malformations	-	607	O
.	-	620	O

Effects	6534871	0	O
of	-	8	O
training	-	11	O
on	-	20	O
the	-	23	O
extent	-	27	O
of	-	34	O
experimental	-	37	O
myocardial	-	50	O
infarction	-	61	O
in	-	72	O
aging	-	75	O
rats	-	81	O
.	-	85	O

The	6534871	87	O
effects	-	91	O
of	-	99	O
exercise	-	102	O
on	-	111	O
the	-	114	O
severity	-	118	O
of	-	127	O
isoproterenol	-	130	B
-	-	143	O
induced	-	144	O
myocardial	-	152	O
infarction	-	163	O
were	-	174	O
studied	-	179	O
in	-	187	O
female	-	190	O
albino	-	197	O
rats	-	204	O
of	-	209	O
20	-	212	O
,	-	214	O
40	-	215	O
,	-	217	O
60	-	218	O
and	-	221	O
80	-	225	O
weeks	-	228	O
of	-	234	O
age	-	237	O
.	-	240	O

The	6534871	242	O
rats	-	246	O
were	-	251	O
trained	-	256	O
to	-	264	O
swim	-	267	O
for	-	272	O
a	-	276	O
specific	-	278	O
duration	-	287	O
and	-	296	O
for	-	300	O
a	-	304	O
particular	-	306	O
period	-	317	O
.	-	323	O

The	6534871	325	O
occurrence	-	329	O
of	-	340	O
infarcts	-	343	O
were	-	352	O
confirmed	-	357	O
by	-	367	O
histological	-	370	O
methods	-	383	O
.	-	390	O

Elevations	6534871	392	O
in	-	403	O
the	-	406	O
serum	-	410	O
GOT	-	416	O
and	-	420	O
GPT	-	424	O
were	-	428	O
maximum	-	433	O
in	-	441	O
the	-	444	O
sedentary	-	448	O
-	-	457	O
isoproterenols	-	458	B
and	-	473	O
minimum	-	477	O
in	-	485	O
the	-	488	O
exercise	-	492	O
-	-	500	O
controls	-	501	O
.	-	509	O

These	6534871	511	O
changes	-	517	O
in	-	525	O
the	-	528	O
serum	-	532	O
transaminases	-	538	O
were	-	552	O
associated	-	557	O
with	-	568	O
corresponding	-	573	O
depletions	-	587	O
in	-	598	O
the	-	601	O
cardiac	-	605	O
GOT	-	613	O
and	-	617	O
GPT	-	621	O
.	-	624	O

However	6534871	626	O
,	-	633	O
age	-	635	O
was	-	639	O
seen	-	643	O
to	-	648	O
interfere	-	651	O
with	-	661	O
the	-	666	O
responses	-	670	O
exhibited	-	680	O
by	-	690	O
the	-	693	O
young	-	697	O
and	-	703	O
old	-	707	O
rats	-	711	O
.	-	715	O

Studies	6534871	717	O
dealing	-	725	O
with	-	733	O
myocardial	-	738	O
infarction	-	749	O
are	-	760	O
more	-	764	O
informative	-	769	O
when	-	781	O
dealt	-	786	O
with	-	792	O
age	-	797	O
.	-	800	O

Effect	6538499	0	O
of	-	7	O
polyethylene	-	10	B
glycol	-	23	I
400	-	30	I
on	-	34	O
adriamycin	-	37	B
toxicity	-	48	O
in	-	57	O
mice	-	60	O
.	-	64	O

The	6538499	66	O
effect	-	70	O
of	-	77	O
a	-	80	O
widely	-	82	O
used	-	89	O
organic	-	94	O
solvent	-	102	O
,	-	109	O
polyethylene	-	111	B
glycol	-	124	I
400	-	131	I
(	-	135	O
PEG	-	136	B
400	-	140	I
)	-	143	O
,	-	144	O
on	-	146	O
the	-	149	O
toxic	-	153	O
action	-	159	O
of	-	166	O
an	-	169	O
acute	-	172	O
or	-	178	O
chronic	-	181	O
treatment	-	189	O
with	-	199	O
adriamycin	-	204	B
(	-	215	O
ADR	-	216	B
)	-	219	O
was	-	221	O
evaluated	-	225	O
in	-	235	O
mice	-	238	O
.	-	242	O

PEG	6538499	244	B
400	-	248	I
impressively	-	252	O
decreased	-	265	O
both	-	275	O
acute	-	280	O
high	-	286	O
-	-	290	O
dose	-	291	O
and	-	296	O
chronic	-	300	O
low	-	308	O
-	-	311	O
dose	-	312	O
-	-	316	O
ADR	-	317	B
-	-	320	O
associated	-	321	O
lethality	-	332	O
.	-	341	O

Light	6538499	343	O
microscopic	-	349	O
analysis	-	361	O
showed	-	370	O
a	-	377	O
significant	-	379	O
protection	-	391	O
against	-	402	O
ADR	-	410	B
-	-	413	O
induced	-	414	O
cardiac	-	422	O
morphological	-	430	O
alterations	-	444	O
.	-	455	O

Such	6538499	457	O
treatment	-	462	O
did	-	472	O
not	-	476	O
diminish	-	480	O
the	-	489	O
ADR	-	493	B
antitumor	-	497	O
activity	-	507	O
in	-	516	O
L1210	-	519	O
leukemia	-	525	O
and	-	534	O
in	-	538	O
Ehrlich	-	541	O
ascites	-	549	O
tumor	-	557	O
.	-	562	O

Intra	6747681	0	O
-	-	5	O
arterial	-	6	O
BCNU	-	15	B
chemotherapy	-	20	O
for	-	33	O
treatment	-	37	O
of	-	47	O
malignant	-	50	O
gliomas	-	60	O
of	-	68	O
the	-	71	O
central	-	75	O
nervous	-	83	O
system	-	91	O
.	-	97	O

Because	6747681	99	O
of	-	107	O
the	-	110	O
rapid	-	114	O
systemic	-	120	O
clearance	-	129	O
of	-	139	O
BCNU	-	142	B
(	-	147	O
1	-	148	B
,	-	149	I
3	-	150	I
-	-	151	I
bis	-	152	I
-	-	155	I
(	-	156	I
2	-	157	I
-	-	158	I
chloroethyl	-	159	I
)	-	170	I
-	-	171	I
1	-	172	I
-	-	173	I
nitrosourea	-	174	I
)	-	185	O
,	-	186	O
intra	-	188	O
-	-	193	O
arterial	-	194	O
administration	-	203	O
should	-	218	O
provide	-	225	O
a	-	233	O
substantial	-	235	O
advantage	-	247	O
over	-	257	O
intravenous	-	262	O
administration	-	274	O
for	-	289	O
the	-	293	O
treatment	-	297	O
of	-	307	O
malignant	-	310	O
gliomas	-	320	O
.	-	327	O

Thirty	6747681	329	O
-	-	335	O
six	-	336	O
patients	-	340	O
were	-	349	O
treated	-	354	O
with	-	362	O
BCNU	-	367	B
every	-	372	O
6	-	378	O
to	-	380	O
8	-	383	O
weeks	-	385	O
,	-	390	O
either	-	392	O
by	-	399	O
transfemoral	-	402	O
catheterization	-	415	O
of	-	431	O
the	-	434	O
internal	-	438	O
carotid	-	447	O
or	-	455	O
vertebral	-	458	O
artery	-	468	O
or	-	475	O
through	-	478	O
a	-	486	O
fully	-	488	O
implantable	-	494	O
intracarotid	-	506	O
drug	-	519	O
delivery	-	524	O
system	-	533	O
,	-	539	O
beginning	-	541	O
with	-	551	O
a	-	556	O
dose	-	558	O
of	-	563	O
200	-	566	O
mg	-	570	O
/	-	572	O
sq	-	573	O
m	-	576	O
body	-	578	O
surface	-	583	O
area	-	591	O
.	-	595	O

Twelve	6747681	597	O
patients	-	604	O
with	-	613	O
Grade	-	618	O
III	-	624	O
or	-	628	O
IV	-	631	O
astrocytomas	-	634	O
were	-	647	O
treated	-	652	O
after	-	660	O
partial	-	666	O
resection	-	674	O
of	-	684	O
the	-	687	O
tumor	-	691	O
without	-	697	O
prior	-	705	O
radiation	-	711	O
therapy	-	721	O
.	-	728	O

After	6747681	730	O
two	-	736	O
to	-	740	O
seven	-	743	O
cycles	-	749	O
of	-	756	O
chemotherapy	-	759	O
,	-	771	O
nine	-	773	O
patients	-	778	O
showed	-	787	O
a	-	794	O
decrease	-	796	O
in	-	805	O
tumor	-	808	O
size	-	814	O
and	-	819	O
surrounding	-	823	O
edema	-	835	O
on	-	841	O
contrast	-	844	O
-	-	852	O
enhanced	-	853	O
computerized	-	862	O
tomography	-	875	O
scans	-	886	O
.	-	891	O

In	6747681	893	O
the	-	896	O
nine	-	900	O
responders	-	905	O
,	-	915	O
median	-	917	O
duration	-	924	O
of	-	933	O
chemotherapy	-	936	O
response	-	949	O
from	-	958	O
the	-	963	O
time	-	967	O
of	-	972	O
operation	-	975	O
was	-	985	O
25	-	989	O
weeks	-	992	O
(	-	998	O
range	-	999	O
12	-	1005	O
to	-	1008	O
more	-	1011	O
than	-	1016	O
91	-	1021	O
weeks	-	1024	O
)	-	1029	O
.	-	1030	O

The	6747681	1032	O
median	-	1036	O
duration	-	1043	O
of	-	1052	O
survival	-	1055	O
in	-	1064	O
the	-	1067	O
12	-	1071	O
patients	-	1074	O
was	-	1083	O
54	-	1087	O
weeks	-	1090	O
(	-	1096	O
range	-	1097	O
21	-	1103	O
to	-	1106	O
more	-	1109	O
than	-	1114	O
156	-	1119	O
weeks	-	1123	O
)	-	1128	O
,	-	1129	O
with	-	1131	O
an	-	1136	O
18	-	1139	O
-	-	1141	O
month	-	1142	O
survival	-	1148	O
rate	-	1157	O
of	-	1162	O
42	-	1165	O
%	-	1167	O
.	-	1168	O

Twenty	6747681	1170	O
-	-	1176	O
four	-	1177	O
patients	-	1182	O
with	-	1191	O
recurrent	-	1196	O
Grade	-	1206	O

I	6747681	1212	O
to	-	1214	O
IV	-	1217	O
astrocytomas	-	1220	O
,	-	1232	O
whose	-	1234	O
resection	-	1240	O
and	-	1250	O
irradiation	-	1254	O
therapy	-	1266	O
had	-	1274	O
failed	-	1278	O
,	-	1284	O
received	-	1286	O
two	-	1295	O
to	-	1299	O
eight	-	1302	O
courses	-	1308	O
of	-	1316	O
intra	-	1319	O
-	-	1324	O
arterial	-	1325	O
BCNU	-	1334	B
therapy	-	1339	O
.	-	1346	O

Seventeen	6747681	1348	O
of	-	1358	O
these	-	1361	O
had	-	1367	O
a	-	1371	O
response	-	1373	O
or	-	1382	O
were	-	1385	O
stable	-	1390	O
for	-	1397	O
a	-	1401	O
median	-	1403	O
of	-	1410	O
20	-	1413	O
weeks	-	1416	O
(	-	1422	O
range	-	1423	O
6	-	1429	O
to	-	1431	O
more	-	1434	O
than	-	1439	O
66	-	1444	O
weeks	-	1447	O
)	-	1452	O
.	-	1453	O

The	6747681	1455	O
catheterization	-	1459	O
procedure	-	1475	O
is	-	1485	O
safe	-	1488	O
,	-	1492	O
with	-	1494	O
no	-	1499	O
immediate	-	1502	O
complication	-	1512	O
in	-	1525	O
111	-	1528	O
infusions	-	1532	O
of	-	1542	O
BCNU	-	1545	B
.	-	1549	O

A	6747681	1551	O
delayed	-	1553	O
complication	-	1561	O
in	-	1574	O
nine	-	1577	O
patients	-	1582	O
has	-	1591	O
been	-	1595	O
unilateral	-	1600	O
loss	-	1611	O
of	-	1616	O
vision	-	1619	O
secondary	-	1626	O
to	-	1636	O
a	-	1639	O
retinal	-	1641	O
vasculitis	-	1649	O
.	-	1659	O

The	6747681	1661	O
frequency	-	1665	O
of	-	1675	O
visual	-	1678	O
loss	-	1685	O
decreased	-	1690	O
after	-	1700	O
the	-	1706	O
concentration	-	1710	O
of	-	1724	O
the	-	1727	O
ethanol	-	1731	B
diluent	-	1739	O
was	-	1747	O
lowered	-	1751	O
.	-	1758	O

Blood	6861444	0	O
pressure	-	6	O
response	-	15	O
to	-	24	O
chronic	-	27	O
low	-	35	O
-	-	38	O
dose	-	39	O
intrarenal	-	44	O
noradrenaline	-	55	B
infusion	-	69	O
in	-	78	O
conscious	-	81	O
rats	-	91	O
.	-	95	O

Sodium	6861444	97	B
chloride	-	104	I
solution	-	113	O
(	-	122	O
0	-	123	O
.	-	124	O
9	-	125	O
%	-	126	O
)	-	127	O
or	-	129	O
noradrenaline	-	132	B
in	-	146	O
doses	-	149	O
of	-	155	O
4	-	158	O
,	-	159	O
12	-	161	O
and	-	164	O
36	-	168	O
micrograms	-	171	O
h	-	182	O
-	-	183	O
1	-	184	O
kg	-	186	O
-	-	188	O
1	-	189	O
was	-	191	O
infused	-	195	O
for	-	203	O
five	-	207	O
consecutive	-	212	O
days	-	224	O
,	-	228	O
either	-	230	O
intrarenally	-	237	O
(	-	250	O
by	-	251	O
a	-	254	O
new	-	256	O
technique	-	260	O
)	-	269	O
or	-	271	O
intravenously	-	274	O
into	-	288	O
rats	-	293	O
with	-	298	O
one	-	303	O
kidney	-	307	O
removed	-	314	O
.	-	321	O

Intrarenal	6861444	323	O
infusion	-	334	O
of	-	343	O
noradrenaline	-	346	B
caused	-	360	O
hypertension	-	367	O
at	-	380	O
doses	-	383	O
which	-	389	O
did	-	395	O
not	-	399	O
do	-	403	O
so	-	406	O
when	-	409	O
infused	-	414	O
intravenously	-	422	O
.	-	435	O

Intrarenal	6861444	437	O
compared	-	448	O
with	-	457	O
intravenous	-	462	O
infusion	-	474	O
of	-	483	O
noradrenaline	-	486	B
caused	-	500	O
higher	-	507	O
plasma	-	514	O
noradrenaline	-	521	B
concentrations	-	535	O
and	-	550	O
a	-	554	O
shift	-	556	O
of	-	562	O
the	-	565	O
plasma	-	569	O
noradrenaline	-	576	B
concentration	-	590	O
-	-	603	O
blood	-	604	O
pressure	-	610	O
effect	-	619	O
curve	-	626	O
towards	-	632	O
lower	-	640	O
plasma	-	646	O
noradrenaline	-	653	B
levels	-	667	O
.	-	673	O

These	6861444	675	O
results	-	681	O
suggest	-	689	O
that	-	697	O
hypertension	-	702	O
after	-	715	O
chronic	-	721	O
intrarenal	-	729	O
noradrenaline	-	740	B
infusion	-	754	O
is	-	763	O
produced	-	766	O
by	-	775	O
relatively	-	778	O
higher	-	789	O
levels	-	796	O
of	-	803	O
circulating	-	806	O
noradrenaline	-	818	B
and	-	832	O
by	-	836	O
triggering	-	839	O
of	-	850	O
an	-	853	O
additional	-	856	O
intrarenal	-	867	O
pressor	-	878	O
mechanism	-	886	O
.	-	895	O

Age	7053303	0	O
and	-	4	O
renal	-	8	O
clearance	-	14	O
of	-	24	O
cimetidine	-	27	B
.	-	37	O

In	7053303	39	O
35	-	42	O
patients	-	45	O
(	-	54	O
ages	-	55	O
20	-	60	O
to	-	63	O
86	-	66	O
yr	-	69	O
)	-	71	O
receiving	-	73	O
cimetidine	-	83	B
therapeutically	-	94	O
two	-	110	O
serum	-	114	O
samples	-	120	O
and	-	128	O
all	-	132	O
urine	-	136	O
formed	-	142	O
in	-	149	O
the	-	152	O
interim	-	156	O
were	-	164	O
collected	-	169	O
for	-	179	O
analysis	-	183	O
of	-	192	O
cimetidine	-	195	B
by	-	206	O
high	-	209	O
-	-	213	O
pressure	-	214	O
liquid	-	223	O
chromatography	-	230	O
and	-	245	O
for	-	249	O
creatinine	-	253	B
.	-	263	O

Cimetidine	7053303	265	B
clearance	-	276	O
decreased	-	286	O
with	-	296	O
age	-	301	O
.	-	304	O

The	7053303	306	O
extrapolated	-	310	O
6	-	323	O
-	-	324	O
hr	-	325	O
serum	-	328	O
concentration	-	334	O
of	-	348	O
cimetidine	-	351	B
per	-	362	O
unit	-	366	O
dose	-	371	O
,	-	375	O
after	-	377	O
intravenous	-	383	O
cimetidine	-	395	B
,	-	405	O
increased	-	407	O
with	-	417	O
age	-	422	O
of	-	426	O
the	-	429	O
patients	-	433	O
.	-	441	O

The	7053303	443	O
ratio	-	447	O
of	-	453	O
cimetidine	-	456	B
clearance	-	467	O
to	-	477	O
creatinine	-	480	B
clearance	-	491	O
(	-	501	O
Rc	-	502	O
)	-	504	O
averaged	-	506	O
4	-	515	O
.	-	516	O
8	-	517	O
+	-	519	O
/	-	520	O
-	-	521	O

2	7053303	523	O
.	-	524	O
0	-	525	O
,	-	526	O
indicating	-	528	O
net	-	539	O
tubular	-	543	O
secretion	-	551	O
for	-	561	O
cimetidine	-	565	B
.	-	575	O

Rc	7053303	577	O
seemed	-	580	O
to	-	587	O
be	-	590	O
independent	-	593	O
of	-	605	O
age	-	608	O
and	-	612	O
decreased	-	616	O
with	-	626	O
increasing	-	631	O
serum	-	642	O
concentration	-	648	O
of	-	662	O
cimetidine	-	665	B
,	-	675	O
suggesting	-	677	O
that	-	688	O
secretion	-	693	O
of	-	703	O
cimetidine	-	706	B
is	-	717	O
a	-	720	O
saturable	-	722	O
process	-	732	O
.	-	739	O

There	7053303	741	O
was	-	747	O
only	-	751	O
one	-	756	O
case	-	760	O
of	-	765	O
dementia	-	768	O
possibly	-	777	O
due	-	786	O
to	-	790	O
cimetidine	-	793	B
(	-	804	O
with	-	805	O
a	-	810	O
drug	-	812	O
level	-	817	O
of	-	823	O
1	-	826	O
.	-	827	O
9	-	828	O
microgram	-	830	O
/	-	839	O
ml	-	840	O
6	-	843	O
hr	-	845	O
after	-	848	O
a	-	854	O
dose	-	856	O
)	-	860	O
in	-	862	O
a	-	865	O
group	-	867	O
of	-	873	O
13	-	876	O
patients	-	879	O
without	-	888	O
liver	-	896	O
or	-	902	O
kidney	-	905	O
disease	-	912	O
who	-	920	O
had	-	924	O
cimetidine	-	928	B
levels	-	939	O
above	-	946	O
1	-	952	O
.	-	953	O
25	-	954	O
microgram	-	957	O
/	-	966	O
ml	-	967	O
.	-	969	O

Thus	7053303	971	O
,	-	975	O
high	-	977	O
cimetidine	-	982	B
levels	-	993	O
alone	-	1000	O
do	-	1006	O
not	-	1009	O
always	-	1013	O
induce	-	1020	O
dementia	-	1027	O
.	-	1035	O

Development	7088431	0	O
of	-	12	O
clear	-	15	O
cell	-	21	O
adenocarcinoma	-	26	O
in	-	41	O
DES	-	44	B
-	-	47	O
exposed	-	48	O
offspring	-	56	O
under	-	66	O
observation	-	72	O
.	-	83	O

Two	7088431	85	O
cases	-	89	O
of	-	95	O
clear	-	98	O
cell	-	104	O
adenocarcinoma	-	109	O
of	-	124	O
the	-	127	O
vagina	-	131	O
detected	-	138	O
at	-	147	O
follow	-	150	O
-	-	156	O
up	-	157	O
in	-	160	O
young	-	163	O
women	-	169	O
exposed	-	175	O
in	-	183	O
utero	-	186	O
to	-	192	O
diethylstilbestrol	-	195	B
are	-	214	O
reported	-	218	O
.	-	226	O

One	7088431	228	O
patient	-	232	O
,	-	239	O
aged	-	241	O
23	-	246	O
,	-	248	O
had	-	250	O
been	-	254	O
followed	-	259	O
for	-	268	O
2	-	272	O
years	-	274	O
before	-	280	O
carcinoma	-	287	O
was	-	297	O
diagnosed	-	301	O
;	-	310	O
the	-	312	O
second	-	316	O
patient	-	323	O
,	-	330	O
aged	-	332	O
22	-	337	O
,	-	339	O
had	-	341	O
been	-	345	O
seen	-	350	O
on	-	355	O
a	-	358	O
regular	-	360	O
basis	-	368	O
for	-	374	O
5	-	378	O
years	-	380	O
,	-	385	O
8	-	387	O
months	-	389	O
.	-	395	O

In	7088431	397	O
both	-	400	O
instances	-	405	O
,	-	414	O
suspicion	-	416	O
of	-	426	O
the	-	429	O
presence	-	433	O
of	-	442	O
carcinoma	-	445	O
was	-	455	O
aroused	-	459	O
by	-	467	O
the	-	470	O
palpation	-	474	O
of	-	484	O
a	-	487	O
small	-	489	O
nodule	-	495	O
in	-	502	O
the	-	505	O
vaginal	-	509	O
fornix	-	517	O
.	-	523	O

Hysterosalpingography	7088431	525	O
was	-	547	O
performed	-	551	O
on	-	561	O
both	-	564	O
patients	-	569	O
and	-	578	O
,	-	581	O
in	-	583	O
1	-	586	O
instance	-	588	O
,	-	596	O
an	-	598	O
abnormal	-	601	O
x	-	610	O
-	-	611	O
ray	-	612	O
film	-	616	O
was	-	621	O
reflected	-	625	O
by	-	635	O
the	-	638	O
gross	-	642	O
appearance	-	648	O
of	-	659	O
the	-	662	O
uterine	-	666	O
cavity	-	674	O
found	-	681	O
in	-	687	O
the	-	690	O
surgical	-	694	O
specimen	-	703	O
.	-	711	O

Phenobarbitone	7248170	0	B
-	-	14	O
induced	-	15	O
enlargement	-	23	O
of	-	35	O
the	-	38	O
liver	-	42	O
in	-	48	O
the	-	51	O
rat	-	55	O
:	-	58	O
its	-	60	O
relationship	-	64	O
to	-	77	O
carbon	-	80	B
tetrachloride	-	87	I
-	-	100	O
induced	-	101	O
cirrhosis	-	109	O
.	-	118	O

The	7248170	120	O
yield	-	124	O
of	-	130	O
severe	-	133	O
cirrhosis	-	140	O
of	-	150	O
the	-	153	O
liver	-	157	O
(	-	163	O
defined	-	164	O
as	-	172	O
a	-	175	O
shrunken	-	177	O
finely	-	186	O
nodular	-	193	O
liver	-	201	O
with	-	207	O
micronodular	-	212	O
histology	-	225	O
,	-	234	O
ascites	-	236	O
greater	-	244	O
than	-	252	O
30	-	257	O
ml	-	260	O
,	-	262	O
plasma	-	264	O
albumin	-	271	O
less	-	279	O
than	-	284	O
2	-	289	O
.	-	290	O
2	-	291	O
g	-	293	O
/	-	294	O
dl	-	295	O
,	-	297	O
splenomegaly	-	299	O
2	-	312	O
-	-	313	O
3	-	314	O
times	-	316	O
normal	-	322	O
,	-	328	O
and	-	330	O
testicular	-	334	O
atrophy	-	345	O
approximately	-	353	O
half	-	367	O
normal	-	372	O
weight	-	379	O
)	-	385	O
after	-	387	O
12	-	393	O
doses	-	396	O
of	-	402	O
carbon	-	405	B
tetrachloride	-	412	I
given	-	426	O
intragastrically	-	432	O
in	-	449	O
the	-	452	O
phenobarbitone	-	456	B
-	-	470	O
primed	-	471	O
rat	-	478	O
was	-	482	O
increased	-	486	O
from	-	496	O
25	-	501	O
%	-	503	O
to	-	505	O
56	-	508	O
%	-	510	O
by	-	512	O
giving	-	515	O
the	-	522	O
initial	-	526	O
""""	-	534	O
calibrating	-	535	O
""""	-	546	O
dose	-	548	O
of	-	553	O
carbon	-	556	B
tetrachloride	-	563	I
at	-	577	O
the	-	580	O
peak	-	584	O
of	-	589	O
the	-	592	O
phenobarbitone	-	596	B
-	-	610	O
induced	-	611	O
enlargement	-	619	O
of	-	631	O
the	-	634	O
liver	-	638	O
.	-	643	O

At	7248170	645	O
this	-	648	O
point	-	653	O
it	-	659	O
was	-	662	O
assumed	-	666	O
that	-	674	O
the	-	679	O
cytochrome	-	683	O
P450	-	694	O
/	-	698	O
CCl4	-	699	B
toxic	-	704	O
state	-	710	O
was	-	716	O
both	-	720	O
maximal	-	725	O
and	-	733	O
stable	-	737	O
.	-	743	O

The	7248170	745	O
optimal	-	749	O
rat	-	757	O
size	-	761	O
to	-	766	O
begin	-	769	O
phenobarbitone	-	775	B
was	-	790	O
determined	-	794	O
as	-	805	O
100	-	808	O
g	-	812	O
,	-	813	O
and	-	815	O
this	-	819	O
size	-	824	O
as	-	829	O
a	-	832	O
group	-	834	O
had	-	840	O
a	-	844	O
mean	-	846	O
maximum	-	851	O
relative	-	859	O
liver	-	868	O
weight	-	874	O
increase	-	881	O
47	-	890	O
%	-	892	O
greater	-	894	O
than	-	902	O
normal	-	907	O
rats	-	914	O
of	-	919	O
the	-	922	O
same	-	926	O
body	-	931	O
weight	-	936	O
.	-	942	O

The	7248170	944	O
optimal	-	948	O
time	-	956	O
for	-	961	O
the	-	965	O
initial	-	969	O
dose	-	977	O
of	-	982	O
carbon	-	985	B
tetrachloride	-	992	I
was	-	1006	O
after	-	1010	O
14	-	1016	O
days	-	1019	O
on	-	1024	O
phenobarbitone	-	1027	B
.	-	1041	O

Attenuation	7453952	0	O
of	-	12	O
the	-	15	O
lithium	-	19	B
-	-	26	O
induced	-	27	O
diabetes	-	35	O
-	-	43	O
insipidus	-	44	O
-	-	53	O
like	-	54	O
syndrome	-	59	O
by	-	68	O
amiloride	-	71	B
in	-	81	O
rats	-	84	O
.	-	88	O

The	7453952	90	O
effect	-	94	O
of	-	101	O
amiloride	-	104	B
on	-	114	O
lithium	-	117	B
-	-	124	O
induced	-	125	O
polydipsia	-	133	O
and	-	144	O
polyuria	-	148	O
and	-	157	O
on	-	161	O
the	-	164	O
lithium	-	168	B
concentration	-	176	O
in	-	190	O
the	-	193	O
plasma	-	197	O
,	-	203	O
brain	-	205	O
,	-	210	O
kidney	-	212	O
,	-	218	O
thyroid	-	220	O
and	-	228	O
red	-	232	O
blood	-	236	O
cells	-	242	O
was	-	248	O
investigated	-	252	O
in	-	265	O
rats	-	268	O
,	-	272	O
chronically	-	274	O
treated	-	286	O
with	-	294	O
LiCl	-	299	B
.	-	303	O

Amiloride	7453952	305	B
reduced	-	315	O
the	-	323	O
drinking	-	327	O
and	-	336	O
urine	-	340	O
volume	-	346	O
of	-	353	O
rats	-	356	O
in	-	361	O
an	-	364	O
acute	-	367	O
(	-	373	O
6	-	374	O
or	-	376	O
12	-	379	O
h	-	382	O
)	-	383	O
and	-	385	O
a	-	389	O
subacute	-	391	O
(	-	400	O
3	-	401	O
days	-	403	O
)	-	407	O
experiment	-	409	O
.	-	419	O

6	7453952	421	O
h	-	423	O
after	-	425	O
the	-	431	O
administration	-	435	O
of	-	450	O
amiloride	-	453	B
,	-	462	O
a	-	464	O
reduction	-	466	O
was	-	476	O
observed	-	480	O
in	-	489	O
the	-	492	O
lithium	-	496	B
content	-	504	O
of	-	512	O
the	-	515	O
renal	-	519	O
medulla	-	525	O
but	-	533	O
not	-	537	O
in	-	541	O
the	-	544	O
other	-	548	O
organs	-	554	O
studied	-	561	O
.	-	568	O

At	7453952	570	O
12	-	573	O
h	-	576	O
,	-	577	O
all	-	579	O
the	-	583	O
tissues	-	587	O
showed	-	595	O
a	-	602	O
slight	-	604	O
increase	-	611	O
in	-	620	O
lithium	-	623	B
levels	-	631	O
.	-	637	O

After	7453952	639	O
3	-	645	O
days	-	647	O
of	-	652	O
combined	-	655	O
treatment	-	664	O
,	-	673	O
a	-	675	O
marked	-	677	O
elevation	-	684	O
in	-	694	O
plasma	-	697	O
and	-	704	O
tissue	-	708	O
lithium	-	715	B
levels	-	723	O
accompanied	-	730	O
a	-	742	O
reduction	-	744	O
in	-	754	O
water	-	757	O
intake	-	763	O
.	-	769	O

In	7453952	771	O
all	-	774	O
the	-	778	O
experiments	-	782	O
,	-	793	O
the	-	795	O
attenuation	-	799	O
of	-	811	O
the	-	814	O
lithium	-	818	B
-	-	825	O
induced	-	826	O
diabetes	-	834	O
-	-	842	O
insipidus	-	843	O
-	-	852	O
like	-	853	O
syndrome	-	858	O
by	-	867	O
amiloride	-	870	B
was	-	880	O
accompanied	-	884	O
by	-	896	O
a	-	899	O
reduction	-	901	O
of	-	911	O
the	-	914	O
ratio	-	918	O
between	-	924	O
the	-	932	O
lithium	-	936	B
concentration	-	944	O
in	-	958	O
the	-	961	O
renal	-	965	O
medulla	-	971	O
and	-	979	O
its	-	983	O
levels	-	987	O
in	-	994	O
the	-	997	O
blood	-	1001	O
and	-	1007	O
an	-	1011	O
elevation	-	1014	O
in	-	1024	O
the	-	1027	O
plasma	-	1031	O
potassium	-	1038	B
level	-	1048	O
.	-	1053	O

It	7453952	1055	O
is	-	1058	O
concluded	-	1061	O
that	-	1071	O
acute	-	1076	O
amiloride	-	1082	B
administration	-	1092	O
to	-	1107	O
lithium	-	1110	B
-	-	1117	O
treated	-	1118	O
patients	-	1126	O
suffering	-	1135	O
from	-	1145	O
polydipsia	-	1150	O
and	-	1161	O
polyuria	-	1165	O
might	-	1174	O
relieve	-	1180	O
these	-	1188	O
patients	-	1194	O
but	-	1203	O
prolonged	-	1207	O
amiloride	-	1217	B
supplementation	-	1227	O
would	-	1243	O
result	-	1249	O
in	-	1256	O
elevated	-	1259	O
lithium	-	1268	B
levels	-	1276	O
and	-	1283	O
might	-	1287	O
be	-	1293	O
hazardous	-	1296	O
.	-	1305	O

Safety	7802851	0	O
and	-	7	O
side	-	11	O
-	-	15	O
effects	-	16	O
of	-	24	O
alprazolam	-	27	B
.	-	37	O

Controlled	7802851	39	O
study	-	50	O
in	-	56	O
agoraphobia	-	59	O
with	-	71	O
panic	-	76	O
disorder	-	82	O
.	-	90	O

BACKGROUND	7802851	92	O
:	-	102	O

The	7802851	104	O
widespread	-	108	O
use	-	119	O
of	-	123	O
benzodiazepines	-	126	B
has	-	142	O
led	-	146	O
to	-	150	O
increasing	-	153	O
recognition	-	164	O
of	-	176	O
their	-	179	O
unwanted	-	185	O
effects	-	194	O
.	-	201	O

The	7802851	203	O
efficacy	-	207	O
of	-	216	O
alprazolam	-	219	B
and	-	230	O
placebo	-	234	O
in	-	242	O
panic	-	245	O
disorder	-	251	O
with	-	260	O
agoraphobia	-	265	O
,	-	276	O
and	-	278	O
the	-	282	O
side	-	286	O
-	-	290	O
effect	-	291	O
and	-	298	O
adverse	-	302	O
effect	-	310	O
profiles	-	317	O
of	-	326	O
both	-	329	O
drug	-	334	O
groups	-	339	O
were	-	346	O
measured	-	351	O
.	-	359	O

METHOD	7802851	361	O
:	-	367	O

In	7802851	369	O
London	-	372	O
and	-	379	O
Toronto	-	383	O
154	-	391	O
patients	-	395	O
who	-	404	O
met	-	408	O
DSM	-	412	O
-	-	415	O
III	-	416	O
criteria	-	420	O
for	-	429	O
panic	-	433	O
disorder	-	439	O
with	-	448	O
agoraphobia	-	453	O
were	-	465	O
randomised	-	470	O
to	-	481	O
alprazolam	-	484	B
or	-	495	O
placebo	-	498	O
.	-	505	O

Subjects	7802851	507	O
in	-	516	O
each	-	519	O
drug	-	524	O
group	-	529	O
also	-	535	O
received	-	540	O
either	-	549	O
exposure	-	556	O
or	-	565	O
relaxation	-	568	O
.	-	578	O

Treatment	7802851	580	O
was	-	590	O
from	-	594	O
weeks	-	599	O
0	-	605	O
to	-	607	O
8	-	610	O
and	-	612	O
was	-	616	O
then	-	620	O
tapered	-	625	O
from	-	633	O
weeks	-	638	O
8	-	644	O
to	-	646	O
16	-	649	O
.	-	651	O

RESULTS	7802851	653	O
:	-	660	O

Mean	7802851	662	O
alprazolam	-	667	B
dose	-	678	O
was	-	683	O
5	-	687	O
mg	-	689	O
daily	-	692	O
.	-	697	O

Compared	7802851	699	O
with	-	708	O
placebo	-	713	O
subjects	-	721	O
,	-	729	O
alprazolam	-	731	B
patients	-	742	O
developed	-	751	O
more	-	761	O
adverse	-	766	O
reactions	-	774	O
(	-	784	O
21	-	785	O
%	-	787	O
v	-	789	O
.	-	790	O
0	-	792	O
%	-	793	O
)	-	794	O
of	-	796	O
depression	-	799	O
,	-	809	O
enuresis	-	811	O
,	-	819	O
disinhibition	-	821	O
and	-	835	O
aggression	-	839	O
;	-	849	O
and	-	851	O
more	-	855	O
side	-	860	O
-	-	864	O
effects	-	865	O
,	-	872	O
particularly	-	874	O
sedation	-	887	O
,	-	895	O
irritability	-	897	O
,	-	909	O
impaired	-	911	O
memory	-	920	O
,	-	926	O
weight	-	928	O
loss	-	935	O
and	-	940	O
ataxia	-	944	O
.	-	950	O

Side	7802851	952	O
-	-	956	O
effects	-	957	O
tended	-	965	O
to	-	972	O
diminish	-	975	O
during	-	984	O
treatment	-	991	O
but	-	1001	O
remained	-	1005	O
significant	-	1014	O
at	-	1026	O
week	-	1029	O
8	-	1034	O
.	-	1035	O

Despite	7802851	1037	O
this	-	1045	O
,	-	1049	O
the	-	1051	O
drop	-	1055	O
-	-	1059	O
out	-	1060	O
rate	-	1064	O
was	-	1069	O
low	-	1073	O
.	-	1076	O

CONCLUSIONS	7802851	1078	O
:	-	1089	O

Alprazolam	7802851	1091	B
caused	-	1102	O
side	-	1109	O
-	-	1113	O
effects	-	1114	O
and	-	1122	O
adverse	-	1126	O
effects	-	1134	O
during	-	1142	O
treatment	-	1149	O
but	-	1159	O
many	-	1163	O
patients	-	1168	O
were	-	1177	O
willing	-	1182	O
to	-	1190	O
accept	-	1193	O
these	-	1200	O
.	-	1205	O

Dup	8319760	0	B
753	-	4	I
prevents	-	8	O
the	-	17	O
development	-	21	O
of	-	33	O
puromycin	-	36	B
aminonucleoside	-	46	I
-	-	61	O
induced	-	62	O
nephrosis	-	70	O
.	-	79	O

The	8319760	81	O
appearance	-	85	O
of	-	96	O
nephrotic	-	99	O
syndromes	-	109	O
such	-	119	O
as	-	124	O
proteinuria	-	127	O
,	-	138	O
hypoalbuminemia	-	140	O
,	-	155	O
hypercholesterolemia	-	157	O
and	-	178	O
increase	-	182	O
in	-	191	O
blood	-	194	B
nitrogen	-	200	I
urea	-	209	I
,	-	213	O
induced	-	215	O
in	-	223	O
rats	-	226	O
by	-	231	O
injection	-	234	O
of	-	244	O
puromycin	-	247	B
aminonucleoside	-	257	I
was	-	273	O
markedly	-	277	O
inhibited	-	286	O
by	-	296	O
oral	-	299	O
administration	-	304	O
of	-	319	O
Dup	-	322	B
753	-	326	I
(	-	330	O
losartan	-	331	B
)	-	339	O
,	-	340	O
a	-	342	O
novel	-	344	O
angiotensin	-	350	B
II	-	362	I
receptor	-	365	O
antagonist	-	374	O
,	-	384	O
at	-	386	O
a	-	389	O
dose	-	391	O
of	-	396	O
1	-	399	O
or	-	401	O
2	-	404	O
mg	-	406	O
/	-	408	O
kg	-	409	O
per	-	412	O
day	-	416	O
.	-	419	O

The	8319760	421	O
results	-	425	O
suggest	-	433	O
a	-	441	O
possible	-	443	O
involvement	-	452	O
of	-	464	O
the	-	467	O
renin	-	471	O
-	-	476	O
angiotensin	-	477	B
system	-	489	O
in	-	496	O
the	-	499	O
development	-	503	O
of	-	515	O
puromycin	-	518	B
aminonucleoside	-	528	I
-	-	543	O
induced	-	544	O
nephrosis	-	552	O
.	-	561	O

Sodium	8386779	0	B
bicarbonate	-	7	I
alleviates	-	19	O
penile	-	30	O
pain	-	37	O
induced	-	42	O
by	-	50	O
intracavernous	-	53	O
injections	-	68	O
for	-	79	O
erectile	-	83	O
dysfunction	-	92	O
.	-	103	O

In	8386779	105	O
an	-	108	O
attempt	-	111	O
to	-	119	O
determine	-	122	O
whether	-	132	O
penile	-	140	O
pain	-	147	O
associated	-	152	O
with	-	163	O
intracorporeal	-	168	O
injections	-	183	O
could	-	194	O
be	-	200	O
due	-	203	O
to	-	207	O
the	-	210	O
acidity	-	214	O
of	-	222	O
the	-	225	O
medication	-	229	O
,	-	239	O
we	-	241	O
performed	-	244	O
a	-	254	O
randomized	-	256	O
study	-	267	O
comparing	-	273	O
the	-	283	O
incidence	-	287	O
of	-	297	O
penile	-	300	O
pain	-	307	O
following	-	312	O
intracorporeal	-	322	O
injections	-	337	O
with	-	348	O
or	-	353	O
without	-	356	O
the	-	364	O
addition	-	368	O
of	-	377	O
sodium	-	380	B
bicarbonate	-	387	I
to	-	399	O
the	-	402	O
intracorporeal	-	406	O
medications	-	421	O
.	-	432	O

A	8386779	434	O
total	-	436	O
of	-	442	O
38	-	445	O
consecutive	-	448	O
patients	-	460	O
who	-	469	O
presented	-	473	O
to	-	483	O
our	-	486	O
clinic	-	490	O
with	-	497	O
impotence	-	502	O
received	-	512	O
0	-	521	O
.	-	522	O
2	-	523	O
ml	-	525	O
.	-	527	O

of	8386779	529	O
a	-	532	O
combination	-	534	O
of	-	546	O
3	-	549	O
drugs	-	551	O
:	-	556	O
6	-	558	O
mg	-	560	O
.	-	562	O
papaverine	-	564	B
,	-	574	O
100	-	576	O
micrograms	-	580	O
.	-	590	O

phentolamine	8386779	592	B
and	-	605	O
10	-	609	O
micrograms	-	612	O
.	-	622	O

prostaglandin	8386779	624	B
E1	-	638	I
with	-	641	O
(	-	646	O
pH	-	647	O
7	-	650	O
.	-	651	O
05	-	652	O
)	-	654	O
or	-	656	O
without	-	659	O
(	-	667	O
pH	-	668	O
4	-	671	O
.	-	672	O
17	-	673	O
)	-	675	O

the	8386779	677	O
addition	-	681	O
of	-	690	O
sodium	-	693	B
bicarbonate	-	700	I
(	-	712	O
0	-	713	O
.	-	714	O
03	-	715	O
mEq	-	718	O
.	-	721	O
)	-	722	O

.	8386779	723	O

Of	8386779	725	O
the	-	728	O
19	-	732	O
patients	-	735	O
without	-	744	O
sodium	-	752	B
bicarbonate	-	759	I
added	-	771	O
to	-	777	O
the	-	780	O
medication	-	784	O
11	-	795	O
(	-	798	O
58	-	799	O
%	-	801	O
)	-	802	O
complained	-	804	O
of	-	815	O
penile	-	818	O
pain	-	825	O
due	-	830	O
to	-	834	O
the	-	837	O
medication	-	841	O
,	-	851	O
while	-	853	O
only	-	859	O
1	-	864	O
of	-	866	O
the	-	869	O
19	-	873	O
men	-	876	O
(	-	880	O
5	-	881	O
%	-	882	O
)	-	883	O
who	-	885	O
received	-	889	O
sodium	-	898	B
bicarbonate	-	905	I
complained	-	917	O
of	-	928	O
penile	-	931	O
pain	-	938	O
.	-	942	O

From	8386779	944	O
these	-	949	O
data	-	955	O
we	-	960	O
conclude	-	963	O
that	-	972	O
the	-	977	O
penile	-	981	O
pain	-	988	O
following	-	993	O
intracorporeal	-	1003	O
injections	-	1018	O
is	-	1029	O
most	-	1032	O
likely	-	1037	O
due	-	1044	O
to	-	1048	O
the	-	1051	O
acidity	-	1055	O
of	-	1063	O
the	-	1066	O
medication	-	1070	O
,	-	1080	O
which	-	1082	O
can	-	1088	O
be	-	1092	O
overcome	-	1095	O
by	-	1104	O
elevating	-	1107	O
the	-	1117	O
pH	-	1121	O
to	-	1124	O
a	-	1127	O
neutral	-	1129	O
level	-	1137	O
.	-	1142	O

Prospective	8421099	0	O
study	-	12	O
of	-	18	O
the	-	21	O
long	-	25	O
-	-	29	O
term	-	30	O
effects	-	35	O
of	-	43	O
somatostatin	-	46	O
analog	-	59	O
(	-	66	O
octreotide	-	67	B
)	-	77	O
on	-	79	O
gallbladder	-	82	O
function	-	94	O
and	-	103	O
gallstone	-	107	O
formation	-	117	O
in	-	127	O
Chinese	-	130	O
acromegalic	-	138	O
patients	-	150	O
.	-	158	O

This	8421099	160	O
article	-	165	O
reports	-	173	O
the	-	181	O
changes	-	185	O
in	-	193	O
gallbladder	-	196	O
function	-	208	O
examined	-	217	O
by	-	226	O
ultrasonography	-	229	O
in	-	245	O
20	-	248	O
Chinese	-	251	O
patients	-	259	O
with	-	268	O
active	-	273	O
acromegaly	-	280	O
treated	-	291	O
with	-	299	O
sc	-	304	O
injection	-	307	O
of	-	317	O
the	-	320	O
somatostatin	-	324	O
analog	-	337	O
octreotide	-	344	B
in	-	355	O
dosages	-	358	O
of	-	366	O
300	-	369	O
-	-	372	O
1500	-	373	O
micrograms	-	378	O
/	-	388	O
day	-	389	O
for	-	393	O
a	-	397	O
mean	-	399	O
of	-	404	O
24	-	407	O
.	-	409	O
2	-	410	O
+	-	412	O
/	-	413	O
-	-	414	O

13	8421099	416	O
.	-	418	O
9	-	419	O
months	-	421	O
.	-	427	O

During	8421099	429	O
treatment	-	436	O
with	-	446	O
octreotide	-	451	B
,	-	461	O
17	-	463	O
patients	-	466	O
developed	-	475	O
sludge	-	485	O
,	-	491	O
10	-	493	O
had	-	496	O
gallstones	-	500	O
,	-	510	O
and	-	512	O
1	-	516	O
developed	-	518	O
acute	-	528	O
cholecystitis	-	534	O
requiring	-	548	O
surgery	-	558	O
.	-	565	O

In	8421099	567	O
all	-	570	O
of	-	574	O
7	-	577	O
patients	-	579	O
examined	-	588	O
acutely	-	597	O
,	-	604	O
gallbladder	-	606	O
contractility	-	618	O
was	-	632	O
inhibited	-	636	O
after	-	646	O
a	-	652	O
single	-	654	O
100	-	661	O
-	-	664	O
micrograms	-	665	O
injection	-	676	O
.	-	685	O

In	8421099	687	O
8	-	690	O
patients	-	692	O
followed	-	701	O
for	-	710	O
24	-	714	O
weeks	-	717	O
,	-	722	O
gallbladder	-	724	O
contractility	-	736	O
remained	-	750	O
depressed	-	759	O
throughout	-	769	O
therapy	-	780	O
.	-	787	O

After	8421099	789	O
withdrawal	-	795	O
of	-	806	O
octreotide	-	809	B
in	-	820	O
10	-	823	O
patients	-	826	O
without	-	835	O
gallstones	-	843	O
,	-	853	O
8	-	855	O
patients	-	857	O
assessed	-	866	O
had	-	875	O
return	-	879	O
of	-	886	O
normal	-	889	O
gallbladder	-	896	O
contractility	-	908	O
within	-	922	O
1	-	929	O
month	-	931	O
.	-	936	O

In	8421099	938	O
8	-	941	O
of	-	943	O
the	-	946	O
remaining	-	950	O
10	-	960	O
patients	-	963	O
who	-	972	O
developed	-	976	O
gallstones	-	986	O
during	-	997	O
treatment	-	1004	O
,	-	1013	O
gallbladder	-	1015	O
contractility	-	1027	O
normalized	-	1041	O
in	-	1052	O
5	-	1055	O
patients	-	1057	O
(	-	1066	O
3	-	1067	O
of	-	1069	O
whom	-	1072	O
has	-	1077	O
disappearance	-	1081	O
of	-	1095	O
their	-	1098	O
stones	-	1104	O
within	-	1111	O
3	-	1118	O
weeks	-	1120	O
)	-	1125	O
,	-	1126	O
and	-	1128	O
remained	-	1132	O
depressed	-	1141	O
in	-	1151	O
3	-	1154	O
(	-	1156	O
2	-	1157	O
of	-	1159	O
whom	-	1162	O
had	-	1167	O
stones	-	1171	O
present	-	1178	O
at	-	1186	O
6	-	1189	O
months	-	1191	O
)	-	1197	O
.	-	1198	O

Our	8421099	1200	O
results	-	1204	O
suggest	-	1212	O
that	-	1220	O
the	-	1225	O
suppression	-	1229	O
of	-	1241	O
gallbladder	-	1244	O
contractility	-	1256	O
is	-	1270	O
the	-	1273	O
cause	-	1277	O
of	-	1283	O
the	-	1286	O
successive	-	1290	O
formation	-	1301	O
of	-	1311	O
bile	-	1314	O
sludge	-	1319	O
,	-	1325	O
gallstones	-	1327	O
,	-	1337	O
and	-	1339	O
cholecystitis	-	1343	O
during	-	1357	O
octreotide	-	1364	B
therapy	-	1375	O
in	-	1383	O
Chinese	-	1386	O
acromegalic	-	1394	O
patients	-	1406	O
.	-	1414	O

It	8421099	1416	O
is	-	1419	O
therefore	-	1422	O
very	-	1432	O
important	-	1437	O
to	-	1447	O
follow	-	1450	O
the	-	1457	O
changes	-	1461	O
of	-	1469	O
gallbladder	-	1472	O
function	-	1484	O
during	-	1493	O
long	-	1500	O
-	-	1504	O
term	-	1505	O
octreotide	-	1510	B
therapy	-	1521	O
of	-	1529	O
acromegalic	-	1532	O
patients	-	1544	O
.	-	1552	O

Improvement	8649546	0	O
of	-	12	O
levodopa	-	15	B
-	-	23	O
induced	-	24	O
dyskinesia	-	32	O
by	-	43	O
propranolol	-	46	B
in	-	58	O
Parkinson	-	61	O
's	-	70	O
disease	-	73	O
.	-	80	O

Seven	8649546	82	O
patients	-	88	O
suffering	-	97	O
from	-	107	O
Parkinson	-	112	O
's	-	121	O
disease	-	124	O
(	-	132	O
PD	-	133	O
)	-	135	O
with	-	137	O
severely	-	142	O
disabling	-	151	O
dyskinesia	-	161	O
received	-	172	O
low	-	181	O
-	-	184	O
dose	-	185	O
propranolol	-	190	B
as	-	202	O
an	-	205	O
adjunct	-	208	O
to	-	216	O
the	-	219	O
currently	-	223	O
used	-	233	O
medical	-	238	O
treatment	-	246	O
.	-	255	O

There	8649546	257	O
was	-	263	O
a	-	267	O
significant	-	269	O
40	-	281	O
%	-	283	O
improvement	-	285	O
in	-	297	O
the	-	300	O
dyskinesia	-	304	O
score	-	315	O
without	-	321	O
increase	-	329	O
of	-	338	O
parkinsonian	-	341	O
motor	-	354	O
disability	-	360	O
.	-	370	O

Ballistic	8649546	372	O
and	-	382	O
choreic	-	386	O
dyskinesia	-	394	O
were	-	405	O
markedly	-	410	O
ameliorated	-	419	O
,	-	430	O
whereas	-	432	O
dystonia	-	440	O
was	-	449	O
not	-	453	O
.	-	456	O

This	8649546	458	O
study	-	463	O
suggests	-	469	O
that	-	478	O
administration	-	483	O
of	-	498	O
low	-	501	O
doses	-	505	O
of	-	511	O
beta	-	514	O
-	-	518	O
blockers	-	519	O
may	-	528	O
improve	-	532	O
levodopa	-	540	B
-	-	548	O
induced	-	549	O
ballistic	-	557	O
and	-	567	O
choreic	-	571	O
dyskinesia	-	579	O
in	-	590	O
PD	-	593	O
.	-	595	O

Morphological	8919272	0	O
features	-	14	O
of	-	23	O
encephalopathy	-	26	O
after	-	41	O
chronic	-	47	O
administration	-	55	O
of	-	70	O
the	-	73	O
antiepileptic	-	77	O
drug	-	91	O
valproate	-	96	B
to	-	106	O
rats	-	109	O
.	-	113	O

A	8919272	115	O
transmission	-	117	O
electron	-	130	O
microscopic	-	139	O
study	-	151	O
of	-	157	O
capillaries	-	160	O
in	-	172	O
the	-	175	O
cerebellar	-	179	O
cortex	-	190	O
.	-	196	O

Long	8919272	198	O
-	-	202	O
term	-	203	O
intragastric	-	208	O
application	-	221	O
of	-	233	O
the	-	236	O
antiepileptic	-	240	O
drug	-	254	O
sodium	-	259	B
valproate	-	266	I
(	-	276	O
Vupral	-	277	O
""""	-	284	O
Polfa	-	285	O
""""	-	290	O
)	-	291	O
at	-	293	O
the	-	296	O
effective	-	300	O
dose	-	310	O
of	-	315	O
200	-	318	O
mg	-	322	O
/	-	324	O
kg	-	325	O
b	-	328	O
.	-	329	O

w	8919272	331	O
.	-	332	O
once	-	334	O
daily	-	339	O
to	-	345	O
rats	-	348	O
for	-	353	O
1	-	357	O
,	-	358	O
3	-	360	O
,	-	361	O
6	-	363	O
,	-	364	O
9	-	366	O
and	-	368	O
12	-	372	O
months	-	375	O
revealed	-	382	O
neurological	-	391	O
disorders	-	404	O
indicating	-	414	O
cerebellum	-	425	O
damage	-	436	O
(	-	443	O
""""	-	444	O
valproate	-	445	B
encephalopathy	-	455	O
""""	-	469	O
)	-	470	O
.	-	471	O

The	8919272	473	O
first	-	477	O
ultrastructural	-	483	O
changes	-	499	O
in	-	507	O
structural	-	510	O
elements	-	521	O
of	-	530	O
the	-	533	O
blood	-	537	O
-	-	542	O
brain	-	543	O
-	-	548	O
barrier	-	549	O
(	-	557	O
BBB	-	558	O
)	-	561	O
in	-	563	O
the	-	566	O
cerebellar	-	570	O
cortex	-	581	O
were	-	588	O
detectable	-	593	O
after	-	604	O
3	-	610	O
months	-	612	O
of	-	619	O
the	-	622	O
experiment	-	626	O
.	-	636	O

They	8919272	638	O
became	-	643	O
more	-	650	O
severe	-	655	O
in	-	662	O
the	-	665	O
later	-	669	O
months	-	675	O
of	-	682	O
the	-	685	O
experiment	-	689	O
,	-	699	O
and	-	701	O
were	-	705	O
most	-	710	O
severe	-	715	O
after	-	722	O
12	-	728	O
months	-	731	O
,	-	737	O
located	-	739	O
mainly	-	747	O
in	-	754	O
the	-	757	O
molecular	-	761	O
layer	-	771	O
of	-	777	O
the	-	780	O
cerebellar	-	784	O
cortex	-	795	O
.	-	801	O

Lesions	8919272	803	O
of	-	811	O
the	-	814	O
capillary	-	818	O
included	-	828	O
necrosis	-	837	O
of	-	846	O
endothelial	-	849	O
cells	-	861	O
.	-	866	O

Organelles	8919272	868	O
of	-	879	O
these	-	882	O
cells	-	888	O
,	-	893	O
in	-	895	O
particular	-	898	O
the	-	909	O
mitochondria	-	913	O
(	-	926	O
increased	-	927	O
number	-	937	O
and	-	944	O
size	-	948	O
,	-	952	O
distinct	-	954	O
degeneration	-	963	O
of	-	976	O
their	-	979	O
matrix	-	985	O
and	-	992	O
cristae	-	996	O
)	-	1003	O
and	-	1005	O
Golgi	-	1009	O
apparatus	-	1015	O
were	-	1025	O
altered	-	1030	O
.	-	1037	O

Reduced	8919272	1039	O
size	-	1047	O
of	-	1052	O
capillary	-	1055	O
lumen	-	1065	O
and	-	1071	O
occlusion	-	1075	O
were	-	1085	O
caused	-	1090	O
by	-	1097	O
swollen	-	1100	O
endothelial	-	1108	O
cells	-	1120	O
which	-	1126	O
had	-	1132	O
luminal	-	1136	B
protrusions	-	1144	O
and	-	1156	O
swollen	-	1160	O
microvilli	-	1168	O
.	-	1178	O

Pressure	8919272	1180	O
on	-	1189	O
the	-	1192	O
vessel	-	1196	O
wall	-	1203	O
was	-	1208	O
produced	-	1212	O
by	-	1221	O
enlarged	-	1224	O
perivascular	-	1233	O
astrocytic	-	1246	O
processes	-	1257	O
.	-	1266	O

Fragments	8919272	1268	O
of	-	1278	O
necrotic	-	1281	O
endothelial	-	1290	O
cells	-	1302	O
were	-	1308	O
in	-	1313	O
the	-	1316	O
vascular	-	1320	O
lumens	-	1329	O
and	-	1336	O
in	-	1340	O
these	-	1343	O
there	-	1349	O
was	-	1355	O
loosening	-	1359	O
and	-	1369	O
breaking	-	1373	O
of	-	1382	O
tight	-	1385	O
cellular	-	1391	O
junctions	-	1400	O
.	-	1409	O

Damage	8919272	1411	O
to	-	1418	O
the	-	1421	O
vascular	-	1425	O
basement	-	1434	O
lamina	-	1443	O
was	-	1450	O
also	-	1454	O
observed	-	1459	O
.	-	1467	O

Damage	8919272	1469	O
to	-	1476	O
the	-	1479	O
capillary	-	1483	O
was	-	1493	O
accompanied	-	1497	O
by	-	1509	O
marked	-	1512	O
damage	-	1519	O
to	-	1526	O
neuroglial	-	1529	O
cells	-	1540	O
,	-	1545	O
mainly	-	1547	O
to	-	1554	O
perivascular	-	1557	O
processes	-	1570	O
of	-	1580	O
astrocytes	-	1583	O
.	-	1593	O

The	8919272	1595	O
proliferation	-	1599	O
of	-	1613	O
astrocytes	-	1616	O
(	-	1627	O
Bergmann	-	1628	O
's	-	1636	O
in	-	1639	O
particular	-	1642	O
)	-	1652	O
and	-	1654	O
occasionally	-	1658	O
of	-	1671	O
oligodendrocytes	-	1674	O
was	-	1691	O
found	-	1695	O
.	-	1700	O

Alterations	8919272	1702	O
in	-	1714	O
the	-	1717	O
structural	-	1721	O
elements	-	1732	O
of	-	1741	O
the	-	1744	O
BBB	-	1748	O
coexisted	-	1752	O
with	-	1762	O
marked	-	1767	O
lesions	-	1774	O
of	-	1782	O
neurons	-	1785	O
of	-	1793	O
the	-	1796	O
cerebellum	-	1800	O
(	-	1811	O
Purkinje	-	1812	O
cells	-	1821	O
are	-	1827	O
earliest	-	1831	O
)	-	1839	O
.	-	1840	O

In	8919272	1842	O
electron	-	1845	O
micrographs	-	1854	O
both	-	1866	O
luminal	-	1871	B
and	-	1879	O
antiluminal	-	1883	O
sides	-	1895	O
of	-	1901	O
the	-	1904	O
BBB	-	1908	O
of	-	1912	O
the	-	1915	O
cerebellar	-	1919	O
cortex	-	1930	O
had	-	1937	O
similar	-	1941	O
lesions	-	1949	O
.	-	1956	O

The	8919272	1958	O
possible	-	1962	O
influence	-	1971	O
of	-	1981	O
the	-	1984	O
hepatic	-	1988	O
damage	-	1996	O
,	-	2002	O
mainly	-	2004	O
hyperammonemia	-	2011	O
,	-	2025	O
upon	-	2027	O
the	-	2032	O
development	-	2036	O
of	-	2048	O
valproate	-	2051	B
encephalopathy	-	2061	O
is	-	2076	O
discussed	-	2079	O
.	-	2088	O

Macula	9199746	0	O
toxicity	-	7	O
after	-	16	O
intravitreal	-	22	O
amikacin	-	35	B
.	-	43	O

BACKGROUND	9199746	45	O
:	-	55	O

Although	9199746	57	O
intravitreal	-	66	O
aminoglycosides	-	79	B
have	-	95	O
substantially	-	100	O
improved	-	114	O
visual	-	123	O
prognosis	-	130	O
in	-	140	O
endophthalmitis	-	143	O
,	-	158	O
macular	-	160	O
infarction	-	168	O
may	-	179	O
impair	-	183	O
full	-	190	O
visual	-	195	O
recovery	-	202	O
.	-	210	O

METHODS	9199746	212	O
:	-	219	O

We	9199746	221	O
present	-	224	O
a	-	232	O
case	-	234	O
of	-	239	O
presumed	-	242	O
amikacin	-	251	B
retinal	-	260	O
toxicity	-	268	O
following	-	277	O
treatment	-	287	O
with	-	297	O
amikacin	-	302	B
and	-	311	O
vancomycin	-	315	B
for	-	326	O
alpha	-	330	O
-	-	335	O
haemolytic	-	336	O
streptococcal	-	347	O
endophthalmitis	-	361	O
.	-	376	O

RESULTS	9199746	378	O
:	-	385	O

Endophthalmitis	9199746	387	O
resolved	-	403	O
with	-	412	O
improvement	-	417	O
in	-	429	O
visual	-	432	O
acuity	-	439	O
to	-	446	O
6	-	449	O
/	-	450	O
24	-	451	O
at	-	454	O
three	-	457	O
months	-	463	O
.	-	469	O

Fundus	9199746	471	O
fluorescein	-	478	B
angiography	-	490	O
confirmed	-	502	O
macular	-	512	O
capillary	-	520	O
closure	-	530	O
and	-	538	O
telangiectasis	-	542	O
.	-	556	O

CONCLUSIONS	9199746	558	O
:	-	569	O

Currently	9199746	571	O
accepted	-	581	O
intravitreal	-	590	O
antibiotic	-	603	O
regimens	-	614	O
may	-	623	O
cause	-	627	O
retinal	-	633	O
toxicity	-	641	O
and	-	650	O
macular	-	654	O
ischaemia	-	662	O
.	-	671	O

Treatment	9199746	673	O
strategies	-	683	O
aimed	-	694	O
at	-	700	O
avoiding	-	703	O
retinal	-	712	O
toxicity	-	720	O
are	-	729	O
discussed	-	733	O
.	-	742	O

Iatrogenically	9249847	0	O
induced	-	15	O
intractable	-	23	O
atrioventricular	-	35	O
reentrant	-	52	O
tachycardia	-	62	O
after	-	74	O
verapamil	-	80	B
and	-	90	O
catheter	-	94	O
ablation	-	103	O
in	-	112	O
a	-	115	O
patient	-	117	O
with	-	125	O
Wolff	-	130	O
-	-	135	O
Parkinson	-	136	O
-	-	145	O
White	-	146	O
syndrome	-	152	O
and	-	161	O
idiopathic	-	165	O
dilated	-	176	O
cardiomyopathy	-	184	O
.	-	198	O

In	9249847	200	O
a	-	203	O
patient	-	205	O
with	-	213	O
WPW	-	218	O
syndrome	-	222	O
and	-	231	O
idiopathic	-	235	O
dilated	-	246	O
cardiomyopathy	-	254	O
,	-	268	O
intractable	-	270	O
atrioventricular	-	282	O
reentrant	-	299	O
tachycardia	-	309	O
(	-	321	O
AVRT	-	322	O
)	-	326	O
was	-	328	O
iatrogenically	-	332	O
induced	-	347	O
.	-	354	O

QRS	9249847	356	O
without	-	360	O
preexcitation	-	368	O
,	-	381	O
caused	-	383	O
by	-	390	O
junctional	-	393	O
escape	-	404	O
beats	-	411	O
after	-	417	O
verapamil	-	423	B
or	-	433	O
unidirectional	-	436	O
antegrade	-	451	O
block	-	461	O
of	-	467	O
accessory	-	470	O
pathway	-	480	O
after	-	488	O
catheter	-	494	O
ablation	-	503	O
,	-	511	O
established	-	513	O
frequent	-	525	O
AVRT	-	534	O
attack	-	539	O
.	-	545	O

Epidemic	9284778	0	O
of	-	9	O
liver	-	12	O
disease	-	18	O
caused	-	26	O
by	-	33	O
hydrochlorofluorocarbons	-	36	B
used	-	61	O
as	-	66	O
ozone	-	69	B
-	-	74	O
sparing	-	75	O
substitutes	-	83	O
of	-	95	O
chlorofluorocarbons	-	98	B
.	-	117	O

BACKGROUND	9284778	119	O
:	-	129	O

Hydrochlorofluorocarbons	9284778	131	B
(	-	156	O
HCFCs	-	157	B
)	-	162	O
are	-	164	O
used	-	168	O
increasingly	-	173	O
in	-	186	O
industry	-	189	O
as	-	198	O
substitutes	-	201	O
for	-	213	O
ozone	-	217	B
-	-	222	O
depleting	-	223	O
chlorofluorocarbons	-	233	B
(	-	253	O
CFCs	-	254	B
)	-	258	O
.	-	259	O

Limited	9284778	261	O
studies	-	269	O
in	-	277	O
animals	-	280	O
indicate	-	288	O
potential	-	297	O
hepatotoxicity	-	307	O
of	-	322	O
some	-	325	O
of	-	330	O
these	-	333	O
compounds	-	339	O
.	-	348	O

We	9284778	350	O
investigated	-	353	O
an	-	366	O
epidemic	-	369	O
of	-	378	O
liver	-	381	O
disease	-	387	O
in	-	395	O
nine	-	398	O
industrial	-	403	O
workers	-	414	O
who	-	422	O
had	-	426	O
had	-	430	O
repeated	-	434	O
accidental	-	443	O
exposure	-	454	O
to	-	463	O
a	-	466	O
mixture	-	468	O
of	-	476	O
1	-	479	B
,	-	480	I
1	-	481	I
-	-	482	I
dichloro	-	483	I
-	-	491	I
2	-	492	I
,	-	493	I
2	-	494	I
,	-	495	I
2	-	496	I
-	-	497	I
trifluoroethane	-	498	I
(	-	514	O
HCFC	-	515	B
123	-	520	I
)	-	523	O
and	-	525	O
1	-	529	B
-	-	530	I
chloro	-	531	I
-	-	537	I
1	-	538	I
,	-	539	I
2	-	540	I
,	-	541	I
2	-	542	I
,	-	543	I
2	-	544	I
-	-	545	I
tetrafluoroethane	-	546	I
(	-	564	O
HCFC	-	565	B
124	-	570	I
)	-	573	O
.	-	574	O

All	9284778	576	O
nine	-	580	O
exposed	-	585	O
workers	-	593	O
were	-	601	O
affected	-	606	O
to	-	615	O
various	-	618	O
degrees	-	626	O
.	-	633	O

Both	9284778	635	O
compounds	-	640	O
are	-	650	O
metabolised	-	654	O
in	-	666	O
the	-	669	O
same	-	673	O
way	-	678	O
as	-	682	O
1	-	685	B
-	-	686	I
bromo	-	687	I
-	-	692	I
1	-	693	I
-	-	694	I
chloro	-	695	I
-	-	701	I
2	-	702	I
,	-	703	I
2	-	704	I
,	-	705	I
2	-	706	I
-	-	707	I
trifluoroethane	-	708	I
(	-	724	O
halothane	-	725	B
)	-	734	O
to	-	736	O
form	-	739	O
reactive	-	744	O
trifluoroacetyl	-	753	B
halide	-	769	O
intermediates	-	776	O
,	-	789	O
which	-	791	O
have	-	797	O
been	-	802	O
implicated	-	807	O
in	-	818	O
the	-	821	O
hepatotoxicity	-	825	O
of	-	840	O
halothane	-	843	B
.	-	852	O

We	9284778	854	O
aimed	-	857	O
to	-	863	O
test	-	866	O
whether	-	871	O
HCFCs	-	879	B
123	-	885	I
and	-	889	I
124	-	893	I
can	-	897	O
result	-	901	O
in	-	908	O
serious	-	911	O
liver	-	919	O
disease	-	925	O
.	-	932	O

METHODS	9284778	934	O
:	-	941	O

For	9284778	943	O
one	-	947	O
severely	-	951	O
affected	-	960	O
worker	-	969	O
liver	-	976	O
biopsy	-	982	O
and	-	989	O
immunohistochemical	-	993	O
stainings	-	1013	O
for	-	1023	O
the	-	1027	O
presence	-	1031	O
of	-	1040	O
trifluoroacetyl	-	1043	B
protein	-	1059	O
adducts	-	1067	O
were	-	1075	O
done	-	1080	O
.	-	1084	O

The	9284778	1086	O
serum	-	1090	O
of	-	1096	O
six	-	1099	O
affected	-	1103	O
workers	-	1112	O
and	-	1120	O
five	-	1124	O
controls	-	1129	O
was	-	1138	O
tested	-	1142	O
for	-	1149	O
autoantibodies	-	1153	O
that	-	1168	O
react	-	1173	O
with	-	1179	O
human	-	1184	O
liver	-	1190	O
cytochrome	-	1196	O
-	-	1206	O
P450	-	1207	O
2E1	-	1212	O
(	-	1216	O
P450	-	1217	O
2E1	-	1222	O
)	-	1225	O
and	-	1227	O
P58	-	1231	O
protein	-	1235	O
disulphide	-	1243	O
isomerase	-	1254	O
isoform	-	1264	O
(	-	1272	O
P58	-	1273	O
)	-	1276	O
.	-	1277	O

FINDINGS	9284778	1279	O
:	-	1287	O

The	9284778	1289	O
liver	-	1293	O
biopsy	-	1299	O
sample	-	1306	O
showed	-	1313	O
hepatocellular	-	1320	O
necrosis	-	1335	O
which	-	1344	O
was	-	1350	O
prominent	-	1354	O
in	-	1364	O
perivenular	-	1367	O
zone	-	1379	O
three	-	1384	O
and	-	1390	O
extended	-	1394	O
focally	-	1403	O
from	-	1411	O
portal	-	1416	O
tracts	-	1423	O
to	-	1430	O
portal	-	1433	O
tracts	-	1440	O
and	-	1447	O
centrilobular	-	1451	O
areas	-	1465	O
(	-	1471	O
bridging	-	1472	O
necrosis	-	1481	O
)	-	1489	O
.	-	1490	O

Trifluoroacetyl	9284778	1492	B
-	-	1507	O
adducted	-	1508	O
proteins	-	1517	O
were	-	1526	O
detected	-	1531	O
in	-	1540	O
surviving	-	1543	O
hepatocytes	-	1553	O
.	-	1564	O

Autoantibodies	9284778	1566	O
against	-	1581	O
P450	-	1589	O
2E1	-	1594	O
or	-	1598	O
P58	-	1601	O
,	-	1604	O
previously	-	1606	O
associated	-	1617	O
with	-	1628	O
halothane	-	1633	O
hepatitis	-	1643	O
,	-	1652	O
were	-	1654	O
detected	-	1659	O
in	-	1668	O
the	-	1671	O
serum	-	1675	O
of	-	1681	O
five	-	1684	O
affected	-	1689	O
workers	-	1698	O
.	-	1705	O

INTERPRETATION	9284778	1707	O
:	-	1721	O

Repeated	9284778	1723	O
exposure	-	1732	O
of	-	1741	O
human	-	1744	O
beings	-	1750	O
to	-	1757	O
HCFCs	-	1760	B
123	-	1766	I
and	-	1770	I
124	-	1774	I
can	-	1778	O
result	-	1782	O
in	-	1789	O
serious	-	1792	O
liver	-	1800	O
injury	-	1806	O
in	-	1813	O
a	-	1816	O
large	-	1818	O
proportion	-	1824	O
of	-	1835	O
the	-	1838	O
exposed	-	1842	O
population	-	1850	O
.	-	1860	O

Although	9284778	1862	O
the	-	1871	O
exact	-	1875	O
mechanism	-	1881	O
of	-	1891	O
hepatotoxicity	-	1894	O
of	-	1909	O
these	-	1912	O
agents	-	1918	O
is	-	1925	O
not	-	1928	O
known	-	1932	O
,	-	1937	O
the	-	1939	O
results	-	1943	O
suggest	-	1951	O
that	-	1959	O
trifluoroacetyl	-	1964	B
-	-	1979	O
altered	-	1980	O
liver	-	1988	O
proteins	-	1994	O
are	-	2003	O
involved	-	2007	O
.	-	2015	O

In	9284778	2017	O
view	-	2020	O
of	-	2025	O
the	-	2028	O
potentially	-	2032	O
widespread	-	2044	O
use	-	2055	O
of	-	2059	O
these	-	2062	O
compounds	-	2068	O
,	-	2077	O
there	-	2079	O
is	-	2085	O
an	-	2088	O
urgent	-	2091	O
need	-	2098	O
to	-	2103	O
develop	-	2106	O
safer	-	2114	O
alternatives	-	2120	O
.	-	2132	O

The	9522143	0	O
effect	-	4	O
of	-	11	O
different	-	14	O
anaesthetic	-	24	O
agents	-	36	O
in	-	43	O
hearing	-	46	O
loss	-	54	O
following	-	59	O
spinal	-	69	O
anaesthesia	-	76	O
.	-	87	O

The	9522143	89	O
cause	-	93	O
of	-	99	O
hearing	-	102	O
loss	-	110	O
after	-	115	O
spinal	-	121	O
anaesthesia	-	128	O
is	-	140	O
unknown	-	143	O
.	-	150	O

Up	9522143	152	O
until	-	155	O
now	-	161	O
,	-	164	O
the	-	166	O
only	-	170	O
factor	-	175	O
studied	-	182	O
has	-	190	O
been	-	194	O
the	-	199	O
effect	-	203	O
of	-	210	O
the	-	213	O
diameter	-	217	O
of	-	226	O
the	-	229	O
spinal	-	233	O
needle	-	240	O
on	-	247	O
post	-	250	O
-	-	254	O
operative	-	255	O
sensorineural	-	265	O
hearing	-	279	O
loss	-	287	O
.	-	291	O

The	9522143	293	O
aim	-	297	O
of	-	301	O
this	-	304	O
study	-	309	O
was	-	315	O
to	-	319	O
describe	-	322	O
this	-	331	O
hearing	-	336	O
loss	-	344	O
and	-	349	O
to	-	353	O
investigate	-	356	O
other	-	368	O
factors	-	374	O
influencing	-	382	O
the	-	394	O
degree	-	398	O
of	-	405	O
hearing	-	408	O
loss	-	416	O
.	-	420	O

Two	9522143	422	O
groups	-	426	O
of	-	433	O
22	-	436	O
similar	-	439	O
patients	-	447	O
were	-	456	O
studied	-	461	O
:	-	468	O
one	-	470	O
group	-	474	O
received	-	480	O
6	-	489	O
mL	-	491	O
prilocaine	-	494	B
2	-	505	O
%	-	506	O
;	-	507	O
and	-	509	O
the	-	513	O
other	-	517	O
received	-	523	O
3	-	532	O
mL	-	534	O
bupivacaine	-	537	B
0	-	549	O
.	-	550	O
5	-	551	O
%	-	552	O
.	-	553	O

Patients	9522143	555	O
given	-	564	O
prilocaine	-	570	B
were	-	581	O
more	-	586	O
likely	-	591	O
to	-	598	O
develop	-	601	O
hearing	-	609	O
loss	-	617	O
(	-	622	O
10	-	623	O
out	-	626	O
of	-	630	O
22	-	633	O
)	-	635	O
than	-	637	O
those	-	642	O
given	-	648	O
bupivacaine	-	654	B
(	-	666	O
4	-	667	O
out	-	669	O
of	-	673	O
22	-	676	O
)	-	678	O
(	-	680	O
P	-	681	O
<	-	683	O
0	-	685	O
.	-	686	O
05	-	687	O
)	-	689	O
.	-	690	O

The	9522143	692	O
average	-	696	O
hearing	-	704	O
loss	-	712	O
for	-	717	O
speech	-	721	O
frequencies	-	728	O
was	-	740	O
about	-	744	O
10	-	750	O
dB	-	753	O
after	-	756	O
prilocaine	-	762	B
and	-	773	O
15	-	777	O
dB	-	780	O
after	-	783	O
bupivacaine	-	789	B
.	-	800	O

None	9522143	802	O
of	-	807	O
the	-	810	O
patients	-	814	O
complained	-	823	O
of	-	834	O
subjective	-	837	O
hearing	-	848	O
loss	-	856	O
.	-	860	O

Long	9522143	862	O
-	-	866	O
term	-	867	O
follow	-	872	O
-	-	878	O
up	-	879	O
of	-	882	O
the	-	885	O
patients	-	889	O
was	-	898	O
not	-	902	O
possible	-	906	O
.	-	914	O

A	9522152	0	O
transient	-	2	O
neurological	-	12	O
deficit	-	25	O
following	-	33	O
intrathecal	-	43	O
injection	-	55	O
of	-	65	O
1	-	68	O
%	-	69	O
hyperbaric	-	71	O
bupivacaine	-	82	B
for	-	94	O
unilateral	-	98	O
spinal	-	109	O
anaesthesia	-	116	O
.	-	127	O

We	9522152	129	O
describe	-	132	O
a	-	141	O
case	-	143	O
of	-	148	O
transient	-	151	O
neurological	-	161	O
deficit	-	174	O
that	-	182	O
occurred	-	187	O
after	-	196	O
unilateral	-	202	O
spinal	-	213	O
anaesthesia	-	220	O
with	-	232	O
8	-	237	O
mg	-	239	O
of	-	242	O
1	-	245	O
%	-	246	O
hyperbaric	-	248	O
bupivacaine	-	259	B
slowly	-	271	O
injected	-	278	O
through	-	287	O
a	-	295	O
25	-	297	O
-	-	299	O
gauge	-	300	O
pencil	-	306	O
-	-	312	O
point	-	313	O
spinal	-	319	O
needle	-	326	O
.	-	332	O

The	9522152	334	O
surgery	-	338	O
and	-	346	O
anaesthesia	-	350	O
were	-	362	O
uneventful	-	367	O
,	-	377	O
but	-	379	O
3	-	383	O
days	-	385	O
after	-	390	O
surgery	-	396	O
,	-	403	O
the	-	405	O
patient	-	409	O
reported	-	417	O
an	-	426	O
area	-	429	O
of	-	434	O
hypoaesthesia	-	437	O
over	-	451	O
L3	-	456	O
-	-	458	O
L4	-	459	O
dermatomes	-	462	O
of	-	473	O
the	-	476	O
leg	-	480	O
which	-	484	O
had	-	490	O
been	-	494	O
operated	-	499	O
on	-	508	O
(	-	511	O
loss	-	512	O
of	-	517	O
pinprick	-	520	O
sensation	-	529	O
)	-	538	O
without	-	540	O
reduction	-	548	O
in	-	558	O
muscular	-	561	O
strength	-	570	O
.	-	578	O

Sensation	9522152	580	O
in	-	590	O
this	-	593	O
area	-	598	O
returned	-	603	O
to	-	612	O
normal	-	615	O
over	-	622	O
the	-	627	O
following	-	631	O
2	-	641	O
weeks	-	643	O
.	-	648	O

Prospective	9522152	650	O
multicentre	-	662	O
studies	-	674	O
with	-	682	O
a	-	687	O
large	-	689	O
population	-	695	O
and	-	706	O
a	-	710	O
long	-	712	O
follow	-	717	O
-	-	723	O
up	-	724	O
should	-	727	O
be	-	734	O
performed	-	737	O
in	-	747	O
order	-	750	O
to	-	756	O
evaluate	-	759	O
the	-	768	O
incidence	-	772	O
of	-	782	O
this	-	785	O
unusual	-	790	O
side	-	798	O
effect	-	803	O
.	-	809	O

However	9522152	811	O
,	-	818	O
we	-	820	O
suggest	-	823	O
that	-	831	O
a	-	836	O
low	-	838	O
solution	-	842	O
concentration	-	851	O
should	-	865	O
be	-	872	O
preferred	-	875	O
for	-	885	O
unilateral	-	889	O
spinal	-	900	O
anaesthesia	-	907	O
with	-	919	O
a	-	924	O
hyperbaric	-	926	O
anaesthetic	-	937	O
solution	-	949	O
(	-	958	O
if	-	959	O
pencil	-	962	O
-	-	968	O
point	-	969	O
needle	-	975	O
and	-	982	O
slow	-	986	O
injection	-	991	O
rate	-	1001	O
are	-	1006	O
employed	-	1010	O
)	-	1018	O
,	-	1019	O
in	-	1021	O
order	-	1024	O
to	-	1030	O
minimize	-	1033	O
the	-	1042	O
risk	-	1046	O
of	-	1051	O
a	-	1054	O
localized	-	1056	O
high	-	1066	O
peak	-	1071	O
anaesthetic	-	1076	O
concentration	-	1088	O
,	-	1101	O
which	-	1103	O
might	-	1109	O
lead	-	1115	O
to	-	1120	O
a	-	1123	O
transient	-	1125	O
neurological	-	1135	O
deficit	-	1148	O
.	-	1155	O

Pethidine	9672936	0	B
-	-	9	O
associated	-	10	O
seizure	-	21	O
in	-	29	O
a	-	32	O
healthy	-	34	O
adolescent	-	42	O
receiving	-	53	O
pethidine	-	63	B
for	-	73	O
postoperative	-	77	O
pain	-	91	O
control	-	96	O
.	-	103	O

A	9672936	105	O
healthy	-	107	O
17	-	115	O
-	-	117	O
year	-	118	O
-	-	122	O
old	-	123	O
male	-	127	O
received	-	132	O
standard	-	141	O
intermittent	-	150	O
doses	-	163	O
of	-	169	O
pethidine	-	172	B
via	-	182	O
a	-	186	O
patient	-	188	O
-	-	195	O
controlled	-	196	O
analgesia	-	207	O
(	-	217	O
PCA	-	218	O
)	-	221	O
pump	-	223	O
for	-	228	O
management	-	232	O
of	-	243	O
postoperative	-	246	O
pain	-	260	O
control	-	265	O
.	-	272	O

Twenty	9672936	274	O
-	-	280	O
three	-	281	O
h	-	287	O
postoperatively	-	289	O
he	-	305	O
developed	-	308	O
a	-	318	O
brief	-	320	O
self	-	326	O
-	-	330	O
limited	-	331	O
seizure	-	339	O
.	-	346	O

Both	9672936	348	O
plasma	-	353	O
pethidine	-	360	B
and	-	370	O
norpethidine	-	374	B
were	-	387	O
elevated	-	392	O
in	-	401	O
the	-	404	O
range	-	408	O
associated	-	414	O
with	-	425	O
clinical	-	430	O
manifestations	-	439	O
of	-	454	O
central	-	457	O
nervous	-	465	O
system	-	473	O
excitation	-	480	O
.	-	490	O

No	9672936	492	O
other	-	495	O
risk	-	501	O
factors	-	506	O
for	-	514	O
CNS	-	518	O
toxicity	-	522	O
were	-	531	O
identified	-	536	O
.	-	546	O

This	9672936	548	O
method	-	553	O
allowed	-	560	O
frequent	-	568	O
self	-	577	O
-	-	581	O
dosing	-	582	O
of	-	589	O
pethidine	-	592	B
at	-	602	O
short	-	605	O
time	-	611	O
intervals	-	616	O
and	-	626	O
rapid	-	630	O
accumulation	-	636	O
of	-	649	O
pethidine	-	652	B
and	-	662	O
norpethidine	-	666	B
.	-	678	O

The	9672936	680	O
routine	-	684	O
use	-	692	O
of	-	696	O
pethidine	-	699	B
via	-	709	O
PCA	-	713	O
even	-	717	O
for	-	722	O
a	-	726	O
brief	-	728	O
postoperative	-	734	O
analgesia	-	748	O
should	-	758	O
be	-	765	O
reconsidered	-	768	O
.	-	780	O

Drug	9721172	0	O
-	-	4	O
associated	-	5	O
acute	-	16	O
-	-	21	O
onset	-	22	O
vanishing	-	28	O
bile	-	38	O
duct	-	43	O
and	-	48	O
Stevens	-	52	O
-	-	59	O
Johnson	-	60	O
syndromes	-	68	O
in	-	78	O
a	-	81	O
child	-	83	O
.	-	88	O

Acute	9721172	90	O
vanishing	-	96	O
bile	-	106	O
duct	-	111	O
syndrome	-	116	O
is	-	125	O
a	-	128	O
rare	-	130	O
but	-	135	O
established	-	139	O
cause	-	151	O
of	-	157	O
progressive	-	160	O
cholestasis	-	172	O
in	-	184	O
adults	-	187	O
,	-	193	O
is	-	195	O
most	-	198	O
often	-	203	O
drug	-	209	O
or	-	214	O
toxin	-	217	O
related	-	223	O
,	-	230	O
and	-	232	O
is	-	236	O
of	-	239	O
unknown	-	242	O
pathogenesis	-	250	O
.	-	262	O

It	9721172	264	O
has	-	267	O
not	-	271	O
been	-	275	O
reported	-	280	O
previously	-	289	O
in	-	300	O
children	-	303	O
.	-	311	O

Stevens	9721172	313	O
-	-	320	O
Johnson	-	321	O
syndrome	-	329	O
is	-	338	O
a	-	341	O
well	-	343	O
-	-	347	O
recognized	-	348	O
immune	-	359	O
complex	-	366	O
-	-	373	O
mediated	-	374	O
hypersensitivity	-	383	O
reaction	-	400	O
that	-	409	O
affects	-	414	O
all	-	422	O
age	-	426	O
groups	-	430	O
,	-	436	O
is	-	438	O
drug	-	441	O
or	-	446	O
infection	-	449	O
induced	-	459	O
,	-	466	O
and	-	468	O
has	-	472	O
classic	-	476	O
systemic	-	484	O
,	-	492	O
mucosal	-	494	O
,	-	501	O
and	-	503	O
dermatologic	-	507	O
manifestations	-	520	O
.	-	534	O

A	9721172	536	O
previously	-	538	O
healthy	-	549	O
child	-	557	O
who	-	563	O
developed	-	567	O
acute	-	577	O
,	-	582	O
severe	-	584	O
,	-	590	O
rapidly	-	592	O
progressive	-	600	O
vanishing	-	612	O
bile	-	622	O
duct	-	627	O
syndrome	-	632	O
shortly	-	641	O
after	-	649	O
Stevens	-	655	O
-	-	662	O
Johnson	-	663	O
syndrome	-	671	O
is	-	680	O
described	-	683	O
;	-	692	O
this	-	694	O
was	-	699	O
temporally	-	703	O
associated	-	714	O
with	-	725	O
ibuprofen	-	730	B
use	-	740	O
.	-	743	O

Despite	9721172	745	O
therapy	-	753	O
with	-	761	O
ursodeoxycholic	-	766	B
acid	-	782	I
,	-	786	O
prednisone	-	788	B
,	-	798	O
and	-	800	O
then	-	804	O
tacrolimus	-	809	B
,	-	819	O
her	-	821	O
cholestatic	-	825	O
disease	-	837	O
was	-	845	O
unrelenting	-	849	O
,	-	860	O
with	-	862	O
cirrhosis	-	867	O
shown	-	877	O
by	-	883	O
biopsy	-	886	O
6	-	893	O
months	-	895	O
after	-	902	O
presentation	-	908	O
.	-	920	O

This	9721172	922	O
case	-	927	O
documents	-	932	O
acute	-	942	O
drug	-	948	O
-	-	952	O
related	-	953	O
vanishing	-	961	O
bile	-	971	O
duct	-	976	O
syndrome	-	981	O
in	-	990	O
the	-	993	O
pediatric	-	997	O
age	-	1007	O
group	-	1011	O
and	-	1017	O
suggests	-	1021	O
shared	-	1030	O
immune	-	1037	O
mechanisms	-	1044	O
in	-	1055	O
the	-	1058	O
pathogenesis	-	1062	O
of	-	1075	O
both	-	1078	O
Stevens	-	1083	O
-	-	1090	O
Johnson	-	1091	O
syndrome	-	1099	O
and	-	1108	O
vanishing	-	1112	O
bile	-	1122	O
duct	-	1127	O
syndrome	-	1132	O
.	-	1140	O

High	9727773	0	O
incidence	-	5	O
of	-	15	O
primary	-	18	O
pulmonary	-	26	O
hypertension	-	36	O
associated	-	49	O
with	-	60	O
appetite	-	65	B
suppressants	-	74	I
in	-	87	O
Belgium	-	90	O
.	-	97	O

Primary	9727773	99	O
pulmonary	-	107	O
hypertension	-	117	O
is	-	130	O
a	-	133	O
rare	-	135	O
,	-	139	O
progressive	-	141	O
and	-	153	O
incurable	-	157	O
disease	-	167	O
,	-	174	O
which	-	176	O
has	-	182	O
been	-	186	O
associated	-	191	O
with	-	202	O
the	-	207	O
intake	-	211	O
of	-	218	O
appetite	-	221	B
suppressant	-	230	I
drugs	-	242	O
.	-	247	O

The	9727773	249	O
importance	-	253	O
of	-	264	O
this	-	267	O
association	-	272	O
was	-	284	O
evaluated	-	288	O
in	-	298	O
Belgium	-	301	O
while	-	309	O
this	-	315	O
country	-	320	O
still	-	328	O
had	-	334	O
no	-	338	O
restriction	-	341	O
on	-	353	O
the	-	356	O
prescription	-	360	O
of	-	373	O
appetite	-	376	B
suppressants	-	385	I
.	-	397	O

Thirty	9727773	399	O
-	-	405	O
five	-	406	O
patients	-	411	O
with	-	420	O
primary	-	425	O
pulmonary	-	433	O
hypertension	-	443	O
and	-	456	O
85	-	460	O
matched	-	463	O
controls	-	471	O
were	-	480	O
recruited	-	485	O
over	-	495	O
32	-	500	O
months	-	503	O
(	-	510	O
1992	-	511	O
-	-	515	O
1994	-	516	O
)	-	520	O
in	-	522	O
Belgium	-	525	O
.	-	532	O

Exposure	9727773	534	O
to	-	543	O
appetite	-	546	B
-	-	554	I
suppressants	-	555	I
was	-	568	O
assessed	-	572	O
on	-	581	O
the	-	584	O
basis	-	588	O
of	-	594	O
hospital	-	597	O
records	-	606	O
and	-	614	O
standardized	-	618	O
interview	-	631	O
.	-	640	O

Twenty	9727773	642	O
-	-	648	O
three	-	649	O
of	-	655	O
the	-	658	O
patients	-	662	O
had	-	671	O
previously	-	675	O
taken	-	686	O
appetite	-	692	B
suppressants	-	701	I
,	-	713	O
mainly	-	715	O
fenfluramines	-	722	B
,	-	735	O
as	-	737	O
compared	-	740	O
with	-	749	O
only	-	754	O
5	-	759	O
of	-	761	O
the	-	764	O
controls	-	768	O
(	-	777	O
66	-	778	O
versus	-	781	O
6	-	788	O
%	-	789	O
,	-	790	O
p	-	792	O
<	-	793	O
0	-	794	O
.	-	795	O
0001	-	796	O
)	-	800	O
.	-	801	O

Five	9727773	803	O
patients	-	808	O
died	-	817	O
before	-	822	O
the	-	829	O
interview	-	833	O
,	-	842	O
all	-	844	O
of	-	848	O
them	-	851	O
had	-	856	O
taken	-	860	O
appetite	-	866	B
suppressants	-	875	I
.	-	887	O

In	9727773	889	O
8	-	892	O
patients	-	894	O
the	-	903	O
diagnosis	-	907	O
of	-	917	O
primary	-	920	O
pulmonary	-	928	O
hypertension	-	938	O
was	-	951	O
uncertain	-	955	O
,	-	964	O
5	-	966	O
of	-	968	O
them	-	971	O
had	-	976	O
taken	-	980	O
appetite	-	986	B
suppressants	-	995	I
.	-	1007	O

The	9727773	1009	O
patients	-	1013	O
who	-	1022	O
had	-	1026	O
been	-	1030	O
exposed	-	1035	O
to	-	1043	O
appetite	-	1046	B
suppressants	-	1055	I
tended	-	1068	O
to	-	1075	O
be	-	1078	O
on	-	1081	O
average	-	1084	O
more	-	1092	O
severely	-	1097	O
ill	-	1106	O
,	-	1109	O
and	-	1111	O
to	-	1115	O
have	-	1118	O
a	-	1123	O
shorter	-	1125	O
median	-	1133	O
delay	-	1140	O
between	-	1146	O
onset	-	1154	O
of	-	1160	O
symptoms	-	1163	O
and	-	1172	O
diagnosis	-	1176	O
.	-	1185	O

A	9727773	1187	O
policy	-	1189	O
of	-	1196	O
unrestricted	-	1199	O
prescription	-	1212	O
of	-	1225	O
appetite	-	1228	B
suppressants	-	1237	I
may	-	1250	O
lead	-	1254	O
to	-	1259	O
a	-	1262	O
high	-	1264	O
incidence	-	1269	O
of	-	1279	O
associated	-	1282	O
primary	-	1293	O
pulmonary	-	1301	O
hypertension	-	1311	O
.	-	1323	O

Intake	9727773	1325	O
of	-	1332	O
appetite	-	1335	B
suppressants	-	1344	I
may	-	1357	O
accelerate	-	1361	O
the	-	1372	O
progression	-	1376	O
of	-	1388	O
the	-	1391	O
disease	-	1395	O
.	-	1402	O

Choreoathetoid	9754849	0	O
movements	-	15	O
associated	-	25	O
with	-	36	O
rapid	-	41	O
adjustment	-	47	O
to	-	58	O
methadone	-	61	B
.	-	70	O

Choreatiform	9754849	72	O
hyperkinesias	-	85	O
are	-	99	O
known	-	103	O
to	-	109	O
be	-	112	O
occasional	-	115	O
movement	-	126	O
abnormalities	-	135	O
during	-	149	O
intoxications	-	156	O
with	-	170	O
cocaine	-	175	B
but	-	183	O
not	-	187	O
opiates	-	191	O
.	-	198	O

This	9754849	200	O
is	-	205	O
a	-	208	O
case	-	210	O
report	-	215	O
of	-	222	O
euphoria	-	225	O
and	-	234	O
choreoathetoid	-	238	O
movements	-	253	O
both	-	263	O
transiently	-	268	O
induced	-	280	O
by	-	288	O
rapid	-	291	O
adjustment	-	297	O
to	-	308	O
the	-	311	O
selective	-	315	O
mu	-	325	O
-	-	327	O
opioid	-	328	O
receptor	-	335	O
agonist	-	344	O
methadone	-	352	B
in	-	362	O
an	-	365	O
inpatient	-	368	O
previously	-	378	O
abusing	-	389	O
heroine	-	397	B
and	-	405	O
cocaine	-	409	B
.	-	416	O

In	9754849	418	O
addition	-	421	O
,	-	429	O
minor	-	431	O
EEG	-	437	O
abnormalities	-	441	O
occurred	-	455	O
.	-	463	O

Possible	9754849	465	O
underlying	-	474	O
neurobiological	-	485	O
phenomena	-	501	O
are	-	511	O
discussed	-	515	O
.	-	524	O

Cocaine	10365197	0	B
-	-	7	O
induced	-	8	O
mood	-	16	O
disorder	-	21	O
:	-	29	O
prevalence	-	31	O
rates	-	42	O
and	-	48	O
psychiatric	-	52	O
symptoms	-	64	O
in	-	73	O
an	-	76	O
outpatient	-	79	O
cocaine	-	90	B
-	-	97	O
dependent	-	98	O
sample	-	108	O
.	-	114	O

This	10365197	116	O
paper	-	121	O
attempts	-	127	O
to	-	136	O
examine	-	139	O
and	-	147	O
compare	-	151	O
prevalence	-	159	O
rates	-	170	O
and	-	176	O
symptom	-	180	O
patterns	-	188	O
of	-	197	O
DSM	-	200	O
substance	-	204	O
-	-	213	O
induced	-	214	O
and	-	222	O
other	-	226	O
mood	-	232	O
disorders	-	237	O
.	-	246	O

243	10365197	248	O
cocaine	-	252	B
-	-	259	O
dependent	-	260	O
outpatients	-	270	O
with	-	282	O
cocaine	-	287	B
-	-	294	O
induced	-	295	O
mood	-	303	O
disorder	-	308	O
(	-	317	O
CIMD	-	318	O
)	-	322	O
,	-	323	O
other	-	325	O
mood	-	331	O
disorders	-	336	O
,	-	345	O
or	-	347	O
no	-	350	O
mood	-	353	O
disorder	-	358	O
were	-	367	O
compared	-	372	O
on	-	381	O
measures	-	384	O
of	-	393	O
psychiatric	-	396	O
symptoms	-	408	O
.	-	416	O

The	10365197	418	O
prevalence	-	422	O
rate	-	433	O
for	-	438	O
CIMD	-	442	O
was	-	447	O
12	-	451	O
%	-	453	O
at	-	455	O
baseline	-	458	O
.	-	466	O

Introduction	10365197	468	O
of	-	481	O
the	-	484	O
DSM	-	488	O
-	-	491	O
IV	-	492	O
diagnosis	-	495	O
of	-	505	O
CIMD	-	508	O
did	-	513	O
not	-	517	O
substantially	-	521	O
affect	-	535	O
rates	-	542	O
of	-	548	O
the	-	551	O
other	-	555	O
depressive	-	561	O
disorders	-	572	O
.	-	581	O

Patients	10365197	583	O
with	-	592	O
CIMD	-	597	O
had	-	602	O
symptom	-	606	O
severity	-	614	O
levels	-	623	O
between	-	630	O
those	-	638	O
of	-	644	O
patients	-	647	O
with	-	656	O
and	-	661	O
without	-	665	O
a	-	673	O
mood	-	675	O
disorder	-	680	O
.	-	688	O

These	10365197	690	O
findings	-	696	O
suggest	-	705	O
some	-	713	O
validity	-	718	O
for	-	727	O
the	-	731	O
new	-	735	O
DSM	-	739	O
-	-	742	O
IV	-	743	O
diagnosis	-	746	O
of	-	756	O
CIMD	-	759	O
,	-	763	O
but	-	765	O
also	-	769	O
suggest	-	774	O
that	-	782	O
it	-	787	O
requires	-	790	O
further	-	799	O
specification	-	807	O
and	-	821	O
replication	-	825	O
.	-	836	O

Hemolysis	10704919	0	O
of	-	10	O
human	-	13	O
erythrocytes	-	19	O
induced	-	32	O
by	-	40	O
tamoxifen	-	43	B
is	-	53	O
related	-	56	O
to	-	64	O
disruption	-	67	O
of	-	78	O
membrane	-	81	O
structure	-	90	O
.	-	99	O

Tamoxifen	10704919	101	B
(	-	111	O
TAM	-	112	B
)	-	115	O
,	-	116	O
the	-	118	O
antiestrogenic	-	122	O
drug	-	137	O
most	-	142	O
widely	-	147	O
prescribed	-	154	O
in	-	165	O
the	-	168	O
chemotherapy	-	172	O
of	-	185	O
breast	-	188	O
cancer	-	195	O
,	-	201	O
induces	-	203	O
changes	-	211	O
in	-	219	O
normal	-	222	O
discoid	-	229	O
shape	-	237	O
of	-	243	O
erythrocytes	-	246	O
and	-	259	O
hemolytic	-	263	O
anemia	-	273	O
.	-	279	O

This	10704919	281	O
work	-	286	O
evaluates	-	291	O
the	-	301	O
effects	-	305	O
of	-	313	O
TAM	-	316	B
on	-	320	O
isolated	-	323	O
human	-	332	O
erythrocytes	-	338	O
,	-	350	O
attempting	-	352	O
to	-	363	O
identify	-	366	O
the	-	375	O
underlying	-	379	O
mechanisms	-	390	O
on	-	401	O
TAM	-	404	B
-	-	407	O
induced	-	408	O
hemolytic	-	416	O
anemia	-	426	O
and	-	433	O
the	-	437	O
involvement	-	441	O
of	-	453	O
biomembranes	-	456	O
in	-	469	O
its	-	472	O
cytostatic	-	476	O
action	-	487	O
mechanisms	-	494	O
.	-	504	O

TAM	10704919	506	B
induces	-	510	O
hemolysis	-	518	O
of	-	528	O
erythrocytes	-	531	O
as	-	544	O
a	-	547	O
function	-	549	O
of	-	558	O
concentration	-	561	O
.	-	574	O

The	10704919	576	O
extension	-	580	O
of	-	590	O
hemolysis	-	593	O
is	-	603	O
variable	-	606	O
with	-	615	O
erythrocyte	-	620	O
samples	-	632	O
,	-	639	O
but	-	641	O
12	-	645	O
.	-	647	O
5	-	648	O
microM	-	650	O
TAM	-	657	B
induces	-	661	O
total	-	669	O
hemolysis	-	675	O
of	-	685	O
all	-	688	O
tested	-	692	O
suspensions	-	699	O
.	-	710	O

Despite	10704919	712	O
inducing	-	720	O
extensive	-	729	O
erythrocyte	-	739	O
lysis	-	751	O
,	-	756	O
TAM	-	758	B
does	-	762	O
not	-	767	O
shift	-	771	O
the	-	777	O
osmotic	-	781	O
fragility	-	789	O
curves	-	799	O
of	-	806	O
erythrocytes	-	809	O
.	-	821	O

The	10704919	823	O
hemolytic	-	827	O
effect	-	837	O
of	-	844	O
TAM	-	847	B
is	-	851	O
prevented	-	854	O
by	-	864	O
low	-	867	O
concentrations	-	871	O
of	-	886	O
alpha	-	889	B
-	-	894	I
tocopherol	-	895	I
(	-	906	O
alpha	-	907	B
-	-	912	I
T	-	913	I
)	-	914	O
and	-	916	O
alpha	-	920	B
-	-	925	I
tocopherol	-	926	I
acetate	-	937	I
(	-	945	O
alpha	-	946	B
-	-	951	I
TAc	-	952	I
)	-	955	O
(	-	957	O
inactivated	-	958	O
functional	-	970	O
hydroxyl	-	981	B
)	-	989	O
indicating	-	991	O
that	-	1002	O
TAM	-	1007	B
-	-	1010	O
induced	-	1011	O
hemolysis	-	1019	O
is	-	1029	O
not	-	1032	O
related	-	1036	O
to	-	1044	O
oxidative	-	1047	O
membrane	-	1057	O
damage	-	1066	O
.	-	1072	O

This	10704919	1074	O
was	-	1079	O
further	-	1083	O
evidenced	-	1091	O
by	-	1101	O
absence	-	1104	O
of	-	1112	O
oxygen	-	1115	B
consumption	-	1122	O
and	-	1134	O
hemoglobin	-	1138	O
oxidation	-	1149	O
both	-	1159	O
determined	-	1164	O
in	-	1175	O
parallel	-	1178	O
with	-	1187	O
TAM	-	1192	B
-	-	1195	O
induced	-	1196	O
hemolysis	-	1204	O
.	-	1213	O

Furthermore	10704919	1215	O
,	-	1226	O
it	-	1228	O
was	-	1231	O
observed	-	1235	O
that	-	1244	O
TAM	-	1249	B
inhibits	-	1253	O
the	-	1262	O
peroxidation	-	1266	O
of	-	1279	O
human	-	1282	O
erythrocytes	-	1288	O
induced	-	1301	O
by	-	1309	O
AAPH	-	1312	B
,	-	1316	O
thus	-	1318	O
ruling	-	1323	O
out	-	1330	O
TAM	-	1334	B
-	-	1337	O
induced	-	1338	O
cell	-	1346	O
oxidative	-	1351	O
stress	-	1361	O
.	-	1367	O

Hemolysis	10704919	1369	O
caused	-	1379	O
by	-	1386	O
TAM	-	1389	B
was	-	1393	O
not	-	1397	O
preceded	-	1401	O
by	-	1410	O
the	-	1413	O
leakage	-	1417	O
of	-	1425	O
K	-	1428	B
(	-	1429	O
+	-	1430	O
)	-	1431	O
from	-	1433	O
the	-	1438	O
cells	-	1442	O
,	-	1447	O
also	-	1449	O
excluding	-	1454	O
a	-	1464	O
colloid	-	1466	O
-	-	1473	O
osmotic	-	1474	O
type	-	1482	O
mechanism	-	1487	O
of	-	1497	O
hemolysis	-	1500	O
,	-	1509	O
according	-	1511	O
to	-	1521	O
the	-	1524	O
effects	-	1528	O
on	-	1536	O
osmotic	-	1539	O
fragility	-	1547	O
curves	-	1557	O
.	-	1563	O

However	10704919	1565	O
,	-	1572	O
TAM	-	1574	B
induces	-	1578	O
release	-	1586	O
of	-	1594	O
peripheral	-	1597	O
proteins	-	1608	O
of	-	1617	O
membrane	-	1620	O
-	-	1628	O
cytoskeleton	-	1629	O
and	-	1642	O
cytosol	-	1646	O
proteins	-	1654	O
essentially	-	1663	O
bound	-	1675	O
to	-	1681	O
band	-	1684	O
3	-	1689	O
.	-	1690	O

Either	10704919	1692	O
alpha	-	1699	B
-	-	1704	I
T	-	1705	I
or	-	1707	O
alpha	-	1710	B
-	-	1715	I
TAc	-	1716	I
increases	-	1720	O
membrane	-	1730	O
packing	-	1739	O
and	-	1747	O
prevents	-	1751	O
TAM	-	1760	B
partition	-	1764	O
into	-	1774	O
model	-	1779	O
membranes	-	1785	O
.	-	1794	O

These	10704919	1796	O
effects	-	1802	O
suggest	-	1810	O
that	-	1818	O
the	-	1823	O
protection	-	1827	O
from	-	1838	O
hemolysis	-	1843	O
by	-	1853	O
tocopherols	-	1856	B
is	-	1868	O
related	-	1871	O
to	-	1879	O
a	-	1882	O
decreased	-	1884	O
TAM	-	1894	B
incorporation	-	1898	O
in	-	1912	O
condensed	-	1915	O
membranes	-	1925	O
and	-	1935	O
the	-	1939	O
structural	-	1943	O
damage	-	1954	O
of	-	1961	O
the	-	1964	O
erythrocyte	-	1968	O
membrane	-	1980	O
is	-	1989	O
consequently	-	1992	O
avoided	-	2005	O
.	-	2012	O

Therefore	10704919	2014	O
,	-	2023	O
TAM	-	2025	B
-	-	2028	O
induced	-	2029	O
hemolysis	-	2037	O
results	-	2047	O
from	-	2055	O
a	-	2060	O
structural	-	2062	O
perturbation	-	2073	O
of	-	2086	O
red	-	2089	O
cell	-	2093	O
membrane	-	2098	O
,	-	2106	O
leading	-	2108	O
to	-	2116	O
changes	-	2119	O
in	-	2127	O
the	-	2130	O
framework	-	2134	O
of	-	2144	O
the	-	2147	O
erythrocyte	-	2151	O
membrane	-	2163	O
and	-	2172	O
its	-	2176	O
cytoskeleton	-	2180	O
caused	-	2193	O
by	-	2200	O
its	-	2203	O
high	-	2207	O
partition	-	2212	O
in	-	2222	O
the	-	2225	O
membrane	-	2229	O
.	-	2237	O

These	10704919	2239	O
defects	-	2245	O
explain	-	2253	O
the	-	2261	O
abnormal	-	2265	O
erythrocyte	-	2274	O
shape	-	2286	O
and	-	2292	O
decreased	-	2296	O
mechanical	-	2306	O
stability	-	2317	O
promoted	-	2327	O
by	-	2336	O
TAM	-	2339	B
,	-	2342	O
resulting	-	2344	O
in	-	2354	O
hemolytic	-	2357	O
anemia	-	2367	O
.	-	2373	O

Additionally	10704919	2375	O
,	-	2387	O
since	-	2389	O
membrane	-	2395	O
leakage	-	2404	O
is	-	2412	O
a	-	2415	O
final	-	2417	O
stage	-	2423	O
of	-	2429	O
cytotoxicity	-	2432	O
,	-	2444	O
the	-	2446	O
disruption	-	2450	O
of	-	2461	O
the	-	2464	O
structural	-	2468	O
characteristics	-	2479	O
of	-	2495	O
biomembranes	-	2498	O
by	-	2511	O
TAM	-	2514	B
may	-	2518	O
contribute	-	2522	O
to	-	2533	O
the	-	2536	O
multiple	-	2540	O
mechanisms	-	2549	O
of	-	2560	O
its	-	2563	O
anticancer	-	2567	O
action	-	2578	O
.	-	2584	O

Changes	10706004	0	O
of	-	8	O
sodium	-	11	B
and	-	18	O
ATP	-	22	B
affinities	-	26	O
of	-	37	O
the	-	40	O
cardiac	-	44	O
(	-	52	O
Na	-	53	B
,	-	55	O
K	-	56	B
)	-	57	O
-	-	58	O
ATPase	-	59	O
during	-	66	O
and	-	73	O
after	-	77	O
nitric	-	83	B
oxide	-	90	I
deficient	-	96	O
hypertension	-	106	O
.	-	118	O

In	10706004	120	O
the	-	123	O
cardiovascular	-	127	O
system	-	142	O
,	-	148	O
NO	-	150	B
is	-	153	O
involved	-	156	O
in	-	165	O
the	-	168	O
regulation	-	172	O
of	-	183	O
a	-	186	O
variety	-	188	O
of	-	196	O
functions	-	199	O
.	-	208	O

Inhibition	10706004	210	O
of	-	221	O
NO	-	224	B
synthesis	-	227	O
induces	-	237	O
sustained	-	245	O
hypertension	-	255	O
.	-	267	O

In	10706004	269	O
several	-	272	O
models	-	280	O
of	-	287	O
hypertension	-	290	O
,	-	302	O
elevation	-	304	O
of	-	314	O
intracellular	-	317	O
sodium	-	331	B
level	-	338	O
was	-	344	O
documented	-	348	O
in	-	359	O
cardiac	-	362	O
tissue	-	370	O
.	-	376	O

To	10706004	378	O
assess	-	381	O
the	-	388	O
molecular	-	392	O
basis	-	402	O
of	-	408	O
disturbances	-	411	O
in	-	424	O
transmembraneous	-	427	O
transport	-	444	O
of	-	454	O
Na	-	457	B
+	-	459	O
,	-	460	O
we	-	462	O
studied	-	465	O
the	-	473	O
response	-	477	O
of	-	486	O
cardiac	-	489	O
(	-	497	O
Na	-	498	B
,	-	500	O
K	-	501	B
)	-	502	O
-	-	503	O
ATPase	-	504	O
to	-	511	O
NO	-	514	B
-	-	516	O
deficient	-	517	O
hypertension	-	527	O
induced	-	540	O
in	-	548	O
rats	-	551	O
by	-	556	O
NO	-	559	B
-	-	561	O
synthase	-	562	O
inhibition	-	571	O
with	-	582	O
40	-	587	O
mg	-	590	O
/	-	592	O
kg	-	593	O
/	-	595	O
day	-	596	O
N	-	600	B
(	-	601	I
G	-	602	I
)	-	603	I
-	-	604	I
nitro	-	605	I
-	-	610	I
L	-	611	I
-	-	612	I
arginine	-	613	I
methyl	-	622	I
ester	-	629	I
(	-	635	O
L	-	636	B
-	-	637	I
NAME	-	638	I
)	-	642	O
for	-	644	O
4	-	648	O
four	-	650	O
weeks	-	655	O
.	-	660	O

After	10706004	662	O
4	-	668	O
-	-	669	O
week	-	670	O
administration	-	675	O
of	-	690	O
L	-	693	B
-	-	694	I
NAME	-	695	I
,	-	699	O
the	-	701	O
systolic	-	705	O
blood	-	714	O
pressure	-	720	O
(	-	729	O
SBP	-	730	O
)	-	733	O
increased	-	735	O
by	-	745	O
36	-	748	O
%	-	750	O
.	-	751	O

Two	10706004	753	O
weeks	-	757	O
after	-	763	O
terminating	-	769	O
the	-	781	O
treatment	-	785	O
,	-	794	O
the	-	796	O
SBP	-	800	O
recovered	-	804	O
to	-	814	O
control	-	817	O
value	-	825	O
.	-	830	O

When	10706004	832	O
activating	-	837	O
the	-	848	O
(	-	852	O
Na	-	853	B
,	-	855	O
K	-	856	B
)	-	857	O
-	-	858	O
ATPase	-	859	O
with	-	866	O
its	-	871	O
substrate	-	875	O
ATP	-	885	B
,	-	888	O
no	-	890	O
changes	-	893	O
in	-	901	O
Km	-	904	O
and	-	907	O
Vmax	-	911	O
values	-	916	O
were	-	923	O
observed	-	928	O
in	-	937	O
NO	-	940	B
-	-	942	O
deficient	-	943	O
rats	-	953	O
.	-	957	O

During	10706004	959	O
activation	-	966	O
with	-	977	O
Na	-	982	B
+	-	984	O
,	-	985	O
the	-	987	O
Vmax	-	991	O
remained	-	996	O
unchanged	-	1005	O
,	-	1014	O
however	-	1016	O
the	-	1024	O
K	-	1028	B
(	-	1029	O
Na	-	1030	B
)	-	1032	O
increased	-	1034	O
by	-	1044	O
50	-	1047	O
%	-	1049	O
,	-	1050	O
indicating	-	1052	O
a	-	1063	O
profound	-	1065	O
decrease	-	1074	O
in	-	1083	O
the	-	1086	O
affinity	-	1090	O
of	-	1099	O
the	-	1102	O
Na	-	1106	B
+	-	1108	O
-	-	1109	O
binding	-	1110	O
site	-	1118	O
in	-	1123	O
NO	-	1126	B
-	-	1128	O
deficient	-	1129	O
rats	-	1139	O
.	-	1143	O

After	10706004	1145	O
recovery	-	1151	O
from	-	1160	O
hypertension	-	1165	O
,	-	1177	O
the	-	1179	O
activity	-	1183	O
of	-	1192	O
(	-	1195	O
Na	-	1196	B
,	-	1198	O
K	-	1199	B
)	-	1200	O
-	-	1201	O
ATPase	-	1202	O
increased	-	1209	O
,	-	1218	O
due	-	1220	O
to	-	1224	O
higher	-	1227	O
affinity	-	1234	O
of	-	1243	O
the	-	1246	O
ATP	-	1250	B
-	-	1253	O
binding	-	1254	O
site	-	1262	O
,	-	1266	O
as	-	1268	O
revealed	-	1271	O
from	-	1280	O
the	-	1285	O
lowered	-	1289	O
Km	-	1297	O
value	-	1300	O
for	-	1306	O
ATP	-	1310	B
.	-	1313	O

The	10706004	1315	O
K	-	1319	B
(	-	1320	O
Na	-	1321	B
)	-	1323	O
value	-	1325	O
for	-	1331	O
Na	-	1335	B
+	-	1337	O
returned	-	1339	O
to	-	1348	O
control	-	1351	O
value	-	1359	O
.	-	1364	O

Inhibition	10706004	1366	O
of	-	1377	O
NO	-	1380	B
-	-	1382	O
synthase	-	1383	O
induced	-	1392	O
a	-	1400	O
reversible	-	1402	O
hypertension	-	1413	O
accompanied	-	1426	O
by	-	1438	O
depressed	-	1441	O
Na	-	1451	B
+	-	1453	O
-	-	1454	O
extrusion	-	1455	O
from	-	1465	O
cardiac	-	1470	O
cells	-	1478	O
as	-	1484	O
a	-	1487	O
consequence	-	1489	O
of	-	1501	O
deteriorated	-	1504	O
Na	-	1517	B
+	-	1519	O
-	-	1520	O
binding	-	1521	O
properties	-	1529	O
of	-	1540	O
the	-	1543	O
(	-	1547	O
Na	-	1548	B
,	-	1550	O
K	-	1551	B
)	-	1552	O
-	-	1553	O
ATPase	-	1554	O
.	-	1560	O

After	10706004	1562	O
recovery	-	1568	O
of	-	1577	O
blood	-	1580	O
pressure	-	1586	O
to	-	1595	O
control	-	1598	O
values	-	1606	O
,	-	1612	O
the	-	1614	O
extrusion	-	1618	O
of	-	1628	O
Na	-	1631	B
+	-	1633	O
from	-	1635	O
cardiac	-	1640	O
cells	-	1648	O
was	-	1654	O
normalized	-	1658	O
,	-	1668	O
as	-	1670	O
revealed	-	1673	O
by	-	1682	O
restoration	-	1685	O
of	-	1697	O
the	-	1700	O
(	-	1704	O
Na	-	1705	B
,	-	1707	O
K	-	1708	B
)	-	1709	O
-	-	1710	O
ATPase	-	1711	O
activity	-	1718	O
.	-	1726	O

Effects	10721819	0	O
of	-	8	O
long	-	11	O
-	-	15	O
term	-	16	O
pretreatment	-	21	O
with	-	34	O
isoproterenol	-	39	B
on	-	53	O
bromocriptine	-	56	B
-	-	69	O
induced	-	70	O
tachycardia	-	78	O
in	-	90	O
conscious	-	93	O
rats	-	103	O
.	-	107	O

It	10721819	109	O
has	-	112	O
been	-	116	O
shown	-	121	O
that	-	127	O
bromocriptine	-	132	B
-	-	145	O
induced	-	146	O
tachycardia	-	154	O
,	-	165	O
which	-	167	O
persisted	-	173	O
after	-	183	O
adrenalectomy	-	189	O
,	-	202	O
is	-	204	O
(	-	207	O
i	-	208	O
)	-	209	O
mediated	-	211	O
by	-	220	O
central	-	223	O
dopamine	-	231	B
D2	-	240	O
receptor	-	243	O
activation	-	252	O
and	-	263	O
(	-	267	O
ii	-	268	O
)	-	270	O
reduced	-	272	O
by	-	280	O
5	-	283	O
-	-	284	O
day	-	285	O
isoproterenol	-	289	B
pretreatment	-	303	O
,	-	315	O
supporting	-	317	O
therefore	-	328	O
the	-	338	O
hypothesis	-	342	O
that	-	353	O
this	-	358	O
effect	-	363	O
is	-	370	O
dependent	-	373	O
on	-	383	O
sympathetic	-	386	O
outflow	-	398	O
to	-	406	O
the	-	409	O
heart	-	413	O
.	-	418	O

This	10721819	420	O
study	-	425	O
was	-	431	O
conducted	-	435	O
to	-	445	O
examine	-	448	O
whether	-	456	O
prolonged	-	464	O
pretreatment	-	474	O
with	-	487	O
isoproterenol	-	492	B
could	-	506	O
abolish	-	512	O
bromocriptine	-	520	B
-	-	533	O
induced	-	534	O
tachycardia	-	542	O
in	-	554	O
conscious	-	557	O
rats	-	567	O
.	-	571	O

Isoproterenol	10721819	573	B
pretreatment	-	587	O
for	-	600	O
15	-	604	O
days	-	607	O
caused	-	612	O
cardiac	-	619	O
hypertrophy	-	627	O
without	-	639	O
affecting	-	647	O
baseline	-	657	O
blood	-	666	O
pressure	-	672	O
and	-	681	O
heart	-	685	O
rate	-	691	O
.	-	695	O

In	10721819	697	O
control	-	700	O
rats	-	708	O
,	-	712	O
intravenous	-	714	O
bromocriptine	-	726	B
(	-	740	O
150	-	741	O
microg	-	745	O
/	-	751	O
kg	-	752	O
)	-	754	O
induced	-	756	O
significant	-	764	O
hypotension	-	776	O
and	-	788	O
tachycardia	-	792	O
.	-	803	O

Bromocriptine	10721819	805	B
-	-	818	O
induced	-	819	O
hypotension	-	827	O
was	-	839	O
unaffected	-	843	O
by	-	854	O
isoproterenol	-	857	B
pretreatment	-	871	O
,	-	883	O
while	-	885	O
tachycardia	-	891	O
was	-	903	O
reversed	-	907	O
to	-	916	O
significant	-	919	O
bradycardia	-	931	O
,	-	942	O
an	-	944	O
effect	-	947	O
that	-	954	O
was	-	959	O
partly	-	963	O
reduced	-	970	O
by	-	978	O
i	-	981	O
.	-	982	O
v	-	983	O
.	-	984	O

domperidone	10721819	986	B
(	-	998	O
0	-	999	O
.	-	1000	O
5	-	1001	O
mg	-	1003	O
/	-	1005	O
kg	-	1006	O
)	-	1008	O
.	-	1009	O

Neither	10721819	1011	O
cardiac	-	1019	O
vagal	-	1027	O
nor	-	1033	O
sympathetic	-	1037	O
tone	-	1049	O
was	-	1054	O
altered	-	1058	O
by	-	1066	O
isoproterenol	-	1069	B
pretreatment	-	1083	O
.	-	1095	O

In	10721819	1097	O
isolated	-	1100	O
perfused	-	1109	O
heart	-	1118	O
preparations	-	1124	O
from	-	1137	O
isoproterenol	-	1142	B
-	-	1155	O
pretreated	-	1156	O
rats	-	1167	O
,	-	1171	O
the	-	1173	O
isoproterenol	-	1177	B
-	-	1190	O
induced	-	1191	O
maximal	-	1199	O
increase	-	1207	O
in	-	1216	O
left	-	1219	O
ventricular	-	1224	O
systolic	-	1236	O
pressure	-	1245	O
was	-	1254	O
significantly	-	1258	O
reduced	-	1272	O
,	-	1279	O
compared	-	1281	O
with	-	1290	O
saline	-	1295	O
-	-	1301	O
pretreated	-	1302	O
rats	-	1313	O
(	-	1318	O
the	-	1319	O
EC50	-	1323	O
of	-	1328	O
the	-	1331	O
isoproterenol	-	1335	B
-	-	1348	O
induced	-	1349	O
increase	-	1357	O
in	-	1366	O
left	-	1369	O
ventricular	-	1374	O
systolic	-	1386	O
pressure	-	1395	O
was	-	1404	O
enhanced	-	1408	O
approximately	-	1417	O
22	-	1431	O
-	-	1433	O
fold	-	1434	O
)	-	1438	O
.	-	1439	O

These	10721819	1441	O
results	-	1447	O
show	-	1455	O
that	-	1460	O
15	-	1465	O
-	-	1467	O
day	-	1468	O
isoproterenol	-	1472	B
pretreatment	-	1486	O
not	-	1499	O
only	-	1503	O
abolished	-	1508	O
but	-	1518	O
reversed	-	1522	O
bromocriptine	-	1531	B
-	-	1544	O
induced	-	1545	O
tachycardia	-	1553	O
to	-	1565	O
bradycardia	-	1568	O
,	-	1579	O
an	-	1581	O
effect	-	1584	O
that	-	1591	O
is	-	1596	O
mainly	-	1599	O
related	-	1606	O
to	-	1614	O
further	-	1617	O
cardiac	-	1625	O
beta	-	1633	O
-	-	1637	O
adrenoceptor	-	1638	O
desensitization	-	1651	O
rather	-	1667	O
than	-	1674	O
to	-	1679	O
impairment	-	1682	O
of	-	1693	O
autonomic	-	1696	O
regulation	-	1706	O
of	-	1717	O
the	-	1720	O
heart	-	1724	O
.	-	1729	O

They	10721819	1731	O
suggest	-	1736	O
that	-	1744	O
,	-	1748	O
in	-	1750	O
normal	-	1753	O
conscious	-	1760	O
rats	-	1770	O
,	-	1774	O
the	-	1776	O
central	-	1780	O
tachycardia	-	1788	O
of	-	1800	O
bromocriptine	-	1803	B
appears	-	1817	O
to	-	1825	O
predominate	-	1828	O
and	-	1840	O
to	-	1844	O
mask	-	1847	O
the	-	1852	O
bradycardia	-	1856	O
of	-	1868	O
this	-	1871	O
agonist	-	1876	O
at	-	1884	O
peripheral	-	1887	O
dopamine	-	1898	B
D2	-	1907	O
receptors	-	1910	O
.	-	1919	O

A	10737864	0	O
developmental	-	2	O
analysis	-	16	O
of	-	25	O
clonidine	-	28	B
's	-	37	O
effects	-	40	O
on	-	48	O
cardiac	-	51	O
rate	-	59	O
and	-	64	O
ultrasound	-	68	O
production	-	79	O
in	-	90	O
infant	-	93	O
rats	-	100	O
.	-	104	O

Under	10737864	106	O
controlled	-	112	O
conditions	-	123	O
,	-	133	O
infant	-	135	O
rats	-	142	O
emit	-	147	O
ultrasonic	-	152	O
vocalizations	-	163	O
during	-	177	O
extreme	-	184	O
cold	-	192	O
exposure	-	197	O
and	-	206	O
after	-	210	O
administration	-	216	O
of	-	231	O
the	-	234	O
alpha	-	238	O
(	-	243	O
2	-	244	O
)	-	245	O
adrenoceptor	-	247	O
agonist	-	260	O
,	-	267	O
clonidine	-	269	B
.	-	278	O

Previous	10737864	280	O
investigations	-	289	O
have	-	304	O
determined	-	309	O
that	-	320	O
,	-	324	O
in	-	326	O
response	-	329	O
to	-	338	O
clonidine	-	341	B
,	-	350	O
ultrasound	-	352	O
production	-	363	O
increases	-	374	O
through	-	384	O
the	-	392	O
2nd	-	396	O
-	-	399	O
week	-	400	O
postpartum	-	405	O
and	-	416	O
decreases	-	420	O
thereafter	-	430	O
.	-	440	O

Given	10737864	442	O
that	-	448	O
sympathetic	-	453	O
neural	-	465	O
dominance	-	472	O
exhibits	-	482	O
a	-	491	O
similar	-	493	O
developmental	-	501	O
pattern	-	515	O
,	-	522	O
and	-	524	O
given	-	528	O
that	-	534	O
clonidine	-	539	B
induces	-	549	O
sympathetic	-	557	O
withdrawal	-	569	O
and	-	580	O
bradycardia	-	584	O
,	-	595	O
we	-	597	O
hypothesized	-	600	O
that	-	613	O
clonidine	-	618	B
's	-	627	O
developmental	-	630	O
effects	-	644	O
on	-	652	O
cardiac	-	655	O
rate	-	663	O
and	-	668	O
ultrasound	-	672	O
production	-	683	O
would	-	694	O
mirror	-	700	O
each	-	707	O
other	-	712	O
.	-	717	O

Therefore	10737864	719	O
,	-	728	O
in	-	730	O
the	-	733	O
present	-	737	O
experiment	-	745	O
,	-	755	O
the	-	757	O
effects	-	761	O
of	-	769	O
clonidine	-	772	B
administration	-	782	O
(	-	797	O
0	-	798	O
.	-	799	O
5	-	800	O
mg	-	802	O
/	-	804	O
kg	-	805	O
)	-	807	O
on	-	809	O
cardiac	-	812	O
rate	-	820	O
and	-	825	O
ultrasound	-	829	O
production	-	840	O
were	-	851	O
examined	-	856	O
in	-	865	O
2	-	868	O
-	-	869	O
,	-	870	O
8	-	872	O
-	-	873	O
,	-	874	O
15	-	876	O
-	-	878	O
,	-	879	O
and	-	881	O
20	-	885	O
-	-	887	O
day	-	888	O
-	-	891	O
old	-	892	O
rats	-	896	O
.	-	900	O

Age	10737864	902	O
-	-	905	O
related	-	906	O
changes	-	914	O
in	-	922	O
ultrasound	-	925	O
production	-	936	O
corresponded	-	947	O
with	-	960	O
changes	-	965	O
in	-	973	O
cardiovascular	-	976	O
variables	-	991	O
,	-	1000	O
including	-	1002	O
baseline	-	1012	O
cardiac	-	1021	O
rate	-	1029	O
and	-	1034	O
clonidine	-	1038	B
-	-	1047	O
induced	-	1048	O
bradycardia	-	1056	O
.	-	1067	O

This	10737864	1069	O
experiment	-	1074	O
is	-	1085	O
discussed	-	1088	O
with	-	1098	O
regard	-	1103	O
to	-	1110	O
the	-	1113	O
hypothesis	-	1117	O
that	-	1128	O
ultrasound	-	1133	O
production	-	1144	O
is	-	1155	O
the	-	1158	O
acoustic	-	1162	O
by	-	1171	O
-	-	1173	O
product	-	1174	O
of	-	1182	O
a	-	1185	O
physiological	-	1187	O
maneuver	-	1201	O
that	-	1210	O
compensates	-	1215	O
for	-	1227	O
clonidine	-	1231	B
's	-	1240	O
detrimental	-	1243	O
effects	-	1255	O
on	-	1263	O
cardiovascular	-	1266	O
function	-	1281	O
.	-	1289	O

Differential	10743446	0	O
effects	-	13	O
of	-	21	O
systemically	-	24	O
administered	-	37	O
ketamine	-	50	B
and	-	59	O
lidocaine	-	63	B
on	-	73	O
dynamic	-	76	O
and	-	84	O
static	-	88	O
hyperalgesia	-	95	O
induced	-	108	O
by	-	116	O
intradermal	-	119	O
capsaicin	-	131	B
in	-	141	O
humans	-	144	O
.	-	150	O

We	10743446	152	O
have	-	155	O
examined	-	160	O
the	-	169	O
effect	-	173	O
of	-	180	O
systemic	-	183	O
administration	-	192	O
of	-	207	O
ketamine	-	210	B
and	-	219	O
lidocaine	-	223	B
on	-	233	O
brush	-	236	O
-	-	241	O
evoked	-	242	O
(	-	249	O
dynamic	-	250	O
)	-	257	O
pain	-	259	O
and	-	264	O
punctate	-	268	O
-	-	276	O
evoked	-	277	O
(	-	284	O
static	-	285	O
)	-	291	O
hyperalgesia	-	293	O
induced	-	306	O
by	-	314	O
capsaicin	-	317	B
.	-	326	O

In	10743446	328	O
a	-	331	O
randomized	-	333	O
,	-	343	O
double	-	345	O
-	-	351	O
blind	-	352	O
,	-	357	O
placebo	-	359	O
-	-	366	O
controlled	-	367	O
,	-	377	O
crossover	-	379	O
study	-	389	O
,	-	394	O
we	-	396	O
studied	-	399	O
12	-	407	O
volunteers	-	410	O
in	-	421	O
three	-	424	O
experiments	-	430	O
.	-	441	O

Capsaicin	10743446	443	B
100	-	453	O
micrograms	-	457	O
was	-	468	O
injected	-	472	O
intradermally	-	481	O
on	-	495	O
the	-	498	O
volar	-	502	O
forearm	-	508	O
followed	-	516	O
by	-	525	O
an	-	528	O
i	-	531	O
.	-	532	O
v	-	533	O
.	-	534	O

infusion	10743446	536	O
of	-	545	O
ketamine	-	548	B
(	-	557	O
bolus	-	558	O
0	-	564	O
.	-	565	O
1	-	566	O
mg	-	568	O
kg	-	571	O
-	-	573	O
1	-	574	O
over	-	576	O
10	-	581	O
min	-	584	O
followed	-	588	O
by	-	597	O
infusion	-	600	O
of	-	609	O
7	-	612	O
micrograms	-	614	O
kg	-	625	O
-	-	627	O
1	-	628	O
min	-	630	O
-	-	633	O
1	-	634	O
)	-	635	O
,	-	636	O
lidocaine	-	638	B
5	-	648	O
mg	-	650	O
kg	-	653	O
-	-	655	O
1	-	656	O
or	-	658	O
saline	-	661	O
for	-	668	O
50	-	672	O
min	-	675	O
.	-	678	O

Infusion	10743446	680	O
started	-	689	O
15	-	697	O
min	-	700	O
after	-	704	O
injection	-	710	O
of	-	720	O
capsaicin	-	723	B
.	-	732	O

The	10743446	734	O
following	-	738	O
were	-	748	O
measured	-	753	O
:	-	761	O
spontaneous	-	763	O
pain	-	775	O
,	-	779	O
pain	-	781	O
evoked	-	786	O
by	-	793	O
punctate	-	796	O
and	-	805	O
brush	-	809	O
stimuli	-	815	O
(	-	823	O
VAS	-	824	O
)	-	827	O
,	-	828	O
and	-	830	O
areas	-	834	O
of	-	840	O
brush	-	843	O
-	-	848	O
evoked	-	849	O
and	-	856	O
punctate	-	860	O
-	-	868	O
evoked	-	869	O
hyperalgesia	-	876	O
.	-	888	O

Ketamine	10743446	890	B
reduced	-	899	O
both	-	907	O
the	-	912	O
area	-	916	O
of	-	921	O
brush	-	924	O
-	-	929	O
evoked	-	930	O
and	-	937	O
punctate	-	941	O
-	-	949	O
evoked	-	950	O
hyperalgesia	-	957	O
significantly	-	970	O
and	-	984	O
it	-	988	O
tended	-	991	O
to	-	998	O
reduce	-	1001	O
brush	-	1008	O
-	-	1013	O
evoked	-	1014	O
pain	-	1021	O
.	-	1025	O

Lidocaine	10743446	1027	B
reduced	-	1037	O
the	-	1045	O
area	-	1049	O
of	-	1054	O
punctate	-	1057	O
-	-	1065	O
evoked	-	1066	O
hyperalgesia	-	1073	O
significantly	-	1086	O
.	-	1099	O

It	10743446	1101	O
tended	-	1104	O
to	-	1111	O
reduce	-	1114	O
VAS	-	1121	O
scores	-	1125	O
of	-	1132	O
spontaneous	-	1135	O
pain	-	1147	O
but	-	1152	O
had	-	1156	O
no	-	1160	O
effect	-	1163	O
on	-	1170	O
evoked	-	1173	O
pain	-	1180	O
.	-	1184	O

The	10743446	1186	O
differential	-	1190	O
effects	-	1203	O
of	-	1211	O
ketamine	-	1214	B
and	-	1223	O
lidocaine	-	1227	B
on	-	1237	O
static	-	1240	O
and	-	1247	O
dynamic	-	1251	O
hyperalgesia	-	1259	O
suggest	-	1272	O
that	-	1280	O
the	-	1285	O
two	-	1289	O
types	-	1293	O
of	-	1299	O
hyperalgesia	-	1302	O
are	-	1315	O
mediated	-	1319	O
by	-	1328	O
separate	-	1331	O
mechanisms	-	1340	O
and	-	1351	O
have	-	1355	O
a	-	1360	O
distinct	-	1362	O
pharmacology	-	1371	O
.	-	1383	O

Cyclosporine	11007689	0	B
and	-	13	O
tacrolimus	-	17	B
-	-	27	O
associated	-	28	O
thrombotic	-	39	O
microangiopathy	-	50	O
.	-	65	O

The	11007689	67	O
development	-	71	O
of	-	83	O
thrombotic	-	86	O
microangiopathy	-	97	O
(	-	113	O
TMA	-	114	O
)	-	117	O
associated	-	119	O
with	-	130	O
the	-	135	O
use	-	139	O
of	-	143	O
cyclosporine	-	146	B
has	-	159	O
been	-	163	O
well	-	168	O
documented	-	173	O
.	-	183	O

Treatments	11007689	185	O
have	-	196	O
included	-	201	O
discontinuation	-	210	O
or	-	226	O
reduction	-	229	O
of	-	239	O
cyclosporine	-	242	B
dose	-	255	O
with	-	260	O
or	-	265	O
without	-	268	O
concurrent	-	276	O
plasma	-	287	O
exchange	-	294	O
,	-	302	O
plasma	-	304	O
infusion	-	311	O
,	-	319	O
anticoagulation	-	321	O
,	-	336	O
and	-	338	O
intravenous	-	342	O
immunoglobulin	-	354	O
G	-	369	O
infusion	-	371	O
.	-	379	O

However	11007689	381	O
,	-	388	O
for	-	390	O
recipients	-	394	O
of	-	405	O
organ	-	408	O
transplantation	-	414	O
,	-	429	O
removing	-	431	O
the	-	440	O
inciting	-	444	O
agent	-	453	O
is	-	459	O
not	-	462	O
without	-	466	O
the	-	474	O
attendant	-	478	O
risk	-	488	O
of	-	493	O
precipitating	-	496	O
acute	-	510	O
rejection	-	516	O
and	-	526	O
graft	-	530	O
loss	-	536	O
.	-	540	O

The	11007689	542	O
last	-	546	O
decade	-	551	O
has	-	558	O
seen	-	562	O
the	-	567	O
emergence	-	571	O
of	-	581	O
tacrolimus	-	584	B
as	-	595	O
a	-	598	O
potent	-	600	O
immunosuppressive	-	607	O
agent	-	625	O
with	-	631	O
mechanisms	-	636	O
of	-	647	O
action	-	650	O
virtually	-	657	O
identical	-	667	O
to	-	677	O
those	-	680	O
of	-	686	O
cyclosporine	-	689	B
.	-	701	O

As	11007689	703	O
a	-	706	O
result	-	708	O
,	-	714	O
switching	-	716	O
to	-	726	O
tacrolimus	-	729	B
has	-	740	O
been	-	744	O
reported	-	749	O
to	-	758	O
be	-	761	O
a	-	764	O
viable	-	766	O
therapeutic	-	773	O
option	-	785	O
in	-	792	O
the	-	795	O
setting	-	799	O
of	-	807	O
cyclosporine	-	810	B
-	-	822	O
induced	-	823	O
TMA	-	831	O
.	-	834	O

With	11007689	836	O
the	-	841	O
more	-	845	O
widespread	-	850	O
application	-	861	O
of	-	873	O
tacrolimus	-	876	B
in	-	887	O
organ	-	890	O
transplantation	-	896	O
,	-	911	O
tacrolimus	-	913	B
-	-	923	O
associated	-	924	O
TMA	-	935	O
has	-	939	O
also	-	943	O
been	-	948	O
recognized	-	953	O
.	-	963	O

However	11007689	965	O
,	-	972	O
literature	-	974	O
regarding	-	985	O
the	-	995	O
incidence	-	999	O
of	-	1009	O
the	-	1012	O
recurrence	-	1016	O
of	-	1027	O
TMA	-	1030	O
in	-	1034	O
patients	-	1037	O
exposed	-	1046	O
sequentially	-	1054	O
to	-	1067	O
cyclosporine	-	1070	B
and	-	1083	O
tacrolimus	-	1087	B
is	-	1098	O
limited	-	1101	O
.	-	1108	O

We	11007689	1110	O
report	-	1113	O
a	-	1120	O
case	-	1122	O
of	-	1127	O
a	-	1130	O
living	-	1132	O
donor	-	1139	O
renal	-	1145	O
transplant	-	1151	O
recipient	-	1162	O
who	-	1172	O
developed	-	1176	O
cyclosporine	-	1186	B
-	-	1198	O
induced	-	1199	O
TMA	-	1207	O
that	-	1211	O
responded	-	1216	O
to	-	1226	O
the	-	1229	O
withdrawal	-	1233	O
of	-	1244	O
cyclosporine	-	1247	B
in	-	1260	O
conjunction	-	1263	O
with	-	1275	O
plasmapheresis	-	1280	O
and	-	1295	O
fresh	-	1299	O
frozen	-	1305	O
plasma	-	1312	O
replacement	-	1319	O
therapy	-	1331	O
.	-	1338	O

Introduction	11007689	1340	O
of	-	1353	O
tacrolimus	-	1356	B
as	-	1367	O
an	-	1370	O
alternative	-	1373	O
immunosuppressive	-	1385	O
agent	-	1403	O
resulted	-	1409	O
in	-	1418	O
the	-	1421	O
recurrence	-	1425	O
of	-	1436	O
TMA	-	1439	O
and	-	1443	O
the	-	1447	O
subsequent	-	1451	O
loss	-	1462	O
of	-	1467	O
the	-	1470	O
renal	-	1474	O
allograft	-	1480	O
.	-	1489	O

Patients	11007689	1491	O
who	-	1500	O
are	-	1504	O
switched	-	1508	O
from	-	1517	O
cyclosporine	-	1522	B
to	-	1535	O
tacrolimus	-	1538	B
or	-	1549	O
vice	-	1552	O
versa	-	1557	O
should	-	1563	O
be	-	1570	O
closely	-	1573	O
monitored	-	1581	O
for	-	1591	O
the	-	1595	O
signs	-	1599	O
and	-	1605	O
symptoms	-	1609	O
of	-	1618	O
recurrent	-	1621	O
TMA	-	1631	O
.	-	1634	O

Repeated	11256525	0	O
transient	-	9	O
anuria	-	19	O
following	-	26	O
losartan	-	36	B
administration	-	45	O
in	-	60	O
a	-	63	O
patient	-	65	O
with	-	73	O
a	-	78	O
solitary	-	80	O
kidney	-	89	O
.	-	95	O

We	11256525	97	O
report	-	100	O
the	-	107	O
case	-	111	O
of	-	116	O
a	-	119	O
70	-	121	O
-	-	123	O
year	-	124	O
-	-	128	O
old	-	129	O
hypertensive	-	133	O
man	-	146	O
with	-	150	O
a	-	155	O
solitary	-	157	O
kidney	-	166	O
and	-	173	O
chronic	-	177	O
renal	-	185	O
insufficiency	-	191	O
who	-	205	O
developed	-	209	O
two	-	219	O
episodes	-	223	O
of	-	232	O
transient	-	235	O
anuria	-	245	O
after	-	252	O
losartan	-	258	B
administration	-	267	O
.	-	281	O

He	11256525	283	O
was	-	286	O
hospitalized	-	290	O
for	-	303	O
a	-	307	O
myocardial	-	309	O
infarction	-	320	O
with	-	331	O
pulmonary	-	336	O
edema	-	346	O
,	-	351	O
treated	-	353	O
with	-	361	O
high	-	366	O
-	-	370	O
dose	-	371	O
diuretics	-	376	O
.	-	385	O

Due	11256525	387	O
to	-	391	O
severe	-	394	O
systolic	-	401	O
dysfunction	-	410	O
losartan	-	422	B
was	-	431	O
prescribed	-	435	O
.	-	445	O

Surprisingly	11256525	447	O
,	-	459	O
the	-	461	O
first	-	465	O
dose	-	471	O
of	-	476	O
50	-	479	O
mg	-	482	O
of	-	485	O
losartan	-	488	B
resulted	-	497	O
in	-	506	O
a	-	509	O
sudden	-	511	O
anuria	-	518	O
,	-	524	O
which	-	526	O
lasted	-	532	O
eight	-	539	O
hours	-	545	O
despite	-	551	O
high	-	559	O
-	-	563	O
dose	-	564	O
furosemide	-	569	B
and	-	580	O
amine	-	584	B
infusion	-	590	O
.	-	598	O

One	11256525	600	O
week	-	604	O
later	-	609	O
,	-	614	O
by	-	616	O
mistake	-	619	O
,	-	626	O
losartan	-	628	B
was	-	637	O
prescribed	-	641	O
again	-	652	O
and	-	658	O
after	-	662	O
the	-	668	O
second	-	672	O
dose	-	679	O
of	-	684	O
50	-	687	O
mg	-	690	O
,	-	692	O
the	-	694	O
patient	-	698	O
developed	-	706	O
a	-	716	O
second	-	718	O
episode	-	725	O
of	-	733	O
transient	-	736	O
anuria	-	746	O
lasting	-	753	O
10	-	761	O
hours	-	764	O
.	-	769	O

During	11256525	771	O
these	-	778	O
two	-	784	O
episodes	-	788	O
,	-	796	O
his	-	798	O
blood	-	802	O
pressure	-	808	O
diminished	-	817	O
but	-	828	O
no	-	832	O
severe	-	835	O
hypotension	-	842	O
was	-	854	O
noted	-	858	O
.	-	863	O

Ultimately	11256525	865	O
,	-	875	O
an	-	877	O
arteriography	-	880	O
showed	-	894	O
a	-	901	O
70	-	903	O
-	-	905	O
80	-	906	O
%	-	908	O
renal	-	910	O
artery	-	916	O
stenosis	-	923	O
.	-	931	O

In	11256525	933	O
this	-	936	O
patient	-	941	O
,	-	948	O
renal	-	950	O
artery	-	956	O
stenosis	-	963	O
combined	-	972	O
with	-	981	O
heart	-	986	O
failure	-	992	O
and	-	1000	O
diuretic	-	1004	O
therapy	-	1013	O
certainly	-	1021	O
resulted	-	1031	O
in	-	1040	O
a	-	1043	O
strong	-	1045	O
activation	-	1052	O
of	-	1063	O
the	-	1066	O
renin	-	1070	O
-	-	1075	O
angiotensin	-	1076	B
system	-	1088	O
(	-	1095	O
RAS	-	1096	O
)	-	1099	O
.	-	1100	O

Under	11256525	1102	O
such	-	1108	O
conditions	-	1113	O
,	-	1123	O
angiotensin	-	1125	B
II	-	1137	I
receptor	-	1140	O
blockade	-	1149	O
by	-	1158	O
losartan	-	1161	B
probably	-	1170	O
induced	-	1179	O
a	-	1187	O
critical	-	1189	O
fall	-	1198	O
in	-	1203	O
glomerular	-	1206	O
filtration	-	1217	O
pressure	-	1228	O
.	-	1236	O

This	11256525	1238	O
case	-	1243	O
report	-	1248	O
highlights	-	1255	O
the	-	1266	O
fact	-	1270	O
that	-	1275	O
the	-	1280	O
angiotensin	-	1284	B
II	-	1296	I
receptor	-	1299	O
antagonist	-	1308	O
losartan	-	1319	B
can	-	1328	O
cause	-	1332	O
serious	-	1338	O
unexpected	-	1346	O
complications	-	1357	O
in	-	1371	O
patients	-	1374	O
with	-	1383	O
renovascular	-	1388	O
disease	-	1401	O
and	-	1409	O
should	-	1413	O
be	-	1420	O
used	-	1423	O
with	-	1428	O
extreme	-	1433	O
caution	-	1441	O
in	-	1449	O
this	-	1452	O
setting	-	1457	O
.	-	1464	O

In	11334364	0	O
vivo	-	3	O
protection	-	8	O
of	-	19	O
dna	-	22	O
damage	-	26	O
associated	-	33	O
apoptotic	-	44	O
and	-	54	O
necrotic	-	58	O
cell	-	67	O
deaths	-	72	O
during	-	79	O
acetaminophen	-	86	B
-	-	99	O
induced	-	100	O
nephrotoxicity	-	108	O
,	-	122	O
amiodarone	-	124	B
-	-	134	O
induced	-	135	O
lung	-	143	O
toxicity	-	148	O
and	-	157	O
doxorubicin	-	161	B
-	-	172	O
induced	-	173	O
cardiotoxicity	-	181	O
by	-	196	O
a	-	199	O
novel	-	201	O
IH636	-	207	B
grape	-	213	I
seed	-	219	I
proanthocyanidin	-	224	I
extract	-	241	I
.	-	248	O

Grape	11334364	250	B
seed	-	256	I
extract	-	261	I
,	-	268	O
primarily	-	270	O
a	-	280	O
mixture	-	282	O
of	-	290	O
proanthocyanidins	-	293	B
,	-	310	O
has	-	312	O
been	-	316	O
shown	-	321	O
to	-	327	O
modulate	-	330	O
a	-	339	O
wide	-	341	O
-	-	345	O
range	-	346	O
of	-	352	O
biological	-	355	O
,	-	365	O
pharmacological	-	367	O
and	-	383	O
toxicological	-	387	O
effects	-	401	O
which	-	409	O
are	-	415	O
mainly	-	419	O
cytoprotective	-	426	O
.	-	440	O

This	11334364	442	O
study	-	447	O
assessed	-	453	O
the	-	462	O
ability	-	466	O
of	-	474	O
IH636	-	477	B
grape	-	483	I
seed	-	489	I
proanthocyanidin	-	494	I
extract	-	511	I
(	-	519	O
GSPE	-	520	B
)	-	524	O
to	-	526	O
prevent	-	529	O
acetaminophen	-	537	B
(	-	551	O
AAP	-	552	B
)	-	555	O
-	-	556	O
induced	-	557	O
nephrotoxicity	-	565	O
,	-	579	O
amiodarone	-	581	B
(	-	592	O
AMI	-	593	B
)	-	596	O
-	-	597	O
induced	-	598	O
lung	-	606	O
toxicity	-	611	O
,	-	619	O
and	-	621	O
doxorubicin	-	625	B
(	-	637	O
DOX	-	638	B
)	-	641	O
-	-	642	O
induced	-	643	O
cardiotoxicity	-	651	O
in	-	666	O
mice	-	669	O
.	-	673	O

Experimental	11334364	675	O
design	-	688	O
consisted	-	695	O
of	-	705	O
four	-	708	O
groups	-	713	O
:	-	719	O
control	-	721	O
(	-	729	O
vehicle	-	730	O
alone	-	738	O
)	-	743	O
,	-	744	O
GSPE	-	746	B
alone	-	751	O
,	-	756	O
drug	-	758	O
alone	-	763	O
and	-	769	O
GSPE	-	773	B
+	-	777	O
drug	-	778	O
.	-	782	O

For	11334364	784	O
the	-	788	O
cytoprotection	-	792	O
study	-	807	O
,	-	812	O
animals	-	814	O
were	-	822	O
orally	-	827	O
gavaged	-	834	O
100	-	842	O
mg	-	846	O
/	-	848	O
Kg	-	849	O
GSPE	-	852	B
for	-	857	O
7	-	861	O
-	-	862	O
10	-	863	O
days	-	866	O
followed	-	871	O
by	-	880	O
i	-	883	O
.	-	884	O
p	-	885	O
.	-	886	O

injections	11334364	888	O
of	-	899	O
organ	-	902	O
specific	-	908	O
three	-	917	O
drugs	-	923	O
(	-	929	O
AAP	-	930	B
:	-	933	O
500	-	935	O
mg	-	939	O
/	-	941	O
Kg	-	942	O
for	-	945	O
24	-	949	O
h	-	952	O
;	-	953	O
AMI	-	955	B
:	-	958	O
50	-	960	O
mg	-	963	O
/	-	965	O
Kg	-	966	O
/	-	968	O
day	-	969	O
for	-	973	O
four	-	977	O
days	-	982	O
;	-	986	O
DOX	-	988	B
:	-	991	O
20	-	993	O
mg	-	996	O
/	-	998	O
Kg	-	999	O
for	-	1002	O
48	-	1006	O
h	-	1009	O
)	-	1010	O
.	-	1011	O

Parameters	11334364	1013	O
of	-	1024	O
study	-	1027	O
included	-	1033	O
analysis	-	1042	O
of	-	1051	O
serum	-	1054	O
chemistry	-	1060	O
(	-	1070	O
ALT	-	1071	O
,	-	1074	O
BUN	-	1076	O
and	-	1080	O
CPK	-	1084	O
)	-	1087	O
,	-	1088	O
and	-	1090	O
orderly	-	1094	O
fragmentation	-	1102	O
of	-	1116	O
genomic	-	1119	O
DNA	-	1127	O
(	-	1131	O
both	-	1132	O
endonuclease	-	1137	O
-	-	1149	O
dependent	-	1150	O
and	-	1160	O
independent	-	1164	O
)	-	1175	O
in	-	1177	O
addition	-	1180	O
to	-	1189	O
microscopic	-	1192	O
evaluation	-	1204	O
of	-	1215	O
damage	-	1218	O
and	-	1225	O
/	-	1228	O
or	-	1229	O
protection	-	1232	O
in	-	1243	O
corresponding	-	1246	O
PAS	-	1260	O
stained	-	1264	O
tissues	-	1272	O
.	-	1279	O

Results	11334364	1281	O
indicate	-	1289	O
that	-	1298	O
GSPE	-	1303	B
preexposure	-	1308	O
prior	-	1320	O
to	-	1326	O
AAP	-	1329	B
,	-	1332	O
AMI	-	1334	B
and	-	1338	O
DOX	-	1342	B
,	-	1345	O
provided	-	1347	O
near	-	1356	O
complete	-	1361	O
protection	-	1370	O
in	-	1381	O
terms	-	1384	O
of	-	1390	O
serum	-	1393	O
chemistry	-	1399	O
changes	-	1409	O
(	-	1417	O
ALT	-	1418	O
,	-	1421	O
BUN	-	1423	O
and	-	1427	O
CPK	-	1431	O
)	-	1434	O
,	-	1435	O
and	-	1437	O
significantly	-	1441	O
reduced	-	1455	O
DNA	-	1463	O
fragmentation	-	1467	O
.	-	1480	O

Histopathological	11334364	1482	O
examination	-	1500	O
of	-	1512	O
kidney	-	1515	O
,	-	1521	O
heart	-	1523	O
and	-	1529	O
lung	-	1533	O
sections	-	1538	O
revealed	-	1547	O
moderate	-	1556	O
to	-	1565	O
massive	-	1568	O
tissue	-	1576	O
damage	-	1583	O
with	-	1590	O
a	-	1595	O
variety	-	1597	O
of	-	1605	O
morphological	-	1608	O
aberrations	-	1622	O
by	-	1634	O
all	-	1637	O
the	-	1641	O
three	-	1645	O
drugs	-	1651	O
in	-	1657	O
the	-	1660	O
absence	-	1664	O
of	-	1672	O
GSPE	-	1675	B
preexposure	-	1680	O
than	-	1692	O
in	-	1697	O
its	-	1700	O
presence	-	1704	O
.	-	1712	O

GSPE	11334364	1714	B
+	-	1718	O
drug	-	1719	O
exposed	-	1724	O
tissues	-	1732	O
exhibited	-	1740	O
minor	-	1750	O
residual	-	1756	O
damage	-	1765	O
or	-	1772	O
near	-	1775	O
total	-	1780	O
recovery	-	1786	O
.	-	1794	O

Additionally	11334364	1796	O
,	-	1808	O
histopathological	-	1810	O
alterations	-	1828	O
mirrored	-	1840	O
both	-	1849	O
serum	-	1854	O
chemistry	-	1860	O
changes	-	1870	O
and	-	1878	O
the	-	1882	O
pattern	-	1886	O
of	-	1894	O
DNA	-	1897	O
fragmentation	-	1901	O
.	-	1914	O

Interestingly	11334364	1916	O
,	-	1929	O
all	-	1931	O
the	-	1935	O
drugs	-	1939	O
,	-	1944	O
such	-	1946	O
as	-	1951	O
,	-	1953	O
AAP	-	1955	B
,	-	1958	O
AMI	-	1960	B
and	-	1964	O
DOX	-	1968	B
induced	-	1972	O
apoptotic	-	1980	O
death	-	1990	O
in	-	1996	O
addition	-	1999	O
to	-	2008	O
necrosis	-	2011	O
in	-	2020	O
the	-	2023	O
respective	-	2027	O
organs	-	2038	O
which	-	2045	O
was	-	2051	O
very	-	2055	O
effectively	-	2060	O
blocked	-	2072	O
by	-	2080	O
GSPE	-	2083	B
.	-	2087	O

Since	11334364	2089	O
AAP	-	2095	B
,	-	2098	O
AMI	-	2100	B
and	-	2104	O
DOX	-	2108	B
undergo	-	2112	O
biotransformation	-	2120	O
and	-	2138	O
are	-	2142	O
known	-	2146	O
to	-	2152	O
produce	-	2155	O
damaging	-	2163	O
radicals	-	2172	O
in	-	2181	O
vivo	-	2184	O
,	-	2188	O
the	-	2190	O
protection	-	2194	O
by	-	2205	O
GSPE	-	2208	B
may	-	2213	O
be	-	2217	O
linked	-	2220	O
to	-	2227	O
both	-	2230	O
inhibition	-	2235	O
of	-	2246	O
metabolism	-	2249	O
and	-	2260	O
/	-	2263	O
or	-	2264	O
detoxification	-	2267	O
of	-	2282	O
cytotoxic	-	2285	O
radicals	-	2295	O
.	-	2303	O

In	11334364	2305	O
addition	-	2308	O
,	-	2316	O
its	-	2318	O
'	-	2321	O
presumed	-	2323	O
contribution	-	2332	O
to	-	2345	O
DNA	-	2348	O
repair	-	2352	O
may	-	2359	O
be	-	2363	O
another	-	2366	O
important	-	2374	O
attribute	-	2384	O
,	-	2393	O
which	-	2395	O
played	-	2401	O
a	-	2408	O
role	-	2410	O
in	-	2415	O
the	-	2418	O
chemoprevention	-	2422	O
process	-	2438	O
.	-	2445	O

Additionally	11334364	2447	O
,	-	2459	O
this	-	2461	O
may	-	2466	O
have	-	2470	O
been	-	2475	O
the	-	2480	O
first	-	2484	O
report	-	2490	O
on	-	2497	O
AMI	-	2500	B
-	-	2503	O
induced	-	2504	O
apoptotic	-	2512	O
death	-	2522	O
in	-	2528	O
the	-	2531	O
lung	-	2535	O
tissue	-	2540	O
.	-	2546	O

Taken	11334364	2548	O
together	-	2554	O
,	-	2562	O
these	-	2564	O
events	-	2570	O
undoubtedly	-	2577	O
establish	-	2589	O
GSPE	-	2599	B
's	-	2603	O
abundant	-	2606	O
bioavailability	-	2615	O
,	-	2630	O
and	-	2632	O
the	-	2636	O
power	-	2640	O
to	-	2646	O
defend	-	2649	O
multiple	-	2656	O
target	-	2665	O
organs	-	2672	O
from	-	2679	O
toxic	-	2684	O
assaults	-	2690	O
induced	-	2699	O
by	-	2707	O
structurally	-	2710	O
diverse	-	2723	O
and	-	2731	O
functionally	-	2735	O
different	-	2748	O
entities	-	2758	O
in	-	2767	O
vivo	-	2770	O
.	-	2774	O

Palpebral	11642480	0	O
twitching	-	10	O
in	-	20	O
a	-	23	O
depressed	-	25	O
adolescent	-	35	O
on	-	46	O
citalopram	-	49	B
.	-	59	O

Current	11642480	61	O
estimates	-	69	O
suggest	-	79	O
that	-	87	O
between	-	92	O
0	-	100	O
.	-	101	O
4	-	102	O
%	-	103	O
and	-	105	O
8	-	109	O
.	-	110	O
3	-	111	O
%	-	112	O
of	-	114	O
children	-	117	O
and	-	126	O
adolescents	-	130	O
are	-	142	O
affected	-	146	O
by	-	155	O
major	-	158	O
depression	-	164	O
.	-	174	O

We	11642480	176	O
report	-	179	O
a	-	186	O
favorable	-	188	O
response	-	198	O
to	-	207	O
treatment	-	210	O
with	-	220	O
citalopram	-	225	B
by	-	236	O
a	-	239	O
15	-	241	O
-	-	243	O
year	-	244	O
-	-	248	O
old	-	249	O
boy	-	253	O
with	-	257	O
major	-	262	O
depression	-	268	O
who	-	279	O
exhibited	-	283	O
palpebral	-	293	O
twitching	-	303	O
during	-	313	O
his	-	320	O
first	-	324	O
2	-	330	O
weeks	-	332	O
of	-	338	O
treatment	-	341	O
.	-	350	O

This	11642480	352	O
may	-	357	O
have	-	361	O
been	-	366	O
a	-	371	O
side	-	373	O
effect	-	378	O
of	-	385	O
citalopram	-	388	B
as	-	399	O
it	-	402	O
remitted	-	405	O
with	-	414	O
redistribution	-	419	O
of	-	434	O
doses	-	437	O
.	-	442	O

Metamizol	12063090	0	B
potentiates	-	10	O
morphine	-	22	B
antinociception	-	31	O
but	-	47	O
not	-	51	O
constipation	-	55	O
after	-	68	O
chronic	-	74	O
treatment	-	82	O
.	-	91	O

This	12063090	93	O
work	-	98	O
evaluates	-	103	O
the	-	113	O
antinociceptive	-	117	O
and	-	133	O
constipating	-	137	O
effects	-	150	O
of	-	158	O
the	-	161	O
combination	-	165	O
of	-	177	O
3	-	180	O
.	-	181	O
2	-	182	O
mg	-	184	O
/	-	186	O
kg	-	187	O
s	-	190	O
.	-	191	O
c	-	192	O
.	-	193	O

morphine	12063090	195	B
with	-	204	O
177	-	209	O
.	-	212	O
8	-	213	O
mg	-	215	O
/	-	217	O
kg	-	218	O
s	-	221	O
.	-	222	O
c	-	223	O
.	-	224	O

metamizol	12063090	226	B
in	-	236	O
acutely	-	239	O
and	-	247	O
chronically	-	251	O
treated	-	263	O
(	-	271	O
once	-	272	O
a	-	277	O
day	-	279	O
for	-	283	O
12	-	287	O
days	-	290	O
)	-	294	O
rats	-	296	O
.	-	300	O

On	12063090	302	O
the	-	305	O
13th	-	309	O
day	-	314	O
,	-	317	O
antinociceptive	-	319	O
effects	-	335	O
were	-	343	O
assessed	-	348	O
using	-	357	O
a	-	363	O
model	-	365	O
of	-	371	O
inflammatory	-	374	O
nociception	-	387	O
,	-	398	O
pain	-	400	O
-	-	404	O
induced	-	405	O
functional	-	413	O
impairment	-	424	O
model	-	435	O
,	-	440	O
and	-	442	O
the	-	446	O
charcoal	-	450	B
meal	-	459	O
test	-	464	O
was	-	469	O
used	-	473	O
to	-	478	O
evaluate	-	481	O
the	-	490	O
intestinal	-	494	O
transit	-	505	O
.	-	512	O

Simultaneous	12063090	514	O
administration	-	527	O
of	-	542	O
morphine	-	545	B
with	-	554	O
metamizol	-	559	B
resulted	-	569	O
in	-	578	O
a	-	581	O
markedly	-	583	O
antinociceptive	-	592	O
potentiation	-	608	O
and	-	621	O
an	-	625	O
increasing	-	628	O
of	-	639	O
the	-	642	O
duration	-	646	O
of	-	655	O
action	-	658	O
after	-	665	O
a	-	671	O
single	-	673	O
(	-	680	O
298	-	681	O
+	-	684	O
/	-	685	O
-	-	686	O
7	-	687	O
vs	-	689	O
.	-	691	O
139	-	693	O
+	-	696	O
/	-	697	O
-	-	698	O
36	-	699	O
units	-	702	O
area	-	708	O
(	-	713	O
ua	-	714	O
)	-	716	O
;	-	717	O
P	-	719	O
<	-	720	O
0	-	721	O
.	-	722	O
001	-	723	O
)	-	726	O
and	-	728	O
repeated	-	732	O
administration	-	741	O
(	-	756	O
280	-	757	O
+	-	760	O
/	-	761	O
-	-	762	O
17	-	763	O
vs	-	766	O
.	-	768	O
131	-	770	O
+	-	773	O
/	-	774	O
-	-	775	O
22	-	776	O
ua	-	779	O
;	-	781	O
P	-	783	O
<	-	784	O
0	-	785	O
.	-	786	O
001	-	787	O
)	-	790	O
.	-	791	O

Antinociceptive	12063090	793	O
effect	-	809	O
of	-	816	O
morphine	-	819	B
was	-	828	O
reduced	-	832	O
in	-	840	O
chronically	-	843	O
treated	-	855	O
rats	-	863	O
(	-	868	O
39	-	869	O
+	-	871	O
/	-	872	O
-	-	873	O
10	-	874	O
vs	-	877	O
.	-	879	O
18	-	881	O
+	-	883	O
/	-	884	O
-	-	885	O
5	-	886	O
au	-	888	O
)	-	890	O
while	-	892	O
the	-	898	O
combination	-	902	O
-	-	913	O
induced	-	914	O
antinociception	-	922	O
was	-	938	O
remained	-	942	O
similar	-	951	O
as	-	959	O
an	-	962	O
acute	-	965	O
treatment	-	971	O
(	-	981	O
298	-	982	O
+	-	985	O
/	-	986	O
-	-	987	O
7	-	988	O
vs	-	990	O
.	-	992	O
280	-	994	O
+	-	997	O
/	-	998	O
-	-	999	O
17	-	1000	O
au	-	1003	O
)	-	1005	O
.	-	1006	O

Acute	12063090	1008	O
antinociceptive	-	1014	O
effects	-	1030	O
of	-	1038	O
the	-	1041	O
combination	-	1045	O
were	-	1057	O
partially	-	1062	O
prevented	-	1072	O
by	-	1082	O
3	-	1085	O
.	-	1086	O
2	-	1087	O
mg	-	1089	O
/	-	1091	O
kg	-	1092	O
naloxone	-	1095	B
s	-	1104	O
.	-	1105	O
c	-	1106	O
.	-	1107	O

(	12063090	1109	O
P	-	1110	O
<	-	1111	O
0	-	1112	O
.	-	1113	O
05	-	1114	O
)	-	1116	O
,	-	1117	O
suggesting	-	1119	O
the	-	1130	O
partial	-	1134	O
involvement	-	1142	O
of	-	1154	O
the	-	1157	O
opioidergic	-	1161	O
system	-	1173	O
in	-	1180	O
the	-	1183	O
synergism	-	1187	O
observed	-	1197	O
.	-	1205	O

In	12063090	1207	O
independent	-	1210	O
groups	-	1222	O
,	-	1228	O
morphine	-	1230	B
inhibited	-	1239	O
the	-	1249	O
intestinal	-	1253	O
transit	-	1264	O
in	-	1272	O
48	-	1275	O
+	-	1277	O
/	-	1278	O
-	-	1279	O
4	-	1280	O
%	-	1281	O
and	-	1283	O
38	-	1287	O
+	-	1289	O
/	-	1290	O
-	-	1291	O
4	-	1292	O
%	-	1293	O
after	-	1295	O
acute	-	1301	O
and	-	1307	O
chronic	-	1311	O
treatment	-	1319	O
,	-	1328	O
respectively	-	1330	O
,	-	1342	O
suggesting	-	1344	O
that	-	1355	O
tolerance	-	1360	O
did	-	1370	O
not	-	1374	O
develop	-	1378	O
to	-	1386	O
the	-	1389	O
constipating	-	1393	O
effects	-	1406	O
.	-	1413	O

The	12063090	1415	O
combination	-	1419	O
inhibited	-	1431	O
intestinal	-	1441	O
transit	-	1452	O
similar	-	1460	O
to	-	1468	O
that	-	1471	O
produced	-	1476	O
by	-	1485	O
morphine	-	1488	B
regardless	-	1497	O
of	-	1508	O
the	-	1511	O
time	-	1515	O
of	-	1520	O
treatment	-	1523	O
,	-	1532	O
suggesting	-	1534	O
that	-	1545	O
metamizol	-	1550	B
did	-	1560	O
not	-	1564	O
potentiate	-	1568	O
morphine	-	1579	B
-	-	1587	O
induced	-	1588	O
constipation	-	1596	O
.	-	1608	O

These	12063090	1610	O
findings	-	1616	O
show	-	1625	O
a	-	1630	O
significant	-	1632	O
interaction	-	1644	O
between	-	1656	O
morphine	-	1664	B
and	-	1673	O
metamizol	-	1677	B
in	-	1687	O
chronically	-	1690	O
treated	-	1702	O
rats	-	1710	O
,	-	1714	O
suggesting	-	1716	O
that	-	1727	O
this	-	1732	O
combination	-	1737	O
could	-	1749	O
be	-	1755	O
useful	-	1758	O
for	-	1765	O
the	-	1769	O
treatment	-	1773	O
of	-	1783	O
chronic	-	1786	O
pain	-	1794	O
.	-	1798	O

Ifosfamide	12084448	0	B
encephalopathy	-	11	O
presenting	-	26	O
with	-	37	O
asterixis	-	42	O
.	-	51	O

CNS	12084448	53	O
toxic	-	57	O
effects	-	63	O
of	-	71	O
the	-	74	O
antineoplastic	-	78	O
agent	-	93	O
ifosfamide	-	99	B
(	-	110	O
IFX	-	111	B
)	-	114	O
are	-	116	O
frequent	-	120	O
and	-	129	O
include	-	133	O
a	-	141	O
variety	-	143	O
of	-	151	O
neurological	-	154	O
symptoms	-	167	O
that	-	176	O
can	-	181	O
limit	-	185	O
drug	-	191	O
use	-	196	O
.	-	199	O

We	12084448	201	O
report	-	204	O
a	-	211	O
case	-	213	O
of	-	218	O
a	-	221	O
51	-	223	O
-	-	225	O
year	-	226	O
-	-	230	O
old	-	231	O
man	-	235	O
who	-	239	O
developed	-	243	O
severe	-	253	O
,	-	259	O
disabling	-	261	O
negative	-	271	O
myoclonus	-	280	O
of	-	290	O
the	-	293	O
upper	-	297	O
and	-	303	O
lower	-	307	O
extremities	-	313	O
after	-	325	O
the	-	331	O
infusion	-	335	O
of	-	344	O
ifosfamide	-	347	B
for	-	358	O
plasmacytoma	-	362	O
.	-	374	O

He	12084448	376	O
was	-	379	O
awake	-	383	O
,	-	388	O
revealed	-	390	O
no	-	399	O
changes	-	402	O
of	-	410	O
mental	-	413	O
status	-	420	O
and	-	427	O
at	-	431	O
rest	-	434	O
there	-	439	O
were	-	445	O
no	-	450	O
further	-	453	O
motor	-	461	O
symptoms	-	467	O
.	-	475	O

Cranial	12084448	477	O
magnetic	-	485	O
resonance	-	494	O
imaging	-	504	O
and	-	512	O
extensive	-	516	O
laboratory	-	526	O
studies	-	537	O
failed	-	545	O
to	-	552	O
reveal	-	555	O
structural	-	562	O
lesions	-	573	O
of	-	581	O
the	-	584	O
brain	-	588	O
and	-	594	O
metabolic	-	598	O
abnormalities	-	608	O
.	-	621	O

An	12084448	623	O
electroencephalogram	-	626	O
showed	-	647	O
continuous	-	654	O
,	-	664	O
generalized	-	666	O
irregular	-	678	O
slowing	-	688	O
with	-	696	O
admixed	-	701	O
periodic	-	709	O
triphasic	-	718	O
waves	-	728	O
indicating	-	734	O
symptomatic	-	745	O
encephalopathy	-	757	O
.	-	771	O

The	12084448	773	O
administration	-	777	O
of	-	792	O
ifosfamide	-	795	B
was	-	806	O
discontinued	-	810	O
and	-	823	O
within	-	827	O
12	-	834	O
h	-	837	O
the	-	839	O
asterixis	-	843	O
resolved	-	853	O
completely	-	862	O
.	-	872	O

In	12084448	874	O
the	-	877	O
patient	-	881	O
described	-	889	O
,	-	898	O
the	-	900	O
presence	-	904	O
of	-	913	O
asterixis	-	916	O
during	-	926	O
infusion	-	933	O
of	-	942	O
ifosfamide	-	945	B
,	-	955	O
normal	-	957	O
laboratory	-	964	O
findings	-	975	O
and	-	984	O
imaging	-	988	O
studies	-	996	O
and	-	1004	O
the	-	1008	O
resolution	-	1012	O
of	-	1023	O
symptoms	-	1026	O
following	-	1035	O
the	-	1045	O
discontinuation	-	1049	O
of	-	1065	O
the	-	1068	O
drug	-	1072	O
suggest	-	1077	O
that	-	1085	O
negative	-	1090	O
myoclonus	-	1099	O
is	-	1109	O
associated	-	1112	O
with	-	1123	O
the	-	1128	O
use	-	1132	O
of	-	1136	O
IFX	-	1139	B
.	-	1142	O

Sub	12684739	0	O
-	-	3	O
chronic	-	4	O
low	-	12	O
dose	-	16	O
gamma	-	21	B
-	-	26	I
vinyl	-	27	I
GABA	-	33	I
(	-	38	O
vigabatrin	-	39	B
)	-	49	O
inhibits	-	51	O
cocaine	-	60	B
-	-	67	O
induced	-	68	O
increases	-	76	O
in	-	86	O
nucleus	-	89	O
accumbens	-	97	O
dopamine	-	107	B
.	-	115	O

RATIONALE	12684739	117	O
:	-	126	O
gamma	-	128	B
-	-	133	I
Vinyl	-	134	I
GABA	-	140	I
(	-	145	O
GVG	-	146	B
)	-	149	O

irreversibly	12684739	151	O
inhibits	-	164	O
GABA	-	173	B
-	-	177	O
transaminase	-	178	O
.	-	190	O

This	12684739	192	O
non	-	197	O
-	-	200	O
receptor	-	201	O
mediated	-	210	O
inhibition	-	219	O
requires	-	230	O
de	-	239	O
novo	-	242	O
synthesis	-	247	O
for	-	257	O
restoration	-	261	O
of	-	273	O
functional	-	276	O
GABA	-	287	B
catabolism	-	292	O
.	-	302	O

OBJECTIVES	12684739	304	O
:	-	314	O

Given	12684739	316	O
its	-	322	O
preclinical	-	326	O
success	-	338	O
for	-	346	O
treating	-	350	O
substance	-	359	O
abuse	-	369	O
and	-	375	O
the	-	379	O
increased	-	383	O
risk	-	393	O
of	-	398	O
visual	-	401	O
field	-	408	O
defects	-	414	O
(	-	422	O
VFD	-	423	O
)	-	426	O
associated	-	428	O
with	-	439	O
cumulative	-	444	O
lifetime	-	455	O
exposure	-	464	O
,	-	472	O
we	-	474	O
explored	-	477	O
the	-	486	O
effects	-	490	O
of	-	498	O
sub	-	501	O
-	-	504	O
chronic	-	505	O
low	-	513	O
dose	-	517	O
GVG	-	522	B
on	-	526	O
cocaine	-	529	B
-	-	536	O
induced	-	537	O
increases	-	545	O
in	-	555	O
nucleus	-	558	O
accumbens	-	566	O
(	-	576	O
NAcc	-	577	O
)	-	581	O
dopamine	-	583	B
(	-	592	O
DA	-	593	B
)	-	595	O
.	-	596	O

METHODS	12684739	598	O
:	-	605	O

Using	12684739	607	O
in	-	613	O
vivo	-	616	O
microdialysis	-	621	O
,	-	634	O
we	-	636	O
compared	-	639	O
acute	-	648	O
exposure	-	654	O
(	-	663	O
450	-	664	O
mg	-	668	O
/	-	670	O
kg	-	671	O
)	-	673	O
to	-	675	O
an	-	678	O
identical	-	681	O
sub	-	691	O
-	-	694	O
chronic	-	695	O
exposure	-	703	O
(	-	712	O
150	-	713	O
mg	-	717	O
/	-	719	O
kg	-	720	O
per	-	723	O
day	-	727	O
for	-	731	O
3	-	735	O
days	-	737	O
)	-	741	O
,	-	742	O
followed	-	744	O
by	-	753	O
1	-	756	O
-	-	757	O
or	-	759	O
3	-	762	O
-	-	763	O
day	-	764	O
washout	-	768	O
.	-	775	O

Finally	12684739	777	O
,	-	784	O
we	-	786	O
examined	-	789	O
the	-	798	O
low	-	802	O
dose	-	806	O
of	-	811	O
150	-	814	O
mg	-	818	O
/	-	820	O
kg	-	821	O
(	-	824	O
50	-	825	O
mg	-	828	O
/	-	830	O
kg	-	831	O
per	-	834	O
day	-	838	O
)	-	841	O
using	-	843	O
a	-	849	O
similar	-	851	O
washout	-	859	O
period	-	867	O
.	-	873	O

RESULTS	12684739	875	O
:	-	882	O

Sub	12684739	884	O
-	-	887	O
chronic	-	888	O
GVG	-	896	B
exposure	-	900	O
inhibited	-	909	O
the	-	919	O
effect	-	923	O
of	-	930	O
cocaine	-	933	B
for	-	941	O
3	-	945	O
days	-	947	O
,	-	951	O
which	-	953	O
exceeded	-	959	O
in	-	968	O
magnitude	-	971	O
and	-	981	O
duration	-	985	O
the	-	994	O
identical	-	998	O
acute	-	1008	O
dose	-	1014	O
.	-	1018	O

CONCLUSIONS	12684739	1020	O
:	-	1031	O

Sub	12684739	1033	O
-	-	1036	O
chronic	-	1037	O
low	-	1045	O
dose	-	1049	O
GVG	-	1054	B
potentiates	-	1058	O
and	-	1070	O
extends	-	1074	O
the	-	1082	O
inhibition	-	1086	O
of	-	1097	O
cocaine	-	1100	B
-	-	1107	O
induced	-	1108	O
increases	-	1116	O
in	-	1126	O
dopamine	-	1129	B
,	-	1137	O
effectively	-	1139	O
reducing	-	1151	O
cumulative	-	1160	O
exposures	-	1171	O
and	-	1181	O
the	-	1185	O
risk	-	1189	O
for	-	1194	O
VFDS	-	1198	O
.	-	1202	O

Amount	12716030	0	O
of	-	7	O
bleeding	-	10	O
and	-	19	O
hematoma	-	23	O
size	-	32	O
in	-	37	O
the	-	40	O
collagenase	-	44	O
-	-	55	O
induced	-	56	O
intracerebral	-	64	O
hemorrhage	-	78	O
rat	-	89	O
model	-	93	O
.	-	98	O

The	12716030	100	O
aggravated	-	104	O
risk	-	115	O
on	-	120	O
intracerebral	-	123	O
hemorrhage	-	137	O
(	-	148	O
ICH	-	149	O
)	-	152	O
with	-	154	O
drugs	-	159	O
used	-	165	O
for	-	170	O
stroke	-	174	O
patients	-	181	O
should	-	190	O
be	-	197	O
estimated	-	200	O
carefully	-	210	O
.	-	219	O

We	12716030	221	O
therefore	-	224	O
established	-	234	O
sensitive	-	246	O
quantification	-	256	O
methods	-	271	O
and	-	279	O
provided	-	283	O
a	-	292	O
rat	-	294	O
ICH	-	298	O
model	-	302	O
for	-	308	O
detection	-	312	O
of	-	322	O
ICH	-	325	O
deterioration	-	329	O
.	-	342	O

In	12716030	344	O
ICH	-	347	O
intrastriatally	-	351	O
induced	-	367	O
by	-	375	O
0	-	378	O
.	-	379	O
014	-	380	O
-	-	383	O
unit	-	384	O
,	-	388	O
0	-	390	O
.	-	391	O
070	-	392	O
-	-	395	O
unit	-	396	O
,	-	400	O
and	-	402	O
0	-	406	O
.	-	407	O
350	-	408	O
-	-	411	O
unit	-	412	O
collagenase	-	417	O
,	-	428	O

the	12716030	430	O
amount	-	434	O
of	-	441	O
bleeding	-	444	O
was	-	453	O
measured	-	457	O
using	-	466	O
a	-	472	O
hemoglobin	-	474	O
assay	-	485	O
developed	-	491	O
in	-	501	O
the	-	504	O
present	-	508	O
study	-	516	O
and	-	522	O
was	-	526	O
compared	-	530	O
with	-	539	O
the	-	544	O
morphologically	-	548	O
determined	-	564	O
hematoma	-	575	O
volume	-	584	O
.	-	590	O

The	12716030	592	O
blood	-	596	O
amounts	-	602	O
and	-	610	O
hematoma	-	614	O
volumes	-	623	O
were	-	631	O
significantly	-	636	O
correlated	-	650	O
,	-	660	O
and	-	662	O
the	-	666	O
hematoma	-	670	O
induced	-	679	O
by	-	687	O
0	-	690	O
.	-	691	O
014	-	692	O
-	-	695	O
unit	-	696	O
collagenase	-	701	O
was	-	713	O
adequate	-	717	O
to	-	726	O
detect	-	729	O
ICH	-	736	O
deterioration	-	740	O
.	-	753	O

In	12716030	755	O
ICH	-	758	O
induction	-	762	O
using	-	772	O
0	-	778	O
.	-	779	O
014	-	780	O
-	-	783	O
unit	-	784	O
collagenase	-	789	O
,	-	800	O
heparin	-	802	B
enhanced	-	810	O
the	-	819	O
hematoma	-	823	O
volume	-	832	O
3	-	839	O
.	-	840	O
4	-	841	O
-	-	842	O
fold	-	843	O
over	-	848	O
that	-	853	O
seen	-	858	O
in	-	863	O
control	-	866	O
ICH	-	874	O
animals	-	878	O
and	-	886	O
the	-	890	O
bleeding	-	894	O
7	-	903	O
.	-	904	O
6	-	905	O
-	-	906	O
fold	-	907	O
.	-	911	O

Data	12716030	913	O
suggest	-	918	O
that	-	926	O
this	-	931	O
sensitive	-	936	O
hemoglobin	-	946	O
assay	-	957	O
is	-	963	O
useful	-	966	O
for	-	973	O
ICH	-	977	O
detection	-	981	O
,	-	990	O
and	-	992	O
that	-	996	O
a	-	1001	O
model	-	1003	O
with	-	1009	O
a	-	1014	O
small	-	1016	O
ICH	-	1022	O
induced	-	1026	O
with	-	1034	O
a	-	1039	O
low	-	1041	O
-	-	1044	O
dose	-	1045	O
collagenase	-	1050	O
should	-	1062	O
be	-	1069	O
used	-	1072	O
for	-	1077	O
evaluation	-	1081	O
of	-	1092	O
drugs	-	1095	O
that	-	1101	O
may	-	1106	O
affect	-	1110	O
ICH	-	1117	O
.	-	1120	O

Estradiol	12757899	0	B
reduces	-	10	O
seizure	-	18	O
-	-	25	O
induced	-	26	O
hippocampal	-	34	O
injury	-	46	O
in	-	53	O
ovariectomized	-	56	O
female	-	71	O
but	-	78	O
not	-	82	O
in	-	86	O
male	-	89	O
rats	-	94	O
.	-	98	O

Estrogens	12757899	100	O
protect	-	110	O
ovariectomized	-	118	O
rats	-	133	O
from	-	138	O
hippocampal	-	143	O
injury	-	155	O
induced	-	162	O
by	-	170	O
kainic	-	173	B
acid	-	180	I
-	-	184	O
induced	-	185	O
status	-	193	O
epilepticus	-	200	O
(	-	212	O
SE	-	213	O
)	-	215	O
.	-	216	O

We	12757899	218	O
compared	-	221	O
the	-	230	O
effects	-	234	O
of	-	242	O
17beta	-	245	B
-	-	251	I
estradiol	-	252	I
in	-	262	O
adult	-	265	O
male	-	271	O
and	-	276	O
ovariectomized	-	280	O
female	-	295	O
rats	-	302	O
subjected	-	307	O
to	-	317	O
lithium	-	320	B
-	-	327	O
pilocarpine	-	328	B
-	-	339	O
induced	-	340	O
SE	-	348	O
.	-	350	O

Rats	12757899	352	O
received	-	357	O
subcutaneous	-	366	O
injections	-	379	O
of	-	390	O
17beta	-	393	B
-	-	399	I
estradiol	-	400	I
(	-	410	O
2	-	411	O
microg	-	413	O
/	-	419	O
rat	-	420	O
)	-	423	O
or	-	425	O
oil	-	428	O
once	-	432	O
daily	-	437	O
for	-	443	O
four	-	447	O
consecutive	-	452	O
days	-	464	O
.	-	468	O

SE	12757899	470	O
was	-	473	O
induced	-	477	O
20	-	485	O
h	-	488	O
following	-	490	O
the	-	500	O
second	-	504	O
injection	-	511	O
and	-	521	O
terminated	-	525	O
3	-	536	O
h	-	538	O
later	-	540	O
.	-	545	O

The	12757899	547	O
extent	-	551	O
of	-	558	O
silver	-	561	B
-	-	567	O
stained	-	568	O
CA3	-	576	O
and	-	580	O
CA1	-	584	O
hippocampal	-	588	O
neurons	-	600	O
was	-	608	O
evaluated	-	612	O
2	-	622	O
days	-	624	O
after	-	629	O
SE	-	635	O
.	-	637	O

17beta	12757899	639	B
-	-	645	I
Estradiol	-	646	I
did	-	656	O
not	-	660	O
alter	-	664	O
the	-	670	O
onset	-	674	O
of	-	680	O
first	-	683	O
clonus	-	689	O
in	-	696	O
ovariectomized	-	699	O
rats	-	714	O
but	-	719	O
accelerated	-	723	O
it	-	735	O
in	-	738	O
males	-	741	O
.	-	746	O

17beta	12757899	748	B
-	-	754	I
Estradiol	-	755	I
reduced	-	765	O
the	-	773	O
argyrophilic	-	777	O
neurons	-	790	O
in	-	798	O
the	-	801	O
CA1	-	805	O
and	-	809	O
CA3	-	813	O
-	-	816	O
C	-	817	O
sectors	-	819	O
of	-	827	O
ovariectomized	-	830	O
rats	-	845	O
.	-	849	O

In	12757899	851	O
males	-	854	O
,	-	859	O
estradiol	-	861	B
increased	-	871	O
the	-	881	O
total	-	885	O
damage	-	891	O
score	-	898	O
.	-	903	O

These	12757899	905	O
findings	-	911	O
suggest	-	920	O
that	-	928	O
the	-	933	O
effects	-	937	O
of	-	945	O
estradiol	-	948	B
on	-	958	O
seizure	-	961	O
threshold	-	969	O
and	-	979	O
damage	-	983	O
may	-	990	O
be	-	994	O
altered	-	997	O
by	-	1005	O
sex	-	1008	O
-	-	1011	O
related	-	1012	O
differences	-	1020	O
in	-	1032	O
the	-	1035	O
hormonal	-	1039	O
environment	-	1048	O
.	-	1059	O

Delirium	12905102	0	O
during	-	9	O
clozapine	-	16	B
treatment	-	26	O
:	-	35	O
incidence	-	37	O
and	-	47	O
associated	-	51	O
risk	-	62	O
factors	-	67	O
.	-	74	O

BACKGROUND	12905102	76	O
:	-	86	O

Incidence	12905102	88	O
and	-	98	O
risk	-	102	O
factors	-	107	O
for	-	115	O
delirium	-	119	O
during	-	128	O
clozapine	-	135	B
treatment	-	145	O
require	-	155	O
further	-	163	O
clarification	-	171	O
.	-	184	O

METHODS	12905102	186	O
:	-	193	O

We	12905102	195	O
used	-	198	O
computerized	-	203	O
pharmacy	-	216	O
records	-	225	O
to	-	233	O
identify	-	236	O
all	-	245	O
adult	-	249	O
psychiatric	-	255	O
inpatients	-	267	O
treated	-	278	O
with	-	286	O
clozapine	-	291	B
(	-	301	O
1995	-	302	O
-	-	306	O
96	-	307	O
)	-	309	O
,	-	310	O
reviewed	-	312	O
their	-	321	O
medical	-	327	O
records	-	335	O
to	-	343	O
score	-	346	O
incidence	-	352	O
and	-	362	O
severity	-	366	O
of	-	375	O
delirium	-	378	O
,	-	386	O
and	-	388	O
tested	-	392	O
associations	-	399	O
with	-	412	O
potential	-	417	O
risk	-	427	O
factors	-	432	O
.	-	439	O

RESULTS	12905102	441	O
:	-	448	O

Subjects	12905102	450	O
(	-	459	O
n	-	460	O
=	-	462	O
139	-	464	O
)	-	467	O
were	-	469	O
72	-	474	O
women	-	477	O
and	-	483	O
67	-	487	O
men	-	490	O
,	-	493	O
aged	-	495	O
40	-	500	O
.	-	502	O
8	-	503	O
+	-	505	O
/	-	506	O
-	-	507	O

12	12905102	509	O
.	-	511	O
1	-	512	O
years	-	514	O
,	-	519	O
hospitalized	-	521	O
for	-	534	O
24	-	538	O
.	-	540	O
9	-	541	O
+	-	543	O
/	-	544	O
-	-	545	O

23	12905102	547	O
.	-	549	O
3	-	550	O
days	-	552	O
,	-	556	O
and	-	558	O
given	-	562	O
clozapine	-	568	B
,	-	577	O
gradually	-	579	O
increased	-	589	O
to	-	599	O
an	-	602	O
average	-	605	O
daily	-	613	O
dose	-	619	O
of	-	624	O
282	-	627	O
+	-	631	O
/	-	632	O
-	-	633	O

203	12905102	635	O
mg	-	639	O
(	-	642	O
3	-	643	O
.	-	644	O
45	-	645	O
+	-	648	O
/	-	649	O
-	-	650	O

2	12905102	652	O
.	-	653	O
45	-	654	O
mg	-	657	O
/	-	659	O
kg	-	660	O
)	-	662	O
for	-	664	O
18	-	668	O
.	-	670	O
9	-	671	O
+	-	673	O
/	-	674	O
-	-	675	O

16	12905102	677	O
.	-	679	O
4	-	680	O
days	-	682	O
.	-	686	O

Delirium	12905102	688	O
was	-	697	O
diagnosed	-	701	O
in	-	711	O
14	-	714	O
(	-	717	O
10	-	718	O
.	-	720	O
1	-	721	O
%	-	723	O
incidence	-	725	O
,	-	734	O
or	-	736	O
1	-	739	O
.	-	740	O
48	-	741	O
cases	-	744	O
/	-	749	O
person	-	750	O
-	-	756	O
years	-	757	O
of	-	763	O
exposure	-	766	O
)	-	774	O
;	-	775	O
71	-	777	O
.	-	779	O
4	-	780	O
%	-	782	O
of	-	784	O
cases	-	787	O
were	-	793	O
moderate	-	798	O
or	-	807	O
severe	-	810	O
.	-	816	O

Associated	12905102	818	O
factors	-	829	O
were	-	837	O
co	-	842	O
-	-	844	O
treatment	-	845	O
with	-	855	O
other	-	860	O
centrally	-	866	O
antimuscarinic	-	876	O
agents	-	891	O
,	-	897	O
poor	-	899	O
clinical	-	904	O
outcome	-	913	O
,	-	920	O
older	-	922	O
age	-	928	O
,	-	931	O
and	-	933	O
longer	-	937	O
hospitalization	-	944	O
(	-	960	O
by	-	961	O
17	-	964	O
.	-	966	O
5	-	967	O
days	-	969	O
,	-	973	O
increasing	-	975	O
cost	-	986	O
)	-	990	O
;	-	991	O
sex	-	993	O
,	-	996	O
diagnosis	-	998	O
or	-	1008	O
medical	-	1011	O
co	-	1019	O
-	-	1021	O
morbidity	-	1022	O
,	-	1031	O
and	-	1033	O
daily	-	1037	O
clozapine	-	1043	B
dose	-	1053	O
,	-	1057	O
which	-	1059	O
fell	-	1065	O
with	-	1070	O
age	-	1075	O
,	-	1078	O
were	-	1080	O
unrelated	-	1085	O
.	-	1094	O

CONCLUSIONS	12905102	1096	O
:	-	1107	O

Delirium	12905102	1109	O
was	-	1118	O
found	-	1122	O
in	-	1128	O
10	-	1131	O
%	-	1134	O
of	-	1136	O
clozapine	-	1139	B
-	-	1148	O
treated	-	1149	O
inpatients	-	1157	O
,	-	1167	O
particularly	-	1169	O
in	-	1182	O
older	-	1185	O
patients	-	1191	O
exposed	-	1200	O
to	-	1208	O
other	-	1211	O
central	-	1217	O
anticholinergics	-	1225	O
.	-	1241	O

Delirium	12905102	1243	O
was	-	1252	O
inconsistently	-	1256	O
recognized	-	1271	O
clinically	-	1282	O
in	-	1293	O
milder	-	1296	O
cases	-	1303	O
and	-	1309	O
was	-	1313	O
associated	-	1317	O
with	-	1328	O
increased	-	1333	O
length	-	1343	O
-	-	1349	O
of	-	1350	O
-	-	1352	O
stay	-	1353	O
and	-	1358	O
higher	-	1362	O
costs	-	1369	O
,	-	1374	O
and	-	1376	O
inferior	-	1380	O
clinical	-	1389	O
outcome	-	1398	O
.	-	1405	O

Ketoconazole	14513889	0	B
-	-	12	O
induced	-	13	O
neurologic	-	21	O
sequelae	-	32	O
.	-	40	O

A	14513889	42	O
77	-	44	O
-	-	46	O
y	-	47	O
-	-	48	O
old	-	49	O
patient	-	53	O
developed	-	61	O
weakness	-	71	O
of	-	80	O
extremities	-	83	O
,	-	94	O
legs	-	96	O
paralysis	-	101	O
,	-	110	O
dysarthria	-	112	O
and	-	123	O
tremor	-	127	O
1	-	134	O
h	-	136	O
after	-	138	O
ingestion	-	144	O
of	-	154	O
200	-	157	O
mg	-	161	O
ketoconazole	-	164	B
for	-	177	O
the	-	181	O
first	-	185	O
time	-	191	O
in	-	196	O
his	-	199	O
life	-	203	O
.	-	207	O

All	14513889	209	O
complaints	-	213	O
faded	-	224	O
away	-	230	O
within	-	235	O
24	-	242	O
h	-	245	O
.	-	246	O

Few	14513889	248	O
days	-	252	O
later	-	257	O
,	-	262	O
the	-	264	O
patient	-	268	O
used	-	276	O
another	-	281	O
200	-	289	O
mg	-	293	O
ketoconazole	-	296	B
tablet	-	309	O
,	-	315	O
and	-	317	O
within	-	321	O
an	-	328	O
hour	-	331	O
experienced	-	336	O
a	-	348	O
similar	-	350	O
clinical	-	358	O
picture	-	367	O
,	-	374	O
which	-	376	O
resolved	-	382	O
again	-	391	O
spontaneously	-	397	O
within	-	411	O
hours	-	418	O
.	-	423	O

Laboratory	14513889	425	O
evaluations	-	436	O
,	-	447	O
including	-	449	O
head	-	459	O
CT	-	464	O
scan	-	467	O
,	-	471	O
were	-	473	O
normal	-	478	O
.	-	484	O

This	14513889	486	O
case	-	491	O
illustrates	-	496	O
the	-	508	O
need	-	512	O
for	-	517	O
close	-	521	O
vigilance	-	527	O
in	-	537	O
adverse	-	540	O
drug	-	548	O
reactions	-	553	O
,	-	562	O
particularly	-	564	O
in	-	577	O
the	-	580	O
elderly	-	584	O
.	-	591	O

Noxious	15009014	0	O
chemical	-	8	O
stimulation	-	17	O
of	-	29	O
rat	-	32	O
facial	-	36	O
mucosa	-	43	O
increases	-	50	O
intracranial	-	60	O
blood	-	73	O
flow	-	79	O
through	-	84	O
a	-	92	O
trigemino	-	94	O
-	-	103	O
parasympathetic	-	104	O
reflex	-	120	O
-	-	126	O
-	-	127	O
an	-	128	O
experimental	-	131	O
model	-	144	O
for	-	150	O
vascular	-	154	O
dysfunctions	-	163	O
in	-	176	O
cluster	-	179	O
headache	-	187	O
.	-	195	O

Cluster	15009014	197	O
headache	-	205	O
is	-	214	O
characterized	-	217	O
by	-	231	O
typical	-	234	O
autonomic	-	242	O
dysfunctions	-	252	O
including	-	265	O
facial	-	275	O
and	-	282	O
intracranial	-	286	O
vascular	-	299	O
disturbances	-	308	O
.	-	320	O

Both	15009014	322	O
the	-	327	O
trigeminal	-	331	O
and	-	342	O
the	-	346	O
cranial	-	350	O
parasympathetic	-	358	O
systems	-	374	O
may	-	382	O
be	-	386	O
involved	-	389	O
in	-	398	O
mediating	-	401	O
these	-	411	O
dysfunctions	-	417	O
.	-	429	O

An	15009014	431	O
experimental	-	434	O
model	-	447	O
was	-	453	O
developed	-	457	O
in	-	467	O
the	-	470	O
rat	-	474	O
to	-	478	O
measure	-	481	O
changes	-	489	O
in	-	497	O
lacrimation	-	500	O
and	-	512	O
intracranial	-	516	O
blood	-	529	O
flow	-	535	O
following	-	540	O
noxious	-	550	O
chemical	-	558	O
stimulation	-	567	O
of	-	579	O
facial	-	582	O
mucosa	-	589	O
.	-	595	O

Blood	15009014	597	O
flow	-	603	O
was	-	608	O
monitored	-	612	O
in	-	622	O
arteries	-	625	O
of	-	634	O
the	-	637	O
exposed	-	641	O
cranial	-	649	O
dura	-	657	O
mater	-	662	O
and	-	668	O
the	-	672	O
parietal	-	676	O
cortex	-	685	O
using	-	692	O
laser	-	698	O
Doppler	-	704	O
flowmetry	-	712	O
.	-	721	O

Capsaicin	15009014	723	B
(	-	733	O
0	-	734	O
.	-	735	O
01	-	736	O
-	-	738	O
1	-	739	O
mm	-	741	O
)	-	743	O
applied	-	745	O
to	-	753	O
oral	-	756	O
or	-	761	O
nasal	-	764	O
mucosa	-	770	O
induced	-	777	O
increases	-	785	O
in	-	795	O
dural	-	798	O
and	-	804	O
cortical	-	808	O
blood	-	817	O
flow	-	823	O
and	-	828	O
provoked	-	832	O
lacrimation	-	841	O
.	-	852	O

These	15009014	854	O
responses	-	860	O
were	-	870	O
blocked	-	875	O
by	-	883	O
systemic	-	886	O
pre	-	895	O
-	-	898	O
administration	-	899	O
of	-	914	O
hexamethonium	-	917	B
chloride	-	931	I
(	-	940	O
20	-	941	O
mg	-	944	O
/	-	946	O
kg	-	947	O
)	-	949	O
.	-	950	O

The	15009014	952	O
evoked	-	956	O
increases	-	963	O
in	-	973	O
dural	-	976	O
blood	-	982	O
flow	-	988	O
were	-	993	O
also	-	998	O
abolished	-	1003	O
by	-	1013	O
topical	-	1016	O
pre	-	1024	O
-	-	1027	O
administration	-	1028	O
of	-	1043	O
atropine	-	1046	B
(	-	1055	O
1	-	1056	O
mm	-	1058	O
)	-	1060	O
and	-	1062	O
[	-	1066	O
Lys1	-	1067	O
,	-	1071	O
Pro2	-	1073	O
,	-	1077	O
5	-	1078	O
,	-	1079	O
Arg3	-	1081	O
,	-	1085	O
4	-	1086	O
,	-	1087	O
Tyr6	-	1089	O
]	-	1093	O
-	-	1094	O
VIP	-	1095	O
(	-	1099	O
0	-	1100	O
.	-	1101	O
1	-	1102	O
mm	-	1104	O
)	-	1106	O
,	-	1107	O
a	-	1109	O
vasoactive	-	1111	O
intestinal	-	1122	O
polypeptide	-	1133	O
(	-	1145	O
VIP	-	1146	O
)	-	1149	O
antagonist	-	1151	O
,	-	1161	O
onto	-	1163	O
the	-	1168	O
exposed	-	1172	O
dura	-	1180	O
mater	-	1185	O
.	-	1190	O

We	15009014	1192	O
conclude	-	1195	O
that	-	1204	O
noxious	-	1209	O
stimulation	-	1217	O
of	-	1229	O
facial	-	1232	O
mucosa	-	1239	O
increases	-	1246	O
intracranial	-	1256	O
blood	-	1269	O
flow	-	1275	O
and	-	1280	O
lacrimation	-	1284	O
via	-	1296	O
a	-	1300	O
trigemino	-	1302	O
-	-	1311	O
parasympathetic	-	1312	O
reflex	-	1328	O
.	-	1334	O

The	15009014	1336	O
blood	-	1340	O
flow	-	1346	O
responses	-	1351	O
seem	-	1361	O
to	-	1366	O
be	-	1369	O
mediated	-	1372	O
by	-	1381	O
the	-	1384	O
release	-	1388	O
of	-	1396	O
acetylcholine	-	1399	B
and	-	1413	O
VIP	-	1417	O
within	-	1421	O
the	-	1428	O
meninges	-	1432	O
.	-	1440	O

Similar	15009014	1442	O
mechanisms	-	1450	O
may	-	1461	O
be	-	1465	O
involved	-	1468	O
in	-	1477	O
the	-	1480	O
pathogenesis	-	1484	O
of	-	1497	O
cluster	-	1500	O
headache	-	1508	O
.	-	1516	O

Recurrent	15120741	0	O
excitation	-	10	O
in	-	21	O
the	-	24	O
dentate	-	28	O
gyrus	-	36	O
of	-	42	O
a	-	45	O
murine	-	47	O
model	-	54	O
of	-	60	O
temporal	-	63	O
lobe	-	72	O
epilepsy	-	77	O
.	-	85	O

Similar	15120741	87	O
to	-	95	O
rats	-	98	O
,	-	102	O
systemic	-	104	O
pilocarpine	-	113	B
injection	-	125	O
causes	-	135	O
status	-	142	O
epilepticus	-	149	O
(	-	161	O
SE	-	162	O
)	-	164	O
and	-	166	O
the	-	170	O
eventual	-	174	O
development	-	183	O
of	-	195	O
spontaneous	-	198	O
seizures	-	210	O
and	-	219	O
mossy	-	223	O
fiber	-	229	O
sprouting	-	235	O
in	-	245	O
C57BL	-	248	O
/	-	253	O
6	-	254	O
and	-	256	O
CD1	-	260	O
mice	-	264	O
,	-	268	O
but	-	270	O
the	-	274	O
physiological	-	278	O
correlates	-	292	O
of	-	303	O
these	-	306	O
events	-	312	O
have	-	319	O
not	-	324	O
been	-	328	O
identified	-	333	O
in	-	344	O
mice	-	347	O
.	-	351	O

Population	15120741	353	O
responses	-	364	O
in	-	374	O
granule	-	377	O
cells	-	385	O
of	-	391	O
the	-	394	O
dentate	-	398	O
gyrus	-	406	O
were	-	412	O
examined	-	417	O
in	-	426	O
transverse	-	429	O
slices	-	440	O
of	-	447	O
the	-	450	O
ventral	-	454	O
hippocampus	-	462	O
from	-	474	O
pilocarpine	-	479	B
-	-	490	O
treated	-	491	O
and	-	499	O
untreated	-	503	O
mice	-	513	O
.	-	517	O

In	15120741	519	O
Mg	-	522	B
(	-	524	O
2	-	525	O
+	-	526	O
)	-	527	O
-	-	528	O
free	-	529	O
bathing	-	534	O
medium	-	542	O
containing	-	549	O
bicuculline	-	560	B
,	-	571	O
conditions	-	573	O
designed	-	584	O
to	-	593	O
increase	-	596	O
excitability	-	605	O
in	-	618	O
the	-	621	O
slices	-	625	O
,	-	631	O
electrical	-	633	O
stimulation	-	644	O
of	-	656	O
the	-	659	O
hilus	-	663	O
resulted	-	669	O
in	-	678	O
a	-	681	O
single	-	683	O
population	-	690	O
spike	-	701	O
in	-	707	O
granule	-	710	O
cells	-	718	O
from	-	724	O
control	-	729	O
mice	-	737	O
and	-	742	O
pilocarpine	-	746	B
-	-	757	O
treated	-	758	O
mice	-	766	O
that	-	771	O
did	-	776	O
not	-	780	O
experience	-	784	O
SE	-	795	O
.	-	797	O

In	15120741	799	O
SE	-	802	O
survivors	-	805	O
,	-	814	O
similar	-	816	O
stimulation	-	824	O
resulted	-	836	O
in	-	845	O
a	-	848	O
population	-	850	O
spike	-	861	O
followed	-	867	O
,	-	875	O
at	-	877	O
a	-	880	O
variable	-	882	O
latency	-	891	O
,	-	898	O
by	-	900	O
negative	-	903	O
DC	-	912	O
shifts	-	915	O
and	-	922	O
repetitive	-	926	O
afterdischarges	-	937	O
of	-	953	O
3	-	956	O
-	-	957	O
60	-	958	O
s	-	961	O
duration	-	963	O
,	-	971	O
which	-	973	O
were	-	979	O
blocked	-	984	O
by	-	992	O
ionotropic	-	995	O
glutamate	-	1006	B
receptor	-	1016	O
antagonists	-	1025	O
.	-	1036	O

Focal	15120741	1038	O
glutamate	-	1044	B
photostimulation	-	1054	O
of	-	1071	O
the	-	1074	O
granule	-	1078	O
cell	-	1086	O
layer	-	1091	O
at	-	1097	O
sites	-	1100	O
distant	-	1106	O
from	-	1114	O
the	-	1119	O
recording	-	1123	O
pipette	-	1133	O
resulted	-	1141	O
in	-	1150	O
population	-	1153	O
responses	-	1164	O
of	-	1174	O
1	-	1177	O
-	-	1178	O
30	-	1179	O
s	-	1182	O
duration	-	1184	O
in	-	1193	O
slices	-	1196	O
from	-	1203	O
SE	-	1208	O
survivors	-	1211	O
but	-	1221	O
not	-	1225	O
other	-	1229	O
groups	-	1235	O
.	-	1241	O

These	15120741	1243	O
data	-	1249	O
support	-	1254	O
the	-	1262	O
hypothesis	-	1266	O
that	-	1277	O
SE	-	1282	O
-	-	1284	O
induced	-	1285	O
mossy	-	1293	O
fiber	-	1299	O
sprouting	-	1305	O
and	-	1315	O
synaptic	-	1319	O
reorganization	-	1328	O
are	-	1343	O
relevant	-	1347	O
characteristics	-	1356	O
of	-	1372	O
seizure	-	1375	O
development	-	1383	O
in	-	1395	O
these	-	1398	O
murine	-	1404	O
strains	-	1411	O
,	-	1418	O
resembling	-	1420	O
rat	-	1431	O
models	-	1435	O
of	-	1442	O
human	-	1445	O
temporal	-	1451	O
lobe	-	1460	O
epilepsy	-	1465	O
.	-	1473	O

The	15275829	0	O
alpha3	-	4	O
and	-	11	O
beta4	-	15	O
nicotinic	-	21	O
acetylcholine	-	31	B
receptor	-	45	O
subunits	-	54	O
are	-	63	O
necessary	-	67	O
for	-	77	O
nicotine	-	81	B
-	-	89	O
induced	-	90	O
seizures	-	98	O
and	-	107	O
hypolocomotion	-	111	O
in	-	126	O
mice	-	129	O
.	-	133	O

Binding	15275829	135	O
of	-	143	O
nicotine	-	146	B
to	-	155	O
nicotinic	-	158	O
acetylcholine	-	168	B
receptors	-	182	O
(	-	192	O
nAChRs	-	193	O
)	-	199	O
elicits	-	201	O
a	-	209	O
series	-	211	O
of	-	218	O
dose	-	221	O
-	-	225	O
dependent	-	226	O
behaviors	-	236	O
that	-	246	O
go	-	251	O
from	-	254	O
altered	-	259	O
exploration	-	267	O
,	-	278	O
sedation	-	280	O
,	-	288	O
and	-	290	O
tremors	-	294	O
,	-	301	O
to	-	303	O
seizures	-	306	O
and	-	315	O
death	-	319	O
.	-	324	O

nAChRs	15275829	326	O
are	-	333	O
pentameric	-	337	O
ion	-	348	O
channels	-	352	O
usually	-	361	O
composed	-	369	O
of	-	378	O
alpha	-	381	O
and	-	387	O
beta	-	391	O
subunits	-	396	O
.	-	404	O

A	15275829	406	O
gene	-	408	O
cluster	-	413	O
comprises	-	421	O
the	-	431	O
alpha3	-	435	O
,	-	441	O
alpha5	-	443	O
and	-	450	O
beta4	-	454	O
subunits	-	460	O
,	-	468	O
which	-	470	O
coassemble	-	476	O
to	-	487	O
form	-	490	O
functional	-	495	O
receptors	-	506	O
.	-	515	O

We	15275829	517	O
examined	-	520	O
the	-	529	O
role	-	533	O
of	-	538	O
the	-	541	O
beta4	-	545	O
subunits	-	551	O
in	-	560	O
nicotine	-	563	B
-	-	571	O
induced	-	572	O
seizures	-	580	O
and	-	589	O
hypolocomotion	-	593	O
in	-	608	O
beta4	-	611	O
homozygous	-	617	O
null	-	628	O
(	-	633	O
beta4	-	634	O
-	-	640	O
/	-	641	O
-	-	642	O
)	-	643	O
and	-	645	O
alpha3	-	649	O
heterozygous	-	656	O
(	-	669	O
+	-	670	O
/	-	671	O
-	-	672	O
)	-	673	O
mice	-	675	O
.	-	679	O

beta4	15275829	681	O
-	-	687	O
/	-	688	O
-	-	689	O
mice	-	691	O
were	-	696	O
less	-	701	O
sensitive	-	706	O
to	-	716	O
the	-	719	O
effects	-	723	O
of	-	731	O
nicotine	-	734	B
both	-	743	O
at	-	748	O
low	-	751	O
doses	-	755	O
,	-	760	O
measured	-	762	O
as	-	771	O
decreased	-	774	O
exploration	-	784	O
in	-	796	O
an	-	799	O
open	-	802	O
field	-	807	O
,	-	812	O
and	-	814	O
at	-	818	O
high	-	821	O
doses	-	826	O
,	-	831	O
measured	-	833	O
as	-	842	O
sensitivity	-	845	O
to	-	857	O
nicotine	-	860	B
-	-	868	O
induced	-	869	O
seizures	-	877	O
.	-	885	O

Using	15275829	887	O
in	-	893	O
situ	-	896	O
hybridization	-	901	O
probes	-	915	O
for	-	922	O
the	-	926	O
alpha3	-	930	O
and	-	937	O
alpha5	-	941	O
subunits	-	948	O
,	-	956	O
we	-	958	O
showed	-	961	O
that	-	968	O
alpha5	-	973	O
mRNA	-	980	O
levels	-	985	O
are	-	992	O
unchanged	-	996	O
,	-	1005	O
whereas	-	1007	O
alpha3	-	1015	O
mRNA	-	1022	O
levels	-	1027	O
are	-	1034	O
selectively	-	1038	O
decreased	-	1050	O
in	-	1060	O
the	-	1063	O
mitral	-	1067	O
cell	-	1074	O
layer	-	1079	O
of	-	1085	O
the	-	1088	O
olfactory	-	1092	O
bulb	-	1102	O
,	-	1106	O
and	-	1108	O
the	-	1112	O
inferior	-	1116	O
and	-	1125	O
the	-	1129	O
superior	-	1133	O
colliculus	-	1142	O
of	-	1153	O
beta4	-	1156	O
-	-	1162	O
/	-	1163	O
-	-	1164	O
brains	-	1166	O
.	-	1172	O

alpha3	15275829	1174	O
+	-	1181	O
/	-	1182	O
-	-	1183	O

mice	15275829	1185	O
were	-	1190	O
partially	-	1195	O
resistant	-	1205	O
to	-	1215	O
nicotine	-	1218	B
-	-	1226	O
induced	-	1227	O
seizures	-	1235	O
when	-	1244	O
compared	-	1249	O
to	-	1258	O
wild	-	1261	O
-	-	1265	O
type	-	1266	O
littermates	-	1271	O
.	-	1282	O

mRNA	15275829	1284	O
levels	-	1289	O
for	-	1296	O
the	-	1300	O
alpha5	-	1304	O
and	-	1311	O
the	-	1315	O
beta4	-	1319	O
subunits	-	1325	O
were	-	1334	O
unchanged	-	1339	O
in	-	1349	O
alpha3	-	1352	O
+	-	1359	O
/	-	1360	O
-	-	1361	O

brains	15275829	1363	O
.	-	1369	O

Together	15275829	1371	O
,	-	1379	O
these	-	1381	O
results	-	1387	O
suggest	-	1395	O
that	-	1403	O
the	-	1408	O
beta4	-	1412	O
and	-	1418	O
the	-	1422	O
alpha3	-	1426	O
subunits	-	1433	O
are	-	1442	O
mediators	-	1446	O
of	-	1456	O
nicotine	-	1459	B
-	-	1467	O
induced	-	1468	O
seizures	-	1476	O
and	-	1485	O
hypolocomotion	-	1489	O
.	-	1503	O

Recurrent	15602202	0	O
acute	-	10	O
interstitial	-	16	O
nephritis	-	29	O
induced	-	39	O
by	-	47	O
azithromycin	-	50	B
.	-	62	O

A	15602202	64	O
14	-	66	O
-	-	68	O
year	-	69	O
-	-	73	O
old	-	74	O
girl	-	78	O
is	-	83	O
reported	-	86	O
with	-	95	O
recurrent	-	100	O
,	-	109	O
azithromycin	-	111	B
-	-	123	O
induced	-	124	O
,	-	131	O
acute	-	133	O
interstitial	-	139	O
nephritis	-	152	O
.	-	161	O

The	15602202	163	O
second	-	167	O
episode	-	174	O
was	-	182	O
more	-	186	O
severe	-	191	O
than	-	198	O
the	-	203	O
first	-	207	O
;	-	212	O
and	-	214	O
although	-	218	O
both	-	227	O
were	-	232	O
treated	-	237	O
with	-	245	O
intensive	-	250	O
corticosteroid	-	260	O
therapy	-	275	O
,	-	282	O
renal	-	284	O
function	-	290	O
remained	-	299	O
impaired	-	308	O
.	-	316	O

Although	15602202	318	O
most	-	327	O
cases	-	332	O
of	-	338	O
antibiotic	-	341	O
induced	-	352	O
acute	-	360	O
interstitial	-	366	O
nephritis	-	379	O
are	-	389	O
benign	-	393	O
and	-	400	O
self	-	404	O
-	-	408	O
limited	-	409	O
,	-	416	O
some	-	418	O
patients	-	423	O
are	-	432	O
at	-	436	O
risk	-	439	O
for	-	444	O
permanent	-	448	O
renal	-	458	O
injury	-	464	O
.	-	470	O

Valproate	16181582	0	B
-	-	9	O
induced	-	10	O
encephalopathy	-	18	O
.	-	32	O

Valproate	16181582	34	B
-	-	43	O
induced	-	44	O
encephalopathy	-	52	O
is	-	67	O
a	-	70	O
rare	-	72	O
syndrome	-	77	O
that	-	86	O
may	-	91	O
manifest	-	95	O
in	-	104	O
otherwise	-	107	O
normal	-	117	O
epileptic	-	124	O
individuals	-	134	O
.	-	145	O

It	16181582	147	O
may	-	150	O
even	-	154	O
present	-	159	O
in	-	167	O
patients	-	170	O
who	-	179	O
have	-	183	O
tolerated	-	188	O
this	-	198	O
medicine	-	203	O
well	-	212	O
in	-	217	O
the	-	220	O
past	-	224	O
.	-	228	O

It	16181582	230	O
is	-	233	O
usually	-	236	O
but	-	244	O
not	-	248	O
necessarily	-	252	O
associated	-	264	O
with	-	275	O
hyperammonemia	-	280	O
.	-	294	O

The	16181582	296	O
EEG	-	300	O
shows	-	304	O
characteristic	-	310	O
triphasic	-	325	O
waves	-	335	O
in	-	341	O
most	-	344	O
patients	-	349	O
with	-	358	O
this	-	363	O
complication	-	368	O
.	-	380	O

A	16181582	382	O
case	-	384	O
of	-	389	O
valproate	-	392	B
-	-	401	O
induced	-	402	O
encephalopathy	-	410	O
is	-	425	O
presented	-	428	O
.	-	437	O

The	16181582	439	O
problems	-	443	O
in	-	452	O
diagnosing	-	455	O
this	-	466	O
condition	-	471	O
are	-	481	O
subsequently	-	485	O
discussed	-	498	O
.	-	507	O

Nitro	16298782	0	B
-	-	5	I
L	-	6	I
-	-	7	I
arginine	-	8	I
methyl	-	17	I
ester	-	24	I
:	-	29	O
a	-	31	O
potential	-	33	O
protector	-	43	O
against	-	53	O
gentamicin	-	61	B
ototoxicity	-	72	O
.	-	83	O

The	16298782	85	O
nitric	-	89	B
oxide	-	96	I
(	-	102	O
NO	-	103	B
)	-	105	O
inhibitor	-	107	O
nitro	-	117	B
-	-	122	I
L	-	123	I
-	-	124	I
arginine	-	125	I
methyl	-	134	I
ester	-	141	I
(	-	147	O
L	-	148	B
-	-	149	I
NAME	-	150	I
)	-	154	O
may	-	156	O
act	-	160	O
as	-	164	O
an	-	167	O
otoprotectant	-	170	O
against	-	184	O
high	-	192	O
-	-	196	O
frequency	-	197	O
hearing	-	207	O
loss	-	215	O
caused	-	220	O
by	-	227	O
gentamicin	-	230	B
,	-	240	O
but	-	242	O
further	-	246	O
studies	-	254	O
are	-	262	O
needed	-	266	O
to	-	273	O
confirm	-	276	O
this	-	284	O
.	-	288	O

Aminoglycoside	16298782	289	B
antibiotics	-	304	O
are	-	316	O
still	-	320	O
widely	-	326	O
used	-	333	O
by	-	338	O
virtue	-	341	O
of	-	348	O
their	-	351	O
efficacy	-	357	O
and	-	366	O
low	-	370	O
cost	-	374	O
.	-	378	O

Their	16298782	380	O
ototoxicity	-	386	O
is	-	398	O
a	-	401	O
serious	-	403	O
health	-	411	O
problem	-	418	O
and	-	426	O
,	-	429	O
as	-	431	O
their	-	434	O
ototoxic	-	440	O
mechanism	-	449	O
involves	-	459	O
the	-	468	O
production	-	472	O
of	-	483	O
NO	-	486	B
,	-	488	O
we	-	490	O
need	-	493	O
to	-	498	O
assess	-	501	O
the	-	508	O
use	-	512	O
of	-	516	O
NO	-	519	B
inhibitors	-	522	O
for	-	533	O
the	-	537	O
prevention	-	541	O
of	-	552	O
aminoglycoside	-	555	B
-	-	569	O
induced	-	570	O
sensorineural	-	578	O
hearing	-	592	O
loss	-	600	O
.	-	604	O

In	16298782	606	O
this	-	609	O
experimental	-	614	O
study	-	627	O
we	-	633	O
used	-	636	O
30	-	641	O
Sprague	-	644	O
-	-	651	O
Dawley	-	652	O
rats	-	659	O
,	-	663	O
27	-	665	O
of	-	668	O
which	-	671	O
had	-	677	O
gentamicin	-	681	B
instilled	-	692	O
into	-	702	O
the	-	707	O
middle	-	711	O
ear	-	718	O
.	-	721	O

The	16298782	723	O
otoprotectant	-	727	O
L	-	741	B
-	-	742	I
NAME	-	743	I
was	-	748	O
administered	-	752	O
topically	-	765	O
to	-	775	O
12	-	778	O
/	-	780	O
27	-	781	O
animals	-	784	O
.	-	791	O

Its	16298782	793	O
effect	-	797	O
was	-	804	O
determined	-	808	O
in	-	819	O
terms	-	822	O
of	-	828	O
attenuation	-	831	O
of	-	843	O
hearing	-	846	O
loss	-	854	O
,	-	858	O
measured	-	860	O
by	-	869	O
shifts	-	872	O
in	-	879	O
the	-	882	O
auditory	-	886	O
brainstem	-	895	O
response	-	905	O
threshold	-	914	O
.	-	923	O

L	16298782	925	B
-	-	926	I
NAME	-	927	I
reduced	-	932	O
gentamicin	-	940	B
-	-	950	O
induced	-	951	O
hearing	-	959	O
loss	-	967	O
in	-	972	O
the	-	975	O
high	-	979	O
-	-	983	O
frequency	-	984	O
range	-	994	O
,	-	999	O
but	-	1001	O
gave	-	1005	O
no	-	1010	O
protection	-	1013	O
in	-	1024	O
the	-	1027	O
middle	-	1031	O
or	-	1038	O
low	-	1041	O
frequencies	-	1045	O
.	-	1056	O

Cerebral	16428221	0	O
vasculitis	-	9	O
following	-	20	O
oral	-	30	O
methylphenidate	-	35	B
intake	-	51	O
in	-	58	O
an	-	61	O
adult	-	64	O
:	-	69	O
a	-	71	O
case	-	73	O
report	-	78	O
.	-	84	O

Methylphenidate	16428221	86	B
is	-	102	O
structurally	-	105	O
and	-	118	O
functionally	-	122	O
similar	-	135	O
to	-	143	O
amphetamine	-	146	B
.	-	157	O

Cerebral	16428221	159	O
vasculitis	-	168	O
associated	-	179	O
with	-	190	O
amphetamine	-	195	O
abuse	-	207	O
is	-	213	O
well	-	216	O
documented	-	221	O
,	-	231	O
and	-	233	O
in	-	237	O
rare	-	240	O
cases	-	245	O
ischaemic	-	251	O
stroke	-	261	O
has	-	268	O
been	-	272	O
reported	-	277	O
after	-	286	O
methylphenidate	-	292	B
intake	-	308	O
in	-	315	O
children	-	318	O
.	-	326	O

We	16428221	328	O
report	-	331	O
the	-	338	O
case	-	342	O
of	-	347	O
a	-	350	O
63	-	352	O
-	-	354	O
year	-	355	O
-	-	359	O
old	-	360	O
female	-	364	O
who	-	371	O
was	-	375	O
treated	-	379	O
with	-	387	O
methylphenidate	-	392	B
due	-	408	O
to	-	412	O
hyperactivity	-	415	O
and	-	429	O
suffered	-	433	O
from	-	442	O
multiple	-	447	O
ischaemic	-	456	O
strokes	-	466	O
.	-	473	O

We	16428221	475	O
consider	-	478	O
drug	-	487	O
-	-	491	O
induced	-	492	O
cerebral	-	500	O
vasculitis	-	509	O
as	-	520	O
the	-	523	O
most	-	527	O
likely	-	532	O
cause	-	539	O
of	-	545	O
recurrent	-	548	O
ischaemic	-	558	O
strokes	-	568	O
in	-	576	O
the	-	579	O
absence	-	583	O
of	-	591	O
any	-	594	O
pathological	-	598	O
findings	-	611	O
during	-	620	O
the	-	627	O
diagnostic	-	631	O
work	-	642	O
-	-	646	O
up	-	647	O
.	-	649	O

We	16428221	651	O
conclude	-	654	O
that	-	663	O
methylphenidate	-	668	B
mediated	-	684	O
vasculitis	-	693	O
should	-	704	O
be	-	711	O
considered	-	714	O
in	-	725	O
patients	-	728	O
with	-	737	O
neurological	-	742	O
symptoms	-	755	O
and	-	764	O
a	-	768	O
history	-	770	O
of	-	778	O
methylphenidate	-	781	B
therapy	-	797	O
.	-	804	O

This	16428221	806	O
potential	-	811	O
side	-	821	O
-	-	825	O
effect	-	826	O
,	-	832	O
though	-	834	O
very	-	841	O
rare	-	846	O
,	-	850	O
represents	-	852	O
one	-	863	O
more	-	867	O
reason	-	872	O
to	-	879	O
be	-	882	O
very	-	885	O
restrictive	-	890	O
in	-	902	O
the	-	905	O
use	-	909	O
of	-	913	O
methylphenidate	-	916	B
.	-	931	O

Cerebral	16858720	0	O
haemorrhage	-	9	O
induced	-	21	O
by	-	29	O
warfarin	-	32	B
-	-	41	O
the	-	43	O
influence	-	47	O
of	-	57	O
drug	-	60	O
-	-	64	O
drug	-	65	O
interactions	-	70	O
.	-	82	O

PURPOSE	16858720	84	O
:	-	91	O

To	16858720	93	O
evaluate	-	96	O
the	-	105	O
frequency	-	109	O
,	-	118	O
severity	-	120	O
and	-	129	O
preventability	-	133	O
of	-	148	O
warfarin	-	151	B
-	-	159	O
induced	-	160	O
cerebral	-	168	O
haemorrhages	-	177	O
due	-	190	O
to	-	194	O
warfarin	-	197	B
and	-	206	O
warfarin	-	210	B
-	-	218	O
drug	-	219	O
interactions	-	224	O
in	-	237	O
patients	-	240	O
living	-	249	O
in	-	256	O
the	-	259	O
county	-	263	O
of	-	270	O
Osterg	-	273	O
tland	-	281	O
,	-	286	O
Sweden	-	288	O
.	-	294	O

METHODS	16858720	296	O
:	-	303	O

All	16858720	305	O
patients	-	309	O
with	-	318	O
a	-	323	O
diagnosed	-	325	O
cerebral	-	335	O
haemorrhage	-	344	O
at	-	356	O
three	-	359	O
hospitals	-	365	O
during	-	375	O
the	-	382	O
period	-	386	O
2000	-	393	O
-	-	397	O
2002	-	398	O
were	-	403	O
identified	-	408	O
.	-	418	O

Medical	16858720	420	O
records	-	428	O
were	-	436	O
studied	-	441	O
retrospectively	-	449	O
to	-	465	O
evaluate	-	468	O
whether	-	477	O
warfarin	-	485	B
and	-	494	O
warfarin	-	498	B
-	-	506	O
drug	-	507	O
interactions	-	512	O
could	-	525	O
have	-	531	O
caused	-	536	O
the	-	543	O
cerebral	-	547	O
haemorrhage	-	556	O
.	-	567	O

The	16858720	569	O
proportion	-	573	O
of	-	584	O
possibly	-	587	O
avoidable	-	596	O
cases	-	606	O
due	-	612	O
to	-	616	O
drug	-	619	O
interactions	-	624	O
was	-	637	O
estimated	-	641	O
.	-	650	O

RESULTS	16858720	652	O
:	-	659	O

Among	16858720	661	O
593	-	667	O
patients	-	671	O
with	-	680	O
cerebral	-	685	O
haemorrhage	-	694	O
,	-	705	O
59	-	707	O
(	-	710	O
10	-	711	O
%	-	713	O
)	-	714	O
were	-	716	O
assessed	-	721	O
as	-	730	O
related	-	733	O
to	-	741	O
warfarin	-	744	B
treatment	-	753	O
.	-	762	O

This	16858720	764	O
imply	-	769	O
an	-	775	O
incidence	-	778	O
of	-	788	O
1	-	791	O
.	-	792	O
7	-	793	O
/	-	794	O
100	-	795	O
,	-	798	O
000	-	799	O
treatment	-	803	O
years	-	813	O
.	-	818	O

Of	16858720	820	O
the	-	823	O
59	-	827	O
cases	-	830	O
,	-	835	O
26	-	837	O
(	-	840	O
44	-	841	O
%	-	843	O
)	-	844	O
had	-	846	O
a	-	850	O
fatal	-	852	O
outcome	-	858	O
,	-	865	O
compared	-	867	O
to	-	876	O
136	-	879	O
(	-	883	O
25	-	884	O
%	-	886	O
)	-	887	O
among	-	889	O
the	-	895	O
non	-	899	O
-	-	902	O
warfarin	-	903	B
patients	-	912	O
(	-	921	O
p	-	922	O
<	-	924	O
0	-	926	O
.	-	927	O
01	-	928	O
)	-	930	O
.	-	931	O

A	16858720	933	O
warfarin	-	935	B
-	-	943	O
drug	-	944	O
interaction	-	949	O
could	-	961	O
have	-	967	O
contributed	-	972	O
to	-	984	O
the	-	987	O
haemorrhage	-	991	O
in	-	1003	O
24	-	1006	O
(	-	1009	O
41	-	1010	O
%	-	1012	O
)	-	1013	O
of	-	1015	O
the	-	1018	O
warfarin	-	1022	B
patients	-	1031	O
and	-	1040	O
in	-	1044	O
7	-	1047	O
of	-	1049	O
these	-	1052	O
(	-	1058	O
12	-	1059	O
%	-	1061	O
)	-	1062	O
the	-	1064	O
bleeding	-	1068	O
complication	-	1077	O
was	-	1090	O
considered	-	1094	O
being	-	1105	O
possible	-	1111	O
to	-	1120	O
avoid	-	1123	O
.	-	1128	O

CONCLUSIONS	16858720	1130	O
:	-	1141	O

Warfarin	16858720	1143	B
-	-	1151	O
induced	-	1152	O
cerebral	-	1160	O
haemorrhages	-	1169	O
are	-	1182	O
a	-	1186	O
major	-	1188	O
clinical	-	1194	O
problem	-	1203	O
with	-	1211	O
a	-	1216	O
high	-	1218	O
fatality	-	1223	O
rate	-	1232	O
.	-	1236	O

Almost	16858720	1238	O
half	-	1245	O
of	-	1250	O
the	-	1253	O
cases	-	1257	O
was	-	1263	O
related	-	1267	O
to	-	1275	O
a	-	1278	O
warfarin	-	1280	B
-	-	1288	O
drug	-	1289	O
interaction	-	1294	O
.	-	1305	O

A	16858720	1307	O
significant	-	1309	O
proportion	-	1321	O
of	-	1332	O
warfarin	-	1335	B
-	-	1343	O
related	-	1344	O
cerebral	-	1352	O
haemorrhages	-	1361	O
might	-	1374	O
have	-	1380	O
been	-	1385	O
prevented	-	1390	O
if	-	1400	O
greater	-	1403	O
caution	-	1411	O
had	-	1419	O
been	-	1423	O
taken	-	1428	O
when	-	1434	O
prescribing	-	1439	O
drugs	-	1451	O
known	-	1457	O
to	-	1463	O
interact	-	1466	O
with	-	1475	O
warfarin	-	1480	B
.	-	1488	O

Side	17466854	0	O
effects	-	5	O
of	-	13	O
postoperative	-	16	O
administration	-	30	O
of	-	45	O
methylprednisolone	-	48	B
and	-	67	O
gentamicin	-	71	B
into	-	82	O
the	-	87	O
posterior	-	91	O
sub	-	101	O
-	-	104	O
Tenon	-	105	O
's	-	110	O
space	-	113	O
.	-	118	O

PURPOSE	17466854	120	O
:	-	127	O

To	17466854	129	O
assess	-	132	O
the	-	139	O
incidence	-	143	O
of	-	153	O
postoperative	-	156	O
emetic	-	170	O
side	-	177	O
effects	-	182	O
after	-	190	O
the	-	196	O
administration	-	200	O
of	-	215	O
methylprednisolone	-	218	B
and	-	237	O
gentamicin	-	241	B
into	-	252	O
the	-	257	O
posterior	-	261	O
sub	-	271	O
-	-	274	O
Tenon	-	275	O
's	-	280	O
space	-	283	O
at	-	289	O
the	-	292	O
end	-	296	O
of	-	300	O
routine	-	303	O
cataract	-	311	O
surgery	-	320	O
.	-	327	O

SETTING	17466854	329	O
:	-	336	O

St	17466854	338	O
.	-	340	O
Luke	-	342	O
's	-	346	O
Hospital	-	349	O
,	-	357	O
Gwardamangia	-	359	O
,	-	371	O
Malta	-	373	O
.	-	378	O

METHODS	17466854	380	O
:	-	387	O

A	17466854	389	O
double	-	391	O
-	-	397	O
blind	-	398	O
double	-	404	O
-	-	410	O
armed	-	411	O
prospective	-	417	O
study	-	429	O
comprised	-	435	O
40	-	445	O
patients	-	448	O
who	-	457	O
had	-	461	O
uneventful	-	465	O
sutureless	-	476	O
phacoemulsification	-	487	O
under	-	507	O
sub	-	513	O
-	-	516	O
Tenon	-	517	O
's	-	522	O
local	-	525	O
infiltration	-	531	O
of	-	544	O
3	-	547	O
mL	-	549	O
of	-	552	O
plain	-	555	O
lignocaine	-	561	B
.	-	571	O

At	17466854	573	O
the	-	576	O
end	-	580	O
of	-	584	O
the	-	587	O
procedure	-	591	O
,	-	600	O
Group	-	602	O
A	-	608	O
(	-	610	O
n	-	611	O
=	-	613	O
20	-	615	O
)	-	617	O
had	-	619	O
20	-	623	O
mg	-	626	O
/	-	628	O
0	-	629	O
.	-	630	O
5	-	631	O
mL	-	633	O
of	-	636	O
methylprednisolone	-	639	B
and	-	658	O
10	-	662	O
mg	-	665	O
/	-	667	O
0	-	668	O
.	-	669	O
5	-	670	O
mL	-	672	O
of	-	675	O
gentamicin	-	678	B
injected	-	689	O
into	-	698	O
the	-	703	O
posterior	-	707	O
sub	-	717	O
-	-	720	O
Tenon	-	721	O
's	-	726	O
space	-	729	O
and	-	735	O
Group	-	739	O
B	-	745	O
(	-	747	O
n	-	748	O
=	-	750	O
20	-	752	O
)	-	754	O
had	-	756	O
the	-	760	O
same	-	764	O
combination	-	769	O
injected	-	781	O
into	-	790	O
the	-	795	O
anterior	-	799	O
sub	-	808	O
-	-	811	O
Tenon	-	812	O
's	-	817	O
space	-	820	O
.	-	825	O

Postoperatively	17466854	827	O
,	-	842	O
all	-	844	O
patients	-	848	O
were	-	857	O
assessed	-	862	O
for	-	871	O
symptoms	-	875	O
of	-	884	O
nausea	-	887	O
,	-	893	O
vomiting	-	895	O
,	-	903	O
and	-	905	O
headache	-	909	O
.	-	917	O

A	17466854	919	O
chi	-	921	O
-	-	924	O
square	-	925	O
test	-	932	O
was	-	937	O
used	-	941	O
to	-	946	O
assess	-	949	O
the	-	956	O
statistical	-	960	O
significance	-	972	O
of	-	985	O
results	-	988	O
.	-	995	O

RESULTS	17466854	997	O
:	-	1004	O

Sixty	17466854	1006	O
percent	-	1012	O
in	-	1020	O
Group	-	1023	O
A	-	1029	O
developed	-	1031	O
postoperative	-	1041	O
emetic	-	1055	O
symptoms	-	1062	O
,	-	1070	O
headache	-	1072	O
,	-	1080	O
or	-	1082	O
both	-	1085	O
;	-	1089	O
1	-	1091	O
patient	-	1093	O
in	-	1101	O
Group	-	1104	O
B	-	1110	O
developed	-	1112	O
symptoms	-	1122	O
.	-	1130	O

CONCLUSIONS	17466854	1132	O
:	-	1143	O

The	17466854	1145	O
administration	-	1149	O
of	-	1164	O
methylprednisolone	-	1167	B
and	-	1186	O
gentamicin	-	1190	B
in	-	1201	O
the	-	1204	O
posterior	-	1208	O
sub	-	1218	O
-	-	1221	O
Tenon	-	1222	O
's	-	1227	O
space	-	1230	O
was	-	1236	O
related	-	1240	O
to	-	1248	O
a	-	1251	O
high	-	1253	O
incidence	-	1258	O
of	-	1268	O
side	-	1271	O
effects	-	1276	O
including	-	1284	O
nausea	-	1294	O
,	-	1300	O
vomiting	-	1302	O
,	-	1310	O
and	-	1312	O
headache	-	1316	O
.	-	1324	O

All	17466854	1326	O
adverse	-	1330	O
effects	-	1338	O
were	-	1346	O
self	-	1351	O
-	-	1355	O
limiting	-	1356	O
.	-	1364	O

Cardiac	17562951	0	O
Angiography	-	8	O
in	-	20	O
Renally	-	23	O
Impaired	-	31	O
Patients	-	40	O
(	-	49	O
CARE	-	50	O
)	-	54	O
study	-	56	O
:	-	61	O
a	-	63	O
randomized	-	65	O
double	-	76	O
-	-	82	O
blind	-	83	O
trial	-	89	O
of	-	95	O
contrast	-	98	O
-	-	106	O
induced	-	107	O
nephropathy	-	115	O
in	-	127	O
patients	-	130	O
with	-	139	O
chronic	-	144	O
kidney	-	152	O
disease	-	159	O
.	-	166	O

BACKGROUND	17562951	168	O
:	-	178	O

No	17562951	180	O
direct	-	183	O
comparisons	-	190	O
exist	-	202	O
of	-	208	O
the	-	211	O
renal	-	215	O
tolerability	-	221	O
of	-	234	O
the	-	237	O
low	-	241	O
-	-	244	O
osmolality	-	245	O
contrast	-	256	B
medium	-	265	I
iopamidol	-	272	B
with	-	282	O
that	-	287	O
of	-	292	O
the	-	295	O
iso	-	299	O
-	-	302	O
osmolality	-	303	O
contrast	-	314	B
medium	-	323	I
iodixanol	-	330	B
in	-	340	O
high	-	343	O
-	-	347	O
risk	-	348	O
patients	-	353	O
.	-	361	O

METHODS	17562951	363	O
AND	-	371	O
RESULTS	-	375	O
:	-	382	O

The	17562951	384	O
present	-	388	O
study	-	396	O
is	-	402	O
a	-	405	O
multicenter	-	407	O
,	-	418	O
randomized	-	420	O
,	-	430	O
double	-	432	O
-	-	438	O
blind	-	439	O
comparison	-	445	O
of	-	456	O
iopamidol	-	459	B
and	-	469	O
iodixanol	-	473	B
in	-	483	O
patients	-	486	O
with	-	495	O
chronic	-	500	O
kidney	-	508	O
disease	-	515	O
(	-	523	O
estimated	-	524	O
glomerular	-	534	O
filtration	-	545	O
rate	-	556	O
,	-	560	O
20	-	562	O
to	-	565	O
59	-	568	O
mL	-	571	O
/	-	573	O
min	-	574	O
)	-	577	O
who	-	579	O
underwent	-	583	O
cardiac	-	593	O
angiography	-	601	O
or	-	613	O
percutaneous	-	616	O
coronary	-	629	O
interventions	-	638	O
.	-	651	O

Serum	17562951	653	O
creatinine	-	659	B
(	-	670	O
SCr	-	671	O
)	-	674	O
levels	-	676	O
and	-	683	O
estimated	-	687	O
glomerular	-	697	O
filtration	-	708	O
rate	-	719	O
were	-	724	O
assessed	-	729	O
at	-	738	O
baseline	-	741	O
and	-	750	O
2	-	754	O
to	-	756	O
5	-	759	O
days	-	761	O
after	-	766	O
receiving	-	772	O
medications	-	782	O
.	-	793	O

The	17562951	795	O
primary	-	799	O
outcome	-	807	O
was	-	815	O
a	-	819	O
postdose	-	821	O
SCr	-	830	O
increase	-	834	O
>	-	843	O
or	-	845	O
=	-	848	O
0	-	850	O
.	-	851	O
5	-	852	O
mg	-	854	O
/	-	856	O
dL	-	857	O
(	-	860	O
44	-	861	O
.	-	863	O
2	-	864	O
micromol	-	866	O
/	-	874	O
L	-	875	O
)	-	876	O
over	-	878	O
baseline	-	883	O
.	-	891	O

Secondary	17562951	893	O
outcomes	-	903	O
were	-	912	O
a	-	917	O
postdose	-	919	O
SCr	-	928	O
increase	-	932	O
>	-	941	O
or	-	943	O
=	-	946	O
25	-	948	O
%	-	950	O
,	-	951	O
a	-	953	O
postdose	-	955	O
estimated	-	964	O
glomerular	-	974	O
filtration	-	985	O
rate	-	996	O
decrease	-	1001	O
of	-	1010	O
>	-	1013	O
or	-	1015	O
=	-	1018	O
25	-	1020	O
%	-	1022	O
,	-	1023	O
and	-	1025	O
the	-	1029	O
mean	-	1033	O
peak	-	1038	O
change	-	1043	O
in	-	1050	O
SCr	-	1053	O
.	-	1056	O

In	17562951	1058	O
414	-	1061	O
patients	-	1065	O
,	-	1073	O
contrast	-	1075	O
volume	-	1084	O
,	-	1090	O
presence	-	1092	O
of	-	1101	O
diabetes	-	1104	O
mellitus	-	1113	O
,	-	1121	O
use	-	1123	O
of	-	1127	O
N	-	1130	B
-	-	1131	I
acetylcysteine	-	1132	I
,	-	1146	O
mean	-	1148	O
baseline	-	1153	O
SCr	-	1162	O
,	-	1165	O
and	-	1167	O
estimated	-	1171	O
glomerular	-	1181	O
filtration	-	1192	O
rate	-	1203	O
were	-	1208	O
comparable	-	1213	O
in	-	1224	O
the	-	1227	O
2	-	1231	O
groups	-	1233	O
.	-	1239	O

SCr	17562951	1241	O
increases	-	1245	O
>	-	1255	O
or	-	1257	O
=	-	1260	O
0	-	1262	O
.	-	1263	O
5	-	1264	O
mg	-	1266	O
/	-	1268	O
dL	-	1269	O
occurred	-	1272	O
in	-	1281	O
4	-	1284	O
.	-	1285	O
4	-	1286	O
%	-	1287	O
(	-	1289	O
9	-	1290	O
of	-	1292	O
204	-	1295	O
patients	-	1299	O
)	-	1307	O
after	-	1309	O
iopamidol	-	1315	B
and	-	1325	O
6	-	1329	O
.	-	1330	O
7	-	1331	O
%	-	1332	O
(	-	1334	O
14	-	1335	O
of	-	1338	O
210	-	1341	O
patients	-	1345	O
)	-	1353	O
after	-	1355	O
iodixanol	-	1361	B
(	-	1371	O
P	-	1372	O
=	-	1373	O
0	-	1374	O
.	-	1375	O
39	-	1376	O
)	-	1378	O
,	-	1379	O
whereas	-	1381	O
rates	-	1389	O
of	-	1395	O
SCr	-	1398	O
increases	-	1402	O
>	-	1412	O
or	-	1414	O
=	-	1417	O
25	-	1419	O
%	-	1421	O
were	-	1423	O
9	-	1428	O
.	-	1429	O
8	-	1430	O
%	-	1431	O
and	-	1433	O
12	-	1437	O
.	-	1439	O
4	-	1440	O
%	-	1441	O
,	-	1442	O
respectively	-	1444	O
(	-	1457	O
P	-	1458	O
=	-	1459	O
0	-	1460	O
.	-	1461	O
44	-	1462	O
)	-	1464	O
.	-	1465	O

In	17562951	1467	O
patients	-	1470	O
with	-	1479	O
diabetes	-	1484	O
,	-	1492	O
SCr	-	1494	O
increases	-	1498	O
>	-	1508	O
or	-	1510	O
=	-	1513	O
0	-	1515	O
.	-	1516	O
5	-	1517	O
mg	-	1519	O
/	-	1521	O
dL	-	1522	O
were	-	1525	O
5	-	1530	O
.	-	1531	O
1	-	1532	O
%	-	1533	O
(	-	1535	O
4	-	1536	O
of	-	1538	O
78	-	1541	O
patients	-	1544	O
)	-	1552	O
with	-	1554	O
iopamidol	-	1559	B
and	-	1569	O
13	-	1573	O
.	-	1575	O
0	-	1576	O
%	-	1577	O
(	-	1579	O
12	-	1580	O
of	-	1583	O
92	-	1586	O
patients	-	1589	O
)	-	1597	O
with	-	1599	O
iodixanol	-	1604	B
(	-	1614	O
P	-	1615	O
=	-	1616	O
0	-	1617	O
.	-	1618	O
11	-	1619	O
)	-	1621	O
,	-	1622	O
whereas	-	1624	O
SCr	-	1632	O
increases	-	1636	O
>	-	1646	O
or	-	1648	O
=	-	1651	O
25	-	1653	O
%	-	1655	O
were	-	1657	O
10	-	1662	O
.	-	1664	O
3	-	1665	O
%	-	1666	O
and	-	1668	O
15	-	1672	O
.	-	1674	O
2	-	1675	O
%	-	1676	O
,	-	1677	O
respectively	-	1679	O
(	-	1692	O
P	-	1693	O
=	-	1694	O
0	-	1695	O
.	-	1696	O
37	-	1697	O
)	-	1699	O
.	-	1700	O

Mean	17562951	1702	O
post	-	1707	O
-	-	1711	O
SCr	-	1712	O
increases	-	1716	O
were	-	1726	O
significantly	-	1731	O
less	-	1745	O
with	-	1750	O
iopamidol	-	1755	B
(	-	1765	O
all	-	1766	O
patients	-	1770	O
:	-	1778	O
0	-	1780	O
.	-	1781	O
07	-	1782	O
versus	-	1785	O
0	-	1792	O
.	-	1793	O
12	-	1794	O
mg	-	1797	O
/	-	1799	O
dL	-	1800	O
,	-	1802	O
6	-	1804	O
.	-	1805	O
2	-	1806	O
versus	-	1808	O
10	-	1815	O
.	-	1817	O
6	-	1818	O
micromol	-	1820	O
/	-	1828	O
L	-	1829	O
,	-	1830	O
P	-	1832	O
=	-	1833	O
0	-	1834	O
.	-	1835	O
03	-	1836	O
;	-	1838	O
patients	-	1840	O
with	-	1849	O
diabetes	-	1854	O
:	-	1862	O
0	-	1864	O
.	-	1865	O
07	-	1866	O
versus	-	1869	O
0	-	1876	O
.	-	1877	O
16	-	1878	O
mg	-	1881	O
/	-	1883	O
dL	-	1884	O
,	-	1886	O
6	-	1888	O
.	-	1889	O
2	-	1890	O
versus	-	1892	O
14	-	1899	O
.	-	1901	O
1	-	1902	O
micromol	-	1904	O
/	-	1912	O
L	-	1913	O
,	-	1914	O
P	-	1916	O
=	-	1917	O
0	-	1918	O
.	-	1919	O
01	-	1920	O
)	-	1922	O
.	-	1923	O

CONCLUSIONS	17562951	1925	O
:	-	1936	O

The	17562951	1938	O
rate	-	1942	O
of	-	1947	O
contrast	-	1950	O
-	-	1958	O
induced	-	1959	O
nephropathy	-	1967	O
,	-	1978	O
defined	-	1980	O
by	-	1988	O
multiple	-	1991	O
end	-	2000	O
points	-	2004	O
,	-	2010	O
is	-	2012	O
not	-	2015	O
statistically	-	2019	O
different	-	2033	O
after	-	2043	O
the	-	2049	O
intraarterial	-	2053	O
administration	-	2067	O
of	-	2082	O
iopamidol	-	2085	B
or	-	2095	O
iodixanol	-	2098	B
to	-	2108	O
high	-	2111	O
-	-	2115	O
risk	-	2116	O
patients	-	2121	O
,	-	2129	O
with	-	2131	O
or	-	2136	O
without	-	2139	O
diabetes	-	2147	O
mellitus	-	2156	O
.	-	2164	O

Any	17562951	2166	O
true	-	2170	O
difference	-	2175	O
between	-	2186	O
the	-	2194	O
agents	-	2198	O
is	-	2205	O
small	-	2208	O
and	-	2214	O
not	-	2218	O
likely	-	2222	O
to	-	2229	O
be	-	2232	O
clinically	-	2235	O
significant	-	2246	O
.	-	2257	O

A	17600377	0	O
novel	-	2	O
compound	-	8	O
,	-	16	O
maltolyl	-	18	B
p	-	27	I
-	-	28	I
coumarate	-	29	I
,	-	38	O
attenuates	-	40	O
cognitive	-	51	O
deficits	-	61	O
and	-	70	O
shows	-	74	O
neuroprotective	-	80	O
effects	-	96	O
in	-	104	O
vitro	-	107	O
and	-	113	O
in	-	117	O
vivo	-	120	O
dementia	-	125	O
models	-	134	O
.	-	140	O

To	17600377	142	O
develop	-	145	O
a	-	153	O
novel	-	155	O
and	-	161	O
effective	-	165	O
drug	-	175	O
that	-	180	O
could	-	185	O
enhance	-	191	O
cognitive	-	199	O
function	-	209	O
and	-	218	O
neuroprotection	-	222	O
,	-	237	O
we	-	239	O
newly	-	242	O
synthesized	-	248	O
maltolyl	-	260	B
p	-	269	I
-	-	270	I
coumarate	-	271	I
by	-	281	O
the	-	284	O
esterification	-	288	O
of	-	303	O
maltol	-	306	B
and	-	313	O
p	-	317	B
-	-	318	I
coumaric	-	319	I
acid	-	328	I
.	-	332	O

In	17600377	334	O
the	-	337	O
present	-	341	O
study	-	349	O
,	-	354	O
we	-	356	O
investigated	-	359	O
whether	-	372	O
maltolyl	-	380	B
p	-	389	I
-	-	390	I
coumarate	-	391	I
could	-	401	O
improve	-	407	O
cognitive	-	415	O
decline	-	425	O
in	-	433	O
scopolamine	-	436	B
-	-	447	O
injected	-	448	O
rats	-	457	O
and	-	462	O
in	-	466	O
amyloid	-	469	B
beta	-	477	I
peptide	-	482	I
(	-	489	I
1	-	490	I
-	-	491	I
42	-	492	I
)	-	494	I
-	-	495	O
infused	-	496	O
rats	-	504	O
.	-	508	O

Maltolyl	17600377	510	B
p	-	519	I
-	-	520	I
coumarate	-	521	I
was	-	531	O
found	-	535	O
to	-	541	O
attenuate	-	544	O
cognitive	-	554	O
deficits	-	564	O
in	-	573	O
both	-	576	O
rat	-	581	O
models	-	585	O
using	-	592	O
passive	-	598	O
avoidance	-	606	O
test	-	616	O
and	-	621	O
to	-	625	O
reduce	-	628	O
apoptotic	-	635	O
cell	-	645	O
death	-	650	O
observed	-	656	O
in	-	665	O
the	-	668	O
hippocampus	-	672	O
of	-	684	O
the	-	687	O
amyloid	-	691	B
beta	-	699	I
peptide	-	704	I
(	-	711	I
1	-	712	I
-	-	713	I
42	-	714	I
)	-	716	I
-	-	717	O
infused	-	718	O
rats	-	726	O
.	-	730	O

We	17600377	732	O
also	-	735	O
examined	-	740	O
the	-	749	O
neuroprotective	-	753	O
effects	-	769	O
of	-	777	O
maltolyl	-	780	B
p	-	789	I
-	-	790	I
coumarate	-	791	I
in	-	801	O
vitro	-	804	O
using	-	810	O
SH	-	816	O
-	-	818	O
SY5Y	-	819	O
cells	-	824	O
.	-	829	O

Cells	17600377	831	O
were	-	837	O
pretreated	-	842	O
with	-	853	O
maltolyl	-	858	B
p	-	867	I
-	-	868	I
coumarate	-	869	I
,	-	878	O
before	-	880	O
exposed	-	887	O
to	-	895	O
amyloid	-	898	B
beta	-	906	I
peptide	-	911	I
(	-	918	I
1	-	919	I
-	-	920	I
42	-	921	I
)	-	923	I
,	-	924	O
glutamate	-	926	B
or	-	936	O
H2O2	-	939	B
.	-	943	O

We	17600377	945	O
found	-	948	O
that	-	954	O
maltolyl	-	959	B
p	-	968	I
-	-	969	I
coumarate	-	970	I
significantly	-	980	O
decreased	-	994	O
apoptotic	-	1004	O
cell	-	1014	O
death	-	1019	O
and	-	1025	O
reduced	-	1029	O
reactive	-	1037	O
oxygen	-	1046	O
species	-	1053	O
,	-	1060	O
cytochrome	-	1062	O
c	-	1073	O
release	-	1075	O
,	-	1082	O
and	-	1084	O
caspase	-	1088	O
3	-	1096	O
activation	-	1098	O
.	-	1108	O

Taking	17600377	1110	O
these	-	1117	O
in	-	1123	O
vitro	-	1126	O
and	-	1132	O
in	-	1136	O
vivo	-	1139	O
results	-	1144	O
together	-	1152	O
,	-	1160	O
our	-	1162	O
study	-	1166	O
suggests	-	1172	O
that	-	1181	O
maltolyl	-	1186	B
p	-	1195	I
-	-	1196	I
coumarate	-	1197	I
is	-	1207	O
a	-	1210	O
potentially	-	1212	O
effective	-	1224	O
candidate	-	1234	O
against	-	1244	O
Alzheimer	-	1252	O
's	-	1261	O
disease	-	1264	O
that	-	1272	O
is	-	1277	O
characterized	-	1280	O
by	-	1294	O
wide	-	1297	O
spread	-	1302	O
neuronal	-	1309	O
death	-	1318	O
and	-	1324	O
progressive	-	1328	O
decline	-	1340	O
of	-	1348	O
cognitive	-	1351	O
function	-	1361	O
.	-	1369	O

Interaction	17639754	0	O
between	-	12	O
warfarin	-	20	B
and	-	29	O
levofloxacin	-	33	B
:	-	45	O
case	-	47	O
series	-	52	O
.	-	58	O

Warfarin	17639754	60	B
is	-	69	O
the	-	72	O
most	-	76	O
widely	-	81	O
used	-	88	O
oral	-	93	O
anticoagulant	-	98	O
and	-	112	O
is	-	116	O
indicated	-	119	O
for	-	129	O
many	-	133	O
clinical	-	138	O
conditions	-	147	O
.	-	157	O

Levofloxacin	17639754	159	B
,	-	171	O
a	-	173	O
fluoroquinolone	-	175	B
,	-	190	O
is	-	192	O
one	-	195	O
of	-	199	O
the	-	202	O
most	-	206	O
commonly	-	211	O
prescribed	-	220	O
antibiotics	-	231	O
in	-	243	O
clinical	-	246	O
practice	-	255	O
and	-	264	O
is	-	268	O
effective	-	271	O
against	-	281	O
Gram	-	289	O
-	-	293	O
positive	-	294	O
,	-	302	O
Gram	-	304	O
-	-	308	O
negative	-	309	O
,	-	317	O
and	-	319	O
atypical	-	323	O
bacteria	-	332	O
.	-	340	O

While	17639754	342	O
small	-	348	O
prospective	-	354	O
studies	-	366	O
have	-	374	O
not	-	379	O
revealed	-	383	O
any	-	392	O
significant	-	396	O
drug	-	408	O
-	-	412	O
drug	-	413	O
interaction	-	418	O
between	-	430	O
warfarin	-	438	B
and	-	447	O
levofloxacin	-	451	B
,	-	463	O
several	-	465	O
case	-	473	O
reports	-	478	O
have	-	486	O
indicated	-	491	O
that	-	501	O
levofloxacin	-	506	B
may	-	519	O
significantly	-	523	O
potentiate	-	537	O
the	-	548	O
anticoagulation	-	552	O
effect	-	568	O
of	-	575	O
warfarin	-	578	B
.	-	586	O

We	17639754	588	O
report	-	591	O
3	-	598	O
cases	-	600	O
of	-	606	O
serious	-	609	O
bleeding	-	617	O
complications	-	626	O
that	-	640	O
appear	-	645	O
to	-	652	O
be	-	655	O
the	-	658	O
result	-	662	O
of	-	669	O
the	-	672	O
interaction	-	676	O
between	-	688	O
warfarin	-	696	B
and	-	705	O
levofloxacin	-	709	B
.	-	721	O

Physicians	17639754	723	O
should	-	734	O
be	-	741	O
aware	-	744	O
of	-	750	O
this	-	753	O
potential	-	758	O
interaction	-	768	O
and	-	780	O
use	-	784	O
caution	-	788	O
when	-	796	O
prescribing	-	801	O
levofloxacin	-	813	B
to	-	826	O
patients	-	829	O
taking	-	838	O
warfarin	-	845	B
.	-	853	O

Mutations	17854040	0	O
associated	-	10	O
with	-	21	O
lamivudine	-	26	B
-	-	36	O
resistance	-	37	O
in	-	48	O
therapy	-	51	O
-	-	58	O
na	-	59	B
ve	-	63	O
hepatitis	-	66	O
B	-	76	O
virus	-	78	O
(	-	84	O
HBV	-	85	O
)	-	88	O
infected	-	90	O
patients	-	99	O
with	-	108	O
and	-	113	O
without	-	117	O
HIV	-	125	O
co	-	129	O
-	-	131	O
infection	-	132	O
:	-	141	O
implications	-	143	O
for	-	156	O
antiretroviral	-	160	O
therapy	-	175	O
in	-	183	O
HBV	-	186	O
and	-	190	O
HIV	-	194	O
co	-	198	O
-	-	200	O
infected	-	201	O
South	-	210	O
African	-	216	O
patients	-	224	O
.	-	232	O

This	17854040	234	O
was	-	239	O
an	-	243	O
exploratory	-	246	O
study	-	258	O
to	-	264	O
investigate	-	267	O
lamivudine	-	279	B
-	-	289	O
resistant	-	290	O
hepatitis	-	300	O
B	-	310	O
virus	-	312	O
(	-	318	O
HBV	-	319	O
)	-	322	O
strains	-	324	O
in	-	332	O
selected	-	335	O
lamivudine	-	344	B
-	-	354	O
na	-	355	B
ve	-	359	O
HBV	-	362	O
carriers	-	366	O
with	-	375	O
and	-	380	O
without	-	384	O
human	-	392	O
immunodeficiency	-	398	O
virus	-	415	O
(	-	421	O
HIV	-	422	O
)	-	425	O
co	-	427	O
-	-	429	O
infection	-	430	O
in	-	440	O
South	-	443	O
African	-	449	O
patients	-	457	O
.	-	465	O

Thirty	17854040	467	O
-	-	473	O
five	-	474	O
lamivudine	-	479	B
-	-	489	O
na	-	490	B

ve	17854040	494	O
HBV	-	497	O
infected	-	501	O
patients	-	510	O
with	-	519	O
or	-	524	O
without	-	527	O

HIV	17854040	535	O
co	-	539	O
-	-	541	O
infection	-	542	O
were	-	552	O
studied	-	557	O
:	-	564	O
15	-	566	O
chronic	-	569	O
HBV	-	577	O
mono	-	581	O
-	-	585	O
infected	-	586	O
patients	-	595	O
and	-	604	O
20	-	608	O
HBV	-	611	O
-	-	614	O
HIV	-	615	O
co	-	619	O
-	-	621	O
infected	-	622	O
patients	-	631	O
.	-	639	O

The	17854040	641	O
latter	-	645	O
group	-	652	O
was	-	658	O
further	-	662	O
sub	-	670	O
-	-	673	O
divided	-	674	O
into	-	682	O
13	-	687	O
occult	-	690	O
HBV	-	697	O
(	-	701	O
HBsAg	-	702	B
-	-	707	O
negative	-	708	O
)	-	716	O
and	-	718	O
7	-	722	O
overt	-	724	O
HBV	-	730	O
(	-	734	O
HBsAg	-	735	B
-	-	740	O
positive	-	742	O
)	-	750	O
patients	-	752	O
.	-	760	O

HBsAg	17854040	762	B
,	-	767	O
anti	-	769	O
-	-	773	O
HBs	-	774	O
,	-	777	O
anti	-	779	O
-	-	783	O
HBc	-	784	O
,	-	787	O
and	-	789	O
anti	-	793	O
-	-	797	O
HIV	-	798	O
1	-	802	O
/	-	803	O
2	-	804	O
were	-	806	O
determined	-	811	O
as	-	822	O
part	-	825	O
of	-	830	O
routine	-	833	O
diagnosis	-	841	O
using	-	851	O
Axsym	-	857	O
assays	-	863	O
(	-	870	O
Abbott	-	871	O
Laboratories	-	878	O
,	-	890	O
North	-	892	O
Chicago	-	898	O
,	-	905	O
IL	-	907	O
)	-	909	O
.	-	910	O

Serum	17854040	912	O
samples	-	918	O
were	-	926	O
PCR	-	931	O
amplified	-	935	O
with	-	945	O
HBV	-	950	O
reverse	-	954	O
transcriptase	-	962	O
(	-	976	O
RT	-	977	O
)	-	979	O
primers	-	981	O
,	-	988	O
followed	-	990	O
by	-	999	O
direct	-	1002	O
sequencing	-	1009	O
across	-	1020	O
the	-	1027	O
tyrosine	-	1031	B
-	-	1039	O
methionine	-	1040	B
-	-	1050	O
aspartate	-	1051	B
-	-	1060	O
aspartate	-	1061	B
(	-	1071	O
YMDD	-	1072	O
)	-	1076	O
motif	-	1078	O
of	-	1084	O
the	-	1087	O
major	-	1091	O
catalytic	-	1097	O
region	-	1107	O
in	-	1114	O
the	-	1117	O
C	-	1121	O
domain	-	1123	O
of	-	1130	O
the	-	1133	O
HBV	-	1137	O
RT	-	1141	O
enzyme	-	1144	O
.	-	1150	O

HBV	17854040	1152	O
viral	-	1156	O
load	-	1162	O
was	-	1167	O
performed	-	1171	O
with	-	1181	O
Amplicor	-	1186	O
HBV	-	1195	O
Monitor	-	1199	O
test	-	1207	O
v2	-	1212	O
.	-	1214	O
0	-	1215	O
(	-	1217	O
Roche	-	1218	O
Diagnostics	-	1224	O
,	-	1235	O
Penzberg	-	1237	O
,	-	1245	O
Germany	-	1247	O
)	-	1254	O
.	-	1255	O

HBV	17854040	1257	O
lamivudine	-	1261	B
-	-	1271	O
resistant	-	1272	O
strains	-	1282	O
were	-	1290	O
detected	-	1295	O
in	-	1304	O
3	-	1307	O
of	-	1309	O
15	-	1312	O
mono	-	1315	O
-	-	1319	O
infected	-	1320	O
chronic	-	1329	O
hepatitis	-	1337	O
B	-	1347	O
patients	-	1349	O
and	-	1358	O
10	-	1362	O
of	-	1365	O
20	-	1368	O
HBV	-	1371	O
-	-	1374	O
HIV	-	1375	O
co	-	1379	O
-	-	1381	O
infected	-	1382	O
patients	-	1391	O
.	-	1399	O

To	17854040	1401	O
the	-	1404	O
best	-	1408	O
of	-	1413	O
our	-	1416	O
knowledge	-	1420	O
,	-	1429	O
this	-	1431	O
constitutes	-	1436	O
the	-	1448	O
first	-	1452	O
report	-	1458	O
of	-	1465	O
HBV	-	1468	O
lamivudine	-	1472	B
-	-	1482	O
resistant	-	1483	O
strains	-	1493	O
in	-	1501	O
therapy	-	1504	O
-	-	1511	O
na	-	1512	B
ve	-	1516	O
HBV	-	1519	O
-	-	1522	O
HIV	-	1523	O
co	-	1527	O
-	-	1529	O
infected	-	1530	O
patients	-	1539	O
.	-	1547	O

The	17854040	1549	O
HBV	-	1553	O
viral	-	1557	O
loads	-	1563	O
for	-	1569	O
mono	-	1573	O
-	-	1577	O
infected	-	1578	O
and	-	1587	O
co	-	1591	O
-	-	1593	O
infected	-	1594	O
patients	-	1603	O
ranged	-	1612	O
from	-	1619	O
3	-	1624	O
.	-	1625	O
32	-	1626	O
x	-	1629	O
10	-	1631	O
(	-	1633	O
2	-	1634	O
)	-	1635	O
to	-	1637	O
3	-	1640	O
.	-	1641	O
82	-	1642	O
x	-	1645	O
10	-	1647	O
(	-	1649	O
7	-	1650	O
)	-	1651	O
and	-	1653	O
<	-	1657	O
200	-	1658	O
to	-	1662	O
4	-	1665	O
.	-	1666	O
40	-	1667	O
x	-	1670	O
10	-	1672	O
(	-	1674	O
3	-	1675	O
)	-	1676	O
copies	-	1678	O
/	-	1684	O
ml	-	1685	O
,	-	1687	O
respectively	-	1689	O
.	-	1701	O

It	17854040	1703	O
remains	-	1706	O
to	-	1714	O
be	-	1717	O
seen	-	1720	O
whether	-	1725	O
such	-	1733	O
pre	-	1738	O
-	-	1741	O
existing	-	1742	O
antiviral	-	1751	O
mutations	-	1761	O
could	-	1771	O
result	-	1777	O
in	-	1784	O
widespread	-	1787	O
emergence	-	1798	O
of	-	1808	O
HBV	-	1811	O
resistant	-	1815	O
strains	-	1825	O
when	-	1833	O
lamivudine	-	1838	B
-	-	1848	O
containing	-	1849	O
highly	-	1860	O
active	-	1867	O
antiretroviral	-	1874	O
(	-	1889	O
ARV	-	1890	O
)	-	1893	O
treatment	-	1895	O
(	-	1905	O
HAART	-	1906	O
)	-	1911	O
regimens	-	1913	O
become	-	1922	O
widely	-	1929	O
applied	-	1936	O
in	-	1944	O
South	-	1947	O
Africa	-	1953	O
,	-	1959	O
as	-	1961	O
this	-	1964	O
is	-	1969	O
likely	-	1972	O
to	-	1979	O
have	-	1982	O
potential	-	1987	O
implications	-	1997	O
in	-	2010	O
the	-	2013	O
management	-	2017	O
of	-	2028	O
HBV	-	2031	O
-	-	2034	O
HIV	-	2035	O
co	-	2039	O
-	-	2041	O
infected	-	2042	O
patients	-	2051	O
.	-	2059	O

Sex	18221780	0	O
differences	-	4	O
in	-	16	O
NMDA	-	19	B
antagonist	-	24	O
enhancement	-	35	O
of	-	47	O
morphine	-	50	B
antihyperalgesia	-	59	O
in	-	76	O
a	-	79	O
capsaicin	-	81	B
model	-	91	O
of	-	97	O
persistent	-	100	O
pain	-	111	O
:	-	115	O
comparisons	-	117	O
to	-	129	O
two	-	132	O
models	-	136	O
of	-	143	O
acute	-	146	O
pain	-	152	O
.	-	156	O

In	18221780	158	O
acute	-	161	O
pain	-	167	O
models	-	172	O
,	-	178	O
N	-	180	B
-	-	181	I
methyl	-	182	I
-	-	188	I
D	-	189	I
-	-	190	I
aspartate	-	191	I
(	-	201	O
NMDA	-	202	B
)	-	206	O
antagonists	-	208	O
enhance	-	220	O
the	-	228	O
antinociceptive	-	232	O
effects	-	248	O
of	-	256	O
morphine	-	259	B
to	-	268	O
a	-	271	O
greater	-	273	O
extent	-	281	O
in	-	288	O
males	-	291	O
than	-	297	O
females	-	302	O
.	-	309	O

The	18221780	311	O
purpose	-	315	O
of	-	323	O
this	-	326	O
investigation	-	331	O
was	-	345	O
to	-	349	O
extend	-	352	O
these	-	359	O
findings	-	365	O
to	-	374	O
a	-	377	O
persistent	-	379	O
pain	-	390	O
model	-	395	O
which	-	401	O
could	-	407	O
be	-	413	O
distinguished	-	416	O
from	-	430	O
acute	-	435	O
pain	-	441	O
models	-	446	O
on	-	453	O
the	-	456	O
basis	-	460	O
of	-	466	O
the	-	469	O
nociceptive	-	473	O
fibers	-	485	O
activated	-	492	O
,	-	501	O
neurochemical	-	503	O
substrates	-	517	O
,	-	527	O
and	-	529	O
duration	-	533	O
of	-	542	O
the	-	545	O
nociceptive	-	549	O
stimulus	-	561	O
.	-	569	O

To	18221780	571	O
this	-	574	O
end	-	579	O
,	-	582	O
persistent	-	584	O
hyperalgesia	-	595	O
was	-	608	O
induced	-	612	O
by	-	620	O
administration	-	623	O
of	-	638	O
capsaicin	-	641	B
in	-	651	O
the	-	654	O
tail	-	658	O
of	-	663	O
gonadally	-	666	O
intact	-	676	O
F344	-	683	O
rats	-	688	O
,	-	692	O
following	-	694	O
which	-	704	O
the	-	710	O
tail	-	714	O
was	-	719	O
immersed	-	723	O
in	-	732	O
a	-	735	O
mildly	-	737	O
noxious	-	744	O
thermal	-	752	O
stimulus	-	760	O
,	-	768	O
and	-	770	O
tail	-	774	O
-	-	778	O
withdrawal	-	779	O
latencies	-	790	O
measured	-	800	O
.	-	808	O

For	18221780	810	O
comparison	-	814	O
,	-	824	O
tests	-	826	O
were	-	832	O
conducted	-	837	O
in	-	847	O
two	-	850	O
acute	-	854	O
pain	-	860	O
models	-	865	O
,	-	871	O
the	-	873	O
hotplate	-	877	O
and	-	886	O
warm	-	890	O
water	-	895	O
tail	-	901	O
-	-	905	O
withdrawal	-	906	O
procedures	-	917	O
.	-	927	O

In	18221780	929	O
males	-	932	O
,	-	937	O
the	-	939	O
non	-	943	O
-	-	946	O
competitive	-	947	O
NMDA	-	959	B
antagonist	-	964	O
dextromethorphan	-	975	B
enhanced	-	992	O
the	-	1001	O
antihyperalgesic	-	1005	O
effect	-	1022	O
of	-	1029	O
low	-	1032	O
to	-	1036	O
moderate	-	1039	O
doses	-	1048	O
of	-	1054	O
morphine	-	1057	B
in	-	1066	O
a	-	1069	O
dose	-	1071	O
-	-	1075	O
and	-	1076	O
time	-	1080	O
-	-	1084	O
dependent	-	1085	O
manner	-	1095	O
.	-	1101	O

Across	18221780	1103	O
the	-	1110	O
doses	-	1114	O
and	-	1120	O
pretreatment	-	1124	O
times	-	1137	O
examined	-	1143	O
,	-	1151	O
enhancement	-	1153	O
was	-	1165	O
not	-	1169	O
observed	-	1173	O
in	-	1182	O
females	-	1185	O
.	-	1192	O

Enhancement	18221780	1194	O
of	-	1206	O
morphine	-	1209	B
antinociception	-	1218	O
by	-	1234	O
dextromethorphan	-	1237	B
was	-	1254	O
seen	-	1258	O
in	-	1263	O
both	-	1266	O
males	-	1271	O
and	-	1277	O
females	-	1281	O
in	-	1289	O
the	-	1292	O
acute	-	1296	O
pain	-	1302	O
models	-	1307	O
,	-	1313	O
with	-	1315	O
the	-	1320	O
magnitude	-	1324	O
of	-	1334	O
this	-	1337	O
effect	-	1342	O
being	-	1349	O
greater	-	1355	O
in	-	1363	O
males	-	1366	O
.	-	1371	O

These	18221780	1373	O
findings	-	1379	O
demonstrate	-	1388	O
a	-	1400	O
sexually	-	1402	O
-	-	1410	O
dimorphic	-	1411	O
interaction	-	1421	O
between	-	1433	O
NMDA	-	1441	B
antagonists	-	1446	O
and	-	1458	O
morphine	-	1462	B
in	-	1471	O
a	-	1474	O
persistent	-	1476	O
pain	-	1487	O
model	-	1492	O
that	-	1498	O
can	-	1503	O
be	-	1507	O
distinguished	-	1510	O
from	-	1524	O
those	-	1529	O
observed	-	1535	O
in	-	1544	O
acute	-	1547	O
pain	-	1553	O
models	-	1558	O
.	-	1564	O

Development	18261172	0	O
of	-	12	O
proteinuria	-	15	O
after	-	27	O
switch	-	33	O
to	-	40	O
sirolimus	-	43	B
-	-	52	O
based	-	53	O
immunosuppression	-	59	O
in	-	77	O
long	-	80	O
-	-	84	O
term	-	85	O
cardiac	-	90	O
transplant	-	98	O
patients	-	109	O
.	-	117	O

Calcineurin	18261172	119	O
-	-	130	O
inhibitor	-	131	O
therapy	-	141	O
can	-	149	O
lead	-	153	O
to	-	158	O
renal	-	161	O
dysfunction	-	167	O
in	-	179	O
heart	-	182	O
transplantation	-	188	O
patients	-	204	O
.	-	212	O

The	18261172	214	O
novel	-	218	O
immunosuppressive	-	224	O
(	-	242	O
IS	-	243	O
)	-	245	O
drug	-	247	O
sirolmus	-	252	B
(	-	261	O
Srl	-	262	B
)	-	265	O
lacks	-	267	O
nephrotoxic	-	273	O
effects	-	285	O
;	-	292	O
however	-	294	O
,	-	301	O
proteinuria	-	303	O
associated	-	315	O
with	-	326	O
Srl	-	331	B
has	-	335	O
been	-	339	O
reported	-	344	O
following	-	353	O
renal	-	363	O
transplantation	-	369	O
.	-	384	O

In	18261172	386	O
cardiac	-	389	O
transplantation	-	397	O
,	-	412	O
the	-	414	O
incidence	-	418	O
of	-	428	O
proteinuria	-	431	O
associated	-	443	O
with	-	454	O
Srl	-	459	B
is	-	463	O
unknown	-	466	O
.	-	473	O

In	18261172	475	O
this	-	478	O
study	-	483	O
,	-	488	O
long	-	490	O
-	-	494	O
term	-	495	O
cardiac	-	500	O
transplant	-	508	O
patients	-	519	O
were	-	528	O
switched	-	533	O
from	-	542	O
cyclosporine	-	547	B
to	-	560	O
Srl	-	563	B
-	-	566	O
based	-	567	O
IS	-	573	O
.	-	575	O

Concomitant	18261172	577	O
IS	-	589	O
consisted	-	592	O
of	-	602	O
mycophenolate	-	605	B
mofetil	-	619	I
+	-	627	O
/	-	628	O
-	-	629	O

steroids	18261172	631	B
.	-	639	O

Proteinuria	18261172	641	O
increased	-	653	O
significantly	-	663	O
from	-	677	O
a	-	682	O
median	-	684	O
of	-	691	O
0	-	694	O
.	-	695	O
13	-	696	O
g	-	699	O
/	-	700	O
day	-	701	O
(	-	705	O
range	-	706	O
0	-	712	O
-	-	713	O
5	-	714	O
.	-	715	O
7	-	716	O
)	-	717	O
preswitch	-	719	O
to	-	729	O
0	-	732	O
.	-	733	O
23	-	734	O
g	-	737	O
/	-	738	O
day	-	739	O
(	-	743	O
0	-	744	O
-	-	745	O
9	-	746	O
.	-	747	O
88	-	748	O
)	-	750	O
at	-	752	O
24	-	755	O
months	-	758	O
postswitch	-	765	O
(	-	776	O
p	-	777	O
=	-	779	O
0	-	781	O
.	-	782	O
0024	-	783	O
)	-	787	O
.	-	788	O

Before	18261172	790	O
the	-	797	O
switch	-	801	O
,	-	807	O
11	-	809	O
.	-	811	O
5	-	812	O
%	-	813	O
of	-	815	O
patients	-	818	O
had	-	827	O
high	-	831	O
-	-	835	O
grade	-	836	O
proteinuria	-	842	O
(	-	854	O
>	-	855	O
1	-	856	O
.	-	857	O
0	-	858	O
g	-	860	O
/	-	861	O
day	-	862	O
)	-	865	O
;	-	866	O
this	-	868	O
increased	-	873	O
to	-	883	O
22	-	886	O
.	-	888	O
9	-	889	O
%	-	890	O
postswitch	-	892	O
(	-	903	O
p	-	904	O
=	-	906	O
0	-	908	O
.	-	909	O
006	-	910	O
)	-	913	O
.	-	914	O

ACE	18261172	916	B
inhibitor	-	920	I
and	-	930	O
angiotensin	-	934	B
-	-	945	I
releasing	-	946	I
blocker	-	956	I
(	-	964	O
ARB	-	965	B
)	-	968	O
therapy	-	970	O
reduced	-	978	O
proteinuria	-	986	O
development	-	998	O
.	-	1009	O

Patients	18261172	1011	O
without	-	1020	O
proteinuria	-	1028	O
had	-	1040	O
increased	-	1044	O
renal	-	1054	O
function	-	1060	O
(	-	1069	O
median	-	1070	O
42	-	1077	O
.	-	1079	O
5	-	1080	O
vs	-	1082	O
.	-	1084	O
64	-	1086	O
.	-	1088	O
1	-	1089	O
,	-	1090	O
p	-	1092	O
=	-	1094	O
0	-	1096	O
.	-	1097	O
25	-	1098	O
)	-	1100	O
,	-	1101	O
whereas	-	1103	O
patients	-	1111	O
who	-	1120	O
developed	-	1124	O
high	-	1134	O
-	-	1138	O
grade	-	1139	O
proteinuria	-	1145	O
showed	-	1157	O
decreased	-	1164	O
renal	-	1174	O
function	-	1180	O
at	-	1189	O
the	-	1192	O
end	-	1196	O
of	-	1200	O
follow	-	1203	O
-	-	1209	O
up	-	1210	O
(	-	1213	O
median	-	1214	O
39	-	1221	O
.	-	1223	O
6	-	1224	O
vs	-	1226	O
.	-	1228	O
29	-	1230	O
.	-	1232	O
2	-	1233	O
,	-	1234	O
p	-	1236	O
=	-	1238	O
0	-	1240	O
.	-	1241	O
125	-	1242	O
)	-	1245	O
.	-	1246	O

Thus	18261172	1248	O
,	-	1252	O
proteinuria	-	1254	O
may	-	1266	O
develop	-	1270	O
in	-	1278	O
cardiac	-	1281	O
transplant	-	1289	O
patients	-	1300	O
after	-	1309	O
switch	-	1315	O
to	-	1322	O
Srl	-	1325	B
,	-	1328	O
which	-	1330	O
may	-	1336	O
have	-	1340	O
an	-	1345	O
adverse	-	1348	O
effect	-	1356	O
on	-	1363	O
renal	-	1366	O
function	-	1372	O
in	-	1381	O
these	-	1384	O
patients	-	1390	O
.	-	1398	O

Srl	18261172	1400	B
should	-	1404	O
be	-	1411	O
used	-	1414	O
with	-	1419	O
ACEi	-	1424	B
/	-	1428	O
ARB	-	1429	B
therapy	-	1433	O
and	-	1441	O
patients	-	1445	O
monitored	-	1454	O
for	-	1464	O
proteinuria	-	1468	O
and	-	1480	O
increased	-	1484	O
renal	-	1494	O
dysfunction	-	1500	O
.	-	1511	O

Synthesis	18329269	0	O
of	-	10	O
N	-	13	B
-	-	14	I
pyrimidinyl	-	15	I
-	-	26	I
2	-	27	I
-	-	28	I
phenoxyacetamides	-	29	I
as	-	47	O
adenosine	-	50	B
A2A	-	60	O
receptor	-	64	O
antagonists	-	73	O
.	-	84	O

A	18329269	86	O
series	-	88	O
of	-	95	O
N	-	98	B
-	-	99	I
pyrimidinyl	-	100	I
-	-	111	I
2	-	112	I
-	-	113	I
phenoxyacetamide	-	114	I
adenosine	-	131	B
A	-	141	O
(	-	142	O
2A	-	143	O
)	-	145	O
antagonists	-	147	O
is	-	159	O
described	-	162	O
.	-	171	O

SAR	18329269	173	O
studies	-	177	O
led	-	185	O
to	-	189	O
compound	-	192	O
14	-	201	O
with	-	204	O
excellent	-	209	O
potency	-	219	O
(	-	227	O
K	-	228	O
(	-	229	O
i	-	230	O
)	-	231	O
=	-	233	O
0	-	235	O
.	-	236	O
4	-	237	O
nM	-	239	O
)	-	241	O
,	-	242	O
selectivity	-	244	O
(	-	256	O
A	-	257	O
(	-	258	O
1	-	259	O
)	-	260	O
/	-	261	O
A	-	262	O
(	-	263	O
2A	-	264	O
)	-	266	O
>	-	268	O
100	-	270	O
)	-	273	O
,	-	274	O
and	-	276	O
efficacy	-	280	O
(	-	289	O
MED	-	290	O
10	-	294	O
mg	-	297	O
/	-	299	O
kg	-	300	O
p	-	303	O
.	-	304	O
o	-	305	O
.	-	306	O
)	-	307	O
in	-	309	O
the	-	312	O
rat	-	316	O
haloperidol	-	320	B
-	-	331	O
induced	-	332	O
catalepsy	-	340	O
model	-	350	O
for	-	356	O
Parkinson	-	360	O
's	-	369	O
disease	-	372	O
.	-	379	O

Methamphetamine	18410508	0	B
-	-	15	O
induced	-	16	O
neurotoxicity	-	24	O
and	-	38	O
microglial	-	42	O
activation	-	53	O
are	-	64	O
not	-	68	O
mediated	-	72	O
by	-	81	O
fractalkine	-	84	O
receptor	-	96	O
signaling	-	105	O
.	-	114	O

Methamphetamine	18410508	116	B
(	-	132	O
METH	-	133	B
)	-	137	O
damages	-	139	O
dopamine	-	147	B
(	-	156	O
DA	-	157	B
)	-	159	O
nerve	-	161	O
endings	-	167	O
by	-	175	O
a	-	178	O
process	-	180	O
that	-	188	O
has	-	193	O
been	-	197	O
linked	-	202	O
to	-	209	O
microglial	-	212	O
activation	-	223	O
but	-	234	O
the	-	238	O
signaling	-	242	O
pathways	-	252	O
that	-	261	O
mediate	-	266	O
this	-	274	O
response	-	279	O
have	-	288	O
not	-	293	O
yet	-	297	O
been	-	301	O
delineated	-	306	O
.	-	316	O

Cardona	18410508	318	O
et	-	326	O
al	-	329	O
.	-	331	O

[	18410508	333	O
Nat	-	334	O
.	-	337	O

Neurosci	18410508	339	O
.	-	347	O

9	18410508	349	O
(	-	351	O
2006	-	352	O
)	-	356	O
,	-	357	O

917	18410508	359	O
]	-	362	O
recently	-	364	O
identified	-	373	O
the	-	384	O
microglial	-	388	O
-	-	398	O
specific	-	399	O
fractalkine	-	408	O
receptor	-	420	O
(	-	429	O
CX3CR1	-	430	O
)	-	436	O
as	-	438	O
an	-	441	O
important	-	444	O
mediator	-	454	O
of	-	463	O
MPTP	-	466	B
-	-	470	O
induced	-	471	O
neurodegeneration	-	479	O
of	-	497	O
DA	-	500	B
neurons	-	503	O
.	-	510	O

Because	18410508	512	O
the	-	520	O
CNS	-	524	O
damage	-	528	O
caused	-	535	O
by	-	542	O
METH	-	545	B
and	-	550	O
MPTP	-	554	B
is	-	559	O
highly	-	562	O
selective	-	569	O
for	-	579	O
the	-	583	O
DA	-	587	B
neuronal	-	590	O
system	-	599	O
in	-	606	O
mouse	-	609	O
models	-	615	O
of	-	622	O
neurotoxicity	-	625	O
,	-	638	O
we	-	640	O
hypothesized	-	643	O
that	-	656	O
the	-	661	O
CX3CR1	-	665	O
plays	-	672	O
a	-	678	O
role	-	680	O
in	-	685	O
METH	-	688	B
-	-	692	O
induced	-	693	O
neurotoxicity	-	701	O
and	-	715	O
microglial	-	719	O
activation	-	730	O
.	-	740	O

Mice	18410508	742	O
in	-	747	O
which	-	750	O
the	-	756	O
CX3CR1	-	760	O
gene	-	767	O
has	-	772	O
been	-	776	O
deleted	-	781	O
and	-	789	O
replaced	-	793	O
with	-	802	O
a	-	807	O
cDNA	-	809	O
encoding	-	814	O
enhanced	-	823	O
green	-	832	O
fluorescent	-	838	O
protein	-	850	O
(	-	858	O
eGFP	-	859	O
)	-	863	O
were	-	865	O
treated	-	870	O
with	-	878	O
METH	-	883	B
and	-	888	O
examined	-	892	O
for	-	901	O
striatal	-	905	O
neurotoxicity	-	914	O
.	-	927	O

METH	18410508	929	B
depleted	-	934	O
DA	-	943	B
,	-	945	O
caused	-	947	O
microglial	-	954	O
activation	-	965	O
,	-	975	O
and	-	977	O
increased	-	981	O
body	-	991	O
temperature	-	996	O
in	-	1008	O
CX3CR1	-	1011	O
knockout	-	1018	O
mice	-	1027	O
to	-	1032	O
the	-	1035	O
same	-	1039	O
extent	-	1044	O
and	-	1051	O
over	-	1055	O
the	-	1060	O
same	-	1064	O
time	-	1069	O
course	-	1074	O
seen	-	1081	O
in	-	1086	O
wild	-	1089	O
-	-	1093	O
type	-	1094	O
controls	-	1099	O
.	-	1107	O

The	18410508	1109	O
effects	-	1113	O
of	-	1121	O
METH	-	1124	B
in	-	1129	O
CX3CR1	-	1132	O
knockout	-	1139	O
mice	-	1148	O
were	-	1153	O
not	-	1158	O
gender	-	1162	O
-	-	1168	O
dependent	-	1169	O
and	-	1179	O
did	-	1183	O
not	-	1187	O
extend	-	1191	O
beyond	-	1198	O
the	-	1205	O
striatum	-	1209	O
.	-	1217	O

Striatal	18410508	1219	O
microglia	-	1228	O
expressing	-	1238	O
eGFP	-	1249	O
constitutively	-	1254	O
show	-	1269	O
morphological	-	1274	O
changes	-	1288	O
after	-	1296	O
METH	-	1302	B
that	-	1307	O
are	-	1312	O
characteristic	-	1316	O
of	-	1331	O
activation	-	1334	O
.	-	1344	O

This	18410508	1346	O
response	-	1351	O
was	-	1360	O
restricted	-	1364	O
to	-	1375	O
the	-	1378	O
striatum	-	1382	O
and	-	1391	O
contrasted	-	1395	O
sharply	-	1406	O
with	-	1414	O
unresponsive	-	1419	O
eGFP	-	1432	O
-	-	1436	O
microglia	-	1437	O
in	-	1447	O
surrounding	-	1450	O
brain	-	1462	O
areas	-	1468	O
that	-	1474	O
are	-	1479	O
not	-	1483	O
damaged	-	1487	O
by	-	1495	O
METH	-	1498	B
.	-	1502	O

We	18410508	1504	O
conclude	-	1507	O
from	-	1516	O
these	-	1521	O
studies	-	1527	O
that	-	1535	O
CX3CR1	-	1540	O
signaling	-	1547	O
does	-	1557	O
not	-	1562	O
modulate	-	1566	O
METH	-	1575	B
neurotoxicity	-	1580	O
or	-	1594	O
microglial	-	1597	O
activation	-	1608	O
.	-	1618	O

Furthermore	18410508	1620	O
,	-	1631	O
it	-	1633	O
appears	-	1636	O
that	-	1644	O
striatal	-	1649	O
-	-	1657	O
resident	-	1658	O
microglia	-	1667	O
respond	-	1677	O
to	-	1685	O
METH	-	1688	B
with	-	1693	O
an	-	1698	O
activation	-	1701	O
cascade	-	1712	O
and	-	1720	O
then	-	1724	O
return	-	1729	O
to	-	1736	O
a	-	1739	O
surveying	-	1741	O
state	-	1751	O
without	-	1757	O
undergoing	-	1765	O
apoptosis	-	1776	O
or	-	1786	O
migration	-	1789	O
.	-	1798	O

Recovery	18503483	0	O
of	-	9	O
tacrolimus	-	12	B
-	-	22	O
associated	-	23	O
brachial	-	34	O
neuritis	-	43	O
after	-	52	O
conversion	-	58	O
to	-	69	O
everolimus	-	72	B
in	-	83	O
a	-	86	O
pediatric	-	88	O
renal	-	98	O
transplant	-	104	O
recipient	-	115	O
-	-	124	O
-	-	125	O
case	-	126	O
report	-	131	O
and	-	138	O
review	-	142	O
of	-	149	O
the	-	152	O
literature	-	156	O
.	-	166	O

TAC	18503483	168	B
has	-	172	O
been	-	176	O
shown	-	181	O
to	-	187	O
be	-	190	O
a	-	193	O
potent	-	195	O
immunosuppressive	-	202	O
agent	-	220	O
for	-	226	O
solid	-	230	O
organ	-	236	O
transplantation	-	242	O
in	-	258	O
pediatrics	-	261	O
.	-	271	O

Neurotoxicity	18503483	273	O
is	-	287	O
a	-	290	O
potentially	-	292	O
serious	-	304	O
toxic	-	312	O
effect	-	318	O
.	-	324	O

It	18503483	326	O
is	-	329	O
characterized	-	332	O
by	-	346	O
encephalopathy	-	349	O
,	-	363	O
headaches	-	365	O
,	-	374	O
seizures	-	376	O
,	-	384	O
or	-	386	O
neurological	-	389	O
deficits	-	402	O
.	-	410	O

Here	18503483	412	O
,	-	416	O
we	-	418	O
describe	-	421	O
an	-	430	O
eight	-	433	O
-	-	438	O
and	-	439	O
-	-	442	O
a	-	443	O
-	-	444	O
half	-	445	O
-	-	449	O
yr	-	450	O
-	-	452	O
old	-	453	O
male	-	457	O
renal	-	462	O
transplant	-	468	O
recipient	-	479	O
with	-	489	O
right	-	494	O
BN	-	500	O
.	-	502	O

MRI	18503483	504	O
demonstrated	-	508	O
hyperintense	-	521	O
T2	-	534	O
signals	-	537	O
in	-	545	O
the	-	548	O
cervical	-	552	O
cord	-	561	O
and	-	566	O
right	-	570	O
brachial	-	576	O
plexus	-	585	O
roots	-	592	O
indicative	-	598	O
of	-	609	O
both	-	612	O
myelitis	-	617	O
and	-	626	O
right	-	630	O
brachial	-	636	O
plexitis	-	645	O
.	-	653	O

Symptoms	18503483	655	O
persisted	-	664	O
for	-	674	O
three	-	678	O
months	-	684	O
despite	-	691	O
TAC	-	699	B
dose	-	703	O
reduction	-	708	O
,	-	717	O
administration	-	719	O
of	-	734	O
IVIG	-	737	O
and	-	742	O
four	-	746	O
doses	-	751	O
of	-	757	O
methylprednisolone	-	760	B
pulse	-	779	O
therapy	-	785	O
.	-	792	O

Improvement	18503483	794	O
and	-	806	O
eventually	-	810	O
full	-	821	O
recovery	-	826	O
only	-	835	O
occurred	-	840	O
after	-	849	O
TAC	-	855	B
was	-	859	O
completely	-	863	O
discontinued	-	874	O
and	-	887	O
successfully	-	891	O
replaced	-	904	O
by	-	913	O
everolimus	-	916	B
.	-	926	O

Valvular	18560792	0	O
heart	-	9	O
disease	-	15	O
in	-	23	O
patients	-	26	O
with	-	35	O
Parkinson	-	40	O
's	-	49	O
disease	-	52	O
treated	-	60	O
with	-	68	O
pergolide	-	73	B
.	-	82	O

Course	18560792	84	O
following	-	91	O
treatment	-	101	O
modifications	-	111	O
.	-	124	O

Valvular	18560792	126	O
heart	-	135	O
abnormalities	-	141	O
have	-	155	O
been	-	160	O
reported	-	165	O
in	-	174	O
patients	-	177	O
with	-	186	O
Parkinson	-	191	O
's	-	200	O
disease	-	203	O
(	-	211	O
PD	-	212	O
)	-	214	O
treated	-	216	O
with	-	224	O
pergolide	-	229	B
.	-	238	O

However	18560792	240	O
,	-	247	O
the	-	249	O
incidence	-	253	O
and	-	263	O
severity	-	267	O
of	-	276	O
these	-	279	O
abnormalities	-	285	O
vary	-	299	O
from	-	304	O
study	-	309	O
to	-	315	O
study	-	318	O
and	-	324	O
their	-	328	O
course	-	334	O
after	-	341	O
drug	-	347	O
withdrawal	-	352	O
has	-	363	O
not	-	367	O
been	-	371	O
systematically	-	376	O
assessed	-	391	O
.	-	399	O

OBJECTIVES	18560792	401	O
:	-	411	O

To	18560792	413	O
estimate	-	416	O
the	-	425	O
frequency	-	429	O
and	-	439	O
severity	-	443	O
of	-	452	O
valvular	-	455	O
heart	-	464	O
abnormality	-	470	O
and	-	482	O
its	-	486	O
possible	-	490	O
reversibility	-	499	O
after	-	513	O
drug	-	519	O
withdrawal	-	524	O
in	-	535	O
a	-	538	O
case	-	540	O
-	-	544	O
control	-	545	O
study	-	553	O
.	-	558	O

METHODS	18560792	560	O
:	-	567	O

All	18560792	569	O
PD	-	573	O
patients	-	576	O
in	-	585	O
the	-	588	O
Amiens	-	592	O
area	-	599	O
treated	-	604	O
with	-	612	O
pergolide	-	617	B
were	-	627	O
invited	-	632	O
to	-	640	O
attend	-	643	O
a	-	650	O
cardiologic	-	652	O
assessment	-	664	O
including	-	675	O
transthoracic	-	685	O
echocardiography	-	699	O
.	-	715	O

Thirty	18560792	717	O
PD	-	724	O
patients	-	727	O
participated	-	736	O
in	-	749	O
the	-	752	O
study	-	756	O
.	-	761	O

A	18560792	763	O
second	-	765	O
echocardiography	-	772	O
was	-	789	O
performed	-	793	O
(	-	803	O
median	-	804	O
interval	-	811	O
:	-	819	O
13	-	821	O
months	-	824	O
)	-	830	O
after	-	832	O
pergolide	-	838	B
withdrawal	-	848	O
(	-	859	O
n	-	860	O
=	-	861	O
10	-	862	O
patients	-	865	O
)	-	873	O
.	-	874	O

Controls	18560792	876	O
were	-	885	O
age	-	890	O
-	-	893	O
and	-	895	O
sex	-	899	O
-	-	902	O
matched	-	903	O
non	-	911	O
-	-	914	O
PD	-	915	O
patients	-	918	O
referred	-	927	O
to	-	936	O
the	-	939	O
cardiology	-	943	O
department	-	954	O
.	-	964	O

RESULTS	18560792	966	O
:	-	973	O

Compared	18560792	975	O
to	-	984	O
controls	-	987	O
,	-	995	O
aortic	-	997	O
regurgitation	-	1004	O
(	-	1018	O
OR	-	1019	O
:	-	1021	O
3	-	1023	O
.	-	1024	O
1	-	1025	O
;	-	1026	O
95	-	1028	O
%	-	1030	O
IC	-	1032	O
:	-	1034	O

1	18560792	1036	O
.	-	1037	O
1	-	1038	O
-	-	1039	O
8	-	1040	O
.	-	1041	O
8	-	1042	O
)	-	1043	O
and	-	1045	O
mitral	-	1049	O
regurgitation	-	1056	O
(	-	1070	O
OR	-	1071	O
:	-	1073	O
10	-	1075	O
.	-	1077	O
7	-	1078	O
;	-	1079	O
95	-	1081	O
%	-	1083	O
IC	-	1085	O
:	-	1087	O
2	-	1089	O
.	-	1090	O
1	-	1091	O
-	-	1092	O
53	-	1093	O
)	-	1095	O
were	-	1097	O
more	-	1102	O
frequent	-	1107	O
in	-	1116	O
PD	-	1119	O
patients	-	1122	O
(	-	1131	O
tricuspid	-	1132	O
:	-	1141	O
NS	-	1143	O
)	-	1145	O
.	-	1146	O

The	18560792	1148	O
number	-	1152	O
of	-	1159	O
affected	-	1162	O
valves	-	1171	O
(	-	1178	O
n	-	1179	O
=	-	1180	O
2	-	1181	O
.	-	1182	O
4	-	1183	O
+	-	1184	O
/	-	1185	O
-	-	1186	O
0	-	1187	O
.	-	1188	O
7	-	1189	O
)	-	1190	O
and	-	1192	O
the	-	1196	O
sum	-	1200	O
of	-	1204	O
regurgitation	-	1207	O
grades	-	1221	O
(	-	1228	O
n	-	1229	O
=	-	1230	O
2	-	1231	O
.	-	1232	O
8	-	1233	O
+	-	1234	O
/	-	1235	O
-	-	1236	O
1	-	1237	O
.	-	1238	O
09	-	1239	O
)	-	1241	O
were	-	1243	O
higher	-	1248	O
(	-	1255	O
p	-	1256	O
=	-	1257	O
0	-	1258	O
.	-	1259	O
008	-	1260	O
and	-	1264	O
p	-	1268	O
=	-	1269	O
0	-	1270	O
.	-	1271	O
006	-	1272	O
,	-	1275	O
respectively	-	1277	O
)	-	1289	O
in	-	1291	O
the	-	1294	O
pergolide	-	1298	B
group	-	1308	O
.	-	1313	O

Severity	18560792	1315	O
of	-	1324	O
regurgitation	-	1327	O
was	-	1341	O
not	-	1345	O
correlated	-	1349	O
with	-	1360	O
pergolide	-	1365	B
cumulative	-	1375	O
dose	-	1386	O
.	-	1390	O

A	18560792	1392	O
restrictive	-	1394	O
pattern	-	1406	O
of	-	1414	O
valvular	-	1417	O
regurgitation	-	1426	O
,	-	1439	O
suggestive	-	1441	O
of	-	1452	O
the	-	1455	O
role	-	1459	O
of	-	1464	O
pergolide	-	1467	B
,	-	1476	O
was	-	1478	O
observed	-	1482	O
in	-	1491	O
12	-	1494	O
/	-	1496	O
30	-	1497	O
(	-	1500	O
40	-	1501	O
%	-	1503	O
)	-	1504	O
patients	-	1506	O
including	-	1515	O
two	-	1525	O
with	-	1529	O
heart	-	1534	O
failure	-	1540	O
.	-	1547	O

Pergolide	18560792	1549	B
was	-	1559	O
discontinued	-	1563	O
in	-	1576	O
10	-	1579	O
patients	-	1582	O
with	-	1591	O
valvular	-	1596	O
heart	-	1605	O
disease	-	1611	O
,	-	1618	O
resulting	-	1620	O
in	-	1630	O
a	-	1633	O
lower	-	1635	O
regurgitation	-	1641	O
grade	-	1655	O
(	-	1661	O
p	-	1662	O
=	-	1663	O
0	-	1664	O
.	-	1665	O
01	-	1666	O
)	-	1668	O
at	-	1670	O
the	-	1673	O
second	-	1677	O
transthoracic	-	1684	O
echocardiography	-	1698	O
and	-	1715	O
the	-	1719	O
two	-	1723	O
patients	-	1727	O
with	-	1736	O
heart	-	1741	O
failure	-	1747	O
returned	-	1755	O
to	-	1764	O
nearly	-	1767	O
normal	-	1774	O
clinical	-	1781	O
examination	-	1790	O
.	-	1801	O

This	18560792	1803	O
study	-	1808	O
supports	-	1814	O
the	-	1823	O
high	-	1827	O
frequency	-	1832	O
of	-	1842	O
restrictive	-	1845	O
valve	-	1857	O
regurgitation	-	1863	O
in	-	1877	O
PD	-	1880	O
patients	-	1883	O
treated	-	1892	O
with	-	1900	O
pergolide	-	1905	B
and	-	1915	O
reveals	-	1919	O
that	-	1927	O
a	-	1932	O
significant	-	1934	O
improvement	-	1946	O
is	-	1958	O
usual	-	1961	O
when	-	1967	O
the	-	1972	O
treatment	-	1976	O
is	-	1986	O
converted	-	1989	O
to	-	1999	O
non	-	2002	O
-	-	2005	O
ergot	-	2006	O
dopamine	-	2012	B
agonists	-	2021	O
.	-	2029	O

Adverse	18726058	0	O
effects	-	8	O
of	-	16	O
topical	-	19	O
papaverine	-	27	B
on	-	38	O
auditory	-	41	O
nerve	-	50	O
function	-	56	O
.	-	64	O

BACKGROUND	18726058	66	O
:	-	76	O
Papaverine	-	78	B
hydrochloride	-	89	I
is	-	103	O
a	-	106	O
direct	-	108	O
-	-	114	O
acting	-	115	O
vasodilator	-	122	O
used	-	134	O
to	-	139	O
manage	-	142	O
vasospasm	-	149	O
during	-	159	O
various	-	166	O
neurosurgical	-	174	O
operations	-	188	O
.	-	198	O

Transient	18726058	200	O
cranial	-	210	O
nerve	-	218	O
dysfunction	-	224	O
has	-	236	O
been	-	240	O
described	-	245	O
in	-	255	O
a	-	258	O
few	-	260	O
cases	-	264	O
with	-	270	O
topical	-	275	O
papaverine	-	283	B
.	-	293	O

This	18726058	295	O
study	-	300	O
supports	-	306	O
previous	-	315	O
reports	-	324	O
and	-	332	O
provides	-	336	O
neurophysiological	-	345	O
evidence	-	364	O
of	-	373	O
an	-	376	O
adverse	-	379	O
effect	-	387	O
on	-	394	O
the	-	397	O
auditory	-	401	O
nerve	-	410	O
.	-	415	O

METHODS	18726058	417	O
:	-	424	O

We	18726058	426	O
conducted	-	429	O
a	-	439	O
retrospective	-	441	O
review	-	455	O
of	-	462	O
70	-	465	O
consecutive	-	468	O
microvascular	-	480	O
decompression	-	494	O
operations	-	508	O
and	-	519	O
studied	-	523	O
those	-	531	O
patients	-	537	O
who	-	546	O
received	-	550	O
topical	-	559	O
papaverine	-	567	B
for	-	578	O
vasospasm	-	582	O
.	-	591	O

Topical	18726058	593	O
papaverine	-	601	B
was	-	612	O
used	-	616	O
as	-	621	O
a	-	624	O
direct	-	626	O
therapeutic	-	633	O
action	-	645	O
to	-	652	O
manage	-	655	O
vasospasm	-	662	O
in	-	672	O
a	-	675	O
total	-	677	O
of	-	683	O
11	-	686	O
patients	-	689	O
.	-	697	O

The	18726058	699	O
timing	-	703	O
of	-	710	O
papaverine	-	713	B
application	-	724	O
and	-	736	O
ongoing	-	740	O
operative	-	748	O
events	-	758	O
was	-	765	O
reviewed	-	769	O
relative	-	778	O
to	-	787	O
changes	-	790	O
in	-	798	O
neurophysiological	-	801	O
recordings	-	820	O
.	-	830	O

Brainstem	18726058	832	O
auditory	-	842	O
evoked	-	851	O
potentials	-	858	O
(	-	869	O
BAEPs	-	870	O
)	-	875	O
were	-	877	O
routinely	-	882	O
used	-	892	O
to	-	897	O
monitor	-	900	O
cochlear	-	908	O
nerve	-	917	O
function	-	923	O
during	-	932	O
these	-	939	O
operations	-	945	O
.	-	955	O

FINDINGS	18726058	957	O
:	-	965	O

A	18726058	967	O
temporal	-	969	O
relationship	-	978	O
was	-	991	O
found	-	995	O
between	-	1001	O
topical	-	1009	O
papaverine	-	1017	B
and	-	1028	O
BAEP	-	1032	O
changes	-	1037	O
leading	-	1045	O
to	-	1053	O
complete	-	1056	O
waveform	-	1065	O
loss	-	1074	O
.	-	1078	O

The	18726058	1080	O
average	-	1084	O
temporal	-	1092	O
delay	-	1101	O
between	-	1107	O
papaverine	-	1115	B
and	-	1126	O
the	-	1130	O
onset	-	1134	O
of	-	1140	O
an	-	1143	O
adverse	-	1146	O
BAEP	-	1154	O
change	-	1159	O
was	-	1166	O
5	-	1170	O
min	-	1172	O
.	-	1175	O

In	18726058	1177	O
10	-	1180	O
of	-	1183	O
11	-	1186	O
patients	-	1189	O
,	-	1197	O
BAEP	-	1199	O
waves	-	1204	O
II	-	1210	O
/	-	1212	O
III	-	1213	O
-	-	1216	O
V	-	1217	O
completely	-	1219	O
disappeared	-	1230	O
within	-	1242	O
2	-	1249	O
to	-	1251	O
25	-	1254	O
min	-	1257	O
after	-	1261	O
papaverine	-	1267	B
.	-	1277	O

Eight	18726058	1279	O
of	-	1285	O
these	-	1288	O
10	-	1294	O
patients	-	1297	O
had	-	1306	O
complete	-	1310	O
loss	-	1319	O
of	-	1324	O
BAEP	-	1327	O
waveforms	-	1332	O
within	-	1342	O
10	-	1349	O
min	-	1352	O
.	-	1355	O

One	18726058	1357	O
patient	-	1361	O
showed	-	1369	O
no	-	1376	O
recovery	-	1379	O
of	-	1388	O
later	-	1391	O
waves	-	1397	O
and	-	1403	O
a	-	1407	O
delayed	-	1409	O
profound	-	1417	O
sensorineural	-	1426	O
hearing	-	1440	O
loss	-	1448	O
.	-	1452	O

The	18726058	1454	O
average	-	1458	O
recovery	-	1466	O
time	-	1475	O
of	-	1480	O
BAEP	-	1483	O
waveforms	-	1488	O
to	-	1498	O
pre	-	1501	O
-	-	1504	O
papaverine	-	1505	B
baseline	-	1516	O
values	-	1525	O
was	-	1532	O
39	-	1536	O
min	-	1539	O
.	-	1542	O

CONCLUSIONS	18726058	1544	O
:	-	1555	O

Topical	18726058	1557	O
papaverine	-	1565	B
for	-	1576	O
the	-	1580	O
treatment	-	1584	O
of	-	1594	O
vasospasm	-	1597	O
was	-	1607	O
associated	-	1611	O
with	-	1622	O
the	-	1627	O
onset	-	1631	O
of	-	1637	O
a	-	1640	O
transient	-	1642	O
disturbance	-	1652	O
in	-	1664	O
neurophysiological	-	1667	O
function	-	1686	O
of	-	1695	O
the	-	1698	O
ascending	-	1702	O
auditory	-	1712	O
brainstem	-	1721	O
pathway	-	1731	O
.	-	1738	O

The	18726058	1740	O
complete	-	1744	O
disappearance	-	1753	O
of	-	1767	O
BAEP	-	1770	O
waveforms	-	1775	O
with	-	1785	O
a	-	1790	O
consistent	-	1792	O
temporal	-	1803	O
delay	-	1812	O
suggests	-	1818	O
a	-	1827	O
possible	-	1829	O
adverse	-	1838	O
effect	-	1846	O
on	-	1853	O
the	-	1856	O
proximal	-	1860	O
eighth	-	1869	O
nerve	-	1876	O
.	-	1881	O

Recommendations	18726058	1883	O
to	-	1899	O
avoid	-	1902	O
potential	-	1908	O
cranial	-	1918	O
nerve	-	1926	O
deficits	-	1932	O
from	-	1941	O
papaverine	-	1946	B
are	-	1957	O
provided	-	1961	O
.	-	1969	O

Massive	18754075	0	O
proteinuria	-	8	O
and	-	20	O
acute	-	24	O
renal	-	30	O
failure	-	36	O
after	-	44	O
oral	-	50	O
bisphosphonate	-	55	B
(	-	70	O
alendronate	-	71	B
)	-	82	O
administration	-	84	O
in	-	99	O
a	-	102	O
patient	-	104	O
with	-	112	O
focal	-	117	O
segmental	-	123	O
glomerulosclerosis	-	133	O
.	-	151	O

A	18754075	153	O
61	-	155	O
-	-	157	O
year	-	158	O
-	-	162	O
old	-	163	O
Japanese	-	167	O
man	-	176	O
with	-	180	O
nephrotic	-	185	O
syndrome	-	195	O
due	-	204	O
to	-	208	O
focal	-	211	O
segmental	-	217	O
glomerulosclerosis	-	227	O
was	-	246	O
initially	-	250	O
responding	-	260	O
well	-	271	O
to	-	276	O
steroid	-	279	B
therapy	-	287	O
.	-	294	O

The	18754075	296	O
amount	-	300	O
of	-	307	O
daily	-	310	O
urinary	-	316	O
protein	-	324	O
decreased	-	332	O
from	-	342	O
15	-	347	O
.	-	349	O
6	-	350	O
to	-	352	O
2	-	355	O
.	-	356	O
8	-	357	O
g	-	359	O
.	-	360	O
Within	-	362	O
14	-	369	O
days	-	372	O
of	-	377	O
the	-	380	O
oral	-	384	O
bisphosphonate	-	389	B
(	-	404	O
alendronate	-	405	B
sodium	-	417	I
)	-	423	O
administration	-	425	O
,	-	439	O
the	-	441	O
amount	-	445	O
of	-	452	O
daily	-	455	O
urinary	-	461	O
protein	-	469	O
increased	-	477	O
rapidly	-	487	O
up	-	495	O
to	-	498	O
12	-	501	O
.	-	503	O
8	-	504	O
g	-	506	O
with	-	508	O
acute	-	513	O
renal	-	519	O
failure	-	525	O
.	-	532	O

After	18754075	534	O
discontinuing	-	540	O
the	-	554	O
oral	-	558	O
alendronate	-	563	B
,	-	574	O
the	-	576	O
patient	-	580	O
underwent	-	588	O
six	-	598	O
cycles	-	602	O
of	-	609	O
hemodialysis	-	612	O
and	-	625	O
four	-	629	O
cycles	-	634	O
of	-	641	O
LDL	-	644	O
apheresis	-	648	O
.	-	657	O

Urinary	18754075	659	O
volume	-	667	O
and	-	674	O
serum	-	678	O
creatinine	-	684	B
levels	-	695	O
recovered	-	702	O
to	-	712	O
the	-	715	O
normal	-	719	O
range	-	726	O
,	-	731	O
with	-	733	O
urinary	-	738	O
protein	-	746	O
disappearing	-	754	O
completely	-	767	O
within	-	778	O
40	-	785	O
days	-	788	O
.	-	792	O

This	18754075	794	O
report	-	799	O
demonstrates	-	806	O
that	-	819	O
not	-	824	O
only	-	828	O
intravenous	-	833	O
,	-	844	O
but	-	846	O
also	-	850	O
oral	-	855	O
bisphosphonates	-	860	B
can	-	876	O
aggravate	-	880	O
proteinuria	-	890	O
and	-	902	O
acute	-	906	O
renal	-	912	O
failure	-	918	O
.	-	925	O

Serum	18768591	0	O
-	-	5	O
and	-	7	O
glucocorticoid	-	11	O
-	-	25	O
inducible	-	26	O
kinase	-	36	O
1	-	43	O
in	-	45	O
doxorubicin	-	48	B
-	-	59	O
induced	-	60	O
nephrotic	-	68	O
syndrome	-	78	O
.	-	86	O

Doxorubicin	18768591	88	B
-	-	99	O
induced	-	100	O
nephropathy	-	108	O
leads	-	120	O
to	-	126	O
epithelial	-	129	O
sodium	-	140	B
channel	-	147	O
(	-	155	O
ENaC	-	156	O
)	-	160	O
-	-	161	O
dependent	-	162	O
volume	-	172	O
retention	-	179	O
and	-	189	O
renal	-	193	O
fibrosis	-	199	O
.	-	207	O

The	18768591	209	O
aldosterone	-	213	B
-	-	224	O
sensitive	-	225	O
serum	-	235	O
-	-	240	O
and	-	242	O
glucocorticoid	-	246	O
-	-	260	O
inducible	-	261	O
kinase	-	271	O
SGK1	-	278	O
has	-	283	O
been	-	287	O
shown	-	292	O
to	-	298	O
participate	-	301	O
in	-	313	O
the	-	316	O
stimulation	-	320	O
of	-	332	O
ENaC	-	335	O
and	-	340	O
to	-	344	O
mediate	-	347	O
renal	-	355	O
fibrosis	-	361	O
following	-	370	O
mineralocorticoid	-	380	O
and	-	398	O
salt	-	402	O
excess	-	407	O
.	-	413	O

The	18768591	415	O
present	-	419	O
study	-	427	O
was	-	433	O
performed	-	437	O
to	-	447	O
elucidate	-	450	O
the	-	460	O
role	-	464	O
of	-	469	O
SGK1	-	472	O
in	-	477	O
the	-	480	O
volume	-	484	O
retention	-	491	O
and	-	501	O
fibrosis	-	505	O
during	-	514	O
nephrotic	-	521	O
syndrome	-	531	O
.	-	539	O

To	18768591	541	O
this	-	544	O
end	-	549	O
,	-	552	O
doxorubicin	-	554	B
(	-	566	O
15	-	567	O
mug	-	570	O
/	-	573	O
g	-	574	O
body	-	576	O
wt	-	581	O
)	-	583	O
was	-	585	O
injected	-	589	O
intravenously	-	598	O
into	-	612	O
gene	-	617	O
-	-	621	O
targeted	-	622	O
mice	-	631	O
lacking	-	636	O
SGK1	-	644	O
(	-	649	O
sgk1	-	650	O
(	-	654	O
-	-	655	O
/	-	656	O
-	-	657	O
)	-	658	O
)	-	659	O
and	-	661	O
their	-	665	O
wild	-	671	O
-	-	675	O
type	-	676	O
littermates	-	681	O
(	-	693	O
sgk1	-	694	O
(	-	698	O
+	-	699	O
/	-	700	O
+	-	701	O
)	-	702	O
)	-	703	O
.	-	704	O

Doxorubicin	18768591	706	B
treatment	-	718	O
resulted	-	728	O
in	-	737	O
heavy	-	740	O
proteinuria	-	746	O
(	-	758	O
>	-	759	O
100	-	760	O
mg	-	764	O
protein	-	767	O
/	-	774	O
mg	-	775	O
crea	-	778	O
)	-	782	O
in	-	784	O
15	-	787	O
/	-	789	O
44	-	790	O
of	-	793	O
sgk1	-	796	O
(	-	800	O
+	-	801	O
/	-	802	O
+	-	803	O
)	-	804	O
and	-	806	O
15	-	810	O
/	-	812	O
44	-	813	O
of	-	816	O
sgk1	-	819	O
(	-	823	O
-	-	824	O
/	-	825	O
-	-	826	O
)	-	827	O
mice	-	829	O
leading	-	834	O
to	-	842	O
severe	-	845	O
nephrotic	-	852	O
syndrome	-	862	O
with	-	871	O
ascites	-	876	O
,	-	883	O
lipidemia	-	885	O
,	-	894	O
and	-	896	O
hypoalbuminemia	-	900	O
in	-	916	O
both	-	919	O
genotypes	-	924	O
.	-	933	O

Plasma	18768591	935	O
aldosterone	-	942	B
levels	-	954	O
increased	-	961	O
in	-	971	O
nephrotic	-	974	O
mice	-	984	O
of	-	989	O
both	-	992	O
genotypes	-	997	O
and	-	1007	O
was	-	1011	O
followed	-	1015	O
by	-	1024	O
increased	-	1027	O
SGK1	-	1037	O
protein	-	1042	O
expression	-	1050	O
in	-	1061	O
sgk1	-	1064	O
(	-	1068	O
+	-	1069	O
/	-	1070	O
+	-	1071	O
)	-	1072	O
mice	-	1074	O
.	-	1078	O

Urinary	18768591	1080	O
sodium	-	1088	B
excretion	-	1095	O
reached	-	1105	O
signficantly	-	1113	O
lower	-	1126	O
values	-	1132	O
in	-	1139	O
sgk1	-	1142	O
(	-	1146	O
+	-	1147	O
/	-	1148	O
+	-	1149	O
)	-	1150	O
mice	-	1152	O
(	-	1157	O
15	-	1158	O
+	-	1161	O
/	-	1162	O
-	-	1163	O

5	18768591	1165	O
mumol	-	1167	O
/	-	1172	O
mg	-	1173	O
crea	-	1176	O
)	-	1180	O
than	-	1182	O
in	-	1187	O
sgk1	-	1190	O
(	-	1194	O
-	-	1195	O
/	-	1196	O
-	-	1197	O
)	-	1198	O

mice	18768591	1200	O
(	-	1205	O
35	-	1206	O
+	-	1209	O
/	-	1210	O
-	-	1211	O

5	18768591	1213	O
mumol	-	1215	O
/	-	1220	O
mg	-	1221	O
crea	-	1224	O
)	-	1228	O
and	-	1230	O
was	-	1234	O
associated	-	1238	O
with	-	1249	O
a	-	1254	O
significantly	-	1256	O
higher	-	1270	O
body	-	1277	O
weight	-	1282	O
gain	-	1289	O
in	-	1294	O
sgk1	-	1297	O
(	-	1301	O
+	-	1302	O
/	-	1303	O
+	-	1304	O
)	-	1305	O
compared	-	1307	O
with	-	1316	O
sgk1	-	1321	O
(	-	1325	O
-	-	1326	O
/	-	1327	O
-	-	1328	O
)	-	1329	O
mice	-	1331	O
(	-	1336	O
+	-	1337	O
6	-	1338	O
.	-	1339	O
6	-	1340	O
+	-	1342	O
/	-	1343	O
-	-	1344	O

0	18768591	1346	O
.	-	1347	O
7	-	1348	O
vs	-	1350	O
.	-	1352	O
+	-	1354	O
4	-	1355	O
.	-	1356	O
1	-	1357	O
+	-	1359	O
/	-	1360	O
-	-	1361	O

0	18768591	1363	O
.	-	1364	O
8	-	1365	O
g	-	1367	O
)	-	1368	O
.	-	1369	O

During	18768591	1371	O
the	-	1378	O
course	-	1382	O
of	-	1389	O
nephrotic	-	1392	O
syndrome	-	1402	O
,	-	1410	O
serum	-	1412	O
urea	-	1418	B
concentrations	-	1423	O
increased	-	1438	O
significantly	-	1448	O
faster	-	1462	O
in	-	1469	O
sgk1	-	1472	O
(	-	1476	O
-	-	1477	O
/	-	1478	O
-	-	1479	O
)	-	1480	O
mice	-	1482	O
than	-	1487	O
in	-	1492	O
sgk1	-	1495	O
(	-	1499	O
+	-	1500	O
/	-	1501	O
+	-	1502	O
)	-	1503	O
mice	-	1505	O
leading	-	1510	O
to	-	1518	O
uremia	-	1521	O
and	-	1528	O
a	-	1532	O
reduced	-	1534	O
median	-	1542	O
survival	-	1549	O
in	-	1558	O
sgk1	-	1561	O
(	-	1565	O
-	-	1566	O
/	-	1567	O
-	-	1568	O
)	-	1569	O
mice	-	1571	O
(	-	1576	O
29	-	1577	O
vs	-	1580	O
.	-	1582	O
40	-	1584	O
days	-	1587	O
in	-	1592	O
sgk1	-	1595	O
(	-	1599	O
+	-	1600	O
/	-	1601	O
+	-	1602	O
)	-	1603	O
mice	-	1605	O
)	-	1609	O
.	-	1610	O

In	18768591	1612	O
conclusion	-	1615	O
,	-	1625	O
gene	-	1627	O
-	-	1631	O
targeted	-	1632	O
mice	-	1641	O
lacking	-	1646	O
SGK1	-	1654	O
showed	-	1659	O
blunted	-	1666	O
volume	-	1674	O
retention	-	1681	O
,	-	1690	O
yet	-	1692	O
were	-	1696	O
not	-	1701	O
protected	-	1705	O
against	-	1715	O
renal	-	1723	O
fibrosis	-	1729	O
during	-	1738	O
experimental	-	1745	O
nephrotic	-	1758	O
syndrome	-	1768	O
.	-	1776	O

Severe	19299179	0	O
and	-	7	O
long	-	11	O
lasting	-	16	O
cholestasis	-	24	O
after	-	36	O
high	-	42	O
-	-	46	O
dose	-	47	O
co	-	52	B
-	-	54	I
trimoxazole	-	55	I
treatment	-	67	O
for	-	77	O
Pneumocystis	-	81	O
pneumonia	-	94	O
in	-	104	O
HIV	-	107	O
-	-	110	O
infected	-	111	O
patients	-	120	O
-	-	128	O
-	-	129	O
a	-	130	O
report	-	132	O
of	-	139	O
two	-	142	O
cases	-	146	O
.	-	151	O

Pneumocystis	19299179	153	O
pneumonia	-	166	O
(	-	176	O
PCP	-	177	O
)	-	180	O
,	-	181	O
a	-	183	O
common	-	185	O
opportunistic	-	192	O
infection	-	206	O
in	-	216	O
HIV	-	219	O
-	-	222	O
infected	-	223	O
individuals	-	232	O
,	-	243	O
is	-	245	O
generally	-	248	O
treated	-	258	O
with	-	266	O
high	-	271	O
doses	-	276	O
of	-	282	O
co	-	285	B
-	-	287	I
trimoxazole	-	288	I
.	-	299	O

However	19299179	301	O
,	-	308	O
treatment	-	310	O
is	-	320	O
often	-	323	O
limited	-	329	O
by	-	337	O
adverse	-	340	O
effects	-	348	O
.	-	355	O

Here	19299179	357	O
,	-	361	O
we	-	363	O
report	-	366	O
two	-	373	O
cases	-	377	O
of	-	383	O
severely	-	386	O
immunocompromised	-	395	O
HIV	-	413	O
-	-	416	O
infected	-	417	O
patients	-	426	O
who	-	435	O
developed	-	439	O
severe	-	449	O
intrahepatic	-	456	O
cholestasis	-	469	O
,	-	480	O
and	-	482	O
in	-	486	O
one	-	489	O
patient	-	493	O
lesions	-	501	O
mimicking	-	509	O
liver	-	519	O
abscess	-	525	O
formation	-	533	O
on	-	543	O
radiologic	-	546	O
exams	-	557	O
,	-	562	O
during	-	564	O
co	-	571	B
-	-	573	I
trimoxazole	-	574	I
treatment	-	586	O
for	-	596	O
PCP	-	600	O
.	-	603	O

Whereas	19299179	605	O
patient	-	613	O
1	-	621	O
showed	-	623	O
lesions	-	630	O
of	-	638	O
up	-	641	O
to	-	644	O
1	-	647	O
cm	-	649	O
readily	-	652	O
detectable	-	660	O
on	-	671	O
magnetic	-	674	O
resonance	-	683	O
imaging	-	693	O
under	-	701	O
prolonged	-	707	O
co	-	717	B
-	-	719	I
trimoxazole	-	720	I
treatment	-	732	O
,	-	741	O
therapy	-	743	O
of	-	751	O
patient	-	754	O
2	-	762	O
was	-	764	O
switched	-	768	O
early	-	777	O
.	-	782	O

Clinically	19356053	0	O
significant	-	11	O
proteinuria	-	23	O
following	-	35	O
the	-	45	O
administration	-	49	O
of	-	64	O
sirolimus	-	67	B
to	-	77	O
renal	-	80	O
transplant	-	86	O
recipients	-	97	O
.	-	107	O

BACKGROUND	19356053	109	O
:	-	119	O

Sirolimus	19356053	121	B
is	-	131	O
the	-	134	O
latest	-	138	O
immunosuppressive	-	145	O
agent	-	163	O
used	-	169	O
to	-	174	O
prevent	-	177	O
rejection	-	185	O
,	-	194	O
and	-	196	O
may	-	200	O
have	-	204	O
less	-	209	O
nephrotoxicity	-	214	O
than	-	229	O
calcineurin	-	234	O
inhibitor	-	246	O
(	-	256	O
CNI	-	257	O
)	-	260	O
-	-	261	O
based	-	262	O
regimens	-	268	O
.	-	276	O

To	19356053	278	O
date	-	281	O
there	-	286	O
has	-	292	O
been	-	296	O
little	-	301	O
documentation	-	308	O
of	-	322	O
clinically	-	325	O
significant	-	336	O
proteinuria	-	348	O
linked	-	360	O
with	-	367	O
the	-	372	O
use	-	376	O
of	-	380	O
sirolimus	-	383	B
.	-	392	O

We	19356053	394	O
have	-	397	O
encountered	-	402	O
several	-	414	O
patients	-	422	O
who	-	431	O
developed	-	435	O
substantial	-	445	O
proteinuria	-	457	O
associated	-	469	O
with	-	480	O
sirolimus	-	485	B
use	-	495	O
.	-	498	O

In	19356053	500	O
each	-	503	O
patient	-	508	O
,	-	515	O
the	-	517	O
close	-	521	O
temporal	-	527	O
association	-	536	O
between	-	548	O
the	-	556	O
commencement	-	560	O
of	-	573	O
sirolimus	-	576	B
therapy	-	586	O
and	-	594	O
proteinuria	-	598	O
implicated	-	610	O
sirolimus	-	621	B
as	-	631	O
the	-	634	O
most	-	638	O
likely	-	643	O
etiology	-	650	O
of	-	659	O
the	-	662	O
proteinuria	-	666	O
.	-	677	O

METHODS	19356053	679	O
:	-	686	O

We	19356053	688	O
analyzed	-	691	O
the	-	700	O
clinical	-	704	O
and	-	713	O
laboratory	-	717	O
information	-	728	O
available	-	740	O
for	-	750	O
all	-	754	O
119	-	758	O
patients	-	762	O
transplanted	-	771	O
at	-	784	O
the	-	787	O
Washington	-	791	O
Hospital	-	802	O
Center	-	811	O
between	-	818	O
1999	-	826	O
-	-	830	O
2003	-	831	O
for	-	836	O
whom	-	840	O
sirolimus	-	845	B
was	-	855	O
a	-	859	O
component	-	861	O
of	-	871	O
their	-	874	O
immunosuppressant	-	880	O
regimen	-	898	O
.	-	905	O

In	19356053	907	O
these	-	910	O
patients	-	916	O
,	-	924	O
the	-	926	O
magnitude	-	930	O
of	-	940	O
proteinuria	-	943	O
was	-	955	O
assessed	-	959	O
on	-	968	O
morning	-	971	O
urine	-	979	O
samples	-	985	O
by	-	993	O
turbidometric	-	996	O
measurement	-	1010	O
or	-	1022	O
random	-	1025	O
urine	-	1032	O
protein	-	1038	O
:	-	1045	O
creatinine	-	1046	B
ratios	-	1057	O
,	-	1063	O
an	-	1065	O
estimate	-	1068	O
of	-	1077	O
grams	-	1080	O
of	-	1086	O
proteinuria	-	1089	O
/	-	1100	O
day	-	1101	O
.	-	1104	O

Laboratory	19356053	1106	O
results	-	1117	O
were	-	1125	O
compared	-	1130	O
between	-	1139	O
prior	-	1147	O
,	-	1152	O
during	-	1154	O
and	-	1161	O
following	-	1165	O
sirolimus	-	1175	B
use	-	1185	O
.	-	1188	O

RESULTS	19356053	1190	O
:	-	1197	O

Twenty	19356053	1199	O
-	-	1205	O
eight	-	1206	O
patients	-	1212	O
(	-	1221	O
24	-	1222	O
%	-	1224	O
)	-	1225	O
developed	-	1227	O
increased	-	1237	O
proteinuria	-	1247	O
from	-	1259	O
baseline	-	1264	O
during	-	1273	O
their	-	1280	O
post	-	1286	O
-	-	1290	O
transplantation	-	1291	O
course	-	1307	O
.	-	1313	O

In	19356053	1315	O
21	-	1318	O
patients	-	1321	O
an	-	1330	O
alternative	-	1333	O
cause	-	1345	O
of	-	1351	O
proteinuria	-	1354	O
was	-	1366	O
either	-	1370	O
obvious	-	1377	O
or	-	1385	O
insufficient	-	1388	O
data	-	1401	O
was	-	1406	O
available	-	1410	O
to	-	1420	O
be	-	1423	O
conclusive	-	1426	O
.	-	1436	O

In	19356053	1438	O
7	-	1441	O
of	-	1443	O
the	-	1446	O
28	-	1450	O
patients	-	1453	O
there	-	1462	O
was	-	1468	O
a	-	1472	O
striking	-	1474	O
temporal	-	1483	O
association	-	1492	O
between	-	1504	O
the	-	1512	O
initiation	-	1516	O
of	-	1527	O
sirolimus	-	1530	B
and	-	1540	O
the	-	1544	O
development	-	1548	O
of	-	1560	O
nephrotic	-	1563	O
-	-	1572	O
range	-	1573	O
proteinuria	-	1579	O
.	-	1590	O

Proteinuria	19356053	1592	O
correlated	-	1604	O
most	-	1615	O
strongly	-	1620	O
with	-	1629	O
sirolimus	-	1634	B
therapy	-	1644	O
when	-	1652	O
compared	-	1657	O
to	-	1666	O
other	-	1669	O
demographic	-	1675	O
and	-	1687	O
clinical	-	1691	O
variables	-	1700	O
.	-	1709	O

In	19356053	1711	O
most	-	1714	O
patients	-	1719	O
,	-	1727	O
discontinuation	-	1729	O
of	-	1745	O
sirolimus	-	1748	B
resulted	-	1758	O
in	-	1767	O
a	-	1770	O
decrease	-	1772	O
,	-	1780	O
but	-	1782	O
not	-	1786	O
resolution	-	1790	O
,	-	1800	O
of	-	1802	O
proteinuria	-	1805	O
.	-	1816	O

CONCLUSIONS	19356053	1818	O
:	-	1829	O

Sirolimus	19356053	1831	B
induces	-	1841	O
or	-	1849	O
aggravates	-	1852	O
pre	-	1863	O
-	-	1866	O
existing	-	1867	O
proteinuria	-	1876	O
in	-	1888	O
an	-	1891	O
unpredictable	-	1894	O
subset	-	1908	O
of	-	1915	O
renal	-	1918	O
allograft	-	1924	O
recipients	-	1934	O
.	-	1944	O

Proteinuria	19356053	1946	O
may	-	1958	O
improve	-	1962	O
,	-	1969	O
but	-	1971	O
does	-	1975	O
not	-	1980	O
resolve	-	1984	O
,	-	1991	O
when	-	1993	O
sirolimus	-	1998	B
is	-	2008	O
withdrawn	-	2011	O
.	-	2020	O

Comparative	19729346	0	O
cognitive	-	12	O
and	-	22	O
subjective	-	26	O
side	-	37	O
effects	-	42	O
of	-	50	O
immediate	-	53	O
-	-	62	O
release	-	63	O
oxycodone	-	71	B
in	-	81	O
healthy	-	84	O
middle	-	92	O
-	-	98	O
aged	-	99	O
and	-	104	O
older	-	108	O
adults	-	114	O
.	-	120	O

This	19729346	122	O
study	-	127	O
measured	-	133	O
the	-	142	O
objective	-	146	O
and	-	156	O
subjective	-	160	O
neurocognitive	-	171	O
effects	-	186	O
of	-	194	O
a	-	197	O
single	-	199	O
10	-	206	O
-	-	208	O
mg	-	209	O
dose	-	212	O
of	-	217	O
immediate	-	220	O
-	-	229	O
release	-	230	O
oxycodone	-	238	B
in	-	248	O
healthy	-	251	O
,	-	258	O
older	-	260	O
(	-	266	O
>	-	267	O
65	-	269	O
years	-	272	O
)	-	277	O
,	-	278	O
and	-	280	O
middle	-	284	O
-	-	290	O
aged	-	291	O
(	-	296	O
35	-	297	O
to	-	300	O
55	-	303	O
years	-	306	O
)	-	311	O
adults	-	313	O
who	-	320	O
were	-	324	O
not	-	329	O
suffering	-	333	O
from	-	343	O
chronic	-	348	O
or	-	356	O
significant	-	359	O
daily	-	371	O
pain	-	377	O
.	-	381	O

Seventy	19729346	383	O
-	-	390	O
one	-	391	O
participants	-	395	O
completed	-	408	O
2	-	418	O
separate	-	420	O
study	-	429	O
days	-	435	O
and	-	440	O
were	-	444	O
blind	-	449	O
to	-	455	O
medication	-	458	O
condition	-	469	O
(	-	479	O
placebo	-	480	O
,	-	487	O
10	-	489	O
-	-	491	O
mg	-	492	O
oxycodone	-	495	B
)	-	504	O
.	-	505	O

Plasma	19729346	507	O
oxycodone	-	514	B
concentration	-	524	O
peaked	-	538	O
between	-	545	O
60	-	553	O
and	-	556	O
90	-	560	O
minutes	-	563	O
postdose	-	571	O
(	-	580	O
P	-	581	O
<	-	583	O
.	-	585	O
01	-	586	O
)	-	588	O
and	-	590	O
pupil	-	594	O
size	-	600	O
,	-	604	O
an	-	606	O
indication	-	609	O
of	-	620	O
physiological	-	623	O
effects	-	637	O
of	-	645	O
the	-	648	O
medication	-	652	O
,	-	662	O
peaked	-	664	O
at	-	671	O
approximately	-	674	O
90	-	688	O
to	-	691	O
120	-	694	O
minutes	-	698	O
postdose	-	706	O
(	-	715	O
P	-	716	O
<	-	718	O
.	-	720	O
01	-	721	O
)	-	723	O
.	-	724	O

Significant	19729346	726	O
declines	-	738	O
in	-	747	O
simple	-	750	O
and	-	757	O
sustained	-	761	O
attention	-	771	O
,	-	780	O
working	-	782	O
memory	-	790	O
,	-	796	O
and	-	798	O
verbal	-	802	O
memory	-	809	O
were	-	816	O
observed	-	821	O
at	-	830	O
1	-	833	O
hour	-	835	O
postdose	-	840	O
compared	-	849	O
to	-	858	O
baseline	-	861	O
for	-	870	O
both	-	874	O
age	-	879	O
groups	-	883	O
with	-	890	O
a	-	895	O
trend	-	897	O
toward	-	903	O
return	-	910	O
to	-	917	O
baseline	-	920	O
by	-	929	O
5	-	932	O
hours	-	934	O
postdose	-	940	O
.	-	948	O

For	19729346	950	O
almost	-	954	O
all	-	961	O
cognitive	-	965	O
measures	-	975	O
,	-	983	O
there	-	985	O
were	-	991	O
no	-	996	O
medication	-	999	O
by	-	1010	O
age	-	1013	O
-	-	1016	O
interaction	-	1017	O
effects	-	1029	O
,	-	1036	O
which	-	1038	O
indicates	-	1044	O
that	-	1054	O
the	-	1059	O
2	-	1063	O
age	-	1065	O
groups	-	1069	O
exhibited	-	1076	O
similar	-	1086	O
responses	-	1094	O
to	-	1104	O
the	-	1107	O
medication	-	1111	O
challenge	-	1122	O
.	-	1131	O

This	19729346	1133	O
study	-	1138	O
suggests	-	1144	O
that	-	1153	O
for	-	1158	O
healthy	-	1162	O
older	-	1170	O
adults	-	1176	O
who	-	1183	O
are	-	1187	O
not	-	1191	O
suffering	-	1195	O
from	-	1205	O
chronic	-	1210	O
pain	-	1218	O
,	-	1222	O
neurocognitive	-	1224	O
and	-	1239	O
pharmacodynamic	-	1243	O
changes	-	1259	O
in	-	1267	O
response	-	1270	O
to	-	1279	O
a	-	1282	O
10	-	1284	O
-	-	1286	O
mg	-	1287	O
dose	-	1290	O
of	-	1295	O
immediate	-	1298	O
-	-	1307	O
release	-	1308	O
oxycodone	-	1316	B
are	-	1326	O
similar	-	1330	O
to	-	1338	O
those	-	1341	O
observed	-	1347	O
for	-	1356	O
middle	-	1360	O
-	-	1366	O
aged	-	1367	O
adults	-	1372	O
.	-	1378	O

PERSPECTIVE	19729346	1380	O
:	-	1391	O
Study	-	1393	O
findings	-	1399	O
indicate	-	1408	O
that	-	1417	O
the	-	1422	O
metabolism	-	1426	O
,	-	1436	O
neurocognitive	-	1438	O
effects	-	1453	O
,	-	1460	O
and	-	1462	O
physical	-	1466	O
side	-	1475	O
effects	-	1480	O
of	-	1488	O
oral	-	1491	O
oxycodone	-	1496	B
are	-	1506	O
similar	-	1510	O
for	-	1518	O
healthy	-	1522	O
middle	-	1530	O
-	-	1536	O
aged	-	1537	O
and	-	1542	O
older	-	1546	O
adults	-	1552	O
.	-	1558	O

Therefore	19729346	1560	O
,	-	1569	O
clinicians	-	1571	O
should	-	1582	O
not	-	1589	O
avoid	-	1593	O
prescribing	-	1599	O
oral	-	1611	O
opioids	-	1616	O
to	-	1624	O
older	-	1627	O
adults	-	1633	O
based	-	1640	O
on	-	1646	O
the	-	1649	O
belief	-	1653	O
that	-	1660	O
older	-	1665	O
adults	-	1671	O
are	-	1678	O
at	-	1682	O
higher	-	1685	O
risk	-	1692	O
for	-	1697	O
side	-	1701	O
effects	-	1706	O
than	-	1714	O
younger	-	1719	O
adults	-	1727	O
.	-	1733	O

Normalizing	20080983	0	O
effects	-	12	O
of	-	20	O
modafinil	-	23	B
on	-	33	O
sleep	-	36	O
in	-	42	O
chronic	-	45	O
cocaine	-	53	B
users	-	61	O
.	-	66	O

OBJECTIVE	20080983	68	O
:	-	77	O
The	-	79	O
purpose	-	83	O
of	-	91	O
the	-	94	O
present	-	98	O
study	-	106	O
was	-	112	O
to	-	116	O
determine	-	119	O
the	-	129	O
effect	-	133	O
of	-	140	O
morning	-	143	O
-	-	150	O
dosed	-	151	O
modafinil	-	157	B
on	-	167	O
sleep	-	170	O
and	-	176	O
daytime	-	180	O
sleepiness	-	188	O
in	-	199	O
chronic	-	202	O
cocaine	-	210	B
users	-	218	O
.	-	223	O

METHOD	20080983	225	O
:	-	231	O

Twenty	20080983	233	O
cocaine	-	240	B
-	-	247	O
dependent	-	248	O
participants	-	258	O
were	-	271	O
randomly	-	276	O
assigned	-	285	O
to	-	294	O
receive	-	297	O
modafinil	-	305	B
,	-	314	O
400	-	316	O
mg	-	320	O
(	-	323	O
N	-	324	O
=	-	325	O
10	-	326	O
)	-	328	O
,	-	329	O
or	-	331	O
placebo	-	334	O
(	-	342	O
N	-	343	O
=	-	344	O
10	-	345	O
)	-	347	O
every	-	349	O
morning	-	355	O
at	-	363	O
7	-	366	O
:	-	367	O
30	-	368	O
a	-	371	O
.	-	372	O
m	-	373	O
.	-	374	O
for	-	376	O
16	-	380	O
days	-	383	O
in	-	388	O
an	-	391	O
inpatient	-	394	O
,	-	403	O
double	-	405	O
-	-	411	O
blind	-	412	O
randomized	-	418	O
trial	-	429	O
.	-	434	O

Participants	20080983	436	O
underwent	-	449	O
polysomnographic	-	459	O
sleep	-	476	O
recordings	-	482	O
on	-	493	O
days	-	496	O
1	-	501	O
to	-	503	O
3	-	506	O
,	-	507	O
7	-	509	O
to	-	511	O
9	-	514	O
,	-	515	O
and	-	517	O
14	-	521	O
to	-	524	O
16	-	527	O
(	-	530	O
first	-	531	O
,	-	536	O
second	-	538	O
,	-	544	O
and	-	546	O
third	-	550	O
weeks	-	556	O
of	-	562	O
abstinence	-	565	O
)	-	575	O
.	-	576	O

The	20080983	578	O
Multiple	-	582	O
Sleep	-	591	O
Latency	-	597	O
Test	-	605	O
was	-	610	O
performed	-	614	O
at	-	624	O
11	-	627	O
:	-	629	O
30	-	630	O
a	-	633	O
.	-	634	O
m	-	635	O
.	-	636	O
,	-	637	O
2	-	639	O
:	-	640	O
00	-	641	O
p	-	644	O
.	-	645	O
m	-	646	O
.	-	647	O
,	-	648	O
and	-	650	O
4	-	654	O
:	-	655	O
30	-	656	O
p	-	659	O
.	-	660	O
m	-	661	O
.	-	662	O
on	-	664	O
days	-	667	O
2	-	672	O
,	-	673	O
8	-	675	O
,	-	676	O
and	-	678	O
15	-	682	O
.	-	684	O

For	20080983	686	O
comparison	-	690	O
of	-	701	O
sleep	-	704	O
architecture	-	710	O
variables	-	723	O
,	-	732	O
12	-	734	O
healthy	-	737	O
comparison	-	745	O
participants	-	756	O
underwent	-	769	O
a	-	779	O
single	-	781	O
night	-	788	O
of	-	794	O
experimental	-	797	O
polysomnography	-	810	O
that	-	826	O
followed	-	831	O
1	-	840	O
night	-	842	O
of	-	848	O
accommodation	-	851	O
polysomnography	-	865	O
.	-	880	O

RESULTS	20080983	882	O
:	-	889	O

Progressive	20080983	891	O
abstinence	-	903	O
from	-	914	O
cocaine	-	919	B
was	-	927	O
associated	-	931	O
with	-	942	O
worsening	-	947	O
of	-	957	O
all	-	960	O
measured	-	964	O
polysomnographic	-	973	O
sleep	-	990	O
outcomes	-	996	O
.	-	1004	O

Compared	20080983	1006	O
with	-	1015	O
placebo	-	1020	O
,	-	1027	O
modafinil	-	1029	B
decreased	-	1039	O
nighttime	-	1049	O
sleep	-	1059	O
latency	-	1065	O
and	-	1073	O
increased	-	1077	O
slow	-	1087	O
-	-	1091	O
wave	-	1092	O
sleep	-	1097	O
time	-	1103	O
in	-	1108	O
cocaine	-	1111	B
-	-	1118	O
dependent	-	1119	O
participants	-	1129	O
.	-	1141	O

The	20080983	1143	O
effect	-	1147	O
of	-	1154	O
modafinil	-	1157	B
interacted	-	1167	O
with	-	1178	O
the	-	1183	O
abstinence	-	1187	O
week	-	1198	O
and	-	1203	O
was	-	1207	O
associated	-	1211	O
with	-	1222	O
longer	-	1227	O
total	-	1234	O
sleep	-	1240	O
time	-	1246	O
and	-	1251	O
shorter	-	1255	O
REM	-	1263	O
sleep	-	1267	O
latency	-	1273	O
in	-	1281	O
the	-	1284	O
third	-	1288	O
week	-	1294	O
of	-	1299	O
abstinence	-	1302	O
.	-	1312	O

Comparison	20080983	1314	O
of	-	1325	O
slow	-	1328	O
-	-	1332	O
wave	-	1333	O
sleep	-	1338	O
time	-	1344	O
,	-	1348	O
total	-	1350	O
sleep	-	1356	O
time	-	1362	O
,	-	1366	O
and	-	1368	O
sleep	-	1372	O
latency	-	1378	O
in	-	1386	O
cocaine	-	1389	B
-	-	1396	O
dependent	-	1397	O
and	-	1407	O
healthy	-	1411	O
participants	-	1419	O
revealed	-	1432	O
a	-	1441	O
normalizing	-	1443	O
effect	-	1455	O
of	-	1462	O
modafinil	-	1465	B
in	-	1475	O
cocaine	-	1478	B
-	-	1485	O
dependent	-	1486	O
participants	-	1496	O
.	-	1508	O

Modafinil	20080983	1510	B
was	-	1520	O
associated	-	1524	O
with	-	1535	O
increased	-	1540	O
daytime	-	1550	O
sleep	-	1558	O
latency	-	1564	O
,	-	1571	O
as	-	1573	O
measured	-	1576	O
by	-	1585	O
the	-	1588	O
Multiple	-	1592	O
Sleep	-	1601	O
Latency	-	1607	O
Test	-	1615	O
,	-	1619	O
and	-	1621	O
a	-	1625	O
nearly	-	1627	O
significant	-	1634	O
decrease	-	1646	O
in	-	1655	O
subjective	-	1658	O
daytime	-	1669	O
sleepiness	-	1677	O
.	-	1687	O

CONCLUSIONS	20080983	1689	O
:	-	1700	O

Morning	20080983	1702	O
-	-	1709	O
dosed	-	1710	O
modafinil	-	1716	B
promotes	-	1726	O
nocturnal	-	1735	O
sleep	-	1745	O
,	-	1750	O
normalizes	-	1752	O
sleep	-	1763	O
architecture	-	1769	O
,	-	1781	O
and	-	1783	O
decreases	-	1787	O
daytime	-	1797	O
sleepiness	-	1805	O
in	-	1816	O
abstinent	-	1819	O
cocaine	-	1829	B
users	-	1837	O
.	-	1842	O

These	20080983	1844	O
effects	-	1850	O
may	-	1858	O
be	-	1862	O
relevant	-	1865	O
in	-	1874	O
the	-	1877	O
treatment	-	1881	O
of	-	1891	O
cocaine	-	1894	B
dependence	-	1902	O
.	-	1912	O

Efficacy	20520283	0	O
and	-	9	O
safety	-	13	O
of	-	20	O
asenapine	-	23	B
in	-	33	O
a	-	36	O
placebo	-	38	O
-	-	45	O
and	-	47	O
haloperidol	-	51	B
-	-	62	O
controlled	-	63	O
trial	-	74	O
in	-	80	O
patients	-	83	O
with	-	92	O
acute	-	97	O
exacerbation	-	103	O
of	-	116	O
schizophrenia	-	119	O
.	-	132	O

Asenapine	20520283	134	B
is	-	144	O
approved	-	147	O
by	-	156	O
the	-	159	O
Food	-	163	O
and	-	168	O
Drugs	-	172	O
Administration	-	178	O
in	-	193	O
adults	-	196	O
for	-	203	O
acute	-	207	O
treatment	-	213	O
of	-	223	O
schizophrenia	-	226	O
or	-	240	O
of	-	243	O
manic	-	246	O
or	-	252	O
mixed	-	255	O
episodes	-	261	O
associated	-	270	O
with	-	281	O
bipolar	-	286	O
I	-	294	O
disorder	-	296	O
with	-	305	O
or	-	310	O
without	-	313	O
psychotic	-	321	O
features	-	331	O
.	-	339	O

In	20520283	341	O
a	-	344	O
double	-	346	O
-	-	352	O
blind	-	353	O
6	-	359	O
-	-	360	O
week	-	361	O
trial	-	366	O
,	-	371	O
458	-	373	O
patients	-	377	O
with	-	386	O
acute	-	391	O
schizophrenia	-	397	O
were	-	411	O
randomly	-	416	O
assigned	-	425	O
to	-	434	O
fixed	-	437	O
-	-	442	O
dose	-	443	O
treatment	-	448	O
with	-	458	O
asenapine	-	463	B
at	-	473	O
5	-	476	O
mg	-	478	O
twice	-	481	O
daily	-	487	O
(	-	493	O
BID	-	494	O
)	-	497	O
,	-	498	O
asenapine	-	500	B
at	-	510	O
10	-	513	O
mg	-	516	O
BID	-	519	O
,	-	522	O
placebo	-	524	O
,	-	531	O
or	-	533	O
haloperidol	-	536	B
at	-	548	O
4	-	551	O
mg	-	553	O
BID	-	556	O
(	-	560	O
to	-	561	O
verify	-	564	O
assay	-	571	O
sensitivity	-	577	O
)	-	588	O
.	-	589	O

With	20520283	591	O
last	-	596	O
observations	-	601	O
carried	-	614	O
forward	-	622	O
(	-	630	O
LOCF	-	631	O
)	-	635	O
,	-	636	O
mean	-	638	O
Positive	-	643	O
and	-	652	O
Negative	-	656	O
Syndrome	-	665	O
Scale	-	674	O
total	-	680	O
score	-	686	O
reductions	-	692	O
from	-	703	O
baseline	-	708	O
to	-	717	O
endpoint	-	720	O
were	-	729	O
significantly	-	734	O
greater	-	748	O
with	-	756	O
asenapine	-	761	B
at	-	771	O
5	-	774	O
mg	-	776	O
BID	-	779	O
(	-	783	O
-	-	784	O
16	-	785	O
.	-	787	O
2	-	788	O
)	-	789	O
and	-	791	O
haloperidol	-	795	B
(	-	807	O
-	-	808	O
15	-	809	O
.	-	811	O
4	-	812	O
)	-	813	O
than	-	815	O
placebo	-	820	O
(	-	828	O
-	-	829	O
10	-	830	O
.	-	832	O
7	-	833	O
;	-	834	O
both	-	836	O
P	-	841	O
<	-	843	O
0	-	845	O
.	-	846	O
05	-	847	O
)	-	849	O
;	-	850	O

using	20520283	852	O
mixed	-	858	O
model	-	864	O
for	-	870	O
repeated	-	874	O
measures	-	883	O
(	-	892	O
MMRM	-	893	O
)	-	897	O
,	-	898	O
changes	-	900	O
at	-	908	O
day	-	911	O
42	-	915	O
were	-	918	O
significantly	-	923	O
greater	-	937	O
with	-	945	O
asenapine	-	950	B
at	-	960	O
5	-	963	O
and	-	965	O
10	-	969	O
mg	-	972	O
BID	-	975	O
(	-	979	O
-	-	980	O
21	-	981	O
.	-	983	O
3	-	984	O
and	-	986	O
-	-	990	O
19	-	991	O
.	-	993	O
4	-	994	O
,	-	995	O
respectively	-	997	O
)	-	1009	O
and	-	1011	O
haloperidol	-	1015	B
(	-	1027	O
-	-	1028	O
20	-	1029	O
.	-	1031	O
0	-	1032	O
)	-	1033	O
than	-	1035	O
placebo	-	1040	O
(	-	1048	O
-	-	1049	O
14	-	1050	O
.	-	1052	O
6	-	1053	O
;	-	1054	O
all	-	1056	O
P	-	1060	O
<	-	1062	O
0	-	1064	O
.	-	1065	O
05	-	1066	O
)	-	1068	O
.	-	1069	O

On	20520283	1071	O
the	-	1074	O
Positive	-	1078	O
and	-	1087	O
Negative	-	1091	O
Syndrome	-	1100	O
Scale	-	1109	O
positive	-	1115	O
subscale	-	1124	O
,	-	1132	O
all	-	1134	O
treatments	-	1138	O
were	-	1149	O
superior	-	1154	O
to	-	1163	O
placebo	-	1166	O
with	-	1174	O
LOCF	-	1179	O
and	-	1184	O
MMRM	-	1188	O
;	-	1192	O
asenapine	-	1194	B
at	-	1204	O
5	-	1207	O
mg	-	1209	O
BID	-	1212	O
was	-	1216	O
superior	-	1220	O
to	-	1229	O
placebo	-	1232	O
on	-	1240	O
the	-	1243	O
negative	-	1247	O
subscale	-	1256	O
with	-	1265	O
MMRM	-	1270	O
and	-	1275	O
on	-	1279	O
the	-	1282	O
general	-	1286	O
psychopathology	-	1294	O
subscale	-	1310	O
with	-	1319	O
LOCF	-	1324	O
and	-	1329	O
MMRM	-	1333	O
.	-	1337	O

Treatment	20520283	1339	O
-	-	1348	O
related	-	1349	O
adverse	-	1357	O
events	-	1365	O
(	-	1372	O
AEs	-	1373	O
)	-	1376	O
occurred	-	1378	O
in	-	1387	O
44	-	1390	O
%	-	1392	O
and	-	1394	O
52	-	1398	O
%	-	1400	O
,	-	1401	O
57	-	1403	O
%	-	1405	O
,	-	1406	O
and	-	1408	O
41	-	1412	O
%	-	1414	O
of	-	1416	O
the	-	1419	O
asenapine	-	1423	B
at	-	1433	O
5	-	1436	O
and	-	1438	O
10	-	1442	O
mg	-	1445	O
BID	-	1448	O
,	-	1451	O
haloperidol	-	1453	B
,	-	1464	O
and	-	1466	O
placebo	-	1470	O
groups	-	1478	O
,	-	1484	O
respectively	-	1486	O
.	-	1498	O

Extrapyramidal	20520283	1500	O
symptoms	-	1515	O
reported	-	1524	O
as	-	1533	O
AEs	-	1536	O
occurred	-	1540	O
in	-	1549	O
15	-	1552	O
%	-	1554	O
and	-	1556	O
18	-	1560	O
%	-	1562	O
,	-	1563	O
34	-	1565	O
%	-	1567	O
,	-	1568	O
and	-	1570	O
10	-	1574	O
%	-	1576	O
of	-	1578	O
the	-	1581	O
asenapine	-	1585	B
at	-	1595	O
5	-	1598	O
and	-	1600	O
10	-	1604	O
mg	-	1607	O
BID	-	1610	O
,	-	1613	O
haloperidol	-	1615	B
,	-	1626	O
and	-	1628	O
placebo	-	1632	O
groups	-	1640	O
,	-	1646	O
respectively	-	1648	O
.	-	1660	O

Across	20520283	1662	O
all	-	1669	O
groups	-	1673	O
,	-	1679	O
no	-	1681	O
more	-	1684	O
than	-	1689	O
5	-	1694	O
%	-	1695	O
of	-	1697	O
patients	-	1700	O
had	-	1709	O
clinically	-	1713	O
significant	-	1724	O
weight	-	1736	O
change	-	1743	O
.	-	1749	O

Post	20520283	1751	O
hoc	-	1756	O
analyses	-	1760	O
indicated	-	1769	O
that	-	1779	O
efficacy	-	1784	O
was	-	1793	O
similar	-	1797	O
with	-	1805	O
asenapine	-	1810	B
and	-	1820	O
haloperidol	-	1824	B
;	-	1835	O
greater	-	1837	O
contrasts	-	1845	O
were	-	1855	O
seen	-	1860	O
in	-	1865	O
AEs	-	1868	O
,	-	1871	O
especially	-	1873	O
extrapyramidal	-	1884	O
symptoms	-	1899	O
.	-	1907	O

Permeability	20588063	0	O
,	-	12	O
ultrastructural	-	14	O
changes	-	30	O
,	-	37	O
and	-	39	O
distribution	-	43	O
of	-	56	O
novel	-	59	O
proteins	-	65	O
in	-	74	O
the	-	77	O
glomerular	-	81	O
barrier	-	92	O
in	-	100	O
early	-	103	O
puromycin	-	109	B
aminonucleoside	-	119	I
nephrosis	-	135	O
.	-	144	O

BACKGROUND	20588063	146	O
/	-	156	O
AIMS	-	157	O
:	-	161	O

It	20588063	163	O
is	-	166	O
still	-	169	O
unclear	-	175	O
what	-	183	O
happens	-	188	O
in	-	196	O
the	-	199	O
glomerulus	-	203	O
when	-	214	O
proteinuria	-	219	O
starts	-	231	O
.	-	237	O

Using	20588063	239	O
puromycin	-	245	B
aminonucleoside	-	255	I
nephrosis	-	271	O
(	-	281	O
PAN	-	282	O
)	-	285	O
rats	-	287	O
,	-	291	O
we	-	293	O
studied	-	296	O
early	-	304	O
ultrastructural	-	310	O
and	-	326	O
permeability	-	330	O
changes	-	343	O
in	-	351	O
relation	-	354	O
to	-	363	O
the	-	366	O
expression	-	370	O
of	-	381	O
the	-	384	O
podocyte	-	388	O
-	-	396	O
associated	-	397	O
molecules	-	408	O
nephrin	-	418	O
,	-	425	O
a	-	427	O
-	-	428	O
actinin	-	429	O
,	-	436	O
dendrin	-	438	O
,	-	445	O
and	-	447	O
plekhh2	-	451	O
,	-	458	O
the	-	460	O
last	-	464	O
two	-	469	O
of	-	473	O
which	-	476	O
were	-	482	O
only	-	487	O
recently	-	492	O
discovered	-	501	O
in	-	512	O
podocytes	-	515	O
.	-	524	O

METHODS	20588063	526	O
:	-	533	O

Using	20588063	535	O
immune	-	541	O
stainings	-	548	O
,	-	557	O
semiquantitative	-	559	O
measurement	-	576	O
was	-	588	O
performed	-	592	O
under	-	602	O
the	-	608	O
electron	-	612	O
microscope	-	621	O
.	-	631	O

Permeability	20588063	633	O
was	-	646	O
assessed	-	650	O
using	-	659	O
isolated	-	665	O
kidney	-	674	O
perfusion	-	681	O
with	-	691	O
tracers	-	696	O
.	-	703	O

Possible	20588063	705	O
effects	-	714	O
of	-	722	O
ACE	-	725	O
inhibition	-	729	O
were	-	740	O
tested	-	745	O
.	-	751	O

RESULTS	20588063	753	O
:	-	760	O

By	20588063	762	O
day	-	765	O
2	-	769	O
,	-	770	O
some	-	772	O
patchy	-	777	O
foot	-	784	O
process	-	789	O
effacement	-	797	O
,	-	807	O
but	-	809	O
no	-	813	O
proteinuria	-	816	O
,	-	827	O
appeared	-	829	O
.	-	837	O

The	20588063	839	O
amount	-	843	O
of	-	850	O
nephrin	-	853	O
was	-	861	O
reduced	-	865	O
in	-	873	O
both	-	876	O
diseased	-	881	O
and	-	890	O
normal	-	894	O
areas	-	901	O
.	-	906	O

The	20588063	908	O
other	-	912	O
proteins	-	918	O
showed	-	927	O
few	-	934	O
changes	-	938	O
,	-	945	O
which	-	947	O
were	-	953	O
limited	-	958	O
to	-	966	O
diseased	-	969	O
areas	-	978	O
.	-	983	O

By	20588063	985	O
day	-	988	O
4	-	992	O
,	-	993	O
foot	-	995	O
process	-	1000	O
effacement	-	1008	O
was	-	1019	O
complete	-	1023	O
and	-	1032	O
proteinuria	-	1036	O
appeared	-	1048	O
in	-	1057	O
parallel	-	1060	O
with	-	1069	O
signs	-	1074	O
of	-	1080	O
size	-	1083	O
barrier	-	1088	O
damage	-	1096	O
.	-	1102	O

Nephrin	20588063	1104	O
decreased	-	1112	O
further	-	1122	O
,	-	1129	O
while	-	1131	O
dendrin	-	1137	O
and	-	1145	O
plekhh2	-	1149	O
also	-	1157	O
decreased	-	1162	O
but	-	1172	O
a	-	1176	O
-	-	1177	O
actinin	-	1178	O
remained	-	1186	O
unchanged	-	1195	O
.	-	1204	O

ACE	20588063	1206	O
inhibition	-	1210	O
had	-	1221	O
no	-	1225	O
significant	-	1228	O
protective	-	1240	O
effect	-	1251	O
.	-	1257	O

CONCLUSIONS	20588063	1259	O
:	-	1270	O

PAN	20588063	1272	O
glomeruli	-	1276	O
already	-	1286	O
showed	-	1294	O
significant	-	1301	O
pathology	-	1313	O
by	-	1323	O
day	-	1326	O
4	-	1330	O
,	-	1331	O
despite	-	1333	O
relatively	-	1341	O
mild	-	1352	O
proteinuria	-	1357	O
.	-	1368	O

This	20588063	1370	O
was	-	1375	O
preceded	-	1379	O
by	-	1388	O
altered	-	1391	O
nephrin	-	1399	O
expression	-	1407	O
,	-	1417	O
supporting	-	1419	O
its	-	1430	O
pivotal	-	1434	O
role	-	1442	O
in	-	1447	O
podocyte	-	1450	O
morphology	-	1459	O
.	-	1469	O

The	20588063	1471	O
novel	-	1475	O
proteins	-	1481	O
dendrin	-	1490	O
and	-	1498	O
plekhh2	-	1502	O
were	-	1510	O
both	-	1515	O
reduced	-	1520	O
,	-	1527	O
suggesting	-	1529	O
roles	-	1540	O
in	-	1546	O
PAN	-	1549	O
,	-	1552	O
whereas	-	1554	O
a	-	1562	O
-	-	1563	O
actinin	-	1564	O
was	-	1572	O
unchanged	-	1576	O
.	-	1585	O

Twin	19820426	0	O
preterm	-	5	O
neonates	-	13	O
with	-	22	O
cardiac	-	27	O
toxicity	-	35	O
related	-	44	O
to	-	52	O
lopinavir	-	55	B
/	-	64	I
ritonavir	-	65	I
therapy	-	75	O
.	-	82	O

We	19820426	84	O
report	-	87	O
twin	-	94	O
neonates	-	99	O
who	-	108	O
were	-	112	O
born	-	117	O
prematurely	-	122	O
at	-	134	O
32	-	137	O
weeks	-	140	O
of	-	146	O
gestation	-	149	O
to	-	159	O
a	-	162	O
mother	-	164	O
with	-	171	O
human	-	176	O
immunodeficiency	-	182	O
virus	-	199	O
infection	-	205	O
.	-	214	O

One	19820426	216	O
of	-	220	O
the	-	223	O
twins	-	227	O
developed	-	233	O
complete	-	243	O
heart	-	252	O
block	-	258	O
and	-	264	O
dilated	-	268	O
cardiomyopathy	-	276	O
related	-	291	O
to	-	299	O
lopinavir	-	302	B
/	-	311	I
ritonavir	-	312	I
therapy	-	322	O
,	-	329	O
a	-	331	O
boosted	-	333	O
protease	-	341	O
-	-	349	O
inhibitor	-	350	O
agent	-	360	O
,	-	365	O
while	-	367	O
the	-	373	O
other	-	377	O
twin	-	383	O
developed	-	388	O
mild	-	398	O
bradycardia	-	403	O
.	-	414	O

We	19820426	416	O
recommend	-	419	O
caution	-	429	O
in	-	437	O
the	-	440	O
use	-	444	O
of	-	448	O
lopinavir	-	451	B
/	-	460	I
ritonavir	-	461	I
in	-	471	O
the	-	474	O
immediate	-	478	O
neonatal	-	488	O
period	-	497	O
.	-	503	O

Learning	1616457	0	O
of	-	9	O
rats	-	12	O
under	-	17	O
amnesia	-	23	O
caused	-	31	O
by	-	38	O
pentobarbital	-	41	B
.	-	54	O

Dissociated	1616457	56	O
learning	-	68	O
of	-	77	O
rats	-	80	O
in	-	85	O
the	-	88	O
normal	-	92	O
state	-	99	O
and	-	105	O
the	-	109	O
state	-	113	O
of	-	119	O
amnesia	-	122	O
produced	-	130	O
by	-	139	O
pentobarbital	-	142	B
(	-	156	O
15	-	157	O
mg	-	160	O
/	-	162	O
kg	-	163	O
,	-	165	O
ip	-	167	O
)	-	169	O
was	-	171	O
carried	-	175	O
out	-	183	O
.	-	186	O

Rats	1616457	188	O
were	-	193	O
trained	-	198	O
to	-	206	O
approach	-	209	O
a	-	218	O
shelf	-	220	O
where	-	226	O
they	-	232	O
received	-	237	O
food	-	246	O
reinforcement	-	251	O
.	-	264	O

In	1616457	266	O
Group	-	269	O
1	-	275	O
the	-	277	O
rats	-	281	O
were	-	286	O
trained	-	291	O
under	-	299	O
the	-	305	O
influence	-	309	O
of	-	319	O
pentobarbital	-	322	B
to	-	336	O
run	-	339	O
to	-	343	O
the	-	346	O
same	-	350	O
shelf	-	355	O
as	-	361	O
in	-	364	O
the	-	367	O
normal	-	371	O
state	-	378	O
.	-	383	O

In	1616457	385	O
Group	-	388	O
2	-	394	O
the	-	396	O
rats	-	400	O
were	-	405	O
trained	-	410	O
to	-	418	O
approach	-	421	O
different	-	430	O
shelves	-	440	O
in	-	448	O
different	-	451	O
drug	-	461	O
states	-	466	O
.	-	472	O

It	1616457	474	O
was	-	477	O
shown	-	481	O
that	-	487	O
memory	-	492	O
dissociation	-	499	O
occurred	-	512	O
in	-	521	O
both	-	524	O
groups	-	529	O
.	-	535	O

Differences	1616457	537	O
in	-	549	O
the	-	552	O
parameters	-	556	O
of	-	567	O
training	-	570	O
under	-	579	O
the	-	585	O
influence	-	589	O
of	-	599	O
pentobarbital	-	602	B
between	-	616	O
Groups	-	624	O
1	-	631	O
and	-	633	O
2	-	637	O
were	-	639	O
revealed	-	644	O
.	-	652	O

These	1616457	654	O
findings	-	660	O
show	-	669	O
that	-	674	O
the	-	679	O
brain	-	683	O
-	-	688	O
dissociated	-	689	O
state	-	701	O
induced	-	707	O
by	-	715	O
pentobarbital	-	718	B
is	-	732	O
formed	-	735	O
with	-	742	O
the	-	747	O
participation	-	751	O
of	-	765	O
the	-	768	O
mechanisms	-	772	O
of	-	783	O
information	-	786	O
perception	-	798	O
.	-	808	O

Angiosarcoma	567256	0	O
of	-	13	O
the	-	16	O
liver	-	20	O
associated	-	26	O
with	-	37	O
diethylstilbestrol	-	42	B
.	-	60	O

Angiosarcoma	567256	62	O
of	-	75	O
the	-	78	O
liver	-	82	O
occurred	-	88	O
in	-	97	O
a	-	100	O
76	-	102	O
-	-	104	O
year	-	105	O
-	-	109	O
old	-	110	O
man	-	114	O
who	-	118	O
had	-	122	O
been	-	126	O
treated	-	131	O
for	-	139	O
a	-	143	O
well	-	145	O
-	-	149	O
differentiated	-	150	O
adenocarcinoma	-	165	O
of	-	180	O
the	-	183	O
liver	-	187	O
with	-	193	O
diethylstilbestrol	-	198	B
for	-	217	O
13	-	221	O
years	-	224	O
.	-	229	O

Angiosarcoma	567256	231	O
was	-	244	O
also	-	248	O
present	-	253	O
within	-	261	O
pulmonary	-	268	O
and	-	278	O
renal	-	282	O
arteries	-	288	O
.	-	296	O

The	567256	298	O
possibility	-	302	O
that	-	314	O
the	-	319	O
intraarterial	-	323	O
lesions	-	337	O
might	-	345	O
represent	-	351	O
independent	-	361	O
primary	-	373	O
tumors	-	381	O
is	-	388	O
considered	-	391	O
.	-	401	O

Role	17439425	0	O
of	-	5	O
xanthine	-	8	B
oxidase	-	17	O
in	-	25	O
dexamethasone	-	28	B
-	-	41	O
induced	-	42	O
hypertension	-	50	O
in	-	63	O
rats	-	66	O
.	-	70	O

1	17439425	72	O
.	-	73	O

Glucocorticoid	17439425	75	O
-	-	89	O
induced	-	90	O
hypertension	-	98	O
(	-	111	O
GC	-	112	O
-	-	114	O
HT	-	115	O
)	-	117	O
in	-	119	O
the	-	122	O
rat	-	126	O
is	-	130	O
associated	-	133	O
with	-	144	O
nitric	-	149	B
oxide	-	156	I
-	-	161	O
redox	-	162	O
imbalance	-	168	O
.	-	177	O

2	17439425	179	O
.	-	180	O

We	17439425	182	O
studied	-	185	O
the	-	193	O
role	-	197	O
of	-	202	O
xanthine	-	205	B
oxidase	-	214	O
(	-	222	O
XO	-	223	O
)	-	225	O
,	-	226	O
which	-	228	O
is	-	234	O
implicated	-	237	O
in	-	248	O
the	-	251	O
production	-	255	O
of	-	266	O
reactive	-	269	O
oxygen	-	278	O
species	-	285	O
,	-	292	O
in	-	294	O
dexamethasone	-	297	B
-	-	310	O
induced	-	311	O
hypertension	-	319	O
(	-	332	O
dex	-	333	B
-	-	336	O
HT	-	337	O
)	-	339	O
.	-	340	O

3	17439425	342	O
.	-	343	O

Thirty	17439425	345	O
male	-	352	O
Sprague	-	357	O
-	-	364	O
Dawley	-	365	O
rats	-	372	O
were	-	377	O
divided	-	382	O
randomly	-	390	O
into	-	399	O
four	-	404	O
treatment	-	409	O
groups	-	419	O
:	-	425	O
saline	-	427	O
,	-	433	O
dexamethasone	-	435	B
(	-	449	O
dex	-	450	B
)	-	453	O
,	-	454	O
allopurinol	-	456	B
plus	-	468	O
saline	-	473	O
,	-	479	O
and	-	481	O
allopurinol	-	485	B
plus	-	497	O
dex	-	502	B
.	-	505	O

4	17439425	507	O
.	-	508	O

Systolic	17439425	510	O
blood	-	519	O
pressures	-	525	O
(	-	535	O
SBP	-	536	O
)	-	539	O
and	-	541	O
bodyweights	-	545	O
were	-	557	O
recorded	-	562	O
each	-	571	O
alternate	-	576	O
day	-	586	O
.	-	589	O

Thymus	17439425	591	O
weight	-	598	O
was	-	605	O
used	-	609	O
as	-	614	O
a	-	617	O
marker	-	619	O
of	-	626	O
glucocorticoid	-	629	O
activity	-	644	O
,	-	652	O
and	-	654	O
serum	-	658	O
urate	-	664	B
to	-	670	O
assess	-	673	O
XO	-	680	O
inhibition	-	683	O
.	-	693	O

5	17439425	695	O
.	-	696	O

Dex	17439425	698	B
increased	-	702	O
SBP	-	712	O
(	-	716	O
110	-	717	O
+	-	721	O
/	-	722	O
-	-	723	O

2	17439425	725	O
-	-	726	O
126	-	727	O
+	-	731	O
/	-	732	O
-	-	733	O

3	17439425	735	O
mmHg	-	737	O
;	-	741	O
P	-	743	O
<	-	745	O
0	-	747	O
.	-	748	O
001	-	749	O
)	-	752	O
and	-	754	O
decreased	-	758	O
thymus	-	768	O
(	-	775	O
P	-	776	O
<	-	778	O
0	-	780	O
.	-	781	O
001	-	782	O
)	-	785	O
and	-	787	O
bodyweights	-	791	O
(	-	803	O
P	-	804	O
""""	-	805	O
<	-	807	O
0	-	809	O
.	-	810	O
01	-	811	O
)	-	813	O
.	-	814	O

Allopurinol	17439425	816	B
decreased	-	828	O
serum	-	838	O
urate	-	844	B
from	-	850	O
76	-	855	O
+	-	858	O
/	-	859	O
-	-	860	O

5	17439425	862	O
to	-	864	O
30	-	867	O
+	-	870	O
/	-	871	O
-	-	872	O

3	17439425	874	O
micromol	-	876	O
/	-	884	O
L	-	885	O
(	-	887	O
P	-	888	O
<	-	890	O
0	-	892	O
.	-	893	O
001	-	894	O
)	-	897	O
in	-	899	O
saline	-	902	O
and	-	909	O
from	-	913	O
84	-	918	O
+	-	921	O
/	-	922	O
-	-	923	O

13	17439425	925	O
to	-	928	O
28	-	931	O
+	-	934	O
/	-	935	O
-	-	936	O
2	-	938	O
micromol	-	940	O
/	-	948	O
L	-	949	O
in	-	951	O
dex	-	954	B
-	-	957	O
treated	-	958	O
(	-	966	O
P	-	967	O
<	-	969	O
0	-	971	O
.	-	972	O
01	-	973	O
)	-	975	O
groups	-	977	O
.	-	983	O

6	17439425	985	O
.	-	986	O

Allopurinol	17439425	988	B
did	-	1000	O
not	-	1004	O
prevent	-	1008	O
dex	-	1016	B
-	-	1019	O
HT	-	1020	O
.	-	1022	O

This	17439425	1024	O
,	-	1028	O
together	-	1030	O
with	-	1039	O
our	-	1044	O
previous	-	1048	O
findings	-	1057	O
that	-	1066	O
allopurinol	-	1071	B
failed	-	1083	O
to	-	1090	O
prevent	-	1093	O
adrenocorticotrophic	-	1101	O
hormone	-	1122	O
induced	-	1130	O
hypertension	-	1138	O
,	-	1150	O
suggests	-	1152	O
that	-	1161	O
XO	-	1166	O
activity	-	1169	O
is	-	1178	O
not	-	1181	O
a	-	1185	O
major	-	1187	O
determinant	-	1193	O
of	-	1205	O
GC	-	1208	O
-	-	1210	O
HT	-	1211	O
in	-	1214	O
the	-	1217	O
rat	-	1221	O
.	-	1224	O

Extrapyramidal	9351491	0	O
side	-	15	O
effects	-	20	O
with	-	28	O
risperidone	-	33	B
and	-	45	O
haloperidol	-	49	B
at	-	61	O
comparable	-	64	O
D2	-	75	O
receptor	-	78	O
occupancy	-	87	O
levels	-	97	O
.	-	103	O

Risperidone	9351491	105	B
is	-	117	O
an	-	120	O
antipsychotic	-	123	O
drug	-	137	O
with	-	142	O
high	-	147	O
affinity	-	152	O
at	-	161	O
dopamine	-	164	B
D2	-	173	O
and	-	176	O
serotonin	-	180	B
5	-	190	I
-	-	191	I
HT2	-	192	I
receptors	-	196	O
.	-	205	O

Previous	9351491	207	O
clinical	-	216	O
studies	-	225	O
have	-	233	O
proposed	-	238	O
that	-	247	O
risperidone	-	252	B
's	-	263	O
pharmacologic	-	266	O
profile	-	280	O
may	-	288	O
produce	-	292	O
improved	-	300	O
efficacy	-	309	O
for	-	318	O
negative	-	322	O
psychotic	-	331	O
symptoms	-	341	O
and	-	350	O
decreased	-	354	O
propensity	-	364	O
for	-	375	O
extrapyramidal	-	379	O
side	-	394	O
effects	-	399	O
;	-	406	O
features	-	408	O
shared	-	417	O
by	-	424	O
so	-	427	O
-	-	429	O
called	-	430	O
'	-	437	O
atypical	-	438	O
'	-	446	O
neuroleptics	-	448	O
.	-	460	O

To	9351491	462	O
determine	-	465	O
if	-	475	O
routine	-	478	O
risperidone	-	486	B
treatment	-	498	O
is	-	508	O
associated	-	511	O
with	-	522	O
a	-	527	O
unique	-	529	O
degree	-	536	O
of	-	543	O
D2	-	546	O
receptor	-	549	O
occupancy	-	558	O
and	-	568	O
pattern	-	572	O
of	-	580	O
clinical	-	583	O
effects	-	592	O
,	-	599	O
we	-	601	O
used	-	604	O
[	-	609	O
123I	-	610	O
]	-	614	O
IBZM	-	615	O
SPECT	-	620	O
to	-	626	O
determine	-	629	O
D2	-	639	O
occupancy	-	642	O
in	-	652	O
subjects	-	655	O
treated	-	664	O
with	-	672	O
routine	-	677	O
clinical	-	685	O
doses	-	694	O
of	-	700	O
risperidone	-	703	B
(	-	715	O
n	-	716	O
=	-	718	O
12	-	720	O
)	-	722	O
or	-	724	O
haloperidol	-	727	B
(	-	739	O
n	-	740	O
=	-	742	O
7	-	744	O
)	-	745	O
.	-	746	O

Both	9351491	748	O
risperidone	-	753	B
and	-	765	O
haloperidol	-	769	B
produced	-	781	O
D2	-	790	O
occupancy	-	793	O
levels	-	803	O
between	-	810	O
approximately	-	818	O
60	-	832	O
and	-	835	O
90	-	839	O
%	-	841	O
at	-	843	O
standard	-	846	O
clinical	-	855	O
doses	-	864	O
.	-	869	O

There	9351491	871	O
was	-	877	O
no	-	881	O
significant	-	884	O
difference	-	896	O
between	-	907	O
occupancy	-	915	O
levels	-	925	O
obtained	-	932	O
with	-	941	O
haloperidol	-	946	B
or	-	958	O
risperidone	-	961	B
.	-	972	O

Drug	9351491	974	O
-	-	978	O
induced	-	979	O
parkinsonism	-	987	O
was	-	1000	O
observed	-	1004	O
in	-	1013	O
subjects	-	1016	O
treated	-	1025	O
with	-	1033	O
risperidone	-	1038	B
(	-	1050	O
42	-	1051	O
%	-	1053	O
)	-	1054	O
and	-	1056	O
haloperidol	-	1060	B
(	-	1072	O
29	-	1073	O
%	-	1075	O
)	-	1076	O
and	-	1078	O
was	-	1082	O
observed	-	1086	O
at	-	1095	O
occupancy	-	1098	O
levels	-	1108	O
above	-	1115	O
60	-	1121	O
%	-	1123	O
.	-	1124	O

Based	9351491	1126	O
on	-	1132	O
these	-	1135	O
observations	-	1141	O
,	-	1153	O
it	-	1155	O
is	-	1158	O
concluded	-	1161	O
that	-	1171	O
5	-	1176	O
-	-	1177	O
HT2	-	1178	O
blockade	-	1182	O
obtained	-	1191	O
with	-	1200	O
risperidone	-	1205	B
at	-	1217	O
D2	-	1220	O
occupancy	-	1223	O
rates	-	1233	O
of	-	1239	O
60	-	1242	O
%	-	1244	O
and	-	1246	O
above	-	1250	O
does	-	1256	O
not	-	1261	O
appear	-	1265	O
to	-	1272	O
protect	-	1275	O
against	-	1283	O
the	-	1291	O
risk	-	1295	O
for	-	1300	O
extrapyramidal	-	1304	O
side	-	1319	O
effects	-	1324	O
.	-	1331	O

Simvastatin	18752389	0	B
-	-	11	I
ezetimibe	-	12	I
-	-	21	O
induced	-	22	O
hepatic	-	30	O
failure	-	38	O
necessitating	-	46	O
liver	-	60	O
transplantation	-	66	O
.	-	81	O

Abstract	18752389	83	O
Serum	-	92	O
aminotransferase	-	98	O
elevations	-	115	O
are	-	126	O
a	-	130	O
commonly	-	132	O
known	-	141	O
adverse	-	147	O
effect	-	155	O
of	-	162	O
3	-	165	O
-	-	166	O
hydroxy	-	167	O
-	-	174	O
3	-	175	O
-	-	176	O
methylglutaryl	-	177	O
coenzyme	-	192	O
A	-	201	O
reductase	-	203	O
inhibitor	-	213	O
(	-	223	O
statin	-	224	B
)	-	230	O
therapy	-	232	O
.	-	239	O

However	18752389	241	O
,	-	248	O
hepatotoxic	-	250	O
events	-	262	O
have	-	269	O
not	-	274	O
been	-	278	O
widely	-	283	O
published	-	290	O
with	-	300	O
ezetimibe	-	305	B
or	-	315	O
the	-	318	O
combination	-	322	O
agent	-	334	O
simvastatin	-	340	B
-	-	351	I
ezetimibe	-	352	I
.	-	361	O

We	18752389	363	O
describe	-	366	O
a	-	375	O
70	-	377	O
-	-	379	O
year	-	380	O
-	-	384	O
old	-	385	O
Hispanic	-	389	O
woman	-	398	O
who	-	404	O
developed	-	408	O
fulminant	-	418	O
hepatic	-	428	O
failure	-	436	O
necessitating	-	444	O
liver	-	458	O
transplantation	-	464	O
10	-	480	O
weeks	-	483	O
after	-	489	O
conversion	-	495	O
from	-	506	O
simvastatin	-	511	B
40	-	523	O
mg	-	526	O
/	-	528	O
day	-	529	O
to	-	533	O
simvastatin	-	536	B
10	-	548	I
mg	-	551	I
-	-	553	I
ezetimibe	-	554	I
40	-	564	I
mg	-	567	I
/	-	569	O
day	-	570	O
.	-	573	O

The	18752389	575	O
patient	-	579	O
's	-	586	O
lipid	-	589	O
panel	-	595	O
had	-	601	O
been	-	605	O
maintained	-	610	O
with	-	621	O
simvastatin	-	626	B
for	-	638	O
18	-	642	O
months	-	645	O
before	-	652	O
the	-	659	O
conversion	-	663	O
without	-	674	O
evidence	-	682	O
of	-	691	O
hepatotoxicity	-	694	O
.	-	708	O

A	18752389	710	O
routine	-	712	O
laboratory	-	720	O
work	-	731	O
-	-	735	O
up	-	736	O
10	-	739	O
weeks	-	742	O
after	-	748	O
conversion	-	754	O
revealed	-	765	O
elevated	-	774	O
serum	-	783	O
aminotransferase	-	789	O
levels	-	806	O
.	-	812	O

Simvastatinezetimibe	18752389	814	B
and	-	835	O
escitalopram	-	839	B
(	-	852	O
which	-	853	O
she	-	859	O
was	-	863	O
taking	-	867	O
for	-	874	O
depression	-	878	O
)	-	888	O
were	-	890	O
discontinued	-	895	O
,	-	907	O
and	-	909	O
other	-	913	O
potential	-	919	O
causes	-	929	O
of	-	936	O
hepatotoxicity	-	939	O
were	-	954	O
excluded	-	959	O
.	-	967	O

A	18752389	969	O
repeat	-	971	O
work	-	978	O
-	-	982	O
up	-	983	O
revealed	-	986	O
further	-	995	O
elevations	-	1003	O
in	-	1014	O
aminotransferase	-	1017	O
levels	-	1034	O
,	-	1040	O
and	-	1042	O
liver	-	1046	O
biopsy	-	1052	O
revealed	-	1059	O
evidence	-	1068	O
of	-	1077	O
moderate	-	1080	O
-	-	1088	O
to	-	1089	O
-	-	1091	O
severe	-	1092	O
drug	-	1099	O
toxicity	-	1104	O
.	-	1112	O

She	18752389	1114	O
underwent	-	1118	O
liver	-	1128	O
transplantation	-	1134	O
with	-	1150	O
an	-	1155	O
uneventful	-	1158	O
postoperative	-	1169	O
course	-	1183	O
.	-	1189	O

Her	18752389	1191	O
aminotransferase	-	1195	O
levels	-	1212	O
returned	-	1219	O
to	-	1228	O
normal	-	1231	O
by	-	1238	O
postoperative	-	1241	O
day	-	1255	O
23	-	1259	O
,	-	1261	O
and	-	1263	O
her	-	1267	O
2	-	1271	O
-	-	1272	O
year	-	1273	O
follow	-	1278	O
-	-	1284	O
up	-	1285	O
showed	-	1288	O
no	-	1295	O
adverse	-	1298	O
events	-	1306	O
.	-	1312	O

Ezetimibe	18752389	1314	B
undergoes	-	1324	O
extensive	-	1334	O
glucuronidation	-	1344	O
by	-	1360	O
uridine	-	1363	B
diphosphate	-	1371	I
glucoronosyltransferases	-	1383	O
(	-	1408	O
UGT	-	1409	O
)	-	1412	O
in	-	1414	O
the	-	1417	O
intestine	-	1421	O
and	-	1431	O
liver	-	1435	O
and	-	1441	O
may	-	1445	O
have	-	1449	O
inhibited	-	1454	O
the	-	1464	O
glucuronidation	-	1468	O
of	-	1484	O
simvastatin	-	1487	B
hydroxy	-	1499	I
acid	-	1507	I
,	-	1511	O
resulting	-	1513	O
in	-	1523	O
increased	-	1526	O
simvastatin	-	1536	B
exposure	-	1548	O
and	-	1557	O
subsequent	-	1561	O
hepatotoxicity	-	1572	O
.	-	1586	O

To	18752389	1588	O
our	-	1591	O
knowledge	-	1595	O
,	-	1604	O
this	-	1606	O
is	-	1611	O
the	-	1614	O
first	-	1618	O
case	-	1624	O
report	-	1629	O
of	-	1636	O
simvastatin	-	1639	B
-	-	1650	I
ezetimibe	-	1651	I
-	-	1660	O
induced	-	1661	O
liver	-	1669	O
failure	-	1675	O
that	-	1683	O
resulted	-	1688	O
in	-	1697	O
liver	-	1700	O
transplantation	-	1706	O
.	-	1721	O

We	18752389	1723	O
postulate	-	1726	O
that	-	1736	O
the	-	1741	O
mechanism	-	1745	O
of	-	1755	O
the	-	1758	O
simvastatinezetimibe	-	1762	B
-	-	1782	O
induced	-	1783	O
hepatotoxicity	-	1791	O
is	-	1806	O
the	-	1809	O
increased	-	1813	O
simvastatin	-	1823	B
exposure	-	1835	O
by	-	1844	O
ezetimibe	-	1847	B
inhibition	-	1857	O
of	-	1868	O
UGT	-	1871	O
enzymes	-	1875	O
.	-	1882	O

Clinicians	18752389	1884	O
should	-	1895	O
be	-	1902	O
aware	-	1905	O
of	-	1911	O
potential	-	1914	O
hepatotoxicity	-	1924	O
with	-	1939	O
simvastatin	-	1944	B
-	-	1955	I
ezetimibe	-	1956	I
especially	-	1966	O
in	-	1977	O
elderly	-	1980	O
patients	-	1988	O
and	-	1997	O
should	-	2001	O
carefully	-	2008	O
monitor	-	2018	O
serum	-	2026	O
aminotransferase	-	2032	O
levels	-	2049	O
when	-	2056	O
starting	-	2061	O
therapy	-	2070	O
and	-	2078	O
titrating	-	2082	O
the	-	2092	O
dosage	-	2096	O
.	-	2102	O

Oral	20098969	0	O
manifestations	-	5	O
of	-	20	O
""""	-	23	O
meth	-	24	O
mouth	-	29	O
""""	-	34	O
:	-	35	O
a	-	37	O
case	-	39	O
report	-	44	O
.	-	50	O

AIM	20098969	52	O
:	-	55	O

The	20098969	57	O
aim	-	61	O
of	-	65	O
the	-	68	O
documentation	-	72	O
of	-	86	O
this	-	89	O
clinical	-	94	O
case	-	103	O
is	-	108	O
to	-	111	O
make	-	114	O
clinicians	-	119	O
aware	-	130	O
of	-	136	O
""""	-	139	O
meth	-	140	O
mouth	-	145	O
""""	-	150	O
and	-	152	O
the	-	156	O
medical	-	160	O
risks	-	168	O
associated	-	174	O
with	-	185	O
this	-	190	O
serious	-	195	O
condition	-	203	O
.	-	212	O

BACKGROUND	20098969	214	O
:	-	224	O

Methamphetamine	20098969	226	B
is	-	242	O
a	-	245	O
very	-	247	O
addictive	-	252	O
,	-	261	O
powerful	-	263	O
stimulant	-	272	O
that	-	282	O
increases	-	287	O
wakefulness	-	297	O
and	-	309	O
physical	-	313	O
activity	-	322	O
and	-	331	O
can	-	335	O
produce	-	339	O
other	-	347	O
effects	-	353	O
such	-	361	O
as	-	366	O
cardiac	-	369	O
dysrhythmias	-	377	O
,	-	389	O
hypertension	-	391	O
,	-	403	O
hallucinations	-	405	O
,	-	419	O
and	-	421	O
violent	-	425	O
behavior	-	433	O
.	-	441	O

Dental	20098969	443	O
patients	-	450	O
abusing	-	459	O
methamphetamine	-	467	B
can	-	483	O
present	-	487	O
with	-	495	O
poor	-	500	O
oral	-	505	O
hygiene	-	510	O
,	-	517	O
xerostomia	-	519	O
,	-	529	O
rampant	-	531	O
caries	-	539	O
(	-	546	O
""""	-	547	O
meth	-	548	O
mouth	-	553	O
""""	-	558	O
)	-	559	O
,	-	560	O
and	-	562	O
excessive	-	566	O
tooth	-	576	O
wear	-	582	O
.	-	586	O

Oral	20098969	588	O
rehabilitation	-	593	O
of	-	608	O
patients	-	611	O
using	-	620	O
methamphetamine	-	626	B
can	-	642	O
be	-	646	O
challenging	-	649	O
.	-	660	O

CASE	20098969	662	O
DESCRIPTION	-	667	O
:	-	678	O

A	20098969	680	O
30	-	682	O
-	-	684	O
year	-	685	O
-	-	689	O
old	-	690	O
Caucasian	-	694	O
woman	-	704	O
presented	-	710	O
with	-	720	O
dental	-	725	O
pain	-	732	O
,	-	736	O
bad	-	738	O
breath	-	742	O
,	-	748	O
and	-	750	O
self	-	754	O
-	-	758	O
reported	-	759	O
poor	-	768	O
esthetics	-	773	O
.	-	782	O

A	20098969	784	O
comprehensive	-	786	O
examination	-	800	O
including	-	812	O
her	-	822	O
medical	-	826	O
history	-	834	O
,	-	841	O
panoramic	-	843	O
radiograph	-	853	O
,	-	863	O
and	-	865	O
intraoral	-	869	O
examination	-	879	O
revealed	-	891	O
19	-	900	O
carious	-	903	O
lesions	-	911	O
,	-	918	O
which	-	920	O
is	-	926	O
not	-	929	O
very	-	933	O
common	-	938	O
for	-	945	O
a	-	949	O
healthy	-	951	O
adult	-	959	O
.	-	964	O

She	20098969	966	O
reported	-	970	O
her	-	979	O
use	-	983	O
of	-	987	O
methamphetamine	-	990	B
for	-	1006	O
five	-	1010	O
years	-	1015	O
and	-	1021	O
had	-	1025	O
not	-	1029	O
experienced	-	1033	O
any	-	1045	O
major	-	1049	O
carious	-	1055	O
episodes	-	1063	O
before	-	1072	O
she	-	1079	O
started	-	1083	O
using	-	1091	O
the	-	1097	O
drug	-	1101	O
.	-	1105	O

SUMMARY	20098969	1107	O
:	-	1114	O

The	20098969	1116	O
patient	-	1120	O
's	-	1127	O
medical	-	1130	O
and	-	1138	O
dental	-	1142	O
histories	-	1149	O
along	-	1159	O
with	-	1165	O
radiographic	-	1170	O
and	-	1183	O
clinical	-	1187	O
findings	-	1196	O
lead	-	1205	O
to	-	1210	O
a	-	1213	O
diagnosis	-	1215	O
of	-	1225	O
""""	-	1228	O
meth	-	1229	O
mouth	-	1234	O
.	-	1239	O
""""	-	1240	O

Although	20098969	1242	O
three	-	1251	O
different	-	1257	O
dental	-	1267	O
treatment	-	1274	O
modalities	-	1284	O
(	-	1295	O
either	-	1296	O
conventional	-	1303	O
or	-	1316	O
implant	-	1319	O
-	-	1326	O
supported	-	1327	O
)	-	1336	O
have	-	1338	O
been	-	1343	O
offered	-	1348	O
to	-	1356	O
the	-	1359	O
patient	-	1363	O
since	-	1371	O
August	-	1377	O
2007	-	1384	O
,	-	1388	O
the	-	1390	O
patient	-	1394	O
has	-	1402	O
yet	-	1406	O
to	-	1410	O
initiate	-	1413	O
any	-	1422	O
treatment	-	1426	O
.	-	1435	O

CLINICAL	20098969	1437	O
SIGNIFICANCE	-	1446	O
:	-	1458	O

This	20098969	1460	O
clinical	-	1465	O
case	-	1474	O
showing	-	1479	O
oral	-	1487	O
manifestations	-	1492	O
of	-	1507	O
meth	-	1510	O
mouth	-	1515	O
was	-	1521	O
presented	-	1525	O
to	-	1535	O
help	-	1538	O
dental	-	1543	O
practitioners	-	1550	O
recognize	-	1564	O
and	-	1574	O
manage	-	1578	O
patients	-	1585	O
who	-	1594	O
may	-	1598	O
be	-	1602	O
abusing	-	1605	O
methamphetamines	-	1613	B
.	-	1629	O

Dental	20098969	1631	O
practitioners	-	1638	O
also	-	1652	O
may	-	1657	O
be	-	1661	O
skeptical	-	1664	O
about	-	1674	O
the	-	1680	O
reliability	-	1684	O
of	-	1696	O
appointment	-	1699	O
keeping	-	1711	O
by	-	1719	O
these	-	1722	O
patients	-	1728	O
,	-	1736	O
as	-	1738	O
they	-	1741	O
frequently	-	1746	O
miss	-	1757	O
their	-	1762	O
appointments	-	1768	O
without	-	1781	O
reasonable	-	1789	O
justification	-	1800	O
.	-	1813	O

Thyroxine	9653867	0	B
abuse	-	10	O
:	-	15	O
an	-	17	O
unusual	-	20	O
case	-	28	O
of	-	33	O
thyrotoxicosis	-	36	O
in	-	51	O
pregnancy	-	54	O
.	-	63	O

Eating	9653867	65	O
disorders	-	72	O
and	-	82	O
the	-	86	O
associated	-	90	O
behavioural	-	101	O
problems	-	113	O
and	-	122	O
drug	-	126	O
abuse	-	131	O
are	-	137	O
uncommon	-	141	O
in	-	150	O
pregnancy	-	153	O
.	-	162	O

When	9653867	164	O
they	-	169	O
do	-	174	O
occur	-	177	O
they	-	183	O
are	-	188	O
often	-	192	O
unrecognized	-	198	O
because	-	211	O
of	-	219	O
denial	-	222	O
but	-	229	O
when	-	233	O
significant	-	238	O
may	-	250	O
pose	-	254	O
a	-	259	O
risk	-	261	O
to	-	266	O
both	-	269	O
the	-	274	O
mother	-	278	O
and	-	285	O
her	-	289	O
fetus	-	293	O
.	-	298	O

This	9653867	300	O
case	-	305	O
illustrates	-	310	O
a	-	322	O
number	-	324	O
of	-	331	O
problems	-	334	O
that	-	343	O
may	-	348	O
be	-	352	O
encountered	-	355	O
in	-	367	O
women	-	370	O
with	-	376	O
eating	-	381	O
disorders	-	388	O
in	-	398	O
pregnancy	-	401	O
,	-	410	O
including	-	412	O
prolonged	-	422	O
and	-	432	O
recurrent	-	436	O
metabolic	-	446	O
disturbances	-	456	O
and	-	469	O
diuretic	-	473	O
abuse	-	482	O
.	-	487	O

In	9653867	489	O
particular	-	492	O
it	-	503	O
illustrates	-	506	O
the	-	518	O
derangements	-	522	O
of	-	535	O
thyroid	-	538	O
function	-	546	O
seen	-	555	O
in	-	560	O
pregnant	-	563	O
women	-	572	O
with	-	578	O
eating	-	583	O
disorders	-	590	O
and	-	600	O
reminds	-	604	O
us	-	612	O
that	-	615	O
when	-	620	O
a	-	625	O
cause	-	627	O
for	-	633	O
thyrotoxicosis	-	637	O
remains	-	652	O
obscure	-	660	O
,	-	667	O
thyroxine	-	669	B
abuse	-	679	O
should	-	685	O
be	-	692	O
considered	-	695	O
and	-	706	O
explored	-	710	O
.	-	718	O

Attenuation	17608141	0	O
of	-	12	O
methamphetamine	-	15	B
-	-	30	O
induced	-	31	O
nigrostriatal	-	39	O
dopaminergic	-	53	O
neurotoxicity	-	66	O
in	-	80	O
mice	-	83	O
by	-	88	O
lipopolysaccharide	-	91	B
pretreatment	-	110	O
.	-	122	O

Immunological	17608141	124	O
activation	-	138	O
has	-	149	O
been	-	153	O
proposed	-	158	O
to	-	167	O
play	-	170	O
a	-	175	O
role	-	177	O
in	-	182	O
methamphetamine	-	185	B
-	-	200	O
induced	-	201	O
dopaminergic	-	209	O
terminal	-	222	O
damage	-	231	O
.	-	237	O

In	17608141	239	O
this	-	242	O
study	-	247	O
,	-	252	O
we	-	254	O
examined	-	257	O
the	-	266	O
roles	-	270	O
of	-	276	O
lipopolysaccharide	-	279	B
,	-	297	O
a	-	299	O
pro	-	301	O
-	-	304	O
inflammatory	-	305	O
and	-	318	O
inflammatory	-	322	O
factor	-	335	O
,	-	341	O
treatment	-	343	O
in	-	353	O
modulating	-	356	O
the	-	367	O
methamphetamine	-	371	B
-	-	386	O
induced	-	387	O
nigrostriatal	-	395	O
dopamine	-	409	B
neurotoxicity	-	418	O
.	-	431	O

Lipopolysaccharide	17608141	433	B
pretreatment	-	452	O
did	-	465	O
not	-	469	O
affect	-	473	O
the	-	480	O
basal	-	484	O
body	-	490	O
temperature	-	495	O
or	-	507	O
methamphetamine	-	510	B
-	-	525	O
elicited	-	526	O
hyperthermia	-	535	O
three	-	548	O
days	-	554	O
later	-	559	O
.	-	564	O

Such	17608141	566	O
systemic	-	571	O
lipopolysaccharide	-	580	B
treatment	-	599	O
mitigated	-	609	O
methamphetamine	-	619	B
-	-	634	O
induced	-	635	O
striatal	-	643	O
dopamine	-	652	B
and	-	661	O
3	-	665	B
,	-	666	I
4	-	667	I
-	-	668	I
dihydroxyphenylacetic	-	669	I
acid	-	691	I
depletions	-	696	O
in	-	707	O
a	-	710	O
dose	-	712	O
-	-	716	O
dependent	-	717	O
manner	-	727	O
.	-	733	O

As	17608141	735	O
the	-	738	O
most	-	742	O
potent	-	747	O
dose	-	754	O
(	-	759	O
1	-	760	O
mg	-	762	O
/	-	764	O
kg	-	765	O
)	-	767	O
of	-	769	O
lipopolysaccharide	-	772	B
was	-	791	O
administered	-	795	O
two	-	808	O
weeks	-	812	O
,	-	817	O
one	-	819	O
day	-	823	O
before	-	827	O
or	-	834	O
after	-	837	O
the	-	843	O
methamphetamine	-	847	B
dosing	-	863	O
regimen	-	870	O
,	-	877	O
methamphetamine	-	879	B
-	-	894	O
induced	-	895	O
striatal	-	903	O
dopamine	-	912	B
and	-	921	O
3	-	925	B
,	-	926	I
4	-	927	I
-	-	928	I
dihydroxyphenylacetic	-	929	I
acid	-	951	I
depletions	-	956	O
remained	-	967	O
unaltered	-	976	O
.	-	985	O

Moreover	17608141	987	O
,	-	995	O
systemic	-	997	O
lipopolysaccharide	-	1006	B
pretreatment	-	1025	O
(	-	1038	O
1	-	1039	O
mg	-	1041	O
/	-	1043	O
kg	-	1044	O
)	-	1046	O
attenuated	-	1048	O
local	-	1059	O
methamphetamine	-	1065	B
infusion	-	1081	O
-	-	1089	O
produced	-	1090	O
dopamine	-	1099	B
and	-	1108	O
3	-	1112	B
,	-	1113	I
4	-	1114	I
-	-	1115	I
dihydroxyphenylacetic	-	1116	I
acid	-	1138	I
depletions	-	1143	O
in	-	1154	O
the	-	1157	O
striatum	-	1161	O
,	-	1169	O
indicating	-	1171	O
that	-	1182	O
the	-	1187	O
protective	-	1191	O
effect	-	1202	O
of	-	1209	O
lipopolysaccharide	-	1212	B
is	-	1231	O
less	-	1234	O
likely	-	1239	O
due	-	1246	O
to	-	1250	O
interrupted	-	1253	O
peripheral	-	1265	O
distribution	-	1276	O
or	-	1289	O
metabolism	-	1292	O
of	-	1303	O
methamphetamine	-	1306	B
.	-	1321	O

We	17608141	1323	O
concluded	-	1326	O
a	-	1336	O
critical	-	1338	O
time	-	1347	O
window	-	1352	O
for	-	1359	O
systemic	-	1363	O
lipopolysaccharide	-	1372	B
pretreatment	-	1391	O
in	-	1404	O
exerting	-	1407	O
effective	-	1416	O
protection	-	1426	O
against	-	1437	O
methamphetamine	-	1445	B
-	-	1460	O
induced	-	1461	O
nigrostriatal	-	1469	O
dopamine	-	1483	B
neurotoxicity	-	1492	O
.	-	1505	O

Effect	2559236	0	O
of	-	7	O
converting	-	10	O
enzyme	-	21	O
inhibition	-	28	O
on	-	39	O
the	-	42	O
course	-	46	O
of	-	53	O
adriamycin	-	56	B
-	-	66	O
induced	-	67	O
nephropathy	-	75	O
.	-	86	O

The	2559236	88	O
effect	-	92	O
of	-	99	O
the	-	102	O
converting	-	106	O
enzyme	-	117	O
inhibitor	-	124	O
(	-	134	O
CEI	-	135	O
)	-	138	O
enalapril	-	140	B
was	-	150	O
assessed	-	154	O
in	-	163	O
Munich	-	166	O
-	-	172	O
Wistar	-	173	O
rats	-	180	O
with	-	185	O
established	-	190	O
adriamycin	-	202	B
nephrosis	-	213	O
.	-	222	O

Rats	2559236	224	O
were	-	229	O
given	-	234	O
a	-	240	O
single	-	242	O
dose	-	249	O
of	-	254	O
adriamycin	-	257	B
and	-	268	O
one	-	272	O
month	-	276	O
later	-	282	O
divided	-	288	O
into	-	296	O
four	-	301	O
groups	-	306	O
matched	-	313	O
for	-	321	O
albuminuria	-	325	O
,	-	336	O
blood	-	338	O
pressure	-	344	O
,	-	352	O
and	-	354	O
plasma	-	358	O
albumin	-	365	O
concentration	-	373	O
.	-	386	O

Groups	2559236	388	O
1	-	395	O
and	-	397	O
3	-	401	O
remained	-	403	O
untreated	-	412	O
while	-	422	O
groups	-	428	O
2	-	435	O
and	-	437	O
4	-	441	O
received	-	443	O
enalapril	-	452	B
.	-	461	O

Groups	2559236	463	O
1	-	470	O
and	-	472	O
2	-	476	O
underwent	-	478	O
micropuncture	-	488	O
studies	-	502	O
after	-	510	O
10	-	516	O
days	-	519	O
.	-	523	O

These	2559236	525	O
short	-	531	O
-	-	536	O
term	-	537	O
studies	-	542	O
showed	-	550	O
that	-	557	O
enalapril	-	562	B
reduced	-	572	O
arterial	-	580	O
blood	-	589	O
pressure	-	595	O
(	-	604	O
101	-	605	O
+	-	609	O
/	-	610	O
-	-	611	O

2	2559236	613	O
vs	-	615	O
.	-	617	O
124	-	619	O
+	-	623	O
/	-	624	O
-	-	625	O

3	2559236	627	O
mm	-	629	O
Hg	-	632	O
,	-	634	O
group	-	636	O
2	-	642	O
vs	-	644	O
.	-	646	O
1	-	648	O
,	-	649	O
P	-	651	O
less	-	653	O
than	-	658	O
0	-	663	O
.	-	664	O
05	-	665	O
)	-	667	O
and	-	669	O
glomerular	-	673	O
capillary	-	684	O
pressure	-	694	O
(	-	703	O
54	-	704	O
+	-	707	O
/	-	708	O
-	-	709	O

1	2559236	711	O
vs	-	713	O
.	-	715	O
61	-	717	O
+	-	720	O
/	-	721	O
-	-	722	O

2	2559236	724	O
mm	-	726	O
Hg	-	729	O
,	-	731	O
P	-	733	O
less	-	735	O
than	-	740	O
0	-	745	O
.	-	746	O
05	-	747	O
)	-	749	O
without	-	751	O
reducing	-	759	O
albuminuria	-	768	O
(	-	780	O
617	-	781	O
+	-	785	O
/	-	786	O
-	-	787	O

50	2559236	789	O
vs	-	792	O
.	-	794	O
570	-	796	O
+	-	800	O
/	-	801	O
-	-	802	O

47	2559236	804	O
mg	-	807	O
/	-	809	O
day	-	810	O
)	-	813	O
or	-	815	O
GFR	-	818	O
(	-	822	O
1	-	823	O
.	-	824	O
03	-	825	O
+	-	828	O
/	-	829	O
-	-	830	O

0	2559236	832	O
.	-	833	O
04	-	834	O
vs	-	837	O
.	-	839	O
1	-	841	O
.	-	842	O
04	-	843	O
+	-	846	O
/	-	847	O
-	-	848	O

0	2559236	850	O
.	-	851	O
11	-	852	O
ml	-	855	O
/	-	857	O
min	-	858	O
)	-	861	O
.	-	862	O

Groups	2559236	864	O
3	-	871	O
and	-	873	O
4	-	877	O
were	-	879	O
studied	-	884	O
at	-	892	O
four	-	895	O
and	-	900	O
at	-	904	O
six	-	907	O
months	-	911	O
to	-	918	O
assess	-	921	O
the	-	928	O
effect	-	932	O
of	-	939	O
enalapril	-	942	B
on	-	952	O
progression	-	955	O
of	-	967	O
renal	-	970	O
injury	-	976	O
in	-	983	O
adriamycin	-	986	B
nephrosis	-	997	O
.	-	1006	O

Chronic	2559236	1008	O
enalapril	-	1016	B
treatment	-	1026	O
reduced	-	1036	O
blood	-	1044	O
pressure	-	1050	O
without	-	1059	O
reducing	-	1067	O
albuminuria	-	1076	O
in	-	1088	O
group	-	1091	O
4	-	1097	O
.	-	1098	O

Untreated	2559236	1100	O
group	-	1110	O
3	-	1116	O
rats	-	1118	O
exhibited	-	1123	O
a	-	1133	O
progressive	-	1135	O
reduction	-	1147	O
in	-	1157	O
GFR	-	1160	O
(	-	1164	O
0	-	1165	O
.	-	1166	O
35	-	1167	O
+	-	1170	O
/	-	1171	O
-	-	1172	O

0	2559236	1174	O
.	-	1175	O
08	-	1176	O
ml	-	1179	O
/	-	1181	O
min	-	1182	O
at	-	1186	O
4	-	1189	O
months	-	1191	O
,	-	1197	O
0	-	1199	O
.	-	1200	O
27	-	1201	O
+	-	1204	O
/	-	1205	O
-	-	1206	O

0	2559236	1208	O
.	-	1209	O
07	-	1210	O
ml	-	1213	O
/	-	1215	O
min	-	1216	O
at	-	1220	O
6	-	1223	O
months	-	1225	O
)	-	1231	O
.	-	1232	O

Enalapril	2559236	1234	B
treatment	-	1244	O
blunted	-	1254	O
but	-	1262	O
did	-	1266	O
not	-	1270	O
prevent	-	1274	O
reduction	-	1282	O
in	-	1292	O
GFR	-	1295	O
in	-	1299	O
group	-	1302	O
4	-	1308	O
(	-	1310	O
0	-	1311	O
.	-	1312	O
86	-	1313	O
+	-	1316	O
/	-	1317	O
-	-	1318	O

0	2559236	1320	O
.	-	1321	O
15	-	1322	O
ml	-	1325	O
/	-	1327	O
min	-	1328	O
at	-	1332	O
4	-	1335	O
months	-	1337	O
,	-	1343	O
0	-	1345	O
.	-	1346	O
69	-	1347	O
+	-	1350	O
/	-	1351	O
-	-	1352	O

0	2559236	1354	O
.	-	1355	O
13	-	1356	O

ml	2559236	1359	O
/	-	1361	O
min	-	1362	O
at	-	1366	O
6	-	1369	O
months	-	1371	O
,	-	1377	O
both	-	1379	O
P	-	1384	O
less	-	1386	O
than	-	1391	O
0	-	1396	O
.	-	1397	O
05	-	1398	O
vs	-	1401	O
.	-	1403	O
group	-	1405	O
3	-	1411	O
)	-	1412	O
.	-	1413	O

Reduction	2559236	1415	O
in	-	1425	O
GFR	-	1428	O
was	-	1432	O
associated	-	1436	O
with	-	1447	O
the	-	1452	O
development	-	1456	O
of	-	1468	O
glomerular	-	1471	O
sclerosis	-	1482	O
in	-	1492	O
both	-	1495	O
treated	-	1500	O
and	-	1508	O
untreated	-	1512	O
rats	-	1522	O
.	-	1526	O
(	-	1527	O
ABSTRACT	-	1528	O
TRUNCATED	-	1537	O
AT	-	1547	O
250	-	1550	O
WORDS	-	1554	O
)	-	1559	O

Butyrylcholinesterase	21029050	0	O
gene	-	22	O
mutations	-	27	O
in	-	37	O
patients	-	40	O
with	-	49	O
prolonged	-	54	O
apnea	-	64	O
after	-	70	O
succinylcholine	-	76	B
for	-	92	O
electroconvulsive	-	96	O
therapy	-	114	O
.	-	121	O

BACKGROUND	21029050	123	O
:	-	133	O
patients	-	135	O
undergoing	-	144	O
electroconvulsive	-	155	O
therapy	-	173	O
(	-	181	O
ECT	-	182	O
)	-	185	O
often	-	187	O
receive	-	193	O
succinylcholine	-	201	B
as	-	217	O
part	-	220	O
of	-	225	O
the	-	228	O
anesthetic	-	232	O
procedure	-	243	O
.	-	252	O

The	21029050	254	O
duration	-	258	O
of	-	267	O
action	-	270	O
may	-	277	O
be	-	281	O
prolonged	-	284	O
in	-	294	O
patients	-	297	O
with	-	306	O
genetic	-	311	O
variants	-	319	O
of	-	328	O
the	-	331	O
butyrylcholinesterase	-	335	O
enzyme	-	357	O
(	-	364	O
BChE	-	365	O
)	-	369	O
,	-	370	O
the	-	372	O
most	-	376	O
common	-	381	O
being	-	388	O
the	-	394	O
K	-	398	O
-	-	399	O
and	-	401	O
the	-	405	O
A	-	409	O
-	-	410	O
variants	-	411	O
.	-	419	O

The	21029050	421	O
aim	-	425	O
of	-	429	O
the	-	432	O
study	-	436	O
was	-	442	O
to	-	446	O
assess	-	449	O
the	-	456	O
clinical	-	460	O
significance	-	469	O
of	-	482	O
genetic	-	485	O
variants	-	493	O
in	-	502	O
butyrylcholinesterase	-	505	O
gene	-	527	O
(	-	532	O
BCHE	-	533	O
)	-	537	O
in	-	539	O
patients	-	542	O
with	-	551	O
a	-	556	O
suspected	-	558	O
prolonged	-	568	O
duration	-	578	O
of	-	587	O
action	-	590	O
of	-	597	O
succinylcholine	-	600	B
after	-	616	O
ECT	-	622	O
.	-	625	O

METHODS	21029050	627	O
:	-	634	O

a	21029050	636	O
total	-	638	O
of	-	644	O
13	-	647	O
patients	-	650	O
were	-	659	O
referred	-	664	O
to	-	673	O
the	-	676	O
Danish	-	680	O
Cholinesterase	-	687	O
Research	-	702	O
Unit	-	711	O
after	-	716	O
ECT	-	722	O
during	-	726	O
38	-	733	O
months	-	736	O
.	-	742	O

We	21029050	744	O
determined	-	747	O
the	-	758	O
BChE	-	762	O
activity	-	767	O
and	-	776	O
the	-	780	O
BCHE	-	784	O
genotype	-	789	O
using	-	798	O
molecular	-	804	O
genetic	-	814	O
methods	-	822	O
,	-	829	O
the	-	831	O
duration	-	835	O
of	-	844	O
apnea	-	847	O
,	-	852	O
time	-	854	O
to	-	859	O
sufficient	-	862	O
spontaneous	-	873	O
ventilation	-	885	O
and	-	897	O
whether	-	901	O
neuromuscular	-	909	O
monitoring	-	923	O
was	-	934	O
used	-	938	O
.	-	942	O

The	21029050	944	O
duration	-	948	O
of	-	957	O
apnea	-	960	O
was	-	966	O
compared	-	970	O
with	-	979	O
published	-	984	O
data	-	994	O
on	-	999	O
normal	-	1002	O
subjects	-	1009	O
.	-	1017	O

RESULTS	21029050	1019	O
:	-	1026	O

in	21029050	1028	O
11	-	1031	O
patients	-	1034	O
,	-	1042	O
mutations	-	1044	O
were	-	1054	O
found	-	1059	O
in	-	1065	O
the	-	1068	O
BCHE	-	1072	O
gene	-	1077	O
,	-	1081	O
the	-	1083	O
K	-	1087	O
-	-	1088	O
variant	-	1089	O
being	-	1097	O
the	-	1103	O
most	-	1107	O
frequent	-	1112	O
.	-	1120	O

The	21029050	1122	O
duration	-	1126	O
of	-	1135	O
apnea	-	1138	O
was	-	1144	O
5	-	1148	O
-	-	1149	O
15	-	1150	O
min	-	1153	O
compared	-	1157	O
with	-	1166	O
3	-	1171	O
-	-	1172	O
5	-	1173	O
.	-	1174	O
3	-	1175	O
min	-	1177	O
from	-	1181	O
the	-	1186	O
literature	-	1190	O
.	-	1200	O

Severe	21029050	1202	O
distress	-	1209	O
was	-	1218	O
noted	-	1222	O
in	-	1228	O
the	-	1231	O
recovery	-	1235	O
phase	-	1244	O
in	-	1250	O
two	-	1253	O
patients	-	1257	O
.	-	1265	O

Neuromuscular	21029050	1267	O
monitoring	-	1281	O
was	-	1292	O
used	-	1296	O
in	-	1301	O
two	-	1304	O
patients	-	1308	O
.	-	1316	O

CONCLUSION	21029050	1318	O
:	-	1328	O
eleven	-	1330	O
of	-	1337	O
13	-	1340	O
patients	-	1343	O
with	-	1352	O
a	-	1357	O
prolonged	-	1359	O
duration	-	1369	O
of	-	1378	O
action	-	1381	O
of	-	1388	O
succinylcholine	-	1391	B

had	21029050	1407	O
mutations	-	1411	O
in	-	1421	O
BCHE	-	1424	O
,	-	1428	O
indicating	-	1430	O
that	-	1441	O
this	-	1446	O
is	-	1451	O
the	-	1454	O
possible	-	1458	O
reason	-	1467	O
for	-	1474	O
a	-	1478	O
prolonged	-	1480	O
period	-	1490	O
of	-	1497	O
apnea	-	1500	O
.	-	1505	O

We	21029050	1507	O
recommend	-	1510	O
objective	-	1520	O
neuromuscular	-	1530	O
monitoring	-	1544	O
during	-	1555	O
the	-	1562	O
first	-	1566	O
ECT	-	1572	O
.	-	1575	O

Ketamine	10901305	0	B
sedation	-	9	O
for	-	18	O
the	-	22	O
reduction	-	26	O
of	-	36	O
children	-	39	O
's	-	47	O
fractures	-	50	O
in	-	60	O
the	-	63	O
emergency	-	67	O
department	-	77	O
.	-	87	O

BACKGROUND	10901305	89	O
:	-	99	O

There	10901305	101	O
recently	-	107	O
has	-	116	O
been	-	120	O
a	-	125	O
resurgence	-	127	O
in	-	138	O
the	-	141	O
utilization	-	145	O
of	-	157	O
ketamine	-	160	B
,	-	168	O
a	-	170	O
unique	-	172	O
anesthetic	-	179	O
,	-	189	O
for	-	191	O
emergency	-	195	O
-	-	204	O
department	-	205	O
procedures	-	216	O
requiring	-	227	O
sedation	-	237	O
.	-	245	O

The	10901305	247	O
purpose	-	251	O
of	-	259	O
the	-	262	O
present	-	266	O
study	-	274	O
was	-	280	O
to	-	284	O
examine	-	287	O
the	-	295	O
safety	-	299	O
and	-	306	O
efficacy	-	310	O
of	-	319	O
ketamine	-	322	B
for	-	331	O
sedation	-	335	O
in	-	344	O
the	-	347	O
treatment	-	351	O
of	-	361	O
children	-	364	O
's	-	372	O
fractures	-	375	O
in	-	385	O
the	-	388	O
emergency	-	392	O
department	-	402	O
.	-	412	O

METHODS	10901305	414	O
:	-	421	O

One	10901305	423	O
hundred	-	427	O
and	-	435	O
fourteen	-	439	O
children	-	448	O
(	-	457	O
average	-	458	O
age	-	466	O
,	-	469	O
5	-	471	O
.	-	472	O
3	-	473	O
years	-	475	O
;	-	480	O
range	-	482	O
,	-	487	O
twelve	-	489	O
months	-	496	O
to	-	503	O
ten	-	506	O
years	-	510	O
and	-	516	O
ten	-	520	O
months	-	524	O
)	-	530	O
who	-	532	O
underwent	-	536	O
closed	-	546	O
reduction	-	553	O
of	-	563	O
an	-	566	O
isolated	-	569	O
fracture	-	578	O
or	-	587	O
dislocation	-	590	O
in	-	602	O
the	-	605	O
emergency	-	609	O
department	-	619	O
at	-	630	O
a	-	633	O
level	-	635	O
-	-	640	O
I	-	641	O
trauma	-	643	O
center	-	650	O
were	-	657	O
prospectively	-	662	O
evaluated	-	676	O
.	-	685	O

Ketamine	10901305	687	B
hydrochloride	-	696	I
was	-	710	O
administered	-	714	O
intravenously	-	727	O
(	-	741	O
at	-	742	O
a	-	745	O
dose	-	747	O
of	-	752	O
two	-	755	O
milligrams	-	759	O
per	-	770	O
kilogram	-	774	O
of	-	783	O
body	-	786	O
weight	-	791	O
)	-	797	O
in	-	799	O
ninety	-	802	O
-	-	808	O
nine	-	809	O
of	-	814	O
the	-	817	O
patients	-	821	O
and	-	830	O
intramuscularly	-	834	O
(	-	850	O
at	-	851	O
a	-	854	O
dose	-	856	O
of	-	861	O
four	-	864	O
milligrams	-	869	O
per	-	880	O
kilogram	-	884	O
of	-	893	O
body	-	896	O
weight	-	901	O
)	-	907	O
in	-	909	O
the	-	912	O
other	-	916	O
fifteen	-	922	O
.	-	929	O

A	10901305	931	O
board	-	933	O
-	-	938	O
certified	-	939	O
emergency	-	949	O
physician	-	959	O
skilled	-	969	O
in	-	977	O
airway	-	980	O
management	-	987	O
supervised	-	998	O
administration	-	1009	O
of	-	1024	O
the	-	1027	O
anesthetic	-	1031	O
,	-	1041	O
and	-	1043	O
the	-	1047	O
patients	-	1051	O
were	-	1060	O
monitored	-	1065	O
by	-	1075	O
a	-	1078	O
registered	-	1080	O
nurse	-	1091	O
.	-	1096	O

Any	10901305	1098	O
pain	-	1102	O
during	-	1107	O
the	-	1114	O
reduction	-	1118	O
was	-	1128	O
rated	-	1132	O
by	-	1138	O
the	-	1141	O
orthopaedic	-	1145	O
surgeon	-	1157	O
treating	-	1165	O
the	-	1174	O
patient	-	1178	O
according	-	1186	O
to	-	1196	O
the	-	1199	O
Children	-	1203	O
's	-	1211	O
Hospital	-	1214	O
of	-	1223	O
Eastern	-	1226	O
Ontario	-	1234	O
Pain	-	1242	O
Scale	-	1247	O
(	-	1253	O
CHEOPS	-	1254	O
)	-	1260	O
.	-	1261	O

RESULTS	10901305	1263	O
:	-	1270	O

The	10901305	1272	O
average	-	1276	O
time	-	1284	O
from	-	1289	O
intravenous	-	1294	O
administration	-	1306	O
of	-	1321	O
ketamine	-	1324	B
to	-	1333	O
manipulation	-	1336	O
of	-	1349	O
the	-	1352	O
fracture	-	1356	O
or	-	1365	O
dislocation	-	1368	O
was	-	1380	O
one	-	1384	O
minute	-	1388	O
and	-	1395	O
thirty	-	1399	O
-	-	1405	O
six	-	1406	O
seconds	-	1410	O
(	-	1418	O
range	-	1419	O
,	-	1424	O
twenty	-	1426	O
seconds	-	1433	O
to	-	1441	O
five	-	1444	O
minutes	-	1449	O
)	-	1456	O
,	-	1457	O
and	-	1459	O
the	-	1463	O
average	-	1467	O
time	-	1475	O
from	-	1480	O
intramuscular	-	1485	O
administration	-	1499	O
to	-	1514	O
manipulation	-	1517	O
was	-	1530	O
four	-	1534	O
minutes	-	1539	O
and	-	1547	O
forty	-	1551	O
-	-	1556	O
two	-	1557	O
seconds	-	1561	O
(	-	1569	O
range	-	1570	O
,	-	1575	O
sixty	-	1577	O
seconds	-	1583	O
to	-	1591	O
fifteen	-	1594	O
minutes	-	1602	O
)	-	1609	O
.	-	1610	O

The	10901305	1612	O
average	-	1616	O
score	-	1624	O
according	-	1630	O
to	-	1640	O
the	-	1643	O
Children	-	1647	O
's	-	1655	O
Hospital	-	1658	O
of	-	1667	O
Eastern	-	1670	O
Ontario	-	1678	O
Pain	-	1686	O
Scale	-	1691	O
was	-	1697	O
6	-	1701	O
.	-	1702	O
4	-	1703	O
points	-	1705	O
(	-	1712	O
range	-	1713	O
,	-	1718	O
5	-	1720	O
to	-	1722	O
10	-	1725	O
points	-	1728	O
)	-	1734	O
,	-	1735	O
reflecting	-	1737	O
minimal	-	1748	O
or	-	1756	O
no	-	1759	O
pain	-	1762	O
during	-	1767	O
fracture	-	1774	O
reduction	-	1783	O
.	-	1792	O

Adequate	10901305	1794	O
fracture	-	1803	O
reduction	-	1812	O
was	-	1822	O
obtained	-	1826	O
in	-	1835	O
111	-	1838	O
of	-	1842	O
the	-	1845	O
children	-	1849	O
.	-	1857	O

Ninety	10901305	1859	O
-	-	1865	O
nine	-	1866	O
percent	-	1871	O
(	-	1879	O
sixty	-	1880	O
-	-	1885	O
eight	-	1886	O
)	-	1891	O
of	-	1893	O
the	-	1896	O
sixty	-	1900	O
-	-	1905	O
nine	-	1906	O
parents	-	1911	O
present	-	1919	O
during	-	1927	O
the	-	1934	O
reduction	-	1938	O
were	-	1948	O
pleased	-	1953	O
with	-	1961	O
the	-	1966	O
sedation	-	1970	O
and	-	1979	O
would	-	1983	O
allow	-	1989	O
it	-	1995	O
to	-	1998	O
be	-	2001	O
used	-	2004	O
again	-	2009	O
in	-	2015	O
a	-	2018	O
similar	-	2020	O
situation	-	2028	O
.	-	2037	O

Patency	10901305	2039	O
of	-	2047	O
the	-	2050	O
airway	-	2054	O
and	-	2061	O
independent	-	2065	O
respiration	-	2077	O
were	-	2089	O
maintained	-	2094	O
in	-	2105	O
all	-	2108	O
of	-	2112	O
the	-	2115	O
patients	-	2119	O
.	-	2127	O

Blood	10901305	2129	O
pressure	-	2135	O
and	-	2144	O
heart	-	2148	O
rate	-	2154	O
remained	-	2159	O
stable	-	2168	O
.	-	2174	O

Minor	10901305	2176	O
side	-	2182	O
effects	-	2187	O
included	-	2195	O
nausea	-	2204	O
(	-	2211	O
thirteen	-	2212	O
patients	-	2221	O
)	-	2229	O
,	-	2230	O
emesis	-	2232	O
(	-	2239	O
eight	-	2240	O
of	-	2246	O
the	-	2249	O
thirteen	-	2253	O
patients	-	2262	O
with	-	2271	O
nausea	-	2276	O
)	-	2282	O
,	-	2283	O
clumsiness	-	2285	O
(	-	2296	O
evident	-	2297	O
as	-	2305	O
ataxic	-	2308	O
movements	-	2315	O
in	-	2325	O
ten	-	2328	O
patients	-	2332	O
)	-	2340	O
,	-	2341	O
and	-	2343	O
dysphoric	-	2347	O
reaction	-	2357	O
(	-	2366	O
one	-	2367	O
patient	-	2371	O
)	-	2378	O
.	-	2379	O

No	10901305	2381	O
long	-	2384	O
-	-	2388	O
term	-	2389	O
sequelae	-	2394	O
were	-	2403	O
noted	-	2408	O
,	-	2413	O
and	-	2415	O
no	-	2419	O
patients	-	2422	O
had	-	2431	O
hallucinations	-	2435	O
or	-	2450	O
nightmares	-	2453	O
.	-	2463	O

CONCLUSIONS	10901305	2465	O
:	-	2476	O

Ketamine	10901305	2478	B
reliably	-	2487	O
,	-	2495	O
safely	-	2497	O
,	-	2503	O
and	-	2505	O
quickly	-	2509	O
provided	-	2517	O
adequate	-	2526	O
sedation	-	2535	O
to	-	2544	O
effectively	-	2547	O
facilitate	-	2559	O
the	-	2570	O
reduction	-	2574	O
of	-	2584	O
children	-	2587	O
's	-	2595	O
fractures	-	2598	O
in	-	2608	O
the	-	2611	O
emergency	-	2615	O
department	-	2625	O
at	-	2636	O
our	-	2639	O
institution	-	2643	O
.	-	2654	O

Ketamine	10901305	2656	B
should	-	2665	O
only	-	2672	O
be	-	2677	O
used	-	2680	O
in	-	2685	O
an	-	2688	O
environment	-	2691	O
such	-	2703	O
as	-	2708	O
the	-	2711	O
emergency	-	2715	O
department	-	2725	O
,	-	2735	O
where	-	2737	O
proper	-	2743	O
one	-	2750	O
-	-	2753	O
on	-	2754	O
-	-	2756	O
one	-	2757	O
monitoring	-	2761	O
is	-	2772	O
used	-	2775	O
and	-	2780	O
board	-	2784	O
-	-	2789	O
certified	-	2790	O
physicians	-	2800	O
skilled	-	2811	O
in	-	2819	O
airway	-	2822	O
management	-	2829	O
are	-	2840	O
directly	-	2844	O
involved	-	2853	O
in	-	2862	O
the	-	2865	O
care	-	2869	O
of	-	2874	O
the	-	2877	O
patient	-	2881	O
.	-	2888	O

Prophylactic	19037603	0	O
use	-	13	O
of	-	17	O
lamivudine	-	20	B
with	-	31	O
chronic	-	36	O
immunosuppressive	-	44	O
therapy	-	62	O
for	-	70	O
rheumatologic	-	74	O
disorders	-	88	O
.	-	97	O

The	19037603	99	O
objective	-	103	O
of	-	113	O
this	-	116	O
study	-	121	O
was	-	127	O
to	-	131	O
report	-	134	O
our	-	141	O
experience	-	145	O
concerning	-	156	O
the	-	167	O
effectiveness	-	171	O
of	-	185	O
the	-	188	O
prophylactic	-	192	O
administration	-	205	O
of	-	220	O
lamivudine	-	223	B
in	-	234	O
hepatitis	-	237	B
B	-	247	I
virus	-	249	I
surface	-	255	I
antigen	-	263	I
(	-	271	O
HBs	-	272	B
Ag	-	276	I
)	-	278	O
positive	-	280	O
patients	-	289	O
with	-	298	O
rheumatologic	-	303	O
disease	-	317	O
.	-	324	O

From	19037603	326	O
June	-	331	O
2004	-	336	O
to	-	341	O
October	-	344	O
2006	-	352	O
,	-	356	O
11	-	358	O
HBs	-	361	B
Ag	-	365	I
positive	-	368	O
patients	-	377	O
with	-	386	O
rheumatologic	-	391	O
diseases	-	405	O
,	-	413	O
who	-	415	O
were	-	419	O
on	-	424	O
both	-	427	O
immunosuppressive	-	432	O
and	-	450	O
prophylactic	-	454	O
lamivudine	-	467	B
therapies	-	478	O
,	-	487	O
were	-	489	O
retrospectively	-	494	O
assessed	-	510	O
.	-	518	O

Liver	19037603	520	O
function	-	526	O
tests	-	535	O
,	-	540	O
hepatitis	-	542	O
B	-	552	O
virus	-	554	O
(	-	560	O
HBV	-	561	O
)	-	564	O
serologic	-	566	O
markers	-	576	O
,	-	583	O
and	-	585	O
HBV	-	589	O
DNA	-	593	O
levels	-	597	O
of	-	604	O
the	-	607	O
patients	-	611	O
during	-	620	O
follow	-	627	O
-	-	633	O
up	-	634	O
were	-	637	O
obtained	-	642	O
from	-	651	O
hospital	-	656	O
file	-	665	O
records	-	670	O
.	-	677	O

Eleven	19037603	679	O
patients	-	686	O
(	-	695	O
six	-	696	O
male	-	700	O
)	-	704	O
with	-	706	O
median	-	711	O
age	-	718	O
47	-	722	O
years	-	725	O
(	-	731	O
range	-	732	O
27	-	738	O
-	-	740	O
73	-	741	O
)	-	743	O
,	-	744	O
median	-	746	O
disease	-	753	O
duration	-	761	O
50	-	770	O
months	-	773	O
(	-	780	O
range	-	781	O
9	-	787	O
-	-	788	O
178	-	789	O
)	-	792	O
and	-	794	O
median	-	798	O
follow	-	805	O
-	-	811	O
up	-	812	O
period	-	815	O
of	-	822	O
patients	-	825	O
13	-	834	O
.	-	836	O
8	-	837	O
months	-	839	O
(	-	846	O
range	-	847	O
5	-	853	O
-	-	854	O
27	-	855	O
)	-	857	O
were	-	859	O
enrolled	-	864	O
in	-	873	O
this	-	876	O
study	-	881	O
.	-	886	O

Lamivudine	19037603	888	B
therapy	-	899	O
was	-	907	O
started	-	911	O
3	-	919	O
-	-	920	O
7	-	921	O
days	-	923	O
prior	-	928	O
to	-	934	O
immunosuppressive	-	937	O
therapy	-	955	O
in	-	963	O
all	-	966	O
patients	-	970	O
.	-	978	O

Baseline	19037603	980	O
,	-	988	O
liver	-	990	O
function	-	996	O
tests	-	1005	O
were	-	1011	O
elevated	-	1016	O
in	-	1025	O
two	-	1028	O
patients	-	1032	O
(	-	1041	O
fourth	-	1042	O
patient	-	1049	O
:	-	1056	O
ALT	-	1058	O
:	-	1061	O
122	-	1062	O
IU	-	1066	O
/	-	1068	O
l	-	1069	O
,	-	1070	O
AST	-	1072	O
:	-	1075	O
111	-	1076	O
IU	-	1080	O
/	-	1082	O
l	-	1083	O
,	-	1084	O
tenth	-	1086	O
patient	-	1092	O
:	-	1099	O
ALT	-	1100	O
:	-	1103	O
294	-	1104	O

IU	19037603	1108	O
/	-	1110	O
l	-	1111	O
,	-	1112	O
AST	-	1114	O
:	-	1117	O
274	-	1118	O
IU	-	1122	O

/	19037603	1124	O
l	-	1125	O
,	-	1126	O
with	-	1128	O
minimal	-	1133	O
changes	-	1141	O
in	-	1149	O
the	-	1152	O
liver	-	1156	O
biopsy	-	1162	O
in	-	1169	O
both	-	1172	O
)	-	1176	O
.	-	1177	O

Shortly	19037603	1179	O
after	-	1187	O
treatment	-	1193	O
their	-	1203	O
tests	-	1209	O
normalized	-	1215	O
and	-	1226	O
during	-	1230	O
follow	-	1237	O
-	-	1243	O
up	-	1244	O
period	-	1247	O
none	-	1254	O
of	-	1259	O
the	-	1262	O
patients	-	1266	O
had	-	1275	O
abnormal	-	1279	O
liver	-	1288	O
function	-	1294	O
tests	-	1303	O
.	-	1308	O

In	19037603	1310	O
four	-	1313	O
patients	-	1318	O
HBV	-	1327	O
DNA	-	1331	O
levels	-	1335	O
were	-	1342	O
higher	-	1347	O
than	-	1354	O
normal	-	1359	O
at	-	1366	O
baseline	-	1369	O
.	-	1377	O

Two	19037603	1379	O
of	-	1383	O
these	-	1386	O
normalized	-	1392	O
and	-	1403	O
the	-	1407	O
others	-	1411	O
increased	-	1418	O
later	-	1428	O
.	-	1433	O

In	19037603	1435	O
three	-	1438	O
additional	-	1444	O
patients	-	1455	O
,	-	1463	O
HBV	-	1465	O
DNA	-	1469	O
levels	-	1473	O
were	-	1480	O
increased	-	1485	O
during	-	1495	O
follow	-	1502	O
-	-	1508	O
up	-	1509	O
.	-	1511	O

None	19037603	1513	O
of	-	1518	O
the	-	1521	O
patients	-	1525	O
had	-	1534	O
significant	-	1538	O
clinical	-	1550	O
sings	-	1559	O
of	-	1565	O
HBV	-	1568	O
activation	-	1572	O
.	-	1582	O

Lamivudine	19037603	1584	B
was	-	1595	O
well	-	1599	O
tolerated	-	1604	O
and	-	1614	O
was	-	1618	O
continued	-	1622	O
in	-	1632	O
all	-	1635	O
patients	-	1639	O
.	-	1647	O

Prophylactic	19037603	1649	O
administration	-	1662	O
of	-	1677	O
lamivudine	-	1680	B
in	-	1691	O
patients	-	1694	O
who	-	1703	O
required	-	1707	O
immunosuppressive	-	1716	O
therapy	-	1734	O
seems	-	1742	O
to	-	1748	O
be	-	1751	O
safe	-	1754	O
,	-	1758	O
well	-	1760	O
tolerated	-	1765	O
and	-	1775	O
effective	-	1779	O
in	-	1789	O
preventing	-	1792	O
HBV	-	1803	O
reactivation	-	1807	O
.	-	1819	O

Safety	20084309	0	O
of	-	7	O
transesophageal	-	10	O
echocardiography	-	26	O
in	-	43	O
adults	-	46	O
:	-	52	O
study	-	54	O
in	-	60	O
a	-	63	O
multidisciplinary	-	65	O
hospital	-	83	O
.	-	91	O

BACKGROUND	20084309	93	O
:	-	103	O
TEE	-	105	O
is	-	109	O
a	-	112	O
semi	-	114	O
-	-	118	O
invasive	-	119	O
tool	-	128	O
broadly	-	133	O
used	-	141	O
and	-	146	O
its	-	150	O
utilization	-	154	O
associated	-	166	O
to	-	177	O
sedatives	-	180	O
drugs	-	190	O
might	-	196	O
to	-	202	O
affect	-	205	O
the	-	212	O
procedure	-	216	O
safety	-	226	O
.	-	232	O

OBJECTIVE	20084309	234	O
:	-	243	O
to	-	245	O
analyze	-	248	O
aspects	-	256	O
of	-	264	O
TEE	-	267	O
safety	-	271	O
associated	-	278	O
to	-	289	O
the	-	292	O
use	-	296	O
of	-	300	O
Midazolan	-	303	B
(	-	313	O
MZ	-	314	B
)	-	316	O
and	-	318	O
Flumazenil	-	322	B
(	-	333	O
FL	-	334	B
)	-	336	O
and	-	338	O
the	-	342	O
influence	-	346	O
of	-	356	O
the	-	359	O
clinical	-	363	O
variables	-	372	O
on	-	382	O
the	-	385	O
event	-	389	O
rate	-	395	O
.	-	399	O

METHOD	20084309	401	O
:	-	407	O
prospective	-	409	O
study	-	421	O
with	-	427	O
137	-	432	O
patients	-	436	O
that	-	445	O
underwent	-	450	O
TEE	-	460	O
with	-	464	O
MZ	-	469	B
associated	-	472	O
to	-	483	O
moderate	-	486	O
sedation	-	495	O
.	-	503	O

We	20084309	505	O
analyzed	-	508	O
the	-	517	O
following	-	521	O
events	-	531	O
:	-	537	O
complications	-	539	O
related	-	553	O
with	-	561	O
the	-	566	O
topical	-	570	O
anesthesia	-	578	O
,	-	588	O
with	-	590	O
MZ	-	595	B
use	-	598	O
and	-	602	O
with	-	606	O
the	-	611	O
procedure	-	615	O
.	-	624	O

Uni	20084309	626	O
-	-	629	O
and	-	631	O
multivariate	-	635	O
analyses	-	648	O
were	-	657	O
used	-	662	O
to	-	667	O
test	-	670	O
the	-	675	O
influence	-	679	O
of	-	689	O
the	-	692	O
clinical	-	696	O
variables	-	705	O
:	-	714	O
age	-	716	O
,	-	719	O
sex	-	721	O
,	-	724	O
stroke	-	726	O
,	-	732	O
myocardiopathy	-	734	O
(	-	749	O
MP	-	750	O
)	-	752	O
,	-	753	O
duration	-	755	O
of	-	764	O
the	-	767	O
test	-	771	O
,	-	775	O
mitral	-	777	O
regurgitation	-	784	O
(	-	798	O
MR	-	799	O
)	-	801	O
and	-	803	O
the	-	807	O
MZ	-	811	B
dose	-	814	O
.	-	818	O

RESULTS	20084309	820	O
:	-	827	O

All	20084309	829	O
patients	-	833	O
(	-	842	O
65	-	843	O
+	-	845	O
/	-	846	O
-	-	847	O
16	-	848	O
yrs	-	851	O
;	-	854	O
58	-	856	O
%	-	858	O
males	-	860	O
)	-	865	O
finished	-	867	O
the	-	876	O
examination	-	880	O
.	-	891	O

The	20084309	893	O
mean	-	897	O
doses	-	902	O
of	-	908	O
MZ	-	911	B
and	-	914	O
FL	-	918	B
were	-	921	O
4	-	926	O
.	-	927	O
3	-	928	O
+	-	929	O
/	-	930	O
-	-	931	O
1	-	932	O
.	-	933	O
9	-	934	O
mg	-	936	O
and	-	939	O
0	-	943	O
.	-	944	O
28	-	945	O
+	-	947	O
/	-	948	O
-	-	949	O
0	-	950	O
.	-	951	O
2	-	952	O
mg	-	954	O
,	-	956	O
respectively	-	958	O
.	-	970	O

The	20084309	972	O
duration	-	976	O
of	-	985	O
the	-	988	O
examination	-	992	O
and	-	1004	O
the	-	1008	O
mean	-	1012	O
ejection	-	1017	O
fraction	-	1026	O
(	-	1035	O
EF	-	1036	O
)	-	1038	O
were	-	1040	O
16	-	1045	O
.	-	1047	O
4	-	1048	O
+	-	1049	O
/	-	1050	O
-	-	1051	O
6	-	1052	O
.	-	1053	O
1	-	1054	O
minutes	-	1056	O
and	-	1064	O
60	-	1068	O
+	-	1070	O
/	-	1071	O
-	-	1072	O
9	-	1073	O
%	-	1074	O
,	-	1075	O
respectively	-	1077	O
.	-	1089	O

Mild	20084309	1091	O
hypoxia	-	1096	O
(	-	1104	O
SO2	-	1105	O
<	-	1108	O
90	-	1109	O
%	-	1111	O
)	-	1112	O
was	-	1114	O
the	-	1118	O
most	-	1122	O
common	-	1127	O
event	-	1134	O
(	-	1140	O
11	-	1141	O
patients	-	1144	O
)	-	1152	O
;	-	1153	O
3	-	1155	O
patients	-	1157	O
(	-	1166	O
2	-	1167	O
%	-	1168	O
)	-	1169	O
presented	-	1171	O
transient	-	1181	O
hypoxia	-	1191	O
due	-	1199	O
to	-	1203	O
upper	-	1206	O
airway	-	1212	O
obstruction	-	1219	O
by	-	1231	O
probe	-	1234	O
introduction	-	1240	O
and	-	1253	O
8	-	1257	O
(	-	1259	O
5	-	1260	O
.	-	1261	O
8	-	1262	O
%	-	1263	O
)	-	1264	O
due	-	1266	O
to	-	1270	O
hypoxia	-	1273	O
caused	-	1281	O
by	-	1288	O
MZ	-	1291	B
use	-	1294	O
.	-	1297	O

Transient	20084309	1299	O
hypotension	-	1309	O
(	-	1321	O
SAP	-	1322	O
<	-	1325	O
90mmHg	-	1326	O
)	-	1332	O
occurred	-	1334	O
in	-	1343	O
1	-	1346	O
patient	-	1348	O
(	-	1356	O
0	-	1357	O
.	-	1358	O
7	-	1359	O
%	-	1360	O
)	-	1361	O
.	-	1362	O

The	20084309	1364	O
multivariate	-	1368	O
analysis	-	1381	O
showed	-	1390	O
that	-	1397	O
severe	-	1402	O
MR	-	1409	O
,	-	1411	O
MP	-	1413	O
(	-	1416	O
EF	-	1417	O
<	-	1419	O
45	-	1420	O
%	-	1422	O
)	-	1423	O
and	-	1425	O
high	-	1429	O
doses	-	1434	O
of	-	1440	O
MZ	-	1443	B
(	-	1446	O
>	-	1447	O
5	-	1448	O
mg	-	1449	O
)	-	1451	O
were	-	1453	O
associated	-	1458	O
with	-	1469	O
events	-	1474	O
(	-	1481	O
p	-	1482	O
<	-	1483	O
0	-	1484	O
.	-	1485	O
001	-	1486	O
)	-	1489	O
.	-	1490	O

The	20084309	1492	O
EF	-	1496	O
was	-	1499	O
40	-	1503	O
%	-	1505	O
,	-	1506	O
in	-	1508	O
the	-	1511	O
group	-	1515	O
with	-	1521	O
MP	-	1526	O
and	-	1529	O
44	-	1533	O
%	-	1535	O
in	-	1537	O
the	-	1540	O
group	-	1544	O
with	-	1550	O
severe	-	1555	O
MR	-	1562	O
and	-	1565	O
it	-	1569	O
can	-	1572	O
be	-	1576	O
a	-	1579	O
factor	-	1581	O
associated	-	1588	O
with	-	1599	O
clinical	-	1604	O
events	-	1613	O
in	-	1620	O
the	-	1623	O
last	-	1627	O
group	-	1632	O
.	-	1637	O

CONCLUSION	20084309	1639	O
:	-	1649	O

TEE	20084309	1651	O
with	-	1655	O
sedation	-	1660	O
presents	-	1669	O
a	-	1678	O
low	-	1680	O
rate	-	1684	O
of	-	1689	O
events	-	1692	O
.	-	1698	O

There	20084309	1700	O
were	-	1706	O
no	-	1711	O
severe	-	1714	O
events	-	1721	O
and	-	1728	O
there	-	1732	O
was	-	1738	O
no	-	1742	O
need	-	1745	O
to	-	1750	O
interrupt	-	1753	O
the	-	1763	O
examinations	-	1767	O
.	-	1779	O

Effects	8231633	0	O
of	-	8	O
calcium	-	11	B
channel	-	19	O
blockers	-	27	O
on	-	36	O
bupivacaine	-	39	B
-	-	50	O
induced	-	51	O
toxicity	-	59	O
.	-	67	O

The	8231633	69	O
purpose	-	73	O
of	-	81	O
this	-	84	O
study	-	89	O
was	-	95	O
to	-	99	O
investigate	-	102	O
the	-	114	O
influence	-	118	O
of	-	128	O
calcium	-	131	B
channel	-	139	O
blockers	-	147	O
on	-	156	O
bupivacaine	-	159	B
-	-	170	O
induced	-	171	O
acute	-	179	O
toxicity	-	185	O
.	-	193	O

For	8231633	195	O
each	-	199	O
of	-	204	O
the	-	207	O
three	-	211	O
tested	-	217	O
calcium	-	224	B
channel	-	232	O
blockers	-	240	O
(	-	249	O
diltiazem	-	250	B
,	-	259	O
verapamil	-	261	B
and	-	271	O
bepridil	-	275	B
)	-	283	O
6	-	285	O
groups	-	287	O
of	-	294	O
mice	-	297	O
were	-	302	O
treated	-	307	O
by	-	315	O
two	-	318	O
different	-	322	O
doses	-	332	O
,	-	337	O
i	-	339	O
.	-	340	O
e	-	341	O
.	-	342	O
2	-	344	O
and	-	346	O
10	-	350	O
mg	-	353	O
/	-	355	O
kg	-	356	O
/	-	358	O
i	-	359	O
.	-	360	O
p	-	361	O
.	-	362	O
,	-	363	O
or	-	365	O
an	-	368	O
equal	-	371	O
volume	-	377	O
of	-	384	O
saline	-	387	O
for	-	394	O
the	-	398	O
control	-	402	O
group	-	410	O
(	-	416	O
n	-	417	O
=	-	419	O
20	-	421	O
)	-	423	O
;	-	424	O
15	-	426	O
minutes	-	429	O
later	-	437	O
,	-	442	O
all	-	444	O
the	-	448	O
animals	-	452	O
were	-	460	O
injected	-	465	O
with	-	474	O
a	-	479	O
single	-	481	O
50	-	488	O
mg	-	491	O
/	-	493	O
kg	-	494	O
/	-	496	O
i	-	497	O
.	-	498	O
p	-	499	O
.	-	500	O

dose	8231633	502	O
of	-	507	O
bupivacaine	-	510	B
.	-	521	O

The	8231633	523	O
convulsant	-	527	O
activity	-	538	O
,	-	546	O
the	-	548	O
time	-	552	O
of	-	557	O
latency	-	560	O
to	-	568	O
convulse	-	571	O
and	-	580	O
the	-	584	O
mortality	-	588	O
rate	-	598	O
were	-	603	O
assessed	-	608	O
in	-	617	O
each	-	620	O
group	-	625	O
.	-	630	O

The	8231633	632	O
local	-	636	O
anesthetic	-	642	O
-	-	652	O
induced	-	653	O
mortality	-	661	O
was	-	671	O
significantly	-	675	O
increased	-	689	O
by	-	699	O
the	-	702	O
three	-	706	O
different	-	712	O
calcium	-	722	B
channel	-	730	O
blockers	-	738	O
.	-	746	O

The	8231633	748	O
convulsant	-	752	O
activity	-	763	O
of	-	772	O
bupivacaine	-	775	B
was	-	787	O
not	-	791	O
significantly	-	795	O
modified	-	809	O
but	-	818	O
calcium	-	822	B
channel	-	830	O
blockers	-	838	O
decreased	-	847	O
the	-	857	O
time	-	861	O
of	-	866	O
latency	-	869	O
to	-	877	O
obtain	-	880	O
bupivacaine	-	887	B
-	-	898	O
induced	-	899	O
convulsions	-	907	O
;	-	918	O
this	-	920	O
effect	-	925	O
was	-	932	O
less	-	936	O
pronounced	-	941	O
with	-	952	O
bepridil	-	957	B
.	-	965	O

Selegiline	10091617	0	B
-	-	10	O
induced	-	11	O
postural	-	19	O
hypotension	-	28	O
in	-	40	O
Parkinson	-	43	O
's	-	52	O
disease	-	55	O
:	-	62	O
a	-	64	O
longitudinal	-	66	O
study	-	79	O
on	-	85	O
the	-	88	O
effects	-	92	O
of	-	100	O
drug	-	103	O
withdrawal	-	108	O
.	-	118	O

OBJECTIVES	10091617	120	O
:	-	130	O

The	10091617	132	O
United	-	136	O
Kingdom	-	143	O
Parkinson	-	151	O
's	-	160	O
Disease	-	163	O
Research	-	171	O
Group	-	180	O
(	-	186	O
UKPDRG	-	187	O
)	-	193	O
trial	-	195	O
found	-	201	O
an	-	207	O
increased	-	210	O
mortality	-	220	O
in	-	230	O
patients	-	233	O
with	-	242	O
Parkinson	-	247	O
's	-	256	O
disease	-	259	O
(	-	267	O
PD	-	268	O
)	-	270	O
randomized	-	272	O
to	-	283	O
receive	-	286	O
10	-	294	O
mg	-	297	O
selegiline	-	300	B
per	-	311	O
day	-	315	O
and	-	319	O
L	-	323	B
-	-	324	I
dopa	-	325	I
compared	-	330	O
with	-	339	O
those	-	344	O
taking	-	350	O
L	-	357	B
-	-	358	I
dopa	-	359	I
alone	-	364	O
.	-	369	O

Recently	10091617	371	O
,	-	379	O
we	-	381	O
found	-	384	O
that	-	390	O
therapy	-	395	O
with	-	403	O
selegiline	-	408	B
and	-	419	O
L	-	423	B
-	-	424	I
dopa	-	425	I
was	-	430	O
associated	-	434	O
with	-	445	O
selective	-	450	O
systolic	-	460	O
orthostatic	-	469	O
hypotension	-	481	O
which	-	493	O
was	-	499	O
abolished	-	503	O
by	-	513	O
withdrawal	-	516	O
of	-	527	O
selegiline	-	530	B
.	-	540	O

This	10091617	542	O
unwanted	-	547	O
effect	-	556	O
on	-	563	O
postural	-	566	O
blood	-	575	O
pressure	-	581	O
was	-	590	O
not	-	594	O
the	-	598	O
result	-	602	O
of	-	609	O
underlying	-	612	O
autonomic	-	623	O
failure	-	633	O
.	-	640	O

The	10091617	642	O
aims	-	646	O
of	-	651	O
this	-	654	O
study	-	659	O
were	-	665	O
to	-	670	O
confirm	-	673	O
our	-	681	O
previous	-	685	O
findings	-	694	O
in	-	703	O
a	-	706	O
separate	-	708	O
cohort	-	717	O
of	-	724	O
patients	-	727	O
and	-	736	O
to	-	740	O
determine	-	743	O
the	-	753	O
time	-	757	O
course	-	762	O
of	-	769	O
the	-	772	O
cardiovascular	-	776	O
consequences	-	791	O
of	-	804	O
stopping	-	807	O
selegiline	-	816	B
in	-	827	O
the	-	830	O
expectation	-	834	O
that	-	846	O
this	-	851	O
might	-	856	O
shed	-	862	O
light	-	867	O
on	-	873	O
the	-	876	O
mechanisms	-	880	O
by	-	891	O
which	-	894	O
the	-	900	O
drug	-	904	O
causes	-	909	O
orthostatic	-	916	O
hypotension	-	928	O
.	-	939	O

METHODS	10091617	941	O
:	-	948	O

The	10091617	950	O
cardiovascular	-	954	O
responses	-	969	O
to	-	979	O
standing	-	982	O
and	-	991	O
head	-	995	O
-	-	999	O
up	-	1000	O
tilt	-	1003	O
were	-	1008	O
studied	-	1013	O
repeatedly	-	1021	O
in	-	1032	O
PD	-	1035	O
patients	-	1038	O
receiving	-	1047	O
selegiline	-	1057	B
and	-	1068	O
as	-	1072	O
the	-	1075	O
drug	-	1079	O
was	-	1084	O
withdrawn	-	1088	O
.	-	1097	O

RESULTS	10091617	1099	O
:	-	1106	O

Head	10091617	1108	O
-	-	1112	O
up	-	1113	O
tilt	-	1116	O
caused	-	1121	O
systolic	-	1128	O
orthostatic	-	1137	O
hypotension	-	1149	O
which	-	1161	O
was	-	1167	O
marked	-	1171	O
in	-	1178	O
six	-	1181	O
of	-	1185	O
20	-	1188	O
PD	-	1191	O
patients	-	1194	O
on	-	1203	O
selegiline	-	1206	B
,	-	1216	O
one	-	1218	O
of	-	1222	O
whom	-	1225	O
lost	-	1230	O
consciousness	-	1235	O
with	-	1249	O
unrecordable	-	1254	O
blood	-	1267	O
pressures	-	1273	O
.	-	1282	O

A	10091617	1284	O
lesser	-	1286	O
degree	-	1293	O
of	-	1300	O
orthostatic	-	1303	O
hypotension	-	1315	O
occurred	-	1327	O
with	-	1336	O
standing	-	1341	O
.	-	1349	O

Orthostatic	10091617	1351	O
hypotension	-	1363	O
was	-	1375	O
ameliorated	-	1379	O
4	-	1391	O
days	-	1393	O
after	-	1398	O
withdrawal	-	1404	O
of	-	1415	O
selegiline	-	1418	B
and	-	1429	O
totally	-	1433	O
abolished	-	1441	O
7	-	1451	O
days	-	1453	O
after	-	1458	O
discontinuation	-	1464	O
of	-	1480	O
the	-	1483	O
drug	-	1487	O
.	-	1491	O

Stopping	10091617	1493	O
selegiline	-	1502	B
also	-	1513	O
significantly	-	1518	O
reduced	-	1532	O
the	-	1540	O
supine	-	1544	O
systolic	-	1551	O
and	-	1560	O
diastolic	-	1564	O
blood	-	1574	O
pressures	-	1580	O
consistent	-	1590	O
with	-	1601	O
a	-	1606	O
previously	-	1608	O
undescribed	-	1619	O
supine	-	1631	O
pressor	-	1638	O
action	-	1646	O
.	-	1652	O

CONCLUSION	10091617	1654	O
:	-	1664	O

This	10091617	1666	O
study	-	1671	O
confirms	-	1677	O
our	-	1686	O
previous	-	1690	O
finding	-	1699	O
that	-	1707	O
selegiline	-	1712	B
in	-	1723	O
combination	-	1726	O
with	-	1738	O
L	-	1743	B
-	-	1744	I
dopa	-	1745	I
is	-	1750	O
associated	-	1753	O
with	-	1764	O
selective	-	1769	O
orthostatic	-	1779	O
hypotension	-	1791	O
.	-	1802	O

The	10091617	1804	O
possibilities	-	1808	O
that	-	1822	O
these	-	1827	O
cardiovascular	-	1833	O
findings	-	1848	O
might	-	1857	O
be	-	1863	O
the	-	1866	O
result	-	1870	O
of	-	1877	O
non	-	1880	O
-	-	1883	O
selective	-	1884	O
inhibition	-	1894	O
of	-	1905	O
monoamine	-	1908	O
oxidase	-	1918	O
or	-	1926	O
of	-	1929	O
amphetamine	-	1932	B
and	-	1944	O
metamphetamine	-	1948	B
are	-	1963	O
discussed	-	1967	O
.	-	1976	O

Explicit	19269743	0	O
episodic	-	9	O
memory	-	18	O
for	-	25	O
sensory	-	29	O
-	-	36	O
discriminative	-	37	O
components	-	52	O
of	-	63	O
capsaicin	-	66	B
-	-	75	O
induced	-	76	O
pain	-	84	O
:	-	88	O
immediate	-	90	O
and	-	100	O
delayed	-	104	O
ratings	-	112	O
.	-	119	O

Pain	19269743	121	O
memory	-	126	O
is	-	133	O
thought	-	136	O
to	-	144	O
affect	-	147	O
future	-	154	O
pain	-	161	O
sensitivity	-	166	O
and	-	178	O
thus	-	182	O
contribute	-	187	O
to	-	198	O
clinical	-	201	O
pain	-	210	O
conditions	-	215	O
.	-	225	O

Systematic	19269743	227	O
investigations	-	238	O
of	-	253	O
the	-	256	O
human	-	260	O
capacity	-	266	O
to	-	275	O
remember	-	278	O
sensory	-	287	O
features	-	295	O
of	-	304	O
experimental	-	307	O
pain	-	320	O
are	-	325	O
sparse	-	329	O
.	-	335	O

In	19269743	337	O
order	-	340	O
to	-	346	O
address	-	349	O
long	-	357	O
-	-	361	O
term	-	362	O
pain	-	367	O
memory	-	372	O
,	-	378	O
nine	-	380	O
healthy	-	385	O
male	-	393	O
volunteers	-	398	O
received	-	409	O
intradermal	-	418	O
injections	-	430	O
of	-	441	O
three	-	444	O
doses	-	450	O
of	-	456	O
capsaicin	-	459	B
(	-	469	O
0	-	470	O
.	-	471	O
05	-	472	O
,	-	474	O
1	-	476	O
and	-	478	O
20	-	482	O
microg	-	485	O
,	-	491	O
separated	-	493	O
by	-	503	O
15	-	506	O
min	-	509	O
breaks	-	513	O
)	-	519	O
,	-	520	O
each	-	522	O
given	-	527	O
three	-	533	O
times	-	539	O
in	-	545	O
a	-	548	O
balanced	-	550	O
design	-	559	O
across	-	566	O
three	-	573	O
sessions	-	579	O
at	-	588	O
one	-	591	O
week	-	595	O
intervals	-	600	O
.	-	609	O

Pain	19269743	611	O
rating	-	616	O
was	-	623	O
performed	-	627	O
using	-	637	O
a	-	643	O
computerized	-	645	O
visual	-	658	O
analogue	-	665	O
scale	-	674	O
(	-	680	O
0	-	681	O
-	-	682	O
100	-	683	O
)	-	686	O
digitized	-	688	O
at	-	698	O
1	-	701	O
/	-	702	O
s	-	703	O
,	-	704	O
either	-	706	O
immediately	-	713	O
online	-	725	O
or	-	732	O
one	-	735	O
hour	-	739	O
or	-	744	O
one	-	747	O
day	-	751	O
after	-	755	O
injection	-	761	O
.	-	770	O

Subjects	19269743	772	O
also	-	781	O
recalled	-	786	O
their	-	795	O
pains	-	801	O
one	-	807	O
week	-	811	O
later	-	816	O
.	-	821	O

Capsaicin	19269743	823	B
injection	-	833	O
reliably	-	843	O
induced	-	852	O
a	-	860	O
dose	-	862	O
-	-	866	O
dependent	-	867	O
flare	-	877	O
(	-	883	O
p	-	884	O
<	-	885	O
0	-	886	O
.	-	887	O
001	-	888	O
)	-	891	O
without	-	893	O
any	-	901	O
difference	-	905	O
within	-	916	O
or	-	923	O
across	-	926	O
sessions	-	933	O
.	-	941	O

The	19269743	943	O
strong	-	947	O
burning	-	954	O
pain	-	962	O
decayed	-	967	O
exponentially	-	975	O
within	-	989	O
a	-	996	O
few	-	998	O
minutes	-	1002	O
.	-	1009	O

Subjects	19269743	1011	O
were	-	1020	O
able	-	1025	O
to	-	1030	O
reliably	-	1033	O
discriminate	-	1042	O
pain	-	1055	O
magnitude	-	1060	O
and	-	1070	O
duration	-	1074	O
across	-	1083	O
capsaicin	-	1090	B
doses	-	1100	O
(	-	1106	O
both	-	1107	O
p	-	1112	O
<	-	1113	O
0	-	1114	O
.	-	1115	O
001	-	1116	O
)	-	1119	O
,	-	1120	O
regardless	-	1122	O
of	-	1133	O
whether	-	1136	O
first	-	1144	O
-	-	1149	O
time	-	1150	O
ratings	-	1155	O
were	-	1163	O
requested	-	1168	O
immediately	-	1178	O
,	-	1189	O
after	-	1191	O
one	-	1197	O
hour	-	1201	O
or	-	1206	O
after	-	1209	O
one	-	1215	O
day	-	1219	O
.	-	1222	O

Pain	19269743	1224	O
recall	-	1229	O
after	-	1236	O
one	-	1242	O
week	-	1246	O
was	-	1251	O
similarly	-	1255	O
precise	-	1265	O
(	-	1273	O
magnitude	-	1274	O
:	-	1283	O
p	-	1285	O
<	-	1286	O
0	-	1287	O
.	-	1288	O
01	-	1289	O
,	-	1291	O
duration	-	1293	O
:	-	1301	O
p	-	1303	O
<	-	1304	O
0	-	1305	O
.	-	1306	O
05	-	1307	O
)	-	1309	O
.	-	1310	O

Correlation	19269743	1312	O
with	-	1324	O
rating	-	1329	O
recall	-	1336	O
after	-	1343	O
one	-	1349	O
week	-	1353	O
was	-	1358	O
best	-	1362	O
when	-	1367	O
first	-	1372	O
-	-	1377	O
time	-	1378	O
ratings	-	1383	O
were	-	1391	O
requested	-	1396	O
as	-	1406	O
late	-	1409	O
as	-	1414	O
one	-	1417	O
day	-	1421	O
after	-	1425	O
injection	-	1431	O
(	-	1441	O
R	-	1442	O
(	-	1443	O
2	-	1444	O
)	-	1445	O
=	-	1446	O
0	-	1447	O
.	-	1448	O
79	-	1449	O
)	-	1451	O
indicating	-	1453	O
that	-	1464	O
both	-	1469	O
rating	-	1474	O
retrievals	-	1481	O
utilized	-	1492	O
similar	-	1501	O
memory	-	1509	O
traces	-	1516	O
.	-	1522	O

These	19269743	1524	O
results	-	1530	O
indicate	-	1538	O
a	-	1547	O
reliable	-	1549	O
memory	-	1558	O
for	-	1565	O
magnitude	-	1569	O
and	-	1579	O
duration	-	1583	O
of	-	1592	O
experimentally	-	1595	O
induced	-	1610	O
pain	-	1618	O
.	-	1622	O

The	19269743	1624	O
data	-	1628	O
further	-	1633	O
suggest	-	1641	O
that	-	1649	O
the	-	1654	O
consolidation	-	1658	O
of	-	1672	O
this	-	1675	O
memory	-	1680	O
is	-	1687	O
an	-	1690	O
important	-	1693	O
interim	-	1703	O
stage	-	1711	O
,	-	1716	O
and	-	1718	O
may	-	1722	O
take	-	1726	O
up	-	1731	O
to	-	1734	O
one	-	1737	O
day	-	1741	O
.	-	1744	O

Reversibility	3070035	0	O
of	-	14	O
captopril	-	17	B
-	-	26	O
induced	-	27	O
renal	-	35	O
insufficiency	-	41	O
after	-	55	O
prolonged	-	61	O
use	-	71	O
in	-	75	O
an	-	78	O
unusual	-	81	O
case	-	89	O
of	-	94	O
renovascular	-	97	O
hypertension	-	110	O
.	-	122	O

We	3070035	124	O
report	-	127	O
a	-	134	O
case	-	136	O
of	-	141	O
severe	-	144	O
hypertension	-	151	O
with	-	164	O
an	-	169	O
occluded	-	172	O
renal	-	181	O
artery	-	187	O
to	-	194	O
a	-	197	O
solitary	-	199	O
kidney	-	208	O
,	-	214	O
who	-	216	O
developed	-	220	O
sudden	-	230	O
deterioration	-	237	O
of	-	251	O
renal	-	254	O
function	-	260	O
following	-	269	O
treatment	-	279	O
with	-	289	O
captopril	-	294	B
.	-	303	O

His	3070035	305	O
renal	-	309	O
function	-	315	O
remained	-	324	O
impaired	-	333	O
but	-	342	O
stable	-	346	O
during	-	353	O
2	-	360	O
years	-	362	O
'	-	367	O
treatment	-	369	O
with	-	379	O
captopril	-	384	B
but	-	394	O
returned	-	398	O
to	-	407	O
pre	-	410	O
-	-	413	O
treatment	-	414	O
levels	-	424	O
soon	-	431	O
after	-	436	O
cessation	-	442	O
of	-	452	O
the	-	455	O
drug	-	459	O
.	-	463	O

This	3070035	465	O
indicates	-	470	O
reversibility	-	480	O
in	-	494	O
captopril	-	497	B
-	-	506	O
induced	-	507	O
renal	-	515	O
failure	-	521	O
even	-	529	O
after	-	534	O
its	-	540	O
prolonged	-	544	O
use	-	554	O
and	-	558	O
suggests	-	562	O
that	-	571	O
no	-	576	O
organic	-	579	O
damage	-	587	O
occurs	-	594	O
to	-	601	O
glomerular	-	604	O
arterioles	-	615	O
following	-	626	O
chronic	-	636	O
ACE	-	644	O
inhibition	-	648	O
.	-	658	O

Liver	1147734	0	O
disease	-	6	O
caused	-	14	O
by	-	21	O
propylthiouracil	-	24	B
.	-	40	O

This	1147734	42	O
report	-	47	O
presents	-	54	O
the	-	63	O
clinical	-	67	O
,	-	75	O
laboratory	-	77	O
,	-	87	O
and	-	89	O
light	-	93	O
and	-	99	O
electron	-	103	O
microscopic	-	112	O
observations	-	124	O
on	-	137	O
a	-	140	O
patient	-	142	O
with	-	150	O
chronic	-	155	O
active	-	163	O
(	-	170	O
aggressive	-	171	O
)	-	181	O
hepatitis	-	183	O
caused	-	193	O
by	-	200	O
the	-	203	O
administration	-	207	O
of	-	222	O
propylthiouracil	-	225	B
.	-	241	O

This	1147734	243	O
is	-	248	O
an	-	251	O
addition	-	254	O
to	-	263	O
the	-	266	O
list	-	270	O
of	-	275	O
drugs	-	278	O
that	-	284	O
must	-	289	O
be	-	294	O
considered	-	297	O
in	-	308	O
the	-	311	O
evaluation	-	315	O
of	-	326	O
chronic	-	329	O
liver	-	337	O
disease	-	343	O
.	-	350	O

Capsaicin	12202650	0	B
-	-	9	O
induced	-	10	O
muscle	-	18	O
pain	-	25	O
alters	-	30	O
the	-	37	O
excitability	-	41	O
of	-	54	O
the	-	57	O
human	-	61	O
jaw	-	67	O
-	-	70	O
stretch	-	71	O
reflex	-	79	O
.	-	85	O

The	12202650	87	O
pathophysiology	-	91	O
of	-	107	O
painful	-	110	O
temporomandibular	-	118	O
disorders	-	136	O
is	-	146	O
not	-	149	O
fully	-	153	O
understood	-	159	O
,	-	169	O
but	-	171	O
evidence	-	175	O
suggests	-	184	O
that	-	193	O
muscle	-	198	O
pain	-	205	O
modulates	-	210	O
motor	-	220	O
function	-	226	O
in	-	235	O
characteristic	-	238	O
ways	-	253	O
.	-	257	O

This	12202650	259	O
study	-	264	O
tested	-	270	O
the	-	277	O
hypothesis	-	281	O
that	-	292	O
activation	-	297	O
of	-	308	O
nociceptive	-	311	O
muscle	-	323	O
afferent	-	330	O
fibers	-	339	O
would	-	346	O
be	-	352	O
linked	-	355	O
to	-	362	O
an	-	365	O
increased	-	368	O
excitability	-	378	O
of	-	391	O
the	-	394	O
human	-	398	O
jaw	-	404	O
-	-	407	O
stretch	-	408	O
reflex	-	416	O
and	-	423	O
whether	-	427	O
this	-	435	O
process	-	440	O
would	-	448	O
be	-	454	O
sensitive	-	457	O
to	-	467	O
length	-	470	O
and	-	477	O
velocity	-	481	O
of	-	490	O
the	-	493	O
stretch	-	497	O
.	-	504	O

Capsaicin	12202650	506	B
(	-	516	O
10	-	517	O
micro	-	520	O
g	-	526	O
)	-	527	O
was	-	529	O
injected	-	533	O
into	-	542	O
the	-	547	O
masseter	-	551	O
muscle	-	560	O
to	-	567	O
induce	-	570	O
pain	-	577	O
in	-	582	O
11	-	585	O
healthy	-	588	O
volunteers	-	596	O
.	-	606	O

Short	12202650	608	O
-	-	613	O
latency	-	614	O
reflex	-	622	O
responses	-	629	O
were	-	639	O
evoked	-	644	O
in	-	651	O
the	-	654	O
masseter	-	658	O
and	-	667	O
temporalis	-	671	O
muscles	-	682	O
by	-	690	O
a	-	693	O
stretch	-	695	O
device	-	703	O
with	-	710	O
different	-	715	O
velocities	-	725	O
and	-	736	O
displacements	-	740	O
before	-	754	O
,	-	760	O
during	-	762	O
,	-	768	O
and	-	770	O
after	-	774	O
the	-	780	O
pain	-	784	O
.	-	788	O

The	12202650	790	O
normalized	-	794	O
reflex	-	805	O
amplitude	-	812	O
increased	-	822	O
with	-	832	O
an	-	837	O
increase	-	840	O
in	-	849	O
velocity	-	852	O
at	-	861	O
a	-	864	O
given	-	866	O
displacement	-	872	O
,	-	884	O
but	-	886	O
remained	-	890	O
constant	-	899	O
with	-	908	O
different	-	913	O
displacements	-	923	O
at	-	937	O
a	-	940	O
given	-	942	O
velocity	-	948	O
.	-	956	O

The	12202650	958	O
normalized	-	962	O
reflex	-	973	O
amplitude	-	980	O
was	-	990	O
significantly	-	994	O
higher	-	1008	O
during	-	1015	O
pain	-	1022	O
,	-	1026	O
but	-	1028	O
only	-	1032	O
at	-	1037	O
faster	-	1040	O
stretches	-	1047	O
in	-	1057	O
the	-	1060	O
painful	-	1064	O
muscle	-	1072	O
.	-	1078	O

Increased	12202650	1080	O
sensitivity	-	1090	O
of	-	1102	O
the	-	1105	O
fusimotor	-	1109	O
system	-	1119	O
during	-	1126	O
acute	-	1133	O
muscle	-	1139	O
pain	-	1146	O
could	-	1151	O
be	-	1157	O
one	-	1160	O
likely	-	1164	O
mechanism	-	1171	O
to	-	1181	O
explain	-	1184	O
the	-	1192	O
findings	-	1196	O
.	-	1204	O

Repetitive	18951540	0	O
transcranial	-	11	O
magnetic	-	24	O
stimulation	-	33	O
for	-	45	O
levodopa	-	49	B
-	-	57	O
induced	-	58	O
dyskinesias	-	66	O
in	-	78	O
Parkinson	-	81	O
's	-	90	O
disease	-	93	O
.	-	100	O

In	18951540	102	O
a	-	105	O
placebo	-	107	O
-	-	114	O
controlled	-	115	O
,	-	125	O
single	-	127	O
-	-	133	O
blinded	-	134	O
,	-	141	O
crossover	-	143	O
study	-	153	O
,	-	158	O
we	-	160	O
assessed	-	163	O
the	-	172	O
effect	-	176	O
of	-	183	O
""""	-	186	O
real	-	187	O
""""	-	191	O
repetitive	-	193	O
transcranial	-	204	O
magnetic	-	217	O
stimulation	-	226	O
(	-	238	O
rTMS	-	239	O
)	-	243	O
versus	-	245	O
""""	-	252	O
sham	-	253	O
""""	-	257	O
rTMS	-	259	O
(	-	264	O
placebo	-	265	O
)	-	272	O
on	-	274	O
peak	-	277	O
dose	-	282	O
dyskinesias	-	287	O
in	-	299	O
patients	-	302	O
with	-	311	O
Parkinson	-	316	O
's	-	325	O
disease	-	328	O
(	-	336	O
PD	-	337	O
)	-	339	O
.	-	340	O

Ten	18951540	342	O
patients	-	346	O
with	-	355	O
PD	-	360	O
and	-	363	O
prominent	-	367	O
dyskinesias	-	377	O
had	-	389	O
rTMS	-	393	O
(	-	398	O
1	-	399	O
,	-	400	O
800	-	401	O
pulses	-	405	O
;	-	411	O
1	-	413	O
Hz	-	415	O
rate	-	418	O
)	-	422	O
delivered	-	424	O
over	-	434	O
the	-	439	O
motor	-	443	O
cortex	-	449	O
for	-	456	O
4	-	460	O
consecutive	-	462	O
days	-	474	O
twice	-	479	O
,	-	484	O
once	-	486	O
real	-	491	O
stimuli	-	496	O
and	-	504	O
once	-	508	O
sham	-	513	O
stimulation	-	518	O
were	-	530	O
used	-	535	O
;	-	539	O
evaluations	-	541	O
were	-	553	O
done	-	558	O
at	-	563	O
the	-	566	O
baseline	-	570	O
and	-	579	O
1	-	583	O
day	-	585	O
after	-	589	O
the	-	595	O
end	-	599	O
of	-	603	O
each	-	606	O
of	-	611	O
the	-	614	O
treatment	-	618	O
series	-	628	O
.	-	634	O

Direct	18951540	636	O
comparison	-	643	O
between	-	654	O
sham	-	662	O
and	-	667	O
real	-	671	O
rTMS	-	676	O
effects	-	681	O
showed	-	689	O
no	-	696	O
significant	-	699	O
difference	-	711	O
in	-	722	O
clinician	-	725	O
-	-	734	O
assessed	-	735	O
dyskinesia	-	744	O
severity	-	755	O
.	-	763	O

However	18951540	765	O
,	-	772	O
comparison	-	774	O
with	-	785	O
the	-	790	O
baseline	-	794	O
showed	-	803	O
small	-	810	O
but	-	816	O
significant	-	820	O
reduction	-	832	O
in	-	842	O
dyskinesia	-	845	O
severity	-	856	O
following	-	865	O
real	-	875	O
rTMS	-	880	O
but	-	885	O
not	-	889	O
placebo	-	893	O
.	-	900	O

The	18951540	902	O
major	-	906	O
effect	-	912	O
was	-	919	O
on	-	923	O
dystonia	-	926	O
subscore	-	935	O
.	-	943	O

Similarly	18951540	945	O
,	-	954	O
in	-	956	O
patient	-	959	O
diaries	-	967	O
,	-	974	O
although	-	976	O
both	-	985	O
treatments	-	990	O
caused	-	1001	O
reduction	-	1008	O
in	-	1018	O
subjective	-	1021	O
dyskinesia	-	1032	O
scores	-	1043	O
during	-	1050	O
the	-	1057	O
days	-	1061	O
of	-	1066	O
intervention	-	1069	O
,	-	1081	O
the	-	1083	O
effect	-	1087	O
was	-	1094	O
sustained	-	1098	O
for	-	1108	O
3	-	1112	O
days	-	1114	O
after	-	1119	O
the	-	1125	O
intervention	-	1129	O
for	-	1142	O
the	-	1146	O
real	-	1150	O
rTMS	-	1155	O
only	-	1160	O
.	-	1164	O

Following	18951540	1166	O
rTMS	-	1176	O
,	-	1180	O
no	-	1182	O
side	-	1185	O
effects	-	1190	O
and	-	1198	O
no	-	1202	O
adverse	-	1205	O
effects	-	1213	O
on	-	1221	O
motor	-	1224	O
function	-	1230	O
and	-	1239	O
PD	-	1243	O
symptoms	-	1246	O
were	-	1255	O
noted	-	1260	O
.	-	1265	O

The	18951540	1267	O
results	-	1271	O
suggest	-	1279	O
the	-	1287	O
existence	-	1291	O
of	-	1301	O
residual	-	1304	O
beneficial	-	1313	O
clinical	-	1324	O
aftereffects	-	1333	O
of	-	1346	O
consecutive	-	1349	O
daily	-	1361	O
applications	-	1367	O
of	-	1380	O
low	-	1383	O
-	-	1386	O
frequency	-	1387	O
rTMS	-	1397	O
on	-	1402	O
dyskinesias	-	1405	O
in	-	1417	O
PD	-	1420	O
.	-	1422	O

The	18951540	1424	O
effects	-	1428	O
may	-	1436	O
be	-	1440	O
further	-	1443	O
exploited	-	1451	O
for	-	1461	O
potential	-	1465	O
therapeutic	-	1475	O
uses	-	1487	O
.	-	1491	O

Disulfiram	19657887	0	B
-	-	10	O
like	-	11	O
syndrome	-	16	O
after	-	25	O
hydrogen	-	31	B
cyanamide	-	40	I
professional	-	50	O
skin	-	63	O
exposure	-	68	O
:	-	76	O
two	-	78	O
case	-	82	O
reports	-	87	O
in	-	95	O
France	-	98	O
.	-	104	O

Hydrogen	19657887	106	B
cyanamide	-	115	I
is	-	125	O
a	-	128	O
plant	-	130	O
growth	-	136	O
regulator	-	143	O
used	-	153	O
in	-	158	O
agriculture	-	161	O
to	-	173	O
induce	-	176	O
bud	-	183	O
break	-	187	O
in	-	193	O
fruit	-	196	O
trees	-	202	O
.	-	207	O

Contact	19657887	209	O
with	-	217	O
the	-	222	O
skin	-	226	O
can	-	231	O
result	-	235	O
in	-	242	O
percutaneous	-	245	O
absorption	-	258	O
of	-	269	O
the	-	272	O
substance	-	276	O
that	-	286	O
inhibits	-	291	O
aldehyde	-	300	B
dehydrogenase	-	309	O
and	-	323	O
can	-	327	O
induce	-	331	O
acetaldehyde	-	338	B
syndrome	-	351	O
in	-	360	O
case	-	363	O
of	-	368	O
alcohol	-	371	B
use	-	379	O
.	-	382	O

The	19657887	384	O
purpose	-	388	O
of	-	396	O
this	-	399	O
report	-	404	O
is	-	411	O
to	-	414	O
describe	-	417	O
two	-	426	O
cases	-	430	O
of	-	436	O
a	-	439	O
disulfiram	-	441	B
-	-	451	O
like	-	452	O
syndrome	-	457	O
following	-	466	O
occupational	-	476	O
exposure	-	489	O
to	-	498	O
hydrogen	-	501	B
cyanamide	-	510	I
.	-	519	O

The	19657887	521	O
first	-	525	O
case	-	531	O
involved	-	536	O
a	-	545	O
59	-	547	O
-	-	549	O
year	-	550	O
-	-	554	O
old	-	555	O
man	-	559	O
who	-	563	O
used	-	567	O
Dormex	-	572	B
,	-	578	O
which	-	580	O
contains	-	586	O
hydrogen	-	595	B
cyanamide	-	604	I
,	-	613	O
without	-	615	O
protection	-	623	O
after	-	634	O
consuming	-	640	O
a	-	650	O
large	-	652	O
amount	-	658	O
of	-	665	O
alcohol	-	668	B
during	-	676	O
a	-	683	O
meal	-	685	O
.	-	689	O

In	19657887	691	O
less	-	694	O
than	-	699	O
1	-	704	O
hour	-	706	O
after	-	711	O
the	-	717	O
ingestion	-	721	O
of	-	731	O
alcohol	-	734	B
,	-	741	O
he	-	743	O
developed	-	746	O
malaise	-	756	O
with	-	764	O
flushing	-	769	O
of	-	778	O
the	-	781	O
face	-	785	O
,	-	789	O
tachycardia	-	791	O
,	-	802	O
and	-	804	O
dyspnea	-	808	O
.	-	815	O

Manifestations	19657887	817	O
regressed	-	832	O
spontaneously	-	842	O
under	-	856	O
surveillance	-	862	O
in	-	875	O
the	-	878	O
hospital	-	882	O
.	-	890	O

The	19657887	892	O
second	-	896	O
case	-	903	O
occurred	-	908	O
in	-	917	O
a	-	920	O
55	-	922	O
-	-	924	O
year	-	925	O
-	-	929	O
old	-	930	O
farmer	-	934	O
following	-	941	O
cutaneous	-	951	O
contact	-	961	O
with	-	969	O
Dormex	-	974	B
.	-	980	O

Five	19657887	982	O
hours	-	987	O
after	-	993	O
exposure	-	999	O
,	-	1007	O
he	-	1009	O
developed	-	1012	O
disulfiram	-	1022	B
-	-	1032	O
like	-	1033	O
syndrome	-	1038	O
with	-	1047	O
flushing	-	1052	O
,	-	1060	O
tachycardia	-	1062	O
,	-	1073	O
and	-	1075	O
arterial	-	1079	O
hypotension	-	1088	O
after	-	1100	O
consuming	-	1106	O
three	-	1116	O
glasses	-	1122	O
of	-	1130	O
wine	-	1133	O
.	-	1137	O

The	19657887	1139	O
patient	-	1143	O
recovered	-	1151	O
spontaneously	-	1161	O
in	-	1175	O
3	-	1178	O
hours	-	1180	O
under	-	1186	O
surveillance	-	1192	O
in	-	1205	O
the	-	1208	O
hospital	-	1212	O
.	-	1220	O

These	19657887	1222	O
cases	-	1228	O
confirm	-	1234	O
the	-	1242	O
necessity	-	1246	O
of	-	1256	O
avoiding	-	1259	O
alcohol	-	1268	B
consumption	-	1276	O
as	-	1288	O
recommended	-	1291	O
in	-	1303	O
the	-	1306	O
instructions	-	1310	O
for	-	1323	O
use	-	1327	O
of	-	1331	O
Dormex	-	1334	B
and	-	1341	O
of	-	1345	O
preventing	-	1348	O
cutaneous	-	1359	O
contact	-	1369	O
during	-	1377	O
use	-	1384	O
.	-	1387	O

Repeated	9660111	0	O
trimipramine	-	9	B
induces	-	22	O
dopamine	-	30	B
D2	-	39	O
/	-	41	O
D3	-	42	O
and	-	45	O
alpha1	-	49	O
-	-	55	O
adrenergic	-	56	O
up	-	67	O
-	-	69	O
regulation	-	70	O
.	-	80	O

Trimipramine	9660111	82	B
(	-	95	O
TRI	-	96	B
)	-	99	O
,	-	100	O
which	-	102	O
shows	-	108	O
a	-	114	O
clinical	-	116	O
antidepressant	-	125	B
activity	-	140	O
,	-	148	O
is	-	150	O
chemically	-	153	O
related	-	164	O
to	-	172	O
imipramine	-	175	B
but	-	186	O
does	-	190	O
not	-	195	O
inhibit	-	199	O
the	-	207	O
reuptake	-	211	O
of	-	220	O
noradrenaline	-	223	B
and	-	237	O
5	-	241	B
-	-	242	I
hydroxytryptamine	-	243	I
,	-	260	O
nor	-	262	O
does	-	266	O
it	-	271	O
induce	-	274	O
beta	-	281	O
-	-	285	O
adrenergic	-	286	O
down	-	297	O
-	-	301	O
regulation	-	302	O
.	-	312	O

The	9660111	314	O
mechanism	-	318	O
of	-	328	O
its	-	331	O
antidepressant	-	335	B
activity	-	350	O
is	-	359	O
still	-	362	O
unknown	-	368	O
.	-	375	O

The	9660111	377	O
aim	-	381	O
of	-	385	O
the	-	388	O
present	-	392	O
study	-	400	O
was	-	406	O
to	-	410	O
find	-	413	O
out	-	418	O
whether	-	422	O
TRI	-	430	B
given	-	434	O
repeatedly	-	440	O
was	-	451	O
able	-	455	O
to	-	460	O
induce	-	463	O
adaptive	-	470	O
changes	-	479	O
in	-	487	O
the	-	490	O
dopaminergic	-	494	O
and	-	507	O
alpha1	-	511	O
-	-	517	O
adrenergic	-	518	O
systems	-	529	O
,	-	536	O
demonstrated	-	538	O
by	-	551	O
us	-	554	O
previously	-	557	O
for	-	568	O
various	-	572	O
antidepressants	-	580	B
.	-	595	O

TRI	9660111	597	B
was	-	601	O
given	-	605	O
to	-	611	O
male	-	614	O
Wistar	-	619	O
rats	-	626	O
and	-	631	O
male	-	635	O
Albino	-	640	O
Swiss	-	647	O
mice	-	653	O
perorally	-	658	O
twice	-	668	O
daily	-	674	O
for	-	680	O
14	-	684	O
days	-	687	O
.	-	691	O

In	9660111	693	O
the	-	696	O
acute	-	700	O
experiment	-	706	O
TRI	-	717	B
(	-	721	O
given	-	722	O
i	-	728	O
.	-	729	O
p	-	730	O
.	-	731	O
)	-	732	O
does	-	734	O
not	-	739	O
antagonize	-	743	O
the	-	754	O
reserpine	-	758	B
hypothermia	-	768	O
in	-	780	O
mice	-	783	O
and	-	788	O
does	-	792	O
not	-	797	O
potentiate	-	801	O
the	-	812	O
5	-	816	B
-	-	817	I
hydroxytryptophan	-	818	I
head	-	836	O
twitches	-	841	O
in	-	850	O
rats	-	853	O
.	-	857	O

TRI	9660111	859	B
given	-	863	O
repeatedly	-	869	O
to	-	880	O
rats	-	883	O
increases	-	888	O
the	-	898	O
locomotor	-	902	O
hyperactivity	-	912	O
induced	-	926	O
by	-	934	O
d	-	937	B
-	-	938	I
amphetamine	-	939	I
,	-	950	O
quinpirole	-	952	B
and	-	963	O
(	-	967	O
+	-	968	O
)	-	969	O
-	-	970	O
7	-	971	O
-	-	972	O
hydroxy	-	973	O
-	-	980	O
dipropyloaminotetralin	-	981	O
(	-	1004	O
dopamine	-	1005	B
D2	-	1014	O
and	-	1017	O
D3	-	1021	O
effects	-	1024	O
)	-	1031	O
.	-	1032	O

The	9660111	1034	O
stereotypies	-	1038	O
induced	-	1051	O
by	-	1059	O
d	-	1062	B
-	-	1063	I
amphetamine	-	1064	I
or	-	1076	O
apomorphine	-	1079	B
are	-	1091	O
not	-	1095	O
potentiated	-	1099	O
by	-	1111	O
TRI	-	1114	B
.	-	1117	O

It	9660111	1119	O
increases	-	1122	O
the	-	1132	O
behaviour	-	1136	O
stimulation	-	1146	O
evoked	-	1158	O
by	-	1165	O
phenylephrine	-	1168	B
(	-	1182	O
given	-	1183	O
intraventricularly	-	1189	O
)	-	1207	O
in	-	1209	O
rats	-	1212	O
,	-	1216	O
evaluated	-	1218	O
in	-	1228	O
the	-	1231	O
open	-	1235	O
field	-	1240	O
test	-	1246	O
as	-	1251	O
well	-	1254	O
as	-	1259	O
the	-	1262	O
aggressiveness	-	1266	O
evoked	-	1281	O
by	-	1288	O
clonidine	-	1291	B
in	-	1301	O
mice	-	1304	O
,	-	1308	O
both	-	1310	O
these	-	1315	O
effects	-	1321	O
being	-	1329	O
mediated	-	1335	O
by	-	1344	O
an	-	1347	O
alpha1	-	1350	O
-	-	1356	O
adrenergic	-	1357	O
receptor	-	1368	O
.	-	1376	O

It	9660111	1378	O
may	-	1381	O
be	-	1385	O
concluded	-	1388	O
that	-	1398	O
,	-	1402	O
like	-	1404	O
other	-	1409	O
tricyclic	-	1415	O
antidepressants	-	1425	B
studied	-	1441	O
previously	-	1449	O
,	-	1459	O
TRI	-	1461	B
given	-	1465	O
repeatedly	-	1471	O
increases	-	1482	O
the	-	1492	O
responsiveness	-	1496	O
of	-	1511	O
brain	-	1514	O
dopamine	-	1520	B
D2	-	1529	O
and	-	1532	O
D3	-	1536	O
(	-	1539	O
locomotor	-	1540	O
activity	-	1550	O
but	-	1559	O
not	-	1563	O
stereotypy	-	1567	O
)	-	1577	O
as	-	1579	O
well	-	1582	O
as	-	1587	O
alpha1	-	1590	O
-	-	1596	O
adrenergic	-	1597	O
receptors	-	1608	O
to	-	1618	O
their	-	1621	O
agonists	-	1627	O
.	-	1635	O

A	9660111	1637	O
question	-	1639	O
arises	-	1648	O
whether	-	1655	O
the	-	1663	O
reuptake	-	1667	O
inhibition	-	1676	O
is	-	1687	O
of	-	1690	O
any	-	1693	O
importance	-	1697	O
to	-	1708	O
the	-	1711	O
adaptive	-	1715	O
changes	-	1724	O
induced	-	1732	O
by	-	1740	O
repeated	-	1743	O
antidepressants	-	1752	B
,	-	1767	O
suggested	-	1769	O
to	-	1779	O
be	-	1782	O
responsible	-	1785	O
for	-	1797	O
the	-	1801	O
antidepressant	-	1805	B
activity	-	1820	O
.	-	1828	O

Ranitidine	11431197	0	B
-	-	10	O
induced	-	11	O
acute	-	19	O
interstitial	-	25	O
nephritis	-	38	O
in	-	48	O
a	-	51	O
cadaveric	-	53	O
renal	-	63	O
allograft	-	69	O
.	-	78	O

Ranitidine	11431197	80	B
frequently	-	91	O
is	-	102	O
used	-	105	O
for	-	110	O
preventing	-	114	O
peptic	-	125	O
ulceration	-	132	O
after	-	143	O
renal	-	149	O
transplantation	-	155	O
.	-	170	O

This	11431197	172	O
drug	-	177	O
occasionally	-	182	O
has	-	195	O
been	-	199	O
associated	-	204	O
with	-	215	O
acute	-	220	O
interstitial	-	226	O
nephritis	-	239	O
in	-	249	O
native	-	252	O
kidneys	-	259	O
.	-	266	O

There	11431197	268	O
are	-	274	O
no	-	278	O
similar	-	281	O
reports	-	289	O
with	-	297	O
renal	-	302	O
transplantation	-	308	O
.	-	323	O

We	11431197	325	O
report	-	328	O
a	-	335	O
case	-	337	O
of	-	342	O
ranitidine	-	345	B
-	-	355	O
induced	-	356	O
acute	-	364	O
interstitial	-	370	O
nephritis	-	383	O
in	-	393	O
a	-	396	O
recipient	-	398	O
of	-	408	O
a	-	411	O
cadaveric	-	413	O
renal	-	423	O
allograft	-	429	O
presenting	-	439	O
with	-	450	O
acute	-	455	O
allograft	-	461	O
dysfunction	-	471	O
within	-	483	O
48	-	490	O
hours	-	493	O
of	-	499	O
exposure	-	502	O
to	-	511	O
the	-	514	O
drug	-	518	O
.	-	522	O

The	11431197	524	O
biopsy	-	528	O
specimen	-	535	O
showed	-	544	O
pathognomonic	-	551	O
features	-	565	O
,	-	573	O
including	-	575	O
eosinophilic	-	585	O
infiltration	-	598	O
of	-	611	O
the	-	614	O
interstitial	-	618	O
compartment	-	631	O
.	-	642	O

Allograft	11431197	644	O
function	-	654	O
improved	-	663	O
rapidly	-	672	O
and	-	680	O
returned	-	684	O
to	-	693	O
baseline	-	696	O
after	-	705	O
stopping	-	711	O
the	-	720	O
drug	-	724	O
.	-	728	O

Late	7449470	0	O
,	-	4	O
late	-	6	O
doxorubicin	-	11	B
cardiotoxicity	-	23	O
.	-	37	O

Cardiac	7449470	39	O
toxicity	-	47	O
is	-	56	O
a	-	59	O
major	-	61	O
complication	-	67	O
which	-	80	O
limits	-	86	O
the	-	93	O
use	-	97	O
of	-	101	O
adriamycin	-	104	B
as	-	115	O
a	-	118	O
chemotherapeutic	-	120	O
agent	-	137	O
.	-	142	O

Cardiomyopathy	7449470	144	O
is	-	159	O
frequent	-	162	O
when	-	171	O
the	-	176	O
total	-	180	O
dose	-	186	O
exceeds	-	191	O
600	-	199	O
mg	-	203	O
/	-	205	O
m2	-	206	O
and	-	209	O
occurs	-	213	O
within	-	220	O
one	-	227	O
to	-	231	O
six	-	234	O
months	-	238	O
after	-	245	O
cessation	-	251	O
of	-	261	O
therapy	-	264	O
.	-	271	O

A	7449470	273	O
patient	-	275	O
is	-	283	O
reported	-	286	O
who	-	295	O
developed	-	299	O
progressive	-	309	O
cardiomyopathy	-	321	O
two	-	336	O
and	-	340	O
one	-	344	O
-	-	347	O
half	-	348	O
years	-	353	O
after	-	359	O
receiving	-	365	O
580	-	375	O
mg	-	379	O
/	-	381	O
m2	-	382	O
which	-	385	O
apparently	-	391	O
represents	-	402	O
late	-	413	O
,	-	417	O
late	-	419	O
cardiotoxicity	-	424	O
.	-	438	O

Acetazolamide	8170551	0	B
-	-	13	O
induced	-	14	O
nephrolithiasis	-	22	O
:	-	37	O
implications	-	39	O
for	-	52	O
treatment	-	56	O
of	-	66	O
neuromuscular	-	69	O
disorders	-	83	O
.	-	92	O

Carbonic	8170551	94	O
anhydrase	-	103	O
inhibitors	-	113	O
can	-	124	O
cause	-	128	O
nephrolithiasis	-	134	O
.	-	149	O

We	8170551	151	O
studied	-	154	O
20	-	162	O
patients	-	165	O
receiving	-	174	O
long	-	184	O
-	-	188	O
term	-	189	O
carbonic	-	194	O
anhydrase	-	203	O
inhibitor	-	213	O
treatment	-	223	O
for	-	233	O
periodic	-	237	O
paralysis	-	246	O
and	-	256	O
myotonia	-	260	O
.	-	268	O

Three	8170551	270	O
patients	-	276	O
on	-	285	O
acetazolamide	-	288	B
(	-	302	O
15	-	303	O
%	-	305	O
)	-	306	O
developed	-	308	O
renal	-	318	O
calculi	-	324	O
.	-	331	O

Extracorporeal	8170551	333	O
lithotripsy	-	348	O
successfully	-	360	O
removed	-	373	O
a	-	381	O
renal	-	383	O
calculus	-	389	O
in	-	398	O
one	-	401	O
patient	-	405	O
and	-	413	O
surgery	-	417	O
removed	-	425	O
a	-	433	O
staghorn	-	435	O
calculus	-	444	O
in	-	453	O
another	-	456	O
,	-	463	O
permitting	-	465	O
continued	-	476	O
treatment	-	486	O
.	-	495	O

Renal	8170551	497	O
function	-	503	O
remained	-	512	O
normal	-	521	O
in	-	528	O
all	-	531	O
patients	-	535	O
.	-	543	O

Nephrolithiasis	8170551	545	O
is	-	561	O
a	-	564	O
complication	-	566	O
of	-	579	O
acetazolamide	-	582	B
but	-	596	O
does	-	600	O
not	-	605	O
preclude	-	609	O
its	-	618	O
use	-	622	O
.	-	625	O

Is	2476560	0	O
the	-	3	O
treatment	-	7	O
of	-	17	O
scabies	-	20	O
hazardous	-	28	O
?	-	37	O

Treatment	2476560	39	O
for	-	49	O
scabies	-	53	O
is	-	61	O
usually	-	64	O
initiated	-	72	O
by	-	82	O
general	-	85	O
practitioners	-	93	O
;	-	106	O
most	-	108	O
consider	-	113	O
lindane	-	122	B
(	-	130	O
gamma	-	131	B
benzene	-	137	I
hexachloride	-	145	I
)	-	157	O
the	-	159	O
treatment	-	163	O
of	-	173	O
choice	-	176	O
.	-	182	O

Lindane	2476560	184	B
is	-	192	O
also	-	195	O
widely	-	200	O
used	-	207	O
as	-	212	O
an	-	215	O
agricultural	-	218	O
and	-	231	O
industrial	-	235	O
pesticide	-	246	O
,	-	255	O
and	-	257	O
as	-	261	O
a	-	264	O
result	-	266	O
the	-	273	O
toxic	-	277	O
profile	-	283	O
of	-	291	O
this	-	294	O
insecticide	-	299	O
is	-	311	O
well	-	314	O
understood	-	319	O
.	-	329	O

Evidence	2476560	331	O
is	-	340	O
accumulating	-	343	O
that	-	356	O
lindane	-	361	B
can	-	369	O
be	-	373	O
toxic	-	376	O
to	-	382	O
the	-	385	O
central	-	389	O
nervous	-	397	O
system	-	405	O
and	-	412	O
may	-	416	O
be	-	420	O
associated	-	423	O
with	-	434	O
aplastic	-	439	O
anaemia	-	448	O
.	-	455	O

Preparations	2476560	457	O
containing	-	470	O
lindane	-	481	B
continue	-	489	O
to	-	498	O
be	-	501	O
sold	-	504	O
over	-	509	O
the	-	514	O
counter	-	518	O
and	-	526	O
may	-	530	O
represent	-	534	O
a	-	544	O
hazard	-	546	O
to	-	553	O
poorly	-	556	O
informed	-	563	O
patients	-	572	O
.	-	580	O

This	2476560	582	O
literature	-	587	O
review	-	598	O
suggests	-	605	O
that	-	614	O
general	-	619	O
practitioners	-	627	O
should	-	641	O
prescribe	-	648	O
scabicides	-	658	O
with	-	669	O
increased	-	674	O
caution	-	684	O
for	-	692	O
certain	-	696	O
at	-	704	O
-	-	706	O
risk	-	707	O
groups	-	712	O
,	-	718	O
and	-	720	O
give	-	724	O
adequate	-	729	O
warnings	-	738	O
regarding	-	747	O
potential	-	757	O
toxicity	-	767	O
.	-	775	O

Anaesthetists	19803309	0	O
'	-	13	O
nightmare	-	15	O
:	-	24	O
masseter	-	26	O
spasm	-	35	O
after	-	41	O
induction	-	47	O
in	-	57	O
an	-	60	O
undiagnosed	-	63	O
case	-	75	O
of	-	80	O
myotonia	-	83	O
congenita	-	92	O
.	-	101	O

We	19803309	103	O
report	-	106	O
an	-	113	O
undiagnosed	-	116	O
case	-	128	O
of	-	133	O
myotonia	-	136	O
congenita	-	145	O
in	-	155	O
a	-	158	O
24	-	160	O
-	-	162	O
year	-	163	O
-	-	167	O
old	-	168	O
previously	-	172	O
healthy	-	183	O
primigravida	-	191	O
,	-	203	O
who	-	205	O
developed	-	209	O
life	-	219	O
threatening	-	224	O
masseter	-	236	O
spasm	-	245	O
following	-	251	O
a	-	261	O
standard	-	263	O
dose	-	272	O
of	-	277	O
intravenous	-	280	O
suxamethonium	-	292	B
for	-	306	O
induction	-	310	O
of	-	320	O
anaesthesia	-	323	O
.	-	334	O

Neither	19803309	336	O
the	-	344	O
patient	-	348	O
nor	-	356	O
the	-	360	O
anaesthetist	-	364	O
was	-	377	O
aware	-	381	O
of	-	387	O
the	-	390	O
diagnosis	-	394	O
before	-	404	O
this	-	411	O
potentially	-	416	O
lethal	-	428	O
complication	-	435	O
occurred	-	448	O
.	-	456	O

Toxicity	18821488	0	O
in	-	9	O
rhesus	-	12	O
monkeys	-	19	O
following	-	27	O
administration	-	37	O
of	-	52	O
the	-	55	O
8	-	59	B
-	-	60	I
aminoquinoline	-	61	I
8	-	76	B
-	-	77	I
[	-	78	I
(	-	79	I
4	-	80	I
-	-	81	I
amino	-	82	I
-	-	87	I
l	-	88	I
-	-	89	I
methylbutyl	-	90	I
)	-	101	I
amino	-	102	I
]	-	107	I
-	-	108	I
5	-	110	I
-	-	111	I
(	-	112	I
l	-	113	I
-	-	114	I
hexyloxy	-	115	I
)	-	123	I
-	-	124	I
6	-	125	I
-	-	126	I
methoxy	-	127	I
-	-	134	I
4	-	135	I
-	-	136	I
methylquinoline	-	137	I
(	-	153	O
WR242511	-	154	B
)	-	162	O
.	-	163	O

INTRODUCTION	18821488	165	O
:	-	177	O

Many	18821488	179	O
substances	-	184	O
that	-	195	O
form	-	200	O
methemoglobin	-	205	O
(	-	219	O
MHb	-	220	O
)	-	223	O
effectively	-	225	O
counter	-	237	O
cyanide	-	245	O
(	-	253	O
CN	-	254	O
)	-	256	O
toxicity	-	258	O
.	-	266	O

Although	18821488	268	O
MHb	-	277	O
formers	-	281	O
are	-	289	O
generally	-	293	O
applied	-	303	O
as	-	311	O
treatments	-	314	O
for	-	325	O
CN	-	329	O
poisoning	-	332	O
,	-	341	O
it	-	343	O
has	-	346	O
been	-	350	O
proposed	-	355	O
that	-	364	O
a	-	369	O
stable	-	371	O
,	-	377	O
long	-	379	O
-	-	383	O
acting	-	384	O
MHb	-	391	O
former	-	395	O
could	-	402	O
serve	-	408	O
as	-	414	O
a	-	417	O
CN	-	419	O
pretreatment	-	422	O
.	-	434	O

Using	18821488	436	O
this	-	442	O
rationale	-	447	O
,	-	456	O
the	-	458	O
8	-	462	B
-	-	463	I
aminoquinoline	-	464	I
WR242511	-	479	B
,	-	487	O
a	-	489	O
potent	-	491	O
long	-	498	O
-	-	502	O
lasting	-	503	O
MHb	-	511	O
former	-	515	O
in	-	522	O
rodents	-	525	O
and	-	533	O
beagle	-	537	O
dogs	-	544	O
,	-	548	O
was	-	550	O
studied	-	554	O
in	-	562	O
the	-	565	O
rhesus	-	569	O
monkey	-	576	O
for	-	583	O
advanced	-	587	O
development	-	596	O
as	-	608	O
a	-	611	O
potential	-	613	O
CN	-	623	O
pretreatment	-	626	O
.	-	638	O

METHODS	18821488	640	O
:	-	647	O

In	18821488	649	O
this	-	652	O
study	-	657	O
,	-	662	O
WR242511	-	664	B
was	-	673	O
administered	-	677	O
intravenously	-	690	O
(	-	704	O
IV	-	705	O
)	-	707	O
in	-	709	O
2	-	712	O
female	-	714	O
and	-	721	O
4	-	725	O
male	-	727	O
rhesus	-	732	O
monkeys	-	739	O
in	-	747	O
doses	-	750	O
of	-	756	O
3	-	759	O
.	-	760	O
5	-	761	O
and	-	763	O
/	-	766	O
or	-	767	O
7	-	770	O
.	-	771	O
0	-	772	O
mg	-	774	O
/	-	776	O
kg	-	777	O
;	-	779	O
a	-	781	O
single	-	783	O
male	-	790	O
also	-	795	O
received	-	800	O
WR242511	-	809	B
orally	-	818	O
(	-	825	O
PO	-	826	O
)	-	828	O
at	-	830	O
7	-	833	O
.	-	834	O
0	-	835	O
mg	-	837	O
/	-	839	O
kg	-	840	O
.	-	842	O

Health	18821488	844	O
status	-	851	O
and	-	858	O
MHb	-	862	O
levels	-	866	O
were	-	873	O
monitored	-	878	O
following	-	888	O
exposure	-	898	O
.	-	906	O

RESULTS	18821488	908	O
:	-	915	O

The	18821488	917	O
selected	-	921	O
doses	-	930	O
of	-	936	O
WR242511	-	939	B
,	-	947	O
which	-	949	O
produced	-	955	O
significant	-	964	O
methemoglobinemia	-	976	O
in	-	994	O
beagle	-	997	O
dogs	-	1004	O
in	-	1009	O
earlier	-	1012	O
studies	-	1020	O
conducted	-	1028	O
elsewhere	-	1038	O
,	-	1047	O
produced	-	1049	O
very	-	1058	O
little	-	1063	O
MHb	-	1070	O
(	-	1074	O
mean	-	1075	O
<	-	1080	O
2	-	1082	O
.	-	1083	O
0	-	1084	O
%	-	1085	O
)	-	1086	O
in	-	1088	O
the	-	1091	O
rhesus	-	1095	O
monkey	-	1102	O
.	-	1108	O

Furthermore	18821488	1110	O
,	-	1121	O
transient	-	1123	O
hemoglobinuria	-	1133	O
was	-	1148	O
noted	-	1152	O
approximately	-	1158	O
60	-	1172	O
minutes	-	1175	O
postinjection	-	1183	O
of	-	1197	O
WR242511	-	1200	B
(	-	1209	O
3	-	1210	O
.	-	1211	O
5	-	1212	O
or	-	1214	O
7	-	1217	O
.	-	1218	O
0	-	1219	O
mg	-	1221	O
/	-	1223	O
kg	-	1224	O
)	-	1226	O
,	-	1227	O
and	-	1229	O
2	-	1233	O
lethalities	-	1235	O
occurred	-	1247	O
(	-	1256	O
one	-	1257	O
IV	-	1261	O
and	-	1264	O
one	-	1268	O
PO	-	1272	O
)	-	1274	O
following	-	1276	O
the	-	1286	O
7	-	1290	O
.	-	1291	O
0	-	1292	O
mg	-	1294	O
/	-	1296	O
kg	-	1297	O
dose	-	1300	O
.	-	1304	O

Myoglobinuria	18821488	1306	O
was	-	1320	O
also	-	1324	O
observed	-	1329	O
following	-	1338	O
the	-	1348	O
7	-	1352	O
.	-	1353	O
0	-	1354	O
mg	-	1356	O
/	-	1358	O
kg	-	1359	O
dose	-	1362	O
.	-	1366	O

Histopathology	18821488	1368	O
analyses	-	1383	O
in	-	1392	O
the	-	1395	O
2	-	1399	O
animals	-	1401	O
that	-	1409	O
died	-	1414	O
revealed	-	1419	O
liver	-	1428	O
and	-	1434	O
kidney	-	1438	O
toxicity	-	1445	O
,	-	1453	O
with	-	1455	O
greater	-	1460	O
severity	-	1468	O
in	-	1477	O
the	-	1480	O
orally	-	1484	O
-	-	1490	O
treated	-	1491	O
animal	-	1499	O
.	-	1505	O

CONCLUSIONS	18821488	1507	O
:	-	1518	O

These	18821488	1520	O
data	-	1526	O
demonstrate	-	1531	O
direct	-	1543	O
and	-	1550	O
/	-	1553	O
or	-	1554	O
indirect	-	1557	O
drug	-	1566	O
-	-	1570	O
induced	-	1571	O
toxicity	-	1579	O
.	-	1587	O

It	18821488	1589	O
is	-	1592	O
concluded	-	1595	O
that	-	1605	O
WR242511	-	1610	B
should	-	1619	O
not	-	1626	O
be	-	1630	O
pursued	-	1633	O
as	-	1641	O
a	-	1644	O
pretreatment	-	1646	O
for	-	1659	O
CN	-	1663	O
poisoning	-	1666	O
unless	-	1676	O
the	-	1683	O
anti	-	1687	O
-	-	1691	O
CN	-	1692	O
characteristics	-	1695	O
of	-	1711	O
this	-	1714	O
compound	-	1719	O
can	-	1728	O
be	-	1732	O
successfully	-	1735	O
dissociated	-	1748	O
from	-	1760	O
those	-	1765	O
producing	-	1771	O
undesirable	-	1781	O
toxicity	-	1793	O
.	-	1801	O

Neuroplasticity	8372922	0	O
of	-	16	O
the	-	19	O
adult	-	23	O
primate	-	29	O
auditory	-	37	O
cortex	-	46	O
following	-	53	O
cochlear	-	63	O
hearing	-	72	O
loss	-	80	O
.	-	84	O

Tonotopic	8372922	86	O
organization	-	96	O
is	-	109	O
an	-	112	O
essential	-	115	O
feature	-	125	O
of	-	133	O
the	-	136	O
primary	-	140	O
auditory	-	148	O
area	-	157	O
(	-	162	O
A1	-	163	O
)	-	165	O
of	-	167	O
primate	-	170	O
cortex	-	178	O
.	-	184	O

In	8372922	186	O
A1	-	189	O
of	-	192	O
macaque	-	195	O
monkeys	-	203	O
,	-	210	O
low	-	212	O
frequencies	-	216	O
are	-	228	O
represented	-	232	O
rostrolaterally	-	244	O
and	-	260	O
high	-	264	O
frequencies	-	269	O
are	-	281	O
represented	-	285	O
caudomedially	-	297	O
.	-	310	O

The	8372922	312	O
purpose	-	316	O
of	-	324	O
this	-	327	O
study	-	332	O
was	-	338	O
to	-	342	O
determine	-	345	O
if	-	355	O
changes	-	358	O
occur	-	366	O
in	-	372	O
this	-	375	O
tonotopic	-	380	O
organization	-	390	O
following	-	403	O
cochlear	-	413	O
hearing	-	422	O
loss	-	430	O
.	-	434	O

Under	8372922	436	O
anesthesia	-	442	O
,	-	452	O
the	-	454	O
superior	-	458	O
temporal	-	467	O
gyrus	-	476	O
of	-	482	O
adult	-	485	O
macaque	-	491	O
monkeys	-	499	O
was	-	507	O
exposed	-	511	O
,	-	518	O
and	-	520	O
the	-	524	O
tonotopic	-	528	O
organization	-	538	O
of	-	551	O
A1	-	554	O
was	-	557	O
mapped	-	561	O
using	-	568	O
conventional	-	574	O
microelectrode	-	587	O
recording	-	602	O
techniques	-	612	O
.	-	622	O

Following	8372922	624	O
recovery	-	634	O
,	-	642	O
the	-	644	O
monkeys	-	648	O
were	-	656	O
selectively	-	661	O
deafened	-	673	O
for	-	682	O
high	-	686	O
frequencies	-	691	O
using	-	703	O
kanamycin	-	709	B
and	-	719	O
furosemide	-	723	B
.	-	733	O

The	8372922	735	O
actual	-	739	O
frequencies	-	746	O
deafened	-	758	O
were	-	767	O
determined	-	772	O
by	-	783	O
the	-	786	O
loss	-	790	O
of	-	795	O
tone	-	798	O
-	-	802	O
burst	-	803	O
elicited	-	809	O
auditory	-	818	O
brainstem	-	827	O
responses	-	837	O
.	-	846	O

Three	8372922	848	O
months	-	854	O
after	-	861	O
deafening	-	867	O
,	-	876	O
A1	-	878	O
was	-	881	O
remapped	-	885	O
.	-	893	O

Postmortem	8372922	895	O
cytoarchitectural	-	906	O
features	-	924	O
identifying	-	933	O
A1	-	945	O
were	-	948	O
correlated	-	953	O
with	-	964	O
the	-	969	O
electrophysiologic	-	973	O
data	-	992	O
.	-	996	O

The	8372922	998	O
results	-	1002	O
indicate	-	1010	O
that	-	1019	O
the	-	1024	O
deprived	-	1028	O
area	-	1037	O
of	-	1042	O
A1	-	1045	O
undergoes	-	1048	O
extensive	-	1058	O
reorganization	-	1068	O
and	-	1083	O
becomes	-	1087	O
responsive	-	1095	O
to	-	1106	O
intact	-	1109	O
cochlear	-	1116	O
frequencies	-	1125	O
.	-	1136	O

The	8372922	1138	O
region	-	1142	O
of	-	1149	O
cortex	-	1152	O
that	-	1159	O
represents	-	1164	O
the	-	1175	O
low	-	1179	O
frequencies	-	1183	O
was	-	1195	O
not	-	1199	O
obviously	-	1203	O
affected	-	1213	O
by	-	1222	O
the	-	1225	O
cochlear	-	1229	O
hearing	-	1238	O
loss	-	1246	O
.	-	1250	O

The	9195768	0	O
site	-	4	O
of	-	9	O
common	-	12	O
side	-	19	O
effects	-	24	O
of	-	32	O
sumatriptan	-	35	B
.	-	46	O

Atypical	9195768	48	O
sensations	-	57	O
following	-	68	O
the	-	78	O
use	-	82	O
of	-	86	O
subcutaneous	-	89	O
sumatriptan	-	102	B
are	-	114	O
common	-	118	O
,	-	124	O
but	-	126	O
of	-	130	O
uncertain	-	133	O
origin	-	143	O
.	-	149	O

They	9195768	151	O
are	-	156	O
almost	-	160	O
always	-	167	O
benign	-	174	O
,	-	180	O
but	-	182	O
can	-	186	O
be	-	190	O
mistaken	-	193	O
for	-	202	O
a	-	206	O
serious	-	208	O
adverse	-	216	O
event	-	224	O
by	-	230	O
the	-	233	O
patient	-	237	O
.	-	244	O

Two	9195768	246	O
patients	-	250	O
are	-	259	O
presented	-	263	O
with	-	273	O
tingling	-	278	O
or	-	287	O
burning	-	290	O
sensations	-	298	O
limited	-	309	O
to	-	317	O
areas	-	320	O
of	-	326	O
heat	-	329	O
exposure	-	334	O
or	-	343	O
sunburn	-	346	O
.	-	353	O

In	9195768	355	O
these	-	358	O
individuals	-	364	O
,	-	375	O
side	-	377	O
effects	-	382	O
are	-	390	O
most	-	394	O
likely	-	399	O
generated	-	406	O
superficially	-	416	O
in	-	430	O
the	-	433	O
skin	-	437	O
.	-	441	O

Tremor	15338796	0	O
side	-	7	O
effects	-	12	O
of	-	20	O
salbutamol	-	23	B
,	-	33	O
quantified	-	35	O
by	-	46	O
a	-	49	O
laser	-	51	O
pointer	-	57	O
technique	-	65	O
.	-	74	O

OBJECTIVE	15338796	76	O
:	-	85	O

To	15338796	87	O
study	-	90	O
tremor	-	96	O
side	-	103	O
effects	-	108	O
of	-	116	O
salbutamol	-	119	B
an	-	130	O
easily	-	133	O
applicable	-	140	O
,	-	150	O
quick	-	152	O
and	-	158	O
low	-	162	O
-	-	165	O
priced	-	166	O
method	-	173	O
is	-	180	O
needed	-	183	O
.	-	189	O

A	15338796	191	O
new	-	193	O
method	-	197	O
using	-	204	O
a	-	210	O
commercially	-	212	O
available	-	225	O
,	-	234	O
pen	-	236	O
-	-	239	O
shaped	-	240	O
laser	-	247	O
pointer	-	253	O
was	-	261	O
developed	-	265	O
.	-	274	O

Aim	15338796	276	O
of	-	280	O
the	-	283	O
study	-	287	O
was	-	293	O
to	-	297	O
determine	-	300	O
sensitivity	-	310	O
,	-	321	O
reproducibility	-	323	O
,	-	338	O
reference	-	340	O
values	-	350	O
and	-	357	O
the	-	361	O
agreement	-	365	O
with	-	375	O
a	-	380	O
questionnaire	-	382	O
.	-	395	O

METHODS	15338796	397	O
:	-	404	O

Tremor	15338796	406	O
was	-	413	O
measured	-	417	O
using	-	426	O
a	-	432	O
laser	-	434	O
pointer	-	440	O
technique	-	448	O
.	-	457	O

To	15338796	459	O
determine	-	462	O
sensitivity	-	472	O
we	-	484	O
assessed	-	487	O
tremor	-	496	O
in	-	503	O
44	-	506	O
patients	-	509	O
with	-	518	O
obstructive	-	523	O
lung	-	535	O
disease	-	540	O
after	-	548	O
administration	-	554	O
of	-	569	O
cumulative	-	572	O
doses	-	583	O
of	-	589	O
salbutamol	-	592	B
.	-	602	O

Subjects	15338796	604	O
were	-	613	O
asked	-	618	O
to	-	624	O
aim	-	627	O
at	-	631	O
the	-	634	O
centre	-	638	O
of	-	645	O
a	-	648	O
target	-	650	O
,	-	656	O
subdivided	-	658	O
in	-	669	O
concentric	-	672	O
circles	-	683	O
,	-	690	O
from	-	692	O
5	-	697	O
m	-	699	O
distance	-	701	O
.	-	709	O

The	15338796	711	O
circle	-	715	O
in	-	722	O
which	-	725	O
the	-	731	O
participant	-	735	O
succeeded	-	747	O
to	-	757	O
aim	-	760	O
was	-	764	O
recorded	-	768	O
in	-	777	O
millimetres	-	780	O
radius	-	792	O
.	-	798	O

In	15338796	800	O
another	-	803	O
series	-	811	O
of	-	818	O
measurements	-	821	O
,	-	833	O
reproducibility	-	835	O
and	-	851	O
reference	-	855	O
values	-	865	O
of	-	872	O
the	-	875	O
tremor	-	879	O
was	-	886	O
assessed	-	890	O
in	-	899	O
65	-	902	O
healthy	-	905	O
subjects	-	913	O
in	-	922	O
three	-	925	O
sessions	-	931	O
,	-	939	O
at	-	941	O
9	-	944	O
a	-	946	O
.	-	947	O
m	-	948	O
.	-	949	O
,	-	950	O
4	-	952	O
p	-	954	O
.	-	955	O
m	-	956	O
.	-	957	O
and	-	959	O
9	-	963	O
a	-	965	O
.	-	966	O
m	-	967	O
.	-	968	O
,	-	969	O
respectively	-	971	O
,	-	983	O
1	-	985	O
week	-	987	O
later	-	992	O
.	-	997	O

Postural	15338796	999	O
tremor	-	1008	O
was	-	1015	O
measured	-	1019	O
with	-	1028	O
the	-	1033	O
arm	-	1037	O
horizontally	-	1041	O
outstretched	-	1054	O
rest	-	1067	O
tremor	-	1072	O
with	-	1079	O
the	-	1084	O
arm	-	1088	O
supported	-	1092	O
by	-	1102	O
an	-	1105	O
armrest	-	1108	O
and	-	1116	O
finally	-	1120	O
tremor	-	1128	O
was	-	1135	O
measured	-	1139	O
after	-	1148	O
holding	-	1154	O
a	-	1162	O
2	-	1164	O
-	-	1165	O
kg	-	1166	O
weight	-	1169	O
until	-	1176	O
exhaustion	-	1182	O
.	-	1192	O

Inter	15338796	1194	O
-	-	1199	O
observer	-	1200	O
variability	-	1209	O
was	-	1221	O
measured	-	1225	O
in	-	1234	O
a	-	1237	O
series	-	1239	O
of	-	1246	O
10	-	1249	O
healthy	-	1252	O
subjects	-	1260	O
.	-	1268	O

Tremor	15338796	1270	O
was	-	1277	O
measured	-	1281	O
simultaneously	-	1290	O
by	-	1305	O
two	-	1308	O
independent	-	1312	O
observers	-	1324	O
.	-	1333	O

RESULTS	15338796	1335	O
:	-	1342	O

Salbutamol	15338796	1344	B
significantly	-	1355	O
increased	-	1369	O
tremor	-	1379	O
severity	-	1386	O
in	-	1395	O
patients	-	1398	O
in	-	1407	O
a	-	1410	O
dose	-	1412	O
-	-	1416	O
dependent	-	1417	O
way	-	1427	O
.	-	1430	O

Within	15338796	1432	O
healthy	-	1439	O
adults	-	1447	O
no	-	1454	O
age	-	1457	O
-	-	1460	O
dependency	-	1461	O
could	-	1472	O
be	-	1478	O
found	-	1481	O
(	-	1487	O
b	-	1488	O
=	-	1490	O
0	-	1492	O
.	-	1493	O
262	-	1494	O
mm	-	1498	O
/	-	1500	O
year	-	1501	O
;	-	1505	O
P	-	1507	O
=	-	1509	O
0	-	1511	O
.	-	1512	O
72	-	1513	O
)	-	1515	O
.	-	1516	O

There	15338796	1518	O
was	-	1524	O
no	-	1528	O
agreement	-	1531	O
between	-	1541	O
the	-	1549	O
questionnaire	-	1553	O
and	-	1567	O
tremor	-	1571	O
severity	-	1578	O
(	-	1587	O
r	-	1588	O
=	-	1590	O
0	-	1592	O
.	-	1593	O
093	-	1594	O
;	-	1597	O
P	-	1599	O
=	-	1601	O
0	-	1603	O
.	-	1604	O
53	-	1605	O
)	-	1607	O
.	-	1608	O

Postural	15338796	1610	O
tremor	-	1619	O
showed	-	1626	O
no	-	1633	O
significant	-	1636	O
difference	-	1648	O
between	-	1659	O
the	-	1667	O
first	-	1671	O
and	-	1677	O
third	-	1681	O
session	-	1687	O
(	-	1695	O
P	-	1696	O
=	-	1698	O
0	-	1700	O
.	-	1701	O
07	-	1702	O
)	-	1704	O
.	-	1705	O

Support	15338796	1707	O
of	-	1715	O
the	-	1718	O
arm	-	1722	O
decreased	-	1726	O
tremor	-	1736	O
severity	-	1743	O
,	-	1751	O
exhaustion	-	1753	O
increased	-	1764	O
tremor	-	1774	O
severity	-	1781	O
significantly	-	1790	O
.	-	1803	O

A	15338796	1805	O
good	-	1807	O
agreement	-	1812	O
was	-	1822	O
found	-	1826	O
between	-	1832	O
two	-	1840	O
independent	-	1844	O
observers	-	1856	O
(	-	1866	O
interclass	-	1867	O
correlation	-	1878	O
coefficient	-	1890	O
0	-	1902	O
.	-	1903	O
72	-	1904	O
)	-	1906	O
.	-	1907	O

DISCUSSION	15338796	1909	O
:	-	1919	O

Quantifying	15338796	1921	O
tremor	-	1933	O
by	-	1940	O
using	-	1943	O
an	-	1949	O
inexpensive	-	1952	O
laser	-	1964	O
pointer	-	1970	O
is	-	1978	O
,	-	1980	O
with	-	1982	O
the	-	1987	O
exception	-	1991	O
of	-	2001	O
children	-	2004	O
(	-	2013	O
<	-	2014	O
12	-	2015	O
years	-	2018	O
)	-	2023	O
a	-	2025	O
sensitive	-	2027	O
and	-	2037	O
reproducible	-	2041	O
method	-	2054	O
.	-	2060	O

Increased	12627929	0	O
frequency	-	10	O
of	-	20	O
venous	-	23	O
thromboembolism	-	30	O
with	-	46	O
the	-	51	O
combination	-	55	O
of	-	67	O
docetaxel	-	70	B
and	-	80	O
thalidomide	-	84	B
in	-	96	O
patients	-	99	O
with	-	108	O
metastatic	-	113	O
androgen	-	124	O
-	-	132	O
independent	-	133	O
prostate	-	145	O
cancer	-	154	O
.	-	160	O

STUDY	12627929	162	O
OBJECTIVE	-	168	O
:	-	177	O

To	12627929	179	O
evaluate	-	182	O
the	-	191	O
frequency	-	195	O
of	-	205	O
venous	-	208	O
thromboembolism	-	215	O
(	-	231	O
VTE	-	232	O
)	-	235	O
in	-	237	O
patients	-	240	O
with	-	249	O
advanced	-	254	O
androgen	-	263	O
-	-	271	O
independent	-	272	O
prostate	-	284	O
cancer	-	293	O
who	-	300	O
were	-	304	O
treated	-	309	O
with	-	317	O
docetaxel	-	322	B
alone	-	332	O
or	-	338	O
in	-	341	O
combination	-	344	O
with	-	356	O
thalidomide	-	361	B
.	-	372	O

DESIGN	12627929	374	O
:	-	380	O

Retrospective	12627929	382	O
analysis	-	396	O
of	-	405	O
a	-	408	O
randomized	-	410	O
phase	-	421	O
II	-	427	O
trial	-	430	O
.	-	435	O

SETTING	12627929	437	O
:	-	444	O
National	-	446	O
Institutes	-	455	O
of	-	466	O
Health	-	469	O
clinical	-	476	O
research	-	485	O
center	-	494	O
.	-	500	O

PATIENTS	12627929	502	O
:	-	510	O

Seventy	12627929	512	O
men	-	520	O
,	-	523	O
aged	-	525	O
50	-	530	O
-	-	532	O
80	-	533	O
years	-	536	O
,	-	541	O
with	-	543	O
advanced	-	548	O
androgen	-	557	O
-	-	565	O
independent	-	566	O
prostate	-	578	O
cancer	-	587	O
.	-	593	O

INTERVENTION	12627929	595	O
:	-	607	O

Each	12627929	609	O
patient	-	614	O
received	-	622	O
either	-	631	O
intravenous	-	638	O
docetaxel	-	650	B
30	-	660	O
mg	-	663	O
/	-	665	O
m2	-	666	O
/	-	668	O
week	-	669	O
for	-	674	O
3	-	678	O
consecutive	-	680	O
weeks	-	692	O
,	-	697	O
followed	-	699	O
by	-	708	O
1	-	711	O
week	-	713	O
off	-	718	O
,	-	721	O
or	-	723	O
the	-	726	O
combination	-	730	O
of	-	742	O
continuous	-	745	O
oral	-	756	O
thalidomide	-	761	B
200	-	773	O
mg	-	777	O
every	-	780	O
evening	-	786	O
plus	-	794	O
the	-	799	O
same	-	803	O
docetaxel	-	808	B
regimen	-	818	O
.	-	825	O

This	12627929	827	O
4	-	832	O
-	-	833	O
week	-	834	O
cycle	-	839	O
was	-	845	O
repeated	-	849	O
until	-	858	O
there	-	864	O
was	-	870	O
evidence	-	874	O
of	-	883	O
excessive	-	886	O
toxicity	-	896	O
or	-	905	O
disease	-	908	O
progression	-	916	O
.	-	927	O

MEASUREMENTS	12627929	929	O
AND	-	942	O
MAIN	-	946	O
RESULTS	-	951	O
:	-	958	O

None	12627929	960	O
of	-	965	O
23	-	968	O
patients	-	971	O
who	-	980	O
received	-	984	O
docetaxel	-	993	B
alone	-	1003	O
developed	-	1009	O
VTE	-	1019	O
,	-	1022	O
whereas	-	1024	O
9	-	1032	O
of	-	1034	O
47	-	1037	O
patients	-	1040	O
(	-	1049	O
19	-	1050	O
%	-	1052	O
)	-	1053	O
who	-	1055	O
received	-	1059	O
docetaxel	-	1068	B
plus	-	1078	O
thalidomide	-	1083	B
developed	-	1095	O
VTE	-	1105	O
(	-	1109	O
p	-	1110	O
=	-	1111	O
0	-	1112	O
.	-	1113	O
025	-	1114	O
)	-	1117	O
.	-	1118	O

CONCLUSION	12627929	1120	O
:	-	1130	O

The	12627929	1132	O
addition	-	1136	O
of	-	1145	O
thalidomide	-	1148	B
to	-	1160	O
docetaxel	-	1163	B
in	-	1173	O
the	-	1176	O
treatment	-	1180	O
of	-	1190	O
prostate	-	1193	O
cancer	-	1202	O
significantly	-	1209	O
increases	-	1223	O
the	-	1233	O
frequency	-	1237	O
of	-	1247	O
VTE	-	1250	O
.	-	1253	O

Clinicians	12627929	1255	O
should	-	1266	O
be	-	1273	O
aware	-	1276	O
of	-	1282	O
this	-	1285	O
potential	-	1290	O
complication	-	1300	O
when	-	1313	O
adding	-	1318	O
thalidomide	-	1325	B
to	-	1337	O
chemotherapeutic	-	1340	O
regimens	-	1357	O
.	-	1365	O

Sublingual	6634932	0	O
absorption	-	11	O
of	-	22	O
the	-	25	O
quaternary	-	29	B
ammonium	-	40	I
antiarrhythmic	-	49	O
agent	-	64	O
,	-	69	O
UM	-	71	B
-	-	73	I
272	-	74	I
.	-	77	O
UM	-	79	B
-	-	81	I
272	-	82	I
(	-	86	O
N	-	87	B
,	-	88	I
N	-	89	I
-	-	90	I
dimethylpropranolol	-	91	I
)	-	110	O
,	-	111	O
a	-	113	O
quaternary	-	115	O
antiarrhythmic	-	126	O
agent	-	141	O
,	-	146	O
was	-	148	O
administered	-	152	O
sublingually	-	165	O
to	-	178	O
dogs	-	181	O
with	-	186	O
ouabain	-	191	B
-	-	198	O
induced	-	199	O
ventricular	-	207	O
tachycardias	-	219	O
.	-	231	O

Both	6634932	233	O
anti	-	238	O
-	-	242	O
arrhythmic	-	243	O
efficacy	-	254	O
and	-	263	O
bioavailability	-	267	O
were	-	283	O
compared	-	288	O
to	-	297	O
oral	-	300	O
drug	-	305	O
.	-	309	O

Sublingual	6634932	311	O
UM	-	322	B
-	-	324	I
272	-	325	I
converted	-	329	O
ventricular	-	339	O
tachycardia	-	351	O
to	-	363	O
sinus	-	366	O
rhythm	-	372	O
in	-	379	O
all	-	382	O
5	-	386	O
dogs	-	388	O
.	-	392	O

The	6634932	394	O
area	-	398	O
under	-	403	O
the	-	409	O
plasma	-	413	O
concentration	-	420	O
time	-	434	O
curve	-	439	O
at	-	445	O
90	-	448	O
min	-	451	O
was	-	455	O
4	-	459	O
-	-	460	O
12	-	461	O
times	-	464	O
greater	-	470	O
than	-	478	O
for	-	483	O
oral	-	487	O
drug	-	492	O
,	-	496	O
suggesting	-	498	O
the	-	509	O
existence	-	513	O
of	-	523	O
an	-	526	O
absorption	-	529	O
-	-	539	O
limiting	-	540	O
process	-	549	O
in	-	557	O
the	-	560	O
intestine	-	564	O
,	-	573	O
and	-	575	O
providing	-	579	O
an	-	589	O
alternate	-	592	O
form	-	602	O
of	-	607	O
administration	-	610	O
for	-	625	O
quaternary	-	629	O
drugs	-	640	O
.	-	645	O

Severe	18791946	0	O
thrombocytopenia	-	7	O
and	-	24	O
haemolytic	-	28	O
anaemia	-	39	O
associated	-	47	O
with	-	58	O
ciprofloxacin	-	63	B
:	-	76	O
a	-	78	O
case	-	80	O
report	-	85	O
with	-	92	O
fatal	-	97	O
outcome	-	103	O
.	-	110	O

Haematological	18791946	112	O
adverse	-	127	O
reactions	-	135	O
associated	-	145	O
with	-	156	O
fatal	-	161	O
outcome	-	167	O
are	-	175	O
rare	-	179	O
during	-	184	O
treatment	-	191	O
with	-	201	O
ciprofloxacin	-	206	B
.	-	219	O

A	18791946	221	O
30	-	223	O
-	-	225	O
year	-	226	O
old	-	231	O
Caucasian	-	235	O
man	-	245	O
reported	-	249	O
with	-	258	O
abdominal	-	263	O
pain	-	273	O
and	-	278	O
jaundice	-	282	O
after	-	291	O
3	-	297	O
-	-	298	O
day	-	299	O
administration	-	303	O
of	-	318	O
oral	-	321	O
ciprofloxacin	-	326	B
for	-	340	O
a	-	344	O
suspect	-	346	O
of	-	354	O
urinary	-	357	O
tract	-	365	O
infection	-	371	O
.	-	380	O

Clinical	18791946	382	O
evaluations	-	391	O
suggested	-	403	O
an	-	413	O
initial	-	416	O
diagnosis	-	424	O
of	-	434	O
severe	-	437	O
thrombocytopenia	-	444	O
and	-	461	O
haemolysis	-	465	O
.	-	475	O

The	18791946	477	O
patient	-	481	O
progressively	-	489	O
developed	-	503	O
petechiae	-	513	O
and	-	523	O
purpura	-	527	O
on	-	535	O
thorax	-	538	O
and	-	545	O
lower	-	549	O
limbs	-	555	O
.	-	560	O

Despite	18791946	562	O
pharmacological	-	570	O
and	-	586	O
supportive	-	590	O
interventions	-	601	O
,	-	614	O
laboratory	-	616	O
parameters	-	627	O
worsened	-	638	O
and	-	647	O
the	-	651	O
patient	-	655	O
died	-	663	O
17	-	668	O
hours	-	671	O
after	-	677	O
admission	-	683	O
.	-	692	O

An	18791946	694	O
accurate	-	697	O
autopsy	-	706	O
revealed	-	714	O
most	-	723	O
organs	-	728	O
with	-	735	O
diffuse	-	740	O
petechial	-	748	O
haemorrhages	-	758	O
.	-	770	O

No	18791946	772	O
signs	-	775	O
of	-	781	O
bone	-	784	O
marrow	-	789	O
depression	-	796	O
were	-	807	O
found	-	812	O
.	-	817	O

No	18791946	819	O
thrombi	-	822	O
or	-	830	O
signs	-	833	O
of	-	839	O
microangiopathies	-	842	O
were	-	860	O
observed	-	865	O
in	-	874	O
arterial	-	877	O
vessels	-	886	O
.	-	893	O

Blood	18791946	895	O
and	-	901	O
urine	-	905	O
cultures	-	911	O
did	-	920	O
not	-	924	O
show	-	928	O
any	-	933	O
bacterial	-	937	O
growth	-	947	O
.	-	953	O

This	18791946	955	O
case	-	960	O
report	-	965	O
shows	-	972	O
that	-	978	O
ciprofloxacin	-	983	B
may	-	997	O
precipitate	-	1001	O
life	-	1013	O
-	-	1017	O
threatening	-	1018	O
thrombocytopenia	-	1030	O
and	-	1047	O
haemolytic	-	1051	O
anaemia	-	1062	O
,	-	1069	O
even	-	1071	O
in	-	1076	O
the	-	1079	O
early	-	1083	O
phases	-	1089	O
of	-	1096	O
treatment	-	1099	O
and	-	1109	O
without	-	1113	O
apparent	-	1121	O
previous	-	1130	O
exposures	-	1139	O
.	-	1148	O

Simvastatin	17344566	0	B
-	-	11	O
induced	-	12	O
bilateral	-	20	O
leg	-	30	O
compartment	-	34	O
syndrome	-	46	O
and	-	55	O
myonecrosis	-	59	O
associated	-	71	O
with	-	82	O
hypothyroidism	-	87	O
.	-	101	O

A	17344566	103	O
54	-	105	O
-	-	107	O
year	-	108	O
-	-	112	O
old	-	113	O
hypothyroid	-	117	O
male	-	129	O
taking	-	134	O
thyroxine	-	141	B
and	-	151	O
simvastatin	-	155	B
presented	-	167	O
with	-	177	O
bilateral	-	182	O
leg	-	192	O
compartment	-	196	O
syndrome	-	208	O
and	-	217	O
myonecrosis	-	221	O
.	-	232	O

Urgent	17344566	234	O
fasciotomies	-	241	O
were	-	254	O
performed	-	259	O
and	-	269	O
the	-	273	O
patient	-	277	O
made	-	285	O
an	-	290	O
uneventful	-	293	O
recovery	-	304	O
with	-	313	O
the	-	318	O
withdrawal	-	322	O
of	-	333	O
simvastatin	-	336	B
.	-	347	O

It	17344566	349	O
is	-	352	O
likely	-	355	O
that	-	362	O
this	-	367	O
complication	-	372	O
will	-	385	O
be	-	390	O
seen	-	393	O
more	-	398	O
often	-	403	O
with	-	409	O
the	-	414	O
increased	-	418	O
worldwide	-	428	O
use	-	438	O
of	-	442	O
this	-	445	O
drug	-	450	O
and	-	455	O
its	-	459	O
approval	-	463	O
for	-	472	O
all	-	476	O
arteriopathic	-	480	O
patients	-	494	O
.	-	502	O

Bile	9293063	0	O
duct	-	5	O
hamartoma	-	10	O
occurring	-	20	O
in	-	30	O
association	-	33	O
with	-	45	O
long	-	50	O
-	-	54	O
term	-	55	O
treatment	-	60	O
with	-	70	O
danazol	-	75	B
.	-	82	O

We	9293063	84	O
report	-	87	O
a	-	94	O
case	-	96	O
of	-	101	O
bile	-	104	O
duct	-	109	O
hamartoma	-	114	O
which	-	124	O
developed	-	130	O
in	-	140	O
a	-	143	O
patient	-	145	O
who	-	153	O
had	-	157	O
been	-	161	O
on	-	166	O
long	-	169	O
-	-	173	O
term	-	174	O
danazol	-	179	B
treatment	-	187	O
.	-	196	O

Such	9293063	198	O
patients	-	203	O
should	-	212	O
be	-	219	O
under	-	222	O
close	-	228	O
follow	-	234	O
-	-	240	O
up	-	241	O
,	-	243	O
preferably	-	245	O
with	-	256	O
periodic	-	261	O
ultrasound	-	270	O
examination	-	281	O
of	-	293	O
the	-	296	O
liver	-	300	O
.	-	305	O

If	9293063	307	O
the	-	310	O
patient	-	314	O
develops	-	322	O
a	-	331	O
liver	-	333	O
mass	-	339	O
,	-	343	O
because	-	345	O
of	-	353	O
non	-	356	O
-	-	359	O
specific	-	360	O
clinical	-	369	O
features	-	378	O
and	-	387	O
imaging	-	391	O
appearances	-	399	O
,	-	410	O
biopsy	-	412	O
may	-	419	O
be	-	423	O
the	-	426	O
only	-	430	O
way	-	435	O
to	-	439	O
achieve	-	442	O
a	-	450	O
definitive	-	452	O
diagnosis	-	463	O
.	-	472	O

Granulomatous	1728522	0	O
hepatitis	-	14	O
due	-	24	O
to	-	28	O
combination	-	31	B
of	-	43	I
amoxicillin	-	46	I
and	-	58	I
clavulanic	-	62	I
acid	-	73	I
.	-	77	O

We	1728522	79	O
report	-	82	O
the	-	89	O
case	-	93	O
of	-	98	O
a	-	101	O
patient	-	103	O
with	-	111	O
amoxicillin	-	116	B
-	-	127	I
clavulanic	-	128	I
acid	-	139	I
-	-	143	O
induced	-	144	O
hepatitis	-	152	O
with	-	162	O
histologic	-	167	O
multiple	-	178	O
granulomas	-	187	O
.	-	197	O

This	1728522	199	O
type	-	204	O
of	-	209	O
lesion	-	212	O
broadens	-	219	O
the	-	228	O
spectrum	-	232	O
of	-	241	O
liver	-	244	O
injury	-	250	O
due	-	257	O
to	-	261	O
this	-	264	O
drug	-	269	O
combination	-	274	O
,	-	285	O
mainly	-	287	O
represented	-	294	O
by	-	306	O
a	-	309	O
benign	-	311	O
cholestatic	-	318	O
syndrome	-	330	O
.	-	338	O

The	1728522	340	O
association	-	344	O
of	-	356	O
granulomas	-	359	O
and	-	370	O
eosinophilia	-	374	O
favor	-	387	O
an	-	393	O
immunoallergic	-	396	O
mechanism	-	411	O
.	-	420	O

As	1728522	422	O
penicillin	-	425	B
derivatives	-	436	O
and	-	448	O
amoxicillin	-	452	B
alone	-	464	O
are	-	470	O
known	-	474	O
to	-	480	O
induce	-	483	O
such	-	490	O
types	-	495	O
of	-	501	O
lesions	-	504	O
,	-	511	O
the	-	513	O
amoxicillin	-	517	B
component	-	529	O
,	-	538	O
with	-	540	O
or	-	545	O
without	-	548	O
a	-	556	O
potentiating	-	558	O
effect	-	571	O
of	-	578	O
clavulanic	-	581	B
acid	-	592	I
,	-	596	O
might	-	598	O
have	-	604	O
a	-	609	O
major	-	611	O
role	-	617	O
.	-	621	O

Intracranial	10807237	0	O
aneurysms	-	13	O
and	-	23	O
cocaine	-	27	O
abuse	-	35	O
:	-	40	O
analysis	-	42	O
of	-	51	O
prognostic	-	54	O
indicators	-	65	O
.	-	75	O

OBJECTIVE	10807237	77	O
:	-	86	O
The	-	88	O
outcome	-	92	O
of	-	100	O
subarachnoid	-	103	O
hemorrhage	-	116	O
associated	-	127	O
with	-	138	O
cocaine	-	143	O
abuse	-	151	O
is	-	157	O
reportedly	-	160	O
poor	-	171	O
.	-	175	O

However	10807237	177	O
,	-	184	O
no	-	186	O
study	-	189	O
in	-	195	O
the	-	198	O
literature	-	202	O
has	-	213	O
reported	-	217	O
the	-	226	O
use	-	230	O
of	-	234	O
a	-	237	O
statistical	-	239	O
model	-	251	O
to	-	257	O
analyze	-	260	O
the	-	268	O
variables	-	272	O
that	-	282	O
influence	-	287	O
outcome	-	297	O
.	-	304	O

METHODS	10807237	306	O
:	-	313	O

A	10807237	315	O
review	-	317	O
of	-	324	O
admissions	-	327	O
during	-	338	O
a	-	345	O
6	-	347	O
-	-	348	O
year	-	349	O
period	-	354	O
revealed	-	361	O
14	-	370	O
patients	-	373	O
with	-	382	O
cocaine	-	387	B
-	-	394	O
related	-	395	O
aneurysms	-	403	O
.	-	412	O

This	10807237	414	O
group	-	419	O
was	-	425	O
compared	-	429	O
with	-	438	O
a	-	443	O
control	-	445	O
group	-	453	O
of	-	459	O
135	-	462	O
patients	-	466	O
with	-	475	O
ruptured	-	480	O
aneurysms	-	489	O
and	-	499	O
no	-	503	O
history	-	506	O
of	-	514	O
cocaine	-	517	O
abuse	-	525	O
.	-	530	O

Age	10807237	532	O
at	-	536	O
presentation	-	539	O
,	-	551	O
time	-	553	O
of	-	558	O
ictus	-	561	O
after	-	567	O
intoxication	-	573	O
,	-	585	O
Hunt	-	587	O
and	-	592	O
Hess	-	596	O
grade	-	601	O
of	-	607	O
subarachnoid	-	610	O
hemorrhage	-	623	O
,	-	633	O
size	-	635	O
of	-	640	O
the	-	643	O
aneurysm	-	647	O
,	-	655	O
location	-	657	O
of	-	666	O
the	-	669	O
aneurysm	-	673	O
,	-	681	O
and	-	683	O
the	-	687	O
Glasgow	-	691	O
Outcome	-	699	O
Scale	-	707	O
score	-	713	O
were	-	719	O
assessed	-	724	O
and	-	733	O
compared	-	737	O
.	-	745	O

RESULTS	10807237	747	O
:	-	754	O

The	10807237	756	O
patients	-	760	O
in	-	769	O
the	-	772	O
study	-	776	O
group	-	782	O
were	-	788	O
significantly	-	793	O
younger	-	807	O
than	-	815	O
the	-	820	O
patients	-	824	O
in	-	833	O
the	-	836	O
control	-	840	O
group	-	848	O
(	-	854	O
P	-	855	O
<	-	857	O
0	-	859	O
.	-	860	O
002	-	861	O
)	-	864	O
.	-	865	O

In	10807237	867	O
patients	-	870	O
in	-	879	O
the	-	882	O
study	-	886	O
group	-	892	O
,	-	897	O
all	-	899	O
aneurysms	-	903	O
were	-	913	O
located	-	918	O
in	-	926	O
the	-	929	O
anterior	-	933	O
circulation	-	942	O
.	-	953	O

The	10807237	955	O
majority	-	959	O
of	-	968	O
these	-	971	O
aneurysms	-	977	O
were	-	987	O
smaller	-	992	O
than	-	1000	O
those	-	1005	O
of	-	1011	O
the	-	1014	O
control	-	1018	O
group	-	1026	O
(	-	1032	O
8	-	1033	O
+	-	1035	O
/	-	1036	O
-	-	1037	O

6	10807237	1039	O
.	-	1040	O
08	-	1041	O
mm	-	1044	O
versus	-	1047	O
11	-	1054	O
+	-	1057	O
/	-	1058	O
-	-	1059	O

5	10807237	1061	O
.	-	1062	O
4	-	1063	O
mm	-	1065	O
;	-	1067	O
P	-	1069	O
=	-	1071	O
0	-	1073	O
.	-	1074	O
05	-	1075	O
)	-	1077	O
.	-	1078	O

The	10807237	1080	O
differences	-	1084	O
in	-	1096	O
mortality	-	1099	O
and	-	1109	O
morbidity	-	1113	O
between	-	1123	O
the	-	1131	O
two	-	1135	O
groups	-	1139	O
were	-	1146	O
not	-	1151	O
significant	-	1155	O
.	-	1166	O

Hunt	10807237	1168	O
and	-	1173	O
Hess	-	1177	O
grade	-	1182	O
(	-	1188	O
P	-	1189	O
<	-	1191	O
0	-	1193	O
.	-	1194	O
005	-	1195	O
)	-	1198	O
and	-	1200	O
age	-	1204	O
(	-	1208	O
P	-	1209	O
<	-	1211	O
0	-	1213	O
.	-	1214	O
007	-	1215	O
)	-	1218	O
were	-	1220	O
significant	-	1225	O
predictors	-	1237	O
of	-	1248	O
outcome	-	1251	O
for	-	1259	O
the	-	1263	O
patients	-	1267	O
with	-	1276	O
cocaine	-	1281	B
-	-	1288	O
related	-	1289	O
aneurysms	-	1297	O
.	-	1306	O

CONCLUSION	10807237	1308	O
:	-	1318	O

Cocaine	10807237	1320	B
use	-	1328	O
predisposed	-	1332	O
aneurysmal	-	1344	O
rupture	-	1355	O
at	-	1363	O
a	-	1366	O
significantly	-	1368	O
earlier	-	1382	O
age	-	1390	O
and	-	1394	O
in	-	1398	O
much	-	1401	O
smaller	-	1406	O
aneurysms	-	1414	O
.	-	1423	O

Contrary	10807237	1425	O
to	-	1434	O
the	-	1437	O
published	-	1441	O
literature	-	1451	O
,	-	1461	O
this	-	1463	O
group	-	1468	O
did	-	1474	O
reasonably	-	1478	O
well	-	1489	O
with	-	1494	O
aggressive	-	1499	O
management	-	1510	O
.	-	1520	O

Anti	12536034	0	O
-	-	4	O
epileptic	-	5	O
drugs	-	15	O
-	-	20	O
induced	-	21	O
de	-	29	O
novo	-	32	O
absence	-	37	O
seizures	-	45	O
.	-	53	O

The	12536034	55	O
authors	-	59	O
present	-	67	O
three	-	75	O
patients	-	81	O
with	-	90	O
de	-	95	O
novo	-	98	O
absence	-	103	O
epilepsy	-	111	O
after	-	120	O
administration	-	126	O
of	-	141	O
carbamazepine	-	144	B
and	-	158	O
vigabatrin	-	162	B
.	-	172	O

Despite	12536034	174	O
the	-	182	O
underlying	-	186	O
diseases	-	197	O
,	-	205	O
the	-	207	O
prognosis	-	211	O
for	-	221	O
drug	-	225	O
-	-	229	O
induced	-	230	O
de	-	238	O
novo	-	241	O
absence	-	246	O
seizure	-	254	O
is	-	262	O
good	-	265	O
because	-	270	O
it	-	278	O
subsides	-	281	O
rapidly	-	290	O
after	-	298	O
discontinuing	-	304	O
the	-	318	O
use	-	322	O
of	-	326	O
the	-	329	O
offending	-	333	O
drugs	-	343	O
.	-	348	O

The	12536034	350	O
gamma	-	354	B
-	-	359	I
aminobutyric	-	360	I
acid	-	373	I
-	-	377	O
transmitted	-	378	O
thalamocortical	-	390	O
circuitry	-	406	O
accounts	-	416	O
for	-	425	O
a	-	429	O
major	-	431	O
part	-	437	O
of	-	442	O
the	-	445	O
underlying	-	449	O
neurophysiology	-	460	O
of	-	476	O
the	-	479	O
absence	-	483	O
epilepsy	-	491	O
.	-	499	O

Because	12536034	501	O
drug	-	509	O
-	-	513	O
induced	-	514	O
de	-	522	O
novo	-	525	O
absence	-	530	O
seizure	-	538	O
is	-	546	O
rare	-	549	O
,	-	553	O
pro	-	555	O
-	-	558	O
absence	-	559	O
drugs	-	567	O
can	-	573	O
only	-	577	O
be	-	582	O
considered	-	585	O
a	-	596	O
promoting	-	598	O
factor	-	608	O
.	-	614	O

The	12536034	616	O
underlying	-	620	O
epileptogenecity	-	631	O
of	-	648	O
the	-	651	O
patients	-	655	O
or	-	664	O
the	-	667	O
synergistic	-	671	O
effects	-	683	O
of	-	691	O
the	-	694	O
accompanying	-	698	O
drugs	-	711	O
is	-	717	O
required	-	720	O
to	-	729	O
trigger	-	732	O
the	-	740	O
de	-	744	O
novo	-	747	O
absence	-	752	O
seizure	-	760	O
.	-	767	O

The	12536034	769	O
possibility	-	773	O
of	-	785	O
drug	-	788	O
-	-	792	O
induced	-	793	O
aggravation	-	801	O
should	-	813	O
be	-	820	O
considered	-	823	O
whenever	-	834	O
an	-	843	O
unexpected	-	846	O
increase	-	857	O
in	-	866	O
seizure	-	869	O
frequency	-	877	O
and	-	887	O
/	-	890	O
or	-	891	O
new	-	894	O
seizure	-	898	O
types	-	906	O
appear	-	912	O
following	-	919	O
a	-	929	O
change	-	931	O
in	-	938	O
drug	-	941	O
treatment	-	946	O
.	-	955	O

By	12536034	957	O
understanding	-	960	O
the	-	974	O
underlying	-	978	O
mechanism	-	989	O
of	-	999	O
absence	-	1002	O
epilepsy	-	1010	O
,	-	1018	O
we	-	1020	O
can	-	1023	O
avoid	-	1027	O
the	-	1033	O
inappropriate	-	1037	O
use	-	1051	O
of	-	1055	O
anticonvulsants	-	1058	O
in	-	1074	O
children	-	1077	O
with	-	1086	O
epilepsy	-	1091	O
and	-	1100	O
prevent	-	1104	O
drug	-	1112	O
-	-	1116	O
induced	-	1117	O
absence	-	1125	O
seizures	-	1133	O
.	-	1141	O

Procainamide	7234705	0	B
-	-	12	O
induced	-	13	O
polymorphous	-	21	O
ventricular	-	34	O
tachycardia	-	46	O
.	-	57	O

Seven	7234705	59	O
cases	-	65	O
of	-	71	O
procainamide	-	74	B
-	-	86	O
induced	-	87	O
polymorphous	-	95	O
ventricular	-	108	O
tachycardia	-	120	O
are	-	132	O
presented	-	136	O
.	-	145	O

In	7234705	147	O
four	-	150	O
patients	-	155	O
,	-	163	O
polymorphous	-	165	O
ventricular	-	178	O
tachycardia	-	190	O
appeared	-	202	O
after	-	211	O
intravenous	-	217	O
administration	-	229	O
of	-	244	O
200	-	247	O
to	-	251	O
400	-	254	O
mg	-	258	O
of	-	261	O
procainamide	-	264	B
for	-	277	O
the	-	281	O
treatment	-	285	O
of	-	295	O
sustained	-	298	O
ventricular	-	308	O
tachycardia	-	320	O
.	-	331	O

In	7234705	333	O
the	-	336	O
remaining	-	340	O
three	-	350	O
patients	-	356	O
,	-	364	O
procainamide	-	366	B
was	-	379	O
administered	-	383	O
orally	-	396	O
for	-	403	O
treatment	-	407	O
of	-	417	O
chronic	-	420	O
premature	-	428	O
ventricular	-	438	O
contractions	-	450	O
or	-	463	O
atrial	-	466	O
flutter	-	473	O
.	-	480	O

These	7234705	482	O
patients	-	488	O
had	-	497	O
Q	-	501	O
-	-	502	O
T	-	503	O
prolongation	-	505	O
and	-	518	O
recurrent	-	522	O
syncope	-	532	O
due	-	540	O
to	-	544	O
polymorphous	-	547	O
ventricular	-	560	O
tachycardia	-	572	O
.	-	583	O

In	7234705	585	O
four	-	588	O
patients	-	593	O
,	-	601	O
the	-	603	O
arrhythmia	-	607	O
was	-	618	O
rapidly	-	622	O
diagnosed	-	630	O
and	-	640	O
treated	-	644	O
with	-	652	O
disappearance	-	657	O
of	-	671	O
further	-	674	O
episodes	-	682	O
of	-	691	O
the	-	694	O
arrhythmia	-	698	O
.	-	708	O

In	7234705	710	O
two	-	713	O
patients	-	717	O
,	-	725	O
the	-	727	O
arrhythmia	-	731	O
degenerated	-	742	O
into	-	754	O
irreversible	-	759	O
ventricular	-	772	O
fibrillation	-	784	O
and	-	797	O
both	-	801	O
patients	-	806	O
died	-	815	O
.	-	819	O

In	7234705	821	O
the	-	824	O
seventh	-	828	O
patient	-	836	O
,	-	843	O
a	-	845	O
permanent	-	847	O
ventricular	-	857	O
pacemaker	-	869	O
was	-	879	O
inserted	-	883	O
and	-	892	O
,	-	895	O
despite	-	897	O
continuation	-	905	O
of	-	918	O
procainamide	-	921	B
therapy	-	934	O
,	-	941	O
polymorphous	-	943	O
ventricular	-	956	O
tachycardia	-	968	O
did	-	980	O
not	-	984	O
reoccur	-	988	O
.	-	995	O

These	7234705	997	O
seven	-	1003	O
cases	-	1009	O
demonstrate	-	1015	O
that	-	1027	O
procainamide	-	1032	B
can	-	1045	O
produce	-	1049	O
an	-	1057	O
acquired	-	1060	O
prolonged	-	1069	O
Q	-	1079	O
-	-	1080	O
T	-	1081	O
syndrome	-	1083	O
with	-	1092	O
polymorphous	-	1097	O
ventricular	-	1110	O
tachycardia	-	1122	O
.	-	1133	O

Role	8955532	0	O
of	-	5	O
activation	-	8	O
of	-	19	O
bradykinin	-	22	B
B2	-	33	O
receptors	-	36	O
in	-	46	O
disruption	-	49	O
of	-	60	O
the	-	63	O
blood	-	67	O
-	-	72	O
brain	-	73	O
barrier	-	79	O
during	-	87	O
acute	-	94	O
hypertension	-	100	O
.	-	112	O

Cellular	8955532	114	O
mechanisms	-	123	O
which	-	134	O
account	-	140	O
for	-	148	O
disruption	-	152	O
the	-	163	O
blood	-	167	O
-	-	172	O
brain	-	173	O
barrier	-	179	O
during	-	187	O
acute	-	194	O
hypertension	-	200	O
are	-	213	O
not	-	217	O
clear	-	221	O
.	-	226	O

The	8955532	228	O
goal	-	232	O
of	-	237	O
this	-	240	O
study	-	245	O
was	-	251	O
to	-	255	O
determine	-	258	O
the	-	268	O
role	-	272	O
of	-	277	O
synthesis	-	280	O
/	-	289	O
release	-	290	O
of	-	298	O
bradykinin	-	301	B
to	-	312	O
activate	-	315	O
B2	-	324	O
receptors	-	327	O
in	-	337	O
disruption	-	340	O
of	-	351	O
the	-	354	O
blood	-	358	O
-	-	363	O
brain	-	364	O
barrier	-	370	O
during	-	378	O
acute	-	385	O
hypertension	-	391	O
.	-	403	O

Permeability	8955532	405	O
of	-	418	O
the	-	421	O
blood	-	425	O
-	-	430	O
brain	-	431	O
barrier	-	437	O
was	-	445	O
quantitated	-	449	O
by	-	461	O
clearance	-	464	O
of	-	474	O
fluorescent	-	477	O
-	-	488	O
labeled	-	489	O
dextran	-	497	B
before	-	505	O
and	-	512	O
during	-	516	O
phenylephrine	-	523	B
-	-	536	O
induced	-	537	O
acute	-	545	O
hypertension	-	551	O
in	-	564	O
rats	-	567	O
treated	-	572	O
with	-	580	O
vehicle	-	585	O
and	-	593	O
Hoe	-	597	B
-	-	600	I
140	-	601	I
(	-	605	O
0	-	606	O
.	-	607	O
1	-	608	O
microM	-	610	O
)	-	616	O
.	-	617	O

Phenylephrine	8955532	619	B
infusion	-	633	O
increased	-	642	O
arterial	-	652	O
pressure	-	661	O
,	-	669	O
arteriolar	-	671	O
diameter	-	682	O
and	-	691	O
clearance	-	695	O
of	-	705	O
fluorescent	-	708	O
dextran	-	720	B
by	-	728	O
a	-	731	O
similar	-	733	O
magnitude	-	741	O
in	-	751	O
both	-	754	O
groups	-	759	O
.	-	765	O

These	8955532	767	O
findings	-	773	O
suggest	-	782	O
that	-	790	O
disruption	-	795	O
of	-	806	O
the	-	809	O
blood	-	813	O
-	-	818	O
brain	-	819	O
barrier	-	825	O
during	-	833	O
acute	-	840	O
hypertension	-	846	O
is	-	859	O
not	-	862	O
related	-	866	O
to	-	874	O
the	-	877	O
synthesis	-	881	O
/	-	890	O
release	-	891	O
of	-	899	O
bradykinin	-	902	B
to	-	913	O
activate	-	916	O
B2	-	925	O
receptors	-	928	O
.	-	937	O

5	2578334	0	B
-	-	1	I
azacytidine	-	2	I
potentiates	-	14	O
initiation	-	26	O
induced	-	37	O
by	-	45	O
carcinogens	-	48	O
in	-	60	O
rat	-	63	O
liver	-	67	O
.	-	72	O

To	2578334	74	O
test	-	77	O
the	-	82	O
validity	-	86	O
of	-	95	O
the	-	98	O
hypothesis	-	102	O
that	-	113	O
hypomethylation	-	118	O
of	-	134	O
DNA	-	137	O
plays	-	141	O
an	-	147	O
important	-	150	O
role	-	160	O
in	-	165	O
the	-	168	O
initiation	-	172	O
of	-	183	O
carcinogenic	-	186	O
process	-	199	O
,	-	206	O
5	-	208	B
-	-	209	I
azacytidine	-	210	I
(	-	222	O
5	-	223	B
-	-	224	I
AzC	-	225	I
)	-	228	O
(	-	230	O
10	-	231	O
mg	-	234	O
/	-	236	O
kg	-	237	O
)	-	239	O
,	-	240	O
an	-	242	O
inhibitor	-	245	O
of	-	255	O
DNA	-	258	O
methylation	-	262	O
,	-	273	O
was	-	275	O
given	-	279	O
to	-	285	O
rats	-	288	O
during	-	293	O
the	-	300	O
phase	-	304	O
of	-	310	O
repair	-	313	O
synthesis	-	320	O
induced	-	330	O
by	-	338	O
the	-	341	O
three	-	345	O
carcinogens	-	351	O
,	-	362	O
benzo	-	364	B
[	-	369	I
a	-	370	I
]	-	371	I
-	-	372	I
pyrene	-	373	I
(	-	380	O
200	-	381	O
mg	-	385	O
/	-	387	O
kg	-	388	O
)	-	390	O
,	-	391	O
N	-	393	B
-	-	394	I
methyl	-	395	I
-	-	401	I
N	-	402	I
-	-	403	I
nitrosourea	-	404	I
(	-	416	O
60	-	417	O
mg	-	420	O
/	-	422	O
kg	-	423	O
)	-	425	O
and	-	427	O
1	-	431	B
,	-	432	I
2	-	433	I
-	-	434	I
dimethylhydrazine	-	435	I
(	-	453	O
1	-	454	B
,	-	455	I
2	-	456	I
-	-	457	I
DMH	-	458	I
)	-	461	O
(	-	463	O
100	-	464	O
mg	-	468	O
/	-	470	O
kg	-	471	O
)	-	473	O
.	-	474	O

The	2578334	476	O
initiated	-	480	O
hepatocytes	-	490	O
in	-	502	O
the	-	505	O
liver	-	509	O
were	-	515	O
assayed	-	520	O
as	-	528	O
the	-	531	O
gamma	-	535	O
-	-	540	O
glutamyltransferase	-	541	O
(	-	561	O
gamma	-	562	O
-	-	567	O
GT	-	568	O
)	-	570	O
positive	-	572	O
foci	-	581	O
formed	-	586	O
following	-	593	O
a	-	603	O
2	-	605	O
-	-	606	O
week	-	607	O
selection	-	612	O
regimen	-	622	O
consisting	-	630	O
of	-	641	O
dietary	-	644	O
0	-	652	O
.	-	653	O
02	-	654	O
%	-	656	O
2	-	658	B
-	-	659	I
acetylaminofluorene	-	660	I
coupled	-	680	O
with	-	688	O
a	-	693	O
necrogenic	-	695	O
dose	-	706	O
of	-	711	O
CCl4	-	714	B
.	-	718	O

The	2578334	720	O
results	-	724	O
obtained	-	732	O
indicate	-	741	O
that	-	750	O
with	-	755	O
all	-	760	O
three	-	764	O
carcinogens	-	770	O
,	-	781	O
administration	-	783	O
of	-	798	O
5	-	801	B
-	-	802	I
AzC	-	803	I
during	-	807	O
repair	-	814	O
synthesis	-	821	O
increased	-	831	O
the	-	841	O
incidence	-	845	O
of	-	855	O
initiated	-	858	O
hepatocytes	-	868	O
,	-	879	O
for	-	881	O
example	-	885	O
10	-	893	O
-	-	895	O
20	-	896	O
foci	-	899	O
/	-	903	O
cm2	-	904	O
in	-	908	O
5	-	911	B
-	-	912	I
AzC	-	913	I
and	-	917	O
carcinogen	-	921	O
-	-	931	O
treated	-	932	O
rats	-	940	O
compared	-	945	O
with	-	954	O
3	-	959	O
-	-	960	O
5	-	961	O
foci	-	963	O
/	-	967	O
cm2	-	968	O
in	-	972	O
rats	-	975	O
treated	-	980	O
with	-	988	O
carcinogen	-	993	O
only	-	1004	O
.	-	1008	O

Administration	2578334	1010	O
of	-	1025	O
[	-	1028	B
3H	-	1029	I
]	-	1031	I
-	-	1032	I
5	-	1033	I
-	-	1034	I
azadeoxycytidine	-	1035	I
during	-	1052	O
the	-	1059	O
repair	-	1063	O
synthesis	-	1070	O
induced	-	1080	O
by	-	1088	O
1	-	1091	B
,	-	1092	I
2	-	1093	I
-	-	1094	I
DMH	-	1095	I
further	-	1099	O
showed	-	1107	O
that	-	1114	O
0	-	1119	O
.	-	1120	O
019	-	1121	O
mol	-	1125	O
%	-	1129	O
of	-	1131	O
cytosine	-	1134	B
residues	-	1143	O
in	-	1152	O
DNA	-	1155	O
were	-	1159	O
substituted	-	1164	O
by	-	1176	O
the	-	1179	O
analogue	-	1183	O
,	-	1191	O
indicating	-	1193	O
that	-	1204	O
incorporation	-	1209	O
of	-	1223	O
5	-	1226	B
-	-	1227	I
AzC	-	1228	I
occurs	-	1232	O
during	-	1239	O
repair	-	1246	O
synthesis	-	1253	O
.	-	1262	O

In	2578334	1264	O
the	-	1267	O
absence	-	1271	O
of	-	1279	O
the	-	1282	O
carcinogen	-	1286	O
,	-	1296	O
5	-	1298	B
-	-	1299	I
AzC	-	1300	I
given	-	1304	O
after	-	1310	O
a	-	1316	O
two	-	1318	O
thirds	-	1322	O
partial	-	1329	O
hepatectomy	-	1337	O
,	-	1348	O
when	-	1350	O
its	-	1355	O
incorporation	-	1359	O
should	-	1373	O
be	-	1380	O
maximum	-	1383	O
,	-	1390	O
failed	-	1392	O
to	-	1399	O
induce	-	1402	O
any	-	1409	O
gamma	-	1413	O
-	-	1418	O
GT	-	1419	O
positive	-	1422	O
foci	-	1431	O
.	-	1435	O

The	2578334	1437	O
results	-	1441	O
suggest	-	1449	O
that	-	1457	O
hypomethylation	-	1462	O
of	-	1478	O
DNA	-	1481	O
per	-	1485	O
se	-	1489	O
may	-	1492	O
not	-	1496	O
be	-	1500	O
sufficient	-	1503	O
for	-	1514	O
initiation	-	1518	O
.	-	1528	O

Perhaps	2578334	1530	O
two	-	1538	O
events	-	1542	O
might	-	1549	O
be	-	1555	O
necessary	-	1558	O
for	-	1568	O
initiation	-	1572	O
,	-	1582	O
the	-	1584	O
first	-	1588	O
caused	-	1594	O
by	-	1601	O
the	-	1604	O
carcinogen	-	1608	O
and	-	1619	O
a	-	1623	O
second	-	1625	O
involving	-	1632	O
hypomethylation	-	1642	O
of	-	1658	O
DNA	-	1661	O
.	-	1664	O

Withdrawal	11532387	0	O
-	-	10	O
emergent	-	11	O
rabbit	-	20	O
syndrome	-	27	O
during	-	36	O
dose	-	43	O
reduction	-	48	O
of	-	58	O
risperidone	-	61	B
.	-	72	O

Rabbit	11532387	74	O
syndrome	-	81	O
(	-	90	O
RS	-	91	O
)	-	93	O
is	-	95	O
a	-	98	O
rare	-	100	O
extrapyramidal	-	105	O
side	-	120	O
effect	-	125	O
caused	-	132	O
by	-	139	O
prolonged	-	142	O
neuroleptic	-	152	O
medication	-	164	O
.	-	174	O

Here	11532387	176	O
we	-	181	O
present	-	184	O
a	-	192	O
case	-	194	O
of	-	199	O
withdrawal	-	202	O
-	-	212	O
emergent	-	213	O
RS	-	222	O
,	-	224	O
which	-	226	O
is	-	232	O
the	-	235	O
first	-	239	O
of	-	245	O
its	-	248	O
kind	-	252	O
to	-	257	O
be	-	260	O
reported	-	263	O
.	-	271	O

The	11532387	273	O
patient	-	277	O
developed	-	285	O
RS	-	295	O
during	-	298	O
dose	-	305	O
reduction	-	310	O
of	-	320	O
risperidone	-	323	B
.	-	334	O

The	11532387	336	O
symptom	-	340	O
was	-	348	O
treated	-	352	O
successfully	-	360	O
with	-	373	O
trihexyphenidyl	-	378	B
anticholinergic	-	394	O
therapy	-	410	O
.	-	417	O

The	11532387	419	O
underlying	-	423	O
mechanism	-	434	O
of	-	444	O
withdrawal	-	447	O
-	-	457	O
emergent	-	458	O
RS	-	467	O
in	-	470	O
the	-	473	O
present	-	477	O
case	-	485	O
may	-	490	O
have	-	494	O
been	-	499	O
related	-	504	O
to	-	512	O
the	-	515	O
pharmacological	-	519	O
profile	-	535	O
of	-	543	O
risperidone	-	546	B
,	-	557	O
a	-	559	O
serotonin	-	561	B
-	-	570	O
dopamine	-	571	B
antagonist	-	580	O
,	-	590	O
suggesting	-	592	O
the	-	603	O
pathophysiologic	-	607	O
influence	-	624	O
of	-	634	O
the	-	637	O
serotonin	-	641	B
system	-	651	O
in	-	658	O
the	-	661	O
development	-	665	O
of	-	677	O
RS	-	680	O
.	-	682	O

Verapamil	3173179	0	B
withdrawal	-	10	O
as	-	21	O
a	-	24	O
possible	-	26	O
cause	-	35	O
of	-	41	O
myocardial	-	44	O
infarction	-	55	O
in	-	66	O
a	-	69	O
hypertensive	-	71	O
woman	-	84	O
with	-	90	O
a	-	95	O
normal	-	97	O
coronary	-	104	O
angiogram	-	113	O
.	-	122	O

Verapamil	3173179	124	B
is	-	134	O
an	-	137	O
effective	-	140	O
and	-	150	O
relatively	-	154	O
-	-	164	O
safe	-	165	O
antihypertensive	-	170	O
drug	-	187	O
.	-	191	O

Serious	3173179	193	O
adverse	-	201	O
effects	-	209	O
are	-	217	O
uncommon	-	221	O
and	-	230	O
mainly	-	234	O
have	-	241	O
been	-	246	O
related	-	251	O
to	-	259	O
the	-	262	O
depression	-	266	O
of	-	277	O
cardiac	-	280	O
contractility	-	288	O
and	-	302	O
conduction	-	306	O
,	-	316	O
especially	-	318	O
when	-	329	O
the	-	334	O
drug	-	338	O
is	-	343	O
combined	-	346	O
with	-	355	O
beta	-	360	O
-	-	364	O
blocking	-	365	O
agents	-	374	O
.	-	380	O

We	3173179	382	O
report	-	385	O
a	-	392	O
case	-	394	O
in	-	399	O
which	-	402	O
myocardial	-	408	O
infarction	-	419	O
coincided	-	430	O
with	-	440	O
the	-	445	O
introduction	-	449	O
of	-	462	O
captopril	-	465	B
and	-	475	O
the	-	479	O
withdrawal	-	483	O
of	-	494	O
verapamil	-	497	B
in	-	507	O
a	-	510	O
previously	-	512	O
asymptomatic	-	523	O
woman	-	536	O
with	-	542	O
severe	-	547	O
hypertension	-	554	O
.	-	566	O

Possible	3173179	568	O
mechanisms	-	577	O
that	-	588	O
involve	-	593	O
a	-	601	O
verapamil	-	603	B
-	-	612	O
related	-	613	O
increase	-	621	O
in	-	630	O
platelet	-	633	O
and	-	642	O
/	-	645	O
or	-	646	O
vascular	-	649	O
alpha	-	658	O
2	-	664	O
-	-	665	O
adrenoreceptor	-	666	O
affinity	-	681	O
for	-	690	O
catecholamines	-	694	B
are	-	709	O
discussed	-	713	O
.	-	722	O

Remission	3856631	0	O
induction	-	10	O
of	-	20	O
meningeal	-	23	O
leukemia	-	33	O
with	-	42	O
high	-	47	O
-	-	51	O
dose	-	52	O
intravenous	-	57	O
methotrexate	-	69	B
.	-	81	O

Twenty	3856631	83	O
children	-	90	O
with	-	99	O
acute	-	104	O
lymphoblastic	-	110	O
leukemia	-	124	O
who	-	133	O
developed	-	137	O
meningeal	-	147	O
disease	-	157	O
were	-	165	O
treated	-	170	O
with	-	178	O
a	-	183	O
high	-	185	O
-	-	189	O
dose	-	190	O
intravenous	-	195	O
methotrexate	-	207	B
regimen	-	220	O
that	-	228	O
was	-	233	O
designed	-	237	O
to	-	246	O
achieve	-	249	O
and	-	257	O
maintain	-	261	O
CSF	-	270	O
methotrexate	-	274	B
concentrations	-	287	O
of	-	302	O
10	-	305	O
(	-	307	O
-	-	308	O
5	-	309	O
)	-	310	O
mol	-	312	O
/	-	315	O

L	3856631	316	O
without	-	318	O
the	-	326	O
need	-	330	O
for	-	335	O
concomitant	-	339	O
intrathecal	-	351	O
dosing	-	363	O
.	-	369	O

The	3856631	371	O
methotrexate	-	375	B
was	-	388	O
administered	-	392	O
as	-	405	O
a	-	408	O
loading	-	410	O
dose	-	418	O
of	-	423	O
6	-	426	O
,	-	427	O
000	-	428	O
mg	-	432	O
/	-	434	O
m2	-	435	O
for	-	438	O
a	-	442	O
period	-	444	O
of	-	451	O
one	-	454	O
hour	-	458	O
followed	-	463	O
by	-	472	O
an	-	475	O
infusion	-	478	O
of	-	487	O
1	-	490	O
,	-	491	O
200	-	492	O
mg	-	496	O
/	-	498	O
m2	-	499	O
/	-	501	O
h	-	502	O
for	-	504	O
23	-	508	O
hours	-	511	O
.	-	516	O

Leucovorin	3856631	518	B
rescue	-	529	O
was	-	536	O
initiated	-	540	O
12	-	550	O
hours	-	553	O
after	-	559	O
the	-	565	O
end	-	569	O
of	-	573	O
the	-	576	O
infusion	-	580	O
with	-	589	O
a	-	594	O
loading	-	596	O
dose	-	604	O
of	-	609	O
200	-	612	O
mg	-	616	O
/	-	618	O
m2	-	619	O
followed	-	622	O
by	-	631	O
12	-	634	O
mg	-	637	O
/	-	639	O
m2	-	640	O
every	-	643	O
three	-	649	O
hours	-	655	O
for	-	661	O
six	-	665	O
doses	-	669	O
and	-	675	O
then	-	679	O
every	-	684	O
six	-	690	O
hours	-	694	O
until	-	700	O
the	-	706	O
plasma	-	710	O
methotrexate	-	717	B
level	-	730	O
decreased	-	736	O
to	-	746	O
less	-	749	O
than	-	754	O
1	-	759	O
X	-	761	O
10	-	763	O
(	-	765	O
-	-	766	O
7	-	767	O
)	-	768	O
mol	-	770	O
/	-	773	O
L	-	774	O
.	-	775	O

The	3856631	777	O
mean	-	781	O
steady	-	786	O
-	-	792	O
state	-	793	O
plasma	-	799	O
and	-	806	O
CSF	-	810	O
methotrexate	-	814	B
concentrations	-	827	O
achieved	-	842	O
were	-	851	O
1	-	856	O
.	-	857	O
1	-	858	O
X	-	860	O
10	-	862	O
(	-	864	O
-	-	865	O
3	-	866	O
)	-	867	O
mol	-	869	O
/	-	872	O
L	-	873	O
and	-	875	O
3	-	879	O
.	-	880	O
6	-	881	O
X	-	883	O
10	-	885	O
(	-	887	O
-	-	888	O
5	-	889	O
)	-	890	O
mol	-	892	O
/	-	895	O
L	-	896	O
,	-	897	O
respectively	-	899	O
.	-	911	O

All	3856631	913	O
20	-	917	O
patients	-	920	O
responded	-	929	O
to	-	939	O
this	-	942	O
regimen	-	947	O
,	-	954	O
16	-	956	O
/	-	958	O
20	-	959	O
(	-	962	O
80	-	963	O
%	-	965	O
)	-	966	O
achieved	-	968	O
a	-	977	O
complete	-	979	O
remission	-	988	O
,	-	997	O
and	-	999	O
20	-	1003	O
%	-	1005	O
obtained	-	1007	O
a	-	1016	O
partial	-	1018	O
remission	-	1026	O
.	-	1035	O

The	3856631	1037	O
most	-	1041	O
common	-	1046	O
toxicities	-	1053	O
encountered	-	1064	O
were	-	1076	O
transient	-	1081	O
serum	-	1091	O
transaminase	-	1097	O
and	-	1110	O
bilirubin	-	1114	B
elevations	-	1124	O
,	-	1134	O
neutropenia	-	1136	O
,	-	1147	O
and	-	1149	O
mucositis	-	1153	O
.	-	1162	O

One	3856631	1164	O
patient	-	1168	O
had	-	1176	O
focal	-	1180	O
seizures	-	1186	O
and	-	1195	O
transient	-	1199	O
hemiparesis	-	1209	O
but	-	1221	O
recovered	-	1225	O
completely	-	1235	O
.	-	1245	O

High	3856631	1247	O
-	-	1251	O
dose	-	1252	O
intravenous	-	1257	O
methotrexate	-	1269	B
is	-	1282	O
an	-	1285	O
effective	-	1288	O
treatment	-	1298	O
for	-	1308	O
the	-	1312	O
induction	-	1316	O
of	-	1326	O
remission	-	1329	O
after	-	1339	O
meningeal	-	1345	O
relapse	-	1355	O
in	-	1363	O
acute	-	1366	O
lymphoblastic	-	1372	O
leukemia	-	1386	O
.	-	1394	O

Hypersensitivity	2522601	0	O
to	-	17	O
carbamazepine	-	20	B
presenting	-	34	O
with	-	45	O
a	-	50	O
leukemoid	-	52	O
reaction	-	62	O
,	-	70	O
eosinophilia	-	72	O
,	-	84	O
erythroderma	-	86	O
,	-	98	O
and	-	100	O
renal	-	104	O
failure	-	110	O
.	-	117	O

We	2522601	119	O
report	-	122	O
a	-	129	O
patient	-	131	O
in	-	139	O
whom	-	142	O
hypersensitivity	-	147	O
to	-	164	O
carbamazepine	-	167	B
presented	-	181	O
with	-	191	O
generalized	-	196	O
erythroderma	-	208	O
,	-	220	O
a	-	222	O
severe	-	224	O
leukemoid	-	231	O
reaction	-	241	O
,	-	249	O
eosinophilia	-	251	O
,	-	263	O
hyponatremia	-	265	O
,	-	277	O
and	-	279	O
renal	-	283	O
failure	-	289	O
.	-	296	O

This	2522601	298	O
is	-	303	O
the	-	306	O
first	-	310	O
report	-	316	O
of	-	323	O
such	-	326	O
an	-	331	O
unusual	-	334	O
reaction	-	342	O
to	-	351	O
carbamazepine	-	354	B
.	-	367	O

The	8741744	0	O
interpeduncular	-	4	O
nucleus	-	20	O
regulates	-	28	O
nicotine	-	38	B
's	-	46	O
effects	-	49	O
on	-	57	O
free	-	60	O
-	-	64	O
field	-	65	O
activity	-	71	O
.	-	79	O

Partial	8741744	81	O
lesions	-	89	O
were	-	97	O
made	-	102	O
with	-	107	O
kainic	-	112	B
acid	-	119	I
in	-	124	O
the	-	127	O
interpeduncular	-	131	O
nucleus	-	147	O
of	-	155	O
the	-	158	O
ventral	-	162	O
midbrain	-	170	O
of	-	179	O
the	-	182	O
rat	-	186	O
.	-	189	O

Compared	8741744	191	O
with	-	200	O
sham	-	205	O
-	-	209	O
operated	-	210	O
controls	-	219	O
,	-	227	O
lesions	-	229	O
significantly	-	237	O
(	-	251	O
p	-	252	O
<	-	254	O
0	-	256	O
.	-	257	O
25	-	258	O
)	-	260	O
blunted	-	262	O
the	-	270	O
early	-	274	O
(	-	280	O
<	-	281	O
60	-	282	O
min	-	285	O
)	-	288	O
free	-	290	O
-	-	294	O
field	-	295	O
locomotor	-	301	O
hypoactivity	-	311	O
caused	-	324	O
by	-	331	O
nicotine	-	334	B
(	-	343	O
0	-	344	O
.	-	345	O
5	-	346	O
mg	-	348	O
kg	-	351	O
(	-	353	O
-	-	354	O
1	-	355	O
)	-	356	O
,	-	357	O
i	-	359	O
.	-	360	O
m	-	361	O
.	-	362	O
)	-	363	O
,	-	364	O
enhanced	-	366	O
the	-	375	O
later	-	379	O
(	-	385	O
60	-	386	O
-	-	388	O
120	-	389	O
min	-	393	O
)	-	396	O
nicotine	-	398	B
-	-	406	O
induced	-	407	O
hyperactivity	-	415	O
,	-	428	O
and	-	430	O
raised	-	434	O
spontaneous	-	441	O
nocturnal	-	453	O
activity	-	463	O
.	-	471	O

Lesions	8741744	473	O
reduced	-	481	O
the	-	489	O
extent	-	493	O
of	-	500	O
immunohistological	-	503	O
staining	-	522	O
for	-	531	O
choline	-	535	B
acetyltransferase	-	543	O
in	-	561	O
the	-	564	O
interpeduncular	-	568	O
nucleus	-	584	O
(	-	592	O
p	-	593	O
<	-	595	O
0	-	596	O
.	-	597	O
025	-	598	O
)	-	601	O
,	-	602	O
but	-	604	O
not	-	608	O
for	-	612	O
tyrosine	-	616	B
hydroxylase	-	625	O
in	-	637	O
the	-	640	O
surrounding	-	644	O
catecholaminergic	-	656	O
A10	-	674	O
region	-	678	O
.	-	684	O

We	8741744	686	O
conclude	-	689	O
that	-	698	O
the	-	703	O
interpeduncular	-	707	O
nucleus	-	723	O
mediates	-	731	O
nicotinic	-	740	O
depression	-	750	O
of	-	761	O
locomotor	-	764	O
activity	-	774	O
and	-	783	O
dampens	-	787	O
nicotinic	-	795	O
arousal	-	805	O
mechanisms	-	813	O
located	-	824	O
elsewhere	-	832	O
in	-	842	O
the	-	845	O
brain	-	849	O
.	-	854	O

Assessment	17491223	0	O
of	-	11	O
a	-	14	O
new	-	16	O
non	-	20	O
-	-	23	O
invasive	-	24	O
index	-	33	O
of	-	39	O
cardiac	-	42	O
performance	-	50	O
for	-	62	O
detection	-	66	O
of	-	76	O
dobutamine	-	79	B
-	-	89	O
induced	-	90	O
myocardial	-	98	O
ischemia	-	109	O
.	-	117	O

BACKGROUND	17491223	119	O
:	-	129	O

Electrocardiography	17491223	131	O
has	-	151	O
a	-	155	O
very	-	157	O
low	-	162	O
sensitivity	-	166	O
in	-	178	O
detecting	-	181	O
dobutamine	-	191	B
-	-	201	O
induced	-	202	O
myocardial	-	210	O
ischemia	-	221	O
.	-	229	O

OBJECTIVES	17491223	231	O
:	-	241	O

To	17491223	243	O
assess	-	246	O
the	-	253	O
added	-	257	O
diagnostic	-	263	O
value	-	274	O
of	-	280	O
a	-	283	O
new	-	285	O
cardiac	-	289	O
performance	-	297	O
index	-	309	O
(	-	315	O
dP	-	316	O
/	-	318	O
dtejc	-	319	O
)	-	324	O
measurement	-	326	O
,	-	337	O
based	-	339	O
on	-	345	O
brachial	-	348	O
artery	-	357	O
flow	-	364	O
changes	-	369	O
,	-	376	O
as	-	378	O
compared	-	381	O
to	-	390	O
standard	-	393	O
12	-	402	O
-	-	404	O
lead	-	405	O
ECG	-	410	O
,	-	413	O
for	-	415	O
detecting	-	419	O
dobutamine	-	429	B
-	-	439	O
induced	-	440	O
myocardial	-	448	O
ischemia	-	459	O
,	-	467	O
using	-	469	O
Tc99m	-	475	B
-	-	480	I
Sestamibi	-	481	I
single	-	491	O
-	-	497	O
photon	-	498	O
emission	-	505	O
computed	-	514	O
tomography	-	523	O
as	-	534	O
the	-	537	O
gold	-	541	O
standard	-	546	O
of	-	555	O
comparison	-	558	O
to	-	569	O
assess	-	572	O
the	-	579	O
presence	-	583	O
or	-	592	O
absence	-	595	O
of	-	603	O
ischemia	-	606	O
.	-	614	O

METHODS	17491223	616	O
:	-	623	O

The	17491223	625	O
study	-	629	O
group	-	635	O
comprised	-	641	O
40	-	651	O
patients	-	654	O
undergoing	-	663	O
Sestamibi	-	674	B
-	-	683	O
SPECT	-	684	O
/	-	689	O
dobutamine	-	690	B
stress	-	701	O
test	-	708	O
.	-	712	O

Simultaneous	17491223	714	O
measurements	-	727	O
of	-	740	O
ECG	-	743	O
and	-	747	O
brachial	-	751	O
artery	-	760	O
dP	-	767	O
/	-	769	O
dtejc	-	770	O
were	-	776	O
performed	-	781	O
at	-	791	O
each	-	794	O
dobutamine	-	799	B
level	-	810	O
.	-	815	O

In	17491223	817	O
19	-	820	O
of	-	823	O
the	-	826	O
40	-	830	O
patients	-	833	O
perfusion	-	842	O
defects	-	852	O
compatible	-	860	O
with	-	871	O
ischemia	-	876	O
were	-	885	O
detected	-	890	O
on	-	899	O
SPECT	-	902	O
.	-	907	O

The	17491223	909	O
increase	-	913	O
in	-	922	O
dP	-	925	O
/	-	927	O
dtejc	-	928	O
during	-	934	O
infusion	-	941	O
of	-	950	O
dobutamine	-	953	B
in	-	964	O
this	-	967	O
group	-	972	O
was	-	978	O
severely	-	982	O
impaired	-	991	O
as	-	1000	O
compared	-	1003	O
to	-	1012	O
the	-	1015	O
non	-	1019	O
-	-	1022	O
ischemic	-	1023	O
group	-	1032	O
.	-	1037	O

dP	17491223	1039	O
/	-	1041	O
dtejc	-	1042	O
outcome	-	1048	O
was	-	1056	O
combined	-	1060	O
with	-	1069	O
the	-	1074	O
ECG	-	1078	O
results	-	1082	O
,	-	1089	O
giving	-	1091	O
an	-	1098	O
ECG	-	1101	O
-	-	1104	O
enhanced	-	1105	O
value	-	1114	O
,	-	1119	O
and	-	1121	O
compared	-	1125	O
to	-	1134	O
ECG	-	1137	O
alone	-	1141	O
.	-	1146	O

RESULTS	17491223	1148	O
:	-	1155	O

The	17491223	1157	O
sensitivity	-	1161	O
improved	-	1173	O
dramatically	-	1182	O
from	-	1195	O
16	-	1200	O
%	-	1202	O
to	-	1204	O
79	-	1207	O
%	-	1209	O
,	-	1210	O
positive	-	1212	O
predictive	-	1221	O
value	-	1232	O
increased	-	1238	O
from	-	1248	O
60	-	1253	O
%	-	1255	O
to	-	1257	O
68	-	1260	O
%	-	1262	O
and	-	1264	O
negative	-	1268	O
predictive	-	1277	O
value	-	1288	O
from	-	1294	O
54	-	1299	O
%	-	1301	O
to	-	1303	O
78	-	1306	O
%	-	1308	O
,	-	1309	O
and	-	1311	O
specificity	-	1315	O
decreased	-	1327	O
from	-	1337	O
90	-	1342	O
%	-	1344	O
to	-	1346	O
67	-	1349	O
%	-	1351	O
.	-	1352	O

CONCLUSIONS	17491223	1354	O
:	-	1365	O

If	17491223	1367	O
ECG	-	1370	O
alone	-	1374	O
is	-	1380	O
used	-	1383	O
for	-	1388	O
specificity	-	1392	O
,	-	1403	O
the	-	1405	O
combination	-	1409	O
with	-	1421	O
dP	-	1426	O
/	-	1428	O
dtejc	-	1429	O
improved	-	1435	O
the	-	1444	O
sensitivity	-	1448	O
of	-	1460	O
the	-	1463	O
test	-	1467	O
and	-	1472	O
could	-	1476	O
be	-	1482	O
a	-	1485	O
cost	-	1487	O
-	-	1491	O
savings	-	1492	O
alternative	-	1500	O
to	-	1512	O
cardiac	-	1515	O
imaging	-	1523	O
or	-	1531	O
perfusion	-	1534	O
studies	-	1544	O
to	-	1552	O
detect	-	1555	O
myocardial	-	1562	O
ischemia	-	1573	O
,	-	1581	O
especially	-	1583	O
in	-	1594	O
patients	-	1597	O
unable	-	1606	O
to	-	1613	O
exercise	-	1616	O
.	-	1624	O

Acute	18004067	0	O
liver	-	6	O
failure	-	12	O
in	-	20	O
two	-	23	O
patients	-	27	O
with	-	36	O
regular	-	41	O
alcohol	-	49	B
consumption	-	57	O
ingesting	-	69	O
paracetamol	-	79	B
at	-	91	O
therapeutic	-	94	O
dosage	-	106	O
.	-	112	O

BACKGROUND	18004067	114	O
:	-	124	O

The	18004067	126	O
possible	-	130	O
role	-	139	O
of	-	144	O
alcohol	-	147	B
in	-	155	O
the	-	158	O
development	-	162	O
of	-	174	O
hepatotoxicity	-	177	O
associated	-	192	O
with	-	203	O
therapeutic	-	208	O
doses	-	220	O
of	-	226	O
paracetamol	-	229	B
(	-	241	O
acetaminophen	-	242	B
)	-	255	O
is	-	257	O
currently	-	260	O
debated	-	270	O
.	-	277	O

CASE	18004067	279	O
REPORT	-	284	O
:	-	290	O

We	18004067	292	O
describe	-	295	O
2	-	304	O
patients	-	306	O
who	-	315	O
were	-	319	O
regular	-	324	O
consumers	-	332	O
of	-	342	O
alcohol	-	345	B
and	-	353	O
who	-	357	O
developed	-	361	O
liver	-	371	O
failure	-	377	O
within	-	385	O
3	-	392	O
-	-	393	O
5	-	394	O
days	-	396	O
after	-	401	O
hospitalization	-	407	O
and	-	423	O
stopping	-	427	O
alcohol	-	436	B
consumption	-	444	O
while	-	456	O
being	-	462	O
treated	-	468	O
with	-	476	O
4	-	481	O
g	-	483	O
paracetamol	-	485	B
/	-	496	O
day	-	497	O
.	-	500	O

A	18004067	502	O
paracetamol	-	504	B
serum	-	516	O
level	-	522	O
obtained	-	528	O
in	-	537	O
one	-	540	O
of	-	544	O
these	-	547	O
patients	-	553	O
was	-	562	O
not	-	566	O
in	-	570	O
the	-	573	O
toxic	-	577	O
range	-	583	O
.	-	588	O

Possible	18004067	590	O
risk	-	599	O
factors	-	604	O
for	-	612	O
the	-	616	O
development	-	620	O
of	-	632	O
hepatotoxicity	-	635	O
in	-	650	O
patients	-	653	O
treated	-	662	O
with	-	670	O
therapeutic	-	675	O
doses	-	687	O
of	-	693	O
paracetamol	-	696	B
are	-	708	O
discussed	-	712	O
.	-	721	O

CONCLUSION	18004067	723	O
:	-	733	O

In	18004067	735	O
patients	-	738	O
with	-	747	O
risk	-	752	O
factors	-	757	O
,	-	764	O
e	-	766	O
.	-	767	O
g	-	768	O
.	-	769	O
regular	-	771	O
consumption	-	779	O
of	-	791	O
alcohol	-	794	B
,	-	801	O
liver	-	803	O
failure	-	809	O
is	-	817	O
possible	-	820	O
when	-	829	O
therapeutic	-	834	O
doses	-	846	O
are	-	852	O
ingested	-	856	O
.	-	864	O

We	18004067	866	O
propose	-	869	O
that	-	877	O
the	-	882	O
paracetamol	-	886	B
dose	-	898	O
should	-	903	O
not	-	910	O
exceed	-	914	O
2	-	921	O
g	-	923	O
/	-	924	O
day	-	925	O
in	-	929	O
such	-	932	O
patients	-	937	O
and	-	946	O
that	-	950	O
their	-	955	O
liver	-	961	O
function	-	967	O
should	-	976	O
be	-	983	O
monitored	-	986	O
closely	-	996	O
while	-	1004	O
being	-	1010	O
treated	-	1016	O
with	-	1024	O
paracetamol	-	1029	B
.	-	1040	O

Cocaine	12443032	0	B
related	-	8	O
chest	-	16	O
pain	-	22	O
:	-	26	O

are	12443032	28	O
we	-	32	O
seeing	-	35	O
the	-	42	O
tip	-	46	O
of	-	50	O
an	-	53	O
iceberg	-	56	O
?	-	63	O

The	12443032	65	O
recreational	-	69	O
use	-	82	O
of	-	86	O
cocaine	-	89	B
is	-	97	O
on	-	100	O
the	-	103	O
increase	-	107	O
.	-	115	O

The	12443032	117	O
emergency	-	121	O
nurse	-	131	O
ought	-	137	O
to	-	143	O
be	-	146	O
familiar	-	149	O
with	-	158	O
some	-	163	O
of	-	168	O
the	-	171	O
cardiovascular	-	175	O
consequences	-	190	O
of	-	203	O
cocaine	-	206	B
use	-	214	O
.	-	217	O

In	12443032	219	O
particular	-	222	O
,	-	232	O
the	-	234	O
tendency	-	238	O
of	-	247	O
cocaine	-	250	B
to	-	258	O
produce	-	261	O
chest	-	269	O
pain	-	275	O
ought	-	280	O
to	-	286	O
be	-	289	O
in	-	292	O
the	-	295	O
mind	-	299	O
of	-	304	O
the	-	307	O
emergency	-	311	O
nurse	-	321	O
when	-	327	O
faced	-	332	O
with	-	338	O
a	-	343	O
young	-	345	O
victim	-	351	O
of	-	358	O
chest	-	361	O
pain	-	367	O
who	-	372	O
is	-	376	O
otherwise	-	379	O
at	-	389	O
low	-	392	O
risk	-	396	O
.	-	400	O

The	12443032	402	O
mechanism	-	406	O
of	-	416	O
chest	-	419	O
pain	-	425	O
related	-	430	O
to	-	438	O
cocaine	-	441	B
use	-	449	O
is	-	453	O
discussed	-	456	O
and	-	466	O
treatment	-	470	O
dilemmas	-	480	O
are	-	489	O
discussed	-	493	O
.	-	502	O

Finally	12443032	504	O
,	-	511	O
moral	-	513	O
issues	-	519	O
relating	-	526	O
to	-	535	O
the	-	538	O
testing	-	542	O
of	-	550	O
potential	-	553	O
cocaine	-	563	B
users	-	571	O
will	-	577	O
be	-	582	O
addressed	-	585	O
.	-	594	O

Severe	17615423	0	O
rhabdomyolysis	-	7	O
and	-	22	O
acute	-	26	O
renal	-	32	O
failure	-	38	O
secondary	-	46	O
to	-	56	O
concomitant	-	59	O
use	-	71	O
of	-	75	O
simvastatin	-	78	B
,	-	89	O
amiodarone	-	91	B
,	-	101	O
and	-	103	O
atazanavir	-	107	B
.	-	117	O

OBJECTIVE	17615423	119	O
:	-	128	O

To	17615423	130	O
report	-	133	O
a	-	140	O
case	-	142	O
of	-	147	O
a	-	150	O
severe	-	152	O
interaction	-	159	O
between	-	171	O
simvastatin	-	179	B
,	-	190	O
amiodarone	-	192	B
,	-	202	O
and	-	204	O
atazanavir	-	208	B
resulting	-	219	O
in	-	229	O
rhabdomyolysis	-	232	O
and	-	247	O
acute	-	251	O
renal	-	257	O
failure	-	263	O
.	-	270	O

BACKGROUND	17615423	272	O
:	-	282	O

A	17615423	284	O
72	-	286	O
-	-	288	O
year	-	289	O
-	-	293	O
old	-	294	O
white	-	298	O
man	-	304	O
with	-	308	O
underlying	-	313	O
human	-	324	O
immunodeficiency	-	330	O
virus	-	347	O
,	-	352	O
atrial	-	354	O
fibrillation	-	361	O
,	-	373	O
coronary	-	375	O
artery	-	384	O
disease	-	391	O
,	-	398	O
and	-	400	O
hyperlipidemia	-	404	O
presented	-	419	O
with	-	429	O
generalized	-	434	O
pain	-	446	O
,	-	450	O
fatigue	-	452	O
,	-	459	O
and	-	461	O
dark	-	465	O
orange	-	470	O
urine	-	477	O
for	-	483	O
3	-	487	O
days	-	489	O
.	-	493	O

The	17615423	495	O
patient	-	499	O
was	-	507	O
taking	-	511	O
80	-	518	O
mg	-	521	O
simvastatin	-	524	B
at	-	536	O
bedtime	-	539	O
(	-	547	O
initiated	-	548	O
27	-	558	O
days	-	561	O
earlier	-	566	O
)	-	573	O
;	-	574	O
amiodarone	-	576	B
at	-	587	O
a	-	590	O
dose	-	592	O
of	-	597	O
400	-	600	O
mg	-	604	O
daily	-	607	O
for	-	613	O
7	-	617	O
days	-	619	O
,	-	623	O
then	-	625	O
200	-	630	O
mg	-	634	O
daily	-	637	O
(	-	643	O
initiated	-	644	O
19	-	654	O
days	-	657	O
earlier	-	662	O
)	-	669	O
;	-	670	O
and	-	672	O
400	-	676	O
mg	-	680	O
atazanavir	-	683	B
daily	-	694	O
(	-	700	O
initiated	-	701	O
at	-	711	O
least	-	714	O
2	-	720	O
years	-	722	O
previously	-	728	O
)	-	738	O
.	-	739	O

Laboratory	17615423	741	O
evaluation	-	752	O
revealed	-	763	O
66	-	772	O
,	-	774	O
680	-	775	O
U	-	779	O
/	-	780	O
L	-	781	O
creatine	-	783	B
kinase	-	792	O
,	-	798	O
93	-	800	O
mg	-	803	O
/	-	805	O
dL	-	806	O
blood	-	809	B
urea	-	815	I
nitrogen	-	820	I
,	-	828	O
4	-	830	O
.	-	831	O
6	-	832	O
mg	-	834	O
/	-	836	O
dL	-	837	O
creatinine	-	840	B
,	-	850	O
1579	-	852	O
U	-	857	O
/	-	858	O
L	-	859	O
aspartate	-	861	B
aminotransferase	-	871	O
,	-	887	O
and	-	889	O
738	-	893	O
U	-	897	O
/	-	898	O
L	-	899	O
alanine	-	901	B
aminotransferase	-	909	O
.	-	925	O

Simvastatin	17615423	927	B
,	-	938	O
amiodarone	-	940	B
,	-	950	O
and	-	952	O
the	-	956	O
patient	-	960	O
's	-	967	O
human	-	970	O
immunodeficiency	-	976	O
virus	-	993	O
medications	-	999	O
were	-	1011	O
all	-	1016	O
temporarily	-	1020	O
discontinued	-	1032	O
and	-	1045	O
the	-	1049	O
patient	-	1053	O
was	-	1061	O
given	-	1065	O
forced	-	1071	O
alkaline	-	1078	O
diuresis	-	1087	O
and	-	1096	O
started	-	1100	O
on	-	1108	O
dialysis	-	1111	O
.	-	1119	O

Nine	17615423	1121	O
days	-	1126	O
later	-	1131	O
the	-	1137	O
patient	-	1141	O
's	-	1148	O
creatine	-	1151	B
kinase	-	1160	O
had	-	1167	O
dropped	-	1171	O
to	-	1179	O
1695	-	1182	O
U	-	1187	O
/	-	1188	O
L	-	1189	O
and	-	1191	O
creatinine	-	1195	B
was	-	1206	O
3	-	1210	O
.	-	1211	O
3	-	1212	O
mg	-	1214	O
/	-	1216	O
dL	-	1217	O
.	-	1219	O
The	-	1221	O
patient	-	1225	O
was	-	1233	O
discharged	-	1237	O
and	-	1248	O
continued	-	1252	O
outpatient	-	1262	O
dialysis	-	1273	O
for	-	1282	O
1	-	1286	O
month	-	1288	O
until	-	1294	O
his	-	1300	O
renal	-	1304	O
function	-	1310	O
recovered	-	1319	O
.	-	1328	O

DISCUSSION	17615423	1330	O
:	-	1340	O

The	17615423	1342	O
risk	-	1346	O
of	-	1351	O
rhabdomyolysis	-	1354	O
is	-	1369	O
increased	-	1372	O
in	-	1382	O
the	-	1385	O
presence	-	1389	O
of	-	1398	O
concomitant	-	1401	O
drugs	-	1413	O
that	-	1419	O
inhibit	-	1424	O
simvastatin	-	1432	B
metabolism	-	1444	O
.	-	1454	O

Simvastatin	17615423	1456	B
is	-	1468	O
metabolized	-	1471	O
by	-	1483	O
CYP3A4	-	1486	O
.	-	1492	O

Amiodarone	17615423	1494	B
and	-	1505	O
atazanavir	-	1509	B
are	-	1520	O
recognized	-	1524	O
CYP3A4	-	1535	O
inhibitors	-	1542	O
.	-	1552	O

CONCLUSIONS	17615423	1554	O
:	-	1565	O

Pharmacokinetic	17615423	1567	O
differences	-	1583	O
in	-	1595	O
statins	-	1598	B
are	-	1606	O
an	-	1610	O
important	-	1613	O
consideration	-	1623	O
for	-	1637	O
assessing	-	1641	O
the	-	1651	O
risk	-	1655	O
of	-	1660	O
potential	-	1663	O
drug	-	1673	O
interactions	-	1678	O
.	-	1690	O

In	17615423	1692	O
patients	-	1695	O
requiring	-	1704	O
the	-	1714	O
concurrent	-	1718	O
use	-	1729	O
of	-	1733	O
statins	-	1736	B
and	-	1744	O
CYP3A4	-	1748	O
inhibitors	-	1755	O
,	-	1765	O
pravastatin	-	1767	B
,	-	1778	O
fluvastatin	-	1780	B
,	-	1791	O
and	-	1793	O
rosuvastatin	-	1797	B
carry	-	1810	O
the	-	1816	O
lowest	-	1820	O
risk	-	1827	O
of	-	1832	O
drug	-	1835	O
interactions	-	1840	O
;	-	1852	O
atorvastatin	-	1854	B
carries	-	1867	O
moderate	-	1875	O
risk	-	1884	O
,	-	1888	O
whereas	-	1890	O
simvastatin	-	1898	B
and	-	1910	O
lovastatin	-	1914	B
have	-	1925	O
the	-	1930	O
highest	-	1934	O
risk	-	1942	O
and	-	1947	O
should	-	1951	O
be	-	1958	O
avoided	-	1961	O
in	-	1969	O
patients	-	1972	O
taking	-	1981	O
concomitant	-	1988	O
CYP3A4	-	2000	O
inhibitors	-	2007	O
.	-	2017	O

Phase	8558192	0	O
II	-	6	O
trial	-	9	O
of	-	15	O
vinorelbine	-	18	B
in	-	30	O
metastatic	-	33	O
squamous	-	44	O
cell	-	53	O
esophageal	-	58	O
carcinoma	-	69	O
.	-	78	O

European	8558192	80	O
Organization	-	89	O
for	-	102	O
Research	-	106	O
and	-	115	O
Treatment	-	119	O
of	-	129	O
Cancer	-	132	O
Gastrointestinal	-	139	O
Treat	-	156	O
Cancer	-	162	O
Cooperative	-	169	O
Group	-	181	O
.	-	186	O

PURPOSE	8558192	188	O
:	-	195	O

To	8558192	197	O
evaluate	-	200	O
the	-	209	O
response	-	213	O
rate	-	222	O
and	-	227	O
toxic	-	231	O
effects	-	237	O
of	-	245	O
vinorelbine	-	248	B
(	-	260	O
VNB	-	261	B
)	-	264	O
administered	-	266	O
as	-	279	O
a	-	282	O
single	-	284	O
agent	-	291	O
in	-	297	O
metastatic	-	300	O
squamous	-	311	O
cell	-	320	O
esophageal	-	325	O
carcinoma	-	336	O
.	-	345	O

PATIENTS	8558192	347	O
AND	-	356	O
METHODS	-	360	O
:	-	367	O

Forty	8558192	369	O
-	-	374	O
six	-	375	O
eligible	-	379	O
patients	-	388	O
with	-	397	O
measurable	-	402	O
lesions	-	413	O
were	-	421	O
included	-	426	O
and	-	435	O
were	-	439	O
stratified	-	444	O
according	-	455	O
to	-	465	O
previous	-	468	O
chemotherapy	-	477	O
.	-	489	O

Thirty	8558192	491	O
patients	-	498	O
without	-	507	O
prior	-	515	O
chemotherapy	-	521	O
and	-	534	O
16	-	538	O
pretreated	-	541	O
with	-	552	O
cisplatin	-	557	B
-	-	566	O
based	-	567	O
chemotherapy	-	573	O
were	-	586	O
assessable	-	591	O
for	-	602	O
toxicity	-	606	O
and	-	615	O
response	-	619	O
.	-	627	O

VNB	8558192	629	B
was	-	633	O
administered	-	637	O
weekly	-	650	O
as	-	657	O
a	-	660	O
25	-	662	O
-	-	664	O
mg	-	665	O
/	-	667	O
m2	-	668	O
short	-	671	O
intravenous	-	677	O
(	-	689	O
i	-	690	O
.	-	691	O
v	-	692	O
.	-	693	O
)	-	694	O
infusion	-	696	O
.	-	704	O

RESULTS	8558192	706	O
:	-	713	O

Six	8558192	715	O
of	-	719	O
30	-	722	O
patients	-	725	O
(	-	734	O
20	-	735	O
%	-	737	O
)	-	738	O
without	-	740	O
prior	-	748	O
chemotherapy	-	754	O
achieved	-	767	O
a	-	776	O
partial	-	778	O
response	-	786	O
(	-	795	O
PR	-	796	O
)	-	798	O
(	-	800	O
95	-	801	O
%	-	803	O
confidence	-	805	O
interval	-	816	O
[	-	825	O
CI	-	826	O
]	-	828	O
,	-	829	O
8	-	831	O
%	-	832	O
to	-	834	O
39	-	837	O
%	-	839	O
)	-	840	O
.	-	841	O

The	8558192	843	O
median	-	847	O
duration	-	854	O
of	-	863	O
response	-	866	O
was	-	875	O
21	-	879	O
weeks	-	882	O
(	-	888	O
range	-	889	O
,	-	894	O
17	-	896	O
to	-	899	O
28	-	902	O
)	-	904	O
.	-	905	O

One	8558192	907	O
of	-	911	O
16	-	914	O
patients	-	917	O
(	-	926	O
6	-	927	O
%	-	928	O
)	-	929	O
with	-	931	O
prior	-	936	O
chemotherapy	-	942	O
had	-	955	O
a	-	959	O
complete	-	961	O
response	-	970	O
(	-	979	O
CR	-	980	O
)	-	982	O
of	-	984	O
31	-	987	O
weeks	-	990	O
'	-	995	O
duration	-	997	O
(	-	1006	O
95	-	1007	O
%	-	1009	O
CI	-	1011	O
,	-	1013	O
0	-	1015	O
%	-	1016	O
to	-	1018	O
30	-	1021	O
%	-	1023	O
)	-	1024	O
.	-	1025	O

The	8558192	1027	O
overall	-	1031	O
response	-	1039	O
rate	-	1048	O
(	-	1053	O
World	-	1054	O
Health	-	1060	O
Organization	-	1067	O
[	-	1080	O
WHO	-	1081	O
]	-	1084	O
criteria	-	1086	O
)	-	1094	O
was	-	1096	O
15	-	1100	O
%	-	1102	O
(	-	1104	O
CR	-	1105	O
,	-	1107	O
2	-	1109	O
%	-	1110	O
;	-	1111	O
PR	-	1113	O
13	-	1116	O
%	-	1118	O
;	-	1119	O
95	-	1121	O
%	-	1123	O
CI	-	1125	O
,	-	1127	O
6	-	1129	O
%	-	1130	O
to	-	1132	O
29	-	1135	O
%	-	1137	O
)	-	1138	O
.	-	1139	O

The	8558192	1141	O
median	-	1145	O
dose	-	1152	O
-	-	1156	O
intensity	-	1157	O
(	-	1167	O
DI	-	1168	O
)	-	1170	O
was	-	1172	O
20	-	1176	O
mg	-	1179	O
/	-	1181	O
m2	-	1182	O
/	-	1184	O
wk	-	1185	O
.	-	1187	O

VNB	8558192	1189	B
was	-	1193	O
well	-	1197	O
tolerated	-	1202	O
and	-	1212	O
zero	-	1216	O
instances	-	1221	O
of	-	1231	O
WHO	-	1234	O
grade	-	1238	O
4	-	1244	O
nonhematologic	-	1246	O
toxicity	-	1261	O
occurred	-	1270	O
.	-	1278	O

At	8558192	1280	O
least	-	1283	O
one	-	1289	O
episode	-	1293	O
of	-	1301	O
grade	-	1304	O
3	-	1310	O
or	-	1312	O
4	-	1315	O
granulocytopenia	-	1317	O
was	-	1334	O
seen	-	1338	O
in	-	1343	O
59	-	1346	O
%	-	1348	O
of	-	1350	O
patients	-	1353	O
.	-	1361	O

A	8558192	1363	O
grade	-	1365	O
2	-	1371	O
or	-	1373	O
3	-	1376	O
infection	-	1378	O
occurred	-	1388	O
in	-	1397	O
16	-	1400	O
%	-	1402	O
of	-	1404	O
patients	-	1407	O
,	-	1415	O
but	-	1417	O
no	-	1421	O
toxic	-	1424	O
deaths	-	1430	O
occurred	-	1437	O
.	-	1445	O

Other	8558192	1447	O
side	-	1453	O
effects	-	1458	O
were	-	1466	O
rare	-	1471	O
,	-	1475	O
and	-	1477	O
peripheral	-	1481	O
neurotoxicity	-	1492	O
has	-	1506	O
been	-	1510	O
minor	-	1515	O
(	-	1521	O
26	-	1522	O
%	-	1524	O
grade	-	1526	O
1	-	1532	O
)	-	1533	O
.	-	1534	O

CONCLUSION	8558192	1536	O
:	-	1546	O

These	8558192	1548	O
data	-	1554	O
indicate	-	1559	O
that	-	1568	O
VNB	-	1573	B
is	-	1577	O
an	-	1580	O
active	-	1583	O
agent	-	1590	O
in	-	1596	O
metastatic	-	1599	O
esophageal	-	1610	O
squamous	-	1621	O
cell	-	1630	O
carcinoma	-	1635	O
.	-	1644	O

Given	8558192	1646	O
its	-	1652	O
excellent	-	1656	O
tolerance	-	1666	O
profile	-	1676	O
and	-	1684	O
low	-	1688	O
toxicity	-	1692	O
,	-	1700	O
further	-	1702	O
evaluation	-	1710	O
of	-	1721	O
VNB	-	1724	B
in	-	1728	O
combination	-	1731	O
therapy	-	1743	O
is	-	1751	O
warranted	-	1754	O
.	-	1763	O

Paclitaxel	11135224	0	B
,	-	10	O
cisplatin	-	12	B
,	-	21	O
and	-	23	O
gemcitabine	-	27	B
combination	-	39	O
chemotherapy	-	51	O
within	-	64	O
a	-	71	O
multidisciplinary	-	73	O
therapeutic	-	91	O
approach	-	103	O
in	-	112	O
metastatic	-	115	O
nonsmall	-	126	O
cell	-	135	O
lung	-	140	O
carcinoma	-	145	O
.	-	154	O

BACKGROUND	11135224	156	O
:	-	166	O

Cisplatin	11135224	168	B
-	-	177	O
based	-	178	O
chemotherapy	-	184	O
combinations	-	197	O
improve	-	210	O
quality	-	218	O
of	-	226	O
life	-	229	O
and	-	234	O
survival	-	238	O
in	-	247	O
advanced	-	250	O
nonsmall	-	259	O
cell	-	268	O
lung	-	273	O
carcinoma	-	278	O
(	-	288	O
NSCLC	-	289	O
)	-	294	O
.	-	295	O

The	11135224	297	O
emergence	-	301	O
of	-	311	O
new	-	314	O
active	-	318	O
drugs	-	325	O
might	-	331	O
translate	-	337	O
into	-	347	O
more	-	352	O
effective	-	357	O
regimens	-	367	O
for	-	376	O
the	-	380	O
treatment	-	384	O
of	-	394	O
this	-	397	O
disease	-	402	O
.	-	409	O

METHODS	11135224	411	O
:	-	418	O

The	11135224	420	O
objective	-	424	O
of	-	434	O
this	-	437	O
study	-	442	O
was	-	448	O
to	-	452	O
determine	-	455	O
the	-	465	O
feasibility	-	469	O
,	-	480	O
response	-	482	O
rate	-	491	O
,	-	495	O
and	-	497	O
toxicity	-	501	O
of	-	510	O
a	-	513	O
paclitaxel	-	515	B
,	-	525	O
cisplatin	-	527	B
,	-	536	O
and	-	538	O
gemcitabine	-	542	B
combination	-	554	O
to	-	566	O
treat	-	569	O
metastatic	-	575	O
NSCLC	-	586	O
.	-	591	O

Thirty	11135224	593	O
-	-	599	O
five	-	600	O
consecutive	-	605	O
chemotherapy	-	617	O
-	-	629	O
naive	-	630	O
patients	-	636	O
with	-	645	O
Stage	-	650	O
IV	-	656	O
NSCLC	-	659	O
and	-	665	O
an	-	669	O
Eastern	-	672	O
Cooperative	-	680	O
Oncology	-	692	O
Group	-	701	O
performance	-	707	O
status	-	719	O
of	-	726	O
0	-	729	O
-	-	730	O
2	-	731	O
were	-	733	O
treated	-	738	O
with	-	746	O
a	-	751	O
combination	-	753	O
of	-	765	O
paclitaxel	-	768	B
(	-	779	O
135	-	780	O
mg	-	784	O
/	-	786	O
m	-	787	O
(	-	788	O
2	-	789	O
)	-	790	O
given	-	792	O
intravenously	-	798	O
in	-	812	O
3	-	815	O
hours	-	817	O
)	-	822	O
on	-	824	O
Day	-	827	O
1	-	831	O
,	-	832	O
cisplatin	-	834	B
(	-	844	O
120	-	845	O
mg	-	849	O
/	-	851	O
m	-	852	O
(	-	853	O
2	-	854	O
)	-	855	O
given	-	857	O
intravenously	-	863	O
in	-	877	O
6	-	880	O
hours	-	882	O
)	-	887	O
on	-	889	O
Day	-	892	O
1	-	896	O
,	-	897	O
and	-	899	O
gemcitabine	-	903	B
(	-	915	O
800	-	916	O
mg	-	920	O
/	-	922	O
m	-	923	O
(	-	924	O
2	-	925	O
)	-	926	O
given	-	928	O
intravenously	-	934	O
in	-	948	O
30	-	951	O
minutes	-	954	O
)	-	961	O
on	-	963	O
Days	-	966	O
1	-	971	O
and	-	973	O
8	-	977	O
,	-	978	O
every	-	980	O
4	-	986	O
weeks	-	988	O
.	-	993	O

Although	11135224	995	O
responding	-	1004	O
patients	-	1015	O
were	-	1024	O
scheduled	-	1029	O
to	-	1039	O
receive	-	1042	O
consolidation	-	1050	O
radiotherapy	-	1064	O
and	-	1077	O
24	-	1081	O
patients	-	1084	O
received	-	1093	O
preplanned	-	1102	O
second	-	1113	O
-	-	1119	O
line	-	1120	O
chemotherapy	-	1125	O
after	-	1138	O
disease	-	1144	O
progression	-	1152	O
,	-	1163	O
the	-	1165	O
response	-	1169	O
and	-	1178	O
toxicity	-	1182	O
rates	-	1191	O
reported	-	1197	O
refer	-	1206	O
only	-	1212	O
to	-	1217	O
the	-	1220	O
chemotherapy	-	1224	O
regimen	-	1237	O
given	-	1245	O
.	-	1250	O

RESULTS	11135224	1252	O
:	-	1259	O

All	11135224	1261	O
the	-	1265	O
patients	-	1269	O
were	-	1278	O
examined	-	1283	O
for	-	1292	O
toxicity	-	1296	O
;	-	1304	O
34	-	1306	O
were	-	1309	O
examinable	-	1314	O
for	-	1325	O
response	-	1329	O
.	-	1337	O

An	11135224	1339	O
objective	-	1342	O
response	-	1352	O
was	-	1361	O
observed	-	1365	O
in	-	1374	O
73	-	1377	O
.	-	1379	O
5	-	1380	O
%	-	1381	O
of	-	1383	O
the	-	1386	O
patients	-	1390	O
(	-	1399	O
95	-	1400	O
%	-	1402	O
confidence	-	1404	O
interval	-	1415	O
[	-	1424	O
CI	-	1425	O
]	-	1427	O
,	-	1428	O
55	-	1430	O
.	-	1432	O
6	-	1433	O
-	-	1434	O
87	-	1435	O
.	-	1437	O
1	-	1438	O
%	-	1439	O
)	-	1440	O
,	-	1441	O
including	-	1443	O
4	-	1453	O
complete	-	1455	O
responses	-	1464	O
(	-	1474	O
11	-	1475	O
.	-	1477	O
7	-	1478	O
%	-	1479	O
)	-	1480	O
.	-	1481	O

According	11135224	1483	O
to	-	1493	O
intention	-	1496	O
-	-	1505	O
to	-	1506	O
-	-	1508	O
treat	-	1509	O
,	-	1514	O
the	-	1516	O
overall	-	1520	O
response	-	1528	O
rate	-	1537	O
was	-	1542	O
71	-	1546	O
.	-	1548	O
4	-	1549	O
%	-	1550	O
(	-	1552	O
95	-	1553	O
%	-	1555	O
CI	-	1557	O
,	-	1559	O
53	-	1561	O
.	-	1563	O

7	11135224	1565	O
-	-	1566	O
85	-	1567	O
.	-	1569	O
4	-	1570	O
%	-	1571	O
)	-	1572	O
.	-	1573	O

After	11135224	1575	O
154	-	1581	O
courses	-	1585	O
of	-	1593	O
therapy	-	1596	O
,	-	1603	O
the	-	1605	O
median	-	1609	O
dose	-	1616	O
intensity	-	1621	O
was	-	1631	O
131	-	1635	O
mg	-	1639	O
/	-	1641	O
m	-	1642	O
(	-	1643	O
2	-	1644	O
)	-	1645	O
for	-	1647	O
paclitaxel	-	1651	B
(	-	1662	O
97	-	1663	O
.	-	1665	O
3	-	1666	O
%	-	1667	O
)	-	1668	O
,	-	1669	O
117	-	1671	O
mg	-	1675	O
/	-	1677	O
m	-	1678	O
(	-	1679	O
2	-	1680	O
)	-	1681	O
for	-	1683	O
cisplatin	-	1687	B
(	-	1697	O
97	-	1698	O
.	-	1700	O
3	-	1701	O
%	-	1702	O
)	-	1703	O
,	-	1704	O
and	-	1706	O
1378	-	1710	O
mg	-	1715	O
/	-	1717	O
m	-	1718	O
(	-	1719	O
2	-	1720	O
)	-	1721	O
for	-	1723	O
gemcitabine	-	1727	B
(	-	1739	O
86	-	1740	O
.	-	1742	O
2	-	1743	O
%	-	1744	O
)	-	1745	O
.	-	1746	O

World	11135224	1748	O
Health	-	1754	O
Organization	-	1761	O
Grade	-	1774	O
3	-	1780	O
-	-	1781	O
4	-	1782	O
neutropenia	-	1784	O
and	-	1796	O
thrombocytopenia	-	1800	O
occurred	-	1817	O
in	-	1826	O
39	-	1829	O
.	-	1831	O
9	-	1832	O
%	-	1833	O
and	-	1835	O
11	-	1839	O
.	-	1841	O
4	-	1842	O
%	-	1843	O
of	-	1845	O
patients	-	1848	O
,	-	1856	O
respectively	-	1858	O
.	-	1870	O

There	11135224	1872	O
was	-	1878	O
one	-	1882	O
treatment	-	1886	O
-	-	1895	O
related	-	1896	O
death	-	1904	O
.	-	1909	O

Nonhematologic	11135224	1911	O
toxicities	-	1926	O
were	-	1937	O
mild	-	1942	O
.	-	1946	O

After	11135224	1948	O
a	-	1954	O
median	-	1956	O
follow	-	1963	O
-	-	1969	O
up	-	1970	O
of	-	1973	O
22	-	1976	O
months	-	1979	O
,	-	1985	O
the	-	1987	O
median	-	1991	O
progression	-	1998	O
free	-	2010	O
survival	-	2015	O
rate	-	2024	O
was	-	2029	O
7	-	2033	O
months	-	2035	O
,	-	2041	O
and	-	2043	O
the	-	2047	O
median	-	2051	O
survival	-	2058	O
time	-	2067	O
was	-	2072	O
16	-	2076	O
months	-	2079	O
.	-	2085	O

CONCLUSIONS	11135224	2087	O
:	-	2098	O

The	11135224	2100	O
combination	-	2104	O
of	-	2116	O
paclitaxel	-	2119	B
,	-	2129	O
cisplatin	-	2131	B
,	-	2140	O
and	-	2142	O
gemcitabine	-	2146	B
is	-	2158	O
well	-	2161	O
tolerated	-	2166	O
and	-	2176	O
shows	-	2180	O
high	-	2186	O
activity	-	2191	O
in	-	2200	O
metastatic	-	2203	O
NSCLC	-	2214	O
.	-	2219	O

This	11135224	2221	O
treatment	-	2226	O
merits	-	2236	O
further	-	2243	O
comparison	-	2251	O
with	-	2262	O
other	-	2267	O
cisplatin	-	2273	B
-	-	2282	O
based	-	2283	O
regimens	-	2289	O
.	-	2297	O

Evaluation	8590259	0	O
of	-	11	O
adverse	-	14	O
reactions	-	22	O
of	-	32	O
aponidine	-	35	B
hydrochloride	-	45	I
ophthalmic	-	59	O
solution	-	70	O
.	-	78	O

We	8590259	80	O
prospectively	-	83	O
evaluated	-	97	O
the	-	107	O
adverse	-	111	O
reactions	-	119	O
of	-	129	O
apraclonidine	-	132	B
in	-	146	O
20	-	149	O
normal	-	152	O
volunteers	-	159	O
by	-	170	O
instilling	-	173	O
a	-	184	O
single	-	186	O
drop	-	193	O
of	-	198	O
1	-	201	O
%	-	202	O
apraclonidine	-	204	B
in	-	218	O
their	-	221	O
right	-	227	O
eyes	-	233	O
.	-	237	O

Examinations	8590259	239	O
,	-	251	O
including	-	253	O
blood	-	263	O
pressure	-	269	O
,	-	277	O
pulse	-	279	O
rate	-	285	O
,	-	289	O
conjunctiva	-	291	O
and	-	303	O
cornea	-	307	O
,	-	313	O
intraocular	-	315	O
pressure	-	327	O
(	-	336	O
IOP	-	337	O
)	-	340	O
,	-	341	O
pupil	-	343	O
diameter	-	349	O
,	-	357	O
basal	-	359	O
tear	-	365	O
secretion	-	370	O
and	-	380	O
margin	-	384	O
reflex	-	391	O
distance	-	398	O
of	-	407	O
both	-	410	O
upper	-	415	O
and	-	421	O
lower	-	425	O
eyelids	-	431	O
,	-	438	O
were	-	440	O
performed	-	445	O
prior	-	455	O
to	-	461	O
entry	-	464	O
and	-	470	O
at	-	474	O
1	-	477	O
,	-	478	O
3	-	480	O
,	-	481	O
5	-	483	O
and	-	485	O
7	-	489	O
hours	-	491	O
after	-	497	O
instillation	-	503	O
.	-	515	O

The	8590259	517	O
ocular	-	521	O
hypotensive	-	528	O
effects	-	540	O
were	-	548	O
statistically	-	553	O
significant	-	567	O
for	-	579	O
apraclonidine	-	583	B
-	-	596	O
treated	-	597	O
eyes	-	605	O
throughout	-	610	O
the	-	621	O
study	-	625	O
and	-	631	O
also	-	635	O
statistically	-	640	O
significant	-	654	O
for	-	666	O
contralateral	-	670	O
eyes	-	684	O
from	-	689	O
three	-	694	O
hours	-	700	O
after	-	706	O
topical	-	712	O
administration	-	720	O
of	-	735	O
1	-	738	O
%	-	739	O
apraclonidine	-	741	B
.	-	754	O

Decreases	8590259	756	O
in	-	766	O
systolic	-	769	O
blood	-	778	O
pressure	-	784	O
were	-	793	O
statistically	-	798	O
,	-	811	O
but	-	813	O
not	-	817	O
clinically	-	821	O
,	-	831	O
significant	-	833	O
.	-	844	O

No	8590259	846	O
significant	-	849	O
changes	-	861	O
in	-	869	O
diastolic	-	872	O
blood	-	882	O
pressure	-	888	O
,	-	896	O
pulse	-	898	O
rate	-	904	O
and	-	909	O
basal	-	913	O
tear	-	919	O
secretion	-	924	O
were	-	934	O
noted	-	939	O
.	-	944	O

Conjunctival	8590259	946	O
blanching	-	959	O
and	-	969	O
mydriasis	-	973	O
were	-	983	O
commonly	-	988	O
found	-	997	O
.	-	1002	O

Upper	8590259	1004	O
lid	-	1010	O
retraction	-	1014	O
was	-	1025	O
frequently	-	1029	O
noted	-	1040	O
.	-	1045	O

While	8590259	1047	O
the	-	1053	O
elevations	-	1057	O
of	-	1068	O
the	-	1071	O
upper	-	1075	O
lid	-	1081	O
margin	-	1085	O
in	-	1092	O
most	-	1095	O
subjects	-	1100	O
were	-	1109	O
not	-	1114	O
more	-	1118	O
than	-	1123	O
2	-	1128	O
mm	-	1130	O
and	-	1133	O
did	-	1137	O
not	-	1141	O
cause	-	1145	O
noticeable	-	1151	O
change	-	1162	O
in	-	1169	O
appearance	-	1172	O
,	-	1182	O
one	-	1184	O
subject	-	1188	O
suffered	-	1196	O
from	-	1205	O
mechanical	-	1210	O
entropion	-	1221	O
and	-	1231	O
marked	-	1235	O
corneal	-	1242	O
abrasion	-	1250	O
3	-	1259	O
hours	-	1261	O
after	-	1267	O
instillation	-	1273	O
of	-	1286	O
the	-	1289	O
medication	-	1293	O
.	-	1303	O

This	8590259	1305	O
may	-	1310	O
well	-	1314	O
be	-	1319	O
a	-	1322	O
particularly	-	1324	O
notable	-	1337	O
finding	-	1345	O
in	-	1353	O
Asian	-	1356	O
people	-	1362	O
.	-	1368	O

Carmofur	2096243	0	B
-	-	8	O
induced	-	9	O
organic	-	17	O
mental	-	25	O
disorders	-	32	O
.	-	41	O

Organic	2096243	43	O
mental	-	51	O
disorder	-	58	O
was	-	67	O
observed	-	71	O
in	-	80	O
a	-	83	O
29	-	85	O
-	-	87	O
year	-	88	O
-	-	92	O
old	-	93	O
female	-	97	O
in	-	104	O
the	-	107	O
prognostic	-	111	O
period	-	122	O
after	-	129	O
the	-	135	O
onset	-	139	O
of	-	145	O
carmofur	-	148	B
-	-	156	O
induced	-	157	O
leukoencephalopathy	-	165	O
.	-	184	O

Symptoms	2096243	186	O
such	-	195	O
as	-	200	O
euphoria	-	203	O
,	-	211	O
emotional	-	213	O
lability	-	223	O
and	-	232	O
puerile	-	236	O
attitude	-	244	O
noted	-	253	O
in	-	259	O
the	-	262	O
patient	-	266	O
were	-	274	O
diagnosed	-	279	O
as	-	289	O
organic	-	292	O
personality	-	300	O
syndrome	-	312	O
according	-	321	O
to	-	331	O
the	-	334	O
criteria	-	338	O
defined	-	347	O
in	-	355	O
the	-	358	O
DSM	-	362	O
-	-	365	O
III	-	366	O
-	-	369	O
R	-	370	O
.	-	371	O

It	2096243	373	O
is	-	376	O
referred	-	379	O
to	-	388	O
as	-	391	O
a	-	394	O
frontal	-	396	O
lobe	-	404	O
syndrome	-	409	O
.	-	417	O

Brain	2096243	419	O
CT	-	425	O
revealed	-	428	O
a	-	437	O
periventricular	-	439	O
low	-	455	O
density	-	459	O
area	-	467	O
in	-	472	O
the	-	475	O
frontal	-	479	O
white	-	487	O
matter	-	493	O
and	-	500	O
moderate	-	504	O
dilatation	-	513	O
of	-	524	O
the	-	527	O
lateral	-	531	O
ventricles	-	539	O
especially	-	550	O
at	-	561	O
the	-	564	O
bilateral	-	568	O
anterior	-	578	O
horns	-	587	O
.	-	592	O

Consequently	2096243	594	O
,	-	606	O
carmofur	-	608	B
-	-	616	O
induced	-	617	O
leukoencephalopathy	-	625	O
may	-	645	O
uncommonly	-	649	O
result	-	660	O
in	-	667	O
organic	-	670	O
personality	-	678	O
syndrome	-	690	O
in	-	699	O
the	-	702	O
residual	-	706	O
state	-	715	O
.	-	720	O

It	2096243	722	O
may	-	725	O
be	-	729	O
attributed	-	732	O
to	-	743	O
the	-	746	O
structural	-	750	O
damage	-	761	O
to	-	768	O
the	-	771	O
frontal	-	775	O
lobe	-	783	O
.	-	787	O

International	6209318	0	O
mexiletine	-	14	B
and	-	25	O
placebo	-	29	O
antiarrhythmic	-	37	O
coronary	-	52	O
trial	-	61	O
:	-	66	O
I	-	68	O
.	-	69	O
Report	-	71	O
on	-	78	O
arrhythmia	-	81	O
and	-	92	O
other	-	96	O
findings	-	102	O
.	-	110	O

Impact	6209318	112	O
Research	-	119	O
Group	-	128	O
.	-	133	O

The	6209318	135	O
antiarrhythmic	-	139	O
effects	-	154	O
of	-	162	O
the	-	165	O
sustained	-	169	O
release	-	179	O
form	-	187	O
of	-	192	O
mexiletine	-	195	B
(	-	206	O
Mexitil	-	207	B
-	-	214	I
Perlongets	-	215	I
)	-	225	O
were	-	227	O
evaluated	-	232	O
in	-	242	O
a	-	245	O
double	-	247	O
-	-	253	O
blind	-	254	O
placebo	-	260	O
trial	-	268	O
in	-	274	O
630	-	277	O
patients	-	281	O
with	-	290	O
recent	-	295	O
documented	-	302	O
myocardial	-	313	O
infarction	-	324	O
.	-	334	O

The	6209318	336	O
primary	-	340	O
response	-	348	O
variable	-	357	O
was	-	366	O
based	-	370	O
on	-	376	O
central	-	379	O
reading	-	387	O
of	-	395	O
24	-	398	O
hour	-	401	O
ambulatory	-	406	O
electrocardiographic	-	417	O
recordings	-	438	O
and	-	449	O
was	-	453	O
defined	-	457	O
as	-	465	O
the	-	468	O
occurrence	-	472	O
of	-	483	O
30	-	486	O
or	-	489	O
more	-	492	O
single	-	497	O
premature	-	504	O
ventricular	-	514	O
complexes	-	526	O
in	-	536	O
any	-	539	O
two	-	543	O
consecutive	-	547	O
30	-	559	O
minute	-	562	O
blocks	-	569	O
or	-	576	O
one	-	579	O
or	-	583	O
more	-	586	O
runs	-	591	O
of	-	596	O
two	-	599	O
or	-	603	O
more	-	606	O
premature	-	611	O
ventricular	-	621	O
complexes	-	633	O
in	-	643	O
the	-	646	O
entire	-	650	O
24	-	657	O
hour	-	660	O
electrocardiographic	-	665	O
recording	-	686	O
.	-	695	O

Large	6209318	697	O
differences	-	703	O
,	-	714	O
regarded	-	716	O
as	-	725	O
statistically	-	728	O
significant	-	742	O
,	-	753	O
between	-	755	O
the	-	763	O
mexiletine	-	767	B
and	-	778	O
placebo	-	782	O
groups	-	790	O
were	-	797	O
noted	-	802	O
in	-	808	O
that	-	811	O
end	-	816	O
point	-	820	O
at	-	826	O
months	-	829	O
1	-	836	O
and	-	838	O
4	-	842	O
,	-	843	O
but	-	845	O
only	-	849	O
trends	-	854	O
were	-	861	O
observed	-	866	O
at	-	875	O
month	-	878	O
12	-	884	O
.	-	886	O

These	6209318	888	O
differences	-	894	O
were	-	906	O
observed	-	911	O
even	-	920	O
though	-	925	O
the	-	932	O
serum	-	936	O
mexiletine	-	942	B
levels	-	953	O
obtained	-	960	O
in	-	969	O
this	-	972	O
study	-	977	O
were	-	983	O
generally	-	988	O
lower	-	998	O
than	-	1004	O
those	-	1009	O
observed	-	1015	O
in	-	1024	O
studies	-	1027	O
that	-	1035	O
have	-	1040	O
used	-	1045	O
the	-	1050	O
regular	-	1054	O
form	-	1062	O
of	-	1067	O
the	-	1070	O
drug	-	1074	O
.	-	1078	O

There	6209318	1080	O
were	-	1086	O
more	-	1091	O
deaths	-	1096	O
in	-	1103	O
the	-	1106	O
mexiletine	-	1110	B
group	-	1121	O
(	-	1127	O
7	-	1128	O
.	-	1129	O
6	-	1130	O
%	-	1131	O
)	-	1132	O
than	-	1134	O
in	-	1139	O
the	-	1142	O
placebo	-	1146	O
group	-	1154	O
(	-	1160	O
4	-	1161	O
.	-	1162	O
8	-	1163	O
%	-	1164	O
)	-	1165	O
;	-	1166	O
the	-	1168	O
difference	-	1172	O
was	-	1183	O
not	-	1187	O
statistically	-	1191	O
significant	-	1205	O
.	-	1216	O

The	6209318	1218	O
incidence	-	1222	O
of	-	1232	O
coronary	-	1235	O
events	-	1244	O
was	-	1251	O
similar	-	1255	O
in	-	1263	O
both	-	1266	O
groups	-	1271	O
.	-	1277	O

Previously	6209318	1279	O
recognized	-	1290	O
side	-	1301	O
effects	-	1306	O
,	-	1313	O
particularly	-	1315	O
tremor	-	1328	O
and	-	1335	O
gastrointestinal	-	1339	O
problems	-	1356	O
,	-	1364	O
were	-	1366	O
more	-	1371	O
frequent	-	1376	O
in	-	1385	O
the	-	1388	O
mexiletine	-	1392	B
group	-	1403	O
than	-	1409	O
in	-	1414	O
the	-	1417	O
placebo	-	1421	O
group	-	1429	O
.	-	1434	O

Regional	3615541	0	O
localization	-	9	O
of	-	22	O
the	-	25	O
antagonism	-	29	O
of	-	40	O
amphetamine	-	43	B
-	-	54	O
induced	-	55	O
hyperactivity	-	63	O
by	-	77	O
intracerebral	-	80	O
calcitonin	-	94	B
injections	-	105	O
.	-	115	O

Calcitonin	3615541	117	B
receptors	-	128	O
are	-	138	O
found	-	142	O
in	-	148	O
the	-	151	O
brain	-	155	O
,	-	160	O
and	-	162	O
intracerebral	-	166	O
infusions	-	180	O
of	-	190	O
calcitonin	-	193	B
can	-	204	O
produce	-	208	O
behavioral	-	216	O
effects	-	227	O
.	-	234	O

Among	3615541	236	O
these	-	242	O
behavioral	-	248	O
effects	-	259	O
are	-	267	O
decreases	-	271	O
in	-	281	O
food	-	284	O
intake	-	289	O
and	-	296	O
decreases	-	300	O
in	-	310	O
amphetamine	-	313	B
-	-	324	O
induced	-	325	O
locomotor	-	333	O
activity	-	343	O
.	-	351	O

In	3615541	353	O
previous	-	356	O
experiments	-	365	O
we	-	377	O
found	-	380	O
that	-	386	O
decreases	-	391	O
in	-	401	O
food	-	404	O
intake	-	409	O
were	-	416	O
induced	-	421	O
by	-	429	O
local	-	432	O
administration	-	438	O
of	-	453	O
calcitonin	-	456	B
into	-	467	O
several	-	472	O
hypothalamic	-	480	O
sites	-	493	O
and	-	499	O
into	-	503	O
the	-	508	O
nucleus	-	512	O
accumbens	-	520	O
.	-	529	O

In	3615541	531	O
the	-	534	O
present	-	538	O
experiment	-	546	O
calcitonin	-	557	B
decreased	-	568	O
locomotor	-	578	O
activity	-	588	O
when	-	597	O
locally	-	602	O
injected	-	610	O
into	-	619	O
the	-	624	O
same	-	628	O
sites	-	633	O
where	-	639	O
it	-	645	O
decreases	-	648	O
food	-	658	O
intake	-	663	O
.	-	669	O

The	3615541	671	O
areas	-	675	O
where	-	681	O
calcitonin	-	687	B
is	-	698	O
most	-	701	O
effective	-	706	O
in	-	716	O
decreasing	-	719	O
locomotor	-	730	O
activity	-	740	O
are	-	749	O
located	-	753	O
in	-	761	O
the	-	764	O
hypothalamus	-	768	O
and	-	781	O
nucleus	-	785	O
accumbens	-	793	O
,	-	802	O
suggesting	-	804	O
that	-	815	O
these	-	820	O
areas	-	826	O
are	-	832	O
the	-	836	O
major	-	840	O
sites	-	846	O
of	-	852	O
action	-	855	O
of	-	862	O
calcitonin	-	865	B
in	-	876	O
inhibiting	-	879	O
amphetamine	-	890	B
-	-	901	O
induced	-	902	O
locomotor	-	910	O
activity	-	920	O
.	-	928	O

Fatal	8953972	0	O
intracranial	-	6	O
bleeding	-	19	O
associated	-	28	O
with	-	39	O
prehospital	-	44	O
use	-	56	O
of	-	60	O
epinephrine	-	63	B
.	-	74	O

We	8953972	76	O
present	-	79	O
a	-	87	O
case	-	89	O
of	-	94	O
paramedic	-	97	O
misjudgment	-	107	O
in	-	119	O
the	-	122	O
execution	-	126	O
of	-	136	O
a	-	139	O
protocol	-	141	O
for	-	150	O
the	-	154	O
treatment	-	158	O
of	-	168	O
allergic	-	171	O
reaction	-	180	O
in	-	189	O
a	-	192	O
case	-	194	O
of	-	199	O
pulmonary	-	202	O
edema	-	212	O
with	-	218	O
wheezing	-	223	O
.	-	231	O

The	8953972	233	O
sudden	-	237	O
onset	-	244	O
of	-	250	O
respiratory	-	253	O
distress	-	265	O
,	-	273	O
rash	-	275	O
,	-	279	O
and	-	281	O
a	-	285	O
history	-	287	O
of	-	295	O
a	-	298	O
new	-	300	O
medicine	-	304	O
led	-	313	O
the	-	317	O
two	-	321	O
paramedics	-	325	O
on	-	336	O
the	-	339	O
scene	-	343	O
to	-	349	O
administer	-	352	O
subcutaneous	-	363	O
epinephrine	-	376	B
.	-	387	O

Subsequently	8953972	389	O
,	-	401	O
acute	-	403	O
cardiac	-	409	O
arrest	-	417	O
and	-	424	O
fatal	-	428	O
subarachnoid	-	434	O
hemorrhage	-	447	O
occurred	-	458	O
.	-	466	O

Epinephrine	8953972	468	B
has	-	480	O
a	-	484	O
proven	-	486	O
role	-	493	O
in	-	498	O
cardiac	-	501	O
arrest	-	509	O
in	-	516	O
prehospital	-	519	O
care	-	531	O
;	-	535	O
however	-	537	O
,	-	544	O
use	-	546	O
by	-	550	O
paramedics	-	553	O
in	-	564	O
patients	-	567	O
with	-	576	O
suspected	-	581	O
allergic	-	591	O
reaction	-	600	O
and	-	609	O
severe	-	613	O
hypertension	-	620	O
should	-	633	O
be	-	640	O
viewed	-	643	O
with	-	650	O
caution	-	655	O
.	-	662	O

A	3782049	0	O
case	-	2	O
of	-	7	O
massive	-	10	O
rhabdomyolysis	-	18	O
following	-	33	O
molindone	-	43	B
administration	-	53	O
.	-	67	O

Rhabdomyolysis	3782049	69	O
is	-	84	O
a	-	87	O
potentially	-	89	O
lethal	-	101	O
syndrome	-	108	O
that	-	117	O
psychiatric	-	122	O
patients	-	134	O
seem	-	143	O
predisposed	-	148	O
to	-	160	O
develop	-	163	O
.	-	170	O

The	3782049	172	O
clinical	-	176	O
signs	-	185	O
and	-	191	O
symptoms	-	195	O
,	-	203	O
typical	-	205	O
laboratory	-	213	O
features	-	224	O
,	-	232	O
and	-	234	O
complications	-	238	O
of	-	252	O
rhabdomyolysis	-	255	O
are	-	270	O
presented	-	274	O
.	-	283	O

The	3782049	285	O
case	-	289	O
of	-	294	O
a	-	297	O
schizophrenic	-	299	O
patient	-	313	O
is	-	321	O
reported	-	324	O
to	-	333	O
illustrate	-	336	O
massive	-	347	O
rhabdomyolysis	-	355	O
and	-	370	O
subsequent	-	374	O
acute	-	385	O
renal	-	391	O
failure	-	397	O
following	-	405	O
molindone	-	415	B
administration	-	425	O
.	-	439	O

Physicians	3782049	441	O
who	-	452	O
prescribe	-	456	O
molindone	-	466	B
should	-	476	O
be	-	483	O
aware	-	486	O
of	-	492	O
this	-	495	O
reaction	-	500	O
.	-	508	O

Cardiovascular	9100294	0	O
alterations	-	15	O
in	-	27	O
rat	-	30	O
fetuses	-	34	O
exposed	-	42	O
to	-	50	O
calcium	-	53	B
channel	-	61	O
blockers	-	69	O
.	-	77	O

Preclinical	9100294	79	O
toxicologic	-	91	O
investigation	-	103	O
suggested	-	117	O
that	-	127	O
a	-	132	O
new	-	134	O
calcium	-	138	B
channel	-	146	O
blocker	-	154	O
,	-	161	O
Ro	-	163	B
40	-	166	I
-	-	168	I
5967	-	169	I
,	-	173	O
induced	-	175	O
cardiovascular	-	183	O
alterations	-	198	O
in	-	210	O
rat	-	213	O
fetuses	-	217	O
exposed	-	225	O
to	-	233	O
this	-	236	O
agent	-	241	O
during	-	247	O
organogenesis	-	254	O
.	-	267	O

The	9100294	269	O
present	-	273	O
study	-	281	O
was	-	287	O
designed	-	291	O
to	-	300	O
investigate	-	303	O
the	-	315	O
hypothesis	-	319	O
that	-	330	O
calcium	-	335	B
channel	-	343	O
blockers	-	351	O
in	-	360	O
general	-	363	O
induce	-	371	O
cardiovascular	-	378	O
malformations	-	393	O
indicating	-	407	O
a	-	418	O
pharmacologic	-	420	O
class	-	434	O
effect	-	440	O
.	-	446	O

We	9100294	448	O
studied	-	451	O
three	-	459	O
calcium	-	465	B
channel	-	473	O
blockers	-	481	O
of	-	490	O
different	-	493	O
structure	-	503	O
,	-	512	O
nifedipine	-	514	B
,	-	524	O
diltiazem	-	526	B
,	-	535	O
and	-	537	O
verapamil	-	541	B
,	-	550	O
along	-	552	O
with	-	558	O
the	-	563	O
new	-	567	O
agent	-	571	O
.	-	576	O

Pregnant	9100294	578	O
rats	-	587	O
were	-	592	O
administered	-	597	O
one	-	610	O
of	-	614	O
these	-	617	O
calcium	-	623	B
channel	-	631	O
blockers	-	639	O
during	-	648	O
the	-	655	O
period	-	659	O
of	-	666	O
cardiac	-	669	O
morphogenesis	-	677	O
and	-	691	O
the	-	695	O
offspring	-	699	O
examined	-	709	O
on	-	718	O
day	-	721	O
20	-	725	O
of	-	728	O
gestation	-	731	O
for	-	741	O
cardiovascular	-	745	O
malformations	-	760	O
.	-	773	O

A	9100294	775	O
low	-	777	O
incidence	-	781	O
of	-	791	O
cardiovascular	-	794	O
malformations	-	809	O
was	-	823	O
observed	-	827	O
after	-	836	O
exposure	-	842	O
to	-	851	O
each	-	854	O
of	-	859	O
the	-	862	O
four	-	866	O
calcium	-	871	B
channel	-	879	O
blockers	-	887	O
,	-	895	O
but	-	897	O
this	-	901	O
incidence	-	906	O
was	-	916	O
statistically	-	920	O
significant	-	934	O
only	-	946	O
for	-	951	O
verapamil	-	955	B
and	-	965	O
nifedipine	-	969	B
.	-	979	O

All	9100294	981	O
four	-	985	O
agents	-	990	O
were	-	997	O
associated	-	1002	O
with	-	1013	O
aortic	-	1018	O
arch	-	1025	O
branching	-	1030	O
variants	-	1040	O
,	-	1048	O
although	-	1050	O
significantly	-	1059	O
increased	-	1073	O
only	-	1083	O
for	-	1088	O
Ro	-	1092	B
40	-	1095	I
-	-	1097	I
5967	-	1098	I
and	-	1103	O
verapamil	-	1107	B
.	-	1116	O

Differential	19889778	0	O
impact	-	13	O
of	-	20	O
immune	-	23	O
escape	-	30	O
mutations	-	37	O
G145R	-	47	O
and	-	53	O
P120	-	57	O
T	-	61	O
on	-	63	O
the	-	66	O
replication	-	70	O
of	-	82	O
lamivudine	-	85	B
-	-	95	O
resistant	-	96	O
hepatitis	-	106	B
B	-	116	I
virus	-	118	I
e	-	124	I
antigen	-	126	I
-	-	133	O
positive	-	134	O
and	-	143	O
-	-	147	O
negative	-	148	O
strains	-	157	O
.	-	164	O

Immune	19889778	166	O
escape	-	173	O
variants	-	180	O
of	-	189	O
the	-	192	O
hepatitis	-	196	O
B	-	206	O
virus	-	208	O
(	-	214	O
HBV	-	215	O
)	-	218	O
represent	-	220	O
an	-	230	O
emerging	-	233	O
clinical	-	242	O
challenge	-	251	O
,	-	260	O
because	-	262	O
they	-	270	O
can	-	275	O
be	-	279	O
associated	-	282	O
with	-	293	O
vaccine	-	298	O
escape	-	306	O
,	-	312	O
HBV	-	314	O
reactivation	-	318	O
,	-	330	O
and	-	332	O
failure	-	336	O
of	-	344	O
diagnostic	-	347	O
tests	-	358	O
.	-	363	O

Recent	19889778	365	O
data	-	372	O
suggest	-	377	O
a	-	385	O
preferential	-	387	O
selection	-	400	O
of	-	410	O
immune	-	413	O
escape	-	420	O
mutants	-	427	O
in	-	435	O
distinct	-	438	O
peripheral	-	447	O
blood	-	458	O
leukocyte	-	464	O
compartments	-	474	O
of	-	487	O
infected	-	490	O
individuals	-	499	O
.	-	510	O

We	19889778	512	O
therefore	-	515	O
systematically	-	525	O
analyzed	-	540	O
the	-	549	O
functional	-	553	O
impact	-	564	O
of	-	571	O
the	-	574	O
most	-	578	O
prevalent	-	583	O
immune	-	593	O
escape	-	600	O
variants	-	607	O
,	-	615	O
the	-	617	O
sG145R	-	621	O
and	-	628	O
sP120	-	632	O
T	-	637	O
mutants	-	639	O
,	-	646	O
on	-	648	O
the	-	651	O
viral	-	655	O
replication	-	661	O
efficacy	-	673	O
and	-	682	O
antiviral	-	686	O
drug	-	696	O
susceptibility	-	701	O
of	-	716	O
common	-	719	O
treatment	-	726	O
-	-	735	O
associated	-	736	O
mutants	-	747	O
with	-	755	O
resistance	-	760	O
to	-	771	O
lamivudine	-	774	B
(	-	785	O
LAM	-	786	B
)	-	789	O
and	-	791	O
/	-	794	O
or	-	795	O
HBeAg	-	798	B
negativity	-	804	O
.	-	814	O

Replication	19889778	816	O
-	-	827	O
competent	-	828	O
HBV	-	838	O
strains	-	842	O
with	-	850	O
sG145R	-	855	O
or	-	862	O
sP120	-	865	O
T	-	870	O
and	-	872	O
LAM	-	876	B
resistance	-	880	O
(	-	891	O
rtM204I	-	892	O
or	-	900	O
rtL180M	-	903	O
/	-	910	O
rtM204V	-	911	O
)	-	918	O
were	-	920	O
generated	-	925	O
on	-	935	O
an	-	938	O
HBeAg	-	941	B
-	-	946	O
positive	-	947	O
and	-	956	O
an	-	960	O
HBeAg	-	963	B
-	-	968	O
negative	-	969	O
background	-	978	O
with	-	989	O
precore	-	994	O
(	-	1002	O
PC	-	1003	O
)	-	1005	O
and	-	1007	O
basal	-	1011	O
core	-	1017	O
promoter	-	1022	O
(	-	1031	O
BCP	-	1032	O
)	-	1035	O
mutants	-	1037	O
.	-	1044	O

The	19889778	1046	O
sG145R	-	1050	O
mutation	-	1057	O
strongly	-	1066	O
reduced	-	1075	O
HBsAg	-	1083	B
levels	-	1089	O
and	-	1096	O
was	-	1100	O
able	-	1104	O
to	-	1109	O
fully	-	1112	O
restore	-	1118	O
the	-	1126	O
impaired	-	1130	O
replication	-	1139	O
of	-	1151	O
LAM	-	1154	B
-	-	1157	O
resistant	-	1158	O
HBV	-	1168	O
mutants	-	1172	O
to	-	1180	O
the	-	1183	O
levels	-	1187	O
of	-	1194	O
wild	-	1197	O
-	-	1201	O
type	-	1202	O
HBV	-	1207	O
,	-	1210	O
and	-	1212	O
PC	-	1216	O
or	-	1219	O
BCP	-	1222	O
mutations	-	1226	O
further	-	1236	O
enhanced	-	1244	O
viral	-	1253	O
replication	-	1259	O
.	-	1270	O

Although	19889778	1272	O
the	-	1281	O
sP120	-	1285	O
T	-	1290	O
substitution	-	1292	O
also	-	1305	O
impaired	-	1310	O
HBsAg	-	1319	B
secretion	-	1325	O
,	-	1334	O
it	-	1336	O
did	-	1339	O
not	-	1343	O
enhance	-	1347	O
the	-	1355	O
replication	-	1359	O
of	-	1371	O
LAM	-	1374	B
-	-	1377	O
resistant	-	1378	O
clones	-	1388	O
.	-	1394	O

However	19889778	1396	O
,	-	1403	O
the	-	1405	O
concomitant	-	1409	O
occurrence	-	1421	O
of	-	1432	O
HBeAg	-	1435	B
negativity	-	1441	O
(	-	1452	O
PC	-	1453	O
/	-	1455	O
BCP	-	1456	O
)	-	1459	O
,	-	1460	O
sP120	-	1462	O
T	-	1467	O
,	-	1468	O
and	-	1470	O
LAM	-	1474	B
resistance	-	1478	O
resulted	-	1489	O
in	-	1498	O
the	-	1501	O
restoration	-	1505	O
of	-	1517	O
replication	-	1520	O
to	-	1532	O
levels	-	1535	O
of	-	1542	O
wild	-	1545	O
-	-	1549	O
type	-	1550	O
HBV	-	1555	O
.	-	1558	O

In	19889778	1560	O
all	-	1563	O
clones	-	1567	O
with	-	1574	O
combined	-	1579	O
immune	-	1588	O
escape	-	1595	O
and	-	1602	O
LAM	-	1606	B
resistance	-	1610	O
mutations	-	1621	O
,	-	1630	O
the	-	1632	O
nucleotide	-	1636	B
analogues	-	1647	O
adefovir	-	1657	B
and	-	1666	O
tenofovir	-	1670	B
remained	-	1680	O
effective	-	1689	O
in	-	1699	O
suppressing	-	1702	O
viral	-	1714	O
replication	-	1720	O
in	-	1732	O
vitro	-	1735	O
.	-	1740	O

These	19889778	1742	O
findings	-	1748	O
reveal	-	1757	O
the	-	1764	O
differential	-	1768	O
impact	-	1781	O
of	-	1788	O
immune	-	1791	O
escape	-	1798	O
variants	-	1805	O
on	-	1814	O
the	-	1817	O
replication	-	1821	O
and	-	1833	O
drug	-	1837	O
susceptibility	-	1842	O
of	-	1857	O
complex	-	1860	O
HBV	-	1868	O
mutants	-	1872	O
,	-	1879	O
supporting	-	1881	O
the	-	1892	O
need	-	1896	O
of	-	1901	O
close	-	1904	O
surveillance	-	1910	O
and	-	1923	O
treatment	-	1927	O
adjustment	-	1937	O
in	-	1948	O
response	-	1951	O
to	-	1960	O
the	-	1963	O
selection	-	1967	O
of	-	1977	O
distinct	-	1980	O
mutational	-	1989	O
patterns	-	2000	O
.	-	2008	O

The	15278670	0	O
effects	-	4	O
of	-	12	O
sevoflurane	-	15	B
on	-	27	O
lidocaine	-	30	B
-	-	39	O
induced	-	40	O
convulsions	-	48	O
.	-	59	O

The	15278670	61	O
influence	-	65	O
of	-	75	O
sevoflurane	-	78	B
on	-	90	O
lidocaine	-	93	B
-	-	102	O
induced	-	103	O
convulsions	-	111	O
was	-	123	O
studied	-	127	O
in	-	135	O
cats	-	138	O
.	-	142	O

The	15278670	144	O
convulsive	-	148	O
threshold	-	159	O
(	-	169	O
mean	-	170	O
+	-	175	O
/	-	176	O
-	-	177	O

SD	15278670	179	O
)	-	181	O
was	-	183	O
41	-	187	O
.	-	189	O
4	-	190	O
+	-	192	O
/	-	193	O
-	-	194	O

6	15278670	196	O
.	-	197	O
5	-	198	O
mg	-	200	O
.	-	202	O

l	15278670	204	O
(	-	205	O
-	-	206	O
1	-	207	O
)	-	208	O
with	-	210	O
lidocaine	-	215	B
infusion	-	225	O
(	-	234	O
6	-	235	O
mg	-	237	O
.	-	239	O
kg	-	240	O
(	-	242	O
-	-	243	O
1	-	244	O
)	-	245	O
.	-	246	O
min	-	247	O
(	-	250	O
-	-	251	O
1	-	252	O
)	-	253	O
)	-	254	O
,	-	255	O
increasing	-	257	O
significantly	-	268	O
to	-	282	O
66	-	285	O
.	-	287	O
6	-	288	O
+	-	290	O
/	-	291	O
-	-	292	O

10	15278670	294	O
.	-	296	O
9	-	297	O
mg	-	299	O
.	-	301	O

l	15278670	303	O
(	-	304	O
-	-	305	O
1	-	306	O
)	-	307	O
when	-	309	O
the	-	314	O
end	-	318	O
-	-	321	O
tidal	-	322	O
concentration	-	328	O
of	-	342	O
sevoflurane	-	345	B
was	-	357	O
0	-	361	O
.	-	362	O
8	-	363	O
%	-	364	O
.	-	365	O

However	15278670	367	O
,	-	374	O
the	-	376	O
threshold	-	380	O
(	-	390	O
61	-	391	O
.	-	393	O
6	-	394	O
+	-	396	O
/	-	397	O
-	-	398	O

8	15278670	400	O
.	-	401	O
7	-	402	O
mg	-	404	O
.	-	406	O

l	15278670	408	O
(	-	409	O
-	-	410	O
1	-	411	O
)	-	412	O
)	-	413	O
during	-	415	O
1	-	422	O
.	-	423	O
6	-	424	O
%	-	425	O
sevoflurane	-	427	B
was	-	439	O
not	-	443	O
significant	-	447	O
from	-	459	O
that	-	464	O
during	-	469	O
0	-	476	O
.	-	477	O
8	-	478	O
%	-	479	O
sevoflurane	-	481	B
,	-	492	O
indicating	-	494	O
a	-	505	O
celling	-	507	O
effect	-	515	O
.	-	521	O

There	15278670	523	O
was	-	529	O
no	-	533	O
significant	-	536	O
difference	-	548	O
in	-	559	O
the	-	562	O
convulsive	-	566	O
threshold	-	577	O
between	-	587	O
sevoflurane	-	595	B
and	-	607	O
enflurane	-	611	B
.	-	620	O

The	15278670	622	O
rise	-	626	O
in	-	631	O
blood	-	634	O
pressure	-	640	O
became	-	649	O
less	-	656	O
marked	-	661	O
when	-	668	O
higher	-	673	O
concentrations	-	680	O
of	-	695	O
sevoflurane	-	698	B
or	-	710	O
enflurane	-	713	B
were	-	723	O
administered	-	728	O
and	-	741	O
the	-	745	O
blood	-	749	O
pressure	-	755	O
at	-	764	O
convulsions	-	767	O
decreased	-	779	O
significantly	-	789	O
in	-	803	O
1	-	806	O
.	-	807	O
6	-	808	O
%	-	809	O
sevoflurane	-	811	B
,	-	822	O
and	-	824	O
in	-	828	O
0	-	831	O
.	-	832	O
8	-	833	O
%	-	834	O
and	-	836	O
1	-	840	O
.	-	841	O
6	-	842	O
%	-	843	O
enflurane	-	845	B
.	-	854	O

However	15278670	856	O
,	-	863	O
there	-	865	O
was	-	871	O
no	-	875	O
significant	-	878	O
difference	-	890	O
in	-	901	O
the	-	904	O
lidocaine	-	908	B
concentrations	-	918	O
measured	-	933	O
when	-	942	O
the	-	947	O
systolic	-	951	O
blood	-	960	O
pressure	-	966	O
became	-	975	O
70	-	982	O
mmHg	-	985	O
.	-	989	O

Apamin	15278670	991	B
,	-	997	O
a	-	999	O
selective	-	1001	O
blocker	-	1011	O
of	-	1019	O
calcium	-	1022	B
-	-	1029	O
dependent	-	1030	O
potassium	-	1040	B
channels	-	1050	O
,	-	1058	O
was	-	1060	O
administered	-	1064	O
intracerebroventricularly	-	1077	O
in	-	1103	O
rats	-	1106	O
anesthetized	-	1111	O
with	-	1124	O
0	-	1129	O
.	-	1130	O
8	-	1131	O
%	-	1132	O
sevoflurane	-	1134	B
to	-	1146	O
investigate	-	1149	O
the	-	1161	O
mechanism	-	1165	O
of	-	1175	O
the	-	1178	O
anticonvulsive	-	1182	O
effects	-	1197	O
.	-	1204	O

Apamin	15278670	1206	B
(	-	1213	O
10	-	1214	O
ng	-	1217	O
)	-	1219	O
had	-	1221	O
a	-	1225	O
tendency	-	1227	O
to	-	1236	O
decrease	-	1239	O
the	-	1248	O
convulsive	-	1252	O
threshold	-	1263	O
(	-	1273	O
21	-	1274	O
.	-	1276	O
6	-	1277	O
+	-	1279	O
/	-	1280	O
-	-	1281	O

2	15278670	1283	O
.	-	1284	O
2	-	1285	O
to	-	1287	O
19	-	1290	O
.	-	1292	O
9	-	1293	O
+	-	1295	O
/	-	1296	O
-	-	1297	O

2	15278670	1299	O
.	-	1300	O
5	-	1301	O
mg	-	1303	O
.	-	1305	O

l	15278670	1307	O
(	-	1308	O
-	-	1309	O
1	-	1310	O
)	-	1311	O
)	-	1312	O

but	15278670	1314	O
this	-	1318	O
was	-	1323	O
not	-	1327	O
statistically	-	1331	O
significant	-	1345	O
.	-	1356	O

It	15278670	1358	O
is	-	1361	O
suggested	-	1364	O
that	-	1374	O
sevoflurane	-	1379	B
reduces	-	1391	O
the	-	1399	O
convulsive	-	1403	O
effect	-	1414	O
of	-	1421	O
lidocaine	-	1424	B
toxicity	-	1434	O
but	-	1443	O
carries	-	1447	O
some	-	1455	O
risk	-	1460	O
due	-	1465	O
to	-	1469	O
circulatory	-	1472	O
depression	-	1484	O
.	-	1494	O

Anti	17042910	0	O
-	-	4	O
oxidant	-	5	O
effects	-	13	O
of	-	21	O
atorvastatin	-	24	B
in	-	37	O
dexamethasone	-	40	B
-	-	53	O
induced	-	54	O
hypertension	-	62	O
in	-	75	O
the	-	78	O
rat	-	82	O
.	-	85	O

1	17042910	87	O
.	-	88	O

Dexamethasone	17042910	90	B
(	-	104	O
Dex	-	105	B
)	-	108	O
-	-	109	O
induced	-	110	O
hypertension	-	118	O
is	-	131	O
characterized	-	134	O
by	-	148	O
endothelial	-	151	O
dysfunction	-	163	O
associated	-	175	O
with	-	186	O
nitric	-	191	B
oxide	-	198	I
(	-	204	O
NO	-	205	B
)	-	207	O
deficiency	-	209	O
and	-	220	O
increased	-	224	O
superoxide	-	234	B
(	-	245	O
O2	-	246	B
-	-	248	I
)	-	249	O
production	-	251	O
.	-	261	O

Atorvastatin	17042910	263	B
(	-	276	O
Ato	-	277	B
)	-	280	O
possesses	-	282	O
pleiotropic	-	292	O
properties	-	304	O
that	-	315	O
have	-	320	O
been	-	325	O
reported	-	330	O
to	-	339	O
improve	-	342	O
endothelial	-	350	O
function	-	362	O
through	-	371	O
increased	-	379	O
availability	-	389	O
of	-	402	O
NO	-	405	B
and	-	408	O
reduced	-	412	O
O2	-	420	B
-	-	422	I
production	-	424	O
in	-	435	O
various	-	438	O
forms	-	446	O
of	-	452	O
hypertension	-	455	O
.	-	467	O

In	17042910	469	O
the	-	472	O
present	-	476	O
study	-	484	O
,	-	489	O
we	-	491	O
investigated	-	494	O
whether	-	507	O
50	-	515	O
mg	-	518	O
/	-	520	O
kg	-	521	O
per	-	524	O
day	-	528	O
,	-	531	O
p	-	533	O
.	-	534	O
o	-	535	O
.	-	536	O
,	-	537	O
Ato	-	539	B
could	-	543	O
prevent	-	549	O
endothelial	-	557	O
NO	-	569	B
synthase	-	572	O
(	-	581	O
eNOS	-	582	O
)	-	586	O
downregulation	-	588	O
and	-	603	O
the	-	607	O
increase	-	611	O
in	-	620	O
O2	-	623	B
-	-	625	I
in	-	627	O
Sprague	-	630	O
-	-	637	O
Dawley	-	638	O
(	-	645	O
SD	-	646	O
)	-	648	O
rats	-	650	O
,	-	654	O
thereby	-	656	O
reducing	-	664	O
blood	-	673	O
pressure	-	679	O
.	-	687	O

2	17042910	689	O
.	-	690	O

Male	17042910	692	O
SD	-	697	O
rats	-	700	O
(	-	705	O
n	-	706	O
=	-	708	O
30	-	710	O
)	-	712	O
were	-	714	O
treated	-	719	O
with	-	727	O
Ato	-	732	B
(	-	736	O
50	-	737	O
mg	-	740	O
/	-	742	O
kg	-	743	O
per	-	746	O
day	-	750	O
in	-	754	O
drinking	-	757	O
water	-	766	O
)	-	771	O
or	-	773	O
tap	-	776	O
water	-	780	O
for	-	786	O
15	-	790	O
days	-	793	O
.	-	797	O

Dexamethasone	17042910	799	B
(	-	813	O
10	-	814	O
microg	-	817	O
/	-	823	O
kg	-	824	O
per	-	827	O
day	-	831	O
,	-	834	O
s	-	836	O
.	-	837	O
c	-	838	O
.	-	839	O
)	-	840	O
or	-	842	O
saline	-	845	O
was	-	852	O
started	-	856	O
after	-	864	O
4	-	870	O
days	-	872	O
in	-	877	O
Ato	-	880	B
-	-	883	O
treated	-	884	O
and	-	892	O
non	-	896	O
-	-	899	O
treated	-	900	O
rats	-	908	O
and	-	913	O
continued	-	917	O
for	-	927	O
11	-	931	O
-	-	933	O
13	-	934	O
days	-	937	O
.	-	941	O

Systolic	17042910	943	O
blood	-	952	O
pressure	-	958	O
(	-	967	O
SBP	-	968	O
)	-	971	O
was	-	973	O
measured	-	977	O
on	-	986	O
alternate	-	989	O
days	-	999	O
using	-	1004	O
the	-	1010	O
tail	-	1014	O
-	-	1018	O
cuff	-	1019	O
method	-	1024	O
.	-	1030	O

Endothelial	17042910	1032	O
function	-	1044	O
was	-	1053	O
assessed	-	1057	O
by	-	1066	O
acetylcholine	-	1069	B
-	-	1082	O
induced	-	1083	O
vasorelaxation	-	1091	O
and	-	1106	O
phenylephrine	-	1110	B
-	-	1123	O
induced	-	1124	O
vasoconstriction	-	1132	O
in	-	1149	O
aortic	-	1152	O
segments	-	1159	O
.	-	1167	O

Vascular	17042910	1169	O
eNOS	-	1178	O
mRNA	-	1183	O
was	-	1188	O
assessed	-	1192	O
by	-	1201	O
semi	-	1204	O
-	-	1208	O
quantitative	-	1209	O
reverse	-	1222	O
transcription	-	1230	O
-	-	1243	O
polymerase	-	1244	O
chain	-	1255	O
reaction	-	1261	O
.	-	1269	O

3	17042910	1271	O
.	-	1272	O

In	17042910	1274	O
rats	-	1277	O
treated	-	1282	O
with	-	1290	O
Dex	-	1295	B
alone	-	1299	O
,	-	1304	O
SBP	-	1306	O
was	-	1310	O
increased	-	1314	O
from	-	1324	O
109	-	1329	O
+	-	1333	O
/	-	1334	O
-	-	1335	O

2	17042910	1337	O
to	-	1339	O
133	-	1342	O
+	-	1346	O
/	-	1347	O
-	-	1348	O

2	17042910	1350	O
mmHg	-	1352	O
on	-	1357	O
Days	-	1360	O
4	-	1365	O
and	-	1367	O
Day	-	1371	O
14	-	1375	O
,	-	1377	O
respectively	-	1379	O
(	-	1392	O
P	-	1393	O
<	-	1395	O
0	-	1397	O
.	-	1398	O
001	-	1399	O
)	-	1402	O
.	-	1403	O

In	17042910	1405	O
the	-	1408	O
Ato	-	1412	B
+	-	1416	O
Dex	-	1418	B
group	-	1422	O
,	-	1427	O
SBP	-	1429	O
was	-	1433	O
increased	-	1437	O
from	-	1447	O
113	-	1452	O
+	-	1456	O
/	-	1457	O
-	-	1458	O

2	17042910	1460	O
to	-	1462	O
119	-	1465	O
+	-	1469	O
/	-	1470	O
-	-	1471	O

2	17042910	1473	O
mmHg	-	1475	O
on	-	1480	O
Days	-	1483	O
4	-	1488	O
to	-	1490	O
14	-	1493	O
,	-	1495	O
respectively	-	1497	O
(	-	1510	O
P	-	1511	O
<	-	1513	O
0	-	1515	O
.	-	1516	O
001	-	1517	O
)	-	1520	O
,	-	1521	O
but	-	1523	O
was	-	1527	O
significantly	-	1531	O
lower	-	1545	O
than	-	1551	O
SBP	-	1556	O
in	-	1560	O
the	-	1563	O
group	-	1567	O
treated	-	1573	O
with	-	1581	O
Dex	-	1586	B
alone	-	1590	O
(	-	1596	O
P	-	1597	O
<	-	1599	O
0	-	1601	O
.	-	1602	O
05	-	1603	O
)	-	1605	O
.	-	1606	O

Endothelial	17042910	1608	O
-	-	1619	O
dependent	-	1620	O
relaxation	-	1630	O
and	-	1641	O
eNOS	-	1645	O
mRNA	-	1650	O
expression	-	1655	O
were	-	1666	O
greater	-	1671	O
in	-	1679	O
the	-	1682	O
Dex	-	1686	B
+	-	1690	O
Ato	-	1692	B
group	-	1696	O
than	-	1702	O
in	-	1707	O
the	-	1710	O
Dex	-	1714	B
only	-	1718	O
group	-	1723	O
(	-	1729	O
P	-	1730	O
<	-	1732	O
0	-	1734	O
.	-	1735	O
05	-	1736	O
and	-	1739	O
P	-	1743	O
<	-	1745	O
0	-	1747	O
.	-	1748	O
0001	-	1749	O
,	-	1753	O
respectively	-	1755	O
)	-	1767	O
.	-	1768	O

Aortic	17042910	1770	O
superoxide	-	1777	B
production	-	1788	O
was	-	1799	O
lower	-	1803	O
in	-	1809	O
the	-	1812	O
Dex	-	1816	B
+	-	1820	O
Ato	-	1822	B
group	-	1826	O
compared	-	1832	O
with	-	1841	O
the	-	1846	O
group	-	1850	O
treated	-	1856	O
with	-	1864	O
Dex	-	1869	B
alone	-	1873	O
(	-	1879	O
P	-	1880	O
<	-	1882	O
0	-	1884	O
.	-	1885	O
0001	-	1886	O
)	-	1890	O
.	-	1891	O

4	17042910	1893	O
.	-	1894	O

Treatment	17042910	1896	O
with	-	1906	O
Ato	-	1911	B
improved	-	1915	O
endothelial	-	1924	O
function	-	1936	O
,	-	1944	O
reduced	-	1946	O
superoxide	-	1954	B
production	-	1965	O
and	-	1976	O
reduced	-	1980	O
SBP	-	1988	O
in	-	1992	O
Dex	-	1995	B
-	-	1998	O
treated	-	1999	O
SD	-	2007	O
rats	-	2010	O
.	-	2014	O

99mTc	11897407	0	B
-	-	5	I
glucarate	-	6	I
for	-	16	O
detection	-	20	O
of	-	30	O
isoproterenol	-	33	B
-	-	46	O
induced	-	47	O
myocardial	-	55	O
infarction	-	66	O
in	-	77	O
rats	-	80	O
.	-	84	O

Infarct	11897407	86	O
-	-	93	O
avid	-	94	O
radiopharmaceuticals	-	99	O
are	-	120	O
necessary	-	124	O
for	-	134	O
rapid	-	138	O
and	-	144	O
timely	-	148	O
diagnosis	-	155	O
of	-	165	O
acute	-	168	O
myocardial	-	174	O
infarction	-	185	O
.	-	195	O

The	11897407	197	O
animal	-	201	O
model	-	208	O
used	-	214	O
to	-	219	O
produce	-	222	O
infarction	-	230	O
implies	-	241	O
artery	-	249	O
ligation	-	256	O
but	-	265	O
chemical	-	269	O
induction	-	278	O
can	-	288	O
be	-	292	O
easily	-	295	O
obtained	-	302	O
with	-	311	O
isoproterenol	-	316	B
.	-	329	O

A	11897407	331	O
new	-	333	O
infarct	-	337	O
-	-	344	O
avid	-	345	O
radiopharmaceutical	-	350	O
based	-	370	O
on	-	376	O
glucaric	-	379	B
acid	-	388	I
was	-	393	O
prepared	-	397	O
in	-	406	O
the	-	409	O
hospital	-	413	O
radiopharmacy	-	422	O
of	-	436	O
the	-	439	O
INCMNSZ	-	443	O
.	-	450	O

99mTc	11897407	452	B
-	-	457	I
glucarate	-	458	I
was	-	468	O
easy	-	472	O
to	-	477	O
prepare	-	480	O
,	-	487	O
stable	-	489	O
for	-	496	O
96	-	500	O
h	-	503	O
and	-	505	O
was	-	509	O
used	-	513	O
to	-	518	O
study	-	521	O
its	-	527	O
biodistribution	-	531	O
in	-	547	O
rats	-	550	O
with	-	555	O
isoproterenol	-	560	B
-	-	573	O
induced	-	574	O
acute	-	582	O
myocardial	-	588	O
infarction	-	599	O
.	-	609	O

Histological	11897407	611	O
studies	-	624	O
demonstrated	-	632	O
that	-	645	O
the	-	650	O
rats	-	654	O
developed	-	659	O
an	-	669	O
infarct	-	672	O
18	-	680	O
h	-	683	O
after	-	685	O
isoproterenol	-	691	B
administration	-	705	O
.	-	719	O

The	11897407	721	O
rat	-	725	O
biodistribution	-	729	O
studies	-	745	O
showed	-	753	O
a	-	760	O
rapid	-	762	O
blood	-	768	O
clearance	-	774	O
via	-	784	O
the	-	788	O
kidneys	-	792	O
.	-	799	O

Thirty	11897407	801	O
minutes	-	808	O
after	-	816	O
99mTc	-	822	B
-	-	827	I
glucarate	-	828	I
administration	-	838	O
the	-	853	O
standardised	-	857	O
heart	-	870	O
uptake	-	876	O
value	-	883	O
S	-	889	O
(	-	890	O
h	-	891	O
)	-	892	O
UV	-	893	O
was	-	896	O
4	-	900	O
.	-	901	O
7	-	902	O
in	-	904	O
infarcted	-	907	O
rat	-	917	O
heart	-	921	O
which	-	927	O
is	-	933	O
six	-	936	O
times	-	940	O
more	-	946	O
than	-	951	O
in	-	956	O
normal	-	959	O
rats	-	966	O
.	-	970	O

ROIs	11897407	972	O
drawn	-	977	O
over	-	983	O
the	-	988	O
gamma	-	992	O
camera	-	998	O
images	-	1005	O
showed	-	1012	O
a	-	1019	O
ratio	-	1021	O
of	-	1027	O
4	-	1030	O
.	-	1031	O
4	-	1032	O
.	-	1033	O

The	11897407	1035	O
high	-	1039	O
image	-	1044	O
quality	-	1050	O
suggests	-	1058	O
that	-	1067	O
high	-	1072	O
contrast	-	1077	O
images	-	1086	O
can	-	1093	O
be	-	1097	O
obtained	-	1100	O
in	-	1109	O
humans	-	1112	O
and	-	1119	O
the	-	1123	O
96	-	1127	O
h	-	1130	O
stability	-	1132	O
makes	-	1142	O
it	-	1148	O
an	-	1151	O
ideal	-	1154	O
agent	-	1160	O
to	-	1166	O
detect	-	1169	O
,	-	1175	O
in	-	1177	O
patients	-	1180	O
,	-	1188	O
early	-	1190	O
cardiac	-	1196	O
infarction	-	1204	O
.	-	1214	O

A	9812111	0	O
randomized	-	2	O
,	-	12	O
placebo	-	14	O
-	-	21	O
controlled	-	22	O
dose	-	33	O
-	-	37	O
comparison	-	38	O
trial	-	49	O
of	-	55	O
haloperidol	-	58	B
for	-	70	O
psychosis	-	74	O
and	-	84	O
disruptive	-	88	O
behaviors	-	99	O
in	-	109	O
Alzheimer	-	112	O
's	-	121	O
disease	-	124	O
.	-	131	O

OBJECTIVE	9812111	133	O
:	-	142	O
The	-	144	O
goal	-	148	O
of	-	153	O
this	-	156	O
study	-	161	O
was	-	167	O
to	-	171	O
compare	-	174	O
the	-	182	O
efficacy	-	186	O
and	-	195	O
side	-	199	O
effects	-	204	O
of	-	212	O
two	-	215	O
doses	-	219	O
of	-	225	O
haloperidol	-	228	B
and	-	240	O
placebo	-	244	O
in	-	252	O
the	-	255	O
treatment	-	259	O
of	-	269	O
psychosis	-	272	O
and	-	282	O
disruptive	-	286	O
behaviors	-	297	O
in	-	307	O
patients	-	310	O
with	-	319	O
Alzheimer	-	324	O
's	-	333	O
disease	-	336	O
.	-	343	O

METHOD	9812111	345	O
:	-	351	O

In	9812111	353	O
a	-	356	O
6	-	358	O
-	-	359	O
week	-	360	O
random	-	365	O
-	-	371	O
assignment	-	372	O
,	-	382	O
double	-	384	O
-	-	390	O
blind	-	391	O
,	-	396	O
placebo	-	398	O
-	-	405	O
controlled	-	406	O
trial	-	417	O
(	-	423	O
phase	-	424	O
A	-	430	O
)	-	431	O
,	-	432	O
haloperidol	-	434	B
,	-	445	O
2	-	447	O
-	-	448	O
3	-	449	O
mg	-	451	O
/	-	453	O
day	-	454	O
(	-	458	O
standard	-	459	O
dose	-	468	O
)	-	472	O
,	-	473	O
and	-	475	O
haloperidol	-	479	B
,	-	490	O
0	-	492	O
.	-	493	O
50	-	494	O
-	-	496	O
0	-	497	O
.	-	498	O
75	-	499	O
mg	-	502	O
/	-	504	O
day	-	505	O
(	-	509	O
low	-	510	O
dose	-	514	O
)	-	518	O
,	-	519	O
were	-	521	O
compared	-	526	O
in	-	535	O
71	-	538	O
outpatients	-	541	O
with	-	553	O
Alzheimer	-	558	O
's	-	567	O
disease	-	570	O
.	-	577	O

For	9812111	579	O
the	-	583	O
subsequent	-	587	O
6	-	598	O
-	-	599	O
week	-	600	O
double	-	605	O
-	-	611	O
blind	-	612	O
crossover	-	618	O
phase	-	628	O
(	-	634	O
phase	-	635	O
B	-	641	O
)	-	642	O
,	-	643	O
patients	-	645	O
taking	-	654	O
standard	-	661	O
-	-	669	O
or	-	671	O
low	-	674	O
-	-	677	O
dose	-	678	O
haloperidol	-	683	B
were	-	695	O
switched	-	700	O
to	-	709	O
placebo	-	712	O
,	-	719	O
and	-	721	O
patients	-	725	O
taking	-	734	O
placebo	-	741	O
were	-	749	O
randomly	-	754	O
assigned	-	763	O
to	-	772	O
standard	-	775	O
-	-	783	O
or	-	785	O
low	-	788	O
-	-	791	O
dose	-	792	O
haloperidol	-	797	B
.	-	808	O

RESULTS	9812111	810	O
:	-	817	O

For	9812111	819	O
the	-	823	O
60	-	827	O
patients	-	830	O
who	-	839	O
completed	-	843	O
phase	-	853	O
A	-	859	O
,	-	860	O
standard	-	862	O
-	-	870	O
dose	-	871	O
haloperidol	-	876	B
was	-	888	O
efficacious	-	892	O
and	-	904	O
superior	-	908	O
to	-	917	O
both	-	920	O
low	-	925	O
-	-	928	O
dose	-	929	O
haloperidol	-	934	B
and	-	946	O
placebo	-	950	O
for	-	958	O
scores	-	962	O
on	-	969	O
the	-	972	O
Brief	-	976	O
Psychiatric	-	982	O
Rating	-	994	O
Scale	-	1001	O
psychosis	-	1007	O
factor	-	1017	O
and	-	1024	O
on	-	1028	O
psychomotor	-	1031	O
agitation	-	1043	O
.	-	1052	O

Response	9812111	1054	O
rates	-	1063	O
according	-	1069	O
to	-	1079	O
three	-	1082	O
sets	-	1088	O
of	-	1093	O
criteria	-	1096	O
were	-	1105	O
greater	-	1110	O
with	-	1118	O
the	-	1123	O
standard	-	1127	O
dose	-	1136	O
(	-	1141	O
55	-	1142	O
%	-	1144	O
-	-	1145	O
60	-	1146	O
%	-	1148	O
)	-	1149	O
than	-	1151	O
the	-	1156	O
low	-	1160	O
dose	-	1164	O
(	-	1169	O
25	-	1170	O
%	-	1172	O
-	-	1173	O
35	-	1174	O
%	-	1176	O
)	-	1177	O
and	-	1179	O
placebo	-	1183	O
(	-	1191	O
25	-	1192	O
%	-	1194	O
-	-	1195	O
30	-	1196	O
%	-	1198	O
)	-	1199	O
.	-	1200	O

The	9812111	1202	O
advantage	-	1206	O
of	-	1216	O
standard	-	1219	O
dose	-	1228	O
over	-	1233	O
low	-	1238	O
dose	-	1242	O
was	-	1247	O
replicated	-	1251	O
in	-	1262	O
phase	-	1265	O
B	-	1271	O
.	-	1272	O

In	9812111	1274	O
phase	-	1277	O
A	-	1283	O
,	-	1284	O
extrapyramidal	-	1286	O
signs	-	1301	O
tended	-	1307	O
to	-	1314	O
be	-	1317	O
greater	-	1320	O
with	-	1328	O
the	-	1333	O
standard	-	1337	O
dose	-	1346	O
than	-	1351	O
in	-	1356	O
the	-	1359	O
other	-	1363	O
two	-	1369	O
conditions	-	1373	O
,	-	1383	O
primarily	-	1385	O
because	-	1395	O
of	-	1403	O
a	-	1406	O
subgroup	-	1408	O
(	-	1417	O
20	-	1418	O
%	-	1420	O
)	-	1421	O
who	-	1423	O
developed	-	1427	O
moderate	-	1437	O
to	-	1446	O
severe	-	1449	O
signs	-	1456	O
.	-	1461	O

Low	9812111	1463	O
-	-	1466	O
dose	-	1467	O
haloperidol	-	1472	B
did	-	1484	O
not	-	1488	O
differ	-	1492	O
from	-	1499	O
placebo	-	1504	O
on	-	1512	O
any	-	1515	O
measure	-	1519	O
of	-	1527	O
efficacy	-	1530	O
or	-	1539	O
side	-	1542	O
effects	-	1547	O
.	-	1554	O

CONCLUSIONS	9812111	1556	O
:	-	1567	O

The	9812111	1569	O
results	-	1573	O
indicated	-	1581	O
a	-	1591	O
favorable	-	1593	O
therapeutic	-	1603	O
profile	-	1615	O
for	-	1623	O
haloperidol	-	1627	B
in	-	1639	O
doses	-	1642	O
of	-	1648	O
2	-	1651	O
-	-	1652	O
3	-	1653	O
mg	-	1655	O
/	-	1657	O
day	-	1658	O
,	-	1661	O
although	-	1663	O
a	-	1672	O
subgroup	-	1674	O
developed	-	1683	O
moderate	-	1693	O
to	-	1702	O
severe	-	1705	O
extrapyramidal	-	1712	O
signs	-	1727	O
.	-	1732	O

A	9812111	1734	O
starting	-	1736	O
dose	-	1745	O
of	-	1750	O
1	-	1753	O
mg	-	1755	O
/	-	1757	O
day	-	1758	O
with	-	1762	O
gradual	-	1767	O
,	-	1774	O
upward	-	1776	O
dose	-	1783	O
titration	-	1788	O
is	-	1798	O
recommended	-	1801	O
.	-	1812	O

The	9812111	1814	O
narrow	-	1818	O
therapeutic	-	1825	O
window	-	1837	O
observed	-	1844	O
with	-	1853	O
haloperidol	-	1858	B
may	-	1870	O
also	-	1874	O
apply	-	1879	O
to	-	1885	O
other	-	1888	O
neuroleptics	-	1894	O
used	-	1907	O
in	-	1912	O
Alzheimer	-	1915	O
's	-	1924	O
disease	-	1927	O
patients	-	1935	O
with	-	1944	O
psychosis	-	1949	O
and	-	1959	O
disruptive	-	1963	O
behaviors	-	1974	O
.	-	1983	O

Individual	15572383	0	O
differences	-	11	O
in	-	23	O
renal	-	26	O
ACE	-	32	O
activity	-	36	O
in	-	45	O
healthy	-	48	O
rats	-	56	O
predict	-	61	O
susceptibility	-	69	O
to	-	84	O
adriamycin	-	87	B
-	-	97	O
induced	-	98	O
renal	-	106	O
damage	-	112	O
.	-	118	O

BACKGROUND	15572383	120	O
:	-	130	O

In	15572383	132	O
man	-	135	O
,	-	138	O
differences	-	140	O
in	-	152	O
angiotensin	-	155	B
-	-	166	O
converting	-	167	O
enzyme	-	178	O
(	-	185	O
ACE	-	186	O
)	-	189	O
levels	-	191	O
,	-	197	O
related	-	199	O
to	-	207	O
ACE	-	210	O
(	-	214	O
I	-	215	O
/	-	216	O
D	-	217	O
)	-	218	O
genotype	-	220	O
,	-	228	O
are	-	230	O
associated	-	234	O
with	-	245	O
renal	-	250	O
prognosis	-	256	O
.	-	265	O

This	15572383	267	O
raises	-	272	O
the	-	279	O
hypothesis	-	283	O
that	-	294	O
individual	-	299	O
differences	-	310	O
in	-	322	O
renal	-	325	O
ACE	-	331	O
activity	-	335	O
are	-	344	O
involved	-	348	O
in	-	357	O
renal	-	360	O
susceptibility	-	366	O
to	-	381	O
inflicted	-	384	O
damage	-	394	O
.	-	400	O

Therefore	15572383	402	O
,	-	411	O
we	-	413	O
studied	-	416	O
the	-	424	O
predictive	-	428	O
effect	-	439	O
of	-	446	O
renal	-	449	O
ACE	-	455	O
activity	-	459	O
for	-	468	O
the	-	472	O
severity	-	476	O
of	-	485	O
renal	-	488	O
damage	-	494	O
induced	-	501	O
by	-	509	O
a	-	512	O
single	-	514	O
injection	-	521	O
of	-	531	O
adriamycin	-	534	B
in	-	545	O
rats	-	548	O
.	-	552	O

METHODS	15572383	554	O
:	-	561	O

Renal	15572383	563	O
ACE	-	569	O
activity	-	573	O
(	-	582	O
Hip	-	583	B
-	-	586	I
His	-	587	I
-	-	590	I
Leu	-	591	I
cleavage	-	595	O
by	-	604	O
cortical	-	607	O
homogenates	-	616	O
)	-	627	O
was	-	629	O
determined	-	633	O
by	-	644	O
renal	-	647	O
biopsy	-	653	O
in	-	660	O
27	-	663	O
adult	-	666	O
male	-	672	O
Wistar	-	677	O
rats	-	684	O
.	-	688	O

After	15572383	690	O
1	-	696	O
week	-	698	O
of	-	703	O
recovery	-	706	O
,	-	714	O
proteinuria	-	716	O
was	-	728	O
induced	-	732	O
by	-	740	O
adriamycin	-	743	B
[	-	754	O
1	-	755	O
.	-	756	O
5	-	757	O
mg	-	759	O
/	-	761	O
kg	-	762	O
intravenously	-	765	O
(	-	779	O
i	-	780	O
.	-	781	O
v	-	782	O
.	-	783	O
)	-	784	O

n	15572383	786	O
=	-	788	O
18	-	790	O
;	-	792	O
controls	-	794	O
,	-	802	O
saline	-	804	O
i	-	811	O
.	-	812	O
v	-	813	O
.	-	814	O

n	15572383	816	O
=	-	818	O
9	-	820	O
]	-	821	O
.	-	822	O

Proteinuria	15572383	824	O
was	-	836	O
measured	-	840	O
every	-	849	O
2	-	855	O
weeks	-	857	O
.	-	862	O

After	15572383	864	O
12	-	870	O
weeks	-	873	O
,	-	878	O
rats	-	880	O
were	-	885	O
sacrificed	-	890	O
and	-	901	O
their	-	905	O
kidneys	-	911	O
harvested	-	919	O
.	-	928	O

RESULTS	15572383	930	O
:	-	937	O

As	15572383	939	O
anticipated	-	942	O
,	-	953	O
adriamycin	-	955	B
elicited	-	966	O
nephrotic	-	975	O
range	-	985	O
proteinuria	-	991	O
,	-	1002	O
renal	-	1004	O
interstitial	-	1010	O
damage	-	1023	O
and	-	1030	O
mild	-	1034	O
focal	-	1039	O
glomerulosclerosis	-	1045	O
.	-	1063	O

Baseline	15572383	1065	O
renal	-	1074	O
ACE	-	1080	O
positively	-	1084	O
correlated	-	1095	O
with	-	1106	O
the	-	1111	O
relative	-	1115	O
rise	-	1124	O
in	-	1129	O
proteinuria	-	1132	O
after	-	1144	O
adriamycin	-	1150	B
(	-	1161	O
r	-	1162	O
=	-	1164	O
0	-	1166	O
.	-	1167	O
62	-	1168	O
,	-	1170	O
P	-	1172	O
<	-	1173	O
0	-	1174	O
.	-	1175	O
01	-	1176	O
)	-	1178	O
,	-	1179	O
renal	-	1181	O
interstitial	-	1187	O
alpha	-	1200	O
-	-	1205	O
smooth	-	1206	O
muscle	-	1213	O
actin	-	1220	O
(	-	1226	O
r	-	1227	O
=	-	1229	O
0	-	1231	O
.	-	1232	O
49	-	1233	O
,	-	1235	O
P	-	1237	O
<	-	1238	O
0	-	1239	O
.	-	1240	O
05	-	1241	O
)	-	1243	O
,	-	1244	O
interstitial	-	1246	O
macrophage	-	1259	O
influx	-	1270	O
(	-	1277	O
r	-	1278	O
=	-	1280	O
0	-	1282	O
.	-	1283	O
56	-	1284	O
,	-	1286	O
P	-	1288	O
<	-	1289	O
0	-	1290	O
.	-	1291	O
05	-	1292	O
)	-	1294	O
,	-	1295	O
interstitial	-	1297	O
collagen	-	1310	O
III	-	1319	O
(	-	1323	O
r	-	1324	O
=	-	1326	O
0	-	1328	O
.	-	1329	O
53	-	1330	O
,	-	1332	O
P	-	1334	O
<	-	1335	O
0	-	1336	O
.	-	1337	O
05	-	1338	O
)	-	1340	O
,	-	1341	O
glomerular	-	1343	O
alpha	-	1354	O
-	-	1359	O
smooth	-	1360	O
muscle	-	1367	O
actin	-	1374	O
(	-	1380	O
r	-	1381	O
=	-	1383	O
0	-	1385	O
.	-	1386	O
74	-	1387	O
,	-	1389	O
P	-	1391	O
<	-	1392	O
0	-	1393	O
.	-	1394	O
01	-	1395	O
)	-	1397	O
and	-	1399	O
glomerular	-	1403	O
desmin	-	1414	O
(	-	1421	O
r	-	1422	O
=	-	1424	O
0	-	1426	O
.	-	1427	O
48	-	1428	O
,	-	1430	O
P	-	1432	O
<	-	1433	O
0	-	1434	O
.	-	1435	O
05	-	1436	O
)	-	1438	O
.	-	1439	O

Baseline	15572383	1441	O
renal	-	1450	O
ACE	-	1456	O
did	-	1460	O
not	-	1464	O
correlate	-	1468	O
with	-	1478	O
focal	-	1483	O
glomerulosclerosis	-	1489	O
(	-	1508	O
r	-	1509	O
=	-	1511	O
0	-	1513	O
.	-	1514	O
22	-	1515	O
,	-	1517	O
NS	-	1519	O
)	-	1521	O
.	-	1522	O

In	15572383	1524	O
controls	-	1527	O
,	-	1535	O
no	-	1537	O
predictive	-	1540	O
values	-	1551	O
for	-	1558	O
renal	-	1562	O
parameters	-	1568	O
were	-	1579	O
observed	-	1584	O
.	-	1592	O

CONCLUSION	15572383	1594	O
:	-	1604	O

Individual	15572383	1606	O
differences	-	1617	O
in	-	1629	O
renal	-	1632	O
ACE	-	1638	O
activity	-	1642	O
predict	-	1651	O
the	-	1659	O
severity	-	1663	O
of	-	1672	O
adriamycin	-	1675	B
-	-	1685	O
induced	-	1686	O
renal	-	1694	O
damage	-	1700	O
in	-	1707	O
this	-	1710	O
outbred	-	1715	O
rat	-	1723	O
strain	-	1727	O
.	-	1733	O

This	15572383	1735	O
supports	-	1740	O
the	-	1749	O
assumption	-	1753	O
that	-	1764	O
differences	-	1769	O
in	-	1781	O
renal	-	1784	O
ACE	-	1790	O
activity	-	1794	O
predispose	-	1803	O
to	-	1814	O
a	-	1817	O
less	-	1819	O
favourable	-	1824	O
course	-	1835	O
of	-	1842	O
renal	-	1845	O
damage	-	1851	O
.	-	1857	O

Clinical	7420681	0	O
nephrotoxicity	-	9	O
of	-	24	O
tobramycin	-	27	B
and	-	38	O
gentamicin	-	42	B
.	-	52	O

A	7420681	54	O
prospective	-	56	O
study	-	68	O
.	-	73	O

Nearly	7420681	75	O
3	-	82	O
.	-	83	O
2	-	84	O
million	-	86	O
people	-	94	O
in	-	101	O
this	-	104	O
country	-	109	O
receive	-	117	O
aminoglycoside	-	125	B
antibiotics	-	140	O
annually	-	152	O
.	-	160	O

Gentamicin	7420681	162	B
sulfate	-	173	I
and	-	181	O
tobramycin	-	185	B
sulfate	-	196	I
continue	-	204	O
to	-	213	O
demonstrate	-	216	O
ototoxicity	-	228	O
and	-	240	O
nephrotoxicity	-	244	O
in	-	259	O
both	-	262	O
animal	-	267	O
and	-	274	O
clinical	-	278	O
studies	-	287	O
.	-	294	O

In	7420681	296	O
this	-	299	O
study	-	304	O
,	-	309	O
62	-	311	O
patients	-	314	O
with	-	323	O
confirmed	-	328	O
initial	-	338	O
normal	-	346	O
renal	-	353	O
function	-	359	O
and	-	368	O
treated	-	372	O
with	-	380	O
2	-	385	O
to	-	387	O
5	-	390	O
mg	-	392	O
/	-	394	O
kg	-	395	O
/	-	397	O
day	-	398	O
of	-	402	O
gentamicin	-	405	B
sulfate	-	416	I
or	-	424	O
tobramycin	-	427	B
sulfate	-	438	I
for	-	446	O
a	-	450	O
minimum	-	452	O
of	-	460	O
seven	-	463	O
days	-	469	O
were	-	474	O
followed	-	479	O
up	-	488	O
prospectively	-	491	O
for	-	505	O
the	-	509	O
development	-	513	O
of	-	525	O
aminoglycoside	-	528	B
-	-	542	O
related	-	543	O
renal	-	551	O
failure	-	557	O
,	-	564	O
defined	-	566	O
as	-	574	O
at	-	577	O
least	-	580	O
a	-	586	O
one	-	588	O
-	-	591	O
third	-	592	O
reduction	-	598	O
in	-	608	O
renal	-	611	O
function	-	617	O
.	-	625	O

In	7420681	627	O
these	-	630	O
62	-	636	O
patients	-	639	O
,	-	647	O
no	-	649	O
other	-	652	O
causes	-	658	O
for	-	665	O
renal	-	669	O
failure	-	675	O
could	-	683	O
be	-	689	O
identified	-	692	O
.	-	702	O

Five	7420681	704	O
of	-	709	O
33	-	712	O
(	-	715	O
15	-	716	O
%	-	718	O
)	-	719	O
of	-	721	O
the	-	724	O
tobramycin	-	728	B
-	-	738	O
treated	-	739	O
patients	-	747	O
and	-	756	O
16	-	760	O
of	-	763	O
29	-	766	O
(	-	769	O
55	-	770	O
.	-	772	O
2	-	773	O
%	-	774	O
)	-	775	O
of	-	777	O
the	-	780	O
gentamicin	-	784	B
-	-	794	O
treated	-	795	O
patients	-	803	O
had	-	812	O
renal	-	816	O
failure	-	822	O
.	-	829	O

Thus	7420681	831	O
,	-	835	O
gentamicin	-	837	B
was	-	848	O
associated	-	852	O
with	-	863	O
renal	-	868	O
failure	-	874	O
more	-	882	O
than	-	887	O
three	-	892	O
times	-	898	O
as	-	904	O
often	-	907	O
as	-	913	O
was	-	916	O
tobramycin	-	920	B
.	-	930	O

Neuroprotective	12907309	0	O
action	-	16	O
of	-	23	O
MPEP	-	26	B
,	-	30	O
a	-	32	O
selective	-	34	O
mGluR5	-	44	O
antagonist	-	51	O
,	-	61	O
in	-	63	O
methamphetamine	-	66	B
-	-	81	O
induced	-	82	O
dopaminergic	-	90	O
neurotoxicity	-	103	O
is	-	117	O
associated	-	120	O
with	-	131	O
a	-	136	O
decrease	-	138	O
in	-	147	O
dopamine	-	150	B
outflow	-	159	O
and	-	167	O
inhibition	-	171	O
of	-	182	O
hyperthermia	-	185	O
in	-	198	O
rats	-	201	O
.	-	205	O

The	12907309	207	O
aim	-	211	O
of	-	215	O
this	-	218	O
study	-	223	O
was	-	229	O
to	-	233	O
examine	-	236	O
the	-	244	O
role	-	248	O
of	-	253	O
metabotropic	-	256	O
glutamate	-	269	B
receptor	-	279	O
5	-	288	O
(	-	290	O
mGluR5	-	291	O
)	-	297	O
in	-	299	O
the	-	302	O
toxic	-	306	O
action	-	312	O
of	-	319	O
methamphetamine	-	322	B
on	-	338	O
dopaminergic	-	341	O
neurones	-	354	O
in	-	363	O
rats	-	366	O
.	-	370	O

Methamphetamine	12907309	372	B
(	-	388	O
10	-	389	O
mg	-	392	O
/	-	394	O
kg	-	395	O
sc	-	398	O
)	-	400	O
,	-	401	O
administered	-	403	O
five	-	416	O
times	-	421	O
,	-	426	O
reduced	-	428	O
the	-	436	O
levels	-	440	O
of	-	447	O
dopamine	-	450	B
and	-	459	O
its	-	463	O
metabolites	-	467	O
in	-	479	O
striatal	-	482	O
tissue	-	491	O
when	-	498	O
measured	-	503	O
72	-	512	O
h	-	515	O
after	-	517	O
the	-	523	O
last	-	527	O
injection	-	532	O
.	-	541	O

A	12907309	543	O
selective	-	545	O
antagonist	-	555	O
of	-	566	O
mGluR5	-	569	O
,	-	575	O
2	-	577	B
-	-	578	I
methyl	-	579	I
-	-	585	I
6	-	586	I
-	-	587	I
(	-	588	I
phenylethynyl	-	589	I
)	-	602	I
pyridine	-	603	I
(	-	612	O
MPEP	-	613	B
;	-	617	O
5	-	619	O
mg	-	621	O
/	-	623	O
kg	-	624	O
ip	-	627	O
)	-	629	O
,	-	630	O
when	-	632	O
administered	-	637	O
five	-	650	O
times	-	655	O
immediately	-	661	O
before	-	673	O
each	-	680	O
methamphetamine	-	685	B
injection	-	701	O
reversed	-	711	O
the	-	720	O
above	-	724	O
-	-	729	O
mentioned	-	730	O
methamphetamine	-	740	B
effects	-	756	O
.	-	763	O

A	12907309	765	O
single	-	767	O
MPEP	-	774	B
(	-	779	O
5	-	780	O
mg	-	782	O
/	-	784	O
kg	-	785	O
ip	-	788	O
)	-	790	O
injection	-	792	O
reduced	-	802	O
the	-	810	O
basal	-	814	O
extracellular	-	820	O
dopamine	-	834	B
level	-	843	O
in	-	849	O
the	-	852	O
striatum	-	856	O
,	-	864	O
as	-	866	O
well	-	869	O
as	-	874	O
dopamine	-	877	B
release	-	886	O
stimulated	-	894	O
either	-	905	O
by	-	912	O
methamphetamine	-	915	B
(	-	931	O
10	-	932	O
mg	-	935	O
/	-	937	O
kg	-	938	O
sc	-	941	O
)	-	943	O
or	-	945	O
by	-	948	O
intrastriatally	-	951	O
administered	-	967	O
veratridine	-	980	B
(	-	992	O
100	-	993	O
microM	-	997	O
)	-	1003	O
.	-	1004	O

Moreover	12907309	1006	O
,	-	1014	O
it	-	1016	O
transiently	-	1019	O
diminished	-	1031	O
the	-	1042	O
methamphetamine	-	1046	B
(	-	1062	O
10	-	1063	O
mg	-	1066	O
/	-	1068	O
kg	-	1069	O
sc	-	1072	O
)	-	1074	O
-	-	1075	O
induced	-	1076	O
hyperthermia	-	1084	O
and	-	1097	O
reduced	-	1101	O
basal	-	1109	O
body	-	1115	O
temperature	-	1120	O
.	-	1131	O

MPEP	12907309	1133	B
administered	-	1138	O
into	-	1151	O
the	-	1156	O
striatum	-	1160	O
at	-	1169	O
high	-	1172	O
concentrations	-	1177	O
(	-	1192	O
500	-	1193	O
microM	-	1197	O
)	-	1203	O
increased	-	1205	O
extracellular	-	1215	O
dopamine	-	1229	B
levels	-	1238	O
,	-	1244	O
while	-	1246	O
lower	-	1252	O
concentrations	-	1258	O
(	-	1273	O
50	-	1274	O
-	-	1276	O
100	-	1277	O
microM	-	1281	O
)	-	1287	O
were	-	1289	O
devoid	-	1294	O
of	-	1301	O
any	-	1304	O
effect	-	1308	O
.	-	1314	O

The	12907309	1316	O
results	-	1320	O
of	-	1328	O
this	-	1331	O
study	-	1336	O
suggest	-	1342	O
that	-	1350	O
the	-	1355	O
blockade	-	1359	O
of	-	1368	O
mGluR5	-	1371	O
by	-	1378	O
MPEP	-	1381	B
may	-	1386	O
protect	-	1390	O
dopaminergic	-	1398	O
neurones	-	1411	O
against	-	1420	O
methamphetamine	-	1428	B
-	-	1443	O
induced	-	1444	O
toxicity	-	1452	O
.	-	1460	O

Neuroprotection	12907309	1462	O
rendered	-	1478	O
by	-	1487	O
MPEP	-	1490	B
may	-	1495	O
be	-	1499	O
associated	-	1502	O
with	-	1513	O
the	-	1518	O
reduction	-	1522	O
of	-	1532	O
the	-	1535	O
methamphetamine	-	1539	B
-	-	1554	O
induced	-	1555	O
dopamine	-	1563	B
efflux	-	1572	O
in	-	1579	O
the	-	1582	O
striatum	-	1586	O
due	-	1595	O
to	-	1599	O
the	-	1602	O
blockade	-	1606	O
of	-	1615	O
extrastriatal	-	1618	O
mGluR5	-	1632	O
,	-	1638	O
and	-	1640	O
with	-	1644	O
a	-	1649	O
decrease	-	1651	O
in	-	1660	O
hyperthermia	-	1663	O
.	-	1675	O

Pharmacokinetics	16680561	0	O
of	-	17	O
desipramine	-	20	B
HCl	-	32	I
when	-	36	O
administered	-	41	O
with	-	54	O
cinacalcet	-	59	B
HCl	-	70	I
.	-	73	O

OBJECTIVE	16680561	75	O
:	-	84	O
In	-	86	O
vitro	-	89	O
work	-	95	O
has	-	100	O
demonstrated	-	104	O
that	-	117	O
cinacalcet	-	122	B
is	-	133	O
a	-	136	O
strong	-	138	O
inhibitor	-	145	O
of	-	155	O
cytochrome	-	158	O
P450	-	169	O
isoenzyme	-	174	O
(	-	184	O
CYP	-	185	O
)	-	188	O
2D6	-	190	O
.	-	193	O

The	16680561	195	O
purpose	-	199	O
of	-	207	O
this	-	210	O
study	-	215	O
was	-	221	O
to	-	225	O
evaluate	-	228	O
the	-	237	O
effect	-	241	O
of	-	248	O
cinacalcet	-	251	B
on	-	262	O
CYP2D6	-	265	O
activity	-	272	O
,	-	280	O
using	-	282	O
desipramine	-	288	B
as	-	300	O
a	-	303	O
probe	-	305	O
substrate	-	311	O
,	-	320	O
in	-	322	O
healthy	-	325	O
subjects	-	333	O
.	-	341	O

METHODS	16680561	343	O
:	-	350	O

Seventeen	16680561	352	O
subjects	-	362	O
who	-	371	O
were	-	375	O
genotyped	-	380	O
as	-	390	O
CYP2D6	-	393	O
extensive	-	400	O
metabolizers	-	410	O
were	-	423	O
enrolled	-	428	O
in	-	437	O
this	-	440	O
randomized	-	445	O
,	-	455	O
open	-	457	O
-	-	461	O
label	-	462	O
,	-	467	O
crossover	-	469	O
study	-	479	O
to	-	485	O
receive	-	488	O
a	-	496	O
single	-	498	O
oral	-	505	O
dose	-	510	O
of	-	515	O
desipramine	-	518	B
(	-	530	O
50	-	531	O
mg	-	534	O
)	-	536	O
on	-	538	O
two	-	541	O
separate	-	545	O
occasions	-	554	O
,	-	563	O
once	-	565	O
alone	-	570	O
and	-	576	O
once	-	580	O
after	-	585	O
multiple	-	591	O
doses	-	600	O
of	-	606	O
cinacalcet	-	609	B
(	-	620	O
90	-	621	O
mg	-	624	O
for	-	627	O
7	-	631	O
days	-	633	O
)	-	637	O
.	-	638	O

Blood	16680561	640	O
samples	-	646	O
were	-	654	O
obtained	-	659	O
predose	-	668	O
and	-	676	O
up	-	680	O
to	-	683	O
72	-	686	O
h	-	689	O
postdose	-	691	O
.	-	699	O

RESULTS	16680561	701	O
:	-	708	O

Fourteen	16680561	710	O
subjects	-	719	O
completed	-	728	O
both	-	738	O
treatment	-	743	O
arms	-	753	O
.	-	757	O

Relative	16680561	759	O
to	-	768	O
desipramine	-	771	B
alone	-	783	O
,	-	788	O
mean	-	790	O
AUC	-	795	O
and	-	799	O
C	-	803	O
(	-	804	O
max	-	805	O
)	-	808	O
of	-	810	O
desipramine	-	813	B
increased	-	825	O
3	-	835	O
.	-	836	O
6	-	837	O
-	-	838	O
and	-	840	O
1	-	844	O
.	-	845	O
8	-	846	O
-	-	847	O
fold	-	848	O
when	-	853	O
coadministered	-	858	O
with	-	873	O
cinacalcet	-	878	B
.	-	888	O

The	16680561	890	O
t	-	894	O
(	-	896	O
1	-	897	O
/	-	898	O
2	-	899	O
,	-	900	O
z	-	901	O
)	-	902	O
of	-	904	O
desipramine	-	907	B
was	-	919	O
longer	-	923	O
when	-	930	O
desipramine	-	935	B
was	-	947	O
coadministered	-	951	O
with	-	966	O
cinacalcet	-	971	B
(	-	982	O
21	-	983	O
.	-	985	O
0	-	986	O
versus	-	988	O
43	-	995	O
.	-	997	O
3	-	998	O
hs	-	1000	O
)	-	1002	O
.	-	1003	O

The	16680561	1005	O
t	-	1009	O
(	-	1011	O
max	-	1012	O
)	-	1015	O
was	-	1017	O
similar	-	1021	O
between	-	1029	O
the	-	1037	O
regimens	-	1041	O
.	-	1049	O

Fewer	16680561	1051	O
subjects	-	1057	O
reported	-	1066	O
adverse	-	1075	O
events	-	1083	O
following	-	1090	O
treatment	-	1100	O
with	-	1110	O
desipramine	-	1115	B
alone	-	1127	O
than	-	1133	O
when	-	1138	O
receiving	-	1143	O
desipramine	-	1153	B
with	-	1165	O
cinacalcet	-	1170	B
(	-	1181	O
33	-	1182	O
versus	-	1185	O
86	-	1192	O
%	-	1194	O
)	-	1195	O
,	-	1196	O
the	-	1198	O
most	-	1202	O
frequent	-	1207	O
of	-	1216	O
which	-	1219	O
(	-	1225	O
nausea	-	1226	O
and	-	1233	O
headache	-	1237	O
)	-	1245	O
have	-	1247	O
been	-	1252	O
reported	-	1257	O
for	-	1266	O
patients	-	1270	O
treated	-	1279	O
with	-	1287	O
either	-	1292	O
desipramine	-	1299	B
or	-	1311	O
cinacalcet	-	1314	B
.	-	1324	O

CONCLUSION	16680561	1326	O
:	-	1336	O

This	16680561	1338	O
study	-	1343	O
demonstrates	-	1349	O
that	-	1362	O
cinacalcet	-	1367	B
is	-	1378	O
a	-	1381	O
strong	-	1383	O
inhibitor	-	1390	O
of	-	1400	O
CYP2D6	-	1403	O
.	-	1409	O

These	16680561	1411	O
data	-	1417	O
suggest	-	1422	O
that	-	1430	O
during	-	1435	O
concomitant	-	1442	O
treatment	-	1454	O
with	-	1464	O
cinacalcet	-	1469	B
,	-	1479	O
dose	-	1481	O
adjustment	-	1486	O
may	-	1497	O
be	-	1501	O
necessary	-	1504	O
for	-	1514	O
drugs	-	1518	O
that	-	1524	O
demonstrate	-	1529	O
a	-	1541	O
narrow	-	1543	O
therapeutic	-	1550	O
index	-	1562	O
and	-	1568	O
are	-	1572	O
metabolized	-	1576	O
by	-	1588	O
CYP2D6	-	1591	O
.	-	1597	O

Proteomic	17532790	0	O
analysis	-	10	O
of	-	19	O
striatal	-	22	O
proteins	-	31	O
in	-	40	O
the	-	43	O
rat	-	47	O
model	-	51	O
of	-	57	O
L	-	60	B
-	-	61	I
DOPA	-	62	I
-	-	66	O
induced	-	67	O
dyskinesia	-	75	O
.	-	85	O

L	17532790	87	B
-	-	88	I
DOPA	-	89	I
-	-	93	O
induced	-	94	O
dyskinesia	-	102	O
(	-	113	O
LID	-	114	O
)	-	117	O
is	-	119	O
among	-	122	O
the	-	128	O
motor	-	132	O
complications	-	138	O
that	-	152	O
arise	-	157	O
in	-	163	O
Parkinson	-	166	O
's	-	175	O
disease	-	178	O
(	-	186	O
PD	-	187	O
)	-	189	O
patients	-	191	O
after	-	200	O
a	-	206	O
prolonged	-	208	O
treatment	-	218	O
with	-	228	O
L	-	233	B
-	-	234	I
DOPA	-	235	I
.	-	239	O

To	17532790	241	O
this	-	244	O
day	-	249	O
,	-	252	O
transcriptome	-	254	O
analysis	-	268	O
has	-	277	O
been	-	281	O
performed	-	286	O
in	-	296	O
a	-	299	O
rat	-	301	O
model	-	305	O
of	-	311	O
LID	-	314	O
[	-	318	O
Neurobiol	-	319	O
.	-	328	O

Dis	17532790	330	O
.	-	333	O

,	17532790	334	O
17	-	336	O
(	-	339	O
2004	-	340	O
)	-	344	O
,	-	345	O
219	-	347	O
]	-	350	O
but	-	352	O
information	-	356	O
regarding	-	368	O
the	-	378	O
proteome	-	382	O
is	-	391	O
still	-	394	O
lacking	-	400	O
.	-	407	O

In	17532790	409	O
the	-	412	O
present	-	416	O
study	-	424	O
,	-	429	O
we	-	431	O
investigated	-	434	O
the	-	447	O
changes	-	451	O
occurring	-	459	O
at	-	469	O
the	-	472	O
protein	-	476	O
level	-	484	O
in	-	490	O
striatal	-	493	O
samples	-	502	O
obtained	-	510	O
from	-	519	O
the	-	524	O
unilaterally	-	528	O
6	-	541	B
-	-	542	I
hydroxydopamine	-	543	I
-	-	558	O
lesion	-	559	O
rat	-	566	O
model	-	570	O
of	-	576	O
PD	-	579	O
treated	-	582	O
with	-	590	O
saline	-	595	O
,	-	601	O
L	-	603	B
-	-	604	I
DOPA	-	605	I
or	-	610	O
bromocriptine	-	613	B
using	-	627	O
two	-	633	O
-	-	636	O
dimensional	-	637	O
difference	-	649	O
gel	-	660	O
electrophoresis	-	664	O
and	-	680	O
mass	-	684	O
spectrometry	-	689	O
(	-	702	O
MS	-	703	O
)	-	705	O
.	-	706	O

Rats	17532790	708	O
treated	-	713	O
with	-	721	O
L	-	726	B
-	-	727	I
DOPA	-	728	I
were	-	733	O
allocated	-	738	O
to	-	748	O
two	-	751	O
groups	-	755	O
based	-	762	O
on	-	768	O
the	-	771	O
presence	-	775	O
or	-	784	O
absence	-	787	O
of	-	795	O
LID	-	798	O
.	-	801	O

Among	17532790	803	O
the	-	809	O
2000	-	813	O
spots	-	818	O
compared	-	824	O
for	-	833	O
statistical	-	837	O
difference	-	849	O
,	-	859	O
67	-	861	O
spots	-	864	O
were	-	870	O
significantly	-	875	O
changed	-	889	O
in	-	897	O
abundance	-	900	O
and	-	910	O
identified	-	914	O
using	-	925	O
matrix	-	931	O
-	-	937	O
assisted	-	938	O
laser	-	947	O
desorption	-	953	O
/	-	963	O
ionization	-	964	O
time	-	975	O
-	-	979	O
of	-	980	O
-	-	982	O
flight	-	983	O
MS	-	990	O
,	-	992	O
atmospheric	-	994	O
pressure	-	1006	O
matrix	-	1015	O
-	-	1021	O
assisted	-	1022	O
laser	-	1031	O
desorption	-	1037	O
/	-	1047	O
ionization	-	1048	O
and	-	1059	O
HPLC	-	1063	O
coupled	-	1068	O
tandem	-	1076	O
MS	-	1083	O
(	-	1086	O
LC	-	1087	O
/	-	1089	O
MS	-	1090	O
/	-	1092	O
MS	-	1093	O
)	-	1095	O
.	-	1096	O

Out	17532790	1098	O
of	-	1102	O
these	-	1105	O
67	-	1111	O
proteins	-	1114	O
,	-	1122	O
LID	-	1124	O
significantly	-	1128	O
changed	-	1142	O
the	-	1150	O
expression	-	1154	O
level	-	1165	O
of	-	1171	O
five	-	1174	O
proteins	-	1179	O
:	-	1187	O
alphabeta	-	1189	O
-	-	1198	O
crystalin	-	1199	O
,	-	1208	O
gamma	-	1210	O
-	-	1215	O
enolase	-	1216	O
,	-	1223	O
guanidoacetate	-	1225	O
methyltransferase	-	1240	O
,	-	1257	O
vinculin	-	1259	O
,	-	1267	O
and	-	1269	O
proteasome	-	1273	O
alpha	-	1284	O
-	-	1289	O
2	-	1290	O
subunit	-	1292	O
.	-	1299	O

Complementary	17532790	1301	O
techniques	-	1315	O
such	-	1326	O
as	-	1331	O
western	-	1334	O
immunoblotting	-	1342	O
and	-	1357	O
immunohistochemistry	-	1361	O
were	-	1382	O
performed	-	1387	O
to	-	1397	O
investigate	-	1400	O
the	-	1412	O
validity	-	1416	O
of	-	1425	O
the	-	1428	O
data	-	1432	O
obtained	-	1437	O
using	-	1446	O
the	-	1452	O
proteomic	-	1456	O
approach	-	1466	O
.	-	1474	O

In	17532790	1476	O
conclusion	-	1479	O
,	-	1489	O
this	-	1491	O
study	-	1496	O
provides	-	1502	O
new	-	1511	O
insights	-	1515	O
into	-	1524	O
the	-	1529	O
protein	-	1533	O
changes	-	1541	O
occurring	-	1549	O
in	-	1559	O
LID	-	1562	O
.	-	1565	O

Pseudo	7582165	0	O
-	-	6	O
allergic	-	7	O
reactions	-	16	O
to	-	26	O
corticosteroids	-	29	B
:	-	44	O
diagnosis	-	46	O
and	-	56	O
alternatives	-	60	O
.	-	72	O

Two	7582165	74	O
patients	-	78	O
treated	-	87	O
with	-	95	O
parenteral	-	100	O
paramethasone	-	111	B
(	-	125	O
Triniol	-	126	O
)	-	133	O
and	-	135	O
dexamethasone	-	139	B
(	-	153	O
Sedionbel	-	154	O
)	-	163	O
are	-	165	O
described	-	169	O
.	-	178	O

A	7582165	180	O
few	-	182	O
minutes	-	186	O
after	-	194	O
administration	-	200	O
of	-	215	O
the	-	218	O
drugs	-	222	O
,	-	227	O
they	-	229	O
presented	-	234	O
urticaria	-	244	O
(	-	254	O
patients	-	255	O
1	-	264	O
and	-	266	O
2	-	270	O
)	-	271	O
and	-	273	O
conjunctivitis	-	277	O
(	-	292	O
patient	-	293	O
1	-	301	O
)	-	302	O
.	-	303	O

The	7582165	305	O
purpose	-	309	O
of	-	317	O
our	-	320	O
study	-	324	O
was	-	330	O
to	-	334	O
determine	-	337	O
the	-	347	O
cause	-	351	O
of	-	357	O
the	-	360	O
patients	-	364	O
'	-	372	O
reactions	-	374	O
,	-	383	O
the	-	385	O
immunological	-	389	O
mechanisms	-	403	O
involved	-	414	O
and	-	423	O
whether	-	427	O
these	-	435	O
patients	-	441	O
would	-	450	O
be	-	456	O
able	-	459	O
to	-	464	O
tolerate	-	467	O
any	-	476	O
kind	-	480	O
of	-	485	O
corticoid	-	488	O
.	-	497	O

Clinical	7582165	499	O
examinations	-	508	O
and	-	521	O
skin	-	525	O
,	-	529	O
oral	-	531	O
and	-	536	O
parenteral	-	540	O
challenges	-	551	O
with	-	562	O
different	-	567	O
corticosteroids	-	577	B
and	-	593	O
ELISA	-	597	O
tests	-	603	O
were	-	609	O
performed	-	614	O
.	-	623	O

In	7582165	625	O
the	-	628	O
two	-	632	O
patients	-	636	O
,	-	644	O
skin	-	646	O
and	-	651	O
ELISA	-	655	O
tests	-	661	O
with	-	667	O
paramethasone	-	672	B
were	-	686	O
negative	-	691	O
,	-	699	O
as	-	701	O
was	-	704	O
the	-	708	O
prick	-	712	O
test	-	718	O
with	-	723	O
each	-	728	O
of	-	733	O
its	-	736	O
excipients	-	740	O
.	-	750	O

A	7582165	752	O
single	-	754	O
-	-	760	O
blind	-	761	O
parenteral	-	767	O
challenge	-	778	O
with	-	788	O
Triniol	-	793	O
was	-	801	O
positive	-	805	O
in	-	814	O
both	-	817	O
patients	-	822	O
after	-	831	O
the	-	837	O
administration	-	841	O
of	-	856	O
1	-	859	O
ml	-	861	O
of	-	864	O
the	-	867	O
drug	-	871	O
,	-	875	O
and	-	877	O
negative	-	881	O
with	-	890	O
its	-	895	O
excipients	-	899	O
.	-	909	O

We	7582165	911	O
also	-	914	O
carried	-	919	O
out	-	927	O
oral	-	931	O
and	-	936	O
parenteral	-	940	O
challenges	-	951	O
with	-	962	O
other	-	967	O
corticosteroids	-	973	B
and	-	989	O
found	-	993	O
intolerance	-	999	O
to	-	1011	O
some	-	1014	O
of	-	1019	O
them	-	1022	O
.	-	1026	O

These	7582165	1028	O
results	-	1034	O
suggest	-	1042	O
that	-	1050	O
paramethasone	-	1055	B
caused	-	1069	O
pseudoallergic	-	1076	O
reactions	-	1091	O
in	-	1101	O
our	-	1104	O
patients	-	1108	O
.	-	1116	O

Corticosteroids	7582165	1118	O
different	-	1134	O
from	-	1144	O
paramethasone	-	1149	B
also	-	1163	O
produced	-	1168	O
hypersensitivity	-	1177	O
reactions	-	1194	O
in	-	1204	O
these	-	1207	O
patients	-	1213	O
;	-	1221	O
however	-	1223	O
,	-	1230	O
a	-	1232	O
few	-	1234	O
of	-	1238	O
them	-	1241	O
were	-	1246	O
tolerated	-	1251	O
.	-	1260	O

The	7582165	1262	O
basic	-	1266	O
mechanisms	-	1272	O
of	-	1283	O
those	-	1286	O
reactions	-	1292	O
are	-	1302	O
not	-	1306	O
yet	-	1310	O
fully	-	1314	O
understood	-	1320	O
.	-	1330	O

To	7582165	1332	O
our	-	1335	O
knowledge	-	1339	O
,	-	1348	O
this	-	1350	O
is	-	1355	O
the	-	1358	O
first	-	1362	O
report	-	1368	O
of	-	1375	O
a	-	1378	O
pseudo	-	1380	O
-	-	1386	O
allergy	-	1387	O
caused	-	1395	O
by	-	1402	O
paramethasone	-	1405	B
.	-	1418	O

Valproic	16787750	0	B
acid	-	9	I
induced	-	14	O
encephalopathy	-	22	O
-	-	36	O
-	-	37	O
19	-	38	O
new	-	41	O
cases	-	45	O
in	-	51	O
Germany	-	54	O
from	-	62	O
1994	-	67	O
to	-	72	O
2003	-	75	O
-	-	79	O
-	-	80	O
a	-	81	O
side	-	83	O
effect	-	88	O
associated	-	95	O
to	-	106	O
VPA	-	109	B
-	-	112	O
therapy	-	113	O
not	-	121	O
only	-	125	O
in	-	130	O
young	-	133	O
children	-	139	O
.	-	147	O

Valproic	16787750	149	B
acid	-	158	I
(	-	163	O
VPA	-	164	B
)	-	167	O
is	-	169	O
a	-	172	O
broad	-	174	O
-	-	179	O
spectrum	-	180	O
antiepileptic	-	189	O
drug	-	203	O
and	-	208	O
is	-	212	O
usually	-	215	O
well	-	223	O
-	-	227	O
tolerated	-	228	O
.	-	237	O

Rare	16787750	239	O
serious	-	244	O
complications	-	252	O
may	-	266	O
occur	-	270	O
in	-	276	O
some	-	279	O
patients	-	284	O
,	-	292	O
including	-	294	O
haemorrhagic	-	304	O
pancreatitis	-	317	O
,	-	329	O
bone	-	331	O
marrow	-	336	O
suppression	-	343	O
,	-	354	O
VPA	-	356	B
-	-	359	O
induced	-	360	O
hepatotoxicity	-	368	O
and	-	383	O
VPA	-	387	B
-	-	390	O
induced	-	391	O
encephalopathy	-	399	O
.	-	413	O

The	16787750	415	O
typical	-	419	O
signs	-	427	O
of	-	433	O
VPA	-	436	B
-	-	439	O
induced	-	440	O
encephalopathy	-	448	O
are	-	463	O
impaired	-	467	O
consciousness	-	476	O
,	-	489	O
sometimes	-	491	O
marked	-	501	O
EEG	-	508	O
background	-	512	O
slowing	-	523	O
,	-	530	O
increased	-	532	O
seizure	-	542	O
frequency	-	550	O
,	-	559	O
with	-	561	O
or	-	566	O
without	-	569	O
hyperammonemia	-	577	O
.	-	591	O

There	16787750	593	O
is	-	599	O
still	-	602	O
no	-	608	O
proof	-	611	O
of	-	617	O
causative	-	620	O
effect	-	630	O
of	-	637	O
VPA	-	640	B
in	-	644	O
patients	-	647	O
with	-	656	O
encephalopathy	-	661	O
,	-	675	O
but	-	677	O
only	-	681	O
of	-	686	O
an	-	689	O
association	-	692	O
with	-	704	O
an	-	709	O
assumed	-	712	O
causal	-	720	O
relation	-	727	O
.	-	735	O

We	16787750	737	O
report	-	740	O
19	-	747	O
patients	-	750	O
with	-	759	O
VPA	-	764	B
-	-	767	O
associated	-	768	O
encephalopathy	-	779	O
in	-	794	O
Germany	-	797	O
from	-	805	O
the	-	810	O
years	-	814	O
1994	-	820	O
to	-	825	O
2003	-	828	O
,	-	832	O
none	-	834	O
of	-	839	O
whom	-	842	O
had	-	847	O
been	-	851	O
published	-	856	O
previously	-	866	O
.	-	876	O

Haemolytic	3173180	0	O
-	-	10	O
uraemic	-	11	O
syndrome	-	19	O
after	-	28	O
treatment	-	34	O
with	-	44	O
metronidazole	-	49	B
.	-	62	O

This	3173180	64	O
paper	-	69	O
describes	-	75	O
the	-	85	O
clinical	-	89	O
features	-	98	O
of	-	107	O
six	-	110	O
children	-	114	O
who	-	123	O
developed	-	127	O
the	-	137	O
haemolytic	-	141	O
-	-	151	O
uraemic	-	152	O
syndrome	-	160	O
after	-	169	O
treatment	-	175	O
with	-	185	O
metronidazole	-	190	B
.	-	203	O

These	3173180	205	O
children	-	211	O
were	-	220	O
older	-	225	O
and	-	231	O
were	-	235	O
more	-	240	O
likely	-	245	O
to	-	252	O
have	-	255	O
undergone	-	260	O
recent	-	270	O
bowel	-	277	O
surgery	-	283	O
than	-	291	O
are	-	296	O
other	-	300	O
children	-	306	O
with	-	315	O
this	-	320	O
condition	-	325	O
.	-	334	O

While	3173180	336	O
the	-	342	O
involvement	-	346	O
of	-	358	O
metronidazole	-	361	B
in	-	375	O
the	-	378	O
aetiology	-	382	O
of	-	392	O
the	-	395	O
haemolytic	-	399	O
-	-	409	O
uraemic	-	410	O
syndrome	-	418	O
is	-	427	O
not	-	430	O
established	-	434	O
firmly	-	446	O
,	-	452	O
the	-	454	O
action	-	458	O
of	-	465	O
this	-	468	O
drug	-	473	O
in	-	478	O
sensitizing	-	481	O
tissues	-	493	O
to	-	501	O
oxidation	-	504	O
injury	-	514	O
and	-	521	O
the	-	525	O
reported	-	529	O
evidence	-	538	O
of	-	547	O
oxidation	-	550	O
changes	-	560	O
in	-	568	O
the	-	571	O
haemolytic	-	575	O
-	-	585	O
uraemic	-	586	O
syndrome	-	594	O
suggest	-	603	O
a	-	611	O
possible	-	613	O
link	-	622	O
between	-	627	O
metronidazole	-	635	B
treatment	-	649	O
and	-	659	O
some	-	663	O
cases	-	668	O
of	-	674	O
the	-	677	O
haemolytic	-	681	O
-	-	691	O
uraemic	-	692	O
syndrome	-	700	O
.	-	708	O

Risk	8996652	0	O
factors	-	5	O
of	-	13	O
sensorineural	-	16	O
hearing	-	30	O
loss	-	38	O
in	-	43	O
preterm	-	46	O
infants	-	54	O
.	-	61	O

Among	8996652	63	O
547	-	69	O
preterm	-	73	O
infants	-	81	O
of	-	89	O
<	-	92	O
or	-	94	O
=	-	97	O
34	-	99	O
weeks	-	102	O
gestation	-	108	O
born	-	118	O
between	-	123	O
1987	-	131	O
and	-	136	O
1991	-	140	O
,	-	144	O
8	-	146	O
children	-	148	O
(	-	157	O
1	-	158	O
.	-	159	O
46	-	160	O
%	-	162	O
)	-	163	O
developed	-	165	O
severe	-	175	O
progressive	-	182	O
and	-	194	O
bilateral	-	198	O
sensorineural	-	208	O
hearing	-	222	O
loss	-	230	O
.	-	234	O

Perinatal	8996652	236	O
risk	-	246	O
factors	-	251	O
of	-	259	O
infants	-	262	O
with	-	270	O
hearing	-	275	O
loss	-	283	O
were	-	288	O
compared	-	293	O
with	-	302	O
those	-	307	O
of	-	313	O
two	-	316	O
control	-	320	O
groups	-	328	O
matched	-	335	O
for	-	343	O
gestation	-	347	O
and	-	357	O
birth	-	361	O
weight	-	367	O
and	-	374	O
for	-	378	O
perinatal	-	382	O
complications	-	392	O
.	-	405	O

Our	8996652	407	O
observations	-	411	O
demonstrated	-	424	O
an	-	437	O
association	-	440	O
of	-	452	O
hearing	-	455	O
loss	-	463	O
with	-	468	O
a	-	473	O
higher	-	475	O
incidence	-	482	O
of	-	492	O
perinatal	-	495	O
complications	-	505	O
.	-	518	O

Ototoxicity	8996652	520	O
appeared	-	532	O
closely	-	541	O
related	-	549	O
to	-	557	O
a	-	560	O
prolonged	-	562	O
administration	-	572	O
and	-	587	O
higher	-	591	O
total	-	598	O
dose	-	604	O
of	-	609	O
ototoxic	-	612	O
drugs	-	621	O
,	-	626	O
particularly	-	628	O
aminoglycosides	-	641	B
and	-	657	O
furosemide	-	661	B
.	-	671	O

Finally	8996652	673	O
,	-	680	O
we	-	682	O
strongly	-	685	O
recommend	-	694	O
to	-	704	O
prospectively	-	707	O
and	-	721	O
regularly	-	725	O
perform	-	735	O
audiologic	-	743	O
assessment	-	754	O
in	-	765	O
sick	-	768	O
preterm	-	773	O
children	-	781	O
as	-	790	O
hearing	-	793	O
loss	-	801	O
is	-	806	O
of	-	809	O
delayed	-	812	O
onset	-	820	O
and	-	826	O
in	-	830	O
most	-	833	O
cases	-	838	O
bilateral	-	844	O
and	-	854	O
severe	-	858	O
.	-	864	O

Pharmacokinetic	84204	0	O
and	-	16	O
clinical	-	20	O
studies	-	29	O
in	-	37	O
patients	-	40	O
with	-	49	O
cimetidine	-	54	B
-	-	64	O
associated	-	65	O
mental	-	76	O
confusion	-	83	O
.	-	92	O

15	84204	94	O
cases	-	97	O
of	-	103	O
cimetidine	-	106	B
-	-	116	O
associated	-	117	O
mental	-	128	O
confusion	-	135	O
have	-	145	O
been	-	150	O
reported	-	155	O
.	-	163	O

In	84204	165	O
order	-	168	O
that	-	174	O
this	-	179	O
syndrome	-	184	O
might	-	193	O
be	-	199	O
investigated	-	202	O
changes	-	215	O
in	-	223	O
mental	-	226	O
status	-	233	O
(	-	240	O
M	-	241	O
.	-	242	O
S	-	243	O
.	-	244	O
)	-	245	O
were	-	247	O
correlated	-	252	O
with	-	263	O
serum	-	268	O
concentrations	-	274	O
and	-	289	O
renal	-	293	O
and	-	299	O
hepatic	-	303	O
function	-	311	O
in	-	320	O
36	-	323	O
patients	-	326	O
,	-	334	O
30	-	336	O
patients	-	339	O
had	-	348	O
no	-	352	O
M	-	355	O
.	-	356	O
S	-	357	O
.	-	358	O
change	-	360	O
on	-	367	O
cimetidine	-	370	B
and	-	381	O
6	-	385	O
had	-	387	O
moderate	-	391	O
to	-	400	O
severe	-	403	O
changes	-	410	O
.	-	417	O

These	84204	419	O
6	-	425	O
patients	-	427	O
had	-	436	O
both	-	440	O
renal	-	445	O
and	-	451	O
liver	-	455	O
dysfunction	-	461	O
(	-	473	O
P	-	474	O
less	-	476	O
than	-	481	O
0	-	486	O
.	-	487	O
05	-	488	O
)	-	490	O
,	-	491	O
as	-	493	O
well	-	496	O
as	-	501	O
cimetidine	-	504	B
trough	-	515	O
-	-	521	O
concentrations	-	522	O
of	-	537	O
more	-	540	O
than	-	545	O
1	-	550	O
.	-	551	O
25	-	552	O
microgram	-	555	O
/	-	564	O
ml	-	565	O
(	-	568	O
P	-	569	O
less	-	571	O
than	-	576	O
0	-	581	O
.	-	582	O
05	-	583	O
)	-	585	O
.	-	586	O

The	84204	588	O
severity	-	592	O
of	-	601	O
M	-	604	O
.	-	605	O
S	-	606	O
.	-	607	O
changes	-	609	O
increased	-	617	O
as	-	627	O
trough	-	630	O
-	-	636	O
concentrations	-	637	O
rose	-	652	O
,	-	656	O
5	-	658	O
patients	-	660	O
had	-	669	O
lumbar	-	673	O
puncture	-	680	O
.	-	688	O

The	84204	690	O
cerebrospinal	-	694	O
fluid	-	708	O
:	-	713	O
serum	-	715	O
ratio	-	721	O
of	-	727	O
cimetidine	-	730	B
concentrations	-	741	O
was	-	756	O
0	-	760	O
.	-	761	O
24	-	762	O
:	-	764	O
1	-	765	O
and	-	767	O
indicates	-	771	O
that	-	781	O
cimetidine	-	786	B
passes	-	797	O
the	-	804	O
blood	-	808	O
-	-	813	O
brain	-	814	O
barrier	-	820	O
;	-	827	O
it	-	829	O
also	-	832	O
raises	-	837	O
the	-	844	O
possibility	-	848	O
that	-	860	O
M	-	865	O
.	-	866	O
S	-	867	O
.	-	868	O
changes	-	870	O
are	-	878	O
due	-	882	O
to	-	886	O
blockade	-	889	O
of	-	898	O
histamine	-	901	B
H2	-	911	O
-	-	913	O
receptors	-	914	O
in	-	924	O
the	-	927	O
central	-	931	O
nervous	-	939	O
system	-	947	O
.	-	953	O

Patients	84204	955	O
likely	-	964	O
to	-	971	O
have	-	974	O
both	-	979	O
raised	-	984	O
trough	-	991	O
-	-	997	O
concentrations	-	998	O
and	-	1013	O
mental	-	1017	O
confusion	-	1024	O
are	-	1034	O
those	-	1038	O
with	-	1044	O
both	-	1049	O
severe	-	1054	O
renal	-	1061	O
and	-	1067	O
hepatic	-	1071	O
dysfunction	-	1079	O
.	-	1090	O

They	84204	1092	O
should	-	1097	O
be	-	1104	O
closely	-	1107	O
observed	-	1115	O
and	-	1124	O
should	-	1128	O
be	-	1135	O
given	-	1138	O
reduced	-	1144	O
doses	-	1152	O
of	-	1158	O
cimetidine	-	1161	B
.	-	1171	O

Different	9862868	0	O
lobular	-	10	O
distributions	-	18	O
of	-	32	O
altered	-	35	O
hepatocyte	-	43	O
tight	-	54	O
junctions	-	60	O
in	-	70	O
rat	-	73	O
models	-	77	O
of	-	84	O
intrahepatic	-	87	O
and	-	100	O
extrahepatic	-	104	O
cholestasis	-	117	O
.	-	128	O

Hepatocyte	9862868	130	O
tight	-	141	O
junctions	-	147	O
(	-	157	O
TJs	-	158	O
)	-	161	O
,	-	162	O
the	-	164	O
only	-	168	O
intercellular	-	173	O
barrier	-	187	O
between	-	195	O
the	-	203	O
sinusoidal	-	207	O
and	-	218	O
the	-	222	O
canalicular	-	226	O
spaces	-	238	O
,	-	244	O
play	-	246	O
a	-	251	O
key	-	253	O
role	-	257	O
in	-	262	O
bile	-	265	O
formation	-	270	O
.	-	279	O

Although	9862868	281	O
hepatocyte	-	290	O
TJs	-	301	O
are	-	305	O
impaired	-	309	O
in	-	318	O
cholestasis	-	321	O
,	-	332	O
attempts	-	334	O
to	-	343	O
localize	-	346	O
the	-	355	O
precise	-	359	O
site	-	367	O
of	-	372	O
hepatocyte	-	375	O
TJ	-	386	O
damage	-	389	O
by	-	396	O
freeze	-	399	O
-	-	405	O
fracture	-	406	O
electron	-	415	O
microscopy	-	424	O
have	-	435	O
produced	-	440	O
limited	-	449	O
information	-	457	O
.	-	468	O

Recently	9862868	470	O
,	-	478	O
several	-	480	O
TJ	-	488	O
-	-	490	O
associated	-	491	O
proteins	-	502	O
like	-	511	O
ZO	-	516	O
-	-	518	O
1	-	519	O
and	-	521	O
7H6	-	525	O
have	-	529	O
been	-	534	O
identified	-	539	O
and	-	550	O
characterized	-	554	O
.	-	567	O

Immunolocalization	9862868	569	O
of	-	588	O
7H6	-	591	O
appears	-	595	O
to	-	603	O
closely	-	606	O
correlate	-	614	O
with	-	624	O
paracellular	-	629	O
permeability	-	642	O
.	-	654	O

We	9862868	656	O
used	-	659	O
rat	-	664	O
models	-	668	O
of	-	675	O
intrahepatic	-	678	O
cholestasis	-	691	O
by	-	703	O
ethinyl	-	706	B
estradiol	-	714	I
(	-	724	O
EE	-	725	B
)	-	727	O
treatment	-	729	O
and	-	739	O
extrahepatic	-	743	O
cholestasis	-	756	O
by	-	768	O
bile	-	771	O
duct	-	776	O
ligation	-	781	O
(	-	790	O
BDL	-	791	O
)	-	794	O
to	-	796	O
precisely	-	799	O
determine	-	809	O
the	-	819	O
site	-	823	O
of	-	828	O
TJ	-	831	O
damage	-	834	O
.	-	840	O

Alterations	9862868	842	O
in	-	854	O
hepatocyte	-	857	O
TJs	-	868	O
were	-	872	O
assessed	-	877	O
by	-	886	O
double	-	889	O
-	-	895	O
immunolabeling	-	896	O
for	-	911	O
7H6	-	915	O
and	-	919	O
ZO	-	923	O
-	-	925	O
1	-	926	O
using	-	928	O
a	-	934	O
confocal	-	936	O
laser	-	945	O
scanning	-	951	O
microscope	-	960	O
.	-	970	O

In	9862868	972	O
control	-	975	O
rats	-	983	O
,	-	987	O
immunostaining	-	989	O
for	-	1004	O
7H6	-	1008	O
and	-	1012	O
ZO	-	1016	O
-	-	1018	O
1	-	1019	O
colocalized	-	1021	O
to	-	1033	O
outline	-	1036	O
bile	-	1044	O
canaliculi	-	1049	O
in	-	1060	O
a	-	1063	O
continuous	-	1065	O
fashion	-	1076	O
.	-	1083	O

In	9862868	1085	O
contrast	-	1088	O
,	-	1096	O
7H6	-	1098	O
and	-	1102	O
ZO	-	1106	O
-	-	1108	O
1	-	1109	O
immunostaining	-	1111	O
was	-	1126	O
more	-	1130	O
discontinuous	-	1135	O
,	-	1148	O
outlining	-	1150	O
the	-	1160	O
bile	-	1164	O
canaliculi	-	1169	O
after	-	1180	O
BDL	-	1186	O
.	-	1189	O

Immunostaining	9862868	1191	O
for	-	1206	O
7H6	-	1210	O
,	-	1213	O
not	-	1215	O
ZO	-	1219	O
-	-	1221	O
1	-	1222	O
,	-	1223	O
decreased	-	1225	O
and	-	1235	O
predominantly	-	1239	O
appeared	-	1253	O
as	-	1262	O
discrete	-	1265	O
signals	-	1274	O
in	-	1282	O
the	-	1285	O
submembranous	-	1289	O
cytoplasm	-	1303	O
of	-	1313	O
periportal	-	1316	O
hepatocytes	-	1327	O
after	-	1339	O
BDL	-	1345	O
.	-	1348	O

After	9862868	1350	O
EE	-	1356	B
treatment	-	1359	O
,	-	1368	O
changes	-	1370	O
in	-	1378	O
immunostaining	-	1381	O
for	-	1396	O
7H6	-	1400	O
and	-	1404	O
ZO	-	1408	O
-	-	1410	O
1	-	1411	O
were	-	1413	O
similar	-	1418	O
to	-	1426	O
those	-	1429	O
seen	-	1435	O
in	-	1440	O
periportal	-	1443	O
hepatocytes	-	1454	O
after	-	1466	O
BDL	-	1472	O
,	-	1475	O
but	-	1477	O
distributed	-	1481	O
more	-	1493	O
diffusely	-	1498	O
throughout	-	1508	O
the	-	1519	O
lobule	-	1523	O
.	-	1529	O

This	9862868	1531	O
study	-	1536	O
is	-	1542	O
the	-	1545	O
first	-	1549	O
to	-	1555	O
demonstrate	-	1558	O
that	-	1570	O
impairment	-	1575	O
of	-	1586	O
hepatocyte	-	1589	O
TJs	-	1600	O
occurs	-	1604	O
heterogenously	-	1611	O
in	-	1626	O
the	-	1629	O
liver	-	1633	O
lobule	-	1639	O
after	-	1646	O
BDL	-	1652	O
and	-	1656	O
suggests	-	1660	O
that	-	1669	O
BDL	-	1674	O
and	-	1678	O
EE	-	1682	B
treatments	-	1685	O
produce	-	1696	O
different	-	1704	O
lobular	-	1714	O
distributions	-	1722	O
of	-	1736	O
increased	-	1739	O
paracellular	-	1749	O
permeability	-	1762	O
.	-	1774	O

Long	15515654	0	O
term	-	5	O
audiological	-	10	O
evaluation	-	23	O
of	-	34	O
beta	-	37	O
-	-	41	O
thalassemic	-	42	O
patients	-	54	O
.	-	62	O

OBJECTIVE	15515654	64	O
:	-	73	O
The	-	75	O
objective	-	79	O
of	-	89	O
this	-	92	O
study	-	97	O
was	-	103	O
to	-	107	O
identify	-	110	O
the	-	119	O
incidence	-	123	O
and	-	133	O
to	-	137	O
monitor	-	140	O
the	-	148	O
progression	-	152	O
of	-	164	O
hearing	-	167	O
loss	-	175	O
in	-	180	O
children	-	183	O
and	-	192	O
young	-	196	O
adults	-	202	O
with	-	209	O
beta	-	214	O
-	-	218	O
thalassemia	-	219	O
major	-	231	O
.	-	236	O

METHODS	15515654	238	O
:	-	245	O

One	15515654	247	O
hundred	-	251	O
and	-	259	O
four	-	263	O
(	-	268	O
104	-	269	O
)	-	272	O
patients	-	274	O
aged	-	283	O
6	-	288	O
-	-	289	O
35	-	290	O
years	-	293	O
(	-	299	O
mean	-	300	O
17	-	305	O
,	-	307	O
2	-	308	O
years	-	310	O
)	-	315	O
participated	-	317	O
in	-	330	O
the	-	333	O
study	-	337	O
.	-	342	O

All	15515654	344	O
patients	-	348	O
were	-	357	O
on	-	362	O
a	-	365	O
regular	-	367	O
transfusion	-	375	O
-	-	386	O
chelation	-	387	O
program	-	397	O
maintaining	-	405	O
a	-	417	O
mean	-	419	O
hemoglobin	-	424	O
level	-	435	O
of	-	441	O
9	-	444	O
.	-	445	O
5	-	446	O
gr	-	448	O
/	-	450	O
dl	-	451	O
.	-	453	O

Subjects	15515654	455	O
were	-	464	O
receiving	-	469	O
desferrioxamine	-	479	B
(	-	495	O
DFO	-	496	B
)	-	499	O
chelation	-	501	O
treatment	-	511	O
with	-	521	O
a	-	526	O
mean	-	528	O
daily	-	533	O
dose	-	539	O
of	-	544	O
50	-	547	O
-	-	549	O
60	-	550	O
mg	-	553	O
/	-	555	O
kg	-	556	O
,	-	558	O
5	-	560	O
-	-	561	O
6	-	562	O
days	-	564	O
a	-	569	O
week	-	571	O
during	-	576	O
the	-	583	O
first	-	587	O
six	-	593	O
years	-	597	O
of	-	603	O
the	-	606	O
study	-	610	O
,	-	615	O
which	-	617	O
was	-	623	O
then	-	627	O
reduced	-	632	O
to	-	640	O
40	-	643	O
-	-	645	O
50	-	646	O
mg	-	649	O
/	-	651	O
kg	-	652	O
for	-	655	O
the	-	659	O
following	-	663	O
eight	-	673	O
years	-	679	O
.	-	684	O

Patients	15515654	686	O
were	-	695	O
followed	-	700	O
for	-	709	O
8	-	713	O
-	-	714	O
14	-	715	O
years	-	718	O
.	-	723	O

RESULTS	15515654	725	O
:	-	732	O

Overall	15515654	734	O
,	-	741	O
21	-	743	O
out	-	746	O
of	-	750	O
104	-	753	O
patients	-	757	O
(	-	766	O
20	-	767	O
.	-	769	O
2	-	770	O
%	-	771	O
)	-	772	O
presented	-	774	O
with	-	784	O
high	-	789	O
frequency	-	794	O
sensorineural	-	804	O
hearing	-	818	O
loss	-	826	O
(	-	831	O
SNHL	-	832	O
)	-	836	O
,	-	837	O
either	-	839	O
unilateral	-	846	O
or	-	857	O
bilateral	-	860	O
.	-	869	O

No	15515654	871	O
ototoxic	-	874	O
factor	-	883	O
,	-	889	O
other	-	891	O
than	-	897	O
DFO	-	902	B
,	-	905	O
was	-	907	O
present	-	911	O
in	-	919	O
any	-	922	O
of	-	926	O
the	-	929	O
patients	-	933	O
.	-	941	O

Patients	15515654	943	O
with	-	952	O
SNHL	-	957	O
presented	-	962	O
with	-	972	O
relatively	-	977	O
lower	-	988	O
serum	-	994	O
ferritin	-	1000	O
levels	-	1009	O
than	-	1016	O
those	-	1021	O
with	-	1027	O
normal	-	1032	O
hearing	-	1039	O
,	-	1046	O
however	-	1048	O
,	-	1055	O
no	-	1057	O
statistically	-	1060	O
significant	-	1074	O
difference	-	1086	O
was	-	1097	O
observed	-	1101	O
.	-	1109	O

Subjects	15515654	1111	O
with	-	1120	O
SNHL	-	1125	O
were	-	1130	O
submitted	-	1135	O
to	-	1145	O
DFO	-	1148	B
reduction	-	1152	O
or	-	1162	O
temporary	-	1165	O
withdrawal	-	1175	O
.	-	1185	O

Following	15515654	1187	O
intervention	-	1197	O
,	-	1209	O
7	-	1211	O
out	-	1213	O
of	-	1217	O
21	-	1220	O
affected	-	1223	O
patients	-	1232	O
recovered	-	1241	O
,	-	1250	O
10	-	1252	O
remained	-	1255	O
stable	-	1264	O
and	-	1271	O
4	-	1275	O
demonstrated	-	1277	O
aggravation	-	1290	O
.	-	1301	O

CONCLUSION	15515654	1303	O
:	-	1313	O

The	15515654	1315	O
findings	-	1319	O
are	-	1328	O
indicative	-	1332	O
of	-	1343	O
DFO	-	1346	B
's	-	1349	O
contributing	-	1352	O
role	-	1365	O
in	-	1370	O
the	-	1373	O
development	-	1377	O
of	-	1389	O
hearing	-	1392	O
impairment	-	1400	O
.	-	1410	O

Regular	15515654	1412	O
audiologic	-	1420	O
evaluation	-	1431	O
is	-	1442	O
imperative	-	1445	O
in	-	1456	O
all	-	1459	O
thalassemic	-	1463	O
patients	-	1475	O
so	-	1484	O
that	-	1487	O
early	-	1492	O
changes	-	1498	O
may	-	1506	O
be	-	1510	O
recognized	-	1513	O
and	-	1524	O
treatment	-	1528	O
may	-	1538	O
be	-	1542	O
judiciously	-	1545	O
adjusted	-	1557	O
in	-	1566	O
order	-	1569	O
to	-	1575	O
prevent	-	1578	O
or	-	1586	O
reverse	-	1589	O
hearing	-	1597	O
impairment	-	1605	O
.	-	1615	O

Design	2024540	0	O
and	-	7	O
analysis	-	11	O
of	-	20	O
the	-	23	O
HYPREN	-	27	O
-	-	33	O
trial	-	34	O
:	-	39	O
safety	-	41	O
of	-	48	O
enalapril	-	51	B
and	-	61	O
prazosin	-	65	B
in	-	74	O
the	-	77	O
initial	-	81	O
treatment	-	89	O
phase	-	99	O
of	-	105	O
patients	-	108	O
with	-	117	O
congestive	-	122	O
heart	-	133	O
failure	-	139	O
.	-	146	O

Since	2024540	148	O
the	-	154	O
introduction	-	158	O
of	-	171	O
angiotensin	-	174	B
converting	-	186	I
enzyme	-	197	I
(	-	204	I
ACE	-	205	I
)	-	208	I
inhibitors	-	210	I
into	-	221	O
the	-	226	O
adjunctive	-	230	O
treatment	-	241	O
of	-	251	O
patients	-	254	O
with	-	263	O
congestive	-	268	O
heart	-	279	O
failure	-	285	O
,	-	292	O
cases	-	294	O
of	-	300	O
severe	-	303	O
hypotension	-	310	O
,	-	321	O
especially	-	323	O
on	-	334	O
the	-	337	O
first	-	341	O
day	-	347	O
of	-	351	O
treatment	-	354	O
,	-	363	O
have	-	365	O
occasionally	-	370	O
been	-	383	O
reported	-	388	O
.	-	396	O

To	2024540	398	O
assess	-	401	O
the	-	408	O
safety	-	412	O
of	-	419	O
the	-	422	O
ACE	-	426	B
inhibitor	-	430	I
enalapril	-	440	B
a	-	450	O
multicenter	-	452	O
,	-	463	O
randomized	-	465	O
,	-	475	O
prazosin	-	477	B
-	-	485	O
controlled	-	486	O
trial	-	497	O
was	-	503	O
designed	-	507	O
that	-	516	O
compared	-	521	O
the	-	530	O
incidence	-	534	O
and	-	544	O
severity	-	548	O
of	-	557	O
symptomatic	-	560	O
hypotension	-	572	O
on	-	584	O
the	-	587	O
first	-	591	O
day	-	597	O
of	-	601	O
treatment	-	604	O
.	-	613	O

Trial	2024540	615	O
medication	-	621	O
was	-	632	O
2	-	636	O
.	-	637	O
5	-	638	O
mg	-	640	O
enalapril	-	643	B
or	-	653	O
0	-	656	O
.	-	657	O
5	-	658	O
prazosin	-	660	B
.	-	668	O

Subjects	2024540	670	O
were	-	679	O
1210	-	684	O
inpatients	-	689	O
with	-	700	O
New	-	705	O
York	-	709	O
Heart	-	714	O
Association	-	720	O
(	-	732	O
NYHA	-	733	O
)	-	737	O
functional	-	739	O
class	-	750	O
II	-	756	O
and	-	759	O
III	-	763	O
.	-	766	O

Patients	2024540	768	O
who	-	777	O
received	-	781	O
enalapril	-	790	B
experienced	-	800	O
clinically	-	812	O
and	-	823	O
statistically	-	827	O
significantly	-	841	O
less	-	855	O
symptomatic	-	860	O
hypotension	-	872	O
(	-	884	O
5	-	885	O
.	-	886	O
2	-	887	O
%	-	888	O
)	-	889	O
than	-	891	O
the	-	896	O
patients	-	900	O
who	-	909	O
received	-	913	O
prazosin	-	922	B
(	-	931	O
12	-	932	O
.	-	934	O
9	-	935	O
%	-	936	O
)	-	937	O
.	-	938	O

All	2024540	940	O
patients	-	944	O
recovered	-	953	O
.	-	962	O

It	2024540	964	O
was	-	967	O
concluded	-	971	O
that	-	981	O
treatment	-	986	O
with	-	996	O
enalapril	-	1001	B
was	-	1011	O
well	-	1015	O
tolerated	-	1020	O
and	-	1030	O
it	-	1034	O
is	-	1037	O
,	-	1039	O
therefore	-	1041	O
,	-	1050	O
unreasonable	-	1052	O
to	-	1065	O
restrict	-	1068	O
the	-	1077	O
initiation	-	1081	O
of	-	1092	O
treatment	-	1095	O
with	-	1105	O
enalapril	-	1110	B
to	-	1120	O
inpatients	-	1123	O
.	-	1133	O

Antagonism	12090760	0	O
between	-	11	O
interleukin	-	19	O
3	-	31	O
and	-	33	O
erythropoietin	-	37	O
in	-	52	O
mice	-	55	O
with	-	60	O
azidothymidine	-	65	B
-	-	79	O
induced	-	80	O
anemia	-	88	O
and	-	95	O
in	-	99	O
bone	-	102	O
marrow	-	107	O
endothelial	-	114	O
cells	-	126	O
.	-	131	O

Azidothymidine	12090760	133	B
(	-	148	O
AZT	-	149	B
)	-	152	O
-	-	153	O
induced	-	154	O
anemia	-	162	O
in	-	169	O
mice	-	172	O
can	-	177	O
be	-	181	O
reversed	-	184	O
by	-	193	O
the	-	196	O
administration	-	200	O
of	-	215	O
IGF	-	218	O
-	-	221	O
IL	-	222	O
-	-	224	O
3	-	225	O
(	-	227	O
fusion	-	228	O
protein	-	235	O
of	-	243	O
insulin	-	246	O
-	-	253	O
like	-	254	O
growth	-	259	O
factor	-	266	O
II	-	273	O
(	-	276	O
IGF	-	277	O
II	-	281	O
)	-	283	O
and	-	285	O
interleukin	-	289	O
3	-	301	O
)	-	302	O
.	-	303	O

Although	12090760	305	O
interleukin	-	314	O
3	-	326	O
(	-	328	O
IL	-	329	O
-	-	331	O
3	-	332	O
)	-	333	O
and	-	335	O
erythropoietin	-	339	O
(	-	354	O
EPO	-	355	O
)	-	358	O
are	-	360	O
known	-	364	O
to	-	370	O
act	-	373	O
synergistically	-	377	O
on	-	393	O
hematopoietic	-	396	O
cell	-	410	O
proliferation	-	415	O
in	-	429	O
vitro	-	432	O
,	-	437	O
injection	-	439	O
of	-	449	O
IGF	-	452	O
-	-	455	O
IL	-	456	O
-	-	458	O
3	-	459	O
and	-	461	O
EPO	-	465	O
in	-	469	O
AZT	-	472	B
-	-	475	O
treated	-	476	O
mice	-	484	O
resulted	-	489	O
in	-	498	O
a	-	501	O
reduction	-	503	O
of	-	513	O
red	-	516	O
cells	-	520	O
and	-	526	O
an	-	530	O
increase	-	533	O
of	-	542	O
plasma	-	545	O
EPO	-	552	O
levels	-	556	O
as	-	563	O
compared	-	566	O
to	-	575	O
animals	-	578	O
treated	-	586	O
with	-	594	O
IGF	-	599	O
-	-	602	O
IL	-	603	O
-	-	605	O
3	-	606	O
or	-	608	O
EPO	-	611	O
alone	-	615	O
.	-	620	O

We	12090760	622	O
tested	-	625	O
the	-	632	O
hypothesis	-	636	O
that	-	647	O
the	-	652	O
antagonistic	-	656	O
effect	-	669	O
of	-	676	O
IL	-	679	O
-	-	681	O
3	-	682	O
and	-	684	O
EPO	-	688	O
on	-	692	O
erythroid	-	695	O
cells	-	705	O
may	-	711	O
be	-	715	O
mediated	-	718	O
by	-	727	O
endothelial	-	730	O
cells	-	742	O
.	-	747	O

Bovine	12090760	749	O
liver	-	756	O
erythroid	-	762	O
cells	-	772	O
were	-	778	O
cultured	-	783	O
on	-	792	O
monolayers	-	795	O
of	-	806	O
human	-	809	O
bone	-	815	O
marrow	-	820	O
endothelial	-	827	O
cells	-	839	O
previously	-	845	O
treated	-	856	O
with	-	864	O
EPO	-	869	O
and	-	873	O
IGF	-	877	O
-	-	880	O
IL	-	881	O
-	-	883	O
3	-	884	O
.	-	885	O

There	12090760	887	O
was	-	893	O
a	-	897	O
significant	-	899	O
reduction	-	911	O
of	-	921	O
thymidine	-	924	B
incorporation	-	934	O
into	-	948	O
both	-	953	O
erythroid	-	958	O
and	-	968	O
endothelial	-	972	O
cells	-	984	O
in	-	990	O
cultures	-	993	O
pre	-	1002	O
-	-	1005	O
treated	-	1006	O
with	-	1014	O
IGF	-	1019	O
-	-	1022	O
IL	-	1023	O
-	-	1025	O
3	-	1026	O
and	-	1028	O
EPO	-	1032	O
.	-	1035	O

Endothelial	12090760	1037	O
cell	-	1049	O
culture	-	1054	O
supernatants	-	1062	O
separated	-	1075	O
by	-	1085	O
ultrafiltration	-	1088	O
and	-	1104	O
ultracentrifugation	-	1108	O
from	-	1128	O
cells	-	1133	O
treated	-	1139	O
with	-	1147	O
EPO	-	1152	O
and	-	1156	O
IL	-	1160	O
-	-	1162	O
3	-	1163	O
significantly	-	1165	O
reduced	-	1179	O
thymidine	-	1187	B
incorporation	-	1197	O
into	-	1211	O
erythroid	-	1216	O
cells	-	1226	O
as	-	1232	O
compared	-	1235	O
to	-	1244	O
identical	-	1247	O
fractions	-	1257	O
obtained	-	1267	O
from	-	1276	O
the	-	1281	O
media	-	1285	O
of	-	1291	O
cells	-	1294	O
cultured	-	1300	O
with	-	1309	O
EPO	-	1314	O
alone	-	1318	O
.	-	1323	O

These	12090760	1325	O
results	-	1331	O
suggest	-	1339	O
that	-	1347	O
endothelial	-	1352	O
cells	-	1364	O
treated	-	1370	O
simultaneously	-	1378	O
with	-	1393	O
EPO	-	1398	O
and	-	1402	O
IL	-	1406	O
-	-	1408	O
3	-	1409	O
have	-	1411	O
a	-	1416	O
negative	-	1418	O
effect	-	1427	O
on	-	1434	O
erythroid	-	1437	O
cell	-	1447	O
production	-	1452	O
.	-	1462	O

Interactive	7516729	0	O
effects	-	12	O
of	-	20	O
variations	-	23	O
in	-	34	O
[	-	37	O
Na	-	38	B
]	-	40	O
o	-	41	O
and	-	43	O
[	-	47	O
Ca	-	48	B
]	-	50	O
o	-	51	O
on	-	53	O
rat	-	56	O
atrial	-	60	O
spontaneous	-	67	O
frequency	-	79	O
.	-	88	O

The	7516729	90	O
effects	-	94	O
of	-	102	O
varying	-	105	O
the	-	113	O
extracellular	-	117	O
concentrations	-	131	O
of	-	146	O
Na	-	149	B
and	-	152	O
Ca	-	156	B
(	-	159	O
[	-	160	O
Na	-	161	B
]	-	163	O
o	-	164	O
and	-	166	O
[	-	170	O
Ca	-	171	B
]	-	173	O
o	-	174	O
)	-	175	O
on	-	177	O
both	-	180	O
,	-	184	O
the	-	186	O
spontaneous	-	190	O
beating	-	202	O
and	-	210	O
the	-	214	O
negative	-	218	O
chronotropic	-	227	O
action	-	240	O
of	-	247	O
verapamil	-	250	B
,	-	259	O
were	-	261	O
studied	-	266	O
in	-	274	O
the	-	277	O
isolated	-	281	O
rat	-	290	O
atria	-	294	O
.	-	299	O

Basal	7516729	301	O
frequency	-	307	O
(	-	317	O
BF	-	318	O
)	-	320	O
evaluated	-	322	O
by	-	332	O
surface	-	335	O
electrogram	-	343	O
was	-	355	O
223	-	359	O
+	-	363	O
/	-	364	O
-	-	365	O

4	7516729	367	O
beats	-	369	O
/	-	374	O
min	-	375	O
.	-	378	O

in	7516729	380	O
control	-	383	O
Krebs	-	391	O
-	-	396	O
Ringer	-	397	O
containing	-	404	O
137	-	415	O
mM	-	419	O
Na	-	422	B
and	-	425	O
1	-	429	O
.	-	430	O
35	-	431	O
mM	-	434	O
Ca	-	437	B
(	-	440	O
N	-	441	O
)	-	442	O
.	-	443	O

It	7516729	445	O
decreased	-	448	O
by	-	458	O
16	-	461	O
+	-	464	O
/	-	465	O
-	-	466	O

3	7516729	468	O
%	-	469	O
by	-	471	O
lowering	-	474	O
[	-	483	O
Na	-	484	B
]	-	486	O
o	-	487	O
to	-	489	O
78	-	492	O
mM	-	495	O
(	-	498	O
LNa	-	499	O
)	-	502	O
,	-	503	O
23	-	505	O
+	-	508	O
/	-	509	O
-	-	510	O
2	-	512	O
%	-	513	O
by	-	515	O
lowering	-	518	O
simultaneously	-	527	O
[	-	542	O
Na	-	543	B
]	-	545	O
o	-	546	O
to	-	548	O
78	-	551	O
mM	-	554	O
and	-	557	O
[	-	561	O
Ca	-	562	B
]	-	564	O
o	-	565	O
to	-	567	O
0	-	570	O
.	-	571	O
675	-	572	O
mM	-	576	O
(	-	579	O
LNa	-	580	O
+	-	583	O
LCa	-	584	O
)	-	587	O
and	-	589	O
31	-	593	O
+	-	596	O
/	-	597	O
-	-	598	O
5	-	600	O
%	-	601	O
by	-	603	O
lowering	-	606	O
[	-	615	O
Na	-	616	B
]	-	618	O
o	-	619	O
to	-	621	O
78	-	624	O
mM	-	627	O
plus	-	630	O
increasing	-	635	O
[	-	646	O
Ca	-	647	B
]	-	649	O
o	-	650	O
to	-	652	O
3	-	655	O
.	-	656	O
6	-	657	O
mM	-	659	O
(	-	662	O
LNa	-	663	O
+	-	666	O
HCa	-	667	O
)	-	670	O
.	-	671	O

At	7516729	673	O
normal	-	676	O
[	-	683	O
Na	-	684	B
]	-	686	O
o	-	687	O
,	-	688	O
decrease	-	690	O
(	-	699	O
0	-	700	O
.	-	701	O
675	-	702	O
mM	-	706	O
)	-	708	O
or	-	710	O
increase	-	713	O
(	-	722	O
3	-	723	O
.	-	724	O
6	-	725	O
mM	-	727	O
)	-	729	O
of	-	731	O
[	-	734	O
Ca	-	735	B
]	-	737	O
o	-	738	O
did	-	740	O
not	-	744	O
modify	-	748	O
BF	-	755	O
;	-	757	O
a	-	759	O
reduction	-	761	O
of	-	771	O
ten	-	774	O
times	-	778	O
(	-	784	O
0	-	785	O
.	-	786	O
135	-	787	O
mM	-	791	O
of	-	794	O
normal	-	797	O
[	-	804	O
Ca	-	805	B
]	-	807	O
o	-	808	O
was	-	810	O
effective	-	814	O
to	-	824	O
reduce	-	827	O
BF	-	834	O
by	-	837	O
40	-	840	O
+	-	843	O
/	-	844	O
-	-	845	O

13	7516729	847	O
%	-	849	O
.	-	850	O

All	7516729	852	O
negative	-	856	O
chronotropic	-	865	O
effects	-	878	O
were	-	886	O
BF	-	891	O
-	-	893	O
dependent	-	894	O
.	-	903	O

Dose	7516729	905	O
-	-	909	O
dependent	-	910	O
bradycardia	-	920	O
induced	-	932	O
by	-	940	O
verapamil	-	943	B
was	-	953	O
potentiated	-	957	O
by	-	969	O
LNa	-	972	O
,	-	975	O
LCa	-	977	O
,	-	980	O
and	-	982	O
HCa	-	986	O
.	-	989	O

Independent	7516729	991	O
but	-	1003	O
not	-	1007	O
additive	-	1011	O
effects	-	1020	O
of	-	1028	O
Na	-	1031	B
and	-	1034	O
Ca	-	1038	B
are	-	1041	O
shown	-	1045	O
by	-	1051	O
decreases	-	1054	O
in	-	1064	O
the	-	1067	O
values	-	1071	O
of	-	1078	O
[	-	1081	O
verapamil	-	1082	B
]	-	1091	O
o	-	1092	O
needed	-	1094	O
to	-	1101	O
reduce	-	1104	O
BF	-	1111	O
by	-	1114	O
30	-	1117	O
%	-	1119	O
(	-	1121	O
IC30	-	1122	O
)	-	1126	O
with	-	1128	O
the	-	1133	O
following	-	1137	O
order	-	1147	O
of	-	1153	O
inhibitory	-	1156	O
potency	-	1167	O
:	-	1174	O
LNa	-	1176	O
>	-	1180	O
LCa	-	1182	O
>	-	1186	O
HCa	-	1188	O
>	-	1192	O
N	-	1194	O
,	-	1195	O
resulting	-	1197	O
LNa	-	1207	O
+	-	1210	O
HCa	-	1211	O
similar	-	1215	O
to	-	1223	O
LNa	-	1226	O
.	-	1229	O

The	7516729	1231	O
[	-	1235	O
verapamil	-	1236	B
]	-	1245	O
o	-	1246	O
that	-	1248	O
arrested	-	1253	O
atrial	-	1262	O
beating	-	1269	O
(	-	1277	O
AC	-	1278	O
)	-	1280	O
was	-	1282	O
also	-	1286	O
potentiated	-	1291	O
with	-	1303	O
the	-	1308	O
order	-	1312	O
LNa	-	1318	O

=	7516729	1322	O
LNa	-	1324	O
+	-	1327	O
LCa	-	1328	O
=	-	1332	O
LNa	-	1334	O
+	-	1337	O
HCa	-	1338	O
=	-	1342	O
LCa	-	1344	O
>	-	1348	O
HCa	-	1350	O
=	-	1354	O

N	7516729	1356	O
.	-	1357	O

The	7516729	1359	O
results	-	1363	O
indicate	-	1371	O
that	-	1380	O
rat	-	1385	O
atrial	-	1389	O
spontaneous	-	1396	O
beating	-	1408	O
is	-	1416	O
more	-	1419	O
dependent	-	1424	O
on	-	1434	O
[	-	1437	O
Na	-	1438	B
]	-	1440	O
o	-	1441	O
than	-	1443	O
on	-	1448	O
[	-	1451	O
Ca	-	1452	B
]	-	1454	O
o	-	1455	O
in	-	1457	O
a	-	1460	O
range	-	1462	O
of	-	1468	O
+	-	1471	O
/	-	1472	O
-	-	1473	O

50	7516729	1475	O
%	-	1477	O
of	-	1479	O
their	-	1482	O
normal	-	1488	O
concentration	-	1495	O
.	-	1508	O

Also	7516729	1510	O
the	-	1515	O
enhancement	-	1519	O
of	-	1531	O
verapamil	-	1534	B
effects	-	1544	O
on	-	1552	O
atrial	-	1555	O
beating	-	1562	O
was	-	1570	O
more	-	1574	O
pronounced	-	1579	O
at	-	1590	O
LNa	-	1593	O
than	-	1597	O
at	-	1602	O
LCa	-	1605	O
.	-	1608	O
(	-	1609	O
ABSTRACT	-	1610	O
TRUNCATED	-	1619	O
AT	-	1629	O
250	-	1632	O
WORDS	-	1636	O
)	-	1641	O

Sodium	2802551	0	B
status	-	7	O
influences	-	14	O
chronic	-	25	O
amphotericin	-	33	B
B	-	46	I
nephrotoxicity	-	48	O
in	-	63	O
rats	-	66	O
.	-	70	O

The	2802551	72	O
nephrotoxic	-	76	O
potential	-	88	O
of	-	98	O
amphotericin	-	101	B
B	-	114	I
(	-	116	O
5	-	117	O
mg	-	119	O
/	-	121	O
kg	-	122	O
per	-	125	O
day	-	129	O
intraperitoneally	-	133	O
for	-	151	O
3	-	155	O
weeks	-	157	O
)	-	162	O
has	-	164	O
been	-	168	O
investigated	-	173	O
in	-	186	O
salt	-	189	O
-	-	193	O
depleted	-	194	O
,	-	202	O
normal	-	204	O
-	-	210	O
salt	-	211	O
,	-	215	O
and	-	217	O
salt	-	221	O
-	-	225	O
loaded	-	226	O
rats	-	233	O
.	-	237	O

In	2802551	239	O
salt	-	242	O
-	-	246	O
depleted	-	247	O
rats	-	256	O
,	-	260	O
amphotericin	-	262	B
B	-	275	I
decreased	-	277	O
creatinine	-	287	B
clearance	-	298	O
linearly	-	308	O
with	-	317	O
time	-	322	O
,	-	326	O
with	-	328	O
an	-	333	O
85	-	336	O
%	-	338	O
reduction	-	340	O
by	-	350	O
week	-	353	O
3	-	358	O
.	-	359	O

In	2802551	361	O
contrast	-	364	O
,	-	372	O
in	-	374	O
normal	-	377	O
-	-	383	O
salt	-	384	O
rats	-	389	O
creatinine	-	394	B
clearance	-	405	O
was	-	415	O
decreased	-	419	O
but	-	429	O
to	-	433	O
a	-	436	O
lesser	-	438	O
extent	-	445	O
at	-	452	O
week	-	455	O
2	-	460	O
and	-	462	O
3	-	466	O
,	-	467	O
and	-	469	O
in	-	473	O
salt	-	476	O
-	-	480	O
loaded	-	481	O
rats	-	488	O
creatinine	-	493	B
clearance	-	504	O
did	-	514	O
not	-	518	O
change	-	522	O
for	-	529	O
2	-	533	O
weeks	-	535	O
and	-	541	O
was	-	545	O
decreased	-	549	O
by	-	559	O
43	-	562	O
%	-	564	O
at	-	566	O
week	-	569	O
3	-	574	O
.	-	575	O

All	2802551	577	O
rats	-	581	O
in	-	586	O
the	-	589	O
sodium	-	593	B
-	-	599	O
depleted	-	600	O
group	-	609	O
had	-	615	O
histopathological	-	619	O
evidence	-	637	O
of	-	646	O
patchy	-	649	O
tubular	-	656	O
cytoplasmic	-	664	O
degeneration	-	676	O
in	-	689	O
tubules	-	692	O
that	-	700	O
was	-	705	O
not	-	709	O
observed	-	713	O
in	-	722	O
any	-	725	O
normal	-	729	O
-	-	735	O
salt	-	736	O
or	-	741	O
salt	-	744	O
-	-	748	O
loaded	-	749	O
rat	-	756	O
.	-	759	O

Concentrations	2802551	761	O
of	-	776	O
amphotericin	-	779	B
B	-	792	I
in	-	794	O
plasma	-	797	O
were	-	804	O
not	-	809	O
significantly	-	813	O
different	-	827	O
among	-	837	O
the	-	843	O
three	-	847	O
groups	-	853	O
at	-	860	O
any	-	863	O
time	-	867	O
during	-	872	O
the	-	879	O
study	-	883	O
.	-	888	O

However	2802551	890	O
,	-	897	O
at	-	899	O
the	-	902	O
end	-	906	O
of	-	910	O
3	-	913	O
weeks	-	915	O
,	-	920	O
amphotericin	-	922	B
B	-	935	I
levels	-	937	O
in	-	944	O
the	-	947	O
kidneys	-	951	O
and	-	959	O
liver	-	963	O
were	-	969	O
significantly	-	974	O
higher	-	988	O
in	-	995	O
salt	-	998	O
-	-	1002	O
depleted	-	1003	O
and	-	1012	O
normal	-	1016	O
-	-	1022	O
salt	-	1023	O
rats	-	1028	O
than	-	1033	O
those	-	1038	O
in	-	1044	O
salt	-	1047	O
-	-	1051	O
loaded	-	1052	O
rats	-	1059	O
,	-	1063	O
with	-	1065	O
plasma	-	1070	O
/	-	1076	O
kidney	-	1077	O
ratios	-	1084	O
of	-	1091	O
21	-	1094	O
,	-	1096	O
14	-	1098	O
,	-	1100	O
and	-	1102	O
8	-	1106	O
in	-	1108	O
salt	-	1111	O
-	-	1115	O
depleted	-	1116	O
,	-	1124	O
normal	-	1126	O
-	-	1132	O
salt	-	1133	O
,	-	1137	O
and	-	1139	O
salt	-	1143	O
-	-	1147	O
loaded	-	1148	O
rats	-	1155	O
,	-	1159	O
respectively	-	1161	O
.	-	1173	O

In	2802551	1175	O
conclusion	-	1178	O
,	-	1188	O
reductions	-	1190	O
in	-	1201	O
creatinine	-	1204	B
clearance	-	1215	O
and	-	1225	O
renal	-	1229	O
amphotericin	-	1235	B
B	-	1248	I
accumulation	-	1250	O
after	-	1263	O
chronic	-	1269	O
amphotericin	-	1277	B
B	-	1290	I
administration	-	1292	O
were	-	1307	O
enhanced	-	1312	O
by	-	1321	O
salt	-	1324	O
depletion	-	1329	O
and	-	1339	O
attenuated	-	1343	O
by	-	1354	O
sodium	-	1357	B
loading	-	1364	O
in	-	1372	O
rats	-	1375	O
.	-	1379	O

Reversible	19346865	0	O
inferior	-	11	O
colliculus	-	20	O
lesion	-	31	O
in	-	38	O
metronidazole	-	41	B
-	-	54	O
induced	-	55	O
encephalopathy	-	63	O
:	-	77	O
magnetic	-	79	O
resonance	-	88	O
findings	-	98	O
on	-	107	O
diffusion	-	110	O
-	-	119	O
weighted	-	120	O
and	-	129	O
fluid	-	133	O
attenuated	-	139	O
inversion	-	150	O
recovery	-	160	O
imaging	-	169	O
.	-	176	O

OBJECTIVE	19346865	178	O
:	-	187	O

This	19346865	189	O
is	-	194	O
to	-	197	O
present	-	200	O
reversible	-	208	O
inferior	-	219	O
colliculus	-	228	O
lesions	-	239	O
in	-	247	O
metronidazole	-	250	B
-	-	263	O
induced	-	264	O
encephalopathy	-	272	O
,	-	286	O
to	-	288	O
focus	-	291	O
on	-	297	O
the	-	300	O
diffusion	-	304	O
-	-	313	O
weighted	-	314	O
imaging	-	323	O
(	-	331	O
DWI	-	332	O
)	-	335	O
and	-	337	O
fluid	-	341	O
attenuated	-	347	O
inversion	-	358	O
recovery	-	368	O
(	-	377	O
FLAIR	-	378	O
)	-	383	O
imaging	-	385	O
.	-	392	O

MATERIALS	19346865	394	O
AND	-	404	O
METHODS	-	408	O
:	-	415	O

From	19346865	417	O
November	-	422	O
2005	-	431	O
to	-	436	O
September	-	439	O
2007	-	449	O
,	-	453	O
8	-	455	O
patients	-	457	O
(	-	466	O
5	-	467	O
men	-	469	O
and	-	473	O
3	-	477	O
women	-	479	O
)	-	484	O
were	-	486	O
diagnosed	-	491	O
as	-	501	O
having	-	504	O
metronidazole	-	511	B
-	-	524	O
induced	-	525	O
encephalopathy	-	533	O
(	-	548	O
age	-	549	O
range	-	553	O
;	-	558	O
43	-	560	O
-	-	562	O
78	-	563	O
years	-	566	O
)	-	571	O
.	-	572	O

They	19346865	574	O
had	-	579	O
been	-	583	O
taking	-	588	O
metronidazole	-	595	B
(	-	609	O
total	-	610	O
dosage	-	616	O
,	-	622	O
45	-	624	O
-	-	626	O
120	-	627	O
g	-	631	O
;	-	632	O
duration	-	634	O
,	-	642	O
30	-	644	O
days	-	647	O
to	-	652	O
2	-	655	O
months	-	657	O
)	-	663	O
to	-	665	O
treat	-	668	O
the	-	674	O
infection	-	678	O
in	-	688	O
various	-	691	O
organs	-	699	O
.	-	705	O

Initial	19346865	707	O
brain	-	715	O
magnetic	-	721	O
resonance	-	730	O
imaging	-	740	O
(	-	748	O
MRI	-	749	O
)	-	752	O
were	-	754	O
obtained	-	759	O
after	-	768	O
the	-	774	O
hospitalization	-	778	O
,	-	793	O
including	-	795	O
DWI	-	805	O
(	-	809	O
8	-	810	O
/	-	811	O
8	-	812	O
)	-	813	O
,	-	814	O
apparent	-	816	O
diffusion	-	825	O
coefficient	-	835	O
(	-	847	O
ADC	-	848	O
)	-	851	O
map	-	853	O
(	-	857	O
4	-	858	O
/	-	859	O
8	-	860	O
)	-	861	O
,	-	862	O
FLAIR	-	864	O
(	-	870	O
7	-	871	O
/	-	872	O
8	-	873	O
)	-	874	O
,	-	875	O
and	-	877	O
T2	-	881	O
-	-	883	O
weighted	-	884	O
image	-	893	O
(	-	899	O
8	-	900	O
/	-	901	O
8	-	902	O
)	-	903	O
.	-	904	O

Follow	19346865	906	O
-	-	912	O
up	-	913	O
MRIs	-	916	O
were	-	921	O
performed	-	926	O
on	-	936	O
5	-	939	O
patients	-	941	O
from	-	950	O
third	-	955	O
to	-	961	O
14th	-	964	O
days	-	969	O
after	-	974	O
discontinuation	-	980	O
of	-	996	O
metronidazole	-	999	B
administration	-	1013	O
.	-	1027	O

Findings	19346865	1029	O
of	-	1038	O
initial	-	1041	O
and	-	1049	O
follow	-	1053	O
-	-	1059	O
up	-	1060	O
MRIs	-	1063	O
were	-	1068	O
retrospectively	-	1073	O
evaluated	-	1089	O
by	-	1099	O
2	-	1102	O
neuroradiologists	-	1104	O
by	-	1122	O
consensus	-	1125	O
,	-	1134	O
to	-	1136	O
analyze	-	1139	O
the	-	1147	O
presence	-	1151	O
of	-	1160	O
abnormal	-	1163	O
signal	-	1172	O
intensities	-	1179	O
,	-	1190	O
their	-	1192	O
locations	-	1198	O
,	-	1207	O
and	-	1209	O
signal	-	1213	O
changes	-	1220	O
on	-	1228	O
follow	-	1231	O
-	-	1237	O
up	-	1238	O
images	-	1241	O
.	-	1247	O

RESULTS	19346865	1249	O
:	-	1256	O

Initial	19346865	1258	O
MRIs	-	1266	O
showed	-	1271	O
abnormal	-	1278	O
high	-	1287	O
signal	-	1292	O
intensities	-	1299	O
on	-	1311	O
DWI	-	1314	O
and	-	1318	O
FLAIR	-	1322	O
(	-	1328	O
or	-	1329	O
T2	-	1332	O
-	-	1334	O
weighted	-	1335	O
image	-	1344	O
)	-	1349	O
at	-	1351	O
the	-	1354	O
dentate	-	1358	O
nucleus	-	1366	O
(	-	1374	O
8	-	1375	O
/	-	1376	O
8	-	1377	O
)	-	1378	O
,	-	1379	O
inferior	-	1381	O
colliculus	-	1390	O
(	-	1401	O
6	-	1402	O
/	-	1403	O
8	-	1404	O
)	-	1405	O
,	-	1406	O
corpus	-	1408	O
callosum	-	1415	O
(	-	1424	O
2	-	1425	O
/	-	1426	O
8	-	1427	O
)	-	1428	O
,	-	1429	O
pons	-	1431	O
(	-	1436	O
2	-	1437	O
/	-	1438	O
8	-	1439	O
)	-	1440	O
,	-	1441	O
medulla	-	1443	O
(	-	1451	O
1	-	1452	O
/	-	1453	O
8	-	1454	O
)	-	1455	O
,	-	1456	O
and	-	1458	O
bilateral	-	1462	O
cerebral	-	1472	O
white	-	1481	O
matter	-	1487	O
(	-	1494	O
1	-	1495	O
/	-	1496	O
8	-	1497	O
)	-	1498	O
.	-	1499	O

High	19346865	1501	O
-	-	1505	O
signal	-	1506	O
intensity	-	1513	O
lesions	-	1523	O
on	-	1531	O
DWI	-	1534	O
tended	-	1538	O
to	-	1545	O
show	-	1548	O
low	-	1553	O
signal	-	1557	O
intensity	-	1564	O
on	-	1574	O
ADC	-	1577	O
map	-	1581	O
(	-	1585	O
3	-	1586	O
/	-	1587	O
4	-	1588	O
)	-	1589	O
,	-	1590	O
but	-	1592	O
in	-	1596	O
one	-	1599	O
patient	-	1603	O
,	-	1610	O
high	-	1612	O
signal	-	1617	O
intensity	-	1624	O
was	-	1634	O
shown	-	1638	O
at	-	1644	O
bilateral	-	1647	O
dentate	-	1657	O
nuclei	-	1665	O
on	-	1672	O
not	-	1675	O
only	-	1679	O
DWI	-	1684	O
but	-	1688	O
also	-	1692	O
ADC	-	1697	O
map	-	1701	O
.	-	1704	O

All	19346865	1706	O
the	-	1710	O
lesions	-	1714	O
in	-	1722	O
dentate	-	1725	O
,	-	1732	O
inferior	-	1734	O
colliculus	-	1743	O
,	-	1753	O
pons	-	1755	O
,	-	1759	O
and	-	1761	O
medullas	-	1765	O
had	-	1774	O
been	-	1778	O
resolved	-	1783	O
completely	-	1792	O
on	-	1803	O
follow	-	1806	O
-	-	1812	O
up	-	1813	O
MRIs	-	1816	O
in	-	1821	O
5	-	1824	O
patients	-	1826	O
,	-	1834	O
but	-	1836	O
in	-	1840	O
1	-	1843	O
patient	-	1845	O
of	-	1853	O
them	-	1856	O
,	-	1860	O
corpus	-	1862	O
callosal	-	1869	O
lesion	-	1878	O
persisted	-	1885	O
.	-	1894	O

CONCLUSIONS	19346865	1896	O
:	-	1907	O

Reversible	19346865	1909	O
inferior	-	1920	O
colliculus	-	1929	O
lesions	-	1940	O
could	-	1948	O
be	-	1954	O
considered	-	1957	O
as	-	1968	O
the	-	1971	O
characteristic	-	1975	O
for	-	1990	O
metronidazole	-	1994	B
-	-	2007	O
induced	-	2008	O
encephalopathy	-	2016	O
,	-	2030	O
next	-	2032	O
to	-	2037	O
the	-	2040	O
dentate	-	2044	O
nucleus	-	2052	O
involvement	-	2060	O
.	-	2071	O

Comparison	2334618	0	O
of	-	11	O
the	-	14	O
respiratory	-	18	O
effects	-	30	O
of	-	38	O
i	-	41	O
.	-	42	O
v	-	43	O
.	-	44	O

infusions	2334618	46	O
of	-	56	O
morphine	-	59	B
and	-	68	O
regional	-	72	O
analgesia	-	81	O
by	-	91	O
extradural	-	94	O
block	-	105	O
.	-	110	O

The	2334618	112	O
incidence	-	116	O
of	-	126	O
postoperative	-	129	O
respiratory	-	143	O
apnoea	-	155	O
was	-	162	O
compared	-	166	O
between	-	175	O
five	-	183	O
patients	-	188	O
receiving	-	197	O
a	-	207	O
continuous	-	209	O
i	-	220	O
.	-	221	O
v	-	222	O
.	-	223	O

infusion	2334618	225	O
of	-	234	O
morphine	-	237	B
(	-	246	O
mean	-	247	O
73	-	252	O
.	-	254	O
6	-	255	O
mg	-	257	O
)	-	259	O
and	-	261	O
five	-	265	O
patients	-	270	O
receiving	-	279	O
a	-	289	O
continuous	-	291	O
extradural	-	302	O
infusion	-	313	O
of	-	322	O
0	-	325	O
.	-	326	O
25	-	327	O
%	-	329	O
bupivacaine	-	331	B
(	-	343	O
mean	-	344	O
192	-	349	O
mg	-	353	O
)	-	355	O
in	-	357	O
the	-	360	O
24	-	364	O
-	-	366	O
h	-	367	O
period	-	369	O
following	-	376	O
upper	-	386	O
abdominal	-	392	O
surgery	-	402	O
.	-	409	O

Monitoring	2334618	411	O
consisted	-	422	O
of	-	432	O
airflow	-	435	O
detection	-	443	O
by	-	453	O
a	-	456	O
carbon	-	458	B
dioxide	-	465	I
analyser	-	473	O
,	-	481	O
chest	-	483	O
wall	-	489	O
movement	-	494	O
detected	-	503	O
by	-	512	O
pneumatic	-	515	O
capsules	-	525	O
,	-	533	O
and	-	535	O
continuous	-	539	O
electrocardiograph	-	550	O
recorded	-	569	O
with	-	578	O
a	-	583	O
Holter	-	585	O
ambulatory	-	592	O
monitor	-	603	O
.	-	610	O

Both	2334618	612	O
obstructive	-	617	O
(	-	629	O
P	-	630	O
less	-	632	O
than	-	637	O
0	-	642	O
.	-	643	O
05	-	644	O
)	-	646	O
and	-	648	O
central	-	652	O
apnoea	-	660	O
(	-	667	O
P	-	668	O
less	-	670	O
than	-	675	O
0	-	680	O
.	-	681	O
05	-	682	O
)	-	684	O
occurred	-	686	O
more	-	695	O
frequently	-	700	O
in	-	711	O
patients	-	714	O
who	-	723	O
had	-	727	O
a	-	731	O
morphine	-	733	B
infusion	-	742	O
.	-	750	O

There	2334618	752	O
was	-	758	O
also	-	762	O
a	-	767	O
higher	-	769	O
incidence	-	776	O
of	-	786	O
tachyarrhythmias	-	789	O
(	-	806	O
P	-	807	O
less	-	809	O
than	-	814	O
0	-	819	O
.	-	820	O
05	-	821	O
)	-	823	O
and	-	825	O
ventricular	-	829	O
ectopic	-	841	O
beats	-	849	O
(	-	855	O
P	-	856	O
less	-	858	O
than	-	863	O
0	-	868	O
.	-	869	O
05	-	870	O
)	-	872	O
in	-	874	O
the	-	877	O
morphine	-	881	B
infusion	-	890	O
group	-	899	O
.	-	904	O

Magnetic	8864707	0	O
resonance	-	9	O
volumetry	-	19	O
of	-	29	O
the	-	32	O
cerebellum	-	36	O
in	-	47	O
epileptic	-	50	O
patients	-	60	O
after	-	69	O
phenytoin	-	75	B
overdosages	-	85	O
.	-	96	O

The	8864707	98	O
aim	-	102	O
of	-	106	O
this	-	109	O
study	-	114	O
was	-	120	O
to	-	124	O
evaluate	-	127	O
the	-	136	O
relationship	-	140	O
between	-	153	O
phenytoin	-	161	B
medication	-	171	O
and	-	182	O
cerebellar	-	186	O
atrophy	-	197	O
in	-	205	O
patients	-	208	O
who	-	217	O
had	-	221	O
experienced	-	225	O
clinical	-	237	O
intoxication	-	246	O
.	-	258	O

Five	8864707	260	O
females	-	265	O
and	-	273	O
6	-	277	O
males	-	279	O
,	-	284	O
21	-	286	O
-	-	288	O
59	-	289	O
years	-	292	O
of	-	298	O
age	-	301	O
,	-	304	O
were	-	306	O
examined	-	311	O
with	-	320	O
a	-	325	O
1	-	327	O
.	-	328	O
5	-	329	O
-	-	330	O
T	-	331	O
whole	-	333	O
-	-	338	O
body	-	339	O
system	-	344	O
using	-	351	O
a	-	357	O
circular	-	359	O
polarized	-	368	O
head	-	378	O
coil	-	383	O
.	-	387	O

Conventional	8864707	389	O
spin	-	402	O
echo	-	407	O
images	-	412	O
were	-	419	O
acquired	-	424	O
in	-	433	O
the	-	436	O
sagittal	-	440	O
and	-	449	O
transverse	-	453	O
orientation	-	464	O
.	-	475	O

In	8864707	477	O
addition	-	480	O
,	-	488	O
we	-	490	O
performed	-	493	O
a	-	503	O
high	-	505	O
-	-	509	O
resolution	-	510	O
3D	-	521	O
gradient	-	524	O
echo	-	533	O
,	-	537	O
T1	-	539	O
-	-	541	O
weighted	-	542	O
sequences	-	551	O
at	-	561	O
a	-	564	O
1	-	566	O
-	-	567	O
mm	-	568	O
slice	-	571	O
thickness	-	577	O
.	-	586	O

The	8864707	588	O
images	-	592	O
were	-	599	O
subsequently	-	604	O
processed	-	617	O
to	-	627	O
obtain	-	630	O
volumetric	-	637	O
data	-	648	O
for	-	653	O
the	-	657	O
cerebellum	-	661	O
.	-	671	O

Cerebellar	8864707	673	O
volume	-	684	O
for	-	691	O
the	-	695	O
patient	-	699	O
group	-	707	O
ranged	-	713	O
between	-	720	O
67	-	728	O
.	-	730	O
66	-	731	O
and	-	734	O
131	-	738	O
.	-	741	O
08	-	742	O
ml	-	745	O
(	-	748	O
mean	-	749	O
108	-	754	O
.	-	757	O
9	-	758	O
ml	-	760	O
)	-	762	O
.	-	763	O

In	8864707	765	O
addition	-	768	O
3D	-	777	O
gradient	-	780	O
echo	-	789	O
data	-	794	O
sets	-	799	O
from	-	804	O
10	-	809	O
healthy	-	812	O
male	-	820	O
and	-	825	O

10	8864707	829	O
healthy	-	832	O
female	-	840	O
age	-	847	O
-	-	850	O
matched	-	851	O
volunteers	-	859	O
were	-	870	O
used	-	875	O
to	-	880	O
compare	-	883	O
cerebellar	-	891	O
volumes	-	902	O
.	-	909	O

Using	8864707	911	O
linear	-	917	O
regression	-	924	O
we	-	935	O
found	-	938	O
that	-	944	O
no	-	949	O
correlation	-	952	O
exists	-	964	O
between	-	971	O
seizure	-	979	O
duration	-	987	O
,	-	995	O
elevation	-	997	O
of	-	1007	O
phenytoin	-	1010	B
serum	-	1020	O
levels	-	1026	O
and	-	1033	O
cerebellar	-	1037	O
volume	-	1048	O
.	-	1054	O

However	8864707	1056	O
,	-	1063	O
multiple	-	1065	O
regression	-	1074	O
for	-	1085	O
the	-	1089	O
daily	-	1093	O
dosage	-	1099	O
,	-	1105	O
duration	-	1107	O
of	-	1116	O
phenytoin	-	1119	B
treatment	-	1129	O
and	-	1139	O
cerebellar	-	1143	O
volume	-	1154	O
revealed	-	1161	O
a	-	1170	O
correlation	-	1172	O
of	-	1184	O
these	-	1187	O
parameters	-	1193	O
.	-	1203	O

We	8864707	1205	O
conclude	-	1208	O
that	-	1217	O
phenytoin	-	1222	B
overdosage	-	1232	O
does	-	1243	O
not	-	1248	O
necessarily	-	1252	O
result	-	1264	O
in	-	1271	O
cerebellar	-	1274	O
atrophy	-	1285	O
and	-	1293	O
it	-	1297	O
is	-	1300	O
unlikely	-	1303	O
that	-	1312	O
phenytoin	-	1317	B
medication	-	1327	O
was	-	1338	O
the	-	1342	O
only	-	1346	O
cause	-	1351	O
of	-	1357	O
cerebellar	-	1360	O
atrophy	-	1371	O
in	-	1379	O
the	-	1382	O
remaining	-	1386	O
patients	-	1396	O
.	-	1404	O

Quantitative	8864707	1406	O
morphometric	-	1419	O
studies	-	1432	O
of	-	1440	O
the	-	1443	O
cerebellum	-	1447	O
provide	-	1458	O
valuable	-	1466	O
insights	-	1475	O
into	-	1484	O
the	-	1489	O
pathogenesis	-	1493	O
of	-	1506	O
cerebellar	-	1509	O
disorders	-	1520	O
.	-	1529	O

Evaluation	12589964	0	O
of	-	11	O
cardiac	-	14	O
troponin	-	22	O
I	-	31	O
and	-	33	O
T	-	37	O
levels	-	39	O
as	-	46	O
markers	-	49	O
of	-	57	O
myocardial	-	60	O
damage	-	71	O
in	-	78	O
doxorubicin	-	81	B
-	-	92	O
induced	-	93	O
cardiomyopathy	-	101	O
rats	-	116	O
,	-	120	O
and	-	122	O
their	-	126	O
relationship	-	132	O
with	-	145	O
echocardiographic	-	150	O
and	-	168	O
histological	-	172	O
findings	-	185	O
.	-	193	O

BACKGROUND	12589964	195	O
:	-	205	O

Cardiac	12589964	207	O
troponins	-	215	O
I	-	225	O
(	-	227	O
cTnI	-	228	O
)	-	232	O
and	-	234	O
T	-	238	O

(	12589964	240	O
cTnT	-	241	O
)	-	245	O
have	-	247	O
been	-	252	O
shown	-	257	O
to	-	263	O
be	-	266	O
highly	-	269	O
sensitive	-	276	O
and	-	286	O
specific	-	290	O
markers	-	299	O
of	-	307	O
myocardial	-	310	O
cell	-	321	O
injury	-	326	O
.	-	332	O

We	12589964	334	O
investigated	-	337	O
the	-	350	O
diagnostic	-	354	O
value	-	365	O
of	-	371	O
cTnI	-	374	O
and	-	379	O
cTnT	-	383	O
for	-	388	O
the	-	392	O
diagnosis	-	396	O
of	-	406	O
myocardial	-	409	O
damage	-	420	O
in	-	427	O
a	-	430	O
rat	-	432	O
model	-	436	O
of	-	442	O
doxorubicin	-	445	B
(	-	457	O
DOX	-	458	B
)	-	461	O
-	-	462	O
induced	-	463	O
cardiomyopathy	-	471	O
,	-	485	O
and	-	487	O
we	-	491	O
examined	-	494	O
the	-	503	O
relationship	-	507	O
between	-	520	O
serial	-	528	O
cTnI	-	535	O

and	12589964	540	O
cTnT	-	544	O
with	-	549	O
the	-	554	O
development	-	558	O
of	-	570	O
cardiac	-	573	O
disorders	-	581	O
monitored	-	591	O
by	-	601	O
echocardiography	-	604	O
and	-	621	O
histological	-	625	O
examinations	-	638	O
in	-	651	O
this	-	654	O
model	-	659	O
.	-	664	O

METHODS	12589964	666	O
:	-	673	O

Thirty	12589964	675	O
-	-	681	O
five	-	682	O
Wistar	-	687	O
rats	-	694	O
were	-	699	O
given	-	704	O
1	-	710	O
.	-	711	O
5	-	712	O
mg	-	714	O
/	-	716	O
kg	-	717	O
DOX	-	720	B
,	-	723	O
i	-	725	O
.	-	726	O
v	-	727	O
.	-	728	O
,	-	729	O
weekly	-	731	O
for	-	738	O
up	-	742	O
to	-	745	O
8	-	748	O
weeks	-	750	O
for	-	756	O
a	-	760	O
total	-	762	O
cumulative	-	768	O
dose	-	779	O
of	-	784	O
12	-	787	O
mg	-	790	O
/	-	792	O
kg	-	793	O
BW	-	796	O
.	-	798	O

Ten	12589964	800	O
rats	-	804	O
received	-	809	O
saline	-	818	O
as	-	825	O
a	-	828	O
control	-	830	O
group	-	838	O
.	-	843	O

cTnI	12589964	845	O
was	-	850	O
measured	-	854	O
with	-	863	O
Access	-	868	O
(	-	874	O
R	-	875	O
)	-	876	O

(	12589964	878	O
ng	-	879	O
/	-	881	O
ml	-	882	O
)	-	884	O
and	-	886	O
a	-	890	O
research	-	892	O
immunoassay	-	901	O
(	-	913	O
pg	-	914	O
/	-	916	O
ml	-	917	O
)	-	919	O
,	-	920	O
and	-	922	O
compared	-	926	O
with	-	935	O
cTnT	-	940	O

,	12589964	944	O
CK	-	946	O
-	-	948	O
MB	-	949	O
mass	-	952	O
and	-	957	O
CK	-	961	O
.	-	963	O

By	12589964	965	O
using	-	968	O
transthoracic	-	974	O
echocardiography	-	988	O
,	-	1004	O
anterior	-	1006	O
and	-	1015	O
posterior	-	1019	O
wall	-	1029	O
thickness	-	1034	O
,	-	1043	O
LV	-	1045	O
diameters	-	1048	O
and	-	1058	O
LV	-	1062	O
fractional	-	1065	O
shortening	-	1076	O
(	-	1087	O
FS	-	1088	O
)	-	1090	O
were	-	1092	O
measured	-	1097	O
in	-	1106	O
all	-	1109	O
rats	-	1113	O
before	-	1118	O
DOX	-	1125	B
or	-	1129	O
saline	-	1132	O
,	-	1138	O
and	-	1140	O
at	-	1144	O
weeks	-	1147	O
6	-	1153	O
and	-	1155	O
9	-	1159	O
after	-	1161	O
treatment	-	1167	O
in	-	1177	O
all	-	1180	O
surviving	-	1184	O
rats	-	1194	O
.	-	1198	O

Histology	12589964	1200	O
was	-	1210	O
performed	-	1214	O
in	-	1224	O
DOX	-	1227	B
-	-	1230	O
rats	-	1231	O
at	-	1236	O
6	-	1239	O
and	-	1241	O
9	-	1245	O
weeks	-	1247	O
after	-	1253	O
the	-	1259	O
last	-	1263	O
DOX	-	1268	B
dose	-	1272	O
and	-	1277	O
in	-	1281	O
all	-	1284	O
controls	-	1288	O
.	-	1296	O

RESULTS	12589964	1298	O
:	-	1305	O

Eighteen	12589964	1307	O
of	-	1316	O
the	-	1319	O
DOX	-	1323	B
rats	-	1327	O
died	-	1332	O
prematurely	-	1337	O
of	-	1349	O
general	-	1352	O
toxicity	-	1360	O
during	-	1369	O
the	-	1376	O
9	-	1380	O
-	-	1381	O
week	-	1382	O
period	-	1387	O
.	-	1393	O

End	12589964	1395	O
-	-	1398	O
diastolic	-	1399	O
(	-	1409	O
ED	-	1410	O
)	-	1412	O
and	-	1414	O
end	-	1418	O
-	-	1421	O
systolic	-	1422	O
(	-	1431	O
ES	-	1432	O
)	-	1434	O
LV	-	1436	O
diameters	-	1439	O
/	-	1448	O
BW	-	1449	O
significantly	-	1452	O
increased	-	1466	O
,	-	1475	O
whereas	-	1477	O
LV	-	1485	O
FS	-	1488	O
was	-	1491	O
decreased	-	1495	O
after	-	1505	O
9	-	1511	O
weeks	-	1513	O
in	-	1519	O
the	-	1522	O
DOX	-	1526	B
group	-	1530	O
(	-	1536	O
p	-	1537	O
<	-	1538	O
0	-	1539	O
.	-	1540	O
001	-	1541	O
)	-	1544	O
.	-	1545	O

These	12589964	1547	O
parameters	-	1553	O
remained	-	1564	O
unchanged	-	1573	O
in	-	1583	O
controls	-	1586	O
.	-	1594	O

Histological	12589964	1596	O
evaluation	-	1609	O
of	-	1620	O
hearts	-	1623	O
from	-	1630	O
all	-	1635	O
rats	-	1639	O
given	-	1644	O
DOX	-	1650	B
revealed	-	1654	O
significant	-	1663	O
slight	-	1675	O
degrees	-	1682	O
of	-	1690	O
perivascular	-	1693	O
and	-	1706	O
interstitial	-	1710	O
fibrosis	-	1723	O
.	-	1731	O

In	12589964	1733	O
7	-	1736	O
of	-	1738	O
the	-	1741	O
18	-	1745	O
rats	-	1748	O
,	-	1752	O
degeneration	-	1754	O
and	-	1767	O
myocyte	-	1771	O
vacuolisation	-	1779	O
were	-	1793	O
found	-	1798	O
.	-	1803	O

Only	12589964	1805	O
five	-	1810	O
of	-	1815	O
the	-	1818	O
controls	-	1822	O
exhibited	-	1831	O
evidence	-	1841	O
of	-	1850	O
very	-	1853	O
slight	-	1858	O
perivascular	-	1865	O
fibrosis	-	1878	O
.	-	1886	O

A	12589964	1888	O
significant	-	1890	O
rise	-	1902	O
in	-	1907	O
cTnT	-	1910	O
was	-	1915	O
found	-	1919	O
in	-	1925	O
DOX	-	1928	B
rats	-	1932	O
after	-	1937	O
cumulative	-	1943	O
doses	-	1954	O
of	-	1960	O
7	-	1963	O
.	-	1964	O
5	-	1965	O
and	-	1967	O
12	-	1971	O
mg	-	1974	O
/	-	1976	O
kg	-	1977	O
in	-	1980	O
comparison	-	1983	O
with	-	1994	O
baseline	-	1999	O
(	-	2008	O
p	-	2009	O
<	-	2010	O
0	-	2011	O
.	-	2012	O
05	-	2013	O
)	-	2015	O
.	-	2016	O

cTnT	12589964	2018	O

found	12589964	2023	O
in	-	2029	O
rats	-	2032	O
after	-	2037	O
12	-	2043	O
mg	-	2046	O
/	-	2048	O
kg	-	2049	O
were	-	2052	O
significantly	-	2057	O
greater	-	2071	O
than	-	2079	O
that	-	2084	O
found	-	2089	O
after	-	2095	O
7	-	2101	O
.	-	2102	O
5	-	2103	O
mg	-	2105	O
/	-	2107	O
kg	-	2108	O
DOX	-	2111	B
.	-	2114	O

Maximal	12589964	2116	O
cTnI	-	2124	O
(	-	2129	O
pg	-	2130	O
/	-	2132	O
ml	-	2133	O
)	-	2135	O
and	-	2137	O
cTnT	-	2141	O

levels	12589964	2146	O
were	-	2153	O
significantly	-	2158	O
increased	-	2172	O
in	-	2182	O
DOX	-	2185	B
rats	-	2189	O
compared	-	2194	O
with	-	2203	O
controls	-	2208	O
(	-	2217	O
p	-	2218	O
=	-	2219	O
0	-	2220	O
.	-	2221	O
006	-	2222	O
,	-	2225	O
0	-	2227	O
.	-	2228	O
007	-	2229	O
)	-	2232	O
.	-	2233	O

cTnI	12589964	2235	O

(	12589964	2240	O
ng	-	2241	O
/	-	2243	O
ml	-	2244	O
)	-	2246	O
,	-	2247	O
CK	-	2249	O
-	-	2251	O
MB	-	2252	O
mass	-	2255	O
and	-	2260	O
CK	-	2264	O
remained	-	2267	O
unchanged	-	2276	O
in	-	2286	O
DOX	-	2289	B
rats	-	2293	O
compared	-	2298	O
with	-	2307	O
controls	-	2312	O
.	-	2320	O

All	12589964	2322	O
markers	-	2326	O
remained	-	2334	O
stable	-	2343	O
in	-	2350	O
controls	-	2353	O
.	-	2361	O

Analysis	12589964	2363	O
of	-	2372	O
data	-	2375	O
revealed	-	2380	O
a	-	2389	O
significant	-	2391	O
correlation	-	2403	O
between	-	2415	O
maximal	-	2423	O
cTnT	-	2431	O
and	-	2436	O
ED	-	2440	O
and	-	2443	O
ES	-	2447	O
LV	-	2450	O
diameters	-	2453	O
/	-	2462	O
BW	-	2463	O
(	-	2466	O
r	-	2467	O
=	-	2468	O
0	-	2469	O
.	-	2470	O
81	-	2471	O
and	-	2474	O
0	-	2478	O
.	-	2479	O
65	-	2480	O
;	-	2482	O
p	-	2484	O
<	-	2485	O
0	-	2486	O
.	-	2487	O
0001	-	2488	O
)	-	2492	O
.	-	2493	O

A	12589964	2495	O
significant	-	2497	O
relationship	-	2509	O
was	-	2522	O
observed	-	2526	O
between	-	2535	O
maximal	-	2543	O
cTnT	-	2551	O

and	12589964	2556	O
the	-	2560	O
extent	-	2564	O
of	-	2571	O
myocardial	-	2574	O
morphological	-	2585	O
changes	-	2599	O
,	-	2606	O
and	-	2608	O
between	-	2612	O
LV	-	2620	O
diameters	-	2623	O
/	-	2632	O
BW	-	2633	O
and	-	2636	O
histological	-	2640	O
findings	-	2653	O
.	-	2661	O

CONCLUSIONS	12589964	2663	O
:	-	2674	O

Among	12589964	2676	O
markers	-	2682	O
of	-	2690	O
ischemic	-	2693	O
injury	-	2702	O
after	-	2709	O
DOX	-	2715	B
in	-	2719	O
rats	-	2722	O
,	-	2726	O
cTnT	-	2728	O
showed	-	2733	O
the	-	2740	O
greatest	-	2744	O
ability	-	2753	O
to	-	2761	O
detect	-	2764	O
myocardial	-	2771	O
damage	-	2782	O
assessed	-	2789	O
by	-	2798	O
echocardiographic	-	2801	O
detection	-	2819	O
and	-	2829	O
histological	-	2833	O
changes	-	2846	O
.	-	2853	O

Although	12589964	2855	O
there	-	2864	O
was	-	2870	O
a	-	2874	O
discrepancy	-	2876	O
between	-	2888	O
the	-	2896	O
amount	-	2900	O
of	-	2907	O
cTnI	-	2910	O
and	-	2915	O
cTnT	-	2919	O
after	-	2924	O
DOX	-	2930	B
,	-	2933	O
probably	-	2935	O
due	-	2944	O
to	-	2948	O
heterogeneity	-	2951	O
in	-	2965	O
cross	-	2968	O
-	-	2973	O
reactivities	-	2974	O
of	-	2987	O
mAbs	-	2990	O
to	-	2995	O
various	-	2998	O
cTnI	-	3006	O
and	-	3011	O
cTnT	-	3015	O
forms	-	3020	O
,	-	3025	O
it	-	3027	O
is	-	3030	O
likely	-	3033	O
that	-	3040	O
cTnT	-	3045	O
in	-	3050	O
rats	-	3053	O
after	-	3058	O
DOX	-	3064	B
indicates	-	3068	O
cell	-	3078	O
damage	-	3083	O
determined	-	3090	O
by	-	3101	O
the	-	3104	O
magnitude	-	3108	O
of	-	3118	O
injury	-	3121	O
induced	-	3128	O
and	-	3136	O
that	-	3140	O
cTnT	-	3145	O
should	-	3150	O
be	-	3157	O
a	-	3160	O
useful	-	3162	O
marker	-	3169	O
for	-	3176	O
the	-	3180	O
prediction	-	3184	O
of	-	3195	O
experimentally	-	3198	O
induced	-	3213	O
cardiotoxicity	-	3221	O
and	-	3236	O
possibly	-	3240	O
for	-	3249	O
cardioprotective	-	3253	O
experiments	-	3270	O
.	-	3281	O

Calcineurin	11263551	0	O
-	-	11	O
inhibitor	-	12	O
induced	-	22	O
pain	-	30	O
syndrome	-	35	O
(	-	44	O
CIPS	-	45	O
)	-	49	O
:	-	50	O
a	-	52	O
severe	-	54	O
disabling	-	61	O
complication	-	71	O
after	-	84	O
organ	-	90	O
transplantation	-	96	O
.	-	111	O

Bone	11263551	113	O
pain	-	118	O
after	-	123	O
transplantation	-	129	O
is	-	145	O
a	-	148	O
frequent	-	150	O
complication	-	159	O
that	-	172	O
can	-	177	O
be	-	181	O
caused	-	184	O
by	-	191	O
several	-	194	O
diseases	-	202	O
.	-	210	O

Treatment	11263551	212	O
strategies	-	222	O
depend	-	233	O
on	-	240	O
the	-	243	O
correct	-	247	O
diagnosis	-	255	O
of	-	265	O
the	-	268	O
pain	-	272	O
.	-	276	O

Nine	11263551	278	O
patients	-	283	O
with	-	292	O
severe	-	297	O
pain	-	304	O
in	-	309	O
their	-	312	O
feet	-	318	O
,	-	322	O
which	-	324	O
was	-	330	O
registered	-	334	O
after	-	345	O
transplantation	-	351	O
,	-	366	O
were	-	368	O
investigated	-	373	O
.	-	385	O

Bone	11263551	387	O
scans	-	392	O
showed	-	398	O
an	-	405	O
increased	-	408	O
tracer	-	418	O
uptake	-	425	O
of	-	432	O
the	-	435	O
foot	-	439	O
bones	-	444	O
.	-	449	O

Magnetic	11263551	451	O
resonance	-	460	O
imaging	-	470	O
demonstrated	-	478	O
bone	-	491	O
marrow	-	496	O
oedema	-	503	O
in	-	510	O
the	-	513	O
painful	-	517	O
bones	-	525	O
.	-	530	O

Pain	11263551	532	O
was	-	537	O
not	-	541	O
explained	-	545	O
by	-	555	O
other	-	558	O
diseases	-	564	O
causing	-	573	O
foot	-	581	O
pain	-	586	O
,	-	590	O
like	-	592	O
reflex	-	597	O
sympathetic	-	604	O
dystrophy	-	616	O
,	-	625	O
polyneuropathy	-	627	O
,	-	641	O
Morton	-	643	O
's	-	649	O
neuralgia	-	652	O
,	-	661	O
gout	-	663	O
,	-	667	O
osteoporosis	-	669	O
,	-	681	O
avascular	-	683	O
necrosis	-	693	O
,	-	701	O
intermittent	-	703	O
claudication	-	716	O
,	-	728	O
orthopaedic	-	730	O
foot	-	742	O
deformities	-	747	O
,	-	758	O
stress	-	760	O
fractures	-	767	O
,	-	776	O
and	-	778	O
hyperparathyroidism	-	782	O
.	-	801	O

The	11263551	803	O
reduction	-	807	O
of	-	817	O
cyclosporine	-	820	B
-	-	832	O
or	-	834	O
tacrolimus	-	837	B
trough	-	848	O
levels	-	855	O
and	-	862	O
the	-	866	O
administration	-	870	O
of	-	885	O
calcium	-	888	B
channel	-	896	O
blockers	-	904	O
led	-	913	O
to	-	917	O
relief	-	920	O
of	-	927	O
pain	-	930	O
.	-	934	O

The	11263551	936	O
Calcineurin	-	940	O
-	-	951	O
inhibitor	-	952	O
Induced	-	962	O
Pain	-	970	O
Syndrome	-	975	O
(	-	984	O
CIPS	-	985	O
)	-	989	O
is	-	991	O
a	-	994	O
rare	-	996	O
but	-	1001	O
severe	-	1005	O
side	-	1012	O
effect	-	1017	O
of	-	1024	O
cyclosporine	-	1027	B
or	-	1040	O
tacrolimus	-	1043	B
and	-	1054	O
is	-	1058	O
accurately	-	1061	O
diagnosed	-	1072	O
by	-	1082	O
its	-	1085	O
typical	-	1089	O
presentation	-	1097	O
,	-	1109	O
magnetic	-	1111	O
resonance	-	1120	O
imaging	-	1130	O
and	-	1138	O
bone	-	1142	O
scans	-	1147	O
.	-	1152	O

Incorrect	11263551	1154	O
diagnosis	-	1164	O
of	-	1174	O
the	-	1177	O
syndrome	-	1181	O
will	-	1190	O
lead	-	1195	O
to	-	1200	O
a	-	1203	O
significant	-	1205	O
reduction	-	1217	O
of	-	1227	O
life	-	1230	O
quality	-	1235	O
in	-	1243	O
patients	-	1246	O
suffering	-	1255	O
from	-	1265	O
CIPS	-	1270	O
.	-	1274	O

The	10520387	0	O
haemodynamic	-	4	O
effects	-	17	O
of	-	25	O
propofol	-	28	B
in	-	37	O
combination	-	40	O
with	-	52	O
ephedrine	-	57	B
in	-	67	O
elderly	-	70	O
patients	-	78	O
(	-	87	O
ASA	-	88	O
groups	-	92	O
3	-	99	O
and	-	101	O
4	-	105	O
)	-	106	O
.	-	107	O

The	10520387	109	O
marked	-	113	O
vasodilator	-	120	O
and	-	132	O
negative	-	136	O
inotropic	-	145	O
effects	-	155	O
of	-	163	O
propofol	-	166	B
are	-	175	O
disadvantages	-	179	O
in	-	193	O
frail	-	196	O
elderly	-	202	O
patients	-	210	O
.	-	218	O

We	10520387	220	O
investigated	-	223	O
the	-	236	O
safety	-	240	O
and	-	247	O
efficacy	-	251	O
of	-	260	O
adding	-	263	O
different	-	270	O
doses	-	280	O
of	-	286	O
ephedrine	-	289	B
to	-	299	O
propofol	-	302	B
in	-	311	O
order	-	314	O
to	-	320	O
obtund	-	323	O
the	-	330	O
hypotensive	-	334	O
response	-	346	O
.	-	354	O

The	10520387	356	O
haemodynamic	-	360	O
effects	-	373	O
of	-	381	O
adding	-	384	O
15	-	391	O
,	-	393	O
20	-	395	O
or	-	398	O
25	-	401	O
mg	-	404	O
of	-	407	O
ephedrine	-	410	B
to	-	420	O
200	-	423	O
mg	-	427	O
of	-	430	O
propofol	-	433	B
were	-	442	O
compared	-	447	O
to	-	456	O
control	-	459	O
in	-	467	O
40	-	470	O
ASA	-	473	O
3	-	477	O
/	-	478	O
4	-	479	O
patients	-	481	O
over	-	490	O
60	-	495	O
years	-	498	O
presenting	-	504	O
for	-	515	O
genito	-	519	O
-	-	525	O
urinary	-	526	O
surgery	-	534	O
.	-	541	O

The	10520387	543	O
addition	-	547	O
of	-	556	O
ephedrine	-	559	B
to	-	569	O
propofol	-	572	B
appears	-	581	O
to	-	589	O
be	-	592	O
an	-	595	O
effective	-	598	O
method	-	608	O
of	-	615	O
obtunding	-	618	O
the	-	628	O
hypotensive	-	632	O
response	-	644	O
to	-	653	O
propofol	-	656	B
at	-	665	O
all	-	668	O
doses	-	672	O
used	-	678	O
in	-	683	O
this	-	686	O
study	-	691	O
.	-	696	O

However	10520387	698	O
,	-	705	O
marked	-	707	O
tachycardia	-	714	O
associated	-	726	O
with	-	737	O
the	-	742	O
use	-	746	O
of	-	750	O
ephedrine	-	753	B
in	-	763	O
combination	-	766	O
with	-	778	O
propofol	-	783	B
occurred	-	792	O
in	-	801	O
the	-	804	O
majority	-	808	O
of	-	817	O
patients	-	820	O
,	-	828	O
occasionally	-	830	O
reaching	-	843	O
high	-	852	O
levels	-	857	O
in	-	864	O
individual	-	867	O
patients	-	878	O
.	-	886	O

Due	10520387	888	O
to	-	892	O
the	-	895	O
risk	-	899	O
of	-	904	O
this	-	907	O
tachycardia	-	912	O
inducing	-	924	O
myocardial	-	933	O
ischemia	-	944	O
,	-	952	O
we	-	954	O
would	-	957	O
not	-	963	O
recommend	-	967	O
the	-	977	O
use	-	981	O
in	-	985	O
elderly	-	988	O
patients	-	996	O
of	-	1005	O
any	-	1008	O
of	-	1012	O
the	-	1015	O
ephedrine	-	1019	B
/	-	1028	O
propofol	-	1029	B
/	-	1037	O
mixtures	-	1038	O
studied	-	1047	O
.	-	1054	O

Neurotoxicity	230316	0	O
of	-	14	O
halogenated	-	17	B
hydroxyquinolines	-	29	I
:	-	46	O
clinical	-	48	O
analysis	-	57	O
of	-	66	O
cases	-	69	O
reported	-	75	O
outside	-	84	O
Japan	-	92	O
.	-	97	O

An	230316	99	O
analysis	-	102	O
is	-	111	O
presented	-	114	O
of	-	124	O
220	-	127	O
cases	-	131	O
of	-	137	O
possible	-	140	O
neurotoxic	-	149	O
reactions	-	160	O
to	-	170	O
halogenated	-	173	B
hydroxyquinolines	-	185	I
reported	-	203	O
from	-	212	O
outside	-	217	O
Japan	-	225	O
.	-	230	O

In	230316	232	O
80	-	235	O
cases	-	238	O
insufficient	-	244	O
information	-	257	O
was	-	269	O
available	-	273	O
for	-	283	O
adequate	-	287	O
comment	-	296	O
and	-	304	O
in	-	308	O
29	-	311	O
a	-	314	O
relationship	-	316	O
to	-	329	O
the	-	332	O
administration	-	336	O
of	-	351	O
clioquinol	-	354	B
could	-	365	O
be	-	371	O
excluded	-	374	O
.	-	382	O

Of	230316	384	O
the	-	387	O
remainder	-	391	O
,	-	400	O
a	-	402	O
relationship	-	404	O
to	-	417	O
clioquinol	-	420	B
was	-	431	O
considered	-	435	O
probable	-	446	O
in	-	455	O
42	-	458	O
and	-	461	O
possible	-	465	O
in	-	474	O
69	-	477	O
cases	-	480	O
.	-	485	O

In	230316	487	O
six	-	490	O
of	-	494	O
the	-	497	O
probable	-	501	O
cases	-	510	O
the	-	516	O
neurological	-	520	O
disturbance	-	533	O
consisted	-	545	O
of	-	555	O
an	-	558	O
acute	-	561	O
reversible	-	567	O
encephalopathy	-	578	O
usually	-	593	O
related	-	601	O
to	-	609	O
the	-	612	O
ingestion	-	616	O
of	-	626	O
a	-	629	O
high	-	631	O
dose	-	636	O
of	-	641	O
clioquinol	-	644	B
over	-	655	O
a	-	660	O
short	-	662	O
period	-	668	O
.	-	674	O

The	230316	676	O
most	-	680	O
common	-	685	O
manifestation	-	692	O
,	-	705	O
observed	-	707	O
in	-	716	O
15	-	719	O
further	-	722	O
cases	-	730	O
,	-	735	O
was	-	737	O
isolated	-	741	O
optic	-	750	O
atrophy	-	756	O
.	-	763	O

This	230316	765	O
was	-	770	O
most	-	774	O
frequently	-	779	O
found	-	790	O
in	-	796	O
children	-	799	O
,	-	807	O
many	-	809	O
of	-	814	O
whom	-	817	O
had	-	822	O
received	-	826	O
clioquinol	-	835	B
as	-	846	O
treatment	-	849	O
for	-	859	O
acrodermatitis	-	863	O
enteropathica	-	878	O
.	-	891	O

In	230316	893	O
the	-	896	O
remaining	-	900	O
cases	-	910	O
,	-	915	O
a	-	917	O
combination	-	919	O
of	-	931	O
myelopathy	-	934	O
,	-	944	O
visual	-	946	O
disturbance	-	953	O
,	-	964	O
and	-	966	O
peripheral	-	970	O
neuropathy	-	981	O
was	-	992	O
the	-	996	O
most	-	1000	O
common	-	1005	O
manifestation	-	1012	O
.	-	1025	O

Isolated	230316	1027	O
myelopathy	-	1036	O
or	-	1047	O
peripheral	-	1050	O
neuropathy	-	1061	O
,	-	1071	O
or	-	1073	O
these	-	1076	O
manifestations	-	1082	O
occurring	-	1097	O
together	-	1107	O
,	-	1115	O
were	-	1117	O
infrequent	-	1122	O
.	-	1132	O

The	230316	1134	O
onset	-	1138	O
of	-	1144	O
all	-	1147	O
manifestations	-	1151	O
(	-	1166	O
except	-	1167	O
toxic	-	1174	O
encephalopathy	-	1180	O
)	-	1194	O
was	-	1196	O
usually	-	1200	O
subacute	-	1208	O
,	-	1216	O
with	-	1218	O
subsequent	-	1223	O
partial	-	1234	O
recovery	-	1242	O
.	-	1250	O

Older	230316	1252	O
subjects	-	1258	O
tended	-	1267	O
to	-	1274	O
display	-	1277	O
more	-	1285	O
side	-	1290	O
effects	-	1295	O
.	-	1302	O

The	230316	1304	O
full	-	1308	O
syndrome	-	1313	O
of	-	1322	O
subacute	-	1325	O
myelo	-	1334	O
-	-	1339	O
optic	-	1340	O
neuropathy	-	1346	O
was	-	1357	O
more	-	1361	O
frequent	-	1366	O
in	-	1375	O
women	-	1378	O
,	-	1383	O
but	-	1385	O
they	-	1389	O
tended	-	1394	O
to	-	1401	O
have	-	1404	O
taken	-	1409	O
greater	-	1415	O
quantities	-	1423	O
of	-	1434	O
the	-	1437	O
drug	-	1441	O
.	-	1445	O

Epileptic	11807648	0	O
seizures	-	10	O
following	-	19	O
cortical	-	29	O
application	-	38	O
of	-	50	O
fibrin	-	53	O
sealants	-	60	O
containing	-	69	O
tranexamic	-	80	B
acid	-	91	I
in	-	96	O
rats	-	99	O
.	-	103	O

BACKGROUND	11807648	105	O
:	-	115	O

Fibrin	11807648	117	O
sealants	-	124	O
(	-	133	O
FS	-	134	O
)	-	136	O
derived	-	138	O
from	-	146	O
human	-	151	O
plasma	-	157	O
are	-	164	O
frequently	-	168	O
used	-	179	O
in	-	184	O
neurosurgery	-	187	O
.	-	199	O

In	11807648	201	O
order	-	204	O
to	-	210	O
increase	-	213	O
clot	-	222	O
stability	-	227	O
,	-	236	O
FS	-	238	O
typically	-	241	O
contain	-	251	O
aprotinin	-	259	O
,	-	268	O
a	-	270	O
natural	-	272	O
fibrinolysis	-	280	O
inhibitor	-	293	O
.	-	302	O

Recently	11807648	304	O
,	-	312	O
synthetic	-	314	O
fibrinolysis	-	324	O
inhibitors	-	337	O
such	-	348	O
as	-	353	O
tranexamic	-	356	B
acid	-	367	I
(	-	372	O
tAMCA	-	373	B
)	-	378	O
have	-	380	O
been	-	385	O
considered	-	390	O
as	-	401	O
substitutes	-	404	O
for	-	416	O
aprotinin	-	420	O
.	-	429	O

However	11807648	431	O
,	-	438	O
tAMCA	-	440	B
has	-	446	O
been	-	450	O
shown	-	455	O
to	-	461	O
cause	-	464	O
epileptic	-	470	O
seizures	-	480	O
.	-	488	O

We	11807648	490	O
wanted	-	493	O
to	-	500	O
study	-	503	O
whether	-	509	O
tAMCA	-	517	B
retains	-	523	O
its	-	531	O
convulsive	-	535	O
action	-	546	O
if	-	553	O
incorporated	-	556	O
into	-	569	O
a	-	574	O
FS	-	576	O
.	-	578	O

METHOD	11807648	580	O
:	-	586	O

FS	11807648	588	O
containing	-	591	O
aprotinin	-	602	O
or	-	612	O
different	-	615	O
concentrations	-	625	O
of	-	640	O
tAMCA	-	643	B
(	-	649	O
0	-	650	O
.	-	651	O
5	-	652	O
-	-	653	O
47	-	654	O
.	-	656	O
5	-	657	O
mg	-	659	O
/	-	661	O
ml	-	662	O
)	-	664	O
were	-	666	O
applied	-	671	O
to	-	679	O
the	-	682	O
pial	-	686	O
surface	-	691	O
of	-	699	O
the	-	702	O
cortex	-	706	O
of	-	713	O
anaesthetized	-	716	O
rats	-	730	O
.	-	734	O

The	11807648	736	O
response	-	740	O
of	-	749	O
the	-	752	O
animals	-	756	O
was	-	764	O
evaluated	-	768	O
using	-	778	O
electroencephalography	-	784	O
and	-	807	O
by	-	811	O
monitoring	-	814	O
the	-	825	O
clinical	-	829	O
behaviour	-	838	O
during	-	848	O
and	-	855	O
after	-	859	O
recovery	-	865	O
from	-	874	O
anaesthesia	-	879	O
.	-	890	O

FINDINGS	11807648	892	O
:	-	900	O
FS	-	902	O
containing	-	905	O
tAMCA	-	916	B
caused	-	922	O
paroxysmal	-	929	O
brain	-	940	O
activity	-	946	O
which	-	955	O
was	-	961	O
associated	-	965	O
with	-	976	O
distinct	-	981	O
convulsive	-	990	O
behaviours	-	1001	O
.	-	1011	O

The	11807648	1013	O
degree	-	1017	O
of	-	1024	O
these	-	1027	O
seizures	-	1033	O
increased	-	1042	O
with	-	1052	O
increasing	-	1057	O
concentration	-	1068	O
of	-	1082	O
tAMCA	-	1085	B
.	-	1090	O

Thus	11807648	1092	O
,	-	1096	O
FS	-	1098	O
containing	-	1101	O
47	-	1112	O
.	-	1114	O
5	-	1115	O
mg	-	1117	O
/	-	1119	O
ml	-	1120	O
tAMCA	-	1123	B
evoked	-	1129	O
generalized	-	1136	O
seizures	-	1148	O
in	-	1157	O
all	-	1160	O
tested	-	1164	O
rats	-	1171	O
(	-	1176	O
n	-	1177	O
=	-	1178	O
6	-	1179	O
)	-	1180	O
while	-	1182	O
the	-	1188	O
lowest	-	1192	O
concentration	-	1199	O
of	-	1213	O
tAMCA	-	1216	B
(	-	1222	O
0	-	1223	O
.	-	1224	O
5	-	1225	O
mg	-	1227	O
/	-	1229	O
ml	-	1230	O
)	-	1232	O
only	-	1234	O
evoked	-	1239	O
brief	-	1246	O
episodes	-	1252	O
of	-	1261	O
jerk	-	1264	O
-	-	1268	O
correlated	-	1269	O
convulsive	-	1280	O
potentials	-	1291	O
in	-	1302	O
1	-	1305	O
of	-	1307	O
6	-	1310	O
rats	-	1312	O
.	-	1316	O

In	11807648	1318	O
contrast	-	1321	O
,	-	1329	O
FS	-	1331	O
containing	-	1334	O
aprotinin	-	1345	O
did	-	1355	O
not	-	1359	O
evoke	-	1363	O
any	-	1369	O
paroxysmal	-	1373	O
activity	-	1384	O
.	-	1392	O

INTERPRETATION	11807648	1394	O
:	-	1408	O

Tranexamic	11807648	1410	B
acid	-	1421	I
retains	-	1426	O
its	-	1434	O
convulsive	-	1438	O
action	-	1449	O
within	-	1456	O
FS	-	1463	O
.	-	1465	O

Thus	11807648	1467	O
,	-	1471	O
use	-	1473	O
of	-	1477	O
FS	-	1480	O
containing	-	1483	O
tAMCA	-	1494	B
for	-	1500	O
surgery	-	1504	O
within	-	1512	O
or	-	1519	O
close	-	1522	O
to	-	1528	O
the	-	1531	O
CNS	-	1535	O
may	-	1539	O
pose	-	1543	O
a	-	1548	O
substantial	-	1550	O
risk	-	1562	O
to	-	1567	O
the	-	1570	O
patient	-	1574	O
.	-	1581	O

A	14596845	0	O
diet	-	2	O
promoting	-	7	O
sugar	-	17	O
dependency	-	23	O
causes	-	34	O
behavioral	-	41	O
cross	-	52	O
-	-	57	O
sensitization	-	58	O
to	-	72	O
a	-	75	O
low	-	77	O
dose	-	81	O
of	-	86	O
amphetamine	-	89	B
.	-	100	O

Previous	14596845	102	O
research	-	111	O
in	-	120	O
this	-	123	O
laboratory	-	128	O
has	-	139	O
shown	-	143	O
that	-	149	O
a	-	154	O
diet	-	156	O
of	-	161	O
intermittent	-	164	O
excessive	-	177	O
sugar	-	187	O
consumption	-	193	O
produces	-	205	O
a	-	214	O
state	-	216	O
with	-	222	O
neurochemical	-	227	O
and	-	241	O
behavioral	-	245	O
similarities	-	256	O
to	-	269	O
drug	-	272	O
dependency	-	277	O
.	-	287	O

The	14596845	289	O
present	-	293	O
study	-	301	O
examined	-	307	O
whether	-	316	O
female	-	324	O
rats	-	331	O
on	-	336	O
various	-	339	O
regimens	-	347	O
of	-	356	O
sugar	-	359	O
access	-	365	O
would	-	372	O
show	-	378	O
behavioral	-	383	O
cross	-	394	O
-	-	399	O
sensitization	-	400	O
to	-	414	O
a	-	417	O
low	-	419	O
dose	-	423	O
of	-	428	O
amphetamine	-	431	B
.	-	442	O

After	14596845	444	O
a	-	450	O
30	-	452	O
-	-	454	O
min	-	455	O
baseline	-	459	O
measure	-	468	O
of	-	476	O
locomotor	-	479	O
activity	-	489	O
(	-	498	O
day	-	499	O
0	-	503	O
)	-	504	O
,	-	505	O
animals	-	507	O
were	-	515	O
maintained	-	520	O
on	-	531	O
a	-	534	O
cyclic	-	536	O
diet	-	543	O
of	-	548	O
12	-	551	O
-	-	553	O
h	-	554	O
deprivation	-	556	O
followed	-	568	O
by	-	577	O
12	-	580	O
-	-	582	O
h	-	583	O
access	-	585	O
to	-	592	O
10	-	595	O
%	-	597	O
sucrose	-	599	B
solution	-	607	O
and	-	616	O
chow	-	620	O
pellets	-	625	O
(	-	633	O
12	-	634	O
h	-	637	O
access	-	639	O
starting	-	646	O
4	-	655	O
h	-	657	O
after	-	659	O
onset	-	665	O
of	-	671	O
the	-	674	O
dark	-	678	O
period	-	683	O
)	-	689	O
for	-	691	O
21	-	695	O
days	-	698	O
.	-	702	O

Locomotor	14596845	704	O
activity	-	714	O
was	-	723	O
measured	-	727	O
again	-	736	O
for	-	742	O
30	-	746	O
min	-	749	O
at	-	753	O
the	-	756	O
beginning	-	760	O
of	-	770	O
days	-	773	O
1	-	778	O
and	-	780	O
21	-	784	O
of	-	787	O
sugar	-	790	O
access	-	796	O
.	-	802	O

Beginning	14596845	804	O
on	-	814	O
day	-	817	O
22	-	821	O
,	-	823	O
all	-	825	O
rats	-	829	O
were	-	834	O
maintained	-	839	O
on	-	850	O
ad	-	853	O
libitum	-	856	O
chow	-	864	O
.	-	868	O

Nine	14596845	870	O
days	-	875	O
later	-	880	O
locomotor	-	886	O
activity	-	896	O
was	-	905	O
measured	-	909	O
in	-	918	O
response	-	921	O
to	-	930	O
a	-	933	O
single	-	935	O
low	-	942	O
dose	-	946	O
of	-	951	O
amphetamine	-	954	B
(	-	966	O
0	-	967	O
.	-	968	O
5	-	969	O
mg	-	971	O
/	-	973	O
kg	-	974	O
)	-	976	O
.	-	977	O

The	14596845	979	O
animals	-	983	O
that	-	991	O
had	-	996	O
experienced	-	1000	O
cyclic	-	1012	O
sucrose	-	1019	B
and	-	1027	O
chow	-	1031	O
were	-	1036	O
hyperactive	-	1041	O
in	-	1053	O
response	-	1056	O
to	-	1065	O
amphetamine	-	1068	B
compared	-	1080	O
with	-	1089	O
four	-	1094	O
control	-	1099	O
groups	-	1107	O
(	-	1114	O
ad	-	1115	O
libitum	-	1118	O
10	-	1126	O
%	-	1128	O
sucrose	-	1130	B
and	-	1138	O
chow	-	1142	O
followed	-	1147	O
by	-	1156	O
amphetamine	-	1159	B
injection	-	1171	O
,	-	1180	O
cyclic	-	1182	O
chow	-	1189	O
followed	-	1194	O
by	-	1203	O
amphetamine	-	1206	B
injection	-	1218	O
,	-	1227	O
ad	-	1229	O
libitum	-	1232	O
chow	-	1240	O
with	-	1245	O
amphetamine	-	1250	B
,	-	1261	O
or	-	1263	O
cyclic	-	1266	O
10	-	1273	O
%	-	1275	O
sucrose	-	1277	B
and	-	1285	O
chow	-	1289	O
with	-	1294	O
a	-	1299	O
saline	-	1301	O
injection	-	1308	O
)	-	1317	O
.	-	1318	O

These	14596845	1320	O
results	-	1326	O
suggest	-	1334	O
that	-	1342	O
a	-	1347	O
diet	-	1349	O
comprised	-	1354	O
of	-	1364	O
alternating	-	1367	O
deprivation	-	1379	O
and	-	1391	O
access	-	1395	O
to	-	1402	O
a	-	1405	O
sugar	-	1407	O
solution	-	1413	O
and	-	1422	O
chow	-	1426	O
produces	-	1431	O
bingeing	-	1440	O
on	-	1449	O
sugar	-	1452	O
that	-	1458	O
leads	-	1463	O
to	-	1469	O
a	-	1472	O
long	-	1474	O
lasting	-	1479	O
state	-	1487	O
of	-	1493	O
increased	-	1496	O
sensitivity	-	1506	O
to	-	1518	O
amphetamine	-	1521	B
,	-	1532	O
possibly	-	1534	O
due	-	1543	O
to	-	1547	O
a	-	1550	O
lasting	-	1552	O
alteration	-	1560	O
in	-	1571	O
the	-	1574	O
dopamine	-	1578	B
system	-	1587	O
.	-	1593	O

D	6666578	0	B
-	-	1	I
penicillamine	-	2	I
-	-	15	O
induced	-	16	O
angiopathy	-	24	O
in	-	35	O
rats	-	38	O
.	-	42	O

The	6666578	44	O
effect	-	48	O
of	-	55	O
high	-	58	O
dose	-	63	O
D	-	68	B
-	-	69	I
penicillamine	-	70	I
treatment	-	84	O
on	-	94	O
aortic	-	97	O
permeability	-	104	O
to	-	117	O
albumin	-	120	O
and	-	128	O
on	-	132	O
the	-	135	O
ultrastructure	-	139	O
of	-	154	O
the	-	157	O
vessel	-	161	O
.	-	167	O

Male	6666578	169	O
Sprague	-	174	O
-	-	181	O
Dawley	-	182	O
rats	-	189	O
were	-	194	O
treated	-	199	O
with	-	207	O
D	-	212	B
-	-	213	I
penicillamine	-	214	I
(	-	228	O
D	-	229	B
-	-	230	I
pen	-	231	I
)	-	234	O
500	-	236	O
mg	-	240	O
/	-	242	O
kg	-	243	O
/	-	245	O
day	-	246	O
for	-	250	O
10	-	254	O
or	-	257	O
42	-	260	O
days	-	263	O
.	-	267	O

Pair	6666578	269	O
fed	-	274	O
rats	-	278	O
served	-	283	O
as	-	290	O
controls	-	293	O
.	-	301	O

Changes	6666578	303	O
in	-	311	O
aortic	-	314	O
morphology	-	321	O
were	-	332	O
examined	-	337	O
by	-	346	O
light	-	349	O
-	-	354	O
and	-	356	O
transmission	-	360	O
-	-	372	O
electron	-	373	O
microscopy	-	382	O
(	-	393	O
TEM	-	394	O
)	-	397	O
.	-	398	O

In	6666578	400	O
addition	-	403	O
,	-	411	O
the	-	413	O
endothelial	-	417	O
permeability	-	429	O
and	-	442	O
the	-	446	O
penetration	-	450	O
through	-	462	O
the	-	470	O
aortic	-	474	O
wall	-	481	O
of	-	486	O
albumin	-	489	O
were	-	497	O
studied	-	502	O
10	-	510	O
minutes	-	513	O
,	-	520	O
24	-	522	O
and	-	525	O
48	-	529	O
hours	-	532	O
after	-	538	O
i	-	544	O
.	-	545	O
v	-	547	O
.	-	548	O
injection	-	550	O
of	-	560	O
human	-	563	O
serum	-	569	O
131I	-	575	O
-	-	579	O
albumin	-	580	O
(	-	588	O
131I	-	589	O
-	-	593	O
HSA	-	594	O
)	-	597	O
.	-	598	O

TEM	6666578	600	O
revealed	-	604	O
extensive	-	613	O
elastolysis	-	623	O
in	-	635	O
the	-	638	O
arterial	-	642	O
wall	-	651	O
of	-	656	O
D	-	659	B
-	-	660	I
pen	-	661	I
-	-	664	O
treated	-	665	O
rats	-	673	O
,	-	677	O
consistent	-	679	O
with	-	690	O
an	-	695	O
inhibitory	-	698	O
effect	-	709	O
on	-	716	O
crosslink	-	719	O
formation	-	729	O
.	-	738	O

In	6666578	740	O
experimental	-	743	O
animals	-	756	O
excess	-	764	O
deposition	-	771	O
of	-	782	O
collagen	-	785	O
and	-	794	O
glycoaminoglycans	-	798	O
was	-	816	O
observed	-	820	O
in	-	829	O
the	-	832	O
subendothelial	-	836	O
and	-	851	O
medial	-	855	O
layer	-	862	O
of	-	868	O
the	-	871	O
aortic	-	875	O
wall	-	882	O
,	-	886	O
together	-	888	O
with	-	897	O
prominent	-	902	O
basal	-	912	O
membrane	-	918	O
substance	-	927	O
around	-	937	O
aortic	-	944	O
smooth	-	951	O
muscle	-	958	O
cells	-	965	O
.	-	970	O

The	6666578	972	O
aorta	-	976	O
/	-	981	O
serum	-	982	O
-	-	987	O
ratio	-	988	O
and	-	994	O
the	-	998	O
radioactive	-	1002	O
build	-	1014	O
-	-	1019	O
up	-	1020	O
24	-	1023	O
and	-	1026	O
48	-	1030	O
hours	-	1033	O
after	-	1039	O
injection	-	1045	O
of	-	1055	O
131I	-	1058	O
-	-	1062	O
HSA	-	1063	O
was	-	1067	O
reduced	-	1071	O
in	-	1079	O
animals	-	1082	O
treated	-	1090	O
with	-	1098	O
D	-	1103	B
-	-	1104	I
pen	-	1105	I
for	-	1109	O
42	-	1113	O
days	-	1116	O
,	-	1120	O
indicating	-	1122	O
an	-	1133	O
impeded	-	1136	O
transmural	-	1144	O
transport	-	1155	O
of	-	1165	O
tracer	-	1168	O
which	-	1175	O
may	-	1181	O
be	-	1185	O
caused	-	1188	O
by	-	1195	O
a	-	1198	O
steric	-	1200	O
exclusion	-	1207	O
effect	-	1217	O
of	-	1224	O
abundant	-	1227	O
hyaluronate	-	1236	B
.	-	1247	O

The	6666578	1249	O
endothelial	-	1253	O
ultrastructure	-	1265	O
was	-	1280	O
unaffected	-	1284	O
by	-	1295	O
D	-	1298	B
-	-	1299	I
pen	-	1300	I
,	-	1303	O
and	-	1305	O
no	-	1309	O
differences	-	1312	O
in	-	1324	O
aortic	-	1327	O
131I	-	1334	O
-	-	1338	O
HSA	-	1339	O
radioactivity	-	1343	O
or	-	1357	O
aorta	-	1360	O
/	-	1365	O
serum	-	1366	O
-	-	1371	O
ratio	-	1372	O
were	-	1378	O
recorded	-	1383	O
between	-	1392	O
experimental	-	1400	O
and	-	1413	O
control	-	1417	O
groups	-	1425	O
10	-	1432	O
minutes	-	1435	O
after	-	1443	O
tracer	-	1449	O
injection	-	1456	O
,	-	1465	O
indicating	-	1467	O
that	-	1478	O
the	-	1483	O
permeability	-	1487	O
of	-	1500	O
the	-	1503	O
endothelial	-	1507	O
barrier	-	1519	O
to	-	1527	O
albumin	-	1530	O
remained	-	1538	O
unaffected	-	1547	O
by	-	1558	O
D	-	1561	B
-	-	1562	I
pen	-	1563	I
treatment	-	1567	O
.	-	1576	O

These	6666578	1578	O
observations	-	1584	O
support	-	1597	O
the	-	1605	O
hypothesis	-	1609	O
that	-	1620	O
treatment	-	1625	O
with	-	1635	O
high	-	1640	O
doses	-	1645	O
of	-	1651	O
D	-	1654	B
-	-	1655	I
pen	-	1656	I
may	-	1660	O
induce	-	1664	O
a	-	1671	O
fibroproliferative	-	1673	O
response	-	1692	O
in	-	1701	O
rat	-	1704	O
aorta	-	1708	O
,	-	1713	O
possibly	-	1715	O
by	-	1724	O
an	-	1727	O
inhibitory	-	1730	O
effect	-	1741	O
on	-	1748	O
the	-	1751	O
cross	-	1755	O
-	-	1760	O
linking	-	1761	O
of	-	1769	O
collagen	-	1772	O
and	-	1781	O
elastin	-	1785	O
.	-	1792	O

Brain	11279304	0	O
natriuretic	-	6	O
peptide	-	18	O
is	-	26	O
a	-	29	O
predictor	-	31	O
of	-	41	O
anthracycline	-	44	B
-	-	57	O
induced	-	58	O
cardiotoxicity	-	66	O
.	-	80	O

Anthracyclines	11279304	82	B
are	-	97	O
effective	-	101	O
antineoplastic	-	111	O
drugs	-	126	O
,	-	131	O
but	-	133	O
they	-	137	O
frequently	-	142	O
cause	-	153	O
dose	-	159	O
-	-	163	O
related	-	164	O
cardiotoxicity	-	172	O
.	-	186	O

The	11279304	188	O
cardiotoxicity	-	192	O
of	-	207	O
conventional	-	210	O
anthracycline	-	223	B
therapy	-	237	O
highlights	-	245	O
a	-	256	O
need	-	258	O
to	-	263	O
search	-	266	O
for	-	273	O
methods	-	277	O
that	-	285	O
are	-	290	O
highly	-	294	O
sensitive	-	301	O
and	-	311	O
capable	-	315	O
of	-	323	O
predicting	-	326	O
cardiac	-	337	O
dysfunction	-	345	O
.	-	356	O

We	11279304	358	O
measured	-	361	O
the	-	370	O
plasma	-	374	O
level	-	381	O
of	-	387	O
brain	-	390	O
natriuretic	-	396	O
peptide	-	408	O
(	-	416	O
BNP	-	417	O
)	-	420	O
to	-	422	O
determine	-	425	O
whether	-	435	O
BNP	-	443	O
might	-	447	O
serve	-	453	O
as	-	459	O
a	-	462	O
simple	-	464	O
diagnostic	-	471	O
indicator	-	482	O
of	-	492	O
anthracycline	-	495	B
-	-	508	O
induced	-	509	O
cardiotoxicity	-	517	O
in	-	532	O
patients	-	535	O
with	-	544	O
acute	-	549	O
leukemia	-	555	O
treated	-	564	O
with	-	572	O
a	-	577	O
daunorubicin	-	579	B
(	-	592	O
DNR	-	593	B
)	-	596	O
-	-	597	O
containing	-	598	O
regimen	-	609	O
.	-	616	O

Thirteen	11279304	618	O
patients	-	627	O
with	-	636	O
acute	-	641	O
leukemia	-	647	O
were	-	656	O
treated	-	661	O
with	-	669	O
a	-	674	O
DNR	-	676	B
-	-	679	O
containing	-	680	O
regimen	-	691	O
.	-	698	O

Cardiac	11279304	700	O
functions	-	708	O
were	-	718	O
evaluated	-	723	O
with	-	733	O
radionuclide	-	738	O
angiography	-	751	O
before	-	763	O
chemotherapies	-	770	O
.	-	784	O

The	11279304	786	O
plasma	-	790	O
levels	-	797	O
of	-	804	O
atrial	-	807	O
natriuretic	-	814	O
peptide	-	826	O
(	-	834	O
ANP	-	835	O
)	-	838	O
and	-	840	O
BNP	-	844	O
were	-	848	O
measured	-	853	O
at	-	862	O
the	-	865	O
time	-	869	O
of	-	874	O
radionuclide	-	877	O
angiography	-	890	O
.	-	901	O

Three	11279304	903	O
patients	-	909	O
developed	-	918	O
congestive	-	928	O
heart	-	939	O
failure	-	945	O
after	-	953	O
the	-	959	O
completion	-	963	O
of	-	974	O
chemotherapy	-	977	O
.	-	989	O

Five	11279304	991	O
patients	-	996	O
were	-	1005	O
diagnosed	-	1010	O
as	-	1020	O
having	-	1023	O
subclinical	-	1030	O
heart	-	1042	O
failure	-	1048	O
after	-	1056	O
the	-	1062	O
completion	-	1066	O
of	-	1077	O
chemotherapy	-	1080	O
.	-	1092	O

The	11279304	1094	O
plasma	-	1098	O
levels	-	1105	O
of	-	1112	O
BNP	-	1115	O
in	-	1119	O
all	-	1122	O
the	-	1126	O
patients	-	1130	O
with	-	1139	O
clinical	-	1144	O
and	-	1153	O
subclinical	-	1157	O
heart	-	1169	O
failure	-	1175	O
increased	-	1183	O
above	-	1193	O
the	-	1199	O
normal	-	1203	O
limit	-	1210	O
(	-	1216	O
40	-	1217	O
pg	-	1220	O
/	-	1222	O
ml	-	1223	O
)	-	1225	O
before	-	1227	O
the	-	1234	O
detection	-	1238	O
of	-	1248	O
clinical	-	1251	O
or	-	1260	O
subclinical	-	1263	O
heart	-	1275	O
failure	-	1281	O
by	-	1289	O
radionuclide	-	1292	O
angiography	-	1305	O
.	-	1316	O

On	11279304	1318	O
the	-	1321	O
other	-	1325	O
hand	-	1331	O
,	-	1335	O
BNP	-	1337	O
did	-	1341	O
not	-	1345	O
increase	-	1349	O
in	-	1358	O
the	-	1361	O
patients	-	1365	O
without	-	1374	O
heart	-	1382	O
failure	-	1388	O
given	-	1396	O
DNR	-	1402	B
,	-	1405	O
even	-	1407	O
at	-	1412	O
more	-	1415	O
than	-	1420	O
700	-	1425	O
mg	-	1429	O
/	-	1431	O
m	-	1432	O
(	-	1433	O
2	-	1434	O
)	-	1435	O
.	-	1436	O

The	11279304	1438	O
plasma	-	1442	O
level	-	1449	O
of	-	1455	O
ANP	-	1458	O
did	-	1462	O
not	-	1466	O
always	-	1470	O
increase	-	1477	O
in	-	1486	O
all	-	1489	O
the	-	1493	O
patients	-	1497	O
with	-	1506	O
clinical	-	1511	O
and	-	1520	O
subclinical	-	1524	O
heart	-	1536	O
failure	-	1542	O
.	-	1549	O

These	11279304	1551	O
preliminary	-	1557	O
results	-	1569	O
suggest	-	1577	O
that	-	1585	O
BNP	-	1590	O
may	-	1594	O
be	-	1598	O
useful	-	1601	O
as	-	1608	O
an	-	1611	O
early	-	1614	O
and	-	1620	O
sensitive	-	1624	O
indicator	-	1634	O
of	-	1644	O
anthracycline	-	1647	B
-	-	1660	O
induced	-	1661	O
cardiotoxicity	-	1669	O
.	-	1683	O

Antibacterial	19884587	0	O
medication	-	14	O
use	-	25	O
during	-	29	O
pregnancy	-	36	O
and	-	46	O
risk	-	50	O
of	-	55	O
birth	-	58	O
defects	-	64	O
:	-	71	O
National	-	73	O
Birth	-	82	O
Defects	-	88	O
Prevention	-	96	O
Study	-	107	O
.	-	112	O

OBJECTIVE	19884587	114	O
:	-	123	O

To	19884587	125	O
estimate	-	128	O
the	-	137	O
association	-	141	O
between	-	153	O
antibacterial	-	161	O
medications	-	175	O
and	-	187	O
selected	-	191	O
birth	-	200	O
defects	-	206	O
.	-	213	O

DESIGN	19884587	215	O
,	-	221	O
SETTING	-	223	O
,	-	230	O
AND	-	232	O
PARTICIPANTS	-	236	O
:	-	248	O
Population	-	250	O
-	-	260	O
based	-	261	O
,	-	266	O
multisite	-	268	O
,	-	277	O
case	-	279	O
-	-	283	O
control	-	284	O
study	-	292	O
of	-	298	O
women	-	301	O
who	-	307	O
had	-	311	O
pregnancies	-	315	O
affected	-	327	O
by	-	336	O
1	-	339	O
of	-	341	O
more	-	344	O
than	-	349	O
30	-	354	O
eligible	-	357	O
major	-	366	O
birth	-	372	O
defects	-	378	O
identified	-	386	O
via	-	397	O
birth	-	401	O
defect	-	407	O
surveillance	-	414	O
programs	-	427	O
in	-	436	O
10	-	439	O
states	-	442	O
(	-	449	O
n	-	450	O
=	-	452	O
13	-	454	O
155	-	457	O
)	-	460	O
and	-	462	O
control	-	466	O
women	-	474	O
randomly	-	480	O
selected	-	489	O
from	-	498	O
the	-	503	O
same	-	507	O
geographical	-	512	O
regions	-	525	O
(	-	533	O
n	-	534	O
=	-	536	O
4941	-	538	O
)	-	542	O
.	-	543	O

MAIN	19884587	545	O
EXPOSURE	-	550	O
:	-	558	O

Reported	19884587	560	O
maternal	-	569	O
use	-	578	O
of	-	582	O
antibacterials	-	585	O
(	-	600	O
1	-	601	O
month	-	603	O
before	-	609	O
pregnancy	-	616	O
through	-	626	O
the	-	634	O
end	-	638	O
of	-	642	O
the	-	645	O
first	-	649	O
trimester	-	655	O
)	-	664	O
.	-	665	O

MAIN	19884587	667	O
OUTCOME	-	672	O
MEASURE	-	680	O
:	-	687	O

Odds	19884587	689	O
ratios	-	694	O
(	-	701	O
ORs	-	702	O
)	-	705	O
measuring	-	707	O
the	-	717	O
association	-	721	O
between	-	733	O
antibacterial	-	741	O
use	-	755	O
and	-	759	O
selected	-	763	O
birth	-	772	O
defects	-	778	O
adjusted	-	786	O
for	-	795	O
potential	-	799	O
confounders	-	809	O
.	-	820	O

RESULTS	19884587	822	O
:	-	829	O

The	19884587	831	O
reported	-	835	O
use	-	844	O
of	-	848	O
antibacterials	-	851	O
increased	-	866	O
during	-	876	O
pregnancy	-	883	O
,	-	892	O
peaking	-	894	O
during	-	902	O
the	-	909	O
third	-	913	O
month	-	919	O
.	-	924	O

Sulfonamides	19884587	926	B
were	-	939	O
associated	-	944	O
with	-	955	O
anencephaly	-	960	O
(	-	972	O
adjusted	-	973	O
OR	-	982	O
[	-	985	O
AOR	-	986	O
]	-	989	O
=	-	991	O

3	19884587	993	O
.	-	994	O
4	-	995	O
;	-	996	O
95	-	998	O
%	-	1000	O
confidence	-	1002	O
interval	-	1013	O
[	-	1022	O
CI	-	1023	O
]	-	1025	O
,	-	1026	O
1	-	1028	O
.	-	1029	O
3	-	1030	O
-	-	1031	O
8	-	1032	O
.	-	1033	O
8	-	1034	O
)	-	1035	O
,	-	1036	O
hypoplastic	-	1038	O
left	-	1050	O
heart	-	1055	O
syndrome	-	1061	O
(	-	1070	O
AOR	-	1071	O
=	-	1075	O
3	-	1077	O
.	-	1078	O
2	-	1079	O
;	-	1080	O
95	-	1082	O
%	-	1084	O
CI	-	1086	O
,	-	1088	O
1	-	1090	O
.	-	1091	O
3	-	1092	O
-	-	1093	O
7	-	1094	O
.	-	1095	O
6	-	1096	O
)	-	1097	O
,	-	1098	O
coarctation	-	1100	O
of	-	1112	O
the	-	1115	O
aorta	-	1119	O
(	-	1125	O
AOR	-	1126	O
=	-	1130	O
2	-	1132	O
.	-	1133	O
7	-	1134	O
;	-	1135	O
95	-	1137	O
%	-	1139	O
CI	-	1141	O
,	-	1143	O
1	-	1145	O
.	-	1146	O
3	-	1147	O
-	-	1148	O
5	-	1149	O
.	-	1150	O
6	-	1151	O
)	-	1152	O
,	-	1153	O
choanal	-	1155	O
atresia	-	1163	O
(	-	1171	O
AOR	-	1172	O
=	-	1176	O
8	-	1178	O
.	-	1179	O
0	-	1180	O
;	-	1181	O
95	-	1183	O
%	-	1185	O
CI	-	1187	O
,	-	1189	O
2	-	1191	O
.	-	1192	O
7	-	1193	O
-	-	1194	O
23	-	1195	O
.	-	1197	O
5	-	1198	O
)	-	1199	O
,	-	1200	O
transverse	-	1202	O
limb	-	1213	O
deficiency	-	1218	O
(	-	1229	O
AOR	-	1230	O
=	-	1234	O
2	-	1236	O
.	-	1237	O
5	-	1238	O
;	-	1239	O
95	-	1241	O
%	-	1243	O
CI	-	1245	O
,	-	1247	O
1	-	1249	O
.	-	1250	O
0	-	1251	O
-	-	1252	O
5	-	1253	O
.	-	1254	O
9	-	1255	O
)	-	1256	O
,	-	1257	O
and	-	1259	O
diaphragmatic	-	1263	O
hernia	-	1277	O
(	-	1284	O
AOR	-	1285	O
=	-	1289	O
2	-	1291	O
.	-	1292	O
4	-	1293	O
;	-	1294	O
95	-	1296	O
%	-	1298	O
CI	-	1300	O
,	-	1302	O
1	-	1304	O
.	-	1305	O
1	-	1306	O
-	-	1307	O
5	-	1308	O
.	-	1309	O
4	-	1310	O
)	-	1311	O
.	-	1312	O

Nitrofurantoins	19884587	1314	B
were	-	1330	O
associated	-	1335	O
with	-	1346	O
anophthalmia	-	1351	O
or	-	1364	O
microphthalmos	-	1367	O
(	-	1382	O
AOR	-	1383	O
=	-	1387	O
3	-	1389	O
.	-	1390	O
7	-	1391	O
;	-	1392	O
95	-	1394	O
%	-	1396	O
CI	-	1398	O
,	-	1400	O
1	-	1402	O
.	-	1403	O
1	-	1404	O
-	-	1405	O
12	-	1406	O
.	-	1408	O
2	-	1409	O
)	-	1410	O
,	-	1411	O
hypoplastic	-	1413	O
left	-	1425	O
heart	-	1430	O
syndrome	-	1436	O
(	-	1445	O
AOR	-	1446	O
=	-	1450	O
4	-	1452	O
.	-	1453	O
2	-	1454	O
;	-	1455	O
95	-	1457	O
%	-	1459	O
CI	-	1461	O
,	-	1463	O
1	-	1465	O
.	-	1466	O
9	-	1467	O
-	-	1468	O
9	-	1469	O
.	-	1470	O
1	-	1471	O
)	-	1472	O
,	-	1473	O
atrial	-	1475	O
septal	-	1482	O
defects	-	1489	O
(	-	1497	O
AOR	-	1498	O
=	-	1502	O
1	-	1504	O
.	-	1505	O
9	-	1506	O
;	-	1507	O
95	-	1509	O
%	-	1511	O
CI	-	1513	O
,	-	1515	O
1	-	1517	O
.	-	1518	O
1	-	1519	O
-	-	1520	O
3	-	1521	O
.	-	1522	O
4	-	1523	O
)	-	1524	O
,	-	1525	O
and	-	1527	O
cleft	-	1531	O
lip	-	1537	O
with	-	1541	O
cleft	-	1546	O
palate	-	1552	O
(	-	1559	O
AOR	-	1560	O
=	-	1564	O
2	-	1566	O
.	-	1567	O
1	-	1568	O
;	-	1569	O
95	-	1571	O
%	-	1573	O
CI	-	1575	O
,	-	1577	O
1	-	1579	O
.	-	1580	O
2	-	1581	O
-	-	1582	O
3	-	1583	O
.	-	1584	O
9	-	1585	O
)	-	1586	O
.	-	1587	O

Other	19884587	1589	O
antibacterial	-	1595	O
agents	-	1609	O
that	-	1616	O
showed	-	1621	O
associations	-	1628	O
included	-	1641	O
erythromycins	-	1650	B
(	-	1664	O
2	-	1665	O
defects	-	1667	O
)	-	1674	O
,	-	1675	O
penicillins	-	1677	B
(	-	1689	O
1	-	1690	O
defect	-	1692	O
)	-	1698	O
,	-	1699	O
cephalosporins	-	1701	B
(	-	1716	O
1	-	1717	O
defect	-	1719	O
)	-	1725	O
,	-	1726	O
and	-	1728	O
quinolones	-	1732	B
(	-	1743	O
1	-	1744	O
defect	-	1746	O
)	-	1752	O
.	-	1753	O

CONCLUSIONS	19884587	1755	O
:	-	1766	O

Reassuringly	19884587	1768	O
,	-	1780	O
penicillins	-	1782	B
,	-	1793	O
erythromycins	-	1795	B
,	-	1808	O
and	-	1810	O
cephalosporins	-	1814	B
,	-	1828	O
although	-	1830	O
used	-	1839	O
commonly	-	1844	O
by	-	1853	O
pregnant	-	1856	O
women	-	1865	O
,	-	1870	O
were	-	1872	O
not	-	1877	O
associated	-	1881	O
with	-	1892	O
many	-	1897	O
birth	-	1902	O
defects	-	1908	O
.	-	1915	O

Sulfonamides	19884587	1917	B
and	-	1930	O
nitrofurantoins	-	1934	B
were	-	1950	O
associated	-	1955	O
with	-	1966	O
several	-	1971	O
birth	-	1979	O
defects	-	1985	O
,	-	1992	O
indicating	-	1994	O
a	-	2005	O
need	-	2007	O
for	-	2012	O
additional	-	2016	O
scrutiny	-	2027	O
.	-	2035	O

Incidence	3970039	0	O
of	-	10	O
neoplasms	-	13	O
in	-	23	O
patients	-	26	O
with	-	35	O
rheumatoid	-	40	O
arthritis	-	51	O
exposed	-	61	O
to	-	69	O
different	-	72	O
treatment	-	82	O
regimens	-	92	O
.	-	100	O

Immunosuppressive	3970039	102	O
drugs	-	120	O
have	-	126	O
been	-	131	O
used	-	136	O
during	-	141	O
the	-	148	O
last	-	152	O
30	-	157	O
years	-	160	O
in	-	166	O
treatment	-	169	O
of	-	179	O
patients	-	182	O
with	-	191	O
severe	-	196	O
rheumatoid	-	203	O
arthritis	-	214	O
.	-	223	O

The	3970039	225	O
drugs	-	229	O
commonly	-	235	O
used	-	244	O
are	-	249	O
cyclophosphamide	-	253	B
and	-	270	O
chlorambucil	-	274	B
(	-	287	O
alkylating	-	288	B
agents	-	299	I
)	-	305	O
,	-	306	O
azathioprine	-	308	B
(	-	321	O
purine	-	322	B
analogue	-	329	O
)	-	337	O
,	-	338	O
and	-	340	O
methotrexate	-	344	B
(	-	357	O
folic	-	358	B
acid	-	364	I
analogue	-	369	O
)	-	377	O
.	-	378	O

There	3970039	380	O
is	-	386	O
evidence	-	389	O
that	-	398	O
all	-	403	O
four	-	407	O
immunosuppressive	-	412	O
drugs	-	430	O
can	-	436	O
reduce	-	440	O
synovitis	-	447	O
,	-	456	O
but	-	458	O
disease	-	462	O
activity	-	470	O
almost	-	479	O
always	-	486	O
recurs	-	493	O
after	-	500	O
therapy	-	506	O
is	-	514	O
stopped	-	517	O
.	-	524	O

Since	3970039	526	O
adverse	-	532	O
reactions	-	540	O
are	-	550	O
frequent	-	554	O
,	-	562	O
less	-	564	O
than	-	569	O
50	-	574	O
percent	-	577	O
of	-	585	O
patients	-	588	O
are	-	597	O
able	-	601	O
to	-	606	O
continue	-	609	O
a	-	618	O
particular	-	620	O
drug	-	631	O
for	-	636	O
more	-	640	O
than	-	645	O
one	-	650	O
year	-	654	O
.	-	658	O

Since	3970039	660	O
it	-	666	O
takes	-	669	O
three	-	675	O
to	-	681	O
12	-	684	O
months	-	687	O
to	-	694	O
achieve	-	697	O
maximal	-	705	O
effects	-	713	O
,	-	720	O
those	-	722	O
patients	-	728	O
who	-	737	O
are	-	741	O
unable	-	745	O
to	-	752	O
continue	-	755	O
the	-	764	O
drug	-	768	O
receive	-	773	O
little	-	781	O
benefit	-	788	O
from	-	796	O
it	-	801	O
.	-	803	O

Patients	3970039	805	O
treated	-	814	O
with	-	822	O
alkylating	-	827	B
agents	-	838	I
have	-	845	O
an	-	850	O
increased	-	853	O
risk	-	863	O
of	-	868	O
development	-	871	O
of	-	883	O
acute	-	886	O
nonlymphocytic	-	892	O
leukemia	-	907	O
,	-	915	O
and	-	917	O
both	-	921	O
alkylating	-	926	B
agents	-	937	I
and	-	944	O
azathioprine	-	948	B
are	-	961	O
associated	-	965	O
with	-	976	O
the	-	981	O
development	-	985	O
of	-	997	O
non	-	1000	O
-	-	1003	O
Hodgkin	-	1004	O
's	-	1011	O
lymphoma	-	1014	O
.	-	1022	O

Cyclophosphamide	3970039	1024	B
therapy	-	1041	O
increases	-	1049	O
the	-	1059	O
risk	-	1063	O
of	-	1068	O
carcinoma	-	1071	O
of	-	1081	O
the	-	1084	O
bladder	-	1088	O
.	-	1095	O

There	3970039	1097	O
have	-	1103	O
been	-	1108	O
several	-	1113	O
long	-	1121	O
-	-	1125	O
term	-	1126	O
studies	-	1131	O
of	-	1139	O
patients	-	1142	O
with	-	1151	O
rheumatoid	-	1156	O
arthritis	-	1167	O
treated	-	1177	O
with	-	1185	O
azathioprine	-	1190	B
and	-	1203	O
cyclophosphamide	-	1207	B
and	-	1224	O
the	-	1228	O
incidence	-	1232	O
of	-	1242	O
most	-	1245	O
of	-	1250	O
the	-	1253	O
common	-	1257	O
cancers	-	1264	O
is	-	1272	O
not	-	1275	O
increased	-	1279	O
.	-	1288	O

Data	3970039	1290	O
on	-	1295	O
the	-	1298	O
possible	-	1302	O
increased	-	1311	O
risk	-	1321	O
of	-	1326	O
malignancy	-	1329	O
in	-	1340	O
rheumatoid	-	1343	O
arthritis	-	1354	O
are	-	1364	O
still	-	1368	O
being	-	1374	O
collected	-	1380	O
,	-	1389	O
and	-	1391	O
until	-	1395	O
further	-	1401	O
information	-	1409	O
is	-	1421	O
available	-	1424	O
,	-	1433	O
the	-	1435	O
use	-	1439	O
of	-	1443	O
immunosuppressive	-	1446	O
drugs	-	1464	O
,	-	1469	O
particularly	-	1471	O
alkylating	-	1484	B
agents	-	1495	I
,	-	1501	O
in	-	1503	O
the	-	1506	O
treatment	-	1510	O
of	-	1520	O
rheumatoid	-	1523	O
arthritis	-	1534	O
should	-	1544	O
be	-	1551	O
reserved	-	1554	O
for	-	1563	O
patients	-	1567	O
with	-	1576	O
severe	-	1581	O
progressive	-	1588	O
disease	-	1600	O
or	-	1608	O
life	-	1611	O
-	-	1615	O
threatening	-	1616	O
complications	-	1628	O
.	-	1641	O

Patterns	424937	0	O
of	-	9	O
hepatic	-	12	O
injury	-	20	O
induced	-	27	O
by	-	35	O
methyldopa	-	38	B
.	-	48	O

Twelve	424937	50	O
patients	-	57	O
with	-	66	O
liver	-	71	O
disease	-	77	O
related	-	85	O
to	-	93	O
methyldopa	-	96	B
were	-	107	O
seen	-	112	O
between	-	117	O
1967	-	125	O
and	-	130	O
1977	-	134	O
.	-	138	O

Illness	424937	140	O
occurred	-	148	O
within	-	157	O
1	-	164	O
-	-	165	O
-	-	166	O
9	-	167	O
weeks	-	169	O
of	-	175	O
commencement	-	178	O
of	-	191	O
therapy	-	194	O
in	-	202	O
9	-	205	O
patients	-	207	O
,	-	215	O
the	-	217	O
remaining	-	221	O
3	-	231	O
patients	-	233	O
having	-	242	O
received	-	249	O
the	-	258	O
drug	-	262	O
for	-	267	O
13	-	271	O
months	-	274	O
,	-	280	O
15	-	282	O
months	-	285	O
and	-	292	O
7	-	296	O
years	-	298	O
before	-	304	O
experiencing	-	311	O
symptoms	-	324	O
.	-	332	O

Jaundice	424937	334	O
with	-	343	O
tender	-	348	O
hepatomegaly	-	355	O
,	-	367	O
usually	-	369	O
preceded	-	377	O
by	-	386	O
symptoms	-	389	O
of	-	398	O
malaise	-	401	O
,	-	408	O
anorexia	-	410	O
,	-	418	O
nausea	-	420	O
and	-	427	O
vomiting	-	431	O
,	-	439	O
and	-	441	O
associated	-	445	O
with	-	456	O
upper	-	461	O
abdominal	-	467	O
pain	-	477	O
,	-	481	O
was	-	483	O
an	-	487	O
invariable	-	490	O
finding	-	501	O
in	-	509	O
all	-	512	O
patients	-	516	O
.	-	524	O

Biochemical	424937	526	O
liver	-	538	O
function	-	544	O
tests	-	553	O
indicated	-	559	O
hepatocellular	-	569	O
necrosis	-	584	O
and	-	593	O
correlated	-	597	O
with	-	608	O
histopathological	-	613	O
evidence	-	631	O
of	-	640	O
hepatic	-	643	O
injury	-	651	O
,	-	657	O
the	-	659	O
spectrum	-	663	O
of	-	672	O
which	-	675	O
ranged	-	681	O
from	-	688	O
fatty	-	693	O
change	-	699	O
and	-	706	O
focal	-	710	O
hepatocellular	-	716	O
necrosis	-	731	O
to	-	740	O
massive	-	743	O
hepatic	-	751	O
necrosis	-	759	O
.	-	767	O

Most	424937	769	O
patients	-	774	O
showed	-	783	O
moderate	-	790	O
to	-	799	O
severe	-	802	O
acute	-	809	O
hepatitis	-	815	O
or	-	825	O
chronic	-	828	O
active	-	836	O
hepatitis	-	843	O
with	-	853	O
associated	-	858	O
cholestasis	-	869	O
.	-	880	O

The	424937	882	O
drug	-	886	O
was	-	891	O
withdrawn	-	895	O
on	-	905	O
presentation	-	908	O
to	-	921	O
hospital	-	924	O
in	-	933	O
11	-	936	O
patients	-	939	O
,	-	947	O
with	-	949	O
rapid	-	954	O
clinical	-	960	O
improvement	-	969	O
in	-	981	O
9	-	984	O
.	-	985	O

One	424937	987	O
patient	-	991	O
died	-	999	O
,	-	1003	O
having	-	1005	O
presented	-	1012	O
in	-	1022	O
hepatic	-	1025	O
failure	-	1033	O
,	-	1040	O
and	-	1042	O
another	-	1046	O
,	-	1053	O
who	-	1055	O
had	-	1059	O
been	-	1063	O
taking	-	1068	O
methyldopa	-	1075	B
for	-	1086	O
7	-	1090	O
years	-	1092	O
,	-	1097	O
showed	-	1099	O
slower	-	1106	O
clinical	-	1113	O
and	-	1122	O
biochemical	-	1126	O
resolution	-	1138	O
over	-	1149	O
a	-	1154	O
period	-	1156	O
of	-	1163	O
several	-	1166	O
months	-	1174	O
.	-	1180	O

The	424937	1182	O
remaining	-	1186	O
patient	-	1196	O
in	-	1204	O
the	-	1207	O
series	-	1211	O
developed	-	1218	O
fulminant	-	1228	O
hepatitis	-	1238	O
when	-	1248	O
the	-	1253	O
drug	-	1257	O
was	-	1262	O
accidentally	-	1266	O
recommenced	-	1279	O
1	-	1291	O
year	-	1293	O
after	-	1298	O
a	-	1304	O
prior	-	1306	O
episode	-	1312	O
of	-	1320	O
methyldopa	-	1323	B
-	-	1333	O
induced	-	1334	O
hepatitis	-	1342	O
.	-	1351	O

In	424937	1353	O
this	-	1356	O
latter	-	1361	O
patient	-	1368	O
,	-	1375	O
and	-	1377	O
in	-	1381	O
2	-	1384	O
others	-	1386	O
,	-	1392	O
the	-	1394	O
causal	-	1398	O
relationship	-	1405	O
between	-	1418	O
methyldopa	-	1426	B
and	-	1437	O
hepatic	-	1441	O
dysfunction	-	1449	O
was	-	1461	O
proved	-	1465	O
with	-	1472	O
the	-	1477	O
recurrence	-	1481	O
of	-	1492	O
hepatitis	-	1495	O
within	-	1505	O
2	-	1512	O
weeks	-	1514	O
of	-	1520	O
re	-	1523	O
-	-	1525	O
exposure	-	1526	O
to	-	1535	O
the	-	1538	O
drug	-	1542	O
.	-	1546	O

A	8643971	0	O
phase	-	2	O
I	-	8	O
/	-	9	O
II	-	10	O
study	-	13	O
of	-	19	O
paclitaxel	-	22	B
plus	-	33	O
cisplatin	-	38	B
as	-	48	O
first	-	51	O
-	-	56	O
line	-	57	O
therapy	-	62	O
for	-	70	O
head	-	74	O
and	-	79	O
neck	-	83	O
cancers	-	88	O
:	-	95	O
preliminary	-	97	O
results	-	109	O
.	-	116	O

Improved	8643971	118	O
outcomes	-	127	O
among	-	136	O
patients	-	142	O
with	-	151	O
head	-	156	O
and	-	161	O
neck	-	165	O
carcinomas	-	170	O
require	-	181	O
investigations	-	189	O
of	-	204	O
new	-	207	O
drugs	-	211	O
for	-	217	O
induction	-	221	O
therapy	-	231	O
.	-	238	O

Preliminary	8643971	240	O
results	-	252	O
of	-	260	O
an	-	263	O
Eastern	-	266	O
Cooperative	-	274	O
Oncology	-	286	O
Group	-	295	O
study	-	301	O
of	-	307	O
single	-	310	O
-	-	316	O
agent	-	317	O
paclitaxel	-	323	B
(	-	334	O

Taxol	8643971	335	B
;	-	340	O
Bristol	-	342	O
-	-	349	O
Myers	-	350	O
Squibb	-	356	O
Company	-	363	O
,	-	370	O
Princeton	-	372	O
,	-	381	O
NJ	-	383	O
)	-	385	O
reported	-	387	O
a	-	396	O
37	-	398	O
%	-	400	O
response	-	402	O
rate	-	411	O
in	-	416	O
patients	-	419	O
with	-	428	O
head	-	433	O
and	-	438	O
neck	-	442	O
cancer	-	447	O
,	-	453	O
and	-	455	O
the	-	459	O
paclitaxel	-	463	B
/	-	473	O
cisplatin	-	474	B
combination	-	484	O
has	-	496	O
been	-	500	O
used	-	505	O
successfully	-	510	O
and	-	523	O
has	-	527	O
significantly	-	531	O
improved	-	545	O
median	-	554	O
response	-	561	O
duration	-	570	O
in	-	579	O
ovarian	-	582	O
cancer	-	590	O
patients	-	597	O
.	-	605	O

We	8643971	607	O
initiated	-	610	O
a	-	620	O
phase	-	622	O
I	-	628	O
/	-	629	O
II	-	630	O
trial	-	633	O
to	-	639	O
determine	-	642	O
the	-	652	O
response	-	656	O
and	-	665	O
toxicity	-	669	O
of	-	678	O
escalating	-	681	O
paclitaxel	-	692	B
doses	-	703	O
combined	-	709	O
with	-	718	O
fixed	-	723	O
-	-	728	O
dose	-	729	O
cisplatin	-	734	B
with	-	744	O
granulocyte	-	749	O
colony	-	761	O
-	-	767	O
stimulating	-	768	O
factor	-	780	O
support	-	787	O
in	-	795	O
patients	-	798	O
with	-	807	O
untreated	-	812	O
locally	-	822	O
advanced	-	830	O
inoperable	-	839	O
head	-	850	O
and	-	855	O
neck	-	859	O
carcinoma	-	864	O
.	-	873	O

To	8643971	875	O
date	-	878	O
,	-	882	O
23	-	884	O
men	-	887	O
with	-	891	O
a	-	896	O
median	-	898	O
age	-	905	O
of	-	909	O
50	-	912	O
years	-	915	O
and	-	921	O
good	-	925	O
performance	-	930	O
status	-	942	O
have	-	949	O
entered	-	954	O
the	-	962	O
trial	-	966	O
.	-	971	O

Primary	8643971	973	O
tumor	-	981	O
sites	-	987	O
were	-	993	O
oropharynx	-	998	O
,	-	1008	O
10	-	1010	O
patients	-	1013	O
;	-	1021	O
hypopharynx	-	1023	O
,	-	1034	O
four	-	1036	O
;	-	1040	O
larynx	-	1042	O
,	-	1048	O
two	-	1050	O
;	-	1053	O
oral	-	1055	O
cavity	-	1060	O
,	-	1066	O
three	-	1068	O
;	-	1073	O
unknown	-	1075	O
primary	-	1083	O
,	-	1090	O
two	-	1092	O
;	-	1095	O
and	-	1097	O
nasal	-	1101	O
cavity	-	1107	O
and	-	1114	O
parotid	-	1118	O
gland	-	1126	O
,	-	1131	O
one	-	1133	O
each	-	1137	O
.	-	1141	O

Of	8643971	1143	O
20	-	1146	O
patients	-	1149	O
evaluable	-	1158	O
for	-	1168	O
toxicity	-	1172	O
,	-	1180	O
four	-	1182	O
had	-	1187	O
stage	-	1191	O
III	-	1197	O
and	-	1201	O
16	-	1205	O
had	-	1208	O
stage	-	1212	O
IV	-	1218	O
disease	-	1221	O
.	-	1228	O

Treatment	8643971	1230	O
,	-	1239	O
given	-	1241	O
every	-	1247	O
21	-	1253	O
days	-	1256	O
for	-	1261	O
a	-	1265	O
maximum	-	1267	O
of	-	1275	O
three	-	1278	O
cycles	-	1284	O
,	-	1290	O
consisted	-	1292	O
of	-	1302	O
paclitaxel	-	1305	B
by	-	1316	O
3	-	1319	O
-	-	1320	O
hour	-	1321	O
infusion	-	1326	O
followed	-	1335	O
the	-	1344	O
next	-	1348	O
day	-	1353	O
by	-	1357	O
a	-	1360	O
fixed	-	1362	O
dose	-	1368	O
of	-	1373	O
cisplatin	-	1376	B
(	-	1386	O
75	-	1387	O
mg	-	1390	O
/	-	1392	O
m2	-	1393	O
)	-	1395	O
.	-	1396	O

The	8643971	1398	O
dose	-	1402	O
levels	-	1407	O
incorporate	-	1414	O
escalating	-	1426	O
paclitaxel	-	1437	B
doses	-	1448	O
,	-	1453	O
and	-	1455	O
intrapatient	-	1459	O
escalations	-	1472	O
within	-	1484	O
a	-	1491	O
given	-	1493	O
dose	-	1499	O
level	-	1504	O
are	-	1510	O
permitted	-	1514	O
if	-	1524	O
toxicity	-	1527	O
permits	-	1536	O
.	-	1543	O

At	8643971	1545	O
the	-	1548	O
time	-	1552	O
of	-	1557	O
this	-	1560	O
writing	-	1565	O
,	-	1572	O
dose	-	1574	O
level	-	1579	O
4	-	1585	O
(	-	1587	O
260	-	1588	O
,	-	1591	O
270	-	1593	O
,	-	1596	O
and	-	1598	O
280	-	1602	O
mg	-	1606	O
/	-	1608	O
m2	-	1609	O
)	-	1611	O
is	-	1613	O
being	-	1616	O
evaluated	-	1622	O
;	-	1631	O
three	-	1633	O
patients	-	1639	O
from	-	1648	O
this	-	1653	O
level	-	1658	O
are	-	1664	O
evaluable	-	1668	O
.	-	1677	O

With	8643971	1679	O
paclitaxel	-	1684	B
doses	-	1695	O
of	-	1701	O
200	-	1704	O
mg	-	1708	O
/	-	1710	O
m2	-	1711	O
and	-	1714	O
higher	-	1718	O
,	-	1724	O
granulocyte	-	1726	O
colony	-	1738	O
-	-	1744	O
stimulating	-	1745	O
factor	-	1757	O
5	-	1764	O
micrograms	-	1766	O
/	-	1776	O
kg	-	1777	O
/	-	1779	O
d	-	1780	O
is	-	1782	O
given	-	1785	O
(	-	1791	O
days	-	1792	O
4	-	1797	O
through	-	1799	O
12	-	1807	O
)	-	1809	O
.	-	1810	O

Of	8643971	1812	O
18	-	1815	O
patients	-	1818	O
evaluable	-	1827	O
for	-	1837	O
response	-	1841	O
,	-	1849	O
seven	-	1851	O
(	-	1857	O
39	-	1858	O
%	-	1860	O
)	-	1861	O
achieved	-	1863	O
a	-	1872	O
complete	-	1874	O
response	-	1883	O
and	-	1892	O
six	-	1896	O
(	-	1900	O
33	-	1901	O
%	-	1903	O
)	-	1904	O
achieved	-	1906	O
a	-	1915	O
partial	-	1917	O
response	-	1925	O
.	-	1933	O

Three	8643971	1935	O
patients	-	1941	O
had	-	1950	O
no	-	1954	O
change	-	1957	O
and	-	1964	O
disease	-	1968	O
progressed	-	1976	O
in	-	1987	O
two	-	1990	O
.	-	1993	O

The	8643971	1995	O
overall	-	1999	O
response	-	2007	O
rate	-	2016	O
is	-	2021	O
72	-	2024	O
%	-	2026	O
.	-	2027	O

Eleven	8643971	2029	O
responding	-	2036	O
patients	-	2047	O
had	-	2056	O
subsequent	-	2060	O
surgery	-	2071	O
/	-	2078	O
radiotherapy	-	2079	O
or	-	2092	O
radical	-	2095	O
radiotherapy	-	2103	O
.	-	2115	O

Two	8643971	2117	O
pathologic	-	2121	O
complete	-	2132	O
responses	-	2141	O
were	-	2151	O
observed	-	2156	O
in	-	2165	O
patients	-	2168	O
who	-	2177	O
had	-	2181	O
achieved	-	2185	O
clinical	-	2194	O
complete	-	2203	O
responses	-	2212	O
.	-	2221	O

Alopecia	8643971	2223	O
,	-	2231	O
paresthesias	-	2233	O
,	-	2245	O
and	-	2247	O
arthralgias	-	2251	O
/	-	2262	O
myalgias	-	2263	O
have	-	2272	O
occurred	-	2277	O
frequently	-	2286	O
,	-	2296	O
but	-	2298	O
with	-	2302	O
one	-	2307	O
exception	-	2311	O
(	-	2321	O
a	-	2322	O
grade	-	2324	O
3	-	2330	O
myalgia	-	2332	O
)	-	2339	O
they	-	2341	O
have	-	2346	O
been	-	2351	O
grade	-	2356	O
1	-	2362	O
or	-	2364	O
2	-	2367	O
.	-	2368	O

No	8643971	2370	O
dose	-	2373	O
-	-	2377	O
limiting	-	2378	O
hematologic	-	2387	O
toxicity	-	2399	O
has	-	2408	O
been	-	2412	O
seen	-	2417	O
.	-	2421	O

Paclitaxel	8643971	2423	B
/	-	2433	O
cisplatin	-	2434	B
is	-	2444	O
an	-	2447	O
effective	-	2450	O
first	-	2460	O
-	-	2465	O
line	-	2466	O
regimen	-	2471	O
for	-	2479	O
locoregionally	-	2483	O
advanced	-	2498	O
head	-	2507	O
and	-	2512	O
neck	-	2516	O
cancer	-	2521	O
and	-	2528	O
continued	-	2532	O
study	-	2542	O
is	-	2548	O
warranted	-	2551	O
.	-	2560	O

Results	8643971	2562	O
thus	-	2570	O
far	-	2575	O
suggest	-	2579	O
no	-	2587	O
dose	-	2590	O
-	-	2594	O
response	-	2595	O
effect	-	2604	O
for	-	2611	O
paclitaxel	-	2615	B
doses	-	2626	O
above	-	2632	O
200	-	2638	O
mg	-	2642	O
/	-	2644	O
m2	-	2645	O
.	-	2647	O

A	2224762	0	O
phase	-	2	O
I	-	8	O
study	-	10	O
of	-	16	O
4'	-	19	B
-	-	21	I
0	-	22	I
-	-	23	I
tetrahydropyranyladriamycin	-	24	I
.	-	51	O

Clinical	2224762	53	O
pharmacology	-	62	O
and	-	75	O
pharmacokinetics	-	79	O
.	-	95	O

A	2224762	97	O
Phase	-	99	O
I	-	105	O
study	-	107	O
of	-	113	O
intravenous	-	116	O
(	-	128	O
IV	-	129	O
)	-	131	O
bolus	-	133	O
4'	-	139	B
-	-	141	I
0	-	142	I
-	-	143	I
tetrahydropyranyladriamycin	-	144	I
(	-	172	O
Pirarubicin	-	173	B
)	-	184	O
was	-	186	O
done	-	190	O
in	-	195	O
55	-	198	O
patients	-	201	O
in	-	210	O
good	-	213	O
performance	-	218	O
status	-	230	O
with	-	237	O
refractory	-	242	O
tumors	-	253	O
.	-	259	O

Twenty	2224762	261	O
-	-	267	O
six	-	268	O
had	-	272	O
minimal	-	276	O
prior	-	284	O
therapy	-	290	O
(	-	298	O
good	-	299	O
risk	-	304	O
)	-	308	O
,	-	309	O
23	-	311	O
had	-	314	O
extensive	-	318	O
prior	-	328	O
therapy	-	334	O
(	-	342	O
poor	-	343	O
risk	-	348	O
)	-	352	O
,	-	353	O
and	-	355	O
six	-	359	O
had	-	363	O
renal	-	367	O
and	-	373	O
/	-	376	O
or	-	377	O
hepatic	-	380	O
dysfunction	-	388	O
.	-	399	O

A	2224762	401	O
total	-	403	O
of	-	409	O
167	-	412	O
courses	-	416	O
at	-	424	O
doses	-	427	O
of	-	433	O
15	-	436	O
to	-	439	O
70	-	442	O
mg	-	445	O
/	-	447	O
m2	-	448	O
were	-	451	O
evaluable	-	456	O
.	-	465	O

Maximum	2224762	467	O
tolerated	-	475	O
dose	-	485	O
in	-	490	O
good	-	493	O
-	-	497	O
risk	-	498	O
patients	-	503	O
was	-	512	O
70	-	516	O
mg	-	519	O
/	-	521	O
m2	-	522	O
,	-	524	O
and	-	526	O
in	-	530	O
poor	-	533	O
-	-	537	O
risk	-	538	O
patients	-	543	O
,	-	551	O
60	-	553	O
mg	-	556	O
/	-	558	O
m2	-	559	O
.	-	561	O

The	2224762	563	O
dose	-	567	O
-	-	571	O
limiting	-	572	O
toxic	-	581	O
effect	-	587	O
was	-	594	O
transient	-	598	O
noncumulative	-	608	O
granulocytopenia	-	622	O
.	-	638	O

Granulocyte	2224762	640	O
nadir	-	652	O
was	-	658	O
on	-	662	O
day	-	665	O
14	-	669	O
(	-	672	O
range	-	673	O
,	-	678	O
4	-	680	O
-	-	681	O
22	-	682	O
)	-	684	O
.	-	685	O

Less	2224762	687	O
frequent	-	692	O
toxic	-	701	O
effects	-	707	O
included	-	715	O
thrombocytopenia	-	724	O
,	-	740	O
anemia	-	742	O
,	-	748	O
nausea	-	750	O
,	-	756	O
mild	-	758	O
alopecia	-	763	O
,	-	771	O
phlebitis	-	773	O
,	-	782	O
and	-	784	O
mucositis	-	788	O
.	-	797	O

Myelosuppression	2224762	799	O
was	-	816	O
more	-	820	O
in	-	825	O
patients	-	828	O
with	-	837	O
hepatic	-	842	O
dysfunction	-	850	O
.	-	861	O

Pharmacokinetic	2224762	863	O
analyses	-	879	O
in	-	888	O
21	-	891	O
patients	-	894	O
revealed	-	903	O
Pirarubicin	-	912	B
plasma	-	924	O
T	-	931	O
1	-	933	O
/	-	934	O
2	-	935	O
alpha	-	937	O
(	-	943	O
+	-	944	O
/	-	945	O
-	-	946	O

SE	2224762	948	O
)	-	950	O
of	-	952	O
2	-	955	O
.	-	956	O
5	-	957	O
+	-	959	O
/	-	960	O
-	-	961	O

0	2224762	963	O
.	-	964	O
85	-	965	O
minutes	-	968	O
,	-	975	O
T	-	977	O
beta	-	979	O
1	-	984	O
/	-	985	O
2	-	986	O
of	-	988	O
25	-	991	O
.	-	993	O
6	-	994	O
+	-	996	O
/	-	997	O
-	-	998	O

6	2224762	1000	O
.	-	1001	O
5	-	1002	O
minutes	-	1004	O
,	-	1011	O
and	-	1013	O
T	-	1017	O
1	-	1019	O
/	-	1020	O
2	-	1021	O
gamma	-	1023	O
of	-	1029	O
23	-	1032	O
.	-	1034	O
6	-	1035	O
+	-	1037	O
/	-	1038	O
-	-	1039	O

7	2224762	1041	O
.	-	1042	O
6	-	1043	O
hours	-	1045	O
.	-	1050	O

The	2224762	1052	O
area	-	1056	O
under	-	1061	O
the	-	1067	O
curve	-	1071	O
was	-	1077	O
537	-	1081	O
+	-	1085	O
/	-	1086	O
-	-	1087	O

149	2224762	1089	O
ng	-	1093	O
/	-	1095	O
ml	-	1096	O
x	-	1099	O
hours	-	1101	O
,	-	1106	O
volume	-	1108	O
of	-	1115	O
distribution	-	1118	O
(	-	1131	O
Vd	-	1132	O
)	-	1134	O
3504	-	1136	O
+	-	1141	O
/	-	1142	O
-	-	1143	O

644	2224762	1145	O
l	-	1149	O
/	-	1150	O
m2	-	1151	O
,	-	1153	O
and	-	1155	O
total	-	1159	O
clearance	-	1165	O
(	-	1175	O
ClT	-	1176	O
)	-	1179	O
was	-	1181	O
204	-	1185	O
+	-	1189	O
39	-	1191	O
.	-	1193	O
3	-	1194	O
l	-	1196	O
/	-	1197	O
hour	-	1198	O
/	-	1202	O
m2	-	1203	O
.	-	1205	O

Adriamycinol	2224762	1207	B
,	-	1219	O
doxorubicin	-	1221	B
,	-	1232	O
adriamycinone	-	1234	B
,	-	1247	O
and	-	1249	O

tetrahydropyranyladriamycinol	2224762	1253	B
were	-	1283	O
the	-	1288	O
metabolites	-	1292	O
detected	-	1304	O
in	-	1313	O
plasma	-	1316	O
and	-	1323	O
the	-	1327	O
amount	-	1331	O
of	-	1338	O
doxorubicin	-	1341	B
was	-	1353	O
less	-	1357	O
than	-	1362	O
or	-	1367	O
equal	-	1370	O
to	-	1376	O
10	-	1379	O
%	-	1381	O
of	-	1383	O
the	-	1386	O
total	-	1390	O
metabolites	-	1396	O
.	-	1407	O

Urinary	2224762	1409	O
excretion	-	1417	O
of	-	1427	O
Pirarubicin	-	1430	B
in	-	1442	O
the	-	1445	O
first	-	1449	O
24	-	1455	O
hours	-	1458	O
was	-	1464	O
less	-	1468	O
than	-	1473	O
or	-	1478	O
equal	-	1481	O
to	-	1487	O
10	-	1490	O
%	-	1492	O
.	-	1493	O

Activity	2224762	1495	O
was	-	1504	O
noted	-	1508	O
in	-	1514	O
mesothelioma	-	1517	O
,	-	1529	O
leiomyosarcoma	-	1531	O
,	-	1545	O
and	-	1547	O
basal	-	1551	O
cell	-	1557	O
carcinoma	-	1562	O
.	-	1571	O

The	2224762	1573	O
recommended	-	1577	O
starting	-	1589	O
dose	-	1598	O
for	-	1603	O
Phase	-	1607	O
II	-	1613	O
trials	-	1616	O
is	-	1623	O
60	-	1626	O
mg	-	1629	O
/	-	1631	O
m2	-	1632	O
IV	-	1635	O
bolus	-	1638	O
every	-	1644	O
3	-	1650	O
weeks	-	1652	O
.	-	1657	O

Differential	2440413	0	O
effects	-	13	O
of	-	21	O
gamma	-	24	B
-	-	29	I
hexachlorocyclohexane	-	30	I
(	-	52	O
lindane	-	53	B
)	-	60	O
on	-	62	O
pharmacologically	-	65	O
-	-	82	O
induced	-	83	O
seizures	-	91	O
.	-	99	O

Gamma	2440413	101	B
-	-	106	I
hexachlorocyclohexane	-	107	I
(	-	129	O
gamma	-	130	B
-	-	135	I
HCH	-	136	I
)	-	139	O
,	-	140	O
the	-	142	O
active	-	146	O
ingredient	-	153	O
of	-	164	O
the	-	167	O
insecticide	-	171	O
lindane	-	183	B
,	-	190	O
has	-	192	O
been	-	196	O
shown	-	201	O
to	-	207	O
decrease	-	210	O
seizure	-	219	O
threshold	-	227	O
to	-	237	O
pentylenetrazol	-	240	O
(	-	256	O
PTZ	-	257	B
)	-	260	O
3	-	262	O
h	-	264	O
after	-	266	O
exposure	-	272	O
to	-	281	O
gamma	-	284	B
-	-	289	I
HCH	-	290	I
and	-	294	O
conversely	-	298	O
increase	-	309	O
threshold	-	318	O
to	-	328	O
PTZ	-	331	B
-	-	334	O
induced	-	335	O
seizures	-	343	O
24	-	352	O
h	-	355	O
after	-	357	O
exposure	-	363	O
to	-	372	O
gamma	-	375	B
-	-	380	I
HCH	-	381	I
(	-	385	O
Vohland	-	386	O
et	-	394	O
al	-	397	O
.	-	399	O
1981	-	401	O
)	-	405	O
.	-	406	O

In	2440413	408	O
this	-	411	O
study	-	416	O
,	-	421	O
the	-	423	O
severity	-	427	O
of	-	436	O
response	-	439	O
to	-	448	O
other	-	451	O
seizure	-	457	O
-	-	464	O
inducing	-	465	O
agents	-	474	O
was	-	481	O
tested	-	485	O
in	-	492	O
mice	-	495	O
1	-	500	O
and	-	502	O
24	-	506	O
h	-	509	O
after	-	511	O
intraperitoneal	-	517	O
administration	-	533	O
of	-	548	O
80	-	551	O
mg	-	554	O
/	-	556	O
kg	-	557	O
gamma	-	560	B
-	-	565	I
HCH	-	566	I
.	-	569	O

One	2440413	571	O
hour	-	575	O
after	-	580	O
the	-	586	O
administration	-	590	O
of	-	605	O
gamma	-	608	B
-	-	613	I
HCH	-	614	I
,	-	617	O
the	-	619	O
activity	-	623	O
of	-	632	O
seizure	-	635	O
-	-	642	O
inducing	-	643	O
agents	-	652	O
was	-	659	O
increased	-	663	O
,	-	672	O
regardless	-	674	O
of	-	685	O
their	-	688	O
mechanism	-	694	O
,	-	703	O
while	-	705	O
24	-	711	O
h	-	714	O
after	-	716	O
gamma	-	722	B
-	-	727	I
HCH	-	728	I
a	-	732	O
differential	-	734	O
response	-	747	O
was	-	756	O
observed	-	760	O
.	-	768	O

Seizure	2440413	770	O
activity	-	778	O
due	-	787	O
to	-	791	O
PTZ	-	794	B
and	-	798	O
picrotoxin	-	802	B
(	-	813	O
PTX	-	814	B
)	-	817	O
was	-	819	O
significantly	-	823	O
decreased	-	837	O
;	-	846	O
however	-	848	O
,	-	855	O
seizure	-	857	O
activity	-	865	O
due	-	874	O
to	-	878	O
3	-	881	B
-	-	882	I
mercaptopropionic	-	883	I
acid	-	901	I
(	-	906	O
MPA	-	907	B
)	-	910	O
,	-	911	O
bicuculline	-	913	B
(	-	925	O
BCC	-	926	B
)	-	929	O
,	-	930	O
methyl	-	932	B
6	-	939	I
,	-	940	I
7	-	941	I
-	-	942	I
dimethoxy	-	943	I
-	-	952	I
4	-	953	I
-	-	954	I
ethyl	-	955	I
-	-	960	I
B	-	961	I
-	-	962	I
carboline	-	963	I
-	-	972	I
3	-	973	I
-	-	974	I
carboxylate	-	975	I
(	-	987	O
DMCM	-	988	B
)	-	992	O
,	-	993	O
or	-	995	O
strychnine	-	998	B
(	-	1009	O
STR	-	1010	B
)	-	1013	O
was	-	1015	O
not	-	1019	O
different	-	1023	O
from	-	1033	O
control	-	1038	O
.	-	1045	O

In	2440413	1047	O
vitro	-	1050	O
,	-	1055	O
gamma	-	1057	B
-	-	1062	I
HCH	-	1063	I
,	-	1066	O
pentylenetetrazol	-	1068	B
and	-	1086	O
picrotoxin	-	1090	B
were	-	1101	O
shown	-	1106	O
to	-	1112	O
inhibit	-	1115	O
3H	-	1123	B
-	-	1125	I
TBOB	-	1126	I
binding	-	1131	O
in	-	1139	O
mouse	-	1142	O
whole	-	1148	O
brain	-	1154	O
,	-	1159	O
with	-	1161	O
IC50	-	1166	O
values	-	1171	O
of	-	1178	O
4	-	1181	O
.	-	1182	O
6	-	1183	O
,	-	1184	O
404	-	1186	O
and	-	1190	O
9	-	1194	O
.	-	1195	O
4	-	1196	O
microM	-	1198	O
,	-	1204	O
respectively	-	1206	O
.	-	1218	O

MPA	2440413	1220	B
,	-	1223	O
BCC	-	1225	B
,	-	1228	O
DMCM	-	1230	B
,	-	1234	O
and	-	1236	O
STR	-	1240	B
showed	-	1244	O
no	-	1251	O
inhibition	-	1254	O
of	-	1265	O
3H	-	1268	B
-	-	1270	I
TBOB	-	1271	I
(	-	1276	O
t	-	1277	B
-	-	1278	I
butyl	-	1279	I
bicyclo	-	1285	I
-	-	1292	I
orthobenzoate	-	1293	I
)	-	1306	O
binding	-	1308	O
at	-	1316	O
concentrations	-	1319	O
of	-	1334	O
100	-	1337	O
micron	-	1341	O
.	-	1347	O

The	2440413	1349	O
pharmacological	-	1353	O
challenge	-	1369	O
data	-	1379	O
suggest	-	1384	O
that	-	1392	O
tolerance	-	1397	O
may	-	1407	O
occur	-	1411	O
to	-	1417	O
seizure	-	1420	O
activity	-	1428	O
induced	-	1437	O
by	-	1445	O
PTZ	-	1448	B
and	-	1452	O
PTX	-	1456	B
24	-	1460	O
h	-	1463	O
after	-	1465	O
gamma	-	1471	B
-	-	1476	I
HCH	-	1477	I
,	-	1480	O
since	-	1482	O
the	-	1488	O
response	-	1492	O
to	-	1501	O
only	-	1504	O
these	-	1509	O
two	-	1515	O
seizure	-	1519	O
-	-	1526	O
inducing	-	1527	O
agents	-	1536	O
is	-	1543	O
decreased	-	1546	O
.	-	1555	O

The	2440413	1557	O
in	-	1561	O
vitro	-	1564	O
data	-	1570	O
suggest	-	1575	O
that	-	1583	O
the	-	1588	O
site	-	1592	O
responsible	-	1597	O
for	-	1609	O
the	-	1613	O
decrease	-	1617	O
in	-	1626	O
seizure	-	1629	O
activity	-	1637	O
24	-	1646	O
h	-	1649	O
after	-	1651	O
gamma	-	1657	B
-	-	1662	I
HCH	-	1663	I
may	-	1667	O
be	-	1671	O
the	-	1674	O
GABA	-	1678	B
-	-	1682	O
A	-	1683	O
receptor	-	1685	O
-	-	1693	O
linked	-	1694	O
chloride	-	1701	O
channel	-	1710	O
.	-	1717	O

Severe	12483326	0	O
ocular	-	7	O
and	-	14	O
orbital	-	18	O
toxicity	-	26	O
after	-	35	O
intracarotid	-	41	O
injection	-	54	O
of	-	64	O
carboplatin	-	67	B
for	-	79	O
recurrent	-	83	O
glioblastomas	-	93	O
.	-	106	O

BACKGROUND	12483326	108	O
:	-	118	O

Glioblastoma	12483326	120	O
is	-	133	O
a	-	136	O
malignant	-	138	O
tumor	-	148	O
that	-	154	O
occurs	-	159	O
in	-	166	O
the	-	169	O
cerebrum	-	173	O
during	-	182	O
adulthood	-	189	O
.	-	198	O

With	12483326	200	O
current	-	205	O
treatment	-	213	O
regimens	-	223	O
including	-	232	O
combined	-	242	O
surgery	-	251	O
,	-	258	O
radiation	-	260	O
and	-	270	O
chemotherapy	-	274	O
,	-	286	O
the	-	288	O
average	-	292	O
life	-	300	O
expectancy	-	305	O
of	-	316	O
the	-	319	O
patients	-	323	O
is	-	332	O
limited	-	335	O
to	-	343	O
approximately	-	346	O
1	-	360	O
year	-	362	O
.	-	366	O

Therefore	12483326	368	O
,	-	377	O
patients	-	379	O
with	-	388	O
glioblastoma	-	393	O
sometimes	-	406	O
have	-	416	O
intracarotid	-	421	O
injection	-	434	O
of	-	444	O
carcinostatics	-	447	O
added	-	462	O
to	-	468	O
the	-	471	O
treatment	-	475	O
regimen	-	485	O
.	-	492	O

Generally	12483326	494	O
,	-	503	O
carboplatin	-	505	B
is	-	517	O
said	-	520	O
to	-	525	O
have	-	528	O
milder	-	533	O
side	-	540	O
effects	-	545	O
than	-	553	O
cisplatin	-	558	B
,	-	567	O
whose	-	569	O
ocular	-	575	O
and	-	582	O
orbital	-	586	O
toxicity	-	594	O
are	-	603	O
well	-	607	O
known	-	612	O
.	-	617	O

However	12483326	619	O
,	-	626	O
we	-	628	O
experienced	-	631	O
a	-	643	O
case	-	645	O
of	-	650	O
severe	-	653	O
ocular	-	660	O
and	-	667	O
orbital	-	671	O
toxicity	-	679	O
after	-	688	O
intracarotid	-	694	O
injection	-	707	O
of	-	717	O
carboplatin	-	720	B
,	-	731	O
which	-	733	O
is	-	739	O
infrequently	-	742	O
reported	-	755	O
.	-	763	O

CASE	12483326	765	O
:	-	769	O

A	12483326	771	O
58	-	773	O
-	-	775	O
year	-	776	O
-	-	780	O
old	-	781	O
man	-	785	O
received	-	789	O
an	-	798	O
intracarotid	-	801	O
injection	-	814	O
of	-	824	O
carboplatin	-	827	B
for	-	839	O
recurrent	-	843	O
glioblastomas	-	853	O
in	-	867	O
his	-	870	O
left	-	874	O
temporal	-	879	O
lobe	-	888	O
.	-	892	O

He	12483326	894	O
complained	-	897	O
of	-	908	O
pain	-	911	O
and	-	916	O
visual	-	920	O
disturbance	-	927	O
in	-	939	O
the	-	942	O
ipsilateral	-	946	O
eye	-	958	O
30	-	962	O
h	-	965	O
after	-	967	O
the	-	973	O
injection	-	977	O
.	-	986	O

Various	12483326	988	O
ocular	-	996	O
symptoms	-	1003	O
and	-	1012	O
findings	-	1016	O
caused	-	1025	O
by	-	1032	O
carboplatin	-	1035	B
toxicity	-	1047	O
were	-	1056	O
seen	-	1061	O
.	-	1065	O

RESULTS	12483326	1067	O
:	-	1074	O

He	12483326	1076	O
was	-	1079	O
treated	-	1083	O
with	-	1091	O
intravenous	-	1096	O
administration	-	1108	O
of	-	1123	O
corticosteroids	-	1126	O
and	-	1142	O
glycerin	-	1146	B
for	-	1155	O
6	-	1159	O
days	-	1161	O
after	-	1166	O
the	-	1172	O
injection	-	1176	O
.	-	1185	O

Although	12483326	1187	O
the	-	1196	O
intraocular	-	1200	O
pressure	-	1212	O
elevation	-	1221	O
caused	-	1231	O
by	-	1238	O
secondary	-	1241	O
acute	-	1251	O
angle	-	1257	O
-	-	1262	O
closure	-	1263	O
glaucoma	-	1271	O
decreased	-	1280	O
and	-	1290	O
ocular	-	1294	O
pain	-	1301	O
diminished	-	1306	O
,	-	1316	O
inexorable	-	1318	O
papilledema	-	1329	O
and	-	1341	O
exudative	-	1345	O
retinal	-	1355	O
detachment	-	1363	O
continued	-	1374	O
for	-	1384	O
3	-	1388	O
weeks	-	1390	O
.	-	1395	O

Finally	12483326	1397	O
,	-	1404	O
6	-	1406	O
weeks	-	1408	O
later	-	1414	O
,	-	1419	O
diffuse	-	1421	O
chorioretinal	-	1429	O
atrophy	-	1443	O
with	-	1451	O
optic	-	1456	O
atrophy	-	1462	O
occurred	-	1470	O
and	-	1479	O
the	-	1483	O
vision	-	1487	O
in	-	1494	O
his	-	1497	O
left	-	1501	O
eye	-	1506	O
was	-	1510	O
lost	-	1514	O
.	-	1518	O

CONCLUSION	12483326	1520	O
:	-	1530	O

When	12483326	1532	O
performing	-	1537	O
intracarotid	-	1548	O
injection	-	1561	O
of	-	1571	O
carboplatin	-	1574	B
,	-	1585	O
we	-	1587	O
must	-	1590	O
be	-	1595	O
aware	-	1598	O
of	-	1604	O
its	-	1607	O
potentially	-	1611	O
blinding	-	1623	O
ocular	-	1632	O
toxicity	-	1639	O
.	-	1647	O

It	12483326	1649	O
is	-	1652	O
recommended	-	1655	O
that	-	1667	O
further	-	1672	O
studies	-	1680	O
and	-	1688	O
investigations	-	1692	O
are	-	1707	O
undertaken	-	1711	O
in	-	1722	O
the	-	1725	O
effort	-	1729	O
to	-	1736	O
minimize	-	1739	O
such	-	1748	O
severe	-	1753	O
side	-	1760	O
effects	-	1765	O
.	-	1772	O

Phase	1664218	0	O
II	-	6	O
study	-	9	O
of	-	15	O
the	-	18	O
amsacrine	-	22	B
analogue	-	32	O
CI	-	41	B
-	-	43	I
921	-	44	I

(	1664218	48	O
NSC	-	49	B
343499	-	53	I
)	-	59	O
in	-	61	O
non	-	64	O
-	-	67	O
small	-	68	O
cell	-	74	O
lung	-	79	O
cancer	-	84	O
.	-	90	O

CI	1664218	92	B
-	-	94	I
921	-	95	I

(	1664218	99	O
NSC	-	100	B
343499	-	104	I
;	-	110	O
9	-	112	B
-	-	113	I
[	-	114	I
[	-	115	I
2	-	116	I
-	-	117	I
methoxy	-	118	I
-	-	125	I
4	-	126	I
-	-	127	I
[	-	128	I
(	-	129	I
methylsulphonyl	-	130	I
)	-	145	I
amino	-	146	I
]	-	151	I
phenyl	-	152	I
]	-	158	I
amino	-	159	I
]	-	164	I
-	-	166	I
N	-	167	I
,	-	168	I
5	-	169	I
-	-	170	I
dimethyl	-	171	I
-	-	179	I
4	-	181	I
-	-	182	I
acridinecarboxamide	-	183	I
)	-	202	O
is	-	204	O
a	-	207	O
topoisomerase	-	209	O
II	-	223	O
poison	-	226	O
with	-	233	O
high	-	238	O
experimental	-	243	O
antitumour	-	256	O
activity	-	267	O
.	-	275	O

It	1664218	277	O
was	-	280	O
administered	-	284	O
by	-	297	O
15	-	300	O
min	-	303	O
infusion	-	307	O
to	-	316	O
16	-	319	O
evaluable	-	322	O
patients	-	332	O
with	-	341	O
non	-	346	O
-	-	349	O
small	-	350	O
cell	-	356	O
lung	-	361	O
cancer	-	366	O
(	-	373	O
NSCLC	-	374	O
)	-	379	O
(	-	381	O
7	-	382	O
with	-	384	O
no	-	389	O
prior	-	392	O
treatment	-	398	O
,	-	407	O
9	-	409	O
patients	-	411	O
in	-	420	O
relapse	-	423	O
following	-	431	O
surgery	-	441	O
/	-	448	O
radiotherapy	-	449	O
)	-	461	O
at	-	463	O
a	-	466	O
dose	-	468	O
(	-	473	O
648	-	474	O
mg	-	478	O
/	-	480	O
m2	-	481	O
divided	-	484	O
over	-	492	O
3	-	497	O
days	-	499	O
,	-	503	O
repeated	-	505	O
every	-	514	O
3	-	520	O
weeks	-	522	O
)	-	527	O
determined	-	529	O
by	-	540	O
phase	-	543	O
I	-	549	O
trial	-	551	O
.	-	556	O

Patients	1664218	558	O
had	-	567	O
a	-	571	O
median	-	573	O
performance	-	580	O
status	-	592	O
of	-	599	O
1	-	602	O
(	-	604	O
WHO	-	605	O
)	-	608	O
,	-	609	O
and	-	611	O
median	-	615	O
age	-	622	O
of	-	626	O
61	-	629	O
years	-	632	O
.	-	637	O

The	1664218	639	O
histology	-	643	O
comprised	-	653	O
squamous	-	663	O
carcinoma	-	672	O
(	-	682	O
11	-	683	O
)	-	685	O
,	-	686	O
adenocarcinoma	-	688	O
(	-	703	O
1	-	704	O
)	-	705	O
,	-	706	O
mixed	-	708	O
histology	-	714	O
(	-	724	O
2	-	725	O
)	-	726	O
,	-	727	O
bronchio	-	729	O
-	-	737	O
alveolar	-	738	O
carcinoma	-	747	O
(	-	757	O
1	-	758	O
)	-	759	O
and	-	761	O
large	-	765	O
cell	-	771	O
undifferentiated	-	776	O
carcinoma	-	793	O
(	-	803	O
1	-	804	O
)	-	805	O
.	-	806	O

Neutropenia	1664218	808	O
grade	-	820	O
greater	-	826	O
than	-	834	O
or	-	839	O
equal	-	842	O
to	-	848	O
3	-	851	O
was	-	853	O
seen	-	857	O
in	-	862	O
15	-	865	O
patients	-	868	O
,	-	876	O
infections	-	878	O
with	-	889	O
recovery	-	894	O
in	-	903	O
3	-	906	O
,	-	907	O
and	-	909	O
grand	-	913	O
mal	-	919	O
seizures	-	923	O
in	-	932	O
1	-	935	O
patient	-	937	O
.	-	944	O

Grade	1664218	946	O
less	-	952	O
than	-	957	O
or	-	962	O
equal	-	965	O
to	-	971	O
2	-	974	O
nausea	-	976	O
and	-	983	O
vomiting	-	987	O
occurred	-	996	O
in	-	1005	O
66	-	1008	O
%	-	1010	O
courses	-	1012	O
and	-	1020	O
phlebitis	-	1024	O
in	-	1034	O
the	-	1037	O
infusion	-	1041	O
arm	-	1050	O
in	-	1054	O
37	-	1057	O
%	-	1059	O
.	-	1060	O

1	1664218	1062	O
patient	-	1064	O
with	-	1072	O
squamous	-	1077	O
cell	-	1086	O
carcinoma	-	1091	O
achieved	-	1101	O
a	-	1110	O
partial	-	1112	O
response	-	1120	O
lasting	-	1129	O
5	-	1137	O
months	-	1139	O
.	-	1145	O

Further	1664218	1147	O
testing	-	1155	O
in	-	1163	O
this	-	1166	O
and	-	1171	O
other	-	1175	O
tumour	-	1181	O
types	-	1188	O
using	-	1194	O
multiple	-	1200	O
daily	-	1209	O
schedules	-	1215	O
is	-	1225	O
warranted	-	1228	O
.	-	1237	O

Alpha	18809400	0	B
-	-	5	I
lipoic	-	6	I
acid	-	13	I
prevents	-	18	O
mitochondrial	-	27	O
damage	-	41	O
and	-	48	O
neurotoxicity	-	52	O
in	-	66	O
experimental	-	69	O
chemotherapy	-	82	O
neuropathy	-	95	O
.	-	105	O

The	18809400	107	O
study	-	111	O
investigates	-	117	O
if	-	130	O
alpha	-	133	B
-	-	138	I
lipoic	-	139	I
acid	-	146	I
is	-	151	O
neuroprotective	-	154	O
against	-	170	O
chemotherapy	-	178	O
induced	-	191	O
neurotoxicity	-	199	O
,	-	212	O
if	-	214	O
mitochondrial	-	217	O
damage	-	231	O
plays	-	238	O
a	-	244	O
critical	-	246	O
role	-	255	O
in	-	260	O
toxic	-	263	O
neurodegenerative	-	269	O
cascade	-	287	O
,	-	294	O
and	-	296	O
if	-	300	O
neuroprotective	-	303	O
effects	-	319	O
of	-	327	O
alpha	-	330	B
-	-	335	I
lipoic	-	336	I
acid	-	343	I
depend	-	348	O
on	-	355	O
mitochondria	-	358	O
protection	-	371	O
.	-	381	O

We	18809400	383	O
used	-	386	O
an	-	391	O
in	-	394	O
vitro	-	397	O
model	-	403	O
of	-	409	O
chemotherapy	-	412	O
induced	-	425	O
peripheral	-	433	O
neuropathy	-	444	O
that	-	455	O
closely	-	460	O
mimic	-	468	O
the	-	474	O
in	-	478	O
vivo	-	481	O
condition	-	486	O
by	-	496	O
exposing	-	499	O
primary	-	508	O
cultures	-	516	O
of	-	525	O
dorsal	-	528	O
root	-	535	O
ganglion	-	540	O
(	-	549	O
DRG	-	550	O
)	-	553	O
sensory	-	555	O
neurons	-	563	O
to	-	571	O
paclitaxel	-	574	B
and	-	585	O
cisplatin	-	589	B
,	-	598	O
two	-	600	O
widely	-	604	O
used	-	611	O
and	-	616	O
highly	-	620	O
effective	-	627	O
chemotherapeutic	-	637	O
drugs	-	654	O
.	-	659	O

This	18809400	661	O
approach	-	666	O
allowed	-	675	O
investigating	-	683	O
the	-	697	O
efficacy	-	701	O
of	-	710	O
alpha	-	713	B
-	-	718	I
lipoic	-	719	I
acid	-	726	I
in	-	731	O
preventing	-	734	O
axonal	-	745	O
damage	-	752	O
and	-	759	O
apoptosis	-	763	O
and	-	773	O
the	-	777	O
function	-	781	O
and	-	790	O
ultrastructural	-	794	O
morphology	-	810	O
of	-	821	O
mitochondria	-	824	O
after	-	837	O
exposure	-	843	O
to	-	852	O
toxic	-	855	O
agents	-	861	O
and	-	868	O
alpha	-	872	B
-	-	877	I
lipoic	-	878	I
acid	-	885	I
.	-	889	O

Our	18809400	891	O
results	-	895	O
demonstrate	-	903	O
that	-	915	O
both	-	920	O
cisplatin	-	925	B
and	-	935	O
paclitaxel	-	939	B
cause	-	950	O
early	-	956	O
mitochondrial	-	962	O
impairment	-	976	O
with	-	987	O
loss	-	992	O
of	-	997	O
membrane	-	1000	O
potential	-	1009	O
and	-	1019	O
induction	-	1023	O
of	-	1033	O
autophagic	-	1036	O
vacuoles	-	1047	O
in	-	1056	O
neurons	-	1059	O
.	-	1066	O

Alpha	18809400	1068	B
-	-	1073	I
lipoic	-	1074	I
acid	-	1081	I
exerts	-	1086	O
neuroprotective	-	1093	O
effects	-	1109	O
against	-	1117	O
chemotherapy	-	1125	O
induced	-	1138	O
neurotoxicity	-	1146	O
in	-	1160	O
sensory	-	1163	O
neurons	-	1171	O
:	-	1178	O
it	-	1180	O
rescues	-	1183	O
the	-	1191	O
mitochondrial	-	1195	O
toxicity	-	1209	O
and	-	1218	O
induces	-	1222	O
the	-	1230	O
expression	-	1234	O
of	-	1245	O
frataxin	-	1248	O
,	-	1256	O
an	-	1258	O
essential	-	1261	O
mitochondrial	-	1271	O
protein	-	1285	O
with	-	1293	O
anti	-	1298	O
-	-	1302	O
oxidant	-	1303	O
and	-	1311	O
chaperone	-	1315	O
properties	-	1325	O
.	-	1335	O

In	18809400	1337	O
conclusion	-	1340	O
mitochondrial	-	1351	O
toxicity	-	1365	O
is	-	1374	O
an	-	1377	O
early	-	1380	O
common	-	1386	O
event	-	1393	O
both	-	1399	O
in	-	1404	O
paclitaxel	-	1407	B
and	-	1418	O
cisplatin	-	1422	B
induced	-	1432	O
neurotoxicity	-	1440	O
.	-	1453	O

Alpha	18809400	1455	B
-	-	1460	I
lipoic	-	1461	I
acid	-	1468	I
protects	-	1473	O
sensory	-	1482	O
neurons	-	1490	O
through	-	1498	O
its	-	1506	O
anti	-	1510	O
-	-	1514	O
oxidant	-	1515	O
and	-	1523	O
mitochondrial	-	1527	O
regulatory	-	1541	O
functions	-	1552	O
,	-	1561	O
possibly	-	1563	O
inducing	-	1572	O
the	-	1581	O
expression	-	1585	O
of	-	1596	O
frataxin	-	1599	O
.	-	1607	O

These	18809400	1609	O
findings	-	1615	O
suggest	-	1624	O
that	-	1632	O
alpha	-	1637	B
-	-	1642	I
lipoic	-	1643	I
acid	-	1650	I
might	-	1655	O
reduce	-	1661	O
the	-	1668	O
risk	-	1672	O
of	-	1677	O
developing	-	1680	O
peripheral	-	1691	O
nerve	-	1702	O
toxicity	-	1708	O
in	-	1717	O
patients	-	1720	O
undergoing	-	1729	O
chemotherapy	-	1740	O
and	-	1753	O
encourage	-	1757	O
further	-	1767	O
confirmatory	-	1775	O
clinical	-	1788	O
trials	-	1797	O
.	-	1803	O

Optimising	17020434	0	O
stroke	-	11	O
prevention	-	18	O
in	-	29	O
non	-	32	O
-	-	35	O
valvular	-	36	O
atrial	-	45	O
fibrillation	-	52	O
.	-	64	O

Atrial	17020434	66	O
fibrillation	-	73	O
is	-	86	O
associated	-	89	O
with	-	100	O
substantial	-	105	O
morbidity	-	117	O
and	-	127	O
mortality	-	131	O
.	-	140	O

Pooled	17020434	142	O
data	-	149	O
from	-	154	O
trials	-	159	O
comparing	-	166	O
antithrombotic	-	176	O
treatment	-	191	O
with	-	201	O
placebo	-	206	O
have	-	214	O
shown	-	219	O
that	-	225	O
warfarin	-	230	B
reduces	-	239	O
the	-	247	O
risk	-	251	O
of	-	256	O
stroke	-	259	O
by	-	266	O
62	-	269	O
%	-	271	O
,	-	272	O
and	-	274	O
that	-	278	O
aspirin	-	283	B
alone	-	291	O
reduces	-	297	O
the	-	305	O
risk	-	309	O
by	-	314	O
22	-	317	O
%	-	319	O
.	-	320	O

Overall	17020434	322	O
,	-	329	O
in	-	331	O
high	-	334	O
-	-	338	O
risk	-	339	O
patients	-	344	O
,	-	352	O
warfarin	-	354	B
is	-	363	O
superior	-	366	O
to	-	375	O
aspirin	-	378	B
in	-	386	O
preventing	-	389	O
strokes	-	400	O
,	-	407	O
with	-	409	O
a	-	414	O
relative	-	416	O
risk	-	425	O
reduction	-	430	O
of	-	440	O
36	-	443	O
%	-	445	O
.	-	446	O

Ximelagatran	17020434	448	B
,	-	460	O
an	-	462	O
oral	-	465	O
direct	-	470	O
thrombin	-	477	O
inhibitor	-	486	O
,	-	495	O
was	-	497	O
found	-	501	O
to	-	507	O
be	-	510	O
as	-	513	O
efficient	-	516	O
as	-	526	O
vitamin	-	529	B
K	-	537	I
antagonist	-	539	O
drugs	-	550	O
in	-	556	O
the	-	559	O
prevention	-	563	O
of	-	574	O
embolic	-	577	O
events	-	585	O
,	-	591	O
but	-	593	O
has	-	597	O
been	-	601	O
recently	-	606	O
withdrawn	-	615	O
because	-	625	O
of	-	633	O
abnormal	-	636	O
liver	-	645	O
function	-	651	O
tests	-	660	O
.	-	665	O

The	17020434	667	O
ACTIVE	-	671	O
-	-	677	O
W	-	678	O
(	-	680	O
Atrial	-	681	O
Fibrillation	-	688	O
Clopidogrel	-	701	B
Trial	-	713	O
with	-	719	O
Irbesartan	-	724	B
for	-	735	O
Prevention	-	739	O
of	-	750	O
Vascular	-	753	O
Events	-	762	O
)	-	768	O
study	-	770	O
has	-	776	O
demonstrated	-	780	O
that	-	793	O
warfarin	-	798	B
is	-	807	O
superior	-	810	O
to	-	819	O
platelet	-	822	O
therapy	-	831	O
(	-	839	O
clopidogrel	-	840	B
plus	-	852	O
aspirin	-	857	B
)	-	864	O
in	-	866	O
the	-	869	O
prevention	-	873	O
af	-	884	O
embolic	-	887	O
events	-	895	O
.	-	901	O

Idraparinux	17020434	903	B
,	-	914	O
a	-	916	O
Factor	-	918	O
Xa	-	925	O
inhibitor	-	928	O
,	-	937	O
is	-	939	O
being	-	942	O
evaluated	-	948	O
in	-	958	O
patients	-	961	O
with	-	970	O
atrial	-	975	O
fibrillation	-	982	O
.	-	994	O

Angiotensin	17020434	996	B
-	-	1007	O
converting	-	1008	O
enzyme	-	1019	O
inhibitors	-	1026	O
and	-	1037	O
angiotensin	-	1041	B
II	-	1053	I
receptor	-	1056	O
-	-	1064	O
blocking	-	1065	O
drugs	-	1074	O
hold	-	1080	O
promise	-	1085	O
in	-	1093	O
atrial	-	1096	O
fibrillation	-	1103	O
through	-	1116	O
cardiac	-	1124	O
remodelling	-	1132	O
.	-	1143	O

Preliminary	17020434	1145	O
studies	-	1157	O
suggest	-	1165	O
that	-	1173	O
statins	-	1178	B
could	-	1186	O
interfere	-	1192	O
with	-	1202	O
the	-	1207	O
risk	-	1211	O
of	-	1216	O
recurrence	-	1219	O
after	-	1230	O
electrical	-	1236	O
cardioversion	-	1247	O
.	-	1260	O

Finally	17020434	1262	O
,	-	1269	O
percutaneous	-	1271	O
methods	-	1284	O
for	-	1292	O
the	-	1296	O
exclusion	-	1300	O
of	-	1310	O
left	-	1313	O
atrial	-	1318	O
appendage	-	1325	O
are	-	1335	O
under	-	1339	O
investigation	-	1345	O
in	-	1359	O
high	-	1362	O
-	-	1366	O
risk	-	1367	O
patients	-	1372	O
.	-	1380	O

Interaction	3865016	0	O
of	-	12	O
cyclosporin	-	15	B
A	-	27	I
with	-	29	O
antineoplastic	-	34	O
agents	-	49	O
.	-	55	O

A	3865016	57	O
synergistic	-	59	O
effect	-	71	O
of	-	78	O
etoposide	-	81	B
and	-	91	O
cyclosporin	-	95	B
A	-	107	I
was	-	109	O
observed	-	113	O
in	-	122	O
a	-	125	O
patient	-	127	O
with	-	135	O
acute	-	140	O
T	-	146	O
-	-	147	O
lymphocytic	-	148	O
leukemia	-	160	O
in	-	169	O
relapse	-	172	O
.	-	179	O

The	3865016	181	O
concomitant	-	185	O
administration	-	197	O
of	-	212	O
etoposide	-	215	B
and	-	225	O
cyclosporin	-	229	B
A	-	241	I
resulted	-	243	O
in	-	252	O
eradication	-	255	O
of	-	267	O
hitherto	-	270	O
refractory	-	279	O
leukemic	-	290	O
infiltration	-	299	O
of	-	312	O
bone	-	315	O
marrow	-	320	O
.	-	326	O

Severe	3865016	328	O
side	-	335	O
effects	-	340	O
in	-	348	O
terms	-	351	O
of	-	357	O
mental	-	360	O
confusion	-	367	O
and	-	377	O
progressive	-	381	O
hyperbilirubinemia	-	393	O
,	-	411	O
however	-	413	O
,	-	420	O
point	-	422	O
to	-	428	O
an	-	431	O
enhancement	-	434	O
not	-	446	O
only	-	450	O
of	-	455	O
antineoplastic	-	458	O
effects	-	473	O
but	-	481	O
also	-	485	O
of	-	490	O
toxicity	-	493	O
in	-	502	O
normal	-	505	O
tissues	-	512	O
.	-	519	O

This	3865016	521	O
report	-	526	O
demonstrates	-	533	O
for	-	546	O
the	-	550	O
first	-	554	O
time	-	560	O
that	-	565	O
the	-	570	O
pharmacodynamic	-	574	O
properties	-	590	O
of	-	601	O
cyclosporin	-	604	B
A	-	616	I
may	-	618	O
not	-	622	O
be	-	626	O
confined	-	629	O
strictly	-	638	O
to	-	647	O
suppression	-	650	O
of	-	662	O
normal	-	665	O
T	-	672	O
-	-	673	O
cell	-	674	O
functions	-	679	O
.	-	688	O

The	3629586	0	O
hematologic	-	4	O
effects	-	16	O
of	-	24	O
cefonicid	-	27	B
and	-	37	O
cefazedone	-	41	B
in	-	52	O
the	-	55	O
dog	-	59	O
:	-	62	O
a	-	64	O
potential	-	66	O
model	-	76	O
of	-	82	O
cephalosporin	-	85	B
hematotoxicity	-	99	O
in	-	114	O
man	-	117	O
.	-	120	O

Cephalosporin	3629586	122	B
antibiotics	-	136	O
cause	-	148	O
a	-	154	O
variety	-	156	O
of	-	164	O
hematologic	-	167	O
disturbances	-	179	O
in	-	192	O
man	-	195	O
,	-	198	O
the	-	200	O
pathogeneses	-	204	O
and	-	217	O
hematopathology	-	221	O
of	-	237	O
which	-	240	O
remain	-	246	O
poorly	-	253	O
characterized	-	260	O
.	-	273	O

There	3629586	275	O
is	-	281	O
a	-	284	O
need	-	286	O
for	-	291	O
a	-	295	O
well	-	297	O
-	-	301	O
defined	-	302	O
animal	-	310	O
model	-	317	O
in	-	323	O
which	-	326	O
these	-	332	O
blood	-	338	O
dyscrasias	-	344	O
can	-	355	O
be	-	359	O
studied	-	362	O
.	-	369	O

In	3629586	371	O
four	-	374	O
subacute	-	379	O
toxicity	-	388	O
studies	-	397	O
,	-	404	O
the	-	406	O
intravenous	-	410	O
administration	-	422	O
of	-	437	O
cefonicid	-	440	B
or	-	450	O
cefazedone	-	453	B
to	-	464	O
beagle	-	467	O
dogs	-	474	O
caused	-	479	O
a	-	486	O
dose	-	488	O
-	-	492	O
dependent	-	493	O
incidence	-	503	O
of	-	513	O
anemia	-	516	O
,	-	522	O
neutropenia	-	524	O
,	-	535	O
and	-	537	O
thrombocytopenia	-	541	O
after	-	558	O
1	-	564	O
-	-	565	O
3	-	566	O
months	-	568	O
of	-	575	O
treatment	-	578	O
.	-	587	O

A	3629586	589	O
nonregenerative	-	591	O
anemia	-	607	O
was	-	614	O
the	-	618	O
most	-	622	O
compromising	-	627	O
of	-	640	O
the	-	643	O
cytopenias	-	647	O
and	-	658	O
occurred	-	662	O
in	-	671	O
approximately	-	674	O
50	-	688	O
%	-	690	O
of	-	692	O
dogs	-	695	O
receiving	-	700	O
400	-	710	O
-	-	713	O
500	-	714	O
mg	-	718	O
/	-	720	O
kg	-	721	O
cefonicid	-	724	B
or	-	734	O
540	-	737	O
-	-	740	O
840	-	741	O
mg	-	745	O
/	-	747	O
kg	-	748	O
cefazedone	-	751	B
.	-	761	O

All	3629586	763	O
three	-	767	O
cytopenias	-	773	O
were	-	784	O
completely	-	789	O
reversible	-	800	O
following	-	811	O
cessation	-	821	O
of	-	831	O
treatment	-	834	O
;	-	843	O
the	-	845	O
time	-	849	O
required	-	854	O
for	-	863	O
recovery	-	867	O
of	-	876	O
the	-	879	O
erythron	-	883	O
(	-	892	O
approximately	-	893	O
1	-	907	O
month	-	909	O
)	-	914	O
was	-	916	O
considerably	-	920	O
longer	-	933	O
than	-	940	O
that	-	945	O
of	-	950	O
the	-	953	O
granulocytes	-	957	O
and	-	970	O
platelets	-	974	O
(	-	984	O
hours	-	985	O
to	-	991	O
a	-	994	O
few	-	996	O
days	-	1000	O
)	-	1004	O
.	-	1005	O

Upon	3629586	1007	O
rechallenge	-	1012	O
with	-	1024	O
either	-	1029	O
cephalosporin	-	1036	B
,	-	1049	O
the	-	1051	O
hematologic	-	1055	O
syndrome	-	1067	O
was	-	1076	O
reproduced	-	1080	O
in	-	1091	O
most	-	1094	O
dogs	-	1099	O
tested	-	1104	O
;	-	1110	O
cefonicid	-	1112	B
(	-	1122	O
but	-	1123	O
not	-	1127	O
cefazedone	-	1131	B
)	-	1141	O
-	-	1142	O
treated	-	1143	O
dogs	-	1151	O
showed	-	1156	O
a	-	1163	O
substantially	-	1165	O
reduced	-	1179	O
induction	-	1187	O
period	-	1197	O
(	-	1204	O
15	-	1205	O
+	-	1208	O
/	-	1209	O
-	-	1210	O

5	3629586	1212	O
days	-	1214	O
)	-	1218	O
compared	-	1220	O
to	-	1229	O
that	-	1232	O
of	-	1237	O
the	-	1240	O
first	-	1244	O
exposure	-	1250	O
to	-	1259	O
the	-	1262	O
drug	-	1266	O
(	-	1271	O
61	-	1272	O
+	-	1275	O
/	-	1276	O
-	-	1277	O

24	3629586	1279	O
days	-	1282	O
)	-	1286	O
.	-	1287	O

This	3629586	1289	O
observation	-	1294	O
,	-	1305	O
along	-	1307	O
with	-	1313	O
the	-	1318	O
rapid	-	1322	O
rate	-	1328	O
of	-	1333	O
decline	-	1336	O
in	-	1344	O
red	-	1347	O
cell	-	1351	O
mass	-	1356	O
parameters	-	1361	O
of	-	1372	O
affected	-	1375	O
dogs	-	1384	O
,	-	1388	O
suggests	-	1390	O
that	-	1399	O
a	-	1404	O
hemolytic	-	1406	O
component	-	1416	O
complicated	-	1426	O
the	-	1438	O
red	-	1442	O
cell	-	1446	O
production	-	1451	O
problem	-	1462	O
and	-	1470	O
that	-	1474	O
multiple	-	1479	O
toxicologic	-	1488	O
mechanisms	-	1500	O
contributed	-	1511	O
to	-	1523	O
the	-	1526	O
cytopenia	-	1530	O
.	-	1539	O

We	3629586	1541	O
conclude	-	1544	O
that	-	1553	O
the	-	1558	O
administration	-	1562	O
of	-	1577	O
high	-	1580	O
doses	-	1585	O
of	-	1591	O
cefonicid	-	1594	B
or	-	1604	O
cefazedone	-	1607	B
to	-	1618	O
dogs	-	1621	O
can	-	1626	O
induce	-	1630	O
hematotoxicity	-	1637	O
similar	-	1652	O
to	-	1660	O
the	-	1663	O
cephalosporin	-	1667	B
-	-	1680	O
induced	-	1681	O
blood	-	1689	O
dyscrasias	-	1695	O
described	-	1706	O
in	-	1716	O
man	-	1719	O
and	-	1723	O
thus	-	1727	O
provides	-	1732	O
a	-	1741	O
useful	-	1743	O
model	-	1750	O
for	-	1756	O
studying	-	1760	O
the	-	1769	O
mechanisms	-	1773	O
of	-	1784	O
these	-	1787	O
disorders	-	1793	O
.	-	1802	O

A	150790	0	O
pyridoxine	-	2	B
-	-	12	O
dependent	-	13	O
behavioral	-	23	O
disorder	-	34	O
unmasked	-	43	O
by	-	52	O
isoniazid	-	55	B
.	-	64	O

A	150790	66	O
3	-	68	O
-	-	69	O
year	-	70	O
-	-	74	O
old	-	75	O
girl	-	79	O
had	-	84	O
behavioral	-	88	O
deterioration	-	99	O
,	-	112	O
with	-	114	O
hyperkinesis	-	119	O
,	-	131	O
irritability	-	133	O
,	-	145	O
and	-	147	O
sleeping	-	151	O
difficulties	-	160	O
after	-	173	O
the	-	179	O
therapeutic	-	183	O
administration	-	195	O
of	-	210	O
isoniazid	-	213	B
.	-	222	O

The	150790	224	O
administration	-	228	O
of	-	243	O
pharmacologic	-	246	O
doses	-	260	O
of	-	266	O
pyridoxine	-	269	B
hydrochloride	-	280	I
led	-	294	O
to	-	298	O
a	-	301	O
disappearance	-	303	O
of	-	317	O
symptoms	-	320	O
.	-	328	O

After	150790	330	O
discontinuing	-	336	O
isoniazid	-	350	B
therapy	-	360	O
a	-	368	O
similar	-	370	O
pattern	-	378	O
of	-	386	O
behavior	-	389	O
was	-	398	O
noted	-	402	O
that	-	408	O
was	-	413	O
controlled	-	417	O
by	-	428	O
pyridoxine	-	431	B
.	-	441	O

A	150790	443	O
placebo	-	445	O
had	-	453	O
no	-	457	O
effect	-	460	O
,	-	466	O
but	-	468	O
niacinamide	-	472	B
was	-	484	O
as	-	488	O
effective	-	491	O
as	-	501	O
pyridoxine	-	504	B
.	-	514	O

Periodic	150790	516	O
withdrawal	-	525	O
of	-	536	O
pyridoxine	-	539	B
was	-	550	O
associated	-	554	O
with	-	565	O
return	-	570	O
of	-	577	O
the	-	580	O
hyperkinesis	-	584	O
.	-	596	O

The	150790	598	O
level	-	602	O
of	-	608	O
pyridoxal	-	611	B
in	-	621	O
the	-	624	O
blood	-	628	O
was	-	634	O
normal	-	638	O
during	-	645	O
the	-	652	O
periods	-	656	O
of	-	664	O
relapse	-	667	O
.	-	674	O

Metabolic	150790	676	O
studies	-	686	O
suggested	-	694	O
a	-	704	O
block	-	706	O
in	-	712	O
the	-	715	O
kynurenine	-	719	B
pathway	-	730	O
of	-	738	O
tryptophan	-	741	B
metabolism	-	752	O
.	-	762	O

The	150790	764	O
patient	-	768	O
has	-	776	O
been	-	780	O
followed	-	785	O
for	-	794	O
six	-	798	O
years	-	802	O
and	-	808	O
has	-	812	O
required	-	816	O
pharmacologic	-	825	O
doses	-	839	O
of	-	845	O
pyridoxine	-	848	B
to	-	859	O
control	-	862	O
her	-	870	O
behavior	-	874	O
.	-	882	O

A	10579464	0	O
selective	-	2	O
dopamine	-	12	B
D4	-	21	O
receptor	-	24	O
antagonist	-	33	O
,	-	43	O
NRA0160	-	45	B
:	-	52	O
a	-	54	O
preclinical	-	56	O
neuropharmacological	-	68	O
profile	-	89	O
.	-	96	O

NRA0160	10579464	98	B
,	-	105	O
5	-	107	B
-	-	109	I
[	-	111	I
2	-	112	I
-	-	113	I
(	-	115	I
4	-	117	I
-	-	118	I
(	-	120	I
3	-	122	I
-	-	124	I
fluorobenzylidene	-	126	I
)	-	143	I
piperidin	-	145	I
-	-	154	I
1	-	155	I
-	-	156	I
yl	-	157	I
)	-	159	I
ethyl	-	161	I
]	-	166	I
-	-	168	I
4	-	170	I
-	-	172	I
(	-	173	I
4	-	174	I
-	-	175	I
fluorophenyl	-	176	I
)	-	188	I
thiazole	-	190	I
-	-	198	I
2	-	199	I
-	-	200	I
carboxamide	-	201	I
,	-	212	O
has	-	214	O
a	-	218	O
high	-	220	O
affinity	-	225	O
for	-	234	O
human	-	238	O
cloned	-	244	O
dopamine	-	251	B
D4	-	260	O
.	-	262	O
2	-	263	O
,	-	264	O
D4	-	266	O
.	-	268	O
4	-	269	O

and	10579464	271	O
D4	-	275	O
.	-	277	O
7	-	278	O
receptors	-	280	O
,	-	289	O
with	-	291	O
Ki	-	296	O
values	-	299	O
of	-	306	O
0	-	309	O
.	-	310	O
5	-	311	O
,	-	312	O
0	-	314	O
.	-	315	O
9	-	316	O
and	-	318	O
2	-	322	O
.	-	323	O
7	-	324	O
nM	-	326	O
,	-	328	O
respectively	-	330	O
.	-	342	O

NRA0160	10579464	344	B
is	-	352	O
over	-	355	O
20	-	360	O
,	-	362	O
000fold	-	363	O
more	-	371	O
potent	-	376	O
at	-	383	O
the	-	386	O
dopamine	-	390	B
D4	-	399	O
.	-	401	O
2	-	402	O
receptor	-	404	O
compared	-	413	O
with	-	422	O
the	-	427	O
human	-	431	O
cloned	-	437	O
dopamine	-	444	B
D2L	-	453	O
receptor	-	457	O
.	-	465	O

NRA0160	10579464	467	B
has	-	475	O
negligible	-	479	O
affinity	-	490	O
for	-	499	O
the	-	503	O
human	-	507	O
cloned	-	513	O
dopamine	-	520	B
D3	-	529	O
receptor	-	532	O
(	-	541	O
Ki	-	542	O
=	-	544	O
39	-	545	O
nM	-	548	O
)	-	550	O
,	-	551	O
rat	-	553	O
serotonin	-	557	B
(	-	567	O
5	-	568	B
-	-	569	I
HT	-	570	I
)	-	572	O
2A	-	573	O
receptors	-	576	O
(	-	586	O
Ki	-	587	O
=	-	589	O
180	-	590	O
nM	-	594	O
)	-	596	O
and	-	598	O
rat	-	602	O
alpha1	-	606	O
adrenoceptor	-	613	O
(	-	626	O
Ki	-	627	O
=	-	629	O
237	-	630	O
nM	-	634	O
)	-	636	O
.	-	637	O

NRA0160	10579464	639	B
and	-	647	O
clozapine	-	651	B
antagonized	-	661	O
locomotor	-	673	O
hyperactivity	-	683	O
induced	-	697	O
by	-	705	O
methamphetamine	-	708	B
(	-	724	O
MAP	-	725	B
)	-	728	O
in	-	730	O
mice	-	733	O
.	-	737	O

NRA0160	10579464	739	B
and	-	747	O
clozapine	-	751	B
antagonized	-	761	O
MAP	-	773	B
-	-	776	O
induced	-	777	O
stereotyped	-	785	O
behavior	-	797	O
in	-	806	O
mice	-	809	O
,	-	813	O
although	-	815	O
their	-	824	O
effects	-	830	O
did	-	838	O
not	-	842	O
exceed	-	846	O
50	-	853	O
%	-	855	O
inhibition	-	857	O
,	-	867	O
even	-	869	O
at	-	874	O
the	-	877	O
highest	-	881	O
dose	-	889	O
given	-	894	O
.	-	899	O

NRA0160	10579464	901	B
and	-	909	O
clozapine	-	913	B
significantly	-	923	O
induced	-	937	O
catalepsy	-	945	O
in	-	955	O
rats	-	958	O
,	-	962	O
although	-	964	O
their	-	973	O
effects	-	979	O
did	-	987	O
not	-	991	O
exceed	-	995	O
50	-	1002	O
%	-	1004	O
induction	-	1006	O
even	-	1016	O
at	-	1021	O
the	-	1024	O
highest	-	1028	O
dose	-	1036	O
given	-	1041	O
.	-	1046	O

NRA0160	10579464	1048	B
and	-	1056	O
clozapine	-	1060	B
significantly	-	1070	O
reversed	-	1084	O
the	-	1093	O
disruption	-	1097	O
of	-	1108	O
prepulse	-	1111	O
inhibition	-	1120	O
(	-	1131	O
PPI	-	1132	O
)	-	1135	O
in	-	1137	O
rats	-	1140	O
produced	-	1145	O
by	-	1154	O
apomorphine	-	1157	B
.	-	1168	O

NRA0160	10579464	1170	B
and	-	1178	O
clozapine	-	1182	B
significantly	-	1192	O
shortened	-	1206	O
the	-	1216	O
phencyclidine	-	1220	B
(	-	1234	O
PCP	-	1235	B
)	-	1238	O
-	-	1239	O
induced	-	1240	O
prolonged	-	1248	O
swimming	-	1258	O
latency	-	1267	O
in	-	1275	O
rats	-	1278	O
in	-	1283	O
a	-	1286	O
water	-	1288	O
maze	-	1294	O
task	-	1299	O
.	-	1303	O

These	10579464	1305	O
findings	-	1311	O
suggest	-	1320	O
that	-	1328	O
NRA0160	-	1333	B
may	-	1341	O
have	-	1345	O
unique	-	1350	O
antipsychotic	-	1357	O
activities	-	1371	O
without	-	1382	O
the	-	1390	O
liability	-	1394	O
of	-	1404	O
motor	-	1407	O
side	-	1413	O
effects	-	1418	O
typical	-	1426	O
of	-	1434	O
classical	-	1437	O
antipsychotics	-	1447	O
.	-	1461	O

Prolonged	3496378	0	O
cholestasis	-	10	O
after	-	22	O
troleandomycin	-	28	B
-	-	42	O
induced	-	43	O
acute	-	51	O
hepatitis	-	57	O
.	-	66	O

We	3496378	68	O
report	-	71	O
the	-	78	O
case	-	82	O
of	-	87	O
a	-	90	O
patient	-	92	O
in	-	100	O
whom	-	103	O
troleandomycin	-	108	B
-	-	122	O
induced	-	123	O
hepatitis	-	131	O
was	-	141	O
followed	-	145	O
by	-	154	O
prolonged	-	157	O
anicteric	-	167	O
cholestasis	-	177	O
.	-	188	O

Jaundice	3496378	190	O
occurred	-	199	O
after	-	208	O
administration	-	214	O
of	-	229	O
troleandomycin	-	232	B
for	-	247	O
7	-	251	O
days	-	253	O
and	-	258	O
was	-	262	O
associated	-	266	O
with	-	277	O
hypereosinophilia	-	282	O
.	-	299	O

Jaundice	3496378	301	O
disappeared	-	310	O
within	-	322	O
3	-	329	O
months	-	331	O
but	-	338	O
was	-	342	O
followed	-	346	O
by	-	355	O
prolonged	-	358	O
anicteric	-	368	O
cholestasis	-	378	O
marked	-	390	O
by	-	397	O
pruritus	-	400	O
and	-	409	O
high	-	413	O
levels	-	418	O
of	-	425	O
alkaline	-	428	O
phosphatase	-	437	O
and	-	449	O
gammaglutamyltransferase	-	453	O
activities	-	478	O
.	-	488	O

Finally	3496378	490	O
,	-	497	O
pruritus	-	499	O
disappeared	-	508	O
within	-	520	O
19	-	527	O
months	-	530	O
,	-	536	O
and	-	538	O
liver	-	542	O
tests	-	548	O
returned	-	554	O
to	-	563	O
normal	-	566	O
27	-	573	O
months	-	576	O
after	-	583	O
the	-	589	O
onset	-	593	O
of	-	599	O
hepatitis	-	602	O
.	-	611	O

This	3496378	613	O
observation	-	618	O
demonstrates	-	630	O
that	-	643	O
prolonged	-	648	O
cholestasis	-	658	O
can	-	670	O
follow	-	674	O
troleandomycin	-	681	B
-	-	695	O
induced	-	696	O
acute	-	704	O
hepatitis	-	710	O
.	-	719	O

HMG	3076126	0	O
CoA	-	4	O
reductase	-	8	O
inhibitors	-	18	O
.	-	28	O

Current	3076126	30	O
clinical	-	38	O
experience	-	47	O
.	-	57	O

Lovastatin	3076126	59	B
and	-	70	O
simvastatin	-	74	B
are	-	86	O
the	-	90	O
2	-	94	O
best	-	96	O
-	-	100	O
known	-	101	O
members	-	107	O
of	-	115	O
the	-	118	O
class	-	122	O
of	-	128	O
hypolipidaemic	-	131	O
agents	-	146	O
known	-	153	O
as	-	159	O
HMG	-	162	O
CoA	-	166	O
reductase	-	170	O
inhibitors	-	180	O
.	-	190	O

Clinical	3076126	192	O
experience	-	201	O
with	-	212	O
lovastatin	-	217	B
includes	-	228	O
over	-	237	O
5000	-	242	O
patients	-	247	O
,	-	255	O
700	-	257	O
of	-	261	O
whom	-	264	O
have	-	269	O
been	-	274	O
treated	-	279	O
for	-	287	O
2	-	291	O
years	-	293	O
or	-	299	O
more	-	302	O
,	-	306	O
and	-	308	O
experience	-	312	O
with	-	323	O
simvastatin	-	328	B
includes	-	340	O
over	-	349	O
3500	-	354	O
patients	-	359	O
,	-	367	O
of	-	369	O
whom	-	372	O
350	-	377	O
have	-	381	O
been	-	386	O
treated	-	391	O
for	-	399	O
18	-	403	O
months	-	406	O
or	-	413	O
more	-	416	O
.	-	420	O

Lovastatin	3076126	422	B
has	-	433	O
been	-	437	O
marketed	-	442	O
in	-	451	O
the	-	454	O
United	-	458	O
States	-	465	O
for	-	472	O
over	-	476	O
6	-	481	O
months	-	483	O
.	-	489	O

Both	3076126	491	O
agents	-	496	O
show	-	503	O
substantial	-	508	O
clinical	-	520	O
efficacy	-	529	O
,	-	537	O
with	-	539	O
reductions	-	544	O
in	-	555	O
total	-	558	O
cholesterol	-	564	B
of	-	576	O
over	-	579	O
30	-	584	O
%	-	586	O
and	-	588	O
in	-	592	O
LDL	-	595	O
-	-	598	O
cholesterol	-	599	B
of	-	611	O
40	-	614	O
%	-	616	O
in	-	618	O
clinical	-	621	O
studies	-	630	O
.	-	637	O

Modest	3076126	639	O
increases	-	646	O
in	-	656	O
HDL	-	659	O
-	-	662	O
cholesterol	-	663	B
levels	-	675	O
of	-	682	O
about	-	685	O
10	-	691	O
%	-	693	O
are	-	695	O
also	-	699	O
reported	-	704	O
.	-	712	O

Clinical	3076126	714	O
tolerability	-	723	O
of	-	736	O
both	-	739	O
agents	-	744	O
has	-	751	O
been	-	755	O
good	-	760	O
,	-	764	O
with	-	766	O
fewer	-	771	O
than	-	777	O
3	-	782	O
%	-	783	O
of	-	785	O
patients	-	788	O
withdrawn	-	797	O
from	-	807	O
treatment	-	812	O
because	-	822	O
of	-	830	O
clinical	-	833	O
adverse	-	842	O
experiences	-	850	O
.	-	861	O

Ophthalmological	3076126	863	O
examinations	-	880	O
in	-	893	O
over	-	896	O
1100	-	901	O
patients	-	906	O
treated	-	915	O
with	-	923	O
one	-	928	O
or	-	932	O
the	-	935	O
other	-	939	O
agent	-	945	O
have	-	951	O
revealed	-	956	O
no	-	965	O
evidence	-	968	O
of	-	977	O
significant	-	980	O
short	-	992	O
term	-	998	O
(	-	1003	O
up	-	1004	O
to	-	1007	O
2	-	1010	O
years	-	1012	O
)	-	1017	O
cataractogenic	-	1019	O
potential	-	1034	O
.	-	1043	O

One	3076126	1045	O
to	-	1049	O
2	-	1052	O
%	-	1053	O
of	-	1055	O
patients	-	1058	O
have	-	1067	O
elevations	-	1072	O
of	-	1083	O
serum	-	1086	O
transaminases	-	1092	O
to	-	1106	O
greater	-	1109	O
than	-	1117	O
3	-	1122	O
times	-	1124	O
the	-	1130	O
upper	-	1134	O
limit	-	1140	O
of	-	1146	O
normal	-	1149	O
.	-	1155	O

These	3076126	1157	O
episodes	-	1163	O
are	-	1172	O
asymptomatic	-	1176	O
and	-	1189	O
reversible	-	1193	O
when	-	1204	O
therapy	-	1209	O
is	-	1217	O
discontinued	-	1220	O
.	-	1232	O

Minor	3076126	1234	O
elevations	-	1240	O
of	-	1251	O
creatine	-	1254	B
kinase	-	1263	O
levels	-	1270	O
are	-	1277	O
reported	-	1281	O
in	-	1290	O
about	-	1293	O
5	-	1299	O
%	-	1300	O
of	-	1302	O
patients	-	1305	O
.	-	1313	O

Myopathy	3076126	1315	O
,	-	1323	O
associated	-	1325	O
in	-	1336	O
some	-	1339	O
cases	-	1344	O
with	-	1350	O
myoglobinuria	-	1355	O
,	-	1368	O
and	-	1370	O
in	-	1374	O
2	-	1377	O
cases	-	1379	O
with	-	1385	O
transient	-	1390	O
renal	-	1400	O
failure	-	1406	O
,	-	1413	O
has	-	1415	O
been	-	1419	O
rarely	-	1424	O
reported	-	1431	O
with	-	1440	O
lovastatin	-	1445	B
,	-	1455	O
especially	-	1457	O
in	-	1468	O
patients	-	1471	O
concomitantly	-	1480	O
treated	-	1494	O
with	-	1502	O
cyclosporin	-	1507	B
,	-	1518	O
gemfibrozil	-	1520	B
or	-	1532	O
niacin	-	1535	B
.	-	1541	O

Lovastatin	3076126	1543	B
and	-	1554	O
simvastatin	-	1558	B
are	-	1570	O
both	-	1574	O
effective	-	1579	O
and	-	1589	O
well	-	1593	O
-	-	1597	O
tolerated	-	1598	O
agents	-	1608	O
for	-	1615	O
lowering	-	1619	O
elevated	-	1628	O
levels	-	1637	O
of	-	1644	O
serum	-	1647	O
cholesterol	-	1653	B
.	-	1664	O

As	3076126	1666	O
wider	-	1669	O
use	-	1675	O
confirms	-	1679	O
their	-	1688	O
safety	-	1694	O
profile	-	1701	O
,	-	1708	O
they	-	1710	O
will	-	1715	O
gain	-	1720	O
increasing	-	1725	O
importance	-	1736	O
in	-	1747	O
the	-	1750	O
therapeutic	-	1754	O
approach	-	1766	O
to	-	1775	O
hypercholesterolaemia	-	1778	O
and	-	1800	O
its	-	1804	O
consequences	-	1808	O
.	-	1820	O

Sulfasalazine	2894766	0	B
-	-	13	O
induced	-	14	O
lupus	-	22	O
erythematosus	-	28	O
.	-	41	O

Pneumonitis	2894766	43	O
,	-	54	O
bilateral	-	56	O
pleural	-	66	O
effusions	-	74	O
,	-	83	O
echocardiographic	-	85	O
evidence	-	103	O
of	-	112	O
cardiac	-	115	O
tamponade	-	123	O
,	-	132	O
and	-	134	O
positive	-	138	O
autoantibodies	-	147	O
developed	-	162	O
in	-	172	O
a	-	175	O
43	-	177	O
-	-	179	O
year	-	180	O
-	-	184	O
old	-	185	O
man	-	189	O
,	-	192	O
who	-	194	O
was	-	198	O
receiving	-	202	O
long	-	212	O
-	-	216	O
term	-	217	O
sulfasalazine	-	222	B
therapy	-	236	O
for	-	244	O
chronic	-	248	O
ulcerative	-	256	O
colitis	-	267	O
.	-	274	O

After	2894766	276	O
cessation	-	282	O
of	-	292	O
the	-	295	O
sulfasalazine	-	299	B
and	-	313	O
completion	-	317	O
of	-	328	O
a	-	331	O
six	-	333	O
-	-	336	O
week	-	337	O
course	-	342	O
of	-	349	O
corticosteroids	-	352	O
,	-	367	O
these	-	369	O
problems	-	375	O
resolved	-	384	O
over	-	393	O
a	-	398	O
period	-	400	O
of	-	407	O
four	-	410	O
to	-	415	O
six	-	418	O
months	-	422	O
.	-	428	O

It	2894766	430	O
is	-	433	O
suggested	-	436	O
that	-	446	O
the	-	451	O
patient	-	455	O
had	-	463	O
sulfasalazine	-	467	B
-	-	480	O
induced	-	481	O
lupus	-	489	O
,	-	494	O
which	-	496	O
manifested	-	502	O
with	-	513	O
serositis	-	518	O
and	-	528	O
pulmonary	-	532	O
parenchymal	-	542	O
involvement	-	554	O
in	-	566	O
the	-	569	O
absence	-	573	O
of	-	581	O
joint	-	584	O
symptoms	-	590	O
.	-	598	O

Physicians	2894766	600	O
who	-	611	O
use	-	615	O
sulfasalazine	-	619	B
to	-	633	O
treat	-	636	O
patients	-	642	O
with	-	651	O
inflammatory	-	656	O
bowel	-	669	O
disease	-	675	O
should	-	683	O
be	-	690	O
aware	-	693	O
of	-	699	O
the	-	702	O
signs	-	706	O
of	-	712	O
sulfasalazine	-	715	B
-	-	728	O
induced	-	729	O
lupus	-	737	O
syndrome	-	743	O
.	-	751	O

Optimization	1549199	0	O
of	-	13	O
levodopa	-	16	B
therapy	-	25	O
.	-	32	O

While	1549199	34	O
there	-	40	O
is	-	46	O
no	-	49	O
single	-	52	O
correct	-	59	O
starting	-	67	O
dose	-	76	O
for	-	81	O
levodopa	-	85	B
therapy	-	94	O
,	-	101	O
many	-	103	O
individuals	-	108	O
can	-	120	O
be	-	124	O
started	-	127	O
on	-	135	O
either	-	138	O
the	-	145	O
25	-	149	O
/	-	151	O
100	-	152	O
or	-	156	O
controlled	-	159	O
-	-	169	O
release	-	170	O
formula	-	178	O
,	-	185	O
following	-	187	O
the	-	197	O
general	-	201	O
rule	-	209	O
not	-	214	O
to	-	218	O
attempt	-	221	O
to	-	229	O
titrate	-	232	O
carbidopa	-	240	B
-	-	249	O
levodopa	-	250	B
to	-	259	O
the	-	262	O
point	-	266	O
of	-	272	O
""""	-	275	O
normality	-	276	O
,	-	285	O
""""	-	286	O
which	-	288	O
can	-	294	O
lead	-	298	O
to	-	303	O
toxicity	-	306	O
.	-	314	O

The	1549199	316	O
physician	-	320	O
should	-	330	O
also	-	337	O
determine	-	342	O
the	-	352	O
proper	-	356	O
use	-	363	O
of	-	367	O
any	-	370	O
adjunctive	-	374	O
medications	-	385	O
;	-	396	O
such	-	398	O
combined	-	403	O
therapy	-	412	O
has	-	420	O
become	-	424	O
the	-	431	O
standard	-	435	O
approach	-	444	O
to	-	453	O
treatment	-	456	O
.	-	465	O

Following	1549199	467	O
the	-	477	O
initial	-	481	O
period	-	489	O
of	-	496	O
therapy	-	499	O
,	-	506	O
emerging	-	508	O
difficulties	-	517	O
require	-	530	O
a	-	538	O
reassessment	-	540	O
of	-	553	O
therapeutic	-	556	O
approaches	-	568	O
,	-	578	O
such	-	580	O
as	-	585	O
dosage	-	588	O
adjustment	-	595	O
or	-	606	O
introduction	-	609	O
of	-	622	O
a	-	625	O
dopamine	-	627	B
agonist	-	636	O
.	-	643	O

Other	1549199	645	O
possible	-	651	O
adverse	-	660	O
effects	-	668	O
-	-	675	O
-	-	676	O
such	-	677	O
as	-	682	O
gastrointestinal	-	685	O
disorders	-	702	O
,	-	711	O
orthostatic	-	713	O
hypotension	-	725	O
,	-	736	O
levodopa	-	738	B
-	-	746	O
induced	-	747	O
psychosis	-	755	O
,	-	764	O
sleep	-	766	O
disturbances	-	772	O
or	-	785	O
parasomnias	-	788	O
,	-	799	O
or	-	801	O
drug	-	804	O
interactions	-	809	O
-	-	821	O
-	-	822	O
also	-	823	O
require	-	828	O
carefully	-	836	O
monitored	-	846	O
individual	-	856	O
treatment	-	867	O
.	-	876	O

Nonpharmacologic	1549199	878	O
concerns	-	895	O
can	-	904	O
help	-	908	O
the	-	913	O
Parkinson	-	917	O
's	-	926	O
disease	-	929	O
patient	-	937	O
achieve	-	945	O
and	-	953	O
maintain	-	957	O
optimal	-	966	O
functioning	-	974	O
,	-	985	O
including	-	987	O
daily	-	997	O
exercise	-	1003	O
,	-	1011	O
physical	-	1013	O
therapy	-	1022	O
,	-	1029	O
and	-	1031	O
involvement	-	1035	O
with	-	1047	O
support	-	1052	O
groups	-	1060	O
.	-	1066	O

Alpha	88336	0	O
and	-	6	O
beta	-	10	O
coma	-	15	O
in	-	20	O
drug	-	23	O
intoxication	-	28	O
uncomplicated	-	41	O
by	-	55	O
cerebral	-	58	O
hypoxia	-	67	O
.	-	74	O

Four	88336	76	O
patients	-	81	O
who	-	90	O
were	-	94	O
rendered	-	99	O
comatose	-	108	O
or	-	117	O
stuporous	-	120	O
by	-	130	O
drug	-	133	O
intoxication	-	138	O
,	-	150	O
but	-	152	O
who	-	156	O
were	-	160	O
not	-	165	O
hypoxic	-	169	O
,	-	176	O
are	-	178	O
described	-	182	O
.	-	191	O

Three	88336	193	O
patients	-	199	O
received	-	208	O
high	-	217	O
doses	-	222	O
of	-	228	O
chlormethiazole	-	231	B
for	-	247	O
alcohol	-	251	B
withdrawal	-	259	O
symptoms	-	270	O
,	-	278	O
and	-	280	O
one	-	284	O
took	-	288	O
a	-	293	O
suicidal	-	295	O
overdose	-	304	O
of	-	313	O
nitrazepam	-	316	B
.	-	326	O

The	88336	328	O
patient	-	332	O
with	-	340	O
nitrazepam	-	345	B
overdose	-	356	O
and	-	365	O
two	-	369	O
of	-	373	O
those	-	376	O
with	-	382	O
chlormethiazole	-	387	B
intoxication	-	403	O
conformed	-	416	O
to	-	426	O
the	-	429	O
criteria	-	433	O
of	-	442	O
'	-	445	O
alpha	-	446	O
coma	-	452	O
'	-	456	O
,	-	457	O
showing	-	459	O
non	-	467	O
-	-	470	O
reactive	-	471	O
generalized	-	480	O
or	-	492	O
frontally	-	495	O
predominant	-	505	O
alpha	-	517	O
activity	-	523	O
in	-	532	O
the	-	535	O
EEG	-	539	O
.	-	542	O

The	88336	544	O
fourth	-	548	O
patient	-	555	O
who	-	563	O
was	-	567	O
unconscious	-	571	O
after	-	583	O
chlormethiazole	-	589	B
administration	-	605	O
exhibite	-	620	O
generalized	-	629	O
non	-	641	O
-	-	644	O
reactive	-	645	O
activity	-	654	O
in	-	663	O
the	-	666	O
slow	-	670	O
beta	-	675	O
range	-	680	O
.	-	685	O

All	88336	687	O
four	-	691	O
recovered	-	696	O
completely	-	706	O
without	-	717	O
neurological	-	725	O
sequelae	-	738	O
following	-	747	O
the	-	757	O
withdrawal	-	761	O
of	-	772	O
the	-	775	O
offending	-	779	O
agents	-	789	O
.	-	795	O

The	88336	797	O
similarities	-	801	O
between	-	814	O
the	-	822	O
effects	-	826	O
of	-	834	O
structural	-	837	O
lesions	-	848	O
and	-	856	O
pharmacological	-	860	O
depression	-	876	O
of	-	887	O
the	-	890	O
brain	-	894	O
stem	-	900	O
reticular	-	905	O
formation	-	915	O
are	-	925	O
discussed	-	929	O
.	-	938	O

It	88336	940	O
is	-	943	O
suggested	-	946	O
that	-	956	O
in	-	961	O
both	-	964	O
situations	-	969	O
disturbed	-	980	O
reticulo	-	990	O
-	-	998	O
thalamic	-	999	O
interactions	-	1008	O
are	-	1021	O
important	-	1025	O
in	-	1035	O
the	-	1038	O
pathogenesis	-	1042	O
of	-	1055	O
alpha	-	1058	O
coma	-	1064	O
.	-	1068	O

It	88336	1070	O
is	-	1073	O
concluded	-	1076	O
that	-	1086	O
when	-	1091	O
this	-	1096	O
electroencephalographic	-	1101	O
and	-	1125	O
behavioural	-	1129	O
picture	-	1141	O
is	-	1149	O
seen	-	1152	O
in	-	1157	O
drug	-	1160	O
intoxication	-	1165	O
,	-	1177	O
in	-	1179	O
the	-	1182	O
absence	-	1186	O
of	-	1194	O
significant	-	1197	O
hypoxaemia	-	1209	O
,	-	1219	O
a	-	1221	O
favourable	-	1223	O
outcome	-	1234	O
may	-	1242	O
be	-	1246	O
anticipated	-	1249	O
.	-	1260	O

Omitting	18544179	0	O
fentanyl	-	9	B
reduces	-	18	O
nausea	-	26	O
and	-	33	O
vomiting	-	37	O
,	-	45	O
without	-	47	O
increasing	-	55	O
pain	-	66	O
,	-	70	O
after	-	72	O
sevoflurane	-	78	B
for	-	90	O
day	-	94	O
surgery	-	98	O
.	-	105	O

BACKGROUND	18544179	107	O
AND	-	118	O
OBJECTIVE	-	122	O
:	-	131	O
Despite	-	133	O
advantages	-	141	O
of	-	152	O
induction	-	155	O
and	-	165	O
maintenance	-	169	O
of	-	181	O
anaesthesia	-	184	O
with	-	196	O
sevoflurane	-	201	B
,	-	212	O
postoperative	-	214	O
nausea	-	228	O
and	-	235	O
vomiting	-	239	O
occurs	-	248	O
frequently	-	255	O
.	-	265	O

Fentanyl	18544179	267	B
is	-	276	O
a	-	279	O
commonly	-	281	O
used	-	290	O
supplement	-	295	O
that	-	306	O
may	-	311	O
contribute	-	315	O
to	-	326	O
this	-	329	O
,	-	333	O
although	-	335	O
it	-	344	O
may	-	347	O
also	-	351	O
improve	-	356	O
analgesia	-	364	O
.	-	373	O

METHODS	18544179	375	O
:	-	382	O

This	18544179	384	O
double	-	389	O
-	-	395	O
blind	-	396	O
study	-	402	O
examined	-	408	O
the	-	417	O
incidence	-	421	O
and	-	431	O
severity	-	435	O
of	-	444	O
postoperative	-	447	O
nausea	-	461	O
and	-	468	O
vomiting	-	472	O
and	-	481	O
pain	-	485	O
in	-	490	O
the	-	493	O
first	-	497	O
24	-	503	O
h	-	506	O
after	-	508	O
sevoflurane	-	514	B
anaesthesia	-	526	O
in	-	538	O
216	-	541	O
adult	-	545	O
day	-	551	O
surgery	-	555	O
patients	-	563	O
.	-	571	O

Patients	18544179	573	O
were	-	582	O
randomly	-	587	O
allocated	-	596	O
to	-	606	O
either	-	609	O
receive	-	616	O
or	-	624	O
not	-	627	O
receive	-	631	O
1	-	639	O
1	-	641	O
fentanyl	-	643	B
,	-	651	O
while	-	653	O
a	-	659	O
third	-	661	O
group	-	667	O
received	-	673	O
dexamethasone	-	682	B
in	-	696	O
addition	-	699	O
to	-	708	O
fentanyl	-	711	B
.	-	719	O

RESULTS	18544179	721	O
:	-	728	O

Omission	18544179	730	O
of	-	739	O
fentanyl	-	742	B
did	-	751	O
not	-	755	O
reduce	-	759	O
the	-	766	O
overall	-	770	O
incidence	-	778	O
of	-	788	O
postoperative	-	791	O
nausea	-	805	O
and	-	812	O
vomiting	-	816	O
,	-	824	O
but	-	826	O
did	-	830	O
reduce	-	834	O
the	-	841	O
incidence	-	845	O
of	-	855	O
vomiting	-	858	O
and	-	867	O
/	-	870	O
or	-	871	O
moderate	-	874	O
to	-	883	O
severe	-	886	O
nausea	-	893	O
prior	-	900	O
to	-	906	O
discharge	-	909	O
from	-	919	O
20	-	924	O
%	-	926	O
and	-	928	O
17	-	932	O
%	-	934	O
with	-	936	O
fentanyl	-	941	B
and	-	950	O
fentanyl	-	954	B
-	-	962	O
dexamethasone	-	963	B
,	-	976	O
respectively	-	978	O
,	-	990	O
to	-	992	O
5	-	995	O
%	-	996	O
(	-	998	O
P	-	999	O
=	-	1001	O
0	-	1003	O
.	-	1004	O
013	-	1005	O
)	-	1008	O
.	-	1009	O

Antiemetic	18544179	1011	O
requirements	-	1022	O
were	-	1035	O
reduced	-	1040	O
from	-	1048	O
24	-	1053	O
%	-	1055	O
and	-	1057	O
31	-	1061	O
%	-	1063	O
to	-	1065	O
7	-	1068	O
%	-	1069	O
(	-	1071	O
P	-	1072	O
=	-	1074	O
0	-	1076	O
.	-	1077	O
0012	-	1078	O
)	-	1082	O
.	-	1083	O

Dexamethasone	18544179	1085	B
had	-	1099	O
no	-	1103	O
significant	-	1106	O
effect	-	1118	O
on	-	1125	O
the	-	1128	O
incidence	-	1132	O
or	-	1142	O
severity	-	1145	O
of	-	1154	O
postoperative	-	1157	O
nausea	-	1171	O
and	-	1178	O
vomiting	-	1182	O
.	-	1190	O

Combining	18544179	1192	O
the	-	1202	O
two	-	1206	O
fentanyl	-	1210	B
groups	-	1219	O
revealed	-	1226	O
further	-	1235	O
significant	-	1243	O
benefits	-	1255	O
from	-	1264	O
the	-	1269	O
avoidance	-	1273	O
of	-	1283	O
opioids	-	1286	O
,	-	1293	O
reducing	-	1295	O
postoperative	-	1304	O
nausea	-	1318	O
and	-	1325	O
vomiting	-	1329	O
and	-	1338	O
nausea	-	1342	O
prior	-	1349	O
to	-	1355	O
discharge	-	1358	O
from	-	1368	O
35	-	1373	O
%	-	1375	O
and	-	1377	O
33	-	1381	O
%	-	1383	O
to	-	1385	O
22	-	1388	O
%	-	1390	O
and	-	1392	O
19	-	1396	O
%	-	1398	O
(	-	1400	O
P	-	1401	O
=	-	1403	O
0	-	1405	O
.	-	1406	O
049	-	1407	O
and	-	1411	O
P	-	1415	O
=	-	1417	O
0	-	1419	O
.	-	1420	O
035	-	1421	O
)	-	1424	O
,	-	1425	O
respectively	-	1427	O
,	-	1439	O
while	-	1441	O
nausea	-	1447	O
in	-	1454	O
the	-	1457	O
first	-	1461	O
24	-	1467	O
h	-	1470	O
was	-	1472	O
decreased	-	1476	O
from	-	1486	O
42	-	1491	O
%	-	1493	O
to	-	1495	O
27	-	1498	O
%	-	1500	O
(	-	1502	O
P	-	1503	O
=	-	1505	O
0	-	1507	O
.	-	1508	O
034	-	1509	O
)	-	1512	O
.	-	1513	O

Pain	18544179	1515	O
severity	-	1520	O
and	-	1529	O
analgesic	-	1533	O
requirements	-	1543	O
were	-	1556	O
unaffected	-	1561	O
by	-	1572	O
the	-	1575	O
omission	-	1579	O
of	-	1588	O
fentanyl	-	1591	B
.	-	1599	O

Fentanyl	18544179	1601	B
did	-	1610	O
reduce	-	1614	O
minor	-	1621	O
intraoperative	-	1627	O
movement	-	1642	O
but	-	1651	O
had	-	1655	O
no	-	1659	O
sevoflurane	-	1662	B
-	-	1673	O
sparing	-	1674	O
effect	-	1682	O
and	-	1689	O
increased	-	1693	O
respiratory	-	1703	O
depression	-	1715	O
,	-	1725	O
hypotension	-	1727	O
and	-	1739	O
bradycardia	-	1743	O
.	-	1754	O

CONCLUSION	18544179	1756	O
:	-	1766	O

As	18544179	1768	O
fentanyl	-	1771	B
exacerbated	-	1780	O
postoperative	-	1792	O
nausea	-	1806	O
and	-	1813	O
vomiting	-	1817	O
without	-	1826	O
an	-	1834	O
improvement	-	1837	O
in	-	1849	O
postoperative	-	1852	O
pain	-	1866	O
and	-	1871	O
also	-	1875	O
had	-	1880	O
adverse	-	1884	O
cardiorespiratory	-	1892	O
effects	-	1910	O
,	-	1917	O
it	-	1919	O
appears	-	1922	O
to	-	1930	O
be	-	1933	O
an	-	1936	O
unnecessary	-	1939	O
and	-	1951	O
possibly	-	1955	O
detrimental	-	1964	O
supplement	-	1976	O
to	-	1987	O
sevoflurane	-	1990	B
in	-	2002	O
day	-	2005	O
surgery	-	2009	O
.	-	2016	O

Renal	18186898	0	O
Fanconi	-	6	O
syndrome	-	14	O
and	-	23	O
myopathy	-	27	O
after	-	36	O
liver	-	42	O
transplantation	-	48	O
:	-	63	O
drug	-	65	O
-	-	69	O
related	-	70	O
mitochondrial	-	78	O
cytopathy	-	92	O
?	-	101	O

Advances	18186898	103	O
in	-	112	O
the	-	115	O
field	-	119	O
of	-	125	O
transplantation	-	128	O
provide	-	144	O
a	-	152	O
better	-	154	O
quality	-	161	O
of	-	169	O
life	-	172	O
and	-	177	O
allow	-	181	O
more	-	187	O
favorable	-	192	O
conditions	-	202	O
for	-	213	O
growth	-	217	O
and	-	224	O
development	-	228	O
in	-	240	O
children	-	243	O
.	-	251	O

However	18186898	253	O
,	-	260	O
combinations	-	262	O
of	-	275	O
different	-	278	O
therapeutic	-	288	O
regimens	-	300	O
require	-	309	O
consideration	-	317	O
of	-	331	O
potential	-	334	O
adverse	-	344	O
reactions	-	352	O
.	-	361	O

We	18186898	363	O
describe	-	366	O
a	-	375	O
15	-	377	O
-	-	379	O
yr	-	380	O
-	-	382	O
old	-	383	O
girl	-	387	O
who	-	392	O
had	-	396	O
orthotopic	-	400	O
liver	-	411	O
transplantation	-	417	O
because	-	433	O
of	-	441	O
Wilson	-	444	O
's	-	450	O
disease	-	453	O
.	-	460	O

Tacrolimus	18186898	462	B
,	-	472	O
MMF	-	474	B
,	-	477	O
and	-	479	O
steroids	-	483	B
were	-	492	O
given	-	497	O
as	-	503	O
immunosuppressant	-	506	O
.	-	523	O

Lamivudine	18186898	525	B
was	-	536	O
added	-	540	O
because	-	546	O
of	-	554	O
de	-	557	O
nova	-	560	O
hepatitis	-	565	O
B	-	575	O
infection	-	577	O
during	-	587	O
her	-	594	O
follow	-	598	O
-	-	604	O
up	-	605	O
.	-	607	O

Three	18186898	609	O
yr	-	615	O
after	-	618	O
transplantation	-	624	O
she	-	640	O
developed	-	644	O
renal	-	654	O
Fanconi	-	660	O
syndrome	-	668	O
with	-	677	O
severe	-	682	O
metabolic	-	689	O
acidosis	-	699	O
,	-	707	O
hypophosphatemia	-	709	O
,	-	725	O
glycosuria	-	727	O
,	-	737	O
and	-	739	O
aminoaciduria	-	743	O
.	-	756	O

Although	18186898	758	O
tacrolimus	-	767	B
was	-	778	O
suspected	-	782	O
to	-	792	O
be	-	795	O
the	-	798	O
cause	-	802	O
of	-	808	O
late	-	811	O
post	-	816	O
-	-	820	O
transplant	-	821	O
renal	-	832	O
acidosis	-	838	O
and	-	847	O
was	-	851	O
replaced	-	855	O
by	-	864	O
sirolimus	-	867	B
,	-	876	O
acidosis	-	878	O
,	-	886	O
and	-	888	O
electrolyte	-	892	O
imbalance	-	904	O
got	-	914	O
worse	-	918	O
.	-	923	O

Proximal	18186898	925	O
muscle	-	934	O
weakness	-	941	O
has	-	950	O
developed	-	954	O
during	-	964	O
her	-	971	O
follow	-	975	O
-	-	981	O
up	-	982	O
.	-	984	O

Fanconi	18186898	986	O
syndrome	-	994	O
,	-	1002	O
as	-	1004	O
well	-	1007	O
as	-	1012	O
myopathy	-	1015	O
,	-	1023	O
is	-	1025	O
well	-	1028	O
recognized	-	1033	O
in	-	1044	O
patients	-	1047	O
with	-	1056	O
mitochondrial	-	1061	O
disorders	-	1075	O
and	-	1085	O
caused	-	1089	O
by	-	1096	O
depletion	-	1099	O
of	-	1109	O
mtDNA	-	1112	O
.	-	1117	O

We	18186898	1119	O
suggest	-	1122	O
that	-	1130	O
our	-	1135	O
patient	-	1139	O
's	-	1146	O
tubular	-	1149	O
dysfunction	-	1157	O
and	-	1169	O
myopathy	-	1173	O
may	-	1182	O
have	-	1186	O
resulted	-	1191	O
from	-	1200	O
mitochondrial	-	1205	O
dysfunction	-	1219	O
which	-	1231	O
is	-	1237	O
triggered	-	1240	O
by	-	1250	O
tacrolimus	-	1253	B
and	-	1264	O
augmented	-	1268	O
by	-	1278	O
lamivudine	-	1281	B
.	-	1291	O

Antipsychotic	16867021	0	O
-	-	13	O
like	-	14	O
profile	-	19	O
of	-	27	O
thioperamide	-	30	B
,	-	42	O
a	-	44	O
selective	-	46	O
H3	-	56	O
-	-	58	O
receptor	-	59	O
antagonist	-	68	O
in	-	79	O
mice	-	82	O
.	-	86	O

Experimental	16867021	88	O
and	-	101	O
clinical	-	105	O
evidence	-	114	O
points	-	123	O
to	-	130	O
a	-	133	O
role	-	135	O
of	-	140	O
central	-	143	O
histaminergic	-	151	O
system	-	165	O
in	-	172	O
the	-	175	O
pathogenesis	-	179	O
of	-	192	O
schizophrenia	-	195	O
.	-	208	O

The	16867021	210	O
present	-	214	O
study	-	222	O
was	-	228	O
designed	-	232	O
to	-	241	O
study	-	244	O
the	-	250	O
effect	-	254	O
of	-	261	O
histamine	-	264	B
H	-	274	O
(	-	275	O
3	-	276	O
)	-	277	O
-	-	278	O
receptor	-	279	O
ligands	-	288	O
on	-	296	O
neuroleptic	-	299	O
-	-	310	O
induced	-	311	O
catalepsy	-	319	O
,	-	328	O
apomorphine	-	330	B
-	-	341	O
induced	-	342	O
climbing	-	350	O
behavior	-	359	O
and	-	368	O
amphetamine	-	372	B
-	-	383	O
induced	-	384	O
locomotor	-	392	O
activities	-	402	O
in	-	413	O
mice	-	416	O
.	-	420	O

Catalepsy	16867021	422	O
was	-	432	O
induced	-	436	O
by	-	444	O
haloperidol	-	447	B
(	-	459	O
2	-	460	O
mg	-	462	O
/	-	464	O
kg	-	465	O
p	-	468	O
.	-	469	O
o	-	470	O
.	-	471	O
)	-	472	O
,	-	473	O
while	-	475	O
apomorphine	-	481	B
(	-	493	O
1	-	494	O
.	-	495	O
5	-	496	O
mg	-	498	O
/	-	500	O
kg	-	501	O
s	-	504	O
.	-	505	O
c	-	506	O
.	-	507	O
)	-	508	O
and	-	510	O
amphetamine	-	514	B
(	-	526	O
2	-	527	O
mg	-	529	O
/	-	531	O
kg	-	532	O
s	-	535	O
.	-	536	O
c	-	537	O
.	-	538	O
)	-	539	O
were	-	541	O
used	-	546	O
for	-	551	O
studying	-	555	O
climbing	-	564	O
behavior	-	573	O
and	-	582	O
locomotor	-	586	O
activities	-	596	O
,	-	606	O
respectively	-	608	O
.	-	620	O

(	16867021	622	B
R	-	623	I
)	-	624	I
-	-	625	I
alpha	-	626	I
-	-	631	I
methylhistamine	-	632	I
(	-	648	O
RAMH	-	649	B
)	-	653	O
(	-	655	O
5	-	656	O
microg	-	658	O
i	-	665	O
.	-	666	O
c	-	667	O
.	-	668	O
v	-	669	O
.	-	670	O
)	-	671	O
and	-	673	O
thioperamide	-	677	B
(	-	690	O
THP	-	691	B
)	-	694	O
(	-	696	O

15	16867021	697	O
mg	-	700	O
/	-	702	O
kg	-	703	O
i	-	706	O
.	-	707	O
p	-	708	O
.	-	709	O
)	-	710	O

,	16867021	711	O
per	-	713	O
se	-	717	O
did	-	720	O
not	-	724	O
cause	-	728	O
catalepsy	-	734	O
.	-	743	O

Administration	16867021	745	O
of	-	760	O
THP	-	763	B
(	-	767	O
3	-	768	O
.	-	769	O
75	-	770	O
,	-	772	O
7	-	774	O
.	-	775	O
5	-	776	O
and	-	778	O
15	-	782	O
mg	-	785	O
/	-	787	O
kg	-	788	O

i	16867021	791	O
.	-	792	O
p	-	793	O
.	-	794	O
)	-	795	O

1	16867021	797	O
h	-	799	O
prior	-	801	O
to	-	807	O
haloperidol	-	810	B
resulted	-	822	O
in	-	831	O
a	-	834	O
dose	-	836	O
-	-	840	O
dependent	-	841	O
increase	-	851	O
in	-	860	O
the	-	863	O
catalepsy	-	867	O
times	-	877	O
(	-	883	O
P	-	884	O
<	-	886	O
0	-	888	O
.	-	889	O
05	-	890	O
)	-	892	O
.	-	893	O

However	16867021	895	O
,	-	902	O
pretreatment	-	904	O
with	-	917	O
RAMH	-	922	B
significantly	-	927	O
reversed	-	941	O
such	-	950	O
an	-	955	O
effect	-	958	O
of	-	965	O
THP	-	968	B
(	-	972	O
15	-	973	O
mg	-	976	O
/	-	978	O
kg	-	979	O
i	-	982	O
.	-	983	O
p	-	984	O
.	-	985	O
)	-	986	O
.	-	987	O

RAMH	16867021	989	B
per	-	994	O
se	-	998	O
showed	-	1001	O
significant	-	1008	O
reduction	-	1020	O
in	-	1030	O
locomotor	-	1033	O
time	-	1043	O
,	-	1047	O
distance	-	1049	O
traveled	-	1058	O
and	-	1067	O
average	-	1071	O
speed	-	1079	O
but	-	1085	O
THP	-	1089	B
(	-	1093	O
15	-	1094	O
mg	-	1097	O
/	-	1099	O
kg	-	1100	O

i	16867021	1103	O
.	-	1104	O
p	-	1105	O
.	-	1106	O
)	-	1107	O

per	16867021	1109	O
se	-	1113	O
had	-	1116	O
no	-	1120	O
effect	-	1123	O
on	-	1130	O
these	-	1133	O
parameters	-	1139	O
.	-	1149	O

On	16867021	1151	O
amphetamine	-	1154	B
-	-	1165	O
induced	-	1166	O
hyperactivity	-	1174	O
,	-	1187	O
THP	-	1189	B
(	-	1193	O
3	-	1194	O
.	-	1195	O
75	-	1196	O
and	-	1199	O
7	-	1203	O
.	-	1204	O
5	-	1205	O
mg	-	1207	O
/	-	1209	O
kg	-	1210	O
i	-	1213	O
.	-	1214	O
p	-	1215	O
.	-	1216	O
)	-	1217	O
reduced	-	1219	O
locomotor	-	1227	O
time	-	1237	O
,	-	1241	O
distance	-	1243	O
traveled	-	1252	O
and	-	1261	O
average	-	1265	O
speed	-	1273	O
(	-	1279	O
P	-	1280	O
<	-	1282	O
0	-	1284	O
.	-	1285	O
05	-	1286	O
)	-	1288	O
.	-	1289	O

Pretreatment	16867021	1291	O
with	-	1304	O
RAMH	-	1309	B
(	-	1314	O
5	-	1315	O
microg	-	1317	O
i	-	1324	O
.	-	1325	O
c	-	1326	O
.	-	1327	O
v	-	1328	O
.	-	1329	O
)	-	1330	O
could	-	1332	O
partially	-	1338	O
reverse	-	1348	O
such	-	1356	O
effects	-	1361	O
of	-	1369	O
THP	-	1372	B
(	-	1376	O
3	-	1377	O
.	-	1378	O
75	-	1379	O
mg	-	1382	O
/	-	1384	O
kg	-	1385	O
i	-	1388	O
.	-	1389	O
p	-	1390	O
.	-	1391	O
)	-	1392	O
.	-	1393	O

Climbing	16867021	1395	O
behavior	-	1404	O
induced	-	1413	O
by	-	1421	O
apomorphine	-	1424	B
was	-	1436	O
reduced	-	1440	O
in	-	1448	O
animals	-	1451	O
treated	-	1459	O
with	-	1467	O
THP	-	1472	B
.	-	1475	O

Such	16867021	1477	O
an	-	1482	O
effect	-	1485	O
was	-	1492	O
,	-	1495	O
however	-	1497	O
,	-	1504	O
reversed	-	1506	O
in	-	1515	O
presence	-	1518	O
of	-	1527	O
RAMH	-	1530	B
.	-	1534	O

THP	16867021	1536	B
exhibited	-	1540	O
an	-	1550	O
antipsychotic	-	1553	O
-	-	1566	O
like	-	1567	O
profile	-	1572	O
by	-	1580	O
potentiating	-	1583	O
haloperidol	-	1596	B
-	-	1607	O
induced	-	1608	O
catalepsy	-	1616	O
,	-	1625	O
reducing	-	1627	O
amphetamine	-	1636	B
-	-	1647	O
induced	-	1648	O
hyperactivity	-	1656	O
and	-	1670	O
reducing	-	1674	O
apomorphine	-	1683	B
-	-	1694	O
induced	-	1695	O
climbing	-	1703	O
in	-	1712	O
mice	-	1715	O
.	-	1719	O

Such	16867021	1721	O
effects	-	1726	O
of	-	1734	O
THP	-	1737	B
were	-	1741	O
reversed	-	1746	O
by	-	1755	O
RAMH	-	1758	B
indicating	-	1763	O
the	-	1774	O
involvement	-	1778	O
of	-	1790	O
histamine	-	1793	B
H	-	1803	O
(	-	1804	O
3	-	1805	O
)	-	1806	O
-	-	1807	O
receptors	-	1808	O
.	-	1817	O

Findings	16867021	1819	O
suggest	-	1828	O
a	-	1836	O
potential	-	1838	O
for	-	1848	O
H	-	1852	O
(	-	1853	O
3	-	1854	O
)	-	1855	O
-	-	1856	O
receptor	-	1857	O
antagonists	-	1866	O
in	-	1878	O
improving	-	1881	O
the	-	1891	O
refractory	-	1895	O
cases	-	1906	O
of	-	1912	O
schizophrenia	-	1915	O
.	-	1928	O

Transient	14976857	0	O
platypnea	-	10	O
-	-	19	O
orthodeoxia	-	20	O
-	-	31	O
like	-	32	O
syndrome	-	37	O
induced	-	46	O
by	-	54	O
propafenone	-	57	B
overdose	-	69	O
in	-	78	O
a	-	81	O
young	-	83	O
woman	-	89	O
with	-	95	O
Ebstein	-	100	O
's	-	107	O
anomaly	-	110	O
.	-	117	O

In	14976857	119	O
this	-	122	O
report	-	127	O
we	-	134	O
describe	-	137	O
the	-	146	O
case	-	150	O
of	-	155	O
a	-	158	O
37	-	160	O
-	-	162	O
year	-	163	O
-	-	167	O
old	-	168	O
white	-	172	O
woman	-	178	O
with	-	184	O
Ebstein	-	189	O
's	-	196	O
anomaly	-	199	O
,	-	206	O
who	-	208	O
developed	-	212	O
a	-	222	O
rare	-	224	O
syndrome	-	229	O
called	-	238	O
platypnea	-	245	O
-	-	254	O
orthodeoxia	-	255	O
,	-	266	O
characterized	-	268	O
by	-	282	O
massive	-	285	O
right	-	293	O
-	-	298	O
to	-	299	O
-	-	301	O
left	-	302	O
interatrial	-	307	O
shunting	-	319	O
with	-	328	O
transient	-	333	O
profound	-	343	O
hypoxia	-	352	O
and	-	360	O
cyanosis	-	364	O
.	-	372	O

This	14976857	374	O
shunt	-	379	O
of	-	385	O
blood	-	388	O
via	-	394	O
a	-	398	O
patent	-	400	O
foramen	-	407	O
ovale	-	415	O
occurred	-	421	O
in	-	430	O
the	-	433	O
presence	-	437	O
of	-	446	O
a	-	449	O
normal	-	451	O
pulmonary	-	458	O
artery	-	468	O
pressure	-	475	O
,	-	483	O
and	-	485	O
was	-	489	O
probably	-	493	O
precipitated	-	502	O
by	-	515	O
a	-	518	O
propafenone	-	520	B
overdose	-	532	O
.	-	540	O

This	14976857	542	O
drug	-	547	O
caused	-	552	O
biventricular	-	559	O
dysfunction	-	573	O
,	-	584	O
due	-	586	O
to	-	590	O
its	-	593	O
negative	-	597	O
inotropic	-	606	O
effect	-	616	O
,	-	622	O
and	-	624	O
hypotension	-	628	O
,	-	639	O
due	-	641	O
to	-	645	O
its	-	648	O
peripheral	-	652	O
vasodilatory	-	663	O
effect	-	676	O
.	-	682	O

These	14976857	684	O
effects	-	690	O
gave	-	698	O
rise	-	703	O
to	-	708	O
an	-	711	O
increase	-	714	O
in	-	723	O
the	-	726	O
right	-	730	O
atrial	-	736	O
pressure	-	743	O
and	-	752	O
a	-	756	O
decrease	-	758	O
in	-	767	O
the	-	770	O
left	-	774	O
one	-	779	O
with	-	783	O
a	-	788	O
consequent	-	790	O
stretching	-	801	O
of	-	812	O
the	-	815	O
foramen	-	819	O
ovale	-	827	O
and	-	833	O
the	-	837	O
creation	-	841	O
of	-	850	O
massive	-	853	O
right	-	861	O
-	-	866	O
to	-	867	O
-	-	869	O
left	-	870	O
shunting	-	875	O
.	-	883	O

In	14976857	885	O
our	-	888	O
case	-	892	O
this	-	897	O
interatrial	-	902	O
shunt	-	914	O
was	-	920	O
very	-	924	O
accurately	-	929	O
detected	-	940	O
at	-	949	O
bubble	-	952	O
contrast	-	959	O
echocardiography	-	968	O
.	-	984	O

A	11745184	0	O
Phase	-	2	O
II	-	8	O
trial	-	11	O
of	-	17	O
cisplatin	-	20	B
plus	-	30	O
WR	-	35	B
-	-	37	I
2721	-	38	I
(	-	43	O
amifostine	-	44	B
)	-	54	O
for	-	56	O
metastatic	-	60	O
breast	-	71	O
carcinoma	-	78	O
:	-	87	O
an	-	89	O
Eastern	-	92	O
Cooperative	-	100	O
Oncology	-	112	O
Group	-	121	O
Study	-	127	O
(	-	133	O
E8188	-	134	O
)	-	139	O
.	-	140	O

BACKGROUND	11745184	142	O
:	-	152	O

Cisplatin	11745184	154	B
has	-	164	O
minimal	-	168	O
antitumor	-	176	O
activity	-	186	O
when	-	195	O
used	-	200	O
as	-	205	O
second	-	208	O
-	-	214	O
or	-	216	O
third	-	219	O
-	-	224	O
line	-	225	O
treatment	-	230	O
of	-	240	O
metastatic	-	243	O
breast	-	254	O
carcinoma	-	261	O
.	-	270	O

Older	11745184	272	O
reports	-	278	O
suggest	-	286	O
an	-	294	O
objective	-	297	O
response	-	307	O
rate	-	316	O
of	-	321	O
8	-	324	O
%	-	325	O
when	-	327	O
60	-	332	O
-	-	334	O
120	-	335	O
mg	-	339	O
/	-	341	O
m2	-	342	O
of	-	345	O
cisplatin	-	348	B
is	-	358	O
administered	-	361	O
every	-	374	O
3	-	380	O
-	-	381	O
4	-	382	O
weeks	-	384	O
.	-	389	O

Although	11745184	391	O
a	-	400	O
dose	-	402	O
-	-	406	O
response	-	407	O
effect	-	416	O
has	-	423	O
been	-	427	O
observed	-	432	O
with	-	441	O
cisplatin	-	446	B
,	-	455	O
the	-	457	O
dose	-	461	O
-	-	465	O
limiting	-	466	O
toxicities	-	475	O
associated	-	486	O
with	-	497	O
cisplatin	-	502	B
(	-	512	O
e	-	513	O
.	-	514	O
g	-	515	O
.	-	516	O
,	-	517	O
nephrotoxicity	-	519	O
,	-	533	O
ototoxicity	-	535	O
,	-	546	O
and	-	548	O
neurotoxicity	-	552	O
)	-	565	O
have	-	567	O
limited	-	572	O
its	-	580	O
use	-	584	O
as	-	588	O
a	-	591	O
treatment	-	593	O
for	-	603	O
breast	-	607	O
carcinoma	-	614	O
.	-	623	O

WR	11745184	625	B
-	-	627	I
2721	-	628	I
or	-	633	O
amifostine	-	636	B
initially	-	647	O
was	-	657	O
developed	-	661	O
to	-	671	O
protect	-	674	O
military	-	682	O
personnel	-	691	O
in	-	701	O
the	-	704	O
event	-	708	O
of	-	714	O
nuclear	-	717	O
war	-	725	O
.	-	728	O

Amifostine	11745184	730	B
subsequently	-	741	O
was	-	754	O
shown	-	758	O
to	-	764	O
protect	-	767	O
normal	-	775	O
tissues	-	782	O
from	-	790	O
the	-	795	O
toxic	-	799	O
effects	-	805	O
of	-	813	O
alkylating	-	816	B
agents	-	827	I
and	-	834	O
cisplatin	-	838	B
without	-	848	O
decreasing	-	856	O
the	-	867	O
antitumor	-	871	O
effect	-	881	O
of	-	888	O
the	-	891	O
chemotherapy	-	895	O
.	-	907	O

Early	11745184	909	O
trials	-	915	O
of	-	922	O
cisplatin	-	925	B
and	-	935	O
amifostine	-	939	B
also	-	950	O
suggested	-	955	O
that	-	965	O
the	-	970	O
incidence	-	974	O
and	-	984	O
severity	-	988	O
of	-	997	O
cisplatin	-	1000	B
-	-	1009	O
induced	-	1010	O
nephrotoxicity	-	1018	O
,	-	1032	O
ototoxicity	-	1034	O
,	-	1045	O
and	-	1047	O
neuropathy	-	1051	O
were	-	1062	O
reduced	-	1067	O
.	-	1074	O

METHODS	11745184	1076	O
:	-	1083	O

A	11745184	1085	O
Phase	-	1087	O
II	-	1093	O
study	-	1096	O
of	-	1102	O
the	-	1105	O
combination	-	1109	O
of	-	1121	O
cisplatin	-	1124	B
plus	-	1134	O
amifostine	-	1139	B
was	-	1150	O
conducted	-	1154	O
in	-	1164	O
patients	-	1167	O
with	-	1176	O
progressive	-	1181	O
metastatic	-	1193	O
breast	-	1204	O
carcinoma	-	1211	O
who	-	1221	O
had	-	1225	O
received	-	1229	O
one	-	1238	O
,	-	1241	O
but	-	1243	O
not	-	1247	O
more	-	1251	O
than	-	1256	O
one	-	1261	O
,	-	1264	O
chemotherapy	-	1266	O
regimen	-	1279	O
for	-	1287	O
metastatic	-	1291	O
disease	-	1302	O
.	-	1309	O

Patients	11745184	1311	O
received	-	1320	O
amifostine	-	1329	B
,	-	1339	O
910	-	1341	O
mg	-	1345	O
/	-	1347	O
m2	-	1348	O
intravenously	-	1351	O
over	-	1365	O
15	-	1370	O
minutes	-	1373	O
.	-	1380	O

After	11745184	1382	O
completion	-	1388	O
of	-	1399	O
the	-	1402	O
amifostine	-	1406	B
infusion	-	1417	O
,	-	1425	O
cisplatin	-	1427	B
120	-	1437	O
mg	-	1441	O
/	-	1443	O
m2	-	1444	O
was	-	1447	O
administered	-	1451	O
over	-	1464	O
30	-	1469	O
minutes	-	1472	O
.	-	1479	O

Intravenous	11745184	1481	O
hydration	-	1493	O
and	-	1503	O
mannitol	-	1507	B
was	-	1516	O
administered	-	1520	O
before	-	1533	O
and	-	1540	O
after	-	1544	O
cisplatin	-	1550	B
.	-	1559	O

Treatment	11745184	1561	O
was	-	1571	O
administered	-	1575	O
every	-	1588	O
3	-	1594	O
weeks	-	1596	O
until	-	1602	O
disease	-	1608	O
progression	-	1616	O
.	-	1627	O

RESULTS	11745184	1629	O
:	-	1636	O

Forty	11745184	1638	O
-	-	1643	O
four	-	1644	O
patients	-	1649	O
were	-	1658	O
enrolled	-	1663	O
in	-	1672	O
the	-	1675	O
study	-	1679	O
of	-	1685	O
which	-	1688	O
7	-	1694	O
(	-	1696	O
16	-	1697	O
%	-	1699	O
)	-	1700	O
were	-	1702	O
ineligible	-	1707	O
.	-	1717	O

A	11745184	1719	O
median	-	1721	O
of	-	1728	O
2	-	1731	O
cycles	-	1733	O
of	-	1740	O
therapy	-	1743	O
was	-	1751	O
administered	-	1755	O
to	-	1768	O
the	-	1771	O
37	-	1775	O
eligible	-	1778	O
patients	-	1787	O
.	-	1795	O

Six	11745184	1797	O
partial	-	1801	O
responses	-	1809	O
were	-	1819	O
observed	-	1824	O
for	-	1833	O
an	-	1837	O
overall	-	1840	O
response	-	1848	O
rate	-	1857	O
of	-	1862	O
16	-	1865	O
%	-	1867	O
.	-	1868	O

Most	11745184	1870	O
patients	-	1875	O
(	-	1884	O
57	-	1885	O
%	-	1887	O
)	-	1888	O
stopped	-	1890	O
treatment	-	1898	O
because	-	1908	O
of	-	1916	O
disease	-	1919	O
progression	-	1927	O
.	-	1938	O

Neurologic	11745184	1940	O
toxicity	-	1951	O
was	-	1960	O
reported	-	1964	O
in	-	1973	O
52	-	1976	O
%	-	1978	O
of	-	1980	O
patients	-	1983	O
.	-	1991	O

Seven	11745184	1993	O
different	-	1999	O
life	-	2009	O
-	-	2013	O
threatening	-	2014	O
toxicities	-	2026	O
were	-	2037	O
observed	-	2042	O
in	-	2051	O
patients	-	2054	O
while	-	2063	O
receiving	-	2069	O
treatment	-	2079	O
.	-	2088	O

CONCLUSIONS	11745184	2090	O
:	-	2101	O

The	11745184	2103	O
combination	-	2107	O
of	-	2119	O
cisplatin	-	2122	B
and	-	2132	O
amifostine	-	2136	B
in	-	2147	O
this	-	2150	O
study	-	2155	O
resulted	-	2161	O
in	-	2170	O
an	-	2173	O
overall	-	2176	O
response	-	2184	O
rate	-	2193	O
of	-	2198	O
16	-	2201	O
%	-	2203	O
.	-	2204	O

Neither	11745184	2206	O
a	-	2214	O
tumor	-	2216	O
-	-	2221	O
protective	-	2222	O
effect	-	2233	O
nor	-	2240	O
reduced	-	2244	O
toxicity	-	2252	O
to	-	2261	O
normal	-	2264	O
tissues	-	2271	O
was	-	2279	O
observed	-	2283	O
with	-	2292	O
the	-	2297	O
addition	-	2301	O
of	-	2310	O
amifostine	-	2313	B
to	-	2324	O
cisplatin	-	2327	B
in	-	2337	O
this	-	2340	O
trial	-	2345	O
.	-	2350	O

Warfarin	3985451	0	B
-	-	8	O
induced	-	9	O
iliopsoas	-	17	O
hemorrhage	-	27	O
with	-	38	O
subsequent	-	43	O
femoral	-	54	O
nerve	-	62	O
palsy	-	68	O
.	-	73	O

We	3985451	75	O
present	-	78	O
the	-	86	O
case	-	90	O
of	-	95	O
a	-	98	O
28	-	100	O
-	-	102	O
year	-	103	O
-	-	107	O
old	-	108	O
man	-	112	O
on	-	116	O
chronic	-	119	O
warfarin	-	127	B
therapy	-	136	O
who	-	144	O
sustained	-	148	O
a	-	158	O
minor	-	160	O
muscle	-	166	O
tear	-	173	O
and	-	178	O
developed	-	182	O
increasing	-	192	O
pain	-	203	O
and	-	208	O
a	-	212	O
flexure	-	214	O
contracture	-	222	O
of	-	234	O
the	-	237	O
right	-	241	O
hip	-	247	O
.	-	250	O

Surgical	3985451	252	O
exploration	-	261	O
revealed	-	273	O
an	-	282	O
iliopsoas	-	285	O
hematoma	-	295	O
and	-	304	O
femoral	-	308	O
nerve	-	316	O
entrapment	-	322	O
,	-	332	O
resulting	-	334	O
in	-	344	O
a	-	347	O
femoral	-	349	O
nerve	-	357	O
palsy	-	363	O
and	-	369	O
partial	-	373	O
loss	-	381	O
of	-	386	O
quadriceps	-	389	O
functions	-	400	O
.	-	409	O

Anticoagulant	3985451	411	O
-	-	424	O
induced	-	425	O
femoral	-	433	O
nerve	-	441	O
palsy	-	447	O
represents	-	453	O
the	-	464	O
most	-	468	O
common	-	473	O
form	-	480	O
of	-	485	O
warfarin	-	488	B
-	-	496	O
induced	-	497	O
peripheral	-	505	O
neuropathy	-	516	O
;	-	526	O
it	-	528	O
is	-	531	O
characterized	-	534	O
by	-	548	O
severe	-	551	O
pain	-	558	O
in	-	563	O
the	-	566	O
inguinal	-	570	O
region	-	579	O
,	-	585	O
varying	-	587	O
degrees	-	595	O
of	-	603	O
motor	-	606	O
and	-	612	O
sensory	-	616	O
impairment	-	624	O
,	-	634	O
and	-	636	O
flexure	-	640	O
contracture	-	648	O
of	-	660	O
the	-	663	O
involved	-	667	O
extremity	-	676	O
.	-	685	O

Myasthenia	3750012	0	O
gravis	-	11	O
caused	-	18	O
by	-	25	O
penicillamine	-	28	B
and	-	42	O
chloroquine	-	46	B
therapy	-	58	O
for	-	66	O
rheumatoid	-	70	O
arthritis	-	81	O
.	-	90	O

We	3750012	92	O
have	-	95	O
described	-	100	O
a	-	110	O
unique	-	112	O
patient	-	119	O
who	-	127	O
had	-	131	O
reversible	-	135	O
and	-	146	O
dose	-	150	O
-	-	154	O
related	-	155	O
myasthenia	-	163	O
gravis	-	174	O
after	-	181	O
penicillamine	-	187	B
and	-	201	O
chloroquine	-	205	B
therapy	-	217	O
for	-	225	O
rheumatoid	-	229	O
arthritis	-	240	O
.	-	249	O

Although	3750012	251	O
acetylcholine	-	260	B
receptor	-	274	O
antibodies	-	283	O
were	-	294	O
not	-	299	O
detectable	-	303	O
,	-	313	O
the	-	315	O
time	-	319	O
course	-	324	O
was	-	331	O
consistent	-	335	O
with	-	346	O
an	-	351	O
autoimmune	-	354	O
process	-	365	O
.	-	372	O

Nephrotoxicity	1130930	0	O
of	-	15	O
combined	-	18	O
cephalothin	-	27	B
-	-	38	O
gentamicin	-	39	B
regimen	-	50	O
.	-	57	O

Two	1130930	59	O
patients	-	63	O
developed	-	72	O
acute	-	82	O
tubular	-	88	O
necrosis	-	96	O
,	-	104	O
characterized	-	106	O
clinically	-	120	O
by	-	131	O
acute	-	134	O
oliguric	-	140	O
renal	-	149	O
failure	-	155	O
,	-	162	O
while	-	164	O
they	-	170	O
were	-	175	O
receiving	-	180	O
a	-	190	O
combination	-	192	O
of	-	204	O
cephalothin	-	207	B
sodium	-	219	I
and	-	226	O
gentamicin	-	230	B
sulfate	-	241	I
therapy	-	249	O
.	-	256	O

Patients	1130930	258	O
who	-	267	O
are	-	271	O
given	-	275	O
this	-	281	O
drug	-	286	O
regimen	-	291	O
should	-	299	O
be	-	306	O
observed	-	309	O
very	-	318	O
carefully	-	323	O
for	-	333	O
early	-	337	O
signs	-	343	O
of	-	349	O
nephrotoxicity	-	352	O
.	-	366	O

High	1130930	368	O
doses	-	373	O
of	-	379	O
this	-	382	O
antibiotic	-	387	O
combination	-	398	O
should	-	410	O
be	-	417	O
avoided	-	420	O
especially	-	428	O
in	-	439	O
elderly	-	442	O
patients	-	450	O
.	-	458	O

Patients	1130930	460	O
with	-	469	O
renal	-	474	O
insufficiency	-	480	O
should	-	494	O
not	-	501	O
be	-	505	O
given	-	508	O
this	-	514	O
regimen	-	519	O
.	-	526	O

Components	19356307	0	O
of	-	11	O
lemon	-	14	O
essential	-	20	O
oil	-	30	O
attenuate	-	34	O
dementia	-	44	O
induced	-	53	O
by	-	61	O
scopolamine	-	64	B
.	-	75	O

The	19356307	77	O
anti	-	81	O
-	-	85	O
dementia	-	86	O
effects	-	95	O
of	-	103	O
s	-	106	B
-	-	107	I
limonene	-	108	I
and	-	117	O
s	-	121	B
-	-	122	I
perillyl	-	123	I
alcohol	-	132	I
were	-	140	O
observed	-	145	O
using	-	154	O
the	-	160	O
passive	-	164	O
avoidance	-	172	O
test	-	182	O
(	-	187	O
PA	-	188	O
)	-	190	O
and	-	192	O
the	-	196	O
open	-	200	O
field	-	205	O
habituation	-	211	O
test	-	223	O
(	-	228	O
OFH	-	229	O
)	-	232	O
.	-	233	O

These	19356307	235	O
lemon	-	241	O
essential	-	247	O
oils	-	257	O
showed	-	262	O
strong	-	269	O
ability	-	276	O
to	-	284	O
improve	-	287	O
memory	-	295	O
impaired	-	302	O
by	-	311	O
scopolamine	-	314	B
;	-	325	O
however	-	327	O
,	-	334	O
s	-	336	B
-	-	337	I
perillyl	-	338	I
alcohol	-	347	I
relieved	-	355	O
the	-	364	O
deficit	-	368	O
of	-	376	O
associative	-	379	O
memory	-	391	O
in	-	398	O
PA	-	401	O
only	-	404	O
,	-	408	O
and	-	410	O
did	-	414	O
not	-	418	O
improve	-	422	O
non	-	430	O
-	-	433	O
associative	-	434	O
memory	-	446	O
significantly	-	453	O
in	-	467	O
OFH	-	470	O
.	-	473	O

Analysis	19356307	475	O
of	-	484	O
neurotransmitter	-	487	O
concentration	-	504	O
in	-	518	O
some	-	521	O
brain	-	526	O
regions	-	532	O
on	-	540	O
the	-	543	O
test	-	547	O
day	-	552	O
showed	-	556	O
that	-	563	O
dopamine	-	568	B
concentration	-	577	O
of	-	591	O
the	-	594	O
vehicle	-	598	O
/	-	605	O
scopolamine	-	606	B
group	-	618	O
was	-	624	O
significantly	-	628	O
lower	-	642	O
than	-	648	O
that	-	653	O
of	-	658	O
the	-	661	O
vehicle	-	665	O
/	-	672	O
vehicle	-	673	O
group	-	681	O
,	-	686	O
but	-	688	O
this	-	692	O
phenomenon	-	697	O
was	-	708	O
reversed	-	712	O
when	-	721	O
s	-	726	B
-	-	727	I
limonene	-	728	I
or	-	737	O
s	-	740	B
-	-	741	I
perillyl	-	742	I
alcohol	-	751	I
were	-	759	O
administered	-	764	O
before	-	777	O
the	-	784	O
injection	-	788	O
of	-	798	O
scopolamine	-	801	B
.	-	812	O

Simultaneously	19356307	814	O
,	-	828	O
we	-	830	O
found	-	833	O
that	-	839	O
these	-	844	O
two	-	850	O
lemon	-	854	O
essential	-	860	O
oil	-	870	O
components	-	874	O
could	-	885	O
inhibit	-	891	O
acetylcholinesterase	-	899	O
activity	-	920	O
in	-	929	O
vitro	-	932	O
using	-	938	O
the	-	944	O
Ellman	-	948	O
method	-	955	O
.	-	961	O

The	15957009	0	O
selective	-	4	O
5	-	14	O
-	-	15	O
HT6	-	16	O
receptor	-	20	O
antagonist	-	29	O
Ro4368554	-	40	B
restores	-	50	O
memory	-	59	O
performance	-	66	O
in	-	78	O
cholinergic	-	81	O
and	-	93	O
serotonergic	-	97	O
models	-	110	O
of	-	117	O
memory	-	120	O
deficiency	-	127	O
in	-	138	O
the	-	141	O
rat	-	145	O
.	-	148	O

Antagonists	15957009	150	O
at	-	162	O
serotonin	-	165	B
type	-	175	O
6	-	180	O
(	-	182	O
5	-	183	B
-	-	184	I
HT	-	185	I
(	-	187	O
6	-	188	O
)	-	189	O
)	-	190	O
receptors	-	192	O
show	-	202	O
activity	-	207	O
in	-	216	O
models	-	219	O
of	-	226	O
learning	-	229	O
and	-	238	O
memory	-	242	O
.	-	248	O

Although	15957009	250	O
the	-	259	O
underlying	-	263	O
mechanism	-	274	O
(	-	283	O
s	-	284	O
)	-	285	O
are	-	287	O
not	-	291	O
well	-	295	O
understood	-	300	O
,	-	310	O
these	-	312	O
effects	-	318	O
may	-	326	O
involve	-	330	O
an	-	338	O
increase	-	341	O
in	-	350	O
acetylcholine	-	353	B
(	-	367	O
ACh	-	368	B
)	-	371	O
levels	-	373	O
.	-	379	O

The	15957009	381	O
present	-	385	O
study	-	393	O
sought	-	399	O
to	-	406	O
characterize	-	409	O
the	-	422	O
cognitive	-	426	O
-	-	435	O
enhancing	-	436	O
effects	-	446	O
of	-	454	O
the	-	457	O
5	-	461	B
-	-	462	I
HT	-	463	I
(	-	465	O
6	-	466	O
)	-	467	O
antagonist	-	469	O
Ro4368554	-	480	B
(	-	490	O
3	-	491	B
-	-	492	I
benzenesulfonyl	-	493	I
-	-	508	I
7	-	509	I
-	-	510	I
(	-	511	I
4	-	512	I
-	-	513	I
methyl	-	514	I
-	-	520	I
piperazin	-	521	I
-	-	530	I
1	-	531	I
-	-	532	I
yl	-	533	I
)	-	535	I
1H	-	536	I
-	-	538	I
indole	-	539	I
)	-	545	O
in	-	547	O
a	-	550	O
rat	-	552	O
object	-	556	O
recognition	-	563	O
task	-	575	O
employing	-	580	O
a	-	590	O
cholinergic	-	592	O
(	-	604	O
scopolamine	-	605	B
pretreatment	-	617	O
)	-	629	O
and	-	631	O
a	-	635	O
serotonergic	-	637	O
-	-	649	O
(	-	651	O
tryptophan	-	652	B
(	-	663	O
TRP	-	664	B
)	-	667	O
depletion	-	669	O
)	-	678	O
deficient	-	680	O
model	-	690	O
,	-	695	O
and	-	697	O
compared	-	701	O
its	-	710	O
pattern	-	714	O
of	-	722	O
action	-	725	O
with	-	732	O
that	-	737	O
of	-	742	O
the	-	745	O
acetylcholinesterase	-	749	O
inhibitor	-	770	O
metrifonate	-	780	B
.	-	791	O

Initial	15957009	793	O
testing	-	801	O
in	-	809	O
a	-	812	O
time	-	814	O
-	-	818	O
dependent	-	819	O
forgetting	-	829	O
task	-	840	O
employing	-	845	O
a	-	855	O
24	-	857	O
-	-	859	O
h	-	860	O
delay	-	862	O
between	-	868	O
training	-	876	O
and	-	885	O
testing	-	889	O
showed	-	897	O
that	-	904	O
metrifonate	-	909	B
improved	-	921	O
object	-	930	O
recognition	-	937	O
(	-	949	O
at	-	950	O
10	-	953	O
and	-	956	O
30	-	960	O
mg	-	963	O
/	-	965	O
kg	-	966	O
,	-	968	O
p	-	970	O
.	-	971	O
o	-	972	O
.	-	973	O
)	-	974	O
,	-	975	O
whereas	-	977	O
Ro4368554	-	985	B
was	-	995	O
inactive	-	999	O
.	-	1007	O

Both	15957009	1009	O
,	-	1013	O
Ro4368554	-	1015	B
(	-	1025	O
3	-	1026	O
and	-	1028	O
10	-	1032	O
mg	-	1035	O
/	-	1037	O
kg	-	1038	O
,	-	1040	O
intraperitoneally	-	1042	O
(	-	1060	O
i	-	1061	O
.	-	1062	O
p	-	1063	O
.	-	1064	O
)	-	1065	O
)	-	1066	O
and	-	1068	O
metrifonate	-	1072	B
(	-	1084	O
10	-	1085	O
mg	-	1088	O
/	-	1090	O
kg	-	1091	O
,	-	1093	O
p	-	1095	O
.	-	1096	O
o	-	1097	O
.	-	1098	O
,	-	1099	O
respectively	-	1101	O
)	-	1113	O
reversed	-	1115	O
memory	-	1124	O
deficits	-	1131	O
induced	-	1140	O
by	-	1148	O
scopolamine	-	1151	B
and	-	1163	O
TRP	-	1167	B
depletion	-	1171	O
(	-	1181	O
10	-	1182	O
mg	-	1185	O
/	-	1187	O
kg	-	1188	O
,	-	1190	O
i	-	1192	O
.	-	1193	O
p	-	1194	O
.	-	1195	O

,	15957009	1196	O
and	-	1198	O
3	-	1202	O
mg	-	1204	O
/	-	1206	O
kg	-	1207	O
,	-	1209	O
p	-	1211	O
.	-	1212	O
o	-	1213	O
.	-	1214	O
,	-	1215	O
respectively	-	1217	O
)	-	1229	O
.	-	1230	O

In	15957009	1232	O
conclusion	-	1235	O
,	-	1245	O
although	-	1247	O
Ro4368554	-	1256	B
did	-	1266	O
not	-	1270	O
improve	-	1274	O
a	-	1282	O
time	-	1284	O
-	-	1288	O
related	-	1289	O
retention	-	1297	O
deficit	-	1307	O
,	-	1314	O
it	-	1316	O
reversed	-	1319	O
a	-	1328	O
cholinergic	-	1330	O
and	-	1342	O
a	-	1346	O
serotonergic	-	1348	O
memory	-	1361	O
deficit	-	1368	O
,	-	1375	O
suggesting	-	1377	O
that	-	1388	O
both	-	1393	O
mechanisms	-	1398	O
may	-	1409	O
be	-	1413	O
involved	-	1416	O
in	-	1425	O
the	-	1428	O
facilitation	-	1432	O
of	-	1445	O
object	-	1448	O
memory	-	1455	O
by	-	1462	O
Ro4368554	-	1465	B
and	-	1475	O
,	-	1478	O
possibly	-	1480	O
,	-	1488	O
other	-	1490	O
5	-	1496	B
-	-	1497	I
HT	-	1498	I
(	-	1500	O
6	-	1501	O
)	-	1502	O
receptor	-	1504	O
antagonists	-	1513	O
.	-	1524	O

Lone	15899738	0	O
atrial	-	5	O
fibrillation	-	12	O
associated	-	25	O
with	-	36	O
creatine	-	41	B
monohydrate	-	50	O
supplementation	-	62	O
.	-	77	O

Atrial	15899738	79	O
fibrillation	-	86	O
in	-	99	O
young	-	102	O
patients	-	108	O
without	-	117	O
structural	-	125	O
heart	-	136	O
disease	-	142	O
is	-	150	O
rare	-	153	O
.	-	157	O

Therefore	15899738	159	O
,	-	168	O
when	-	170	O
the	-	175	O
arrhythmia	-	179	O
is	-	190	O
present	-	193	O
in	-	201	O
this	-	204	O
population	-	209	O
,	-	219	O
reversible	-	221	O
causes	-	232	O
must	-	239	O
be	-	244	O
identified	-	247	O
and	-	258	O
resolved	-	262	O
.	-	270	O

Thyroid	15899738	272	O
disorders	-	280	O
,	-	289	O
illicit	-	291	O
drug	-	299	O
or	-	304	O
stimulant	-	307	O
use	-	317	O
,	-	320	O
and	-	322	O
acute	-	326	O
alcohol	-	332	O
intoxication	-	340	O
are	-	353	O
among	-	357	O
these	-	363	O
causes	-	369	O
.	-	375	O

We	15899738	377	O
report	-	380	O
the	-	387	O
case	-	391	O
of	-	396	O
a	-	399	O
30	-	401	O
-	-	403	O
year	-	404	O
-	-	408	O
old	-	409	O
Caucasian	-	413	O
man	-	423	O
who	-	427	O
came	-	431	O
to	-	436	O
the	-	439	O
emergency	-	443	O
department	-	453	O
in	-	464	O
atrial	-	467	O
fibrillation	-	474	O
with	-	487	O
rapid	-	492	O
ventricular	-	498	O
response	-	510	O
.	-	518	O

His	15899738	520	O
medical	-	524	O
history	-	532	O
was	-	540	O
unremarkable	-	544	O
,	-	556	O
except	-	558	O
for	-	565	O
minor	-	569	O
fractures	-	575	O
of	-	585	O
the	-	588	O
fingers	-	592	O
and	-	600	O
foot	-	604	O
.	-	608	O

Thyroid	15899738	610	O
-	-	617	O
stimulating	-	618	O
hormone	-	630	O
,	-	637	O
magnesium	-	639	B
,	-	648	O
and	-	650	O
potassium	-	654	B
levels	-	664	O
were	-	671	O
within	-	676	O
normal	-	683	O
limits	-	690	O
,	-	696	O
urine	-	698	O
drug	-	704	O
screen	-	709	O
was	-	716	O
negative	-	720	O
,	-	728	O
and	-	730	O
alcohol	-	734	B
use	-	742	O
was	-	746	O
denied	-	750	O
.	-	756	O

However	15899738	758	O
,	-	765	O
when	-	767	O
the	-	772	O
patient	-	776	O
was	-	784	O
questioned	-	788	O
about	-	799	O
use	-	805	O
of	-	809	O
herbal	-	812	O
products	-	819	O
and	-	828	O
supplements	-	832	O
,	-	843	O
the	-	845	O
use	-	849	O
of	-	853	O
creatine	-	856	B
monohydrate	-	865	O
was	-	877	O
revealed	-	881	O
.	-	889	O

The	15899738	891	O
patient	-	895	O
was	-	903	O
admitted	-	907	O
to	-	916	O
the	-	919	O
hospital	-	923	O
,	-	931	O
anticoagulated	-	933	O
with	-	948	O
unfractionated	-	953	O
heparin	-	968	B
,	-	975	O
and	-	977	O
given	-	981	O
intravenous	-	987	O
diltiazem	-	999	B
for	-	1009	O
rate	-	1013	O
control	-	1018	O
and	-	1026	O
intravenous	-	1030	O
amiodarone	-	1042	B
for	-	1053	O
rate	-	1057	O
and	-	1062	O
rhythm	-	1066	O
control	-	1073	O
.	-	1080	O

When	15899738	1082	O
discharged	-	1087	O
less	-	1098	O
than	-	1103	O
24	-	1108	O
hours	-	1111	O
later	-	1117	O
,	-	1122	O
he	-	1124	O
was	-	1127	O
receiving	-	1131	O
metoprolol	-	1141	B
and	-	1152	O
aspirin	-	1156	B
,	-	1163	O
with	-	1165	O
follow	-	1170	O
-	-	1176	O
up	-	1177	O
plans	-	1180	O
for	-	1186	O
echocardiography	-	1190	O
and	-	1207	O
nuclear	-	1211	O
imaging	-	1219	O
to	-	1227	O
assess	-	1230	O
perfusion	-	1237	O
.	-	1246	O

Exogenous	15899738	1248	O
creatine	-	1258	B
is	-	1267	O
used	-	1270	O
by	-	1275	O
athletes	-	1278	O
to	-	1287	O
theoretically	-	1290	O
improve	-	1304	O
exercise	-	1312	O
performance	-	1321	O
.	-	1332	O

Vegetarians	15899738	1334	O
may	-	1346	O
also	-	1350	O
take	-	1355	O
creatine	-	1360	B
to	-	1369	O
replace	-	1372	O
what	-	1380	O
they	-	1385	O
are	-	1390	O
not	-	1394	O
consuming	-	1398	O
from	-	1408	O
meat	-	1413	O
,	-	1417	O
fish	-	1419	O
,	-	1423	O
and	-	1425	O
other	-	1429	O
animal	-	1435	O
products	-	1442	O
.	-	1450	O

Previous	15899738	1452	O
anecdotal	-	1461	O
reports	-	1471	O
have	-	1479	O
linked	-	1484	O
creatine	-	1491	B
to	-	1500	O
the	-	1503	O
development	-	1507	O
of	-	1519	O
arrhythmia	-	1522	O
.	-	1532	O

Clinicians	15899738	1534	O
must	-	1545	O
be	-	1550	O
diligent	-	1553	O
when	-	1562	O
interviewing	-	1567	O
patients	-	1580	O
about	-	1589	O
their	-	1595	O
drug	-	1601	O
therapy	-	1606	O
histories	-	1614	O
and	-	1624	O
include	-	1628	O
questions	-	1636	O
about	-	1646	O
their	-	1652	O
use	-	1658	O
of	-	1662	O
herbal	-	1665	O
products	-	1672	O
and	-	1681	O
dietary	-	1685	O
supplements	-	1693	O
.	-	1704	O

In	15899738	1706	O
addition	-	1709	O
,	-	1717	O
it	-	1719	O
is	-	1722	O
important	-	1725	O
to	-	1735	O
report	-	1738	O
adverse	-	1745	O
effects	-	1753	O
associated	-	1761	O
with	-	1772	O
frequently	-	1777	O
consumed	-	1788	O
supplements	-	1797	O
and	-	1809	O
herbal	-	1813	O
products	-	1820	O
to	-	1829	O
the	-	1832	O
Food	-	1836	O
and	-	1841	O
Drug	-	1845	O
Administration	-	1850	O
and	-	1865	O
in	-	1869	O
the	-	1872	O
literature	-	1876	O
.	-	1886	O

Comparison	15863244	0	O
of	-	11	O
developmental	-	14	O
toxicity	-	28	O
of	-	37	O
selective	-	40	O
and	-	50	O
non	-	54	O
-	-	57	O
selective	-	58	O
cyclooxygenase	-	68	O
-	-	82	O
2	-	83	O
inhibitors	-	85	O
in	-	96	O
CRL	-	99	O
:	-	102	O
(	-	103	O
WI	-	104	O
)	-	106	O
WUBR	-	107	O
Wistar	-	112	O
rats	-	119	O
-	-	123	O
-	-	124	O
DFU	-	125	B
and	-	129	O
piroxicam	-	133	B
study	-	143	O
.	-	148	O

BACKGROUND	15863244	150	O
:	-	160	O

Cyclooxygenase	15863244	162	O
(	-	177	O
COX	-	178	O
)	-	181	O
inhibitors	-	183	O
are	-	194	O
one	-	198	O
of	-	202	O
the	-	205	O
most	-	209	O
often	-	214	O
ingested	-	220	O
drugs	-	229	O
during	-	235	O
pregnancy	-	242	O
.	-	251	O

Unlike	15863244	253	O
general	-	260	O
toxicity	-	268	O
data	-	277	O
,	-	281	O
their	-	283	O
prenatal	-	289	O
toxic	-	298	O
effects	-	304	O
were	-	312	O
not	-	317	O
extensively	-	321	O
studied	-	333	O
before	-	341	O
.	-	347	O

The	15863244	349	O
aim	-	353	O
of	-	357	O
the	-	360	O
experiment	-	364	O
was	-	375	O
to	-	379	O
evaluate	-	382	O
the	-	391	O
developmental	-	395	O
toxicity	-	409	O
of	-	418	O
the	-	421	O
non	-	425	O
-	-	428	O
selective	-	429	O
(	-	439	O
piroxicam	-	440	B
)	-	449	O
and	-	451	O
selective	-	455	O
(	-	465	O
DFU	-	466	B
;	-	469	O
5	-	471	B
,	-	472	I
5	-	473	I
-	-	474	I
dimethyl	-	475	I
-	-	483	I
3	-	484	I
-	-	485	I
(	-	486	I
3	-	487	I
-	-	488	I
fluorophenyl	-	489	I
)	-	501	I
-	-	502	I
4	-	503	I
-	-	504	I
(	-	505	I
4	-	506	I
-	-	507	I
methylsulphonyl	-	508	I
)	-	523	I
phenyl	-	525	I
-	-	531	I
2	-	532	I
(	-	533	I
5H	-	534	I
)	-	536	I
-	-	537	I
furanon	-	538	I
)	-	545	O

COX	15863244	547	O
-	-	550	O
2	-	551	O
inhibitors	-	553	O
.	-	563	O

METHODS	15863244	565	O
:	-	572	O

Drugs	15863244	574	O
were	-	580	O
separately	-	585	O
,	-	595	O
orally	-	597	O
once	-	604	O
daily	-	609	O
dosed	-	615	O
to	-	621	O
pregnant	-	624	O
rats	-	633	O
from	-	638	O
day	-	643	O
8	-	647	O
to	-	649	O
21	-	652	O
(	-	655	O
GD1	-	656	O
=	-	659	O
plug	-	660	O
day	-	665	O
)	-	668	O
.	-	669	O

Doses	15863244	671	O
were	-	677	O
set	-	682	O
at	-	686	O
0	-	689	O
.	-	690	O
3	-	691	O
,	-	692	O
3	-	694	O
.	-	695	O
0	-	696	O
and	-	698	O
30	-	702	O
.	-	704	O
0mg	-	705	O
/	-	708	O
kg	-	709	O
for	-	712	O
piroxicam	-	716	B
and	-	726	O
0	-	730	O
.	-	731	O
2	-	732	O
,	-	733	O
2	-	735	O
.	-	736	O
0	-	737	O
and	-	739	O
20	-	743	O
.	-	745	O
0mg	-	746	O
/	-	749	O
kg	-	750	O
for	-	753	O
DFU	-	757	B
.	-	760	O

Fetuses	15863244	762	O
were	-	770	O
delivered	-	775	O
on	-	785	O
GD	-	788	O
21	-	791	O
and	-	794	O
routinely	-	798	O
examined	-	808	O
.	-	816	O

Comprehensive	15863244	818	O
clinical	-	832	O
and	-	841	O
developmental	-	845	O
measurements	-	859	O
were	-	872	O
done	-	877	O
.	-	881	O

The	15863244	883	O
pooled	-	887	O
statistical	-	894	O
analysis	-	906	O
for	-	915	O
ventricular	-	919	O
septal	-	931	O
(	-	938	O
VSD	-	939	O
)	-	942	O
and	-	944	O
midline	-	948	O
(	-	956	O
MD	-	957	O
)	-	959	O
defects	-	961	O
was	-	969	O
performed	-	973	O
for	-	983	O
rat	-	987	O
fetuses	-	991	O
exposed	-	999	O
to	-	1007	O
piroxicam	-	1010	B
,	-	1019	O
selective	-	1021	O
and	-	1031	O
non	-	1035	O
-	-	1038	O
selective	-	1039	O
COX	-	1049	O
-	-	1052	O
2	-	1053	O
inhibitor	-	1055	O
based	-	1065	O
on	-	1071	O
present	-	1074	O
and	-	1082	O
historic	-	1086	O
data	-	1095	O
.	-	1099	O

RESULTS	15863244	1101	O
:	-	1108	O

Maternal	15863244	1110	O
toxicity	-	1119	O
,	-	1127	O
intrauterine	-	1129	O
growth	-	1142	O
retardation	-	1149	O
,	-	1160	O
and	-	1162	O
increase	-	1166	O
of	-	1175	O
external	-	1178	O
and	-	1187	O
skeletal	-	1191	O
variations	-	1200	O
were	-	1211	O
found	-	1216	O
in	-	1222	O
rats	-	1225	O
treated	-	1230	O
with	-	1238	O
the	-	1243	O
highest	-	1247	O
dose	-	1255	O
of	-	1260	O
piroxicam	-	1263	B
.	-	1272	O

Decrease	15863244	1274	O
of	-	1283	O
fetal	-	1286	O
length	-	1292	O
was	-	1299	O
the	-	1303	O
only	-	1307	O
signs	-	1312	O
of	-	1318	O
the	-	1321	O
DFU	-	1325	B
developmental	-	1329	O
toxicity	-	1343	O
observed	-	1352	O
in	-	1361	O
pups	-	1364	O
exposed	-	1369	O
to	-	1377	O
the	-	1380	O
highest	-	1384	O
compound	-	1392	O
dose	-	1401	O
.	-	1405	O

Lack	15863244	1407	O
of	-	1412	O
teratogenicity	-	1415	O
was	-	1430	O
found	-	1434	O
in	-	1440	O
piroxicam	-	1443	B
and	-	1453	O
DFU	-	1457	B
-	-	1460	O
exposed	-	1461	O
groups	-	1469	O
.	-	1475	O

Prenatal	15863244	1477	O
exposure	-	1486	O
to	-	1495	O
non	-	1498	O
-	-	1501	O
selective	-	1502	O
COX	-	1512	O
inhibitors	-	1516	O
increases	-	1527	O
the	-	1537	O
risk	-	1541	O
of	-	1546	O
VSD	-	1549	O
and	-	1553	O
MD	-	1557	O
when	-	1560	O
compared	-	1565	O
to	-	1574	O
historic	-	1577	O
control	-	1586	O
but	-	1594	O
not	-	1598	O
with	-	1602	O
selective	-	1607	O
COX	-	1617	O
-	-	1620	O
2	-	1621	O
inhibitors	-	1623	O
.	-	1633	O

CONCLUSION	15863244	1635	O
:	-	1645	O

Both	15863244	1647	O
selective	-	1652	O
and	-	1662	O
non	-	1666	O
-	-	1669	O
selective	-	1670	O
COX	-	1680	O
-	-	1683	O
2	-	1684	O
inhibitors	-	1686	O
were	-	1697	O
toxic	-	1702	O
for	-	1708	O
rats	-	1712	O
fetuses	-	1717	O
when	-	1725	O
administered	-	1730	O
in	-	1743	O
the	-	1746	O
highest	-	1750	O
dose	-	1758	O
.	-	1762	O

Unlike	15863244	1764	O
DFU	-	1771	B
,	-	1774	O
piroxicam	-	1776	B
was	-	1786	O
also	-	1790	O
highly	-	1795	O
toxic	-	1802	O
to	-	1808	O
the	-	1811	O
dams	-	1815	O
.	-	1819	O

Prenatal	15863244	1821	O
exposure	-	1830	O
to	-	1839	O
selective	-	1842	O
COX	-	1852	O
-	-	1855	O
2	-	1856	O
inhibitors	-	1858	O
does	-	1869	O
not	-	1874	O
increase	-	1878	O
the	-	1887	O
risk	-	1891	O
of	-	1896	O
ventricular	-	1899	O
septal	-	1911	O
and	-	1918	O
midline	-	1922	O
defects	-	1930	O
in	-	1938	O
rat	-	1941	O
when	-	1945	O
compared	-	1950	O
to	-	1959	O
non	-	1962	O
-	-	1965	O
selective	-	1966	O
drugs	-	1976	O
and	-	1982	O
historic	-	1986	O
control	-	1995	O
.	-	2002	O

Protective	12921865	0	O
efficacy	-	11	O
of	-	20	O
neuroactive	-	23	O
steroids	-	35	B
against	-	44	O
cocaine	-	52	B
kindled	-	60	O
-	-	67	O
seizures	-	68	O
in	-	77	O
mice	-	80	O
.	-	84	O

Neuroactive	12921865	86	O
steroids	-	98	B
demonstrate	-	107	O
pharmacological	-	119	O
actions	-	135	O
that	-	143	O
have	-	148	O
relevance	-	153	O
for	-	163	O
a	-	167	O
host	-	169	O
of	-	174	O
neurological	-	177	O
and	-	190	O
psychiatric	-	194	O
disorders	-	206	O
.	-	215	O

They	12921865	217	O
offer	-	222	O
protection	-	228	O
against	-	239	O
seizures	-	247	O
in	-	256	O
a	-	259	O
range	-	261	O
of	-	267	O
models	-	270	O
and	-	277	O
seem	-	281	O
to	-	286	O
inhibit	-	289	O
certain	-	297	O
stages	-	305	O
of	-	312	O
drug	-	315	O
dependence	-	320	O
in	-	331	O
preclinical	-	334	O
assessments	-	346	O
.	-	357	O

The	12921865	359	O
present	-	363	O
study	-	371	O
was	-	377	O
designed	-	381	O
to	-	390	O
evaluate	-	393	O
two	-	402	O
endogenous	-	406	O
and	-	417	O
one	-	421	O
synthetic	-	425	O
neuroactive	-	435	O
steroid	-	447	B
that	-	455	O
positively	-	460	O
modulate	-	471	O
the	-	480	O
gamma	-	484	B
-	-	489	I
aminobutyric	-	490	I
acid	-	503	I
(	-	508	O
GABA	-	509	B
(	-	513	O
A	-	514	O
)	-	515	O
)	-	516	O
receptor	-	518	O
against	-	527	O
the	-	535	O
increase	-	539	O
in	-	548	O
sensitivity	-	551	O
to	-	563	O
the	-	566	O
convulsant	-	570	O
effects	-	581	O
of	-	589	O
cocaine	-	592	B
engendered	-	600	O
by	-	611	O
repeated	-	614	O
cocaine	-	623	B
administration	-	631	O
(	-	646	O
seizure	-	647	O
kindling	-	655	O
)	-	663	O
.	-	664	O

Allopregnanolone	12921865	666	B
(	-	683	O
3alpha	-	684	B
-	-	690	I
hydroxy	-	691	I
-	-	698	I
5alpha	-	699	I
-	-	705	I
pregnan	-	706	I
-	-	713	I
20	-	714	I
-	-	716	I
one	-	717	I
)	-	720	O
,	-	721	O
pregnanolone	-	723	B
(	-	736	O
3alpha	-	737	B
-	-	743	I
hydroxy	-	744	I
-	-	751	I
5beta	-	752	I
-	-	757	I
pregnan	-	758	I
-	-	765	I
20	-	766	I
-	-	768	I
one	-	769	I
)	-	772	O
and	-	774	O
ganaxolone	-	778	B
(	-	789	O
a	-	790	O
synthetic	-	792	O
derivative	-	802	O
of	-	813	O
allopregnanolone	-	816	B
3alpha	-	833	B
-	-	839	I
hydroxy	-	840	I
-	-	847	I
3beta	-	848	I
-	-	853	I
methyl	-	854	I
-	-	860	I
5alpha	-	861	I
-	-	867	I
pregnan	-	868	I
-	-	875	I
20	-	876	I
-	-	878	I
one	-	879	I
)	-	882	O
were	-	884	O
tested	-	889	O
for	-	896	O
their	-	900	O
ability	-	906	O
to	-	914	O
suppress	-	917	O
the	-	926	O
expression	-	930	O
(	-	941	O
anticonvulsant	-	942	O
effect	-	957	O
)	-	963	O
and	-	965	O
development	-	969	O
(	-	981	O
antiepileptogenic	-	982	O
effect	-	1000	O
)	-	1006	O
of	-	1008	O
cocaine	-	1011	B
-	-	1018	O
kindled	-	1019	O
seizures	-	1027	O
in	-	1036	O
male	-	1039	O
,	-	1043	O
Swiss	-	1045	O
-	-	1050	O
Webster	-	1051	O
mice	-	1059	O
.	-	1063	O

Kindled	12921865	1065	O
seizures	-	1073	O
were	-	1082	O
induced	-	1087	O
by	-	1095	O
daily	-	1098	O
administration	-	1104	O
of	-	1119	O
60	-	1122	O
mg	-	1125	O
/	-	1127	O
kg	-	1128	O
cocaine	-	1131	B
for	-	1139	O
5	-	1143	O
days	-	1145	O
.	-	1149	O

All	12921865	1151	O
of	-	1155	O
these	-	1158	O
positive	-	1164	O
GABA	-	1173	B
(	-	1177	O
A	-	1178	O
)	-	1179	O
modulators	-	1181	O
suppressed	-	1192	O
the	-	1203	O
expression	-	1207	O
of	-	1218	O
kindled	-	1221	O
seizures	-	1229	O
,	-	1237	O
whereas	-	1239	O
only	-	1247	O
allopregnanolone	-	1252	B
and	-	1269	O
ganaxolone	-	1273	B
inhibited	-	1284	O
the	-	1294	O
development	-	1298	O
of	-	1310	O
kindling	-	1313	O
.	-	1321	O

Allopregnanolone	12921865	1323	B
and	-	1340	O
pregnanolone	-	1344	B
,	-	1356	O
but	-	1358	O
not	-	1362	O
ganaxolone	-	1366	B
,	-	1376	O
also	-	1378	O
reduced	-	1383	O
cumulative	-	1391	O
lethality	-	1402	O
associated	-	1412	O
with	-	1423	O
kindling	-	1428	O
.	-	1436	O

These	12921865	1438	O
findings	-	1444	O
demonstrate	-	1453	O
that	-	1465	O
some	-	1470	O
neuroactive	-	1475	O
steroids	-	1487	B
attenuate	-	1496	O
convulsant	-	1506	O
and	-	1517	O
sensitizing	-	1521	O
properties	-	1533	O
of	-	1544	O
cocaine	-	1547	B
and	-	1555	O
add	-	1559	O
to	-	1563	O
a	-	1566	O
growing	-	1568	O
literature	-	1576	O
on	-	1587	O
their	-	1590	O
potential	-	1596	O
use	-	1606	O
in	-	1610	O
the	-	1613	O
modulation	-	1617	O
of	-	1628	O
effects	-	1631	O
of	-	1639	O
drugs	-	1642	O
of	-	1648	O
abuse	-	1651	O
.	-	1656	O

Kidney	12584269	0	O
function	-	7	O
and	-	16	O
morphology	-	20	O
after	-	31	O
short	-	37	O
-	-	42	O
term	-	43	O
combination	-	48	O
therapy	-	60	O
with	-	68	O
cyclosporine	-	73	B
A	-	86	I
,	-	87	O
tacrolimus	-	89	B
and	-	100	O
sirolimus	-	104	B
in	-	114	O
the	-	117	O
rat	-	121	O
.	-	124	O

BACKGROUND	12584269	126	O
:	-	136	O
Sirolimus	-	138	B
(	-	148	O
SRL	-	149	B
)	-	152	O
may	-	154	O
supplement	-	158	O
calcineurin	-	169	O
inhibitors	-	181	O
in	-	192	O
clinical	-	195	O
organ	-	204	O
transplantation	-	210	O
.	-	225	O

These	12584269	227	O
are	-	233	O
nephrotoxic	-	237	O
,	-	248	O
but	-	250	O
SRL	-	254	B
seems	-	258	O
to	-	264	O
act	-	267	O
differently	-	271	O
displaying	-	283	O
only	-	294	O
minor	-	299	O
nephrotoxic	-	305	O
effects	-	317	O
,	-	324	O
although	-	326	O
this	-	335	O
question	-	340	O
is	-	349	O
still	-	352	O
open	-	358	O
.	-	362	O

In	12584269	364	O
a	-	367	O
number	-	369	O
of	-	376	O
treatment	-	379	O
protocols	-	389	O
where	-	399	O
SRL	-	405	B
was	-	409	O
combined	-	413	O
with	-	422	O
a	-	427	O
calcineurin	-	429	O
inhibitor	-	441	O
indications	-	451	O
of	-	463	O
a	-	466	O
synergistic	-	468	O
nephrotoxic	-	480	O
effect	-	492	O
were	-	499	O
described	-	504	O
.	-	513	O

The	12584269	515	O
aim	-	519	O
of	-	523	O
this	-	526	O
study	-	531	O
was	-	537	O
to	-	541	O
examine	-	544	O
further	-	552	O
the	-	560	O
renal	-	564	O
function	-	570	O
,	-	578	O
including	-	580	O
morphological	-	590	O
analysis	-	604	O
of	-	613	O
the	-	616	O
kidneys	-	620	O
of	-	628	O
male	-	631	O
Sprague	-	636	O
-	-	643	O
Dawley	-	644	O
rats	-	651	O
treated	-	656	O
with	-	664	O
either	-	669	O
cyclosporine	-	676	B
A	-	689	I
(	-	691	O
CsA	-	692	B
)	-	695	O
,	-	696	O
tacrolimus	-	698	B
(	-	709	O
FK506	-	710	B
)	-	715	O
or	-	717	O
SRL	-	720	B
as	-	724	O
monotherapies	-	727	O
or	-	741	O
in	-	744	O
different	-	747	O
combinations	-	757	O
.	-	769	O

METHODS	12584269	771	O
:	-	778	O

For	12584269	780	O
a	-	784	O
period	-	786	O
of	-	793	O
2	-	796	O
weeks	-	798	O
,	-	803	O
CsA	-	805	B
15	-	809	O
mg	-	812	O
/	-	814	O
kg	-	815	O
/	-	817	O
day	-	818	O
(	-	822	O
given	-	823	O
orally	-	829	O
)	-	835	O
,	-	836	O
FK506	-	838	B
3	-	844	O
.	-	845	O
0	-	846	O
mg	-	848	O
/	-	850	O
kg	-	851	O
/	-	853	O
day	-	854	O
(	-	858	O
given	-	859	O
orally	-	865	O
)	-	871	O
or	-	873	O
SRL	-	876	B
0	-	880	O
.	-	881	O
4	-	882	O
mg	-	884	O
/	-	886	O
kg	-	887	O
/	-	889	O
day	-	890	O
(	-	894	O
given	-	895	O
intraperitoneally	-	901	O
)	-	918	O
was	-	920	O
administered	-	924	O
once	-	937	O
a	-	942	O
day	-	944	O
as	-	948	O
these	-	951	O
doses	-	957	O
have	-	963	O
earlier	-	968	O
been	-	976	O
found	-	981	O
to	-	987	O
achieve	-	990	O
a	-	998	O
significant	-	1000	O
immunosuppressive	-	1012	O
effect	-	1030	O
in	-	1037	O
Sprague	-	1040	O
-	-	1047	O
Dawley	-	1048	O
rats	-	1055	O
.	-	1059	O

In	12584269	1061	O
the	-	1064	O
'	-	1068	O
conscious	-	1069	O
catheterized	-	1079	O
rat	-	1092	O
'	-	1095	O
model	-	1097	O
,	-	1102	O
the	-	1104	O
glomerular	-	1108	O
filtration	-	1119	O
rate	-	1130	O
(	-	1135	O
GFR	-	1136	O
)	-	1139	O
was	-	1141	O
measured	-	1145	O
as	-	1154	O
the	-	1157	O
clearance	-	1161	O
of	-	1171	O
Cr	-	1174	O
(	-	1176	O
EDTA	-	1177	O
)	-	1181	O
.	-	1182	O

The	12584269	1184	O
morphological	-	1188	O
analysis	-	1202	O
of	-	1211	O
the	-	1214	O
kidneys	-	1218	O
included	-	1226	O
a	-	1235	O
semi	-	1237	O
-	-	1241	O
quantitative	-	1242	O
scoring	-	1255	O
system	-	1263	O
analysing	-	1270	O
the	-	1280	O
degree	-	1284	O
of	-	1291	O
striped	-	1294	O
fibrosis	-	1302	O
,	-	1310	O
subcapsular	-	1312	O
fibrosis	-	1324	O
and	-	1333	O
the	-	1337	O
number	-	1341	O
of	-	1348	O
basophilic	-	1351	O
tubules	-	1362	O
,	-	1369	O
plus	-	1371	O
an	-	1376	O
additional	-	1379	O
stereological	-	1390	O
analysis	-	1404	O
of	-	1413	O
the	-	1416	O
total	-	1420	O
grade	-	1426	O
of	-	1432	O
fibrosis	-	1435	O
in	-	1444	O
the	-	1447	O
cortex	-	1451	O
stained	-	1458	O
with	-	1466	O
Sirius	-	1471	O
Red	-	1478	O
.	-	1481	O

RESULTS	12584269	1483	O
:	-	1490	O
CsA	-	1492	B
,	-	1495	O
FK506	-	1497	B
and	-	1503	O
SRL	-	1507	B

all	12584269	1511	O
significantly	-	1515	O
decreased	-	1529	O
the	-	1539	O
GFR	-	1543	O
.	-	1546	O

A	12584269	1548	O
further	-	1550	O
deterioration	-	1558	O
was	-	1572	O
seen	-	1576	O
when	-	1581	O
CsA	-	1586	B
was	-	1590	O
combined	-	1594	O
with	-	1603	O
either	-	1608	O
FK506	-	1615	B
or	-	1621	O
SRL	-	1624	B
,	-	1627	O
whereas	-	1629	O
the	-	1637	O
GFR	-	1641	O
remained	-	1645	O
unchanged	-	1654	O
in	-	1664	O
the	-	1667	O
group	-	1671	O
treated	-	1677	O
with	-	1685	O
FK506	-	1690	B
plus	-	1696	O
SRL	-	1701	B
when	-	1705	O
compared	-	1710	O
with	-	1719	O
treatment	-	1724	O
with	-	1734	O
any	-	1739	O
of	-	1743	O
the	-	1746	O
single	-	1750	O
substances	-	1757	O
.	-	1767	O

The	12584269	1769	O
morphological	-	1773	O
changes	-	1787	O
presented	-	1795	O
a	-	1805	O
similar	-	1807	O
pattern	-	1815	O
.	-	1822	O

The	12584269	1824	O
semi	-	1828	O
-	-	1832	O
quantitative	-	1833	O
scoring	-	1846	O
was	-	1854	O
significantly	-	1858	O
worst	-	1872	O
in	-	1878	O
the	-	1881	O
group	-	1885	O
treated	-	1891	O
with	-	1899	O
CsA	-	1904	B
plus	-	1908	O
SRL	-	1913	B
(	-	1917	O
P	-	1918	O
<	-	1919	O
0	-	1920	O
.	-	1921	O
001	-	1922	O
compared	-	1926	O
with	-	1935	O
controls	-	1940	O
)	-	1948	O
and	-	1950	O
the	-	1954	O
analysis	-	1958	O
of	-	1967	O
the	-	1970	O
total	-	1974	O
grade	-	1980	O
of	-	1986	O
fibrosis	-	1989	O
also	-	1998	O
showed	-	2003	O
the	-	2010	O
highest	-	2014	O
proportion	-	2022	O
in	-	2033	O
the	-	2036	O
same	-	2040	O
group	-	2045	O
and	-	2051	O
was	-	2055	O
significantly	-	2059	O
different	-	2073	O
from	-	2083	O
controls	-	2088	O
(	-	2097	O
P	-	2098	O
<	-	2099	O
0	-	2100	O
.	-	2101	O
02	-	2102	O
)	-	2104	O
.	-	2105	O

The	12584269	2107	O
FK506	-	2111	B
plus	-	2117	O
SRL	-	2122	B
combination	-	2126	O
showed	-	2138	O
only	-	2145	O
a	-	2150	O
marginally	-	2152	O
higher	-	2163	O
degree	-	2170	O
of	-	2177	O
fibrosis	-	2180	O
as	-	2189	O
compared	-	2192	O
with	-	2201	O
controls	-	2206	O
(	-	2215	O
P	-	2216	O
=	-	2217	O
0	-	2218	O
.	-	2219	O
05	-	2220	O
)	-	2222	O
.	-	2223	O

CONCLUSION	12584269	2225	O
:	-	2235	O

This	12584269	2237	O
rat	-	2242	O
study	-	2246	O
demonstrated	-	2252	O
a	-	2265	O
synergistic	-	2267	O
nephrotoxic	-	2279	O
effect	-	2291	O
of	-	2298	O
CsA	-	2301	B
plus	-	2305	O
SRL	-	2310	B
,	-	2313	O
whereas	-	2315	O
FK506	-	2323	B
plus	-	2329	O
SRL	-	2334	B
was	-	2338	O
better	-	2342	O
tolerated	-	2349	O
.	-	2358	O

Effect	10406016	0	O
of	-	7	O
fucoidan	-	10	B
treatment	-	19	O
on	-	29	O
collagenase	-	32	O
-	-	43	O
induced	-	44	O
intracerebral	-	52	O
hemorrhage	-	66	O
in	-	77	O
rats	-	80	O
.	-	84	O

Inflammatory	10406016	86	O
cells	-	99	O
are	-	105	O
postulated	-	109	O
to	-	120	O
mediate	-	123	O
some	-	131	O
of	-	136	O
the	-	139	O
brain	-	143	O
damage	-	149	O
following	-	156	O
ischemic	-	166	O
stroke	-	175	O
.	-	181	O

Intracerebral	10406016	183	O
hemorrhage	-	197	O
is	-	208	O
associated	-	211	O
with	-	222	O
more	-	227	O
inflammation	-	232	O
than	-	245	O
ischemic	-	250	O
stroke	-	259	O
.	-	265	O

We	10406016	267	O
tested	-	270	O
the	-	277	O
sulfated	-	281	O
polysaccharide	-	290	O
fucoidan	-	305	B
,	-	313	O
which	-	315	O
has	-	321	O
been	-	325	O
reported	-	330	O
to	-	339	O
reduce	-	342	O
inflammatory	-	349	O
brain	-	362	O
damage	-	368	O
,	-	374	O
in	-	376	O
a	-	379	O
rat	-	381	O
model	-	385	O
of	-	391	O
intracerebral	-	394	O
hemorrhage	-	408	O
induced	-	419	O
by	-	427	O
injection	-	430	O
of	-	440	O
bacterial	-	443	O
collagenase	-	453	O
into	-	465	O
the	-	470	O
caudate	-	474	O
nucleus	-	482	O
.	-	489	O

Rats	10406016	491	O
were	-	496	O
treated	-	501	O
with	-	509	O
seven	-	514	O
day	-	520	O
intravenous	-	524	O
infusion	-	536	O
of	-	545	O
fucoidan	-	548	B
(	-	557	O
30	-	558	O
micrograms	-	561	O
h	-	572	O
-	-	573	O
1	-	574	O
)	-	575	O
or	-	577	O
vehicle	-	580	O
.	-	587	O

The	10406016	589	O
hematoma	-	593	O
was	-	602	O
assessed	-	606	O
in	-	615	O
vivo	-	618	O
by	-	623	O
magnetic	-	626	O
resonance	-	635	O
imaging	-	645	O
.	-	652	O

Motor	10406016	654	O
behavior	-	660	O
,	-	668	O
passive	-	670	O
avoidance	-	678	O
,	-	687	O
and	-	689	O
skilled	-	693	O
forelimb	-	701	O
function	-	710	O
were	-	719	O
tested	-	724	O
repeatedly	-	731	O
for	-	742	O
six	-	746	O
weeks	-	750	O
.	-	755	O

Fucoidan	10406016	757	B
-	-	765	O
treated	-	766	O
rats	-	774	O
exhibited	-	779	O
evidence	-	789	O
of	-	798	O
impaired	-	801	O
blood	-	810	O
clotting	-	816	O
and	-	825	O
hemodilution	-	829	O
,	-	841	O
had	-	843	O
larger	-	847	O
hematomas	-	854	O
,	-	863	O
and	-	865	O
tended	-	869	O
to	-	876	O
have	-	879	O
less	-	884	O
inflammation	-	889	O
in	-	902	O
the	-	905	O
vicinity	-	909	O
of	-	918	O
the	-	921	O
hematoma	-	925	O
after	-	934	O
three	-	940	O
days	-	946	O
.	-	950	O

They	10406016	952	O
showed	-	957	O
significantly	-	964	O
more	-	978	O
rapid	-	983	O
improvement	-	989	O
of	-	1001	O
motor	-	1004	O
function	-	1010	O
in	-	1019	O
the	-	1022	O
first	-	1026	O
week	-	1032	O
following	-	1037	O
hemorrhage	-	1047	O
and	-	1058	O
better	-	1062	O
memory	-	1069	O
retention	-	1076	O
in	-	1086	O
the	-	1089	O
passive	-	1093	O
avoidance	-	1101	O
test	-	1111	O
.	-	1115	O

Acute	10406016	1117	O
white	-	1123	O
matter	-	1129	O
edema	-	1136	O
and	-	1142	O
eventual	-	1146	O
neuronal	-	1155	O
loss	-	1164	O
in	-	1169	O
the	-	1172	O
striatum	-	1176	O
adjacent	-	1185	O
to	-	1194	O
the	-	1197	O
hematoma	-	1201	O
did	-	1210	O
not	-	1214	O
differ	-	1218	O
between	-	1225	O
the	-	1233	O
two	-	1237	O
groups	-	1241	O
.	-	1247	O

Investigation	10406016	1249	O
of	-	1263	O
more	-	1266	O
specific	-	1271	O
anti	-	1280	O
-	-	1284	O
inflammatory	-	1285	O
agents	-	1298	O
and	-	1305	O
hemodiluting	-	1309	O
agents	-	1322	O
are	-	1329	O
warranted	-	1333	O
in	-	1343	O
intracerebral	-	1346	O
hemorrhage	-	1360	O
.	-	1370	O

Paracetamol	3403780	0	B
-	-	11	O
associated	-	12	O
coma	-	23	O
,	-	27	O
metabolic	-	29	O
acidosis	-	39	O
,	-	47	O
renal	-	49	O
and	-	55	O
hepatic	-	59	O
failure	-	67	O
.	-	74	O

A	3403780	76	O
case	-	78	O
of	-	83	O
metabolic	-	86	O
acidosis	-	96	O
,	-	104	O
acute	-	106	O
renal	-	112	O
failure	-	118	O
and	-	126	O
hepatic	-	130	O
failure	-	138	O
following	-	146	O
paracetamol	-	156	B
ingestion	-	168	O
is	-	178	O
presented	-	181	O
.	-	190	O

The	3403780	192	O
diagnostic	-	196	O
difficulty	-	207	O
at	-	218	O
presentation	-	221	O
is	-	234	O
highlighted	-	237	O
.	-	248	O

Continuous	3403780	250	O
arteriovenous	-	261	O
haemofiltration	-	275	O
proved	-	291	O
a	-	298	O
valuable	-	300	O
means	-	309	O
of	-	315	O
maintaining	-	318	O
fluid	-	330	O
and	-	336	O
electrolyte	-	340	O
balance	-	352	O
.	-	359	O

The	3403780	361	O
patient	-	365	O
recovered	-	373	O
.	-	382	O

Hepatic	3101906	0	O
reactions	-	8	O
associated	-	18	O
with	-	29	O
ketoconazole	-	34	B
in	-	47	O
the	-	50	O
United	-	54	O
Kingdom	-	61	O
.	-	68	O

Ketoconazole	3101906	70	B
was	-	83	O
introduced	-	87	O
in	-	98	O
the	-	101	O
United	-	105	O
Kingdom	-	112	O
in	-	120	O
1981	-	123	O
.	-	127	O

By	3101906	129	O
November	-	132	O
1984	-	141	O
the	-	146	O
Committee	-	150	O
on	-	160	O
Safety	-	163	O
of	-	170	O
Medicines	-	173	O
had	-	183	O
received	-	187	O
82	-	196	O
reports	-	199	O
of	-	207	O
possible	-	210	O
hepatotoxicity	-	219	O
associated	-	234	O
with	-	245	O
the	-	250	O
drug	-	254	O
,	-	258	O
including	-	260	O
five	-	270	O
deaths	-	275	O
.	-	281	O

An	3101906	283	O
analysis	-	286	O
of	-	295	O
the	-	298	O
75	-	302	O
cases	-	305	O
that	-	311	O
had	-	316	O
been	-	320	O
adequately	-	325	O
followed	-	336	O
up	-	345	O
suggested	-	348	O
that	-	358	O
16	-	363	O
,	-	365	O
including	-	367	O
three	-	377	O
deaths	-	383	O
,	-	389	O
were	-	391	O
probably	-	396	O
related	-	405	O
to	-	413	O
treatment	-	416	O
with	-	426	O
the	-	431	O
drug	-	435	O
.	-	439	O

Of	3101906	441	O
the	-	444	O
remainder	-	448	O
,	-	457	O
48	-	459	O
were	-	462	O
possibly	-	467	O
related	-	476	O
to	-	484	O
treatment	-	487	O
,	-	496	O
five	-	498	O
were	-	503	O
unlikely	-	508	O
to	-	517	O
be	-	520	O
so	-	523	O
,	-	525	O
and	-	527	O
six	-	531	O
were	-	535	O
unclassifiable	-	540	O
.	-	554	O

The	3101906	556	O
mean	-	560	O
age	-	565	O
of	-	569	O
patients	-	572	O
in	-	581	O
the	-	584	O
16	-	588	O
probable	-	591	O
cases	-	600	O
was	-	606	O
57	-	610	O
.	-	612	O
9	-	613	O
,	-	614	O
with	-	616	O
hepatotoxicity	-	621	O
being	-	636	O
more	-	642	O
common	-	647	O
in	-	654	O
women	-	657	O
.	-	662	O

The	3101906	664	O
average	-	668	O
duration	-	676	O
of	-	685	O
treatment	-	688	O
before	-	698	O
the	-	705	O
onset	-	709	O
of	-	715	O
jaundice	-	718	O
was	-	727	O
61	-	731	O
days	-	734	O
.	-	738	O

None	3101906	740	O
of	-	745	O
these	-	748	O
well	-	754	O
validated	-	759	O
cases	-	769	O
occurred	-	775	O
within	-	784	O
the	-	791	O
first	-	795	O
10	-	801	O
days	-	804	O
after	-	809	O
treatment	-	815	O
.	-	824	O

The	3101906	826	O
results	-	830	O
of	-	838	O
serum	-	841	O
liver	-	847	O
function	-	853	O
tests	-	862	O
suggested	-	868	O
hepatocellular	-	878	O
injury	-	893	O
in	-	900	O
10	-	903	O
(	-	906	O
63	-	907	O
%	-	909	O
)	-	910	O
;	-	911	O
the	-	913	O
rest	-	917	O
showed	-	922	O
a	-	929	O
mixed	-	931	O
pattern	-	937	O
.	-	944	O

In	3101906	946	O
contrast	-	949	O
,	-	957	O
the	-	959	O
results	-	963	O
of	-	971	O
histological	-	974	O
examination	-	987	O
of	-	999	O
the	-	1002	O
liver	-	1006	O
often	-	1012	O
showed	-	1018	O
evidence	-	1025	O
of	-	1034	O
cholestasis	-	1037	O
.	-	1048	O

The	3101906	1050	O
characteristics	-	1054	O
of	-	1070	O
the	-	1073	O
48	-	1077	O
patients	-	1080	O
in	-	1089	O
the	-	1092	O
possible	-	1096	O
cases	-	1105	O
were	-	1111	O
similar	-	1116	O
.	-	1123	O

Allergic	3101906	1125	O
manifestations	-	1134	O
such	-	1149	O
as	-	1154	O
rash	-	1157	O
and	-	1162	O
eosinophilia	-	1166	O
were	-	1179	O
rare	-	1184	O
.	-	1188	O

Hepatitis	3101906	1190	O
was	-	1200	O
usually	-	1204	O
reversible	-	1212	O
when	-	1223	O
treatment	-	1228	O
was	-	1238	O
stopped	-	1242	O
,	-	1249	O
with	-	1251	O
the	-	1256	O
results	-	1260	O
of	-	1268	O
liver	-	1271	O
function	-	1277	O
tests	-	1286	O
returning	-	1292	O
to	-	1302	O
normal	-	1305	O
after	-	1312	O
an	-	1318	O
average	-	1321	O
of	-	1329	O
3	-	1332	O
.	-	1333	O
1	-	1334	O
months	-	1336	O
.	-	1342	O

In	3101906	1344	O
two	-	1347	O
of	-	1351	O
the	-	1354	O
three	-	1358	O
deaths	-	1364	O
probably	-	1371	O
associated	-	1380	O
with	-	1391	O
ketoconazole	-	1396	B
treatment	-	1409	O
the	-	1419	O
drug	-	1423	O
had	-	1428	O
been	-	1432	O
continued	-	1437	O
after	-	1447	O
the	-	1453	O
onset	-	1457	O
of	-	1463	O
jaundice	-	1466	O
and	-	1475	O
other	-	1479	O
symptoms	-	1485	O
of	-	1494	O
hepatitis	-	1497	O
.	-	1506	O

Clinical	3101906	1508	O
and	-	1517	O
biochemical	-	1521	O
monitoring	-	1533	O
at	-	1544	O
regular	-	1547	O
intervals	-	1555	O
for	-	1565	O
evidence	-	1569	O
of	-	1578	O
hepatitis	-	1581	O
is	-	1591	O
advised	-	1594	O
during	-	1602	O
long	-	1609	O
term	-	1614	O
treatment	-	1619	O
with	-	1629	O
ketoconazole	-	1634	B
to	-	1647	O
prevent	-	1650	O
possible	-	1658	O
serious	-	1667	O
hepatic	-	1675	O
injury	-	1683	O
.	-	1689	O

Combined	9088814	0	O
effects	-	9	O
of	-	17	O
prolonged	-	20	O
prostaglandin	-	30	B
E1	-	44	I
-	-	46	O
induced	-	47	O
hypotension	-	55	O
and	-	67	O
haemodilution	-	71	O
on	-	85	O
human	-	88	O
hepatic	-	94	O
function	-	102	O
.	-	110	O

Combined	9088814	112	O
effects	-	121	O
of	-	129	O
prolonged	-	132	O
prostaglandin	-	142	B
E1	-	156	I
(	-	159	O
PGE1	-	160	B
)	-	164	O
-	-	165	O
induced	-	166	O
hypotension	-	174	O
and	-	186	O
haemodilution	-	190	O
on	-	204	O
hepatic	-	207	O
function	-	215	O
were	-	224	O
studied	-	229	O
in	-	237	O
30	-	240	O
patients	-	243	O
undergoing	-	252	O
hip	-	263	O
surgery	-	267	O
.	-	274	O

The	9088814	276	O
patients	-	280	O
were	-	289	O
randomly	-	294	O
allocated	-	303	O
to	-	313	O
one	-	316	O
of	-	320	O
three	-	323	O
groups	-	329	O
;	-	335	O
those	-	337	O
in	-	343	O
group	-	346	O
A	-	352	O
(	-	354	O
n	-	355	O
=	-	357	O
10	-	359	O
)	-	361	O
were	-	363	O
subjected	-	368	O
to	-	378	O
controlled	-	381	O
hypotension	-	392	O
alone	-	404	O
,	-	409	O
those	-	411	O
in	-	417	O
group	-	420	O
B	-	426	O
(	-	428	O
n	-	429	O
=	-	431	O
10	-	433	O
)	-	435	O
to	-	437	O
haemodilution	-	440	O
alone	-	454	O
and	-	460	O
those	-	464	O
in	-	470	O
group	-	473	O
C	-	479	O
(	-	481	O
n	-	482	O
=	-	484	O
10	-	486	O
)	-	488	O
to	-	490	O
both	-	493	O
controlled	-	498	O
hypotension	-	509	O
and	-	521	O
haemodilution	-	525	O
.	-	538	O

Haemodilution	9088814	540	O
in	-	554	O
groups	-	557	O
B	-	564	O
and	-	566	O
C	-	570	O
was	-	572	O
produced	-	576	O
by	-	585	O
withdrawing	-	588	O
approximately	-	600	O
1000	-	614	O
mL	-	619	O
of	-	622	O
blood	-	625	O
and	-	631	O
replacing	-	635	O
it	-	645	O
with	-	648	O
the	-	653	O
same	-	657	O
amount	-	662	O
of	-	669	O
dextran	-	672	B
solution	-	680	O
,	-	688	O
and	-	690	O
final	-	694	O
haematocrit	-	700	O
values	-	712	O
were	-	719	O
21	-	724	O
or	-	727	O
22	-	730	O
%	-	732	O
.	-	733	O

Controlled	9088814	735	O
hypotension	-	746	O
in	-	758	O
groups	-	761	O
A	-	768	O
and	-	770	O
C	-	774	O
was	-	776	O
induced	-	780	O
with	-	788	O
PGE1	-	793	B
to	-	798	O
maintain	-	801	O
mean	-	810	O
arterial	-	815	O
blood	-	824	O
pressure	-	830	O
at	-	839	O
55	-	842	O
mmHg	-	845	O
for	-	850	O
180	-	854	O
min	-	858	O
.	-	861	O

Measurements	9088814	863	O
included	-	876	O
arterial	-	885	O
ketone	-	894	O
body	-	901	O
ratio	-	906	O
(	-	912	O
AKBR	-	913	O
,	-	917	O
aceto	-	919	B
-	-	924	I
acetate	-	925	I
/	-	932	O
3	-	933	B
-	-	934	I
hydroxybutyrate	-	935	I
)	-	950	O
and	-	952	O
clinical	-	956	O
hepatic	-	965	O
function	-	973	O
parameters	-	982	O
.	-	992	O

AKBR	9088814	994	O
and	-	999	O
biological	-	1003	O
hepatic	-	1014	O
function	-	1022	O
tests	-	1031	O
showed	-	1037	O
no	-	1044	O
change	-	1047	O
throughout	-	1054	O
the	-	1065	O
time	-	1069	O
course	-	1074	O
in	-	1081	O
groups	-	1084	O
A	-	1091	O
and	-	1093	O
B	-	1097	O
.	-	1098	O

In	9088814	1100	O
group	-	1103	O
C	-	1109	O
,	-	1110	O
AKBR	-	1112	O
showed	-	1117	O
a	-	1124	O
significant	-	1126	O
decrease	-	1138	O
at	-	1147	O
120	-	1150	O
min	-	1154	O
(	-	1158	O
-	-	1159	O
40	-	1160	O
%	-	1162	O
)	-	1163	O
and	-	1165	O
at	-	1169	O
180	-	1172	O
min	-	1176	O
(	-	1180	O
-	-	1181	O
49	-	1182	O
%	-	1184	O
)	-	1185	O
after	-	1187	O
the	-	1193	O
start	-	1197	O
of	-	1203	O
hypotension	-	1206	O
and	-	1218	O
at	-	1222	O
60	-	1225	O
min	-	1228	O
(	-	1232	O
-	-	1233	O
32	-	1234	O
%	-	1236	O
)	-	1237	O
after	-	1239	O
recovery	-	1245	O
of	-	1254	O
normotension	-	1257	O
,	-	1269	O
and	-	1271	O
SGOT	-	1275	O
,	-	1279	O
SGPT	-	1281	O
,	-	1285	O
LDH	-	1287	O
and	-	1291	O
total	-	1295	O
bilirubin	-	1301	B
showed	-	1311	O
significant	-	1318	O
increases	-	1330	O
after	-	1340	O
operation	-	1346	O
.	-	1355	O

The	9088814	1357	O
results	-	1361	O
suggest	-	1369	O
that	-	1377	O
a	-	1382	O
prolonged	-	1384	O
combination	-	1394	O
of	-	1406	O
more	-	1409	O
than	-	1414	O
120	-	1419	O
min	-	1423	O
of	-	1427	O
PGE1	-	1430	B
-	-	1434	O
induced	-	1435	O
hypotension	-	1443	O
and	-	1455	O
moderate	-	1459	O
haemodilution	-	1468	O
would	-	1482	O
cause	-	1488	O
impairment	-	1494	O
of	-	1505	O
hepatic	-	1508	O
function	-	1516	O
.	-	1524	O

Levodopa	20880751	0	B
-	-	8	O
induced	-	9	O
dyskinesias	-	17	O
in	-	29	O
patients	-	32	O
with	-	41	O
Parkinson	-	46	O
's	-	55	O
disease	-	58	O
:	-	65	O
filling	-	67	O
the	-	75	O
bench	-	79	O
-	-	84	O
to	-	85	O
-	-	87	O
bedside	-	88	O
gap	-	96	O
.	-	99	O

Levodopa	20880751	101	B
is	-	110	O
the	-	113	O
most	-	117	O
effective	-	122	O
drug	-	132	O
for	-	137	O
the	-	141	O
treatment	-	145	O
of	-	155	O
Parkinson	-	158	O
's	-	167	O
disease	-	170	O
.	-	177	O

However	20880751	179	O
,	-	186	O
the	-	188	O
long	-	192	O
-	-	196	O
term	-	197	O
use	-	202	O
of	-	206	O
this	-	209	O
dopamine	-	214	B
precursor	-	223	O
is	-	233	O
complicated	-	236	O
by	-	248	O
highly	-	251	O
disabling	-	258	O
fluctuations	-	268	O
and	-	281	O
dyskinesias	-	285	O
.	-	296	O

Although	20880751	298	O
preclinical	-	307	O
and	-	319	O
clinical	-	323	O
findings	-	332	O
suggest	-	341	O
pulsatile	-	349	O
stimulation	-	359	O
of	-	371	O
striatal	-	374	O
postsynaptic	-	383	O
receptors	-	396	O
as	-	406	O
a	-	409	O
key	-	411	O
mechanism	-	415	O
underlying	-	425	O
levodopa	-	436	B
-	-	444	O
induced	-	445	O
dyskinesias	-	453	O
,	-	464	O
their	-	466	O
pathogenesis	-	472	O
is	-	485	O
still	-	488	O
unclear	-	494	O
.	-	501	O

In	20880751	503	O
recent	-	506	O
years	-	513	O
,	-	518	O
evidence	-	520	O
from	-	529	O
animal	-	534	O
models	-	541	O
of	-	548	O
Parkinson	-	551	O
's	-	560	O
disease	-	563	O
has	-	571	O
provided	-	575	O
important	-	584	O
information	-	594	O
to	-	606	O
understand	-	609	O
the	-	620	O
effect	-	624	O
of	-	631	O
specific	-	634	O
receptor	-	643	O
and	-	652	O
post	-	656	O
-	-	660	O
receptor	-	661	O
molecular	-	670	O
mechanisms	-	680	O
underlying	-	691	O
the	-	702	O
development	-	706	O
of	-	718	O
dyskinetic	-	721	O
movements	-	732	O
.	-	741	O

Recent	20880751	743	O
preclinical	-	750	O
and	-	762	O
clinical	-	766	O
data	-	775	O
from	-	780	O
promising	-	785	O
lines	-	795	O
of	-	801	O
research	-	804	O
focus	-	813	O
on	-	819	O
the	-	822	O
differential	-	826	O
role	-	839	O
of	-	844	O
presynaptic	-	847	O
versus	-	859	O
postsynaptic	-	866	O
mechanisms	-	879	O
,	-	889	O
dopamine	-	891	B
receptor	-	900	O
subtypes	-	909	O
,	-	917	O
ionotropic	-	919	O
and	-	930	O
metabotropic	-	934	O
glutamate	-	947	B
receptors	-	957	O
,	-	966	O
and	-	968	O
non	-	972	O
-	-	975	O
dopaminergic	-	976	O
neurotransmitter	-	989	O
systems	-	1006	O
in	-	1014	O
the	-	1017	O
pathophysiology	-	1021	O
of	-	1037	O
levodopa	-	1040	B
-	-	1048	O
induced	-	1049	O
dyskinesias	-	1057	O
.	-	1068	O

Prevention	20080419	0	O
of	-	11	O
seizures	-	14	O
and	-	23	O
reorganization	-	27	O
of	-	42	O
hippocampal	-	45	O
functions	-	57	O
by	-	67	O
transplantation	-	70	O
of	-	86	O
bone	-	89	O
marrow	-	94	O
cells	-	101	O
in	-	107	O
the	-	110	O
acute	-	114	O
phase	-	120	O
of	-	126	O
experimental	-	129	O
epilepsy	-	142	O
.	-	150	O

In	20080419	152	O
this	-	155	O
study	-	160	O
,	-	165	O
we	-	167	O
investigated	-	170	O
the	-	183	O
therapeutic	-	187	O
potential	-	199	O
of	-	209	O
bone	-	212	O
marrow	-	217	O
mononuclear	-	224	O
cells	-	236	O
(	-	242	O
BMCs	-	243	O
)	-	247	O
in	-	249	O
a	-	252	O
model	-	254	O
of	-	260	O
epilepsy	-	263	O
induced	-	272	O
by	-	280	O
pilocarpine	-	283	B
in	-	295	O
rats	-	298	O
.	-	302	O

BMCs	20080419	304	O
obtained	-	309	O
from	-	318	O
green	-	323	O
fluorescent	-	329	O
protein	-	341	O
(	-	349	O
GFP	-	350	O
)	-	353	O
transgenic	-	355	O
mice	-	366	O
or	-	371	O
rats	-	374	O
were	-	379	O
transplanted	-	384	O
intravenously	-	397	O
after	-	411	O
induction	-	417	O
of	-	427	O
status	-	430	O
epilepticus	-	437	O
(	-	449	O
SE	-	450	O
)	-	452	O
.	-	453	O

Spontaneous	20080419	455	O
recurrent	-	467	O
seizures	-	477	O
(	-	486	O
SRS	-	487	O
)	-	490	O
were	-	492	O
monitored	-	497	O
using	-	507	O
Racine	-	513	O
's	-	519	O
seizure	-	522	O
severity	-	530	O
scale	-	539	O
.	-	544	O

All	20080419	546	O
of	-	550	O
the	-	553	O
rats	-	557	O
in	-	562	O
the	-	565	O
saline	-	569	O
-	-	575	O
treated	-	576	O
epileptic	-	584	O
control	-	594	O
group	-	602	O
developed	-	608	O
SRS	-	618	O
,	-	621	O
whereas	-	623	O
none	-	631	O
of	-	636	O
the	-	639	O
BMC	-	643	O
-	-	646	O
treated	-	647	O
epileptic	-	655	O
animals	-	665	O
had	-	673	O
seizures	-	677	O
in	-	686	O
the	-	689	O
short	-	693	O
term	-	699	O
(	-	704	O
15	-	705	O
days	-	708	O
after	-	713	O
transplantation	-	719	O
)	-	734	O
,	-	735	O
regardless	-	737	O
of	-	748	O
the	-	751	O
BMC	-	755	O
source	-	759	O
.	-	765	O

Over	20080419	767	O
the	-	772	O
long	-	776	O
-	-	780	O
term	-	781	O
chronic	-	786	O
phase	-	794	O
(	-	800	O
120	-	801	O
days	-	805	O
after	-	810	O
transplantation	-	816	O
)	-	831	O
,	-	832	O
only	-	834	O
25	-	839	O
%	-	841	O
of	-	843	O
BMC	-	846	O
-	-	849	O
treated	-	850	O
epileptic	-	858	O
animals	-	868	O
had	-	876	O
seizures	-	880	O
,	-	888	O
but	-	890	O
with	-	894	O
a	-	899	O
lower	-	901	O
frequency	-	907	O
and	-	917	O
duration	-	921	O
compared	-	930	O
to	-	939	O
the	-	942	O
epileptic	-	946	O
control	-	956	O
group	-	964	O
.	-	969	O

The	20080419	971	O
density	-	975	O
of	-	983	O
hippocampal	-	986	O
neurons	-	998	O
in	-	1006	O
the	-	1009	O
brains	-	1013	O
of	-	1020	O
animals	-	1023	O
treated	-	1031	O
with	-	1039	O
BMCs	-	1044	O
was	-	1049	O
markedly	-	1053	O
preserved	-	1062	O
.	-	1071	O

At	20080419	1073	O
hippocampal	-	1076	O
Schaeffer	-	1088	O
collateral	-	1098	O
-	-	1108	O
CA1	-	1109	O
synapses	-	1113	O
,	-	1121	O
long	-	1123	O
-	-	1127	O
term	-	1128	O
potentiation	-	1133	O
was	-	1146	O
preserved	-	1150	O
in	-	1160	O
BMC	-	1163	O
-	-	1166	O
transplanted	-	1167	O
rats	-	1180	O
compared	-	1185	O
to	-	1194	O
epileptic	-	1197	O
controls	-	1207	O
.	-	1215	O

The	20080419	1217	O
donor	-	1221	O
-	-	1226	O
derived	-	1227	O
GFP	-	1235	O
(	-	1238	O
+	-	1239	O
)	-	1240	O
cells	-	1242	O
were	-	1248	O
rarely	-	1253	O
found	-	1260	O
in	-	1266	O
the	-	1269	O
brains	-	1273	O
of	-	1280	O
transplanted	-	1283	O
epileptic	-	1296	O
rats	-	1306	O
.	-	1310	O

In	20080419	1312	O
conclusion	-	1315	O
,	-	1325	O
treatment	-	1327	O
with	-	1337	O
BMCs	-	1342	O
can	-	1347	O
prevent	-	1351	O
the	-	1359	O
development	-	1363	O
of	-	1375	O
chronic	-	1378	O
seizures	-	1386	O
,	-	1394	O
reduce	-	1396	O
neuronal	-	1403	O
loss	-	1412	O
,	-	1416	O
and	-	1418	O
influence	-	1422	O
the	-	1432	O
reorganization	-	1436	O
of	-	1451	O
the	-	1454	O
hippocampal	-	1458	O
neuronal	-	1470	O
network	-	1479	O
.	-	1486	O

Cardioprotective	19445921	0	O
effect	-	17	O
of	-	24	O
salvianolic	-	27	B
acid	-	39	I
A	-	44	I
on	-	46	O
isoproterenol	-	49	B
-	-	62	O
induced	-	63	O
myocardial	-	71	O
infarction	-	82	O
in	-	93	O
rats	-	96	O
.	-	100	O

The	19445921	102	O
present	-	106	O
study	-	114	O
was	-	120	O
designed	-	124	O
to	-	133	O
evaluate	-	136	O
the	-	145	O
cardioprotective	-	149	O
potential	-	166	O
of	-	176	O
salvianolic	-	179	B
acid	-	191	I
A	-	196	I
on	-	198	O
isoproterenol	-	201	B
-	-	214	O
induced	-	215	O
myocardial	-	223	O
infarction	-	234	O
in	-	245	O
rats	-	248	O
.	-	252	O

Hemodynamic	19445921	254	O
parameters	-	266	O
and	-	277	O
lead	-	281	O
II	-	286	O
electrocardiograph	-	289	O
were	-	308	O
monitored	-	313	O
and	-	323	O
recorded	-	327	O
continuously	-	336	O
.	-	348	O

Cardiac	19445921	350	O
marker	-	358	O
enzymes	-	365	O
and	-	373	O
antioxidative	-	377	O
parameters	-	391	O
in	-	402	O
serum	-	405	O
and	-	411	O
heart	-	415	O
tissues	-	421	O
were	-	429	O
measured	-	434	O
.	-	442	O

Assay	19445921	444	O
for	-	450	O
mitochondrial	-	454	O
respiratory	-	468	O
function	-	480	O
and	-	489	O
histopathological	-	493	O
examination	-	511	O
of	-	523	O
heart	-	526	O
tissues	-	532	O
were	-	540	O
performed	-	545	O
.	-	554	O

Isoproterenol	19445921	556	B
-	-	569	O
treated	-	570	O
rats	-	578	O
showed	-	583	O
significant	-	590	O
increases	-	602	O
in	-	612	O
the	-	615	O
levels	-	619	O
of	-	626	O
lactate	-	629	B
dehydrogenase	-	637	O
,	-	650	O
aspartate	-	652	B
transaminase	-	662	O
,	-	674	O
creatine	-	676	B
kinase	-	685	O
and	-	692	O
malondialdehyde	-	696	B
and	-	712	O
significant	-	716	O
decreases	-	728	O
in	-	738	O
the	-	741	O
activities	-	745	O
of	-	756	O
superoxide	-	759	B
dismutase	-	770	O
,	-	779	O
catalase	-	781	O
and	-	790	O
glutathione	-	794	B
peroxidase	-	806	O
in	-	817	O
serum	-	820	O
and	-	826	O
heart	-	830	O
.	-	835	O

These	19445921	837	O
rats	-	843	O
also	-	848	O
showed	-	853	O
declines	-	860	O
in	-	869	O
left	-	872	O
ventricular	-	877	O
systolic	-	889	O
pressure	-	898	O
,	-	906	O
maximum	-	908	O
and	-	916	O
minimum	-	920	O
rate	-	928	O
of	-	933	O
developed	-	936	O
left	-	946	O
ventricular	-	951	O
pressure	-	963	O
,	-	971	O
and	-	973	O
elevation	-	977	O
of	-	987	O
left	-	990	O
ventricular	-	995	O
end	-	1007	O
-	-	1010	O
diastolic	-	1011	O
pressure	-	1021	O
and	-	1030	O
ST	-	1034	O
-	-	1036	O
segment	-	1037	O
.	-	1044	O

In	19445921	1046	O
addition	-	1049	O
,	-	1057	O
mitochondrial	-	1059	O
respiratory	-	1073	O
dysfunction	-	1085	O
characterized	-	1097	O
by	-	1111	O
decreased	-	1114	O
respiratory	-	1124	O
control	-	1136	O
ratio	-	1144	O
and	-	1150	O
ADP	-	1154	B
/	-	1157	O
O	-	1158	O
was	-	1160	O
observed	-	1164	O
in	-	1173	O
isoproterenol	-	1176	B
-	-	1189	O
treated	-	1190	O
rats	-	1198	O
.	-	1202	O

Administration	19445921	1204	O
of	-	1219	O
salvianolic	-	1222	B
acid	-	1234	I
A	-	1239	I
for	-	1241	O
a	-	1245	O
period	-	1247	O
of	-	1254	O
8	-	1257	O
days	-	1259	O
significantly	-	1264	O
attenuated	-	1278	O
isoproterenol	-	1289	B
-	-	1302	O
induced	-	1303	O
cardiac	-	1311	O
dysfunction	-	1319	O
and	-	1331	O
myocardial	-	1335	O
injury	-	1346	O
and	-	1353	O
improved	-	1357	O
mitochondrial	-	1366	O
respiratory	-	1380	O
function	-	1392	O
.	-	1400	O

The	19445921	1402	O
protective	-	1406	O
role	-	1417	O
of	-	1422	O
salvianolic	-	1425	B
acid	-	1437	I
A	-	1442	I
against	-	1444	O
isoproterenol	-	1452	B
-	-	1465	O
induced	-	1466	O
myocardial	-	1474	O
damage	-	1485	O
was	-	1492	O
further	-	1496	O
confirmed	-	1504	O
by	-	1514	O
histopathological	-	1517	O
examination	-	1535	O
.	-	1546	O

The	19445921	1548	O
results	-	1552	O
of	-	1560	O
our	-	1563	O
study	-	1567	O
suggest	-	1573	O
that	-	1581	O
salvianolic	-	1586	B
acid	-	1598	I
A	-	1603	I
possessing	-	1605	O
antioxidant	-	1616	O
activity	-	1628	O
has	-	1637	O
a	-	1641	O
significant	-	1643	O
protective	-	1655	O
effect	-	1666	O
against	-	1673	O
isoproterenol	-	1681	B
-	-	1694	O
induced	-	1695	O
myocardial	-	1703	O
infarction	-	1714	O
.	-	1724	O

Acute	18439803	0	O
effects	-	6	O
of	-	14	O
N	-	17	B
-	-	18	I
(	-	19	I
2	-	20	I
-	-	21	I
propylpentanoyl	-	22	I
)	-	37	I
urea	-	38	I
on	-	43	O
hippocampal	-	46	O
amino	-	58	B
acid	-	64	I
neurotransmitters	-	69	O
in	-	87	O
pilocarpine	-	90	B
-	-	101	O
induced	-	102	O
seizure	-	110	O
in	-	118	O
rats	-	121	O
.	-	125	O

The	18439803	127	O
present	-	131	O
study	-	139	O
aimed	-	145	O
to	-	151	O
investigate	-	154	O
the	-	166	O
anticonvulsant	-	170	O
activity	-	185	O
as	-	194	O
well	-	197	O
as	-	202	O
the	-	205	O
effects	-	209	O
on	-	217	O
the	-	220	O
level	-	224	O
of	-	230	O
hippocampal	-	233	O
amino	-	245	B
acid	-	251	I
neurotransmitters	-	256	O
(	-	274	O
glutamate	-	275	B
,	-	284	O
aspartate	-	286	B
,	-	295	O
glycine	-	297	B
and	-	305	O
GABA	-	309	B
)	-	313	O
of	-	315	O
N	-	318	B
-	-	319	I
(	-	320	I
2	-	321	I
-	-	322	I
propylpentanoyl	-	323	I
)	-	338	I
urea	-	339	I
(	-	344	O
VPU	-	345	B
)	-	348	O
in	-	350	O
comparison	-	353	O
to	-	364	O
its	-	367	O
parent	-	371	O
compound	-	378	O
,	-	386	O
valproic	-	388	B
acid	-	397	I
(	-	402	O
VPA	-	403	B
)	-	406	O
.	-	407	O

VPU	18439803	409	B
was	-	413	O
more	-	417	O
potent	-	422	O
than	-	429	O
VPA	-	434	B
,	-	437	O
exhibiting	-	439	O
the	-	450	O
median	-	454	O
effective	-	461	O
dose	-	471	O
(	-	476	O
ED	-	477	O
(	-	479	O
50	-	480	O
)	-	482	O
)	-	483	O
of	-	485	O
49	-	488	O
mg	-	491	O
/	-	493	O
kg	-	494	O
in	-	497	O
protecting	-	500	O
rats	-	511	O
against	-	516	O
pilocarpine	-	524	B
-	-	535	O
induced	-	536	O
seizure	-	544	O
whereas	-	552	O
the	-	560	O
corresponding	-	564	O
value	-	578	O
for	-	584	O
VPA	-	588	B
was	-	592	O
322	-	596	O
mg	-	600	O
/	-	602	O
kg	-	603	O
.	-	605	O

In	18439803	607	O
vivo	-	610	O
microdialysis	-	615	O
demonstrated	-	629	O
that	-	642	O
an	-	647	O
intraperitoneal	-	650	O
administration	-	666	O
of	-	681	O
pilocarpine	-	684	B
induced	-	696	O
a	-	704	O
pronounced	-	706	O
increment	-	717	O
of	-	727	O
hippocampal	-	730	O
glutamate	-	742	B
and	-	752	O
aspartate	-	756	B
whereas	-	766	O
no	-	774	O
significant	-	777	O
change	-	789	O
was	-	796	O
observed	-	800	O
on	-	809	O
the	-	812	O
level	-	816	O
of	-	822	O
glycine	-	825	B
and	-	833	O
GABA	-	837	B
.	-	841	O

Pretreatment	18439803	843	O
with	-	856	O
either	-	861	O
VPU	-	868	B
(	-	872	O
50	-	873	O
and	-	876	O
100	-	880	O
mg	-	884	O
/	-	886	O
kg	-	887	O
)	-	889	O
or	-	891	O
VPA	-	894	B
(	-	898	O
300	-	899	O
and	-	903	O
600	-	907	O
mg	-	911	O
/	-	913	O
kg	-	914	O
)	-	916	O
completely	-	918	O
abolished	-	929	O
pilocarpine	-	939	B
-	-	950	O
evoked	-	951	O
increases	-	958	O
in	-	968	O
extracellular	-	971	O
glutamate	-	985	B
and	-	995	O
aspartate	-	999	B
.	-	1008	O

In	18439803	1010	O
addition	-	1013	O
,	-	1021	O
a	-	1023	O
statistically	-	1025	O
significant	-	1039	O
reduction	-	1051	O
was	-	1061	O
also	-	1065	O
observed	-	1070	O
on	-	1079	O
the	-	1082	O
level	-	1086	O
of	-	1092	O
GABA	-	1095	B
and	-	1100	O
glycine	-	1104	B
but	-	1112	O
less	-	1116	O
than	-	1121	O
a	-	1126	O
drastic	-	1128	O
reduction	-	1136	O
of	-	1146	O
glutamate	-	1149	B
and	-	1159	O
aspartate	-	1163	B
level	-	1173	O
.	-	1178	O

Based	18439803	1180	O
on	-	1186	O
the	-	1189	O
finding	-	1193	O
that	-	1201	O
VPU	-	1206	B
and	-	1210	O
VPA	-	1214	B
could	-	1218	O
protect	-	1224	O
the	-	1232	O
animals	-	1236	O
against	-	1244	O
pilocarpine	-	1252	B
-	-	1263	O
induced	-	1264	O
seizure	-	1272	O
it	-	1280	O
is	-	1283	O
suggested	-	1286	O
that	-	1296	O
the	-	1301	O
reduction	-	1305	O
of	-	1315	O
inhibitory	-	1318	O
amino	-	1329	B
acid	-	1335	I
neurotransmitters	-	1340	O
was	-	1358	O
comparatively	-	1362	O
minor	-	1376	O
and	-	1382	O
offset	-	1386	O
by	-	1393	O
a	-	1396	O
pronounced	-	1398	O
reduction	-	1409	O
of	-	1419	O
glutamate	-	1422	B
and	-	1432	O
aspartate	-	1436	B
.	-	1445	O

Therefore	18439803	1447	O
,	-	1456	O
like	-	1458	O
VPA	-	1463	B
,	-	1466	O
the	-	1468	O
finding	-	1472	O
that	-	1480	O
VPU	-	1485	B
could	-	1489	O
drastically	-	1495	O
reduce	-	1507	O
pilocarpine	-	1514	B
-	-	1525	O
induced	-	1526	O
increases	-	1534	O
in	-	1544	O
glutamate	-	1547	B
and	-	1557	O
aspartate	-	1561	B
should	-	1571	O
account	-	1578	O
,	-	1585	O
at	-	1587	O
least	-	1590	O
partly	-	1596	O
,	-	1602	O
for	-	1604	O
its	-	1608	O
anticonvulsant	-	1612	O
activity	-	1627	O
observed	-	1636	O
in	-	1645	O
pilocarpine	-	1648	B
-	-	1659	O
induced	-	1660	O
seizure	-	1668	O
in	-	1676	O
experimental	-	1679	O
animals	-	1692	O
.	-	1699	O

Some	18439803	1701	O
other	-	1706	O
mechanism	-	1712	O
than	-	1722	O
those	-	1727	O
being	-	1733	O
reported	-	1739	O
herein	-	1748	O
should	-	1755	O
be	-	1762	O
further	-	1765	O
investigated	-	1773	O
.	-	1785	O

Acute	17919553	0	O
hepatitis	-	6	O
attack	-	16	O
after	-	23	O
exposure	-	29	O
to	-	38	O
telithromycin	-	41	B
.	-	54	O

INTRODUCTION	17919553	56	O
:	-	68	O

Antibiotic	17919553	70	O
-	-	80	O
associated	-	81	O
hepatotoxicity	-	92	O
is	-	107	O
rare	-	110	O
.	-	114	O

With	17919553	116	O
widespread	-	121	O
use	-	132	O
of	-	136	O
antimicrobial	-	139	O
agents	-	153	O
,	-	159	O
however	-	161	O
,	-	168	O
hepatic	-	170	O
injury	-	178	O
occurs	-	185	O
frequently	-	192	O
,	-	202	O
and	-	204	O
among	-	208	O
adverse	-	214	O
drug	-	222	O
reactions	-	227	O
,	-	236	O
idiosyncratic	-	238	O
reactions	-	252	O
are	-	262	O
the	-	266	O
most	-	270	O
serious	-	275	O
.	-	282	O

CASE	17919553	284	O
SUMMARY	-	289	O
:	-	296	O

A	17919553	298	O
25	-	300	O
-	-	302	O
year	-	303	O
-	-	307	O
old	-	308	O
male	-	312	O
patient	-	317	O
,	-	324	O
with	-	326	O
a	-	331	O
height	-	333	O
of	-	340	O
175	-	343	O
cm	-	347	O
and	-	350	O
weight	-	354	O
of	-	361	O
72	-	364	O
kg	-	367	O
presented	-	370	O
to	-	380	O
Marmara	-	383	O
University	-	391	O
Hospital	-	402	O
Emergency	-	411	O
Department	-	421	O
,	-	431	O
Istanbul	-	433	O
,	-	441	O
Turkey	-	443	O
,	-	449	O
with	-	451	O
5	-	456	O
days	-	458	O
'	-	462	O
history	-	464	O
of	-	472	O
jaundice	-	475	O
,	-	483	O
malaise	-	485	O
,	-	492	O
nausea	-	494	O
,	-	500	O
and	-	502	O
vomiting	-	506	O
.	-	514	O

He	17919553	516	O
had	-	519	O
been	-	523	O
prescribed	-	528	O
telithromycin	-	539	B
400	-	553	O
mg	-	557	O
/	-	559	O
d	-	560	O
PO	-	562	O
to	-	565	O
treat	-	568	O
an	-	574	O
upper	-	577	O
respiratory	-	583	O
tract	-	595	O
infection	-	601	O
7	-	611	O
days	-	613	O
prior	-	618	O
.	-	623	O

Admission	17919553	625	O
laboratory	-	635	O
tests	-	646	O
were	-	652	O
as	-	657	O
follows	-	660	O
:	-	667	O

alanine	17919553	669	B
aminotransferase	-	677	O
,	-	693	O
67	-	695	O
U	-	698	O
/	-	699	O
L	-	700	O
(	-	702	O
reference	-	703	O
range	-	713	O
,	-	718	O
10	-	720	O
-	-	722	O
37	-	723	O
U	-	726	O
/	-	727	O
L	-	728	O
)	-	729	O
;	-	730	O
aspartate	-	732	B
aminotransferase	-	742	O
,	-	758	O
98	-	760	O
U	-	763	O
/	-	764	O
L	-	765	O
(	-	767	O
10	-	768	O
-	-	770	O
40	-	771	O
U	-	774	O
/	-	775	O
L	-	776	O
)	-	777	O
;	-	778	O
alkaline	-	780	O
phosphatase	-	789	O
,	-	800	O
513	-	802	O
U	-	806	O
/	-	807	O
L	-	808	O
(	-	810	O
0	-	811	O
-	-	812	O
270	-	813	O
U	-	817	O
/	-	818	O
L	-	819	O
)	-	820	O
;	-	821	O
gamma	-	823	O
-	-	828	O
glutamyltransferase	-	829	O
,	-	848	O
32	-	850	O
U	-	853	O
/	-	854	O
L	-	855	O
(	-	857	O
7	-	858	O
-	-	859	O
49	-	860	O
U	-	863	O
/	-	864	O
L	-	865	O
)	-	866	O
;	-	867	O
amylase	-	869	O
,	-	876	O
46	-	878	O
U	-	881	O
/	-	882	O
L	-	883	O
(	-	885	O
0	-	886	O
-	-	887	O
220	-	888	O
U	-	892	O
/	-	893	O
L	-	894	O
)	-	895	O
;	-	896	O
total	-	898	O
bilirubin	-	904	B
,	-	913	O
20	-	915	O
.	-	917	O
1	-	918	O
mg	-	920	O
/	-	922	O
dL	-	923	O
(	-	926	O
0	-	927	O
.	-	928	O
2	-	929	O
-	-	930	O
1	-	931	O
.	-	932	O
0	-	933	O
mg	-	935	O
/	-	937	O
dL	-	938	O
)	-	940	O
;	-	941	O
direct	-	943	O
bilirubin	-	950	B
,	-	959	O
14	-	961	O
.	-	963	O
8	-	964	O
mg	-	966	O
/	-	968	O
dL	-	969	O

(	17919553	972	O
0	-	973	O
-	-	974	O
0	-	975	O
.	-	976	O
3	-	977	O
mg	-	979	O
/	-	981	O
dL	-	982	O
)	-	984	O
;	-	985	O
and	-	987	O
albumin	-	991	O
,	-	998	O
4	-	1000	O
.	-	1001	O
7	-	1002	O
mg	-	1004	O
/	-	1006	O
dL	-	1007	O
(	-	1010	O
3	-	1011	O
.	-	1012	O
5	-	1013	O
-	-	1014	O
5	-	1015	O
.	-	1016	O
4	-	1017	O
mg	-	1019	O
/	-	1021	O
dL	-	1022	O
)	-	1024	O
.	-	1025	O

No	17919553	1027	O
toxin	-	1030	O
,	-	1035	O
alcohol	-	1037	B
,	-	1044	O
or	-	1046	O
other	-	1049	O
drugs	-	1055	O
were	-	1061	O
reported	-	1066	O
.	-	1074	O

The	17919553	1076	O
patient	-	1080	O
had	-	1088	O
suffered	-	1092	O
a	-	1101	O
previous	-	1103	O
episode	-	1112	O
of	-	1120	O
""""	-	1123	O
acute	-	1124	O
hepatitis	-	1130	O
of	-	1140	O
unknown	-	1143	O
origin	-	1151	O
,	-	1157	O
""""	-	1158	O
that	-	1160	O
occurred	-	1165	O
after	-	1174	O
telithromycin	-	1180	B
usage	-	1194	O
.	-	1199	O

Both	17919553	1201	O
incidents	-	1206	O
occurred	-	1216	O
within	-	1225	O
a	-	1232	O
year	-	1234	O
.	-	1238	O

DISCUSSION	17919553	1240	O
:	-	1250	O

Telithromycin	17919553	1252	B
is	-	1266	O
the	-	1269	O
first	-	1273	O
of	-	1279	O
the	-	1282	O
ketolide	-	1286	O
antibacterials	-	1295	O
to	-	1310	O
receive	-	1313	O
US	-	1321	O
Food	-	1324	O
and	-	1329	O
Drug	-	1333	O
Administration	-	1338	O
approval	-	1353	O
for	-	1362	O
clinical	-	1366	O
use	-	1375	O
.	-	1378	O

It	17919553	1380	O
has	-	1383	O
been	-	1387	O
associated	-	1392	O
with	-	1403	O
infrequent	-	1408	O
and	-	1419	O
usually	-	1423	O
reversible	-	1431	O
severe	-	1442	O
hepatic	-	1449	O
dysfunction	-	1457	O
.	-	1468	O

Based	17919553	1470	O
on	-	1476	O
a	-	1479	O
score	-	1481	O
of	-	1487	O
8	-	1490	O
on	-	1492	O
the	-	1495	O
Naranjo	-	1499	O
adverse	-	1507	O
drug	-	1515	O
reaction	-	1520	O
probability	-	1529	O
scale	-	1541	O
,	-	1546	O
telithromycin	-	1548	B
was	-	1562	O
the	-	1566	O
probable	-	1570	O
cause	-	1579	O
of	-	1585	O
acute	-	1588	O
hepatitis	-	1594	O
in	-	1604	O
this	-	1607	O
patient	-	1612	O
,	-	1619	O
and	-	1621	O
pathological	-	1625	O
findings	-	1638	O
suggested	-	1647	O
drug	-	1657	O
-	-	1661	O
induced	-	1662	O
toxic	-	1670	O
hepatitis	-	1676	O
.	-	1685	O

Recurrence	17919553	1687	O
of	-	1698	O
hepatitis	-	1701	O
attack	-	1711	O
might	-	1718	O
have	-	1724	O
been	-	1729	O
avoided	-	1734	O
if	-	1742	O
the	-	1745	O
initial	-	1749	O
incident	-	1757	O
had	-	1766	O
been	-	1770	O
communicated	-	1775	O
to	-	1788	O
the	-	1791	O
attending	-	1795	O
physician	-	1805	O
who	-	1815	O
prescribed	-	1819	O
telithromycin	-	1830	B
the	-	1844	O
second	-	1848	O
time	-	1855	O
.	-	1859	O

CONCLUSION	17919553	1861	O
:	-	1871	O

Here	17919553	1873	O
we	-	1878	O
report	-	1881	O
a	-	1888	O
case	-	1890	O
of	-	1895	O
acute	-	1898	O
hepatitis	-	1904	O
probably	-	1914	O
associated	-	1923	O
with	-	1934	O
the	-	1939	O
administration	-	1943	O
of	-	1958	O
telithromycin	-	1961	B
.	-	1974	O

Spironolactone	15632880	0	B
-	-	14	O
induced	-	15	O
renal	-	23	O
insufficiency	-	29	O
and	-	43	O
hyperkalemia	-	47	O
in	-	60	O
patients	-	63	O
with	-	72	O
heart	-	77	O
failure	-	83	O
.	-	90	O

BACKGROUND	15632880	92	O
:	-	102	O

A	15632880	104	O
previous	-	106	O
randomized	-	115	O
controlled	-	126	O
trial	-	137	O
evaluating	-	143	O
the	-	154	O
use	-	158	O
of	-	162	O
spironolactone	-	165	B
in	-	180	O
heart	-	183	O
failure	-	189	O
patients	-	197	O
reported	-	206	O
a	-	215	O
low	-	217	O
risk	-	221	O
of	-	226	O
hyperkalemia	-	229	O
(	-	242	O
2	-	243	O
%	-	244	O
)	-	245	O
and	-	247	O
renal	-	251	O
insufficiency	-	257	O
(	-	271	O
0	-	272	O
%	-	273	O
)	-	274	O
.	-	275	O

Because	15632880	277	O
treatments	-	285	O
for	-	296	O
heart	-	300	O
failure	-	306	O
have	-	314	O
changed	-	319	O
since	-	327	O
the	-	333	O
benefits	-	337	O
of	-	346	O
spironolactone	-	349	B
were	-	364	O
reported	-	369	O
,	-	377	O
the	-	379	O
prevalence	-	383	O
of	-	394	O
these	-	397	O
complications	-	403	O
may	-	417	O
differ	-	421	O
in	-	428	O
current	-	431	O
clinical	-	439	O
practice	-	448	O
.	-	456	O

We	15632880	458	O
therefore	-	461	O
sought	-	471	O
to	-	478	O
determine	-	481	O
the	-	491	O
prevalence	-	495	O
and	-	506	O
clinical	-	510	O
associations	-	519	O
of	-	532	O
hyperkalemia	-	535	O
and	-	548	O
renal	-	552	O
insufficiency	-	558	O
in	-	572	O
heart	-	575	O
failure	-	581	O
patients	-	589	O
treated	-	598	O
with	-	606	O
spironolactone	-	611	B
.	-	625	O

METHODS	15632880	627	O
:	-	634	O

We	15632880	636	O
performed	-	639	O
a	-	649	O
case	-	651	O
control	-	656	O
study	-	664	O
of	-	670	O
heart	-	673	O
failure	-	679	O
patients	-	687	O
treated	-	696	O
with	-	704	O
spironolactone	-	709	B
in	-	724	O
our	-	727	O
clinical	-	731	O
practice	-	740	O
.	-	748	O

Cases	15632880	750	O
were	-	756	O
patients	-	761	O
who	-	770	O
developed	-	774	O
hyperkalemia	-	784	O
(	-	797	O
K	-	798	B
(	-	799	O
+	-	800	O
)	-	801	O
>	-	803	O
5	-	804	O
.	-	805	O
0	-	806	O
mEq	-	808	O
/	-	811	O
L	-	812	O
)	-	813	O
or	-	815	O
renal	-	818	O
insufficiency	-	824	O
(	-	838	O
Cr	-	839	B
>	-	842	O
or	-	843	O
=	-	845	O
2	-	846	O
.	-	847	O
5	-	848	O
mg	-	850	O
/	-	852	O
dL	-	853	O
)	-	855	O
,	-	856	O
and	-	858	O
they	-	862	O
were	-	867	O
compared	-	872	O
to	-	881	O
2	-	884	O
randomly	-	886	O
selected	-	895	O
controls	-	904	O
per	-	913	O
case	-	917	O
.	-	921	O

Clinical	15632880	923	O
characteristics	-	932	O
,	-	947	O
medications	-	949	O
,	-	960	O
and	-	962	O
serum	-	966	O
chemistries	-	972	O
at	-	984	O
baseline	-	987	O
and	-	996	O
follow	-	1000	O
-	-	1006	O
up	-	1007	O
time	-	1010	O
periods	-	1015	O
were	-	1023	O
compared	-	1028	O
.	-	1036	O

RESULTS	15632880	1038	O
:	-	1045	O

Sixty	15632880	1047	O
-	-	1052	O
seven	-	1053	O
of	-	1059	O
926	-	1062	O
patients	-	1066	O
(	-	1075	O
7	-	1076	O
.	-	1077	O
2	-	1078	O
%	-	1079	O
)	-	1080	O
required	-	1082	O
discontinuation	-	1091	O
of	-	1107	O
spironolactone	-	1110	B
due	-	1125	O
to	-	1129	O
hyperkalemia	-	1132	O
(	-	1145	O
n	-	1146	O
=	-	1148	O
33	-	1150	O
)	-	1152	O
or	-	1154	O
renal	-	1157	O
failure	-	1163	O
(	-	1171	O
n	-	1172	O
=	-	1174	O
34	-	1176	O
)	-	1178	O
.	-	1179	O

Patients	15632880	1181	O
who	-	1190	O
developed	-	1194	O
hyperkalemia	-	1204	O
were	-	1217	O
older	-	1222	O
and	-	1228	O
more	-	1232	O
likely	-	1237	O
to	-	1244	O
have	-	1247	O
diabetes	-	1252	O
,	-	1260	O
had	-	1262	O
higher	-	1266	O
baseline	-	1273	O
serum	-	1282	O
potassium	-	1288	B
levels	-	1298	O
and	-	1305	O
lower	-	1309	O
baseline	-	1315	O
potassium	-	1324	B
supplement	-	1334	O
doses	-	1345	O
,	-	1350	O
and	-	1352	O
were	-	1356	O
more	-	1361	O
likely	-	1366	O
to	-	1373	O
be	-	1376	O
treated	-	1379	O
with	-	1387	O
beta	-	1392	O
-	-	1396	O
blockers	-	1397	O
than	-	1406	O
controls	-	1411	O
(	-	1420	O
n	-	1421	O
=	-	1423	O
134	-	1425	O
)	-	1428	O
.	-	1429	O

Patients	15632880	1431	O
who	-	1440	O
developed	-	1444	O
renal	-	1454	O
insufficiency	-	1460	O
had	-	1474	O
lower	-	1478	O
baseline	-	1484	O
body	-	1493	O
weight	-	1498	O
and	-	1505	O
higher	-	1509	O
baseline	-	1516	O
serum	-	1525	O
creatinine	-	1531	B
,	-	1541	O
required	-	1543	O
higher	-	1552	O
doses	-	1559	O
of	-	1565	O
loop	-	1568	O
diuretics	-	1573	O
,	-	1582	O
and	-	1584	O
were	-	1588	O
more	-	1593	O
likely	-	1598	O
to	-	1605	O
be	-	1608	O
treated	-	1611	O
with	-	1619	O
thiazide	-	1624	B
diuretics	-	1633	O
than	-	1643	O
controls	-	1648	O
.	-	1656	O

CONCLUSIONS	15632880	1658	O
:	-	1669	O

Spironolactone	15632880	1671	B
-	-	1685	O
induced	-	1686	O
hyperkalemia	-	1694	O
and	-	1707	O
renal	-	1711	O
insufficiency	-	1717	O
are	-	1731	O
more	-	1735	O
common	-	1740	O
in	-	1747	O
our	-	1750	O
clinical	-	1754	O
experience	-	1763	O
than	-	1774	O
reported	-	1779	O
previously	-	1788	O
.	-	1798	O

This	15632880	1800	O
difference	-	1805	O
is	-	1816	O
explained	-	1819	O
by	-	1829	O
patient	-	1832	O
comorbidities	-	1840	O
and	-	1854	O
more	-	1858	O
frequent	-	1863	O
use	-	1872	O
of	-	1876	O
beta	-	1879	O
-	-	1883	O
blockers	-	1884	O
.	-	1892	O

End	11773892	0	O
-	-	3	O
stage	-	4	O
renal	-	10	O
disease	-	16	O
(	-	24	O
ESRD	-	25	O
)	-	29	O
after	-	31	O
orthotopic	-	37	O
liver	-	48	O
transplantation	-	54	O
(	-	70	O
OLTX	-	71	O
)	-	75	O
using	-	77	O
calcineurin	-	83	O
-	-	94	O
based	-	95	O
immunotherapy	-	101	O
:	-	114	O
risk	-	116	O
of	-	121	O
development	-	124	O
and	-	136	O
treatment	-	140	O
.	-	149	O

BACKGROUND	11773892	151	O
:	-	161	O

The	11773892	163	O
calcineurin	-	167	O
inhibitors	-	179	O
cyclosporine	-	190	B
and	-	203	O
tacrolimus	-	207	B
are	-	218	O
both	-	222	O
known	-	227	O
to	-	233	O
be	-	236	O
nephrotoxic	-	239	O
.	-	250	O

Their	11773892	252	O
use	-	258	O
in	-	262	O
orthotopic	-	265	O
liver	-	276	O
transplantation	-	282	O
(	-	298	O
OLTX	-	299	O
)	-	303	O
has	-	305	O
dramatically	-	309	O
improved	-	322	O
success	-	331	O
rates	-	339	O
.	-	344	O

Recently	11773892	346	O
,	-	354	O
however	-	356	O
,	-	363	O
we	-	365	O
have	-	368	O
had	-	373	O
an	-	377	O
increase	-	380	O
of	-	389	O
patients	-	392	O
who	-	401	O
are	-	405	O
presenting	-	409	O
after	-	420	O
OLTX	-	426	O
with	-	431	O
end	-	436	O
-	-	439	O
stage	-	440	O
renal	-	446	O
disease	-	452	O
(	-	460	O
ESRD	-	461	O
)	-	465	O
.	-	466	O

This	11773892	468	O
retrospective	-	473	O
study	-	487	O
examines	-	493	O
the	-	502	O
incidence	-	506	O
and	-	516	O
treatment	-	520	O
of	-	530	O
ESRD	-	533	O
and	-	538	O
chronic	-	542	O
renal	-	550	O
failure	-	556	O
(	-	564	O
CRF	-	565	O
)	-	568	O
in	-	570	O
OLTX	-	573	O
patients	-	578	O
.	-	586	O

METHODS	11773892	588	O
:	-	595	O

Patients	11773892	597	O
receiving	-	606	O
an	-	616	O
OLTX	-	619	O
only	-	624	O
from	-	629	O
June	-	634	O
1985	-	639	O
through	-	644	O
December	-	652	O
of	-	661	O
1994	-	664	O
who	-	669	O
survived	-	673	O
6	-	682	O
months	-	684	O
postoperatively	-	691	O
were	-	707	O
studied	-	712	O
(	-	720	O
n	-	721	O
=	-	722	O
834	-	723	O
)	-	726	O
.	-	727	O

Our	11773892	729	O
prospectively	-	733	O
collected	-	747	O
database	-	757	O
was	-	766	O
the	-	770	O
source	-	774	O
of	-	781	O
information	-	784	O
.	-	795	O

Patients	11773892	797	O
were	-	806	O
divided	-	811	O
into	-	819	O
three	-	824	O
groups	-	830	O
:	-	836	O
Controls	-	838	O
,	-	846	O
no	-	848	O
CRF	-	851	O
or	-	855	O
ESRD	-	858	O
,	-	862	O
n	-	864	O
=	-	865	O
748	-	866	O
;	-	869	O
CRF	-	871	O
,	-	874	O
sustained	-	876	O
serum	-	886	O
creatinine	-	892	B
>	-	903	O
2	-	904	O
.	-	905	O
5	-	906	O
mg	-	908	O
/	-	910	O
dl	-	911	O
,	-	913	O
n	-	915	O
=	-	916	O
41	-	917	O
;	-	919	O
and	-	921	O
ESRD	-	925	O
,	-	929	O
n	-	931	O
=	-	932	O
45	-	933	O
.	-	935	O

Groups	11773892	937	O
were	-	944	O
compared	-	949	O
for	-	958	O
preoperative	-	962	O
laboratory	-	975	O
variables	-	986	O
,	-	995	O
diagnosis	-	997	O
,	-	1006	O
postoperative	-	1008	O
variables	-	1022	O
,	-	1031	O
survival	-	1033	O
,	-	1041	O
type	-	1043	O
of	-	1048	O
ESRD	-	1051	O
therapy	-	1056	O
,	-	1063	O
and	-	1065	O
survival	-	1069	O
from	-	1078	O
onset	-	1083	O
of	-	1089	O
ESRD	-	1092	O
.	-	1096	O

RESULTS	11773892	1098	O
:	-	1105	O

At	11773892	1107	O
13	-	1110	O
years	-	1113	O
after	-	1119	O
OLTX	-	1125	O
,	-	1129	O
the	-	1131	O
incidence	-	1135	O
of	-	1145	O
severe	-	1148	O
renal	-	1155	O
dysfunction	-	1161	O
was	-	1173	O
18	-	1177	O
.	-	1179	O
1	-	1180	O
%	-	1181	O
(	-	1183	O
CRF	-	1184	O
8	-	1188	O
.	-	1189	O
6	-	1190	O
%	-	1191	O
and	-	1193	O
ESRD	-	1197	O
9	-	1202	O
.	-	1203	O
5	-	1204	O
%	-	1205	O
)	-	1206	O
.	-	1207	O

Compared	11773892	1209	O
with	-	1218	O
control	-	1223	O
patients	-	1231	O
,	-	1239	O
CRF	-	1241	O
and	-	1245	O
ESRD	-	1249	O
patients	-	1254	O
had	-	1263	O
higher	-	1267	O
preoperative	-	1274	O
serum	-	1287	O
creatinine	-	1293	B
levels	-	1304	O
,	-	1310	O
a	-	1312	O
greater	-	1314	O
percentage	-	1322	O
of	-	1333	O
patients	-	1336	O
with	-	1345	O
hepatorenal	-	1350	O
syndrome	-	1362	O
,	-	1370	O
higher	-	1372	O
percentage	-	1379	O
requirement	-	1390	O
for	-	1402	O
dialysis	-	1406	O
in	-	1415	O
the	-	1418	O
first	-	1422	O
3	-	1428	O
months	-	1430	O
postoperatively	-	1437	O
,	-	1452	O
and	-	1454	O
a	-	1458	O
higher	-	1460	O
1	-	1467	O
-	-	1468	O
year	-	1469	O
serum	-	1474	O
creatinine	-	1480	B
.	-	1490	O

Multivariate	11773892	1492	O
stepwise	-	1505	O
logistic	-	1514	O
regression	-	1523	O
analysis	-	1534	O
using	-	1543	O
preoperative	-	1549	O
and	-	1562	O
postoperative	-	1566	O
variables	-	1580	O
identified	-	1590	O
that	-	1601	O
an	-	1606	O
increase	-	1609	O
of	-	1618	O
serum	-	1621	O
creatinine	-	1627	B
compared	-	1638	O
with	-	1647	O
average	-	1652	O
at	-	1660	O
1	-	1663	O
year	-	1665	O
,	-	1669	O
3	-	1671	O
months	-	1673	O
,	-	1679	O
and	-	1681	O
4	-	1685	O
weeks	-	1687	O
postoperatively	-	1693	O
were	-	1709	O
independent	-	1714	O
risk	-	1726	O
factors	-	1731	O
for	-	1739	O
the	-	1743	O
development	-	1747	O
of	-	1759	O
CRF	-	1762	O
or	-	1766	O
ESRD	-	1769	O
with	-	1774	O
odds	-	1779	O
ratios	-	1784	O
of	-	1791	O
2	-	1794	O
.	-	1795	O
6	-	1796	O
,	-	1797	O
2	-	1799	O
.	-	1800	O
2	-	1801	O
,	-	1802	O
and	-	1804	O
1	-	1808	O
.	-	1809	O
6	-	1810	O
,	-	1811	O
respectively	-	1813	O
.	-	1825	O

Overall	11773892	1827	O
survival	-	1835	O
from	-	1844	O
the	-	1849	O
time	-	1853	O
of	-	1858	O
OLTX	-	1861	O
was	-	1866	O
not	-	1870	O
significantly	-	1874	O
different	-	1888	O
among	-	1898	O
groups	-	1904	O
,	-	1910	O
but	-	1912	O
by	-	1916	O
year	-	1919	O
13	-	1924	O
,	-	1926	O
the	-	1928	O
survival	-	1932	O
of	-	1941	O
the	-	1944	O
patients	-	1948	O
who	-	1957	O
had	-	1961	O
ESRD	-	1965	O
was	-	1970	O
only	-	1974	O
28	-	1979	O
.	-	1981	O
2	-	1982	O
%	-	1983	O
compared	-	1985	O
with	-	1994	O
54	-	1999	O
.	-	2001	O
6	-	2002	O
%	-	2003	O
in	-	2005	O
the	-	2008	O
control	-	2012	O
group	-	2020	O
.	-	2025	O

Patients	11773892	2027	O
developing	-	2036	O
ESRD	-	2047	O
had	-	2052	O
a	-	2056	O
6	-	2058	O
-	-	2059	O
year	-	2060	O
survival	-	2065	O
after	-	2074	O
onset	-	2080	O
of	-	2086	O
ESRD	-	2089	O
of	-	2094	O
27	-	2097	O
%	-	2099	O
for	-	2101	O
the	-	2105	O
patients	-	2109	O
receiving	-	2118	O
hemodialysis	-	2128	O
versus	-	2141	O
71	-	2148	O
.	-	2150	O
4	-	2151	O
%	-	2152	O
for	-	2154	O
the	-	2158	O
patients	-	2162	O
developing	-	2171	O
ESRD	-	2182	O
who	-	2187	O
subsequently	-	2191	O
received	-	2204	O
kidney	-	2213	O
transplants	-	2220	O
.	-	2231	O

CONCLUSIONS	11773892	2233	O
:	-	2244	O

Patients	11773892	2246	O
who	-	2255	O
are	-	2259	O
more	-	2263	O
than	-	2268	O
10	-	2273	O
years	-	2276	O
post	-	2282	O
-	-	2286	O
OLTX	-	2287	O
have	-	2292	O
CRF	-	2297	O
and	-	2301	O
ESRD	-	2305	O
at	-	2310	O
a	-	2313	O
high	-	2315	O
rate	-	2320	O
.	-	2324	O

The	11773892	2326	O
development	-	2330	O
of	-	2342	O
ESRD	-	2345	O
decreases	-	2350	O
survival	-	2360	O
,	-	2368	O
particularly	-	2370	O
in	-	2383	O
those	-	2386	O
patients	-	2392	O
treated	-	2401	O
with	-	2409	O
dialysis	-	2414	O
only	-	2423	O
.	-	2427	O

Patients	11773892	2429	O
who	-	2438	O
develop	-	2442	O
ESRD	-	2450	O
have	-	2455	O
a	-	2460	O
higher	-	2462	O
preoperative	-	2469	O
and	-	2482	O
1	-	2486	O
-	-	2487	O
year	-	2488	O
serum	-	2493	O
creatinine	-	2499	B
and	-	2510	O
are	-	2514	O
more	-	2518	O
likely	-	2523	O
to	-	2530	O
have	-	2533	O
hepatorenal	-	2538	O
syndrome	-	2550	O
.	-	2558	O

However	11773892	2560	O
,	-	2567	O
an	-	2569	O
increase	-	2572	O
of	-	2581	O
serum	-	2584	O
creatinine	-	2590	B
at	-	2601	O
various	-	2604	O
times	-	2612	O
postoperatively	-	2618	O
is	-	2634	O
more	-	2637	O
predictive	-	2642	O
of	-	2653	O
the	-	2656	O
development	-	2660	O
of	-	2672	O
CRF	-	2675	O
or	-	2679	O
ESRD	-	2682	O
.	-	2686	O

New	11773892	2688	O
strategies	-	2692	O
for	-	2703	O
long	-	2707	O
-	-	2711	O
term	-	2712	O
immunosuppression	-	2717	O
may	-	2735	O
be	-	2739	O
needed	-	2742	O
to	-	2749	O
decrease	-	2752	O
this	-	2761	O
complication	-	2766	O
.	-	2778	O

Effect	10835440	0	O
of	-	7	O
intravenous	-	10	O
nimodipine	-	22	B
on	-	33	O
blood	-	36	O
pressure	-	42	O
and	-	51	O
outcome	-	55	O
after	-	63	O
acute	-	69	O
stroke	-	75	O
.	-	81	O

BACKGROUND	10835440	83	O
AND	-	94	O
PURPOSE	-	98	O
:	-	105	O

The	10835440	107	O
Intravenous	-	111	O
Nimodipine	-	123	B
West	-	134	O
European	-	139	O
Stroke	-	148	O
Trial	-	155	O
(	-	161	O
INWEST	-	162	O
)	-	168	O
found	-	170	O
a	-	176	O
correlation	-	178	O
between	-	190	O
nimodipine	-	198	B
-	-	208	O
induced	-	209	O
reduction	-	217	O
in	-	227	O
blood	-	230	O
pressure	-	236	O
(	-	245	O
BP	-	246	O
)	-	248	O
and	-	250	O
an	-	254	O
unfavorable	-	257	O
outcome	-	269	O
in	-	277	O
acute	-	280	O
stroke	-	286	O
.	-	292	O

We	10835440	294	O
sought	-	297	O
to	-	304	O
confirm	-	307	O
this	-	315	O
correlation	-	320	O
with	-	332	O
and	-	337	O
without	-	341	O
adjustment	-	349	O
for	-	360	O
prognostic	-	364	O
variables	-	375	O
and	-	385	O
to	-	389	O
investigate	-	392	O
outcome	-	404	O
in	-	412	O
subgroups	-	415	O
with	-	425	O
increasing	-	430	O
levels	-	441	O
of	-	448	O
BP	-	451	O
reduction	-	454	O
.	-	463	O

METHODS	10835440	465	O
:	-	472	O

Patients	10835440	474	O
with	-	483	O
a	-	488	O
clinical	-	490	O
diagnosis	-	499	O
of	-	509	O
ischemic	-	512	O
stroke	-	521	O
(	-	528	O
within	-	529	O
24	-	536	O
hours	-	539	O
)	-	544	O
were	-	546	O
consecutively	-	551	O
allocated	-	565	O
to	-	575	O
receive	-	578	O
placebo	-	586	O
(	-	594	O
n	-	595	O
=	-	596	O
100	-	597	O
)	-	600	O
,	-	601	O
1	-	603	O
mg	-	605	O
/	-	607	O
h	-	608	O
(	-	610	O
low	-	611	O
-	-	614	O
dose	-	615	O
)	-	619	O
nimodipine	-	621	B
(	-	632	O
n	-	633	O
=	-	634	O
101	-	635	O
)	-	638	O
,	-	639	O
or	-	641	O
2	-	644	O
mg	-	646	O
/	-	648	O
h	-	649	O
(	-	651	O
high	-	652	O
-	-	656	O
dose	-	657	O
)	-	661	O
nimodipine	-	663	B
(	-	674	O
n	-	675	O
=	-	676	O
94	-	677	O
)	-	679	O
.	-	680	O

The	10835440	682	O
correlation	-	686	O
between	-	698	O
average	-	706	O
BP	-	714	O
change	-	717	O
during	-	724	O
the	-	731	O
first	-	735	O
2	-	741	O
days	-	743	O
and	-	748	O
the	-	752	O
outcome	-	756	O
at	-	764	O
day	-	767	O
21	-	771	O
was	-	774	O
analyzed	-	778	O
.	-	786	O

RESULTS	10835440	788	O
:	-	795	O

Two	10835440	797	O
hundred	-	801	O
sixty	-	809	O
-	-	814	O
five	-	815	O
patients	-	820	O
were	-	829	O
included	-	834	O
in	-	843	O
this	-	846	O
analysis	-	851	O
(	-	860	O
n	-	861	O
=	-	862	O
92	-	863	O
,	-	865	O
93	-	867	O
,	-	869	O
and	-	871	O
80	-	875	O
for	-	878	O
placebo	-	882	O
,	-	889	O
low	-	891	O
dose	-	895	O
,	-	899	O
and	-	901	O
high	-	905	O
dose	-	910	O
,	-	914	O
respectively	-	916	O
)	-	928	O
.	-	929	O

Nimodipine	10835440	931	B
treatment	-	942	O
resulted	-	952	O
in	-	961	O
a	-	964	O
statistically	-	966	O
significant	-	980	O
reduction	-	992	O
in	-	1002	O
systolic	-	1005	O
BP	-	1014	O
(	-	1017	O
SBP	-	1018	O
)	-	1021	O
and	-	1023	O
diastolic	-	1027	O
BP	-	1037	O
(	-	1040	O
DBP	-	1041	O
)	-	1044	O
from	-	1046	O
baseline	-	1051	O
compared	-	1060	O
with	-	1069	O
placebo	-	1074	O
during	-	1082	O
the	-	1089	O
first	-	1093	O
few	-	1099	O
days	-	1103	O
.	-	1107	O

In	10835440	1109	O
multivariate	-	1112	O
analysis	-	1125	O
,	-	1133	O
a	-	1135	O
significant	-	1137	O
correlation	-	1149	O
between	-	1161	O
DBP	-	1169	O
reduction	-	1173	O
and	-	1183	O
worsening	-	1187	O
of	-	1197	O
the	-	1200	O
neurological	-	1204	O
score	-	1217	O
was	-	1223	O
found	-	1227	O
for	-	1233	O
the	-	1237	O
high	-	1241	O
-	-	1245	O
dose	-	1246	O
group	-	1251	O
(	-	1257	O
beta	-	1258	O
=	-	1262	O
0	-	1263	O
.	-	1264	O
49	-	1265	O
,	-	1267	O
P	-	1269	O
=	-	1270	O
0	-	1271	O
.	-	1272	O
048	-	1274	O
)	-	1277	O
.	-	1278	O

Patients	10835440	1280	O
with	-	1289	O
a	-	1294	O
DBP	-	1296	O
reduction	-	1300	O
of	-	1310	O
>	-	1313	O
or	-	1315	O
=	-	1318	O
20	-	1319	O
%	-	1321	O
in	-	1323	O
the	-	1326	O
high	-	1330	O
-	-	1334	O
dose	-	1335	O
group	-	1340	O
had	-	1346	O
a	-	1350	O
significantly	-	1352	O
increased	-	1366	O
adjusted	-	1376	O
OR	-	1385	O
for	-	1388	O
the	-	1392	O
compound	-	1396	O
outcome	-	1405	O
variable	-	1413	O
death	-	1422	O
or	-	1428	O
dependency	-	1431	O
(	-	1442	O
Barthel	-	1443	O
Index	-	1451	O
<	-	1457	O
60	-	1458	O
)	-	1460	O
(	-	1462	O
n	-	1463	O
/	-	1464	O
N	-	1465	O
=	-	1466	O
25	-	1467	O
/	-	1469	O
26	-	1470	O
,	-	1472	O
OR	-	1474	O
10	-	1477	O
.	-	1479	O
16	-	1481	O
,	-	1483	O
95	-	1485	O
%	-	1487	O
CI	-	1489	O
1	-	1492	O
.	-	1493	O
02	-	1494	O
to	-	1497	O
101	-	1500	O
.	-	1503	O
74	-	1504	O
)	-	1506	O
and	-	1508	O
death	-	1512	O
alone	-	1518	O
(	-	1524	O
n	-	1525	O
/	-	1526	O
N	-	1527	O
=	-	1528	O
9	-	1529	O
/	-	1530	O
26	-	1531	O
,	-	1533	O
OR	-	1535	O
4	-	1538	O
.	-	1539	O
336	-	1540	O
,	-	1543	O
95	-	1545	O
%	-	1547	O
CI	-	1549	O
1	-	1552	O
.	-	1553	O
131	-	1554	O
16	-	1558	O
.	-	1560	O
619	-	1561	O
)	-	1564	O
compared	-	1566	O
with	-	1575	O
all	-	1580	O
placebo	-	1584	O
patients	-	1592	O
(	-	1601	O
n	-	1602	O
/	-	1603	O
N	-	1604	O
=	-	1605	O
62	-	1606	O
/	-	1608	O
92	-	1609	O
and	-	1612	O
14	-	1616	O
/	-	1618	O
92	-	1619	O
,	-	1621	O
respectively	-	1623	O
)	-	1635	O
.	-	1636	O

There	10835440	1638	O
was	-	1644	O
no	-	1648	O
correlation	-	1651	O
between	-	1663	O
SBP	-	1671	O
change	-	1675	O
and	-	1682	O
outcome	-	1686	O
.	-	1693	O

CONCLUSIONS	10835440	1695	O
:	-	1706	O
DBP	-	1708	O
,	-	1711	O
but	-	1713	O
not	-	1717	O
SBP	-	1721	O
,	-	1724	O

reduction	10835440	1726	O
was	-	1736	O
associated	-	1740	O
with	-	1751	O
neurological	-	1756	O
worsening	-	1769	O
after	-	1779	O
the	-	1785	O
intravenous	-	1789	O
administration	-	1801	O
of	-	1816	O
high	-	1819	O
-	-	1823	O
dose	-	1824	O
nimodipine	-	1829	B
after	-	1840	O
acute	-	1846	O
stroke	-	1852	O
.	-	1858	O

For	10835440	1860	O
low	-	1864	O
-	-	1867	O
dose	-	1868	O
nimodipine	-	1873	B
,	-	1883	O
the	-	1885	O
results	-	1889	O
were	-	1897	O
not	-	1902	O
conclusive	-	1906	O
.	-	1916	O

These	10835440	1918	O
results	-	1924	O
do	-	1932	O
not	-	1935	O
confirm	-	1939	O
or	-	1947	O
exclude	-	1950	O
a	-	1958	O
neuroprotective	-	1960	O
property	-	1976	O
of	-	1985	O
nimodipine	-	1988	B
.	-	1998	O

Transient	9523805	0	O
neurologic	-	10	O
symptoms	-	21	O
after	-	30	O
spinal	-	36	O
anesthesia	-	43	O
:	-	53	O
a	-	55	O
lower	-	57	O
incidence	-	63	O
with	-	73	O
prilocaine	-	78	B
and	-	89	O
bupivacaine	-	93	B
than	-	105	O
with	-	110	O
lidocaine	-	115	B
.	-	124	O

BACKGROUND	9523805	126	O
:	-	136	O

Recent	9523805	138	O
evidence	-	145	O
suggests	-	154	O
that	-	163	O
transient	-	168	O
neurologic	-	178	O
symptoms	-	189	O
(	-	198	O
TNSs	-	199	O
)	-	203	O
frequently	-	205	O
follow	-	216	O
lidocaine	-	223	B
spinal	-	233	O
anesthesia	-	240	O
but	-	251	O
are	-	255	O
infrequent	-	259	O
with	-	270	O
bupivacaine	-	275	B
.	-	286	O

However	9523805	288	O
,	-	295	O
identification	-	297	O
of	-	312	O
a	-	315	O
short	-	317	O
-	-	322	O
acting	-	323	O
local	-	330	O
anesthetic	-	336	O
to	-	347	O
substitute	-	350	O
for	-	361	O
lidocaine	-	365	B
for	-	375	O
brief	-	379	O
surgical	-	385	O
procedures	-	394	O
remains	-	405	O
an	-	413	O
important	-	416	O
goal	-	426	O
.	-	430	O

Prilocaine	9523805	432	B
is	-	443	O
an	-	446	O
amide	-	449	O
local	-	455	O
anesthetic	-	461	O
with	-	472	O
a	-	477	O
duration	-	479	O
of	-	488	O
action	-	491	O
similar	-	498	O
to	-	506	O
that	-	509	O
of	-	514	O
lidocaine	-	517	B
.	-	526	O

Accordingly	9523805	528	O
,	-	539	O
the	-	541	O
present	-	545	O
,	-	552	O
prospective	-	554	O
double	-	566	O
-	-	572	O
blind	-	573	O
study	-	579	O
compares	-	585	O
prilocaine	-	594	B
with	-	605	O
lidocaine	-	610	B
and	-	620	O
bupivacaine	-	624	B
with	-	636	O
respect	-	641	O
to	-	649	O
duration	-	652	O
of	-	661	O
action	-	664	O
and	-	671	O
relative	-	675	O
risk	-	684	O
of	-	689	O
TNSs	-	692	O
.	-	696	O

METHODS	9523805	698	O
:	-	705	O

Ninety	9523805	707	O
patients	-	714	O
classified	-	723	O
as	-	734	O
American	-	737	O
Society	-	746	O
of	-	754	O
Anesthesiologists	-	757	O
physical	-	775	O
status	-	784	O

I	9523805	791	O
or	-	793	O
II	-	796	O
who	-	799	O
were	-	803	O
scheduled	-	808	O
for	-	818	O
short	-	822	O
gynecologic	-	828	O
procedures	-	840	O
under	-	851	O
spinal	-	857	O
anesthesia	-	864	O
were	-	875	O
randomly	-	880	O
allocated	-	889	O
to	-	899	O
receive	-	902	O
2	-	910	O
.	-	911	O
5	-	912	O
ml	-	914	O
2	-	917	O
%	-	918	O
lidocaine	-	920	B
in	-	930	O
7	-	933	O
.	-	934	O
5	-	935	O
%	-	936	O
glucose	-	938	B
,	-	945	O
2	-	947	O
%	-	948	O
prilocaine	-	950	B
in	-	961	O
7	-	964	O
.	-	965	O
5	-	966	O
%	-	967	O
glucose	-	969	B
,	-	976	O
or	-	978	O
0	-	981	O
.	-	982	O
5	-	983	O
%	-	984	O
bupivacaine	-	986	B
in	-	998	O
7	-	1001	O
.	-	1002	O
5	-	1003	O
%	-	1004	O
glucose	-	1006	B
.	-	1013	O

All	9523805	1015	O
solutions	-	1019	O
were	-	1029	O
provided	-	1034	O
in	-	1043	O
blinded	-	1046	O
vials	-	1054	O
by	-	1060	O
the	-	1063	O
hospital	-	1067	O
pharmacy	-	1076	O
.	-	1084	O

Details	9523805	1086	O
of	-	1094	O
spinal	-	1097	O
puncture	-	1104	O
,	-	1112	O
extension	-	1114	O
and	-	1124	O
regression	-	1128	O
of	-	1139	O
spinal	-	1142	O
block	-	1149	O
,	-	1154	O
and	-	1156	O
the	-	1160	O
times	-	1164	O
to	-	1170	O
reach	-	1173	O
discharge	-	1179	O
criteria	-	1189	O
were	-	1198	O
noted	-	1203	O
.	-	1208	O

In	9523805	1210	O
the	-	1213	O
evening	-	1217	O
of	-	1225	O
postoperative	-	1228	O
day	-	1242	O
1	-	1246	O
,	-	1247	O
patients	-	1249	O
were	-	1258	O
evaluated	-	1263	O
for	-	1273	O
TNSs	-	1277	O
by	-	1282	O
a	-	1285	O
physician	-	1287	O
unaware	-	1297	O
of	-	1305	O
the	-	1308	O
drug	-	1312	O
administered	-	1317	O
and	-	1330	O
the	-	1334	O
details	-	1338	O
of	-	1346	O
the	-	1349	O
anesthetic	-	1353	O
procedure	-	1364	O
.	-	1373	O

RESULTS	9523805	1375	O
:	-	1382	O

Nine	9523805	1384	O
of	-	1389	O
30	-	1392	O
patients	-	1395	O
receiving	-	1404	O
lidocaine	-	1414	B
experienced	-	1424	O
TNSs	-	1436	O
,	-	1440	O
1	-	1442	O
of	-	1444	O
30	-	1447	O
patients	-	1450	O
receiving	-	1459	O
prilocaine	-	1469	B
(	-	1480	O
P	-	1481	O
=	-	1483	O
0	-	1485	O
.	-	1486	O
03	-	1487	O
)	-	1489	O
had	-	1491	O
them	-	1495	O
,	-	1499	O
and	-	1501	O
none	-	1505	O
of	-	1510	O
30	-	1513	O
patients	-	1516	O
receiving	-	1525	O
bupivacaine	-	1535	B
had	-	1547	O
TNSs	-	1551	O
.	-	1555	O

Times	9523805	1557	O
to	-	1563	O
ambulate	-	1566	O
and	-	1575	O
to	-	1579	O
void	-	1582	O
were	-	1587	O
similar	-	1592	O
after	-	1600	O
lidocaine	-	1606	B
and	-	1616	O
prilocaine	-	1620	B
(	-	1631	O
150	-	1632	O
vs	-	1636	O
.	-	1638	O
165	-	1640	O
min	-	1644	O
and	-	1648	O
238	-	1652	O
vs	-	1656	O
.	-	1658	O
253	-	1660	O
min	-	1664	O
,	-	1667	O
respectively	-	1669	O
)	-	1681	O
but	-	1683	O
prolonged	-	1687	O
after	-	1697	O
bupivacaine	-	1703	B
(	-	1715	O
200	-	1716	O
and	-	1720	O
299	-	1724	O
min	-	1728	O
,	-	1731	O
respectively	-	1733	O
;	-	1745	O
P	-	1747	O
<	-	1749	O
0	-	1751	O
.	-	1752	O
05	-	1753	O
)	-	1755	O
.	-	1756	O

CONCLUSIONS	9523805	1758	O
:	-	1769	O

Prilocaine	9523805	1771	B
may	-	1782	O
be	-	1786	O
preferable	-	1789	O
to	-	1800	O
lidocaine	-	1803	B
for	-	1813	O
short	-	1817	O
surgical	-	1823	O
procedures	-	1832	O
because	-	1843	O
it	-	1851	O
has	-	1854	O
a	-	1858	O
similar	-	1860	O
duration	-	1868	O
of	-	1877	O
action	-	1880	O
but	-	1887	O
a	-	1891	O
lower	-	1893	O
incidence	-	1899	O
of	-	1909	O
TNSs	-	1912	O
.	-	1916	O

The	9245658	0	O
role	-	4	O
of	-	9	O
nicotine	-	12	B
in	-	21	O
smoking	-	24	O
-	-	31	O
related	-	32	O
cardiovascular	-	40	O
disease	-	55	O
.	-	62	O

Nicotine	9245658	64	B
activates	-	73	O
the	-	83	O
sympathetic	-	87	O
nervous	-	99	O
system	-	107	O
and	-	114	O
in	-	118	O
this	-	121	O
way	-	126	O
could	-	130	O
contribute	-	136	O
to	-	147	O
cardiovascular	-	150	O
disease	-	165	O
.	-	172	O

Animal	9245658	174	O
studies	-	181	O
and	-	189	O
mechanistic	-	193	O
studies	-	205	O
indicate	-	213	O
that	-	222	O
nicotine	-	227	B
could	-	236	O
play	-	242	O
a	-	247	O
role	-	249	O
in	-	254	O
accelerating	-	257	O
atherosclerosis	-	270	O
,	-	285	O
but	-	287	O
evidence	-	291	O
among	-	300	O
humans	-	306	O
is	-	313	O
too	-	316	O
inadequate	-	320	O
to	-	331	O
be	-	334	O
definitive	-	337	O
about	-	348	O
such	-	354	O
an	-	359	O
effect	-	362	O
.	-	368	O

Almost	9245658	370	O
certainly	-	377	O
,	-	386	O
nicotine	-	388	B
via	-	397	O
its	-	401	O
hemodynamic	-	405	O
effects	-	417	O
contributes	-	425	O
to	-	437	O
acute	-	440	O
cardiovascular	-	446	O
events	-	461	O
,	-	467	O
although	-	469	O
current	-	478	O
evidence	-	486	O
suggests	-	495	O
that	-	504	O
the	-	509	O
effects	-	513	O
of	-	521	O
nicotine	-	524	B
are	-	533	O
much	-	537	O
less	-	542	O
important	-	547	O
than	-	557	O
are	-	562	O
the	-	566	O
prothrombotic	-	570	O
effects	-	584	O
of	-	592	O
cigarette	-	595	O
smoking	-	605	O
or	-	613	O
the	-	616	O
effects	-	620	O
of	-	628	O
carbon	-	631	B
monoxide	-	638	I
.	-	646	O

Nicotine	9245658	648	B
does	-	657	O
not	-	662	O
appear	-	666	O
to	-	673	O
enhance	-	676	O
thrombosis	-	684	O
among	-	695	O
humans	-	701	O
.	-	707	O

Clinical	9245658	709	O
studies	-	718	O
of	-	726	O
pipe	-	729	O
smokers	-	734	O
and	-	742	O
people	-	746	O
using	-	753	O
transdermal	-	759	O
nicotine	-	771	B
support	-	780	O
the	-	788	O
idea	-	792	O
that	-	797	O
toxins	-	802	O
other	-	809	O
than	-	815	O
nicotine	-	820	B
are	-	829	O
the	-	833	O
most	-	837	O
important	-	842	O
causes	-	852	O
of	-	859	O
acute	-	862	O
cardiovascular	-	868	O
events	-	883	O
.	-	889	O

Finally	9245658	891	O
,	-	898	O
the	-	900	O
dose	-	904	O
response	-	909	O
for	-	918	O
cardiovascular	-	922	O
events	-	937	O
of	-	944	O
nicotine	-	947	B
appears	-	956	O
to	-	964	O
be	-	967	O
flat	-	970	O
,	-	974	O
suggesting	-	976	O
that	-	987	O
if	-	992	O
nicotine	-	995	B
is	-	1004	O
involved	-	1007	O
,	-	1015	O
adverse	-	1017	O
effects	-	1025	O
might	-	1033	O
be	-	1039	O
seen	-	1042	O
with	-	1047	O
relatively	-	1052	O
low	-	1063	O
-	-	1066	O
level	-	1067	O
cigarette	-	1073	O
exposures	-	1083	O
.	-	1092	O

Seizure	9034419	0	O
resulting	-	8	O
from	-	18	O
a	-	23	O
venlafaxine	-	25	B
overdose	-	37	O
.	-	45	O

OBJECTIVE	9034419	47	O
:	-	56	O

To	9034419	58	O
report	-	61	O
a	-	68	O
case	-	70	O
of	-	75	O
venlafaxine	-	78	B
overdose	-	90	O
.	-	98	O

CASE	9034419	100	O
SUMMARY	-	105	O
:	-	112	O

A	9034419	114	O
40	-	116	O
-	-	118	O
year	-	119	O
-	-	123	O
old	-	124	O
woman	-	128	O
with	-	134	O
major	-	139	O
depression	-	145	O
took	-	156	O
an	-	161	O
overdose	-	164	O
of	-	173	O
venlafaxine	-	176	B
in	-	188	O
an	-	191	O
apparent	-	194	O
suicide	-	203	O
attempt	-	211	O
.	-	218	O

After	9034419	220	O
the	-	226	O
ingestion	-	230	O
of	-	240	O
26	-	243	O
venlafaxine	-	246	B
50	-	258	O
-	-	260	O
mg	-	261	O
tablets	-	264	O
,	-	271	O
the	-	273	O
patient	-	277	O
experienced	-	285	O
a	-	297	O
witnessed	-	299	O
generalized	-	309	O
seizure	-	321	O
.	-	328	O

She	9034419	330	O
was	-	334	O
admitted	-	338	O
to	-	347	O
the	-	350	O
medical	-	354	O
intensive	-	362	O
care	-	372	O
unit	-	377	O
,	-	381	O
venlafaxine	-	383	B
was	-	395	O
discontinued	-	399	O
,	-	411	O
and	-	413	O
no	-	417	O
further	-	420	O
sequelae	-	428	O
were	-	437	O
seen	-	442	O
.	-	446	O

DISCUSSION	9034419	448	O
:	-	458	O

To	9034419	460	O
our	-	463	O
knowledge	-	467	O
,	-	476	O
this	-	478	O
is	-	483	O
the	-	486	O
first	-	490	O
reported	-	496	O
case	-	505	O
of	-	510	O
venlafaxine	-	513	B
overdose	-	525	O
that	-	534	O
resulted	-	539	O
in	-	548	O
a	-	551	O
generalized	-	553	O
seizure	-	565	O
.	-	572	O

Based	9034419	574	O
on	-	580	O
nonoverdose	-	583	O
pharmacokinetics	-	595	O
and	-	612	O
pharmacodynamics	-	616	O
of	-	633	O
venlafaxine	-	636	B
and	-	648	O
the	-	652	O
potential	-	656	O
risks	-	666	O
of	-	672	O
available	-	675	O
interventions	-	685	O
,	-	698	O
no	-	700	O
emergent	-	703	O
therapy	-	712	O
was	-	720	O
instituted	-	724	O
.	-	734	O

CONCLUSIONS	9034419	736	O
:	-	747	O

The	9034419	749	O
venlafaxine	-	753	B
overdose	-	765	O
in	-	774	O
our	-	777	O
patient	-	781	O
resulted	-	789	O
in	-	798	O
a	-	801	O
single	-	803	O
episode	-	810	O
of	-	818	O
generalized	-	821	O
seizure	-	833	O
but	-	841	O
elicited	-	845	O
no	-	854	O
further	-	857	O
sequelae	-	865	O
.	-	873	O

Effect	8829025	0	O
of	-	7	O
nifedipine	-	10	B
on	-	21	O
renal	-	24	O
function	-	30	O
in	-	39	O
liver	-	42	O
transplant	-	48	O
recipients	-	59	O
receiving	-	70	O
tacrolimus	-	80	B
.	-	90	O

The	8829025	92	O
effect	-	96	O
of	-	103	O
nifedipine	-	106	B
on	-	117	O
renal	-	120	O
function	-	126	O
in	-	135	O
liver	-	138	O
transplant	-	144	O
recipients	-	155	O
who	-	166	O
were	-	170	O
receiving	-	175	O
tacrolimus	-	185	B
was	-	196	O
evaluated	-	200	O
between	-	210	O
January	-	218	O
1992	-	226	O
and	-	231	O
January	-	235	O
1996	-	243	O
.	-	247	O

Two	8829025	249	O
groups	-	253	O
of	-	260	O
patients	-	263	O
receiving	-	272	O
tacrolimus	-	282	B
were	-	293	O
compared	-	298	O
over	-	307	O
a	-	312	O
period	-	314	O
of	-	321	O
1	-	324	O
year	-	326	O
,	-	330	O
one	-	332	O
group	-	336	O
comprising	-	342	O
hypertensive	-	353	O
patients	-	366	O
who	-	375	O
were	-	379	O
receiving	-	384	O
nifedipine	-	394	B
,	-	404	O
and	-	406	O
the	-	410	O
other	-	414	O
comprising	-	420	O
nonhypertensive	-	431	O
patients	-	447	O
not	-	456	O
receiving	-	460	O
nifedipine	-	470	B
.	-	480	O

The	8829025	482	O
time	-	486	O
from	-	491	O
transplant	-	496	O
to	-	507	O
baseline	-	510	O
was	-	519	O
similar	-	523	O
in	-	531	O
all	-	534	O
patients	-	538	O
.	-	546	O

Nifedipine	8829025	548	B
significantly	-	559	O
improved	-	573	O
kidney	-	582	O
function	-	589	O
as	-	598	O
indicated	-	601	O
by	-	611	O
a	-	614	O
significant	-	616	O
lowering	-	628	O
of	-	637	O
serum	-	640	O
creatinine	-	646	B
levels	-	657	O
at	-	664	O
6	-	667	O
and	-	669	O
12	-	673	O
months	-	676	O
.	-	682	O

The	8829025	684	O
observed	-	688	O
positive	-	697	O
impact	-	706	O
of	-	713	O
nifedipine	-	716	B
on	-	727	O
reducing	-	730	O
the	-	739	O
nephrotoxicity	-	743	O
associated	-	758	O
with	-	769	O
tacrolimus	-	774	B
in	-	785	O
liver	-	788	O
transplant	-	794	O
recipients	-	805	O
should	-	816	O
be	-	823	O
an	-	826	O
important	-	829	O
factor	-	839	O
in	-	846	O
selecting	-	849	O
an	-	859	O
agent	-	862	O
to	-	868	O
treat	-	871	O
hypertension	-	877	O
in	-	890	O
this	-	893	O
population	-	898	O
.	-	908	O

Sinus	8437969	0	O
arrest	-	6	O
associated	-	13	O
with	-	24	O
continuous	-	29	O
-	-	39	O
infusion	-	40	O
cimetidine	-	49	B
.	-	59	O

The	8437969	61	O
administration	-	65	O
of	-	80	O
intermittent	-	83	O
intravenous	-	96	O
infusions	-	108	O
of	-	118	O
cimetidine	-	121	B
is	-	132	O
infrequently	-	135	O
associated	-	148	O
with	-	159	O
the	-	164	O
development	-	168	O
of	-	180	O
bradyarrhythmias	-	183	O
.	-	199	O

A	8437969	201	O
40	-	203	O
-	-	205	O
year	-	206	O
-	-	210	O
old	-	211	O
man	-	215	O
with	-	219	O
leukemia	-	224	O
and	-	233	O
no	-	237	O
history	-	240	O
of	-	248	O
cardiac	-	251	O
disease	-	259	O
developed	-	267	O
recurrent	-	277	O
,	-	286	O
brief	-	288	O
episodes	-	294	O
of	-	303	O
apparent	-	306	O
sinus	-	315	O
arrest	-	321	O
while	-	328	O
receiving	-	334	O
continuous	-	344	O
-	-	354	O
infusion	-	355	O
cimetidine	-	364	B
50	-	375	O
mg	-	378	O
/	-	380	O
hour	-	381	O
.	-	385	O

The	8437969	387	O
arrhythmias	-	391	O
were	-	403	O
temporally	-	408	O
related	-	419	O
to	-	427	O
cimetidine	-	430	B
administration	-	441	O
,	-	455	O
disappeared	-	457	O
after	-	469	O
dechallenge	-	475	O
,	-	486	O
and	-	488	O
did	-	492	O
not	-	496	O
recur	-	500	O
during	-	506	O
ranitidine	-	513	B
treatment	-	524	O
.	-	533	O

This	8437969	535	O
is	-	540	O
the	-	543	O
first	-	547	O
reported	-	553	O
case	-	562	O
of	-	567	O
sinus	-	570	O
arrest	-	576	O
associated	-	583	O
with	-	594	O
continuous	-	599	O
-	-	609	O
infusion	-	610	O
cimetidine	-	619	B
.	-	629	O

Composition	7890216	0	O
of	-	12	O
gall	-	15	O
bladder	-	20	O
stones	-	28	O
associated	-	35	O
with	-	46	O
octreotide	-	51	B
:	-	61	O
response	-	63	O
to	-	72	O
oral	-	75	O
ursodeoxycholic	-	80	B
acid	-	96	I
.	-	100	O

Octreotide	7890216	102	B
,	-	112	O
an	-	114	O
effective	-	117	O
treatment	-	127	O
for	-	137	O
acromegaly	-	141	O
,	-	151	O
induces	-	153	O
gall	-	161	O
bladder	-	166	O
stones	-	174	O
in	-	181	O
13	-	184	O
-	-	186	O
60	-	187	O
%	-	189	O
of	-	191	O
patients	-	194	O
.	-	202	O

Because	7890216	204	O
knowledge	-	212	O
of	-	222	O
stone	-	225	O
composition	-	231	O
is	-	243	O
essential	-	246	O
for	-	256	O
studies	-	260	O
of	-	268	O
their	-	271	O
pathogenesis	-	277	O
,	-	289	O
treatment	-	291	O
,	-	300	O
and	-	302	O
prevention	-	306	O
,	-	316	O
this	-	318	O
was	-	323	O
investigated	-	327	O
by	-	340	O
direct	-	343	O
and	-	350	O
indirect	-	354	O
methods	-	363	O
in	-	371	O
14	-	374	O
octreotide	-	377	B
treated	-	388	O
acromegalic	-	396	O
patients	-	408	O
with	-	417	O
gall	-	422	O
stones	-	427	O
.	-	433	O

Chemical	7890216	435	O
analysis	-	444	O
of	-	453	O
gall	-	456	O
stones	-	461	O
retrieved	-	468	O
at	-	478	O
cholecystectomy	-	481	O
from	-	497	O
two	-	502	O
patients	-	506	O
,	-	514	O
showed	-	516	O
that	-	523	O
they	-	528	O
contained	-	533	O
71	-	543	O
%	-	545	O
and	-	547	O
87	-	551	O
%	-	553	O
cholesterol	-	555	B
by	-	567	O
weight	-	570	O
.	-	576	O

In	7890216	578	O
the	-	581	O
remaining	-	585	O
12	-	595	O
patients	-	598	O
,	-	606	O
localised	-	608	O
computed	-	618	O
tomography	-	627	O
of	-	638	O
the	-	641	O
gall	-	645	O
bladder	-	650	O
showed	-	658	O
that	-	665	O
eight	-	670	O
had	-	676	O
stones	-	680	O
with	-	687	O
maximum	-	692	O
attenuation	-	700	O
scores	-	712	O
of	-	719	O
<	-	722	O
100	-	724	O
Hounsfield	-	728	O
units	-	739	O
(	-	745	O
values	-	746	O
of	-	753	O
<	-	756	O
100	-	758	O
HU	-	762	O
predict	-	765	O
cholesterol	-	773	B
rich	-	785	O
,	-	789	O
dissolvable	-	791	O
stones	-	803	O
)	-	809	O
.	-	810	O

Gall	7890216	812	O
bladder	-	817	O
bile	-	825	O
was	-	830	O
obtained	-	834	O
by	-	843	O
ultrasound	-	846	O
guided	-	857	O
,	-	863	O
fine	-	865	O
needle	-	870	O
puncture	-	877	O
from	-	886	O
six	-	891	O
patients	-	895	O
.	-	903	O

All	7890216	905	O
six	-	909	O
patients	-	913	O
had	-	922	O
supersaturated	-	926	O
bile	-	941	O
(	-	946	O
mean	-	947	O
(	-	952	O
SEM	-	953	O
)	-	956	O
cholesterol	-	958	B
saturation	-	970	O
index	-	981	O
of	-	987	O
1	-	990	O
.	-	991	O
19	-	992	O
(	-	995	O
0	-	996	O
.	-	997	O
08	-	998	O
)	-	1000	O
(	-	1002	O
range	-	1003	O
1	-	1009	O
.	-	1010	O
01	-	1011	O
-	-	1013	O
1	-	1014	O
.	-	1015	O
53	-	1016	O
)	-	1018	O
)	-	1019	O
and	-	1021	O
all	-	1025	O
had	-	1029	O
abnormally	-	1033	O
rapid	-	1044	O
cholesterol	-	1050	B
microcrystal	-	1062	O
nucleation	-	1075	O
times	-	1086	O
(	-	1092	O
<	-	1093	O
4	-	1095	O
days	-	1097	O
(	-	1102	O
range	-	1103	O
1	-	1109	O
-	-	1110	O
4	-	1111	O
)	-	1112	O
)	-	1113	O
,	-	1114	O
whilst	-	1116	O
in	-	1123	O
four	-	1126	O
,	-	1130	O
the	-	1132	O
bile	-	1136	O
contained	-	1141	O
cholesterol	-	1151	B
microcrystals	-	1163	O
immediately	-	1177	O
after	-	1189	O
sampling	-	1195	O
.	-	1203	O

Of	7890216	1205	O
the	-	1208	O
12	-	1212	O
patients	-	1215	O
considered	-	1224	O
for	-	1235	O
oral	-	1239	O
ursodeoxycholic	-	1244	B
acid	-	1260	I
(	-	1265	O
UDCA	-	1266	B
)	-	1270	O
treatment	-	1272	O
,	-	1281	O
two	-	1283	O
had	-	1287	O
a	-	1291	O
blocked	-	1293	O
cystic	-	1301	O
duct	-	1308	O
and	-	1313	O
were	-	1317	O
not	-	1322	O
started	-	1326	O
on	-	1334	O
UDCA	-	1337	B
while	-	1342	O
one	-	1348	O
was	-	1352	O
lost	-	1356	O
to	-	1361	O
follow	-	1364	O
up	-	1371	O
.	-	1373	O

After	7890216	1375	O
one	-	1381	O
year	-	1385	O
of	-	1390	O
treatment	-	1393	O
,	-	1402	O
five	-	1404	O
of	-	1409	O
the	-	1412	O
remaining	-	1416	O
nine	-	1426	O
patients	-	1431	O
showed	-	1440	O
either	-	1447	O
partial	-	1454	O
(	-	1462	O
n	-	1463	O
=	-	1465	O
3	-	1467	O
)	-	1468	O
or	-	1470	O
complete	-	1473	O
(	-	1482	O
n	-	1483	O
=	-	1485	O
2	-	1487	O
)	-	1488	O
gall	-	1490	O
stone	-	1495	O
dissolution	-	1501	O
,	-	1512	O
suggesting	-	1514	O
that	-	1525	O
their	-	1530	O
stones	-	1536	O
were	-	1543	O
cholesterol	-	1548	B
rich	-	1560	O
.	-	1564	O

This	7890216	1566	O
corresponds	-	1571	O
,	-	1582	O
by	-	1584	O
actuarial	-	1587	O
(	-	1597	O
life	-	1598	O
table	-	1603	O
)	-	1608	O
analysis	-	1610	O
,	-	1618	O
to	-	1620	O
a	-	1623	O
combined	-	1625	O
gall	-	1634	O
stone	-	1639	O
dissolution	-	1645	O
rate	-	1657	O
of	-	1662	O
58	-	1665	O
.	-	1667	O
3	-	1668	O
(	-	1670	O
15	-	1671	O
.	-	1673	O
9	-	1674	O
%	-	1675	O
)	-	1676	O
.	-	1677	O

In	7890216	1679	O
conclusion	-	1682	O
,	-	1692	O
octreotide	-	1694	B
induced	-	1705	O
gall	-	1713	O
stones	-	1718	O
are	-	1725	O
generally	-	1729	O
small	-	1739	O
,	-	1744	O
multiple	-	1746	O
,	-	1754	O
and	-	1756	O
cholesterol	-	1760	B
rich	-	1772	O
although	-	1777	O
,	-	1785	O
in	-	1787	O
common	-	1790	O
with	-	1797	O
spontaneous	-	1802	O
gall	-	1814	O
stone	-	1819	O
disease	-	1825	O
,	-	1832	O
at	-	1834	O
presentation	-	1837	O
some	-	1850	O
patients	-	1855	O
will	-	1864	O
have	-	1869	O
a	-	1874	O
blocked	-	1876	O
cystic	-	1884	O
duct	-	1891	O
and	-	1896	O
some	-	1900	O
gall	-	1905	O
stones	-	1910	O
containing	-	1917	O
calcium	-	1928	B
.	-	1935	O

Cardiovascular	7468724	0	O
complications	-	15	O
associated	-	29	O
with	-	40	O
terbutaline	-	45	B
treatment	-	57	O
for	-	67	O
preterm	-	71	O
labor	-	79	O
.	-	84	O

Severe	7468724	86	O
cardiovascular	-	93	O
complications	-	108	O
occurred	-	122	O
in	-	131	O
eight	-	134	O
of	-	140	O
160	-	143	O
patients	-	147	O
treated	-	156	O
with	-	164	O
terbutaline	-	169	B
for	-	181	O
preterm	-	185	O
labor	-	193	O
.	-	198	O

Associated	7468724	200	O
corticosteroid	-	211	O
therapy	-	226	O
and	-	234	O
twin	-	238	O
gestations	-	243	O
appear	-	254	O
to	-	261	O
be	-	264	O
predisposing	-	267	O
factors	-	280	O
.	-	287	O

Potential	7468724	289	O
mechanisms	-	299	O
of	-	310	O
the	-	313	O
pathophysiology	-	317	O
are	-	333	O
briefly	-	337	O
discussed	-	345	O
.	-	354	O

Neurologic	7199841	0	O
effects	-	11	O
of	-	19	O
subarachnoid	-	22	O
administration	-	35	O
of	-	50	O
2	-	53	B
-	-	54	I
chloroprocaine	-	55	I
-	-	69	I
CE	-	70	I
,	-	72	O
bupivacaine	-	74	B
,	-	85	O
and	-	87	O
low	-	91	O
pH	-	95	O
normal	-	98	O
saline	-	105	O
in	-	112	O
dogs	-	115	O
.	-	119	O

The	7199841	121	O
purpose	-	125	O
of	-	133	O
this	-	136	O
study	-	141	O
was	-	147	O
to	-	151	O
evaluate	-	154	O
the	-	163	O
neurologic	-	167	O
consequences	-	178	O
of	-	191	O
deliberate	-	194	O
subarachnoid	-	205	O
injection	-	218	O
of	-	228	O
large	-	231	O
volumes	-	237	O
of	-	245	O
2	-	248	B
-	-	249	I
chloroprocaine	-	250	I
-	-	264	I
CE	-	265	I
in	-	268	O
experimental	-	271	O
animals	-	284	O
.	-	291	O

The	7199841	293	O
possible	-	297	O
role	-	306	O
of	-	311	O
low	-	314	O
pH	-	318	O
as	-	321	O
well	-	324	O
as	-	329	O
total	-	332	O
volume	-	338	O
as	-	345	O
potential	-	348	O
factors	-	358	O
in	-	366	O
causing	-	369	O
neurotoxicity	-	377	O
was	-	391	O
evaluated	-	395	O
.	-	404	O

The	7199841	406	O
65	-	410	O
dogs	-	413	O
in	-	418	O
the	-	421	O
study	-	425	O
received	-	431	O
injections	-	440	O
in	-	451	O
the	-	454	O
subarachnoid	-	458	O
space	-	471	O
as	-	477	O
follows	-	480	O
:	-	487	O
6	-	489	O
to	-	491	O
8	-	494	O
ml	-	496	O
of	-	499	O
bupivacaine	-	502	B
(	-	514	O
N	-	515	O
=	-	517	O
15	-	519	O
)	-	521	O
,	-	522	O
2	-	524	B
-	-	525	I
chloroprocaine	-	526	I
-	-	540	I
CE	-	541	I
(	-	544	O
N	-	545	O
=	-	547	O
20	-	549	O
)	-	551	O
,	-	552	O
low	-	554	O
pH	-	558	O
normal	-	561	O
saline	-	568	O
(	-	575	O
pH	-	576	O
3	-	579	O
.	-	580	O
0	-	581	O
)	-	582	O

(	7199841	584	O
N	-	585	O
=	-	587	O
20	-	589	O
)	-	591	O
,	-	592	O
or	-	594	O
normal	-	597	O
saline	-	604	O
(	-	611	O
N	-	612	O
=	-	614	O
10	-	616	O
)	-	618	O
.	-	619	O

Of	7199841	621	O
the	-	624	O
20	-	628	O
animals	-	631	O
that	-	639	O
received	-	644	O
subarachnoid	-	653	O
injection	-	666	O
of	-	676	O
2	-	679	B
-	-	680	I
chloroprocaine	-	681	I
-	-	695	I
CE	-	696	I
seven	-	699	O
(	-	705	O
35	-	706	O
%	-	708	O
)	-	709	O
developed	-	711	O
hind	-	721	O
-	-	725	O
limb	-	726	O
paralysis	-	731	O
.	-	740	O

None	7199841	742	O
of	-	747	O
the	-	750	O
animals	-	754	O
that	-	762	O
received	-	767	O
bupivacaine	-	776	B
,	-	787	O
normal	-	789	O
saline	-	796	O
,	-	802	O
or	-	804	O
normal	-	807	O
saline	-	814	O
titrated	-	821	O
to	-	830	O
a	-	833	O
pH	-	835	O
3	-	838	O
.	-	839	O
0	-	840	O
developed	-	842	O
hind	-	852	O
-	-	856	O
limb	-	857	O
paralysis	-	862	O
.	-	871	O

Of	7199841	873	O
the	-	876	O
15	-	880	O
spinal	-	883	O
cords	-	890	O
of	-	896	O
the	-	899	O
animals	-	903	O
that	-	911	O
received	-	916	O
2	-	925	B
-	-	926	I
chloroprocaine	-	927	I
-	-	941	I
CE	-	942	I
,	-	944	O
13	-	946	O
showed	-	949	O
subpial	-	956	O
necrosis	-	964	O
;	-	972	O
the	-	974	O
nerve	-	978	O
roots	-	984	O
and	-	990	O
subarachnoid	-	994	O
vessels	-	1007	O
were	-	1015	O
normal	-	1020	O
.	-	1026	O

The	7199841	1028	O
spinal	-	1032	O
cords	-	1039	O
of	-	1045	O
the	-	1048	O
animals	-	1052	O
that	-	1060	O
received	-	1065	O
bupivacaine	-	1074	B
,	-	1085	O
low	-	1087	O
pH	-	1091	O
normal	-	1094	O
saline	-	1101	O
(	-	1108	O
pH	-	1109	O
3	-	1112	O
.	-	1113	O
0	-	1114	O
)	-	1115	O
,	-	1116	O
or	-	1118	O
normal	-	1121	O
saline	-	1128	O
did	-	1135	O
not	-	1139	O
show	-	1143	O
abnormal	-	1148	O
findings	-	1157	O
.	-	1165	O

Early	6640832	0	O
adjuvant	-	6	O
adriamycin	-	15	B
in	-	26	O
superficial	-	29	O
bladder	-	41	O
carcinoma	-	49	O
.	-	58	O

A	6640832	60	O
multicenter	-	62	O
study	-	74	O
was	-	80	O
performed	-	84	O
in	-	94	O
110	-	97	O
patients	-	101	O
with	-	110	O
superficial	-	115	O
transitional	-	127	O
cell	-	140	O
carcinoma	-	145	O
of	-	155	O
the	-	158	O
bladder	-	162	O
.	-	169	O

Adriamycin	6640832	171	B
(	-	182	O
50	-	183	O
mg	-	186	O
/	-	188	O
50	-	189	O
ml	-	192	O
)	-	194	O
was	-	196	O
administered	-	200	O
intravesically	-	213	O
within	-	228	O
24	-	235	O
h	-	238	O
after	-	240	O
transurethral	-	246	O
resection	-	260	O
of	-	270	O
TA	-	273	O
-	-	275	O
T1	-	276	O
(	-	279	O
O	-	280	O
-	-	281	O
A	-	282	O
)	-	283	O
bladder	-	285	O
tumors	-	293	O
.	-	299	O

Instillation	6640832	301	O
was	-	314	O
repeated	-	318	O
twice	-	327	O
during	-	333	O
the	-	340	O
first	-	344	O
week	-	350	O
,	-	354	O
then	-	356	O
weekly	-	361	O
during	-	368	O
the	-	375	O
first	-	379	O
month	-	385	O
and	-	391	O
afterwards	-	395	O
monthly	-	406	O
for	-	414	O
1	-	418	O
year	-	420	O
.	-	424	O

The	6640832	426	O
tolerance	-	430	O
was	-	440	O
evaluated	-	444	O
in	-	454	O
these	-	457	O
110	-	463	O
patients	-	467	O
,	-	475	O
and	-	477	O
29	-	481	O
patients	-	484	O
presented	-	493	O
with	-	503	O
local	-	508	O
side	-	514	O
-	-	518	O
effects	-	519	O
.	-	526	O

In	6640832	528	O
24	-	531	O
of	-	534	O
these	-	537	O
patients	-	543	O
chemical	-	552	O
cystitis	-	561	O
was	-	570	O
severe	-	574	O
enough	-	581	O
for	-	588	O
them	-	592	O
to	-	597	O
drop	-	600	O
out	-	605	O
of	-	609	O
the	-	612	O
study	-	616	O
.	-	621	O

No	6640832	623	O
systemic	-	626	O
side	-	635	O
-	-	639	O
effects	-	640	O
were	-	648	O
observed	-	653	O
.	-	661	O

Recurrence	6640832	663	O
was	-	674	O
studied	-	678	O
in	-	686	O
82	-	689	O
evaluable	-	692	O
patients	-	702	O
after	-	711	O
1	-	717	O
year	-	719	O
of	-	724	O
follow	-	727	O
-	-	733	O
up	-	734	O
and	-	737	O
in	-	741	O
72	-	744	O
patients	-	747	O
followed	-	756	O
for	-	765	O
2	-	769	O
-	-	770	O
3	-	771	O
years	-	773	O
(	-	779	O
mean	-	780	O
32	-	785	O
months	-	788	O
)	-	794	O
.	-	795	O

Of	6640832	797	O
the	-	800	O
82	-	804	O
patients	-	807	O
studied	-	816	O
after	-	824	O
1	-	830	O
year	-	832	O
,	-	836	O
23	-	838	O
had	-	841	O
primary	-	845	O
and	-	853	O
59	-	857	O
recurrent	-	860	O
disease	-	870	O
.	-	877	O

Of	6640832	879	O
the	-	882	O
82	-	886	O
evaluable	-	889	O
patients	-	899	O
,	-	907	O
50	-	909	O
did	-	912	O
not	-	916	O
show	-	920	O
any	-	925	O
recurrence	-	929	O
after	-	940	O
1	-	946	O
year	-	948	O
(	-	953	O
61	-	954	O
%	-	956	O
)	-	957	O
,	-	958	O
while	-	960	O
32	-	966	O
presented	-	969	O
with	-	979	O
one	-	984	O
or	-	988	O
more	-	991	O
recurrences	-	996	O
(	-	1008	O
39	-	1009	O
%	-	1011	O
)	-	1012	O
.	-	1013	O

Of	6640832	1015	O
these	-	1018	O
recurrences	-	1024	O
,	-	1035	O
27	-	1037	O
were	-	1040	O
T1	-	1045	O
tumors	-	1048	O
while	-	1055	O
five	-	1061	O
progressed	-	1066	O
to	-	1077	O
more	-	1080	O
highly	-	1085	O
invasive	-	1092	O
lesions	-	1101	O
.	-	1108	O

In	6640832	1110	O
patients	-	1113	O
that	-	1122	O
were	-	1127	O
free	-	1132	O
of	-	1137	O
recurrence	-	1140	O
during	-	1151	O
the	-	1158	O
first	-	1162	O
year	-	1168	O
,	-	1172	O
80	-	1174	O
%	-	1176	O
remained	-	1178	O
tumor	-	1187	O
-	-	1192	O
free	-	1193	O
during	-	1198	O
the	-	1205	O
2	-	1209	O
-	-	1210	O
to	-	1212	O
3	-	1215	O
-	-	1216	O
year	-	1217	O
follow	-	1222	O
-	-	1228	O
up	-	1229	O
period	-	1232	O
.	-	1238	O

Of	6640832	1240	O
the	-	1243	O
patients	-	1247	O
developing	-	1256	O
one	-	1267	O
or	-	1271	O
more	-	1274	O
recurrences	-	1279	O
during	-	1291	O
the	-	1298	O
first	-	1302	O
year	-	1308	O
,	-	1312	O
only	-	1314	O
50	-	1319	O
%	-	1321	O
presented	-	1323	O
with	-	1333	O
further	-	1338	O
recurrence	-	1346	O
once	-	1357	O
the	-	1362	O
instillations	-	1366	O
were	-	1380	O
stopped	-	1385	O
.	-	1392	O

The	6640832	1394	O
beneficial	-	1398	O
effect	-	1409	O
of	-	1416	O
Adriamycin	-	1419	B
appears	-	1430	O
obvious	-	1438	O
and	-	1446	O
might	-	1450	O
be	-	1456	O
related	-	1459	O
to	-	1467	O
the	-	1470	O
drug	-	1474	O
itself	-	1479	O
,	-	1485	O
the	-	1487	O
early	-	1491	O
and	-	1497	O
repeated	-	1501	O
instillations	-	1510	O
after	-	1524	O
TUR	-	1530	O
,	-	1533	O
or	-	1535	O
both	-	1538	O
.	-	1542	O

Hyperkalemia	3560096	0	O
associated	-	13	O
with	-	24	O
sulindac	-	29	B
therapy	-	38	O
.	-	45	O

Hyperkalemia	3560096	47	O
has	-	60	O
recently	-	64	O
been	-	73	O
recognized	-	78	O
as	-	89	O
a	-	92	O
complication	-	94	O
of	-	107	O
nonsteroidal	-	110	O
antiinflammatory	-	123	O
agents	-	140	O
(	-	147	O
NSAID	-	148	O
)	-	153	O
such	-	155	O
as	-	160	O
indomethacin	-	163	B
.	-	175	O

Several	3560096	177	O
recent	-	185	O
studies	-	192	O
have	-	200	O
stressed	-	205	O
the	-	214	O
renal	-	218	O
sparing	-	224	O
features	-	232	O
of	-	241	O
sulindac	-	244	B
,	-	252	O
owing	-	254	O
to	-	260	O
its	-	263	O
lack	-	267	O
of	-	272	O
interference	-	275	O
with	-	288	O
renal	-	293	O
prostacyclin	-	299	B
synthesis	-	312	O
.	-	321	O

We	3560096	323	O
describe	-	326	O
4	-	335	O
patients	-	337	O
in	-	346	O
whom	-	349	O
hyperkalemia	-	354	O
ranging	-	367	O
from	-	375	O
6	-	380	O
.	-	381	O
1	-	382	O
to	-	384	O
6	-	387	O
.	-	388	O
9	-	389	O
mEq	-	391	O
/	-	394	O
l	-	395	O
developed	-	397	O
within	-	407	O
3	-	414	O
to	-	416	O
8	-	419	O
days	-	421	O
of	-	426	O
sulindac	-	429	B
administration	-	438	O
.	-	452	O

In	3560096	454	O
all	-	457	O
of	-	461	O
them	-	464	O
normal	-	469	O
serum	-	476	O
potassium	-	482	B
levels	-	492	O
reached	-	499	O
within	-	507	O
2	-	514	O
to	-	516	O
4	-	519	O
days	-	521	O
of	-	526	O
stopping	-	529	O
sulindac	-	538	B
.	-	546	O

As	3560096	548	O
no	-	551	O
other	-	554	O
medications	-	560	O
known	-	572	O
to	-	578	O
effect	-	581	O
serum	-	588	O
potassium	-	594	B
had	-	604	O
been	-	608	O
given	-	613	O
concomitantly	-	619	O
,	-	632	O
this	-	634	O
course	-	639	O
of	-	646	O
events	-	649	O
is	-	656	O
suggestive	-	659	O
of	-	670	O
a	-	673	O
cause	-	675	O
-	-	680	O
and	-	681	O
-	-	684	O
effect	-	685	O
relationship	-	692	O
between	-	705	O
sulindac	-	713	B
and	-	722	O
hyperkalemia	-	726	O
.	-	738	O

These	3560096	740	O
observations	-	746	O
indicate	-	759	O
that	-	768	O
initial	-	773	O
hopes	-	781	O
that	-	787	O
sulindac	-	792	B
may	-	801	O
not	-	805	O
be	-	809	O
associated	-	812	O
with	-	823	O
the	-	828	O
adverse	-	832	O
renal	-	840	O
effects	-	846	O
of	-	854	O
other	-	857	O
NSAID	-	863	O
are	-	869	O
probably	-	873	O
not	-	882	O
justified	-	886	O
.	-	895	O

Ventricular	3358181	0	O
tachyarrhythmias	-	12	O
during	-	29	O
cesarean	-	36	O
section	-	45	O
after	-	53	O
ritodrine	-	59	B
therapy	-	69	O
:	-	76	O
interaction	-	78	O
with	-	90	O
anesthetics	-	95	O
.	-	106	O

This	3358181	108	O
case	-	113	O
illustrates	-	118	O
that	-	130	O
patients	-	135	O
receiving	-	144	O
ritodrine	-	154	B
for	-	164	O
preterm	-	168	O
labor	-	176	O
may	-	182	O
risk	-	186	O
interactions	-	191	O
between	-	204	O
the	-	212	O
residual	-	216	O
betamimetic	-	225	O
effects	-	237	O
of	-	245	O
ritodrine	-	248	B
and	-	258	O
the	-	262	O
effects	-	266	O
of	-	274	O
anesthetics	-	277	O
during	-	289	O
cesarean	-	296	O
section	-	305	O
.	-	312	O

Such	3358181	314	O
interactions	-	319	O
may	-	332	O
result	-	336	O
in	-	343	O
serious	-	346	O
cardiovascular	-	354	O
complications	-	369	O
even	-	383	O
after	-	388	O
cessation	-	394	O
of	-	404	O
an	-	407	O
infusion	-	410	O
of	-	419	O
ritodrine	-	422	B
.	-	431	O

Preoperative	3358181	433	O
assessment	-	446	O
should	-	457	O
focus	-	464	O
on	-	470	O
cardiovascular	-	473	O
status	-	488	O
and	-	495	O
serum	-	499	O
potassium	-	505	B
level	-	515	O
.	-	520	O

Delaying	3358181	522	O
induction	-	531	O
of	-	541	O
anesthesia	-	544	O
should	-	555	O
be	-	562	O
considered	-	565	O
whenever	-	576	O
possible	-	585	O
.	-	593	O

Careful	3358181	595	O
fluid	-	603	O
administration	-	609	O
and	-	624	O
cautious	-	628	O
use	-	637	O
of	-	641	O
titrated	-	644	O
doses	-	653	O
of	-	659	O
ephedrine	-	662	B
are	-	672	O
advised	-	676	O
.	-	683	O

After	3358181	685	O
delivery	-	691	O
of	-	700	O
the	-	703	O
infant	-	707	O
,	-	713	O
there	-	715	O
should	-	721	O
be	-	728	O
no	-	731	O
contraindication	-	734	O
to	-	751	O
the	-	754	O
use	-	758	O
of	-	762	O
an	-	765	O
alpha	-	768	O
-	-	773	O
adrenergic	-	774	O
vasopressor	-	785	O
such	-	797	O
as	-	802	O
phenylephrine	-	805	B
to	-	819	O
treat	-	822	O
hypotensive	-	828	O
patients	-	840	O
with	-	849	O
tachycardia	-	854	O
.	-	865	O

Immunohistochemical	2887062	0	O
,	-	19	O
electron	-	21	O
microscopic	-	30	O
and	-	42	O
morphometric	-	46	O
studies	-	59	O
of	-	67	O
estrogen	-	70	B
-	-	78	O
induced	-	79	O
rat	-	87	O
prolactinomas	-	91	O
after	-	105	O
bromocriptine	-	111	B
treatment	-	125	O
.	-	134	O

To	2887062	136	O
clarify	-	139	O
the	-	147	O
effects	-	151	O
of	-	159	O
bromocriptine	-	162	B
on	-	176	O
prolactinoma	-	179	O
cells	-	192	O
in	-	198	O
vivo	-	201	O
,	-	205	O
immunohistochemical	-	207	O
,	-	226	O
ultrastructural	-	228	O
and	-	244	O
morphometrical	-	248	O
analyses	-	263	O
were	-	272	O
applied	-	277	O
to	-	285	O
estrogen	-	288	B
-	-	296	O
induced	-	297	O
rat	-	305	O
prolactinoma	-	309	O
cells	-	322	O
1	-	328	O
h	-	330	O
and	-	332	O
6	-	336	O
h	-	338	O
after	-	340	O
injection	-	346	O
of	-	356	O
bromocriptine	-	359	B
(	-	373	O
3	-	374	O
mg	-	376	O
/	-	378	O
kg	-	379	O
of	-	382	O
body	-	385	O
weight	-	390	O
)	-	396	O
.	-	397	O

One	2887062	399	O
h	-	403	O
after	-	405	O
treatment	-	411	O
,	-	420	O
serum	-	422	O
prolactin	-	428	O
levels	-	438	O
decreased	-	445	O
markedly	-	455	O
.	-	463	O

Electron	2887062	465	O
microscopy	-	474	O
disclosed	-	485	O
many	-	495	O
secretory	-	500	O
granules	-	510	O
,	-	518	O
slightly	-	520	O
distorted	-	529	O
rough	-	539	O
endoplasmic	-	545	O
reticulum	-	557	O
,	-	566	O
and	-	568	O
partially	-	572	O
dilated	-	582	O
Golgi	-	590	O
cisternae	-	596	O
in	-	606	O
the	-	609	O
prolactinoma	-	613	O
cells	-	626	O
.	-	631	O

Morphometric	2887062	633	O
analysis	-	646	O
revealed	-	655	O
that	-	664	O
the	-	669	O
volume	-	673	O
density	-	680	O
of	-	688	O
secretory	-	691	O
granules	-	701	O
increased	-	710	O
,	-	719	O
while	-	721	O
the	-	727	O
volume	-	731	O
density	-	738	O
of	-	746	O
cytoplasmic	-	749	O
microtubules	-	761	O
decreased	-	774	O
.	-	783	O

These	2887062	785	O
findings	-	791	O
suggest	-	800	O
that	-	808	O
lowered	-	813	O
serum	-	821	O
prolactin	-	827	O
levels	-	837	O
in	-	844	O
the	-	847	O
early	-	851	O
phase	-	857	O
of	-	863	O
bromocriptine	-	866	B
treatment	-	880	O
may	-	890	O
result	-	894	O
from	-	901	O
an	-	906	O
impaired	-	909	O
secretion	-	918	O
of	-	928	O
prolactin	-	931	O
due	-	941	O
to	-	945	O
decreasing	-	948	O
numbers	-	959	O
of	-	967	O
cytoplasmic	-	970	O
microtubules	-	982	O
.	-	994	O

At	2887062	996	O
6	-	999	O
h	-	1001	O
after	-	1003	O
injection	-	1009	O
,	-	1018	O
serum	-	1020	O
prolactin	-	1026	O
levels	-	1036	O
were	-	1043	O
still	-	1048	O
considerably	-	1054	O
lower	-	1067	O
than	-	1073	O
in	-	1078	O
controls	-	1081	O
.	-	1089	O

The	2887062	1091	O
prolactinoma	-	1095	O
cells	-	1108	O
at	-	1114	O
this	-	1117	O
time	-	1122	O
were	-	1127	O
well	-	1132	O
granulated	-	1137	O
,	-	1147	O
with	-	1149	O
vesiculated	-	1154	O
rough	-	1166	O
endoplasmic	-	1172	O
reticulum	-	1184	O
and	-	1194	O
markedly	-	1198	O
dilated	-	1207	O
Golgi	-	1215	O
cisternae	-	1221	O
.	-	1230	O

Electron	2887062	1232	O
microscopical	-	1241	O
immunohistochemistry	-	1255	O
revealed	-	1276	O
positive	-	1285	O
reaction	-	1294	O
products	-	1303	O
noted	-	1312	O
on	-	1318	O
the	-	1321	O
secretory	-	1325	O
granules	-	1335	O
,	-	1343	O
Golgi	-	1345	O
cisternae	-	1351	O
,	-	1360	O
and	-	1362	O
endoplasmic	-	1366	O
reticulum	-	1378	O
of	-	1388	O
the	-	1391	O
untreated	-	1395	O
rat	-	1405	O
prolactinoma	-	1409	O
cells	-	1422	O
.	-	1427	O

However	2887062	1429	O
,	-	1436	O
only	-	1438	O
secretory	-	1443	O
granules	-	1453	O
showed	-	1462	O
the	-	1469	O
positive	-	1473	O
reaction	-	1482	O
products	-	1491	O
for	-	1500	O
prolactin	-	1504	O
6	-	1514	O
h	-	1516	O
after	-	1518	O
bromocriptine	-	1524	B
treatment	-	1538	O
of	-	1548	O
the	-	1551	O
adenoma	-	1555	O
cells	-	1563	O
.	-	1568	O

An	2887062	1570	O
increase	-	1573	O
in	-	1582	O
the	-	1585	O
volume	-	1589	O
density	-	1596	O
of	-	1604	O
secretory	-	1607	O
granules	-	1617	O
and	-	1626	O
a	-	1630	O
decrease	-	1632	O
in	-	1641	O
the	-	1644	O
volume	-	1648	O
densities	-	1655	O
of	-	1665	O
rough	-	1668	O
endoplasmic	-	1674	O
reticulum	-	1686	O
and	-	1696	O
microtubules	-	1700	O
was	-	1713	O
determined	-	1717	O
by	-	1728	O
morphometric	-	1731	O
analysis	-	1744	O
,	-	1752	O
suggesting	-	1754	O
that	-	1765	O
bromocriptine	-	1770	B
inhibits	-	1784	O
protein	-	1793	O
synthesis	-	1801	O
as	-	1811	O
well	-	1814	O
as	-	1819	O
bringing	-	1822	O
about	-	1831	O
a	-	1837	O
disturbance	-	1839	O
of	-	1851	O
the	-	1854	O
prolactin	-	1858	O
secretion	-	1868	O
.	-	1877	O

On	2425813	0	O
two	-	3	O
paradoxical	-	7	O
side	-	19	O
-	-	23	O
effects	-	24	O
of	-	32	O
prednisolone	-	35	B
in	-	48	O
rats	-	51	O
,	-	55	O
ribosomal	-	57	O
RNA	-	67	O
biosyntheses	-	71	O
,	-	83	O
and	-	85	O
a	-	89	O
mechanism	-	91	O
of	-	101	O
action	-	104	O
.	-	110	O

Liver	2425813	112	O
enlargement	-	118	O
and	-	130	O
muscle	-	134	O
wastage	-	141	O
occurred	-	149	O
in	-	158	O
Wistar	-	161	O
rats	-	168	O
following	-	173	O
the	-	183	O
subcutaneous	-	187	O
administration	-	200	O
of	-	215	O
prednisolone	-	218	B
.	-	230	O

In	2425813	232	O
the	-	235	O
liver	-	239	O
both	-	245	O
the	-	250	O
content	-	254	O
of	-	262	O
RNA	-	265	O
and	-	269	O
the	-	273	O
biosynthesis	-	277	O
of	-	290	O
ribosomal	-	293	O
RNA	-	303	O
increased	-	307	O
while	-	317	O
both	-	323	O
the	-	328	O
RNA	-	332	O
content	-	336	O
and	-	344	O
ribosomal	-	348	O
RNA	-	358	O
biosynthesis	-	362	O
were	-	375	O
reduced	-	380	O
in	-	388	O
the	-	391	O
gastrocnemius	-	395	O
muscle	-	409	O
.	-	415	O

It	2425813	417	O
is	-	420	O
suggested	-	423	O
that	-	433	O
the	-	438	O
drug	-	442	O
acted	-	447	O
in	-	453	O
a	-	456	O
selective	-	458	O
and	-	468	O
tissue	-	472	O
-	-	478	O
specific	-	479	O
manner	-	488	O
to	-	495	O
enhance	-	498	O
ribosomal	-	506	O
RNA	-	516	O
synthesis	-	520	O
in	-	530	O
the	-	533	O
liver	-	537	O
and	-	543	O
depress	-	547	O
such	-	555	O
synthesis	-	560	O
in	-	570	O
the	-	573	O
muscle	-	577	O
.	-	583	O

This	2425813	585	O
view	-	590	O
supports	-	595	O
the	-	604	O
contention	-	608	O
that	-	619	O
the	-	624	O
liver	-	628	O
and	-	634	O
muscle	-	638	O
are	-	645	O
independent	-	649	O
sites	-	661	O
of	-	667	O
prednisolone	-	670	B
action	-	683	O
.	-	689	O

Possible	2375138	0	O
intramuscular	-	9	O
midazolam	-	23	B
-	-	32	O
associated	-	33	O
cardiorespiratory	-	44	O
arrest	-	62	O
and	-	69	O
death	-	73	O
.	-	78	O

Midazolam	2375138	80	B
hydrochloride	-	90	I
is	-	104	O
commonly	-	107	O
used	-	116	O
for	-	121	O
dental	-	125	O
or	-	132	O
endoscopic	-	135	O
procedures	-	146	O
.	-	156	O

Although	2375138	158	O
generally	-	167	O
consisted	-	177	O
safe	-	187	O
when	-	192	O
given	-	197	O
intramuscularly	-	203	O
,	-	218	O
intravenous	-	220	O
administration	-	232	O
is	-	247	O
known	-	250	O
to	-	256	O
cause	-	259	O
respiratory	-	265	O
and	-	277	O
cardiovascular	-	281	O
depression	-	296	O
.	-	306	O

This	2375138	308	O
report	-	313	O
describes	-	320	O
the	-	330	O
first	-	334	O
published	-	340	O
case	-	350	O
of	-	355	O
cardiorespiratory	-	358	O
arrest	-	376	O
and	-	383	O
death	-	387	O
associated	-	393	O
with	-	404	O
intramuscular	-	409	O
administration	-	423	O
of	-	438	O
midazolam	-	441	B
.	-	450	O

Information	2375138	452	O
regarding	-	464	O
midazolam	-	474	B
use	-	484	O
is	-	488	O
reviewed	-	491	O
to	-	500	O
provide	-	503	O
recommendation	-	511	O
for	-	526	O
safe	-	530	O
administration	-	535	O
.	-	549	O

Serial	2265898	0	O
epilepsy	-	7	O
caused	-	16	O
by	-	23	O
levodopa	-	26	B
/	-	34	I
carbidopa	-	35	I
administration	-	45	O
in	-	60	O
two	-	63	O
patients	-	67	O
on	-	76	O
hemodialysis	-	79	O
.	-	91	O

Two	2265898	93	O
patients	-	97	O
with	-	106	O
similar	-	111	O
clinical	-	119	O
features	-	128	O
are	-	137	O
presented	-	141	O
:	-	150	O
both	-	152	O
patients	-	157	O
had	-	166	O
chronic	-	170	O
renal	-	178	O
failure	-	184	O
,	-	191	O
on	-	193	O
hemodialysis	-	196	O
for	-	209	O
many	-	213	O
years	-	218	O
but	-	224	O
recently	-	228	O
begun	-	237	O
on	-	243	O
a	-	246	O
high	-	248	O
-	-	252	O
flux	-	253	O
dialyzer	-	258	O
;	-	266	O
both	-	268	O
had	-	273	O
been	-	277	O
receiving	-	282	O
a	-	292	O
carbidopa	-	294	B
/	-	303	I
levodopa	-	304	I
preparation	-	313	O
;	-	324	O
and	-	326	O
both	-	330	O
had	-	335	O
the	-	339	O
onset	-	343	O
of	-	349	O
hallucinosis	-	352	O
and	-	365	O
recurrent	-	369	O
seizures	-	379	O
,	-	387	O
which	-	389	O
were	-	395	O
refractory	-	400	O
to	-	411	O
anticonvulsants	-	414	O
.	-	429	O

The	2265898	431	O
first	-	435	O
patient	-	441	O
died	-	449	O
without	-	454	O
a	-	462	O
diagnosis	-	464	O
;	-	473	O
the	-	475	O
second	-	479	O
patient	-	486	O
had	-	494	O
a	-	498	O
dramatic	-	500	O
recovery	-	509	O
following	-	518	O
the	-	528	O
administration	-	532	O
of	-	547	O
vitamin	-	550	B
B6	-	558	I
.	-	560	O

Neither	2265898	562	O
patient	-	570	O
was	-	578	O
considered	-	582	O
to	-	593	O
have	-	596	O
a	-	601	O
renal	-	603	O
state	-	609	O
sufficiently	-	615	O
severe	-	628	O
enough	-	635	O
to	-	642	O
explain	-	645	O
their	-	653	O
presentation	-	659	O
.	-	671	O

Effect	2071257	0	O
of	-	7	O
L	-	10	B
-	-	11	I
alpha	-	12	I
-	-	17	I
glyceryl	-	18	I
-	-	26	I
phosphorylcholine	-	27	I
on	-	45	O
amnesia	-	48	O
caused	-	56	O
by	-	63	O
scopolamine	-	66	B
.	-	77	O

The	2071257	79	O
present	-	83	O
study	-	91	O
was	-	97	O
carried	-	101	O
out	-	109	O
to	-	113	O
test	-	116	O
the	-	121	O
effects	-	125	O
of	-	133	O
L	-	136	B
-	-	137	I
alpha	-	138	I
-	-	143	I
glycerylphosphorylcholine	-	144	I
(	-	170	O
L	-	171	B
-	-	172	I
alpha	-	173	I
-	-	178	I
GFC	-	179	I
)	-	182	O
on	-	184	O
memory	-	187	O
impairment	-	194	O
induced	-	205	O
by	-	213	O
scopolamine	-	216	B
in	-	228	O
man	-	231	O
.	-	234	O

Thirty	2071257	236	O
-	-	242	O
two	-	243	O
healthy	-	247	O
young	-	255	O
volunteers	-	261	O
were	-	272	O
randomly	-	277	O
allocated	-	286	O
to	-	296	O
four	-	299	O
different	-	304	O
groups	-	314	O
.	-	320	O

They	2071257	322	O
were	-	327	O
given	-	332	O
a	-	338	O
ten	-	340	O
day	-	344	O
pretreatment	-	348	O
with	-	361	O
either	-	366	O
L	-	373	B
-	-	374	I
alpha	-	375	I
-	-	380	I
GFC	-	381	I
or	-	385	O
placebo	-	388	O
,	-	395	O
p	-	397	O
.	-	398	O
o	-	399	O
.	-	400	O
,	-	401	O
and	-	403	O
on	-	407	O
the	-	410	O
eleventh	-	414	O
day	-	423	O
either	-	427	O
scopolamine	-	434	B
or	-	446	O
placebo	-	449	O
,	-	456	O
i	-	458	O
.	-	459	O
m	-	460	O
.	-	461	O

Before	2071257	463	O
and	-	470	O
0	-	474	O
.	-	475	O
5	-	476	O
,	-	477	O
1	-	479	O
,	-	480	O
2	-	482	O
,	-	483	O
3	-	485	O
,	-	486	O
and	-	488	O
6	-	492	O
h	-	494	O
after	-	496	O
injection	-	502	O
the	-	512	O
subjects	-	516	O
were	-	525	O
given	-	530	O
attention	-	536	O
and	-	546	O
mnemonic	-	550	O
tests	-	559	O
.	-	564	O

The	2071257	566	O
findings	-	570	O
of	-	579	O
this	-	582	O
study	-	587	O
indicate	-	593	O
that	-	602	O
the	-	607	O
drug	-	611	O
is	-	616	O
able	-	619	O
to	-	624	O
antagonize	-	627	O
impairment	-	638	O
of	-	649	O
attention	-	652	O
and	-	662	O
memory	-	666	O
induced	-	673	O
by	-	681	O
scopolamine	-	684	B
.	-	695	O

Seizures	1592014	0	O
induced	-	9	O
by	-	17	O
the	-	20	O
cocaine	-	24	B
metabolite	-	32	O
benzoylecgonine	-	43	B
in	-	59	O
rats	-	62	O
.	-	66	O

The	1592014	68	O
half	-	72	O
-	-	76	O
life	-	77	O
(	-	82	O
t1	-	83	O
/	-	85	O
2	-	86	O
)	-	87	O
of	-	89	O
cocaine	-	92	B
is	-	100	O
relatively	-	103	O
short	-	114	O
,	-	119	O
but	-	121	O
some	-	125	O
of	-	130	O
the	-	133	O
consequences	-	137	O
of	-	150	O
its	-	153	O
use	-	157	O
,	-	160	O
such	-	162	O
as	-	167	O
seizures	-	170	O
and	-	179	O
strokes	-	183	O
,	-	190	O
can	-	192	O
occur	-	196	O
hours	-	202	O
after	-	208	O
exposure	-	214	O
.	-	222	O

This	1592014	224	O
led	-	229	O
us	-	233	O
to	-	236	O
hypothesize	-	239	O
that	-	251	O
a	-	256	O
metabolite	-	258	O
of	-	269	O
cocaine	-	272	B
may	-	280	O
be	-	284	O
responsible	-	287	O
for	-	299	O
some	-	303	O
of	-	308	O
those	-	311	O
delayed	-	317	O
sequelae	-	325	O
.	-	333	O

We	1592014	335	O
evaluated	-	338	O
the	-	348	O
potential	-	352	O
of	-	362	O
the	-	365	O
major	-	369	O
metabolite	-	375	O
of	-	386	O
cocaine	-	389	B
,	-	396	O
benzoylecgonine	-	398	B
(	-	414	O
BE	-	415	B
)	-	417	O
,	-	418	O
to	-	420	O
cause	-	423	O
seizures	-	429	O
.	-	437	O

Two	1592014	439	O
separate	-	443	O
equimolar	-	452	O
doses	-	462	O
(	-	468	O
0	-	469	O
.	-	470	O
2	-	471	O
and	-	473	O
0	-	477	O
.	-	478	O
4	-	479	O
mumol	-	481	O
)	-	486	O
of	-	488	O
either	-	491	O
cocaine	-	498	B
or	-	506	O
BE	-	509	B
were	-	512	O
injected	-	517	O
ventricularly	-	526	O
in	-	540	O
unanesthetized	-	543	O
juvenile	-	558	O
rats	-	567	O
.	-	571	O

Treated	1592014	573	O
rats	-	581	O
were	-	586	O
then	-	591	O
evaluated	-	596	O
for	-	606	O
incidence	-	610	O
,	-	619	O
latency	-	621	O
,	-	628	O
and	-	630	O
seizure	-	634	O
pattern	-	642	O
or	-	650	O
for	-	653	O
locomotor	-	657	O
activity	-	667	O
in	-	676	O
animals	-	679	O
without	-	687	O
seizures	-	695	O
.	-	703	O

BE	1592014	705	B
-	-	707	O
Induced	-	708	O
seizures	-	716	O
occurred	-	725	O
more	-	734	O
frequently	-	739	O
and	-	750	O
had	-	754	O
significantly	-	758	O
longer	-	772	O
latencies	-	779	O
than	-	789	O
those	-	794	O
induced	-	800	O
by	-	808	O
equimolar	-	811	O
amounts	-	821	O
of	-	829	O
cocaine	-	832	B
.	-	839	O

Whereas	1592014	841	O
cocaine	-	849	B
-	-	856	O
induced	-	857	O
seizures	-	865	O
were	-	874	O
best	-	879	O
characterized	-	884	O
as	-	898	O
brief	-	901	O
,	-	906	O
generalized	-	908	O
,	-	919	O
and	-	921	O
tonic	-	925	O
and	-	931	O
resulted	-	935	O
in	-	944	O
death	-	947	O
,	-	952	O
those	-	954	O
induced	-	960	O
by	-	968	O
BE	-	971	B
were	-	974	O
prolonged	-	979	O
,	-	988	O
often	-	990	O
multiple	-	996	O
and	-	1005	O
mixed	-	1009	O
in	-	1015	O
type	-	1018	O
,	-	1022	O
and	-	1024	O
rarely	-	1028	O
resulted	-	1035	O
in	-	1044	O
death	-	1047	O
.	-	1052	O

Electrical	1592014	1054	O
recordings	-	1065	O
from	-	1076	O
the	-	1081	O
hippocampus	-	1085	O
showed	-	1097	O
a	-	1104	O
rhythmic	-	1106	O
progression	-	1115	O
in	-	1127	O
EEG	-	1130	O
frequency	-	1134	O
and	-	1144	O
voltage	-	1148	O
with	-	1156	O
clinical	-	1161	O
seizure	-	1170	O
expression	-	1178	O
.	-	1188	O

BE	1592014	1190	B
-	-	1192	O
Injected	-	1193	O
rats	-	1202	O
that	-	1207	O
did	-	1212	O
not	-	1216	O
have	-	1220	O
seizures	-	1225	O
had	-	1234	O
significantly	-	1238	O
more	-	1252	O
locomotor	-	1257	O
activity	-	1267	O
than	-	1276	O
cocaine	-	1281	B
-	-	1288	O
injected	-	1289	O
animals	-	1298	O
without	-	1306	O
seizures	-	1314	O
.	-	1322	O

The	1592014	1324	O
finding	-	1328	O
that	-	1336	O
cocaine	-	1341	B
-	-	1348	O
and	-	1350	O
BE	-	1354	B
-	-	1356	O
induced	-	1357	O
seizures	-	1365	O
differ	-	1374	O
in	-	1381	O
several	-	1384	O
respects	-	1392	O
suggests	-	1401	O
more	-	1410	O
than	-	1415	O
one	-	1420	O
mechanism	-	1424	O
for	-	1434	O
cocaine	-	1438	B
-	-	1445	O
induced	-	1446	O
seizures	-	1454	O
and	-	1463	O
emphasizes	-	1467	O
the	-	1478	O
importance	-	1482	O
of	-	1493	O
a	-	1496	O
cocaine	-	1498	B
metabolite	-	1506	O
,	-	1516	O
BE	-	1518	B
.	-	1520	O

Protection	1436384	0	O
against	-	11	O
amphetamine	-	19	B
-	-	30	O
induced	-	31	O
neurotoxicity	-	39	O
toward	-	53	O
striatal	-	60	O
dopamine	-	69	B
neurons	-	78	O
in	-	86	O
rodents	-	89	O
by	-	97	O
LY274614	-	100	B
,	-	108	O
an	-	110	O
excitatory	-	113	O
amino	-	124	B
acid	-	130	I
antagonist	-	135	O
.	-	145	O

LY274614	1436384	147	B
,	-	155	O
3SR	-	157	B
,	-	160	I
4aRS	-	161	I
,	-	165	I
6SR	-	166	I
,	-	169	I
8aRS	-	170	I
-	-	174	I
6	-	175	I
-	-	176	I
[	-	177	I
phosphonomethyl	-	178	I
]	-	193	I
decahydr	-	194	I
oisoquinoline	-	203	I
-	-	216	I
3	-	217	I
-	-	218	I

carboxylic	1436384	220	I
acid	-	231	I
,	-	235	O
has	-	237	O
been	-	241	O
described	-	246	O
as	-	256	O
a	-	259	O
potent	-	261	O
antagonist	-	268	O
of	-	279	O
the	-	282	O
N	-	286	B
-	-	287	I
methyl	-	288	I
-	-	294	I
D	-	295	I
-	-	296	I
aspartate	-	297	I
(	-	307	O
NMDA	-	308	B
)	-	312	O
subtype	-	314	O
of	-	322	O
glutamate	-	325	B
receptor	-	335	O
.	-	343	O

Here	1436384	345	O
its	-	350	O
ability	-	354	O
to	-	362	O
antagonize	-	365	O
the	-	376	O
prolonged	-	380	O
depletion	-	390	O
of	-	400	O
dopamine	-	403	B
in	-	412	O
the	-	415	O
striatum	-	419	O
by	-	428	O
amphetamine	-	431	B
in	-	443	O
iprindole	-	446	B
-	-	455	O
treated	-	456	O
rats	-	464	O
is	-	469	O
reported	-	472	O
.	-	480	O

A	1436384	482	O
single	-	484	O
18	-	491	O
.	-	493	O
4	-	494	O
mg	-	496	O
/	-	498	O
kg	-	499	O
(	-	502	O
i	-	503	O
.	-	504	O
p	-	505	O
.	-	506	O
)	-	507	O
dose	-	509	O
of	-	514	O
(	-	517	O
+	-	518	O
/	-	519	O
-	-	520	O
)	-	521	O
-	-	522	O
amphetamine	-	523	B
hemisulfate	-	535	O
,	-	546	O
given	-	548	O
to	-	554	O
rats	-	557	O
pretreated	-	562	O
with	-	573	O
iprindole	-	578	B
,	-	587	O
resulted	-	589	O
in	-	598	O
persistent	-	601	O
depletion	-	612	O
of	-	622	O
dopamine	-	625	B
in	-	634	O
the	-	637	O
striatum	-	641	O
1	-	650	O
week	-	652	O
later	-	657	O
.	-	662	O

This	1436384	664	O
prolonged	-	669	O
depletion	-	679	O
of	-	689	O
dopamine	-	692	B
in	-	701	O
the	-	704	O
striatum	-	708	O
was	-	717	O
antagonized	-	721	O
by	-	733	O
dizocilpine	-	736	B
(	-	748	O
MK	-	749	B
-	-	751	I
801	-	752	I
,	-	755	O
a	-	757	O
non	-	759	O
-	-	762	O
competitive	-	763	O
antagonist	-	775	O
of	-	786	O
NMDA	-	789	B
receptors	-	794	O
)	-	803	O
or	-	805	O
by	-	808	O
LY274614	-	811	B
(	-	820	O
a	-	821	O
competitive	-	823	O
antagonist	-	835	O
of	-	846	O
NMDA	-	849	B
receptors	-	854	O
)	-	863	O
.	-	864	O

The	1436384	866	O
protective	-	870	O
effect	-	881	O
of	-	888	O
LY274614	-	891	B
was	-	900	O
dose	-	904	O
-	-	908	O
dependent	-	909	O
,	-	918	O
being	-	920	O
maximum	-	926	O
at	-	934	O
10	-	937	O
-	-	939	O
40	-	940	O
mgkg	-	943	O
(	-	948	O
i	-	949	O
.	-	950	O
p	-	951	O
.	-	952	O
)	-	953	O
.	-	954	O

A	1436384	956	O
10	-	958	O
mg	-	961	O
/	-	963	O
kg	-	964	O
dose	-	967	O
of	-	972	O
LY274614	-	975	B
was	-	984	O
effective	-	988	O
in	-	998	O
antagonizing	-	1001	O
the	-	1014	O
depletion	-	1018	O
of	-	1028	O
dopamine	-	1031	B
in	-	1040	O
the	-	1043	O
striatum	-	1047	O
,	-	1055	O
when	-	1057	O
given	-	1062	O
as	-	1068	O
long	-	1071	O
as	-	1076	O
8	-	1079	O
hr	-	1081	O
prior	-	1084	O
to	-	1090	O
amphetamine	-	1093	B
but	-	1105	O
not	-	1109	O
when	-	1113	O
given	-	1118	O
24	-	1124	O
hr	-	1127	O
prior	-	1130	O
to	-	1136	O
amphetamine	-	1139	B
.	-	1150	O

Depletion	1436384	1152	O
of	-	1162	O
dopamine	-	1165	B
in	-	1174	O
the	-	1177	O
striatum	-	1181	O
was	-	1190	O
also	-	1194	O
antagonized	-	1199	O
when	-	1211	O
LY274614	-	1216	B
was	-	1225	O
given	-	1229	O
after	-	1235	O
the	-	1241	O
injection	-	1245	O
of	-	1255	O
amphetamine	-	1258	B
;	-	1269	O
LY274614	-	1271	B
protected	-	1280	O
when	-	1290	O
given	-	1295	O
up	-	1301	O
to	-	1304	O
4	-	1307	O
hr	-	1309	O
after	-	1312	O
but	-	1318	O
not	-	1322	O
when	-	1326	O
given	-	1331	O
8	-	1337	O
or	-	1339	O
24	-	1342	O
hr	-	1345	O
after	-	1348	O
amphetamine	-	1354	B
.	-	1365	O

The	1436384	1367	O
prolonged	-	1371	O
depletion	-	1381	O
of	-	1391	O
dopamine	-	1394	B
in	-	1403	O
the	-	1406	O
striatum	-	1410	O
in	-	1419	O
mice	-	1422	O
,	-	1426	O
given	-	1428	O
multiple	-	1434	O
injections	-	1443	O
of	-	1454	O
methamphetamine	-	1457	B
,	-	1472	O
was	-	1474	O
also	-	1478	O
antagonized	-	1483	O
dose	-	1495	O
-	-	1499	O
dependently	-	1500	O
and	-	1512	O
completely	-	1516	O
by	-	1527	O
LY274614	-	1530	B
.	-	1538	O

The	1436384	1540	O
data	-	1544	O
strengthen	-	1549	O
the	-	1560	O
evidence	-	1564	O
that	-	1573	O
the	-	1578	O
neurotoxic	-	1582	O
effect	-	1593	O
of	-	1600	O
amphetamine	-	1603	B
and	-	1615	O
related	-	1619	O
compounds	-	1627	O
toward	-	1637	O
nigrostriatal	-	1644	O
dopamine	-	1658	B
neurons	-	1667	O
involves	-	1675	O
NMDA	-	1684	B
receptors	-	1689	O
and	-	1699	O
that	-	1703	O
LY274614	-	1708	B
is	-	1717	O
an	-	1720	O
NMDA	-	1723	B
receptor	-	1728	O
antagonist	-	1737	O
with	-	1748	O
long	-	1753	O
-	-	1757	O
lasting	-	1758	O
in	-	1766	O
vivo	-	1769	O
effects	-	1774	O
in	-	1782	O
rats	-	1785	O
.	-	1789	O

Neonatal	1085609	0	O
pyridoxine	-	9	B
responsive	-	20	O
convulsions	-	31	O
due	-	43	O
to	-	47	O
isoniazid	-	50	B
therapy	-	60	O
.	-	67	O

A	1085609	69	O
17	-	71	O
-	-	73	O
day	-	74	O
-	-	77	O
old	-	78	O
infant	-	82	O
on	-	89	O
isoniazid	-	92	B
therapy	-	102	O
13	-	110	O
mg	-	113	O
/	-	115	O
kg	-	116	O
daily	-	119	O
from	-	125	O
birth	-	130	O
because	-	136	O
of	-	144	O
maternal	-	147	O
tuberculosis	-	156	O
was	-	169	O
admitted	-	173	O
after	-	182	O
4	-	188	O
days	-	190	O
of	-	195	O
clonic	-	198	O
fits	-	205	O
.	-	209	O

No	1085609	211	O
underlying	-	214	O
infective	-	225	O
or	-	235	O
biochemical	-	238	O
cause	-	250	O
could	-	256	O
be	-	262	O
found	-	265	O
.	-	270	O

The	1085609	272	O
fits	-	276	O
ceased	-	281	O
within	-	288	O
4	-	295	O
hours	-	297	O
of	-	303	O
administering	-	306	O
intramuscular	-	320	O
pyridoxine	-	334	B
,	-	344	O
suggesting	-	346	O
an	-	357	O
aetiology	-	360	O
of	-	370	O
pyridoxine	-	373	B
deficiency	-	384	O
secondary	-	395	O
to	-	405	O
isoniazid	-	408	B
medication	-	418	O
.	-	428	O

Reversal	809711	0	O
by	-	9	O
phenylephrine	-	12	B
of	-	26	O
the	-	29	O
beneficial	-	33	O
effects	-	44	O
of	-	52	O
intravenous	-	55	O
nitroglycerin	-	67	B
in	-	81	O
patients	-	84	O
with	-	93	O
acute	-	98	O
myocardial	-	104	O
infarction	-	115	O
.	-	125	O

Nitroglycerin	809711	127	B
has	-	141	O
been	-	145	O
shown	-	150	O
to	-	156	O
reduce	-	159	O
ST	-	166	O
-	-	168	O
segment	-	169	O
elevation	-	177	O
during	-	187	O
acute	-	194	O
myocardial	-	200	O
infarction	-	211	O
,	-	221	O
an	-	223	O
effect	-	226	O
potentiated	-	233	O
in	-	245	O
the	-	248	O
dog	-	252	O
by	-	256	O
agents	-	259	O
that	-	266	O
reverse	-	271	O
nitroglycerin	-	279	B
-	-	292	O
induced	-	293	O
hypotension	-	301	O
.	-	312	O

Our	809711	314	O
study	-	318	O
was	-	324	O
designed	-	328	O
to	-	337	O
determine	-	340	O
the	-	350	O
effects	-	354	O
of	-	362	O
combined	-	365	O
nitroglycerin	-	374	B
and	-	388	O
phenylephrine	-	392	B
therapy	-	406	O
.	-	413	O

Ten	809711	415	O
patients	-	419	O
with	-	428	O
acute	-	433	O
transmural	-	439	O
myocardial	-	450	O
infarctions	-	461	O
received	-	473	O
intravenous	-	482	O
nitroglycerin	-	494	B
,	-	507	O
sufficient	-	509	O
to	-	520	O
reduce	-	523	O
mean	-	530	O
arterial	-	535	O
pressure	-	544	O
from	-	553	O
107	-	558	O
+	-	562	O
/	-	563	O
-	-	564	O

6	809711	566	O
to	-	568	O
85	-	571	O
+	-	574	O
/	-	575	O
-	-	576	O

6	809711	578	O
mm	-	580	O
Hg	-	583	O
(	-	586	O
P	-	587	O
less	-	589	O
than	-	594	O
0	-	599	O
.	-	600	O
001	-	601	O
)	-	604	O
,	-	605	O
for	-	607	O
60	-	611	O
minutes	-	614	O
.	-	621	O

Left	809711	623	O
ventricular	-	628	O
filling	-	640	O
pressure	-	648	O
decreased	-	657	O
from	-	667	O
19	-	672	O
+	-	675	O
/	-	676	O
-	-	677	O

2	809711	679	O
to	-	681	O
11	-	684	O
+	-	687	O
/	-	688	O
-	-	689	O

2	809711	691	O
mm	-	693	O
Hg	-	696	O
(	-	699	O
P	-	700	O
less	-	702	O
than	-	707	O
0	-	712	O
.	-	713	O
001	-	714	O
)	-	717	O
.	-	718	O

SigmaST	809711	720	O
,	-	727	O
the	-	729	O
sum	-	733	O
of	-	737	O
ST	-	740	O
-	-	742	O
segment	-	743	O
elevations	-	751	O
in	-	762	O
16	-	765	O
precordial	-	768	O
leads	-	779	O
,	-	784	O
decreased	-	786	O
(	-	796	O
P	-	797	O
less	-	799	O
than	-	804	O
0	-	809	O
.	-	810	O
02	-	811	O
)	-	813	O
with	-	815	O
intravenous	-	820	O
nitroglycerin	-	832	B
.	-	845	O

Subsequent	809711	847	O
addition	-	858	O
of	-	867	O
phenylephrine	-	870	B
infusion	-	884	O
,	-	892	O
sufficient	-	894	O
to	-	905	O
re	-	908	O
-	-	910	O
elevate	-	911	O
mean	-	919	O
arterial	-	924	O
pressure	-	933	O
to	-	942	O
106	-	945	O
+	-	949	O
/	-	950	O
-	-	951	O

4	809711	953	O
mm	-	955	O
Hg	-	958	O
(	-	961	O
P	-	962	O
less	-	964	O
than	-	969	O
0	-	974	O
.	-	975	O
001	-	976	O
)	-	979	O
for	-	981	O
30	-	985	O
minutes	-	988	O
,	-	995	O
increased	-	997	O
left	-	1007	O
ventricular	-	1012	O
filling	-	1024	O
pressure	-	1032	O
to	-	1041	O
17	-	1044	O
+	-	1047	O
/	-	1048	O
-	-	1049	O

2	809711	1051	O
mm	-	1053	O
Hg	-	1056	O
(	-	1059	O
P	-	1060	O
less	-	1062	O
than	-	1067	O
0	-	1072	O
.	-	1073	O
05	-	1074	O
)	-	1076	O
and	-	1078	O
also	-	1082	O
significantly	-	1087	O
increased	-	1101	O
sigmaST	-	1111	O
(	-	1119	O
P	-	1120	O
less	-	1122	O
than	-	1127	O
0	-	1132	O
.	-	1133	O
05	-	1134	O
)	-	1136	O
.	-	1137	O

Our	809711	1139	O
results	-	1143	O
suggest	-	1151	O
that	-	1159	O
addition	-	1164	O
of	-	1173	O
phenylephrine	-	1176	B
to	-	1190	O
nitroglycerin	-	1193	B
is	-	1207	O
not	-	1210	O
beneficial	-	1214	O
in	-	1225	O
the	-	1228	O
treatment	-	1232	O
of	-	1242	O
patients	-	1245	O
with	-	1254	O
acute	-	1259	O
myocardial	-	1265	O
infarction	-	1276	O
.	-	1286	O

Elevation	20621845	0	O
of	-	10	O
ADAM10	-	13	O
,	-	19	O
ADAM17	-	21	O
,	-	27	O
MMP	-	29	O
-	-	32	O
2	-	33	O
and	-	35	O
MMP	-	39	O
-	-	42	O
9	-	43	O
expression	-	45	O
with	-	56	O
media	-	61	O
degeneration	-	67	O
features	-	80	O
CaCl2	-	89	B
-	-	94	O
induced	-	95	O
thoracic	-	103	O
aortic	-	112	O
aneurysm	-	119	O
in	-	128	O
a	-	131	O
rat	-	133	O
model	-	137	O
.	-	142	O

PURPOSE	20621845	144	O
:	-	151	O

This	20621845	153	O
study	-	158	O
was	-	164	O
designed	-	168	O
to	-	177	O
establish	-	180	O
a	-	190	O
rat	-	192	O
model	-	196	O
of	-	202	O
thoracic	-	205	O
aortic	-	214	O
aneurysm	-	221	O
(	-	230	O
TAA	-	231	O
)	-	234	O
by	-	236	O
calcium	-	239	B
chloride	-	247	I
(	-	256	O
CaCl	-	257	B
(	-	261	I
2	-	262	I
)	-	263	I
)	-	264	O
-	-	265	O
induced	-	266	O
arterial	-	274	O
injury	-	283	O
and	-	290	O
to	-	294	O
explore	-	297	O
the	-	305	O
potential	-	309	O
role	-	319	O
of	-	324	O
a	-	327	O
disintegrin	-	329	O
and	-	341	O
metalloproteinase	-	345	O
(	-	363	O
ADAM	-	364	O
)	-	368	O
,	-	369	O
matrix	-	371	O
metalloproteinases	-	378	O
(	-	397	O
MMPs	-	398	O
)	-	402	O
and	-	404	O
their	-	408	O
endogenous	-	414	O
inhibitors	-	425	O
(	-	436	O
TIMPs	-	437	O
)	-	442	O
in	-	444	O
TAA	-	447	O
formation	-	451	O
.	-	460	O

METHODS	20621845	462	O
:	-	469	O

Thoracic	20621845	471	O
aorta	-	480	O
of	-	486	O
male	-	489	O
Sprague	-	494	O
-	-	501	O
Dawley	-	502	O
rats	-	509	O
was	-	514	O
exposed	-	518	O
to	-	526	O
0	-	529	O
.	-	530	O
5	-	531	O
M	-	532	O
CaCl	-	534	B
(	-	538	I
2	-	539	I
)	-	540	I
or	-	542	O
normal	-	545	O
saline	-	552	O
(	-	559	O
NaCl	-	560	B
)	-	564	O
.	-	565	O

After	20621845	567	O
12weeks	-	573	O
,	-	580	O
animals	-	582	O
were	-	590	O
euthanized	-	595	O
,	-	605	O
and	-	607	O
CaCl	-	611	B
(	-	615	I
2	-	616	I
)	-	617	I
-	-	618	O
treated	-	619	O
,	-	626	O
CaCl	-	628	B
(	-	632	I
2	-	633	I
)	-	634	I
-	-	635	O
untreated	-	636	O
(	-	646	O
n	-	647	O
=	-	648	O
12	-	649	O
)	-	651	O
and	-	653	O
NaCl	-	657	B
-	-	661	O
treated	-	662	O
aortic	-	670	O
segments	-	677	O
(	-	686	O
n	-	687	O
=	-	688	O
12	-	689	O
)	-	691	O
were	-	693	O
collected	-	698	O
for	-	708	O
histological	-	712	O
and	-	725	O
molecular	-	729	O
assessments	-	739	O
.	-	750	O

MMP	20621845	752	O
-	-	755	O
TIMP	-	756	O
and	-	761	O
ADAM	-	765	O
mRNAs	-	770	O
were	-	776	O
semi	-	781	O
-	-	785	O
quantitatively	-	786	O
analyzed	-	801	O
and	-	810	O
protein	-	814	O
expressions	-	822	O
were	-	834	O
determined	-	839	O
by	-	850	O
immunohistochemistry	-	853	O
.	-	873	O

RESULTS	20621845	875	O
:	-	882	O

Despite	20621845	884	O
similar	-	892	O
external	-	900	O
diameters	-	909	O
among	-	919	O
CaCl	-	925	B
(	-	929	I
2	-	930	I
)	-	931	I
-	-	932	O
treated	-	933	O
,	-	940	O
non	-	942	O
-	-	945	O
CaCl	-	946	B
(	-	950	I
2	-	951	I
)	-	952	I
-	-	953	O
treated	-	954	O
and	-	962	O
NaCl	-	966	B
-	-	970	O
treated	-	971	O
segments	-	979	O
,	-	987	O
aneurymal	-	989	O
alteration	-	999	O
(	-	1010	O
n	-	1011	O
=	-	1012	O
6	-	1013	O
,	-	1014	O
50	-	1016	O
%	-	1018	O
)	-	1019	O
,	-	1020	O
media	-	1022	O
degeneration	-	1028	O
with	-	1041	O
regional	-	1046	O
disruption	-	1055	O
,	-	1065	O
fragmentation	-	1067	O
of	-	1081	O
elastic	-	1084	O
fiber	-	1092	O
,	-	1097	O
and	-	1099	O
increased	-	1103	O
collagen	-	1113	O
deposition	-	1122	O
(	-	1133	O
n	-	1134	O
=	-	1135	O
12	-	1136	O
,	-	1138	O
100	-	1140	O
%	-	1143	O
)	-	1144	O
were	-	1146	O
demonstrated	-	1151	O
in	-	1164	O
CaCl	-	1167	B
(	-	1171	I
2	-	1172	I
)	-	1173	I
-	-	1174	O
treated	-	1175	O
segments	-	1183	O
.	-	1191	O

MMP	20621845	1193	O
-	-	1196	O
2	-	1197	O
,	-	1198	O
MMP	-	1200	O
-	-	1203	O
9	-	1204	O
,	-	1205	O
ADAM	-	1207	O
-	-	1211	O
10	-	1212	O
and	-	1215	O
ADAM	-	1219	O
-	-	1223	O
17	-	1224	O
mRNA	-	1227	O
levels	-	1232	O
were	-	1239	O
increased	-	1244	O
in	-	1254	O
CaCl	-	1257	B
(	-	1261	I
2	-	1262	I
)	-	1263	I
-	-	1264	O
treated	-	1265	O
segments	-	1273	O
(	-	1282	O
all	-	1283	O
p	-	1287	O
<	-	1288	O
0	-	1289	O
.	-	1290	O
01	-	1291	O
)	-	1293	O
,	-	1294	O
with	-	1296	O
trends	-	1301	O
of	-	1308	O
elevation	-	1311	O
in	-	1321	O
CaCl	-	1324	B
(	-	1328	I
2	-	1329	I
)	-	1330	I
-	-	1331	O
untreated	-	1332	O
segments	-	1342	O
,	-	1350	O
as	-	1352	O
compared	-	1355	O
with	-	1364	O
NaCl	-	1369	B
-	-	1373	O
treated	-	1374	O
segments	-	1382	O
.	-	1390	O

Immunohistochemistry	20621845	1392	O
displayed	-	1413	O
significantly	-	1423	O
increased	-	1437	O
expressions	-	1447	O
of	-	1459	O
MMP	-	1462	O
-	-	1465	O
2	-	1466	O
,	-	1467	O
MMP	-	1469	O
-	-	1472	O
9	-	1473	O
,	-	1474	O
ADAM	-	1476	O
-	-	1480	O
10	-	1481	O
and	-	1484	O
ADAM	-	1488	O
-	-	1492	O
17	-	1493	O
(	-	1496	O
all	-	1497	O
p	-	1501	O
<	-	1502	O
0	-	1503	O
.	-	1504	O
01	-	1505	O
)	-	1507	O
in	-	1509	O
intima	-	1512	O
and	-	1519	O
media	-	1523	O
for	-	1529	O
CaCl	-	1533	B
(	-	1537	I
2	-	1538	I
)	-	1539	I
-	-	1540	O
treated	-	1541	O
segments	-	1549	O
.	-	1557	O

TIMP	20621845	1559	O
mRNA	-	1564	O
and	-	1569	O
tissue	-	1573	O
levels	-	1580	O
did	-	1587	O
not	-	1591	O
differ	-	1595	O
obviously	-	1602	O
among	-	1612	O
the	-	1618	O
three	-	1622	O
aortic	-	1628	O
segments	-	1635	O
.	-	1643	O

CONCLUSION	20621845	1645	O
:	-	1655	O

This	20621845	1657	O
study	-	1662	O
establishes	-	1668	O
a	-	1680	O
TAA	-	1682	O
model	-	1686	O
by	-	1692	O
periarterial	-	1695	O
CaCl	-	1708	B
(	-	1712	I
2	-	1713	I
)	-	1714	I
exposure	-	1716	O
in	-	1725	O
rats	-	1728	O
,	-	1732	O
and	-	1734	O
demonstrates	-	1738	O
a	-	1751	O
significant	-	1753	O
elevation	-	1765	O
of	-	1775	O
expression	-	1778	O
of	-	1789	O
MMP	-	1792	O
-	-	1795	O
2	-	1796	O
,	-	1797	O
MMP	-	1799	O
-	-	1802	O
9	-	1803	O
,	-	1804	O
ADAM10	-	1806	O
and	-	1813	O
ADAM17	-	1817	O
in	-	1824	O
the	-	1827	O
pathogenesis	-	1831	O
of	-	1844	O
vascular	-	1847	O
remodeling	-	1856	O
.	-	1866	O

When	19843802	0	O
drugs	-	5	O
disappear	-	11	O
from	-	21	O
the	-	26	O
patient	-	30	O
:	-	37	O
elimination	-	39	O
of	-	51	O
intravenous	-	54	O
medication	-	66	O
by	-	77	O
hemodiafiltration	-	80	O
.	-	97	O

Twenty	19843802	99	O
-	-	105	O
three	-	106	O
hours	-	112	O
after	-	118	O
heart	-	124	O
transplantation	-	130	O
,	-	145	O
life	-	147	O
-	-	151	O
threatening	-	152	O
acute	-	164	O
right	-	170	O
heart	-	176	O
failure	-	182	O
was	-	190	O
diagnosed	-	194	O
in	-	204	O
a	-	207	O
patient	-	209	O
requiring	-	217	O
continuous	-	227	O
venovenous	-	238	O
hemodiafiltration	-	249	O
(	-	267	O
CVVHDF	-	268	O
)	-	274	O
.	-	275	O

Increasing	19843802	277	O
doses	-	288	O
of	-	294	O
catecholamines	-	297	B
,	-	311	O
sedatives	-	313	O
,	-	322	O
and	-	324	O
muscle	-	328	O
relaxants	-	335	O
administered	-	345	O
through	-	358	O
a	-	366	O
central	-	368	O
venous	-	376	O
catheter	-	383	O
were	-	392	O
ineffective	-	397	O
.	-	408	O

However	19843802	410	O
,	-	417	O
a	-	419	O
bolus	-	421	O
of	-	427	O
epinephrine	-	430	B
injected	-	442	O
through	-	451	O
an	-	459	O
alternative	-	462	O
catheter	-	474	O
provoked	-	483	O
a	-	492	O
hypertensive	-	494	O
crisis	-	507	O
.	-	513	O

Thus	19843802	515	O
,	-	519	O
interference	-	521	O
with	-	534	O
the	-	539	O
central	-	543	O
venous	-	551	O
infusion	-	558	O
by	-	567	O
the	-	570	O
dialysis	-	574	O
catheter	-	583	O
was	-	592	O
suspected	-	596	O
.	-	605	O

The	19843802	607	O
catheters	-	611	O
were	-	621	O
changed	-	626	O
,	-	633	O
and	-	635	O
hemodynamics	-	639	O
stabilized	-	652	O
at	-	663	O
lower	-	666	O
catecholamine	-	672	B
doses	-	686	O
.	-	691	O

When	19843802	693	O
the	-	698	O
effects	-	702	O
of	-	710	O
IV	-	713	O
drugs	-	716	O
are	-	722	O
inadequate	-	726	O
in	-	737	O
patients	-	740	O
receiving	-	749	O
CVVHDF	-	759	O
,	-	765	O
interference	-	767	O
with	-	780	O
adjacent	-	785	O
catheters	-	794	O
resulting	-	804	O
in	-	814	O
elimination	-	817	O
of	-	829	O
the	-	832	O
drug	-	836	O
by	-	841	O
CVVHDF	-	844	O
should	-	851	O
be	-	858	O
suspected	-	861	O
.	-	870	O

Long	19473225	0	O
-	-	4	O
term	-	5	O
glutamate	-	10	B
supplementation	-	20	O
failed	-	36	O
to	-	43	O
protect	-	46	O
against	-	54	O
peripheral	-	62	O
neurotoxicity	-	73	O
of	-	87	O
paclitaxel	-	90	B
.	-	100	O

Toxic	19473225	102	O
peripheral	-	108	O
neuropathy	-	119	O
is	-	130	O
still	-	133	O
a	-	139	O
significant	-	141	O
limiting	-	153	O
factor	-	162	O
for	-	169	O
chemotherapy	-	173	O
with	-	186	O
paclitaxel	-	191	B
(	-	202	O
PAC	-	203	B
)	-	206	O
,	-	207	O
although	-	209	O
glutamate	-	218	B
and	-	228	O
its	-	232	O
closely	-	236	O
related	-	244	O
amino	-	252	B
acid	-	258	I
glutamine	-	263	B
were	-	273	O
claimed	-	278	O
to	-	286	O
ameliorate	-	289	O
PAC	-	300	B
neurotoxicity	-	304	O
.	-	317	O

This	19473225	319	O
pilot	-	324	O
trial	-	330	O
aimed	-	336	O
to	-	342	O
evaluate	-	345	O
the	-	354	O
role	-	358	O
of	-	363	O
glutamate	-	366	B
supplementation	-	376	O
for	-	392	O
preventing	-	396	O
PAC	-	407	B
-	-	410	O
induced	-	411	O
peripheral	-	419	O
neuropathy	-	430	O
in	-	441	O
a	-	444	O
randomized	-	446	O
,	-	456	O
placebo	-	458	O
-	-	465	O
controlled	-	466	O
,	-	476	O
double	-	478	O
-	-	484	O
blinded	-	485	O
clinical	-	493	O
and	-	502	O
electro	-	506	O
-	-	513	O
diagnostic	-	514	O
study	-	525	O
.	-	530	O

Forty	19473225	532	O
-	-	537	O
three	-	538	O
ovarian	-	544	O
cancer	-	552	O
patients	-	559	O
were	-	568	O
available	-	573	O
for	-	583	O
analysis	-	587	O
following	-	596	O
six	-	606	O
cycles	-	610	O
of	-	617	O
the	-	620	O
same	-	624	O
PAC	-	629	B
-	-	632	O
containing	-	633	O
regimen	-	644	O
:	-	651	O
23	-	653	O
had	-	656	O
been	-	660	O
supplemented	-	665	O
by	-	678	O
glutamate	-	681	B
all	-	691	O
along	-	695	O
the	-	701	O
treatment	-	705	O
period	-	715	O
,	-	721	O
at	-	723	O
a	-	726	O
daily	-	728	O
dose	-	734	O
of	-	739	O
three	-	742	O
times	-	748	O
500	-	754	O
mg	-	758	O
(	-	761	O
group	-	762	O
G	-	768	O
)	-	769	O
,	-	770	O
and	-	772	O
20	-	776	O
had	-	779	O
received	-	783	O
a	-	792	O
placebo	-	794	O
(	-	802	O
group	-	803	O
P	-	809	O
)	-	810	O
.	-	811	O

Patients	19473225	813	O
were	-	822	O
evaluated	-	827	O
by	-	837	O
neurological	-	840	O
examinations	-	853	O
,	-	865	O
questionnaires	-	867	O
and	-	882	O
sensory	-	886	O
-	-	893	O
motor	-	894	O
nerve	-	900	O
conduction	-	906	O
studies	-	917	O
.	-	924	O

There	19473225	926	O
was	-	932	O
no	-	936	O
significant	-	939	O
difference	-	951	O
in	-	962	O
the	-	965	O
frequency	-	969	O
of	-	979	O
signs	-	982	O
or	-	988	O
symptoms	-	991	O
between	-	1000	O
the	-	1008	O
two	-	1012	O
groups	-	1016	O
although	-	1023	O
neurotoxicity	-	1032	O
symptoms	-	1046	O
presented	-	1055	O
mostly	-	1065	O
with	-	1072	O
lower	-	1077	O
scores	-	1083	O
of	-	1090	O
severity	-	1093	O
in	-	1102	O
group	-	1105	O
G	-	1111	O
.	-	1112	O

However	19473225	1114	O
,	-	1121	O
this	-	1123	O
difference	-	1128	O
reached	-	1139	O
statistical	-	1147	O
significance	-	1159	O
only	-	1172	O
with	-	1177	O
regard	-	1182	O
to	-	1189	O
reported	-	1192	O
pain	-	1201	O
sensation	-	1206	O
(	-	1216	O
P	-	1217	O
=	-	1219	O
0	-	1221	O
.	-	1222	O
011	-	1223	O
)	-	1226	O
.	-	1227	O

Also	19473225	1229	O
the	-	1234	O
frequency	-	1238	O
of	-	1248	O
abnormal	-	1251	O
electro	-	1260	O
-	-	1267	O
diagnostic	-	1268	O
findings	-	1279	O
showed	-	1288	O
similarity	-	1295	O
between	-	1306	O
the	-	1314	O
two	-	1318	O
groups	-	1322	O
(	-	1329	O
G	-	1330	O
:	-	1331	O
7	-	1333	O
/	-	1334	O
23	-	1335	O
=	-	1338	O
30	-	1340	O
.	-	1342	O
4	-	1343	O
%	-	1344	O
;	-	1345	O
P	-	1347	O
:	-	1348	O
6	-	1350	O
/	-	1351	O
20	-	1352	O
=	-	1355	O
30	-	1357	O
%	-	1359	O
)	-	1360	O
.	-	1361	O

This	19473225	1363	O
pilot	-	1368	O
study	-	1374	O
leads	-	1380	O
to	-	1386	O
the	-	1389	O
conclusion	-	1393	O
that	-	1404	O
glutamate	-	1409	B
supplementation	-	1419	O
at	-	1435	O
the	-	1438	O
chosen	-	1442	O
regimen	-	1449	O
fails	-	1457	O
to	-	1463	O
protect	-	1466	O
against	-	1474	O
peripheral	-	1482	O
neurotoxicity	-	1493	O
of	-	1507	O
PAC	-	1510	B
.	-	1513	O

Attentional	19387625	0	O
modulation	-	12	O
of	-	23	O
perceived	-	26	O
pain	-	36	O
intensity	-	41	O
in	-	51	O
capsaicin	-	54	B
-	-	63	O
induced	-	64	O
secondary	-	72	O
hyperalgesia	-	82	O
.	-	94	O

Perceived	19387625	96	O
pain	-	106	O
intensity	-	111	O
is	-	121	O
modulated	-	124	O
by	-	134	O
attention	-	137	O
.	-	146	O

However	19387625	148	O
,	-	155	O
it	-	157	O
is	-	160	O
not	-	163	O
known	-	167	O
that	-	173	O
how	-	178	O
pain	-	182	O
intensity	-	187	O
ratings	-	197	O
are	-	205	O
affected	-	209	O
by	-	218	O
attention	-	221	O
in	-	231	O
capsaicin	-	234	B
-	-	243	O
induced	-	244	O
secondary	-	252	O
hyperalgesia	-	262	O
.	-	274	O

Here	19387625	276	O
we	-	281	O
show	-	284	O
that	-	289	O
perceived	-	294	O
pain	-	304	O
intensity	-	309	O
in	-	319	O
secondary	-	322	O
hyperalgesia	-	332	O
is	-	345	O
decreased	-	348	O
when	-	358	O
attention	-	363	O
is	-	373	O
distracted	-	376	O
away	-	387	O
from	-	392	O
the	-	397	O
painful	-	401	O
pinprick	-	409	O
stimulus	-	418	O
with	-	427	O
a	-	432	O
visual	-	434	O
task	-	441	O
.	-	445	O

Furthermore	19387625	447	O
,	-	458	O
it	-	460	O
was	-	463	O
found	-	467	O
that	-	473	O
the	-	478	O
magnitude	-	482	O
of	-	492	O
attentional	-	495	O
modulation	-	507	O
in	-	518	O
secondary	-	521	O
hyperalgesia	-	531	O
is	-	544	O
very	-	547	O
similar	-	552	O
to	-	560	O
that	-	563	O
of	-	568	O
capsaicin	-	571	B
-	-	580	O
untreated	-	581	O
,	-	590	O
control	-	592	O
condition	-	600	O
.	-	609	O

Our	19387625	611	O
findings	-	615	O
,	-	623	O
showing	-	625	O
no	-	633	O
interaction	-	636	O
between	-	648	O
capsaicin	-	656	B
treatment	-	666	O
and	-	676	O
attentional	-	680	O
modulation	-	692	O
suggest	-	703	O
that	-	711	O
capsaicin	-	716	B
-	-	725	O
induced	-	726	O
secondary	-	734	O
hyperalgesia	-	744	O
and	-	757	O
attention	-	761	O
might	-	771	O
affect	-	777	O
mechanical	-	784	O
pain	-	795	O
through	-	800	O
independent	-	808	O
mechanisms	-	820	O
.	-	830	O

Testosterone	19211690	0	B
-	-	12	O
dependent	-	13	O
hypertension	-	23	O
and	-	36	O
upregulation	-	40	O
of	-	53	O
intrarenal	-	56	O
angiotensinogen	-	67	O
in	-	83	O
Dahl	-	86	O
salt	-	91	B
-	-	95	O
sensitive	-	96	O
rats	-	106	O
.	-	110	O

Blood	19211690	112	O
pressure	-	118	O
(	-	127	O
BP	-	128	O
)	-	130	O
is	-	132	O
more	-	135	O
salt	-	140	B
sensitive	-	145	O
in	-	155	O
men	-	158	O
than	-	162	O
in	-	167	O
premenopausal	-	170	O
women	-	184	O
.	-	189	O

In	19211690	191	O
Dahl	-	194	O
salt	-	199	B
-	-	203	O
sensitive	-	204	O
rats	-	214	O
(	-	219	O
DS	-	220	O
)	-	222	O
,	-	223	O
high	-	225	O
-	-	229	O
salt	-	230	B
(	-	235	O
HS	-	236	O
)	-	238	O
diet	-	240	O
increases	-	245	O
BP	-	255	O
more	-	258	O
in	-	263	O
males	-	266	O
than	-	272	O
females	-	277	O
.	-	284	O

In	19211690	286	O
contrast	-	289	O
to	-	298	O
the	-	301	O
systemic	-	305	O
renin	-	314	O
-	-	319	O
angiotensin	-	320	B
system	-	332	O
,	-	338	O
which	-	340	O
is	-	346	O
suppressed	-	349	O
in	-	360	O
response	-	363	O
to	-	372	O
HS	-	375	O
in	-	378	O
male	-	381	O
DS	-	386	O
,	-	388	O
intrarenal	-	390	O
angiotensinogen	-	401	O
expression	-	417	O
is	-	428	O
increased	-	431	O
,	-	440	O
and	-	442	O
intrarenal	-	446	O
levels	-	457	O
of	-	464	O
ANG	-	467	O
II	-	471	O
are	-	474	O
not	-	478	O
suppressed	-	482	O
.	-	492	O

In	19211690	494	O
this	-	497	O
study	-	502	O
,	-	507	O
the	-	509	O
hypothesis	-	513	O
was	-	524	O
tested	-	528	O
that	-	535	O
there	-	540	O
is	-	546	O
a	-	549	O
sexual	-	551	O
dimorphism	-	558	O
in	-	569	O
HS	-	572	O
-	-	574	O
induced	-	575	O
upregulation	-	583	O
of	-	596	O
intrarenal	-	599	O
angiotensinogen	-	610	O
mediated	-	626	O
by	-	635	O
testosterone	-	638	B
that	-	651	O
also	-	656	O
causes	-	661	O
increases	-	668	O
in	-	678	O
BP	-	681	O
and	-	684	O
renal	-	688	O
injury	-	694	O
.	-	700	O

On	19211690	702	O
a	-	705	O
low	-	707	O
-	-	710	O
salt	-	711	B
(	-	716	O
LS	-	717	O
)	-	719	O
diet	-	721	O
,	-	725	O
male	-	727	O
DS	-	732	O
had	-	735	O
higher	-	739	O
levels	-	746	O
of	-	753	O
intrarenal	-	756	O
angiotensinogen	-	767	O
mRNA	-	783	O
than	-	788	O
females	-	793	O
.	-	800	O

HS	19211690	802	O
diet	-	805	O
for	-	810	O
4	-	814	O
wk	-	816	O
increased	-	819	O
renal	-	829	O
cortical	-	835	O
angiotensinogen	-	844	O
mRNA	-	860	O
and	-	865	O
protein	-	869	O
only	-	877	O
in	-	882	O
male	-	885	O
DS	-	890	O
,	-	892	O
which	-	894	O
was	-	900	O
prevented	-	904	O
by	-	914	O
castration	-	917	O
.	-	927	O

Ovariectomy	19211690	929	O
of	-	941	O
female	-	944	O
DS	-	951	O
had	-	954	O
no	-	958	O
effect	-	961	O
on	-	968	O
intrarenal	-	971	O
angiotensinogen	-	982	O
expression	-	998	O
on	-	1009	O
either	-	1012	O
diet	-	1019	O
.	-	1023	O

Radiotelemetric	19211690	1025	O
BP	-	1041	O
was	-	1044	O
similar	-	1048	O
between	-	1056	O
males	-	1064	O
and	-	1070	O
castrated	-	1074	O
rats	-	1084	O
on	-	1089	O
LS	-	1092	O
diet	-	1095	O
.	-	1099	O

HS	19211690	1101	O
diet	-	1104	O
for	-	1109	O
4	-	1113	O
wk	-	1115	O
caused	-	1118	O
a	-	1125	O
progressive	-	1127	O
increase	-	1139	O
in	-	1148	O
BP	-	1151	O
,	-	1153	O
protein	-	1155	O
and	-	1163	O
albumin	-	1167	O
excretion	-	1175	O
,	-	1184	O
and	-	1186	O
glomerular	-	1190	O
sclerosis	-	1201	O
in	-	1211	O
male	-	1214	O
DS	-	1219	O
rats	-	1222	O
,	-	1226	O
which	-	1228	O
were	-	1234	O
attenuated	-	1239	O
by	-	1250	O
castration	-	1253	O
.	-	1263	O

Testosterone	19211690	1265	B
replacement	-	1278	O
in	-	1290	O
castrated	-	1293	O
DS	-	1303	O
rats	-	1306	O
increased	-	1311	O
BP	-	1321	O
,	-	1323	O
renal	-	1325	O
injury	-	1331	O
,	-	1337	O
and	-	1339	O
upregulation	-	1343	O
of	-	1356	O
renal	-	1359	O
angiotensinogen	-	1365	O
associated	-	1381	O
with	-	1392	O
HS	-	1397	O
diet	-	1400	O
.	-	1404	O

Testosterone	19211690	1406	B
contributes	-	1419	O
to	-	1431	O
the	-	1434	O
development	-	1438	O
of	-	1450	O
hypertension	-	1453	O
and	-	1466	O
renal	-	1470	O
injury	-	1476	O
in	-	1483	O
male	-	1486	O
DS	-	1491	O
rats	-	1494	O
on	-	1499	O
HS	-	1502	O
diet	-	1505	O
possibly	-	1510	O
through	-	1519	O
upregulation	-	1527	O
of	-	1540	O
the	-	1543	O
intrarenal	-	1547	O
renin	-	1558	O
-	-	1563	O
angiotensin	-	1564	B
system	-	1576	O
.	-	1582	O

Prenatal	18703024	0	O
protein	-	9	O
deprivation	-	17	O
alters	-	29	O
dopamine	-	36	B
-	-	44	O
mediated	-	45	O
behaviors	-	54	O
and	-	64	O
dopaminergic	-	68	O
and	-	81	O
glutamatergic	-	85	O
receptor	-	99	O
binding	-	108	O
.	-	115	O

Epidemiological	18703024	117	O
evidence	-	133	O
indicates	-	142	O
that	-	152	O
prenatal	-	157	O
nutritional	-	166	O
deprivation	-	178	O
may	-	190	O
increase	-	194	O
the	-	203	O
risk	-	207	O
of	-	212	O
schizophrenia	-	215	O
.	-	228	O

The	18703024	230	O
goal	-	234	O
of	-	239	O
these	-	242	O
studies	-	248	O
was	-	256	O
to	-	260	O
use	-	263	O
an	-	267	O
animal	-	270	O
model	-	277	O
to	-	283	O
examine	-	286	O
the	-	294	O
effects	-	298	O
of	-	306	O
prenatal	-	309	O
protein	-	318	O
deprivation	-	326	O
on	-	338	O
behaviors	-	341	O
and	-	351	O
receptor	-	355	O
binding	-	364	O
with	-	372	O
relevance	-	377	O
to	-	387	O
schizophrenia	-	390	O
.	-	403	O

We	18703024	405	O
report	-	408	O
that	-	415	O
prenatally	-	420	O
protein	-	431	O
deprived	-	439	O
(	-	448	O
PD	-	449	O
)	-	451	O
female	-	453	O
rats	-	460	O
showed	-	465	O
an	-	472	O
increased	-	475	O
stereotypic	-	485	O
response	-	497	O
to	-	506	O
apomorphine	-	509	B
and	-	521	O
an	-	525	O
increased	-	528	O
locomotor	-	538	O
response	-	548	O
to	-	557	O
amphetamine	-	560	B
in	-	572	O
adulthood	-	575	O
.	-	584	O

These	18703024	586	O
differences	-	592	O
were	-	604	O
not	-	609	O
observed	-	613	O
during	-	622	O
puberty	-	629	O
.	-	636	O

No	18703024	638	O
changes	-	641	O
in	-	649	O
haloperidol	-	652	B
-	-	663	O
induced	-	664	O
catalepsy	-	672	O
or	-	682	O
MK	-	685	B
-	-	687	I
801	-	688	I
-	-	691	O
induced	-	692	O
locomotion	-	700	O
were	-	711	O
seen	-	716	O
following	-	721	O
PD	-	731	O
.	-	733	O

In	18703024	735	O
addition	-	738	O
,	-	746	O
PD	-	748	O
female	-	751	O
rats	-	758	O
showed	-	763	O
increased	-	770	O
(	-	780	O
3	-	781	O
)	-	782	O
H	-	783	B
-	-	784	O
MK	-	785	B
-	-	787	I
801	-	788	I
binding	-	792	O
in	-	800	O
the	-	803	O
striatum	-	807	O
and	-	816	O
hippocampus	-	820	O
,	-	831	O
but	-	833	O
not	-	837	O
in	-	841	O
the	-	844	O
cortex	-	848	O
.	-	854	O

PD	18703024	856	O
female	-	859	O
rats	-	866	O
also	-	871	O
showed	-	876	O
increased	-	883	O
(	-	893	O
3	-	894	O
)	-	895	O
H	-	896	B
-	-	897	O
haloperidol	-	898	B
binding	-	910	O
and	-	918	O
decreased	-	922	O
dopamine	-	932	B
transporter	-	941	O
binding	-	953	O
in	-	961	O
striatum	-	964	O
.	-	972	O

No	18703024	974	O
statistically	-	977	O
significant	-	991	O
changes	-	1003	O
in	-	1011	O
behavior	-	1014	O
or	-	1023	O
receptor	-	1026	O
binding	-	1035	O
were	-	1043	O
found	-	1048	O
in	-	1054	O
PD	-	1057	O
males	-	1060	O
with	-	1066	O
the	-	1071	O
exception	-	1075	O
of	-	1085	O
increased	-	1088	O
(	-	1098	O
3	-	1099	O
)	-	1100	O
H	-	1101	B
-	-	1102	O
MK	-	1103	B
-	-	1105	I
801	-	1106	I
binding	-	1110	O
in	-	1118	O
cortex	-	1121	O
.	-	1127	O

This	18703024	1129	O
animal	-	1134	O
model	-	1141	O
may	-	1147	O
be	-	1151	O
useful	-	1154	O
to	-	1161	O
explore	-	1164	O
the	-	1172	O
mechanisms	-	1176	O
by	-	1187	O
which	-	1190	O
prenatal	-	1196	O
nutritional	-	1205	O
deficiency	-	1217	O
enhances	-	1228	O
risk	-	1237	O
for	-	1242	O
schizophrenia	-	1246	O
in	-	1260	O
humans	-	1263	O
and	-	1270	O
may	-	1274	O
also	-	1278	O
have	-	1283	O
implications	-	1288	O
for	-	1301	O
developmental	-	1305	O
processes	-	1319	O
leading	-	1329	O
to	-	1337	O
differential	-	1340	O
sensitivity	-	1353	O
to	-	1365	O
drugs	-	1368	O
of	-	1374	O
abuse	-	1377	O
.	-	1382	O

mToR	18631865	0	O
inhibitors	-	5	O
-	-	15	O
induced	-	16	O
proteinuria	-	24	O
:	-	35	O
mechanisms	-	37	O
,	-	47	O
significance	-	49	O
,	-	61	O
and	-	63	O
management	-	67	O
.	-	77	O

Massive	18631865	79	O
urinary	-	87	O
protein	-	95	O
excretion	-	103	O
has	-	113	O
been	-	117	O
observed	-	122	O
after	-	131	O
conversion	-	137	O
from	-	148	O
calcineurin	-	153	O
inhibitors	-	165	O
to	-	176	O
mammalian	-	179	O
target	-	189	O
of	-	196	O
rapamycin	-	199	B
(	-	209	O
mToR	-	210	O
)	-	214	O
inhibitors	-	216	O
,	-	226	O
especially	-	228	O
sirolimus	-	239	B
,	-	248	O
in	-	250	O
renal	-	253	O
transplant	-	259	O
recipients	-	270	O
with	-	281	O
chronic	-	286	O
allograft	-	294	O
nephropathy	-	304	O
.	-	315	O

Because	18631865	317	O
proteinuria	-	325	O
is	-	337	O
a	-	340	O
major	-	342	O
predictive	-	348	O
factor	-	359	O
of	-	366	O
poor	-	369	O
transplantation	-	374	O
outcome	-	390	O
,	-	397	O
many	-	399	O
studies	-	404	O
focused	-	412	O
on	-	420	O
this	-	423	O
adverse	-	428	O
event	-	436	O
during	-	442	O
the	-	449	O
past	-	453	O
years	-	458	O
.	-	463	O

Whether	18631865	465	O
proteinuria	-	473	O
was	-	485	O
due	-	489	O
to	-	493	O
sirolimus	-	496	B
or	-	506	O
only	-	509	O
a	-	514	O
consequence	-	516	O
of	-	528	O
calcineurin	-	531	O
inhibitors	-	543	O
withdrawal	-	554	O
remained	-	565	O
unsolved	-	574	O
until	-	583	O
high	-	589	O
range	-	594	O
proteinuria	-	600	O
has	-	612	O
been	-	616	O
observed	-	621	O
during	-	630	O
sirolimus	-	637	B
therapy	-	647	O
in	-	655	O
islet	-	658	O
transplantation	-	664	O
and	-	680	O
in	-	684	O
patients	-	687	O
who	-	696	O
received	-	700	O
sirolimus	-	709	B
de	-	719	O
novo	-	722	O
.	-	726	O

Podocyte	18631865	728	O
injury	-	737	O
and	-	744	O
focal	-	748	O
segmental	-	754	O
glomerulosclerosis	-	764	O
have	-	783	O
been	-	788	O
related	-	793	O
to	-	801	O
mToR	-	804	O
inhibition	-	809	O
in	-	820	O
some	-	823	O
patients	-	828	O
,	-	836	O
but	-	838	O
the	-	842	O
pathways	-	846	O
underlying	-	855	O
these	-	866	O
lesions	-	872	O
remain	-	880	O
hypothetic	-	887	O
.	-	897	O

We	18631865	899	O
discuss	-	902	O
herein	-	910	O
the	-	917	O
possible	-	921	O
mechanisms	-	930	O
and	-	941	O
the	-	945	O
significance	-	949	O
of	-	962	O
mToR	-	965	O
blockade	-	970	O
-	-	978	O
induced	-	979	O
proteinuria	-	987	O
.	-	998	O

Hypothalamic	18162529	0	O
prolactin	-	13	O
receptor	-	23	O
messenger	-	32	O
ribonucleic	-	42	B
acid	-	54	I
levels	-	59	O
,	-	65	O
prolactin	-	67	O
signaling	-	77	O
,	-	86	O
and	-	88	O
hyperprolactinemic	-	92	O
inhibition	-	111	O
of	-	122	O
pulsatile	-	125	O
luteinizing	-	135	O
hormone	-	147	O
secretion	-	155	O
are	-	165	O
dependent	-	169	O
on	-	179	O
estradiol	-	182	B
.	-	191	O

Hyperprolactinemia	18162529	193	O
can	-	212	O
reduce	-	216	O
fertility	-	223	O
and	-	233	O
libido	-	237	O
.	-	243	O

Although	18162529	245	O
central	-	254	O
prolactin	-	262	O
actions	-	272	O
are	-	280	O
thought	-	284	O
to	-	292	O
contribute	-	295	O
to	-	306	O
this	-	309	O
,	-	313	O
the	-	315	O
mechanisms	-	319	O
are	-	330	O
poorly	-	334	O
understood	-	341	O
.	-	351	O

We	18162529	353	O
first	-	356	O
tested	-	362	O
whether	-	369	O
chronic	-	377	O
hyperprolactinemia	-	385	O
inhibited	-	404	O
two	-	414	O
neuroendocrine	-	418	O
parameters	-	433	O
necessary	-	444	O
for	-	454	O
female	-	458	O
fertility	-	465	O
:	-	474	O
pulsatile	-	476	O
LH	-	486	O
secretion	-	489	O
and	-	499	O
the	-	503	O
estrogen	-	507	B
-	-	515	O
induced	-	516	O
LH	-	524	O
surge	-	527	O
.	-	532	O

Chronic	18162529	534	O
hyperprolactinemia	-	542	O
induced	-	561	O
by	-	569	O
the	-	572	O
dopamine	-	576	B
antagonist	-	585	O
sulpiride	-	596	B
caused	-	606	O
a	-	613	O
40	-	615	O
%	-	617	O
reduction	-	619	O
LH	-	629	O
pulse	-	632	O
frequency	-	638	O
in	-	648	O
ovariectomized	-	651	O
rats	-	666	O
,	-	670	O
but	-	672	O
only	-	676	O
in	-	681	O
the	-	684	O
presence	-	688	O
of	-	697	O
chronic	-	700	O
low	-	708	O
levels	-	712	O
of	-	719	O
estradiol	-	722	B
.	-	731	O

Sulpiride	18162529	733	B
did	-	743	O
not	-	747	O
affect	-	751	O
the	-	758	O
magnitude	-	762	O
of	-	772	O
a	-	775	O
steroid	-	777	B
-	-	784	O
induced	-	785	O
LH	-	793	O
surge	-	796	O
or	-	802	O
the	-	805	O
percentage	-	809	O
of	-	820	O
GnRH	-	823	O
neurons	-	828	O
activated	-	836	O
during	-	846	O
the	-	853	O
surge	-	857	O
.	-	862	O

Estradiol	18162529	864	B
is	-	874	O
known	-	877	O
to	-	883	O
influence	-	886	O
expression	-	896	O
of	-	907	O
the	-	910	O
long	-	914	O
form	-	919	O
of	-	924	O
prolactin	-	927	O
receptors	-	937	O
(	-	947	O
PRL	-	948	O
-	-	951	O
R	-	952	O
)	-	953	O
and	-	955	O
components	-	959	O
of	-	970	O
prolactin	-	973	O
's	-	982	O
signaling	-	985	O
pathway	-	995	O
.	-	1002	O

To	18162529	1004	O
test	-	1007	O
the	-	1012	O
hypothesis	-	1016	O
that	-	1027	O
estrogen	-	1032	B
increases	-	1041	O
PRL	-	1051	O
-	-	1054	O
R	-	1055	O
expression	-	1057	O
and	-	1068	O
sensitivity	-	1072	O
to	-	1084	O
prolactin	-	1087	O
,	-	1096	O
we	-	1098	O
next	-	1101	O
demonstrated	-	1106	O
that	-	1119	O
estradiol	-	1124	B
greatly	-	1134	O
augments	-	1142	O
prolactin	-	1151	O
-	-	1160	O
induced	-	1161	O
STAT5	-	1169	O
activation	-	1175	O
.	-	1185	O

Lastly	18162529	1187	O
,	-	1193	O
we	-	1195	O
measured	-	1198	O
PRL	-	1207	O
-	-	1210	O
R	-	1211	O
and	-	1213	O
suppressor	-	1217	O
of	-	1228	O
cytokine	-	1231	O
signaling	-	1240	O
(	-	1250	O
SOCS	-	1251	O
-	-	1255	O
1	-	1256	O
and	-	1258	O
-	-	1262	O
3	-	1263	O
and	-	1265	O
CIS	-	1269	O
,	-	1272	O
which	-	1274	O
reflect	-	1280	O
the	-	1288	O
level	-	1292	O
of	-	1298	O
prolactin	-	1301	O
signaling	-	1311	O
)	-	1320	O
mRNAs	-	1322	O
in	-	1328	O
response	-	1331	O
to	-	1340	O
sulpiride	-	1343	B
and	-	1353	O
estradiol	-	1357	B
.	-	1366	O

Sulpiride	18162529	1368	B
induced	-	1378	O
only	-	1386	O
SOCS	-	1391	O
-	-	1395	O
1	-	1396	O
in	-	1398	O
the	-	1401	O
medial	-	1405	O
preoptic	-	1412	O
area	-	1421	O
,	-	1425	O
where	-	1427	O
GnRH	-	1433	O
neurons	-	1438	O
are	-	1446	O
regulated	-	1450	O
,	-	1459	O
but	-	1461	O
in	-	1465	O
the	-	1468	O
arcuate	-	1472	O
nucleus	-	1480	O
and	-	1488	O
choroid	-	1492	O
plexus	-	1500	O
,	-	1506	O
PRL	-	1508	O
-	-	1511	O
R	-	1512	O
,	-	1513	O
SOCS	-	1515	O
-	-	1519	O
3	-	1520	O
,	-	1521	O
and	-	1523	O
CIS	-	1527	O
mRNA	-	1531	O
levels	-	1536	O
were	-	1543	O
also	-	1548	O
induced	-	1553	O
.	-	1560	O

Estradiol	18162529	1562	B
enhanced	-	1572	O
these	-	1581	O
effects	-	1587	O
on	-	1595	O
SOCS	-	1598	O
-	-	1602	O
3	-	1603	O
and	-	1605	O
CIS	-	1609	O
.	-	1612	O

Interestingly	18162529	1614	O
,	-	1627	O
estradiol	-	1629	B
also	-	1639	O
induced	-	1644	O
PRL	-	1652	O
-	-	1655	O
R	-	1656	O
,	-	1657	O
SOCS	-	1659	O
-	-	1663	O
3	-	1664	O
,	-	1665	O
and	-	1667	O
CIS	-	1671	O
mRNA	-	1675	O
levels	-	1680	O
independently	-	1687	O
.	-	1700	O

These	18162529	1702	O
data	-	1708	O
show	-	1713	O
that	-	1718	O
GnRH	-	1723	O
pulse	-	1728	O
frequency	-	1734	O
is	-	1744	O
inhibited	-	1747	O
by	-	1757	O
chronic	-	1760	O
hyperprolactinemia	-	1768	O
in	-	1787	O
a	-	1790	O
steroid	-	1792	B
-	-	1799	O
dependent	-	1800	O
manner	-	1810	O
.	-	1816	O

They	18162529	1818	O
also	-	1823	O
provide	-	1828	O
evidence	-	1836	O
for	-	1845	O
estradiol	-	1849	B
-	-	1858	O
dependent	-	1859	O
and	-	1869	O
brain	-	1873	O
region	-	1879	O
-	-	1885	O
specific	-	1886	O
regulation	-	1895	O
of	-	1906	O
PRL	-	1909	O
-	-	1912	O
R	-	1913	O
expression	-	1915	O
and	-	1926	O
signaling	-	1930	O
responses	-	1940	O
by	-	1950	O
prolactin	-	1953	O
.	-	1962	O

Estrogen	17879945	0	O
prevents	-	9	O
cholesteryl	-	18	B
ester	-	30	I
accumulation	-	36	O
in	-	49	O
macrophages	-	52	O
induced	-	64	O
by	-	72	O
the	-	75	O
HIV	-	79	O
protease	-	83	O
inhibitor	-	92	O
ritonavir	-	102	B
.	-	111	O

Individuals	17879945	113	O
with	-	125	O
HIV	-	130	O
can	-	134	O
now	-	138	O
live	-	142	O
long	-	147	O
lives	-	152	O
with	-	158	O
drug	-	163	O
therapy	-	168	O
that	-	176	O
often	-	181	O
includes	-	187	O
protease	-	196	O
inhibitors	-	205	O
such	-	216	O
as	-	221	O
ritonavir	-	224	B
.	-	233	O

Many	17879945	235	O
patients	-	240	O
,	-	248	O
however	-	250	O
,	-	257	O
develop	-	259	O
negative	-	267	O
long	-	276	O
-	-	280	O
term	-	281	O
side	-	286	O
effects	-	291	O
such	-	299	O
as	-	304	O
premature	-	307	O
atherosclerosis	-	317	O
.	-	332	O

We	17879945	334	O
have	-	337	O
previously	-	342	O
demonstrated	-	353	O
that	-	366	O
ritonavir	-	371	B
treatment	-	381	O
increases	-	391	O
atherosclerotic	-	401	O
lesion	-	417	O
formation	-	424	O
in	-	434	O
male	-	437	O
mice	-	442	O
to	-	447	O
a	-	450	O
greater	-	452	O
extent	-	460	O
than	-	467	O
in	-	472	O
female	-	475	O
mice	-	482	O
.	-	486	O

Furthermore	17879945	488	O
,	-	499	O
peripheral	-	501	O
blood	-	512	O
monocytes	-	518	O
isolated	-	528	O
from	-	537	O
ritonavir	-	542	B
-	-	551	O
treated	-	552	O
females	-	560	O
had	-	568	O
less	-	572	O
cholesteryl	-	577	B
ester	-	589	I
accumulation	-	595	O
.	-	607	O

In	17879945	609	O
the	-	612	O
present	-	616	O
study	-	624	O
,	-	629	O
we	-	631	O
have	-	634	O
investigated	-	639	O
the	-	652	O
molecular	-	656	O
mechanisms	-	666	O
by	-	677	O
which	-	680	O
female	-	686	O
hormones	-	693	O
influence	-	702	O
cholesterol	-	712	B
metabolism	-	724	O
in	-	735	O
macrophages	-	738	O
in	-	750	O
response	-	753	O
to	-	762	O
the	-	765	O
HIV	-	769	O
protease	-	773	O
inhibitor	-	782	O
ritonavir	-	792	B
.	-	801	O

We	17879945	803	O
have	-	806	O
utilized	-	811	O
the	-	820	O
human	-	824	O
monocyte	-	830	O
cell	-	839	O
line	-	844	O
,	-	848	O

THP	17879945	850	O
-	-	853	O
1	-	854	O
as	-	856	O
a	-	859	O
model	-	861	O
to	-	867	O
address	-	870	O
this	-	878	O
question	-	883	O
.	-	891	O

Briefly	17879945	893	O
,	-	900	O
cells	-	902	O
were	-	908	O
differentiated	-	913	O
for	-	928	O
72	-	932	O
h	-	935	O
with	-	937	O
100	-	942	O
nM	-	946	O
PMA	-	949	O
to	-	953	O
obtain	-	956	O
a	-	963	O
macrophage	-	965	O
-	-	975	O
like	-	976	O
phenotype	-	981	O
in	-	991	O
the	-	994	O
presence	-	998	O
or	-	1007	O
absence	-	1010	O
of	-	1018	O
1	-	1021	O
nM	-	1023	O
17beta	-	1026	B
-	-	1032	I
estradiol	-	1033	I
(	-	1043	O
E2	-	1044	B
)	-	1046	O
,	-	1047	O
100	-	1049	O
nM	-	1053	O
progesterone	-	1056	B
or	-	1069	O
vehicle	-	1072	O
(	-	1080	O
0	-	1081	O
.	-	1082	O
01	-	1083	O
%	-	1085	O
ethanol	-	1087	B
)	-	1094	O
.	-	1095	O

Cells	17879945	1097	O
were	-	1103	O
then	-	1108	O
treated	-	1113	O
with	-	1121	O
30	-	1126	O
ng	-	1129	O
/	-	1131	O
ml	-	1132	O
ritonavir	-	1135	B
or	-	1145	O
vehicle	-	1148	O
in	-	1156	O
the	-	1159	O
presence	-	1163	O
of	-	1172	O
aggregated	-	1175	O
LDL	-	1186	O
for	-	1190	O
24	-	1194	O
h	-	1197	O
.	-	1198	O
Cell	-	1200	O
extracts	-	1205	O
were	-	1214	O
harvested	-	1219	O
,	-	1228	O
and	-	1230	O
lipid	-	1234	O
or	-	1240	O
total	-	1243	O
RNA	-	1249	O
was	-	1253	O
isolated	-	1257	O
.	-	1265	O

E2	17879945	1267	B
decreased	-	1270	O
the	-	1280	O
accumulation	-	1284	O
of	-	1297	O
cholesteryl	-	1300	B
esters	-	1312	I
in	-	1319	O
macrophages	-	1322	O
following	-	1334	O
ritonavir	-	1344	B
treatment	-	1354	O
.	-	1363	O

Ritonavir	17879945	1365	B
increased	-	1375	O
the	-	1385	O
expression	-	1389	O
of	-	1400	O
the	-	1403	O
scavenger	-	1407	O
receptor	-	1417	O
,	-	1425	O
CD36	-	1427	O
mRNA	-	1432	O
,	-	1436	O
responsible	-	1438	O
for	-	1450	O
the	-	1454	O
uptake	-	1458	O
of	-	1465	O
LDL	-	1468	O
.	-	1471	O

Additionally	17879945	1473	O
,	-	1485	O
ritonavir	-	1487	B
treatment	-	1497	O
selectively	-	1507	O
increased	-	1519	O
the	-	1529	O
relative	-	1533	O
levels	-	1542	O
of	-	1549	O
PPARgamma	-	1552	O
mRNA	-	1562	O
,	-	1566	O
a	-	1568	O
transcription	-	1570	O
factor	-	1584	O
responsible	-	1591	O
for	-	1603	O
the	-	1607	O
regulation	-	1611	O
of	-	1622	O
CD36	-	1625	O
mRNA	-	1630	O
expression	-	1635	O
.	-	1645	O

Treatment	17879945	1647	O
with	-	1657	O
E2	-	1662	B
,	-	1664	O
however	-	1666	O
,	-	1673	O
failed	-	1675	O
to	-	1682	O
prevent	-	1685	O
these	-	1693	O
increases	-	1699	O
at	-	1709	O
the	-	1712	O
mRNA	-	1716	O
level	-	1721	O
.	-	1726	O

E2	17879945	1728	B
did	-	1731	O
,	-	1734	O
however	-	1736	O
,	-	1743	O
significantly	-	1745	O
suppress	-	1759	O
CD36	-	1768	O
protein	-	1773	O
levels	-	1781	O
as	-	1788	O
measured	-	1791	O
by	-	1800	O
fluorescent	-	1803	O
immunocytochemistry	-	1815	O
.	-	1834	O

This	17879945	1836	O
data	-	1841	O
suggests	-	1846	O
that	-	1855	O
E2	-	1860	B
modifies	-	1863	O
the	-	1872	O
expression	-	1876	O
of	-	1887	O
CD36	-	1890	O
at	-	1895	O
the	-	1898	O
level	-	1902	O
of	-	1908	O
protein	-	1911	O
expression	-	1919	O
in	-	1930	O
monocyte	-	1933	O
-	-	1941	O
derived	-	1942	O
macrophages	-	1950	O
resulting	-	1962	O
in	-	1972	O
reduced	-	1975	O
cholesteryl	-	1983	B
ester	-	1995	I
accumulation	-	2001	O
following	-	2014	O
ritonavir	-	2024	B
treatment	-	2034	O
.	-	2043	O

Upregulation	17437408	0	O
of	-	13	O
brain	-	16	O
expression	-	22	O
of	-	33	O
P	-	36	O
-	-	37	O
glycoprotein	-	38	O
in	-	51	O
MRP2	-	54	O
-	-	58	O
deficient	-	59	O
TR	-	69	O
(	-	71	O
-	-	72	O
)	-	73	O
rats	-	75	O
resembles	-	80	O
seizure	-	90	O
-	-	97	O
induced	-	98	O
up	-	106	O
-	-	108	O
regulation	-	109	O
of	-	120	O
this	-	123	O
drug	-	128	O
efflux	-	133	O
transporter	-	140	O
in	-	152	O
normal	-	155	O
rats	-	162	O
.	-	166	O

PURPOSE	17437408	168	O
:	-	175	O

The	17437408	177	O
multidrug	-	181	O
resistance	-	191	O
protein	-	202	O
2	-	210	O
(	-	212	O
MRP2	-	213	O
)	-	217	O
is	-	219	O
a	-	222	O
drug	-	224	O
efflux	-	229	O
transporter	-	236	O
that	-	248	O
is	-	253	O
expressed	-	256	O
predominantly	-	266	O
at	-	280	O
the	-	283	O
apical	-	287	O
domain	-	294	O
of	-	301	O
hepatocytes	-	304	O
but	-	316	O
seems	-	320	O
also	-	326	O
to	-	331	O
be	-	334	O
expressed	-	337	O
at	-	347	O
the	-	350	O
apical	-	354	O
membrane	-	361	O
of	-	370	O
brain	-	373	O
capillary	-	379	O
endothelial	-	389	O
cells	-	401	O
that	-	407	O
form	-	412	O
the	-	417	O
blood	-	421	O
-	-	426	O
brain	-	427	O
barrier	-	433	O
(	-	441	O
BBB	-	442	O
)	-	445	O
.	-	446	O

MRP2	17437408	448	O
is	-	453	O
absent	-	456	O
in	-	463	O
the	-	466	O
transport	-	470	O
-	-	479	O
deficient	-	480	O
(	-	490	O
TR	-	491	O
(	-	493	O
-	-	494	O
)	-	495	O
)	-	496	O

Wistar	17437408	498	O
rat	-	505	O
mutant	-	509	O
,	-	515	O
so	-	517	O
that	-	520	O
this	-	525	O
rat	-	530	O
strain	-	534	O
was	-	541	O
very	-	545	O
helpful	-	550	O
in	-	558	O
defining	-	561	O
substrates	-	570	O
of	-	581	O
MRP2	-	584	O
by	-	589	O
comparing	-	592	O
tissue	-	602	O
concentrations	-	609	O
or	-	624	O
functional	-	627	O
activities	-	638	O
of	-	649	O
compounds	-	652	O
in	-	662	O
MRP2	-	665	O
-	-	669	O
deficient	-	670	O
rats	-	680	O
with	-	685	O
those	-	690	O
in	-	696	O
transport	-	699	O
-	-	708	O
competent	-	709	O
Wistar	-	719	O
rats	-	726	O
.	-	730	O

By	17437408	732	O
using	-	735	O
this	-	741	O
strategy	-	746	O
to	-	755	O
study	-	758	O
the	-	764	O
involvement	-	768	O
of	-	780	O
MRP2	-	783	O
in	-	788	O
brain	-	791	O
access	-	797	O
of	-	804	O
antiepileptic	-	807	O
drugs	-	821	O
(	-	827	O
AEDs	-	828	O
)	-	832	O
,	-	833	O
we	-	835	O
recently	-	838	O
reported	-	847	O
that	-	856	O
phenytoin	-	861	B
is	-	871	O
a	-	874	O
substrate	-	876	O
for	-	886	O
MRP2	-	890	O
in	-	895	O
the	-	898	O
BBB	-	902	O
.	-	905	O

However	17437408	907	O
,	-	914	O
one	-	916	O
drawback	-	920	O
of	-	929	O
such	-	932	O
studies	-	937	O
in	-	945	O
genetically	-	948	O
deficient	-	960	O
rats	-	970	O
is	-	975	O
the	-	978	O
fact	-	982	O
that	-	987	O
compensatory	-	992	O
changes	-	1005	O
with	-	1013	O
upregulation	-	1018	O
of	-	1031	O
other	-	1034	O
transporters	-	1040	O
can	-	1053	O
occur	-	1057	O
.	-	1062	O

This	17437408	1064	O
prompted	-	1069	O
us	-	1078	O
to	-	1081	O
study	-	1084	O
the	-	1090	O
brain	-	1094	O
expression	-	1100	O
of	-	1111	O
P	-	1114	O
-	-	1115	O
glycoprotein	-	1116	O
(	-	1129	O
Pgp	-	1130	O
)	-	1133	O
,	-	1134	O
a	-	1136	O
major	-	1138	O
drug	-	1144	O
efflux	-	1149	O
transporter	-	1156	O
in	-	1168	O
many	-	1171	O
tissues	-	1176	O
,	-	1183	O
including	-	1185	O
the	-	1195	O
BBB	-	1199	O
,	-	1202	O
in	-	1204	O
TR	-	1207	O
(	-	1209	O
-	-	1210	O
)	-	1211	O
rats	-	1213	O
compared	-	1218	O
with	-	1227	O
nonmutant	-	1232	O
(	-	1242	O
wild	-	1243	O
-	-	1247	O
type	-	1248	O
)	-	1252	O
Wistar	-	1254	O
rats	-	1261	O
.	-	1265	O

METHODS	17437408	1267	O
:	-	1274	O

The	17437408	1276	O
expression	-	1280	O
of	-	1291	O
MRP2	-	1294	O
and	-	1299	O
Pgp	-	1303	O
in	-	1307	O
brain	-	1310	O
and	-	1316	O
liver	-	1320	O
sections	-	1326	O
of	-	1335	O
TR	-	1338	O
(	-	1340	O
-	-	1341	O
)	-	1342	O
rats	-	1344	O
and	-	1349	O
normal	-	1353	O
Wistar	-	1360	O
rats	-	1367	O
was	-	1372	O
determined	-	1376	O
with	-	1387	O
immunohistochemistry	-	1392	O
,	-	1412	O
by	-	1414	O
using	-	1417	O
a	-	1423	O
novel	-	1425	O
,	-	1430	O
highly	-	1432	O
selective	-	1439	O
monoclonal	-	1449	O
MRP2	-	1460	O
antibody	-	1465	O
and	-	1474	O
the	-	1478	O
monoclonal	-	1482	O
Pgp	-	1493	O
antibody	-	1497	O
C219	-	1506	O
,	-	1510	O
respectively	-	1512	O
.	-	1524	O

RESULTS	17437408	1526	O
:	-	1533	O

Immunofluorescence	17437408	1535	O
staining	-	1554	O
with	-	1563	O
the	-	1568	O
MRP2	-	1572	O
antibody	-	1577	O
was	-	1586	O
found	-	1590	O
to	-	1596	O
label	-	1599	O
a	-	1605	O
high	-	1607	O
number	-	1612	O
of	-	1619	O
microvessels	-	1622	O
throughout	-	1635	O
the	-	1646	O
brain	-	1650	O
in	-	1656	O
normal	-	1659	O
Wistar	-	1666	O
rats	-	1673	O
,	-	1677	O
whereas	-	1679	O
such	-	1687	O
labeling	-	1692	O
was	-	1701	O
absent	-	1705	O
in	-	1712	O
TR	-	1715	O
(	-	1717	O
-	-	1718	O
)	-	1719	O
rats	-	1721	O
.	-	1725	O

TR	17437408	1727	O
(	-	1729	O
-	-	1730	O
)	-	1731	O
rats	-	1733	O
exhibited	-	1738	O
a	-	1748	O
significant	-	1750	O
up	-	1762	O
-	-	1764	O
regulation	-	1765	O
of	-	1776	O
Pgp	-	1779	O
in	-	1783	O
brain	-	1786	O
capillary	-	1792	O
endothelial	-	1802	O
cells	-	1814	O
compared	-	1820	O
with	-	1829	O
wild	-	1834	O
-	-	1838	O
type	-	1839	O
controls	-	1844	O
.	-	1852	O

No	17437408	1854	O
such	-	1857	O
obvious	-	1862	O
upregulation	-	1870	O
of	-	1883	O
Pgp	-	1886	O
was	-	1890	O
observed	-	1894	O
in	-	1903	O
liver	-	1906	O
sections	-	1912	O
.	-	1920	O

A	17437408	1922	O
comparable	-	1924	O
overexpression	-	1935	O
of	-	1950	O
Pgp	-	1953	O
in	-	1957	O
the	-	1960	O
BBB	-	1964	O
was	-	1968	O
obtained	-	1972	O
after	-	1981	O
pilocarpine	-	1987	B
-	-	1998	O
induced	-	1999	O
seizures	-	2007	O
in	-	2016	O
wild	-	2019	O
-	-	2023	O
type	-	2024	O
Wistar	-	2029	O
rats	-	2036	O
.	-	2040	O

Experiments	17437408	2042	O
with	-	2054	O
systemic	-	2059	O
administration	-	2068	O
of	-	2083	O
the	-	2086	O
Pgp	-	2090	O
substrate	-	2094	O
phenobarbital	-	2104	B
and	-	2118	O
the	-	2122	O
selective	-	2126	O
Pgp	-	2136	O
inhibitor	-	2140	O
tariquidar	-	2150	B
in	-	2161	O
TR	-	2164	O
(	-	2166	O
-	-	2167	O
)	-	2168	O
rats	-	2170	O
substantiated	-	2175	O
that	-	2189	O
Pgp	-	2194	O
is	-	2198	O
functional	-	2201	O
and	-	2212	O
compensates	-	2216	O
for	-	2228	O
the	-	2232	O
lack	-	2236	O
of	-	2241	O
MRP2	-	2244	O
in	-	2249	O
the	-	2252	O
BBB	-	2256	O
.	-	2259	O

CONCLUSIONS	17437408	2261	O
:	-	2272	O

The	17437408	2274	O
data	-	2278	O
on	-	2283	O
TR	-	2286	O
(	-	2288	O
-	-	2289	O
)	-	2290	O
rats	-	2292	O
indicate	-	2297	O
that	-	2306	O
Pgp	-	2311	O
plays	-	2315	O
an	-	2321	O
important	-	2324	O
role	-	2334	O
in	-	2339	O
the	-	2342	O
compensation	-	2346	O
of	-	2359	O
MRP2	-	2362	O
deficiency	-	2367	O
in	-	2378	O
the	-	2381	O
BBB	-	2385	O
.	-	2388	O

Because	17437408	2390	O
such	-	2398	O
a	-	2403	O
compensatory	-	2405	O
mechanism	-	2418	O
most	-	2428	O
likely	-	2433	O
occurs	-	2440	O
to	-	2447	O
reduce	-	2450	O
injury	-	2457	O
to	-	2464	O
the	-	2467	O
brain	-	2471	O
from	-	2477	O
cytotoxic	-	2482	O
compounds	-	2492	O
,	-	2501	O
the	-	2503	O
present	-	2507	O
data	-	2515	O
substantiate	-	2520	O
the	-	2533	O
concept	-	2537	O
that	-	2545	O
MRP2	-	2550	O
performs	-	2555	O
a	-	2564	O
protective	-	2566	O
role	-	2577	O
in	-	2582	O
the	-	2585	O
BBB	-	2589	O
.	-	2592	O

Furthermore	17437408	2594	O
,	-	2605	O
our	-	2607	O
data	-	2611	O
suggest	-	2616	O
that	-	2624	O
TR	-	2629	O
(	-	2631	O
-	-	2632	O
)	-	2633	O
rats	-	2635	O
are	-	2640	O
an	-	2644	O
interesting	-	2647	O
tool	-	2659	O
to	-	2664	O
study	-	2667	O
consequences	-	2673	O
of	-	2686	O
overexpression	-	2689	O
of	-	2704	O
Pgp	-	2707	O
in	-	2711	O
the	-	2714	O
BBB	-	2718	O
on	-	2722	O
access	-	2725	O
of	-	2732	O
drugs	-	2735	O
in	-	2741	O
the	-	2744	O
brain	-	2748	O
,	-	2753	O
without	-	2755	O
the	-	2763	O
need	-	2767	O
of	-	2772	O
inducing	-	2775	O
seizures	-	2784	O
or	-	2793	O
other	-	2796	O
Pgp	-	2802	O
-	-	2805	O
enhancing	-	2806	O
events	-	2816	O
for	-	2823	O
this	-	2827	O
purpose	-	2832	O
.	-	2839	O

Use	17242861	0	O
of	-	4	O
chromosome	-	7	O
substitution	-	18	O
strains	-	31	O
to	-	39	O
identify	-	42	O
seizure	-	51	O
susceptibility	-	59	O
loci	-	74	O
in	-	79	O
mice	-	82	O
.	-	86	O

Seizure	17242861	88	O
susceptibility	-	96	O
varies	-	111	O
among	-	118	O
inbred	-	124	O
mouse	-	131	O
strains	-	137	O
.	-	144	O

Chromosome	17242861	146	O
substitution	-	157	O
strains	-	170	O
(	-	178	O
CSS	-	179	O
)	-	182	O
,	-	183	O
in	-	185	O
which	-	188	O
a	-	194	O
single	-	196	O
chromosome	-	203	O
from	-	214	O
one	-	219	O
inbred	-	223	O
strain	-	230	O
(	-	237	O
donor	-	238	O
)	-	243	O
has	-	245	O
been	-	249	O
transferred	-	254	O
onto	-	266	O
a	-	271	O
second	-	273	O
strain	-	280	O
(	-	287	O
host	-	288	O
)	-	292	O
by	-	294	O
repeated	-	297	O
backcrossing	-	306	O
,	-	318	O
may	-	320	O
be	-	324	O
used	-	327	O
to	-	332	O
identify	-	335	O
quantitative	-	344	O
trait	-	357	O
loci	-	363	O
(	-	368	O
QTLs	-	369	O
)	-	373	O
that	-	375	O
contribute	-	380	O
to	-	391	O
seizure	-	394	O
susceptibility	-	402	O
.	-	416	O

QTLs	17242861	418	O
for	-	423	O
susceptibility	-	427	O
to	-	442	O
pilocarpine	-	445	B
-	-	456	O
induced	-	457	O
seizures	-	465	O
,	-	473	O
a	-	475	O
model	-	477	O
of	-	483	O
temporal	-	486	O
lobe	-	495	O
epilepsy	-	500	O
,	-	508	O
have	-	510	O
not	-	515	O
been	-	519	O
reported	-	524	O
,	-	532	O
and	-	534	O
CSS	-	538	O
have	-	542	O
not	-	547	O
previously	-	551	O
been	-	562	O
used	-	567	O
to	-	572	O
localize	-	575	O
seizure	-	584	O
susceptibility	-	592	O
genes	-	607	O
.	-	612	O

We	17242861	614	O
report	-	617	O
QTLs	-	624	O
identified	-	629	O
using	-	640	O
a	-	646	O
B6	-	648	O
(	-	651	O
host	-	652	O
)	-	656	O
x	-	658	O

A	17242861	660	O
/	-	661	O
J	-	662	O
(	-	664	O
donor	-	665	O
)	-	670	O
CSS	-	672	O
panel	-	676	O
to	-	682	O
localize	-	685	O
genes	-	694	O
involved	-	700	O
in	-	709	O
susceptibility	-	712	O
to	-	727	O
pilocarpine	-	730	B
-	-	741	O
induced	-	742	O
seizures	-	750	O
.	-	758	O

Three	17242861	760	O
hundred	-	766	O
fifty	-	774	O
-	-	779	O
five	-	780	O
adult	-	785	O
male	-	791	O
CSS	-	796	O
mice	-	800	O
,	-	804	O
58	-	806	O
B6	-	809	O
,	-	811	O
and	-	813	O
39	-	817	O
A	-	820	O
/	-	821	O
J	-	822	O
were	-	824	O
tested	-	829	O
for	-	836	O
susceptibility	-	840	O
to	-	855	O
pilocarpine	-	858	B
-	-	869	O
induced	-	870	O
seizures	-	878	O
.	-	886	O

Highest	17242861	888	O
stage	-	896	O
reached	-	902	O
and	-	910	O
latency	-	914	O
to	-	922	O
each	-	925	O
stage	-	930	O
were	-	936	O
recorded	-	941	O
for	-	950	O
all	-	954	O
mice	-	958	O
.	-	962	O

B6	17242861	964	O
mice	-	967	O
were	-	972	O
resistant	-	977	O
to	-	987	O
seizures	-	990	O
and	-	999	O
slower	-	1003	O
to	-	1010	O
reach	-	1013	O
stages	-	1019	O
compared	-	1026	O
to	-	1035	O
A	-	1038	O
/	-	1039	O
J	-	1040	O
mice	-	1042	O
.	-	1046	O

The	17242861	1048	O
CSS	-	1052	O
for	-	1056	O
Chromosomes	-	1060	O
10	-	1072	O
and	-	1075	O
18	-	1079	O
progressed	-	1082	O
to	-	1093	O
the	-	1096	O
most	-	1100	O
severe	-	1105	O
stages	-	1112	O
,	-	1118	O
diverging	-	1120	O
dramatically	-	1130	O
from	-	1143	O
the	-	1148	O
B6	-	1152	O
phenotype	-	1155	O
.	-	1164	O

Latencies	17242861	1166	O
to	-	1176	O
stages	-	1179	O
were	-	1186	O
also	-	1191	O
significantly	-	1196	O
shorter	-	1210	O
for	-	1218	O
CSS10	-	1222	O
and	-	1228	O
CSS18	-	1232	O
mice	-	1238	O
.	-	1242	O

CSS	17242861	1244	O
mapping	-	1248	O
suggests	-	1256	O
seizure	-	1265	O
susceptibility	-	1273	O
loci	-	1288	O
on	-	1293	O
mouse	-	1296	O
Chromosomes	-	1302	O
10	-	1314	O
and	-	1317	O
18	-	1321	O
.	-	1323	O

This	17242861	1325	O
approach	-	1330	O
provides	-	1339	O
a	-	1348	O
framework	-	1350	O
for	-	1360	O
identifying	-	1364	O
potentially	-	1376	O
novel	-	1388	O
homologous	-	1394	O
candidate	-	1405	O
genes	-	1415	O
for	-	1421	O
human	-	1425	O
temporal	-	1431	O
lobe	-	1440	O
epilepsy	-	1445	O
.	-	1453	O

Investigation	16337777	0	O
of	-	14	O
mitochondrial	-	17	O
involvement	-	31	O
in	-	43	O
the	-	46	O
experimental	-	50	O
model	-	63	O
of	-	69	O
epilepsy	-	72	O
induced	-	81	O
by	-	89	O
pilocarpine	-	92	B
.	-	103	O

Mitochondrial	16337777	105	O
abnormalities	-	119	O
have	-	133	O
been	-	138	O
associated	-	143	O
with	-	154	O
several	-	159	O
aspects	-	167	O
of	-	175	O
epileptogenesis	-	178	O
,	-	193	O
such	-	195	O
as	-	200	O
energy	-	203	O
generation	-	210	O
,	-	220	O
control	-	222	O
of	-	230	O
cell	-	233	O
death	-	238	O
,	-	243	O
neurotransmitter	-	245	O
synthesis	-	262	O
,	-	271	O
and	-	273	O
free	-	277	O
radical	-	282	O
(	-	290	O
FR	-	291	O
)	-	293	O
production	-	295	O
.	-	305	O

Increased	16337777	307	O
production	-	317	O
of	-	328	O
FRs	-	331	O
may	-	335	O
cause	-	339	O
mtDNA	-	345	O
damage	-	351	O
leading	-	358	O
to	-	366	O
decreased	-	369	O
activities	-	379	O
of	-	390	O
oxidative	-	393	O
phosphorylation	-	403	O
complexes	-	419	O
containing	-	429	O
mtDNA	-	440	O
-	-	445	O
encoded	-	446	O
subunits	-	454	O
.	-	462	O

In	16337777	464	O
this	-	467	O
study	-	472	O
,	-	477	O
we	-	479	O
investigated	-	482	O
whether	-	495	O
increased	-	503	O
generation	-	513	O
of	-	524	O
FR	-	527	O
during	-	530	O
status	-	537	O
epilepticus	-	544	O
would	-	556	O
be	-	562	O
sufficient	-	565	O
to	-	576	O
provoke	-	579	O
abnormalities	-	587	O
in	-	601	O
mtDNA	-	604	O
and	-	610	O
in	-	614	O
the	-	617	O
expression	-	621	O
and	-	632	O
activity	-	636	O
of	-	645	O
cytochrome	-	648	O
c	-	659	O
oxidase	-	661	O
(	-	669	O
CCO	-	670	O
)	-	673	O
,	-	674	O
complex	-	676	O
IV	-	684	O
of	-	687	O
the	-	690	O
respiratory	-	694	O
chain	-	706	O
,	-	711	O
in	-	713	O
the	-	716	O
chronic	-	720	O
phase	-	728	O
of	-	734	O
the	-	737	O
pilocarpine	-	741	B
model	-	753	O
of	-	759	O
temporal	-	762	O
lobe	-	771	O
epilepsy	-	776	O
.	-	784	O

DNA	16337777	786	O
analysis	-	790	O
revealed	-	799	O
low	-	808	O
amounts	-	812	O
of	-	820	O
a	-	823	O
4	-	825	O
.	-	826	O
8	-	827	O
kb	-	829	O
mtDNA	-	832	O
deletion	-	838	O
but	-	847	O
with	-	851	O
no	-	856	O
differences	-	859	O
in	-	871	O
frequency	-	874	O
or	-	884	O
quantity	-	887	O
in	-	896	O
the	-	899	O
control	-	903	O
and	-	911	O
experimental	-	915	O
groups	-	928	O
.	-	934	O

We	16337777	936	O
did	-	939	O
not	-	943	O
find	-	947	O
abnormalities	-	952	O
in	-	966	O
the	-	969	O
expression	-	973	O
and	-	984	O
distribution	-	988	O
of	-	1001	O
an	-	1004	O
mtDNA	-	1007	O
-	-	1012	O
encoded	-	1013	O
subunit	-	1021	O
of	-	1029	O
CCO	-	1032	O
(	-	1036	O
CCO	-	1037	O
-	-	1040	O
I	-	1041	O
)	-	1042	O
or	-	1044	O
a	-	1047	O
relative	-	1049	O
decrease	-	1058	O
in	-	1067	O
CCO	-	1070	O
-	-	1073	O
I	-	1074	O
when	-	1076	O
compared	-	1081	O
with	-	1090	O
nuclear	-	1095	O
-	-	1102	O
encoded	-	1103	O
subunits	-	1111	O
(	-	1120	O
CCO	-	1121	O
-	-	1124	O
IV	-	1125	O
and	-	1128	O
SDH	-	1132	O
-	-	1135	O
fp	-	1136	O
)	-	1138	O
.	-	1139	O

No	16337777	1141	O
abnormality	-	1144	O
in	-	1156	O
CCO	-	1159	O
activity	-	1163	O
was	-	1172	O
observed	-	1176	O
through	-	1185	O
histochemistry	-	1193	O
.	-	1207	O

Although	16337777	1209	O
evidences	-	1218	O
of	-	1228	O
mitochondrial	-	1231	O
abnormalities	-	1245	O
were	-	1259	O
found	-	1264	O
in	-	1270	O
previously	-	1273	O
published	-	1284	O
studies	-	1294	O
,	-	1301	O
our	-	1303	O
results	-	1307	O
do	-	1315	O
not	-	1318	O
suggest	-	1322	O
that	-	1330	O
the	-	1335	O
FRs	-	1339	O
,	-	1342	O
generated	-	1344	O
during	-	1354	O
the	-	1361	O
acute	-	1365	O
phase	-	1371	O
,	-	1376	O
determined	-	1378	O
important	-	1389	O
abnormalities	-	1399	O
in	-	1413	O
mtDNA	-	1416	O
,	-	1421	O
in	-	1423	O
expression	-	1426	O
of	-	1437	O
CCO	-	1440	O
-	-	1443	O
I	-	1444	O
,	-	1445	O
and	-	1447	O
in	-	1451	O
CCO	-	1454	O
activity	-	1458	O
.	-	1466	O

Causes	15859940	0	O
of	-	7	O
acute	-	10	O
thrombotic	-	16	O
microangiopathy	-	27	O
in	-	43	O
patients	-	46	O
receiving	-	55	O
kidney	-	65	O
transplantation	-	72	O
.	-	87	O

OBJECTIVES	15859940	89	O
:	-	99	O

Thrombotic	15859940	101	O
microangiopathy	-	112	O
is	-	128	O
a	-	131	O
well	-	133	O
-	-	137	O
known	-	138	O
problem	-	144	O
in	-	152	O
patients	-	155	O
following	-	164	O
renal	-	174	O
transplantation	-	180	O
.	-	195	O

In	15859940	197	O
postrenal	-	200	O
transplantation	-	210	O
,	-	225	O
thrombotic	-	227	O
microangiopathy	-	238	O
is	-	254	O
often	-	257	O
a	-	263	O
reflection	-	265	O
of	-	276	O
hemolytic	-	279	O
uremic	-	289	O
syndrome	-	296	O
.	-	304	O

We	15859940	306	O
aimed	-	309	O
to	-	315	O
determine	-	318	O
the	-	328	O
causes	-	332	O
of	-	339	O
thrombotic	-	342	O
microangiopathy	-	353	O
in	-	369	O
a	-	372	O
population	-	374	O
of	-	385	O
renal	-	388	O
transplantation	-	394	O
recipients	-	410	O
and	-	421	O
discuss	-	425	O
the	-	433	O
literature	-	437	O
.	-	447	O

MATERIALS	15859940	449	O
AND	-	459	O
METHODS	-	463	O
:	-	470	O

We	15859940	472	O
investigated	-	475	O
the	-	488	O
causes	-	492	O
of	-	499	O
thrombotic	-	502	O
microangiopathy	-	513	O
during	-	529	O
a	-	536	O
1	-	538	O
-	-	539	O
year	-	540	O
period	-	545	O
,	-	551	O
from	-	553	O
June	-	558	O
2003	-	563	O
to	-	568	O
June	-	571	O
2004	-	576	O
,	-	580	O
at	-	582	O
the	-	585	O
King	-	589	O
Fahad	-	594	O
National	-	600	O
Guard	-	609	O
Hospital	-	615	O
in	-	624	O
Riyadh	-	627	O
,	-	633	O
Saudi	-	635	O
Arabia	-	641	O
,	-	647	O
by	-	649	O
reviewing	-	652	O
the	-	662	O
slides	-	666	O
of	-	673	O
all	-	676	O
transplant	-	680	O
biopsies	-	691	O
(	-	700	O
n	-	701	O
=	-	702	O
25	-	703	O
)	-	705	O
performed	-	707	O
during	-	717	O
this	-	724	O
interval	-	729	O
.	-	737	O

Pre	15859940	739	O
-	-	742	O
and	-	744	O
posttransplant	-	748	O
crossmatching	-	763	O
was	-	777	O
done	-	781	O
when	-	786	O
possible	-	791	O
.	-	799	O

RESULTS	15859940	801	O
:	-	808	O

Five	15859940	810	O
cases	-	815	O
of	-	821	O
thrombotic	-	824	O
microangiopathy	-	835	O
were	-	851	O
found	-	856	O
.	-	861	O

Three	15859940	863	O
of	-	869	O
these	-	872	O
cases	-	878	O
were	-	884	O
from	-	889	O
the	-	894	O
25	-	898	O
transplantations	-	901	O
performed	-	918	O
at	-	928	O
King	-	931	O
Fahad	-	936	O
National	-	942	O
Guard	-	951	O
Hospital	-	957	O
,	-	965	O
while	-	967	O
the	-	973	O
other	-	977	O
2	-	983	O
transplantations	-	985	O
had	-	1002	O
been	-	1006	O
performed	-	1011	O
abroad	-	1021	O
and	-	1028	O
were	-	1032	O
referred	-	1037	O
to	-	1046	O
us	-	1049	O
for	-	1052	O
follow	-	1056	O
-	-	1062	O
up	-	1063	O
.	-	1065	O

Three	15859940	1067	O
cases	-	1073	O
were	-	1079	O
related	-	1084	O
to	-	1092	O
cyclosporine	-	1095	B
,	-	1107	O
and	-	1109	O
1	-	1113	O
case	-	1115	O
was	-	1120	O
secondary	-	1124	O
to	-	1134	O
both	-	1137	O
cyclosporine	-	1142	B
and	-	1155	O
tacrolimus	-	1159	B
.	-	1169	O

The	15859940	1171	O
fifth	-	1175	O
case	-	1181	O
had	-	1186	O
features	-	1190	O
of	-	1199	O
thrombotic	-	1202	O
microangiopathy	-	1213	O
related	-	1229	O
to	-	1237	O
an	-	1240	O
antiphospholipid	-	1243	O
syndrome	-	1260	O
in	-	1269	O
a	-	1272	O
patient	-	1274	O
with	-	1282	O
systemic	-	1287	O
lupus	-	1296	O
erythematosus	-	1302	O
.	-	1315	O

CONCLUSIONS	15859940	1317	O
:	-	1328	O

In	15859940	1330	O
the	-	1333	O
literature	-	1337	O
,	-	1347	O
the	-	1349	O
most	-	1353	O
-	-	1357	O
frequent	-	1358	O
cause	-	1367	O
of	-	1373	O
hemolytic	-	1376	O
uremic	-	1386	O
syndrome	-	1393	O
in	-	1402	O
patients	-	1405	O
following	-	1414	O
renal	-	1424	O
transplantation	-	1430	O
is	-	1446	O
recurrence	-	1449	O
of	-	1460	O
the	-	1463	O
hemolytic	-	1467	O
uremic	-	1477	O
syndrome	-	1484	O
.	-	1492	O

Other	15859940	1494	O
causes	-	1500	O
include	-	1507	O
drug	-	1515	O
-	-	1519	O
related	-	1520	O
(	-	1528	O
cyclosporine	-	1529	B
,	-	1541	O
tacrolimus	-	1543	B
)	-	1553	O
toxicity	-	1555	O
,	-	1563	O
procoagulant	-	1565	O
status	-	1578	O
,	-	1584	O
and	-	1586	O
antibody	-	1590	O
-	-	1598	O
mediated	-	1599	O
rejection	-	1608	O
.	-	1617	O

We	15859940	1619	O
found	-	1622	O
that	-	1628	O
the	-	1633	O
most	-	1637	O
-	-	1641	O
frequent	-	1642	O
cause	-	1651	O
of	-	1657	O
thrombotic	-	1660	O
microangiopathy	-	1671	O
was	-	1687	O
drug	-	1691	O
related	-	1696	O
,	-	1703	O
secondary	-	1705	O
mainly	-	1715	O
to	-	1722	O
cyclosporine	-	1725	B
.	-	1737	O

In	15859940	1739	O
the	-	1742	O
current	-	1746	O
study	-	1754	O
,	-	1759	O
the	-	1761	O
frequency	-	1765	O
of	-	1775	O
thrombotic	-	1778	O
microangiopathy	-	1789	O
was	-	1805	O
similar	-	1809	O
to	-	1817	O
the	-	1820	O
percentage	-	1824	O
reported	-	1835	O
in	-	1844	O
the	-	1847	O
literature	-	1851	O
(	-	1862	O
20	-	1863	O
%	-	1865	O
)	-	1866	O
.	-	1867	O

Severe	15188772	0	O
reversible	-	7	O
left	-	18	O
ventricular	-	23	O
systolic	-	35	O
and	-	44	O
diastolic	-	48	O
dysfunction	-	58	O
due	-	70	O
to	-	74	O
accidental	-	77	O
iatrogenic	-	88	O
epinephrine	-	99	B
overdose	-	111	O
.	-	119	O

Catecholamine	15188772	121	B
-	-	134	O
induced	-	135	O
cardiomyopathy	-	143	O
due	-	158	O
to	-	162	O
chronic	-	165	O
excess	-	173	O
of	-	180	O
endogenous	-	183	O
catecholamines	-	194	B
has	-	209	O
been	-	213	O
recognized	-	218	O
for	-	229	O
decades	-	233	O
as	-	241	O
a	-	244	O
clinical	-	246	O
phenomenon	-	255	O
.	-	265	O

In	15188772	267	O
contrast	-	270	O
,	-	278	O
reports	-	280	O
of	-	288	O
myocardial	-	291	O
dysfunction	-	302	O
due	-	314	O
to	-	318	O
acute	-	321	O
iatrogenic	-	327	O
overdose	-	338	O
are	-	347	O
rare	-	351	O
.	-	355	O

A	15188772	357	O
35	-	359	O
-	-	361	O
year	-	362	O
-	-	366	O
old	-	367	O
woman	-	371	O
whose	-	377	O
cervix	-	383	O
uteri	-	390	O
was	-	396	O
inadvertently	-	400	O
injected	-	414	O
with	-	423	O
8	-	428	O
mg	-	430	O
of	-	433	O
epinephrine	-	436	B
developed	-	448	O
myocardial	-	458	O
stunning	-	469	O
that	-	478	O
was	-	483	O
characterized	-	487	O
by	-	501	O
severe	-	504	O
hemodynamic	-	511	O
compromise	-	523	O
,	-	533	O
profound	-	535	O
,	-	543	O
albeit	-	545	O
transient	-	552	O
,	-	561	O
left	-	563	O
ventricular	-	568	O
systolic	-	580	O
and	-	589	O
diastolic	-	593	O
dysfunction	-	603	O
,	-	614	O
and	-	616	O
only	-	620	O
modestly	-	625	O
elevated	-	634	O
biochemical	-	643	O
markers	-	655	O
of	-	663	O
myocardial	-	666	O
necrosis	-	677	O
.	-	685	O

Our	15188772	687	O
case	-	691	O
illustrates	-	696	O
the	-	708	O
serious	-	712	O
consequences	-	720	O
of	-	733	O
medical	-	736	O
errors	-	744	O
that	-	751	O
can	-	756	O
be	-	760	O
avoided	-	763	O
through	-	771	O
improved	-	779	O
medication	-	788	O
labeling	-	799	O
and	-	808	O
staff	-	812	O
supervision	-	818	O
.	-	829	O

Urinary	15130900	0	O
bladder	-	8	O
cancer	-	16	O
in	-	23	O
Wegener	-	26	O
's	-	33	O
granulomatosis	-	36	O
:	-	50	O
risks	-	52	O
and	-	58	O
relation	-	62	O
to	-	71	O
cyclophosphamide	-	74	B
.	-	90	O

OBJECTIVE	15130900	92	O
:	-	101	O

To	15130900	103	O
assess	-	106	O
and	-	113	O
characterise	-	117	O
the	-	130	O
risk	-	134	O
of	-	139	O
bladder	-	142	O
cancer	-	150	O
,	-	156	O
and	-	158	O
its	-	162	O
relation	-	166	O
to	-	175	O
cyclophosphamide	-	178	B
,	-	194	O
in	-	196	O
patients	-	199	O
with	-	208	O
Wegener	-	213	O
's	-	220	O
granulomatosis	-	223	O
.	-	237	O

METHODS	15130900	239	O
:	-	246	O

In	15130900	248	O
the	-	251	O
population	-	255	O
based	-	266	O
,	-	271	O
nationwide	-	273	O
Swedish	-	284	O
Inpatient	-	292	O
Register	-	302	O
a	-	311	O
cohort	-	313	O
of	-	320	O
1065	-	323	O
patients	-	328	O
with	-	337	O
Wegener	-	342	O
's	-	349	O
granulomatosis	-	352	O
,	-	366	O
1969	-	368	O
-	-	372	O
95	-	373	O
,	-	375	O
was	-	377	O
identified	-	381	O
.	-	391	O

Through	15130900	393	O
linkage	-	401	O
with	-	409	O
the	-	414	O
Swedish	-	418	O
Cancer	-	426	O
Register	-	433	O
,	-	441	O
all	-	443	O
subjects	-	447	O
in	-	456	O
this	-	459	O
cohort	-	464	O
diagnosed	-	471	O
with	-	481	O
bladder	-	486	O
cancer	-	494	O
were	-	501	O
identified	-	506	O
.	-	516	O

Nested	15130900	518	O
within	-	525	O
the	-	532	O
cohort	-	536	O
,	-	542	O
a	-	544	O
matched	-	546	O
case	-	554	O
-	-	558	O
control	-	559	O
study	-	567	O
was	-	573	O
performed	-	577	O
to	-	587	O
estimate	-	590	O
the	-	599	O
association	-	603	O
between	-	615	O
cyclophosphamide	-	623	B
and	-	640	O
bladder	-	644	O
cancer	-	652	O
using	-	659	O
odds	-	665	O
ratios	-	670	O
(	-	677	O
ORs	-	678	O
)	-	681	O
as	-	683	O
relative	-	686	O
risk	-	695	O
.	-	699	O

In	15130900	701	O
the	-	704	O
cohort	-	708	O
the	-	715	O
cumulative	-	719	O
risk	-	730	O
of	-	735	O
bladder	-	738	O
cancer	-	746	O
after	-	753	O
Wegener	-	759	O
's	-	766	O
granulomatosis	-	769	O
,	-	783	O
and	-	785	O
the	-	789	O
relative	-	793	O
prevalence	-	802	O
of	-	813	O
a	-	816	O
history	-	818	O
of	-	826	O
bladder	-	829	O
cancer	-	837	O
at	-	844	O
the	-	847	O
time	-	851	O
of	-	856	O
diagnosis	-	859	O
of	-	869	O
Wegener	-	872	O
's	-	879	O
granulomatosis	-	882	O
,	-	896	O
were	-	898	O
also	-	903	O
estimated	-	908	O
.	-	917	O

RESULTS	15130900	919	O
:	-	926	O

The	15130900	928	O
median	-	932	O
cumulative	-	939	O
doses	-	950	O
of	-	956	O
cyclophosphamide	-	959	B
among	-	976	O
cases	-	982	O
(	-	988	O
n	-	989	O
=	-	991	O
11	-	993	O
)	-	995	O
and	-	997	O
controls	-	1001	O
(	-	1010	O
n	-	1011	O
=	-	1013	O
25	-	1015	O
)	-	1017	O
were	-	1019	O
113	-	1024	O
g	-	1028	O
and	-	1030	O
25	-	1034	O
g	-	1037	O
,	-	1038	O
respectively	-	1040	O
.	-	1052	O

The	15130900	1054	O
risk	-	1058	O
of	-	1063	O
bladder	-	1066	O
cancer	-	1074	O
doubled	-	1081	O
for	-	1089	O
every	-	1093	O
10	-	1099	O
g	-	1102	O
increment	-	1104	O
in	-	1114	O
cyclophosphamide	-	1117	B
(	-	1134	O
OR	-	1135	O
=	-	1138	O
2	-	1140	O
.	-	1141	O
0	-	1142	O
,	-	1143	O
95	-	1145	O
%	-	1147	O
confidence	-	1149	O
interval	-	1160	O
(	-	1169	O
CI	-	1170	O
)	-	1172	O
0	-	1174	O
.	-	1175	O
8	-	1176	O
to	-	1178	O
4	-	1181	O
.	-	1182	O
9	-	1183	O
)	-	1184	O
.	-	1185	O

Treatment	15130900	1187	O
duration	-	1197	O
longer	-	1206	O
than	-	1213	O
1	-	1218	O
year	-	1220	O
was	-	1225	O
associated	-	1229	O
with	-	1240	O
an	-	1245	O
eightfold	-	1248	O
increased	-	1258	O
risk	-	1268	O
(	-	1273	O
OR	-	1274	O
=	-	1277	O
7	-	1279	O
.	-	1280	O
7	-	1281	O
,	-	1282	O
95	-	1284	O
%	-	1286	O
CI	-	1288	O
0	-	1291	O
.	-	1292	O
9	-	1293	O
to	-	1295	O
69	-	1298	O
)	-	1300	O
.	-	1301	O

The	15130900	1303	O
absolute	-	1307	O
risk	-	1316	O
for	-	1321	O
bladder	-	1325	O
cancer	-	1333	O
in	-	1340	O
the	-	1343	O
cohort	-	1347	O
reached	-	1354	O
10	-	1362	O
%	-	1364	O
16	-	1366	O
years	-	1369	O
after	-	1375	O
diagnosis	-	1381	O
of	-	1391	O
Wegener	-	1394	O
's	-	1401	O
granulomatosis	-	1404	O
,	-	1418	O
and	-	1420	O
a	-	1424	O
history	-	1426	O
of	-	1434	O
bladder	-	1437	O
cancer	-	1445	O
was	-	1452	O
(	-	1456	O
non	-	1457	O
-	-	1460	O
significantly	-	1461	O
)	-	1474	O
twice	-	1476	O
as	-	1482	O
common	-	1485	O
as	-	1492	O
expected	-	1495	O
at	-	1504	O
the	-	1507	O
time	-	1511	O
of	-	1516	O
diagnosis	-	1519	O
of	-	1529	O
Wegener	-	1532	O
's	-	1539	O
granulomatosis	-	1542	O
.	-	1556	O

CONCLUSION	15130900	1558	O
:	-	1568	O

The	15130900	1570	O
results	-	1574	O
indicate	-	1582	O
a	-	1591	O
dose	-	1593	O
-	-	1597	O
response	-	1598	O
relationship	-	1607	O
between	-	1620	O
cyclophosphamide	-	1628	B
and	-	1645	O
the	-	1649	O
risk	-	1653	O
of	-	1658	O
bladder	-	1661	O
cancer	-	1669	O
,	-	1675	O
high	-	1677	O
cumulative	-	1682	O
risks	-	1693	O
in	-	1699	O
the	-	1702	O
entire	-	1706	O
cohort	-	1713	O
,	-	1719	O
and	-	1721	O
also	-	1725	O
the	-	1730	O
possibility	-	1734	O
of	-	1746	O
risk	-	1749	O
factors	-	1754	O
operating	-	1762	O
even	-	1772	O
before	-	1777	O
Wegener	-	1784	O
's	-	1791	O
granulomatosis	-	1794	O
.	-	1808	O

L	12707296	0	B
-	-	1	I
arginine	-	2	I
transport	-	11	O
in	-	21	O
humans	-	24	O
with	-	31	O
cortisol	-	36	B
-	-	44	O
induced	-	45	O
hypertension	-	53	O
.	-	65	O

A	12707296	67	O
deficient	-	69	O
L	-	79	B
-	-	80	I
arginine	-	81	I
-	-	89	O
nitric	-	90	B
oxide	-	97	I
system	-	103	O
is	-	110	O
implicated	-	113	O
in	-	124	O
cortisol	-	127	B
-	-	135	O
induced	-	136	O
hypertension	-	144	O
.	-	156	O

We	12707296	158	O
investigate	-	161	O
whether	-	173	O
abnormalities	-	181	O
in	-	195	O
L	-	198	B
-	-	199	I
arginine	-	200	I
uptake	-	209	O
contribute	-	216	O
to	-	227	O
this	-	230	O
deficiency	-	235	O
.	-	245	O

Eight	12707296	247	O
healthy	-	253	O
men	-	261	O
were	-	265	O
recruited	-	270	O
.	-	279	O

Hydrocortisone	12707296	281	B
acetate	-	296	I
(	-	304	O
50	-	305	O
mg	-	308	O
)	-	310	O
was	-	312	O
given	-	316	O
orally	-	322	O
every	-	329	O
6	-	335	O
hours	-	337	O
for	-	343	O
24	-	347	O
hours	-	350	O
after	-	356	O
a	-	362	O
5	-	364	O
-	-	365	O
day	-	366	O
fixed	-	370	O
-	-	375	O
salt	-	376	O
diet	-	381	O
(	-	386	O
150	-	387	O
mmol	-	391	O
/	-	395	O
d	-	396	O
)	-	397	O
.	-	398	O

Crossover	12707296	400	O
studies	-	410	O
were	-	418	O
performed	-	423	O
2	-	433	O
weeks	-	435	O
apart	-	441	O
.	-	446	O

Thirty	12707296	448	O
milliliters	-	455	O
of	-	467	O
blood	-	470	O
was	-	476	O
obtained	-	480	O
for	-	489	O
isolation	-	493	O
of	-	503	O
peripheral	-	506	O
blood	-	517	O
mononuclear	-	523	O
cells	-	535	O
after	-	541	O
each	-	547	O
treatment	-	552	O
period	-	562	O
.	-	568	O

L	12707296	570	B
-	-	571	I
arginine	-	572	I
uptake	-	581	O
was	-	588	O
assessed	-	592	O
in	-	601	O
mononuclear	-	604	O
cells	-	616	O
incubated	-	622	O
with	-	632	O
L	-	637	B
-	-	638	I
arginine	-	639	I
(	-	648	O
1	-	649	O
to	-	651	O
300	-	654	O
micromol	-	658	O
/	-	666	O
L	-	667	O
)	-	668	O
,	-	669	O
incorporating	-	671	O
100	-	685	O
nmol	-	689	O
/	-	693	O
L	-	694	O
[	-	696	B
3H	-	697	I
]	-	699	I
-	-	700	I
l	-	701	I
-	-	702	I
arginine	-	703	I
for	-	712	O
a	-	716	O
period	-	718	O
of	-	725	O
5	-	728	O
minutes	-	730	O
at	-	738	O
37	-	741	O
degrees	-	744	O
C	-	752	O
.	-	753	O
Forearm	-	755	O
[	-	763	B
3H	-	764	I
]	-	766	I
-	-	767	I
L	-	768	I
-	-	769	I
arginine	-	770	I
extraction	-	779	O
was	-	790	O
calculated	-	794	O
after	-	805	O
infusion	-	811	O
of	-	820	O
[	-	823	B
3H	-	824	I
]	-	826	I
-	-	827	I
L	-	828	I
-	-	829	I
arginine	-	830	I
into	-	839	O
the	-	844	O
brachial	-	848	O
artery	-	857	O
at	-	864	O
a	-	867	O
rate	-	869	O
of	-	874	O
100	-	877	O
nCi	-	881	O
/	-	884	O
min	-	885	O
for	-	889	O
80	-	893	O
minutes	-	896	O
.	-	903	O

Deep	12707296	905	O
forearm	-	910	O
venous	-	918	O
samples	-	925	O
were	-	933	O
collected	-	938	O
for	-	948	O
determination	-	952	O
of	-	966	O
L	-	969	B
-	-	970	I
arginine	-	971	I
extraction	-	980	O
.	-	990	O

Plasma	12707296	992	O
cortisol	-	999	B
concentrations	-	1008	O
were	-	1023	O
significantly	-	1028	O
raised	-	1042	O
during	-	1049	O
the	-	1056	O
active	-	1060	O
phase	-	1067	O
(	-	1073	O
323	-	1074	O
+	-	1077	O
/	-	1078	O
-	-	1079	O
43	-	1080	O
to	-	1083	O
1082	-	1086	O
+	-	1090	O
/	-	1091	O
-	-	1092	O
245	-	1093	O
mmol	-	1097	O
/	-	1101	O
L	-	1102	O
,	-	1103	O
P	-	1105	O
<	-	1106	O
0	-	1107	O
.	-	1108	O
05	-	1109	O
)	-	1111	O
.	-	1112	O

Systolic	12707296	1114	O
blood	-	1123	O
pressure	-	1129	O
was	-	1138	O
elevated	-	1142	O
by	-	1151	O
an	-	1154	O
average	-	1157	O
of	-	1165	O
7	-	1168	O
mm	-	1170	O
Hg	-	1173	O
.	-	1175	O

Neither	12707296	1177	O
L	-	1185	B
-	-	1186	I
arginine	-	1187	I
transport	-	1196	O
into	-	1206	O
mononuclear	-	1211	O
cells	-	1223	O
(	-	1229	O
placebo	-	1230	O
vs	-	1238	O
active	-	1241	O
,	-	1247	O
26	-	1249	O
.	-	1251	O
3	-	1252	O
+	-	1253	O
/	-	1254	O
-	-	1255	O
3	-	1256	O
.	-	1257	O
6	-	1258	O
vs	-	1260	O
29	-	1263	O
.	-	1265	O
0	-	1266	O
+	-	1267	O
/	-	1268	O
-	-	1269	O
2	-	1270	O
.	-	1271	O
1	-	1272	O
pmol	-	1274	O
/	-	1278	O
10	-	1279	O
000	-	1282	O
cells	-	1286	O
per	-	1292	O
5	-	1296	O
minutes	-	1298	O
,	-	1305	O
respectively	-	1307	O
,	-	1319	O
at	-	1321	O
an	-	1324	O
l	-	1327	B
-	-	1328	I
arginine	-	1329	I
concentration	-	1338	O
of	-	1352	O
300	-	1355	O
micromol	-	1359	O
/	-	1367	O
L	-	1368	O
)	-	1369	O
nor	-	1371	O
L	-	1375	B
-	-	1376	I
arginine	-	1377	I
extraction	-	1386	O
in	-	1397	O
the	-	1400	O
forearm	-	1404	O
(	-	1412	O
at	-	1413	O
80	-	1416	O
minutes	-	1419	O
,	-	1426	O
placebo	-	1428	O
vs	-	1436	O
active	-	1439	O
,	-	1445	O
1	-	1447	O
868	-	1449	O
904	-	1453	O
+	-	1456	O
/	-	1457	O
-	-	1458	O
434	-	1459	O
962	-	1463	O
vs	-	1467	O
2	-	1470	O
013	-	1472	O
910	-	1476	O
+	-	1479	O
/	-	1480	O
-	-	1481	O
770	-	1482	O
619	-	1486	O
disintegrations	-	1490	O
per	-	1506	O
minute	-	1510	O
)	-	1516	O
was	-	1518	O
affected	-	1522	O
by	-	1531	O
cortisol	-	1534	B
treatment	-	1543	O
;	-	1552	O
ie	-	1554	O
,	-	1556	O
that	-	1558	O
L	-	1563	B
-	-	1564	I
arginine	-	1565	I
uptake	-	1574	O
is	-	1581	O
not	-	1584	O
affected	-	1588	O
by	-	1597	O
short	-	1600	O
-	-	1605	O
term	-	1606	O
cortisol	-	1611	B
treatment	-	1620	O
.	-	1629	O

We	12707296	1631	O
conclude	-	1634	O
that	-	1643	O
cortisol	-	1648	B
-	-	1656	O
induced	-	1657	O
increases	-	1665	O
in	-	1675	O
blood	-	1678	O
pressure	-	1684	O
are	-	1693	O
not	-	1697	O
associated	-	1701	O
with	-	1712	O
abnormalities	-	1717	O
in	-	1731	O
the	-	1734	O
l	-	1738	B
-	-	1739	I
arginine	-	1740	I
transport	-	1749	O
system	-	1759	O
.	-	1765	O

MR	12695819	0	O
imaging	-	3	O
with	-	11	O
quantitative	-	16	O
diffusion	-	29	O
mapping	-	39	O
of	-	47	O
tacrolimus	-	50	B
-	-	60	O
induced	-	61	O
neurotoxicity	-	69	O
in	-	83	O
organ	-	86	O
transplant	-	92	O
patients	-	103	O
.	-	111	O

Our	12695819	113	O
objective	-	117	O
was	-	127	O
to	-	131	O
investigate	-	134	O
brain	-	146	O
MR	-	152	O
imaging	-	155	O
findings	-	163	O
and	-	172	O
the	-	176	O
utility	-	180	O
of	-	188	O
diffusion	-	191	O
-	-	200	O
weighted	-	201	O
(	-	210	O
DW	-	211	O
)	-	213	O
imaging	-	215	O
in	-	223	O
organ	-	226	O
transplant	-	232	O
patients	-	243	O
who	-	252	O
developed	-	256	O
neurologic	-	266	O
symptoms	-	277	O
during	-	286	O
tacrolimus	-	293	B
therapy	-	304	O
.	-	311	O

Brain	12695819	313	O
MR	-	319	O
studies	-	322	O
,	-	329	O
including	-	331	O
DW	-	341	O
imaging	-	344	O
,	-	351	O
were	-	353	O
prospectively	-	358	O
performed	-	372	O
in	-	382	O
14	-	385	O
organ	-	388	O
transplant	-	394	O
patients	-	405	O
receiving	-	414	O
tacrolimus	-	424	B
who	-	435	O
developed	-	439	O
neurologic	-	449	O
complications	-	460	O
.	-	473	O

In	12695819	475	O
each	-	478	O
patient	-	483	O
who	-	491	O
had	-	495	O
abnormalities	-	499	O
on	-	513	O
the	-	516	O
initial	-	520	O
MR	-	528	O
study	-	531	O
,	-	536	O
a	-	538	O
follow	-	540	O
-	-	546	O
up	-	547	O
MR	-	550	O
study	-	553	O
was	-	559	O
performed	-	563	O
1	-	573	O
month	-	575	O
later	-	581	O
.	-	586	O

Apparent	12695819	588	O
diffusion	-	597	O
coefficient	-	607	O
(	-	619	O
ADC	-	620	O
)	-	623	O
values	-	625	O
on	-	632	O
the	-	635	O
initial	-	639	O
MR	-	647	O
study	-	650	O
were	-	656	O
correlated	-	661	O
with	-	672	O
reversibility	-	677	O
of	-	691	O
the	-	694	O
lesions	-	698	O
.	-	705	O

Of	12695819	707	O
the	-	710	O
14	-	714	O
patients	-	717	O
,	-	725	O
5	-	727	O
(	-	729	O
35	-	730	O
.	-	732	O
7	-	733	O
%	-	734	O
)	-	735	O
had	-	737	O
white	-	741	O
matter	-	747	O
abnormalities	-	754	O
,	-	767	O
1	-	769	O
(	-	771	O
7	-	772	O
.	-	773	O
1	-	774	O
%	-	775	O
)	-	776	O
had	-	778	O
putaminal	-	782	O
hemorrhage	-	792	O
,	-	802	O
and	-	804	O
8	-	808	O
(	-	810	O
57	-	811	O
.	-	813	O
1	-	814	O
%	-	815	O
)	-	816	O
had	-	818	O
normal	-	822	O
findings	-	829	O
on	-	838	O
initial	-	841	O
MR	-	849	O
images	-	852	O
.	-	858	O

Among	12695819	860	O
the	-	866	O
5	-	870	O
patients	-	872	O
with	-	881	O
white	-	886	O
matter	-	892	O
abnormalities	-	899	O
,	-	912	O
4	-	914	O
patients	-	916	O
(	-	925	O
80	-	926	O
.	-	928	O
0	-	929	O
%	-	930	O
)	-	931	O
showed	-	933	O
higher	-	940	O
than	-	947	O
normal	-	952	O
ADC	-	959	O
values	-	963	O
on	-	970	O
initial	-	973	O
MR	-	981	O
images	-	984	O
,	-	990	O
and	-	992	O
all	-	996	O
showed	-	1000	O
complete	-	1007	O
resolution	-	1016	O
on	-	1027	O
follow	-	1030	O
-	-	1036	O
up	-	1037	O
images	-	1040	O
.	-	1046	O

The	12695819	1048	O
remaining	-	1052	O
1	-	1062	O
patient	-	1064	O
(	-	1072	O
20	-	1073	O
.	-	1075	O
0	-	1076	O
%	-	1077	O
)	-	1078	O
showed	-	1080	O
lower	-	1087	O
than	-	1093	O
normal	-	1098	O
ADC	-	1105	O
value	-	1109	O
and	-	1115	O
showed	-	1119	O
incomplete	-	1126	O
resolution	-	1137	O
with	-	1148	O
cortical	-	1153	O
laminar	-	1162	O
necrosis	-	1170	O
.	-	1178	O

Diffusion	12695819	1180	O
-	-	1189	O
weighted	-	1190	O
imaging	-	1199	O
may	-	1207	O
be	-	1211	O
useful	-	1214	O
in	-	1221	O
predicting	-	1224	O
the	-	1235	O
outcomes	-	1239	O
of	-	1248	O
the	-	1251	O
lesions	-	1255	O
of	-	1263	O
tacrolimus	-	1266	B
-	-	1276	O
induced	-	1277	O
neurotoxicity	-	1285	O
.	-	1298	O

Octreotide	12596116	0	B
-	-	10	O
induced	-	11	O
hypoxemia	-	19	O
and	-	29	O
pulmonary	-	33	O
hypertension	-	43	O
in	-	56	O
premature	-	59	O
neonates	-	69	O
.	-	77	O

The	12596116	79	O
authors	-	83	O
report	-	91	O
2	-	98	O
cases	-	100	O
of	-	106	O
premature	-	109	O
neonates	-	119	O
who	-	128	O
had	-	132	O
enterocutaneous	-	136	O
fistula	-	152	O
complicating	-	160	O
necrotizing	-	173	O
enterocolitis	-	185	O
.	-	198	O

Pulmonary	12596116	200	O
hypertension	-	210	O
developed	-	223	O
after	-	233	O
administration	-	239	O
of	-	254	O
a	-	257	O
somatostatin	-	259	O
analogue	-	272	O
,	-	280	O
octreotide	-	282	B
,	-	292	O
to	-	294	O
enhance	-	297	O
resolution	-	305	O
of	-	316	O
the	-	319	O
fistula	-	323	O
.	-	330	O

The	12596116	332	O
authors	-	336	O
discuss	-	344	O
the	-	352	O
mechanism	-	356	O
of	-	366	O
the	-	369	O
occurrence	-	373	O
of	-	384	O
this	-	387	O
complication	-	392	O
and	-	405	O
recommend	-	409	O
caution	-	419	O
of	-	427	O
its	-	430	O
use	-	434	O
in	-	438	O
high	-	441	O
-	-	445	O
risk	-	446	O
premature	-	451	O
neonates	-	461	O
.	-	469	O

Sequential	11875660	0	O
observations	-	11	O
of	-	24	O
exencephaly	-	27	O
and	-	39	O
subsequent	-	43	O
morphological	-	54	O
changes	-	68	O
by	-	76	O
mouse	-	79	O
exo	-	85	O
utero	-	89	O
development	-	95	O
system	-	107	O
:	-	113	O
analysis	-	115	O
of	-	124	O
the	-	127	O
mechanism	-	131	O
of	-	141	O
transformation	-	144	O
from	-	159	O
exencephaly	-	164	O
to	-	176	O
anencephaly	-	179	O
.	-	190	O

Anencephaly	11875660	192	O
has	-	204	O
been	-	208	O
suggested	-	213	O
to	-	223	O
develop	-	226	O
from	-	234	O
exencephaly	-	239	O
;	-	250	O
however	-	252	O
,	-	259	O
there	-	261	O
is	-	267	O
little	-	270	O
direct	-	277	O
experimental	-	284	O
evidence	-	297	O
to	-	306	O
support	-	309	O
this	-	317	O
,	-	321	O
and	-	323	O
the	-	327	O
mechanism	-	331	O
of	-	341	O
transformation	-	344	O
remains	-	359	O
unclear	-	367	O
.	-	374	O

We	11875660	376	O
examined	-	379	O
this	-	388	O
theory	-	393	O
using	-	400	O
the	-	406	O
exo	-	410	O
utero	-	414	O
development	-	420	O
system	-	432	O
that	-	439	O
allows	-	444	O
direct	-	451	O
and	-	458	O
sequential	-	462	O
observations	-	473	O
of	-	486	O
mid	-	489	O
-	-	492	O
to	-	494	O
late	-	497	O
-	-	501	O
gestation	-	502	O
mouse	-	512	O
embryos	-	518	O
.	-	525	O

We	11875660	527	O
observed	-	530	O
the	-	539	O
exencephaly	-	543	O
induced	-	555	O
by	-	563	O
5	-	566	B
-	-	567	I
azacytidine	-	568	I
at	-	580	O
embryonic	-	583	O
day	-	593	O
13	-	597	O
.	-	599	O
5	-	600	O
(	-	602	O
E13	-	603	O
.	-	606	O
5	-	607	O
)	-	608	O
,	-	609	O
let	-	611	O
the	-	615	O
embryos	-	619	O
develop	-	627	O
exo	-	635	O
utero	-	639	O
until	-	645	O
E18	-	651	O
.	-	654	O
5	-	655	O
,	-	656	O
and	-	658	O
re	-	662	O
-	-	664	O
observed	-	665	O
the	-	674	O
same	-	678	O
embryos	-	683	O
at	-	691	O
E18	-	694	O
.	-	697	O
5	-	698	O
.	-	699	O

We	11875660	701	O
confirmed	-	704	O
several	-	714	O
cases	-	722	O
of	-	728	O
transformation	-	731	O
from	-	746	O
exencephaly	-	751	O
to	-	763	O
anencephaly	-	766	O
.	-	777	O

However	11875660	779	O
,	-	786	O
in	-	788	O
many	-	791	O
cases	-	796	O
,	-	801	O
the	-	803	O
exencephalic	-	807	O
brain	-	820	O
tissue	-	826	O
was	-	833	O
preserved	-	837	O
with	-	847	O
more	-	852	O
or	-	857	O
less	-	860	O
reduction	-	865	O
during	-	875	O
this	-	882	O
period	-	887	O
.	-	893	O

To	11875660	895	O
analyze	-	898	O
the	-	906	O
transformation	-	910	O
patterns	-	925	O
,	-	933	O
we	-	935	O
classified	-	938	O
the	-	949	O
exencephaly	-	953	O
by	-	965	O
size	-	968	O
and	-	973	O
shape	-	977	O
of	-	983	O
the	-	986	O
exencephalic	-	990	O
tissue	-	1003	O
into	-	1010	O
several	-	1015	O
types	-	1023	O
at	-	1029	O
E13	-	1032	O
.	-	1035	O
5	-	1036	O
and	-	1038	O
E18	-	1042	O
.	-	1045	O
5	-	1046	O
.	-	1047	O

It	11875660	1049	O
was	-	1052	O
found	-	1056	O
that	-	1062	O
the	-	1067	O
transformation	-	1071	O
of	-	1086	O
exencephalic	-	1089	O
tissue	-	1102	O
was	-	1109	O
not	-	1113	O
simply	-	1117	O
size	-	1124	O
-	-	1128	O
dependent	-	1129	O
,	-	1138	O
and	-	1140	O
all	-	1144	O
cases	-	1148	O
of	-	1154	O
anencephaly	-	1157	O
at	-	1169	O
E18	-	1172	O
.	-	1175	O
5	-	1176	O
resulted	-	1178	O
from	-	1187	O
embryos	-	1192	O
with	-	1200	O
a	-	1205	O
large	-	1207	O
amount	-	1213	O
of	-	1220	O
exencephalic	-	1223	O
tissue	-	1236	O
at	-	1243	O
E13	-	1246	O
.	-	1249	O
5	-	1250	O
.	-	1251	O

Microscopic	11875660	1253	O
observation	-	1265	O
showed	-	1277	O
the	-	1284	O
configuration	-	1288	O
of	-	1302	O
exencephaly	-	1305	O
at	-	1317	O
E13	-	1320	O
.	-	1323	O
5	-	1324	O
,	-	1325	O
frequent	-	1327	O
hemorrhaging	-	1336	O
and	-	1349	O
detachment	-	1353	O
of	-	1364	O
the	-	1367	O
neural	-	1371	O
plate	-	1378	O
from	-	1384	O
surface	-	1389	O
ectoderm	-	1397	O
in	-	1406	O
the	-	1409	O
exencephalic	-	1413	O
head	-	1426	O
at	-	1431	O
E15	-	1434	O
.	-	1437	O
5	-	1438	O
,	-	1439	O
and	-	1441	O
multiple	-	1445	O
modes	-	1454	O
of	-	1460	O
reduction	-	1463	O
in	-	1473	O
the	-	1476	O
exencephalic	-	1480	O
tissue	-	1493	O
at	-	1500	O
E18	-	1503	O
.	-	1506	O
5	-	1507	O
.	-	1508	O

From	11875660	1510	O
observations	-	1515	O
of	-	1528	O
the	-	1531	O
vasculature	-	1535	O
,	-	1546	O
altered	-	1548	O
distribution	-	1556	O
patterns	-	1569	O
of	-	1578	O
vessels	-	1581	O
were	-	1589	O
identified	-	1594	O
in	-	1605	O
the	-	1608	O
exencephalic	-	1612	O
head	-	1625	O
.	-	1629	O

These	11875660	1631	O
findings	-	1637	O
suggest	-	1646	O
that	-	1654	O
overgrowth	-	1659	O
of	-	1670	O
the	-	1673	O
exencephalic	-	1677	O
neural	-	1690	O
tissue	-	1697	O
causes	-	1704	O
the	-	1711	O
altered	-	1715	O
distribution	-	1723	O
patterns	-	1736	O
of	-	1745	O
vessels	-	1748	O
,	-	1755	O
subsequent	-	1757	O
peripheral	-	1768	O
circulatory	-	1779	O
failure	-	1791	O
and	-	1799	O
/	-	1802	O
or	-	1803	O
hemorrhaging	-	1806	O
in	-	1819	O
various	-	1822	O
parts	-	1830	O
of	-	1836	O
the	-	1839	O
exencephalic	-	1843	O
head	-	1856	O
,	-	1860	O
leading	-	1862	O
to	-	1870	O
the	-	1873	O
multiple	-	1877	O
modes	-	1886	O
of	-	1892	O
tissue	-	1895	O
reduction	-	1902	O
during	-	1912	O
transformation	-	1919	O
from	-	1934	O
exencephaly	-	1939	O
to	-	1951	O
anencephaly	-	1954	O
.	-	1965	O

Acute	11166519	0	O
cocaine	-	6	B
-	-	13	O
induced	-	14	O
seizures	-	22	O
:	-	30	O
differential	-	32	O
sensitivity	-	45	O
of	-	57	O
six	-	60	O
inbred	-	64	O
mouse	-	71	O
strains	-	77	O
.	-	84	O

Mature	11166519	86	O
male	-	93	O
and	-	98	O
female	-	102	O
mice	-	109	O
from	-	114	O
six	-	119	O
inbred	-	123	O
stains	-	130	O
were	-	137	O
tested	-	142	O
for	-	149	O
susceptibility	-	153	O
to	-	168	O
behavioral	-	171	O
seizures	-	182	O
induced	-	191	O
by	-	199	O
a	-	202	O
single	-	204	O
injection	-	211	O
of	-	221	O
cocaine	-	224	B
.	-	231	O

Cocaine	11166519	233	B
was	-	241	O
injected	-	245	O
ip	-	254	O
over	-	257	O
a	-	262	O
range	-	264	O
of	-	270	O
doses	-	273	O
(	-	279	O
50	-	280	O
-	-	282	O
100	-	283	O
mg	-	287	O
/	-	289	O
kg	-	290	O
)	-	292	O
and	-	294	O
behavior	-	298	O
was	-	307	O
monitored	-	311	O
for	-	321	O
20	-	325	O
minutes	-	328	O
.	-	335	O

Seizure	11166519	337	O
end	-	345	O
points	-	349	O
included	-	356	O
latency	-	365	O
to	-	373	O
forelimb	-	376	O
or	-	385	O
hindlimb	-	388	O
clonus	-	397	O
,	-	403	O
latency	-	405	O
to	-	413	O
clonic	-	416	O
running	-	423	O
seizure	-	431	O
and	-	439	O
latency	-	443	O
to	-	451	O
jumping	-	454	O
bouncing	-	462	O
seizure	-	471	O
.	-	478	O

A	11166519	480	O
range	-	482	O
of	-	488	O
strain	-	491	O
specific	-	498	O
sensitivities	-	507	O
was	-	521	O
documented	-	525	O
with	-	536	O
A	-	541	O
/	-	542	O
J	-	543	O
and	-	545	O
SJL	-	549	O
mice	-	553	O
being	-	558	O
most	-	564	O
sensitive	-	569	O
and	-	579	O
C57BL	-	583	O
/	-	588	O
6J	-	589	O
most	-	592	O
resistant	-	597	O
.	-	606	O

DBA	11166519	608	O
/	-	611	O
2J	-	612	O
,	-	614	O
BALB	-	616	O
/	-	620	O
cByJ	-	621	O
and	-	626	O
NZW	-	630	O
/	-	633	O
LacJ	-	634	O
strains	-	639	O
exhibited	-	647	O
intermediate	-	657	O
sensitivity	-	670	O
.	-	681	O

EEG	11166519	683	O
recordings	-	687	O
were	-	698	O
made	-	703	O
in	-	708	O
SJL	-	711	O
,	-	714	O
A	-	716	O
/	-	717	O
J	-	718	O
and	-	720	O
C57BL	-	724	O
/	-	729	O
6J	-	730	O
mice	-	733	O
revealing	-	738	O
a	-	748	O
close	-	750	O
correspondence	-	756	O
between	-	771	O
electrical	-	779	O
activity	-	790	O
and	-	799	O
behavior	-	803	O
.	-	811	O

Additionally	11166519	813	O
,	-	825	O
levels	-	827	O
of	-	834	O
cocaine	-	837	B
determined	-	845	O
in	-	856	O
hippocampus	-	859	O
and	-	871	O
cortex	-	875	O
were	-	882	O
not	-	887	O
different	-	891	O
between	-	901	O
sensitive	-	909	O
and	-	919	O
resistant	-	923	O
strains	-	933	O
.	-	940	O

Additional	11166519	942	O
studies	-	953	O
of	-	961	O
these	-	964	O
murine	-	970	O
strains	-	977	O
may	-	985	O
be	-	989	O
useful	-	992	O
for	-	999	O
investigating	-	1003	O
genetic	-	1017	O
influences	-	1025	O
on	-	1036	O
cocaine	-	1039	B
-	-	1046	O
induced	-	1047	O
seizures	-	1055	O
.	-	1063	O

Microangiopathic	8701950	0	O
hemolytic	-	17	O
anemia	-	27	O
complicating	-	34	O
FK506	-	47	B
(	-	53	O
tacrolimus	-	54	B
)	-	64	O
therapy	-	66	O
.	-	73	O

We	8701950	75	O
describe	-	78	O
3	-	87	O
episodes	-	89	O
of	-	98	O
microangiopathic	-	101	O
hemolytic	-	118	O
anemia	-	128	O
(	-	135	O
MAHA	-	136	O
)	-	140	O
in	-	142	O
2	-	145	O
solid	-	147	O
organ	-	153	O
recipients	-	159	O
under	-	170	O
FK506	-	176	B
(	-	182	O
tacrolimus	-	183	B
)	-	193	O
therapy	-	195	O
.	-	202	O

In	8701950	204	O
both	-	207	O
cases	-	212	O
,	-	217	O
discontinuation	-	219	O
of	-	235	O
FK506	-	238	B
and	-	244	O
treatment	-	248	O
with	-	258	O
plasma	-	263	O
exchange	-	270	O
,	-	278	O
fresh	-	280	O
frozen	-	286	O
plasma	-	293	O
replacement	-	300	O
,	-	311	O
corticosteroids	-	313	B
,	-	328	O
aspirin	-	330	B
,	-	337	O
and	-	339	O
dipyridamole	-	343	B
led	-	356	O
to	-	360	O
resolution	-	363	O
of	-	374	O
MAHA	-	377	O
.	-	381	O

In	8701950	383	O
one	-	386	O
patient	-	390	O
,	-	397	O
reintroduction	-	399	O
of	-	414	O
FK506	-	417	B
led	-	423	O
to	-	427	O
rapid	-	430	O
recurrence	-	436	O
of	-	447	O
MAHA	-	450	O
.	-	454	O

FK506	8701950	456	B
-	-	461	O
associated	-	462	O
MAHA	-	473	O
is	-	478	O
probably	-	481	O
rare	-	490	O
but	-	495	O
physicians	-	499	O
must	-	510	O
be	-	515	O
aware	-	518	O
of	-	524	O
this	-	527	O
severe	-	532	O
complication	-	539	O
.	-	551	O

In	8701950	553	O
our	-	556	O
experience	-	560	O
and	-	571	O
according	-	575	O
to	-	585	O
the	-	588	O
literature	-	592	O
,	-	602	O
FK506	-	604	B
does	-	610	O
not	-	615	O
seem	-	619	O
to	-	624	O
cross	-	627	O
-	-	632	O
react	-	633	O
with	-	639	O
cyclosporin	-	644	B
A	-	656	I
(	-	658	O
CyA	-	659	B
)	-	662	O
,	-	663	O
an	-	665	O
immuno	-	668	O
-	-	674	O
suppressive	-	675	O
drug	-	687	O
already	-	692	O
known	-	700	O
to	-	706	O
induce	-	709	O
MAHA	-	716	O
.	-	720	O

Variant	7292072	0	O
ventricular	-	8	O
tachycardia	-	20	O
in	-	32	O
desipramine	-	35	B
toxicity	-	47	O
.	-	55	O

We	7292072	57	O
report	-	60	O
a	-	67	O
case	-	69	O
of	-	74	O
variant	-	77	O
ventricular	-	85	O
tachycardia	-	97	O
induced	-	109	O
by	-	117	O
desipramine	-	120	B
toxicity	-	132	O
.	-	140	O

Unusual	7292072	142	O
features	-	150	O
of	-	159	O
the	-	162	O
arrhythmia	-	166	O
are	-	177	O
repetitive	-	181	O
group	-	192	O
beating	-	198	O
,	-	205	O
progressive	-	207	O
shortening	-	219	O
of	-	230	O
the	-	233	O
R	-	237	O
-	-	238	O
R	-	239	O
interval	-	241	O
,	-	249	O
progressive	-	251	O
widening	-	263	O
of	-	272	O
the	-	275	O
QRS	-	279	O
complex	-	283	O
with	-	291	O
eventual	-	296	O
failure	-	305	O
of	-	313	O
intraventricular	-	316	O
conduction	-	333	O
,	-	343	O
and	-	345	O
changes	-	349	O
in	-	357	O
direction	-	360	O
of	-	370	O
the	-	373	O
QRS	-	377	O
axis	-	381	O
.	-	385	O

Recognition	7292072	387	O
of	-	399	O
variant	-	402	O
ventricular	-	410	O
tachycardia	-	422	O
is	-	434	O
important	-	437	O
because	-	447	O
therapy	-	455	O
differs	-	463	O
from	-	471	O
that	-	476	O
of	-	481	O
classic	-	484	O
ventricular	-	492	O
tachycardia	-	504	O
.	-	515	O

Desipramine	4027862	0	B
-	-	11	O
induced	-	12	O
delirium	-	20	O
at	-	29	O
""""	-	32	O
subtherapeutic	-	33	O
""""	-	47	O
concentrations	-	49	O
:	-	63	O
a	-	65	O
case	-	67	O
report	-	72	O
.	-	78	O

An	4027862	80	O
elderly	-	83	O
patient	-	91	O
treated	-	99	O
with	-	107	O
low	-	112	O
dose	-	116	O
Desipramine	-	121	B
developed	-	133	O
a	-	143	O
delirium	-	145	O
while	-	154	O
her	-	160	O
plasma	-	164	O
level	-	171	O
was	-	177	O
in	-	181	O
the	-	184	O
""""	-	188	O
subtherapeutic	-	189	O
""""	-	203	O
range	-	205	O
.	-	210	O

Delirium	4027862	212	O
,	-	220	O
which	-	222	O
may	-	228	O
be	-	232	O
induced	-	235	O
by	-	243	O
tricyclic	-	246	O
drug	-	256	O
therapy	-	261	O
in	-	269	O
the	-	272	O
elderly	-	276	O
,	-	283	O
can	-	285	O
be	-	289	O
caused	-	292	O
by	-	299	O
tricyclics	-	302	O
with	-	313	O
low	-	318	O
anticholinergic	-	322	O
potency	-	338	O
.	-	345	O

Therapeutic	4027862	347	O
ranges	-	359	O
for	-	366	O
antidepressants	-	370	B
that	-	386	O
have	-	391	O
been	-	396	O
derived	-	401	O
from	-	409	O
general	-	414	O
adult	-	422	O
population	-	428	O
studies	-	439	O
may	-	447	O
not	-	451	O
be	-	455	O
appropriate	-	458	O
for	-	470	O
the	-	474	O
elderly	-	478	O
.	-	485	O

Further	4027862	487	O
studies	-	495	O
of	-	503	O
specifically	-	506	O
elderly	-	519	O
patients	-	527	O
are	-	536	O
now	-	540	O
required	-	544	O
to	-	553	O
establish	-	556	O
safer	-	566	O
and	-	572	O
more	-	576	O
appropriate	-	581	O
guidelines	-	593	O
for	-	604	O
drug	-	608	O
therapy	-	613	O
.	-	620	O

Mouse	2484011	0	O
strain	-	6	O
-	-	12	O
dependent	-	13	O
effect	-	23	O
of	-	30	O
amantadine	-	33	B
on	-	44	O
motility	-	47	O
and	-	56	O
brain	-	60	O
biogenic	-	66	O
amines	-	75	B
.	-	81	O

The	2484011	83	O
effect	-	87	O
of	-	94	O
amantadine	-	97	B
hydrochloride	-	108	I
,	-	121	O
injected	-	123	O
i	-	132	O
.	-	133	O
p	-	134	O
.	-	135	O

in	2484011	137	O
6	-	140	O
increments	-	142	O
of	-	153	O
100	-	156	O
mg	-	160	O
/	-	162	O
kg	-	163	O
each	-	166	O
over	-	171	O
30	-	176	O
hr	-	179	O
,	-	181	O
on	-	183	O
mouse	-	186	O
motility	-	192	O
and	-	201	O
whole	-	205	O
brain	-	211	O
content	-	217	O
of	-	225	O
selected	-	228	O
biogenic	-	237	O
amines	-	246	B
and	-	253	O
major	-	257	O
metabolites	-	263	O
was	-	275	O
studied	-	279	O
in	-	287	O
4	-	290	O
strains	-	292	O
of	-	300	O
mice	-	303	O
.	-	307	O

These	2484011	309	O
were	-	315	O
the	-	320	O
albino	-	324	O
Sprague	-	331	O
-	-	338	O
Dawley	-	339	O
ICR	-	346	O
and	-	350	O
BALB	-	354	O
/	-	358	O
C	-	359	O
,	-	360	O
the	-	362	O
black	-	366	O
C57BL	-	372	O
/	-	377	O
6	-	378	O
and	-	380	O
the	-	384	O
brown	-	388	O
CDF	-	394	O
-	-	397	O
I	-	398	O
mouse	-	400	O
strains	-	406	O
.	-	413	O

Amantadine	2484011	415	B
treatment	-	426	O
produced	-	436	O
a	-	445	O
biphasic	-	447	O
effect	-	456	O
on	-	463	O
mouse	-	466	O
motility	-	472	O
.	-	480	O

The	2484011	482	O
initial	-	486	O
dose	-	494	O
of	-	499	O
amantadine	-	502	B
depressed	-	513	O
locomotor	-	523	O
activity	-	533	O
in	-	542	O
all	-	545	O
mouse	-	549	O
strains	-	555	O
studied	-	563	O
with	-	571	O
the	-	576	O
BALB	-	580	O
/	-	584	O
C	-	585	O
mice	-	587	O
being	-	592	O
the	-	598	O
most	-	602	O
sensitive	-	607	O
.	-	616	O

Subsequent	2484011	618	O
amantadine	-	629	B
treatments	-	640	O
produced	-	651	O
enhancement	-	660	O
of	-	672	O
motility	-	675	O
from	-	684	O
corresponding	-	689	O
control	-	703	O
in	-	711	O
all	-	714	O
mouse	-	718	O
strains	-	724	O
with	-	732	O
the	-	737	O
BALB	-	741	O
/	-	745	O
C	-	746	O
mice	-	748	O
being	-	753	O
the	-	759	O
least	-	763	O
sensitive	-	769	O
.	-	778	O

The	2484011	780	O
locomotor	-	784	O
activity	-	794	O
was	-	803	O
decreased	-	807	O
from	-	817	O
corresponding	-	822	O
controls	-	836	O
in	-	845	O
all	-	848	O
strains	-	852	O
studied	-	860	O
,	-	867	O
except	-	869	O
for	-	876	O
the	-	880	O
ICR	-	884	O
mice	-	888	O
,	-	892	O
during	-	894	O
an	-	901	O
overnight	-	904	O
drug	-	914	O
-	-	918	O
free	-	919	O
period	-	924	O
following	-	931	O
the	-	941	O
fourth	-	945	O
amantadine	-	952	B
treatment	-	963	O
.	-	972	O

Readministration	2484011	974	O
of	-	991	O
amantadine	-	994	B
,	-	1004	O
after	-	1006	O
a	-	1012	O
drug	-	1014	O
-	-	1018	O
free	-	1019	O
overnight	-	1024	O
period	-	1034	O
,	-	1040	O
increased	-	1042	O
motility	-	1052	O
from	-	1061	O
respective	-	1066	O
saline	-	1077	O
control	-	1084	O
in	-	1092	O
all	-	1095	O
strains	-	1099	O
with	-	1107	O
exception	-	1112	O
of	-	1122	O
the	-	1125	O
BALB	-	1129	O
/	-	1133	O
C	-	1134	O
mice	-	1136	O
where	-	1141	O
suppression	-	1147	O
of	-	1159	O
motility	-	1162	O
occurred	-	1171	O
.	-	1179	O

Treatment	2484011	1181	O
with	-	1191	O
amantadine	-	1196	B
did	-	1207	O
not	-	1211	O
alter	-	1215	O
whole	-	1221	O
brain	-	1227	O
dopamine	-	1233	B
levels	-	1242	O
but	-	1249	O
decreased	-	1253	O
the	-	1263	O
amounts	-	1267	O
of	-	1275	O
3	-	1278	B
,	-	1279	I
4	-	1280	I
-	-	1281	I
dihydroxyphenylacetic	-	1282	I
acid	-	1304	I
in	-	1309	O
the	-	1312	O
BALB	-	1316	O
/	-	1320	O
C	-	1321	O
mice	-	1323	O
compared	-	1328	O
to	-	1337	O
saline	-	1340	O
control	-	1347	O
.	-	1354	O

Conversely	2484011	1356	O
,	-	1366	O
brain	-	1368	O
normetanephrine	-	1374	B
concentration	-	1390	O
was	-	1404	O
increased	-	1408	O
from	-	1418	O
saline	-	1423	O
control	-	1430	O
by	-	1438	O
amantadine	-	1441	B
in	-	1452	O
the	-	1455	O
BALB	-	1459	O
/	-	1463	O
C	-	1464	O
mice	-	1466	O
.	-	1470	O

The	2484011	1472	O
results	-	1476	O
suggest	-	1484	O
a	-	1492	O
strain	-	1494	O
-	-	1500	O
dependent	-	1501	O
effect	-	1511	O
of	-	1518	O
amantadine	-	1521	B
on	-	1532	O
motility	-	1535	O
and	-	1544	O
indicate	-	1548	O
a	-	1557	O
differential	-	1559	O
response	-	1572	O
to	-	1581	O
the	-	1584	O
acute	-	1588	O
and	-	1594	O
multiple	-	1598	O
dose	-	1607	O
regimens	-	1612	O
used	-	1621	O
.	-	1625	O

The	2484011	1627	O
BALB	-	1631	O
/	-	1635	O
C	-	1636	O
mouse	-	1638	O
was	-	1644	O
the	-	1648	O
most	-	1652	O
sensitive	-	1657	O
strain	-	1667	O
and	-	1674	O
could	-	1678	O
serve	-	1684	O
as	-	1690	O
the	-	1693	O
strain	-	1697	O
of	-	1704	O
choice	-	1707	O
for	-	1714	O
evaluating	-	1718	O
the	-	1729	O
side	-	1733	O
effects	-	1738	O
of	-	1746	O
amantadine	-	1749	B
.	-	1759	O

The	2484011	1761	O
biochemical	-	1765	O
results	-	1777	O
of	-	1785	O
brain	-	1788	O
biogenic	-	1794	O
amines	-	1803	B
of	-	1810	O
BALB	-	1813	O
/	-	1817	O
C	-	1818	O
mouse	-	1820	O
strain	-	1826	O
suggest	-	1833	O
a	-	1841	O
probable	-	1843	O
decrease	-	1852	O
of	-	1861	O
catecholamine	-	1864	B
turnover	-	1878	O
rate	-	1887	O
and	-	1892	O
/	-	1895	O
or	-	1896	O
metabolism	-	1899	O
by	-	1910	O
monoamine	-	1913	O
oxidase	-	1923	O
and	-	1931	O
a	-	1935	O
resulting	-	1937	O
increase	-	1947	O
in	-	1956	O
O	-	1959	O
-	-	1960	O
methylation	-	1961	O
of	-	1973	O
norepinephrine	-	1976	B
which	-	1991	O
may	-	1997	O
account	-	2001	O
for	-	2009	O
a	-	2013	O
behavioral	-	2015	O
depression	-	2026	O
caused	-	2037	O
by	-	2044	O
amantadine	-	2047	B
in	-	2058	O
the	-	2061	O
BALB	-	2065	O
/	-	2069	O
C	-	2070	O
mice	-	2072	O
.	-	2076	O

No	2396046	0	O
enhancement	-	3	O
by	-	15	O
phenobarbital	-	18	B
of	-	32	O
the	-	35	O
hepatocarcinogenicity	-	39	O
of	-	61	O
a	-	64	O
choline	-	66	B
-	-	73	O
devoid	-	74	O
diet	-	81	O
in	-	86	O
the	-	89	O
rat	-	93	O
.	-	96	O

An	2396046	98	O
experiment	-	101	O
was	-	112	O
performed	-	116	O
to	-	126	O
test	-	129	O
whether	-	134	O
inclusion	-	142	O
of	-	152	O
phenobarbital	-	155	B
in	-	169	O
a	-	172	O
choline	-	174	B
-	-	181	O
devoid	-	182	O
diet	-	189	O
would	-	194	O
increase	-	200	O
the	-	209	O
hepatocarcinogenicity	-	213	O
of	-	235	O
the	-	238	O
diet	-	242	O
.	-	246	O

Groups	2396046	248	O
of	-	255	O
5	-	258	O
-	-	259	O
week	-	260	O
old	-	265	O
male	-	269	O
Fischer	-	274	O
-	-	281	O
344	-	282	O
rats	-	286	O
were	-	291	O
fed	-	296	O
for	-	300	O
7	-	304	O
-	-	305	O
25	-	306	O
months	-	309	O
semipurified	-	316	O
choline	-	329	B
-	-	336	O
devoid	-	337	O
or	-	344	O
choline	-	347	B
-	-	354	O
supplemented	-	355	O
diets	-	368	O
,	-	373	O
containing	-	375	O
or	-	386	O
not	-	389	O
0	-	393	O
.	-	394	O
06	-	395	O
%	-	397	O
phenobarbital	-	399	B
.	-	412	O

No	2396046	414	O
hepatic	-	417	O
preneoplastic	-	425	O
nodules	-	439	O
or	-	447	O
hepatocellular	-	450	O
carcinomas	-	465	O
developed	-	476	O
in	-	486	O
rats	-	489	O
fed	-	494	O
the	-	498	O
plain	-	502	O
choline	-	508	B
-	-	515	O
supplemented	-	516	O
diet	-	529	O
,	-	533	O
while	-	535	O
one	-	541	O
preneoplastic	-	545	O
nodule	-	559	O
and	-	566	O
one	-	570	O
hepatocellular	-	574	O
carcinoma	-	589	O
developed	-	599	O
in	-	609	O
two	-	612	O
rats	-	616	O
fed	-	621	O
the	-	625	O
same	-	629	O
diet	-	634	O
containing	-	639	O
phenobarbital	-	650	B
.	-	663	O

The	2396046	665	O
incidence	-	669	O
of	-	679	O
preneoplastic	-	682	O
nodules	-	696	O
and	-	704	O
of	-	708	O
hepatocellular	-	711	O
carcinomas	-	726	O
was	-	737	O
10	-	741	O
%	-	743	O
and	-	745	O
37	-	749	O
%	-	751	O
,	-	752	O
respectively	-	754	O
,	-	766	O
in	-	768	O
rats	-	771	O
fed	-	776	O
the	-	780	O
plain	-	784	O
choline	-	790	B
-	-	797	O
devoid	-	798	O
diet	-	805	O
,	-	809	O
and	-	811	O
17	-	815	O
%	-	817	O
and	-	819	O
30	-	823	O
%	-	825	O
,	-	826	O
in	-	828	O
rats	-	831	O
fed	-	836	O
the	-	840	O
phenobarbital	-	844	B
-	-	857	O
containing	-	858	O
choline	-	869	B
-	-	876	O
devoid	-	877	O
diet	-	884	O
.	-	888	O

The	2396046	890	O
results	-	894	O
evinced	-	902	O
no	-	910	O
enhancement	-	913	O
of	-	925	O
the	-	928	O
hepatocarcinogenicity	-	932	O
of	-	954	O
the	-	957	O
choline	-	961	B
-	-	968	O
devoid	-	969	O
diet	-	976	O
by	-	981	O
phenobarbital	-	984	B
.	-	997	O

Sporadic	2396046	999	O
neoplastic	-	1008	O
lesions	-	1019	O
were	-	1027	O
observed	-	1032	O
in	-	1041	O
organs	-	1044	O
other	-	1051	O
than	-	1057	O
the	-	1062	O
liver	-	1066	O
of	-	1072	O
some	-	1075	O
of	-	1080	O
the	-	1083	O
animals	-	1087	O
,	-	1094	O
irrespective	-	1096	O
of	-	1109	O
the	-	1112	O
diet	-	1116	O
fed	-	1121	O
.	-	1124	O

Effect	2008831	0	O
of	-	7	O
direct	-	10	O
intracoronary	-	17	O
administration	-	31	O
of	-	46	O
methylergonovine	-	49	B
in	-	66	O
patients	-	69	O
with	-	78	O
and	-	83	O
without	-	87	O
variant	-	95	O
angina	-	103	O
.	-	109	O

The	2008831	111	O
effects	-	115	O
of	-	123	O
intracoronary	-	126	O
administration	-	140	O
of	-	155	O
methylergonovine	-	158	B
were	-	175	O
studied	-	180	O
in	-	188	O
21	-	191	O
patients	-	194	O
with	-	203	O
variant	-	208	O
angina	-	216	O
and	-	223	O
22	-	227	O
patients	-	230	O
with	-	239	O
atypical	-	244	O
chest	-	253	O
pain	-	259	O
and	-	264	O
in	-	268	O
others	-	271	O
without	-	278	O
angina	-	286	O
pectoris	-	293	O
(	-	302	O
control	-	303	O
group	-	311	O
)	-	316	O
.	-	317	O

Methylergonovine	2008831	319	B
was	-	336	O
administered	-	340	O
continuously	-	353	O
at	-	366	O
a	-	369	O
rate	-	371	O
of	-	376	O
10	-	379	O
micrograms	-	382	O
/	-	392	O
min	-	393	O
up	-	397	O
to	-	400	O
50	-	403	O
micrograms	-	406	O
.	-	416	O

In	2008831	418	O
all	-	421	O
patients	-	425	O
with	-	434	O
variant	-	439	O
angina	-	447	O
,	-	453	O
coronary	-	455	O
spasm	-	464	O
was	-	470	O
provoked	-	474	O
at	-	483	O
a	-	486	O
mean	-	488	O
dose	-	493	O
of	-	498	O
28	-	501	O
+	-	504	O
/	-	505	O
-	-	506	O

13	2008831	508	O
micrograms	-	511	O
(	-	522	O
mean	-	523	O
+	-	528	O
/	-	529	O
-	-	530	O

SD	2008831	532	O
)	-	534	O
.	-	535	O

In	2008831	537	O
the	-	540	O
control	-	544	O
group	-	552	O
neither	-	558	O
ischemic	-	566	O
ST	-	575	O
change	-	578	O
nor	-	585	O
localized	-	589	O
spasm	-	599	O
occurred	-	605	O
.	-	613	O

The	2008831	615	O
basal	-	619	O
tone	-	625	O
of	-	630	O
the	-	633	O
right	-	637	O
coronary	-	643	O
artery	-	652	O
was	-	659	O
significantly	-	663	O
lower	-	677	O
than	-	683	O
that	-	688	O
of	-	693	O
the	-	696	O
left	-	700	O
coronary	-	705	O
artery	-	714	O
.	-	720	O

The	2008831	722	O
percentage	-	726	O
of	-	737	O
vasoconstriction	-	740	O
of	-	757	O
the	-	760	O
right	-	764	O
coronary	-	770	O
artery	-	779	O
was	-	786	O
significantly	-	790	O
higher	-	804	O
than	-	811	O
that	-	816	O
of	-	821	O
the	-	824	O
left	-	828	O
coronary	-	833	O
artery	-	842	O
.	-	848	O

These	2008831	850	O
results	-	856	O
suggest	-	864	O
that	-	872	O
spasm	-	877	O
provocation	-	883	O
tests	-	895	O
,	-	900	O
which	-	902	O
use	-	908	O
an	-	912	O
intracoronary	-	915	O
injection	-	929	O
of	-	939	O
a	-	942	O
relatively	-	944	O
low	-	955	O
dose	-	959	O
of	-	964	O
methylergonovine	-	967	B
,	-	983	O
have	-	985	O
a	-	990	O
high	-	992	O
sensitivity	-	997	O
in	-	1009	O
variant	-	1012	O
angina	-	1020	O
and	-	1027	O
the	-	1031	O
vasoreactivity	-	1035	O
of	-	1050	O
the	-	1053	O
right	-	1057	O
coronary	-	1063	O
artery	-	1072	O
may	-	1079	O
be	-	1083	O
greater	-	1086	O
than	-	1094	O
that	-	1099	O
of	-	1104	O
the	-	1107	O
other	-	1111	O
coronary	-	1117	O
arteries	-	1126	O
.	-	1134	O

Dobutamine	1732369	0	B
stress	-	11	O
echocardiography	-	18	O
:	-	34	O
a	-	36	O
sensitive	-	38	O
indicator	-	48	O
of	-	58	O
diminished	-	61	O
myocardial	-	72	O
function	-	83	O
in	-	92	O
asymptomatic	-	95	O
doxorubicin	-	108	B
-	-	119	O
treated	-	120	O
long	-	128	O
-	-	132	O
term	-	133	O
survivors	-	138	O
of	-	148	O
childhood	-	151	O
cancer	-	161	O
.	-	167	O

Doxorubicin	1732369	169	B
is	-	181	O
an	-	184	O
effective	-	187	O
anticancer	-	197	O
chemotherapeutic	-	208	O
agent	-	225	O
known	-	231	O
to	-	237	O
cause	-	240	O
acute	-	246	O
and	-	252	O
chronic	-	256	O
cardiomyopathy	-	264	O
.	-	278	O

To	1732369	280	O
develop	-	283	O
a	-	291	O
more	-	293	O
sensitive	-	298	O
echocardiographic	-	308	O
screening	-	326	O
test	-	336	O
for	-	341	O
cardiac	-	345	O
damage	-	353	O
due	-	360	O
to	-	364	O
doxorubicin	-	367	B
,	-	378	O
a	-	380	O
cohort	-	382	O
study	-	389	O
was	-	395	O
performed	-	399	O
using	-	409	O
dobutamine	-	415	B
infusion	-	426	O
to	-	435	O
differentiate	-	438	O
asymptomatic	-	452	O
long	-	465	O
-	-	469	O
term	-	470	O
survivors	-	475	O
of	-	485	O
childhood	-	488	O
cancer	-	498	O
treated	-	505	O
with	-	513	O
doxorubicin	-	518	B
from	-	530	O
healthy	-	535	O
control	-	543	O
subjects	-	551	O
.	-	559	O

Echocardiographic	1732369	561	O
data	-	579	O
from	-	584	O
the	-	589	O
experimental	-	593	O
group	-	606	O
of	-	612	O
21	-	615	O
patients	-	618	O
(	-	627	O
mean	-	628	O
age	-	633	O
16	-	637	O
+	-	640	O
/	-	641	O
-	-	642	O

5	1732369	644	O
years	-	646	O
)	-	651	O
treated	-	653	O
from	-	661	O
1	-	666	O
.	-	667	O
6	-	668	O
to	-	670	O
14	-	673	O
.	-	675	O
3	-	676	O
years	-	678	O
(	-	684	O
median	-	685	O
5	-	692	O
.	-	693	O
3	-	694	O
)	-	695	O
before	-	697	O
this	-	704	O
study	-	709	O
with	-	715	O
27	-	720	O
to	-	723	O
532	-	726	O
mg	-	730	O
/	-	732	O
m2	-	733	O
of	-	736	O
doxorubicin	-	739	B
(	-	751	O
mean	-	752	O
196	-	757	O
)	-	760	O
were	-	762	O
compared	-	767	O
with	-	776	O
echocardiographic	-	781	O
data	-	799	O
from	-	804	O
12	-	809	O
normal	-	812	O
age	-	819	O
-	-	822	O
matched	-	823	O
control	-	831	O
subjects	-	839	O
.	-	847	O

Graded	1732369	849	O
dobutamine	-	856	B
infusions	-	867	O
of	-	877	O
0	-	880	O
.	-	881	O
5	-	882	O
,	-	883	O
2	-	885	O
.	-	886	O
5	-	887	O
,	-	888	O
5	-	890	O
and	-	892	O
10	-	896	O
micrograms	-	899	O
/	-	909	O
kg	-	910	O
per	-	913	O
min	-	917	O
were	-	921	O
administered	-	926	O
.	-	938	O

Echocardiographic	1732369	940	O
Doppler	-	958	O
studies	-	966	O
were	-	974	O
performed	-	979	O
before	-	989	O
infusion	-	996	O
and	-	1005	O
after	-	1009	O
15	-	1015	O
min	-	1018	O
of	-	1022	O
infusion	-	1025	O
at	-	1034	O
each	-	1037	O
rate	-	1042	O
.	-	1046	O

Dobutamine	1732369	1048	B
infusion	-	1059	O
at	-	1068	O
10	-	1071	O
micrograms	-	1074	O
/	-	1084	O
kg	-	1085	O
per	-	1088	O
min	-	1092	O
was	-	1096	O
discontinued	-	1100	O
after	-	1113	O
six	-	1119	O
studies	-	1123	O
secondary	-	1131	O
to	-	1141	O
a	-	1144	O
50	-	1146	O
%	-	1148	O
incidence	-	1150	O
rate	-	1160	O
of	-	1165	O
adverse	-	1168	O
symptoms	-	1176	O
.	-	1184	O

The	1732369	1186	O
most	-	1190	O
important	-	1195	O
findings	-	1205	O
were	-	1214	O
that	-	1219	O
compared	-	1224	O
with	-	1233	O
values	-	1238	O
in	-	1245	O
control	-	1248	O
subjects	-	1256	O
,	-	1264	O
end	-	1266	O
-	-	1269	O
systolic	-	1270	O
left	-	1279	O
ventricular	-	1284	O
posterior	-	1296	O
wall	-	1306	O
dimension	-	1311	O
and	-	1321	O
percent	-	1325	O
of	-	1333	O
left	-	1336	O
ventricular	-	1341	O
posterior	-	1353	O
wall	-	1363	O
thickening	-	1368	O
in	-	1379	O
doxorubicin	-	1382	B
-	-	1393	O
treated	-	1394	O
patients	-	1402	O
were	-	1411	O
decreased	-	1416	O
at	-	1426	O
baseline	-	1429	O
study	-	1438	O
and	-	1444	O
these	-	1448	O
findings	-	1454	O
were	-	1463	O
more	-	1468	O
clearly	-	1473	O
delineated	-	1481	O
with	-	1492	O
dobutamine	-	1497	B
stimulation	-	1508	O
.	-	1519	O

End	1732369	1521	O
-	-	1524	O
systolic	-	1525	O
left	-	1534	O
ventricular	-	1539	O
posterior	-	1551	O
wall	-	1561	O
dimension	-	1566	O
at	-	1576	O
baseline	-	1579	O
for	-	1588	O
the	-	1592	O
doxorubicin	-	1596	B
-	-	1607	O
treated	-	1608	O
group	-	1616	O
was	-	1622	O
11	-	1626	O
+	-	1629	O
/	-	1630	O
-	-	1631	O

1	1732369	1633	O
.	-	1634	O
9	-	1635	O
mm	-	1637	O
versus	-	1640	O
13	-	1647	O
.	-	1649	O
1	-	1650	O
+	-	1652	O
/	-	1653	O
-	-	1654	O

1	1732369	1656	O
.	-	1657	O
5	-	1658	O
mm	-	1660	O
for	-	1663	O
control	-	1667	O
subjects	-	1675	O
(	-	1684	O
p	-	1685	O
less	-	1687	O
than	-	1692	O
0	-	1697	O
.	-	1698	O
01	-	1699	O
)	-	1701	O
.	-	1702	O

End	1732369	1704	O
-	-	1707	O
systolic	-	1708	O
left	-	1717	O
ventricular	-	1722	O
posterior	-	1734	O
wall	-	1744	O
dimension	-	1749	O
at	-	1759	O
the	-	1762	O
5	-	1766	O
-	-	1767	O
micrograms	-	1768	O
/	-	1778	O
kg	-	1779	O
per	-	1782	O
min	-	1786	O
dobutamine	-	1790	B
infusion	-	1801	O
for	-	1810	O
the	-	1814	O
doxorubicin	-	1818	B
-	-	1829	O
treated	-	1830	O
group	-	1838	O
was	-	1844	O
14	-	1848	O
.	-	1850	O
1	-	1851	O
+	-	1853	O
/	-	1854	O
-	-	1855	O

2	1732369	1857	O
.	-	1858	O
4	-	1859	O
mm	-	1861	O
versus	-	1864	O
19	-	1871	O
.	-	1873	O
3	-	1874	O
+	-	1876	O
/	-	1877	O
-	-	1878	O

2	1732369	1880	O
.	-	1881	O
6	-	1882	O
mm	-	1884	O
for	-	1887	O
control	-	1891	O
subjects	-	1899	O
(	-	1908	O
p	-	1909	O
less	-	1911	O
than	-	1916	O
0	-	1921	O
.	-	1922	O
01	-	1923	O
)	-	1925	O
.	-	1926	O
(	-	1927	O
ABSTRACT	-	1928	O

TRUNCATED	1732369	1937	O
AT	-	1947	O
250	-	1950	O
WORDS	-	1954	O
)	-	1959	O

Effects	234669	0	O
of	-	8	O
aminophylline	-	11	B
on	-	25	O
the	-	28	O
threshold	-	32	O
for	-	42	O
initiating	-	46	O
ventricular	-	57	O
fibrillation	-	69	O
during	-	82	O
respiratory	-	89	O
failure	-	101	O
.	-	108	O

Cardiac	234669	110	O
arrhythmias	-	118	O
have	-	130	O
frequently	-	135	O
been	-	146	O
reported	-	151	O
in	-	160	O
association	-	163	O
with	-	175	O
respiratory	-	180	O
failure	-	192	O
.	-	199	O

The	234669	201	O
possible	-	205	O
additive	-	214	O
role	-	223	O
of	-	228	O
pharmacologic	-	231	O
agents	-	245	O
in	-	252	O
precipitating	-	255	O
cardiac	-	269	O
disturbances	-	277	O
in	-	290	O
patients	-	293	O
with	-	302	O
respiratory	-	307	O
failure	-	319	O
has	-	327	O
only	-	331	O
recently	-	336	O
been	-	345	O
emphasized	-	350	O
.	-	360	O

The	234669	362	O
effects	-	366	O
of	-	374	O
aminophylline	-	377	B
on	-	391	O
the	-	394	O
ventricular	-	398	O
fibrillation	-	410	O
threshold	-	423	O
during	-	433	O
normal	-	440	O
acid	-	447	O
-	-	451	O
base	-	452	O
conditions	-	457	O
and	-	468	O
during	-	472	O
respiratory	-	479	O
failure	-	491	O
were	-	499	O
studied	-	504	O
in	-	512	O
anesthetized	-	515	O
open	-	528	O
chest	-	533	O
dogs	-	539	O
.	-	543	O

The	234669	545	O
ventricular	-	549	O
fibrillation	-	561	O
threshold	-	574	O
was	-	584	O
measured	-	588	O
by	-	597	O
passing	-	600	O
a	-	608	O
gated	-	610	O
train	-	616	O
of	-	622	O
12	-	625	O
constant	-	628	O
current	-	637	O
pulses	-	645	O
through	-	652	O
the	-	660	O
ventricular	-	664	O
myocardium	-	676	O
during	-	687	O
the	-	694	O
vulnerable	-	698	O
period	-	709	O
of	-	716	O
the	-	719	O
cardiac	-	723	O
cycle	-	731	O
.	-	736	O

During	234669	738	O
the	-	745	O
infusion	-	749	O
of	-	758	O
aminophylline	-	761	B
,	-	774	O
the	-	776	O
ventricular	-	780	O
fibrillation	-	792	O
threshold	-	805	O
was	-	815	O
reduced	-	819	O
by	-	827	O
30	-	830	O
to	-	833	O
40	-	836	O
percent	-	839	O
of	-	847	O
the	-	850	O
control	-	854	O
when	-	862	O
pH	-	867	O
and	-	870	O
partial	-	874	O
pressures	-	882	O
of	-	892	O
oxygen	-	895	B
(	-	902	O
PO2	-	903	B
)	-	906	O
and	-	908	O
carbon	-	912	B
dioxide	-	919	I
(	-	927	O
CO2	-	928	B
)	-	931	O
were	-	933	O
kept	-	938	O
within	-	943	O
normal	-	950	O
limits	-	957	O
.	-	963	O

When	234669	965	O
respiratory	-	970	O
failure	-	982	O
was	-	990	O
produced	-	994	O
by	-	1003	O
hypoventilation	-	1006	O
(	-	1022	O
pH	-	1023	O
7	-	1026	O
.	-	1027	O
05	-	1028	O
to	-	1031	O
7	-	1034	O
.	-	1035	O
25	-	1036	O
;	-	1038	O
PC02	-	1040	O
70	-	1045	O
to	-	1048	O
100	-	1051	O
mm	-	1055	O
Hg	-	1058	O
:	-	1060	O
P02	-	1062	O
20	-	1066	O
to	-	1069	O
40	-	1072	O
mm	-	1075	O
Hg	-	1078	O
)	-	1080	O
,	-	1081	O
infusion	-	1083	O
of	-	1092	O
aminophylline	-	1095	B
resulted	-	1109	O
in	-	1118	O
an	-	1121	O
even	-	1124	O
greater	-	1129	O
decrease	-	1137	O
in	-	1146	O
ventricular	-	1149	O
fibrillation	-	1161	O
threshold	-	1174	O
to	-	1184	O
60	-	1187	O
percent	-	1190	O
of	-	1198	O
the	-	1201	O
control	-	1205	O
level	-	1213	O
.	-	1218	O

These	234669	1220	O
experiments	-	1226	O
suggest	-	1238	O
that	-	1246	O
although	-	1251	O
many	-	1260	O
factors	-	1265	O
may	-	1273	O
contribute	-	1277	O
to	-	1288	O
the	-	1291	O
increased	-	1295	O
incidence	-	1305	O
of	-	1315	O
ventricular	-	1318	O
arrhythmias	-	1330	O
in	-	1342	O
respiratory	-	1345	O
failure	-	1357	O
,	-	1364	O
pharmacologic	-	1366	O
agents	-	1380	O
,	-	1386	O
particularly	-	1388	O
aminophylline	-	1401	B
,	-	1414	O
may	-	1416	O
play	-	1420	O
a	-	1425	O
significant	-	1427	O
role	-	1439	O
.	-	1443	O

Case	16740173	0	O
report	-	5	O
:	-	11	O
acute	-	13	O
unintentional	-	19	O
carbachol	-	33	B
intoxication	-	43	O
.	-	55	O

INTRODUCTION	16740173	57	O
:	-	69	O

Intoxications	16740173	71	O
with	-	85	O
carbachol	-	90	B
,	-	99	O
a	-	101	O
muscarinic	-	103	O
cholinergic	-	114	O
receptor	-	126	O
agonist	-	135	O
are	-	143	O
rare	-	147	O
.	-	151	O

We	16740173	153	O
report	-	156	O
an	-	163	O
interesting	-	166	O
case	-	178	O
investigating	-	183	O
a	-	197	O
(	-	199	O
near	-	200	O
)	-	204	O
fatal	-	206	O
poisoning	-	212	O
.	-	221	O

METHODS	16740173	223	O
:	-	230	O

The	16740173	232	O
son	-	236	O
of	-	240	O
an	-	243	O
84	-	246	O
-	-	248	O
year	-	249	O
-	-	253	O
old	-	254	O
male	-	258	O
discovered	-	263	O
a	-	274	O
newspaper	-	276	O
report	-	286	O
stating	-	293	O
clinical	-	301	O
success	-	310	O
with	-	318	O
plant	-	323	O
extracts	-	329	O
in	-	338	O
Alzheimer	-	341	O
's	-	350	O
disease	-	353	O
.	-	360	O

The	16740173	362	O
mode	-	366	O
of	-	371	O
action	-	374	O
was	-	381	O
said	-	385	O
to	-	390	O
be	-	393	O
comparable	-	396	O
to	-	407	O
that	-	410	O
of	-	415	O
the	-	418	O
synthetic	-	422	O
compound	-	432	O
'	-	441	O
carbamylcholin	-	442	B
'	-	456	O
;	-	457	O
that	-	459	O
is	-	464	O
,	-	466	O
carbachol	-	468	B
.	-	477	O

He	16740173	479	O
bought	-	482	O
25	-	489	O
g	-	492	O
of	-	494	O
carbachol	-	497	B
as	-	507	O
pure	-	510	O
substance	-	515	O
in	-	525	O
a	-	528	O
pharmacy	-	530	O
,	-	538	O
and	-	540	O
the	-	544	O
father	-	548	O
was	-	555	O
administered	-	559	O
400	-	572	O
to	-	576	O
500	-	579	O
mg	-	583	O
.	-	585	O

Carbachol	16740173	587	B
concentrations	-	597	O
in	-	612	O
serum	-	615	O
and	-	621	O
urine	-	625	O
on	-	631	O
day	-	634	O
1	-	638	O
and	-	640	O
2	-	644	O
of	-	646	O
hospital	-	649	O
admission	-	658	O
were	-	668	O
analysed	-	673	O
by	-	682	O
HPLC	-	685	O
-	-	689	O
mass	-	690	O
spectrometry	-	695	O
.	-	707	O

RESULTS	16740173	709	O
:	-	716	O

Minutes	16740173	718	O
after	-	726	O
oral	-	732	O
administration	-	737	O
,	-	751	O
the	-	753	O
patient	-	757	O
developed	-	765	O
nausea	-	775	O
,	-	781	O
sweating	-	783	O
and	-	792	O
hypotension	-	796	O
,	-	807	O
and	-	809	O
finally	-	813	O
collapsed	-	821	O
.	-	830	O

Bradycardia	16740173	832	O
,	-	843	O
cholinergic	-	845	O
symptoms	-	857	O
and	-	866	O
asystole	-	870	O
occurred	-	879	O
.	-	887	O

Initial	16740173	889	O
cardiopulmonary	-	897	O
resuscitation	-	913	O
and	-	927	O
immediate	-	931	O
treatment	-	941	O
with	-	951	O
adrenaline	-	956	B
(	-	967	O
epinephrine	-	968	B
)	-	979	O
,	-	980	O
atropine	-	982	B
and	-	991	O
furosemide	-	995	B
was	-	1006	O
successful	-	1010	O
.	-	1020	O

On	16740173	1022	O
hospital	-	1025	O
admission	-	1034	O
,	-	1043	O
blood	-	1045	O
pressure	-	1051	O
of	-	1060	O
the	-	1063	O
intubated	-	1067	O
,	-	1076	O
bradyarrhythmic	-	1078	O
patient	-	1094	O
was	-	1102	O
100	-	1106	O
/	-	1109	O
65	-	1110	O
mmHg	-	1113	O
.	-	1117	O

Further	16740173	1119	O
signs	-	1127	O
were	-	1133	O
hyperhidrosis	-	1138	O
,	-	1151	O
hypersalivation	-	1153	O
,	-	1168	O
bronchorrhoea	-	1170	O
,	-	1183	O
and	-	1185	O
severe	-	1189	O
miosis	-	1196	O
;	-	1202	O
the	-	1204	O
electrocardiographic	-	1208	O
finding	-	1229	O
was	-	1237	O
atrio	-	1241	O
-	-	1246	O
ventricular	-	1247	O
dissociation	-	1259	O
.	-	1271	O

High	16740173	1273	O
doses	-	1278	O
of	-	1284	O
atropine	-	1287	B

(	16740173	1296	O
up	-	1297	O
to	-	1300	O
50	-	1303	O
mg	-	1306	O
per	-	1309	O
24	-	1313	O
hours	-	1316	O
)	-	1321	O
,	-	1322	O
adrenaline	-	1324	B
and	-	1335	O
dopamine	-	1339	B
were	-	1348	O
necessary	-	1353	O
.	-	1362	O

The	16740173	1364	O
patient	-	1368	O
was	-	1376	O
extubated	-	1380	O
1	-	1390	O
week	-	1392	O
later	-	1397	O
.	-	1402	O

However	16740173	1404	O
,	-	1411	O
increased	-	1413	O
dyspnoea	-	1423	O
and	-	1432	O
bronchospasm	-	1436	O
necessitated	-	1449	O
reintubation	-	1462	O
.	-	1474	O

Respiratory	16740173	1476	O
insufficiency	-	1488	O
was	-	1502	O
further	-	1506	O
worsened	-	1514	O
by	-	1523	O
Proteus	-	1526	O
mirabilis	-	1534	O
infection	-	1544	O
and	-	1554	O
severe	-	1558	O
bronchoconstriction	-	1565	O
.	-	1584	O

One	16740173	1586	O
week	-	1590	O
later	-	1595	O
,	-	1600	O
the	-	1602	O
patient	-	1606	O
was	-	1614	O
again	-	1618	O
extubated	-	1624	O
and	-	1634	O
3	-	1638	O
days	-	1640	O
later	-	1645	O
was	-	1651	O
transferred	-	1655	O
to	-	1667	O
a	-	1670	O
peripheral	-	1672	O
ward	-	1683	O
.	-	1687	O

On	16740173	1689	O
the	-	1692	O
next	-	1696	O
day	-	1701	O
he	-	1705	O
died	-	1708	O
,	-	1712	O
probably	-	1714	O
as	-	1723	O
a	-	1726	O
result	-	1728	O
of	-	1735	O
heart	-	1738	O
failure	-	1744	O
.	-	1751	O

Serum	16740173	1753	O
samples	-	1759	O
from	-	1767	O
the	-	1772	O
first	-	1776	O
and	-	1782	O
second	-	1786	O
days	-	1793	O
contained	-	1798	O
3	-	1808	O
.	-	1809	O
6	-	1810	O
and	-	1812	O
1	-	1816	O
.	-	1817	O
9	-	1818	O
mg	-	1820	O
/	-	1822	O
l	-	1823	O
carbachol	-	1825	B
,	-	1834	O
respectively	-	1836	O
.	-	1848	O

The	16740173	1850	O
corresponding	-	1854	O
urine	-	1868	O
concentrations	-	1874	O
amounted	-	1889	O
to	-	1898	O
374	-	1901	O
and	-	1905	O
554	-	1909	O
mg	-	1913	O
/	-	1915	O
l	-	1916	O
.	-	1917	O

CONCLUSION	16740173	1919	O
:	-	1929	O

This	16740173	1931	O
case	-	1936	O
started	-	1941	O
with	-	1949	O
a	-	1954	O
media	-	1956	O
report	-	1962	O
in	-	1969	O
a	-	1972	O
popular	-	1974	O
newspaper	-	1982	O
,	-	1991	O
initiated	-	1993	O
by	-	2003	O
published	-	2006	O
,	-	2015	O
peer	-	2017	O
-	-	2021	O
reviewed	-	2022	O
research	-	2031	O
on	-	2040	O
herbals	-	2043	O
,	-	2050	O
and	-	2052	O
involved	-	2056	O
human	-	2065	O
failure	-	2071	O
in	-	2079	O
a	-	2082	O
case	-	2084	O
history	-	2089	O
,	-	2096	O
medical	-	2098	O
examination	-	2106	O
and	-	2118	O
clinical	-	2122	O
treatment	-	2131	O
.	-	2140	O

For	16740173	2142	O
the	-	2146	O
first	-	2150	O
time	-	2156	O
,	-	2160	O
an	-	2162	O
analytical	-	2165	O
method	-	2176	O
for	-	2183	O
the	-	2187	O
determination	-	2191	O
of	-	2205	O
carbachol	-	2208	B
in	-	2218	O
plasma	-	2221	O
and	-	2228	O
urine	-	2232	O
has	-	2238	O
been	-	2242	O
developed	-	2247	O
.	-	2256	O

The	16740173	2258	O
analysed	-	2262	O
carbachol	-	2271	B
concentration	-	2281	O
exceeded	-	2295	O
the	-	2304	O
supposed	-	2308	O
serum	-	2317	O
level	-	2323	O
resulting	-	2329	O
from	-	2339	O
a	-	2344	O
therapeutic	-	2346	O
dose	-	2358	O
by	-	2363	O
a	-	2366	O
factor	-	2368	O
of	-	2375	O
130	-	2378	O
to	-	2382	O
260	-	2385	O
.	-	2388	O

Especially	16740173	2390	O
in	-	2401	O
old	-	2404	O
patients	-	2408	O
,	-	2416	O
intensivists	-	2418	O
should	-	2431	O
consider	-	2438	O
intoxications	-	2447	O
(	-	2461	O
with	-	2462	O
cholinergics	-	2467	O
)	-	2479	O
as	-	2481	O
a	-	2484	O
cause	-	2486	O
of	-	2492	O
acute	-	2495	O
cardiovascular	-	2501	O
failure	-	2516	O
.	-	2523	O

Crossover	12464714	0	O
comparison	-	10	O
of	-	21	O
efficacy	-	24	O
and	-	33	O
preference	-	37	O
for	-	48	O
rizatriptan	-	52	B
10	-	64	O
mg	-	67	O
versus	-	70	O
ergotamine	-	77	B
/	-	87	O
caffeine	-	88	B
in	-	97	O
migraine	-	100	O
.	-	108	O

Rizatriptan	12464714	110	B
is	-	122	O
a	-	125	O
selective	-	127	O
5	-	137	B
-	-	138	I
HT	-	139	I
(	-	141	O
1B	-	142	O
/	-	144	O
1D	-	145	O
)	-	147	O
receptor	-	149	O
agonist	-	158	O
with	-	166	O
rapid	-	171	O
oral	-	177	O
absorption	-	182	O
and	-	193	O
early	-	197	O
onset	-	203	O
of	-	209	O
action	-	212	O
in	-	219	O
the	-	222	O
acute	-	226	O
treatment	-	232	O
of	-	242	O
migraine	-	245	O
.	-	253	O

This	12464714	255	O
randomized	-	260	O
double	-	271	O
-	-	277	O
blind	-	279	O
crossover	-	285	O
outpatient	-	295	O
study	-	306	O
assessed	-	312	O
the	-	321	O
preference	-	325	O
for	-	336	O
1	-	340	O
rizatriptan	-	342	B
10	-	354	O
mg	-	357	O
tablet	-	360	O
to	-	367	O
2	-	370	O
ergotamine	-	372	B
1	-	383	O
mg	-	385	O
/	-	387	O
caffeine	-	388	B
100	-	397	O
mg	-	401	O
tablets	-	404	O
in	-	412	O
439	-	415	O
patients	-	419	O
treating	-	428	O
a	-	437	O
single	-	439	O
migraine	-	446	O
attack	-	455	O
with	-	462	O
each	-	467	O
therapy	-	472	O
.	-	479	O

Of	12464714	481	O
patients	-	484	O
expressing	-	493	O
a	-	504	O
preference	-	506	O
(	-	517	O
89	-	518	O
.	-	520	O
1	-	521	O
%	-	522	O
)	-	523	O
,	-	524	O
more	-	526	O
than	-	531	O
twice	-	536	O
as	-	542	O
many	-	545	O
preferred	-	550	O
rizatriptan	-	560	B
to	-	572	O
ergotamine	-	575	B
/	-	585	O
caffeine	-	586	B
(	-	595	O
69	-	596	O
.	-	598	O
9	-	599	O
vs	-	601	O
.	-	603	O
30	-	605	O
.	-	607	O
1	-	608	O
%	-	609	O
,	-	610	O
p	-	612	O
<	-	614	O
or	-	616	O
=	-	619	O
0	-	621	O
.	-	622	O
001	-	623	O
)	-	626	O
.	-	627	O

Faster	12464714	629	O
relief	-	636	O
of	-	643	O
headache	-	646	O
was	-	655	O
the	-	659	O
most	-	663	O
important	-	668	O
reason	-	678	O
for	-	685	O
preference	-	689	O
,	-	699	O
cited	-	701	O
by	-	707	O
67	-	710	O
.	-	712	O
3	-	713	O
%	-	714	O
of	-	716	O
patients	-	719	O
preferring	-	728	O
rizatriptan	-	739	B
and	-	751	O
54	-	755	O
.	-	757	O
2	-	758	O
%	-	759	O
of	-	761	O
patients	-	764	O
who	-	773	O
preferred	-	777	O
ergotamine	-	787	B
/	-	797	O
caffeine	-	798	B
.	-	806	O

The	12464714	808	O
co	-	812	O
-	-	814	O
primary	-	815	O
endpoint	-	823	O
of	-	832	O
being	-	835	O
pain	-	841	O
free	-	846	O
at	-	851	O
2	-	854	O
h	-	856	O
was	-	858	O
also	-	862	O
in	-	867	O
favor	-	870	O
of	-	876	O
rizatriptan	-	879	B
.	-	890	O

Forty	12464714	892	O
-	-	897	O
nine	-	898	O
percent	-	903	O
of	-	911	O
patients	-	914	O
were	-	923	O
pain	-	928	O
free	-	933	O
2	-	938	O
h	-	940	O
after	-	942	O
rizatriptan	-	948	B
,	-	959	O
compared	-	961	O
with	-	970	O
24	-	975	O
.	-	977	O
3	-	978	O
%	-	979	O
treated	-	981	O
with	-	989	O
ergotamine	-	994	B
/	-	1004	O
caffeine	-	1005	B
(	-	1014	O
p	-	1015	O
<	-	1017	O
or	-	1019	O
=	-	1022	O
0	-	1024	O
.	-	1025	O
001	-	1026	O
)	-	1029	O
,	-	1030	O
rizatriptan	-	1032	B
being	-	1044	O
superior	-	1050	O
within	-	1059	O
1	-	1066	O
h	-	1068	O
of	-	1070	O
treatment	-	1073	O
.	-	1082	O

Headache	12464714	1084	O
relief	-	1093	O
at	-	1100	O
2	-	1103	O
h	-	1105	O
was	-	1107	O
75	-	1111	O
.	-	1113	O
9	-	1114	O
%	-	1115	O
for	-	1117	O
rizatriptan	-	1121	B
and	-	1133	O
47	-	1137	O
.	-	1139	O
3	-	1140	O
%	-	1141	O
for	-	1143	O
ergotamine	-	1147	B
/	-	1157	O
caffeine	-	1158	B
(	-	1167	O
p	-	1168	O
<	-	1170	O
or	-	1172	O
=	-	1175	O
0	-	1177	O
.	-	1178	O
001	-	1179	O
)	-	1182	O
,	-	1183	O
with	-	1185	O
rizatriptan	-	1190	B
being	-	1202	O
superior	-	1208	O
to	-	1217	O
ergotamine	-	1220	B
/	-	1230	O
caffeine	-	1231	B
within	-	1240	O
30	-	1247	O
min	-	1250	O
of	-	1254	O
dosing	-	1257	O
.	-	1263	O

Almost	12464714	1265	O
36	-	1272	O
%	-	1274	O
of	-	1276	O
patients	-	1279	O
taking	-	1288	O
rizatriptan	-	1295	B
were	-	1307	O
pain	-	1312	O
free	-	1317	O
at	-	1322	O
2	-	1325	O
h	-	1327	O
and	-	1329	O
had	-	1333	O
no	-	1337	O
recurrence	-	1340	O
or	-	1351	O
need	-	1354	O
for	-	1359	O
additional	-	1363	O
medication	-	1374	O
within	-	1385	O
24	-	1392	O
h	-	1395	O
,	-	1396	O
compared	-	1398	O
to	-	1407	O
20	-	1410	O
%	-	1412	O
of	-	1414	O
patients	-	1417	O
on	-	1426	O
ergotamine	-	1429	B
/	-	1439	O
caffeine	-	1440	B
(	-	1449	O
p	-	1450	O
<	-	1452	O
or	-	1454	O
=	-	1457	O
0	-	1459	O
.	-	1460	O
001	-	1461	O
)	-	1464	O
.	-	1465	O

Rizatriptan	12464714	1467	B
was	-	1479	O
also	-	1483	O
superior	-	1488	O
to	-	1497	O
ergotamine	-	1500	B
/	-	1510	O
caffeine	-	1511	B
in	-	1520	O
the	-	1523	O
proportions	-	1527	O
of	-	1539	O
patients	-	1542	O
with	-	1551	O
no	-	1556	O
nausea	-	1559	O
,	-	1565	O
vomiting	-	1567	O
,	-	1575	O
phonophobia	-	1577	O
or	-	1589	O
photophobia	-	1592	O
and	-	1604	O
for	-	1608	O
patients	-	1612	O
with	-	1621	O
normal	-	1626	O
function	-	1633	O
2	-	1642	O
h	-	1644	O
after	-	1646	O
drug	-	1652	O
intake	-	1657	O
(	-	1664	O
p	-	1665	O
<	-	1667	O
or	-	1669	O
=	-	1672	O
0	-	1674	O
.	-	1675	O
001	-	1676	O
)	-	1679	O
.	-	1680	O

More	12464714	1682	O
patients	-	1687	O
were	-	1696	O
(	-	1701	O
completely	-	1702	O
,	-	1712	O
very	-	1714	O
or	-	1719	O
somewhat	-	1722	O
)	-	1730	O
satisfied	-	1732	O
2	-	1742	O
h	-	1744	O
after	-	1746	O
treatment	-	1752	O
with	-	1762	O
rizatriptan	-	1767	B
(	-	1779	O
69	-	1780	O
.	-	1782	O
8	-	1783	O
%	-	1784	O
)	-	1785	O
than	-	1787	O
at	-	1792	O
2	-	1795	O
h	-	1797	O
after	-	1799	O
treatment	-	1805	O
with	-	1815	O
ergotamine	-	1820	B
/	-	1830	O
caffeine	-	1831	B
(	-	1840	O
38	-	1841	O
.	-	1843	O
6	-	1844	O
%	-	1845	O
,	-	1846	O
p	-	1848	O
<	-	1850	O
or	-	1852	O
=	-	1855	O
0	-	1857	O
.	-	1858	O
001	-	1859	O
)	-	1862	O
.	-	1863	O

Recurrence	12464714	1865	O
rates	-	1876	O
were	-	1882	O
31	-	1887	O
.	-	1889	O
4	-	1890	O
%	-	1891	O
with	-	1893	O
rizatriptan	-	1898	B
and	-	1910	O
15	-	1914	O
.	-	1916	O
3	-	1917	O
%	-	1918	O
with	-	1920	O
ergotamine	-	1925	B
/	-	1935	O
caffeine	-	1936	B
.	-	1944	O

Both	12464714	1946	O
active	-	1951	O
treatments	-	1958	O
were	-	1969	O
well	-	1974	O
tolerated	-	1979	O
.	-	1988	O

The	12464714	1990	O
most	-	1994	O
common	-	1999	O
adverse	-	2006	O
events	-	2014	O
(	-	2021	O
incidence	-	2022	O
>	-	2032	O
or	-	2034	O
=	-	2037	O
5	-	2039	O
%	-	2040	O
in	-	2042	O
one	-	2045	O
group	-	2049	O
)	-	2054	O
after	-	2056	O
rizatriptan	-	2062	B
and	-	2074	O
ergotamine	-	2078	B
/	-	2088	O
caffeine	-	2089	B
,	-	2097	O
respectively	-	2099	O
,	-	2111	O
were	-	2113	O
dizziness	-	2118	O
(	-	2128	O
6	-	2129	O
.	-	2130	O
7	-	2131	O
and	-	2133	O
5	-	2137	O
.	-	2138	O
3	-	2139	O
%	-	2140	O
)	-	2141	O
,	-	2142	O
nausea	-	2144	O
(	-	2151	O
4	-	2152	O
.	-	2153	O
2	-	2154	O
and	-	2156	O
8	-	2160	O
.	-	2161	O
5	-	2162	O
%	-	2163	O
)	-	2164	O
and	-	2166	O
somnolence	-	2170	O
(	-	2181	O
5	-	2182	O
.	-	2183	O
5	-	2184	O
and	-	2186	O
2	-	2190	O
.	-	2191	O
3	-	2192	O
%	-	2193	O
)	-	2194	O
.	-	2195	O

Thrombotic	6203452	0	O
microangiopathy	-	11	O
and	-	27	O
renal	-	31	O
failure	-	37	O
associated	-	45	O
with	-	56	O
antineoplastic	-	61	O
chemotherapy	-	76	O
.	-	88	O

Five	6203452	90	O
patients	-	95	O
with	-	104	O
carcinoma	-	109	O
developed	-	119	O
thrombotic	-	129	O
microangiopathy	-	140	O
(	-	156	O
characterized	-	157	O
by	-	171	O
renal	-	174	O
insufficiency	-	180	O
,	-	193	O
microangiopathic	-	195	O
hemolytic	-	212	O
anemia	-	222	O
,	-	228	O
and	-	230	O
usually	-	234	O
thrombocytopenia	-	242	O
)	-	258	O
after	-	260	O
treatment	-	266	O
with	-	276	O
cisplatin	-	281	B
,	-	290	O
bleomycin	-	292	B
,	-	301	O
and	-	303	O
a	-	307	O
vinca	-	309	B
alkaloid	-	315	I
.	-	323	O

One	6203452	325	O
patient	-	329	O
had	-	337	O
thrombotic	-	341	O
thrombocytopenic	-	352	O
purpura	-	369	O
,	-	376	O
three	-	378	O
the	-	384	O
hemolytic	-	388	O
-	-	397	O
uremic	-	398	O
syndrome	-	405	O
,	-	413	O
and	-	415	O
one	-	419	O
an	-	423	O
apparent	-	426	O
forme	-	435	O
fruste	-	441	O
of	-	448	O
one	-	451	O
of	-	455	O
these	-	458	O
disorders	-	464	O
.	-	473	O

Histologic	6203452	475	O
examination	-	486	O
of	-	498	O
the	-	501	O
renal	-	505	O
tissue	-	511	O
showed	-	518	O
evidence	-	525	O
of	-	534	O
intravascular	-	537	O
coagulation	-	551	O
,	-	562	O
primarily	-	564	O
affecting	-	574	O
the	-	584	O
small	-	588	O
arteries	-	594	O
,	-	602	O
arterioles	-	604	O
,	-	614	O
and	-	616	O
glomeruli	-	620	O
.	-	629	O

Because	6203452	631	O
each	-	639	O
patient	-	644	O
was	-	652	O
tumor	-	656	O
-	-	661	O
free	-	662	O
or	-	667	O
had	-	670	O
only	-	674	O
a	-	679	O
small	-	681	O
tumor	-	687	O
at	-	693	O
the	-	696	O
onset	-	700	O
of	-	706	O
this	-	709	O
syndrome	-	714	O
,	-	722	O
the	-	724	O
thrombotic	-	728	O
microangiopathy	-	739	O
may	-	755	O
have	-	759	O
been	-	764	O
induced	-	769	O
by	-	777	O
chemotherapy	-	780	O
.	-	792	O

Diagnosis	6203452	794	O
of	-	804	O
this	-	807	O
potentially	-	812	O
fatal	-	824	O
complication	-	830	O
may	-	843	O
be	-	847	O
delayed	-	850	O
or	-	858	O
missed	-	861	O
if	-	868	O
renal	-	871	O
tissue	-	877	O
or	-	884	O
the	-	887	O
peripheral	-	891	O
blood	-	902	O
smear	-	908	O
is	-	914	O
not	-	917	O
examined	-	921	O
,	-	929	O
because	-	931	O
renal	-	939	O
failure	-	945	O
may	-	953	O
be	-	957	O
ascribed	-	960	O
to	-	969	O
cisplatin	-	972	B
nephrotoxicity	-	982	O
and	-	997	O
the	-	1001	O
anemia	-	1005	O
and	-	1012	O
thrombocytopenia	-	1016	O
to	-	1033	O
drug	-	1036	O
-	-	1040	O
induced	-	1041	O
bone	-	1049	O
marrow	-	1054	O
suppression	-	1061	O
.	-	1072	O

Salvage	20528871	0	O
therapy	-	8	O
with	-	16	O
nelarabine	-	21	B
,	-	31	O
etoposide	-	33	B
,	-	42	O
and	-	44	O
cyclophosphamide	-	48	B
in	-	65	O
relapsed	-	68	O
/	-	76	O
refractory	-	77	O
paediatric	-	88	O
T	-	99	O
-	-	100	O
cell	-	101	O
lymphoblastic	-	106	O
leukaemia	-	120	O
and	-	130	O
lymphoma	-	134	O
.	-	142	O

A	20528871	144	O
combination	-	146	O
of	-	158	O
5	-	161	O
d	-	163	O
of	-	165	O
nelarabine	-	168	B
(	-	179	O
AraG	-	180	B
)	-	184	O
with	-	186	O
5	-	191	O
d	-	193	O
of	-	195	O
etoposide	-	198	B
(	-	208	O
VP	-	209	B
)	-	211	O
and	-	213	O
cyclophosphamide	-	217	B
(	-	234	O
CPM	-	235	B
)	-	238	O
and	-	240	O
prophylactic	-	244	O
intrathecal	-	257	O
chemotherapy	-	269	O
was	-	282	O
used	-	286	O
as	-	291	O
salvage	-	294	O
therapy	-	302	O
in	-	310	O
seven	-	313	O
children	-	319	O
with	-	328	O
refractory	-	333	O
or	-	344	O
relapsed	-	347	O
T	-	356	O
-	-	357	O
cell	-	358	O
leukaemia	-	363	O
or	-	373	O
lymphoma	-	376	O
.	-	384	O

The	20528871	386	O
most	-	390	O
common	-	395	O
side	-	402	O
effects	-	407	O
attributable	-	415	O
to	-	428	O
the	-	431	O
AraG	-	435	B
included	-	440	O
Grade	-	449	O
2	-	455	O
and	-	457	O
3	-	461	O
sensory	-	463	O
and	-	471	O
motor	-	475	O
neuropathy	-	481	O
and	-	492	O
musculoskeletal	-	496	O
pain	-	512	O
.	-	516	O

Haematological	20528871	518	O
toxicity	-	533	O
was	-	542	O
greater	-	546	O
for	-	554	O
the	-	558	O
combination	-	562	O
than	-	574	O
AraG	-	579	B
alone	-	584	O
,	-	589	O
although	-	591	O
median	-	600	O
time	-	607	O
to	-	612	O
neutrophil	-	615	O
and	-	626	O
platelet	-	630	O
recovery	-	639	O
was	-	648	O
consistent	-	652	O
with	-	663	O
other	-	668	O
salvage	-	674	O
therapies	-	682	O
.	-	691	O

All	20528871	693	O
patients	-	697	O
had	-	706	O
some	-	710	O
response	-	715	O
to	-	724	O
the	-	727	O
combined	-	731	O
therapy	-	740	O
and	-	748	O
five	-	752	O
of	-	757	O
the	-	760	O
seven	-	764	O
went	-	770	O
into	-	775	O
complete	-	780	O
remission	-	789	O
after	-	799	O
one	-	805	O
or	-	809	O
two	-	812	O
courses	-	816	O
of	-	824	O
AraG	-	827	B
/	-	831	O
VP	-	832	B
/	-	834	O
CPM	-	835	B
.	-	838	O

Our	20528871	840	O
experience	-	844	O
supports	-	855	O
the	-	864	O
safety	-	868	O
of	-	875	O
giving	-	878	O
AraG	-	885	B
as	-	890	O
salvage	-	893	O
therapy	-	901	O
in	-	909	O
synchrony	-	912	O
with	-	922	O
etoposide	-	927	B
and	-	937	O
cyclophosphamide	-	941	B
,	-	957	O
although	-	959	O
neurological	-	968	O
toxicity	-	981	O
must	-	990	O
be	-	995	O
closely	-	998	O
monitored	-	1006	O
.	-	1015	O

The	11672959	0	O
3	-	4	O
-	-	5	O
week	-	6	O
sulphasalazine	-	11	B
syndrome	-	26	O
strikes	-	35	O
again	-	43	O
.	-	48	O

A	11672959	50	O
34	-	52	O
-	-	54	O
year	-	55	O
-	-	59	O
old	-	60	O
lady	-	64	O
developed	-	69	O
a	-	79	O
constellation	-	81	O
of	-	95	O
dermatitis	-	98	O
,	-	108	O
fever	-	110	O
,	-	115	O
lymphadenopathy	-	117	O
and	-	133	O
hepatitis	-	137	O
,	-	146	O
beginning	-	148	O
on	-	158	O
the	-	161	O
17th	-	165	O
day	-	170	O
of	-	174	O
a	-	177	O
course	-	179	O
of	-	186	O
oral	-	189	O
sulphasalazine	-	194	B
for	-	209	O
sero	-	213	O
-	-	217	O
negative	-	218	O
rheumatoid	-	227	O
arthritis	-	238	O
.	-	247	O

Cervical	11672959	249	O
and	-	258	O
inguinal	-	262	O
lymph	-	271	O
node	-	277	O
biopsies	-	282	O
showed	-	291	O
the	-	298	O
features	-	302	O
of	-	311	O
severe	-	314	O
necrotising	-	321	O
lymphadenitis	-	333	O
,	-	346	O
associated	-	348	O
with	-	359	O
erythrophagocytosis	-	364	O
and	-	384	O
prominent	-	388	O
eosinophilic	-	398	O
infiltrates	-	411	O
,	-	422	O
without	-	424	O
viral	-	432	O
inclusion	-	438	O
bodies	-	448	O
,	-	454	O
suggestive	-	456	O
of	-	467	O
an	-	470	O
adverse	-	473	O
drug	-	481	O
reaction	-	486	O
.	-	494	O

A	11672959	495	O
week	-	497	O
later	-	502	O
,	-	507	O
fulminant	-	509	O
drug	-	519	O
-	-	523	O
induced	-	524	O
hepatitis	-	532	O
,	-	541	O
associated	-	543	O
with	-	554	O
the	-	559	O
presence	-	563	O
of	-	572	O
anti	-	575	O
-	-	579	O
nuclear	-	580	O
autoantibodies	-	588	O
(	-	603	O
but	-	604	O
not	-	608	O
with	-	612	O
other	-	617	O
markers	-	623	O
of	-	631	O
autoimmunity	-	634	O
)	-	646	O
,	-	647	O
and	-	649	O
accompanied	-	653	O
by	-	665	O
multi	-	668	O
-	-	673	O
organ	-	674	O
failure	-	680	O
and	-	688	O
sepsis	-	692	O
,	-	698	O
supervened	-	700	O
.	-	710	O

She	11672959	712	O
subsequently	-	716	O
died	-	729	O
some	-	734	O
5	-	739	O
weeks	-	741	O
after	-	747	O
the	-	753	O
commencement	-	757	O
of	-	770	O
her	-	773	O
drug	-	777	O
therapy	-	782	O
.	-	789	O

Post	11672959	790	O
-	-	794	O
mortem	-	795	O
examination	-	802	O
showed	-	814	O
evidence	-	821	O
of	-	830	O
massive	-	833	O
hepatocellular	-	841	O
necrosis	-	856	O
,	-	864	O
acute	-	866	O
hypersensitivity	-	872	O
myocarditis	-	889	O
,	-	900	O
focal	-	902	O
acute	-	908	O
tubulo	-	914	O
-	-	920	O
interstitial	-	921	O
nephritis	-	934	O
and	-	944	O
extensive	-	948	O
bone	-	958	O
marrow	-	963	O
necrosis	-	970	O
,	-	978	O
with	-	980	O
no	-	985	O
evidence	-	988	O
of	-	997	O
malignancy	-	1000	O
.	-	1010	O

It	11672959	1012	O
is	-	1015	O
thought	-	1018	O
that	-	1026	O
the	-	1031	O
clinico	-	1035	O
-	-	1042	O
pathological	-	1043	O
features	-	1056	O
and	-	1065	O
chronology	-	1069	O
of	-	1080	O
this	-	1083	O
case	-	1088	O
bore	-	1093	O
the	-	1098	O
hallmarks	-	1102	O
of	-	1112	O
the	-	1115	O
so	-	1119	O
-	-	1121	O
called	-	1122	O
""""	-	1129	O
3	-	1130	O
-	-	1131	O
week	-	1132	O
sulphasalazine	-	1137	B
syndrome	-	1152	O
""""	-	1160	O
,	-	1161	O
a	-	1163	O
rare	-	1165	O
,	-	1169	O
but	-	1171	O
often	-	1175	O
fatal	-	1181	O
,	-	1186	O
immunoallergic	-	1188	O
reaction	-	1203	O
to	-	1212	O
sulphasalazine	-	1215	B
.	-	1229	O

Bupropion	11928786	0	B
(	-	10	O
Zyban	-	11	B
)	-	16	O
toxicity	-	18	O
.	-	26	O

Bupropion	11928786	28	B
is	-	38	O
a	-	41	O
monocyclic	-	43	O
antidepressant	-	54	B
structurally	-	69	O
related	-	82	O
to	-	90	O
amphetamine	-	93	B
.	-	104	O

Zyban	11928786	106	B
,	-	111	O
a	-	113	O
sustained	-	115	O
-	-	124	O
release	-	125	O
formulation	-	133	O
of	-	145	O
bupropion	-	148	B
hydrochloride	-	158	I
,	-	171	O
was	-	173	O
recently	-	177	O
released	-	186	O
in	-	195	O
Ireland	-	198	O
,	-	205	O
as	-	207	O
a	-	210	O
smoking	-	212	O
cessation	-	220	O
aid	-	230	O
.	-	233	O

In	11928786	235	O
the	-	238	O
initial	-	242	O
6	-	250	O
months	-	252	O
since	-	259	O
it	-	265	O
's	-	267	O
introduction	-	270	O
,	-	282	O
12	-	284	O
overdose	-	287	O
cases	-	296	O
have	-	302	O
been	-	307	O
reported	-	312	O
to	-	321	O
The	-	324	O
National	-	328	O
Poisons	-	337	O
Information	-	345	O
Centre	-	357	O
.	-	363	O

8	11928786	365	O
patients	-	367	O
developed	-	376	O
symptoms	-	386	O
of	-	395	O
toxicity	-	398	O
.	-	406	O

Common	11928786	408	O
features	-	415	O
included	-	424	O
tachycardia	-	433	O
,	-	444	O
drowsiness	-	446	O
,	-	456	O
hallucinations	-	458	O
and	-	473	O
convulsions	-	477	O
.	-	488	O

Two	11928786	490	O
patients	-	494	O
developed	-	503	O
severe	-	513	O
cardiac	-	520	O
arrhythmias	-	528	O
,	-	539	O
including	-	541	O
one	-	551	O
patient	-	555	O
who	-	563	O
was	-	567	O
resuscitated	-	571	O
following	-	584	O
a	-	594	O
cardiac	-	596	O
arrest	-	604	O
.	-	610	O

All	11928786	612	O
patients	-	616	O
recovered	-	625	O
without	-	635	O
sequelae	-	643	O
.	-	651	O

We	11928786	653	O
report	-	656	O
a	-	663	O
case	-	665	O
of	-	670	O
a	-	673	O
31	-	675	O
year	-	678	O
old	-	683	O
female	-	687	O
who	-	694	O
required	-	698	O
admission	-	707	O
to	-	717	O
the	-	720	O
Intensive	-	724	O
Care	-	734	O
Unit	-	739	O
for	-	744	O
ventilation	-	748	O
and	-	760	O
full	-	764	O
supportive	-	769	O
therapy	-	780	O
,	-	787	O
following	-	789	O
ingestion	-	799	O
of	-	809	O
13	-	812	O
.	-	814	O
5	-	815	O
g	-	816	O
bupropion	-	818	B
.	-	827	O

Recurrent	11928786	829	O
seizures	-	839	O
were	-	848	O
treated	-	853	O
with	-	861	O
diazepam	-	866	B
and	-	875	O
broad	-	879	O
complex	-	885	O
tachycardia	-	893	O
was	-	905	O
successfully	-	909	O
treated	-	922	O
with	-	930	O
adenosine	-	935	B
.	-	944	O

Zyban	11928786	946	B
caused	-	952	O
significant	-	959	O
neurological	-	971	O
and	-	984	O
cardiovascular	-	988	O
toxicity	-	1003	O
in	-	1012	O
overdose	-	1015	O
.	-	1023	O

The	11928786	1025	O
potential	-	1029	O
toxic	-	1039	O
effects	-	1045	O
should	-	1053	O
be	-	1060	O
considered	-	1063	O
when	-	1074	O
prescribing	-	1079	O
it	-	1091	O
as	-	1094	O
a	-	1097	O
smoking	-	1099	O
cessation	-	1107	O
aid	-	1117	O
.	-	1120	O

Survey	7977601	0	O
of	-	7	O
complications	-	10	O
of	-	24	O
indocyanine	-	27	B
green	-	39	I
angiography	-	45	O
in	-	57	O
Japan	-	60	O
.	-	65	O

PURPOSE	7977601	67	O
:	-	74	O

We	7977601	76	O
evaluated	-	79	O
the	-	89	O
safety	-	93	O
of	-	100	O
indocyanine	-	103	B
green	-	115	I
for	-	121	O
use	-	125	O
in	-	129	O
fundus	-	132	O
angiography	-	139	O
.	-	150	O

METHODS	7977601	152	O
:	-	159	O

We	7977601	161	O
sent	-	164	O
a	-	169	O
questionnaire	-	171	O
concerning	-	185	O
complications	-	196	O
of	-	210	O
indocyanine	-	213	B
green	-	225	I
to	-	231	O
32	-	234	O
institutions	-	237	O
in	-	250	O
Japan	-	253	O
,	-	258	O
which	-	260	O
were	-	266	O
selected	-	271	O
on	-	280	O
the	-	283	O
basis	-	287	O
of	-	293	O
the	-	296	O
client	-	300	O
list	-	307	O
from	-	312	O
the	-	317	O
Topcon	-	321	O
Company	-	328	O
,	-	335	O
which	-	337	O
manufactures	-	343	O
the	-	356	O
indocyanine	-	360	B
green	-	372	I
fundus	-	378	O
camera	-	385	O
.	-	391	O

RESULTS	7977601	393	O
:	-	400	O

Ophthalmologists	7977601	402	O
at	-	419	O
15	-	422	O
institutions	-	425	O
responded	-	438	O
,	-	447	O
reporting	-	449	O
a	-	459	O
total	-	461	O
of	-	467	O
3	-	470	O
,	-	471	O
774	-	472	O
indocyanine	-	476	B
green	-	488	I
angiograms	-	494	O
performed	-	505	O
on	-	515	O
2	-	518	O
,	-	519	O
820	-	520	O
patients	-	524	O
between	-	533	O
June	-	541	O
1984	-	546	O
and	-	551	O
September	-	555	O
1992	-	565	O
.	-	569	O

Before	7977601	571	O
angiography	-	578	O
,	-	589	O
intradermal	-	591	O
or	-	603	O
intravenous	-	606	O
indocyanine	-	618	B
green	-	630	I
testing	-	636	O
,	-	643	O
or	-	645	O
both	-	648	O
was	-	653	O
performed	-	657	O
at	-	667	O
13	-	670	O
of	-	673	O
15	-	676	O
institutions	-	679	O
.	-	691	O

For	7977601	693	O
three	-	697	O
patients	-	703	O
,	-	711	O
the	-	713	O
decision	-	717	O
was	-	726	O
made	-	730	O
not	-	735	O
to	-	739	O
proceed	-	742	O
with	-	750	O
angiography	-	755	O
after	-	767	O
positive	-	773	O
preangiographic	-	782	O
testing	-	798	O
.	-	805	O

The	7977601	807	O
dosage	-	811	O
of	-	818	O
indocyanine	-	821	B
green	-	833	I
used	-	839	O
for	-	844	O
angiography	-	848	O
varied	-	860	O
from	-	867	O
25	-	872	O
to	-	875	O
75	-	878	O
mg	-	881	O
,	-	883	O
depending	-	885	O
upon	-	895	O
the	-	900	O
institution	-	904	O
.	-	915	O

There	7977601	917	O
were	-	923	O
13	-	928	O
cases	-	931	O
of	-	937	O
adverse	-	940	O
reactions	-	948	O
(	-	958	O
0	-	959	O
.	-	960	O
34	-	961	O
%	-	963	O
)	-	964	O
,	-	965	O
ten	-	967	O
of	-	971	O
which	-	974	O
were	-	980	O
mild	-	985	O
reactions	-	990	O
such	-	1000	O
as	-	1005	O
nausea	-	1008	O
,	-	1014	O
exanthema	-	1016	O
,	-	1025	O
urtication	-	1027	O
,	-	1037	O
itchiness	-	1039	O
,	-	1048	O
and	-	1050	O
urgency	-	1054	O
to	-	1062	O
defecate	-	1065	O
,	-	1073	O
and	-	1075	O
did	-	1079	O
not	-	1083	O
require	-	1087	O
treatment	-	1095	O
.	-	1104	O

Also	7977601	1106	O
recorded	-	1111	O
were	-	1120	O
one	-	1125	O
case	-	1129	O
of	-	1134	O
pain	-	1137	O
of	-	1142	O
the	-	1145	O
vein	-	1149	O
,	-	1153	O
which	-	1155	O
required	-	1161	O
treatment	-	1170	O
,	-	1179	O
and	-	1181	O
two	-	1185	O
cases	-	1189	O
of	-	1195	O
hypotension	-	1198	O
.	-	1209	O

The	7977601	1211	O
two	-	1215	O
hypotensive	-	1219	O
patients	-	1231	O
required	-	1240	O
treatment	-	1249	O
for	-	1259	O
shock	-	1263	O
.	-	1268	O

CONCLUSIONS	7977601	1270	O
:	-	1281	O

A	7977601	1283	O
comparison	-	1285	O
of	-	1296	O
frequency	-	1299	O
of	-	1309	O
adverse	-	1312	O
reactions	-	1320	O
to	-	1330	O
indocyanine	-	1333	B
green	-	1345	I
with	-	1351	O
the	-	1356	O
previously	-	1360	O
reported	-	1371	O
frequency	-	1380	O
of	-	1390	O
such	-	1393	O
reactions	-	1398	O
to	-	1408	O
fluorescein	-	1411	B
sodium	-	1423	I
indicated	-	1430	O
that	-	1440	O
indocyanine	-	1445	B
green	-	1457	I
is	-	1463	O
a	-	1466	O
safe	-	1468	O
as	-	1473	O
fluorescein	-	1476	B
for	-	1488	O
use	-	1492	O
in	-	1496	O
angiography	-	1499	O
.	-	1510	O

Bradykinin	19300402	0	B
receptors	-	11	O
antagonists	-	21	O
and	-	33	O
nitric	-	37	B
oxide	-	44	I
synthase	-	50	O
inhibitors	-	59	O
in	-	70	O
vincristine	-	73	B
and	-	85	O
streptozotocin	-	89	B
induced	-	104	O
hyperalgesia	-	112	O
in	-	125	O
chemotherapy	-	128	O
and	-	141	O
diabetic	-	145	O
neuropathy	-	154	O
rat	-	165	O
model	-	169	O
.	-	174	O

PURPOSE	19300402	176	O
:	-	183	O

The	19300402	185	O
influence	-	189	O
of	-	199	O
an	-	202	O
irreversible	-	205	O
inhibitor	-	218	O
of	-	228	O
constitutive	-	231	O
NO	-	244	B
synthase	-	247	O
(	-	256	O
L	-	257	O
-	-	258	O
NOArg	-	259	O
;	-	264	O
1	-	266	O
.	-	267	O
0	-	268	O
mg	-	270	O
/	-	272	O
kg	-	273	O
ip	-	276	O
)	-	278	O
,	-	279	O
a	-	281	O
relatively	-	283	O
selective	-	294	O
inhibitor	-	304	O
of	-	314	O
inducible	-	317	O
NO	-	327	B
synthase	-	330	O
(	-	339	O
L	-	340	O
-	-	341	O
NIL	-	342	O
;	-	345	O
1	-	347	O
.	-	348	O
0	-	349	O
mg	-	351	O
/	-	353	O
kg	-	354	O
ip	-	357	O
)	-	359	O
and	-	361	O
a	-	365	O
relatively	-	367	O
specific	-	378	O
inhibitor	-	387	O
of	-	397	O
neuronal	-	400	O
NO	-	409	B
synthase	-	412	O
(	-	421	O
7	-	422	O
-	-	423	O
NI	-	424	O
;	-	426	O
0	-	428	O
.	-	429	O
1	-	430	O
mg	-	432	O
/	-	434	O
kg	-	435	O
ip	-	438	O
)	-	440	O
,	-	441	O
on	-	443	O
antihyperalgesic	-	446	O
action	-	463	O
of	-	470	O
selective	-	473	O
antagonists	-	483	O
of	-	495	O
B2	-	498	O
and	-	501	O
B1	-	505	O
receptors	-	508	O
:	-	517	O
D	-	519	O
-	-	520	O
Arg	-	521	O
-	-	524	O
[	-	525	O
Hyp3	-	526	O
,	-	530	O
Thi5	-	531	O
,	-	535	O
D	-	536	O
-	-	537	O
Tic7	-	538	O
,	-	542	O
Oic8	-	543	O
]	-	547	O
bradykinin	-	549	B
(	-	560	O
HOE	-	561	B
140	-	565	I
;	-	568	O
70	-	570	O
nmol	-	573	O
/	-	577	O
kg	-	578	O
ip	-	581	O
)	-	583	O
or	-	585	O
des	-	588	B

Arg10	19300402	592	I
HOE	-	598	I
140	-	602	I
(	-	606	O
70	-	607	O
nmol	-	610	O
/	-	614	O
kg	-	615	O
ip	-	618	O
)	-	620	O
respectively	-	622	O
,	-	634	O
in	-	636	O
model	-	639	O
of	-	645	O
diabetic	-	648	O
(	-	657	O
streptozotocin	-	658	O
-	-	672	O
induced	-	673	O
)	-	680	O
and	-	682	O
toxic	-	686	O
(	-	692	O
vincristine	-	693	O
-	-	704	O
induced	-	705	O
)	-	712	O
neuropathy	-	714	O
was	-	725	O
investigated	-	729	O
.	-	741	O

METHODS	19300402	743	O
:	-	750	O

The	19300402	752	O
changes	-	756	O
in	-	764	O
pain	-	767	O
thresholds	-	772	O
were	-	783	O
determined	-	788	O
using	-	799	O
mechanical	-	805	O
stimuli	-	816	O
-	-	823	O
-	-	824	O
the	-	825	O
modification	-	829	O
of	-	842	O
the	-	845	O
classic	-	849	O
paw	-	857	O
withdrawal	-	861	O
test	-	872	O
described	-	877	O
by	-	887	O
Randall	-	890	O
-	-	897	O
Selitto	-	898	O
.	-	905	O

RESULTS	19300402	907	O
:	-	914	O

The	19300402	916	O
results	-	920	O
of	-	928	O
this	-	931	O
paper	-	936	O
confirm	-	942	O
that	-	950	O
inhibition	-	955	O
of	-	966	O
bradykinin	-	969	B
receptors	-	980	O
and	-	990	O
inducible	-	994	O
NO	-	1004	B
synthase	-	1007	O
but	-	1016	O
not	-	1020	O
neuronal	-	1024	O

NO	19300402	1033	B
synthase	-	1036	O
activity	-	1045	O
reduces	-	1054	O
diabetic	-	1062	O
hyperalgesia	-	1071	O
.	-	1083	O

Pretreatment	19300402	1085	O
with	-	1098	O
L	-	1103	O
-	-	1104	O
NOArg	-	1105	O
and	-	1111	O
L	-	1115	O
-	-	1116	O
NIL	-	1117	O
but	-	1121	O
not	-	1125	O
7	-	1129	O
-	-	1130	O
NI	-	1131	O
,	-	1133	O
significantly	-	1135	O
increases	-	1149	O
antihyperalgesic	-	1159	O
activity	-	1176	O
both	-	1185	O
HOE	-	1190	B
140	-	1194	I
and	-	1198	O
des	-	1202	B
Arg10	-	1206	I
HOE	-	1212	I
140	-	1216	I
.	-	1219	O

It	19300402	1221	O
was	-	1224	O
also	-	1228	O
shown	-	1233	O
that	-	1239	O
both	-	1244	O
products	-	1249	O
of	-	1258	O
inducible	-	1261	O
NO	-	1271	B
synthase	-	1274	O
and	-	1283	O
neuronal	-	1287	O
NO	-	1296	B
synthase	-	1299	O
activation	-	1308	O
as	-	1319	O
well	-	1322	O
as	-	1327	O
bradykinin	-	1330	B
are	-	1341	O
involved	-	1345	O
in	-	1354	O
hyperalgesia	-	1357	O
produced	-	1370	O
by	-	1379	O
vincristine	-	1382	B
.	-	1393	O

Moreover	19300402	1395	O
,	-	1403	O
L	-	1405	O
-	-	1406	O
NOArg	-	1407	O
and	-	1413	O
7	-	1417	O
-	-	1418	O
NI	-	1419	O
but	-	1422	O
not	-	1426	O
L	-	1430	O
-	-	1431	O
NIL	-	1432	O
intensify	-	1436	O
antihyperalgesic	-	1446	O
activity	-	1463	O
of	-	1472	O
HOE	-	1475	B
140	-	1479	I
or	-	1483	O
des	-	1486	B
-	-	1489	I
Arg10HOE	-	1490	I
140	-	1499	I
in	-	1503	O
toxic	-	1506	O
neuropathy	-	1512	O
.	-	1522	O

CONCLUSIONS	19300402	1524	O
:	-	1535	O

Results	19300402	1537	O
of	-	1545	O
these	-	1548	O
studies	-	1554	O
suggest	-	1562	O
that	-	1570	O
B1	-	1575	O
and	-	1578	O
B2	-	1582	O
receptors	-	1585	O
are	-	1595	O
engaged	-	1599	O
in	-	1607	O
transmission	-	1610	O
of	-	1623	O
nociceptive	-	1626	O
stimuli	-	1638	O
in	-	1646	O
both	-	1649	O
diabetic	-	1654	O
and	-	1663	O
toxic	-	1667	O
neuropathy	-	1673	O
.	-	1683	O

In	19300402	1685	O
streptozotocin	-	1688	B
-	-	1702	O
induced	-	1703	O
hyperalgesia	-	1711	O
,	-	1723	O
inducible	-	1725	O
NO	-	1735	B
synthase	-	1738	O
participates	-	1747	O
in	-	1760	O
pronociceptive	-	1763	O
activity	-	1778	O
of	-	1787	O
bradykinin	-	1790	B
,	-	1800	O
whereas	-	1802	O
in	-	1810	O
vincristine	-	1813	B
-	-	1824	O
induced	-	1825	O
hyperalgesia	-	1833	O
bradykinin	-	1846	B
seemed	-	1857	O
to	-	1864	O
activate	-	1867	O
neuronal	-	1876	O
NO	-	1885	B
synthase	-	1888	O
pathway	-	1897	O
.	-	1904	O

Therefore	19300402	1906	O
,	-	1915	O
concomitant	-	1917	O
administration	-	1929	O
of	-	1944	O
small	-	1947	O
doses	-	1953	O
of	-	1959	O
bradykinin	-	1962	B
receptor	-	1973	O
antagonists	-	1982	O
and	-	1994	O
NO	-	1998	B
synthase	-	2001	O
inhibitors	-	2010	O
can	-	2021	O
be	-	2025	O
effective	-	2028	O
in	-	2038	O
alleviation	-	2041	O
of	-	2053	O
neuropathic	-	2056	O
pain	-	2068	O
,	-	2072	O
even	-	2074	O
in	-	2079	O
hospital	-	2082	O
care	-	2091	O
.	-	2095	O

Cardiac	15325671	0	O
toxicity	-	8	O
observed	-	17	O
in	-	26	O
association	-	29	O
with	-	41	O
high	-	46	O
-	-	50	O
dose	-	51	O
cyclophosphamide	-	56	B
-	-	72	O
based	-	73	O
chemotherapy	-	79	O
for	-	92	O
metastatic	-	96	O
breast	-	107	O
cancer	-	114	O
.	-	120	O

INTRODUCTION	15325671	122	O
:	-	134	O

Cyclophosphamide	15325671	136	B
is	-	153	O
an	-	156	O
alkylating	-	159	O
agent	-	170	O
given	-	176	O
frequently	-	182	O
as	-	193	O
a	-	196	O
component	-	198	O
of	-	208	O
many	-	211	O
conditioning	-	216	O
regimens	-	229	O
.	-	237	O

In	15325671	239	O
high	-	242	O
doses	-	247	O
,	-	252	O
its	-	254	O
nonhematological	-	258	O
dose	-	275	O
-	-	279	O
limiting	-	280	O
toxicity	-	289	O
is	-	298	O
cardiomyopathy	-	301	O
.	-	315	O

STUDY	15325671	317	O
DESIGN	-	323	O
:	-	329	O

We	15325671	331	O
combined	-	334	O
paclitaxel	-	343	B
,	-	353	O
melphalan	-	355	B
and	-	365	O
high	-	369	O
-	-	373	O
dose	-	374	O
cyclophosphamide	-	379	B
,	-	395	O
thiotepa	-	397	B
,	-	405	O
and	-	407	O
carboplatin	-	411	B
in	-	423	O
a	-	426	O
triple	-	428	O
sequential	-	435	O
high	-	446	O
-	-	450	O
dose	-	451	O
regimen	-	456	O
for	-	464	O
patients	-	468	O
with	-	477	O
metastatic	-	482	O
breast	-	493	O
cancer	-	500	O
.	-	506	O

Analysis	15325671	508	O
was	-	517	O
performed	-	521	O
on	-	531	O
61	-	534	O
women	-	537	O
with	-	543	O
chemotherapy	-	548	O
-	-	560	O
responsive	-	561	O
metastatic	-	572	O
breast	-	583	O
cancer	-	590	O
receiving	-	597	O
96	-	607	O
-	-	609	O
h	-	610	O
infusional	-	612	O
cyclophosphamide	-	623	B
as	-	640	O
part	-	643	O
of	-	648	O
a	-	651	O
triple	-	653	O
sequential	-	660	O
high	-	671	O
-	-	675	O
dose	-	676	O
regimen	-	681	O
to	-	689	O
assess	-	692	O
association	-	699	O
between	-	711	O
presence	-	719	O
of	-	728	O
peritransplant	-	731	O
congestive	-	746	O
heart	-	757	O
failure	-	763	O
(	-	771	O
CHF	-	772	O
)	-	775	O
and	-	777	O
the	-	781	O
following	-	785	O
pretreatment	-	795	O
characteristics	-	808	O
:	-	823	O
presence	-	825	O
of	-	834	O
electrocardiogram	-	837	O
(	-	855	O
EKG	-	856	O
)	-	859	O
abnormalities	-	861	O
,	-	874	O
age	-	876	O
,	-	879	O
hypertension	-	881	O
,	-	893	O
prior	-	895	O
cardiac	-	901	O
history	-	909	O
,	-	916	O
smoking	-	918	O
,	-	925	O
diabetes	-	927	O
mellitus	-	936	O
,	-	944	O
prior	-	946	O
use	-	952	O
of	-	956	O
anthracyclines	-	959	B
,	-	973	O
and	-	975	O
left	-	979	O
-	-	983	O
sided	-	984	O
chest	-	990	O
irradiation	-	996	O
.	-	1007	O

RESULTS	15325671	1009	O
:	-	1016	O

Six	15325671	1018	O
of	-	1022	O
61	-	1025	O
women	-	1028	O
(	-	1034	O
10	-	1035	O
%	-	1037	O
)	-	1038	O
developed	-	1040	O
clinically	-	1050	O
reversible	-	1061	O
grade	-	1072	O
3	-	1078	O
CHF	-	1080	O
following	-	1084	O
infusional	-	1094	O
cyclophosphamide	-	1105	B
with	-	1122	O
a	-	1127	O
median	-	1129	O
percent	-	1136	O
decline	-	1144	O
in	-	1152	O
ejection	-	1155	O
fraction	-	1164	O
of	-	1173	O
31	-	1176	O
%	-	1178	O
.	-	1179	O

Incidence	15325671	1181	O
of	-	1191	O
transient	-	1194	O
cyclophosphamide	-	1204	B
-	-	1220	O
related	-	1221	O
cardiac	-	1229	O
toxicity	-	1237	O
(	-	1246	O
10	-	1247	O
%	-	1249	O
)	-	1250	O
is	-	1252	O
comparable	-	1255	O
to	-	1266	O
previous	-	1269	O
recorded	-	1278	O
literature	-	1287	O
.	-	1297	O

Older	15325671	1299	O
age	-	1305	O
was	-	1309	O
significantly	-	1313	O
correlated	-	1327	O
with	-	1338	O
the	-	1343	O
CHF	-	1347	O
development	-	1351	O
;	-	1362	O
with	-	1364	O
median	-	1369	O
ages	-	1376	O
for	-	1381	O
the	-	1385	O
entire	-	1389	O
group	-	1396	O
and	-	1402	O
for	-	1406	O
patients	-	1410	O
developing	-	1419	O
CHF	-	1430	O
of	-	1434	O
45	-	1437	O
and	-	1440	O
59	-	1444	O
,	-	1446	O
respectively	-	1448	O
.	-	1460	O

No	15325671	1462	O
association	-	1465	O
was	-	1477	O
found	-	1481	O
with	-	1487	O
other	-	1492	O
pretreatment	-	1498	O
characteristics	-	1511	O
.	-	1526	O

CONCLUSIONS	15325671	1528	O
:	-	1539	O

As	15325671	1541	O
a	-	1544	O
result	-	1546	O
of	-	1553	O
these	-	1556	O
findings	-	1562	O
,	-	1570	O
oncologists	-	1572	O
should	-	1584	O
carefully	-	1591	O
monitor	-	1601	O
fluid	-	1609	O
balance	-	1615	O
in	-	1623	O
older	-	1626	O
patients	-	1632	O
.	-	1640	O

Routine	15325671	1642	O
EKG	-	1650	O
monitoring	-	1654	O
during	-	1665	O
infusional	-	1672	O
cyclophosphamide	-	1683	B
did	-	1700	O
not	-	1704	O
predict	-	1708	O
CHF	-	1716	O
development	-	1720	O
.	-	1731	O

Inappropriate	9746003	0	O
use	-	14	O
of	-	18	O
carbamazepine	-	21	B
and	-	35	O
vigabatrin	-	39	B
in	-	50	O
typical	-	53	O
absence	-	61	O
seizures	-	69	O
.	-	77	O

Carbamazepine	9746003	79	B
and	-	93	O
vigabatrin	-	97	B
are	-	108	O
contraindicated	-	112	O
in	-	128	O
typical	-	131	O
absence	-	139	O
seizures	-	147	O
.	-	155	O

Of	9746003	157	O
18	-	160	O
consecutive	-	163	O
referrals	-	175	O
of	-	185	O
children	-	188	O
with	-	197	O
resistant	-	202	O
typical	-	212	O
absences	-	220	O
only	-	229	O
,	-	233	O
eight	-	235	O
were	-	241	O
erroneously	-	246	O
treated	-	258	O
with	-	266	O
carbamazepine	-	271	B
either	-	285	O
as	-	292	O
monotherapy	-	295	O
or	-	307	O
as	-	310	O
an	-	313	O
add	-	316	O
-	-	319	O
on	-	320	O
.	-	322	O

Vigabatrin	9746003	324	B
was	-	335	O
also	-	339	O
used	-	344	O
in	-	349	O
the	-	352	O
treatment	-	356	O
of	-	366	O
two	-	369	O
children	-	373	O
.	-	381	O

Frequency	9746003	383	O
of	-	393	O
absences	-	396	O
increased	-	405	O
in	-	415	O
four	-	418	O
children	-	423	O
treated	-	432	O
with	-	440	O
carbamazepine	-	445	B
and	-	459	O
two	-	463	O
of	-	467	O
these	-	470	O
developed	-	476	O
myoclonic	-	486	O
jerks	-	496	O
,	-	501	O
which	-	503	O
resolved	-	509	O
on	-	518	O
withdrawal	-	521	O
of	-	532	O
carbamazepine	-	535	B
.	-	548	O

Absences	9746003	550	O
were	-	559	O
aggravated	-	564	O
in	-	575	O
both	-	578	O
cases	-	583	O
where	-	589	O
vigabatrin	-	595	B
was	-	606	O
added	-	610	O
on	-	616	O
to	-	619	O
concurrent	-	622	O
treatment	-	633	O
.	-	642	O

Optimal	9746003	644	O
control	-	652	O
of	-	660	O
the	-	663	O
absences	-	667	O
was	-	676	O
achieved	-	680	O
with	-	689	O
sodium	-	694	B
valproate	-	701	I
,	-	710	O
lamotrigine	-	712	B
,	-	723	O
or	-	725	O
ethosuximide	-	728	B
alone	-	741	O
or	-	747	O
in	-	750	O
combination	-	753	O
.	-	764	O

Hemolytic	1992636	0	O
anemia	-	10	O
associated	-	17	O
with	-	28	O
the	-	33	O
use	-	37	O
of	-	41	O
omeprazole	-	44	B
.	-	54	O

Omeprazole	1992636	56	B
is	-	67	O
the	-	70	O
first	-	74	O
drug	-	80	O
designed	-	85	O
to	-	94	O
block	-	97	O
the	-	103	O
final	-	107	O
step	-	113	O
in	-	118	O
the	-	121	O
acid	-	125	O
secretory	-	130	O
process	-	140	O
within	-	148	O
the	-	155	O
parietal	-	159	O
cell	-	168	O
.	-	172	O

It	1992636	174	O
has	-	177	O
been	-	181	O
shown	-	186	O
to	-	192	O
be	-	195	O
extremely	-	198	O
effective	-	208	O
in	-	218	O
the	-	221	O
treatment	-	225	O
of	-	235	O
peptic	-	238	O
ulcer	-	245	O
disease	-	251	O
,	-	258	O
reflux	-	260	O
esophagitis	-	267	O
,	-	278	O
and	-	280	O
the	-	284	O
Zollinger	-	288	O
-	-	297	O
Ellison	-	298	O
syndrome	-	306	O
.	-	314	O

Although	1992636	316	O
clinical	-	325	O
experience	-	334	O
with	-	345	O
omeprazole	-	350	B
is	-	361	O
still	-	364	O
limited	-	370	O
,	-	377	O
many	-	379	O
controlled	-	384	O
studies	-	395	O
have	-	403	O
established	-	408	O
the	-	420	O
short	-	424	O
-	-	429	O
term	-	430	O
safety	-	435	O
of	-	442	O
this	-	445	O
drug	-	450	O
.	-	454	O

We	1992636	456	O
report	-	459	O
the	-	466	O
first	-	470	O
case	-	476	O
of	-	481	O
a	-	484	O
serious	-	486	O
short	-	494	O
-	-	499	O
term	-	500	O
adverse	-	505	O
reaction	-	513	O
with	-	522	O
the	-	527	O
use	-	531	O
of	-	535	O
omeprazole	-	538	B
:	-	548	O
hemolytic	-	550	O
anemia	-	560	O
.	-	566	O

The	1992636	568	O
patient	-	572	O
developed	-	580	O
weakness	-	590	O
,	-	598	O
lethargy	-	600	O
,	-	608	O
and	-	610	O
shortness	-	614	O
of	-	624	O
breath	-	627	O
2	-	634	O
days	-	636	O
after	-	641	O
starting	-	647	O
therapy	-	656	O
with	-	664	O
omeprazole	-	669	B
.	-	679	O

Two	1992636	681	O
weeks	-	685	O
after	-	691	O
the	-	697	O
initiation	-	701	O
of	-	712	O
therapy	-	715	O
,	-	722	O
her	-	724	O
hematocrit	-	728	O
had	-	739	O
decreased	-	743	O
from	-	753	O
44	-	758	O
.	-	760	O
1	-	761	O
%	-	762	O
to	-	764	O
20	-	767	O
.	-	769	O
4	-	770	O
%	-	771	O
,	-	772	O
and	-	774	O
she	-	778	O
had	-	782	O
a	-	786	O
positive	-	788	O
direct	-	797	O
Coombs	-	804	O
antiglobulin	-	811	O
test	-	824	O
and	-	829	O
an	-	833	O
elevated	-	836	O
indirect	-	845	O
bilirubin	-	854	B
.	-	863	O

After	1992636	865	O
she	-	871	O
discontinued	-	875	O
the	-	888	O
omeprazole	-	892	B
,	-	902	O
her	-	904	O
hemoglobin	-	908	O
and	-	919	O
hematocrit	-	923	O
gradually	-	934	O
returned	-	944	O
to	-	953	O
normal	-	956	O
.	-	962	O

The	1992636	964	O
mechanism	-	968	O
by	-	978	O
which	-	981	O
omeprazole	-	987	B
caused	-	998	O
the	-	1005	O
patient	-	1009	O
's	-	1016	O
hemolytic	-	1019	O
anemia	-	1029	O
is	-	1036	O
uncertain	-	1039	O
,	-	1048	O
but	-	1050	O
physicians	-	1054	O
should	-	1065	O
be	-	1072	O
alerted	-	1075	O
to	-	1083	O
this	-	1086	O
possible	-	1091	O
adverse	-	1100	O
effect	-	1108	O
.	-	1114	O

The	8387218	0	O
use	-	4	O
and	-	8	O
toxicity	-	12	O
of	-	21	O
didanosine	-	24	B
(	-	35	O
ddI	-	36	B
)	-	39	O
in	-	41	O
HIV	-	44	O
antibody	-	48	O
-	-	56	O
positive	-	57	O
individuals	-	66	O
intolerant	-	78	O
to	-	89	O
zidovudine	-	92	B
(	-	103	O
AZT	-	104	B
)	-	107	O

One	8387218	109	O
hundred	-	113	O
and	-	121	O
fifty	-	125	O
-	-	130	O
one	-	131	O
patients	-	135	O
intolerant	-	144	O
to	-	155	O
zidovudine	-	158	B
(	-	169	O
AZT	-	170	B
)	-	173	O
received	-	175	O
didanosine	-	184	B
(	-	195	O
ddI	-	196	B
)	-	199	O
to	-	201	O
a	-	204	O
maximum	-	206	O
dose	-	214	O
of	-	219	O
12	-	222	O
.	-	224	O
5	-	225	O
mg	-	227	O
/	-	229	O
kg	-	230	O
/	-	232	O
day	-	233	O
.	-	236	O

Patient	8387218	238	O
response	-	246	O
was	-	255	O
assessed	-	259	O
using	-	268	O
changes	-	274	O
in	-	282	O
CD4	-	285	O
+	-	288	O
lymphocyte	-	290	O
subset	-	301	O
count	-	308	O
,	-	313	O
HIV	-	315	O
p24	-	319	O
antigen	-	323	O
,	-	330	O
weight	-	332	O
,	-	338	O
and	-	340	O
quality	-	344	O
of	-	352	O
life	-	355	O
.	-	359	O

Seventy	8387218	361	O
patients	-	369	O
developed	-	378	O
major	-	388	O
opportunistic	-	394	O
infections	-	408	O
whilst	-	419	O
on	-	426	O
therapy	-	429	O
;	-	436	O
this	-	438	O
was	-	443	O
the	-	447	O
first	-	451	O
AIDS	-	457	O
diagnosis	-	462	O
in	-	472	O
17	-	475	O
.	-	477	O

Only	8387218	479	O
minor	-	484	O
changes	-	490	O
in	-	498	O
CD4	-	501	O
+	-	504	O
lymphocyte	-	506	O
subset	-	517	O
count	-	524	O
were	-	530	O
observed	-	535	O
in	-	544	O
AIDS	-	547	O
patients	-	552	O
,	-	560	O
although	-	562	O
a	-	571	O
more	-	573	O
significant	-	578	O
rise	-	590	O
occurred	-	595	O
in	-	604	O
those	-	607	O
with	-	613	O
earlier	-	618	O
stages	-	626	O
of	-	633	O
disease	-	636	O
.	-	643	O

Of	8387218	645	O
those	-	648	O
positive	-	654	O
for	-	663	O
p24	-	667	O
antigen	-	671	O
at	-	679	O
the	-	682	O
commencement	-	686	O
of	-	699	O
the	-	702	O
study	-	706	O
67	-	712	O
%	-	714	O
showed	-	716	O
a	-	723	O
positive	-	725	O
response	-	734	O
,	-	742	O
and	-	744	O
this	-	748	O
was	-	753	O
most	-	757	O
likely	-	762	O
in	-	769	O
those	-	772	O
with	-	778	O
CD4	-	783	O
+	-	786	O
lymphocyte	-	788	O
subset	-	799	O
counts	-	806	O
above	-	813	O
100	-	819	O
mm3	-	823	O
.	-	826	O

A	8387218	828	O
positive	-	830	O
weight	-	839	O
response	-	846	O
was	-	855	O
seen	-	859	O
in	-	864	O
16	-	867	O
%	-	869	O
of	-	871	O
patients	-	874	O
.	-	882	O

Most	8387218	884	O
patients	-	889	O
showed	-	898	O
improvement	-	905	O
in	-	917	O
individual	-	920	O
parameters	-	931	O
and	-	942	O
global	-	946	O
score	-	953	O
of	-	959	O
quality	-	962	O
of	-	970	O
life	-	973	O
.	-	977	O

Adverse	8387218	979	O
reactions	-	987	O
possibly	-	997	O
attributable	-	1006	O
to	-	1019	O
didanosine	-	1022	B
were	-	1033	O
common	-	1038	O
.	-	1044	O

The	8387218	1046	O
most	-	1050	O
common	-	1055	O
side	-	1062	O
-	-	1066	O
effect	-	1067	O
was	-	1074	O
diarrhoea	-	1078	O
,	-	1087	O
which	-	1089	O
resulted	-	1095	O
in	-	1104	O
cessation	-	1107	O
of	-	1117	O
therapy	-	1120	O
in	-	1128	O
19	-	1131	O
individuals	-	1134	O
.	-	1145	O

Peripheral	8387218	1147	O
neuropathy	-	1158	O
occurred	-	1169	O
in	-	1178	O
12	-	1181	O
patients	-	1184	O
and	-	1193	O
pancreatitis	-	1197	O
in	-	1210	O
six	-	1213	O
.	-	1216	O

Thirteen	8387218	1218	O
patients	-	1227	O
developed	-	1236	O
a	-	1246	O
raised	-	1248	O
serum	-	1255	O
amylase	-	1261	O
without	-	1269	O
abdominal	-	1277	O
pain	-	1287	O
.	-	1291	O

Seven	8387218	1293	O
patients	-	1299	O
developed	-	1308	O
glucose	-	1318	O
tolerance	-	1326	O
curves	-	1336	O
characteristic	-	1343	O
of	-	1358	O
diabetes	-	1361	O
but	-	1370	O
these	-	1374	O
were	-	1380	O
mild	-	1385	O
,	-	1389	O
did	-	1391	O
not	-	1395	O
require	-	1399	O
treatment	-	1407	O
and	-	1417	O
returned	-	1421	O
to	-	1430	O
normal	-	1433	O
on	-	1440	O
ceasing	-	1443	O
didanosine	-	1451	B
.	-	1461	O

Can	20698227	0	O
angiogenesis	-	4	O
be	-	17	O
a	-	20	O
target	-	22	O
of	-	29	O
treatment	-	32	O
for	-	42	O
ribavirin	-	46	B
associated	-	56	O
hemolytic	-	67	O
anemia	-	77	O
?	-	83	O

BACKGROUND	20698227	85	O
/	-	95	O
AIMS	-	96	O
:	-	100	O

Recently	20698227	102	O
ribavirin	-	111	B
has	-	121	O
been	-	125	O
found	-	130	O
to	-	136	O
inhibit	-	139	O
angiogenesis	-	147	O
and	-	160	O
a	-	164	O
number	-	166	O
of	-	173	O
angiogenesis	-	176	O
inhibitors	-	189	O
such	-	200	O
as	-	205	O
sunitinib	-	208	B
and	-	218	O
sorafenib	-	222	B
have	-	232	O
been	-	237	O
found	-	242	O
to	-	248	O
cause	-	251	O
acute	-	257	O
hemolysis	-	263	O
.	-	272	O

We	20698227	274	O
aimed	-	277	O
to	-	283	O
investigate	-	286	O
whether	-	298	O
there	-	306	O
is	-	312	O
a	-	315	O
relation	-	317	O
between	-	326	O
hemoglobin	-	334	O
,	-	344	O
haptoglobin	-	346	O
and	-	358	O
angiogenesis	-	362	O
soluble	-	375	O
markers	-	383	O
which	-	391	O
are	-	397	O
modifiable	-	401	O
and	-	412	O
can	-	416	O
help	-	420	O
in	-	425	O
developing	-	428	O
strategies	-	439	O
against	-	450	O
anemia	-	458	O
.	-	464	O

METHODS	20698227	466	O
:	-	473	O

Fourteen	20698227	475	O
patients	-	484	O
chronically	-	493	O
infected	-	505	O
with	-	514	O
hepatitis	-	519	O
C	-	529	O
virus	-	531	O
were	-	537	O
treated	-	542	O
by	-	550	O
pegylated	-	553	B
interferon	-	563	I
alpha	-	574	I
2a	-	580	I
and	-	583	O
ribavirin	-	587	B
.	-	596	O

Serum	20698227	598	O
hemoglobin	-	604	O
,	-	614	O
haptoglobin	-	616	O
and	-	628	O
angiogenesis	-	632	O
markers	-	645	O
of	-	653	O
vascular	-	656	O
endothelial	-	665	O
growth	-	677	O
factor	-	684	O
and	-	691	O
angiopoetin	-	695	O
-	-	706	O
2	-	707	O
were	-	709	O
investigated	-	714	O
before	-	727	O
and	-	734	O
after	-	738	O
therapy	-	744	O
.	-	751	O

RESULTS	20698227	753	O
:	-	760	O

We	20698227	762	O
observed	-	765	O
a	-	774	O
significant	-	776	O
decrease	-	788	O
in	-	797	O
haptoglobin	-	800	O
levels	-	812	O
at	-	819	O
the	-	822	O
end	-	826	O
of	-	830	O
the	-	833	O
treatment	-	837	O
period	-	847	O
.	-	853	O

Hemoglobin	20698227	855	O
levels	-	866	O
also	-	873	O
decreased	-	878	O
but	-	888	O
insignificantly	-	892	O
by	-	908	O
treatment	-	911	O
.	-	920	O

In	20698227	922	O
contrast	-	925	O
with	-	934	O
the	-	939	O
literature	-	943	O
,	-	953	O
serum	-	955	O
levels	-	961	O
of	-	968	O
angiogenesis	-	971	O
factors	-	984	O
did	-	992	O
not	-	996	O
change	-	1000	O
significantly	-	1007	O
by	-	1021	O
pegylated	-	1024	B
interferon	-	1034	I
and	-	1045	O
ribavirin	-	1049	B
therapy	-	1059	O
.	-	1066	O

We	20698227	1068	O
found	-	1071	O
no	-	1077	O
correlation	-	1080	O
of	-	1092	O
angiogenesis	-	1095	O
soluble	-	1108	O
markers	-	1116	O
with	-	1124	O
either	-	1129	O
hemoglobin	-	1136	O
or	-	1147	O
haptoglobin	-	1150	O
.	-	1161	O

CONCLUSION	20698227	1163	O
:	-	1173	O

This	20698227	1175	O
is	-	1180	O
the	-	1183	O
first	-	1187	O
study	-	1193	O
in	-	1199	O
the	-	1202	O
literature	-	1206	O
investigating	-	1217	O
a	-	1231	O
link	-	1233	O
between	-	1238	O
angiogenesis	-	1246	O
soluble	-	1259	O
markers	-	1267	O
and	-	1275	O
ribavirin	-	1279	B
induced	-	1289	O
anemia	-	1297	O
in	-	1304	O
patients	-	1307	O
with	-	1316	O
hepatitis	-	1321	O
C	-	1331	O
and	-	1333	O
we	-	1337	O
could	-	1340	O
not	-	1346	O
find	-	1350	O
any	-	1355	O
relation	-	1359	O
.	-	1367	O

Future	20698227	1369	O
research	-	1376	O
with	-	1385	O
larger	-	1390	O
number	-	1397	O
of	-	1404	O
patients	-	1407	O
is	-	1416	O
needed	-	1419	O
to	-	1426	O
find	-	1429	O
out	-	1434	O
modifiable	-	1438	O
factors	-	1449	O
that	-	1457	O
will	-	1462	O
improve	-	1467	O
the	-	1475	O
safety	-	1479	O
of	-	1486	O
ribavirin	-	1489	B
therapy	-	1499	O
.	-	1506	O

Cocaine	20477932	0	B
causes	-	8	O
memory	-	15	O
and	-	22	O
learning	-	26	O
impairments	-	35	O
in	-	47	O
rats	-	50	O
:	-	54	O
involvement	-	56	O
of	-	68	O
nuclear	-	71	O
factor	-	79	O
kappa	-	86	O
B	-	92	O
and	-	94	O
oxidative	-	98	O
stress	-	108	O
,	-	114	O
and	-	116	O
prevention	-	120	O
by	-	131	O
topiramate	-	134	B
.	-	144	O

Different	20477932	146	O
mechanisms	-	156	O
have	-	167	O
been	-	172	O
suggested	-	177	O
for	-	187	O
cocaine	-	191	B
toxicity	-	199	O
including	-	208	O
an	-	218	O
increase	-	221	O
in	-	230	O
oxidative	-	233	O
stress	-	243	O
but	-	250	O
the	-	254	O
association	-	258	O
between	-	270	O
oxidative	-	278	O
status	-	288	O
in	-	295	O
the	-	298	O
brain	-	302	O
and	-	308	O
cocaine	-	312	B
induced	-	320	O
-	-	327	O
behaviour	-	328	O
is	-	338	O
poorly	-	341	O
understood	-	348	O
.	-	358	O

Nuclear	20477932	360	O
factor	-	368	O
kappa	-	375	O
B	-	381	O
(	-	383	O
NFkappaB	-	384	O
)	-	392	O
is	-	394	O
a	-	397	O
sensor	-	399	O
of	-	406	O
oxidative	-	409	O
stress	-	419	O
and	-	426	O
participates	-	430	O
in	-	443	O
memory	-	446	O
formation	-	453	O
that	-	463	O
could	-	468	O
be	-	474	O
involved	-	477	O
in	-	486	O
drug	-	489	O
toxicity	-	494	O
and	-	503	O
addiction	-	507	O
mechanisms	-	517	O
.	-	527	O

Therefore	20477932	529	O
NFkappaB	-	539	O
activity	-	548	O
,	-	556	O
oxidative	-	558	O
stress	-	568	O
,	-	574	O
neuronal	-	576	O
nitric	-	585	B
oxide	-	592	I
synthase	-	598	O
(	-	607	O
nNOS	-	608	O
)	-	612	O
activity	-	614	O
,	-	622	O
spatial	-	624	O
learning	-	632	O
and	-	641	O
memory	-	645	O
as	-	652	O
well	-	655	O
as	-	660	O
the	-	663	O
effect	-	667	O
of	-	674	O
topiramate	-	677	B
,	-	687	O
a	-	689	O
previously	-	691	O
proposed	-	702	O
therapy	-	711	O
for	-	719	O
cocaine	-	723	O
addiction	-	731	O
,	-	740	O
were	-	742	O
evaluated	-	747	O
in	-	757	O
an	-	760	O
experimental	-	763	O
model	-	776	O
of	-	782	O
cocaine	-	785	B
administration	-	793	O
in	-	808	O
rats	-	811	O
.	-	815	O

NFkappaB	20477932	817	O
activity	-	826	O
was	-	835	O
decreased	-	839	O
in	-	849	O
the	-	852	O
frontal	-	856	O
cortex	-	864	O
of	-	871	O
cocaine	-	874	B
treated	-	882	O
rats	-	890	O
,	-	894	O
as	-	896	O
well	-	899	O
as	-	904	O
GSH	-	907	B
concentration	-	911	O
and	-	925	O
glutathione	-	929	B
peroxidase	-	941	O
activity	-	952	O
in	-	961	O
the	-	964	O
hippocampus	-	968	O
,	-	979	O
whereas	-	981	O
nNOS	-	989	O
activity	-	994	O
in	-	1003	O
the	-	1006	O
hippocampus	-	1010	O
was	-	1022	O
increased	-	1026	O
.	-	1035	O

Memory	20477932	1037	O
retrieval	-	1044	O
of	-	1054	O
experiences	-	1057	O
acquired	-	1069	O
prior	-	1078	O
to	-	1084	O
cocaine	-	1087	B
administration	-	1095	O
was	-	1110	O
impaired	-	1114	O
and	-	1123	O
negatively	-	1127	O
correlated	-	1138	O
with	-	1149	O
NFkappaB	-	1154	O
activity	-	1163	O
in	-	1172	O
the	-	1175	O
frontal	-	1179	O
cortex	-	1187	O
.	-	1193	O

In	20477932	1195	O
contrast	-	1198	O
,	-	1206	O
learning	-	1208	O
of	-	1217	O
new	-	1220	O
tasks	-	1224	O
was	-	1230	O
enhanced	-	1234	O
and	-	1243	O
correlated	-	1247	O
with	-	1258	O
the	-	1263	O
increase	-	1267	O
of	-	1276	O
nNOS	-	1279	O
activity	-	1284	O
and	-	1293	O
the	-	1297	O
decrease	-	1301	O
of	-	1310	O
glutathione	-	1313	B
peroxidase	-	1325	O
.	-	1335	O

These	20477932	1337	O
results	-	1343	O
provide	-	1351	O
evidence	-	1359	O
for	-	1368	O
a	-	1372	O
possible	-	1374	O
mechanistic	-	1383	O
role	-	1395	O
of	-	1400	O
oxidative	-	1403	O
and	-	1413	O
nitrosative	-	1417	O
stress	-	1429	O
and	-	1436	O
NFkappaB	-	1440	O
in	-	1449	O
the	-	1452	O
alterations	-	1456	O
induced	-	1468	O
by	-	1476	O
cocaine	-	1479	B
.	-	1486	O

Topiramate	20477932	1488	B
prevented	-	1499	O
all	-	1509	O
the	-	1513	O
alterations	-	1517	O
observed	-	1529	O
,	-	1537	O
showing	-	1539	O
novel	-	1547	O
neuroprotective	-	1553	O
properties	-	1569	O
.	-	1579	O

Antinociceptive	9495837	0	O
and	-	16	O
antiamnesic	-	20	O
properties	-	32	O
of	-	43	O
the	-	46	O
presynaptic	-	50	O
cholinergic	-	62	O
amplifier	-	74	O
PG	-	84	B
-	-	86	I
9	-	87	I
.	-	88	O

The	9495837	90	O
antinociceptive	-	94	O
effect	-	110	O
of	-	117	O
3	-	120	B
alpha	-	122	I
-	-	127	I
tropyl	-	128	I
2	-	135	I
-	-	136	I
(	-	137	I
p	-	138	I
-	-	139	I
bromophenyl	-	140	I
)	-	151	I
propionate	-	152	I
[	-	163	O
(	-	164	O
+	-	165	O
/	-	166	O
-	-	167	O
)	-	168	O
-	-	169	O
PG	-	170	B
-	-	172	I
9	-	173	I
]	-	174	O

(	9495837	176	O
10	-	177	O
-	-	179	O
40	-	180	O
mg	-	183	O
kg	-	186	O
-	-	188	O
1	-	189	O
s	-	191	O
.	-	192	O
c	-	193	O
.	-	194	O
;	-	195	O

30	9495837	197	O
-	-	199	O
60	-	200	O
mg	-	203	O
kg	-	206	O
-	-	208	O
1	-	209	O

p	9495837	211	O
.	-	212	O
o	-	213	O
.	-	214	O

;	9495837	215	O
10	-	217	O
-	-	219	O
30	-	220	O
mg	-	223	O
kg	-	226	O
-	-	228	O
1	-	229	O
i	-	231	O
.	-	232	O
v	-	233	O
.	-	234	O

;	9495837	235	O
10	-	237	O
-	-	239	O
30	-	240	O
micrograms	-	243	O
/	-	253	O
mouse	-	254	O
i	-	260	O
.	-	261	O
c	-	262	O
.	-	263	O
v	-	264	O
.	-	265	O
)	-	266	O
was	-	268	O
examined	-	272	O
in	-	281	O
mice	-	284	O
,	-	288	O
rats	-	290	O
and	-	295	O
guinea	-	299	O
pigs	-	306	O
by	-	311	O
use	-	314	O
of	-	318	O
the	-	321	O
hot	-	325	O
-	-	328	O
plate	-	329	O
,	-	334	O
abdominal	-	336	O
-	-	345	O
constriction	-	346	O
,	-	358	O
tail	-	360	O
-	-	364	O
flick	-	365	O
and	-	371	O
paw	-	375	O
-	-	378	O
pressure	-	379	O
tests	-	388	O
.	-	393	O

(	9495837	395	O

+	9495837	396	O
/	-	397	O
-	-	398	O
)	-	399	O
-	-	400	O
PG	-	401	B
-	-	403	I
9	-	404	I
antinociception	-	406	O
peaked	-	422	O
15	-	429	O
min	-	432	O
after	-	436	O
injection	-	442	O
and	-	452	O
then	-	456	O
slowly	-	461	O
diminished	-	468	O
.	-	478	O

The	9495837	480	O
antinociception	-	484	O
produced	-	500	O
by	-	509	O
(	-	512	O
+	-	513	O
/	-	514	O
-	-	515	O
)	-	516	O
-	-	517	O
PG	-	518	B
-	-	520	I
9	-	521	I
was	-	523	O
prevented	-	527	O
by	-	537	O
the	-	540	O
unselective	-	544	O
muscarinic	-	556	O
antagonist	-	567	O
atropine	-	578	B
,	-	586	O
the	-	588	O
M1	-	592	O
-	-	594	O
selective	-	595	O
antagonists	-	605	O
pirenzepine	-	617	B
and	-	629	O
dicyclomine	-	633	B
and	-	645	O
the	-	649	O
acetylcholine	-	653	B
depletor	-	667	O
hemicholinium	-	676	B
-	-	689	I
3	-	690	I
,	-	691	O
but	-	693	O
not	-	697	O
by	-	701	O
the	-	704	O
opioid	-	708	O
antagonist	-	715	O
naloxone	-	726	B
,	-	734	O
the	-	736	O
gamma	-	740	B
-	-	745	I
aminobutyric	-	746	I
acidB	-	759	I
antagonist	-	765	O
3	-	776	B
-	-	777	I
aminopropyl	-	778	I
-	-	789	I
diethoxy	-	790	I
-	-	798	I
methyl	-	799	I
-	-	805	I
phosphinic	-	806	I
acid	-	817	I
,	-	821	O
the	-	823	O
H3	-	827	O
agonist	-	830	O
R	-	838	B
-	-	839	I
(	-	840	I
alpha	-	841	I
)	-	846	I
-	-	847	I
methylhistamine	-	848	I
,	-	863	O
the	-	865	O
D2	-	869	O
antagonist	-	872	O
quinpirole	-	883	B
,	-	893	O
the	-	895	O
5	-	899	B
-	-	900	I
hydroxytryptamine4	-	901	I
antagonist	-	920	O
2	-	931	B
-	-	932	I
methoxy	-	933	I
-	-	940	I
4	-	941	I
-	-	942	I
amino	-	943	I
-	-	948	I
5	-	949	I
-	-	950	I
chlorobenzoic	-	951	I
acid	-	965	I
2	-	970	I
-	-	971	I
(	-	972	I
diethylamino	-	973	I
)	-	985	I
ethyl	-	986	I
ester	-	992	I
hydrochloride	-	998	O
,	-	1011	O
the	-	1013	O
5	-	1017	B
-	-	1018	I
hydroxytryptamin1A	-	1019	I
antagonist	-	1038	O
1	-	1049	B
-	-	1050	I
(	-	1051	I
2	-	1052	I
-	-	1053	I
methoxyphenyl	-	1054	I
)	-	1067	I
-	-	1068	I
4	-	1069	I
-	-	1070	I
[	-	1071	I
4	-	1072	I
-	-	1073	I
(	-	1074	I
2	-	1075	I
-	-	1076	I
phthalimido	-	1077	I
)	-	1088	I
butyl	-	1089	I
]	-	1094	I
piperazine	-	1095	I
hydrobromide	-	1106	O
and	-	1119	O
the	-	1123	O
polyamines	-	1127	O
depletor	-	1138	O
reserpine	-	1147	B
.	-	1156	O

Based	9495837	1158	O
on	-	1164	O
these	-	1167	O
data	-	1173	O
,	-	1177	O
it	-	1179	O
can	-	1182	O
be	-	1186	O
postulated	-	1189	O
that	-	1200	O
(	-	1205	O
+	-	1206	O
/	-	1207	O
-	-	1208	O
)	-	1209	O
-	-	1210	O
PG	-	1211	B
-	-	1213	I
9	-	1214	I
exerted	-	1216	O
an	-	1224	O
antinociceptive	-	1227	O
effect	-	1243	O
mediated	-	1250	O
by	-	1259	O
a	-	1262	O
central	-	1264	O
potentiation	-	1272	O
of	-	1285	O
cholinergic	-	1288	O
transmission	-	1300	O
.	-	1312	O

(	9495837	1314	O
+	-	1315	O
/	-	1316	O
-	-	1317	O
)	-	1318	O
-	-	1319	O
PG	-	1320	B
-	-	1322	I
9	-	1323	I
(	-	1325	O
10	-	1326	O
-	-	1328	O
40	-	1329	O
mg	-	1332	O
kg	-	1335	O
-	-	1337	O
1	-	1338	O
i	-	1340	O
.	-	1341	O
p	-	1342	O
.	-	1343	O
)	-	1344	O
was	-	1346	O
able	-	1350	O
to	-	1355	O
prevent	-	1358	O
amnesia	-	1366	O
induced	-	1374	O
by	-	1382	O
scopolamine	-	1385	B
(	-	1397	O
1	-	1398	O
mg	-	1400	O
kg	-	1403	O
-	-	1405	O
1	-	1406	O
i	-	1408	O
.	-	1409	O
p	-	1410	O
.	-	1411	O
)	-	1412	O
and	-	1414	O
dicyclomine	-	1418	B
(	-	1430	O
2	-	1431	O
mg	-	1433	O
kg	-	1436	O
-	-	1438	O
1	-	1439	O
i	-	1441	O
.	-	1442	O
p	-	1443	O
.	-	1444	O
)	-	1445	O
in	-	1447	O
the	-	1450	O
mouse	-	1454	O
passive	-	1460	O
-	-	1467	O
avoidance	-	1468	O
test	-	1478	O
.	-	1482	O

Affinity	9495837	1484	O
profiles	-	1493	O
of	-	1502	O
(	-	1505	O
+	-	1506	O
/	-	1507	O
-	-	1508	O
)	-	1509	O
-	-	1510	O
PG	-	1511	B
-	-	1513	I
9	-	1514	I
for	-	1516	O
muscarinic	-	1520	O
receptor	-	1531	O
subtypes	-	1540	O
,	-	1548	O
determined	-	1550	O
by	-	1561	O
functional	-	1564	O
studies	-	1575	O
(	-	1583	O
rabbit	-	1584	O
vas	-	1591	O
deferens	-	1595	O
for	-	1604	O
M1	-	1608	O
,	-	1610	O
guinea	-	1612	O
pig	-	1619	O
atrium	-	1623	O
for	-	1630	O
M2	-	1634	O
,	-	1636	O
guinea	-	1638	O
pig	-	1645	O
ileum	-	1649	O
for	-	1655	O
M3	-	1659	O
and	-	1662	O
immature	-	1666	O
guinea	-	1675	O
pig	-	1682	O
uterus	-	1686	O
for	-	1693	O
putative	-	1697	O
M4	-	1706	O
)	-	1708	O
,	-	1709	O
have	-	1711	O
shown	-	1716	O
an	-	1722	O
M4	-	1725	O
/	-	1727	O
M1	-	1728	O
selectivity	-	1731	O
ratio	-	1743	O
of	-	1749	O
10	-	1752	O
.	-	1754	O
2	-	1755	O
that	-	1757	O
might	-	1762	O
be	-	1768	O
responsible	-	1771	O
for	-	1783	O
the	-	1787	O
antinociception	-	1791	O
and	-	1807	O
the	-	1811	O
anti	-	1815	O
-	-	1819	O
amnesic	-	1820	O
effect	-	1828	O
induced	-	1835	O
by	-	1843	O
(	-	1846	O
+	-	1847	O
/	-	1848	O
-	-	1849	O
)	-	1850	O
-	-	1851	O
PG	-	1852	B
-	-	1854	I
9	-	1855	I
through	-	1857	O
an	-	1865	O
increase	-	1868	O
in	-	1877	O
acetylcholine	-	1880	B
extracellular	-	1894	O
levels	-	1908	O
.	-	1914	O

In	9495837	1916	O
the	-	1919	O
antinociceptive	-	1923	O
and	-	1939	O
antiamnesic	-	1943	O
dose	-	1955	O
range	-	1960	O
,	-	1965	O
(	-	1967	O
+	-	1968	O
/	-	1969	O
-	-	1970	O
)	-	1971	O
-	-	1972	O
PG	-	1973	B
-	-	1975	I
9	-	1976	I
did	-	1978	O
not	-	1982	O
impair	-	1986	O
mouse	-	1993	O
performance	-	1999	O
evaluated	-	2011	O
by	-	2021	O
the	-	2024	O
rota	-	2028	O
-	-	2032	O
rod	-	2033	O
test	-	2037	O
and	-	2042	O
Animex	-	2046	O
apparatus	-	2053	O
.	-	2062	O

Hyperbaric	1468485	0	O
oxygen	-	11	B
therapy	-	18	O
for	-	26	O
control	-	30	O
of	-	38	O
intractable	-	41	O
cyclophosphamide	-	53	B
-	-	69	O
induced	-	70	O
hemorrhagic	-	78	O
cystitis	-	90	O
.	-	98	O

We	1468485	100	O
report	-	103	O
a	-	110	O
case	-	112	O
of	-	117	O
intractable	-	120	O
hemorrhagic	-	132	O
cystitis	-	144	O
due	-	153	O
to	-	157	O
cyclophosphamide	-	160	B
therapy	-	177	O
for	-	185	O
Wegener	-	189	O
's	-	196	O
granulomatosis	-	199	O
.	-	213	O

Conservative	1468485	215	O
treatment	-	228	O
,	-	237	O
including	-	239	O
bladder	-	249	O
irrigation	-	257	O
with	-	268	O
physiological	-	273	O
saline	-	287	O
and	-	294	O
instillation	-	298	O
of	-	311	O
prostaglandin	-	314	B
F2	-	328	I
alpha	-	331	I
,	-	336	O
failed	-	338	O
to	-	345	O
totally	-	348	O
control	-	356	O
hemorrhage	-	364	O
.	-	374	O

We	1468485	376	O
then	-	379	O
used	-	384	O
hyperbaric	-	389	O
oxygen	-	400	B
at	-	407	O
an	-	410	O
absolute	-	413	O
pressure	-	422	O
of	-	431	O
2	-	434	O
atm	-	436	O
,	-	439	O
5	-	441	O
days	-	443	O
a	-	448	O
week	-	450	O
for	-	455	O
8	-	459	O
consecutive	-	461	O
weeks	-	473	O
.	-	478	O

The	1468485	480	O
bleeding	-	484	O
ceased	-	493	O
completely	-	500	O
by	-	511	O
the	-	514	O
end	-	518	O
of	-	522	O
treatment	-	525	O
and	-	535	O
the	-	539	O
patient	-	543	O
remained	-	551	O
free	-	560	O
of	-	565	O
hematuria	-	568	O
thereafter	-	578	O
.	-	588	O

No	1468485	590	O
side	-	593	O
effect	-	598	O
was	-	605	O
noted	-	609	O
during	-	615	O
the	-	622	O
course	-	626	O
of	-	633	O
therapy	-	636	O
.	-	643	O

In	1468485	645	O
future	-	648	O
,	-	654	O
this	-	656	O
form	-	661	O
of	-	666	O
therapy	-	669	O
can	-	677	O
offer	-	681	O
a	-	687	O
safe	-	689	O
alternative	-	694	O
in	-	706	O
the	-	709	O
treatment	-	713	O
of	-	723	O
cyclophosphamide	-	726	B
-	-	742	O
induced	-	743	O
hemorrhagic	-	751	O
cystitis	-	763	O
.	-	771	O

Further	1009330	0	O
studies	-	8	O
on	-	16	O
effects	-	19	O
of	-	27	O
irrigation	-	30	O
solutions	-	41	O
on	-	51	O
rat	-	54	O
bladders	-	58	O
.	-	66	O

Further	1009330	68	O
studies	-	76	O
on	-	84	O
the	-	87	O
effects	-	91	O
of	-	99	O
certain	-	102	O
irrigating	-	110	O
fluids	-	121	O
on	-	128	O
the	-	131	O
rat	-	135	O
bladder	-	139	O
for	-	147	O
18	-	151	O
hours	-	154	O
are	-	160	O
reported	-	164	O
.	-	172	O

The	1009330	174	O
results	-	178	O
have	-	186	O
shown	-	191	O
that	-	197	O
the	-	202	O
degradation	-	206	O
product	-	218	O
p	-	226	B
-	-	227	I
choloroaniline	-	228	I
is	-	243	O
not	-	246	O
a	-	250	O
significant	-	252	O
factor	-	264	O
in	-	271	O
chlorhexidine	-	274	B
-	-	287	I
digluconate	-	288	I
associated	-	300	O
erosive	-	311	O
cystitis	-	319	O
.	-	327	O

A	1009330	329	O
high	-	331	O
percentage	-	336	O
of	-	347	O
kanamycin	-	350	B
-	-	359	O
colistin	-	360	B
and	-	369	O
povidone	-	373	B
-	-	381	I
iodine	-	382	I
irrigations	-	389	O
were	-	401	O
associated	-	406	O
with	-	417	O
erosive	-	422	O
cystitis	-	430	O
and	-	439	O
suggested	-	443	O
a	-	453	O
possible	-	455	O
complication	-	464	O
with	-	477	O
human	-	482	O
usage	-	488	O
.	-	493	O

Picloxydine	1009330	495	B
irrigations	-	507	O
appeared	-	519	O
to	-	528	O
have	-	531	O
a	-	536	O
lower	-	538	O
incidence	-	544	O
of	-	554	O
erosive	-	557	O
cystitis	-	565	O
but	-	574	O
further	-	578	O
studies	-	586	O
would	-	594	O
have	-	600	O
to	-	605	O
be	-	608	O
performed	-	611	O
before	-	621	O
it	-	628	O
could	-	631	O
be	-	637	O
recommended	-	640	O
for	-	652	O
use	-	656	O
in	-	660	O
urological	-	663	O
procedures	-	674	O
.	-	684	O

Clinical	347884	0	O
experiences	-	9	O
in	-	21	O
an	-	24	O
open	-	27	O
and	-	32	O
a	-	36	O
double	-	38	O
-	-	44	O
blind	-	45	O
trial	-	51	O
.	-	56	O

A	347884	58	O
total	-	60	O
of	-	66	O
sixty	-	69	O
patients	-	75	O
were	-	84	O
trated	-	89	O
with	-	96	O
bromperidol	-	101	B
first	-	113	O
in	-	119	O
open	-	122	O
conditions	-	127	O
(	-	138	O
20	-	139	O
patients	-	142	O
)	-	150	O
,	-	151	O
then	-	153	O
on	-	158	O
a	-	161	O
double	-	163	O
blind	-	170	O
basis	-	176	O
(	-	182	O
40	-	183	O
patients	-	186	O
)	-	194	O
with	-	196	O
haloperidol	-	201	B
as	-	213	O
the	-	216	O
reference	-	220	O
substance	-	230	O
.	-	239	O

The	347884	241	O
open	-	245	O
study	-	250	O
lasted	-	256	O
for	-	263	O
four	-	267	O
weeks	-	272	O
;	-	277	O
the	-	279	O
drug	-	283	O
was	-	288	O
administrated	-	292	O
in	-	306	O
the	-	309	O
form	-	313	O
of	-	318	O
1	-	321	O
mg	-	323	O
tablets	-	326	O
.	-	333	O

The	347884	335	O
daily	-	339	O
dose	-	345	O
(	-	350	O
initial	-	351	O
dose	-	359	O
:	-	363	O
1	-	365	O
mg	-	367	O
;	-	369	O
mean	-	371	O
dose	-	376	O
at	-	381	O
the	-	384	O
end	-	388	O
of	-	392	O
the	-	395	O
trial	-	399	O
:	-	404	O
4	-	406	O
.	-	407	O
47	-	408	O
mg	-	411	O
)	-	413	O
was	-	415	O
always	-	419	O
administered	-	426	O
in	-	439	O
one	-	442	O
single	-	446	O
dose	-	453	O
.	-	457	O

Nineteen	347884	459	O
patients	-	468	O
finished	-	477	O
the	-	486	O
trial	-	490	O
,	-	495	O
and	-	497	O
in	-	501	O
18	-	504	O
cases	-	507	O
the	-	513	O
therapeutic	-	517	O
result	-	529	O
was	-	536	O
considered	-	540	O
very	-	551	O
good	-	556	O
to	-	561	O
good	-	564	O
.	-	568	O

These	347884	570	O
results	-	576	O
were	-	584	O
confirmed	-	589	O
by	-	599	O
statistical	-	602	O
analysis	-	614	O
.	-	622	O

Nine	347884	624	O
patients	-	629	O
exhibited	-	638	O
mild	-	648	O
to	-	653	O
moderate	-	656	O
extrapyramidal	-	665	O
concomitant	-	680	O
symptoms	-	692	O
;	-	700	O
no	-	702	O
other	-	705	O
side	-	711	O
effects	-	716	O
were	-	724	O
observed	-	729	O
.	-	737	O

The	347884	739	O
results	-	743	O
of	-	751	O
detailed	-	754	O
laboratory	-	763	O
tests	-	774	O
and	-	780	O
evaluations	-	784	O
of	-	796	O
various	-	799	O
quantitative	-	807	O
and	-	820	O
qualitative	-	824	O
tolerability	-	836	O
parameters	-	849	O
were	-	860	O
not	-	865	O
indicative	-	869	O
of	-	880	O
toxic	-	883	O
effects	-	889	O
.	-	896	O

In	347884	898	O
the	-	901	O
double	-	905	O
blind	-	912	O
study	-	918	O
with	-	924	O
haloperidol	-	929	B
,	-	940	O
both	-	942	O
substances	-	947	O
were	-	958	O
found	-	963	O
to	-	969	O
be	-	972	O
highly	-	975	O
effective	-	982	O
in	-	992	O
the	-	995	O
treatment	-	999	O
of	-	1009	O
psychotic	-	1012	O
syndromes	-	1022	O
belonging	-	1032	O
predominantly	-	1042	O
to	-	1056	O
the	-	1059	O
schizophrenia	-	1063	O
group	-	1077	O
.	-	1082	O

Certain	347884	1084	O
clues	-	1092	O
,	-	1097	O
including	-	1099	O
the	-	1109	O
onset	-	1113	O
of	-	1119	O
action	-	1122	O
,	-	1128	O
seem	-	1130	O
to	-	1135	O
be	-	1138	O
indicative	-	1141	O
of	-	1152	O
the	-	1155	O
superiority	-	1159	O
of	-	1171	O
bromperidol	-	1174	B
.	-	1185	O

No	347884	1187	O
differences	-	1190	O
were	-	1202	O
observed	-	1207	O
with	-	1216	O
respect	-	1221	O
to	-	1229	O
side	-	1232	O
effects	-	1237	O
and	-	1245	O
general	-	1249	O
tolerability	-	1257	O
.	-	1269	O

Curcumin	20667451	0	B
ameliorates	-	9	O
cognitive	-	21	O
dysfunction	-	31	O
and	-	43	O
oxidative	-	47	O
damage	-	57	O
in	-	64	O
phenobarbitone	-	67	B
and	-	82	O
carbamazepine	-	86	B
administered	-	100	O
rats	-	113	O
.	-	117	O

The	20667451	119	O
antiepileptic	-	123	O
drugs	-	137	O
,	-	142	O
phenobarbitone	-	144	B
and	-	159	O
carbamazepine	-	163	B
are	-	177	O
well	-	181	O
known	-	186	O
to	-	192	O
cause	-	195	O
cognitive	-	201	O
impairment	-	211	O
on	-	222	O
chronic	-	225	O
use	-	233	O
.	-	236	O

The	20667451	238	O
increase	-	242	O
in	-	251	O
free	-	254	O
radical	-	259	O
generation	-	267	O
has	-	278	O
been	-	282	O
implicated	-	287	O
as	-	298	O
one	-	301	O
of	-	305	O
the	-	308	O
important	-	312	O
mechanisms	-	322	O
of	-	333	O
cognitive	-	336	O
impairment	-	346	O
by	-	357	O
antiepileptic	-	360	O
drugs	-	374	O
.	-	379	O

Curcumin	20667451	381	B
has	-	390	O
shown	-	394	O
antioxidant	-	400	O
,	-	411	O
anti	-	413	O
-	-	417	O
inflammatory	-	418	O
and	-	431	O
neuro	-	435	O
-	-	440	O
protective	-	441	O
properties	-	452	O
.	-	462	O

Therefore	20667451	464	O
,	-	473	O
the	-	475	O
present	-	479	O
study	-	487	O
was	-	493	O
carried	-	497	O
out	-	505	O
to	-	509	O
investigate	-	512	O
the	-	524	O
effect	-	528	O
of	-	535	O
chronic	-	538	O
curcumin	-	546	B
administration	-	555	O
on	-	570	O
phenobarbitone	-	573	B
-	-	587	O
and	-	589	O
carbamazepine	-	593	B
-	-	606	O
induced	-	607	O
cognitive	-	615	O
impairment	-	625	O
and	-	636	O
oxidative	-	640	O
stress	-	650	O
in	-	657	O
rats	-	660	O
.	-	664	O

Pharmacokinetic	20667451	666	O
interactions	-	682	O
of	-	695	O
curcumin	-	698	B
with	-	707	O
phenobarbitone	-	712	B
and	-	727	O
carbamazepine	-	731	B
were	-	745	O
also	-	750	O
studied	-	755	O
.	-	762	O

Vehicle	20667451	764	O
/	-	771	O
drugs	-	772	O
were	-	778	O
administered	-	783	O
daily	-	796	O
for	-	802	O
21days	-	806	O
to	-	813	O
male	-	816	O
Wistar	-	821	O
rats	-	828	O
.	-	832	O

Passive	20667451	834	O
avoidance	-	842	O
paradigm	-	852	O
and	-	861	O
elevated	-	865	O
plus	-	874	O
maze	-	879	O
test	-	884	O
were	-	889	O
used	-	894	O
to	-	899	O
assess	-	902	O
cognitive	-	909	O
function	-	919	O
.	-	927	O

At	20667451	929	O
the	-	932	O
end	-	936	O
of	-	940	O
study	-	943	O
period	-	949	O
,	-	955	O
serum	-	957	O
phenobarbitone	-	963	B
and	-	978	O
carbamazepine	-	982	B
,	-	995	O
whole	-	997	O
brain	-	1003	O
malondialdehyde	-	1009	B
and	-	1025	O
reduced	-	1029	O
glutathione	-	1037	B
levels	-	1049	O
were	-	1056	O
estimated	-	1061	O
.	-	1070	O

The	20667451	1072	O
administration	-	1076	O
of	-	1091	O
phenobarbitone	-	1094	B
and	-	1109	O
carbamazepine	-	1113	B
for	-	1127	O
21days	-	1131	O
caused	-	1138	O
a	-	1145	O
significant	-	1147	O
impairment	-	1159	O
of	-	1170	O
learning	-	1173	O
and	-	1182	O
memory	-	1186	O
as	-	1193	O
well	-	1196	O
as	-	1201	O
an	-	1204	O
increased	-	1207	O
oxidative	-	1217	O
stress	-	1227	O
.	-	1233	O

Concomitant	20667451	1235	O
curcumin	-	1247	B
administration	-	1256	O
prevented	-	1271	O
the	-	1281	O
cognitive	-	1285	O
impairment	-	1295	O
and	-	1306	O
decreased	-	1310	O
the	-	1320	O
increased	-	1324	O
oxidative	-	1334	O
stress	-	1344	O
induced	-	1351	O
by	-	1359	O
these	-	1362	O
antiepileptic	-	1368	O
drugs	-	1382	O
.	-	1387	O

Curcumin	20667451	1389	B
co	-	1398	O
-	-	1400	O
administration	-	1401	O
did	-	1416	O
not	-	1420	O
cause	-	1424	O
any	-	1430	O
significant	-	1434	O
alteration	-	1446	O
in	-	1457	O
the	-	1460	O
serum	-	1464	O
concentrations	-	1470	O
of	-	1485	O
both	-	1488	O
phenobarbitone	-	1493	B
as	-	1508	O
well	-	1511	O
as	-	1516	O
carbamazepine	-	1519	B
.	-	1532	O

These	20667451	1534	O
results	-	1540	O
show	-	1548	O
that	-	1553	O
curcumin	-	1558	B
has	-	1567	O
beneficial	-	1571	O
effect	-	1582	O
in	-	1589	O
mitigating	-	1592	O
the	-	1603	O
deterioration	-	1607	O
of	-	1621	O
cognitive	-	1624	O
functions	-	1634	O
and	-	1644	O
oxidative	-	1648	O
damage	-	1658	O
in	-	1665	O
rats	-	1668	O
treated	-	1673	O
with	-	1681	O
phenobarbitone	-	1686	B
and	-	1701	O
carbamazepine	-	1705	B
without	-	1719	O
significantly	-	1727	O
altering	-	1741	O
their	-	1750	O
serum	-	1756	O
concentrations	-	1762	O
.	-	1776	O

The	20667451	1778	O
findings	-	1782	O
suggest	-	1791	O
that	-	1799	O
curcumin	-	1804	B
can	-	1813	O
be	-	1817	O
considered	-	1820	O
as	-	1831	O
a	-	1834	O
potential	-	1836	O
safe	-	1846	O
and	-	1851	O
effective	-	1855	O
adjuvant	-	1865	O
to	-	1874	O
phenobarbitone	-	1877	B
and	-	1892	O
carbamazepine	-	1896	B
therapy	-	1910	O
in	-	1918	O
preventing	-	1921	O
cognitive	-	1932	O
impairment	-	1942	O
associated	-	1953	O
with	-	1964	O
these	-	1969	O
drugs	-	1975	O
.	-	1980	O

Pyrrolidine	19767176	0	B
dithiocarbamate	-	12	I
protects	-	28	O
the	-	37	O
piriform	-	41	O
cortex	-	50	O
in	-	57	O
the	-	60	O
pilocarpine	-	64	B
status	-	76	O
epilepticus	-	83	O
model	-	95	O
.	-	100	O

Pyrrolidine	19767176	102	B
dithiocarbamate	-	114	I
(	-	130	O
PDTC	-	131	B
)	-	135	O
has	-	137	O
a	-	141	O
dual	-	143	O
mechanism	-	148	O
of	-	158	O
action	-	161	O
as	-	168	O
an	-	171	O
antioxidant	-	174	O
and	-	186	O
an	-	190	O
inhibitor	-	193	O
of	-	203	O
the	-	206	O
transcription	-	210	O
factor	-	224	O
kappa	-	231	O
-	-	236	O
beta	-	237	O
.	-	241	O

Both	19767176	243	O
,	-	247	O
production	-	249	O
of	-	260	O
reactive	-	263	O
oxygen	-	272	B
species	-	279	O
as	-	287	O
well	-	290	O
as	-	295	O
activation	-	298	O
of	-	309	O
NF	-	312	O
-	-	314	O
kappaB	-	315	O
have	-	322	O
been	-	327	O
implicated	-	332	O
in	-	343	O
severe	-	346	O
neuronal	-	353	O
damage	-	362	O
in	-	369	O
different	-	372	O
sub	-	382	O
-	-	385	O
regions	-	386	O
of	-	394	O
the	-	397	O
hippocampus	-	401	O
as	-	413	O
well	-	416	O
as	-	421	O
in	-	424	O
the	-	427	O
surrounding	-	431	O
cortices	-	443	O
.	-	451	O

The	19767176	453	O
effect	-	457	O
of	-	464	O
PDTC	-	467	B
on	-	472	O
status	-	475	O
epilepticus	-	482	O
-	-	493	O
associated	-	494	O
cell	-	505	O
loss	-	510	O
in	-	515	O
the	-	518	O
hippocampus	-	522	O
and	-	534	O
piriform	-	538	O
cortex	-	547	O
was	-	554	O
evaluated	-	558	O
in	-	568	O
the	-	571	O
rat	-	575	O
fractionated	-	579	O
pilocarpine	-	592	B
model	-	604	O
.	-	609	O

Treatment	19767176	611	O
with	-	621	O
150	-	626	O
mg	-	630	O
/	-	632	O
kg	-	633	O
PDTC	-	636	B
before	-	641	O
and	-	648	O
following	-	652	O
status	-	662	O
epilepticus	-	669	O
significantly	-	681	O
increased	-	695	O
the	-	705	O
mortality	-	709	O
rate	-	719	O
to	-	724	O
100	-	727	O
%	-	730	O
.	-	731	O

Administration	19767176	733	O
of	-	748	O
50	-	751	O
mg	-	754	O
/	-	756	O
kg	-	757	O
PDTC	-	760	B
(	-	765	O
low	-	766	O
-	-	769	O
dose	-	770	O
)	-	774	O
did	-	776	O
not	-	780	O
exert	-	784	O
major	-	790	O
effects	-	796	O
on	-	804	O
the	-	807	O
development	-	811	O
of	-	823	O
a	-	826	O
status	-	828	O
epilepticus	-	835	O
or	-	847	O
the	-	850	O
mortality	-	854	O
rate	-	864	O
.	-	868	O

In	19767176	870	O
vehicle	-	873	O
-	-	880	O
treated	-	881	O
rats	-	889	O
,	-	893	O
status	-	895	O
epilepticus	-	902	O
caused	-	914	O
pronounced	-	921	O
neuronal	-	932	O
damage	-	941	O
in	-	948	O
the	-	951	O
piriform	-	955	O
cortex	-	964	O
comprising	-	971	O
both	-	982	O
pyramidal	-	987	O
cells	-	997	O
and	-	1003	O
interneurons	-	1007	O
.	-	1019	O

Low	19767176	1021	O
-	-	1024	O
dose	-	1025	O
PDTC	-	1030	B
treatment	-	1035	O
almost	-	1045	O
completely	-	1052	O
protected	-	1063	O
from	-	1073	O
lesions	-	1078	O
in	-	1086	O
the	-	1089	O
piriform	-	1093	O
cortex	-	1102	O
.	-	1108	O

A	19767176	1110	O
significant	-	1112	O
decrease	-	1124	O
in	-	1133	O
neuronal	-	1136	O
density	-	1145	O
of	-	1153	O
the	-	1156	O
hippocampal	-	1160	O
hilar	-	1172	O
formation	-	1178	O
was	-	1188	O
identified	-	1192	O
in	-	1203	O
vehicle	-	1206	O
-	-	1213	O
and	-	1215	O
PDTC	-	1219	B
-	-	1223	O
treated	-	1224	O
rats	-	1232	O
following	-	1237	O
status	-	1247	O
epilepticus	-	1254	O
.	-	1265	O

In	19767176	1267	O
conclusion	-	1270	O
,	-	1280	O
the	-	1282	O
NF	-	1286	O
-	-	1288	O
kappaB	-	1289	O
inhibitor	-	1296	O
and	-	1306	O
antioxidant	-	1310	O
PDTC	-	1322	B
protected	-	1327	O
the	-	1337	O
piriform	-	1341	O
cortex	-	1350	O
,	-	1356	O
whereas	-	1358	O
it	-	1366	O
did	-	1369	O
not	-	1373	O
affect	-	1377	O
hilar	-	1384	O
neuronal	-	1390	O
loss	-	1399	O
.	-	1403	O

These	19767176	1405	O
data	-	1411	O
might	-	1416	O
indicate	-	1422	O
that	-	1431	O
the	-	1436	O
generation	-	1440	O
of	-	1451	O
reactive	-	1454	O
oxygen	-	1463	B
species	-	1470	O
and	-	1478	O
activation	-	1482	O
of	-	1493	O
NF	-	1496	O
-	-	1498	O
kappaB	-	1499	O
plays	-	1506	O
a	-	1512	O
more	-	1514	O
central	-	1519	O
role	-	1527	O
in	-	1532	O
seizure	-	1535	O
-	-	1542	O
associated	-	1543	O
neuronal	-	1554	O
damage	-	1563	O
in	-	1570	O
the	-	1573	O
temporal	-	1577	O
cortex	-	1586	O
as	-	1593	O
compared	-	1596	O
to	-	1605	O
the	-	1608	O
hippocampal	-	1612	O
hilus	-	1624	O
.	-	1629	O

However	19767176	1631	O
,	-	1638	O
future	-	1640	O
investigations	-	1647	O
are	-	1662	O
necessary	-	1666	O
to	-	1676	O
exactly	-	1679	O
analyze	-	1687	O
the	-	1695	O
biochemical	-	1699	O
mechanisms	-	1711	O
by	-	1722	O
which	-	1725	O
PDTC	-	1731	B
exerted	-	1736	O
its	-	1744	O
beneficial	-	1748	O
effects	-	1759	O
in	-	1767	O
the	-	1770	O
piriform	-	1774	O
cortex	-	1783	O
.	-	1789	O

Safety	16330293	0	O
profile	-	7	O
of	-	15	O
a	-	18	O
nicotine	-	20	B
lozenge	-	29	O
compared	-	37	O
with	-	46	O
that	-	51	O
of	-	56	O
nicotine	-	59	B
gum	-	68	O
in	-	72	O
adult	-	75	O
smokers	-	81	O
with	-	89	O
underlying	-	94	O
medical	-	105	O
conditions	-	113	O
:	-	123	O
a	-	125	O
12	-	127	O
-	-	129	O
week	-	130	O
,	-	134	O
randomized	-	136	O
,	-	146	O
open	-	148	O
-	-	152	O
label	-	153	O
study	-	159	O
.	-	164	O

BACKGROUND	16330293	166	O
:	-	176	O

Nicotine	16330293	178	B
polacrilex	-	187	O
lozenges	-	198	O
deliver	-	207	O
25	-	215	O
%	-	217	O
to	-	219	O
27	-	222	O
%	-	224	O
more	-	226	O
nicotine	-	231	B
compared	-	240	O
with	-	249	O
equivalent	-	254	O
doses	-	265	O
of	-	271	O
nicotine	-	274	B
polacrilex	-	283	O
gum	-	294	O
.	-	297	O

The	16330293	299	O
increased	-	303	O
nicotine	-	313	B
exposure	-	322	O
from	-	331	O
the	-	336	O
lozenge	-	340	O
has	-	348	O
raised	-	352	O
questions	-	359	O
about	-	369	O
the	-	375	O
relative	-	379	O
safety	-	388	O
of	-	395	O
the	-	398	O
lozenge	-	402	O
and	-	410	O
gum	-	414	O
.	-	417	O

OBJECTIVE	16330293	419	O
:	-	428	O
The	-	430	O
objective	-	434	O
of	-	444	O
this	-	447	O
study	-	452	O
was	-	458	O
to	-	462	O
compare	-	465	O
the	-	473	O
safety	-	477	O
profiles	-	484	O
of	-	493	O
the	-	496	O
4	-	500	O
-	-	501	O
mg	-	502	O
nicotine	-	505	B
lozenge	-	514	O
and	-	522	O
4	-	526	O
-	-	527	O
mg	-	528	O
nicotine	-	531	B
gum	-	540	O
in	-	544	O
smokers	-	547	O
with	-	555	O
selected	-	560	O
label	-	569	O
-	-	574	O
restricted	-	575	O
diseases	-	586	O
.	-	594	O

METHODS	16330293	596	O
:	-	603	O

This	16330293	605	O
was	-	610	O
a	-	614	O
multicenter	-	616	O
,	-	627	O
randomized	-	629	O
,	-	639	O
open	-	641	O
-	-	645	O
label	-	646	O
study	-	652	O
in	-	658	O
adult	-	661	O
smokers	-	667	O
with	-	675	O
heart	-	680	O
disease	-	686	O
,	-	693	O
hypertension	-	695	O
not	-	708	O
controlled	-	712	O
by	-	723	O
medication	-	726	O
,	-	736	O
and	-	738	O
/	-	741	O
or	-	742	O
diabetes	-	745	O
mellitus	-	754	O
.	-	762	O

Patients	16330293	764	O
were	-	773	O
randomized	-	778	O
in	-	789	O
a	-	792	O
1	-	794	O
:	-	795	O
1	-	796	O
ratio	-	798	O
to	-	804	O
receive	-	807	O
the	-	815	O
4	-	819	O
-	-	820	O
mg	-	821	O
nicotine	-	824	B
lozenge	-	833	O
or	-	841	O
4	-	844	O
-	-	845	O
mg	-	846	O
nicotine	-	849	B
gum	-	858	O
.	-	861	O

Safety	16330293	863	O
assessments	-	870	O
were	-	882	O
made	-	887	O
at	-	892	O
baseline	-	895	O
and	-	904	O
at	-	908	O
2	-	911	O
,	-	912	O
4	-	914	O
,	-	915	O
6	-	917	O
,	-	918	O
and	-	920	O
12	-	924	O
weeks	-	927	O
after	-	933	O
the	-	939	O
start	-	943	O
of	-	949	O
product	-	952	O
use	-	960	O
.	-	963	O

RESULTS	16330293	965	O
:	-	972	O

Nine	16330293	974	O
hundred	-	979	O
one	-	987	O
patients	-	991	O
were	-	1000	O
randomized	-	1005	O
to	-	1016	O
treatment	-	1019	O
,	-	1028	O
447	-	1030	O
who	-	1034	O
received	-	1038	O
the	-	1047	O
lozenge	-	1051	O
and	-	1059	O
454	-	1063	O
who	-	1067	O
received	-	1071	O
the	-	1080	O
gum	-	1084	O
(	-	1088	O
safety	-	1089	O
population	-	1096	O
)	-	1106	O
.	-	1107	O

The	16330293	1109	O
majority	-	1113	O
were	-	1122	O
women	-	1127	O
(	-	1133	O
52	-	1134	O
.	-	1136	O
7	-	1137	O
%	-	1138	O
)	-	1139	O
.	-	1140	O

Patients	16330293	1142	O
'	-	1150	O
mean	-	1152	O
age	-	1157	O
was	-	1161	O
53	-	1165	O
.	-	1167	O
9	-	1168	O
years	-	1170	O
,	-	1175	O
their	-	1177	O
mean	-	1183	O
weight	-	1188	O
was	-	1195	O
193	-	1199	O
.	-	1202	O
9	-	1203	O
pounds	-	1205	O
,	-	1211	O
and	-	1213	O
they	-	1217	O
smoked	-	1222	O
a	-	1229	O
mean	-	1231	O
of	-	1236	O
25	-	1239	O
.	-	1241	O
2	-	1242	O
cigarettes	-	1244	O
per	-	1255	O
day	-	1259	O
at	-	1263	O
baseline	-	1266	O
.	-	1274	O

Five	16330293	1276	O
hundred	-	1281	O
fifty	-	1289	O
-	-	1294	O
three	-	1295	O
patients	-	1301	O
,	-	1309	O
264	-	1311	O
taking	-	1315	O
the	-	1322	O
lozenge	-	1326	O
and	-	1334	O
289	-	1338	O
taking	-	1342	O
the	-	1349	O
gum	-	1353	O
,	-	1356	O
used	-	1358	O
the	-	1363	O
study	-	1367	O
product	-	1373	O
for	-	1381	O
>	-	1385	O
or	-	1387	O
=	-	1390	O
4	-	1391	O
days	-	1393	O
per	-	1398	O
week	-	1402	O
during	-	1407	O
the	-	1414	O
first	-	1418	O
2	-	1424	O
weeks	-	1426	O
(	-	1432	O
evaluable	-	1433	O
population	-	1443	O
)	-	1453	O
.	-	1454	O

The	16330293	1456	O
nicotine	-	1460	B
lozenge	-	1469	O
and	-	1477	O
nicotine	-	1481	B
gum	-	1490	O
were	-	1494	O
equally	-	1499	O
well	-	1507	O
tolerated	-	1512	O
,	-	1521	O
despite	-	1523	O
increased	-	1531	O
nicotine	-	1541	B
exposure	-	1550	O
from	-	1559	O
the	-	1564	O
lozenge	-	1568	O
.	-	1575	O

The	16330293	1577	O
incidence	-	1581	O
of	-	1591	O
adverse	-	1594	O
events	-	1602	O
in	-	1609	O
the	-	1612	O
2	-	1616	O
groups	-	1618	O
was	-	1625	O
similar	-	1629	O
during	-	1637	O
the	-	1644	O
first	-	1648	O
2	-	1654	O
weeks	-	1656	O
of	-	1662	O
product	-	1665	O
use	-	1673	O
(	-	1677	O
evaluation	-	1678	O
population	-	1689	O
:	-	1699	O
55	-	1701	O
.	-	1703	O
3	-	1704	O
%	-	1705	O
lozenge	-	1707	O
,	-	1714	O
54	-	1716	O
.	-	1718	O
7	-	1719	O
%	-	1720	O
gum	-	1722	O
)	-	1725	O
,	-	1726	O
as	-	1728	O
well	-	1731	O
as	-	1736	O
during	-	1739	O
the	-	1746	O
entire	-	1750	O
study	-	1757	O
(	-	1763	O
safety	-	1764	O
population	-	1771	O
:	-	1781	O
63	-	1783	O
.	-	1785	O
8	-	1786	O
%	-	1787	O
and	-	1789	O
58	-	1793	O
.	-	1795	O
6	-	1796	O
%	-	1797	O
,	-	1798	O
respectively	-	1800	O
)	-	1812	O
.	-	1813	O

Stratification	16330293	1815	O
of	-	1830	O
patients	-	1833	O
by	-	1842	O
sex	-	1845	O
,	-	1848	O
age	-	1850	O
,	-	1853	O
extent	-	1855	O
of	-	1862	O
concurrent	-	1865	O
smoking	-	1876	O
,	-	1883	O
extent	-	1885	O
of	-	1892	O
product	-	1895	O
use	-	1903	O
,	-	1906	O
and	-	1908	O
severity	-	1912	O
of	-	1921	O
adverse	-	1924	O
events	-	1932	O
revealed	-	1939	O
no	-	1948	O
clinically	-	1951	O
significant	-	1962	O
differences	-	1974	O
between	-	1986	O
the	-	1994	O
lozenge	-	1998	O
and	-	2006	O
gum	-	2010	O
.	-	2013	O

The	16330293	2015	O
most	-	2019	O
common	-	2024	O
adverse	-	2031	O
events	-	2039	O
were	-	2046	O
nausea	-	2051	O
(	-	2058	O
17	-	2059	O
.	-	2061	O
2	-	2062	O
%	-	2063	O
and	-	2065	O
16	-	2069	O
.	-	2071	O
1	-	2072	O
%	-	2073	O
;	-	2074	O
95	-	2076	O
%	-	2078	O
CI	-	2080	O
,	-	2082	O
-	-	2084	O
3	-	2085	O
.	-	2086	O
7	-	2087	O
to	-	2089	O
6	-	2092	O
.	-	2093	O
0	-	2094	O
)	-	2095	O
,	-	2096	O
hiccups	-	2098	O
(	-	2106	O
10	-	2107	O
.	-	2109	O
7	-	2110	O
%	-	2111	O
and	-	2113	O
6	-	2117	O
.	-	2118	O
6	-	2119	O
%	-	2120	O
;	-	2121	O
95	-	2123	O
%	-	2125	O
CI	-	2127	O
,	-	2129	O
0	-	2131	O
.	-	2132	O
5	-	2133	O
to	-	2135	O
7	-	2138	O
.	-	2139	O
8	-	2140	O
)	-	2141	O
,	-	2142	O
and	-	2144	O
headache	-	2148	O
(	-	2157	O
8	-	2158	O
.	-	2159	O
7	-	2160	O
%	-	2161	O
and	-	2163	O
9	-	2167	O
.	-	2168	O
9	-	2169	O
%	-	2170	O
;	-	2171	O
95	-	2173	O
%	-	2175	O
Cl	-	2177	O
,	-	2179	O
-	-	2181	O
5	-	2182	O
.	-	2183	O
0	-	2184	O
to	-	2186	O
2	-	2189	O
.	-	2190	O
6	-	2191	O
)	-	2192	O
.	-	2193	O

Serious	16330293	2195	O
adverse	-	2203	O
events	-	2211	O
were	-	2218	O
reported	-	2223	O
in	-	2232	O
11	-	2235	O
and	-	2238	O
13	-	2242	O
patients	-	2245	O
in	-	2254	O
the	-	2257	O
respective	-	2261	O
groups	-	2272	O
.	-	2278	O

Fewer	16330293	2280	O
than	-	2286	O
6	-	2291	O
%	-	2292	O
of	-	2294	O
patients	-	2297	O
in	-	2306	O
either	-	2309	O
group	-	2316	O
were	-	2322	O
considered	-	2327	O
by	-	2338	O
the	-	2341	O
investigator	-	2345	O
to	-	2358	O
have	-	2361	O
a	-	2366	O
worsening	-	2368	O
of	-	2378	O
their	-	2381	O
overall	-	2387	O
disease	-	2395	O
condition	-	2403	O
during	-	2413	O
the	-	2420	O
study	-	2424	O
.	-	2429	O

The	16330293	2431	O
majority	-	2435	O
of	-	2444	O
patients	-	2447	O
(	-	2456	O
>	-	2457	O
60	-	2458	O
%	-	2460	O
)	-	2461	O
experienced	-	2463	O
no	-	2475	O
change	-	2478	O
in	-	2485	O
their	-	2488	O
disease	-	2494	O
status	-	2502	O
from	-	2509	O
baseline	-	2514	O
.	-	2522	O

CONCLUSION	16330293	2524	O
:	-	2534	O

The	16330293	2536	O
4	-	2540	O
-	-	2541	O
mg	-	2542	O
nicotine	-	2545	B
lozenge	-	2554	O
and	-	2562	O
4	-	2566	O
-	-	2567	O
mg	-	2568	O
nicotine	-	2571	B
gum	-	2580	O
had	-	2584	O
comparable	-	2588	O
safety	-	2599	O
profiles	-	2606	O
in	-	2615	O
these	-	2618	O
patients	-	2624	O
with	-	2633	O
label	-	2638	O
-	-	2643	O
restricted	-	2644	O
medical	-	2655	O
conditions	-	2663	O
.	-	2673	O

Development	14568327	0	O
of	-	12	O
levodopa	-	15	B
-	-	23	O
induced	-	24	O
dyskinesias	-	32	O
in	-	44	O
parkinsonian	-	47	O
monkeys	-	60	O
may	-	68	O
depend	-	72	O
upon	-	79	O
rate	-	84	O
of	-	89	O
symptom	-	92	O
onset	-	100	O
and	-	106	O
/	-	109	O
or	-	110	O
duration	-	113	O
of	-	122	O
symptoms	-	125	O
.	-	133	O

Levodopa	14568327	135	B
-	-	143	O
induced	-	144	O
dyskinesias	-	152	O
(	-	164	O
LIDs	-	165	O
)	-	169	O
present	-	171	O
a	-	179	O
major	-	181	O
problem	-	187	O
for	-	195	O
the	-	199	O
long	-	203	O
-	-	207	O
term	-	208	O
management	-	213	O
of	-	224	O
Parkinson	-	227	O
's	-	236	O
disease	-	239	O
(	-	247	O
PD	-	248	O
)	-	250	O
patients	-	252	O
.	-	260	O

Due	14568327	262	O
to	-	266	O
the	-	269	O
interdependence	-	273	O
of	-	289	O
risk	-	292	O
factors	-	297	O
in	-	305	O
clinical	-	308	O
populations	-	317	O
,	-	328	O
it	-	330	O
is	-	333	O
difficult	-	336	O
to	-	346	O
independently	-	349	O
examine	-	363	O
factors	-	371	O
that	-	379	O
may	-	384	O
influence	-	388	O
the	-	398	O
development	-	402	O
of	-	414	O
LIDs	-	417	O
.	-	421	O

Using	14568327	423	O
macaque	-	429	O
monkeys	-	437	O
with	-	445	O
different	-	450	O
types	-	460	O
of	-	466	O
MPTP	-	469	B
-	-	473	O
induced	-	474	O
parkinsonism	-	482	O
,	-	494	O
the	-	496	O
current	-	500	O
study	-	508	O
evaluated	-	514	O
the	-	524	O
degree	-	528	O
to	-	535	O
which	-	538	O
rate	-	544	O
of	-	549	O
symptom	-	552	O
progression	-	560	O
,	-	571	O
symptom	-	573	O
severity	-	581	O
,	-	589	O
and	-	591	O
response	-	595	O
to	-	604	O
and	-	607	O
duration	-	611	O
of	-	620	O
levodopa	-	623	B
therapy	-	632	O
may	-	640	O
be	-	644	O
involved	-	647	O
in	-	656	O
the	-	659	O
development	-	663	O
of	-	675	O
LIDs	-	678	O
.	-	682	O

Monkeys	14568327	684	O
with	-	692	O
acute	-	697	O
(	-	703	O
short	-	704	O
-	-	709	O
term	-	710	O
)	-	714	O
MPTP	-	716	B
exposure	-	721	O
,	-	729	O
rapid	-	731	O
symptom	-	737	O
onset	-	745	O
and	-	751	O
short	-	755	O
symptom	-	761	O
duration	-	769	O
prior	-	778	O
to	-	784	O
initiation	-	787	O
of	-	798	O
levodopa	-	801	B
therapy	-	810	O
developed	-	818	O
dyskinesia	-	828	O
between	-	839	O
11	-	847	O
and	-	850	O
24	-	854	O
days	-	857	O
of	-	862	O
daily	-	865	O
levodopa	-	871	B
administration	-	880	O
.	-	894	O

In	14568327	896	O
contrast	-	899	O
,	-	907	O
monkeys	-	909	O
with	-	917	O
long	-	922	O
-	-	926	O
term	-	927	O
MPTP	-	932	B
exposure	-	937	O
,	-	945	O
slow	-	947	O
symptom	-	952	O
progression	-	960	O
and	-	972	O
/	-	975	O
or	-	976	O
long	-	979	O
symptom	-	984	O
duration	-	992	O
prior	-	1001	O
to	-	1007	O
initiation	-	1010	O
of	-	1021	O
levodopa	-	1024	B
therapy	-	1033	O
were	-	1041	O
more	-	1046	O
resistant	-	1051	O
to	-	1061	O
developing	-	1064	O
LIDs	-	1075	O
(	-	1080	O
e	-	1081	O
.	-	1082	O
g	-	1083	O
.	-	1084	O
,	-	1085	O
dyskinesia	-	1087	O
developed	-	1098	O
no	-	1108	O
sooner	-	1111	O
than	-	1118	O
146	-	1123	O
days	-	1127	O
of	-	1132	O
chronic	-	1135	O
levodopa	-	1143	B
administration	-	1152	O
)	-	1166	O
.	-	1167	O

All	14568327	1169	O
animals	-	1173	O
were	-	1181	O
similarly	-	1186	O
symptomatic	-	1196	O
at	-	1208	O
the	-	1211	O
start	-	1215	O
of	-	1221	O
levodopa	-	1224	B
treatment	-	1233	O
and	-	1243	O
had	-	1247	O
similar	-	1251	O
therapeutic	-	1259	O
responses	-	1271	O
to	-	1281	O
the	-	1284	O
drug	-	1288	O
.	-	1292	O

These	14568327	1294	O
data	-	1300	O
suggest	-	1305	O
distinct	-	1313	O
differences	-	1322	O
in	-	1334	O
the	-	1337	O
propensity	-	1341	O
to	-	1352	O
develop	-	1355	O
LIDs	-	1363	O
in	-	1368	O
monkeys	-	1371	O
with	-	1379	O
different	-	1384	O
rates	-	1394	O
of	-	1400	O
symptom	-	1403	O
progression	-	1411	O
or	-	1423	O
symptom	-	1426	O
durations	-	1434	O
prior	-	1444	O
to	-	1450	O
levodopa	-	1453	B
and	-	1462	O
demonstrate	-	1466	O
the	-	1478	O
value	-	1482	O
of	-	1488	O
these	-	1491	O
models	-	1497	O
for	-	1504	O
further	-	1508	O
studying	-	1516	O
the	-	1525	O
pathophysiology	-	1529	O
of	-	1545	O
LIDs	-	1548	O
.	-	1552	O

Propylthiouracil	11250767	0	B
-	-	16	O
induced	-	17	O
perinuclear	-	25	O
-	-	36	O
staining	-	37	O
antineutrophil	-	46	O
cytoplasmic	-	61	O
autoantibody	-	73	O
-	-	85	O
positive	-	86	O
vasculitis	-	95	O
in	-	106	O
conjunction	-	109	O
with	-	121	O
pericarditis	-	126	O
.	-	138	O

OBJECTIVE	11250767	140	O
:	-	149	O

To	11250767	151	O
describe	-	154	O
a	-	163	O
case	-	165	O
of	-	170	O
propylthiouracil	-	173	B
-	-	189	O
induced	-	190	O
vasculitis	-	198	O
manifesting	-	209	O
with	-	221	O
pericarditis	-	226	O
.	-	238	O

METHODS	11250767	240	O
:	-	247	O

We	11250767	249	O
present	-	252	O
the	-	260	O
first	-	264	O
case	-	270	O
report	-	275	O
of	-	282	O
a	-	285	O
woman	-	287	O
with	-	293	O
hyperthyroidism	-	298	O
treated	-	314	O
with	-	322	O
propylthiouracil	-	327	B
in	-	344	O
whom	-	347	O
a	-	352	O
syndrome	-	354	O
of	-	363	O
pericarditis	-	366	O
,	-	378	O
fever	-	380	O
,	-	385	O
and	-	387	O
glomerulonephritis	-	391	O
developed	-	410	O
.	-	419	O

Serologic	11250767	421	O
testing	-	431	O
and	-	439	O
immunologic	-	443	O
studies	-	455	O
were	-	463	O
done	-	468	O
,	-	472	O
and	-	474	O
a	-	478	O
pericardial	-	480	O
biopsy	-	492	O
was	-	499	O
performed	-	503	O
.	-	512	O

RESULTS	11250767	514	O
:	-	521	O

A	11250767	523	O
25	-	525	O
-	-	527	O
year	-	528	O
-	-	532	O
old	-	533	O
woman	-	537	O
with	-	543	O
Graves	-	548	O
'	-	554	O
disease	-	556	O
had	-	564	O
a	-	568	O
febrile	-	570	O
illness	-	578	O
and	-	586	O
evidence	-	590	O
of	-	599	O
pericarditis	-	602	O
,	-	614	O
which	-	616	O
was	-	622	O
confirmed	-	626	O
by	-	636	O
biopsy	-	639	O
.	-	645	O

Serologic	11250767	647	O
evaluation	-	657	O
revealed	-	668	O
the	-	677	O
presence	-	681	O
of	-	690	O
perinuclear	-	693	O
-	-	704	O
staining	-	705	O
antineutrophil	-	714	O
cytoplasmic	-	729	O
autoantibodies	-	741	O
(	-	756	O
pANCA	-	757	O
)	-	762	O
against	-	764	O
myeloperoxidase	-	772	O
(	-	788	O
MPO	-	789	O
)	-	792	O
.	-	793	O

Propylthiouracil	11250767	795	B
therapy	-	812	O
was	-	820	O
withdrawn	-	824	O
,	-	833	O
and	-	835	O
she	-	839	O
was	-	843	O
treated	-	847	O
with	-	855	O
a	-	860	O
1	-	862	O
-	-	863	O
month	-	864	O
course	-	870	O
of	-	877	O
prednisone	-	880	B
,	-	890	O
which	-	892	O
alleviated	-	898	O
her	-	909	O
symptoms	-	913	O
.	-	921	O

A	11250767	923	O
literature	-	925	O
review	-	936	O
revealed	-	943	O
no	-	952	O
prior	-	955	O
reports	-	961	O
of	-	969	O
pericarditis	-	972	O
in	-	985	O
anti	-	988	O
-	-	992	O
MPO	-	993	O
pANCA	-	997	O
-	-	1002	O
positive	-	1003	O
vasculitis	-	1012	O
associated	-	1023	O
with	-	1034	O
propylthio	-	1039	B
-	-	1049	I
uracil	-	1051	I
therapy	-	1058	O
.	-	1065	O

CONCLUSION	11250767	1067	O
:	-	1077	O

Pericarditis	11250767	1079	O
may	-	1092	O
be	-	1096	O
the	-	1099	O
initial	-	1103	O
manifestation	-	1111	O
of	-	1125	O
drug	-	1128	O
-	-	1132	O
induced	-	1133	O
vasculitis	-	1141	O
attributable	-	1152	O
to	-	1165	O
propylthio	-	1168	B
-	-	1178	I
uracil	-	1180	I
therapy	-	1187	O
.	-	1194	O

Two	11206082	0	O
mouse	-	4	O
lines	-	10	O
selected	-	16	O
for	-	25	O
differential	-	29	O
sensitivities	-	42	O
to	-	56	O
beta	-	59	B
-	-	63	I
carboline	-	64	I
-	-	73	O
induced	-	74	O
seizures	-	82	O
are	-	91	O
also	-	95	O
differentially	-	100	O
sensitive	-	115	O
to	-	125	O
various	-	128	O
pharmacological	-	136	O
effects	-	152	O
of	-	160	O
other	-	163	O
GABA	-	169	B
(	-	173	O
A	-	174	O
)	-	175	O
receptor	-	177	O
ligands	-	186	O
.	-	193	O

Two	11206082	195	O
mouse	-	199	O
lines	-	205	O
were	-	211	O
selectively	-	216	O
bred	-	228	O
according	-	233	O
to	-	243	O
their	-	246	O
sensitivity	-	252	O
(	-	264	O
BS	-	265	O
line	-	268	O
)	-	272	O
or	-	274	O
resistance	-	277	O
(	-	288	O
BR	-	289	O
line	-	292	O
)	-	296	O
to	-	298	O
seizures	-	301	O
induced	-	310	O
by	-	318	O
a	-	321	O
single	-	323	O
i	-	330	O
.	-	331	O
p	-	332	O
.	-	333	O

injection	11206082	335	O
of	-	345	O
methyl	-	348	B
beta	-	355	I
-	-	359	I
carboline	-	360	I
-	-	369	I
3	-	370	I
-	-	371	I
carboxylate	-	372	I
(	-	384	O
beta	-	385	B
-	-	389	I
CCM	-	390	I
)	-	393	O
,	-	394	O
an	-	396	O
inverse	-	399	O
agonist	-	407	O
of	-	415	O
the	-	418	O
GABA	-	422	B
(	-	426	O
A	-	427	O
)	-	428	O
receptor	-	430	O
benzodiazepine	-	439	B
site	-	454	O
.	-	458	O

Our	11206082	460	O
aim	-	464	O
was	-	468	O
to	-	472	O
characterize	-	475	O
both	-	488	O
lines	-	493	O
'	-	498	O
sensitivities	-	500	O
to	-	514	O
various	-	517	O
physiological	-	525	O
effects	-	539	O
of	-	547	O
other	-	550	O
ligands	-	556	O
of	-	564	O
the	-	567	O
GABA	-	571	B
(	-	575	O
A	-	576	O
)	-	577	O
receptor	-	579	O
.	-	587	O

We	11206082	589	O
measured	-	592	O
diazepam	-	601	B
-	-	609	O
induced	-	610	O
anxiolysis	-	618	O
with	-	629	O
the	-	634	O
elevated	-	638	O
plus	-	647	O
-	-	651	O
maze	-	652	O
test	-	657	O
,	-	661	O
diazepam	-	663	B
-	-	671	O
induced	-	672	O
sedation	-	680	O
by	-	689	O
recording	-	692	O
the	-	702	O
vigilance	-	706	O
states	-	716	O
,	-	722	O
and	-	724	O
picrotoxin	-	728	B
-	-	738	O
and	-	740	O
pentylenetetrazol	-	744	B
-	-	761	O
induced	-	762	O
seizures	-	770	O
after	-	779	O
i	-	785	O
.	-	786	O
p	-	787	O
.	-	788	O

injections	11206082	790	O
.	-	800	O

Results	11206082	802	O
presented	-	810	O
here	-	820	O
show	-	825	O
that	-	830	O
the	-	835	O
differential	-	839	O
sensitivities	-	852	O
of	-	866	O
BS	-	869	O
and	-	872	O
BR	-	876	O
lines	-	879	O
to	-	885	O
beta	-	888	B
-	-	892	I
CCM	-	893	I
can	-	897	O
be	-	901	O
extended	-	904	O
to	-	913	O
diazepam	-	916	B
,	-	924	O
picrotoxin	-	926	B
,	-	936	O
and	-	938	O
pentylenetetrazol	-	942	B
,	-	959	O
suggesting	-	961	O
a	-	972	O
genetic	-	974	O
selection	-	982	O
of	-	992	O
a	-	995	O
general	-	997	O
sensitivity	-	1005	O
and	-	1017	O
resistance	-	1021	O
to	-	1032	O
several	-	1035	O
ligands	-	1043	O
of	-	1051	O
the	-	1054	O
GABA	-	1058	B
(	-	1062	O
A	-	1063	O
)	-	1064	O
receptor	-	1066	O
.	-	1074	O

Analgesic	11027905	0	O
effect	-	10	O
of	-	17	O
intravenous	-	20	O
ketamine	-	32	B
in	-	41	O
cancer	-	44	O
patients	-	51	O
on	-	60	O
morphine	-	63	B
therapy	-	72	O
:	-	79	O
a	-	81	O
randomized	-	83	O
,	-	93	O
controlled	-	95	O
,	-	105	O
double	-	107	O
-	-	113	O
blind	-	114	O
,	-	119	O
crossover	-	121	O
,	-	130	O
double	-	132	O
-	-	138	O
dose	-	139	O
study	-	144	O
.	-	149	O

Pain	11027905	151	O
not	-	156	O
responsive	-	160	O
to	-	171	O
morphine	-	174	B
is	-	183	O
often	-	186	O
problematic	-	192	O
.	-	203	O

Animal	11027905	205	O
and	-	212	O
clinical	-	216	O
studies	-	225	O
have	-	233	O
suggested	-	238	O
that	-	248	O
N	-	253	B
-	-	254	I
methyl	-	255	I
-	-	261	I
D	-	262	I
-	-	263	I
aspartate	-	264	I
(	-	274	O
NMDA	-	275	B
)	-	279	O
antagonists	-	281	O
,	-	292	O
such	-	294	O
as	-	299	O
ketamine	-	302	B
,	-	310	O
may	-	312	O
be	-	316	O
effective	-	319	O
in	-	329	O
improving	-	332	O
opioid	-	342	O
analgesia	-	349	O
in	-	359	O
difficult	-	362	O
pain	-	372	O
syndromes	-	377	O
,	-	386	O
such	-	388	O
as	-	393	O
neuropathic	-	396	O
pain	-	408	O
.	-	412	O

A	11027905	414	O
slow	-	416	O
bolus	-	421	O
of	-	427	O
subhypnotic	-	430	O
doses	-	442	O
of	-	448	O
ketamine	-	451	B
(	-	460	O
0	-	461	O
.	-	462	O
25	-	463	O
mg	-	466	O
/	-	468	O
kg	-	469	O
or	-	472	O
0	-	475	O
.	-	476	O
50	-	477	O
mg	-	480	O
/	-	482	O
kg	-	483	O
)	-	485	O
was	-	487	O
given	-	491	O
to	-	497	O
10	-	500	O
cancer	-	503	O
patients	-	510	O
whose	-	519	O
pain	-	525	O
was	-	530	O
unrelieved	-	534	O
by	-	545	O
morphine	-	548	B
in	-	557	O
a	-	560	O
randomized	-	562	O
,	-	572	O
double	-	574	O
-	-	580	O
blind	-	581	O
,	-	586	O
crossover	-	588	O
,	-	597	O
double	-	599	O
-	-	605	O
dose	-	606	O
study	-	611	O
.	-	616	O

Pain	11027905	618	O
intensity	-	623	O
on	-	633	O
a	-	636	O
0	-	638	O
to	-	640	O
10	-	643	O
numerical	-	646	O
scale	-	656	O
;	-	661	O
nausea	-	663	O
and	-	670	O
vomiting	-	674	O
,	-	682	O
drowsiness	-	684	O
,	-	694	O
confusion	-	696	O
,	-	705	O
and	-	707	O
dry	-	711	O
mouth	-	715	O
,	-	720	O
using	-	722	O
a	-	728	O
scale	-	730	O
from	-	736	O
0	-	741	O
to	-	743	O
3	-	746	O
(	-	748	O
not	-	749	O
at	-	753	O
all	-	756	O
,	-	759	O
slight	-	761	O
,	-	767	O
a	-	769	O
lot	-	771	O
,	-	774	O
awful	-	776	O
)	-	781	O
;	-	782	O
Mini	-	784	O
-	-	788	O
Mental	-	789	O
State	-	796	O
Examination	-	802	O
(	-	814	O
MMSE	-	815	O
)	-	819	O
(	-	821	O
0	-	822	O
-	-	823	O
30	-	824	O
)	-	826	O
;	-	827	O
and	-	829	O
arterial	-	833	O
pressure	-	842	O
were	-	851	O
recorded	-	856	O
before	-	865	O
administration	-	872	O
of	-	887	O
drugs	-	890	O
(	-	896	O
T0	-	897	O
)	-	899	O
and	-	901	O
after	-	905	O
30	-	911	O
minutes	-	914	O
(	-	922	O
T30	-	923	O
)	-	926	O
,	-	927	O
60	-	929	O
minutes	-	932	O
(	-	940	O
T60	-	941	O
)	-	944	O
,	-	945	O
120	-	947	O
minutes	-	951	O
(	-	959	O
T120	-	960	O
)	-	964	O
,	-	965	O
and	-	967	O
180	-	971	O
minutes	-	975	O
(	-	983	O
T180	-	984	O
)	-	988	O
.	-	989	O

Ketamine	11027905	991	B
,	-	999	O
but	-	1001	O
not	-	1005	O
saline	-	1009	O
solution	-	1016	O
,	-	1024	O
significantly	-	1026	O
reduced	-	1040	O
the	-	1048	O
pain	-	1052	O
intensity	-	1057	O
in	-	1067	O
almost	-	1070	O
all	-	1077	O
the	-	1081	O
patients	-	1085	O
at	-	1094	O
both	-	1097	O
doses	-	1102	O
.	-	1107	O

This	11027905	1109	O
effect	-	1114	O
was	-	1121	O
more	-	1125	O
relevant	-	1130	O
in	-	1139	O
patients	-	1142	O
treated	-	1151	O
with	-	1159	O
higher	-	1164	O
doses	-	1171	O
.	-	1176	O

Hallucinations	11027905	1178	O
occurred	-	1193	O
in	-	1202	O
4	-	1205	O
patients	-	1207	O
,	-	1215	O
and	-	1217	O
an	-	1221	O
unpleasant	-	1224	O
sensation	-	1235	O
(	-	1245	O
""""	-	1246	O
empty	-	1247	O
head	-	1253	O
""""	-	1257	O
)	-	1258	O
was	-	1260	O
also	-	1264	O
reported	-	1269	O
by	-	1278	O
2	-	1281	O
patients	-	1283	O
.	-	1291	O

These	11027905	1293	O
episodes	-	1299	O
reversed	-	1308	O
after	-	1317	O
the	-	1323	O
administration	-	1327	O
of	-	1342	O
diazepam	-	1345	B
1	-	1354	O
mg	-	1356	O
intravenously	-	1359	O
.	-	1372	O

Significant	11027905	1374	O
increases	-	1386	O
in	-	1396	O
drowsiness	-	1399	O
were	-	1410	O
reported	-	1415	O
in	-	1424	O
patients	-	1427	O
treated	-	1436	O
with	-	1444	O
ketamine	-	1449	B
in	-	1458	O
both	-	1461	O
groups	-	1466	O
and	-	1473	O
were	-	1477	O
more	-	1482	O
marked	-	1487	O
with	-	1494	O
ketamine	-	1499	B
0	-	1508	O
.	-	1509	O
50	-	1510	O
mg	-	1513	O
/	-	1515	O
kg	-	1516	O
.	-	1518	O

A	11027905	1520	O
significant	-	1522	O
difference	-	1534	O
in	-	1545	O
MMSE	-	1548	O
was	-	1553	O
observed	-	1557	O
at	-	1566	O
T30	-	1569	O
in	-	1573	O
patients	-	1576	O
who	-	1585	O
received	-	1589	O
0	-	1598	O
.	-	1599	O
50	-	1600	O
mg	-	1603	O
/	-	1605	O
kg	-	1606	O
of	-	1609	O
ketamine	-	1612	B
.	-	1620	O

Ketamine	11027905	1622	B
can	-	1631	O
improve	-	1635	O
morphine	-	1643	B
analgesia	-	1652	O
in	-	1662	O
difficult	-	1665	O
pain	-	1675	O
syndromes	-	1680	O
,	-	1689	O
such	-	1691	O
as	-	1696	O
neuropathic	-	1699	O
pain	-	1711	O
.	-	1715	O

However	11027905	1717	O
,	-	1724	O
the	-	1726	O
occurrence	-	1730	O
of	-	1741	O
central	-	1744	O
adverse	-	1752	O
effects	-	1760	O
should	-	1768	O
be	-	1775	O
taken	-	1778	O
into	-	1784	O
account	-	1789	O
,	-	1796	O
especially	-	1798	O
when	-	1809	O
using	-	1814	O
higher	-	1820	O
doses	-	1827	O
.	-	1832	O

This	11027905	1834	O
observation	-	1839	O
should	-	1851	O
be	-	1858	O
tested	-	1861	O
in	-	1868	O
studies	-	1871	O
of	-	1879	O
prolonged	-	1882	O
ketamine	-	1892	B
administration	-	1901	O
.	-	1915	O

Endocrine	9334596	0	O
screening	-	10	O
in	-	20	O
1	-	23	O
,	-	24	O
022	-	25	O
men	-	29	O
with	-	33	O
erectile	-	38	O
dysfunction	-	47	O
:	-	58	O
clinical	-	60	O
significance	-	69	O
and	-	82	O
cost	-	86	O
-	-	90	O
effective	-	91	O
strategy	-	101	O
.	-	109	O

PURPOSE	9334596	111	O
:	-	118	O

We	9334596	120	O
reviewed	-	123	O
the	-	132	O
results	-	136	O
of	-	144	O
serum	-	147	O
testosterone	-	153	B
and	-	166	O
prolactin	-	170	O
determination	-	180	O
in	-	194	O
1	-	197	O
,	-	198	O
022	-	199	O
patients	-	203	O
referred	-	212	O
because	-	221	O
of	-	229	O
erectile	-	232	O
dysfunction	-	241	O
and	-	253	O
compared	-	257	O
the	-	266	O
data	-	270	O
with	-	275	O
history	-	280	O
,	-	287	O
results	-	289	O
of	-	297	O
physical	-	300	O
examination	-	309	O
,	-	320	O
other	-	322	O
etiological	-	328	O
investigations	-	340	O
and	-	355	O
effects	-	359	O
of	-	367	O
endocrine	-	370	O
therapy	-	380	O
to	-	388	O
refine	-	391	O
the	-	398	O
rules	-	402	O
of	-	408	O
cost	-	411	O
-	-	415	O
effective	-	416	O
endocrine	-	426	O
screening	-	436	O
and	-	446	O
to	-	450	O
pinpoint	-	453	O
actual	-	462	O
responsibility	-	469	O
for	-	484	O
hormonal	-	488	O
abnormalities	-	497	O
.	-	510	O

MATERIALS	9334596	512	O
AND	-	522	O
METHODS	-	526	O
:	-	533	O

Testosterone	9334596	535	B
and	-	548	O
prolactin	-	552	O
were	-	562	O
determined	-	567	O
by	-	578	O
radioimmunoassay	-	581	O
.	-	597	O

Every	9334596	599	O
patient	-	605	O
was	-	613	O
screened	-	617	O
for	-	626	O
testosterone	-	630	B
and	-	643	O
451	-	647	O
were	-	651	O
screened	-	656	O
for	-	665	O
prolactin	-	669	O
on	-	679	O
the	-	682	O
basis	-	686	O
of	-	692	O
low	-	695	O
sexual	-	699	O
desire	-	706	O
,	-	712	O
gynecomastia	-	714	O
or	-	727	O
testosterone	-	730	B

less	9334596	743	O
than	-	748	O
4	-	753	O
ng	-	755	O
.	-	757	O
/	-	758	O
ml	-	759	O
.	-	761	O

Determination	9334596	763	O
was	-	777	O
repeated	-	781	O
in	-	790	O
case	-	793	O
of	-	798	O
abnormal	-	801	O
first	-	810	O
results	-	816	O
.	-	823	O

Prolactin	9334596	825	O
results	-	835	O
were	-	843	O
compared	-	848	O
with	-	857	O
those	-	862	O
of	-	868	O
a	-	871	O
previous	-	873	O
personal	-	882	O
cohort	-	891	O
of	-	898	O
1	-	901	O
,	-	902	O
340	-	903	O
patients	-	907	O
with	-	916	O
erectile	-	921	O
dysfunction	-	930	O
and	-	942	O
systematic	-	946	O
prolactin	-	957	O
determination	-	967	O
.	-	980	O

Main	9334596	982	O
clinical	-	987	O
criteria	-	996	O
tested	-	1005	O
regarding	-	1012	O
efficiency	-	1022	O
in	-	1033	O
hormone	-	1036	O
determination	-	1044	O
were	-	1058	O
low	-	1063	O
sexual	-	1067	O
desire	-	1074	O
,	-	1080	O
small	-	1082	O
testes	-	1088	O
and	-	1095	O
gynecomastia	-	1099	O
.	-	1111	O

Endocrine	9334596	1113	O
therapy	-	1123	O
consisted	-	1131	O
of	-	1141	O
testosterone	-	1144	B
heptylate	-	1157	I
or	-	1167	O
human	-	1170	O
chorionic	-	1176	O
gonadotropin	-	1186	O
for	-	1199	O
hypogonadism	-	1203	O
and	-	1216	O
bromocriptine	-	1220	B
for	-	1234	O
hyperprolactinemia	-	1238	O
.	-	1256	O

RESULTS	9334596	1258	O
:	-	1265	O

Testosterone	9334596	1267	B
was	-	1280	O
less	-	1284	O
than	-	1289	O
3	-	1294	O
ng	-	1296	O
.	-	1298	O
/	-	1299	O
ml	-	1300	O
.	-	1302	O

in	9334596	1304	O
107	-	1307	O
patients	-	1311	O
but	-	1320	O
normal	-	1324	O
in	-	1331	O
40	-	1334	O
%	-	1336	O
at	-	1338	O
repeat	-	1341	O
determination	-	1348	O
.	-	1361	O

The	9334596	1363	O
prevalence	-	1367	O
of	-	1378	O
repeatedly	-	1381	O
low	-	1392	O
testosterone	-	1396	B
increased	-	1409	O
with	-	1419	O
age	-	1424	O
(	-	1428	O
4	-	1429	O
%	-	1430	O
before	-	1432	O
age	-	1439	O
50	-	1443	O
years	-	1446	O
and	-	1452	O
9	-	1456	O
%	-	1457	O
50	-	1459	O
years	-	1462	O
or	-	1468	O
older	-	1471	O
)	-	1476	O
.	-	1477	O

Two	9334596	1479	O
pituitary	-	1483	O
tumors	-	1493	O
were	-	1500	O
discovered	-	1505	O
after	-	1516	O
testosterone	-	1522	B
determination	-	1535	O
.	-	1548	O

Most	9334596	1550	O
of	-	1555	O
the	-	1558	O
other	-	1562	O
low	-	1568	O
testosterone	-	1572	B
levels	-	1585	O
seemed	-	1592	O
to	-	1599	O
result	-	1602	O
from	-	1609	O
nonorganic	-	1614	O
hypothalamic	-	1625	O
dysfunction	-	1638	O
because	-	1650	O
of	-	1658	O
normal	-	1661	O
serum	-	1668	O
luteinizing	-	1674	O
hormone	-	1686	O
and	-	1694	O
prolactin	-	1698	O
and	-	1708	O
to	-	1712	O
have	-	1715	O
only	-	1720	O
a	-	1725	O
small	-	1727	O
role	-	1733	O
in	-	1738	O
erectile	-	1741	O
dysfunction	-	1750	O
(	-	1762	O
definite	-	1763	O
improvement	-	1772	O
in	-	1784	O
only	-	1787	O
16	-	1792	O
of	-	1795	O
44	-	1798	O
[	-	1801	O
36	-	1802	O
%	-	1804	O
]	-	1805	O
after	-	1807	O
androgen	-	1813	O
therapy	-	1822	O
,	-	1829	O
normal	-	1831	O
morning	-	1838	O
or	-	1846	O
nocturnal	-	1849	O
erections	-	1859	O
in	-	1869	O
30	-	1872	O
%	-	1874	O
and	-	1876	O
definite	-	1880	O
vasculogenic	-	1889	O
contributions	-	1902	O
in	-	1916	O
42	-	1919	O
%	-	1921	O
)	-	1922	O
.	-	1923	O

Determining	9334596	1925	O
testosterone	-	1937	B
only	-	1950	O
in	-	1955	O
cases	-	1958	O
of	-	1964	O
low	-	1967	O
sexual	-	1971	O
desire	-	1978	O
or	-	1985	O
abnormal	-	1988	O
physical	-	1997	O
examination	-	2006	O
would	-	2018	O
have	-	2024	O
missed	-	2029	O
40	-	2036	O
%	-	2038	O
of	-	2040	O
the	-	2043	O
cases	-	2047	O
with	-	2053	O
low	-	2058	O
testosterone	-	2062	B
,	-	2074	O
including	-	2076	O
37	-	2086	O
%	-	2088	O
of	-	2090	O
those	-	2093	O
subsequently	-	2099	O
improved	-	2112	O
by	-	2121	O
androgen	-	2124	O
therapy	-	2133	O
.	-	2140	O

Prolactin	9334596	2142	O
exceeded	-	2152	O
20	-	2161	O
ng	-	2164	O
.	-	2166	O
/	-	2167	O
ml	-	2168	O
.	-	2170	O

in	9334596	2172	O
5	-	2175	O
men	-	2177	O
and	-	2181	O
was	-	2185	O
normal	-	2189	O
in	-	2196	O
2	-	2199	O
at	-	2201	O
repeat	-	2204	O
determination	-	2211	O
.	-	2224	O

Only	9334596	2226	O
1	-	2231	O
prolactinoma	-	2233	O
was	-	2246	O
discovered	-	2250	O
.	-	2260	O

These	9334596	2262	O
data	-	2268	O
are	-	2273	O
lower	-	2277	O
than	-	2283	O
those	-	2288	O
we	-	2294	O
found	-	2297	O
during	-	2303	O
the	-	2310	O
last	-	2314	O
2	-	2319	O
decades	-	2321	O
(	-	2329	O
overall	-	2330	O
prolactin	-	2338	O
greater	-	2348	O
than	-	2356	O
20	-	2361	O
ng	-	2364	O
.	-	2366	O
/	-	2367	O
ml	-	2368	O
.	-	2370	O

in	9334596	2372	O
1	-	2375	O
.	-	2376	O
86	-	2377	O
%	-	2379	O
of	-	2381	O
1	-	2384	O
,	-	2385	O
821	-	2386	O
patients	-	2390	O
,	-	2398	O
prolactinomas	-	2400	O
in	-	2414	O
7	-	2417	O
,	-	2418	O
0	-	2420	O
.	-	2421	O
38	-	2422	O
%	-	2424	O
)	-	2425	O
.	-	2426	O

Bromocriptine	9334596	2428	B
was	-	2442	O
definitely	-	2446	O
effective	-	2457	O
in	-	2467	O
cases	-	2470	O
with	-	2476	O
prolactin	-	2481	O
greater	-	2491	O
than	-	2499	O
35	-	2504	O
ng	-	2507	O
.	-	2509	O
/	-	2510	O
ml	-	2511	O
.	-	2513	O

(	9334596	2515	O
8	-	2516	O
of	-	2518	O
12	-	2521	O
compared	-	2524	O
to	-	2533	O
only	-	2536	O
9	-	2541	O
of	-	2543	O
22	-	2546	O
cases	-	2549	O
with	-	2555	O
prolactin	-	2560	O
between	-	2570	O
20	-	2578	O
and	-	2581	O
35	-	2585	O
ng	-	2588	O
.	-	2590	O
/	-	2591	O
ml	-	2592	O
.	-	2594	O
)	-	2595	O
.	-	2596	O

Testosterone	9334596	2598	B
was	-	2611	O
low	-	2615	O
in	-	2619	O
less	-	2622	O
than	-	2627	O
50	-	2632	O
%	-	2634	O
of	-	2636	O
cases	-	2639	O
with	-	2645	O
prolactin	-	2650	O
greater	-	2660	O
than	-	2668	O
35	-	2673	O
ng	-	2676	O
.	-	2678	O
/	-	2679	O
ml	-	2680	O
.	-	2682	O

CONCLUSIONS	9334596	2684	O
:	-	2695	O

Low	9334596	2697	O
prevalences	-	2701	O
and	-	2713	O
effects	-	2717	O
of	-	2725	O
low	-	2728	O
testosterone	-	2732	B
and	-	2745	O
high	-	2749	O
prolactin	-	2754	O
in	-	2764	O
erectile	-	2767	O
dysfunction	-	2776	O
can	-	2788	O
not	-	2791	O
justify	-	2795	O
their	-	2803	O
routine	-	2809	O
determination	-	2817	O
.	-	2830	O

However	9334596	2832	O
,	-	2839	O
cost	-	2841	O
-	-	2845	O
effective	-	2846	O
screening	-	2856	O
strategies	-	2866	O
recommended	-	2877	O
so	-	2889	O
far	-	2892	O
missed	-	2896	O
40	-	2903	O
to	-	2906	O
50	-	2909	O
%	-	2911	O
of	-	2913	O
cases	-	2916	O
improved	-	2922	O
with	-	2931	O
endocrine	-	2936	O
therapy	-	2946	O
and	-	2954	O
the	-	2958	O
pituitary	-	2962	O
tumors	-	2972	O
.	-	2978	O

We	9334596	2980	O
now	-	2983	O
advocate	-	2987	O
that	-	2996	O
before	-	3001	O
age	-	3008	O
50	-	3012	O
years	-	3015	O
testosterone	-	3021	B
be	-	3034	O
determined	-	3037	O
only	-	3048	O
in	-	3053	O
cases	-	3056	O
of	-	3062	O
low	-	3065	O
sexual	-	3069	O
desire	-	3076	O
and	-	3083	O
abnormal	-	3087	O
physical	-	3096	O
examination	-	3105	O
but	-	3117	O
that	-	3121	O
it	-	3126	O
be	-	3129	O
measured	-	3132	O
in	-	3141	O
all	-	3144	O
men	-	3148	O
older	-	3152	O
than	-	3158	O
50	-	3163	O
years	-	3166	O
.	-	3171	O

Prolactin	9334596	3173	O
should	-	3183	O
be	-	3190	O
determined	-	3193	O
only	-	3204	O
in	-	3209	O
cases	-	3212	O
of	-	3218	O
low	-	3221	O
sexual	-	3225	O
desire	-	3232	O
,	-	3238	O
gynecomastia	-	3240	O
and	-	3253	O
/	-	3256	O
or	-	3257	O
testosterone	-	3260	B
less	-	3273	O
than	-	3278	O
4	-	3283	O
ng	-	3285	O
.	-	3287	O
/	-	3288	O
ml	-	3289	O
.	-	3291	O

Thiopentone	8595686	0	B
pretreatment	-	12	O
for	-	25	O
propofol	-	29	B
injection	-	38	O
pain	-	48	O
in	-	53	O
ambulatory	-	56	O
patients	-	67	O
.	-	75	O

This	8595686	77	O
study	-	82	O
investigated	-	88	O
propofol	-	101	B
injection	-	110	O
pain	-	120	O
in	-	125	O
patients	-	128	O
undergoing	-	137	O
ambulatory	-	148	O
anaesthesia	-	159	O
.	-	170	O

In	8595686	172	O
a	-	175	O
randomized	-	177	O
,	-	187	O
double	-	189	O
-	-	195	O
blind	-	196	O
trial	-	202	O
,	-	207	O
90	-	209	O
women	-	212	O
were	-	218	O
allocated	-	223	O
to	-	233	O
receive	-	236	O
one	-	244	O
of	-	248	O
three	-	251	O
treatments	-	257	O
prior	-	268	O
to	-	274	O
induction	-	277	O
of	-	287	O
anaesthesia	-	290	O
with	-	302	O
propofol	-	307	B
.	-	315	O

Patients	8595686	317	O
in	-	326	O
Group	-	329	O
C	-	335	O
received	-	337	O
2	-	346	O
ml	-	348	O
normal	-	351	O
saline	-	358	O
,	-	364	O
Group	-	366	O
L	-	372	O
,	-	373	O
2	-	375	O
ml	-	377	O
,	-	379	O
lidocaine	-	381	B
2	-	391	O
%	-	392	O
(	-	394	O
40	-	395	O
mg	-	398	O
)	-	400	O
and	-	402	O
Group	-	406	O
T	-	412	O
,	-	413	O
2	-	415	O
ml	-	417	O

thiopentone	8595686	420	B
2	-	432	O
.	-	433	O
5	-	434	O
%	-	435	O
(	-	437	O
50	-	438	O
mg	-	441	O
)	-	443	O
.	-	444	O

Venous	8595686	446	O
discomfort	-	453	O
was	-	464	O
assessed	-	468	O
with	-	477	O
a	-	482	O
visual	-	484	O
analogue	-	491	O
scale	-	500	O
(	-	506	O
VAS	-	507	O
)	-	510	O
5	-	512	O
-	-	513	O
15	-	514	O
sec	-	517	O
after	-	521	O
commencing	-	527	O
propofol	-	538	B
administration	-	547	O
using	-	562	O
an	-	568	O
infusion	-	571	O
pump	-	580	O
(	-	585	O
rate	-	586	O
1000	-	591	O
micrograms	-	596	O
.	-	606	O
kg	-	607	O
-	-	609	O
1	-	610	O
.	-	611	O
min	-	612	O
-	-	615	O
1	-	616	O
)	-	617	O
.	-	618	O

Loss	8595686	620	O
of	-	625	O
consciousness	-	628	O
occurred	-	642	O
in	-	651	O
60	-	654	O
-	-	656	O
90	-	657	O
sec	-	660	O
.	-	663	O

Visual	8595686	665	O
analogue	-	672	O
scores	-	681	O
(	-	688	O
mean	-	689	O
+	-	694	O
/	-	695	O
-	-	696	O

SD	8595686	698	O
)	-	700	O
during	-	702	O
induction	-	709	O
were	-	719	O
lower	-	724	O
in	-	730	O
Groups	-	733	O
L	-	740	O
(	-	742	O
3	-	743	O
.	-	744	O
3	-	745	O
+	-	747	O
/	-	748	O
-	-	749	O

2	8595686	751	O
.	-	752	O
5	-	753	O
)	-	754	O
and	-	756	O
T	-	760	O
(	-	762	O
4	-	763	O
.	-	764	O
1	-	765	O
+	-	767	O
/	-	768	O
-	-	769	O
2	-	771	O
.	-	772	O
7	-	773	O
)	-	774	O
than	-	776	O
in	-	781	O
Group	-	784	O
C	-	790	O
(	-	792	O
5	-	793	O
.	-	794	O
6	-	795	O
+	-	797	O
/	-	798	O
-	-	799	O

2	8595686	801	O
.	-	802	O
3	-	803	O
)	-	804	O
;	-	805	O
P	-	807	O
=	-	809	O
0	-	811	O
.	-	812	O
0031	-	813	O
.	-	817	O

The	8595686	819	O
incidence	-	823	O
of	-	833	O
venous	-	836	O
discomfort	-	843	O
was	-	854	O
lower	-	858	O
in	-	864	O
Group	-	867	O
L	-	873	O
(	-	875	O
76	-	876	O
.	-	878	O
6	-	879	O
%	-	880	O
;	-	881	O
P	-	883	O
<	-	885	O
0	-	887	O
.	-	888	O
05	-	889	O
)	-	891	O
than	-	893	O
in	-	898	O
Group	-	901	O
C	-	907	O
(	-	909	O
100	-	910	O
%	-	913	O
)	-	914	O
but	-	916	O
not	-	920	O
different	-	924	O
from	-	934	O
Group	-	939	O
T	-	945	O
(	-	947	O
90	-	948	O
%	-	950	O
)	-	951	O
.	-	952	O

The	8595686	954	O
VAS	-	958	O
scores	-	962	O
for	-	969	O
recall	-	973	O
of	-	980	O
pain	-	983	O
in	-	988	O
the	-	991	O
recovery	-	995	O
room	-	1004	O
were	-	1009	O
correlated	-	1014	O
with	-	1025	O
the	-	1030	O
VAS	-	1034	O
scores	-	1038	O
during	-	1045	O
induction	-	1052	O
(	-	1062	O
r	-	1063	O
=	-	1065	O
0	-	1067	O
.	-	1068	O
7045	-	1069	O
;	-	1073	O
P	-	1075	O
<	-	1077	O
0	-	1079	O
.	-	1080	O
0001	-	1081	O
)	-	1085	O
.	-	1086	O

Recovery	8595686	1088	O
room	-	1097	O
discharge	-	1102	O
times	-	1112	O
were	-	1118	O
similar	-	1123	O
:	-	1130	O
C	-	1132	O
(	-	1134	O
75	-	1135	O
.	-	1137	O
9	-	1138	O
+	-	1140	O
/	-	1141	O
-	-	1142	O

19	8595686	1144	O
.	-	1146	O
4	-	1147	O
min	-	1149	O
)	-	1152	O
;	-	1153	O
L	-	1155	O
73	-	1157	O
.	-	1159	O
6	-	1160	O
+	-	1162	O
/	-	1163	O
-	-	1164	O

21	8595686	1166	O
.	-	1168	O
6	-	1169	O
min	-	1171	O
)	-	1174	O
;	-	1175	O
T	-	1177	O
(	-	1179	O
77	-	1180	O
.	-	1182	O
1	-	1183	O
+	-	1185	O
/	-	1186	O
-	-	1187	O

18	8595686	1189	O
.	-	1191	O
9	-	1192	O
min	-	1194	O
)	-	1197	O
.	-	1198	O

Assessing	8595686	1200	O
their	-	1210	O
overall	-	1216	O
satisfaction	-	1224	O
,	-	1236	O
89	-	1238	O
.	-	1240	O
7	-	1241	O
%	-	1242	O
would	-	1244	O
choose	-	1250	O
propofol	-	1257	B
anaesthesia	-	1266	O
again	-	1278	O
.	-	1283	O

We	8595686	1285	O
conclude	-	1288	O
that	-	1297	O
lidocaine	-	1302	B
reduces	-	1312	O
the	-	1320	O
incidence	-	1324	O
and	-	1334	O
severity	-	1338	O
of	-	1347	O
propofol	-	1350	B
injection	-	1359	O
pain	-	1369	O
in	-	1374	O
ambulatory	-	1377	O
patients	-	1388	O
whereas	-	1397	O
thiopentone	-	1405	B
only	-	1417	O
reduces	-	1422	O
its	-	1430	O
severity	-	1434	O
.	-	1442	O

Comparison	6466532	0	O
of	-	11	O
i	-	14	O
.	-	15	O
v	-	16	O
.	-	17	O

glycopyrrolate	6466532	19	B
and	-	34	O
atropine	-	38	B
in	-	47	O
the	-	50	O
prevention	-	54	O
of	-	65	O
bradycardia	-	68	O
and	-	80	O
arrhythmias	-	84	O
following	-	96	O
repeated	-	106	O
doses	-	115	O
of	-	121	O
suxamethonium	-	124	B
in	-	138	O
children	-	141	O
.	-	149	O

The	6466532	151	O
effectiveness	-	155	O
of	-	169	O
administration	-	172	O
of	-	187	O
glycopyrrolate	-	190	B
5	-	205	O
and	-	207	O
10	-	211	O
micrograms	-	214	O
kg	-	225	O
-	-	227	O
1	-	228	O
and	-	230	O
atropine	-	234	B
10	-	243	O
and	-	246	O
20	-	250	O
micrograms	-	253	O
kg	-	264	O
-	-	266	O
1	-	267	O
i	-	269	O
.	-	270	O
v	-	271	O
.	-	272	O

immediately	6466532	274	O
before	-	286	O
the	-	293	O
induction	-	297	O
of	-	307	O
anaesthesia	-	310	O
,	-	321	O
to	-	323	O
prevent	-	326	O
arrhythmia	-	334	O
and	-	345	O
bradycardia	-	349	O
following	-	361	O
repeated	-	371	O
doses	-	380	O
of	-	386	O
suxamethonium	-	389	B
in	-	403	O
children	-	406	O
,	-	414	O
was	-	416	O
studied	-	420	O
.	-	427	O

A	6466532	429	O
control	-	431	O
group	-	439	O
was	-	445	O
included	-	449	O
for	-	458	O
comparison	-	462	O
with	-	473	O
the	-	478	O
lower	-	482	O
dose	-	488	O
range	-	493	O
of	-	499	O
glycopyrrolate	-	502	B
and	-	517	O
atropine	-	521	B
.	-	529	O

A	6466532	531	O
frequency	-	533	O
of	-	543	O
bradycardia	-	546	O
of	-	558	O
50	-	561	O
%	-	563	O
was	-	565	O
noted	-	569	O
in	-	575	O
the	-	578	O
control	-	582	O
group	-	590	O
,	-	595	O
but	-	597	O
this	-	601	O
was	-	606	O
not	-	610	O
significantly	-	614	O
different	-	628	O
from	-	638	O
the	-	643	O
frequency	-	647	O
with	-	657	O
the	-	662	O
active	-	666	O
drugs	-	673	O
.	-	678	O

Bradycardia	6466532	680	O
(	-	692	O
defined	-	693	O
as	-	701	O
a	-	704	O
decrease	-	706	O
in	-	715	O
heart	-	718	O
rate	-	724	O
to	-	729	O
less	-	732	O
than	-	737	O
50	-	742	O
beat	-	745	O
min	-	750	O
-	-	753	O
1	-	754	O
)	-	755	O
was	-	757	O
prevented	-	761	O
when	-	771	O
the	-	776	O
larger	-	780	O
dose	-	787	O
of	-	792	O
either	-	795	O
active	-	802	O
drug	-	809	O
was	-	814	O
used	-	818	O
.	-	822	O

It	6466532	824	O
is	-	827	O
recommended	-	830	O
that	-	842	O
either	-	847	O
glycopyrrolate	-	854	B
10	-	869	O
micrograms	-	872	O
kg	-	883	O
-	-	885	O
1	-	886	O
or	-	888	O
atropine	-	891	B
20	-	900	O
micrograms	-	903	O
kg	-	914	O
-	-	916	O
1	-	917	O
i	-	919	O
.	-	920	O
v	-	921	O
.	-	922	O
should	-	924	O
immediately	-	931	O
precede	-	943	O
induction	-	951	O
of	-	961	O
anaesthesia	-	964	O
,	-	975	O
in	-	977	O
children	-	980	O
,	-	988	O
if	-	990	O
the	-	993	O
repeated	-	997	O
administration	-	1006	O
of	-	1021	O
suxamethonium	-	1024	B
is	-	1038	O
anticipated	-	1041	O
.	-	1052	O

Reduction	6308277	0	O
in	-	10	O
caffeine	-	13	B
toxicity	-	22	O
by	-	31	O
acetaminophen	-	34	B
.	-	47	O

A	6308277	49	O
patient	-	51	O
who	-	59	O
allegedly	-	63	O
consumed	-	73	O
100	-	82	O
tablets	-	86	O
of	-	94	O
an	-	97	O
over	-	100	O
-	-	104	O
the	-	105	O
-	-	108	O
counter	-	109	O
analgesic	-	117	O
containing	-	127	O
sodium	-	138	B
acetylsalicylate	-	145	I
,	-	161	O
caffeine	-	163	B
,	-	171	O
and	-	173	O
acetaminophen	-	177	B
displayed	-	191	O
no	-	201	O
significant	-	204	O
CNS	-	216	O
stimulation	-	220	O
despite	-	232	O
the	-	240	O
presence	-	244	O
of	-	253	O
175	-	256	O
micrograms	-	260	O
of	-	271	O
caffeine	-	274	B
per	-	283	O
mL	-	287	O
of	-	290	O
serum	-	293	O
.	-	298	O

Because	6308277	300	O
salicylates	-	308	O
have	-	320	O
been	-	325	O
reported	-	330	O
to	-	339	O
augment	-	342	O
the	-	350	O
stimulatory	-	354	O
effects	-	366	O
of	-	374	O
caffeine	-	377	B
on	-	386	O
the	-	389	O
CNS	-	393	O
,	-	396	O
attention	-	398	O
was	-	408	O
focused	-	412	O
on	-	420	O
the	-	423	O
possibility	-	427	O
that	-	439	O
the	-	444	O
presence	-	448	O
of	-	457	O
acetaminophen	-	460	B
(	-	474	O
52	-	475	O
micrograms	-	478	O
/	-	488	O
mL	-	489	O
)	-	491	O
reduced	-	493	O
the	-	501	O
CNS	-	505	O
toxicity	-	509	O
of	-	518	O
caffeine	-	521	B
.	-	529	O

Studies	6308277	531	O
in	-	539	O
DBA	-	542	O
/	-	545	O
2J	-	546	O
mice	-	549	O
showed	-	554	O
that	-	561	O
:	-	565	O
1	-	567	O
)	-	568	O
pretreatment	-	570	O
with	-	583	O
acetaminophen	-	588	B
(	-	602	O
100	-	603	O
mg	-	607	O
/	-	609	O
kg	-	610	O
)	-	612	O
increased	-	614	O
the	-	624	O
interval	-	628	O
between	-	637	O
the	-	645	O
administration	-	649	O
of	-	664	O
caffeine	-	667	B
(	-	676	O
300	-	677	O
to	-	681	O
450	-	684	O
mg	-	688	O
/	-	690	O
kg	-	691	O
IP	-	694	O
)	-	696	O
and	-	698	O
the	-	702	O
onset	-	706	O
of	-	712	O
fatal	-	715	O
convulsions	-	721	O
by	-	733	O
a	-	736	O
factor	-	738	O
of	-	745	O
about	-	748	O
two	-	754	O
;	-	757	O
and	-	759	O
2	-	763	O
)	-	764	O
pretreatment	-	766	O
with	-	779	O
acetaminophen	-	784	B
(	-	798	O
75	-	799	O
mg	-	802	O
/	-	804	O
kg	-	805	O
)	-	807	O
reduced	-	809	O
the	-	817	O
incidence	-	821	O
of	-	831	O
audiogenic	-	834	O
seizures	-	845	O
produced	-	854	O
in	-	863	O
the	-	866	O
presence	-	870	O
of	-	879	O
caffeine	-	882	B
(	-	891	O
12	-	892	O
.	-	894	O
5	-	895	O
to	-	897	O
75	-	900	O
mg	-	903	O
/	-	905	O
kg	-	906	O
IP	-	909	O
)	-	911	O
.	-	912	O

The	6308277	914	O
frequency	-	918	O
of	-	928	O
sound	-	931	O
-	-	936	O
induced	-	937	O
seizures	-	945	O
after	-	954	O
12	-	960	O
.	-	962	O
5	-	963	O
or	-	965	O
25	-	968	O
mg	-	971	O
/	-	973	O
kg	-	974	O
caffeine	-	977	B
was	-	986	O
reduced	-	990	O
from	-	998	O
50	-	1003	O
to	-	1006	O
5	-	1009	O
%	-	1010	O
by	-	1012	O
acetaminophen	-	1015	B
.	-	1028	O

In	6308277	1030	O
the	-	1033	O
absence	-	1037	O
of	-	1045	O
caffeine	-	1048	B
,	-	1056	O
acetaminophen	-	1058	B
(	-	1072	O
up	-	1073	O
to	-	1076	O
300	-	1079	O
mg	-	1083	O
/	-	1085	O
kg	-	1086	O
)	-	1088	O
did	-	1090	O
not	-	1094	O
modify	-	1098	O
the	-	1105	O
seizures	-	1109	O
induced	-	1118	O
by	-	1126	O
maximal	-	1129	O
electroshock	-	1137	O
and	-	1150	O
did	-	1154	O
not	-	1158	O
alter	-	1162	O
the	-	1168	O
convulsant	-	1172	O
dose	-	1183	O
of	-	1188	O
pentylenetetrezol	-	1191	B
in	-	1209	O
mice	-	1212	O
(	-	1217	O
tests	-	1218	O
performed	-	1224	O
by	-	1234	O
the	-	1237	O
Anticonvulsant	-	1241	O
Screening	-	1256	O
Project	-	1266	O
of	-	1274	O
NINCDS	-	1277	O
)	-	1283	O
.	-	1284	O

Acetaminophen	6308277	1286	B
(	-	1300	O
up	-	1301	O
to	-	1304	O
150	-	1307	O
micrograms	-	1311	O
/	-	1321	O
mL	-	1322	O
)	-	1324	O
did	-	1326	O
not	-	1330	O
retard	-	1334	O
the	-	1341	O
incorporation	-	1345	O
of	-	1359	O
radioactive	-	1362	O
adenosine	-	1374	B
into	-	1384	O
ATP	-	1389	B
in	-	1393	O
slices	-	1396	O
of	-	1403	O
rat	-	1406	O
cerebral	-	1410	O
cortex	-	1419	O
.	-	1425	O

Thus	6308277	1427	O
the	-	1432	O
mechanism	-	1436	O
by	-	1446	O
which	-	1449	O
acetaminophen	-	1455	B
antagonizes	-	1469	O
the	-	1481	O
actions	-	1485	O
of	-	1493	O
caffeine	-	1496	B
in	-	1505	O
the	-	1508	O
CNS	-	1512	O
remains	-	1516	O
unknown	-	1524	O
.	-	1531	O

Flestolol	2870085	0	B
:	-	9	O
an	-	11	O
ultra	-	14	O
-	-	19	O
short	-	20	O
-	-	25	O
acting	-	26	O
beta	-	33	O
-	-	37	O
adrenergic	-	38	O
blocking	-	49	O
agent	-	58	O
.	-	63	O

Flestolol	2870085	65	B
(	-	75	O
ACC	-	76	B
-	-	79	I
9089	-	80	I
)	-	84	O
is	-	86	O
a	-	89	O
nonselective	-	91	O
,	-	103	O
competitive	-	105	O
,	-	116	O
ultra	-	118	O
-	-	123	O
short	-	124	O
-	-	129	O
acting	-	130	O
beta	-	137	O
-	-	141	O
adrenergic	-	142	O
blocking	-	153	O
agent	-	162	O
,	-	167	O
without	-	169	O
any	-	177	O
intrinsic	-	181	O
sympathomimetic	-	191	O
activity	-	207	O
.	-	215	O

Flestolol	2870085	217	B
is	-	227	O
metabolized	-	230	O
by	-	242	O
plasma	-	245	O
esterases	-	252	O
and	-	262	O
has	-	266	O
an	-	270	O
elimination	-	273	O
half	-	285	O
-	-	289	O
life	-	290	O
of	-	295	O
approximately	-	298	O
6	-	312	O
.	-	313	O
5	-	314	O
minutes	-	316	O
.	-	323	O

This	2870085	325	O
agent	-	330	O
was	-	336	O
well	-	340	O
tolerated	-	345	O
in	-	355	O
healthy	-	358	O
volunteers	-	366	O
at	-	377	O
doses	-	380	O
up	-	386	O
to	-	389	O
100	-	392	O
micrograms	-	396	O
/	-	406	O
kg	-	407	O
/	-	409	O
min	-	410	O
.	-	413	O

In	2870085	415	O
long	-	418	O
-	-	422	O
term	-	423	O
infusion	-	428	O
studies	-	437	O
,	-	444	O
flestolol	-	446	B
was	-	456	O
well	-	460	O
tolerated	-	465	O
at	-	475	O
the	-	478	O
effective	-	482	O
beta	-	492	O
-	-	496	O
blocking	-	497	O
dose	-	506	O
(	-	511	O
5	-	512	O
micrograms	-	514	O
/	-	524	O
kg	-	525	O
/	-	527	O
min	-	528	O
)	-	531	O
for	-	533	O
up	-	537	O
to	-	540	O
seven	-	543	O
days	-	549	O
.	-	553	O

Flestolol	2870085	555	B
blood	-	565	O
concentrations	-	571	O
increased	-	586	O
linearly	-	596	O
with	-	605	O
increasing	-	610	O
dose	-	621	O
and	-	626	O
good	-	630	O
correlation	-	635	O
exists	-	647	O
between	-	654	O
blood	-	662	O
concentrations	-	668	O
of	-	683	O
flestolol	-	686	B
and	-	696	O
beta	-	700	O
-	-	704	O
adrenergic	-	705	O
blockade	-	716	O
.	-	724	O

Flestolol	2870085	726	B
produced	-	736	O
a	-	745	O
dose	-	747	O
-	-	751	O
dependent	-	752	O
attenuation	-	762	O
of	-	774	O
isoproterenol	-	777	B
-	-	790	O
induced	-	791	O
tachycardia	-	799	O
.	-	810	O

Electrophysiologic	2870085	812	O
and	-	831	O
hemodynamic	-	835	O
effects	-	847	O
of	-	855	O
flestolol	-	858	B
are	-	868	O
similar	-	872	O
to	-	880	O
those	-	883	O
of	-	889	O
other	-	892	O
beta	-	898	O
blockers	-	903	O
.	-	911	O

In	2870085	913	O
contrast	-	916	O
with	-	925	O
other	-	930	O
beta	-	936	O
blockers	-	941	O
,	-	949	O
flestolol	-	951	B
-	-	960	O
induced	-	961	O
effects	-	969	O
reverse	-	977	O
rapidly	-	985	O
(	-	993	O
within	-	994	O
30	-	1001	O
minutes	-	1004	O
)	-	1011	O
following	-	1013	O
discontinuation	-	1023	O
because	-	1039	O
of	-	1047	O
its	-	1050	O
short	-	1054	O
half	-	1060	O
-	-	1064	O
life	-	1065	O
.	-	1069	O

Flestolol	2870085	1071	B
effectively	-	1081	O
reduced	-	1093	O
heart	-	1101	O
rate	-	1107	O
in	-	1112	O
patients	-	1115	O
with	-	1124	O
supraventricular	-	1129	O
tachyarrhythmia	-	1146	O
.	-	1161	O

In	2870085	1163	O
patients	-	1166	O
with	-	1175	O
unstable	-	1180	O
angina	-	1189	O
,	-	1195	O
flestolol	-	1197	B
infusion	-	1207	O
was	-	1216	O
found	-	1220	O
to	-	1226	O
be	-	1229	O
safe	-	1232	O
and	-	1237	O
effective	-	1241	O
in	-	1251	O
controlling	-	1254	O
chest	-	1266	O
pain	-	1272	O
.	-	1276	O

It	2870085	1278	O
is	-	1281	O
concluded	-	1284	O
that	-	1294	O
flestolol	-	1299	B
is	-	1309	O
a	-	1312	O
potent	-	1314	O
,	-	1320	O
well	-	1322	O
-	-	1326	O
tolerated	-	1327	O
,	-	1336	O
ultra	-	1338	O
-	-	1343	O
short	-	1344	O
-	-	1349	O
acting	-	1350	O
beta	-	1357	O
-	-	1361	O
adrenergic	-	1362	O
blocking	-	1373	O
agent	-	1382	O
.	-	1387	O

Use	2870085	1389	O
of	-	1393	O
flestolol	-	1396	B
in	-	1406	O
the	-	1409	O
critical	-	1413	O
care	-	1422	O
setting	-	1427	O
is	-	1435	O
currently	-	1438	O
undergoing	-	1448	O
investigation	-	1459	O
.	-	1472	O

Adverse	1639466	0	O
effect	-	8	O
of	-	15	O
the	-	18	O
calcium	-	22	B
channel	-	30	O
blocker	-	38	O
nitrendipine	-	46	B
on	-	59	O
nephrosclerosis	-	62	O
in	-	78	O
rats	-	81	O
with	-	86	O
renovascular	-	91	O
hypertension	-	104	O
.	-	116	O

The	1639466	118	O
effect	-	122	O
of	-	129	O
a	-	132	O
6	-	134	O
-	-	135	O
week	-	136	O
treatment	-	141	O
with	-	151	O
the	-	156	O
calcium	-	160	B
channel	-	168	O
blocker	-	176	O
nitrendipine	-	184	B
or	-	197	O
the	-	200	O
angiotensin	-	204	B
converting	-	216	O
enzyme	-	227	O
inhibitor	-	234	O
enalapril	-	244	B
on	-	254	O
blood	-	257	O
pressure	-	263	O
,	-	271	O
albuminuria	-	273	O
,	-	284	O
renal	-	286	O
hemodynamics	-	292	O
,	-	304	O
and	-	306	O
morphology	-	310	O
of	-	321	O
the	-	324	O
nonclipped	-	328	O
kidney	-	339	O
was	-	346	O
studied	-	350	O
in	-	358	O
rats	-	361	O
with	-	366	O
two	-	371	O
-	-	374	O
kidney	-	375	O
,	-	381	O
one	-	383	O
clip	-	387	O
renovascular	-	392	O
hypertension	-	405	O
.	-	417	O

Six	1639466	419	O
weeks	-	423	O
after	-	429	O
clipping	-	435	O
of	-	444	O
one	-	447	O
renal	-	451	O
artery	-	457	O
,	-	463	O
hypertensive	-	465	O
rats	-	478	O
(	-	483	O
178	-	484	O
+	-	488	O
/	-	489	O
-	-	490	O

4	1639466	492	O
mm	-	494	O
Hg	-	497	O
)	-	499	O
were	-	501	O
randomly	-	506	O
assigned	-	515	O
to	-	524	O
three	-	527	O
groups	-	533	O
:	-	539	O
untreated	-	541	O
hypertensive	-	551	O
controls	-	564	O
(	-	573	O
n	-	574	O
=	-	576	O
8	-	578	O
)	-	579	O
,	-	580	O
enalapril	-	582	B
-	-	591	O
treated	-	592	O
(	-	600	O
n	-	601	O
=	-	603	O
8	-	605	O
)	-	606	O
,	-	607	O
or	-	609	O
nitrendipine	-	612	B
-	-	624	O
treated	-	625	O
(	-	633	O
n	-	634	O
=	-	636	O
10	-	638	O
)	-	640	O
.	-	641	O

Sham	1639466	643	O
-	-	647	O
operated	-	648	O
rats	-	657	O
served	-	662	O
as	-	669	O
normotensive	-	672	O
controls	-	685	O
(	-	694	O
128	-	695	O
+	-	699	O
/	-	700	O
-	-	701	O
3	-	703	O
mm	-	705	O
Hg	-	708	O
,	-	710	O
n	-	712	O
=	-	714	O
8	-	716	O
)	-	717	O
.	-	718	O

After	1639466	720	O
6	-	726	O
weeks	-	728	O
of	-	734	O
treatment	-	737	O
,	-	746	O
renal	-	748	O
hemodynamics	-	754	O
(	-	767	O
glomerular	-	768	O
filtration	-	779	O
rate	-	790	O
and	-	795	O
renal	-	799	O
plasma	-	805	O
flow	-	812	O
)	-	816	O
were	-	818	O
measured	-	823	O
in	-	832	O
the	-	835	O
anesthetized	-	839	O
rats	-	852	O
.	-	856	O

Renal	1639466	858	O
tissue	-	864	O
was	-	871	O
obtained	-	875	O
for	-	884	O
determination	-	888	O
of	-	902	O
glomerular	-	905	O
size	-	916	O
and	-	921	O
sclerosis	-	925	O
.	-	934	O

Enalapril	1639466	936	B
but	-	946	O
not	-	950	O
nitrendipine	-	954	B
reduced	-	967	O
blood	-	975	O
pressure	-	981	O
significantly	-	990	O
.	-	1003	O

After	1639466	1005	O
6	-	1011	O
weeks	-	1013	O
of	-	1019	O
therapy	-	1022	O
,	-	1029	O
glomerular	-	1031	O
filtration	-	1042	O
rate	-	1053	O
was	-	1058	O
not	-	1062	O
different	-	1066	O
among	-	1076	O
the	-	1082	O
studied	-	1086	O
groups	-	1094	O
.	-	1100	O

Renal	1639466	1102	O
plasma	-	1108	O
flow	-	1115	O
increased	-	1120	O
,	-	1129	O
but	-	1131	O
albumin	-	1135	O
excretion	-	1143	O
and	-	1153	O
glomerulosclerosis	-	1157	O
did	-	1176	O
not	-	1180	O
change	-	1184	O
after	-	1191	O
enalapril	-	1197	B
treatment	-	1207	O
.	-	1216	O

In	1639466	1218	O
contrast	-	1221	O
,	-	1229	O
in	-	1231	O
the	-	1234	O
nitrendipine	-	1238	B
-	-	1250	O
treated	-	1251	O
group	-	1259	O
albuminuria	-	1265	O
increased	-	1277	O
from	-	1287	O
12	-	1292	O
.	-	1294	O
8	-	1295	O
+	-	1297	O
/	-	1298	O
-	-	1299	O

2	1639466	1301	O
progressively	-	1303	O
to	-	1317	O
163	-	1320	O
+	-	1324	O
/	-	1325	O
-	-	1326	O

55	1639466	1328	O
compared	-	1331	O
with	-	1340	O
19	-	1345	O
.	-	1347	O
2	-	1348	O
+	-	1350	O
/	-	1351	O
-	-	1352	O

9	1639466	1354	O
mg	-	1356	O
/	-	1358	O
24	-	1359	O
hr	-	1362	O
in	-	1365	O
the	-	1368	O
hypertensive	-	1372	O
controls	-	1385	O
.	-	1393	O

Furthermore	1639466	1395	O
,	-	1406	O
glomerulosclerosis	-	1408	O
index	-	1427	O
was	-	1433	O
significantly	-	1437	O
increased	-	1451	O
in	-	1461	O
the	-	1464	O
nitrendipine	-	1468	B
-	-	1480	O
treated	-	1481	O
group	-	1489	O
compared	-	1495	O
with	-	1504	O
the	-	1509	O
hypertensive	-	1513	O
controls	-	1526	O
(	-	1535	O
0	-	1536	O
.	-	1537	O
38	-	1538	O
+	-	1541	O
/	-	1542	O
-	-	1543	O

0	1639466	1545	O
.	-	1546	O
1	-	1547	O
versus	-	1549	O
0	-	1556	O
.	-	1557	O
13	-	1558	O
+	-	1561	O
/	-	1562	O
-	-	1563	O

0	1639466	1565	O
.	-	1566	O
04	-	1567	O
)	-	1569	O
.	-	1570	O

In	1639466	1572	O
addition	-	1575	O
,	-	1583	O
glomerular	-	1585	O
size	-	1596	O
was	-	1601	O
higher	-	1605	O
in	-	1612	O
the	-	1615	O
nitrendipine	-	1619	B
-	-	1631	O
treated	-	1632	O
group	-	1640	O
(	-	1646	O
14	-	1647	O
.	-	1649	O
9	-	1650	O
+	-	1652	O
/	-	1653	O
-	-	1654	O

0	1639466	1656	O
.	-	1657	O
17	-	1658	O
10	-	1661	O
(	-	1663	O
-	-	1664	O
3	-	1665	O
)	-	1666	O
mm2	-	1668	O
)	-	1671	O
but	-	1673	O
lower	-	1677	O
in	-	1683	O
the	-	1686	O
enalapril	-	1690	B
-	-	1699	O
treated	-	1700	O
group	-	1708	O
(	-	1714	O
11	-	1715	O
.	-	1717	O
5	-	1718	O
+	-	1720	O
/	-	1721	O
-	-	1722	O

0	1639466	1724	O
.	-	1725	O
15	-	1726	O
10	-	1729	O
(	-	1731	O
-	-	1732	O
3	-	1733	O
)	-	1734	O
mm2	-	1736	O
)	-	1739	O
compared	-	1741	O
with	-	1750	O
the	-	1755	O
hypertensive	-	1759	O
controls	-	1772	O
(	-	1781	O
12	-	1782	O
.	-	1784	O
1	-	1785	O
+	-	1787	O
/	-	1788	O
-	-	1789	O

0	1639466	1791	O
.	-	1792	O
17	-	1793	O
10	-	1796	O
(	-	1798	O
-	-	1799	O
3	-	1800	O

)	1639466	1801	O
mm2	-	1803	O
)	-	1806	O
.	-	1807	O
(	-	1808	O
ABSTRACT	-	1809	O

TRUNCATED	1639466	1818	O
AT	-	1828	O
250	-	1831	O
WORDS	-	1835	O
)	-	1840	O

Treatment	1527456	0	O
of	-	10	O
tinnitus	-	13	O
by	-	22	O
intratympanic	-	25	O
instillation	-	39	O
of	-	52	O
lignocaine	-	55	B
(	-	66	O
lidocaine	-	67	B
)	-	76	O
2	-	78	O
per	-	80	O
cent	-	84	O
through	-	89	O
ventilation	-	97	O
tubes	-	109	O
.	-	114	O

Idiopathic	1527456	116	O
subjective	-	127	O
tinnitus	-	138	O
(	-	147	O
IST	-	148	O
)	-	151	O
is	-	153	O
one	-	156	O
of	-	160	O
the	-	163	O
most	-	167	O
obscure	-	172	O
otological	-	180	O
pathologies	-	191	O
.	-	202	O

This	1527456	204	O
paper	-	209	O
presents	-	215	O
the	-	224	O
results	-	228	O
of	-	236	O
treating	-	239	O
IST	-	248	O
by	-	252	O
intratympanic	-	255	O
instillation	-	269	O
of	-	282	O
lignocaine	-	285	B
(	-	296	O
lidocaine	-	297	B
)	-	306	O
2	-	308	O
per	-	310	O
cent	-	314	O
through	-	319	O
a	-	327	O
grommet	-	329	O
,	-	336	O
for	-	338	O
five	-	342	O
weekly	-	347	O
courses	-	354	O
.	-	361	O

Fifty	1527456	363	O
-	-	368	O
two	-	369	O
patients	-	373	O
suffering	-	382	O
from	-	392	O
intractable	-	397	O
tinnitus	-	409	O
entered	-	418	O
this	-	426	O
therapeutic	-	431	O
trial	-	443	O
,	-	448	O
but	-	450	O
only	-	454	O
nine	-	459	O
finished	-	464	O
all	-	473	O
five	-	477	O
courses	-	482	O
.	-	489	O

In	1527456	491	O
one	-	494	O
patient	-	498	O
,	-	505	O
the	-	507	O
tinnitus	-	511	O
was	-	520	O
almost	-	524	O
completely	-	531	O
abolished	-	542	O
,	-	551	O
but	-	553	O
in	-	557	O
all	-	560	O
the	-	564	O
nine	-	568	O
patients	-	573	O
the	-	582	O
decompensated	-	586	O
tinnitus	-	600	O
changed	-	609	O
to	-	617	O
a	-	620	O
compensated	-	622	O
one	-	634	O
.	-	637	O

We	1527456	639	O
suggest	-	642	O
this	-	650	O
mode	-	655	O
of	-	660	O
treatment	-	663	O
for	-	673	O
patients	-	677	O
that	-	686	O
were	-	691	O
previously	-	696	O
treated	-	707	O
by	-	715	O
drugs	-	718	O
,	-	723	O
acupuncture	-	725	O
and	-	737	O
biofeedback	-	741	O
,	-	752	O
with	-	754	O
disappointing	-	759	O
results	-	773	O
.	-	780	O

Patients	1527456	782	O
should	-	791	O
be	-	798	O
warned	-	801	O
about	-	808	O
the	-	814	O
side	-	818	O
effects	-	823	O
of	-	831	O
vertigo	-	834	O
and	-	842	O
vomiting	-	846	O
,	-	854	O
which	-	856	O
subsides	-	862	O
gradually	-	871	O
with	-	881	O
every	-	886	O
new	-	892	O
instillation	-	896	O
,	-	908	O
and	-	910	O
that	-	914	O
the	-	919	O
tinnitus	-	923	O
may	-	932	O
not	-	936	O
disappear	-	940	O
but	-	950	O
will	-	954	O
be	-	959	O
alleviated	-	962	O
,	-	972	O
enabling	-	974	O
them	-	983	O
to	-	988	O
cope	-	991	O
more	-	996	O
easily	-	1001	O
with	-	1008	O
the	-	1013	O
disease	-	1017	O
and	-	1025	O
lead	-	1029	O
a	-	1034	O
more	-	1036	O
normal	-	1041	O
life	-	1048	O
.	-	1052	O

Perhexiline	220563	0	B
maleate	-	12	I
and	-	20	O
peripheral	-	24	O
neuropathy	-	35	O
.	-	45	O

Peripheral	220563	47	O
neuropathy	-	58	O
has	-	69	O
been	-	73	O
noted	-	78	O
as	-	84	O
a	-	87	O
complication	-	89	O
of	-	102	O
therapy	-	105	O
with	-	113	O
perhexiline	-	118	B
maleate	-	130	I
,	-	137	O
a	-	139	O
drug	-	141	O
widely	-	146	O
used	-	153	O
in	-	158	O
France	-	161	O
(	-	168	O
and	-	169	O
in	-	173	O
clinical	-	176	O
trials	-	185	O
in	-	192	O
the	-	195	O
United	-	199	O
States	-	206	O
)	-	212	O
for	-	214	O
the	-	218	O
prophylactic	-	222	O
treatment	-	235	O
of	-	245	O
angina	-	248	O
pectoris	-	255	O
.	-	263	O

In	220563	265	O
24	-	268	O
patients	-	271	O
with	-	280	O
this	-	285	O
complication	-	290	O
,	-	302	O
the	-	304	O
marked	-	308	O
slowing	-	315	O
of	-	323	O
motor	-	326	O
nerve	-	332	O
conduction	-	338	O
velocity	-	349	O
and	-	358	O
the	-	362	O
electromyographic	-	366	O
changes	-	384	O
imply	-	392	O
mainly	-	398	O
a	-	405	O
demyelinating	-	407	O
disorder	-	421	O
.	-	429	O

Improvement	220563	431	O
was	-	443	O
noted	-	447	O
with	-	453	O
cessation	-	458	O
of	-	468	O
therapy	-	471	O
.	-	478	O

In	220563	480	O
a	-	483	O
few	-	485	O
cases	-	489	O
the	-	495	O
presence	-	499	O
of	-	508	O
active	-	511	O
denervation	-	518	O
signified	-	530	O
a	-	540	O
poor	-	542	O
prognosis	-	547	O
,	-	556	O
with	-	558	O
only	-	563	O
slight	-	568	O
improvement	-	575	O
.	-	586	O

The	220563	588	O
underlying	-	592	O
mechanism	-	603	O
causing	-	613	O
the	-	621	O
neuropathy	-	625	O
is	-	636	O
not	-	639	O
yet	-	643	O
fully	-	647	O
known	-	653	O
,	-	658	O
although	-	660	O
some	-	669	O
evidence	-	674	O
indicates	-	683	O
that	-	693	O
it	-	698	O
may	-	701	O
be	-	705	O
a	-	708	O
lipid	-	710	O
storage	-	716	O
process	-	724	O
.	-	731	O

Effect	137340	0	O
of	-	7	O
humoral	-	10	O
modulators	-	18	O
of	-	29	O
morphine	-	32	B
-	-	40	O
induced	-	41	O
increase	-	49	O
in	-	58	O
locomotor	-	61	O
activity	-	71	O
of	-	80	O
mice	-	83	O
.	-	87	O

The	137340	89	O
effect	-	93	O
of	-	100	O
humoral	-	103	O
modulators	-	111	O
on	-	122	O
the	-	125	O
morphine	-	129	B
-	-	137	O
induced	-	138	O
increase	-	146	O
in	-	155	O
locomotor	-	158	O
activity	-	168	O
of	-	177	O
mice	-	180	O
was	-	185	O
studied	-	189	O
.	-	196	O

The	137340	198	O
subcutaneous	-	202	O
administration	-	215	O
of	-	230	O
10	-	233	O
mg	-	236	O
/	-	238	O
kg	-	239	O
of	-	242	O
morphine	-	245	B
-	-	253	O
HC1	-	254	O
produced	-	258	O
a	-	267	O
marked	-	269	O
increase	-	276	O
in	-	285	O
locomotor	-	288	O
activity	-	298	O
in	-	307	O
mice	-	310	O
.	-	314	O

The	137340	316	O
morphine	-	320	B
-	-	328	O
induced	-	329	O
hyperactivity	-	337	O
was	-	351	O
potentiated	-	355	O
by	-	367	O
scopolamine	-	370	B
and	-	382	O
attenuated	-	386	O
by	-	397	O
physostigmine	-	400	B
.	-	413	O

In	137340	415	O
contrast	-	418	O
,	-	426	O
both	-	428	O
methscopolamine	-	433	B
and	-	449	O
neostigmine	-	453	B
,	-	464	O
which	-	466	O
do	-	472	O
not	-	475	O
penetrate	-	479	O
the	-	489	O
blood	-	493	O
-	-	498	O
brain	-	499	O
barrier	-	505	O
,	-	512	O
had	-	514	O
no	-	518	O
effect	-	521	O
on	-	528	O
the	-	531	O
hyperactivity	-	535	O
produced	-	549	O
by	-	558	O
morphine	-	561	B
.	-	569	O

Pretreatment	137340	571	O
of	-	584	O
mice	-	587	O
with	-	592	O
alpha	-	597	B
-	-	602	I
methyltyrosine	-	603	I
(	-	618	O
20	-	619	O
mg	-	622	O
/	-	624	O
kg	-	625	O

i	137340	628	O
.	-	629	O
p	-	630	O
.	-	631	O

,	137340	632	O
one	-	634	O
hour	-	638	O
)	-	642	O
,	-	643	O
an	-	645	O
inhibitor	-	648	O
of	-	658	O
tyrosine	-	661	B
hydroxylase	-	670	O
,	-	681	O
significantly	-	683	O
decreased	-	697	O
the	-	707	O
activity	-	711	O
-	-	719	O
increasing	-	720	O
effects	-	731	O
of	-	739	O
morphine	-	742	B
.	-	750	O

On	137340	752	O
the	-	755	O
other	-	759	O
hand	-	765	O
,	-	769	O
pretreatment	-	771	O
with	-	784	O
p	-	789	B
-	-	790	I
chlorophenylalamine	-	791	I
(	-	811	O
3	-	812	O
X	-	814	O
320	-	816	O
mg	-	820	O
/	-	822	O
kg	-	823	O

i	137340	826	O
.	-	827	O
p	-	828	O
.	-	829	O

,	137340	830	O
24	-	832	O
hr	-	835	O
)	-	837	O
,	-	838	O
a	-	840	O
serotonin	-	842	B
depletor	-	852	O
,	-	860	O
caused	-	862	O
no	-	869	O
significant	-	872	O
change	-	884	O
in	-	891	O
the	-	894	O
hyperactivity	-	898	O
.	-	911	O

The	137340	913	O
study	-	917	O
suggests	-	923	O
that	-	932	O
the	-	937	O
activity	-	941	O
-	-	949	O
increasing	-	950	O
effects	-	961	O
of	-	969	O
morphine	-	972	B
are	-	981	O
mediated	-	985	O
by	-	994	O
the	-	997	O
release	-	1001	O
of	-	1009	O
catecholamines	-	1012	B
from	-	1027	O
adrenergic	-	1032	O
neurons	-	1043	O
in	-	1051	O
the	-	1054	O
brain	-	1058	O
.	-	1063	O

And	137340	1065	O
the	-	1069	O
results	-	1073	O
are	-	1081	O
consistent	-	1085	O
with	-	1096	O
the	-	1101	O
hypothesis	-	1105	O
that	-	1116	O
morphine	-	1121	B
acts	-	1130	O
by	-	1135	O
retarding	-	1138	O
the	-	1148	O
release	-	1152	O
of	-	1160	O
acetylcholine	-	1163	B
at	-	1177	O
some	-	1180	O
central	-	1185	O
cholinergic	-	1193	O
synapses	-	1205	O
.	-	1213	O

It	137340	1215	O
is	-	1218	O
also	-	1221	O
suggested	-	1226	O
from	-	1236	O
collected	-	1241	O
evidence	-	1251	O
that	-	1260	O
the	-	1265	O
activity	-	1269	O
-	-	1277	O
increasing	-	1278	O
effects	-	1289	O
of	-	1297	O
morphine	-	1300	B
in	-	1309	O
mice	-	1312	O
are	-	1317	O
mediated	-	1321	O
by	-	1330	O
mechanisms	-	1333	O
different	-	1344	O
from	-	1354	O
those	-	1359	O
which	-	1365	O
mediate	-	1371	O
the	-	1379	O
activity	-	1383	O
-	-	1391	O
increasing	-	1392	O
effects	-	1403	O
of	-	1411	O
morphine	-	1414	B
in	-	1423	O
rats	-	1426	O
.	-	1430	O

Mechanisms	9931093	0	O
of	-	11	O
FK	-	14	B
506	-	17	I
-	-	20	O
induced	-	21	O
hypertension	-	29	O
in	-	42	O
the	-	45	O
rat	-	49	O
.	-	52	O

-	9931093	54	O
Tacrolimus	-	55	B
(	-	66	O

FK	9931093	67	B
506	-	70	I
)	-	73	O
is	-	75	O
a	-	78	O
powerful	-	80	O
,	-	88	O
widely	-	90	O
used	-	97	O
immunosuppressant	-	102	O
.	-	119	O

The	9931093	121	O
clinical	-	125	O
utility	-	134	O
of	-	142	O
FK	-	145	B
506	-	148	I
is	-	152	O
complicated	-	155	O
by	-	167	O
substantial	-	170	O
hypertension	-	182	O
and	-	195	O
nephrotoxicity	-	199	O
.	-	213	O

To	9931093	215	O
clarify	-	218	O
the	-	226	O
mechanisms	-	230	O
of	-	241	O
FK	-	244	B
506	-	247	I
-	-	250	O
induced	-	251	O
hypertension	-	259	O
,	-	271	O
we	-	273	O
studied	-	276	O
the	-	284	O
chronic	-	288	O
effects	-	296	O
of	-	304	O
FK	-	307	B
506	-	310	I
on	-	314	O
the	-	317	O
synthesis	-	321	O
of	-	331	O
endothelin	-	334	O
-	-	344	O
1	-	345	O
(	-	347	O
ET	-	348	O
-	-	350	O
1	-	351	O
)	-	352	O
,	-	353	O
the	-	355	O
expression	-	359	O
of	-	370	O
mRNA	-	373	O
of	-	378	O
ET	-	381	O
-	-	383	O
1	-	384	O
and	-	386	O
endothelin	-	390	O
-	-	400	O
converting	-	401	O
enzyme	-	412	O
-	-	418	O
1	-	419	O
(	-	421	O
ECE	-	422	O
-	-	425	O
1	-	426	O
)	-	427	O
,	-	428	O
the	-	430	O
endothelial	-	434	O
nitric	-	446	B
oxide	-	453	I
synthase	-	459	O
(	-	468	O
eNOS	-	469	O
)	-	473	O
activity	-	475	O
,	-	483	O
and	-	485	O
the	-	489	O
expression	-	493	O
of	-	504	O
mRNA	-	507	O
of	-	512	O
eNOS	-	515	O
and	-	520	O
C	-	524	O
-	-	525	O
type	-	526	O
natriuretic	-	531	O
peptide	-	543	O
(	-	551	O
CNP	-	552	O
)	-	555	O
in	-	557	O
rat	-	560	O
blood	-	564	O
vessels	-	570	O
.	-	577	O

In	9931093	579	O
addition	-	582	O
,	-	590	O
the	-	592	O
effect	-	596	O
of	-	603	O
the	-	606	O
specific	-	610	O
endothelin	-	619	O
type	-	630	O
A	-	635	O
receptor	-	637	O
antagonist	-	646	O
FR	-	657	B
139317	-	660	I
on	-	667	O
FK	-	670	B
506	-	673	I
-	-	676	O
induced	-	677	O
hypertension	-	685	O
in	-	698	O
rats	-	701	O
was	-	706	O
studied	-	710	O
.	-	717	O

FK	9931093	719	B
506	-	722	I
,	-	725	O
5	-	727	O
mg	-	729	O
.	-	731	O

kg	9931093	733	O
-	-	735	O
1	-	736	O
.	-	737	O

d	9931093	739	O
-	-	740	O
1	-	741	O
given	-	743	O
for	-	749	O
4	-	753	O
weeks	-	755	O
,	-	760	O
elevated	-	762	O
blood	-	771	O
pressure	-	777	O
from	-	786	O
102	-	791	O
+	-	794	O
/	-	795	O
-	-	796	O
13	-	797	O
to	-	800	O
152	-	803	O
+	-	806	O
/	-	807	O
-	-	808	O
15	-	809	O
mm	-	812	O
Hg	-	815	O
and	-	818	O
increased	-	822	O
the	-	832	O
synthesis	-	836	O
of	-	846	O
ET	-	849	O
-	-	851	O
1	-	852	O
and	-	854	O
the	-	858	O
levels	-	862	O
of	-	869	O
ET	-	872	O
-	-	874	O
1	-	875	O
mRNA	-	877	O
in	-	882	O
the	-	885	O
mesenteric	-	889	O
artery	-	900	O
(	-	907	O
240	-	908	O
%	-	911	O
and	-	913	O
230	-	917	O
%	-	920	O
,	-	921	O
respectively	-	923	O
)	-	935	O
.	-	936	O

Little	9931093	938	O
change	-	945	O
was	-	952	O
observed	-	956	O
in	-	965	O
the	-	968	O
expression	-	972	O
of	-	983	O
ECE	-	986	O
-	-	989	O
1	-	990	O
mRNA	-	992	O
and	-	997	O
CNP	-	1001	O
mRNA	-	1005	O
.	-	1009	O

FK	9931093	1011	B
506	-	1014	I
decreased	-	1018	O
eNOS	-	1028	O
activity	-	1033	O
and	-	1042	O
the	-	1046	O
levels	-	1050	O
of	-	1057	O
eNOS	-	1060	O
mRNA	-	1065	O
in	-	1070	O
the	-	1073	O
aorta	-	1077	O
(	-	1083	O
48	-	1084	O
%	-	1086	O
and	-	1088	O
55	-	1092	O
%	-	1094	O
,	-	1095	O
respectively	-	1097	O
)	-	1109	O
.	-	1110	O

The	9931093	1112	O
administration	-	1116	O
of	-	1131	O
FR	-	1134	B
139317	-	1137	I
(	-	1144	O
10	-	1145	O
mg	-	1148	O
.	-	1150	O

kg	9931093	1152	O
-	-	1154	O
1	-	1155	O
.	-	1156	O

d	9931093	1158	O
-	-	1159	O
1	-	1160	O
)	-	1161	O
prevented	-	1163	O
FK	-	1173	B
506	-	1176	I
-	-	1179	O
induced	-	1180	O
hypertension	-	1188	O
in	-	1201	O
rats	-	1204	O
.	-	1208	O

These	9931093	1210	O
results	-	1216	O
indicate	-	1224	O
that	-	1233	O
FK	-	1238	B
506	-	1241	I
may	-	1245	O
increase	-	1249	O
blood	-	1258	O
pressure	-	1264	O
not	-	1273	O
only	-	1277	O
by	-	1282	O
increasing	-	1285	O
ET	-	1296	O
-	-	1298	O
1	-	1299	O
production	-	1301	O
but	-	1312	O
also	-	1316	O
by	-	1321	O
decreasing	-	1324	O
NO	-	1335	B
synthesis	-	1338	O
in	-	1348	O
the	-	1351	O
vasculature	-	1355	O
.	-	1366	O

Suxamethonium	20633755	0	B
induced	-	14	O
prolonged	-	22	O
apnea	-	32	O
in	-	38	O
a	-	41	O
patient	-	43	O
receiving	-	51	O
electroconvulsive	-	61	O
therapy	-	79	O
.	-	86	O

Suxamethonium	20633755	88	B
causes	-	102	O
prolonged	-	109	O
apnea	-	119	O
in	-	125	O
patients	-	128	O
in	-	137	O
whom	-	140	O
pseudocholinesterase	-	145	O
enzyme	-	166	O
gets	-	173	O
deactivated	-	178	O
by	-	190	O
organophosphorus	-	193	B
(	-	210	I
OP	-	211	I
)	-	213	I
poisons	-	215	I
.	-	222	O

Here	20633755	224	O
,	-	228	O
we	-	230	O
present	-	233	O
a	-	241	O
similar	-	243	O
incident	-	251	O
in	-	260	O
a	-	263	O
severely	-	265	O
depressed	-	274	O
patient	-	284	O
who	-	292	O
received	-	296	O
electroconvulsive	-	305	O
therapy	-	323	O
(	-	331	O
ECT	-	332	O
)	-	335	O
.	-	336	O

Prolonged	20633755	338	O
apnea	-	348	O
in	-	354	O
our	-	357	O
case	-	361	O
ensued	-	366	O
because	-	373	O
the	-	381	O
information	-	385	O
about	-	397	O
suicidal	-	403	O
attempt	-	412	O
by	-	420	O
OP	-	423	B
compound	-	426	I
was	-	435	O
concealed	-	439	O
from	-	449	O
the	-	454	O
treating	-	458	O
team	-	467	O
.	-	471	O

The	20067456	0	O
effects	-	4	O
of	-	12	O
the	-	15	O
adjunctive	-	19	O
bupropion	-	30	B
on	-	40	O
male	-	43	O
sexual	-	48	O
dysfunction	-	55	O
induced	-	67	O
by	-	75	O
a	-	78	O
selective	-	80	B
serotonin	-	90	I
reuptake	-	100	I
inhibitor	-	109	I
:	-	118	O
a	-	120	O
double	-	122	O
-	-	128	O
blind	-	129	O
placebo	-	135	O
-	-	142	O
controlled	-	143	O
and	-	154	O
randomized	-	158	O
study	-	169	O
.	-	174	O

OBJECTIVE	20067456	176	O
:	-	185	O

To	20067456	187	O
determine	-	190	O
the	-	200	O
safety	-	204	O
and	-	211	O
efficacy	-	215	O
of	-	224	O
adjunctive	-	227	O
bupropion	-	238	B
sustained	-	248	O
-	-	257	O
release	-	258	O
(	-	266	O
SR	-	267	O
)	-	269	O
on	-	271	O
male	-	274	O
sexual	-	279	O
dysfunction	-	286	O
(	-	298	O
SD	-	299	O
)	-	301	O
induced	-	303	O
by	-	311	O
a	-	314	O
selective	-	316	B
serotonin	-	326	I
reuptake	-	336	I
inhibitor	-	345	I
(	-	355	O
SSRI	-	356	B
)	-	360	O
,	-	361	O
as	-	363	O
SD	-	366	O
is	-	369	O
a	-	372	O
common	-	374	O
side	-	381	O
-	-	385	O
effect	-	386	O
of	-	393	O
SSRIs	-	396	B
and	-	402	O
the	-	406	O
most	-	410	O
effective	-	415	O
treatments	-	425	O
have	-	436	O
yet	-	441	O
to	-	445	O
be	-	448	O
determined	-	451	O
.	-	461	O

PATIENTS	20067456	463	O
AND	-	472	O
METHODS	-	476	O
:	-	483	O

The	20067456	485	O
randomized	-	489	O
sample	-	500	O
consisted	-	507	O
of	-	517	O
234	-	520	O
euthymic	-	524	O
men	-	533	O
who	-	537	O
were	-	541	O
receiving	-	546	O
some	-	556	O
type	-	561	O
of	-	566	O
SSRI	-	569	B
.	-	573	O

The	20067456	575	O
men	-	579	O
were	-	583	O
randomly	-	588	O
assigned	-	597	O
to	-	606	O
bupropion	-	609	B
SR	-	619	O
(	-	622	O
150	-	623	O
mg	-	627	O
twice	-	630	O
daily	-	636	O
,	-	641	O
117	-	643	O
)	-	646	O
or	-	648	O
placebo	-	651	O
(	-	659	O
twice	-	660	O
daily	-	666	O
,	-	671	O
117	-	673	O
)	-	676	O
for	-	678	O
12	-	682	O
weeks	-	685	O
.	-	690	O

Efficacy	20067456	692	O
was	-	701	O
evaluated	-	705	O
using	-	715	O
the	-	721	O
Clinical	-	725	O
Global	-	734	O
Impression	-	741	O
-	-	751	O
Sexual	-	752	O
Function	-	759	O
(	-	768	O
CGI	-	769	O
-	-	772	O
SF	-	773	O
;	-	775	O
the	-	777	O
primary	-	781	O
outcome	-	789	O
measure	-	797	O
)	-	804	O
,	-	805	O
the	-	807	O
International	-	811	O
Index	-	825	O
of	-	831	O
Erectile	-	834	O
Function	-	843	O
(	-	852	O
IIEF	-	853	O
)	-	857	O
,	-	858	O
Arizona	-	860	O
Sexual	-	868	O
Experience	-	875	O
Scale	-	886	O
(	-	892	O
ASEX	-	893	O
)	-	897	O
,	-	898	O
and	-	900	O
Erectile	-	904	O
Dysfunction	-	913	O
Inventory	-	925	O
of	-	935	O
Treatment	-	938	O
Satisfaction	-	948	O
(	-	961	O
EDITS	-	962	O
)	-	967	O
(	-	969	O
secondary	-	970	O
outcome	-	980	O
measures	-	988	O
)	-	996	O
.	-	997	O

Participants	20067456	999	O
were	-	1012	O
followed	-	1017	O
biweekly	-	1026	O
during	-	1035	O
study	-	1042	O
period	-	1048	O
.	-	1054	O

RESULTS	20067456	1056	O
:	-	1063	O

After	20067456	1065	O
12	-	1071	O
weeks	-	1074	O
of	-	1080	O
treatment	-	1083	O
,	-	1092	O
the	-	1094	O
mean	-	1098	O
(	-	1103	O
sd	-	1104	O
)	-	1106	O
scores	-	1108	O
for	-	1115	O
CGI	-	1119	O
-	-	1122	O
SF	-	1123	O
were	-	1126	O
significantly	-	1131	O
lower	-	1145	O
,	-	1150	O
i	-	1152	O
.	-	1153	O
e	-	1154	O
.	-	1155	O
better	-	1157	O
,	-	1163	O
in	-	1165	O
patients	-	1168	O
on	-	1177	O
bupropion	-	1180	B
SR	-	1190	O
,	-	1192	O
at	-	1194	O
2	-	1197	O
.	-	1198	O
4	-	1199	O
(	-	1201	O
1	-	1202	O
.	-	1203	O
2	-	1204	O
)	-	1205	O
,	-	1206	O
than	-	1208	O
in	-	1213	O
the	-	1216	O
placebo	-	1220	O
group	-	1228	O
,	-	1233	O
at	-	1235	O
3	-	1238	O
.	-	1239	O
9	-	1240	O
(	-	1242	O
1	-	1243	O
.	-	1244	O
1	-	1245	O
)	-	1246	O
(	-	1248	O
P	-	1249	O
=	-	1250	O
0	-	1252	O
.	-	1253	O
01	-	1254	O
)	-	1256	O
.	-	1257	O

Men	20067456	1259	O
who	-	1263	O
received	-	1267	O
bupropion	-	1276	B
had	-	1286	O
a	-	1290	O
significant	-	1292	O
increase	-	1304	O
in	-	1313	O
the	-	1316	O
total	-	1320	O
IIEF	-	1326	O
score	-	1331	O
(	-	1337	O
54	-	1338	O
.	-	1340	O
4	-	1341	O
%	-	1342	O
vs	-	1344	O
1	-	1347	O
.	-	1348	O
2	-	1349	O
%	-	1350	O
;	-	1351	O
P	-	1353	O
=	-	1354	O
0	-	1356	O
.	-	1357	O
003	-	1358	O
)	-	1361	O
,	-	1362	O
and	-	1364	O
in	-	1368	O
the	-	1371	O
five	-	1375	O
different	-	1380	O
domains	-	1390	O
of	-	1398	O
the	-	1401	O
IIEF	-	1405	O
.	-	1409	O

Total	20067456	1411	O
ASEX	-	1417	O
scores	-	1422	O
were	-	1429	O
significantly	-	1434	O
lower	-	1448	O
,	-	1453	O
i	-	1455	O
.	-	1456	O
e	-	1457	O
.	-	1458	O
better	-	1460	O
,	-	1466	O
among	-	1468	O
men	-	1474	O
who	-	1478	O
received	-	1482	O
bupropion	-	1491	B
than	-	1501	O
placebo	-	1506	O
,	-	1513	O
at	-	1515	O
15	-	1518	O
.	-	1520	O
5	-	1521	O
(	-	1523	O
4	-	1524	O
.	-	1525	O
3	-	1526	O
)	-	1527	O
vs	-	1529	O
21	-	1532	O
.	-	1534	O
5	-	1535	O
(	-	1537	O
4	-	1538	O
.	-	1539	O
7	-	1540	O
)	-	1541	O
(	-	1543	O
P	-	1544	O
=	-	1545	O
0	-	1547	O
.	-	1548	O
002	-	1549	O
)	-	1552	O
.	-	1553	O

The	20067456	1555	O
EDITS	-	1559	O
scores	-	1565	O
were	-	1572	O
67	-	1577	O
.	-	1579	O
4	-	1580	O
(	-	1582	O
10	-	1583	O
.	-	1585	O
2	-	1586	O
)	-	1587	O
for	-	1589	O
the	-	1593	O
bupropion	-	1597	B
and	-	1607	O
36	-	1611	O
.	-	1613	O
3	-	1614	O
(	-	1616	O
11	-	1617	O
.	-	1619	O
7	-	1620	O
)	-	1621	O
for	-	1623	O
the	-	1627	O
placebo	-	1631	O
group	-	1639	O
(	-	1645	O
P	-	1646	O
=	-	1647	O
0	-	1649	O
.	-	1650	O
001	-	1651	O
)	-	1654	O
.	-	1655	O

The	20067456	1657	O
ASEX	-	1661	O
score	-	1666	O
and	-	1672	O
CGI	-	1676	O
-	-	1679	O
SF	-	1680	O
score	-	1683	O
were	-	1689	O
correlated	-	1694	O
(	-	1705	O
P	-	1706	O
=	-	1707	O
0	-	1709	O
.	-	1710	O
003	-	1711	O
)	-	1714	O
.	-	1715	O

In	20067456	1717	O
linear	-	1720	O
regression	-	1727	O
analyses	-	1738	O
the	-	1747	O
CGI	-	1751	O
-	-	1754	O
SF	-	1755	O
score	-	1758	O
was	-	1764	O
not	-	1768	O
affected	-	1772	O
significantly	-	1781	O
by	-	1795	O
the	-	1798	O
duration	-	1802	O
of	-	1811	O
SD	-	1814	O
,	-	1816	O
type	-	1818	O
of	-	1823	O
SSRI	-	1826	B
used	-	1831	O
and	-	1836	O
age	-	1840	O
.	-	1843	O

CONCLUSIONS	20067456	1845	O
:	-	1856	O

Bupropion	20067456	1858	B
is	-	1868	O
an	-	1871	O
effective	-	1874	O
treatment	-	1884	O
for	-	1894	O
male	-	1898	O
SD	-	1903	O
induced	-	1906	O
by	-	1914	O
SSRIs	-	1917	B
.	-	1922	O

These	20067456	1924	O
results	-	1930	O
provide	-	1938	O
empirical	-	1946	O
support	-	1956	O
for	-	1964	O
conducting	-	1968	O
a	-	1979	O
further	-	1981	O
study	-	1989	O
of	-	1995	O
bupropion	-	1998	B
.	-	2007	O

Lamivudine	18464113	0	B
for	-	11	O
the	-	15	O
prevention	-	19	O
of	-	30	O
hepatitis	-	33	O
B	-	43	O
virus	-	45	O
reactivation	-	51	O
in	-	64	O
hepatitis	-	67	B
-	-	76	I
B	-	77	I
surface	-	79	I
antigen	-	87	I
(	-	95	O
HBSAG	-	96	B
)	-	101	O

seropositive	18464113	103	O
cancer	-	116	O
patients	-	123	O
undergoing	-	132	O
cytotoxic	-	143	O
chemotherapy	-	153	O
.	-	165	O

Hepatitis	18464113	167	O
B	-	177	O
virus	-	179	O
(	-	185	O
HBV	-	186	O
)	-	189	O
is	-	191	O
one	-	194	O
of	-	198	O
the	-	201	O
major	-	205	O
causes	-	211	O
of	-	218	O
chronic	-	221	O
liver	-	229	O
disease	-	235	O
worldwide	-	243	O
.	-	252	O

Cancer	18464113	254	O
patients	-	261	O
who	-	270	O
are	-	274	O
chronic	-	278	O
carriers	-	286	O
of	-	295	O
HBV	-	298	O
have	-	302	O
a	-	307	O
higher	-	309	O
hepatic	-	316	O
complication	-	324	O
rate	-	337	O
while	-	342	O
receiving	-	348	O
cytotoxic	-	358	O
chemotherapy	-	368	O
(	-	381	O
CT	-	382	O
)	-	384	O
and	-	386	O
this	-	390	O
has	-	395	O
mainly	-	399	O
been	-	406	O
attributed	-	411	O
to	-	422	O
HBV	-	425	O
reactivation	-	429	O
.	-	441	O

In	18464113	443	O
this	-	446	O
study	-	451	O
,	-	456	O
cancer	-	458	O
patients	-	465	O
who	-	474	O
have	-	478	O
solid	-	483	O
and	-	489	O
hematological	-	493	O
malignancies	-	507	O
with	-	520	O
chronic	-	525	O
HBV	-	533	O
infection	-	537	O
received	-	547	O
the	-	556	O
antiviral	-	560	O
agent	-	570	O
lamivudine	-	576	B
prior	-	587	O
and	-	593	O
during	-	597	O
CT	-	604	O
compared	-	607	O
with	-	616	O
historical	-	621	O
control	-	632	O
group	-	640	O
who	-	646	O
did	-	650	O
not	-	654	O
receive	-	658	O
lamivudine	-	666	B
.	-	676	O

The	18464113	678	O
objectives	-	682	O
were	-	693	O
to	-	698	O
assess	-	701	O
the	-	708	O
efficacy	-	712	O
of	-	721	O
lamivudine	-	724	B
in	-	735	O
reducing	-	738	O
the	-	747	O
incidence	-	751	O
of	-	761	O
HBV	-	764	O
reactivation	-	768	O
,	-	780	O
and	-	782	O
diminishing	-	786	O
morbidity	-	798	O
and	-	808	O
mortality	-	812	O
during	-	822	O
CT	-	829	O
.	-	831	O

Two	18464113	833	O
groups	-	837	O
were	-	844	O
compared	-	849	O
in	-	858	O
this	-	861	O
study	-	866	O
.	-	871	O

The	18464113	873	O
prophylactic	-	877	O
lamivudin	-	890	B
group	-	900	O
consisted	-	906	O
of	-	916	O
37	-	919	O
patients	-	922	O
who	-	931	O
received	-	935	O
prophylactic	-	944	O
lamivudine	-	957	B
treatment	-	968	O
.	-	977	O

The	18464113	979	O
historical	-	983	O
controls	-	994	O
consisted	-	1003	O
of	-	1013	O
50	-	1016	O
consecutive	-	1019	O
patients	-	1031	O
who	-	1040	O
underwent	-	1044	O
CT	-	1054	O
without	-	1057	O
prophylactic	-	1065	O
lamivudine	-	1078	B
.	-	1088	O

They	18464113	1090	O
were	-	1095	O
followed	-	1100	O
up	-	1109	O
during	-	1112	O
and	-	1119	O
for	-	1123	O
8	-	1127	O
weeks	-	1129	O
after	-	1135	O
CT	-	1141	O
.	-	1143	O

The	18464113	1145	O
outcomes	-	1149	O
were	-	1158	O
compared	-	1163	O
for	-	1172	O
both	-	1176	O
groups	-	1181	O
.	-	1187	O

Of	18464113	1189	O
our	-	1192	O
control	-	1196	O
group	-	1204	O
(	-	1210	O
n	-	1211	O
=	-	1212	O
50	-	1214	O
)	-	1216	O
,	-	1217	O
21	-	1219	O
patients	-	1222	O
(	-	1231	O
42	-	1232	O
%	-	1234	O
)	-	1235	O
were	-	1237	O
established	-	1242	O
hepatitis	-	1254	O
.	-	1263	O

Twelve	18464113	1265	O
(	-	1272	O
24	-	1273	O
%	-	1275	O
)	-	1276	O
of	-	1278	O
them	-	1281	O
were	-	1286	O
evaluated	-	1291	O
as	-	1301	O
severe	-	1304	O
hepatitis	-	1311	O
.	-	1320	O

In	18464113	1322	O
the	-	1325	O
prophylactic	-	1329	O
lamivudine	-	1342	B
group	-	1353	O
severe	-	1359	O
hepatitis	-	1366	O
were	-	1376	O
observed	-	1381	O
only	-	1390	O
in	-	1395	O
1	-	1398	O
patient	-	1400	O
(	-	1408	O
2	-	1409	O
.	-	1410	O
7	-	1411	O
%	-	1412	O
)	-	1413	O
of	-	1415	O
37	-	1418	O
patients	-	1421	O
(	-	1430	O
p	-	1431	O
<	-	1433	O
0	-	1435	O
.	-	1436	O
006	-	1437	O
)	-	1440	O
.	-	1441	O

Comparison	18464113	1443	O
of	-	1454	O
the	-	1457	O
mean	-	1461	O
ALT	-	1466	O
values	-	1470	O
revealed	-	1477	O
significantly	-	1486	O
higher	-	1500	O
mean	-	1507	O
alanine	-	1512	B
aminotransferase	-	1520	O
(	-	1537	O
ALT	-	1538	O
)	-	1541	O
values	-	1543	O
in	-	1550	O
the	-	1553	O
control	-	1557	O
group	-	1565	O
than	-	1571	O
the	-	1576	O
prophylactic	-	1580	O
lamivudine	-	1593	B
group	-	1604	O
;	-	1609	O
154	-	1611	O
:	-	1614	O
64	-	1615	O
(	-	1618	O
p	-	1619	O
<	-	1621	O
0	-	1623	O
.	-	1624	O
32	-	1625	O
)	-	1627	O
.	-	1628	O

Our	18464113	1630	O
study	-	1634	O
suggests	-	1640	O
that	-	1649	O
prophylactic	-	1654	O
lamivudine	-	1667	B
significantly	-	1678	O
decreases	-	1692	O
the	-	1702	O
incidence	-	1706	O
of	-	1716	O
HBV	-	1719	O
reactivation	-	1723	O
and	-	1736	O
overall	-	1740	O
morbidity	-	1748	O
in	-	1758	O
cancer	-	1761	O
patients	-	1768	O
during	-	1777	O
and	-	1784	O
after	-	1788	O
immunosuppressive	-	1794	O
therapy	-	1812	O
.	-	1819	O

Further	18464113	1821	O
studies	-	1829	O
are	-	1837	O
needed	-	1841	O
to	-	1848	O
determine	-	1851	O
the	-	1861	O
most	-	1865	O
appropriate	-	1870	O
nucleoside	-	1882	B
or	-	1893	O
nucleotide	-	1896	B
analogue	-	1907	O
for	-	1916	O
antiviral	-	1920	O
prophylaxis	-	1930	O
during	-	1942	O
CT	-	1949	O
and	-	1952	O
the	-	1956	O
optimal	-	1960	O
duration	-	1968	O
of	-	1977	O
administration	-	1980	O
after	-	1995	O
completion	-	2001	O
of	-	2012	O
CT	-	2015	O
.	-	2017	O

Ginsenoside	18308784	0	B
Rg1	-	12	I
restores	-	16	O
the	-	25	O
impairment	-	29	O
of	-	40	O
learning	-	43	O
induced	-	52	O
by	-	60	O
chronic	-	63	O
morphine	-	71	B
administration	-	80	O
in	-	95	O
rats	-	98	O
.	-	102	O

Rg1	18308784	104	B
,	-	107	O
as	-	109	O
a	-	112	O
ginsenoside	-	114	B
extracted	-	126	O
from	-	136	O
Panax	-	141	O
ginseng	-	147	O
,	-	154	O
could	-	156	O
ameliorate	-	162	O
spatial	-	173	O
learning	-	181	O
impairment	-	190	O
.	-	200	O

Previous	18308784	202	O
studies	-	211	O
have	-	219	O
demonstrated	-	224	O
that	-	237	O
Rg1	-	242	B
might	-	246	O
be	-	252	O
a	-	255	O
useful	-	257	O
agent	-	264	O
for	-	270	O
the	-	274	O
prevention	-	278	O
and	-	289	O
treatment	-	293	O
of	-	303	O
the	-	306	O
adverse	-	310	O
effects	-	318	O
of	-	326	O
morphine	-	329	B
.	-	337	O

The	18308784	339	O
aim	-	343	O
of	-	347	O
this	-	350	O
study	-	355	O
was	-	361	O
to	-	365	O
investigate	-	368	O
the	-	380	O
effect	-	384	O
of	-	391	O
Rg1	-	394	B
on	-	398	O
learning	-	401	O
impairment	-	410	O
by	-	421	O
chronic	-	424	O
morphine	-	432	B
administration	-	441	O
and	-	456	O
the	-	460	O
mechanism	-	464	O
responsible	-	474	O
for	-	486	O
this	-	490	O
effect	-	495	O
.	-	501	O

Male	18308784	503	O
rats	-	508	O
were	-	513	O
subcutaneously	-	518	O
injected	-	533	O
with	-	542	O
morphine	-	547	B
(	-	556	O
10	-	557	O
mg	-	560	O
/	-	562	O
kg	-	563	O
)	-	565	O
twice	-	567	O
a	-	573	O
day	-	575	O
at	-	579	O
12	-	582	O
hour	-	585	O
intervals	-	590	O
for	-	600	O
10	-	604	O
days	-	607	O
,	-	611	O
and	-	613	O
Rg1	-	617	B
(	-	621	O
30	-	622	O
mg	-	625	O
/	-	627	O
kg	-	628	O
)	-	630	O
was	-	632	O
intraperitoneally	-	636	O
injected	-	654	O
2	-	663	O
hours	-	665	O
after	-	671	O
the	-	677	O
second	-	681	O
injection	-	688	O
of	-	698	O
morphine	-	701	B
once	-	710	O
a	-	715	O
day	-	717	O
for	-	721	O
10	-	725	O
days	-	728	O
.	-	732	O

Spatial	18308784	734	O
learning	-	742	O
capacity	-	751	O
was	-	760	O
assessed	-	764	O
in	-	773	O
the	-	776	O
Morris	-	780	O
water	-	787	O
maze	-	793	O
.	-	797	O

The	18308784	799	O
results	-	803	O
showed	-	811	O
that	-	818	O
rats	-	823	O
treated	-	828	O
with	-	836	O
Morphine	-	841	B
/	-	849	O
Rg1	-	850	B
decreased	-	854	O
escape	-	864	O
latency	-	871	O
and	-	879	O
increased	-	883	O
the	-	893	O
time	-	897	O
spent	-	902	O
in	-	908	O
platform	-	911	O
quadrant	-	920	O
and	-	929	O
entering	-	933	O
frequency	-	942	O
.	-	951	O

By	18308784	953	O
implantation	-	956	O
of	-	969	O
electrodes	-	972	O
and	-	983	O
electrophysiological	-	987	O
recording	-	1008	O
in	-	1018	O
vivo	-	1021	O
,	-	1025	O
the	-	1027	O
results	-	1031	O
showed	-	1039	O
that	-	1046	O
Rg1	-	1051	B
restored	-	1055	O
the	-	1064	O
long	-	1068	O
-	-	1072	O
term	-	1073	O
potentiation	-	1078	O
(	-	1091	O
LTP	-	1092	O
)	-	1095	O
impaired	-	1097	O
by	-	1106	O
morphine	-	1109	B
in	-	1118	O
both	-	1121	O
freely	-	1126	O
moving	-	1133	O
and	-	1140	O
anaesthetised	-	1144	O
rats	-	1158	O
.	-	1162	O

The	18308784	1164	O
electrophysiological	-	1168	O
recording	-	1189	O
in	-	1199	O
vitro	-	1202	O
showed	-	1208	O
that	-	1215	O
Rg1	-	1220	B
restored	-	1224	O
the	-	1233	O
LTP	-	1237	O
in	-	1241	O
slices	-	1244	O
from	-	1251	O
the	-	1256	O
rats	-	1260	O
treated	-	1265	O
with	-	1273	O
morphine	-	1278	B
,	-	1286	O
but	-	1288	O
not	-	1292	O
changed	-	1296	O
LTP	-	1304	O
in	-	1308	O
the	-	1311	O
slices	-	1315	O
from	-	1322	O
normal	-	1327	O
saline	-	1334	O
-	-	1340	O
or	-	1342	O
morphine	-	1345	B
/	-	1353	O
Rg1	-	1354	B
-	-	1357	O
treated	-	1358	O
rats	-	1366	O
;	-	1370	O
this	-	1372	O
restoration	-	1377	O
could	-	1389	O
be	-	1395	O
inhibited	-	1398	O
by	-	1408	O
N	-	1411	B
-	-	1412	I
methyl	-	1413	I
-	-	1419	I
D	-	1420	I
-	-	1421	I
aspartate	-	1422	I
(	-	1432	O
NMDA	-	1433	B
)	-	1437	O
receptor	-	1439	O
antagonist	-	1448	O
MK801	-	1459	B
.	-	1464	O

We	18308784	1466	O
conclude	-	1469	O
that	-	1478	O
Rg1	-	1483	B
may	-	1487	O
significantly	-	1491	O
improve	-	1505	O
the	-	1513	O
spatial	-	1517	O
learning	-	1525	O
capacity	-	1534	O
impaired	-	1543	O
by	-	1552	O
chonic	-	1555	O
morphine	-	1562	B
administration	-	1571	O
and	-	1586	O
restore	-	1590	O
the	-	1598	O
morphine	-	1602	B
-	-	1610	O
inhibited	-	1611	O
LTP	-	1621	O
.	-	1624	O

This	18308784	1626	O
effect	-	1631	O
is	-	1638	O
NMDA	-	1641	B
receptor	-	1646	O
dependent	-	1655	O
.	-	1664	O

A	17931375	0	O
study	-	2	O
on	-	8	O
the	-	11	O
effect	-	15	O
of	-	22	O
the	-	25	O
duration	-	29	O
of	-	38	O
subcutaneous	-	41	O
heparin	-	54	B
injection	-	62	O
on	-	72	O
bruising	-	75	O
and	-	84	O
pain	-	88	O
.	-	92	O

AIM	17931375	94	O
:	-	97	O

This	17931375	99	O
study	-	104	O
was	-	110	O
carried	-	114	O
out	-	122	O
to	-	126	O
determine	-	129	O
the	-	139	O
effect	-	143	O
of	-	150	O
injection	-	153	O
duration	-	163	O
on	-	172	O
bruising	-	175	O
and	-	184	O
pain	-	188	O
following	-	193	O
the	-	203	O
administration	-	207	O
of	-	222	O
the	-	225	O
subcutaneous	-	229	O
injection	-	242	O
of	-	252	O
heparin	-	255	B
.	-	262	O

BACKGROUND	17931375	264	O
:	-	274	O

Although	17931375	276	O
different	-	285	O
methods	-	295	O
to	-	303	O
prevent	-	306	O
bruising	-	314	O
and	-	323	O
pain	-	327	O
following	-	332	O
the	-	342	O
subcutaneous	-	346	O
injection	-	359	O
of	-	369	O
heparin	-	372	B
have	-	380	O
been	-	385	O
widely	-	390	O
studied	-	397	O
and	-	405	O
described	-	409	O
,	-	418	O
the	-	420	O
effect	-	424	O
of	-	431	O
injection	-	434	O
duration	-	444	O
on	-	453	O
the	-	456	O
occurrence	-	460	O
of	-	471	O
bruising	-	474	O
and	-	483	O
pain	-	487	O
is	-	492	O
little	-	495	O
documented	-	502	O
.	-	512	O

DESIGN	17931375	514	O
:	-	520	O

This	17931375	522	O
study	-	527	O
was	-	533	O
designed	-	537	O
as	-	546	O
within	-	549	O
-	-	555	O
subject	-	556	O
,	-	563	O
quasi	-	565	O
-	-	570	O
experimental	-	571	O
research	-	584	O
.	-	592	O

METHOD	17931375	594	O
:	-	600	O

The	17931375	602	O
sample	-	606	O
for	-	613	O
the	-	617	O
study	-	621	O
consisted	-	627	O
of	-	637	O
50	-	640	O
patients	-	643	O
to	-	652	O
whom	-	655	O
subcutaneous	-	660	O
heparin	-	673	B
was	-	681	O
administered	-	685	O
.	-	697	O

Heparin	17931375	699	B
was	-	707	O
injected	-	711	O
over	-	720	O
10	-	725	O
seconds	-	728	O
on	-	736	O
the	-	739	O
right	-	743	O
abdominal	-	749	O
site	-	759	O
and	-	764	O
30	-	768	O
seconds	-	771	O
on	-	779	O
the	-	782	O
left	-	786	O
abdominal	-	791	O
site	-	801	O
.	-	805	O

Injections	17931375	807	O
areas	-	818	O
were	-	824	O
assessed	-	829	O
for	-	838	O
the	-	842	O
presence	-	846	O
of	-	855	O
bruising	-	858	O
at	-	867	O
48	-	870	O
and	-	873	O
72	-	877	O
hours	-	880	O
after	-	886	O
each	-	892	O
injection	-	897	O
.	-	906	O

Dimensions	17931375	908	O
of	-	919	O
the	-	922	O
bruising	-	926	O
on	-	935	O
the	-	938	O
heparin	-	942	B
applied	-	950	O
areas	-	958	O
were	-	964	O
measured	-	969	O
using	-	978	O
transparent	-	984	O
millimetric	-	996	O
measuring	-	1008	O
paper	-	1018	O
.	-	1023	O

The	17931375	1025	O
visual	-	1029	O
analog	-	1036	O
scale	-	1043	O
(	-	1049	O
VAS	-	1050	O
)	-	1053	O
was	-	1055	O
used	-	1059	O
to	-	1064	O
measure	-	1067	O
pain	-	1075	O
intensity	-	1080	O
and	-	1090	O
a	-	1094	O
stop	-	1096	O
-	-	1100	O
watch	-	1101	O
was	-	1107	O
used	-	1111	O
to	-	1116	O
time	-	1119	O
the	-	1124	O
pain	-	1128	O
period	-	1133	O
.	-	1139	O

Data	17931375	1141	O
were	-	1146	O
analysed	-	1151	O
using	-	1160	O
chi	-	1166	O
-	-	1169	O
square	-	1170	O
test	-	1177	O
,	-	1181	O
Mann	-	1183	O
-	-	1187	O
Whitney	-	1188	O
U	-	1196	O
,	-	1197	O
Wilcoxon	-	1199	O
signed	-	1208	O
ranks	-	1215	O
tests	-	1221	O
and	-	1227	O
correlation	-	1231	O
.	-	1242	O

RESULTS	17931375	1244	O
:	-	1251	O

The	17931375	1253	O
percentage	-	1257	O
of	-	1268	O
bruising	-	1271	O
occurrence	-	1280	O
was	-	1291	O
64	-	1295	O
%	-	1297	O
with	-	1299	O
the	-	1304	O
injection	-	1308	O
of	-	1318	O
10	-	1321	O
seconds	-	1324	O
duration	-	1332	O
and	-	1341	O
42	-	1345	O
%	-	1347	O
in	-	1349	O
the	-	1352	O
30	-	1356	O
-	-	1358	O
second	-	1359	O
injection	-	1366	O
.	-	1375	O

It	17931375	1377	O
was	-	1380	O
determined	-	1384	O
that	-	1395	O
the	-	1400	O
size	-	1404	O
of	-	1409	O
the	-	1412	O
bruising	-	1416	O
was	-	1425	O
smaller	-	1429	O
in	-	1437	O
the	-	1440	O
30	-	1444	O
-	-	1446	O
second	-	1447	O
injection	-	1454	O
.	-	1463	O

Pain	17931375	1465	O
intensity	-	1470	O
and	-	1480	O
pain	-	1484	O
period	-	1489	O
were	-	1496	O
statistically	-	1501	O
significantly	-	1515	O
lower	-	1529	O
for	-	1535	O
the	-	1539	O
30	-	1543	O
-	-	1545	O
second	-	1546	O
injection	-	1553	O
than	-	1563	O
for	-	1568	O
the	-	1572	O
10	-	1576	O
-	-	1578	O
second	-	1579	O
injection	-	1586	O
.	-	1595	O

CONCLUSIONS	17931375	1597	O
:	-	1608	O

It	17931375	1610	O
was	-	1613	O
determined	-	1617	O
that	-	1628	O
injection	-	1633	O
duration	-	1643	O
had	-	1652	O
an	-	1656	O
effect	-	1659	O
on	-	1666	O
bruising	-	1669	O
and	-	1678	O
pain	-	1682	O
following	-	1687	O
the	-	1697	O
subcutaneous	-	1701	O
administration	-	1714	O
of	-	1729	O
heparin	-	1732	B
.	-	1739	O

This	17931375	1741	O
study	-	1746	O
should	-	1752	O
be	-	1759	O
repeated	-	1762	O
on	-	1771	O
a	-	1774	O
larger	-	1776	O
sample	-	1783	O
.	-	1789	O

RELEVANCE	17931375	1791	O
TO	-	1801	O

CLINICAL	17931375	1804	O
PRACTICE	-	1813	O
:	-	1821	O

When	17931375	1823	O
administering	-	1828	O
subcutaneous	-	1842	O
heparin	-	1855	B
injections	-	1863	O
,	-	1873	O
it	-	1875	O
is	-	1878	O
important	-	1881	O
to	-	1891	O
extend	-	1894	O
the	-	1901	O
duration	-	1905	O
of	-	1914	O
the	-	1917	O
injection	-	1921	O
.	-	1930	O

Acute	15649445	0	O
reserpine	-	6	B
and	-	16	O
subchronic	-	20	O
haloperidol	-	31	B
treatments	-	43	O
change	-	54	O
synaptosomal	-	61	O
brain	-	74	O
glutamate	-	80	B
uptake	-	90	O
and	-	97	O
elicit	-	101	O
orofacial	-	108	O
dyskinesia	-	118	O
in	-	129	O
rats	-	132	O
.	-	136	O

Reserpine	15649445	138	B
-	-	147	O
and	-	149	O
haloperidol	-	153	B
-	-	164	O
induced	-	165	O
orofacial	-	173	O
dyskinesia	-	183	O
are	-	194	O
putative	-	198	O
animal	-	207	O
models	-	214	O
of	-	221	O
tardive	-	224	O
dyskinesia	-	232	O
(	-	243	O
TD	-	244	O
)	-	246	O
whose	-	248	O
pathophysiology	-	254	O
has	-	270	O
been	-	274	O
related	-	279	O
to	-	287	O
free	-	290	O
radical	-	295	O
generation	-	303	O
and	-	314	O
oxidative	-	318	O
stress	-	328	O
.	-	334	O

In	15649445	336	O
the	-	339	O
present	-	343	O
study	-	351	O
,	-	356	O
the	-	358	O
authors	-	362	O
induced	-	370	O
orofacial	-	378	O
dyskinesia	-	388	O
by	-	399	O
acute	-	402	O
reserpine	-	408	B
and	-	418	O
subchronic	-	422	O
haloperidol	-	433	B
administration	-	445	O
to	-	460	O
rats	-	463	O
.	-	467	O

Reserpine	15649445	469	B
injection	-	479	O
(	-	489	O
one	-	490	O
dose	-	494	O
of	-	499	O
1	-	502	O
mg	-	504	O
/	-	506	O
kg	-	507	O
s	-	510	O
.	-	511	O
c	-	512	O
.	-	513	O
)	-	514	O

every	15649445	516	O
other	-	522	O
day	-	528	O
for	-	532	O
3	-	536	O
days	-	538	O
caused	-	543	O
a	-	550	O
significant	-	552	O
increase	-	564	O
in	-	573	O
vacuous	-	576	O
chewing	-	584	O
,	-	591	O
tongue	-	593	O
protrusion	-	600	O
and	-	611	O
duration	-	615	O
of	-	624	O
facial	-	627	O
twitching	-	634	O
,	-	643	O
compared	-	645	O
to	-	654	O
the	-	657	O
control	-	661	O
.	-	668	O

Haloperidol	15649445	670	B
administration	-	682	O
(	-	697	O
one	-	698	O
dose	-	702	O
of	-	707	O
12	-	710	O
mg	-	713	O
/	-	715	O
kg	-	716	O
once	-	719	O
a	-	724	O
week	-	726	O
s	-	731	O
.	-	732	O
c	-	733	O
.	-	734	O
)	-	735	O
for	-	737	O
4	-	741	O
weeks	-	743	O
caused	-	749	O
an	-	756	O
increase	-	759	O
in	-	768	O
vacuous	-	771	O
chewing	-	779	O
,	-	786	O
tongue	-	788	O
protrusion	-	795	O
and	-	806	O
duration	-	810	O
of	-	819	O
facial	-	822	O
twitching	-	829	O
observed	-	839	O
in	-	848	O
four	-	851	O
weekly	-	856	O
evaluations	-	863	O
.	-	874	O

After	15649445	876	O
the	-	882	O
treatments	-	886	O
and	-	897	O
behavioral	-	901	O
observation	-	912	O
,	-	923	O
glutamate	-	925	B
uptake	-	935	O
by	-	942	O
segments	-	945	O
of	-	954	O
the	-	957	O
brain	-	961	O
was	-	967	O
analyzed	-	971	O
.	-	979	O

A	15649445	981	O
decreased	-	983	O
glutamate	-	993	B
uptake	-	1003	O
was	-	1010	O
observed	-	1014	O
in	-	1023	O
the	-	1026	O
subcortical	-	1030	O
parts	-	1042	O
of	-	1048	O
animals	-	1051	O
treated	-	1059	O
with	-	1067	O
reserpine	-	1072	B
and	-	1082	O
haloperidol	-	1086	B
,	-	1097	O
compared	-	1099	O
to	-	1108	O
the	-	1111	O
control	-	1115	O
.	-	1122	O

Importantly	15649445	1124	O
,	-	1135	O
a	-	1137	O
decrease	-	1139	O
in	-	1148	O
glutamate	-	1151	B
uptake	-	1161	O
correlates	-	1168	O
negatively	-	1179	O
with	-	1190	O
an	-	1195	O
increase	-	1198	O
in	-	1207	O
the	-	1210	O
incidence	-	1214	O
of	-	1224	O
orofacial	-	1227	O
diskinesia	-	1237	O
.	-	1247	O

These	15649445	1249	O
results	-	1255	O
indicate	-	1263	O
that	-	1272	O
early	-	1277	O
changes	-	1283	O
in	-	1291	O
glutamate	-	1294	B
transport	-	1304	O
may	-	1314	O
be	-	1318	O
related	-	1321	O
to	-	1329	O
the	-	1332	O
development	-	1336	O
of	-	1348	O
vacuous	-	1351	O
chewing	-	1359	O
movements	-	1367	O
in	-	1377	O
rats	-	1380	O
.	-	1384	O

Acute	14698717	0	O
psychosis	-	6	O
due	-	16	O
to	-	20	O
treatment	-	23	O
with	-	33	O
phenytoin	-	38	B
in	-	48	O
a	-	51	O
nonepileptic	-	53	O
patient	-	66	O
.	-	73	O

The	14698717	75	O
development	-	79	O
of	-	91	O
psychosis	-	94	O
related	-	104	O
to	-	112	O
antiepileptic	-	115	O
drug	-	129	O
treatment	-	134	O
is	-	144	O
usually	-	147	O
attributed	-	155	O
to	-	166	O
the	-	169	O
interaction	-	173	O
between	-	185	O
the	-	193	O
epileptic	-	197	O
brain	-	207	O
substratum	-	213	O
and	-	224	O
the	-	228	O
antiepileptic	-	232	O
drugs	-	246	O
.	-	251	O

The	14698717	253	O
case	-	257	O
of	-	262	O
a	-	265	O
nonepileptic	-	267	O
patient	-	280	O
who	-	288	O
developed	-	292	O
psychosis	-	302	O
following	-	312	O
phenytoin	-	322	B
treatment	-	332	O
for	-	342	O
trigeminal	-	346	O
neuralgia	-	357	O
is	-	367	O
described	-	370	O
.	-	379	O

This	14698717	381	O
case	-	386	O
suggests	-	391	O
that	-	400	O
the	-	405	O
psychotic	-	409	O
symptoms	-	419	O
that	-	428	O
occur	-	433	O
following	-	439	O
phenytoin	-	449	B
treatment	-	459	O
in	-	469	O
some	-	472	O
epileptic	-	477	O
patients	-	487	O
may	-	496	O
be	-	500	O
the	-	503	O
direct	-	507	O
result	-	514	O
of	-	521	O
medication	-	524	O
,	-	534	O
unrelated	-	536	O
to	-	546	O
seizures	-	549	O
.	-	557	O

The	12617329	0	O
effect	-	4	O
of	-	11	O
treatment	-	14	O
with	-	24	O
gum	-	29	B
Arabic	-	33	I
on	-	40	O
gentamicin	-	43	B
nephrotoxicity	-	54	O
in	-	69	O
rats	-	72	O
:	-	76	O
a	-	78	O
preliminary	-	80	O
study	-	92	O
.	-	97	O

In	12617329	99	O
the	-	102	O
present	-	106	O
work	-	114	O
we	-	119	O
assessed	-	122	O
the	-	131	O
effect	-	135	O
of	-	142	O
treatment	-	145	O
of	-	155	O
rats	-	158	O
with	-	163	O
gum	-	168	B
Arabic	-	172	I
on	-	179	O
acute	-	182	O
renal	-	188	O
failure	-	194	O
induced	-	202	O
by	-	210	O
gentamicin	-	213	B
(	-	224	O
GM	-	225	B
)	-	227	O
nephrotoxicity	-	229	O
.	-	243	O

Rats	12617329	245	O
were	-	250	O
treated	-	255	O
with	-	263	O
the	-	268	O
vehicle	-	272	O
(	-	280	O
2	-	281	O
mL	-	283	O
/	-	285	O
kg	-	286	O
of	-	289	O
distilled	-	292	O
water	-	302	O
and	-	308	O
5	-	312	O
%	-	313	O
w	-	315	O
/	-	316	O
v	-	317	O
cellulose	-	319	O
,	-	328	O
10	-	330	O
days	-	333	O
)	-	337	O
,	-	338	O
gum	-	340	B
Arabic	-	344	I
(	-	351	O
2	-	352	O
mL	-	354	O
/	-	356	O
kg	-	357	O
of	-	360	O
a	-	363	O
10	-	365	O
%	-	367	O
w	-	369	O
/	-	370	O
v	-	371	O
aqueous	-	373	O
suspension	-	381	O
of	-	392	O
gum	-	395	B
Arabic	-	399	I
powder	-	406	O
,	-	412	O
orally	-	414	O
for	-	421	O
10	-	425	O
days	-	428	O
)	-	432	O
,	-	433	O
or	-	435	O
gum	-	438	B
Arabic	-	442	I
concomitantly	-	449	O
with	-	463	O
GM	-	468	B
(	-	471	O
80mg	-	472	O
/	-	476	O
kg	-	477	O
/	-	479	O
day	-	480	O
intramuscularly	-	484	O
,	-	499	O
during	-	501	O
the	-	508	O
last	-	512	O
six	-	517	O
days	-	521	O
of	-	526	O
the	-	529	O
treatment	-	533	O
period	-	543	O
)	-	549	O
.	-	550	O

Nephrotoxicity	12617329	552	O
was	-	567	O
assessed	-	571	O
by	-	580	O
measuring	-	583	O
the	-	593	O
concentrations	-	597	O
of	-	612	O
creatinine	-	615	B
and	-	626	O
urea	-	630	B
in	-	635	O
the	-	638	O
plasma	-	642	O
and	-	649	O
reduced	-	653	O
glutathione	-	661	B
(	-	673	O
GSH	-	674	B
)	-	677	O
in	-	679	O
the	-	682	O
kidney	-	686	O
cortex	-	693	O
,	-	699	O
and	-	701	O
by	-	705	O
light	-	708	O
microscopic	-	714	O
examination	-	726	O
of	-	738	O
kidney	-	741	O
sections	-	748	O
.	-	756	O

The	12617329	758	O
results	-	762	O
indicated	-	770	O
that	-	780	O
concomitant	-	785	O
treatment	-	797	O
with	-	807	O
gum	-	812	B
Arabic	-	816	I
and	-	823	O
GM	-	827	B
significantly	-	830	O
increased	-	844	O
creatinine	-	854	B
and	-	865	O
urea	-	869	B
by	-	874	O
about	-	877	O
183	-	883	O
and	-	887	O
239	-	891	O
%	-	894	O
,	-	895	O
respectively	-	897	O
(	-	910	O
compared	-	911	O
to	-	920	O
432	-	923	O
and	-	927	O
346	-	931	O
%	-	934	O
,	-	935	O
respectively	-	937	O
,	-	949	O
in	-	951	O
rats	-	954	O
treated	-	959	O
with	-	967	O
cellulose	-	972	O
and	-	982	O
GM	-	986	B
)	-	988	O
,	-	989	O
and	-	991	O
decreased	-	995	O
that	-	1005	O
of	-	1010	O
cortical	-	1013	O
GSH	-	1022	B
by	-	1026	O
21	-	1029	O
%	-	1031	O
(	-	1033	O
compared	-	1034	O
to	-	1043	O
27	-	1046	O
%	-	1048	O
in	-	1050	O
the	-	1053	O
cellulose	-	1057	O
plus	-	1067	O
GM	-	1072	B
group	-	1075	O
)	-	1080	O

The	12617329	1082	O
GM	-	1086	B
-	-	1088	O
induced	-	1089	O
proximal	-	1097	O
tubular	-	1106	O
necrosis	-	1114	O
appeared	-	1123	O
to	-	1132	O
be	-	1135	O
slightly	-	1138	O
less	-	1147	O
severe	-	1152	O
in	-	1159	O
rats	-	1162	O
given	-	1167	O
GM	-	1173	B
together	-	1176	O
with	-	1185	O
gum	-	1190	B
Arabic	-	1194	I
than	-	1201	O
in	-	1206	O
those	-	1209	O
given	-	1215	O
GM	-	1221	B
and	-	1224	O
cellulose	-	1228	O
.	-	1237	O

It	12617329	1239	O
could	-	1242	O
be	-	1248	O
inferred	-	1251	O
that	-	1260	O
gum	-	1265	B
Arabic	-	1269	I
treatment	-	1276	O
has	-	1286	O
induced	-	1290	O
a	-	1298	O
modest	-	1300	O
amelioration	-	1307	O
of	-	1320	O
some	-	1323	O
of	-	1328	O
the	-	1331	O
histological	-	1335	O
and	-	1348	O
biochemical	-	1352	O
indices	-	1364	O
of	-	1372	O
GM	-	1375	B
nephrotoxicity	-	1378	O
.	-	1392	O

Further	12617329	1394	O
work	-	1402	O
is	-	1407	O
warranted	-	1410	O
on	-	1420	O
the	-	1423	O
effect	-	1427	O
of	-	1434	O
the	-	1437	O
treatments	-	1441	O
on	-	1452	O
renal	-	1455	O
functional	-	1461	O
aspects	-	1472	O
in	-	1480	O
models	-	1483	O
of	-	1490	O
chronic	-	1493	O
renal	-	1501	O
failure	-	1507	O
,	-	1514	O
and	-	1516	O
on	-	1520	O
the	-	1523	O
mechanism	-	1527	O
(	-	1536	O
s	-	1537	O
)	-	1538	O
involved	-	1540	O
.	-	1548	O

Visual	12523465	0	O
hallucinations	-	7	O
associated	-	22	O
with	-	33	O
zonisamide	-	38	B
.	-	48	O

Zonisamide	12523465	50	B
is	-	61	O
a	-	64	O
broad	-	66	O
-	-	71	O
spectrum	-	72	O
antiepileptic	-	81	O
drug	-	95	O
used	-	100	O
to	-	105	O
treat	-	108	O
various	-	114	O
types	-	122	O
of	-	128	O
seizures	-	131	O
.	-	139	O

Although	12523465	141	O
visual	-	150	O
hallucinations	-	157	O
have	-	172	O
not	-	177	O
been	-	181	O
reported	-	186	O
as	-	195	O
an	-	198	O
adverse	-	201	O
effect	-	209	O
of	-	216	O
this	-	219	O
agent	-	224	O
,	-	229	O
we	-	231	O
describe	-	234	O
three	-	243	O
patients	-	249	O
who	-	258	O
experienced	-	262	O
complex	-	274	O
visual	-	282	O
hallucinations	-	289	O
and	-	304	O
altered	-	308	O
mental	-	316	O
status	-	323	O
after	-	330	O
zonisamide	-	336	B
treatment	-	347	O
was	-	357	O
begun	-	361	O
or	-	367	O
its	-	370	O
dosage	-	374	O
increased	-	381	O
.	-	390	O

All	12523465	392	O
three	-	396	O
had	-	402	O
been	-	406	O
diagnosed	-	411	O
earlier	-	421	O
with	-	429	O
epilepsy	-	434	O
,	-	442	O
and	-	444	O
their	-	448	O
electroencephalogram	-	454	O
(	-	475	O
EEG	-	476	O
)	-	479	O
findings	-	481	O
were	-	490	O
abnormal	-	495	O
.	-	503	O

During	12523465	505	O
monitoring	-	512	O
,	-	522	O
visual	-	524	O
hallucinations	-	531	O
did	-	546	O
not	-	550	O
correlate	-	554	O
with	-	564	O
EEG	-	569	O
readings	-	573	O
,	-	581	O
nor	-	583	O
did	-	587	O
video	-	591	O
recording	-	597	O
capture	-	607	O
any	-	615	O
of	-	619	O
the	-	622	O
described	-	626	O
events	-	636	O
.	-	642	O

None	12523465	644	O
of	-	649	O
the	-	652	O
patients	-	656	O
had	-	665	O
experienced	-	669	O
visual	-	681	O
hallucinations	-	688	O
before	-	703	O
this	-	710	O
event	-	715	O
.	-	720	O

The	12523465	722	O
only	-	726	O
recent	-	731	O
change	-	738	O
in	-	745	O
their	-	748	O
treatment	-	754	O
was	-	764	O
the	-	768	O
introduction	-	772	O
or	-	785	O
increased	-	788	O
dosage	-	798	O
of	-	805	O
zonisamide	-	808	B
.	-	818	O

With	12523465	820	O
either	-	825	O
discontinuation	-	832	O
or	-	848	O
decreased	-	851	O
dosage	-	861	O
of	-	868	O
the	-	871	O
drug	-	875	O
the	-	880	O
symptoms	-	884	O
disappeared	-	893	O
and	-	905	O
did	-	909	O
not	-	913	O
recur	-	917	O
.	-	922	O

Further	12523465	924	O
observations	-	932	O
and	-	945	O
reports	-	949	O
will	-	957	O
help	-	962	O
clarify	-	967	O
this	-	975	O
adverse	-	980	O
effect	-	988	O
.	-	994	O

Until	12523465	996	O
then	-	1002	O
,	-	1006	O
clinicians	-	1008	O
need	-	1019	O
to	-	1024	O
be	-	1027	O
aware	-	1030	O
of	-	1036	O
this	-	1039	O
possible	-	1044	O
complication	-	1053	O
associated	-	1066	O
with	-	1077	O
zonisamide	-	1082	B
.	-	1092	O

GLEPP1	11961407	0	O
receptor	-	7	O
tyrosine	-	16	B
phosphatase	-	25	O
(	-	37	O
Ptpro	-	38	O
)	-	43	O
in	-	45	O
rat	-	48	O
PAN	-	52	B
nephrosis	-	56	O
.	-	65	O

A	11961407	67	O
marker	-	69	O
of	-	76	O
acute	-	79	O
podocyte	-	85	O
injury	-	94	O
.	-	100	O

Glomerular	11961407	102	O
epithelial	-	113	O
protein	-	124	O
1	-	132	O
(	-	134	O
GLEPP1	-	135	O
)	-	141	O
is	-	143	O
a	-	146	O
podocyte	-	148	O
receptor	-	157	O
membrane	-	166	O
protein	-	175	O
tyrosine	-	183	B
phosphatase	-	192	O
located	-	204	O
on	-	212	O
the	-	215	O
apical	-	219	O
cell	-	226	O
membrane	-	231	O
of	-	240	O
visceral	-	243	O
glomerular	-	252	O
epithelial	-	263	O
cell	-	274	O
and	-	279	O
foot	-	283	O
processes	-	288	O
.	-	297	O

This	11961407	299	O
receptor	-	304	O
plays	-	313	O
a	-	319	O
role	-	321	O
in	-	326	O
regulating	-	329	O
the	-	340	O
structure	-	344	O
and	-	354	O
function	-	358	O
of	-	367	O
podocyte	-	370	O
foot	-	379	O
process	-	384	O
.	-	391	O

To	11961407	393	O
better	-	396	O
understand	-	403	O
the	-	414	O
utility	-	418	O
of	-	426	O
GLEPP1	-	429	O
as	-	436	O
a	-	439	O
marker	-	441	O
of	-	448	O
glomerular	-	451	O
injury	-	462	O
,	-	468	O
the	-	470	O
amount	-	474	O
and	-	481	O
distribution	-	485	O
of	-	498	O
GLEPP1	-	501	O
protein	-	508	O
and	-	516	O
mRNA	-	520	O
were	-	525	O
examined	-	530	O
by	-	539	O
immunohistochemistry	-	542	O
,	-	562	O
Western	-	564	O
blot	-	572	O
and	-	577	O
RNase	-	581	O
protection	-	587	O
assay	-	598	O
in	-	604	O
a	-	607	O
model	-	609	O
of	-	615	O
podocyte	-	618	O
injury	-	627	O
in	-	634	O
the	-	637	O
rat	-	641	O
.	-	644	O

Puromycin	11961407	646	B
aminonucleoside	-	656	I
nephrosis	-	672	O
was	-	682	O
induced	-	686	O
by	-	694	O
single	-	697	O
intraperitoneal	-	704	O
injection	-	720	O
of	-	730	O
puromycin	-	733	B
aminonucleoside	-	743	I
(	-	759	O
PAN	-	760	B
,	-	763	O
20	-	765	O
mg	-	768	O
/	-	770	O
100	-	771	O
g	-	774	O
BW	-	776	O
)	-	778	O
.	-	779	O

Tissues	11961407	781	O
were	-	789	O
analyzed	-	794	O
at	-	803	O
0	-	806	O
,	-	807	O
5	-	809	O
,	-	810	O
7	-	812	O
,	-	813	O
11	-	815	O
,	-	817	O
21	-	819	O
,	-	821	O
45	-	823	O
,	-	825	O
80	-	827	O
and	-	830	O
126	-	834	O
days	-	838	O
after	-	843	O
PAN	-	849	B
injection	-	853	O
so	-	863	O
as	-	866	O
to	-	869	O
include	-	872	O
both	-	880	O
the	-	885	O
acute	-	889	O
phase	-	895	O
of	-	901	O
proteinuria	-	904	O
associated	-	916	O
with	-	927	O
foot	-	932	O
process	-	937	O
effacement	-	945	O
(	-	956	O
days	-	957	O
5	-	962	O
-	-	963	O
11	-	964	O
)	-	966	O
and	-	968	O
the	-	972	O
chronic	-	976	O
phase	-	984	O
of	-	990	O
proteinuria	-	993	O
associated	-	1005	O
with	-	1016	O
glomerulosclerosis	-	1021	O
(	-	1040	O
days	-	1041	O
45	-	1046	O
-	-	1048	O
126	-	1049	O
)	-	1052	O
.	-	1053	O

At	11961407	1055	O
day	-	1058	O
5	-	1062	O
,	-	1063	O
GLEPP1	-	1065	O
protein	-	1072	O
and	-	1080	O
mRNA	-	1084	O
were	-	1089	O
reduced	-	1094	O
from	-	1102	O
the	-	1107	O
normal	-	1111	O
range	-	1118	O
(	-	1124	O
265	-	1125	O
.	-	1128	O
2	-	1129	O
+	-	1131	O
/	-	1132	O
-	-	1133	O

79	11961407	1135	O
.	-	1137	O
6	-	1138	O
x	-	1140	O
10	-	1142	O
(	-	1144	O
6	-	1145	O
)	-	1146	O
moles	-	1148	O
/	-	1153	O
glomerulus	-	1154	O
and	-	1165	O
100	-	1169	O
%	-	1172	O
)	-	1173	O
to	-	1175	O
15	-	1178	O
%	-	1180	O
of	-	1182	O
normal	-	1185	O
(	-	1192	O
41	-	1193	O
.	-	1195	O
8	-	1196	O
+	-	1198	O
/	-	1199	O
-	-	1200	O

4	11961407	1202	O
.	-	1203	O
8	-	1204	O
x	-	1206	O
10	-	1208	O
(	-	1210	O
6	-	1211	O
)	-	1212	O
moles	-	1214	O
/	-	1219	O
glomerulus	-	1220	O
,	-	1230	O
p	-	1232	O
<	-	1234	O
0	-	1236	O
.	-	1237	O
005	-	1238	O
)	-	1241	O
.	-	1242	O

This	11961407	1244	O
occurred	-	1249	O
in	-	1258	O
association	-	1261	O
with	-	1273	O
an	-	1278	O
increase	-	1281	O
in	-	1290	O
urinary	-	1293	O
protein	-	1301	O
content	-	1309	O
from	-	1317	O
1	-	1322	O
.	-	1323	O
8	-	1324	O
+	-	1326	O
/	-	1327	O
-	-	1328	O

1	11961407	1330	O
to	-	1332	O
99	-	1335	O
.	-	1337	O
0	-	1338	O
+	-	1340	O
/	-	1341	O
-	-	1342	O

61	11961407	1344	O
mg	-	1347	O
/	-	1349	O
day	-	1350	O
(	-	1354	O
p	-	1355	O
<	-	1357	O
0	-	1359	O
.	-	1360	O
001	-	1361	O
)	-	1364	O
.	-	1365	O

In	11961407	1367	O
contrast	-	1370	O
,	-	1378	O
podocalyxin	-	1380	O
did	-	1392	O
not	-	1396	O
change	-	1400	O
significantly	-	1407	O
at	-	1421	O
this	-	1424	O
time	-	1429	O
.	-	1433	O

By	11961407	1435	O
day	-	1438	O
11	-	1442	O
,	-	1444	O
GLEPP1	-	1446	O
protein	-	1453	O
and	-	1461	O
mRNA	-	1465	O
had	-	1470	O
begun	-	1474	O
to	-	1480	O
return	-	1483	O
towards	-	1490	O
baseline	-	1498	O
.	-	1506	O

By	11961407	1508	O
day	-	1511	O
45	-	1515	O
-	-	1517	O
126	-	1518	O
,	-	1521	O
at	-	1523	O
a	-	1526	O
time	-	1528	O
when	-	1533	O
glomerular	-	1538	O
scarring	-	1549	O
was	-	1558	O
present	-	1562	O
,	-	1569	O
GLEPP1	-	1571	O
was	-	1578	O
absent	-	1582	O
from	-	1589	O
glomerulosclerotic	-	1594	O
areas	-	1613	O
although	-	1619	O
the	-	1628	O
total	-	1632	O
glomerular	-	1638	O
content	-	1649	O
of	-	1657	O
GLEPP1	-	1660	O
was	-	1667	O
not	-	1671	O
different	-	1675	O
from	-	1685	O
normal	-	1690	O
.	-	1696	O

We	11961407	1698	O
conclude	-	1701	O
that	-	1710	O
GLEPP1	-	1715	O
expression	-	1722	O
,	-	1732	O
unlike	-	1734	O
podocalyxin	-	1741	O
,	-	1752	O
reflects	-	1754	O
podocyte	-	1763	O
injury	-	1772	O
induced	-	1779	O
by	-	1787	O
PAN	-	1790	B
.	-	1793	O

GLEPP1	11961407	1795	O
expression	-	1802	O
may	-	1813	O
be	-	1817	O
a	-	1820	O
useful	-	1822	O
marker	-	1829	O
of	-	1836	O
podocyte	-	1839	O
injury	-	1848	O
.	-	1854	O

Ticlopidine	9401499	0	B
-	-	11	O
induced	-	12	O
aplastic	-	20	O
anemia	-	29	O
:	-	35	O
report	-	37	O
of	-	44	O
three	-	47	O
Chinese	-	53	O
patients	-	61	O
and	-	70	O
review	-	74	O
of	-	81	O
the	-	84	O
literature	-	88	O
.	-	98	O

In	9401499	100	O
this	-	103	O
study	-	108	O
,	-	113	O
three	-	115	O
Chinese	-	121	O
patients	-	129	O
with	-	138	O
ticlopidine	-	143	B
-	-	154	O
induced	-	155	O
aplastic	-	163	O
anemia	-	172	O
were	-	179	O
reported	-	184	O
and	-	193	O
another	-	197	O
13	-	205	O
patients	-	208	O
in	-	217	O
the	-	220	O
English	-	224	O
literature	-	232	O
were	-	243	O
reviewed	-	248	O
.	-	256	O

We	9401499	258	O
attempted	-	261	O
to	-	271	O
find	-	274	O
underlying	-	279	O
similarities	-	290	O
,	-	302	O
evaluate	-	304	O
the	-	313	O
risk	-	317	O
factors	-	322	O
,	-	329	O
and	-	331	O
identify	-	335	O
appropriate	-	344	O
treatment	-	356	O
for	-	366	O
this	-	370	O
complication	-	375	O
.	-	387	O

All	9401499	389	O
but	-	393	O
one	-	397	O
of	-	401	O
the	-	404	O
patients	-	408	O
were	-	417	O
over	-	422	O
60	-	427	O
years	-	430	O
old	-	436	O
,	-	439	O
and	-	441	O
the	-	445	O
6	-	449	O
who	-	451	O
died	-	455	O
were	-	460	O
all	-	465	O
older	-	469	O
than	-	475	O
65	-	480	O
.	-	482	O

Therefore	9401499	484	O
,	-	493	O
old	-	495	O
age	-	499	O
may	-	503	O
be	-	507	O
a	-	510	O
risk	-	512	O
factor	-	517	O
for	-	524	O
developing	-	528	O
this	-	539	O
complication	-	544	O
.	-	556	O

Agranulocytosis	9401499	558	O
occurred	-	574	O
3	-	583	O
-	-	584	O
20	-	585	O
weeks	-	588	O
after	-	594	O
initiation	-	600	O
of	-	611	O
ticlopidine	-	614	B
,	-	625	O
so	-	627	O
frequent	-	630	O
examination	-	639	O
of	-	651	O
white	-	654	O
cell	-	660	O
count	-	665	O
during	-	671	O
treatment	-	678	O
is	-	688	O
recommended	-	691	O
.	-	702	O

There	9401499	704	O
seemed	-	710	O
to	-	717	O
be	-	720	O
no	-	723	O
direct	-	726	O
correlation	-	733	O
between	-	745	O
the	-	753	O
dose	-	757	O
or	-	762	O
duration	-	765	O
used	-	774	O
and	-	779	O
the	-	783	O
severity	-	787	O
of	-	796	O
bone	-	799	O
marrow	-	804	O
suppression	-	811	O
.	-	822	O

Treatment	9401499	824	O
for	-	834	O
ticlopidine	-	838	B
-	-	849	O
induced	-	850	O
aplastic	-	858	O
anemia	-	867	O
with	-	874	O
colony	-	879	O
-	-	885	O
stimulating	-	886	O
factors	-	898	O
seemed	-	906	O
to	-	913	O
have	-	916	O
little	-	921	O
effect	-	928	O
.	-	934	O

The	9401499	936	O
fact	-	940	O
that	-	945	O
5	-	950	O
of	-	952	O
the	-	955	O
6	-	959	O
patients	-	961	O
who	-	970	O
received	-	974	O
concurrent	-	983	O
calcium	-	994	B
channel	-	1002	O
blockers	-	1010	O
died	-	1019	O
,	-	1023	O
should	-	1025	O
alert	-	1032	O
clinicians	-	1038	O
to	-	1049	O
be	-	1052	O
more	-	1055	O
cautious	-	1060	O
when	-	1069	O
using	-	1074	O
these	-	1080	O
two	-	1086	O
drugs	-	1090	O
simultaneously	-	1096	O
.	-	1110	O

Facilitation	2273650	0	O
of	-	13	O
memory	-	16	O
retrieval	-	23	O
by	-	33	O
pre	-	36	O
-	-	39	O
test	-	40	O
morphine	-	45	B
and	-	54	O
its	-	58	O
state	-	62	O
dependency	-	68	O
in	-	79	O
the	-	82	O
step	-	86	O
-	-	90	O
through	-	91	O
type	-	99	O
passive	-	104	O
avoidance	-	112	O
learning	-	122	O
test	-	131	O
in	-	136	O
mice	-	139	O
.	-	143	O

Amnesia	2273650	145	O
produced	-	153	O
by	-	162	O
scopolamine	-	165	B
and	-	177	O
cycloheximide	-	181	B
were	-	195	O
reversed	-	200	O
by	-	209	O
morphine	-	212	B
given	-	221	O
30	-	227	O
min	-	230	O
before	-	234	O
the	-	241	O
test	-	245	O
trial	-	250	O
(	-	256	O
pre	-	257	O
-	-	260	O
test	-	261	O
)	-	265	O
,	-	266	O
and	-	268	O
pre	-	272	O
-	-	275	O
test	-	276	O
morphine	-	281	B
also	-	290	O
facilitated	-	295	O
the	-	307	O
memory	-	311	O
retrieval	-	318	O
in	-	328	O
the	-	331	O
animals	-	335	O
administered	-	343	O
naloxone	-	356	B
during	-	365	O
the	-	372	O
training	-	376	O
trial	-	385	O
.	-	390	O

Similarly	2273650	392	O
,	-	401	O
pre	-	403	O
-	-	406	O
test	-	407	O
scopolamine	-	412	B
partially	-	424	O
reversed	-	434	O
the	-	443	O
scopolamine	-	447	B
-	-	458	O
induced	-	459	O
amnesia	-	467	O
,	-	474	O
but	-	476	O
not	-	480	O
significantly	-	484	O
;	-	497	O
and	-	499	O
pre	-	503	O
-	-	506	O
test	-	507	O
cycloheximide	-	512	B
failed	-	526	O
to	-	533	O
reverse	-	536	O
the	-	544	O
cycloheximide	-	548	B
-	-	561	O
induced	-	562	O
amnesia	-	570	O
.	-	577	O

These	2273650	579	O
results	-	585	O
suggest	-	593	O
that	-	601	O
the	-	606	O
facilitation	-	610	O
of	-	623	O
memory	-	626	O
retrieval	-	633	O
by	-	643	O
pre	-	646	O
-	-	649	O
test	-	650	O
morphine	-	655	B
might	-	664	O
be	-	670	O
the	-	673	O
direct	-	677	O
action	-	684	O
of	-	691	O
morphine	-	694	B
rather	-	703	O
than	-	710	O
a	-	715	O
state	-	717	O
dependent	-	723	O
effect	-	733	O
.	-	739	O

Test	10683478	0	O
conditions	-	5	O
influence	-	16	O
the	-	26	O
response	-	30	O
to	-	39	O
a	-	42	O
drug	-	44	O
challenge	-	49	O
in	-	59	O
rodents	-	62	O
.	-	69	O

These	10683478	71	O
studies	-	77	O
were	-	85	O
conducted	-	90	O
to	-	100	O
examine	-	103	O
the	-	111	O
differential	-	115	O
response	-	128	O
to	-	137	O
a	-	140	O
drug	-	142	O
challenge	-	147	O
under	-	157	O
varied	-	163	O
experimental	-	170	O
test	-	183	O
conditions	-	188	O
routinely	-	199	O
employed	-	209	O
to	-	218	O
study	-	221	O
drug	-	227	O
-	-	231	O
induced	-	232	O
behavioral	-	240	O
and	-	251	O
neurophysiological	-	255	O
responses	-	274	O
in	-	284	O
rodents	-	287	O
.	-	294	O

Apomorphine	10683478	296	B
,	-	307	O
a	-	309	O
nonselective	-	311	O
dopamine	-	324	B
agonist	-	333	I
,	-	340	O
was	-	342	O
selected	-	346	O
due	-	355	O
to	-	359	O
its	-	362	O
biphasic	-	366	O
behavioral	-	375	O
effects	-	386	O
,	-	393	O
its	-	395	O
ability	-	399	O
to	-	407	O
induce	-	410	O
hypothermia	-	417	O
,	-	428	O
and	-	430	O
to	-	434	O
produce	-	437	O
distinct	-	445	O
changes	-	454	O
to	-	462	O
dopamine	-	465	B
turnover	-	474	O
in	-	483	O
the	-	486	O
rodent	-	490	O
brain	-	497	O
.	-	502	O

From	10683478	504	O
such	-	509	O
experiments	-	514	O
there	-	526	O
is	-	532	O
evidence	-	535	O
that	-	544	O
characterization	-	549	O
and	-	566	O
detection	-	570	O
of	-	580	O
apomorphine	-	583	B
-	-	594	O
induced	-	595	O
activity	-	603	O
in	-	612	O
rodents	-	615	O
critically	-	623	O
depends	-	634	O
upon	-	642	O
the	-	647	O
test	-	651	O
conditions	-	656	O
employed	-	667	O
.	-	675	O

In	10683478	677	O
rats	-	680	O
,	-	684	O
detection	-	686	O
of	-	696	O
apomorphine	-	699	B
-	-	710	O
induced	-	711	O
hyperactivity	-	719	O
was	-	733	O
facilitated	-	737	O
by	-	749	O
a	-	752	O
period	-	754	O
of	-	761	O
acclimatization	-	764	O
to	-	780	O
the	-	783	O
test	-	787	O
conditions	-	792	O
.	-	802	O

Moreover	10683478	804	O
,	-	812	O
test	-	814	O
conditions	-	819	O
can	-	830	O
impact	-	834	O
upon	-	841	O
other	-	846	O
physiological	-	852	O
responses	-	866	O
to	-	876	O
apomorphine	-	879	B
such	-	891	O
as	-	896	O
drug	-	899	O
-	-	903	O
induced	-	904	O
hypothermia	-	912	O
.	-	923	O

In	10683478	925	O
mice	-	928	O
,	-	932	O
apomorphine	-	934	B
produced	-	946	O
qualitatively	-	955	O
different	-	969	O
responses	-	979	O
under	-	989	O
novel	-	995	O
conditions	-	1001	O
when	-	1012	O
compared	-	1017	O
to	-	1026	O
those	-	1029	O
behaviors	-	1035	O
elicited	-	1045	O
in	-	1054	O
the	-	1057	O
home	-	1061	O
test	-	1066	O
cage	-	1071	O
.	-	1075	O

Drug	10683478	1077	O
-	-	1081	O
induced	-	1082	O
gross	-	1090	O
activity	-	1096	O
counts	-	1105	O
were	-	1112	O
increased	-	1117	O
in	-	1127	O
the	-	1130	O
novel	-	1134	O
exploratory	-	1140	O
box	-	1152	O
only	-	1156	O
,	-	1160	O
while	-	1162	O
measures	-	1168	O
of	-	1177	O
stereotypic	-	1180	O
behavior	-	1192	O
were	-	1201	O
similar	-	1206	O
in	-	1214	O
both	-	1217	O
.	-	1221	O

By	10683478	1223	O
contrast	-	1226	O
,	-	1234	O
apomorphine	-	1236	B
-	-	1247	O
induced	-	1248	O
locomotion	-	1256	O
was	-	1267	O
more	-	1271	O
prominent	-	1276	O
in	-	1286	O
the	-	1289	O
novel	-	1293	O
exploratory	-	1299	O
box	-	1311	O
.	-	1314	O

Dopamine	10683478	1316	B
turnover	-	1325	O
ratios	-	1334	O
(	-	1341	O
DOPAC	-	1342	B
:	-	1347	O
DA	-	1348	B
and	-	1351	O
HVA	-	1355	B
:	-	1358	O
DA	-	1359	B
)	-	1361	O
were	-	1363	O
found	-	1368	O
to	-	1374	O
be	-	1377	O
lower	-	1380	O
in	-	1386	O
those	-	1389	O
animals	-	1395	O
exposed	-	1403	O
to	-	1411	O
the	-	1414	O
exploratory	-	1418	O
box	-	1430	O
when	-	1434	O
compared	-	1439	O
to	-	1448	O
their	-	1451	O
home	-	1457	O
cage	-	1462	O
counterparts	-	1467	O
.	-	1479	O

However	10683478	1481	O
,	-	1488	O
apomorphine	-	1490	B
-	-	1501	O
induced	-	1502	O
reductions	-	1510	O
in	-	1521	O
striatal	-	1524	O
dopamine	-	1533	B
turnover	-	1542	O
were	-	1551	O
detected	-	1556	O
in	-	1565	O
both	-	1568	O
novel	-	1573	O
and	-	1579	O
home	-	1583	O
cage	-	1588	O
environments	-	1593	O
.	-	1605	O

The	10683478	1607	O
implications	-	1611	O
of	-	1624	O
these	-	1627	O
findings	-	1633	O
are	-	1642	O
discussed	-	1646	O
with	-	1656	O
particular	-	1661	O
emphasis	-	1672	O
upon	-	1681	O
conducting	-	1686	O
psychopharmacological	-	1697	O
challenge	-	1719	O
tests	-	1729	O
in	-	1735	O
rodents	-	1738	O
.	-	1745	O

